藥品代碼,藥品學名,藥品名稱,藥品分類,適應症,禁忌,副作用,儲存,用法用量,肝功能異常(Y/N),肝功能異常說明,腎功能異常(Y/N),懷孕用藥危險分級,孕期用藥建議,孕期附帶說明,哺乳期用藥建議,哺乳期附帶說明,給藥途徑,乾粉稀釋液,輸注點滴液,IVP用法建議,IVD用法建議,注意事項
OEZE,Ezetimibe,Ezetrol 10mg,CAVS,,適應症:為降血脂藥(B024058100),,RT,10 mg once daily.,,,,除非治療上需要,,,,,,,,,,
OELME,Dihydroergotoxine,Elmesatt 2mg,CAVS,,適應症:Adjunct in treating symptoms of mild to moderate dementia in the elderly 副作用: Abdominal cramps， nausea， vomiting， headache， blurred vision， skin rashes， nasal congestion， flushing of the skin， dizziness， bradycardia， & orthostatic hypotension 禁忌: Severe bradycardia.,,室溫,Should be taken with food 1 tab tid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OCHA1,Varenicline,CHAMPIX 1mg,ZADT,Aid to smoking cessation treatment.,,Nausea， sleep disturbance， constipation， flatulence， vomiting. Diarrhea， gingivitis， chest pain， flu-like illness， edema， thirst， abnormal liver function test， increased weight， arthralgia， back pain， muscle cramp， musculoskeletal pain， myalgia， attention disturbance， dizziness， sensory disturbance， anxiety， depression， emotional disorder， irritability， restlessness， polyuria， menstrual disorder， epistaxis， respiratory disorders， hyperhidrosis， hot flush， HTN. Gastrointestinal: Constipation (5% to 8% )， Flatulence (6% to 9% )， Nausea (16% to 40% )， Vomiting (1% to 5% ) Neurologic: Dream disorder (9% to 13% )， Headache (15% to 19% )， Insomnia (18% to 19% ),25℃,"Days 1-3: 0.5 mg once daily.Days 4-7: 0.5 mg twice daily.Days 8 and later (maintenance): 1 mg twice daily. Continue maintenance dose for at least 11 weeks to 1 year (for a total of at least 12 weeks of treatment).Approaches to selecting a tobacco quit date: May either choose a fixed quit date (ie， start varenicline， then quit on day 8) or a flexible quit date (ie， start varenicline， then quit between days 8-35). Alternatively， consider a gradual quit date (ie， start varenicline and reduce smoking 50% by week 4， reduce an additional 50% by week 8， and continue reducing with a goal of complete abstinence by week 12) followed by a maintenance dose for 12 weeks (for a total of at least 24 weeks of treatment).",無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
EAZE,Azelastine,Azela nasal spray 100dose,TENT,,適應症: Allergic rhinitis. 副作用: Rarely， irritation of inflamed nasal mucosa on spraying. Improper administration may produce a taste disturbance. Gastrointestinal: Abnormal taste in mouth， Bitter (nasal， 4% to 19.7%; ophthalmic， approximately 10% ) Neurologic: Headache (nasal， 1% to 14.8%; ophthalmic， approximately 15% )， Somnolence (up to 11.5% ) Ophthalmic: Burning sensation in eye (ophthalmic， 30% ) Respiratory: Epistaxis (1% to 7% )， Nasal irritation (nasal， 1% to 4% )， Pharyngitis (nasal， 3.8%; ophthalmic， 1% to 10% )， Rhinitis (adults nasal， 2.3%; children nasal， 17%; ophthalmic， 1% to 10% )， Sneezing (3.1% ) Other: Fatigue (nasal， 2% to 2.3%; ophthalmic， 1% to 10% ),,室溫,>6 ys 1 puff into each nostril bid.,,,,除非治療上需要,,,,,,,,,,
EPAT,NaCl + KCl + Boric Acid,Patear eye lotion 10mL,TOPH,,適應症: Mild to moderate dry eyes. 禁忌: Glaucoma.,,室溫,Instill 2-3 drops 3-6 times daily.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OCON1,Bisoprolol,Concor 1.25mg康肯錠,CAVS,1.25 mg & 2.5 mg tab Stable chronic moderate to severe heart failure. 5 mg & 10 mg tab Management of hypertension， angina pectoris & stable， chronic moderate to severe heart failure (NYHA class III， IV).,Acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy， cardiogenic shock， AV block of grades II & III (without pacemaker)， sick sinus syndrome， SA block， bradycardia with < 60 beats/min; severe bronchial asthma or severe COPD， hypotension (systolic BP < 100 mmHg)， advanced stages of peripheral arterial circulatory disturbance & Raynaud's syndrome， untreated pheochromocytoma， metabolic acidosis.,Feeling of coldness or numbness in the extremities， nausea， vomiting， diarrhea， constipation. Tiredness， exhaustion， dizziness， headache (occur at the beginning of the therapy & usually disappear within 1-2 weeks). Gastrointestinal: Diarrhea (2.6% to 3.5% ) Neurologic: Headache (8.8% to 10.9% ) Respiratory: Rhinitis (2.9% to 4% )， Upper respiratory infection (4.8% to 5% .) Other: Fatigue (6.6% to 8.2%),25℃以下,Stable mild to server chronic heart failure: Patient must be treated at optimal dose with an ACE inhibitor， a diuretic， & optionally cardiac glycosides， prior to the administration of bisoprolol. Titrate gradually as follows: Week 1: 1.25 mg QD. Week 2: 2.5 mg QD. Week 3: 3.75 mg QD. Week 4-7: 5 mg QD. Week 8-11: 7.5 mg QD. Week 12 and beyond: 10 mg QD as maintenance therapy. Maximum: 10 mg daily.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
IHEP,Heparin,Heparin inj 25KIU/5mL,HEMT,,適應症: Unstable angina; Venous thromboembolism; Peripheral arterial embolism， Prevention of re-occlusion of the coronary arteries following thrombolytic therapy ， Venous thromboembolism ，Prophylaxis of post-op venous thromboembolism， Prevention of mural thrombosis 副作用:Slight fever， headache， chills， nausea， vomiting， constipation， epistaxis， bruising， slight haematuria， skin necrosis (SC inj)， osteoporosis， alopecia. Hypersensitivity reactions include urticaria， conjunctivitis， rhinitis， asthma， angioedema and anaphylactic shock. Priapism. Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding Dermatologic: Erythema， Injection site ulcer， After deep subcutaneous injection Hematologic: Hematoma， Heparin-induced thrombocytopenia (up to 30% ) Neurologic: Pain (Mild) Other: Irritation symptom， Local 禁忌: Patients predisposed to active bleeding including thrombocytopenia， peptic ulcer disease， cerebrovascular disorders， haemorrhagic blood disorders， bacterial endocarditis， severe hypertension， oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage， abdominal or thoracic bleeding into closed space， severe traumatic bleed， hepatic， renal， splenic or arterial injury， severe haemostatic defect， arterial thrombosis with heparin-associated thrombocytopenia. IM admin.,,15-30℃,IV Unstable angina; Venous thromboembolism; Peripheral arterial embolism Loading dose: 5，000 u， then 1，000-2，000 u/hr. Prevention of re-occlusion of the coronary arteries following thrombolytic therapy in MI 5，000 u， then 1，000 u/hr w/ alteplase. SC Venous thromboembolism 15，000 u 12 hrly. Prophylaxis of post-op venous thromboembolism 5，000 u 2 hr before surgery， then 8-12 hrly for 7 days or until patient is ambulant. Prevention of mural thrombosis 12，500 u 12 hrly for at least 10 days,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,1.未稀釋亦可使用
IHBIG,Hepatitis B Immune Globulin,HBIG (B肝免疫球蛋白，政府提供) 0.5mL/dose,HIMM,Prophylaxis of hepatitis B.,Severe platelet deficiency or other coagulation disorders.,Occasionally temporary tenderness at inj site， skin reactions & elevations of temperature.,2-8℃避免冷凍,IM， acute exposure to blood containing HBsAg 0.06 mL/kg within 24 hours. Prophylaxis of infants born to HBsAg & HBeAg postive mothers 0.5 mL to be given within 12 hours of birth. Sexual exposure to an HBsAg postive person 0.06 mL/kg as a single dose within 14 days of sexual contact. Household exposure to persons with acute HBV infection Infants < 12 months 0.5 mL.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,[仿單]孕婦使用後是否會傷害胎兒、或影響生殖能力也不太清楚，唯有明確需要時才可投與。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,
ODAL3,Flurazepam,Dalmadorm 30mg,CNEU,,,,,,,,,,,,,,,,,,,
OPROG,Progesterone,Progeffik 100mg,HM,,適應症: Progesterone eficiency， Luteal insufficiency: premenstrual syndrome， benign mastopathy， menstrual irregularities， Prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogen HRT ， Oocyte donation programme from the day of transfer till pregnancy is confirmed， Luteal support in IVF or embryo transfer starting with the day of inj of hCG up to the 12th week of pregnancy， Repeated abortions up to the 12th week of pregnancy. 副作用: Abdominal pain， perineal pain， headache， constipation， diarrhea， nausea， joint pain， depression， decreased libido， nervousness， somnolence， breast tenderness & pain， dyspareunia， nocturia， allergy， bloating， cramps， fatigue， pain， dizziness， vomiting， genital moniliasis & pruritus， aggressive reactions， forgetfulness， vag dryness， cystitis， UTI， vag discharge. Gastrointestinal: Abdominal pain (oral， 10% to 20%; vaginal gel， 5% to 12%; vaginal insert， 12% )， Constipation (vaginal gel， 27%; vaginal insert， 2% to 3% )， Nausea (oral， 8%; vaginal gel， 6% to 22%; vaginal insert; 7% to 8% ) Immunologic: Viral disease (oral， 7% to 12% ) Musculoskeletal: Cramp (vaginal gel， 15% to 26% ) Neurologic: Dizziness (oral， 15% to 24%; vaginal gel， 5% )， Headache (oral， 10% to 31%; vaginal gel， 13% to 19%， vaginal insert， 3% to 4% )， Sleep disorder (vaginal gel， 18% )， Somnolence (vaginal gel， 27% ) Psychiatric: Depression (oral， 19%; vaginal gel， 11% to 19% )， Feeling nervous (vaginal gel， 16% )， Mood swings (oral， 6%; vaginal gel， 22% to 23% ) Reproductive: Breast tenderness (oral， 16% to 27% )， Large breast (vaginal gel， 40% )， Pain， Post-oocyte retrieval (vaginal insert， 25% to 28% )， Pain of breast (oral， 6% to 16%; vaginal gel， 13% )， Perineal pain (vaginal gel， 17% ) Other: Fatigue (oral， 8% to 9%; vaginal gel， 21% to 22%; vaginal insert， 2% to 3% ) 禁忌: Undiagnosed vag bleeding; known or suspected malignancy of breast or genital organs; severe liver dysfunction or disease; thrombophlebitis， thromboembolic disorders， cerebral apoplexy or patients with a history of these conditions; missed abortion; as a diagnostic test for pregnancy.,,室溫,Revention: 200-400 mg q8h on the 1st day， then 100-200 mg q8h afterward till 36th week of pregnancy. Supplement: 100-200 mg hs x 10-14 days (may give an extra 100 mg in the morning if needed) starting from the 12th day of the menstrual cycle.,,,,可能安全,,,,,,,,,,
ESER1,Salmeterol + Fluticasone,SERETIDE 125 EVOHALER,ERSP,Regular treatment of reversible obstructive airways disease (ROAD)， including asthma in adult & children， where combination therapy (bronchodilator & inhaled corticosteroid) is appropriate. Seretide Accuhaler 250/Seretide Evohaler 125/Seretide Evohaler 250 Maintenance treatment of COPD including chronic bronchitis & emphysema.,History of hypersensitivity to any of the ingredients of Seretide.,Hoarseness or dysphonia， throat irritation， headache， candidiasis of mouth & throat， palpitations， tremor， paradoxical bronchospasm， arthralgia. Gastrointestinal: Nausea (COPD， above 5% )， Oral candidiasis (asthma， 1% to 4%; COPD， 10% ) Musculoskeletal: Musculoskeletal pain (asthma， 2% to 7%; COPD， 9% ) Neurologic: Dizziness (asthma， 1% to 4%; COPD， 4% and greater )， Headache (9% to 21% ) Respiratory: Bronchitis (asthma， 2% to 8% )， Cough (asthma， 3% to 6% )， Difficulty speaking， Hoarse， Pharyngitis (asthma， 10% to 13% )， Throat irritation (7% to 9% )， Upper respiratory infection (asthma， 16% to 27%; COPD， greater than 5% )， Viral lower respiratory infection (3% to 6% ),乾燥避曬30℃以下,Asthma: Adults and adolescents 12 years and older: Two inhalations of 25 mcg salmeterol and 125 mcg fluticasone propionate twice daily. or Two inhalations of 25 mcg salmeterol and 250 mcg fluticasone propionate twice daily. Children 4 years and older: 2 inhalation of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily. There are no recommended doses available in children aged under 4 years. Chronic Obstructive Pulmonary Disease (COPD): For adult patients the recommended dose is 2 inhalation 50/250 micrograms to 50/500 micrograms salmeterol/fluticasone propionate twice daily.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;INHL;,,,,,
IRECB,Epoetin beta,Recormon inj 2000IU(限洗腎室用),HEMT,Treatment of anaemia associated w/ chronic renal failure (CRF) in patients on dialysis; treatment of symptomatic renal anaemia in patient not yet undergoing dialysis. Treatment of symptomatic anaemia in adult patients w/ non-myeloid malignancies receving chemotherapy. Increasing the yield of autologous blood from patients in pre-donation programmes. Prevention of anaemia in premature infant (<34 wk; 750-1，500 g birth wt).,Hypersensitivity. Poorly controlled HTN. Patients， who in the mth preceding treatment， have suffered a MI or stroke. Unstable angina pectoris. Patients at risk of DVT.,Increased BP， increased platelet count， encephalopathy-like symptoms， thromboembolic event， rash， pruritus， urticaria or inj site reactions.,2-8℃避光,Anaemia with CRF: (Initially)SC， 3 x 20 IU/kg/week ， if the increase of hemoglobin level is inadequate (<0.25g/dL per week)， may be increased every 4 week by 3 x 20 IU/kg/week; IV， 3 x 40 IU/kg， may up to 80 IU/kg after 4 weeks， 3 times a week. (Maintenance) Half of initial dose， depend on individuals. Symptomatic anemia in patients with tumors/Multiple myeloma/Low grade non-Hodgkin’s lymphoma/Chronic lymphocytic leukemia: Initial dose of 450 IU/kg/week， may up to 900 IU/kg/week.,無需調整劑量,仿單資料： 在人類授乳期間使用本品目前僅有有限的經驗。內源性紅血球生成素會分泌進入人類的乳汁，並且 很容易為新生兒的胃腸道所吸收。應衡量餵哺母乳對兒童的效益以及使用epoetin beta治療對婦女的 效益，再做出是否要繼續或停止餵哺母乳，或是否要繼續或停止使用epoetin beta治療之決定。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,仿單資料： 動物研究並未顯示本品會對懷孕、胚胎/胎兒發育、分娩或出生後發育造成直接或間接的傷害。 就epoetin beta而言，在懷孕期間接觸到容可曼有關的所有安全性資料，都是源自上市後的使用經驗。 在一項針對現有之上市後資料所進行的探討中，並未發現任何證據顯示懷孕、胚胎/胎兒發育或出生後 發育方面的傷害作用和使用容可曼治療之間有因果上的關聯性。 不過，由於缺乏臨床研究的資料，對懷孕婦女處方本品時仍應謹慎從事。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,仿單資料： 在人類授乳期間使用本品目前僅有有限的經驗。內源性紅血球生成素會分泌進入人類的乳汁，並且 很容易為新生兒的胃腸道所吸收。應衡量餵哺母乳對兒童的效益以及使用epoetin beta治療對婦女的 效益，再做出是否要繼續或停止餵哺母乳，或是否要繼續或停止使用epoetin beta治療之決定。,IVD;IVP;IVPUSH;SC;,,,注射藥劑的時間要大於兩分鐘，血液透析病人可以在洗腎結束時經由動-靜脈婁管進行注射。,靜脈注射時，注射藥劑的時間要大於兩分鐘，血液透析病人可以在洗腎結束時經由動-靜脈婁管進行注射。,1.在沒有相容性研究的情況下，本品不可與其它藥物混合使用。 2.配製好溶液可以經由皮下或是靜脈注射使用。當使用靜脈注射時，注射藥劑的時間要大於兩分鐘，譬如說，血液透析病人可以在洗腎結束時經由動-靜脈婁管進行注射。
IRIF,Rifamycin SV,Rifocin inj 500mg/10mL,QANB,,,,,,,,,,,,,,,,,,,
EASA,Mesalazine,Asacol 500mg suppository,ALIM,Treatment of mildly to moderately active ulcerative proctitis， colitis， or proctosigmoiditis.,Patients with known or suspected hypersensitivity to salicylates or aminosalicylates or to any ingredients in the suppository vehicle. Severe renal impairment: eGFR<30mL/min/1.73m2. Severe liver impairment. Age <2 years.,Common Dermatologic: Rash (Up to 6% ; pediatrics， 5% ) Gastrointestinal: Abdominal pain (Adult， 2.2% to 18% ; pediatrics 5% or more )， Burping (16% )， Diarrhea (Adults， up to 8% ; pediatrics， 5% )， Nausea (Up to 4% )， Vomiting (Less than 1% to 5% ; pediatric， 5% or more ) Musculoskeletal: Arthralgia (Less than 3% to greater than 5% ) Neurologic: Asthenia (Less than 1% to greater than 5% )， Headache (Adults， 2.9% to 14% ; pediatrics， 5% or more ) Respiratory: Nasopharyngitis (Adults， 1.4% to 4% ; pediatrics， 15% )， Rhinitis (5% or more ) Other: Pain (Up to 14% ) Serious Cardiovascular: Myocarditis， Pericarditis Dermatologic: Generalized exanthematous pustulosis， acute， Stevens-Johnson syndrome， Toxic epidermal necrolysis Gastrointestinal: Exacerbation of ulcerative colitis (Pediatrics， 12% )， Gastrointestinal hemorrhage (2% or greater )， Pancreatitis (Less than 1% )， Rectal hemorrhage (Less than 3% to 2% or greater.) Hematologic: Agranulocytosis， Aplastic anemia， Leukopenia， Neutropenia， Pancytopenia， Thrombocytopenia (Less than 1% ) Hepatic: Cholestatic hepatitis (Less than 3% )， Hepatotoxicity， Liver failure， Sclerosing cholangitis Immunologic: Anaphylaxis， Angioedema， Drug reaction with eosinophilia and systemic symptoms， Edema of face (Less than 1% )， Hypersensitivity reaction Renal: Renal impairment Other: Infectious disease， Intolerance to drug， Syndrome,乾燥陰涼(15-25℃)處,1-2 suppository TID， after a bowel movement. The dose depends on the response.,需調整劑量,[仿單]N-acetyl-5-aminosalicylic acid及少量Mesalazine被排至乳汁，雖其臨床意義不確定。 迄今為止哺乳之相關研究有限。嬰幼兒無法排除之過敏反應，如:腹瀉。 因此，哺乳期間使用Mesalazine應判斷治療需要性大於可能發生之風險。 假如病人在治療期間出現嬰幼兒腹瀉症狀，應立即停止哺乳。,需調整劑量,沒有資料,Human data suggest low risk,[仿單]Mesalazine用於懷孕婦女之臨床研究非常有限。 有限的研究中(627位)並未發現Mesalazine對懷孕婦女或健康胎兒/新生兒造成傷害。 迄今為止還未有其他相流行病學數據。 曾有一例報告顯示，在懷孕期間長期服用高劑量(2-4g，口服)的Mesalazine，導致新生兒的腎功能衰竭。 以Mesalazine做動物口服試驗，對懷孕、胚胎/胎兒的發展並無直接或間接傷害，特別試產後發展。 懷孕期間，Mesalazine應僅限於醫師判斷治療需要性大於可能發生之風險，且應謹慎使用。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]N-acetyl-5-aminosalicylic acid及少量Mesalazine被排至乳汁，雖其臨床意義不確定。 迄今為止哺乳之相關研究有限。嬰幼兒無法排除之過敏反應，如:腹瀉。 因此，哺乳期間使用Mesalazine應判斷治療需要性大於可能發生之風險。 假如病人在治療期間出現嬰幼兒腹瀉症狀，應立即停止哺乳。,R;RECT;,,,,,1. 儲存於乾燥陰涼(15-25℃)處。 2. 請儲存於原包裝中避光保存，使用前需拆開塑膠包裝.
ODEL,Dexchlorpheniramine,Delamin 2mg,HIMM,Palliative treatment of allergic reaction.,Acute attack of asthma. Premature infants.,Drowsiness， dizziness; dry mouth. GIT disturbances. Hypotension， muscular weakness， tinnitus， euphoria， headache. CNS stimulation. Allergic reaction. Blood disorders.,25℃以下,Adult: 1 TAB. TID-QID. Children : 6-12 years 1/2 TAB. 3-6 years 1/4 TAB. TID-QID.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OBCO,Vitamin B complex,Betacom(B complex) 限自費,NUTR,,適應症: Prevention & treatment of vit B deficiency.,,室溫,Adult 2-3 tab daily， children 8-12 years 1 tab daily， 5-7 years 1/2 tab daily.,,,,安全,,,Compatible 哺乳時可使用,,,,,,,
YGLU,Glucosamine 150m,噢立喜樂葡胺300'S,NUTR,,,,,,,,,,,,,,,,,,,
OCELA,Pergolide,CELANCE 0.25mg,CNEU,,適應症:控制週期性肢體顫動、腦神經激素調整等(B019552100),,,Initially 0.05 mg daily for the first 2 days， gradually increased by 0.1 or 0.15 mg daily every 3rd day over the next 12 days . Then increase by 0.25 mg daily every 3rd day until optimal response. Max: 5 mg daily. Usually administered in divided dose 3 times/day. Dosage of concurrent l-dopa/carbidopa may be cautiously decreased during dosage titration.,,,,可能安全,,,,,,,,,,
OLOD,Zotepine,Lodopin 25mg,CNEU,,適應症: Schizophrenia. 副作用: Sleepiness， weakness， malaise， insomnia， thirst， constipation， dizziness. 禁忌:Patients with coma or circulatory collapse， patients on epinephrine， hypersensitivity to phenothiazines， suspected subcortical lesions (eg encephalitis， cerebral tumor & sequelae of brain trauma).,,室溫,Adult: 75-150 mg daily in divided doses， up to 450 mg/day,,,,沒有資料,,,,,,,,,,
INOV3,Insulin Aspart 30 + NPH 70,Novomix 30 penfill 3mL,META,,適應症:Treatment of patients with diabetes mellitus. 副作用:Hypoglycaemia， edema， refraction anomalies， hypersensitivity reactions， lipodystrophy 禁忌:Hypoglycaemia.,,2-8℃,Individualised dosage. Administered by SC inj. Penfill should be used with NovoPen 4 & NovoFine Needles,,,,沒有資料,,,Compatible 哺乳時可使用,,,,,,,
OFOX,Flavoxate,FOXate 200 mg,SGU,,適應症: Symptomatic relief of prostatitis， urinary frequency. 副作用: GI disturbances; hypersensitivity reactions; headache， sedation， vertigo， confusion; intraocular pressure. Rarely， leukopenia. 禁忌: GI hemorrhage; obstructive uropathies of the lower urinary tract. Children <12 years. Pyloric or duodenal obstruction， obstructive intestinal lesions of ileus.,,室溫,Adult:1 tab tid.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IFIB,Sodium Tetradecyl Sulphate,FIBRO-VEIN inj 3%， 5mL,ZOTH,,,,,,,,,,,,,,,,,,,
IPUR3,Follitropin beta,PUREGON cartridge 300IU,HM,,適應症:Treatment of female infertility due to anovulation in women who have been unresponsive to treatment with clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs. 副作用:Ovarian hyperstimulation， bruising， pain， redness， swelling & itching， ectopic pregnancy， multiple gestations， arterio-thromboembolisms. 禁忌:Ovarian， breast， uterine， pituitary or hypothalamic tumours. Pregnancy or lactation. Undiagnosed vag bleeding. Primary ovarian failure. Ovarian cysts or enlarged ovaries， not related to polycystic ovarian disease (PCOD). Sexual organ malformations incompatible with pregnancy. Uterine fibroid tumours incompatible with pregnancy.,,2 ~ 8 °C,Anovulation 50 iu daily， maintained for at least 7 days. Controlled ovarian hyperstimulation in medically assisted reproduction programs Starting dose of 100-225 iu for at least the 1st 4 days,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,SC;,,,,,1. 本藥品是注射匣設計，與注射筆配合使用。
IDEX,Low Molecular Dextran Dextrose,Dextran (血賜多朗滴) inj 500mL,HEMT,As plasma expander in haemorrhage.,Hypersensitivity. Severe renal disease with oliguria or anuria. Marked cardiac decompensation. Pregnancy.,GI disturbances; headache， dizziness; allergic reactions; raised liver enzyme values; alopecia; bone marrow suppression.,30℃以下,Normally IV 500mL one time. IV 20 mL/kg on the first 24 hours. For treatment or prevention of thrombosis， 10mL/kg daily in 5 days.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,"注射速率:20~40mL/mins，Max:20mL/kg/day",1.未稀釋亦可使用 2.Max:20mL/kg/day
EGENO,Gentamicin,Gentamicin 眼藥膏 0.3%， 5gm,TOPH,,適應症: Treatment of ocular infections due to susceptible organisms. 副作用: Rarely， transient stinging. 禁忌: Hypersensitivity.,,室溫,Apply bid-tid to the affected eye(s).,無需調整劑量,,無需調整劑量,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
EGEN,Gentamicin,Gentamycin OPH sol 0.3%， 3mL,TOPH,,適應症: Bacterial inflammations of conjunctiva， cornea， lid margin & lacrimal sac; styes， corneal ulcers， corneal infections. 副作用: Irritation， pain， stinging & burning.,,室溫,1-2 drop 3-8 times daily.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
IGW250A,Glucose,配藥用 Glucose inj 5% 250mL,MSIV,,,,,配藥用子醫令,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,
ETOPC,Fluocinonide,Topsym 軟膏5gm (自費),TDER,,適應症: Eczema; dermatitis; psoriasis; vitiligo; alopecia; pustulosis; prurigo. 副作用: Burning， itching， irritation， dryness; perioral dermatitis; allergic contact dermatitis; skin atrophy. 禁忌: Vaccinia & varicella.,,室溫,Apply once-tid.,,,,沒有資料,,,,,,,,,,
OAVA2,Rosiglitazone + Metformin,AvandaMet 2mg/500mg,META,,適應症: Type 2 DM. 副作用:Upper resp tract infection， headache， back pain， hyperglycemia， fatigue， sinusitis， diarrhea， viral infection， arthralgia. Anaemia. Rosiglitazone: Hypoglycaemia， oedema， anaemia， hypercholesterolaemia， dose-related wt gain， CHF， pulmonary oedema， pleural effusions. Metformin: Nausea， vomiting， diarrhoea， abdominal pain， loss of appetite， metallic taste. Cardiovascular: Edema (6% to 25% ) Endocrine metabolic: Hypoglycemia (12% ) Gastrointestinal: Diarrhea (12.7% to 14%) Hematologic: Anemia (4% to 7.1% ) 禁忌: ketoacidosis or pre-coma， renal failure. 衛生署公告(99.10.14) 1.不建議該成分(rosiglitazone)使用於缺血性心臟病之病人。 2.不建議該成分使用於心臟衰竭之病人。 3.禁用於心衰竭第3級或第4級(NYHA Class III or IV cardiac status )病人,,室溫,starting does : 2/ 500 mg daily. max daily dose: 8 / 2000 mg.,,,,除非治療上需要,,,,,,,,,,
ETRI,Fluocinolone + Hydroquinone + Tretinoin,TRI-LUMA cream 15gm,TDER,,適應症: Short-term treatment of moderate to severe melasma of the face， in the presence of measures for sun avoidance， including the use of sunscreens. 副作用: Erythema， desquamation， burning， dryness & pruritus at the site of application. 禁忌: Individuals with a history of hypersensitivity， allergy， or intolerance to Tri-Luma or any of its components.,,室溫,Apply a thin film of cream to hyperpigmented areas of melasma including about 0.5 inch of normal appearing skin surrounding each lesion. Rub lightly & uniformly into the skin. Apply once daily at night 30 minutes before bedtime.,,,,沒有資料,,,,,,,,,,
OSES,Timepidium,Sesden 30mg,ALIM,,適應症: Pain associated with smooth muscle spasm eg. gastritis， peptic ulcer， enteritis， gallbladder & bile-duct diseases; lithangiuria， pancreatitis. 副作用: Rarely shock; photophobia， visual disturbances; headache， dizziness， lightheadedness， drowsiness; dry mouth， nausea， vomiting， constipation， anorexia， abdominal distention; palpitation， tachycardia; hypersensitivity reactions; difficulty in micturition， dysuria; flushing & lassitude. 禁忌: Glaucoma; dysuria; severe cardiac disease; paralytic ileus.,,室溫,30 mg tid.,,,,沒有資料,,,,,,,,,,
IGS5A,Dextrose + Sodium Chloride,配藥用 5%Dextrose in 0.9% NaCl 500mL,MSIV,,,,,,,,,,,,,,IVD;,,,,,
OARC,Etoricoxib,Arcoxia 60mg,CNEU,Acute & chronic treatment of the signs & symptoms of osteoarthritis (OA) & rheumatoid arthritis (RA); acute gouty arthritis; primary dysmenorrhea.,CHF (NYHA II-IV)， established ischemic heart disease &/or cerebrovascular disease (including those who have recently undergone coronary artery bypass graft surgery or angioplasty). Patient with coronary artery bypass graft (CABG) in 14 days.,Asthenia/fatigue， dizziness， lower extremity edema， hypertension， dyspepsia， heartburn， nausea， headache， increased ALT & AST levels. Also， hypersensitivity reactions， dysgeusia， CHF， abdominal pain， peptic ulceration & bleeding， vomiting， angioedema， pruritus， rash， urticaria， renal insufficiency.,30℃以下,Osteoarthritis: 30mg or 60mg QD Rheumatoid arthritis: 60mg or 90mg QD Ankylosing spondylitis: 60mg or 90mg QD Acute gouty arthritis: 120mg QD， treatment should not exceed 8 days Primary menstrual pain: 120mg QD， treatment should not exceed 8 days Pain relief after dental surgery: 90mg， treatment should not exceed 3 days Pain relief after gynecological surgery: 90mg or 120mg QD， treatment should not exceed 5 days No dose adjustment is required based on age， gender or race.,需調整劑量,[仿單]Etoricoxib 會分泌進入授乳大鼠的乳汁中，目前尚不確知本藥是否會分泌進入人類的乳汁。由於許多藥物都會分泌進入人類乳汁，而且餵哺母乳的嬰兒可能會因本藥抑制前列腺素合成而產生副作用，因此，應謹慎考慮本藥對母親的重要性，並據以決定要停止餵哺母乳或是停用本藥。,無需調整劑量,沒有資料,Uknown 沒有資料,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少；妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。 [仿單] 和其他已知會抑制前列腺素合成的藥物一樣，在懷孕約30週或之後應避免使用ARCOXIA，因為可能會導致動脈導管過早閉鎖。在懷孕20週或之後接受NSAIDs治療的孕婦曾被報導有胎兒腎功能異常導致羊水量減少(羊水過少)。在某些情況下，這可能會導致新生兒腎功能異常。平均而言，此類作用可能在NSAID治療開始數天至數週後發生，但在頻率極低的情況下曾通報於開始使用NSAID後48小時內；羊水過少通常(但並非總是如此)可於治療中斷後逆轉。長時間羊水過少的併發症可能包括例如肢體攣縮和延遲肺成熟。在某些上市後新生兒腎功能不全的個案中，需要進行侵入性程序，例如交換輸血或透析。不建議懷孕20週之後的孕婦使用ARCOXIA；如果發生羊水過少，請停用ARCOXIA，並根據臨床實務進行追蹤。 以兔子所進行的生殖研究顯示，在高達15 mg/kg/day的劑量下(全身 暴藥量約為人類劑量[90毫克]的1.5倍)，並未出現任何發育異常的 跡象。在全身暴藥量約為2倍成人劑量(90毫克)的etoricoxib治療的 雌兔，觀察到其心血管畸形但發生率低，亦見增加著床後流產(post implantation loss)。而以全身暴藥量約等於或小於人類每日劑量(90 毫克)，未觀察到對發育有影響。不過，動物生殖研究並不一定能預 測人類的反應。目前並無任何適當且控制良好的孕婦研究。只有在 潛在效益確定超越對胎兒的潛在危險時，才可於懷孕的最初20週期 間使用ARCOXIA。,Unknown 沒有資料,[仿單]Etoricoxib 會分泌進入授乳大鼠的乳汁中，目前尚不確知本藥是否會分泌進入人類的乳汁。由於許多藥物都會分泌進入人類乳汁，而且餵哺母乳的嬰兒可能會因本藥抑制前列腺素合成而產生副作用，因此，應謹慎考慮本藥對母親的重要性，並據以決定要停止餵哺母乳或是停用本藥。,AC;AC15;PC;PO;WM;,,,,,
EIND,Indomethacin,Indomethacin supp 50mg,CNEU,,適應症: Alleviation of pain. 副作用: GI upsets， headache， dizziness， tinnitus， lightheadedness， depression， insomnia， psychiatric disturbances， peripheral neuropathy， blurred vision， confusion; hyperglycaemia， hyperkalaemia. Gastrointestinal: Abdominal pain (1% to 3% )， Constipation (1% to 3% )， Diarrhea (1% to 3% )， Indigestion (3% to 9% )， Nausea (3% to 9% ) Neurologic: Dizziness， Headache， Somnolence Otic: Tinnitus Psychiatric: Depression Other: Fatigue 禁忌: Active peptic ulcer; pregnancy (3rd trimester)， hypersensitivity to aspirin and other NSAIDs; treatment of perioperative pain in CABG surgery; severe renal impairment; rectal admin in patients with proctitis and haemorrhoids; neonates with necrotizing enterocolitis， active bleeding， thrombocytopenia， coagulation defects and untreated infections.,,室溫,50-100 mg qd.,無需調整劑量,,無需調整劑量,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,RECT;,,,,,
ODIVI,Estradiol + Medroxyprogesterone,Diviseq 28's/pk,HM,,I: Signs & symptoms of naturally or surgically induced estrogen deficiency due to monopause. 副作用: GI disturbances， nausea， vomiting， weight gain， breast tenderness， decreased libido， headache， chloasma， itching. CI: known， suspected or past history of breast carcinoma， pregnancy. Undiagnosed abnormal gentital bleeding. Known or suspected estrogen-dependent neoplasia. Active thrombophlebitis or thromboembolic disorders. Application on the breast & vulvar mucosa areas. Acute or chronic liver disease， porphyria.,,室溫,1 tab daily in a 28-day cycle.,,,,不可使用,,,,,,,,,,
OACEO,Acemetacin,ACEO 90mg,CNEU,,Analgesia， antipyresis， anti-inflammatory， actue gout.,,,1-2 tab daily Acute gout: 180 mg (1 tab BID) until pain is relieved.,,,,,,,,,,,,,,
OPAN3,Nefopam,Panagesic 30mg,CNEU,,適應症: Acute & chronic pain including post-op， dental， musculoskeletal， acute traumatic & cancer pain. 副作用: Nausea， vomiting， nervousness， dry mouth & light-headedness， blurred vision， drowsiness， sweating， insomnia， headache， tachycardia. 禁忌: History of convulsive disorders or those taking MAOI. Pregnancy.,,室溫,Adult: 1 tab tid-qid In severe pain， single dose can be increased to 90 mg. Max recommanded dose in 24 hr: 300 mg,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IGEL,Succinylated Gelatin,Gelofusine 500mL， 4%,HEMT,Primary vol replacement in hypovolaemia & shock due to acute blood or fluid loss， burns & sepsis; prophylaxis of hypotension during epidural or spinal anaesth; haemodilution & autologous transfusion; extracorporeal circulation (haemodialysis， heart lung machine).,Hypervolemia; hyperhydration; severe cardiac insufficiency; severe bleeding disorders; severe renal insufficiency.,As with all colloidal vol substitutes， allergic， (anaphylactic or anaphylactoid) reactions of varying severity can occur after infusion of Gelafundin/Gelofusine.,25℃以下,Compensation of minor losses of blood or plasma， pre- & intraoperative routine prophylaxis 500-1，000 mL infused over 1-3 hr. Major losses of blood or plasma Average dose is between 1，000 & 2，000 mL. Emergency situations or shock conditions Initially 500 mL administered by forced infusion over 5-10 mins. Thereafter， the infusion can be continued with doses corresponding to actual losses of blood or plasma. During extracorporal circulation Normally， between 500-1，000 mL.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,500~1000 mL 滴注超過 1-3 hs,此產品廠商未做相容性試驗，故不建議稀釋使用
ICRA,Levofloxacin,Cravit 針劑 500mg/100mL,QANB,,適應症: Respiratory tract， ENT， GUT infection. Intrauterine infections， cervicitis， uterine adnesxitis， folliculitis. GIT infections， lymphangitis， mild to moderate skin & skin tissue infections. 副作用: Dizziness， GI disturbances， rash， pruritus， vaginitis， genital moniliasis， taste perversion， insomnia， tendinitis. Rarely， anaphylactic reactions， Lyell's syndrome， Stevens-Johnson's syndrome. Gastrointestinal: Diarrhea (ophthalmic， 1% to 2%; oral or intravenous， 5% )， Nausea (ophthalmic， 1% to 2%; oral or intravenous， 7% ) Neurologic: Headache (ophthalmic， 8% to 10% ; oral and intravenous， 6% ) 禁忌: Hypersensitivity to quinolones. Pregnancy & lactation. Children & growing adolescents < 18 years. Tendinitis or tendon rupture.,,室溫,adult: by slow IV infusion. Community-acquired pneumonia 500 mg once-bid. Complicated UTI 250 mg once daily Skin and soft tissue infections 500 mg bid. Dosage may be increased if necessary in severe infections. Max treatment duration: 14 days,,,,除非治療上需要,,,,,,,,,,
LAUG3,Amoxicillin + Clavulanic Acid,Augmentin糖漿 457mg/5mL， 35mL,QANB,Treatment of infections due to Staph， Strep， pneumococcus， meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract， GUT， skin & soft tissue， bone & joint. Dental infections， septic abortion， puerperal sepsis， intra-abdominal sepsis. Vial Also indicated for prophylaxis against infection which may be associated with major surgical procedures such as GI， pelvic， head & neck， cardiac， renal， joint replacement & biliary tract.,Hypersensitivity to penicillins， possible cross sensitivity with other β-lactam antibiotics. History of penicillin-associated cholestatic jaundice/hepatic dysfunction.,Diarrhea， nausea， vomiting， skin candidiasis. Uncommonly dizziness， headache， indigestion， rash， pruritus， urticaria. Rarely， reversible leucopenia， thrombocytopenia， erythema multiforme.,30℃以下且置於乾燥處。泡製成溶液後請儲存於2-8℃且不使用超過七天。不可冷凍。,Usual dose (amoxicillin/clavulanate): 25/3.6-45/6.4 mg/kg/day. Children 2 years and over: 2-6 years (13-21 kg): 2.5-5 mL twice daily; 7-12 years (22-40 kg): 5-10 mL twice daily. Children aged 2 months to under 2 years: dose according to body weight: 2 kg: 0.3-0.6 mL every 12 hours， 3 kg: 0.5-0.8 mL every 12 hours， 4 kg: 0.6-1.1 mL every 12 hours， 5 kg: 0.8-1.4 mL every 12 hours， 6 kg: 0.9-1.7 mL every 12 hours， 7 kg: 1.1-2.0 mL every 12 hours， 8 kg: 1.3-2.3 mL every 12 hours， 9 kg: 1.4-2.5 mL every 12 hours， 10 kg: 1.6-2.8 mL every 12 hours， 11 kg: 1.7-3.1 mL every 12 hours， 12 kg: 1.9-3.4 mL every 12 hours， 13 kg: 2.0-3.7 mL every 12 hours， 14 kg: 2.2-3.9 mL every 12 hours， 15 kg: 2.3-4.2 mL every 12 hours. The following Pediatric dose recommendation is from Sanford Guide to Antimicrobial Therapy.(2022/11/08): Age>28 days: 25-100mg/kg/day divided Q8-12H.,無需調整劑量,WHO: Compatible with breastfeeding Micromedex: Infant AMOXICILLIN BREASTFEEDING RECOMMENDATION: Compatible CLAVULANATE， POTASSIUM BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,需調整劑量,可能安全,Human data suggest risk in 1st and 3 rd trimesters,AMOXICILLIN PREGNANCY RECOMMENDATION: Human Data Suggest Risk in 1st and 3rd Trimesters CLAVULANATE， POTASSIUM PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,WHO: Compatible with breastfeeding Micromedex: Infant AMOXICILLIN BREASTFEEDING RECOMMENDATION: Compatible CLAVULANATE， POTASSIUM BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,AC;AC15;PC;PO;WM;,,,,,
OAUG1,Amoxicillin + Clavulanic Acid,AUGMENTIN 1gm,QANB,,適應症:Treatment of infections due to Staph， Strep， pneumococcus， meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract， GUT， skin & soft tissue， bone & joint. Dental infections， septic abortion， puerperal sepsis， intra-abdominal sepsis. 副作用:Diarrhea， nausea， vomiting， mucocutaneous candidiasis. Dermatologic: Diaper rash (3.5% )， Rash (1.1% to 3% ) Gastrointestinal: Diarrhea (2.9% to 14.5% )， Loose stool (1.6% )， Nausea (2.1% to 3% )， Vomiting (1% to 2.2% ) Reproductive: Mycosis (3.3% )， Vaginitis (1% ) Other: Candidiasis (1.4% ) 禁忌:History of hypersensitivity to β-lactams. History of penicillin-associated jaundice/hepatic dysfunction.,,室溫,(Amoxicillin 875 mg and clavulanate 125 mg per Tab) Acute otitis media: (immediate-release tablets， suspension) severe infections， 875 mg ORALLY every 12 hr Infection of skin AND/OR subcutaneous tissue: (immediate-release tablets， suspension) severe infections， 875 mg ORALLY every 12 hr Lower respiratory tract infection: (immediate-release tablets， suspension) 875 mg ORALLY every 12 hr Sinusitis: (initial empiric therapy) 875 mg/125 mg ORALLY twice daily for 5 to 7 days Urinary tract infectious disease: (immediate-release tablets， suspension) severe infections， 875 mg ORALLY every 12 hr Acute otitis media: severe infections or treatment failure， 90 mg/kg/day (amoxicillin component) ORALLY in 2 divided doses for 10 days Acute otitis media:3 months and older and under 40 kg， 25 to 45 mg/kg/day (amoxicillin component) ORALLY divided every 12 hr for 10 days， depending on severity of infection Acute otitis media: (immediate-release tablets， suspension) severe infections， 40 kg and greater; 875 mg ORALLY every 12 hr Infection of skin AND/OR subcutaneous tissue: 3 months and older and under 40 kg， 25 to 45 mg/kg/day (amoxicillin component) ORALLY divided every 12 hr， depending on severity of infection Infection of skin AND/OR subcutaneous tissue: (immediate-release tablets， suspension) severe infections， 40 kg and greater; 875 mg ORALLY every 12 hr Lower respiratory tract infection:3 months and older and under 40 kg， 25 to 45 mg/kg/day (based on amoxicillin component) ORALLY divided every 12 hr， depending on severity of infection Lower respiratory tract infection: 40 kg and greater; 875 mg ORALLY every 12 hr Sinusitis: (initial empiric therapy) 45 mg/kg/day (amoxicillin component) ORALLY twice daily for 10 to 14 days Sinusitis: (second-line， high-dose) 90 mg/kg/day (amoxicillin component) ORALLY twice daily Sinusitis: 3 months and older and under 40 kg， 25 to 45 mg/kg/day (amoxicillin component) ORALLY divided every 12 hours， depending on severity of infection Sinusitis: severe infections， 40 kg and greater; 875 mg (amoxicillin component) ORALLY every 12 hr Urinary tract infectious disease: 3 months and older and under 40 kg， 25 to 45 mg/kg/day (amoxicillin component) ORALLY divided every 12 hr， depending on severity of infection Urinary tract infectious disease: severe infections， 40 kg and greater; 875 mg ORALLY every 12 hr,無需調整劑量,WHO: Compatible with breastfeeding Micromedex: Infant,需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,WHO: Compatible with breastfeeding Micromedex: Infant,,,,,,
OHEPS,Adefovir Dipivoxil,Hepsera 10mg,QANB,,適應症:Treatment of chronic hepatitis B in adults with evidence of hepatitis B viral replication. 副作用： Neurologic: Asthenia (13% ) Renal: Serum creatinine raised,,室溫,Adult 18-65 years 10 mg once daily.,,Contraindicated (HIV),,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Contraindicated (HIV),,,,,,
OCRE,Rosuvastatin,Crestor 10mg,CAVS,Treatment of primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet & other non-pharmacological measures are inadequate. Treatment of homozygous familial hypercholesterolaemia， either alone or as an adjunct to diet & other non-pharmacological (e.g. exercise， weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.,Active liver disease including unexplained， persistent elevations of serum transaminases & any serum transaminase elevation exceeding 3 times the upper limit of normal; severe renal impairment (creatinine clearance <30 mL/min)， myopathy; patients on concomitant cyclosporin; pregnancy & lactation.,Constipation， nausea， abdominal pain， headache， dizziness， myalgia， asthenia. Gastrointestinal: Abdominal pain (2.4% )， Nausea (2% to 3.4% ) Musculoskeletal: Arthralgia (10.1% )， Myalgia (2.8% to 12.7% ， ) Neurologic: Asthenia (0.9% to 4.7% )， Headache (3.1% to 5.5% ) Renal: Urinary tract infectious disease (2.3% .),30℃以下,Adult and children (10-17 years): 5-20 mg orally once daily with or without food.,需調整劑量,,需調整劑量,不可使用,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,
OAMD,Alum Hydroxide + Mag Hydroxide + Dimethylpolysilox,A.M.D.,ALIM,,I: Hyperacidity， functional gastric bloating， gastritis， flatulence.,,RT,2 tab tid~qid pc 1hr.,,,,可能安全,,,,,,,,,,
OGOW,Dihydroxyalumium Allantoinate + Metamagnesium Alum,Gowell,ALIM,,I: Hyperacidity， peptic and doudenal ulcer， gastritis， flatulence.,,RT,2 tab tid pc 1hr.,,,,沒有資料,,,,,,,,,,
OMEI,Diclofenac,Meitifen SR 75mg,CNEU,,I: An analgesic， antipyretic， anti-inflammatory agents used in RA. and other rheumatic disorders. ADR: Occasionally， GI disorders; edema; headache， dizziness， vertigo; rash. Rarely， peptic ulcer， GI bleeding; hepatitis. Blood disorders. CI: Peptic ulcer. Hypersensitivity to diclofenac， aspirin and other prostaglanding-synthetase inhibiting drugs.,,RT,75 mg qd - bid,,,,可能安全,,,,,,,,,,
IINF,Combined DPT+ Inactivated Polio + Hib,Infanrix-IPV+Hib(五合一疫苗),HIMM,,I: Active immunization against diphtheria， tetanus， pertussis， po-liomyelitis and Haemophilus influenzae type b caused diseases. CI: Acute febrile illness. Encephalopathy of unknown aetiology， occurring within 7 days following previous vaccination with per-tussis-containing vaccination. Hypersensitive to neomycin or any other components of this product. ADR: Redness， swelling and pain at injection site. Fever， unusual crying， vomitting diarrhea， loss of appetite， restlessness.,,2 ~ 8 °C,Deep IM. Primary immunization: complete all 3 doses before the first 6 mth of life， start from the age of 2 mth， subsequent doses at intervals > 1 mth. A reinforcing 4th dose is recommended to be given in the 2nd yr of life.,,,,沒有資料,,,,,,,,,,
OEXE,Rivastigmine,Exelon 3mg,CNEU,Mild to moderately severe dementia of the Alzheimer type.,Serious hypersensitivity to other carbamate derivatives.,Nausea， vomiting， diarrhea， abdominal pain， loss of appetite， dyspepsia， dizziness， headache. Gastrointestinal: Diarrhea (6% )， Nausea (7% )， Vomiting (6% ),30℃以下,Initially 1.5 mg BID for 2 weeks. If well tolerated， increase in increments of 1.5 mg orally twice daily at minimum of every 2 weeks. Maintenance: 3-12 mg daily. Maximun: 12 mg/day.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,PC;PO;WM;,,,,,
EARTI,Hydroxypropylmethylcellulose,Artificial tear 10mL,TOPH,,適應症:人工淚液(A034503429),,RT,D: 1-2 gtt as needed.,,,,沒有資料,,,,,,,,,,
ETIL5,Timolol,Timolast 0.5%， 5mL,TOPH,,,,,,,,,,,,,,,,,,,
ETIL2,Timolol,Timolast 0.25%， 5mL,TOPH,,,,,,,,,,,,,,,,,,,
OACET,Acetazolamide,Acetazolamide 250mg,CAVS,Management of glaucoma; edema， epilepsy.,Na or K depletion; marked kidney or liver dysfunction; suprarenal gland failure; hyper-chloremic acidosis; hepatic cirrhosis. Long-term administration in patients with chronic non-congestive angle-closure glaucoma.,Malaise， fatigue， depression， excitement; headache; weight gain; GI disturbances; drowsiness， paresthesia. Occasionally， severe metabolic acidosis (elderly， diabetic patients， impaired renal function). Rarely， blood dyscrasias; crystalluria， renal calculi & colic; renal lesions; allergic skin reactions， fever， thirst， ataxia; tinnitus， myopia， melena， haematuria， glycosuria， convulsions， hepatic insufficiency.,15-30℃,Adult usual dosage: Glaucoma， open-angle: Initial， 250 mg QD-QID. Glaucoma， secondary or preoperative treatment to reduce intraocular pressure: 250 mg BID to Q4H， or 500 mg initial dose followed by 125 or 250 mg every 4 hours. Epilepsy: 8-30 mg/kg daily in divided doses， optimum range: 375-1000 mg daily. Edema: 5 mg/kg (usual dosage: 250 to 375 mg) QD in the morning for 1 or 2 days， alternating with a day of rest. [Micromedex 2021/06/17] Acute mountain sickness; Treatment and Prophylaxis: 500-1000 mg daily， in divided doses; during rapid ascent， 1000 mg/day is recommended; initiate 24-48 hours before ascent and continue for 48 hours or longer while at high altitude. Pediatric usual dosage: Glaucoma: 8-30 mg/kg (usual dosage: 10-15 mg/kg) or 300-900 mg/m2 daily in divided doses. Epilepsy: 8-30 mg/kg daily in divided doses. Edema: 5 mg/kg or 150 mg/m2 QD in the morning for 1 or 2 days， alternating with a day of rest.,無需調整劑量,,需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
IOLI2,TPN Solution,Oliclinomel N7-1000E 1500mL,NUTR,,適應症: Parenteral nutrition for adults and children > 2 years when oral or enteral nutrition is impossible， insufficient or contraindicated. 副作用:Hyperthermia， excessive sweating， tremors， nause， headaches， dyspnea. 禁忌:Use in premature neonates， infants & children < 2 years. Severe renal failure without the possibility of hemofiltration or dialysis. Severe hepatic insufficiency， blood coagulation disorder or hyperlipidemia. Congenital abnormalities of amino acid metabolism. Hyperglycemia which requires >6 u insulin/hr.,,RT,By IV administration through a central vein. Adult Average nitrogen requirements: 0.16-0.35 g/kg/day (approximately 1-2 g of amino acids/kg/day). Average energy requirements: 25-40 kcal/kg/day. Max daily dose: 40 mL/kg. Children > 2 years Average nitrogen requirements: 0.35-0.45 g/kg/day (approximately 2-3 g of amino acids/kg/day). Average energy requirements: 60-110 kCal/kg/day. Max daily dose: 75 mL/kg.,,,,沒有資料,,,,,,,,,,
OEME,Domperidone,Emetrol (DMP) 10 mg,ALIM,,適應症: Nausea， vomiting & flatulence. 副作用: Rarely， transient abdominal cramps. Raised prolactin levels,,室溫,,,,,除非治療上需要,,,,,,,,,,
OMOB1,Meloxicam,Mobic 15mg,CNEU,,適應症: Painful osteoarthritis， rheumatoid arthritis， ankylosing spondylitis. 副作用: Dyspepsia， nausea， vomiting， abdominal pain， constipation， flatulence， diarrhoea， anaemia， pruritus， rash， lightheadedness， headache， oedema. Cardiovascular: Edema (0.6% to 4.5% ) Gastrointestinal: Abdominal pain (1.9% to 4.7% )， Constipation (0.8% to 2.6% )， Diarrhea (1.9% to 7.8% )， Flatulence (3.2% )， Indigestion (3.8% to 9.5% )， Nausea (2.4% to 7.2% )， Vomiting Neurologic: Dizziness (1.1% to 3.8% )， Headache (2.4% to 8.3% ) Respiratory: Upper respiratory infection (up to 8.3% ) Other: Fever 禁忌: Hypersensitivity to NSAIDs or aspirin. Active peptic ulceration， severe hepatic insufficiency， non-dialysed severe renal insufficiency. Children < 15 years. Pregnancy & lactation.,,室溫,Osteoarthritis 7.5 mg/day. May be increased to 15 mg/day. RA 15 mg/day. May be reduced to 7.5 mg/day. Ankylosing spondylitis 15 mg/day. Max: 15 mg/day.,,,,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
LWEM,Domperidone,Wempty 1mg/mL， 60mL suspension,ALIM,Symptomatic treatment of nausea & vomiting， diabetic gastroparesis.,Prolactinoma; co-administration with ketoconazole; GI hemorrhage， mechanical obstruction， perforation.,Rarely hypersensitivity reactions， raised serum prolactin levels， extrapyramidal reactions; GI abnormalities， urticaria， galactorrhea， gynecomastia， menstrual irregularity.,25℃以下，不需冰存並避免陽光直射,Adult & > 12 years with > 35 kg: 10 mg before meal or before bed time 15~30 minuts. up to 3 times a day. Children < 12 years or body weight < 35 kg: 0.25 mg/kg each time. up to 3 times a day.,無需調整劑量,,需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
OCEF1,Cefixime,Cefspan 100mg,QANB,,適應症: 細菌性感染(A033225100) Bronchitis， infected bronchiectasis， secondary infections of chronic respiratory tract diseases， pneumonia; pyelonephritis， cystitis， gonococcal urethritis; otitis media， sinusitis. 副作用: Shock， hypersensitivity， haematologic disorders， GI disorders， vit K deficiency. 禁忌: Hypersensitivity to cephalosporins. Infant <6 months.,,室溫,Adult & child over 30 kg: 50-100 mg q12h， up to 200 mg q12h. Child: 3-9.9 mg/kg/day devide 2~3 times， up to 6 mg/kg q12h Gonorrhea a) uncomplicated， 400 mg ORALLY as one-time dose,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
OCLE,Clindamycin,Cleocin 150mg,QANB,,Serious clindamycin-sensitive infections.,,,Adult: 150-450 mg q6h. Child: 8-25 mg/kg/day in 3-4 divided doses.,,,,可能安全,,,,,,,,,,
OKLA,Clarithromycin,Klaricid 250mg,QANB,,Upper & lower resp tract，uncomplicated skin & skin structure infections.Eradication of H. pylori in patient with duodenal ulcer when use with omeprazole.,,,250-500 mg bid. Eradication of H. pylori inpatient with duodenal ulcer: Adult& elderly 250mg bid for 14 days. Klaricid should be given with oral omeprazole 40 mg qd. Renal impairment if adjustment is necessary，total daily dose shoud be reduced by 1/2.,,,,除非治療上需要,,,,,,,,,,
OLUC,Silymarin,Luckyhepa 70mg (複方),ALIM,,適應症: Chronic liver diseases， liver cirrhosis， fatty liver. 副作用: GI disturbance， nausea， vomiting， flatulence， diarrhea， diuresis 禁忌: Hypersensitivity to any ingredients of the capsule.,,室溫,1-2 cap three times a days after meals. Each cap contains: Siymarin 70mg， Niacinamide 12mg， Thiamine HCl 4mg， Riboflavin 4mg， Pyridoxine HCl 4 mg， Cyanocobalamin 1.2mcg， Pantothenate Calcium 8 mg,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OMUCS,Ambroxol,Mucosolvan 30mg,ERSP,,適應症:為化痰劑(A028453100) ADR: Mild GI effects & Allergic reactions.,,RT,Adult or child over 6 yrs.: 1 tab tid. Child under 5 yrs.: 1.2-1.6 mg/kg bid-tid.,,,,沒有資料,,,,,,,,,,
OCRA5,Levofloxacin,Cravit F.C. 500mg,QANB,Respiratory tract， ENT， GUT infection. Intrauterine infections， cervicitis， uterine adnesxitis， folliculitis. GIT infections， lymphangitis， mild to moderate skin & skin tissue infections.,Hypersensitivity to quinolones. Epilepsy. History of tendon disorders related to fluoroquinolone administration. Children or growing adolescents. Pregnancy & lactation.,Common Gastrointestinal: Diarrhea (oral or intravenous， 5% )， Nausea (oral or intravenous， 7% ) Neurologic: Dizziness (3% )， Headache (6% to 10% )， Insomnia (4% ) Serious Cardiovascular: Aortic aneurysm， Or dissection， Cardiac arrest (0.1% to 1% )， Prolonged QT interval， Torsades de pointes， Ventricular tachycardia (0.1% to 1% ) Dermatologic: Erythema multiforme， Stevens-Johnson syndrome Endocrine metabolic: Hypoglycemia (0.1% to 1% ) Hematologic: Aplastic anemia， Pancytopenia， Thrombocytopenic purpura Hepatic: Hepatitis， Liver failure Immunologic: Hypersensitivity reaction (0.1% to 1% )， Non-allergic anaphylaxis Musculoskeletal: Myasthenia gravis， Exacerbation， Rupture of tendon， Tendinitis (0.1% to 1% ) Neurologic: Disorientated， Disturbance of attention， Guillain-Barre syndrome， Memory impairment， Peripheral neuropathy， Pseudotumor cerebri， Raised intracranial pressure， Seizure (0.1% to 1% ) Ophthalmic: Retinal detachment Psychiatric: Delirium， Depression (0.1% to 1% )， Hallucinations (0.1% to 1% )， Paranoid disorder， Psychotic disorder， Suicidal Renal: Acute renal failure (0.1% to 1% )， Tubulointerstitial nephritis,25℃以下,(仿單) Adult: 250-500 mg po/IV 1-2 times daily. Administer 250 mg injection over 30 minutes， 500 mg injection over 60 minutes. (熱病) Adult: 250-750 mg po/IV Q24H (depends on indication). For most indications， in patients with normal renal function， the 750 mg dose is preferred. Pediatric (age > 28 days): 16-20 mg/kg/day (divided Q12H) (maximum: 750 mg/day) For oral therapy， avoid concomitant exposure to multivalent cations (Ca， Fe， Al， Mg， Zn) in dairy products， multivitamins and antacids. Cations chelate the drug and prevent absorption.,無需調整劑量,[仿單] CravitR錠劑禁用於哺乳中的婦女。目前沒有足夠的資訊以了解levofloxacin是否會進入人類母乳中； 不過其他fluoroquinolone類的藥物會進入母乳中。 在缺乏人類資料，且Fluoroquinolones具有破壞成長生物承重軟骨的可能實驗風險的情況下， levofloxacin不應用於哺乳女性。,需調整劑量,不可使用,Contraindicated,[仿單] 關於懷孕婦女使用levofloxacin的資料，其數量相當有限，而動物實驗並沒有發現直接或間接的生殖毒性。 不過在缺乏人類資料，且實驗室的資料說明Fluoroquinolones具有破壞成長生物承重軟骨的風險， levofloxacin不應用於懷孕女性。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] CravitR錠劑禁用於哺乳中的婦女。目前沒有足夠的資訊以了解levofloxacin是否會進入人類母乳中； 不過其他fluoroquinolone類的藥物會進入母乳中。 在缺乏人類資料，且Fluoroquinolones具有破壞成長生物承重軟骨的可能實驗風險的情況下， levofloxacin不應用於哺乳女性。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議須整粒吞服，可剝半但不要咀嚼或壓碎。因廠商未有相關安定性及療效數據，若有磨粉需求請密切監測病患臨床反應。
ITHYR,Thyrotropin alfa,Thyrogen inj 1.1mg,META,Adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer. Adjunctive diagnostic tool for serum Tg testing w/ or w/o radioiodine imaging.,Hypersensitivity to thyrotropin alfa or any component of the formulation.,Nausea， vomiting， headache， asthenia， chills， fever， flu syndrome， dizziness， paresthesia.,2-8°C避光,IM， 2 injection regimen， initial 0.9 mg followed by second 0.9 mg 24 hours later.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;,IM: 1.2 mL D/W,,,,配製與給藥 1.為凍晶粉末，以1.2 mL的無菌注射用水加入含有THYROGEN凍晶粉末的注射瓶中。 2.轉動注射瓶直到內容物溶解，不可搖晃溶液，配製後的THYROGEN 溶液濃度為每mL含thyrotropin alfa 0.9 mg。 3.配製後的溶液應該是透明無色的，若溶液有雜質或混濁不清切勿使用。 4.抽出1 mL的THYROGEN配製溶液(含thyrotropin alfa 0.9 mg)進行臀部肌肉注射。 5.配製後的THYROGEN溶液若無冷藏，則必須在3小時內完成注射，若有冷藏，最多可放置24小時。 6.未用完的部分必須丟棄，不可與其他藥物混合使用。
IAHIB,Haemophilus b Conjugate Vaccine,Act-HIB inj 0.5 mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
OTAK,Lansoprazole,Takepron OD 30mg,ALIM,Gastric & duodenal ulcer， reflux esophagitis & Zollinger-Ellison syndrome. In combination of antibiotics to treat H. pylori related peptic ulcer.,Hypersensitivity to any component of the formulation.,Common: Abdominal pain (0-5%)， Constipation (1-5%)， Diarrhea (0-7.4%)， Nausea(1.3-% )， Headache (1%) Serious: Cutaneous lupus erythematosus， Erythema multiforme， Generalized exanthematous pustulosis， acute， Generalized exanthematous pustulosis， acute， Stevens-Johnson syndrome (SJS)， Toxic epidermal necrolysis (TEN)， Hypomagnesemia， Clostridium difficile diarrhea， Fundic gland polyposis of stomach， Pancreatitis， Anaphylaxis， Drug reaction with eosinophilia and systemic symptoms (DRESS)， Bone Fracture， Rhabdomyolysis， Acute tubulointerstitial nephritis,貯存於 25°C,OD tablet Gastric & duodenal ulcer， Zollinger-Ellison syndrome 30 mg once daily for 6 weeks in gastric ulcer & 8 weeks in duodenal ulcer. Reflux esophagitis 30 mg once daily for 8 weeks. Maintenance: 15 mg once daily. May adjust to 30 mg once daily is desired result is not achieved. Adjunct to eradication of H. pylori associated with gastric ulcer or duodenal ulcer lansoprazole 30 mg BID， amoxycillin 750 mg (potency) BID & clarithromycin 200 mg (potency) BID for 7 days.,需調整劑量,,無需調整劑量,可能安全,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,[磨粉/管灌註記]本藥為口溶錠。可溶水崩解後管灌。
IHIB,Haemophilus b Conjugate Vaccine,Hiberix inj 0.5 mL,HIMM,,Active immunisation of all infants > 6 weeks against disease caused by Haemophilus influenza type b,,2-8,Primary vaccination 3 doses by IM in the 1st 6 months of life. Maybe starting from the age of 6 weeks. booster dose: in 2nd years of life. Previously unvaccinated children 1-5 years 1 dose， children 6-12 months 2 dose 1 month apart， followed by 1 booster dose in 2nd years of life,,,,除非治療上需要,,,,,,,,,,
OCOU2,Warfarin,Coumadin 2.5mg,HEMT,,,,,,,,,,,,,,,,,,,
IERY,Erythromycin,Erythrocin I.V. 500mg,QANB,,,,,,,,,,,,,,,,,,,
OLEV,Vardenafil,Levitra F.C. 20mg， 4's/box,SGU,,適應症: Treatment of erectile dysfunction. 副作用: Headache， flushing， dyspepsia， nausea， dizziness， rhinitis. Dermatologic: Flushing (7.6% to 11% ) Neurologic: Dizziness (2% to 2.3% )， Headache (14.4% to 15% ) Respiratory: Rhinitis (9% ) 禁忌: Coadministration with nitrates or nitric oxide donors. Concomitant use of vardenafil with HIV protease inhibitors such as indinavir or ritonavir.,,室溫,Adult 10 mg approximately 25-60 mins before sexual activity. Max: 20 mg once daily. A max dose of 5 mg should not be exceeded when used in combination with an α-blocker， erythromycin， ketoconazole or itraconazole. Starting dose of 5 mg is recommended for elderly (over 65 years).,,,,可能安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OMON1,Fosinopril,Monopril 10mg,CAVS,,,,,,,,,,,,,,,,,,,
OMODI,Flunitrazepam,Modipanol 2mg,CNEU,,適應症: Insomnia. 副作用: Drowsiness & lightheadedness the next day; confusion & ataxia; dependence. 禁忌: Respiratory depression; acute pulmonary insufficiency; severe hepatic impairment， myasthenia gravis， sleep apnoea syndrome.,,室溫,Adult 0.5-1 mg at bedtime. Max: 2 mg/day. Elderly or debilitated patients Initially 0.5 mg at bedtime. Max: 1 mg/day.,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IBUR,Bumetanide,Burinex inj 2mg/4mL,CAVS,,適應症: Edema associated with CHF， liver cirrhosis， renal diseases. Acute pulmonary edema， drug-induced fluid retention， drug poisoning that can be treated by forced diuresis. Hypertension. 副作用: Hypokalemia & hypochloremic alkalosis (long-term therapy); muscular cramps in patients with severe chronic renal failure; asymptomatic hyperuricemia. Rarely， skin rashes， depression of formed elements in the blood; abdominal discomfort. 禁忌: Hepatic coma， severe electrolyte depletion， concurrent administration with lithium， anuria.,,室溫,adult: Edema: 0.5-2 mg ORALLY daily， maximum 10 mg/day Edema: 0.5-1 mg IV or IM， given over 1-2 min; can give a second and third dose at intervals of 2-3 hr to maximum of 10 mg/day pediatric: Not FDA-approved in children less than 18 years of age Edema: (over 6 months) 0.015-0.1 mg/kg/dose ORALLY， IV， or IM every 6-24 hrs; max dose 10 mg/day Edema: (neonates) 0.01-0.05 mg/kg/dose ORALLY， IV， OR IM every 24 to 28 hrs.,,,,除非治療上需要,,,,,,,,,,
OMOP,Mosapride,Mopride 5mg,ALIM,Treatment of GI motility disorders e.g. heartburn， nausea &/or vomiting.,GI hemorrhage， mechanical obstruction， or perforation.,Hypersensitivity reactions， rash， urticaria， hematological changes， GI disturbances， increased hepatic enzyme levels. Palpitation， dizziness， headache， fatigue， hypertriglyceridemia， tremor.,25℃以下,Adult 15 mg/day in 3 divided doses.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;,,,,,
OSB,Benzoate,Sod. Benzoate 250 mg,META,,適應症: Nonketotic hyperglycinemia. 副作用: GI discomfort.,,室溫,initial dose: 250 mg/kg/day divided into 3-6 times up to 750 mg/kg/day if necessary max dose: 10 gm/day,,,,沒有資料,,,,,,,,,,
OONEH,Alfacalcidol,Onealfa 0.5mcg(腎臟內科使用),META,,適應症:為維他命D3製劑(B018274100)(B023031100),,RT,Osteoporosis: Adult: 0.5-1 mcg qd. Child: 0.01-0.03 mcg/kg qd. Hypoparathyroidism: 1-4 mcg qd.,,,,安全,,,,,,,,,,
OOSC5,Ca Carbonate from Oyster Shell,Stanley Calcium(Ca= 500mg),ALIM,,Calcium supplement.,,,1-2 cap tid.,,,,,,,,,,,,,,
OPER,Dipyridamole,Persantin S.C. 50mg,HEMT,,適應症: Coronary insufficiency， Inhibition of platelet aggregation. 副作用: Worsening of angina， flushing， dizziness， palpitations. Lightheadedness， headache， asthenia， hypersensitivity reactions. GI disturbances. Cardiovascular: Electrocardiogram abnormal (15.9%)， Hypotension， IV (4.6%) Gastrointestinal: Abdominal discomfort， Oral (6.1%)， Nausea， IV (4.6%) Neurologic: Dizziness (12%)， Headache， IV (12.2%)， Headache， Oral (2.3%),,室溫,Adult: Coronary insufficiency :150-225mg daily in divided doses. Inhibition of platelet aggregation : 300- 450mg daily in divided doses. Childn in general， 5-10mg/kg body weight.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OPZAT,Pyrazinamide,Pyrazinamide 500mg,QANB,,適應症: Treatment of pulmonary & extrapulmonary TB. 副作用: Hepatotoxicity， jaundice， hyperuricemia leading to attacks of gout， anorexia， nausea， vomiting， arthralgia， malaise， fever， sideroblastic anemia， difficulty in micturition. Endocrine metabolic: Hyperuricemia Gastrointestinal: Nausea， Vomiting Musculoskeletal: Arthralgia (40%) 禁忌: Hypersensitivity to pyrazinamide or any component of the formulation; acute gout; severe hepatic damage,,室溫,Always administer in combination with other antitubercular drugs. 20-35 mg/kg daily in 3-4 divided doses. (max. 3 gm/day).,無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OPON,Mefenamic Acid,Ponstan 250mg,CNEU,Mild to moderate pain， RA， osteoarthritis， dysmenorrhea， menorrhagia， Still's disease， pyrexia.,Patients in whom aspirin and/or other NSAIDs have induced symptoms of bronchospasm， allergic rhinitis or urticaria. Active ulceration or chronic inflammation of GIT. Kidney disease. Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Severe renal， hepatic & heart failure.,Hematologic disorders; hypersensitivity reactions; glucose intolerance in diabetic patients， hyponatremia; nervousness; aseptic meningitis， blurred vision， convulsion， dizziness， drowsiness， headache， insomnia; eye irritation， reversible loss of color vision; ear pain; palpitation; hypotension; asthma， dyspnea; abdominal pain， diarrhea， nausea with or without vomiting; skin & SC tissue disorders; dysuria， hematuria， renal failure including papillary necrosis. Cardiovascular: Edema Hepatic: Increased liver function test (up to 15%),15-30℃,Adult and teenagers >14 years old: 500 mg TID. Still's Disease or antipyretic therapy for children of 6 months to 14 years old: 19.5-25mg/kg/day divided into 3 doses.,無需調整劑量,[仿單] 微量的mefenamic acid可能會分泌至乳汁中，而進入吃母奶的嬰兒體內， 因此授乳的母親不可以服用本藥。,需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,[仿單] 因無足夠且控制良好的研究，所以只有在對母親的潛在效益超過對胎兒可能造成的危險時，方可在懷孕期間使用本藥。 Mefenamic acid或它的代謝產物能不能通過胎盤仍未知。由於此類藥物會影響胎兒CV系統（例如早發性動脈導管閉鎖），所以不建議在懷孕期間使用本藥，且應避免在懷孕後期使用。 Mefenamic acid抑制前列腺素合成，在懷孕後期給藥可能會造成懷孕期延長，而且妨礙分娩。流行病學研究的數據顯示在懷孕初期使用前列腺素合成抑制劑後導致自然流產的危險性增加。 NSAID若使用於懷孕中期或後期，可能會引起胎兒腎臟功能不全，嚴重時會造成羊水量減少或羊水過少。此類作用會發生於開始治療後不久，停藥後一般具可逆性。懷孕女性接受mefenamic acid治療時，應密切監測羊水量。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 微量的mefenamic acid可能會分泌至乳汁中，而進入吃母奶的嬰兒體內， 因此授乳的母親不可以服用本藥。,PC;PO;WM;,,,,,
IBCG0,BCG Vaccine,BCG (卡介苗，政府提供) 0.5mg/mL,HIMM,Active immunisation against TB.,Individuals who are tuberculin +ve. Congenital or acquired immunodeficiencies， including treatment w/ immunosuppressive drugs or radiation.,Ulceration of the inoculation site， lymphadenitis， keloid formation. Rarely， enlargement of the regional lymph glands.,8℃以下避光,By intradermal inj. Adult & children >1 year 0.1 mL.,無需調整劑量,[仿單]無相關資訊。,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]無相關資訊。,SC;,,,,,
EATRU,Ipratropium,Atrovent U.D.V.0.5mg,ERSP,,適應症:主治慢性阻塞性氣管炎、支氣管氣喘等(B018863412) AR: Dry mouth， throat irritation or allergic reactions， cough， rise of intraocular pressure may occur if substance accidentally enters eyes in patients with narrow-angle glaucoma. CI: Hyperseneitivity of atropine-like substances.Chronic obstructive bronchitis， bronchial， asthma.,,RT,Oral inhalation: Inhaler: Over 12 yrs: 1-2 inhalations tid-qid， Nebulizer Soln: Adult: 2 ml， Child: 1 ml， q4-6h.,,,,可能安全,,,,,,,,,,
OSERQ,Quetiapine,SEROQUEL 200 mg,CNEU,,適應症：身心科用藥。(B022544100),,RT,Day 1: 50 mg Day 2: 100 mg Day 3: 200 mg Day 4: 300 mg From day 4 onwards， the dose should be titrated to 400800 mg/day,,,,除非治療上需要,,,,,,,,,,
OELM,Pentosan Polysulfate,Elmiron 100mg,SGU,,適應症: 使用於因間質性膀胱炎引起的膀胱疼痛或不適的解除。 副作用: Alopecia， diarrhea， nausea， headache， rash， dyspepsia， abdominal pain， liver function abnormalities， dizziness， increased bleeding time. Dermatologic: Alopecia (4%) Gastrointestinal: Abdominal pain (2%)， Diarrhea (4%)， Indigestion (2%)， Nausea (4%) Neurologic: Headache (3%) 禁忌: 已知對此藥物、化學結構相關的化合物或賦形劑過敏的病患不可使用。,,室溫,100 mg tid.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ECOL,Dexamethasone + Neomycin,Colsamin eye oint 3.5gm,TOPH,,適應症: Non-infectious forms of conjunctivitis， keratitis & blepharitis， especially of allergic origin， inflammation of the anterior uvea， scleritis， episcleritis & orbital myositis. Sympathetic ophthalmia. 副作用:Glaucoma， cataract， transient blurred vision. Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin， Finding of skin healing， Impaired Endocrine metabolic: Cushing's syndrome， Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )， Raised intraocular pressure (25% ) Psychiatric: Depression， Euphoria Respiratory: Pulmonary tuberculosis 禁忌: Herpes cornea superficialis; injuries & ulcerous processes of the cornea; ocular TB; ophth mycosis; ulcerous lesions of the cornea; narrow- & open-angle glaucoma.,,室溫,Once to several times daily.,,,,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EAGNO3P,Silver Nitrate,Silver nitrate powder 25gm,AGENT,,,,,,,,,,,,,,,,,,,
LALU,Oxethazaine+Aluminum Hydroxide+Magnesium Hydroxid,Aluzaine susp 360mL,ALIM,,適應症: Gastro duodenal ulcer & esophagitis. 副作用: Anorexia， dry mouth， constipation， diarrhea; phosphate depletion; headache， drowsiness， dizziness， weakness. 禁忌: Renal failure; hypophosphatemia.,,室溫,Adult 5-10 mL taken 15 minutes before meals & at bedtime.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OTANL,Nabumetone,Tanleeg F.C. 500mg,CNEU,,,,,,,,,,,,,,,,,,,
IBONV,Ibandronate,Bonviva inj 3mg/3mL,META,Treatment of osteoporosis in postmenopausal women.,Uncorrected hypocalcaemia. Severe renal impairment.,Back pain， pain in extremity， infection， asthenia， allergic reaction; GI disturbances; hypercholesterolemia; myalgia， joint disorder; arthritis; headache， dizziness， vertigo， nerve root lesion; upper resp infection， bronchitis， pneumonia， pharyngitis; UTI. Cardiovascular: Hypertension (5.3% to 7.3% ) Gastrointestinal: Abdominal pain (5.1% to 7.8% )， Diarrhea (2.4% to 6.8% )， Indigestion (3.6% to 11.9% )， Nausea (2.1% to 5.1% ) Musculoskeletal: Backache (4.3% to 13.5% ) Neurologic: Headache (2.6% to 6.5% ) Respiratory: Bronchitis (2.1% to 10% )， Upper respiratory infection (2% to 33.7% ),15-30℃,3 mg IV every 3 months.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVP;IVPUSH;,,【D5W】可選 。【N/S】可選 。,IV over 15-30 seconds,,1.不可與含鈣溶液或其他靜脈輸注藥物混合使用 2.以15-30秒的時間靜脈推注3mg藥物，使用時務必小心，「不可」將Bonviva注入動脈或靜脈旁側，否則可能造成組織傷害。
OLOE,Levonorgestrel + Ethinylestradiol,Loette (28's/pk),HM,,,,,,,,,,,,,,,,,,,
OBAC5,Baclofen,Baclospas 5mg,CNEU,Alleviation of signs & symptoms of painful spasticity resulting from cerebral & spinal cord injuries， multiple sclerosis， cerebral palsy， trigeminal neuralgia， low back syndrome， flexor spasm， tardive dyskinesia.,Epilepsy or convulsive disorders.,Sedation， headache， GI disturbances. Gastrointestinal: Nausea， Vomiting Musculoskeletal: Poor muscle tone Neurologic: Asthenia (5% to 15% )， Dizziness (5% to 15% )， Headache (4% to 8% )， Somnolence (10 to 63% ),25℃以下乾燥處避免陽光照射,Adult: Initially 5-15 mg daily divided in 1-3 doses. May increase dosage by 15 mg/day increments every 3 days until optimum effect is achieved. Usual daily dose is 30 mg. (MicroMedex maximum: 80mg/day) Children: Initially 5 mg daily in 2 divided doses. Usual daily dose: 4-6 years old， 5-15 mg; 7-11 years old， 5-20 mg; 12-15 years old， 5-25 mg.,無需調整劑量,,需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;,,,,,
LSTR,Fenoterol,Strolin liquid 0.5mg/mL， 60mL,ERSP,Prophylaxis & treatment of symptoms of reversible obstructive pulmonary disease (including asthma & acute bronchospasm)， chronic bronchitis， emphysema.,Hypertrophic obstructive cardiomyopathy， tachyarrhythmias.,Fine tremor of skeletal muscles & nervousness. Less frequently， tachycardia， dizziness， palpitations or headache. Very rarely， local irritation or allergic reactions; cough， paradoxical bronchospasm. Potentially serious hypokalemia may result from β2-agonist therapy.,25℃以下，不需冰存並避免陽光直射,Age >14 years: 5-10 mL TID. Age 6-14 years: 5 mL TID. Age 1-6 years 2.5-5 mL TID. Age <1 year: 2.5 mL BID.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
OMEPE,Mepenzolate,Mepenzolate 7.5mg,ALIM,,適應症: Diarrhea， abdominal pain & flatulence due to irritable colon， colitis， acute enterocolitis， diverticulitis. 副作用: GI disturbances， dry mouth， mental confusion， dizziness， weakness， drowsiness， headache， nervousness， increased ocular pressure， cycloplegia， blurred vision， dilation of the pupil， hypersensitivity reactions， tachycardia， palpitations， urinary retention， decreased sweating， drowsiness， insomnia， impotence， suppression of lactation. 禁忌: Glaucoma， obstructive uropathy， urinary or GI obstruction， paralytic ileus， intestinal atony of the elderly or debilitated patient， unstable CV status in acute GI hemorrhage， toxic megacolon complicating ulcerative colitis， myasthenia gravis.,,室溫,2 tab tid,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OMYLI,Ginkgo Biloba,Mylin 40mg,CAVS,,適應症: Disturbed cerebral performance. Supporting treatment in reduced hearing capacity due to cervical syndrome. Peripheral arterial circulatory disturbances with saved circulatory reserve.,,室溫,1 tab tid.,,,,沒有資料,,,,,,,,,,
EFLUR,Flurbiprofen,Flurbi PAP(4片/包),CNEU,Analgesics and anti-inflammatory for arthrosis deformans， scapulohumural periarthritis， tenosynovitis， perimyositis， muscle pain， post-trauma swelling.,Hypersensitivity to flurbiprofen.,Local irritation,儲存於陰涼乾燥處,Apply 1 patch daily.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,Compatible 哺乳時可使用,,EXT;,,,,,
OUROT,Propiverine,Urotrol 15mg,SGU,,適應症:為排尿機能改善劑(A045700100),,RT,15 mg bid.,,,,沒有資料,,,,,,,,,,
OFERI,Iron,Ferich 150mg,NUTR,,適應症:預防及治療鐵質缺乏症、缺鐵性貧血症(A045855100),,RT,1 tab daily. If required， 1 tab. bid.,,,,除非治療上需要,,,,,,,,,,
EEVR,Norelgestromin + Estradiol,Evra patch 3's/box,HM,,適應症: Female contraception. 副作用: Fluid retention， change in body wt， reduced glucose tolerance， mood changes， depression， irritability， changes in libido， estrogen-induced chorea， alteration in contact lens tolerance， slight rise in BP， GI disturbances， bloating， erythema nodosum， rash， pruritus， chloasma， melasma， erythema multiforme， acne， seborrhea， alopecia， intermenstrual bleeding， amenorrhea， absence of withdrawal bleeding， change in size of uterine fibromyomata， vag candidosis， dysmenorrhoea， breast tenderness， galactorrhea， breast pain， application site reaction， headache. 禁忌: Thrombophlebitis， thromboembolic disorders or a past history of these conditions; cerebro-vascular or coronary artery disease; valvular heart disease with complications; severe hypertension; diabetes with vascular involvement; migraine with focal aura; known or suspected carcinoma of the breast， endometrium or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use; acute or chronic hepatocellular disease with abnormal liver function; hepatic adenomas or carcinomas; known or suspected pregnancy.,,室溫,Apply 1 patch weekly for 3 weeks， followed by a patch-free interval of 1 week to clean， dry， hairless， intact healthy skin on the buttock， abdomen， upper outer arm or upper torso (excluding the breast).,,,,不可使用,,,,,,,,,,
OVIA1,Glucosamine Sulphate,Viartril-S powder 1.5gm,CNEU,,適應症: All forms of degenerative osteoarticular disease. Primary & secondary osteoarthrosis such as: cervical arthrosis， coxofemoral arthrosis， gonarthrosis， dorsal arthrosis， lumbosacral arthrosis， scapulohumeral arthrosis， periarthritis， lumbago， fractures， osteoarticular dystrophies， chronic & subacute arthritis. 副作用: Headache， fatigue， drowsiness， flushing. 禁忌: Hypersensitivity to glucosamine and shellfish.,,室溫,Sachet 0.5 sachet once daily for 3 mth. Repeat at an interval of 2 mth.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OADA1,Nifedipine,Adalat 10mg,CAVS,,適應症: Hypertension， chronic stable angina pectoris 副作用: Initially mild & transient vasodilatation， hypotension， rarely GI， skin & other reactions. Very rarely: transient visual change; chest discomfort (if relation established， discontinue therapy). Extremely rare: on prolonged use gingival hyperplasia， gynaecomastia (both regressing on discontinuation); hepatobiliary disorders. Cardiovascular: Hypotension (up to 5% )， Palpitations (up to 7% )， Peripheral edema (7% to 29% ) Dermatologic: Flushing (4% to 25%) Gastrointestinal: Nausea (up to 10% ) Neurologic: Dizziness (4% to 10% )， Headache (19% to 23%) Psychiatric: Feeling nervous Respiratory: Cough， Dyspnea 禁忌: CV shock; pregnancy & lactation. Unstable angina & after recent MI (immediate release).,,室溫,Usually 1 cap tid， can be increased to 2 cap tid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OFUG,Flutamide,Fuferel 250mg,RACA,,,,,,,,,,,,,,,,,,,
OCONQ,Mebendazole,Conquer 100mg,QANP,Whipworm， pinworm， hookworm， roundworm， tapeworm， strongyloides infestations.,Pregnancy.,Transient abdominal pain， diarrhea. At high doses， Allergic reactions， raised liver enzyme values， leukopenia， alopecia.,25℃以下避光,Trichuriasis (whipworm)， ascariasis (roundworm)， ancylostoma duodenale or necator americanus (hookworm): 100 mg orally twice daily for 3 days; repeat in 3 weeks if not cured with initial treatment. Enterobiasis (pinworm): 100 mg orally as a single dose.,無需調整劑量,,需調整劑量,除非治療上需要,Human data suggest risk in 1st trimester,PREGNANCY RECOMMENDATION: Compatible (2nd & 3rd Trimesters),No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
ECUT,Fluticasone,Cutivate cream 5gm,TDER,,適應症: Relief of the inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses such as: eczema including atopic， infantile & discoid eczemas; prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses including lichen simplex; lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus; an adjunct to systemic steroid therapy in generalised erythroderma; insect bite reactions; prickly heat. 副作用: Local burning， pruritus， local atrophic skin changes. Secondary infection， exacerbation of the signs & symptoms of the dermatoses， hypercorticism. Neurologic: Headache (8% to 9% ) Respiratory: Epistaxis (4% to 20% ) 禁忌: Rosacea， acne vulgaris， perioral dermatitis; primary cutaneous viral infections (eg. Herpes simplex， chickenpox; perianal & genital pruritus， dermatoses in infant < 3 month including dermatitis & napkin eruptions. Primarily infected skin lesions caused by infection with fungi or bacteria.,,室溫,Inflammatory dermatoses Adult， children， infants >=3 months Apply thinly to the affected skin areas once-bid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IDPT1,Diphtheria + Tetanus + Pertussis,Infanrix (DTPa) inj 0.5mL,HIMM,,Active immunization against diphtheria， tetanus and pertussis,,冷藏,IM， for child 6 wks-6 yrs， 0.5 ml/dose. Primary immunization: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months-1 yr later. Booster dose: Given at 4-6 yrs.,,,,沒有資料,,,,,,,,,,
IDIG2,Digoxin,Lanoxin inj 0.5mg/2mL (Digoxin),CAVS,Emergency heart failure.,Digitalis toxicity， ventricular tachycardia/fibrillation， obstructive cardiomyopathy. Arrhythmias due to accessory pathways (e.g. Wolff-Parkinson-White syndrome).,Extra beats， anorexia， nausea and vomiting. Diarrhoea in elderly， confusion， dizziness， drowsiness， restlessness， nervousness， agitation and amnesia， visual disturbances， gynaecomastia， local irritation (IM/SC inj)， rapid IV admin may lead to vasocostriction and transient hypertension.,25℃以下避光,Adults and children over 10 years old: Loading dose: ""Totally"" 500-1000 mcg (0.5-1 mg). Fist dose: half of full dose. Remaining dose: in divided doses at 4-8 hour intervals. Each dose should be given by IV infusion at a rate of 10-20 minutes. Maintenance dose: Based on the percentage of peak body storage lost through daily loss. Maintenance dose = peak body storage (loading dose) * daily loss/100 daily loss% = 14 + Ccr/5 Ccr (Corrected to 70 kg body weight or 1.73 m2 body surface area creatinine clearance rate) = (140-age)/Scr(mg/100mL) Newborns， infants and children under 10 years of age: Loading dose， should be divided. (Fist dose: half of full dose. Remaining dose: in divided doses at 4-8 hour intervals. Pre-term newborns less than 1.5 kg: 20 mcg/kg within 24 hours. 1.5 to 2.5 kg preterm newborns: 30 mcg/kg within 24 hours. Full-term newborns to 2-year-old child: 35 mcg/kg within 24 hours. Children 2 to 5 years old: 35 mcg/kg within 24 hours. Children 5 to 10 years old: 25 mcg/kg within 24 hours. Each dose should be given by IV infusion at a rate of 10-20 minutes. Maintenance dose: Adjust the dose according to the serum digoxin concentration.,無需調整劑量,,需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。【H/S】可選 。【L/R】可選 。,May be administered undiluted or diluted. Inject slowly over ?5 minutes.,IV infusion over 10-20 mins,1.未稀釋亦可使用
IPAN4,Pantoprazole,Pantoloc I.V. inj 40 mg,ALIM,Maintenance therapy of Erosive esophagitis. Gastroesophageal reflux disease. Gastric hypersecretion， Pathological. Zollinger-Ellison syndrome.,Known hypersensitivity including anaphylaxis， anaphylactic shock， angioedema， bronchospasm， acute tubulointerstitial nephritis， and urticaria to substituted benzimidazoles or any component of the product. Concomitant use with rilpivirine-containing products.,Common Gastrointestinal: Abdominal pain (3% )， Diarrhea (4% )， Flatulence (4% ) Neurologic: Headache (5% ) Serious Dermatologic: Cutaneous lupus erythematosus Gastrointestinal: Atrophic gastritis， Clostridium difficile diarrhea， Fundic gland polyposis of stomach Hematologic: Thrombocytopenia (less than 1% ) Immunologic: Stevens-Johnson syndrome， Toxic epidermal necrolysis Musculoskeletal: Disorder of muscle， Fracture of bone， Osteoporosis-related， Hip fracture， Rhabdomyolysis Renal: Tubulointerstitial nephritis， acute,25℃以下避光,Peptic or duodenal ulcer， Gastric ulcer & GERD: 40 mg IV infusion once daily Zollinger-Ellison syndrome Initial， 80 mg IV infusion QD- Q12H,需調整劑量,[仿單]動物試驗證實 pantoprazole 會分泌至乳汁內。 目前有關 pantoprazole 是否會分泌至人類乳汁內之資料不足，但的確曾發生藥物分泌至人類乳汁內之案例。 無法排除可能對新生兒 / 嬰兒造成風險之可能性。 因此決定是否停止哺乳或停止 / 禁用Pantoloc i.v. 治療時，應將哺乳對孩童之效益以及Pantoloc i.v. 治療對病人之效益納入考量。,無需調整劑量,沒有資料,Human data suggest low risk,[仿單]有關懷孕婦女之充足數據 (300 – 1000 件懷孕結果案例 ) 顯示，Pantoloc i.v. 無致畸胎或胎兒 / 新生兒毒性。 動物試驗則觀察到生殖毒性。為以防萬一，懷孕期間最好避免使用 Pantoloc i.v.。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]動物試驗證實 pantoprazole 會分泌至乳汁內。 目前有關 pantoprazole 是否會分泌至人類乳汁內之資料不足，但的確曾發生藥物分泌至人類乳汁內之案例。 無法排除可能對新生兒 / 嬰兒造成風險之可能性。 因此決定是否停止哺乳或停止 / 禁用Pantoloc i.v. 治療時，應將哺乳對孩童之效益以及Pantoloc i.v. 治療對病人之效益納入考量。,IVD;IVPUSH;,每一小瓶內注入 10mL 注射用生理食鹽水 sodium chloride 9mg/mL (0.9%) 溶解。,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,administer over a period of at least 2 minutes,Reconstitute 1 vial (40 mg) with 10 mL of Normal Saline injection and then dilute to a total volume of 100 mL to a final concentration of approximately 0.4 mg/mL for a 40-mg dose. Administer IV over a period of 15 minutes at a rate of approximately 7 mL/min.,配製後的溶液可直接注射投予或以100mL注射用生理食鹽水0.9% sodium chloride 9 mg/mL或5%葡萄糖注射液混合滴注。應使用玻璃或塑膠容器進行稀釋。配製後，或配製且稀釋後，使用期之化學與物理穩定性為25°C下可維持12小時。依據微生物觀點，應立即使用產品。除特定溶劑外，Pantoloc i.v. 不可與非指定溶劑進行配製或混和。使用靜脈注射投予，於2–15分鐘內注射完畢。
OHYP,Barnidipine HCL,Hypoca 15mg,CAVS,,I: Hypertension， renal parenchymatous hypertension & renovas-cular hypertension. CI: Pregnancy， lactation， children. ADR: Headache， dizziness.,,,D: Adult: initially 5 ~ 10 mg daily， may be increased to 10 ~ 15 mg daily.,,,,,,,,,,,,,,
ONEU,Gabapentin,Neurontin 300mg,CNEU,Adjunctive treatment of partial seizures in adults & children ? 3 years with epilepsy. Post-herpetic neuralgia.,Patients who are hypersensitive to gabapentin and other components of Neurontin.,Somnolence， dizziness， ataxia， fatigue， nystagmus， headache， tremor， diplopia， nausea &/or vomiting， rhinitis， amblyopia. Cardiovascular: Peripheral edema (1.7% to 8.3% ) Gastrointestinal: Nausea (3.9% )， Vomiting (3.3% ) Immunologic: Viral disease (10.9% ) Neurologic: Ataxia (3.3% to 12.5% )， Dizziness (adults， 17.1% to 28%; pediatrics， 2.5% )， Nystagmus (0.1% to 8.3% )， Somnolence (8.4% to 21.4% ) Psychiatric: Hostile behavior (1% to 7.6% ) Other: Fatigue (3.4% to 11% )， Fever (10.1% ),15-30℃,Epilepsy: Adult & children > 12 years 900-1800 mg/day in 3 divided doses. May be increased to 1800 mg/day. On the other long term clinical trials，being increased to 2400 mg/day ，some patient may be in the good tolerance .Children 3-12 years Initially 10- 15 mg/kg/day in 3 divided doses， then titrated upward over a period of about 3 days to the effective dose of 25-35 mg/kg/day for children over 5 years. May require up to 40 mg/kg/day for children over 3-5 years.Not recommand that over 12 hrs of maximum interval when dosage up to 50 mg/kg/day.Post-herpetic neuralgia :Adult Initially 900 mg TID. May titrate dosage up to 1800 mg/day.,無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OUNA,Sultamicillin,Unasyn 375mg,QANB,,I: Infection caused by G(+) & G(-) bacteria including some an-aerobes. ADR: GI disturbance， skin rashes， itching， blood disorders， ana-phylaxis & superinfection. CI: History of allergic reaction to any penicillins.,,,D: Adult 750 ~ 1500 mg/day 12 hrly. Children， infants & neonate 25 ~ 50 mg/kg/day 12 hrly.,,,,可能安全,,,,,,,,,,
OGAL,Zinc Acetate,Galzin 25mg,META,,I: Maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent. CI: In patients with known hypersensitivity to any of the components of this formulation. ADR: gastric irritation; elevations of serum alkaline phosphatase，Amylase & lipase lasting from weeks to months suggesting,,,D: Adults : recommended dose is 50mg as zinc 3 times daily. Children 10 years of age or older or in women who are pregnant: 25 mg 3 times a day . The dose can be raised to 50 mg tid if monitoring indicates a lessening control.,,,,安全,,,,,,,,,,
EJMC,Naftifine,Jia mei cream 1% 5gm,TDER,,適應症: Mycotic infections of skin & skin folds; onychomycosis; Candida infections of the skin; pityriasis versicolor; dermatomycosis (with or without pruritus). 副作用: Burning， stinging， dryness， redness. Dermatologic: Dry skin (3%)， Erythema， Pruritus， Sensation of burning of skin， Local (5%) Other: Irritation symptom (2%),,室溫,1% applied topically once or bid. Continue for at least 2 weeks after clinical healing.,無需調整劑量,,無需調整劑量,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
LZYR,Cetirizine,Zyrtec soln 0.1%， 60mL,HIMM,,適應症: Symptomatic treatment of seasonal rhinitis & conjunctivitis， perennial allergic rhinitis as well as pruritus & urticaria of allergic origin. 副作用: Headache， dizziness， drowsiness， agitation， dry mouth， GI discomfort， skin reactions & angioedema. 禁忌: Lactation.,,室溫,Children 2-5years: initial dose: 2.5mg qd， may be increased to 2.5mg every 12 hours or up to 5 mg/day. Children >6 years and Adults: 5-10 mg once daily， depending upon symptom severity.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EPIL1,Pilocarpine,Pilocarpine oph soln 1%， 15mL,TOPH,,適應症: Control of intraocular pressure. 副作用: Burning， itching & smarting of the eyes， blurred vision， conjunctival vascular congestion， myopia， lens changes (chronic use)， vitreous haemorrhage， pupillary block， headache. Dermatologic: Flushing， Oral formulation (8-13%)， Sweating symptom， Oral formulation (29-68%) Endocrine metabolic: Shivering， Oral formulation (3-15%) Gastrointestinal: Nausea， Oral formulation (6-15%) Neurologic: Dizziness， Oral formulation (5-12%) Ophthalmic: Blurred vision， Ophthalmic formulation， Burning sensation in eye， Ophthalmic formulation， Itching of eye， Ophthalmic formulation， Scotopic sensitivity， Difficulty， with ophthalmic formulation Renal: Increased frequency of urination， Oral formulation (9-12%) Respiratory: Rhinitis， Oral formulation (5-14%) 禁忌: Acute iritis， anterior uveitis， acute inflammatory disease of the anterior segment.,,室溫,1 drop up to qid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EPIL2,Pilocarpine,PILOCARPINE 2% oph soln 15mL,TOPH,,適應症: Control of intraocular pressure. 副作用: Burning， itching & smarting of the eyes， blurred vision， conjunctival vascular congestion， myopia， lens changes (chronic use)， vitreous haemorrhage， pupillary block， headache. Dermatologic: Flushing， Oral formulation (8-13%)， Sweating symptom， Oral formulation (29-68%) Endocrine metabolic: Shivering， Oral formulation (3-15%) Gastrointestinal: Nausea， Oral formulation (6-15%) Neurologic: Dizziness， Oral formulation (5-12%) Ophthalmic: Blurred vision， Ophthalmic formulation， Burning sensation in eye， Ophthalmic formulation， Itching of eye， Ophthalmic formulation， Scotopic sensitivity， Difficulty， with ophthalmic formulation Renal: Increased frequency of urination， Oral formulation (9-12%) Respiratory: Rhinitis， Oral formulation (5-14%) 禁忌: Acute iritis， anterior uveitis， acute inflammatory disease of the anterior segment.,,室溫,1 drop up to qid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EPRED,Prednisolone,Pred Forte 1% 5mL ophthalmic suspension,TOPH,The treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva， cornea， and anterior segment of the globe.,Acute untreated purulent ocular infections， in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis)， vaccinia， and varicella， and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Hypersensitivity to any of the ingredients of this preparation.,Increased intraocular pressure with optic nerve damage， visual field defects. Posterior subcapsular cataract formation (heavy or protracted use)， secondary ocular infection from fungi or viruses liberated from ocular tissues & perforation of the globe when there is thinning of the cornea or sclera. Systemic side effects may occur with extensive use of steroids.,室溫下(15-25℃)貯存，不需冷藏或冷凍。,Shake well before using. Instill 1-2 drops BID-QID into the conjunctival sac. During the initial 24 to 48 hours， the dosing frequency may be increased to 2 drops every hour if necessary. Care should be taken not to discontinue therapy prematurely.,無需調整劑量,[仿單]用於授乳婦女：對於局部類固醇之使用是否會導致足以產生全身性吸收，並於乳汁中產生可偵測的量，至今仍未知。因此，不建議授乳婦女使用本品。當投與本品於授乳婦女時，應審慎考慮本品對其之的重要性。,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]用於孕婦：妊娠期間之長期使用或增加劑量時的安全性仍未確定。因此，處方本品於孕婦病人，僅限對胎兒療效益處多於壞處時。於動物試驗中，類固醇的使用顯示有畸胎反應。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]用於授乳婦女：對於局部類固醇之使用是否會導致足以產生全身性吸收，並於乳汁中產生可偵測的量，至今仍未知。因此，不建議授乳婦女使用本品。當投與本品於授乳婦女時，應審慎考慮本品對其之的重要性。,OD;OL;OU;,,,,,
EXAL2,Latanoprost + Timolol,Xalacom eye drops 2.5mL,TOPH,,,,,,,,,,,,,,,,,,,
OANG,Drospirenone + Estradiol,Angeliq 28's/pk,HM,,適應症: 治療停經一年以上婦女之更年期症候群 副作用: Enlarged abdomen， abdominal pain， diarrhoea， dyspepsia， gastroenteritis， nausea， tooth disorder， vomiting， wt gain. Depression， dizziness， emotional lability， fever， headache， migraine， nervousness， pain. Acne， pruritus， rash. Amenorrhoea， breast pain， dysmenorrhoea， hyperlipidaemia， intermenstrual bleeding， reduced libido， irregular menstrual cycles. Bronchitis， cough， pharyngitis， rhinitis， sinusitis， upper respiratory infection. 禁忌: Undiagnosed abnormal genital bleeding. Renal insufficiency， hepatic dysfunction or tumor. Adrenal insufficiency， cholestatic jaundice of pregnancy， jaundice with prior oral contraceptive use. Major surgery with prolonged immobilisation. Heavy smoking (>=15 cigarettes/day) in patients >35 y. History of or current thrombophlebitis or venous thromboembolic disorders. Active or recent (within 1 yr) arterial thromboembolic disease; cerebral vascular disease， coronary artery disease， severe hypertension， valvular heart disease with thrombogenic complications. Diabetes with vascular involvement; headache with focal neurological symptoms. Known or suspected breast carcinoma， endometrial cancer， oestrogen-dependent neoplasms. Pregnancy.,,室溫,1 tab/day,,,,不可使用,,,,,,,,,,
IFLUO,5-Fluorouracil,Fluorouracil inj 1000mg/20mL,RACA,,適應症: Palliative management of carcinoma of the colon， rectum， breast， stomach & pancreas. 副作用: Stomatitis， esophagopharyngitis， diarrhea， anorexia， nausea， vomiting， enteritis， cramps， abdominal pain & ulceration， glossitis， pharyngitis， leukopenia， alopecia， dermatitis， ocular irritation， central neurotoxicity (acute cerebellar syndrome)， myocardial ischemia & angina. 禁忌: Patients in a poor nutritional state; with depressed bone marrow function or potentially serious infections.,,室溫,IV inj Initial dosage 12 mg/kg once daily (to a max of 800 mg daily) for 4 days. If no toxicity is observed， this may be followed by 6 mg/kg on the 6th， 8th， 10th & 12th days， unless toxicity occurs. Poor risk patients or those in a poor nutritional state 6 mg/kg/day (to a max of 400 mg daily) for 3 days. If no toxicity is observed， 3 mg/kg is given on the 5th， 7th & 9th days， unless toxicity occurs. Maintenance therapy Repeat the dosage of the 1st course every 30 days after the last day of the previous course of treatment. Alternatively， administer a maintenance dose of 10-15 mg/kg/week (to a max of 1 g/week) as a single dose. IV infusion 15 mg/kg/day (to a max of 1 g daily) being infused in 500 mL of 5% dextrose or 0.9% NaCl over 4 hours & repeated on successive days until toxicity occurs or a total of 12-15 g has been given. Continuous infusion may also be used. The course may be repeated after 4-6 weeks.,,,,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、血糖變化 (DM病人)。
IACE,Amikacin,Acemycin inj 500mg/2mL,QANB,Respiratory tract infection， UTI， bacteremia， septicemia， skin & soft tissue infection， intra-abdominal， burns， post-op infection.,Hypersensitivity to aminoglycosides. Pregnancy. Myasthenia gravis,Neurotoxicity， ototoxicity， nephrotoxicity， proteinuria， oliguria.,25℃以下,Adults and children: 7.5-15 mg/kg/day divided into 2 doses infused over 30-60 minutes; neonates and premature infants: 10-15 mg/kg/day divided into 2 doses infused over 1-2 hours. For adults with life-threatening infections: 500 mg every 8 hours (Maximum dose 1.5 g/day; duration < or = 10 days). Amikacin in concentrations 0.25% (2.5 mg/ml) may be used as an irrigating solution in abscess cavities， the pleural space， the peritoneum (adults: 0.5 g/dose) and the cerebral ventricles. Intraventricular injection: 1-5 mg/day in concentrations 1 mg/mL for 3 days. *****NEONATE ANTIBIOTICS DOSE***** Amikacin: Draw peak 30 min after completion infusion; draw trough just before next dose (於第4個dose給藥前) PMA <=29 week Postnatal 0 to 7 days dose : 18mg/kg Q48h PMA <=29 week Postnatal 8 to 28 days dose : 15mg/kg Q36 h PMA <=29 week Postnatal >=29 days dose :15mg/kg Q24 h PMA 30 – 34 week Postnatal 0 to 7 days dose : 18mg/kg Q36 h PMA 30 – 34 week Postnatal >= 8 days dose : 15mg/kg Q24 h PMA 35 - 44 week ， dose : 15mg/kg Q24 h,無需調整劑量,,需調整劑量,盡量避免,Human data suggest low risk,,Compatible 哺乳時可使用,,EXT;IH;IM;INS;IVD;IVI;SCI;SUBCI;,,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【D5NS】可選 。【H/S】可選 。,,成人:每500 mg 滴注時間大於 30 ~ 60 分鐘。Infant:滴注時間應大於1 ~ 2 小時。Pediatrics: 滴注時間應大於30 ~ 60 分鐘。,1. 監測體溫、CBC、腎功能、聽覺功能。 2. 建議監測藥物血中濃度。
EEXT6,Nystatin+Neomycin+Gramicidin+Triamcinolone,Extracomb cream 6gm,TDER,,適應症:濕疹、過敏性和發炎性皮膚病，並抑制細菌、黴菌之感染症(A023133323),,,,,,,,,,,,,,,,,
OIWE,Aluminum Dihydroxyallantoinate+magnesium silicate,Iwell 50/450mg,ALIM,,適應症: Relief of gastric hyperacidity， gastric & duodenal ulcer， acute & chronic gastritis. 副作用: Constipation or diarrhea.,,室溫,1 tab TID ~ QID,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
LIDO,Ibuprofen,Idofen susp 20mg/mL， 60 mL,CNEU,,適應症: Relief of pain， inflammation & fever. 副作用: GI effects including ulceration; rashes; bronchospasm. Rarely， thrombocytopenia. 禁忌: Peptic ulceration; patients in whom attacks of asthma， angioedema， urticaria or rhinitis are precipitated by aspirin & other NSAIDs.,,室溫,Adult Initially 80 mL daily in 3-4 divided doses. Juvenile RA Children > 7 kg body wt 1.5-2 mL/kg daily in 3-4 divided doses. Fever & pain in children Children > 7 kg 0.25-0.5 mL/kg daily in divided doses.,,,,可能安全,,,,,,,,,,
YSIC,Sea salt,SiccOral spray 50mL,ZOTH,,,,,,,,,,,,,,,,,,,
ENIC2,Nicotine,Nicotinell TTS 20,ZADT,To aid smoking cessation.,Non-smokers， children & occasional smokers. Acute MI， unstable or worsening angina pectoris， severe cardiac arrhythmias， recent CVA， skin diseases. Pregnancy， lactation.,Most frequent: Reaction at application site (usually erythema or pruritus)， headache， cold & flu-like symptoms， insomnia， nausea， myalgia & dizziness. Less common: BP changes， other CNS effects & GI disturbances. Also see lit.,室溫,(Uptodate) Nicotinell TTS 10: 10 cm2 (7 mg/day); TTS 20: 20 cm2 (14 mg/day); TTS 30: 30 cm2 (21 mg/day). Transdermal patch: Adjustment may be required during initial treatment (move to higher dose if experiencing withdrawal symptoms; lower dose if side effects are experienced). Patients smoking > 10 cigarettes/day: Begin with step 1 (21 mg/day) for 6 weeks， followed by step 2 (14 mg/day) for 2 weeks; finish with step 3 (7 mg/day) for 2 weeks. Patients smoking < or = 10 cigarettes/day: Begin with step 2 (14 mg/day) for 6 weeks， followed by step 3 (7 mg/day) for 2 weeks. Do not exceed more than 3 months of treatment.,無需調整劑量,,無需調整劑量,盡量避免,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,EXT;SKIN;,,,,,
ENIC3,Nicotine,Nicotinell TTS 30,ZADT,To aid smoking cessation.,Non-smokers， children & occasional smokers. Acute MI， unstable or worsening angina pectoris， severe cardiac arrhythmias， recent CVA， skin diseases. Pregnancy， lactation.,Most frequent: Reaction at application site (usually erythema or pruritus)， headache， cold & flu-like symptoms， insomnia， nausea， myalgia & dizziness. Less common: BP changes， other CNS effects & GI disturbances. Also see lit.,25℃以下,(Uptodate) Nicotinell TTS 10: 10 cm2 (7 mg/day); TTS 20: 20 cm2 (14 mg/day); TTS 30: 30 cm2 (21 mg/day). Transdermal patch: Adjustment may be required during initial treatment (move to higher dose if experiencing withdrawal symptoms; lower dose if side effects are experienced). Patients smoking > 10 cigarettes/day: Begin with step 1 (21 mg/day) for 6 weeks， followed by step 2 (14 mg/day) for 2 weeks; finish with step 3 (7 mg/day) for 2 weeks. Patients smoking ? 10 cigarettes/day: Begin with step 2 (14 mg/day) for 6 weeks， followed by step 3 (7 mg/day) for 2 weeks. Do not exceed more than 3 months of treatment.,無需調整劑量,,無需調整劑量,盡量避免,Compatible,NICOTINE REPLACEMENT THERAPY PREGNANCY RECOMMENDATION: Compatible—Maternal Benefit >> Embryo–Fetal Risk Contraindicated (with any use of tobacco),No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,EXT;,,,,,
OHALC,Triazolam,Halcion 0.25 mg,CNEU,,適應症: Transient & short-term insomnia， short-term adjunctive treatment in long-term insomnia. 副作用: Drowsiness， dizziness， lightheadedness， impaired coordination. Occasionally， anterograde amnesia， confusion， agitation. 禁忌: Patients with known sensitivity to benzodiazepines.,,室溫,Adult 0.25 mg before retiring. Elderly &/or debilitated patient 0.125-0.25 mg (therapy initiated at 0.125 mg) before retiring.,,,,不可使用,,,,,,,,,,
OLIPS,Fenofibrate,Lipanthyl 160mg,CAVS,Hypercholesterolaemia， hypertriglyceridaemia & mixed dyslipidaemias (types IIa， IIb， III， IV， & V).,Children. Pregnant & breastfeeding women. Severe liver dysfunction， including unexplained persistent liver function abnormalities; patients with active liver disease， including primary biliary cirrhosis. Gallbladder disease. Severe chronic kidney disease， including end-stage renal disease or those receiving dialysis. Chronic or acute pancreatitis (except for acute pancreatitis caused by severe hypertriglyceridemia). Hypersensitivity to fibrates or ketoprofen， especially if there's a history of photosensitivity or phototoxic reactions. Hypersensitivity to fenofibrate or its excipients. Hypersensitivity to peanuts， peanut oil， or legume phospholipids.,Common: Abdominal pain (4.6%)， Nausea (2.3%)， Aspartate aminotransferase serum level above reference range (3.4%)， Liver function tests outside reference range (7.5%; 3x ULN or greater， 13% with fenofibrate 87-130 mg， 0% with fenofibrate 43 mg or less)， Backache (3.4%)， Rhinitis (2.3%) Serious: Stevens-Johnson syndrome， Toxic epidermal necrolysis due to drug， Pancreatitis， Cholestatic hepatitis， Injury of liver， drug-induced， Anaphylaxis， Drug reaction with eosinophilia and systemic symptoms， Hypersensitivity reaction， Acute， Delayed hypersensitivity reaction， Rhabdomyolysis Serum creatinine above reference range (12-27%)， Angioedema,30℃以下,Adults: one 160mg tablet daily， taken with a main meal. Monitoring treatment response through blood lipid measurements is recommended. If there's inadequate response after a few months (e.g.， 3 months)， consider supplementation or an alternative treatment.,無需調整劑量,[仿單] 目前沒有fenofibrate和/或其代謝物從母體轉移至母乳中的相關資料。不可在授乳期間使用。 未知fenofibrate是否會排泄及/或它的代謝物到人類乳汁中。不能排除對喝母奶之兒童的風險。 因此，fenofibrate不應於授乳期間使用。,需調整劑量,沒有資料,No (limited) human data – animal data suggest risk,[仿單] 動物試驗中並未顯示任何致畸作用。在造成母體毒性之劑量範圍下已顯示有胚胎毒性。 對人類之潛在風險未知。不可使用在懷孕的婦女。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 目前沒有fenofibrate和/或其代謝物從母體轉移至母乳中的相關資料。不可在授乳期間使用。 未知fenofibrate是否會排泄及/或它的代謝物到人類乳汁中。不能排除對喝母奶之兒童的風險。 因此，fenofibrate不應於授乳期間使用。,PO;WM;,,,,,
ICAM,Irinotecan,Campto inj 100mg/5mL,RACA,,適應症：晚期性大腸直腸癌之第一線治療藥物，與5-FU及folinic acid合併，使用於未曾接受過化學治療之患者，單獨使用於曾接受5-FU療程治療無效之患者。(B022473221) 禁忌症：(1)患有慢性發炎性腸疾病或腸道阻塞之病人。 (2)對Campto任一成份過敏之病患。 (3)懷孕期與哺乳期。 (4)膽紅素 > 1.5 倍正常值上限的病患。 (5)嚴重骨髓功能衰竭之病患。 (6) WHO健康狀態 > 2 之病患。,,12 hrs at room temp.,Monotherapy : 300 ~ 350 mg / m2， iv infusion for 30 ~ 90 minutes， every 3 weekly. Combined Therapy : 180 mg / m2 Campto， iv infusion for 30 ~ 90 minutes， followed by folinic acid and 5-FU， every 2 weekly.,,,,盡量避免,,,,,,,,,,
IETO,Etoposide,Eposin inj 100mg/5mL,RACA,,適應症:Small cell carcinoma of lung， In combination with other approved chemotherapeutic agents as first line， Testicular cancer， In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical， chemotherapeutic， and radiotherapeutic therapy 副作用:Alopecia， Shivering， Diarrhea， Inflammatory disease of mucous membrane， Loss of appetite， Nausea， Vomiting， Asthenia， Fever， Malaise 禁忌:Hypersensitivity to etoposide phosphate or etoposide.,,室溫,Small cell carcinoma of lung， In combination with other approved chemotherapeutic agents as first line: range， 35 mg/m(2)/day IV for 4 days， to 50 mg/m(2)/day IV for 5 days; in combination with other approved chemotherapeutic agents; repeat at 3 to 4 wk intervals Testicular cancer， In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical， chemotherapeutic， and radiotherapeutic therapy: range， 50-100 mg/m(2)/day IV days 1-5， to 100 mg/m(2)/day IV on days 1， 3， 5; in combination with other approved chemotherapeutic agents; repeat at 3-4 wk intervals,,,,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 配製好的輸注溶液濃度在 0.2 - 0.4 mg/mL，使用前應再次目視檢查是否有顆粒沉澱或變色。 3. 輸注過快可能發生低血壓。 4. 監測CBC、肝腎功能。
IGEM,Gemcitabine,Gemzar inj 200mg,RACA,1-line treatment of metastatic breast cancer (in combination with paclitaxel) after failure of adjuvant chemotherapy which contained an anthracycline (unless contraindicated). 1-line treatment (in combination with cisplatin) of inoperable， locally advanced (stage IIIA or IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC). Treatment of advanced ovarian cancer， pancreatic cancer (locally advanced or metastatic).,Patients with a known hypersensitivity to gemcitabine.,Myelosuppression with anemia， leukopenia or thrombocytopenia; nausea & vomiting， diarrhea & stomatitis; transient elevations in serum transminases; mild proteinuria & hematuria， hemolytic uremic syndrome (discontinue); fever & flu-like symptoms; rash， pruritus; dyspnea， occasionally accompanied by bronchospasm， pulmonary toxicity (discontinue); edema; infections， sepsis (rare); alopecia; paresthesia; inj site reactions; allergic reactions; CV events (rare). Cardiovascular: Peripheral edema (20% ) Dermatologic: Alopecia (15% to 90% )， Rash (10% to 30% ) Endocrine metabolic: Hyperglycemia (30% )， Hypomagnesemia (30% ) Gastrointestinal: Constipation (10% to 42%)， Diarrhea (14% to 25% )， Nausea and vomiting (64% to 96% )， Stomatitis Hematologic: Anemia， All grade (65% to 89% )， Leukopenia， All grade (21% to 86% )， Neutropenia， All grade (62% to 90% )， Thrombocytopenia， All grade (24% to 85% ) Hepatic: Alkaline phosphatase raised (16% to 71% )， ALT/SGPT level raised (6% to 72% )， AST/SGOT level raised (3% to 72% ) Immunologic: Infectious disease (8 to 28% ) Musculoskeletal: Arthralgia (24% )， Myalgia (33% ) Neurologic: Paresthesia (2% to 38% )， Peripheral motor neuropathy (15% to 35% )， Sensory neuropathy (23% to 64% ) Otic: Hearing disorder (25% ) Renal: Hematuria (13% to 35% )， Proteinuria (10% to 45% )， Serum creatinine raised (2% to 38% ) Respiratory: Dyspnea (1% to 23% ) Other: Fatigue (40% )， Fever (6% to 41% )， Pain (10% to 48% ),30℃以下,[Ovarian Cancer] 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle， in combination with carboplatin AUC 4 intravenously after Gemzar administration on Day 1 of each 21-day cycle. [Breast Cancer] 1250 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle that includes paclitaxel. Paclitaxel should be administered at 175 mg/m2 on Day 1 as a 3-hour intravenous infusion before Gemzar. [Non-Small Cell Lung Cancer] Every 4-week schedule: 1000 mg/m2 over 30 minutes on Days 1， 8， and 15 in combination with cisplatin 100 mg/m2 on Day 1 after Gemzar. Every 3-week schedule: 1250 mg/m2 over 30 minutes on Days 1 and 8 in combination with cisplatin 100 mg/m2 on Day 1 after Gemzar. [Pancreatic Cancer] 1000 mg/m2 over 30 minutes intravenously.The recommended treatment schedule:• Weeks 1-8: weekly dosing for the first 7 weeks followed by one week rest.• After Week 8: weekly dosing on Days 1， 8， and 15 of 28-day cycles. [Bladder cancer] 1000 mg/m2 over 30 minutes on days 1， 8， and 15 in combination with cisplatin 70 mg/m2 on day 1; repeat cycle every 28 days. [Biliary tract cancer] 1000 mg/m2 as a single agent over 30 minutes once weekly for 3 weeks followed by 1 week rest; repeat cycle every 28 days. 1000 mg/m2 over 30 minutes in combination with cisplatin 25 mg/m2 on Days 1 and 8; repeat cycle every 21 days.,需調整劑量,Micromedex:Infant risk cannot be reled out.,無需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,Micromedex:Infant risk cannot be reled out.,IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 配製好的輸注溶液濃度約 0.1 mg/mL，室溫安定性維持 24 小時。本藥品不可冷藏，藥物會產生結晶。 3. 監測CBC、肝腎功能。
IMIT,Mitomycin C,Mitomycin-C inj 2mg,RACA,,Gastrointestinal， breast， lung， cervix and bladder carcinomas.,,,IV (through a running IV infusion): 10-20 mg/m2 (max. 20mg/m2) as a single dose every 6-8 wks; or 2 mg/m2/day for 5 days and after 2 drug-free days for a further 5 days， repeated every 6-8 wks. Bladder instillation: prevention: 4-10 mg/day， treatment: 10-40 mg/day.,,,,盡量避免,,,,,,,,,,
IONC,Vincristine,Oncovin inj 1mg,RACA,,Hodgkin's disease， leukemia， neuroblastoma， rhabdomyosarcoma， Wilms' tumor.,,,IV (injected carefully or through a running IV infusion): Adult: 0.4-1.4 mg/m2 (max. 2 mg/m2 as a single dose over 1 min once weekly.) Child over 1 yr: 1.5-2 mg/m2 once weekly. Under 10 kg: 0.05 mg/kg once weekly.,,,,盡量避免,,,,,,,,,,
IPLA5,Cisplatin,Platinex inj 50mg/100mL,RACA,,適應症:為抗腫瘤藥(B022602255),,RT,IV infusion over 6-8 hrs， As a single agent: 50-100 mg/ml once every 4 wks. Metastatic testicular tumors: combined with vinblastine & bleomycin， 20/mL/day for 5 days every 3 wks for 3 courses. Metastatic ovarian tumors: combined with doxorubicin， 50 mg/mL once every 3 wks.,,,,盡量避免,,,,,,,,,,
ICAL1,Calcitriol,Calcijex 1mcg,META,,適應症: Management of hypocalcemia in patients undergoing chronic renal dialysis. 副作用: Weakness， headache， somnolence; nausea， vomiting， dry mouth， constipation; muscle pain， bone pain & metallic taste. 禁忌: Hypercalcemia or evidence of vit D toxicity.,,室溫,Initially 1 mcg (0.02 mcg/kg) administered 3 times weekly， approximately every other day. Dose may be increased by 0.5-1 mcg at 2-4 weeks intervals.,,,,除非治療上需要,,,,,,,,,,
OAZO,Acetazolamide,Azol 250mg,CAVS,,,,,,,,,,,,,,,,,,,
IDAN,Dantrolene,Dantrolene inj 20mg (專案進口),CNEU,Treatment of malignant hyperthermia.,Hypersensitivity to Dantrolene.,Common: Flushing (27%)， Diarrhea， Nausea (10%)， Somnolence (17%)， Fatigue， Malaise Serious: Heart failure， Tachycardia (3%)， Dysphagia (10%)， Gastrointestinal hemorrhage， Aplastic anemia， Leukopenia， Small lymphocytic lymphoma， Thrombocytopenia， Anaphylaxis， Muscle weakness (3-21.7%)， Decreased vital capacity， inspiratory， Dyspnea， Muscle weakness， respiratory,20-25℃避光,Malignant hyperthermia: (FDA dosage) Minimum 1 mg/kg IV push; if physiologic and metabolic abnormalities continue， administer additional IV boluses to a MAX cumulative dose of 10 mg/kg; if abnormalities reappear， repeat dosing starting with 1 mg/kg IV push. (Guideline dosage) Initially， give 2-3 mg/kg IV push， then 1 mg/kg every 5 minutes as needed with active cooling until CO2 levels are <6 kPa， normal ventilation， and core temperature is <38.5°C. Additional doses may be required for rebound increases in CO2 and temperature， typically within 14 hours of initial control. If rebound occurs within 6 hours， use 1 mg/kg; if >6 hours since the last dose， administer 2-3 mg/kg. After a cumulative dose of 10 mg/kg， reevaluate the diagnosis; if malignant hyperthermia is still likely， continue dantrolene administration. Obese patients: Use actual body weight for initial dose calculation Malignant hyperthermia， Post-crisis follow-up: Individualize dose starting with 1 mg/kg IV or more as the clinical situation dictates. Malignant hyperthermia; Prophylaxis: 2.5 mg/kg IVD over 1 hour， starting approximately 1.25 hours before anesthesia.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,,Hold Breast Feeding 暫停哺乳,,IVD;IVP;IVPUSH;,廠商提供之注射用水 (每瓶藥物含20mg Dantrolene，必須與60毫升的注射用水混合。),,起始劑量：2~3毫克/公斤快速輸入，視症狀緩解程度 (例如Hypercarbia， rigidity， tachycardia， fever) 每5分鐘追加，總劑量可至10 毫克/公斤。 (每瓶藥物含20mg Dantrolene，必須與60毫升的注射用水混合。),起始劑量：2~3毫克/公斤快速輸入，視症狀緩解程度 (例如Hypercarbia， rigidity， tachycardia， fever) 每5分鐘追加，總劑量可至10 毫克/公斤。 (每瓶藥物含20mg Dantrolene，必須與60毫升的注射用水混合。),1. 稀釋後的藥液超過6小時應丟棄不用。 2. 注射部位：最好是中央靜脈，以避免周邊血管栓塞。 3. 藥物稀釋：每瓶藥物含20mg Dantrolene，必須與60毫升的注射用水混合。 4. 起始劑量：2~3毫克/公斤快速輸入，視症狀緩解程度 (例如Hypercarbia， rigidity， tachycardia， fever) 每5分鐘追加，總劑量可至10 毫克/公斤。 5. 如已注射 Dantrolene，絕對避免使用鈣離子阻斷劑。 6. 每瓶 Dantrolene 已含3 克 mannitol，最好有中央靜脈導管或肺動脈導管監測體液狀態。
YSDE,舒摩兒醋酸灌洗液133mL/twin,舒摩兒醋酸灌洗液133mL/twin,MSGO,,,,,,,,,,,,,,,,,,,
IXY15,Lidocaine,Xylocaine inj 1% 5mL局麻,ZANE,For the production of local or regional anesth by infiltration， IV regional anesth， minor & major nerve blocks， epidural block & subarachnoid block.,Epidural or spinal anesth in patients with uncorrected hypotension or with coagulation disorders or receiving anti-coagulation treatment; inflammation &/or sepsis in the region of proposed inj or in the presence of septicemia; general contraindications related to epidural anesth should also be taken into account.,CNS reactions， either excitatory or depressant. CV reactions， mainly depressant. Maternal hypotension. Rarely allergic reactions.,25℃以下,Maximum recommended single dose of lidocaine is 3 mg/kg (plain solution) or 7 mg/kg (solution with adrenaline). Adult， 70 kg: Infiltration: 20 mL of 1% solution (200 mg). Paravertebral nerve block: 3-5 mL of 1% solution (30-50 mg). Pudendal block: 10 mL of 1% solution (100 mg) on each side. Paracervical block: 10 mL of 1% solution (100 mg). Stellate ganglion block， Cervical: 5 mL of 1% solution (50 mg). Stellate ganglion block， Lumbar: 10 mL of 1% solution (100 mg). Epidural anesthesia， Thoracic: 10-20 mL of 1% solution (100-200 mg). Lumbar or caudal epidural analgesia: 10-20 mL of 1% solution (100-200 mg).,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;LA;LI;,,,,,
OGLI,Glibenclamide,Gliben 5mg,META,,適應症:為降血糖藥(A002863100) ADR: Hypoglycaemia， temporary visual impairment esp at the start of treatment， GI disturbance. Rarely， mild to severe thrombocytopenia. Isolated cases of haemolytic anemia， hypersensitivity reactions. CI: Type I IDDM， diabetic ketoacidosis， diabetic precoma or coma. Severe renal or hepatic dysfunction. Pregnancy & lactation.,,RT,Initial， 2.5-5 mg/day with breakfast， increased as needed; (max daily dose: 20 mg ).,,,,可能安全,,,,,,,,,,
YCAL,,噢立喜樂 90'S/瓶,NUTR,,,,,,,,,,,,,,,,,,,
EFRA,Fradiomycin,Framycin gauze dressing 10x10cm,TDER,Wounds， burns， ulcers & other infections skin conditions.,Hypersensitivity to any component of the formulation.,Possible ototoxicity.,25℃以下,Apply the paraffin gauze dressing directly to the cleaned wound QD-BID.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;SKIN;,,,,,
IVANC,Vancomycin,Vanco inj 1gm,QANB,Endocarditis， osteomyelitis， pneumonia， septicemia， soft tissue infections， enteritis caused by Staphylococcus aureus infections， and pseudomembranous colitis caused by Clostridium difficile infections.,Hypersensitivity to vancomycin.,Anaphylactoid reactions following rapid infusion. Nephrotoxicity， ototoxicity， reversible neutropenia， pseudomembranous colitis; chemical peritonitis following intraperitoneal administration.,,Adult 500 mg Q6H or 1 g Q12H by intermittent infusion. Duration: At least 3 weeks in staphylococcal endocarditis. Prophylaxis of endocarditis in high-risk penicillin-allergic patients undergoing dental or other procedures 1 g by IV infusion as a single dose before the procedure together with gentamicin IV. Repeat doses Q8H for patients undergoing GI or GU procedures. Children 10 mg/kg body weight Q6H. Neonates initial 15 mg/kg followed by 10 mg/kg Q12H in 1st weeks of life & Q8H up to 1 month of age. *****NEONATE ANTIBIOTICS DOSE***** Vancomycin: Dilute to a final concentration <=5 mg/mL; IV infusion over 90 minutes Draw trough level within 30 mins before the fourth dose. peak level 60 mins after end of infusion Sepsis PMA <=29 week Postnatal 0-14 days， dose: 10mg/kg Q18H PMA <=29 week Postnatal >=15 days， dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days， dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days， dose: 10mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days， dose 10mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days， dose 10mg/kg Q8H PMA >=45 week: 10mg/kg Q6H Meningitis PMA<=29 week Postnatal 0-14 days dose: 15mg/kg Q18H PMA <=29 week Postnatal >=15 days， dose: : 15mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days， dose: 15mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days， dose: 15mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days， dose: 15mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days， dose: 15mg/kg Q8H PMA >=45 week: 15mg/kg Q6H,無需調整劑量,,需調整劑量,沒有資料,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IMP;INS;IRR;IS;IVD;IVI;SCI;SUBCI;,IVD: 20 mL D/W (water for injection),【N/S】可選 仿單建議。,,給藥濃度 2.5~5mg/mL，輸注速率< 10 mg/min，兒童至少以超過60分鐘以上時間緩慢滴注。,1. 監測體溫、CBC、腎功能、聽覺功能。 2. 注意輸注過快時的不良反應：低血壓、呼吸困難、蕁麻疹。 3. 建議監測藥物血中濃度。 4. 給藥濃度: 2.5~5mg/mL，利用輸注液給藥，濃度不可超過 5mg/mL。 5. 調配及抽藥時建議使用G21號針頭(外徑0.8mm)，並且於橡膠塞中央位置針頭90度向下穿刺，避免產生橡膠塞碎屑。 6. 加入10 mL滅菌注射用水於500 mg無菌vancomycin乾粉之小瓶內。以此法調得50 mg/ mL的溶液，須進一步稀釋。溶液調配之後需冷藏，可於冰箱中保存14天而不會明顯降低力價。
OMID,Pyrazinamide,Mide 500mg,QANB,,適應症: Treatment of pulmonary & extrapulmonary TB. 副作用: Hepatotoxicity， jaundice， hyperuricemia leading to attacks of gout， anorexia， nausea， vomiting， arthralgia， malaise， fever， sideroblastic anemia， difficulty in micturition. Endocrine metabolic: Hyperuricemia Gastrointestinal: Nausea， Vomiting Musculoskeletal: Arthralgia (40%) 禁忌: Liver damage.,,室溫,20-35 mg/kg daily in 3-4 divided doses. (max. 3 g/day).,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
YAMS,N-acetyl-D-glucosamine,Amsun nasal spray,ZOTH,,,,,,,,,,,,,,,,,,,
IFIB0,Sodium Tetradecyl Sulphate,Fibro-Vein 3%， 0.5 mL,ZOTH,,適應症: As a sclerosant in the treatment of varicose veins of the leg by compression sclerotherapy. 副作用: Local pain or burning， skin pigmentation， tissue necrosis & ulceration may occur with extravasation. paraesthesia & anesth may occur if an inj effects a cutaneous nerve. Superficial thrombophlebitis. 禁忌: Patients unable to walk due to any cause. Patients currently taking OCs. Significant obesity. Acute superficial thrombophlebitis. Local or systemic infection. Varicosities caused by pelvic or abdominal tumours. Uncontrolled systemic disease eg. DM. Significant valvular incompetence requiring surgical treatment.,,室溫,Adult 0.5-1 mL IV into the lumen of an isolated superficial vein， followed by immediate continuous compression. Max. 4 sites may be injected during 1 treatment session.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,限由醫師使用
OANG0,Drospirenone + Estradiol,Angeliq 28's/pk (臨床試驗藥),HM,,,,,,,,,,,,,,,,,,,
EMEN,Butenafine,Mentax cream 1% 15gm,TDER,Dermatophytoses eg interdigital tinea pedis， tinea corporis， tinea cruris,Burning， stinging & itching at application site.,Individuals who have known or suspected sensitivity to butenafine HCl or to any of the components of Mentax. Patients who are known to be sensitive to allylamine antifungals should use Mentax with caution， since cross-sensitivity may occur.,25℃以下,Tinea corporis， tinea cruris: Topical: Apply once daily for 2 weeks Tinea versicolor: Topical: Apply once daily for 2 weeks Tinea pedis: Topical: Apply twice daily for 1 week or once daily for 4 weeks to affected skin between and around the toes,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;SKIN;TOPI;,,,,,
IAMI2,Amino Acids,Amiparen inj 10% 200mL,NUTR,Nutritional support for patients with hypoproteinemia， malnutrition,Hepatic coma， severely impaired renal function， abnormal amino acid metabolism.,Hypersensitivity， GI upsets， chest discomfort， palpitations， occasional chills， hot flushes， fever， headache， increase of GOT，GPT & BUN level.,30℃以下,Central vein infusion: The usual adult dosage is 400-800 mL per day by drip infusion. Peripheral vein infusion: The usual adult dosage is 200-400 mL per dose by drip infusion. A typical infusion rate in adults is 100 mL over 60 minutes The dosage and the rate may be increased or decreased depending on the patient's age， symptoms and body weight.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,IVF:100mL/60min,1. 中央靜脈投與：成人一日400-800mL施行高熱量輸液法。 2. 周邊靜脈投與：成人一日200-400mL施行高熱量輸液法。成人標準投與速度為60分鐘內輸注100mL。小孩、老人與重症患者營緩慢注射。
OHYD,Hydroxyurea,Hydrea 500mg,RACA,Chronic myeloid leukemia， malignant neoplastic disease.,Hypersensitivity. Bone marrow depression eg leukopenia， thrombocytopenia or severe anemia. Pregnancy & lactation.,Bone-marrow suppression; rarely， GI disorders， skin rash， headache， disorientation， pulmonary edema， dysuria， renal tubular function impairment.,25℃以下，避免高溫,[Solid tumor] Intermittent therapy: 80 mg/kg once every 3 days; Continuous therapy: 20-30 mg/kg once daily [Squamous cell carcinoma of head and neck or cervical cancer， in combination with radiation therapy] 80 mg/kg once every 3 days [Chronic myeloid leukemia] 20-30 mg/kg once daily,無需調整劑量,,需調整劑量,盡量避免,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
YPHY,Isoflavones,Phyto Soya 60's/box,NUTR,,,,,服用方式: 每日早晚飯後服用1-2粒，以水吞服，多食無益 每膠囊含(8種)-- 大豆異黃酮素: 17.5毫克(去糖基大豆異黃酮素11毫克) 鎂: 40毫克 鋅: 7.5毫克 硒: 25微克 維生素B6: 1毫克 維生素B9: 100微克 維生素B12: 0.5微克 維生素E: 5毫克,,,,,,,,,,,,,,
YSOY,Isoflavones,SOYGERM C,NUTR,,,,,,,,,,,,,,,,,,,
IPCT,Penicillin G,Penicillin test reagent 300U/0.1mL/dose,TEST,,,,,For penicillin skin testing.,無需調整劑量,,無需調整劑量,,,,,,ID;,,,,,For Penicillin Skin Test use only
OIRE,Gefitinib,Iressa 250mg,RACA,Treatment of patients with locally advanced or metastatic adenocarcinoma of the lung who have previously received chemotherapy.,Patients with known severe hypersensitivity to gefinitib or to any of the excipients of Iressa.,Diarrhoea， nausea， skin rash， dry skin， vomiting， anorexia， stomatitis， liver function abnormalities， nail disorder， alopecia， asthenia， conjunctivitis & blepharitis. Dermatologic: Acne (25% to 33% )， Dry skin (13% to 26% )， Pruritus (8% to 9% )， Rash (43% to 54% ) Endocrine metabolic: Weight loss (3% to 5% ) Gastrointestinal: Diarrhea (48% to 67% )， Loss of appetite (7% to 10% )， Nausea (13% to 18% )， Vomiting (9% to 12% ) Neurologic: Asthenia (4% to 6% ),30℃以下,250 mg orally once daily with or without food.,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OSTA,Nateglinide,Starlix 120mg,META,,適應症: Treatment of type 2 diabetes， as monotherapy or in combination with metformin. 副作用: Hypoglycaemic symptoms， GI disturbances， headache. Rarely: raised liver enzymes， hypersensitivity reactions. Endocrine metabolic: Hypoglycemia (1.3% to 3%% ) Respiratory: Upper respiratory infection (10.5% ) 禁忌: Type 1 diabetes， diabetic ketoacidosis. Pregnancy， lactation.,,室溫,120 mg before meals,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OCATI,Calcium Citrate,Catin 950mg,NUTR,,適應症:補充鈣質,,室溫,1-2 Tab bid,,,,沒有資料,,,,,,,,,,
OTONE,Aceclofenac,Tonec 100mg,CNEU,Relief of pain & inflammation in osteoarthritis， rheumatoid arthritis & ankylosing spondylitis.,Hypersensitivity to aspirin or other NSAIDs; previous or active peptic ulceration or GI bleeding; moderate to severe renal impairment.,GI disturbances， ulceration or bleeding; dizziness; hypersensitivity reactions including skin rash， angioedema or bronchospasm; headache， nervousness， depression， drowsiness， insomnia， vertigo， tinnitus， photosensitivity reactions， hematuria， blood disorders， fluid retention， disturbances in renal function.,25℃以下避光,100 mg BID,需調整劑量,仿單:本藥無授乳婦使用的相關資訊，故不建議使用.但是鼠實驗中藥品不會進入乳汁.,無需調整劑量,沒有資料,Uknown 沒有資料,仿單:本藥無孕婦使用的相關資訊，故不建議使用，且於第三孕期使用NSAIDs可能增加子宮張力，促進子宮收縮.可能使胎兒動脈導管早期閉鎖，造成新生兒肺動脈高壓.分娩延遲和時間延長. [20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,Unknown 沒有資料,仿單:本藥無授乳婦使用的相關資訊，故不建議使用.但是鼠實驗中藥品不會進入乳汁.,PC;PO;WM;,,,,,
OKAS,S-Carboxymethylcysteine,Kasteine 375mg,ERSP,,適應症:化痰劑(A028142100),,RT,500 mg tid.,,,,沒有資料,,,,,,,,,,
ICHI,Levobupivacaine,Chirocaine inj 0.5%，10mL,ZANE,,適應症:Adult Surgical anesth & pain management. Children Infiltration analgesia. 副作用:Hypotension， nausea， post-op pain， fever， vomiting， anemia， pruritis， pain， headache， constipation， dizziness， fetal distress. 禁忌: Hypersensitivity to local anesth amide agents. IV regional anesth (eg Bier block)， obstetric procedures， paracervical blocks in obstetrics.,,室溫,Adult a) Local anesthesia: local anesthetic， 60 mL of 0.25% solution (150 mg) b) Obstetric pain: 10-20 mL of 0.25% solution EPIDURAL bolus (25-50 mg) c) Postoperative pain: 4-10 mL/hr of 0.125% or 0.25% solution EPIDURAL infusion (5-25 mg/hour) ; 0.125% used only in combination with fentanyl or clonidine d) Regional anesthesia: 1) peribulbar infiltration， 5-15 mL of 0.75% solution (37.5-112.5 mg) 2) peripheral block， 30 mL or 0.4 mL/kg of 0.25%-0.5% solution (75-150 mg (1-2 mg/kg)) 3) epidural (surgical)， 10-20 mL of 0.5-0.75% solution (50-150 mg) 4) epidural (cesarean section) 20-30 mL of 0.5% solution (100-150 mg),,,,可能安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,外科麻醉：硬膜外阻斷麻醉以進行外科手術，包括剖腹產及區域阻斷。 急性疼痛處理：持續性硬膜外輸注或間歇性之一次注射給藥，如：手術後或產後疼痛。 兒童適用於浸潤麻醉。 本品僅供有麻醉經驗的臨床醫生或在其指導下使用。
OURO1,Potassium Citrate,UROCIT-K 10meq,SGU,,Renal tubular acidosis (RTA) with calcium stones， hypocitraturic calcium oxalate nephrolithiasis of any etiology， and uric acid lithiasis with or without calcium stones.,,,Mild to moderate hypocitraturia: 2 tab tid. Do not exceed 100 mEq/day. Severe hypocitraturia: 4 tab tid or 3 tab qid with meals.,,,,除非治療上需要,,,,,,,,,,
OFUC,Fusidate,Fucidin 250mg,QANB,Treatment of infections caused by susceptible organisms especially Staph eg osteomyelitis， septicaemia， endocarditis， pneumonia， cutaneous infections， surgical & traumatic wound infections. Also other Staph infections including MRSA.,Hypersensitivity to Fusidate.,GI disturbances.,,Adult: 2 TAB TID Skin & soft tissue infection 1-2 TAB BID,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,,,,,,
IARE,Pamidronate,Aredia inj 15mg/5mL,META,,適應症:Treatment of conditions associated with increased osteoclast activity such as predominantly lytic bone metastases & multiple myeloma; tumor-induced hypercalcemia; Paget's disease of bone. 副作用: Mild transient pyrexia & lymphocytopenia may occur at start of treatment. Hypocalcaemia mostly asymptomatic & transient. Also see lit. 禁忌: Known hypersensitivity to Aredia or other bisphosphonates.,,室溫,should be diluted in a Ca-free infusion soln (e.g. 0.9 % sodium chloride or 5 % glucose) & infused slowly via cannula in a relatively large vein. The infusion rate should not exceed 60 mg/hr (1 mg/min)， & the concentration of Aredia in the infusion solution should not exceed 90 mg/250 mL. Adults & elderly Lytic bone metastases of malignancy 90 mg administered as a single infusion every 4 weeks (or every 3 weeks in patients who receive chemotherapy at 3-weekly intervals). Tumor-induced hypercalcemia Total dose of 15-90 mg according to the initial serum Ca concentration. The dose may be administered either in a single infusion or in multiple infusions over 2-4 consecutive days. Max dose per treatment course (for both initial and repeated courses): 90 mg. Paget's disease of bone Either 6 unit doses of 30 mg once weekly (total dose 180 mg)， OR initial dose of 30 mg followed by 3 unit doses of 60 mg every other week (total dose 210 mg). The latter regimen， omitting the initial dose， may be repeated after 6 months until remission of disease or relapse occurs.,,,,盡量避免,,,,,,,,,,
OBET1,Betahistine,Betaserc 16mg,CNEU,,適應症:治療眩暈、聽力障礙(B023041100),,RT,1 tab tid.,,,,沒有資料,,,,,,,,,,
ODOX4,Doxazosin,Doxaben XL 4mg,CAVS,Hypertension. Benign prostatic hyperplasia.(B023711100),Patients with known hypersensitivity to quinazolines， doxazosin or any of the excipients of Doxaben/Doxaben XL.,Dizziness， headache， fatigue， vertigo， edema & asthenia. Cardiovascular: Edema (2.7% to 4%)， Hypotension (1.7%-10%) Gastrointestinal: Nausea (1.2% to 4.3%) Neurologic: Dizziness (5.3% to 19%)， Headache (4% to 15.8%)， Somnolence (1.2% to 5%)， Vertigo (1.5% to 7%) Other: Fatigue (8% to 12%),30℃以下,Extended release tablet should be swallowed whole; do not crush， cut， chew， or divide. Adult usual dosage: 4 mg QD， may increase if necessary at the 4-week interval to a maximum 8 mg QD.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為緩釋錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。若有磨粉管灌需求可改用院內其它Alpha-Blockers。
OTEM,Buprenorphine,Temgesic Sublingual 0.2mg,CNEU,,Moderate to severe pain,,,1-2 tab 6-8 hrly or as required,,,,除非治療上需要,,,,,,,,,,
EFDF,Flurbiprofen,富帝芬貼片(4片/包),CNEU,,RA， osteoarthritis,,,apply twice daily in adequate size,,,,可能安全,,,,,,,,,,
OCIS,Carbocysteine,Cisdyne 250mg,ERSP,,適應症:化痰劑(A040125100)(B020459100),,RT,2 tab tid,,,,沒有資料,,,,,,,,,,
IETOM,Etomidate,Etomidate-Lipuro 20mg/10mL,ZANE,Induction of general anesthesia， Maintenance of general anesthesia; Adjunct,Hypersensitivity to etomidate products,:njection site pain ， Nausea， Vomiting,25℃以下避光避免冷凍,Dosage should be individualized， for IV use only. Adult dosage: IV 0.15-0.3 mg/kg (equivalent to 0.075 to 0.15 mL/kg Etomidate-Lipuro) over 30 to 60 seconds for induction of anesthesia. Children under 15 years old and the elderly: Single dose IV 0.15- 0.2 mg/kg (equivalent to 0.075-0.15 ml/kg Etomidate-Lipuro). In patients with liver cirrhosis and patients having been premedicated with neuroleptics， the dose has to be reduced. In the special case of narcosis to terminate a status epilepticus or serial epilepticus seizures a sufficient dose of etomidate (0.3 mg/kg) should be injected quickly (within 10 seconds). This dose may be repeated several times， if required.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVP;IVPUSH;,,,推注時間>30秒 Administer IV push over 30 to 60 seconds.,,1. Etomidate-Lipuro未作相容性測試前，不得與其他輸注液混合。此外，除非已確認相容性，否則Etomidate-Lipuro不得同時與其他注射液以同一輸注管給予；需要合併給予之藥物如止痛劑，以同一輸注管或個別靜脈插管接續給藥。 2. Etomidate-Lipuro不含抗菌防腐劑。因為脂肪乳劑會促進微生物生長，安瓿開瓶後應於無菌狀態下立即以注射器抽出並輸注。剩餘部份應丟棄。 3. 投予Etomidate-Lipuro前應適度前驅給藥以避免肌陣痙的發生。建議於投藥前1小時IM給予或10分鐘前IV給予BZD類藥物。
YISO,Isoflavones,Isoflavone 30's/box,NUTR,,,,室溫,服用方式: 每日1-3次，每次1粒，多食無益 每膠囊含(15種)-- 大豆萃取物(含異黃酮素40%): 120毫克(異黃酮素: 48毫克) 蜂王乳: 60毫克 花粉: 60毫克 泛酸鈣: 50毫克 維生素D3: 250IU 維生素E: 50毫克 維生素B1: 0.5毫克 維生素B2: 0.5毫克 維生素B6: 0.5毫克 維生素B12: 50微克 葉酸: 250微克 小麥胚芽油: 110毫克 明膠: 170毫克 甘油: 60毫克 純水: 15毫克,,,,可能安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OSINC,Levodopa + Carbidopa,SINEMET CR(持續錠) 50/200MG,CNEU,,適應症: Symptomatic treatment of Parkinsonism. 副作用: Dyskinesia including choreiform， dystonic & other involuntary movements. Mental changes including paranoid ideation & psychotic episodes; depression with or without development of suicidal tendencies; dementia; & GI disturbances. Gastrointestinal: Nausea (5.5% to 5.7% ) 禁忌: Narrow-angle glaucoma. Undiagnosed skin lesions or history of melanoma. Hypersensitivity to any component of this product.,,室溫,Patient who has not received prior L-dopa therapy Initially 1 tab bid or tid. Max 600 mg/day of L-dopa.,,,,除非治療上需要,,,,,,,,,,
IALB1,Albumin,Human Albumin 20% 100mL,HEMT,,,,,,,,,,,,,,,,,,,
IVAX2,Purified Split Inactivated Influenza Virus,自費流感疫苗( <三歲) 0.25mL/支,HIMM,,I: Prophylaxis against influenza. ADR: Erythema (rash)， swelling， pain， ecchymosis， induration， fever， dizziness， shivering， tiredness， headaches， sweating， muscle pain， joint pains. CI: Allergy to eggs， chicken protein or any constituents of the vaccine. Febrile illness or acute infection.,,2 ~ 8 °C,Children 6 ~ 35 mth 0.25ml IV or deep SC. Chidren have not been vaccinated previously， the 2nd dose can be given at an interval of at least 4 wk.,,,,除非治療上需要,,,,,,,,,,
EALBS,Policresulen,Albothyl solution,SGU,,適應症: Local treatment of cervical & vag inflammatory & concomitant discharge. Vaginitis & cervicitis， cervical erosion; trichomoniasis & moniliasis. To stop bleeding after biopsy & removal of cervical polyps. Decubital ulcers caused by pessaries. After electrocoagulation to activate regeneration. 副作用: Occasionally， mild local discomfort at beginning of treatment which disappears on discontinuation. 禁忌: Concomitant use of other topical agents in treating the affected areas.,,室溫,Concentrate Undiluted for cauterization 1-2 times weekly; diluted for vag douches.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EDUA2,Budesonide,Duasma MDI 200mcg/puff,ERSP,,適應症: Chronic control of bronchial asthma. 副作用: Mild irritation of the throat， coughing， reversible hoarseness of voice， bad taste， dryness of the throat. Candidiasis of the mouth & throat. Paradoxical bronchoconstriction. Gastrointestinal: Diarrhea (inhalation， 4%; oral， 10% )， Nausea (inhalation， 1.8% to 6%; oral， 11% ) Musculoskeletal: Arthralgia (inhalation， 6%; oral， 5% ) Neurologic: Headache (inhalation， 3%; oral， 21% ) Respiratory: Epistaxis (intranasal， 8%; inhalation， 2% to 4% )， Nasal stinging/burning (intranasal， greater than 1% )， Respiratory tract infection (inhalation， 3% to 38%; oral， 11% )， Sinusitis (inhalation， 3% to 16%; oral， 8% ) 禁忌: Moderate to severe bronchiectasis.,,室溫,Adult & children > 12 years Initially 400-1600 mcg daily. Maintenance: 200-400 mcg bid， up to 2000 mcg/day. Children 6-12 years Initially 200-400 mcg daily.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IMETR,Metronidazole,Metronidazole inj 500mg/100mL,QANB,Infections with anaerobic causative agents. Infections of the GIT， after colon surgery， in peritonitis， purulent diseases of the pelvic cavity， infections of the female genital tract as well as puerperal fever.,Hypersensitivity. Blood dyscrasias.,GI disturbances， somnolence， vertigo， headache， ataxia， darkening of urine， itch， cutaneous eruption， peripheral neuropathy. Gastrointestinal: Abdominal discomfort (7%)， Loss of appetite， Metallic taste， Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )， Headache (tablets， 15% to 18%; vaginal gel， 5% )， Peripheral neuropathy Reproductive: Candida infection of genital region， Symptomatic cervicitis/vaginitis (10%)， Vaginal discharge (12%) Other: Drug interaction with alcohol， Disulfiram-like reaction,25℃以下避光,(仿單) Anaerobic infections: Adults and children >= 12 years: 500 mg Q8H IV at a rate of 25 mg/minute (5 mL/minute) or 22.5 mg/kg/day; children < 12 years: 22.5 mg/kg/day once daily. Pre- and post-operation: 500-1500 mg at a rate of 25 mg/minute (5 mL/minute). *****NEONATE ANTIBIOTICS DOSE***** Metronidazole: Loading dose: 15 mg/kg; (參考 馬偕)， IV drip> 0.5-1hour， at conc < 8mg/ml Maintenance dose: as below Body weight <1kg ge<=7day 7.5mg/kg QD  Age 8-14 day 7.5mg/kg QD  Age 15-28 day 7.5 mg/kg QD Body weight 1-2kg ge<=7day 7.5mg/kg Q12H  Age 8-14 day 7.5 mg/kg Q12H  Age 15-28 day 7.5 mg/kg Q12H Body weight >2kg Age<=7day 7.5mg/kg Q8H  Age 8-14 day 10 mg/kg Q8H  Age 15-28 day 10mg/kg Q8H,需調整劑量,,無需調整劑量,可能安全,Human data suggest low risk,,Hold Breast Feeding 暫停哺乳,,IVD;,,,,< 5mL/min,1. 監測體溫、CBC、血球分化計數，注意心智與神經功能變化。 2. 療程建議不超過10天。
OTAN,Imidapril,Tanatril 10mg,CAVS,,適應症: Hypertension. 副作用: Cough， dizziness， hypotension， headache， pharynx discomfort， rash. Rarely angioedema， thrombocytopenia， acute renal failure. Pancytopenia， pancreatitis. 禁忌: History of angioedema due to an ACE inhibitor， patients who undergo LDL apheresis using dextran cellulose sulfate or hemodialysis with acrylonitrile methallyl sulfonate Na membrane. Pregnancy， lactation.,,室溫,Adult: 5-10 mg once daily Severe hypertension: initially 2.5 mg once daily,無需調整劑量,,需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
YPAR,Multivitamin,Paragon 30's(速麗康),NUTR,,,,,,,,,,,,,,,,,,,
ORE15,Sibutramine,REDUCTIL 15mg 28's/box,META,,適應症: Adjunctive therapy within a weight management programme for obese patients with BMI >= 30 kg/m2， overweight patients with BMI >= 27 kg/m2 or above who have obesity-related risk factors like type 2 diabetes or dyslipidemia. 副作用: Loss of appetite， constipation; dry mouth， insomnia; tachycardia， palpitations， hypertension; dizziness， paresthesia， headache， anxiety; sweating; taste disturbances. 禁忌: Bulimia nervosa， psychiatric illness， Gilles de la Tourette's syndrome， coronary artery disease， CHF， tachycardia， occlusive artery disease， heart rhythm disorder， cerebrovascular disease， inadequately controlled hypertension， hyperthyroidism， severely hepatic/renal impairment， benign prostatic hyperplasia， pheochromocytoma， narrow angle glaucoma， pregnancy， lactation， children < 16， elderly ? 65. Concomitant use of MAOIs or other CNS active drugs for the treatment of mental disorders (such as antidepressants or antipsychotics)， for sleep disorders (tryptophan) or for weight reduction. Misuse of drugs， medicines or alcohol.,,室溫,D: Initial dose is 10 mg qd; if weight loss < 2 kg in 4 weeks and well-toleranted patients can increased to 15 mg qd.,,,,除非治療上需要,,,,,,,,,,
IOXY,Oxytocin,Oxytocin inj 10 IU/1mL,SGU,Induction of labor for medical reasons; stimulation or reinforcement of labor in hypotonic uterine inertia; during caesarean section， following delivery of the child; adjunctive therapy in the management of incomplete， inevitable， or missed abortion; prevention & treatment of postpartum uterine atony & haemorrhage.,Significant cephalopelvic disproportion or unfavorable presentation of the fetus， placenta praevia or vasa praevia， cord presentation or prolapse， mechanical obstruction to delivery， fetal distress or hypertonic uterine contractions; multiple pregnancy or high parity， polyhydramnios， or the presence of a uterine scar from previous caesarean section. Avoid prolonged administration in patients with oxytocin-resistant uterine inertia， severe pre-eclampsia or severe CV disorders.,Uterine spasm， uterine overstimulation (usually with excessive doses); water intoxication associated with maternal & neonatal hyponatraemia; nausea， vomiting， arrhythmias; rashes & anaphylactoid reactions. Rapid IV bolus inj may result in an acute short-lasting drop in BP.,25℃以下,Induction or stimulation of labor: 3 IU (0.3mL) IM or SC. Or 10 IU(1mL) in 0.9% NaCl or 5% glucose solution IV infusion 15 drops/minutes. Treatment and prophylaxis of postpartum haemorrhage: 0.6-2 IU(0.06-0.2mL) in 3-5mL 0.9% NaCl intravenously slowly. [Micromedex 2021/08/04] Induction of labor， Medically indicated: initial， 0.5 to 1 milliunit/min IV (3 to 6 mL/h of a 10 units/1000 mL dilute oxytocin solution); gradually increase dose in increments of 1 to 2 milliunits/min every 30 to 60 min until desired contraction pattern has been established; once desired frequency of contractions has been reached and labor progressed to 5 to 6 cm dilation， the dose may be reduced by similar increments. Postpartum hemorrhage 10 to 40 units of oxytocin added to running IV infusion (maximum 40 units to 1000 mL IV solution); adjust infusion rate to sustain uterine contractions and control uterine atony. 10 units IM given after delivery of the placenta.,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,IM;IVD;IVP;IVPUSH;SC;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【D5NS】可選 。【L/R】可選 。,Slow IV injections (5 or 10 units over 1 minute) are preferred for women without cardiovascular risk factors; very slow injections (?5 minutes) are preferred for women with cardiovascular risk factors.,注射速率:10~20 milliunit/min (postpartum bleeding) 輸注速率< 9~10 milliunit/min Maximum 40 units to 1000 mL IV solution.,
OSTR2,Atomoxetine,Strattera 25mg,CNEU,Treatment of attention-deficit/hyperactivity disorder (ADHD).,with a MAOI or within 2 weeks after discontinuing a MAOI， narrow-Angle Glaucoma.,Nausea， vomiting， fatigue， decreased appetite， abdominal pain， somnolence. Endocrine metabolic: Weight loss (pediatrics， 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults， 7%; pediatrics， 17% to 18% )， Constipation (adults， 9%; pediatric， 1% to 2%)， Decrease in appetite (adult， 11%; pediatrics， 16% ，)， Nausea (adults， 21%; pediatrics， 7% to 13% )， Vomiting (adults， 3%; pediatrics， 11%)， Xerostomia (adults， 21% ) Neurologic: Headache (pediatrics， 19% )， Insomnia (adults， 16%; pediatrics， at least 2%; )， Somnolence (adult， 4%; pediatrics， 11% ) Renal: Delay when starting to pass urine (adults， 5.6% )， Urinary retention (adults， 1.7% ) Reproductive: Dysmenorrhea (adults， 6% )， Erectile dysfunction (adults， 9% ) Other: Menopausal flushing (adults， 8% ),25℃以下,Adult， adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg， whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult， adolescent & children>70 kg maximum dose is 100 mg total daily .,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OREB,Ribavirin,Rebetol 200mg,QANB,,適應症: In combination with interferon α-2b for the treatment of chronic hepatitis C in adult patients who are α-interferon-naive or who have relapsed following α-interferon therapy. 副作用: Haemolysis， anaemia， neutropenia， dry mouth， hyperhidrosis， asthenia， chest pain， fatigue， fever， headache， flu-like symptoms， malaise， rigors， weight loss， dizziness， paresthesia， GI disturbances， arthralgia， myalgia， CNS effects， viral infection， cough， dyspnoea， pharyngitis， rhinitis， alopecia， pruritus， rash， dry skin， parageusia， blurred vision. 禁忌: History of severe pre-existing cardiac disease; haemoglobinopathies; severe， debilitating medical conditions; chronic renal failure or CrCl < 50 mL/minute. Pregnancy & lactation.,,室溫,Adult > 18 years >75 kg 600 mg bid as morning & evening doses. <=75 kg 400 mg in the morning; 600 mg in the evening. To be given in combination with interferon α-2b soln for SC inj at a dose of 3 million IU three times a weeks for 24 weeks.,,,,不可使用,,,,,,,,,,
IPRE0,Pneumococcal Vaccine Polyvalent,Prevenar (北市提供，13價肺炎) 0.5mL/dose,HIMM,,適應症:Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1， 3， 4， 5， 6A， 6B， 7F， 9V， 14， 18C， 19A， 19F and 23F in infants and children from 2 month-5 years. 副作用:Decreased appetite， irritability， drowsiness/increased sleep， restless sleep/decreased sleep， fever， inj site erythema， induration/swelling or pain/tenderness， rash. 禁忌:Hypersensitivity.,,2-8℃,0.5 mL/dose via IM inj. Infant 6 week-6 months Recommended 3-dose schedule: 1st dose at 2 month but can be given as young as 6 week with 1-month interval between doses， followed by a 4th (booster) dose to be administered at 12-15 months. Unvaccinated children 2-5 years 1 dose， 12-23 months 2 doses with at least 2-months interval between doses， Infant 7-11 months 2 doses with at least 1 month interval between doses， 3rd dose by 2nd year.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,IM;,,,,,1. 應以肌肉注射方式投予，最好注射在嬰兒大腿前外側的股外側肌，或是幼童上臂的三角肌。
IPAM,Pralidoxime,PAM inj 500mg/10mL,ZADT,,適應症:Organic phosphorus intoxication 副作用:Dizziness， hallucination， blurred vision， tachycardia， headache， vomiting， nausea， hypernea， myasthenia.,,RT,Adult 500 mg-1 g slow IV/inj. Children 20-40 mg/kg/inj,,,,除非治療上需要,,,Hold Breast Feeding 暫停哺乳,,,,,,,
OKLA5,Clarithromycin,Klaricid 500mg,QANB,Upper & lower respiratory tract. Eradication of H. pylori when used with omeprazole.,Known hypersensitivity to macrolides. Concomitant administration with astemizole， terfenadine， pimozide or cisapride.,Diarrhea， vomiting， abdominal pain， dyspepsia， nausea， headache， taste perversion， transient elevation of liver enzymes. Allergic reactions ranging from urticaria & mild skin eruptions to anaphylaxis & Stevens-Johnson syndrome/toxic epidermal necrolysis. Transient CNS effects including dizziness， vertigo， anxiety， insomnia， bad dreams， tinnitus， confusion， disorientation， hallucination， psychosis & depersonalization. Alteration of sense of smell with taste perversion. Glossitis， stomatitis， oral monilia， tongue discoloration， tooth discoloration. Gastrointestinal: Abdominal pain (adults， 2%; pediatrics 3% )， Diarrhea (adults， 3% to 6%， pediatrics， 6% )， Disorder of taste (3% to 18.9% )， Indigestion (2% )， Nausea (3% )， Vomiting (6% ) Neurologic: Headache (2% up to 9%),15-30℃避光,Adults and children > 12 years of age: 250-500 mg orally Q12H. (熱病) Pediatric age > 28 days: 15 mg/kg/day， divided Q12H (maximum 1 gm/day),需調整劑量,,需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
ODES,Potassium Citrate,Destone 540mg (5mEq),SGU,,適應症: Prevention of uric acid nephrolithiasis; prevention of Ca renal stones in patients with hypocitraturia; avoidance of the complication of Ca stone formation in uric lithiasis. 副作用: Abdominal pain; dyspepsia; gastroenteritis; hyperkinesia; nervousness. 禁忌: Hyperkalemia， peptic ulcer， abnormal renal function， anuria.,,室溫,Sever hypocitraturia 60 mEq/day. Mild to moderate hypocitraturia 30 mEq/day. Do not exceed 100 mEq/day.,,,,安全,,,,,,,,,,
IWIN,Cefazolin,Winzolin inj 1gm,QANB,,適應症:細菌性感染(A021012209)(B014405221),,RT,Adult 1 g in 2 divided doses， increase to 1.5-3 g in 3 divided doses; dose may be increased up to 5 g/day in individed doses. Childn 20-40 mg/kg daily in 2 divided doses， increase to 50 mg/kg in 3 divided doses; dose may be increased to100 mg/kg/day.,,,,可能安全,,,,,,,,,,
OZEL,Tegaserod,Zelmac 6mg,ALIM,,Treatment of abdominal pain & discomfort， bloating & altered bowel function in patients w/ irritable bowel syndrome (IBS) whose main symptoms are pain/discomfort & constipation.,,RT,6 mg bid,,,,可能安全,,,,,,,,,,
ESTE,Diazepam,Stesolid rectal tubes 10mg,CNEU,Convulsions， including febrile convulsions in children. As sedative before exploratory examination & treatment.,Myasthenia gravis， sleep apnoea， severe hepatic insufficiency， acute respiratory depression.,Fatigue， drowsiness， dizziness， memory loss， ataxia， disturbed balance， anterograde amnesia， confusion， paradoxical reactions eg confusion， excitation & dysphoria， respiratory depression. Cardiovascular: Hypotension Dermatologic: Rash (3%， rectal gel ) Gastrointestinal: Diarrhea (4%， rectal gel ) Musculoskeletal: Muscle weakness Neurologic: Ataxia， Incoordination (3%， rectal gel )， Somnolence Psychiatric: Euphoria (3%， rectal gel ) Respiratory: Respiratory depression Other: Fatigue,25℃以下,Adult & children 0.25-1 mg/kg.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,R;RECT;,,,,,
EBRU,Ciclopiroxolamine,Brumixol cream 10gm,TDER,,適應症:表皮黴菌感染(B021515329),,RT,Apply once daily to the affected skin area and its vicinity after thorough cleaning and drying. To prevent recurrent infection continue treatment for at least 2 weeks after clinical healing.,,,,可能安全,,,,,,,,,,
OLEXA,Escitalopram,LexaPRO 10mg,CNEU,,適應症: Treatment of major depressive episodes. Treatment of social anxiety disorder (social phobia). Treatment of generalised anxiety disorder. Treatment of obsessive-compulsive disorder (OCD). 副作用: Appetite decreased， libido decreased， anorgasmia (female)， insomnia， somnolence， dizziness， sinusitis， yawning， nausea， diarrhoea， constipation， sweating increased， ejaculation disorder， impotence， fatigue， pyrexia. Rarely， hyponatraemia， seizures， ecchymoses. Cardiovascular: Hypertension (1% or greater )， Palpitations (1% or greater ) Dermatologic: Diaphoresis (4% to 5% )， Rash (1% or greater ) Endocrine metabolic: Weight increased (1% or greater ) Gastrointestinal: Constipation (3% to 6% )， Diarrhea (6% to 14% )， Gastroenteritis (1% or greater )， Heartburn (1% or greater )， Indigestion (2% to 6% )， Nausea (15% to 18% )， Xerostomia (4% to 9% ) Musculoskeletal: Arthralgia (1% or greater )， Myalgia (1% or greater ) Neurologic: Dizziness (4% to 7% )， Headache (24% )， Insomnia (7% to 14% )， Lightheadedness (1% or greater )， Somnolence (4% to 9% ) Reproductive: Disorder of ejaculation (9% to 14%)， Impotence (3% )， Orgasm incapacity (females， 2% to 6% )， Reduced libido (males， 6%; females， 3%) Other: Fatigue (2% to 6% ) 禁忌: Concomitant treatment with non-selective， irreversible MAOIs.,,室溫,Social anxiety disorder 10 mg once daily for 2-4 weeks. Dose may be adjusted to 5 mg or max 20 mg daily. Treatment for 3 months is recommended. Generalised anxiety disorder 10 mg once daily; may be increased to max 20 mg daily. Obsessive-compulsive disorder 10 mg once daily; may be increased to max 20 mg daily. Duration may be several months or longer.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OVGR1,Sildenafil,VIAGRA 100mg (4 tablets/box),SGU,Treatment of erectile dysfunction.,Patients who use nitric oxide donors or nitrates. Viagra should not be used in men for whom sexual activity is inadvisable (patients with severe CV disorders eg unstable angina or severe cardiac failure). Severe hepatic impairment， hypotension (< 90/50 mm Hg) or hypertension (> 170/100 mm Hg)， recent history of stroke or MI， known hereditary degenerative retinal disorders such as retinitis pigmentosa. Not indicated for women.,Headache， flushing， dizziness， dyspepsia， nasal congestion， altered vision. Dermatologic: Erythema (6% )， Flushing (10% ) Gastrointestinal: Indigestion (4% to 17% ) Neurologic: Headache (16% to 46% )， Insomnia (up to 7% ) Ophthalmic: Visual disturbance (3% to 11% ) Respiratory: Epistaxis (3% to 9% )， Nasal congestion (4% )， Rhinitis (4% ),30℃以下,Erectile dysfunction: Sildenafil 25 to 100 mg (50 mg usual dose) orally 1 hour (range 0.5 to 4 hours) prior to sexual activity; the maximum frequency of administration once daily.,需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥不應用於管灌病患。
OCIA,Tadalafil,Cialis 20mg 4's/box,SGU,,Erectile dysfunction,,RT,Erectile dysfunction a) ONCE-DAILY DOSING 1) Once-daily doses of 50 milligrams (mg) have been effective in nondiabetic patients with mild or moderate erectile dysfunction; doses were taken each morning (Porst， 2002b). The longest duration of once-daily treatment has been 3 weeks. 2) This dose regimen provides "round-the-clock coverage，" eliminating the need for planning of sexual activity and enhancing spontaneity; however， it has not been evaluated as extensively as on-demand dosing. b) ON-DEMAND DOSING 1) For on-demand dosing， the manufacturer recommends an initial dose of 10 milligrams (mg) prior to sexual activity. The dose may be increased to 20 mg or decreased to 5 mg depending upon individual efficacy and tolerability. The maximum recommended dosing frequency is once daily. Tadalafil has been shown to improve erectile function for up to 36 hours after administration. Tadalafil may be taken with or without food (Prod Info Cialis(R)， 2003n). 2) In patients taking concomitant potent inhibitors of CYP3A4 (eg， ketoconazole， ritonavir)， the maximum recommended dose of tadalafil is 10 milligrams， not to exceed once every 72 hours (Prod Info Cialis(R)， 2003n). 3) Studies indicate that doses of 10 to 25 milligrams are effective in mild-to-severe erectile dysfunction， including diabetics (Anon， 2001a; Porst， 2002b; Padma-Nathan et al， 2001b; Sorbera et al， 2001b; Saenz de Tejada et al， 2001a). 4) Successful erections upon sexual stimulation have been achieved as early as 15 minutes postdosing (Anon， 2001a; Brock， 2001a); most responding patients will achieve an adequate erection within 30 to 45 minutes (Brock， 2001a). Thus， administration 30 to 60 minutes prior to sexual activity would appear sufficient. The duration of effect is up to 36 hours (Porst et al， 2003; Brock， 2001a; Porst， 2002b; Anon， 2001a) and only one dose per 24 hours (as needed) is indicated (Padma-Nathan et al， 2001b). The longest duration of on-demand treatment has been 12 weeks.,,,,沒有資料,,,,,,,,,,
OGAS,Metoclopramide,Gastro-Timelets 30mg,ALIM,,適應症:治療消化系統異常或預防嘔吐(B019538100),,RT,1 tab daily,,,,可能安全,,,,,,,,,,
ORISU,Amezinium,Risumic 10mg,CAVS,,Essential & orthostatic hypotension， hypotension during hemodialysis,,RT,Essential & orthostatic hypotension: 10 mg bid Hypotension during hemodialysis: 10 mg at start,,,,沒有資料,,,,,,,,,,
OCOU1,Warfarin,Coumadin 1mg,HEMT,,I: Thrombolic conditions. CI: Pregnancy; haemorrhagic tendency or blood dyscrasias; recent or contemplated surgery of CNS， eye; traumatic surgery resulting in large open surfaces; bleeding tendencies associated with active ulceration or overt bleeding; threatened abortion; spinal puncture.,,RT,Initial: 40-60 mg/day. Maintenance: 2-10 mg/day,,,,不可使用,,,,,,,,,,
OASP,Acetylsalicylic Acid,Aspirin protect 100mg,HEMT,Reducing the risk of mortality in patients with a suspected acute MI or a history of MI; secondary prevention of stroke; reducing the risk of transient ischaemic attacks (TIA) & stroke in patients with TIA; reducing the risk of morbidity & death in patients with stable & unstable angina pectoris; prevention of thromboembolism after vascular surgery or interventions (e.g. PTCA， CABG， carotid endarterectomy， arteriovenous shunts); prophylaxis of deep vein thrombosis & lung embolism after longer-term immobilisation (e.g. after major surgery); reducing the risk of first MI in patients with CV risk factors (e.g. diabetes mellitus， hyperlipidaemia， hypertension， obesity， smoking， old age).,Active peptic ulcers; haemorrhagic diathesis; a history of asthma induced by acetylsalicylic acid or other NSAIDs; combination with methotrexate at doses of ? 15 mg/week; last trimester of pregnancy.,Hypersensitivity reactions; GI disturbances; GI bleeding， ulceration or perforation; bleeding; dizziness & tinnitus.,25℃以下,Take 100-200 mg every day or 300 mg every other day: Reduce the mortality of patients who may have acute myocardial infarction， Prevent deep vein thrombosis and pulmonary embolism caused by long-term immobility， Reduce the risk of first myocardial infarction in patients with cardiovascular risk factors， such as diabetes， hyperlipidemia， hypertension， obesity， smoking， and the elderly. Take 100-300 mg every day: Reduce the recurrence rate and mortality of patients with myocardial infarction， Prevent secondary-stroke， Reduce the recurrence of transient ischemic attack and stroke in patients with transient ischemic attack， Reduce the incidence and mortality of patients with stable and unstable angina， Prevent thromboembolism caused by vascular surgery or invasive treatment， such as percutaneous coronary angioplasty， coronary artery separation， flow transplantation， carotid endarterectomy， arteriovenous catheter.,需調整劑量,,需調整劑量,除非治療上需要,Compatible,1.Compatible (Low Dose) 40~150mg/day 2.PREGNANCY RECOMMENDATION: Human Data Suggest Risk in 1st and 3rd Trimesters (Full Dose),No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;PO;,,,,,[磨粉/管灌註記]本藥為腸溶錠，請整粒吞服，不可撥半或磨粉。
IARA,Darbepoetin alfa,Aranesp 25mcg/mL (限自費-洗腎室用),HEMT,,適應症:Treatment of anemia associated with chronic renal failure (CRF)， including patients either on or not on dialysis. Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. 副作用:Vascular access thrombosis， CHF， sepsis， cardiac arrhythmia， infections， hypertension， hypotension， myalgia， headache， diarrhea， fever， nausea， chest pain 禁忌: Uncontrolled hypertension.,,2-8℃,CRF patients Starting dose: 0.45 mcg/kg body weight as a single weekly IV or SC inj. Cancer patients receiving chemotherapy Starting dose: 2.25 mcg/kg as a weekly SC inj. Doses should be titrated to not exceed a target hemoglobin concentration of 12 g/dL or cause a rapid rise in hemoglobin levels (e.g. >1 g/dL in any 2-week period).,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
LCAR,Digoxin,Cardiacin elixir 0.05mg/mL,CAVS,,適應症: Heart failure， atrial fibrillation &/or flutter & supraventricular tachycardia. 副作用: Anorexia， nausea， vomiting. Rarely psychosis， verbal & visual disturbances including hallucinations. GI disturbances， arrhythmia， tachycardia， bradycardia， dizziness， headache， confusion. Hypersensitivity reactions. 禁忌: Intermittent complete heart block or 2nd degree AV block; arrhythmias caused by cardiac glycoside intoxication.,,室溫,Oral digitalizing dose Children 4-6 years Initially 10-12 mL (0.5-0.6 mg). Maintenance: 3-4 mL (0.15-0.2 mg); 2-3 years Initially 8 mL (0.4 mg). Maintenance: 2-3 mL (0.1-0.15 mg); >12 months Initially 6-8 mL (0.3-0.4 mg). Maintenance: 2 mL (0.1 mg); >3 months Initially 4-6 mL (0.2-0.3 mg). Maintenance: 1.5-2 mL (0.075-0.1 mg); >1 month Initially 2-4 mL (0.1-0.2 mg). Maintenance: 1 mL (0.05 mg). To be taken daily in 3-4 divided doses.,無需調整劑量,,需調整劑量,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
EELE1,Carteolol,Elebloc 1%， 5mL,TOPH,,適應症: Glaucoma， ocular hypertension. 副作用: Burning or transient ocular itching， blepharoconjunctivitis， decreased corneal sensitivity， decreased tear secretion. 禁忌: Bronchial asthma， significant bradycardia (< 45-50 beats/min)， 2nd or 3rd degree AV block or uncontrolled CHF， Raynaud's disease.,,室溫,Initially 1 drop of 1% soln bid (morning & evening) into each affected eye. Dose may be increased to 1 drop of 2% soln bid. Max: 2 drops daily. If intraocular pressure is controlled， 1 drop daily.,,,,盡量避免,,,,,,,,,,
EELE2,Carteolol,Elebloc 2%， 5mL,TOPH,,適應症: Glaucoma， ocular hypertension. 副作用: Burning or transient ocular itching， blepharoconjunctivitis， decreased corneal sensitivity， decreased tear secretion. 禁忌: Bronchial asthma， significant bradycardia (< 45-50 beats/min)， 2nd or 3rd degree AV block or uncontrolled CHF， Raynaud's disease.,,室溫,Initially 1 drop of 1% soln bid (morning & evening) into each affected eye. Dose may be increased to 1 drop of 2% soln bid. Max: 2 drops daily. If intraocular pressure is controlled， 1 drop daily.,,,,盡量避免,,,,,,,,,,
IKA1,Triamcinolone Acetonide,Kenacort-A 10mg/1mL,HM,,適應症：關節炎(A034743209),,RT,Intra-articular: 2.5-15 mg. Intradermal or intralesional: less than 1 mg/site.,,,,除非治療上需要,,,,,,,,,,
IVAX4,Purified Split Inactivated Influenza Virus,免費成人流感 0.5mL/dose (12~64歲擴大對象),HIMM,,I: Prophylaxis against influenza. ADR: Erythema (rash)， swelling， pain， ecchymosis， induration， fever， dizziness， shivering， tiredness， headaches， sweating， muscle pain， joint pains. CI: Allergy to eggs， chicken protein or any constituents of the vaccine. Febrile illness or acute infection.,,2 ~ 8 °C,Adult & Children >= 36 mth 0.5ml IV or deep SC. Chidren <= 8 yr who have not been vaccinated previously， the 2nd dose can be given at an interval of at least 4 wk.,,,,除非治療上需要,,,,,,,,,,
LMUS,Ambroxol,Musco soln 3mg/mL， 60mL,ERSP,,,,,,,,,,,,,,,,,,,
OACT3,Pioglitazone,Actos 30mg,META,Monotherapy or in combination with sulphonylureas， metformin or insulin in patients with type II diabetes.,Type 1 diabetes， diabetic ketoacidosis. Active hepatic disease or ALT levels > 2.5 times the upper limit of normal. NYHA class III or IV heart failure.,Edema， upper respiratory tract infection， headache， myalgia. Cardiovascular: Edema (4.8% to 15.3% ) Endocrine metabolic: Weight gain Hematologic: Anemia (less than or equal to 2% ) Musculoskeletal: Fracture of bone (5.1% )， Myalgia (5.4%) Neurologic: Headache (9.1% ) Respiratory: Pharyngitis (5.1% )， Sinusitis (6.3% )， Upper respiratory infection (13.2% ),15-30℃，25℃為佳,15-30 mg once daily， maximum: 45 mg/day.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OMINE,Gestodene + Ethinylestradiol,Minesse F.C 28's/box,HM,,I: Oral contraceptive. CI: Defects of coagulation system， valvular heart disease， atrial fibrillation， acute & chronic liver function disturbance， sex ster-oid dependent neoplasia， sickle cell anemia， severe diabetes with vascular changes， herpes gestations， undiagnosed vag bleeding， pregnancy， disorders of lipometabolism. ADR: Headache， pain， asthenia， elevated BP， nausea， flatulence， vomiting， edema， hypercholesterolemia， wt gain， depression， dizziness/vertigo， emotional lability， nervousness， acne pruritus， breast pain， dysmenorrhea， metrorrhagia， amenorrhea， breast engorgement， breast enlargement， beast neoplasm， cervix dis-order， leukorrhea， menorrhea， vag moniliasis， vaginitis.,,RT,D: 1 tab daily， starting on day 1 of menstrual cycle. Tab: 28's (24 tab with ethinylestradiol 15ug & gestodene 60ug， plus 4 inactive tab),,,,不可使用,,,,,,,,,,
ESERE,Salmeterol + Fluticasone,Seretide 50 evohaler,ERSP,Regular treatment of reversible obstructive airways disease (ROAD)， including asthma in adult & children， where combination therapy (bronchodilator & inhaled corticosteroid) is appropriate. Seretide Accuhaler 250/Seretide Evohaler 125/Seretide Evohaler 250 Maintenance treatment of COPD including chronic bronchitis & emphysema.,History of hypersensitivity to any of the ingredients of Seretide.,Hoarseness or dysphonia， throat irritation， headache， candidiasis of mouth & throat， palpitations， tremor， paradoxical bronchospasm， arthralgia. Gastrointestinal: Nausea (COPD， above 5% )， Oral candidiasis (asthma， 1% to 4%; COPD， 10% ) Musculoskeletal: Musculoskeletal pain (asthma， 2% to 7%; COPD， 9% ) Neurologic: Dizziness (asthma， 1% to 4%; COPD， 4% and greater )， Headache (9% to 21% ) Respiratory: Bronchitis (asthma， 2% to 8% )， Cough (asthma， 3% to 6% )， Difficulty speaking， Hoarse， Pharyngitis (asthma， 10% to 13% )， Throat irritation (7% to 9% )， Upper respiratory infection (asthma， 16% to 27%; COPD， greater than 5% )， Viral lower respiratory infection (3% to 6% ),乾燥避曬30℃以下,Asthma: Adults and adolescents 12 years and older: Two inhalations of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily. Children 4 years and older: 2 inhalation of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily. There are no recommended doses available in children aged under 4 years.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
OENTE,Entecavir,Entecavir 0.5mg,QANB,,,,,,,,,,,,,,,,,,,
OGAB,Glibenclamide,Gabemid (Glibenclamide) 5 mg,META,,適應症: Diabetes mellitus. 副作用: Mild or severe hypoglycaemia， GI distress; dizziness， edema & hyponatraemia， urticaria， pruritus， rash， photosensitivity， cholestatic jaundice， hepatic porphyria. 禁忌: Insulin-dependent diabetes， hepatic or renal dysfunction， uraemia， acidosis， ketosis， coma， pregnancy， severe cases of stress， fever， infection， trauma， juvenile onset or unstable diabetes.,,室溫,Initially 2.5 mg daily for 3-5 days. Adjust dose by 2.5 mg increment if required. Max: 15 mg daily.,,,,除非治療上需要,,,,,,,,,,
OBAR,Entecavir,Baraclude 0.5mg,QANB,Treatment of chronic active type B viral hepatitis or reactivation of hepatitis B viral hepatitis in adults and children over 2 years of age.,Hypersensitivity to entecavir or any component of the formulation.,Common Gastrointestinal: Nausea (Adult， less than 1%; Pediatric， greater than 1% ) Neurologic: Dizziness (Less than 1% )， Headache (2% to 4% ) Other: Fatigue (1% to 3% ) Serious Endocrine metabolic: Lactic acidosis Hepatic: Hepatomegaly (Severe)， With steatosis， Recurrent hepatitis,30℃以下避光,Administer on an empty stomach (2 hours before or after a meal). Adults and adolescents > 16 years: nucleoside-treatment naive， compensated liver disease: 0.5 mg once daily; decompensated liver disease: 1 mg once daily. Children and adolescents 2 to <16 years: 10 to 11 kg: 0.15 mg oral solution once daily >11 to 14 kg: 0.2 mg oral solution once daily >14 to 17 kg: 0.25 mg oral solution once daily >17 to 20 kg: 0.3 mg oral solution once daily >20 to 23 kg: 0.35 mg oral solution once daily >23 to 26 kg: 0.4 mg oral solution once daily >26 to 30 kg: 0.45 mg oral solution once daily >30 kg: 0.5 mg oral solution or tablet once daily,無需調整劑量,Breastfeeding Recommendation: Contraindicated (HIV) ; No Human Data—Probably Compatible (Hepatitis B) [仿單]目前尚不清楚BARACLUDE是否會排入人類乳汁、影響母乳分泌，或對哺乳嬰兒造成影響。在大鼠哺乳期施用時，entecavir會出現在乳汁中(請見資料)。在考量哺餵母乳對發育和健康效益時，應一併考量產婦對BARACLUDE的臨床需求，以及BARACLUDE或產婦的身體狀況對餵哺母乳嬰兒的所有可能不良反應。在大鼠哺乳第7天口服單劑entecavir 10mg/kg後，entecavir會分泌至大鼠的乳汁中。乳汁中的entecavir約為母體血漿中的25%(根據AUC)。,需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,[仿單]在孕婦中並無適當且具有良好對照的BARACLUDE研究。因為動物生殖研究未必能預測人體的反應，所以只有在潛在效益高於對胎兒的潛在風險時，方能於懷孕期間使用BARACLUDE(entecavir)。在動物生殖研究中，entecavir達到臨床意義暴露時，並未觀察到不良發育影響。全身暴露量(AUC)約為人類最大建議劑量(MRHD)每日1mg的25倍(大鼠)與200倍(兔子)時，並未觀察到發育毒性。在胎兒器官形成期間(妊娠第6至15天[大鼠]與妊娠第6至18天[兔子])，對懷孕的大鼠(每日每公斤體重2、20及200毫克)與兔子(每日每公斤體重1、4及16毫克)口服施用entecavir。在大鼠中，當母體全身暴露(AUC)為MRHD的3100倍時，觀察到胚胎－胎兒毒性，包括著床後流產、胚胎再吸收、尾巴與脊椎畸形、骨骼變化，包括成骨不全(脊椎、胸骨節與指骨)、多餘的腰椎與肋骨、胎兒體重較輕。在該劑量濃度也觀察到母體毒性。在兔子中，當母體全身暴露(AUC)為MRHD的883倍時，觀察到胚胎－胎兒毒性，包括著床後流產、胚胎再吸收及骨骼變化，包括成骨不全(舌骨)、第13肋骨的發生率增加。當懷孕動物口服施用的entecavir約為28倍(大鼠)與212倍(兔子)之MRHD人體暴露量(AUC)時，並無胚胎－胎兒毒性的現象。在產前及產後發育試驗中，從妊娠第6天至哺乳期/產後20天，對懷孕大鼠口服施用entecavir，劑量為每日每公斤體重0.3、3及30毫克。在評估的最高劑量下，暴露量(AUC)高於MRHD94倍，並未對後代產生不良影響。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Breastfeeding Recommendation: Contraindicated (HIV) ; No Human Data—Probably Compatible (Hepatitis B) [仿單]目前尚不清楚BARACLUDE是否會排入人類乳汁、影響母乳分泌，或對哺乳嬰兒造成影響。在大鼠哺乳期施用時，entecavir會出現在乳汁中(請見資料)。在考量哺餵母乳對發育和健康效益時，應一併考量產婦對BARACLUDE的臨床需求，以及BARACLUDE或產婦的身體狀況對餵哺母乳嬰兒的所有可能不良反應。在大鼠哺乳第7天口服單劑entecavir 10mg/kg後，entecavir會分泌至大鼠的乳汁中。乳汁中的entecavir約為母體血漿中的25%(根據AUC)。,AC;AC15;PO;,,,,,
ITRA9,Atosiban,Tractocile inj 7.5mg/mL， 0.9mL,SGU,,適應症: Delay imminent preterm birth in pregnant women with regular uterine contractions of at least 30 seconds duration at a rate of >=4 per 30 mins; cervical dilation of 1-3 cm (0-3 for nulliparas) & effacement of >=50%， age >=18 years; gestational age of 24-33 weeks， normal fetal heart rate. 副作用: Very common (>10%): nausea. Common (1-10%): headache， dizziness， hot flushes， vomiting， tachycardia， hypotension， inj site reactions， hyperglycemia. Uncommon (0.1%-1%): fever， insomnia， pruritus， rash. Rare (<0.1%): incidental cases of uterine haemorrhage/uterine atony and one case of allergic reaction were reported. 禁忌: Gestation ages <24 weeks or >33 weeks premature rupture of the membranes > 30 weeks of gestation， intrauterine growth retardation & abnormal fetal heart rate， antepartum uterine hemorrhage requiring immediate delivery， eclampsia & severe pre-eclampsia requiring delivery， intrauterine fetal death， suspected intrauterine infection， placenta praevia， abruptio placenta， abnormal or high-risk pregnancy.,,2-8℃,Initially 6.75 mg via slow IV over 1 min， followed by continuous IV infusion at 18 mg/ hr for 3 hrs. Thereafter， administer 6 mg / hr via continuous IV infusion up to 45 hr.,,,,沒有資料,,,,,,,,,,
ONIL,Betahistine,Nilasen 16mg,CNEU,,適應症: Vertigo & hearing impairment associated with Meniere's syndrome. Treatment of vestibular vertigo. 副作用: Mild gastric complaints. Very rarely， rash， pruritus， urticaria.,,室溫,Adult 24-48 mg daily in divided doses.,,,,沒有資料,,,,,,,,,,
OSPI,Spironolactone,Spironolactone 25mg,CAVS,Edematous disorders， Congestive cardiac failure， Liver cirrhosis， Nephrotic syndrome， Idiopathic edema， Hypertension.,Acute renal insufficiency; significant impairment of renal function; anuria; hyperkalaemia; hypersensitivity.,GI symptoms; drowsiness; lethargy; headache; cutaneous eruptions; urticaria; mental confusion; drug fever; ataxia; impotence; amenorrhea; post-menopausal bleeding; gynecomastia; rarely agranulocytosis.,陰涼(15-30℃) 乾燥處所,Diuretic-induced hypokalemia: 25-100 mg/day in 2-4 divided doses. Congestive cardiac failure/Liver cirrhosis/Nephrotic syndrome， Edematous disorders: Initially， 25-200 mg/day in 2-4 divided doses， administer for at least 5 days before increasing dose to obtain desired effect. Maintenance dose: 75-400 mg/day in 2-4 divided doses. Hypertension: 50-100 mg/day given in divided doses or as a single daily dose. For difficult or severe cases， gradually increased at 2-weekly intervals up to 200 mg/day. Hyperaldosteronism: Preparation for surgery: 100-400 mg/day in 2-4 divided doses. Long-term therapy for patients unsuitable for surgery: use lowest effective dosage. Children: Initial daily dose approximately 1-3 mg/kg in a single or divided doses， administer for at least 5 days before increasing dose to obtain desired effect.,需調整劑量,,需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,No reports linking spironolactone with human congenital defects have been located. Some have commented， however， that spironolactone may be contraindicated during pregnancy based on the known antiandrogenic effects in humans and the feminization observed in male rat fetuses. Other investigators consider diuretics in general to be contraindicated in pregnancy， except for patients with cardiovascular disorders， because they do not prevent or alter the course of toxemia and they may decrease placental perfusion. In general， diuretics are not recommended for the treatment of gestational hypertension because of the maternal hypovolemia characteristic of this disease.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
ILOF1,Cephradine,LofaDine 針劑 1gm,QANB,,適應症: Treatment of infections of the respiratory tract， urinary tract， skin & soft tissue， bones & joints; septicaemia; endocarditis. 副作用: Pain at inj site， thrombophlebitis， GI disturbances， hypersensitivity reactions including skin rashes， overgrowth of non-susceptible organisms， transient increases in hepatic enzyme levels. Rarely， pseudomembranous colitis， nephrotoxicity. 禁忌: Hypersensitivity to cephalosporins.,,室溫,Adult: 0.5-1 g q4-6h， (max. 8 g/day). Child over 1 yr: 50-100 mg/kg/day in 4 divided doses; max. daily dose should not exceed the recommended adult dose.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
IBAY5,Hepatitis B Immune Globulin,Bay Hep B 5mL,HIMM,,適應症:Post-exposure prophylaxis of hepatitis. Acute exposure to blood containing HBsAg， perinatal exposure of infants born to HBsAg +ve mothers， sexual exposure to an HBsAg +ve person， household exposure to persons with acute HBV infection. 副作用: Local pain & tenderness at the inj site， urticaria & angioedema， anaphylactic reactions.,,2-8℃,By IM inj only. Acute exposure to blood containing HBsAg 0.06 mL/kg body weight within 24 hr. Prophylaxis of infants born to HBsAg & HBeAg +ve mothers 0.5 mL to be given within 12 hr of birth. Sexual exposure to an HBsAg +ve person 0.06 mL/kg as a single dose within 14 days of sexual contact. Give together with 1st dose of 1 mL IM of vaccine. Household exposure to persons with acute HBV infection Infants < 12 months 0.5 mL.,,,,除非治療上需要,,,,,,,,,,
OAMZ,Dihydroxyalumium allantoinate + Metamagnesium alum,A.M.Z,ALIM,,適應症: Relief of gastric hyperacidity， gastric & duodenal ulcer， acute & chronic gastritis. 副作用: Constipation or diarrhea.,,室溫,1 tab TID ~ QID,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OALUS,Aldioxa,Alusa 100mg,ALIM,,適應症:Acute & chronic gastritis， indigestion， hyperacidity & symptomatic relief of pain due to peptic or duodenal ulceration. 副作用:Constipation. 禁忌:Hypophosphatemia,,室溫,100mg TID ~ QID,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OZIN,Zinc Acetate,Zinca 50 mg,META,,,,,,,,,,,,,,,,,,,
IPREV,Pneumococcal Vaccine Polyvalent,Prevenar (七價肺炎疫苗) 0.5mL/dose,HIMM,,適應症: Active immunisation of infants & toddlers against invasive disease caused by Strep pneumoniae serotypes (4， 6B， 9V， 14， 18C， 19F & 23F) at 2， 4， 6 & 12-15 months of age. Active immunisation of infants & toddlers < 2 years against otitis media caused by Strep pneumoniae serotypes (4， 6B， 9V， 14， 18C， 19F & 23F). 副作用: Decreased appetite， vomiting， diarrhoea， injection site reactions (e.g. erythema， induration/swelling， pain/tenderness)， tenderness interfering with movement， fever， irritability， drowsiness， restless sleep.,,2-8℃,Children 24 months-9 years A single dose of 0.5 mL IM， 12-23 months 2 doses of 0.5 mL with an interval of at least 2 months. Infants 7-11 months 2 doses of 0.5 mL with an interval of at least 1 month. A 3rd dose is recommended in the 2nd year of life， 2-6 months 3 doses of 0.5 mL with the 1st dose given at 2 months of age & with an interval of at least 1 month between doses. A 4th dose is recommended in the 2nd year of life.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EVID,Carbomer,Vidisic gel 10gm,TOPH,Substitute for lacrimal fluid in deficiency of tear production or dry eye.,Hypersensitivity to cetrimide.,Transient blurring in vision.,25℃以下,Instill 1 drop into conjunctival sac 3-5 times daily or more frequently during the day & before bed.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,OD;OL;OU;,,,,,
OWIT1,Memantine,Witgen 10mg,CNEU,Alzheimer's disease (Moderate to Severe),Hypersensitivity to memantine hydrochloride or any other components of the product,Common Gastrointestinal: Constipation (3% to 5% )， Diarrhea (5% )， Vomiting (2% to 3% ) Neurologic: Confusion (6% )， Dizziness (5% to 7% )， Headache (adults， 6% ; pediatrics， 8% ) Serious Neurologic: Cerebrovascular accident， Seizure (up to 0.3% ) Renal: Acute renal failure Respiratory: Pneumonia,25°C以下,Initial， 5 mg orally once daily; titrate in 5-mg increments at intervals of at least 1 week to 10 mg/day (5 mg twice daily)， 15 mg/day (5 mg and 10 mg in separate doses)， and 20 mg/day (10 mg twice daily); target daily dose is 20 mg/day,無需調整劑量,仿單未有說明,需調整劑量,沒有資料,Uknown 沒有資料,仿單未有說明,Unknown 沒有資料,仿單未有說明,AC;PO;WM;,,,,,
OMIZ,Mizolastine,Mizollen 10mg (自費),HIMM,,【I】Symptomatic treatment of seasonal & perennial allergic rhinoconjunctivitis & urticaria..,,RT,【D】Adult & childn > 12 yr 1 tab once daily,,,,沒有資料,,,,,,,,,,
OKYT,Granisetron,Kytril 1mg,CNEU,Prevention or treatment of nausea & vomiting induced by cytostatic therapy & radiation.,Hypersensitivity to granisetron or related substances.,Headache， constipation. Gastrointestinal: Constipation (5.4% ),30℃以下,Chemotherapy-induced nausea and vomiting; Prophylaxis: Adult: 1 mg BID or 2 mg once daily start from 1 hour before chemotherapy. Radiation-induced nausea and vomiting; Prophylaxis: Adult: 2mg QD for 7 days at most， start from 1 hour before radiotherapy. Children: There is not enough suggested information.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
IREC2,Propofol,RECOFOL 20mg/mL，10mL,ZANE,,,,,,,,,,,,,,,,,,,
ONOV,Prochlorperazine,Novamin 5mg,CNEU,Pyschosis， nausea， vomiting.,Bone-marrow depression.,CV & haematological changes， GI disturbances. Hepatic dysfunction， Malin syndrome， extrapyrimidal reactions， visual disturbances， weight increase， breast enlargement changes in libido， dysmenorrhoea， CNS disorders， photosensitivity.,30℃以下乾燥避光,Adult: 5-10 mg TID-QID (maximum: 150 mg/day). Children > 2 years or > 9 kg: 0.1 mg/kg or 2.5mg/m2 QID. Antiemetic: Body weight 9-13 kg: 2.5mg QD-BID， maximum: 7.5mg/day. Body weight 14-17 kg: 2.5mg BID-TID， maximum: 10 mg/day. Body weight 18-39 kg: 2.5mg TID or 5mg BID， maximum: 15 mg/day. For antipsychotic or sedation (2-12 years): 2.5mg BID-TID. Note: 1. Not recommended for children under 9 kg. Maximum dosage: first day， 10 mg; thereafter (2-5 years) 20mg/day; (6 to 12 years) 25 mg/day. 2. Children with an acute illness or dehydration are at increased risk of extrapyramidal syndrome.,無需調整劑量,[仿單]無相關記載,無需調整劑量,沒有資料,Compatible,[仿單]無相關記載,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]無相關記載,AC;AC15;PC;PO;WM;,,,,,
OPARL,Bromocriptine,Volbro 2.5mg,CNEU,Galactorrhea &/or prolactin-dependent amenorrhea， female infertility， Suppression of lactation， Pre-menstrual syndrome， Male hypogonadism， Acromegaly， Parkinson's disease.,Hypersensitivity to bromocriptine or ergot alkaloids， uncontrolled hypertension during pregnancy， post-partum or puerperal period.,Slight nausea， dizziness， fatigue， vomiting， orthostatic hypotension， constipation， drowsiness. Cardiovascular: Hypotension (type 2 diabetes， 2.2% ) Gastrointestinal: Constipation (acromegaly， 14%; hyperprolactinemic indications， 3%; type 2 diabetes， 5.8% to 11.3% )， Diarrhea (hyperprolactinemic indications， 3%; type 2 diabetes， 8.1% to 8.8% )， Indigestion (acromegaly， 4%; type 2 diabetes， 7.5% )， Nausea (acromegaly， 18%; hyperprolactinemic indications， 49%; type 2 diabetes， 25.4% to 32.5% )， Vomiting (acromegaly， 2%; hyperprolactinemic indications， 5%; type 2 diabetes， 5.3% to 8.1% ) Neurologic: Asthenia (type 2 diabetes， 12.5% to 18.9% )， Dizziness (hyperprolactinemic indications， 17%; type 2 diabetes， 11.9% to 14.8% )， Headache (hyperprolactinemic indications， 19%; type 2 diabetes， 11.4% to 16.8% )， Somnolence ( 3% to 6.6% ) Ophthalmic: Amblyopia (type 2 diabetes， 5.3% to 7.5% ) Respiratory: Rhinitis (type 2 diabetes 10.7% to 13.8% )， Sinusitis (type 2 diabetes， 7.4% to 10% ) Other: Fatigue (hyperprolactinemia indications， 7%; type 2 diabetes， 13.9% ),室溫藥品，仿單無特別指示儲存溫度條件,Galactorrhea/hyperprolactinemia related amenorrhea or female infertility: 2.5 mg BID-TID. If the effect is not significant， can slowly increased to 5mg BID-TID. Inhibition of lactation: 5 mg BID for 14 days to maximum of 21 days. Premenstrual syndrome: 2.5 mg once daily from day 14 of the cycle， increment of 2.5mg every day to 2.5 mg twice daily， continue use until menstruation. Prolactin induced male hypogonadism: 10-20 mg daily. Prolactinoma: 2.5 mg BID-TID initially， slowly increase dose until optimal therapeutic response achieved. Acromegaly: 5mg daily and slowly increased to 20-40mg/day in 4 divided doses. Parkinsonism: start from 1.25 mg QD-BID， increased by 2.5 mg daily in 3-day or longer intervals as tolerated. Usual dose: 20-40mg/day.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Contraindicated 哺乳期使用禁忌,,PC;PO;WM;,,,,,
OSIL,Silymarin,Silimin 150mg,ALIM,,適應症:Chronic hepatitis， liver cirrhosis， fatty liver.,,室溫,150 mg bid-tid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OLOF,Cephalexin,Lofaxin 250mg,QANB,,適應症: Infections caused by Staph， Strep， pneumococci & other susceptible bacteria. 副作用: Diarrhea; superinfection; hypersensitivity reactions; eosinophilia; neutropenia， thrombopenia; rarely erythema multiforme， anaphylaxis; pseudomembranous colitis. 禁忌: Hypersensitivity to cephalosporins.,,室溫,Adult: 250 mg q6h， (max. 4g/day). Child: 6.25-12.5 mg/kg q6h， up to 25 mg/kg q6h.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
ODDA,Desmopressin,Minirin (DDAVP) 0.1mg,HM,,適應症: 主治尿崩症、夜尿症(B020826100) Central Diabetes Insipidus， Primary Nocturnal Enuresis， Renal Concentrating Capacity Test，Symptomatic treatment of nocturia in adults associated with nocturnal polyuria ie， nocturnal urine production exceeding bladder capacity. Hemophilia A and von Willebrand's Disease 副作用: Nausea， abdominal pain， headache， nasal congestion/rhinitis， nose bleeds. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl. Dermatologic: Flushing Gastrointestinal: Nausea， Will respond to dosage decrease Neurologic: Fatigue (10% )， Headache (22.5% ) 禁忌:Habitual & psychogenic polydipsia， syndrome of inappropriate ADH secretion (SIADH)， known hyponatremia， known or suspected cardiac decompensation & other conditions that require diuretics， moderate & severe renal impairment.,,室溫,Central diabetes insipidus:0.1-0.2mg tid. Primary nocturnal enuresis:0.2-0.4mg at bedtime.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
OVIO,Rofecoxib,Vioxx 25mg,CNEU,,I: Relief of the signs & symptoms of osteoarthritis. Pain relief. Treatment of primary dysmenorrhoea. AR: Abdominal pain， asthenia， dizziness， influenza-like disease， lower extremity edema， upper respiratory infection， hypertension， GI effects， sinusitis， back pain， headache， bronchitis， urinary tract infection， post-dental extraction alveolitis， fever. Rarely， serious GI ulceration & bleeding. CI: Patients who have experienced asthma， urticaria of allergic-type reactions after taking aspirin or other NSAIDs. Late pregnacy.,,,D: Osteoarthritis: 12.5 mg once daily. Max: 25 mg daily. Management of acute pain & treatment of primary dysmenorrhoea: 50 mg once daily.,,,,除非治療上需要,,,,,,,,,,
YSWS,''舒摩兒''浴潔露 237mL,舒摩兒浴潔露 237mL,MSGO,,,,,,,,,,,,,,,,,,,
YSFM,''舒摩兒''衛生清潔噴劑 118mL,舒摩兒衛生清潔噴劑 118mL,MSGO,,,,,,,,,,,,,,,,,,,
YSFB,''舒摩兒''沐浴凝膠 340mL,舒摩兒沐浴凝膠 340mL,MSGO,,,,,,,,,,,,,,,,,,,
YSLJ,water， propylene glycol， methycelluose,舒摩兒陰道潤澤凝膠 113gm,MSGO,,,,,,,,,,,,,,,,,,,
OTS11,Tegafur + Gimeracil + Oteracil K,TS-1 capsules 25mg,RACA,,適應症:Post-op adjuvant chemotherapy for locally advanced [stage II (excluding T1)， IIIA or IIIB) gastric cancer.Treatment for advanced Inoperable or recurrent gastric cancer. 副作用:Leukopenia， decreased Hb， thrombocytopenia， decreased neutrophil count; increased AST/ALT， bilirubin & creatinine; glycosuria， stomatitis， anorexia， nausea， vomiting， diarrhea， abdominal pain， constipation， rash， pigmentation， lacrimation， taste abnormality， dizziness， decreased weight， pyrexia， nasopharyngitis & fatigue. 禁忌:Severe bone marrow depression， renal & hepatic disorder. Treatment with other fluoropyrimidine-group anticancer drugs (including combination therapies) & flucytosine. Pregnancy & lactation.,,室溫,Adult <1.25 m2 BSA Initially 40 mg; 1.25- <1.5 m2 BSA Initially 50 mg; >=1.5 m2 BSA Initially 60 mg. All doses are to be taken bid， for 28 consecutive days followed by a 14-day rest.,,,,不可使用,,,Hold Breast Feeding 暫停哺乳,,,,,,,
YSMP,"舒摩兒"爽身粉 198G,舒摩兒爽身粉 198gm,MSGO,,,,,,,,,,,,,,,,,,,
ODIZ,Diazepam,Diazepam 2mg,CNEU,,適應症: 焦慮、失眠、肌肉痙攣、幫助內耳循環及其他(A001646100) Short-term use in anxiety or insomnia. 副作用: Drowsiness， lightheadedness， confusion， ataxia， amnesia， dependence， muscle weakness. Cardiovascular: Hypotension Dermatologic: Rash (3%， rectal gel ) Gastrointestinal: Diarrhea (4%， rectal gel ) Musculoskeletal: Muscle weakness Neurologic: Ataxia， Incoordination (3%， rectal gel )， Somnolence Psychiatric: Euphoria (3%， rectal gel ) Respiratory: Respiratory depression Other: Fatigue 禁忌: Respiratory depression; acute pulmonary insufficiency; sleep apnoea; severe hepatic impairment; chronic psychosis; myasthenia gravis.,,室溫,Adult: Antianxiety: 2-10 mg bid-qid. Sedative-hypnotic (acute alcohol withdrawal): 10 mg tid-qid during the first 24 hrs， then 5 mg tid-qid as needed. Anticonvulsant and skeletal muscle relaxant: 2-10 mg bid-qid. Child 6 months of age and over: 0.04-0.2 mg/kg tid-qid.,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
EOEK,Estriol,Oekolp forte ovula栓劑 0.5mg,SGU,,適應症: Vag or cervical inflammation， atrophic vaginitis. 副作用: Local irritation or itch， breast tenderness， fluid retention.,,室溫,Atrophic vaginitis Insert 1-2 ovules daily for 3 weeks. A maintenance dose of 1 ovule twice a week may be used after restoration of the vaginal mucosa has been achieved. Pre- & post-operative treatment related to vaginal surgery in women with estrogen deficiency Insert 1-2 ovules daily for 2 weeks prior to surgery & 2 ovules/week after surgery.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EGYN,Clotrimazole,Gynox VT 500mg,SGU,,適應症: Vulvovaginal candidiasis 副作用: Erythema， stinging， irritation; hypersensitivity reactions. 禁忌: Hypersensitivity.,,室溫,1 vag. tab every three days at sleeping time.,無需調整劑量,,無需調整劑量,可能安全,,,Compatible 哺乳時可使用,,VAG;,,,,,
EEXT1,Nystatin+Neomycin+Gramicidin+Triamcinolone,Extracomb cream 15gm,TDER,,適應症: Treatment of inflammatory skin lesions where bacterial or candidal infections are suspected. 副作用: Skin atrophy; ototoxicity; nephrotoxicity. 禁忌: Tuberculous & most viral lesions of skin， especially herpes simplex， vaccinia， varicella.,,室溫,apply bid or tid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OERAF,Oseltamivir,Eraflu 75mg (政府提供),QANB,Prophylaxis & treatment of influenza in adult & children.,Hypersensitivity.,Nausea， vomiting， abdominal pain， headache. Insomnia， diarrhea. Gastrointestinal: Abdominal pain (2% to 5% )， Nausea (4% to 10% )， Vomiting (2% to 15% ),25℃以下,(仿單) Influenza: Treatment (for patients > 1 year): - Adult: Usual Dose for uncomplicated influenza of <48 hrs duration: 75 mg po BID x 5 days; complicated influenza in immunocompromised patients even if ill over 48 hrs: 75 mg po BID x 10 or more days. - Children > 40 kg: 75 mg BID x 5 days - Children > 23-40 kg: 60 mg BID x 5 days - Children > 15-23 kg: 45 mg BID x 5 days - Children <= 15 kg: 30 mg BID x 5 days - Infant 0-12 months: 3 mg/kg BID x 5 days Prophylaxis (for patients > 1 year): - Adults: 75 mg orally once daily for 10 days to 6 weeks. - Children > 40 kg: 75 mg QD x 10 days - Children > 23-40 kg: 60 mg QD x 10 days - Children > 15-23 kg: 45 mg QD x 10 days - Children <= 15 kg: 30 mg QD x 10 days - Infants 3-11 months: 3 mg/kg once daily (熱病),無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OCOD,Valsartan + Hydrochlorothiazide,Co-Diovan 80/12.5mg,CAVS,2nd-line therapy for HTN in patients whose BP is not adequately controlled by monotherapy.,Severe hepatic impairment， biliary cirrhosis & cholestasis. Anuria， severe renal impairment. Refractory hypokalemia， hyponatremia， hypercalcemia & symptomatic hyperuricemia. Pregnancy.,Headache， dizziness， nasopharyngitis， fatigue， upper respiratory tract infection， cough， diarrhea， arthralgia， back pain. Cardiovascular: Hypotension Gastrointestinal: Diarrhea (3%) Neurologic: Dizziness (9%)， Headache (2%) Renal: Serum blood urea nitrogen raised (15% )， Serum creatinine raised (2% ) Respiratory: Cough (3%) Other: Fatigue (5%),30℃以下乾燥處,HTN adult: initial therapy 1-2 tablet QD. Maximum dose: Valsartan 320 mg/hydrochlorothiazide 25 mg per day.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議本藥不可分割。
OKEP,Levetiracetam,Keppra 500mg,CNEU,Monotherapy for focal seizures (with or without secondary generalized seizures) in patients above 16 years of age. Adjunctive therapy for (1) focal seizures (with or without secondary generalized seizures) in children aged 4 years and above， (2) in adolescents and adults aged 12 years and above for myoclonic seizures and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy.,Hypersensitivity to levetiracetam.,Common: Loss of appetite (3-8%)， Vomiting (15%)， Infectious disease (13%)， Decreased bone mineral density (70%)， Neck pain (2-8%)， Asthenia (15%)， Dizziness (5-9%)， Headache (14-19%)， Abnormal behavior (7-37.6%)， Irritability (6-12%)， Cough (2-9%)， Nasopharyngitis (7-15%)， Fatigue (10-11%) Serious: Stevens-Johnson syndrome (SJS)， Toxic epidermal necrolysis (TEN)， Decreased erythrocyte production， Decreased white blood cell count (2.4-3.2%)， Eosinophil count above reference range (8.6%)， Neutropenia ( 2.4%)， Pancytopenia， Thrombocytopenia， Liver failure， Anaphylaxis， Somnolence (8-45%)， Suicidal intent (0.5%)， Suicide， Angioedema,30℃以下,Monotherapy: Adults， 16 Years and Older: Initial， 250 mg twice daily IV/orally; titration， may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum: 3000 mg/day. Adjunctive therapy: Adults， 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily， increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily. Child >6 years and dosage <250mg should use solution of Levetiracetam.,無需調整劑量,[仿單] Levetiracetam 會排泄至人類乳汁中，故不建議授乳。 但如果在授乳期間需要服用levetiracetam，須評估治療效益及風險與授乳的重要性。,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,[仿單]在一大量上市後資料中，接受 levetiracetam 單一治療的孕婦（超過 1800 例，其中超過 1500 例發生在懷孕的前三個月期間）主要先天性畸形的風險並未增加。 關於在子宮內接受 levetiracetam 單一治療的兒童神經發育，目前僅有有限的證據。但目前流行病學研究（約 100 名兒童）並未有神經發育障礙或延遲的風險增加。 Levetiracetam 如果在經仔細評估後認為它是臨床上所需要時，才可以在懷孕期間使用。 在這種情況下，建議使用最低有效劑量。懷孕期間的生理變化也可能會影響 levetiracetam 的濃度。 曾有在懷孕期間出現血漿中 levetiracetam 濃度降低現象的報告。這種濃度降低的現象在第三孕期會更為顯著(降低程度最高可達懷孕前之基礎濃度的 60%)。 請務必為接受治療的懷孕婦女進行適當的臨床處置。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] Levetiracetam 會排泄至人類乳汁中，故不建議授乳。 但如果在授乳期間需要服用levetiracetam，須評估治療效益及風險與授乳的重要性。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議無法吞服藥錠之病人，應使用Levetiracetam口服液劑。本院臨採清單包含Keppra solution。
ODUP1,Dydrogesterone,Duphaston 10mg,HM,Treatment of progesterone deficiencies; counteract unopposed estrogen in hormone replacement therapy. Luteal support as part of assisted reproductive technology.,Hypersensitivity， progestogen dependent neoplasm to prevent endometrial hyperplasia， abnormal vag bleeding.,Migraines/headache， jaundice， asthenia (weakness) or malaise， abdominal pain， rash， pruritus， urticaria， metrorrhagia， breast pain/tenderness.,30℃以下,Hormone replacement therapy :In combination with continuous sequential therapy: 10 mg daily during 14 consecutive days per cycle of 28 days.In combination with cyclical oestrogen therapy: 10 mg daily during 14 consecutive days per cycle of 28 days.If the endometrial section or ultrasound shows an inappropriate progestational response， should give 20mg.Primary dysmenorrhea: 10 mg BID from day 5-25 of the cycle.Endometriosis: 10 mg BID-TID from day 5-25 of the cycle or continuously. Dysfunction bleeding: 10mg BID 5-7 days.Secondary amenorrhea: An oestrogen once daily from day 1-25 of the cycle and then with 10 mg dydrogesterone BID from day 11-25 of the cyclePremenstrual syndrome， Irregular menstuation: 10 mg BID from day 11-25 of the cycle.Threatened abortion: 40 mg at once then 10 mg 8 hourly until symptoms remit.Habitual abortion: 10 mg BID until the 20th week of pregnancyInfertility: 10 mg QD from day 14-25 of the cycle.Luteal support as part of assisted reproductive technology: 10 mg TID starting at the day of oocyte retrieval & continuing for 10 weeks if pregnancy is confirmed.,無需調整劑量,Breastfeeding recommendations vary by manufacturer; the decision to breastfeed during therapy should consider the risk of infant exposure， the benefits of breastfeeding to the infant， and the benefits of treatment to the mother. (UpToDate)2021/0125,無需調整劑量,沒有資料,Uknown 沒有資料,Use of vaginal progesterone may be considered to decrease the risk of recurrent spontaneous preterm birth in women with a singleton pregnancy and prior spontaneous preterm singleton birth (therapy may begin at 16 to 24 weeks， regardless of cervical length). It may also be used to prevent spontaneous preterm birth in women with a singleton pregnancy who have a cervix <20 mm before or at 24 weeks' gestation. Use is not recommended as an intervention for women with multiple gestations (ACOG 2012) .(UpToDate)2021/0125,Unknown 沒有資料,Breastfeeding recommendations vary by manufacturer; the decision to breastfeed during therapy should consider the risk of infant exposure， the benefits of breastfeeding to the infant， and the benefits of treatment to the mother. (UpToDate)2021/0125,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉。
OPZA,Pyrazinamide,Pyramide 250mg,QANB,,I: Tuberculosis. ADR: nausea， vomiting， anorexia， thrombocytopenia， sideroblastic anemia with erythroid hyperplasia， vacuolation of erythrocytes， increased serum iron concentration and adverse effects on blood clotting mechanisms (rare)， hepatotoxicity (dose-related)， mild arthralgia and myalgia (frequent)， hypersensitivity reactions including rashes， urticaria， pruritus. Photosensitivity， porphyria， dysuria， interstitial nephritis (rare). CI: severe hepatic damage， hypersensitivity， acute gout.,,Room Temp,20-35 mg/kg daily in 3-4 divided doses. (max. 3 g/day).,,,,除非治療上需要,,,,,,,,,,
OROC,Calcitriol,Rocaltrol 0.25mcg,META,,I: Hypoparathyroidism & rickets; Renal osteodystroghy; Postmenopausal osteoporosis. ADR: Hypercalcemia syndrome， Ca intoxication. CI: Hypercalcemia. Vit D containing prep.,,,Initially 0.25 mcg/day Adults: 0.5-3 mcg/day or more. Childn: 0.5-2 mcg/day. Hypoparathyroidism: Adults: 0.25-207 mcg/day. Childn: 0.04-0.08 mcg/kg/day. Renal osteodystroghy: Adults: 0.25 mcg qod to 3 mcg/day or more. Childn: 0.014-0.041 mcg/kg/day.,,,,,,,,,,,,,,
INS100,Sodium Chloride,0.9% NaCl inj 100mL,MSIV,水份補充(A001085255),Hypersensitivity to sodium chloride or any component of the formulation; hypertonic uterus， hypernatremia， fluid retention,Cardiovascular: Cardiac failure， hypotension， localized phlebitis， thrombosis. Central nervous system: Osmotic demyelination syndrome (due to rapid correction of hyponatremia) Endocrine & metabolic: Electrolyte disturbance (dilution of electrolytes)， hypernatremia， hypervolemia， hypokalemia， water intoxication Gastrointestinal: Nausea， vomiting (oral administration) Respiratory: Bronchospasm (inhalation with hypertonic solutions)， pulmonary edema,室溫,Individualized dosage.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
IGW100,Glucose,Glucose inj 5% 100mL,MSIV,Treatment of carbohydrate & fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,30℃以下避光,Individualise dosage. Adult 500-1000 mL each time IV drip.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,
OORF3,Warfarin,Orfarin 3mg,HEMT,,適應症: Treatment & prophylaxis of thromboembolic disorders. 副作用: Alopecia， skin rashes of various kinds， hemorrhagic skin necrosis. Cardiovascular: Cholesterol embolus syndrome Dermatologic: Tissue necrosis Hematologic: Hemorrhage Immunologic: Hypersensitivity reaction (infrequent ) Ophthalmic: Intraocular hemorrhage (5% to 11% ) 禁忌: Severe hepatic or renal disease， actual or potential haemorrhagic conditions， severe hypertension， endocarditis， ulceration of the GI & urinary tract， visceral carcinoma， endocarditis， neurosurgery， recent surgery on the eye， brain or spinal cord. Pregnancy.,,室溫,Initially， 10-15 mg daily， adjusted with relation to the result of control tests. Maintenance dosage adjusted according to INR.,,WHO:Compatible with breast-feeding.,,不可使用,,,Compatible 哺乳時可使用,WHO:Compatible with breast-feeding.,,,,,,
OGASD,Famotidine,Gaster D 20mg,ALIM,,適應症: 主治潰瘍、逆流性食道炎(A022903100)(B024185100) Gastric， duodenal & anastomotic ulcers， upper GI hemorrhage， reflux esophagitis， Zollinger-Ellison syndrome 副作用: Infrequently， rash; constipation， diarrhea; dry mouth， nausea. Rarely， leukopenia， thrombocytopenia; tinnitus， increased pulse & BP; reversible mental confusion. Gastrointestinal: Constipation (1.2% )， Diarrhea (1.7% ),,室溫,Adult 20 mg bid or 40 mg at bedtime. Micromedex: Gastric hypersecretion: 20 to 160 mg ORALLY every 6 h,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IPPD1,Tuberculin PPD RT,PPD 2TU/0.1mL/dose (限健診用),HIMM,Skin test in diagnosis of tuberculosis,Hypersensitivity to tuberculin purified protein derivative (PPD) or any component of the formulation; previous severe reaction to tuberculin PPD skin test (TST),Dermatologic: Rash Local: Injection site reactions: Bleeding， bruising， discomfort， erythematous reaction， hematoma， necrosis， pain， pruritus， redness， scarring， ulceration， vesiculation Miscellaneous: Anaphylaxis,2-8℃避光避免冷凍,ID， 0.1 mL， in the middle third of the forearm.,無需調整劑量,WHO:Compatible with breastfeeding.,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,WHO:Compatible with breastfeeding.,ID;,,,,,
OZIN2,Zinc Acetate,Zinca 25mg,META,Maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.,Hypersensitivity to any component of the formulation.,Gastric irritation.,25℃以下陰涼乾燥處，避免陽光直接照射,Adult 50 mg TID. Children 1-6 years 25 mg BID， 6-16 years， < 57 kg 25 mg TID， > 57 kg 50 mg TID， 16-18 years 50 mg TID.,無需調整劑量,,無需調整劑量,安全,Uknown 沒有資料,,Unknown 沒有資料,,AC;PO;,,,,,
IRIS,Risperidone,Risperdal Consta 25mg,CNEU,,適應症:Treatment of acute & chronic schizophrenic psychoses & other psychotic conditions in which +ve &/or -ve symptoms are prominent. Alleviates affective symptoms associated with schizophrenia 副作用:Wt gain， depression， fatigue， extrapyramidal symptoms. Uncommonly， hypotension， tardive dyskinesia， neuroleptic malignant syndrome， seizures， impaired concentration. 禁忌:Patients with a known hypersensitivity to Risperdal Consta or any of the components,,2-8℃,Adult 25 mg IM every 2 weeks. Some patients may benefit from higher doses of 37.5 mg or 50 mg. Max: 50 mg every 2 weeks. Upward dose adjustments should not be made more frequently than every 4 weeks. Elderly 25 mg IM every 2 weeks.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;,,,,,
ODIP,Diphenidol,Dinidol 25mg,CNEU,Vertigo caused by inner ear disturbance.,Renal failure,Thirst， anorexia， heartburn.,25℃以下,Adult: 25-50mg QID (maximum: 300mg/day). Child over 6 months or over 12kg: 0.9mg/kg， may be repeated in 1hr with subsequent doses of Q4H as needed， (maximum: 5.5mg/kg/day).,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PC;PO;,,,,,
LPHO,Sodium Phosphate,Phospho-Soda 90mL,ALIM,,適應症: Relief of occasional constipation. For use as part of a bowel cleansing regimen in preparing the patient for surgery or for preparing the colon for X-ray or endoscopic exam. 副作用: Nausea， vomiting， bloating. 禁忌: Congenital megacolon， intestinal obstruction or CHF. Children < 5 years.,,室溫,Prep for diagnostic procedures & pre-op 45 mL the evening before & repeat on the morning of the procedure. Constipation Adult & children >= 12 years Dilute 15 mL in 240 mL liqd & drink at least 240 mL. Max: 45 mL/24 hr. Children 10-11 yearsDilute 15 mL in 240 mL liqd & drink at least 240 mL. Max: 15 mL/24 hr. 5-9 years Dilute 7.5 mL in 240 mL liqd & drink at least 240 mL. Max: 7.5 mL/24 hr. Take 120 ml cool water with half (45 ml) of the Fleet phospho-soda to drink， and follow up more than 240 ml of cool water. Twice a day.,,,,沒有資料,,,,,,,,,,
OKON,Psyllium hydrophilic mucilloid,Konsyl 6gm,ALIM,,適應症: Treatment of constipation 副作用:Flatulence & abdominal distension 禁忌: Intestinal obstruction or colonic atony， fecal impaction.,,室溫,Adult: 1 sachet 1-3 times daily Child >= 6.5 yr : adult dose or less,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ODIT,Oxybutynin,Ditropan 2.5mg,SGU,,適應症: 為排尿機能改善劑(A030803100) Relief of symptoms associated with voiding in patients with uninhibited neurogenic & reflex neurogenic bladder. 副作用: Dose-related anticholinergic effects; dry mouth， blurred vision， tachycardia， dizziness， impotence; allergic reactions. Dermatologic: Application site erythema (5.6% to 8.3% )， Application site rash (3.3% )， Pruritus (14% to 16.8% ) Gastrointestinal: Constipation (3.3% )， Diarrhea (3.2% )， Xerostomia (4.1% to 9.6% ) 禁忌: Glaucoma; GI obstruction， paralytic ileus， intestinal atony， megacolon， severe colitis; myasthenia gravis; acute haemorrhage.,,室溫,Adult: 1 tab bid-tid Child > 5 yr: 1 tab bid,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OGEO,Ziprasidone,Geodon 40mg,CNEU,,適應症: Management of schizophrenia and acute bipolar mania. 副作用: Asthenia， extrapyramidal syndrome， nausea， somnolence， respiratory disorder. 禁忌: QT-interval prolongation， acute MI， uncompensated heart failure， cardiac arrhythmias requiring treatment with Class I & III antiarrhythmic drugs.,,室溫,Adult Initially 40 mg bid. Recommended dosage: 60 mg bid， up to max 80 mg bid.,,,,除非治療上需要,,,,,,,,,,
ENS2,Sodium Chloride,0.9%NaCl irrigation 2000mL,MSIV,Wound cleansing， irrigation & flushing.,Not to be used to induce emesis.,,室溫,For Irrigation Only. Not for Injection. As sterile irrigation of tissues or wounds， and for washing， rinsing medical device.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,EXT;G;GAR;IH;IN;INHL;IRR;IRRI;RT;SHA;SKIN;TOPI;,,,,,
ENS3,Sodium Chloride,0.9%NaCl irrigation 3000mL,MSIV,Wound cleansing， irrigation & flushing.,Not to be used to induce emesis.,,室溫,For Irrigation Only. Not for Injection. As sterile irrigation of tissues or wounds， and for washing， rinsing medical device.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,EXT;G;GAR;IH;IN;INHL;IRR;IRRI;SKIN;TOPI;,,,,,
OEVI,Raloxifene,Evista 60mg， 28's/包,META,,適應症:主治骨質疏鬆症(B022717100),,RT,1 tab daily,,,,不可使用,,,,,,,,,,
OSIM,Polysiloxane + Co-dried Gel,Simagal,ALIM,,Hyperacidity， heartburn， flatulence.,,,Adult: 1-2 tab tid-qid. Child 5-12yrs: 1 tab bid-tid. Under 5yrs: 1/2 tab bid-tid.,,,,,,,,,,,,,,
OSPO,Itraconazole,Sporanox 100mg,QANB,,,,RT,PO， take with meals. Dermatomycosis: 100-200 mg/day x 7-30 days. Fungal keratitis: 200mg qd x 21 days. Oral candidiasis: 100mg qd x 15 days. Vaginal candidiasis: 200mg bid x 1 day or 200mg/day x 3 days.,,,,除非治療上需要,,,,,,,,,,
OTON,Allopurinol,Tonsaric 100mg,CNEU,Reduces urate conc， manifestations of urate/uric acid deposition. Prevention & treatment of Ca oxalate/phosphate renal stones. Manifestations of hyperuricaemia &/or hyperuricosuria.,GI intolerance.,Acute attack of gouty arthritis in early stages of therapy. Skin reactions (discontinue use). Very rarely， granulomatous hepatitis. Occasionally， thrombocytopenia， agranulocytosis & aplastic anaemia in patients with impaired renal function. Dermatologic: Maculopapular eruption， Pruritus (less than 1% ),緊密容器中，室溫下且避光保存,Adults: Antigout agent: Initial dose:100mg QD， increase by 100 mg/day during one-week intervals until the required serum uric acid concentration is reached. maximum:800mg/day. Maintenance dose:100mg-200mg BID-TID， or 300mg QD. The general maintenance dose for people with mild gout is 200 to 300 mg per day. In moderately severe Tophaceaus gout， the general maintenance dose is 400 to 600 mg per day. Neoplastic disease therapy:12 hours to 3 days (preferably 2 to 3 days) before the start of chemotherapy or radiotherapy， 600 mg to 800 mg per day. Antiurolithic(Uric acid caliculi):100-200mg QD. maximum dose: each dose 300mg， 800mg/day Children: Neoplastic disease therapy:<6 years old:50mg TID 6-12 years old: 100mg TID or 300mg QD. After 48 hours of treatment， adjust the dose according to the patient's condition.,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OVERM,Mebendazole,Vermox 100mg,QANP,,Treament of pinworm， whipworm， roundworm， hookworm， in single or mixed infections.,,,Pinworm infestation: Adult & child: 100 mg as a single dose. Roundworm， whipworm & hookworm infestations: Adult & child: 100 mg bid for 3 days. Tapeworm infestation: Adult: 200 mg bid for 3 days. Child: 100 mg bid for 3 days. If necessary， a second course may be given after 2-3 wks.,,,,除非治療上需要,,,,,,,,,,
OZYR,Cetirizine,Zyrtec 10mg,HIMM,,Symptomatic treatment of seasonal rhinitis & conjunctivte perennial allergic rhinitis as well as pruritus & urticaria of allergic origin.,,,Adult or under 6 year is 10mg/day or 5mg bid.,,,,可能安全,,,,,,,,,,
EPRO1,Tacrolimus,Protopic oint 0.1%，10gm,TDER,,適應症: Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis. 副作用: Burning sensation， pruritus， flu-like symptoms & headache. 禁忌: Patients with a history of hypersensitivity to tacrolimus or any other component of Protopic.,,15-30℃,Adult & children 2-15 years Apply thinly & rub in bid， continue for 1 week after signs & symptoms clear.,,,,沒有資料,,,,,,,,,,
IKAT,Phytonadione,Katimin"1" inj 10mg/1mL,HEMT,Vit K deficiency due to drugs or malabsorption， Over-anticoagulation.,Hypersensitivity.,Anaphylaxis， dyspnoea， cyanosis， pain， swelling， phloebitis at the Inj site， diaphoresis， dizziness， hypotension (rare)， allergic reactions after SC and IM inj.,存於冷暗處,Prevention and controlling bleeding of infant: IM 1-2 mg， increased if needed. Prevention of hypoprothrombinemia in infant: IM 10 mg daily 1-2 weeks before delivery or slow IV 1-2 mg before delivery. Antagonistic anticoagulant: IM 5-10mg， up to 20mg if needed. Control bleeding & Severe bleeding: slow IV 10-15mg.(do not exceed 1mg/min) Prevention of bleeding during surgery: IM 25-50mg before surgery.(do not exceed 25mg at same site),無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;IVP;IVPUSH;,,,Slow IV，推注速率 < 1mg/min,,
IAMP,Ampicillin,Ampolin inj 0.5gm,QANB,Respiratory tract infections， UTI， gonorrhea， enteric infections， meningitis， septicemia， bacillary dysentery， shigellosis， salmonellosis.,Hypersensitivity to penicillins. Infectious mononucleosis.,Allergic reactions， GI disturbances， pseudomembranous colitis， hemolytic anemia， leukopenia.,25℃以下,Usually， adults: 250-500 mg IM 2-4 times daily， children weighing < 20 kg: 25-60 mg/kg/day IM/IV in 3-4 divided doses. Infection of respiratory tract， skin or soft tissue and genitourinary tract: adults 250-500 mg every 6 hours; children weighing < 40 kg: 25-50 mg/kg/day in 4 divided doses. Urinary tract infection due to N. Gonorrhea: adults 500 mg every 12 hours. Bacterial meningitis: adults 8-14 g/day; children 100-200 mg/kg/day. Administer in equally divided doses every 3-4 hours. Treatment may be initiated with intravenous drip therapy and continued with intramuscular injections. *****NEONATE ANTIBIOTICS DOSE***** Ampicillin: Total dose: General infection: 100 mg/kg/day Group B streptococcal bacteremia (GBS) sepsis: 200mg/kg/day PMA (postmenstrual age ) = gestational age plus postnatal age Drug Interval: PMA <=29 week Postnatal 0-28 days Q12H PMA <=29 week Postnatal >= 29 days Q8H PMA 30 to 36 week Postnatal 0-14 days Q12H PMA 30 to 36 week Postnatal >=15 days Q8H PMA 37 to 44 week Postnatal 0-7 days Q12H PMA 37 to 44 week Postnatal >= 8 days Q8H PMA >=45 week Q6H GBS meningitis: total dose 0-7 days: 200 to 300 mg/kg/day divided Q8H 8 days and older: 300 mg/kg/day divided Q6H,無需調整劑量,,需調整劑量,可能安全,Human data suggest risk in 1st trimester,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,IM: 1.8 mL D/W IV: 5mL D/W,【D5W】可選 仿單建議。【N/S】可選 仿單建議。【L/R】可選 。,over 3 to 5 minutes,IV infusion: 以50 ~ 100 mL適當輸注液稀釋，濃度 < 30mg/mL。每1gm劑量以至少10 ~ 15分鐘時間緩慢滴注，兒童的滴注速率建議超過30分鐘。 NeoFax建議：Doses 500 mg or less should be administered slowly over 3 to 5 minutes IV and over at least 10 to 15 minutes for doses 1 g or greater. Recommended concentrations are 30， 40， 50， and 100 mg/mL for intermittent IV. For ampicillin 100 mg/mL， consider central line administration due to potential osmolality greater than 600 mOsm/kg.,1. 注射前檢查病患是否有PCN過敏史。 2. 稀釋液需在一小時內用完。 3. 乾粉稀釋：(IM) 0.5gm/vial 乾粉加入1.8 mL D/W泡製，(IV bolus) 0.5gm/vial 乾粉加入5 mL D/W泡製。 4. IV infusion: 以50 ~ 100 mL適當輸注液稀釋，濃度 < 30mg/mL。每1gm劑量以至少10 ~ 15分鐘時間緩慢滴注，兒童的滴注速率建議超過30分鐘。
LMUS1,Ambroxol,Musco soln 3mg/mL， 100mL,ERSP,,適應症: Expectorant. 副作用: Mild GI effects & Allergic reactions.,,室溫,Adult & children >10 years 10 mL tid， 5-10 years 5 mL tid. < 2 years 2.5 mL bid. Reduce dose in long-term therapy.,,,,沒有資料,,,,,,,,,,
EFUB,Flurbiprofen,Fubifen PAP (4片/包),CNEU,,適應症: Relief of pain & inflammation in rheumatic disease & other musculoskeletal disorders e.g. ankylosing spondylitis， osteoarthritis， sprains & strains， post-op pain. 副作用: Occasionally， redness， rashes， pruritus， dryness， irritation， edema， photosensitivity. 禁忌: Patients with a history of hypersensitivity to aspirin & other NSAIDs.,,室溫,Apply 1 sheet to the affected area bid.,,,,可能安全,,,,,,,,,,
ILIPI,Iodine， combined ethyl ester of fatty acid oil,Lipiodol ultra-fluid 4800mg/10mL,SCAN,Diagnostic radiology: Lymphography， hysterosalpingography， sialography. Interventional radiology: Visualisation， localisation & vectorisation during trans-arterial chemo-embolisation (TACE) of hepatocellular carcinoma at intermediate stage， in adults.,Hypersensitivity to iodine-containing products or ethyl esters of iodised fatty acids of poppy seed oil. Acute pelvic inflammation. Confirmed hyperthyroidism or pulmonary insufficiency. Traumatic lesions， haemorrhage or recent bleeding (risk of extravasation or embolism). Bronchography. Pregnancy. Administration in liver areas w/ dilated bile ducts (specific for use in interventional radiology).,Increase temp followed by a fever (38-39°C)， fat microembolism. Post embolisation syndrome (fever， abdominal pain， nausea， vomiting) and transitory changes in liver function tests. Hypersensitivity， anaphylactic reaction; hyperthyroidism; cerebral embolism; pulmonary embolism; vomiting， diarrhoea， nausea; pain; fat embolism. Spinal cord injury.,室溫,Diagnostic radiology adult: Lymphography: Unilateral lymphography of upper extremities: 2 to 4 mL. Unilateral lymphography of lower extremities: 6 to 8 mL. Penile lymphography: 2 to 3 mL. Cervical lymphography: 1 to 2 mL. child: 1-6 mL， max: =<0.25mL/kg. Hysterosalpingography: Inject in 2 mL increments into the endometrial cavity until tubal patency is observed. Selective hepatic intra-arterial injection: 1.5 to 15 mL administered slowly under continuous radiologic monitoring; discontinue administration when stagnation or reflux is evident， maximum total dose: 20 mL.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IA;LI;,,,,,Lipiodol ultra-fluid 不可由靜脈內、動脈內(除了選擇性插管)或腦脊髓膜內的途徑給藥。
ITRI4,Triamcinolone,4% TRIAMCINOLONE 40mg/1mL,HM,Inflammatory skin conditions.,Untreated systemic fungal， bacterial， viral or parasitic infection， hypersensitivity. Neonates (Parenteral),HPA axis supression， intracranial hypertension， Cushing's syndrome， growth retardation in children; osteoporosis， fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas， broken skin or under occlusive dressing.,25℃以下避光,Adult: INS 2.5-40mg or IM 40-60mg per time， could inject 2-3 times if symptoms reappear. Children > 6 years: IM 30-200mcg daily to weekly.,無需調整劑量,,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,ID;IM;INS;IVI;SKIN;SUBCI;,,,,,
EZAD,Ketotifen,Zaditen eye drops 5mL,TOPH,,適應症: Treatment of signs & symptoms of allergic conjunctivitis. 副作用: Ocular: Burning/stinging， punctate corneal epithelial erosion， blurring of vision， dry eyes， eyelid disorder， conjunctivitis， eye pain， photophobia， subconjunctival hemorrhage. Systemic: Headache， somnolence， skin rash， eczema， urticaria， dry mouth & allergic reaction. Neurologic: Headache (10%-25%) Ophthalmic: Dry eyes， Eye irritation， Conjunctival (10%-25%)， Pain in eye Respiratory: Pharyngitis， Rhinitis (10%-25%) Other: Influenza 禁忌: Hypersensitivity to ketotifen or to any of the excipients of Zaditen eye drops.,,室溫,Adult， elderly & children >=3 years Instill 1 drop bid into the conjunctival sac.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OSTR8,Atomoxetine,Strattera 18mg,CNEU,,適應症:Treatment of attention-deficit/hyperactivity disorder (ADHD). 副作用: Nausea， vomiting， fatigue， decreased appetite， abdominal pain， somnolence. Endocrine metabolic: Weight loss (pediatrics， 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults， 7%; pediatrics， 17% to 18% )， Constipation (adults， 9%; pediatric， 1% to 2%)， Decrease in appetite (adult， 11%; pediatrics， 16% ，)， Nausea (adults， 21%; pediatrics， 7% to 13% )， Vomiting (adults， 3%; pediatrics， 11%)， Xerostomia (adults， 21% ) Neurologic: Headache (pediatrics， 19% )， Insomnia (adults， 16%; pediatrics， at least 2%; )， Somnolence (adult， 4%; pediatrics， 11% ) Renal: Delay when starting to pass urine (adults， 5.6% )， Urinary retention (adults， 1.7% ) Reproductive: Dysmenorrhea (adults， 6% )， Erectile dysfunction (adults， 9% ) Other: Menopausal flushing (adults， 8% ) 禁忌: with a MAOI or within 2 weeks after discontinuing a MAOI， narrow-Angle Glaucoma.,,室溫,Adult， adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses; max: 1.4 mg/kg or 100 mg， whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approx 80 mg administered as single or divided doses. Dose may be increased to a max of 100 mg after 2-4 additional weeks. Max: 100 mg.,需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OSTR1,Atomoxetine,Strattera 10mg,CNEU,Treatment of attention-deficit/hyperactivity disorder (ADHD).,with a MAOI or within 2 weeks after discontinuing a MAOI， narrow-Angle Glaucoma.,Nausea， vomiting， fatigue， decreased appetite， abdominal pain， somnolence. Endocrine metabolic: Weight loss (pediatrics， 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults， 7%; pediatrics， 17% to 18% )， Constipation (adults， 9%; pediatric， 1% to 2%)， Decrease in appetite (adult， 11%; pediatrics， 16% ，)， Nausea (adults， 21%; pediatrics， 7% to 13% )， Vomiting (adults， 3%; pediatrics， 11%)， Xerostomia (adults， 21% ) Neurologic: Headache (pediatrics， 19% )， Insomnia (adults， 16%; pediatrics， at least 2%; )， Somnolence (adult， 4%; pediatrics， 11% ) Renal: Delay when starting to pass urine (adults， 5.6% )， Urinary retention (adults， 1.7% ) Reproductive: Dysmenorrhea (adults， 6% )， Erectile dysfunction (adults， 9% ) Other: Menopausal flushing (adults， 8% ),25℃以下,Adult， adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approximate 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg， whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult， adolescent & children>70 kg maximum dose is 100 mg total daily .,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,[磨粉/管灌註記]本藥請整顆膠囊吞服。若有磨粉需求請使用前自行磨粉並注意本藥粉末具有眼部刺激性。
OHAV,Estradiol + Norethisterone,Havina 28's/pk,HM,,適應症:為荷爾蒙補充劑(A044203100),,RT,D: 1 tab daily,,,,沒有資料,,,,,,,,,,
OINDI,Estradiol + Medroxyprogesterone,Indivina (1/2.5) 28's/box,HM,,適應症: Hormone replacement therapy (HRT) for estrogen deficiency symptoms & prophylaxis of osteoporosis in women with an intact uterus. 副作用: Breast tenderness & enlargement， uterine bleeding， increase in size of uterine fibroids， headache， GI discomfort， weight changes， edema， mood changes including anxiety & depressive mood， changes in libido. 禁忌: Pregnancy & lactation. Known， suspected or past history of breast cancer or estrogen-dependent tumour， undiagnosed vag bleeding， confirmed active venous thromboembolism (VTE) within the last 2 years. History of recurrent VTE or known thrombophilic disease in patients not on anticoagulant， acute or chronic liver diseases or a history of liver disease.,,室溫,1 tab daily. Women w/ amenorrhoea & not taking HRT or women switching from another continuous combined HRT regimen Indivina may be started on any day. Women switching from cyclic HRT Start Indivina 1 wk after completion of cyclic HRT regimen.,,,,沒有資料,,,,,,,,,,
IESO,Isosorbide Dinitrate,Esokit 0.1% 10 mL,CAVS,,,,室溫,Adult 2-12 mg/hr by IV infusion; some patients may require up to 20 mg/hr. Administration during percutaneous transluminal coronary angioplasty By the intracoronary route: 1 mg as a bolus before balloon inflation. Max recommended dose: 5 mg within a 30-min period.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 一般稀釋濃度：50 mL Angidil 0.1 % 以適當溶液稀釋至500 mL，每mL含有100 mcg isosorbide dinitrate。 2. 稀釋時應使用玻璃或非PVC之硬塑膠材質容器的稀釋溶液。 3. 注射時建議使用聚乙烯(PE)材質的輸注套或硬塑膠材質的針筒幫浦。 4. 投藥期間應嚴密監測脈搏與血壓。
IDIPE,Alanine 8.2% + glutamine 13.64%,Dipeptiven inj 100mL,NUTR,Part of an IV parenteral nutrition regimen as a supplement to amino acid soln,Severe renal insufficiency (CrCl <25 mL/min)， severe hepatic insufficiency. Pregnancy， lactation， childn.,None known when correctly administered.,25℃以下,1.5-2.5 mL/kg body weight/day for maximum 3 weeks. Maximum dose: 2.5 mL/kg body weight/day. Rate of infusion should not exceed 0.1g amino acids/kg body weight/hr. Should be mixed with a compatible amino acid carrier solution or an amino acid containing infusion regimen and proportion of amino acid supplied through Dipeptiven should not exceed 30% of total amino acid.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,【D10W】可選 。【D5W】可選 。【N/S】可選 。,,< 0.1 g amino acid/kg/hr (dilution:Dipeptiven 100 mL + Compatible solution 500 mL),1.Dipeptiven should be mixed with a compatible amino acid carrier solution or an amino acid-containing infusion regimen prior to administration. 2.One part volume of Dipeptiven is to be mixed with at least 5 parts volume of carrier solution (eg， Dipeptiven 100 mL + amino acid solution at least 500 mL). Water rationing:dilute Dipeptiven to an osmolarity =< 800 mosmol/l (e.g. 100 ml Dipeptiven + 100 mL saline.) 3.The maximum concentration < 3.5%. The duration of use should not exceed 3 weeks.
OMEC,Meclizine,Meclizine 25mg,CNEU,Prophylaxis & symptomatic relief of nausea， vomiting， vertigo.,Hypersensitivity to any component of the formulation.,Drowsiness; dry mouth， fatigue， vomiting; rarely， blurred vision.,25℃以下緊密容器，避光儲存,Adult and children over 12 years: for motion sickness， take 30-60 minutes before boarding， 50 mg daily.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OAND4,Testosterone,Andriol 40mg,HM,,適應症: Testosterone replacement therapy in male hypogonadal disorders. Osteoporosis due to androgen deficiency. 副作用: Priapism， signs of excessive sexual stimulation; oligospermia， decreased ejaculatory vol; fluid & salt retention. In prepubertal boys， precocious sexual development， increased frequency of erections， phallic enlargement & premature epiphyseal closure. 禁忌: Known or suspected prostatic or mammary carcinoma.,,室溫,Initially 120-160 mg daily for 2-3 weeks. Maintenance 40-120 mg daily.,,,,不可使用,,,,,,,,,,
ITAZ,Piperacillin + Tazobactam,Tazocin inj 2.25gm,QANB,,,,,,,,,,,,,,,,,,,
ENEU,Rotigotine,Neupro patch 6mg/24h,CNEU,Parkinson's disease,Hypersensitivity to rotigotine or any component of the product.,(Common) Cardiovascular: Orthostatic hypotension (up to 18% )， Peripheral edema (2% to 9% ) Dermatologic: Application site reaction (21% to 46% )， Diaphoresis (Parkinson disease， 3% to 11%; restless leg syndrome， 1% to 5% )， Pruritus (3% to 9% ) Endocrine metabolic: Weight increased (2% to 9% ) Gastrointestinal: Loss of appetite (2% to 8% )， Nausea (Parkinson disease， 28% to 48%; restless leg syndrome， 15% to 23% )， Vomiting (Parkinson disease， 10% to 20%; restless leg syndrome， 2% to 4% )， Xerostomia (3% to 7% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (7% to 14%)， Dizziness (Parkinson disease， 14% to 23%; restless leg syndrome， 5% to 9% )， Dysesthesia (5% )， Dyskinesia (7% to 14% )， Headache (Parkinson disease， 8% to 14%; restless leg syndrome， 15% to 21% )， Insomnia (5% to 11% )， Paresthesia (5%)， Sleep disorder (2% to 10% )， Somnolence (Parkinson disease， 12% to 32%; restless leg syndrome， 5% to 10% ) (Serious) Cardiovascular: Syncope Neurologic: Sleep attack (1% to 2% ) Psychiatric: Compulsive behavior， Hallucinations (4% to 7% )， Impulse control disorder,30℃以下,Apply a new patch to a new site daily， wear continually for 24 hours and apply a new patch at approximately the same time every day. Parkinson's disease: Early-stage， the recommended initial dose is 2 mg/24 hr intradermally. Depending on clinical response and tolerability， doses may be increased weekly in 2 mg/24 hr increments to a minimum effective dose of 4 mg/24 hr or further to the highest recommended dose of 8 mg/24 hr. Advanced-stage， the recommended initial dose is 4 mg/24 hours. Doses may be increased weekly in 2 mg/24 hour increments to the highest recommended dose of 8 mg/24 hours. When discontinuing therapy， reduce the dose by a maximum of 2 mg/24 hour increments everyday.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,每張30cm2貼片含有13.5mg，每24小時釋放6mg主成分。
OKLE1,Polyethylene Glycol,Klean-Prep (腸癌專案),ALIM,,Bowel prep before colonoscopy， colonic surgery， radiological exam & other related procedures.,,RT,Adult including elderly & renal insufficiency patient 1 sachet In 1 L water . 250ml to be drunk rapidly every 10-15 mins until all soln has been consumed. Repeat procedure with 2-4 sachets or until the rectal effuent is clear.,,,,沒有資料,,,,,,,,,,
ENEOE,Phenylephrine,Neosinicin eye drop 5%,TOPH,,,,,,,,,,,,,,,,,,,
EBNO,Bacitracin + Neomycin,Bacitracin neomycin oint 30gm,TDER,,適應症:皮膚外傷、潰瘍、膿皮病等細菌感染症(A022990343),,,,,,,,,,,,,,,,,
LBIS,Bromhexine,Bisolvon solution 2mg/mL， 50mL,ERSP,As expectorant.,Rare hereditary problems of galactose intolerance eg. galactosemia.,Diarrhea， nausea， vomiting & other mild GI disturbances. Allergic reactions include skin rashes， urticaria， bronchospasm， angio-edema & anaphylaxis.,30℃以下,Oral: Age > 14 years old and Adult: 4-8mL TID. Age 6-14 years old: 4mL TID. Age < 6 years old: 2mL TID. Recommended doses of Adult: Maximum: 48mL/day. Inhaleration: Age > 6 years old and Adult: 4mL BID. Age 2-6 years old: 2-4mL BID. Age < 2 years old: 2mL BID. Needs to be diluted with 0.9% sodium chloride at a ratio of 1:1.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;IH;INHL;PC;PO;WM;,,,,,
EMAX,Dexamethasone + Neomycin + Polymyxin B,Maxitrol oph oint 3.5g,TOPH,,適應症: SInflammatory ocular conditions: Management of corticosteroid-responsive inflammatory ocular conditions where bacterial infection or a risk of bacterial infection exists. 副作用: Hypersensitivity: Hypersensitivity reaction Infection: Secondary infection Ophthalmic: Glaucoma， increased intraocular pressure， optic nerve damage (infrequent)， subcapsular posterior cataract Miscellaneous: Wound healing impairment 禁忌: Hypersensitivity to neomycin， polymyxin B， dexamethasone， or any component of the formulation; viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis [dendritic keratitis]， vaccinia， varicella); mycobacterial ophthalmic infection; fungal diseases of ocular structures.,,室溫,Apply a small amount into the conjunctival sac up to tid or qid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OXYZ,Levocetirizine,Xyzal 5mg,HIMM,Treatment of symptoms associated with allergic conditions in adults & children >= 6 years， such as seasonal allergic rhinitis， perennial allergic rhinitis & chronic urticaria.,Severe renal impairment (creatinine clearance < 10 mL/min).,Dry mouth， headache， fatigue， somnolence， asthenia， rhinitis， pharyngitis， abdominal pain & migraine. Neurologic: Asthenia (2.3% )， Somnolence (children 3%; adults 5% to 6% ) Respiratory: Nasopharyngitis (4% to 6% )， Pharyngitis (1% to 2% )， Xerostomia (2% to 3% ) Other: Fatigue (1% to 4% )， Fever (children 4% ),30℃以下乾燥的場所,Adult & children >= 6 years 5 mg once daily.,無需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
IGON4,Follitropin Alpha,GONAL-F 注射筆 450 IU/ 0.75mL,HM,女性患者 (1)婦女經CLOMIPHENE CITRATE治療，仍無法排卵者(含多囊性卵巢症，PCOD) 。(2)對於實施人工生殖協助技術(ART)，如體外受精(IVF)，配子輸卵管植入(GIFT)，合子輸卵管植入(ZIFT)的病人，可刺激其多濾泡發育。(3)與黃體刺激素(LH)併用，使用於嚴重缺乏黃體刺激激素與濾泡刺激激素患者的濾泡刺激成長。 男性患者 治療男性對於患有先天或後天性腺刺激素不足之性腺功能低下症，併用人類絨毛膜性腺刺激素(hCG)，刺激精子生成。,Pregnancy & lactation， ovarian enlargement or cyst not due to polycystic ovarian disease， gynaecological haemorrhages of unknown aetiology， ovarian， uterine or mammary carcinoma， case of tumours of the hypothalamus & pituitary gland， hypersensitivity to follitropin α， FSH or to any of the excipients. When an effective response cannot be obtained， such as primary ovarian failure， malformation of sexual organs incompatible with pregnancy， fibroid tumours of the uterus incompatible with pregnancy.,Local reactions at the inj site. Fever， arthralgia， pain in the lower abdominal region， nausea， vomiting， weight gain.,2-8℃避光避免冷凍,Women with anovulation (including PCOD) 75-150 IU daily & increased by 37.5 or 75 IU at 7 or 14 day intervals. Maximum daily dose: 225 IU. When an optimal response is obtained a single injection of up to 5，000 IU， up to 10，000 IU hCG should be given 24-48 hr after the last Gonal-F injection. The patient is recommended to have coitus on the day of， & the day after hCG administration. Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilization or other ART 150-225 IU of Gonal-F daily， commencing on day 2 or 3 of the cycle. When an optimal response is obtained a single injection of up to 5，000 IU， up to 10，000 IU hCG should be given 24-48 hour after the last Gonal-F injection. Dose adjustment should not exceed 450 IU daily. A single inj of up to 10，000 IU hCG is administered 24-48 hour after the last Gonal-f inj to induce final follicular maturation. Women with anovulation resulting from severe LH and FSH deficiency usually is starting as dose of GONAL-f 75-150 IU together with 75 IU of lutropin alfa， dose increased should be after 7-14 day intervals and preferablt by 37.5-75 IU. When an optimal response is obtained a single injection of up to 5，000 IU， up to 10，000 IU hCG should be given 24-48 hr after the last Gonal-F injection. Men with hypogonadotrophic hypogonadism should be given at a dose of 150 IU three times a week， together with hCG， for minimum of 4 months.,無需調整劑量,Micromedex:Infant risk cannot be ruled out,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,Micromedex:Infant risk cannot be ruled out,SC;,,,,,
IHBIG1,Hepatitis B Immune Globulin,HBIG 1 mL (自費),HIMM,,,,,,,,,,,,,,,,,,,
OTOP1,Alginic Acid+Colloidal Al(OH)3+MgHCO3,Topaal chewable Tab (自費),ALIM,,,,,,,,,,,,,,,,,,,
OEUP,Theophylline,Euphyllin Retard 250mg,ERSP,,I: Bronchitic syndrome， spastic conditions of the bronchial system， bronchial & cardiac asthma， pulmonary emphysema， conditions of dyspnea， Cheyne-Stokes resp， cor pulmonale. CI: Recent MI. ADR: Occasional GI disturbances， overstimulation of CNS， ver-tigo & convulsions in high doses. Hypersensitivity.,,,D:Adult > 50 kg :1 Tab bid ~ tid， 45 ~ 50 kg :1/2 Tab bid ~ tid. Children: 10 ~ 15 mg/kg/day.,,,,除非治療上需要,,,,,,,,,,
OMEQ,Mequitazine,Mequitazine 5mg,HIMM,Allergic & vasomotor rhinitis， hay fever， urticaria， ocular allergies & other allergic reactions.,Coadministration with MAOIs.,Drowsiness， headache， psychomotor impairment， urinary retention， dry mouth， blurred vision， GI disturbances.,室溫藥品，仿單無特別指示儲存溫度條件,Adult: PO 5 mg twice daily. Children 0.25 mg/kg/day.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
EWAR,Podophyllotoxin,Wartec cream 0.15%， 5gm,TDER,,I: Topical treatment of anogenital warts. CI: Not for use on open wounds. Pregnancy， lactation. ADR: Itching， irritation， tenderness， smarting.,,RT,Apply bid for 3 days， followed by 4 treatment-free days at wkly intervals.,,,,不可使用,,,,,,,,,,
EVIR,Tromantadine,Viru-Merz 5gm,TDER,,I: Herpes simplex infection of skin & semimucous membranes; Eczema herpeticum， dermal manifestations of herpes zoster.,,RT,Apply tid.,,,,沒有資料,,,,,,,,,,
OFOS7,Alendronate,Fosamax 70mg,META,,適應症:主治骨質疏鬆症(B023167100) 副作用: Esophagitis， esophageal erosions， esophageal ulcers， abdominal distension. Rash， erythema; bone， muscle & joint pain; constipation， diarrhea， flatulence， headache， urticaria， angioedema， nausea， vomiting， oropharyngeal ulceration， gastric or duodenal ulcer. 禁忌: (1) Abnormalities of the oesophagus which delay oesophageal emptying eg stricture or achalasia. Inability to stand or sit upright for at least 30 mins. (2) Hypocalcemia. (3) Hypersensitivity.,,室溫,70mg once weekly.,,,,除非治療上需要,,,,,,,,,,
IHIG3,Human Immunoglobulin,Human Immunoglobulin 3gm/60mL,HIMM,,,,,,,,,,,,,,,,,,,
IMIXTI,Human Insulin Regular/NPH 30/70,Mixtard insulin 30/70 (IU) 100IU/mL,META,,,,,,,,,,,,,,,,,,,
IHUMRI,Insulin Regular Human,Humulin R inj100IU/mL (IU),META,,適應症:為短效型胰島素，糖尿病用藥(A034983299)(K000663299),,,,,,,,,,,,,,,,,
IHUMNI,Human NPH Insulin,Humulin N inj100IU/mL (IU),META,,適應症:為中效型胰島素，糖尿病用藥(A034984299)(K000657299),,,,,,,,,,,,,,,,,
OFOSR,Lanthanum carbonate,Fosrenol Chewable 750mg,META,Reduction of serum phosphate in patients with stage 5 chronic kidney disease (end-stage renal disease ; kidney failure: GFR <15 mL/minute/1.73 m2 or dialysis),Bowel obstruction， fecal impaction， ileus， Hypersensitivity to lanthanum carbonate or any component of the formulation; hypophosphatemia,Nausea， headache， Vomiting， abdominal pain， Allergic skin reactions， bowel obstruction， constipation， dyspepsia， fecal impaction， hypophosphatemia， ileus,25℃以下,The daily dose in divided doses with meals or immediately after meals. Control of serum phosphate level has been demonstrated at doses starting from 750 mg per day. Then titrate at intervals of 2 to 3 weeks until an acceptable serum phosphate level is reached. The recommended maximum dosage: 3750mg/day. [Micromedex 20210731] Initial dosage: 1500 mg per day， then titrate in increments of 750 mg/day at intervals of 2 to 3 weeks until an acceptable serum phosphate level is reached. Maintenance dosage: 1500 to 3000 mg per day is usually required to achieve plasma phosphate levels less than 6 mg/dL. Maximum dosage: 4500 mg/day was evaluated in ESRD patients.,無需調整劑量,upper table (according to up to date of Pregnancy Risk Factor and Lactation ),無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,upper table (according to up to date of Pregnancy Risk Factor and Lactation ),PC;PO;WM;,,,,,
OMETH,Methyldopa,MethylDOPA 250mg,CAVS,Hypertension.,Active hepatic disease.,Sedation， headache， asthenia， weakness， fever， bradycardia， hypotension， GI disturbances， sore or 'black' tongue， liver disorders， +ve Coombs test， nasal congestion， anxiety， depression， arthralgia， rash.,室溫保存,HTN Adult: initial 250 mg BID， titrate up to 2-4 tablets/day (maximum: 6 tablets/day),無需調整劑量,,需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PO;WM;,,,,,
OTIN5,Tinidazole,Tinidazole 500mg,QANB,,,,,,,,,,,,,,,,,,,
OVYT,Ezetimibe + Simvastatin,Vytorin 10/20mg,CAVS,Primary hypercholesterolemia: Adjunctive therapy to diet for the reduction of elevated total-C， LDL-C， Apo B， TG & non-HDL-C， & to increase HDL-C in patients with primary (heterozygous familial & non-familial) hypercholesterolemia or mixed hyperlipidemia. Homozygous familial hypercholesterolemia (HoFH): For the reduction of elevated total-C & LDL-C levels in patients with HoFH， as an adjunct to other lipid-lowering treatments (eg LDL apheresis) or if such treatments are unavailable.,Active liver disease or unexplained persistent elevations of serum transaminases. Pregnancy， lactation.,Flatulence， abdominal pain， diarrhea， myalgia， headache， fatigue， thrombocytopenia， hepatitis， increased CPK， elevations of liver transaminases. Gastrointestinal: Diarrhea (2.8% ) Neurologic: Headache (5.8% ) Respiratory: Upper respiratory infection (3.6% ),30℃以下密閉儲存,Adult: usual dosage range: 10/10 mg/day to 10/40 mg/day. Usual starting dose: 10/10 mg/day or 10/20 mg/day. Take as a single daily dose in the evening， with or without food.,無需調整劑量,Ezetimibe - Contraindicated Simvastatin - Contraindicated,無需調整劑量,不可使用,Contraindicated – 1st trimester,Ezetimibe - Limited Human Data—Animal Data Suggest Moderate Risk Simvastatin - Contraindicated 1st Trimester,Contraindicated 哺乳期使用禁忌,Ezetimibe - Contraindicated Simvastatin - Contraindicated,,,,,,
ILID2E,Lidocaine + Epinephrine,Lidophrine inj (2%+E) 20mL,ZANE,For production of local anesth by nerve block or infiltration inj.,Thyrotoxicosis， hypertension， severe heart disease (particularly when tachycardia is present)， diabetes; hypovolaemia， shock， heart block; when inflammation or sepsis is present in the region of the proposed inj. Soln containing epinephrine should not be used for local anesth inj in digits & appendages.,Common: Nervousness， dizziness， blurred vision， tremor， drowsiness， tinnitus， numbness， disorientation， nausea & vomiting. Less common: Convulsions， unconsciousness， respiratory depression or arrest， hypotension， CV collapse & bradycardia which may lead to cardiac arrest.,避光,Each mL contains 20mg Lidocaine and 0.02mg Epinephrine. Maximum dose of lidocaine when given with epinephrine is 500 mg in a normal healthy adult. Dental local anesthesia is according to the patient's physical condition and inject the minimum dose that can obtain effective local anesthetic effect. Oral infiltration or mandibular block: Initial dose: 1-2 mL. Children < 10 years usually need no more than 10 mL of Lidophrine 2%+E.,無需調整劑量,[4] due to epinephrine [3] lidocain,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,[17] due to epinephrine [1] lidocain,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[4] due to epinephrine [3] lidocain,LA;LI;,,,,,
OSUT,Sunitinib,Sutent 12.5mg,RACA,Treatment of GI stromal tumor after disease progression on or intolerance to imatinib mesylate. Treatment of advanced or metastatic renal cell carcinoma (clear cell carcinoma in pathology).,Pregnancy. Women of childbearing potential should avoid becoming pregnant while receiving treatment.,Fatigue， asthenia， diarrhea， nausea， mucositis/stomatitis， vomiting， dyspensia， abdominal pain， constipation， hypertension， rash， hand-foot syndrome， skin discoloration， altered taste， anorexia & bleeding. Potentially serious adverse reactions of LV dysfunction， QT interval prolongation， hemorrhage， hypertension & adrenal dysfunction. Dermatologic: Discoloration of skin， Yellow (GIST， 30%; MRCC， 19% )， Dry skin (MRCC， 18% )， Rash (GIST， 14%; MRCC， 27% ) Endocrine metabolic: Hypothyroidism (GIST， 4% to 36%; MRCC， 3% ) Gastrointestinal: Abdominal pain (MRCC， 22% )， Constipation (GIST， 20%; MRCC， 16% )， Diarrhea (GIST， 40%; MRCC， 58% )， Increased serum lipase level (GIST， 25%; MRCC， 52% )， Indigestion (MRCC， 28% )， Inflammatory disease of mucous membrane (GIST， 29%; MRCC， 43% )， Loss of appetite (GIST， 33%; MRCC， 38% )， Nausea (MRCC， 49% )， Pain of oral cavity structure (GIST， 6%; MRCC， 10% )， Taste sense altered (GIST， 21%; MRCC， 44% )， Vomiting (MRCC， 28% ) Hematologic: Anemia (GIST， 26%; MRCC， 71% )， Bleeding (GIST， 18%; MRCC， 30% )， Leukopenia (MRCC， 78% )， Lymphocytopenia (GIST， 38%; MRCC， 59% )， Neutropenic disorder (GIST， 53%; MRCC， 72% ) Hepatic: Liver function tests abnormal (GIST， 10% to 39%; MRCC， 13% to 56% ) Neurologic: Asthenia (GIST， 22%; MRCC， 21% ) Renal: Increased uric acid level (MRCC， 41% ),儲存於25 oC,[Gastrointestinal Stromal Tumor (GIST) and Advanced Renal Cell Carcinoma (RCC)] 50 mg orally with or without food once daily， on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2). [Pancreatic neuroendocrine tumors (pNET)] 37.5 mg orally with or without food once daily continuously without a scheduled off-treatment period. [Adjuvant Treatment of RCC] 50 mg orally with or without food once daily， on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2)， for nine 6-week cycles.,無需調整劑量,[仿單] 沒有關於sunitinib與其代謝物會存在於人類乳汁的資訊。Sunitinib與其代謝物會分泌 至大鼠乳汁中，濃度高達血漿濃度的12倍(見資料)。因可能會使哺餵之嬰兒產生嚴重的 不良反應，建議婦女於 SUTENT治療期間至最後一次服藥後至少4週內不要哺乳。,需調整劑量,沒有資料,Contraindicated,[仿單] 根據動物生殖研究與其作用機制，對孕婦投予 SUTENT可能會造成胎兒傷害。沒有使用 於孕婦的資料以告知藥品相關的風險。在動物發育與生殖毒理學研究中，於整個器官形成期 間，分別口服給予懷孕大鼠和兔子sunitinib達病人每日建議劑量50 mg之AUC總和5.5倍與0.3倍時 引起致畸性(胚胎致死、顱面和骨骼畸形)。告知有生育能力婦女對胎兒的潛在風險。,Contraindicated 哺乳期使用禁忌,[仿單] 沒有關於sunitinib與其代謝物會存在於人類乳汁的資訊。Sunitinib與其代謝物會分泌 至大鼠乳汁中，濃度高達血漿濃度的12倍(見資料)。因可能會使哺餵之嬰兒產生嚴重的 不良反應，建議婦女於 SUTENT治療期間至最後一次服藥後至少4週內不要哺乳。,,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
ODIP5,Valproic Acid,Dipachro S.R. 500mg,CNEU,,,,室溫,Adult & >15 yr or wt. >25 kg: 20-30 mg/kg/day. Child: 30 mg/kg/day.,,,,盡量避免,,,,,,,,,,
OPREL,Estrogen + Medroxyprogesterone,Premelle LITE 0.3/1.5mg 28's,HM,,適應症: Moderate-to-severe vasomotor symptoms associated with estrogen deficiency. Prevention & treatment of osteoporosis associated with estrogen deficiency. Atrophic vaginitis & atrophic urethritis. 副作用: Abdominal pain， back pain， flu syndrome， headache， infection， pain， nausea & other GI disturbances， pharyngitis， pruritus， breast pain. Also reported， changes in vag bleeding pattern & abnormal withdrawal bleeding or flow， breakthrough bleeding， change in amount of cervical secretion， breast tenderness & enlargement， venous thromboembolism， cholestatic jaundice， increased incidence of gallbladder disease， pancreatitis， enlargement of hepatic hemangiomas， chloasma or melasma， neuro-ocular lesions， CNS disturbances， wt changes， edema， changes in libido， reduced carbohydrate tolerance， aggravation of porphyria， pyrexia， hypocalcemia， exacerbation of asthma， increased triglycerides. 禁忌: Undiagnosed abnormal genital bleeding. Known， suspected or history of breast cancer. Known or suspected estrogen-dependent neoplasia. Active or history of deep vein thrombosis， pulmonary embolism. Active or recent arterial thromboembolic disease e.g. stroke， MI. Liver dysfunction. Known or suspected pregnancy.,,室溫,1 tab once dialy.,,,,不可使用,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ITD,Diphtheria + Tetanus,Td (白喉破傷風，政府提供) 0.5mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
OTAM0,Oseltamivir,Tamiflu 75mg (合約專案),QANB,,適應症: 30 mg cap Prophylaxis & treatment of influenza in adult & children >= 1 yr. 75 mg cap Prophylaxis & treatment of influenza in adult & children >= 13 yr. 副作用: Nausea， vomiting， abdominal pain， headache. Insomnia， diarrhea. 禁忌: Hypersensitivity.,,室溫,Treatment of influenza Begin treatment within the 1st or 2nd day of onset of symptoms. Adult & adolescent >= 13 years 75 mg， children > 1 year， > 40 kg 75 mg， > 23-40 kg 60 mg， >15-23 kg 45 mg， <= 15 kg 30 mg. Doses to be given bid for 5 days. Prophylaxis of influenza Adult & adolescent > 13 years 75 mg once daily for 10 days， children > 1 year， > 40 kg 75 mg， > 23-40 kg 60 mg， >15-23 kg 45 mg， <= 15 kg 30 mg. Doses to be given once daily for 10 days.,,,,除非治療上需要,,,,,,,,,,
IHCG5,Chorionic Gonadotropin,Pregnyl (HCG) 5000 IU,HM,,適應症: Male Hypogonadotrophic hypogonadism， Delayed puberty associated with insufficiency gonadotrophic pituitary function，Cryptorchism Female Sterility due to absence of ovulation 副作用:Fluid & salt retention (occasionally). Skin rash (rare 禁忌:Known or suspected androgen-dependent tumours. Precocious puberty.,,2-8℃,Male Hypogonadotrophic hypogonadism 500-1000 iu 2-3 times/wk. Delayed puberty associated with insufficiency gonadotrophic pituitary function 1500 iu 2 times/wk for >= 6 months. Cryptorchism 6 years 1000 iu， <6 years 500 iu; to be given 2 times/wk for 6 weeks. Sterility 3000 iu/wk in combination with FSH or HMG prep. Female Sterility due to absence of ovulation 5000-10，000 iu for 1 or 3 days. Repeat inj of 5000 iu 7 days later to prevent corpus luteum insufficiency.,,,,不可使用,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ECOMU,Ipratropium + Salbutamol,Combivent UDV 2.5mL,ERSP,Management of reversible bronchospasm associated with obstructive airways diseases in patients who require more than a single bronchodilator.,Hypertrophic obstructive cardiomyopathy or tachyarrhythmia,Headache， dizziness， nervousness， tachycardia， fine tremor， palpitations. Potentially serious hypokalaemia may result from β2 agonist therapy. Dry mouth， dysphonia， ocular complications， allergic-type reactions.,30℃以下儲存,Adult 1-2 inhalations BID-QID. [Micromedexs 2021/06/11] Asthma: >12years moderate to severe asthma every 4- 6hours 1 unit dose， severe asthma every 20 minutes use 1 unit dose for 3 times as needed for up to 3hours. 0-12year severe asthma every 20 minutes use 0.5- 1 unit dose for 3 times as needed for up to 3hours. COPD requring second bronchodilator 1 inhalation QID. Maximum: 6 inhalations in 24 hours.,無需調整劑量,IPRATROPIUM BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible ALBUTEROL BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,除非治療上需要,Human data suggest low risk,IPRATROPIUM PREGNANCY RECOMMENDATION: Human Data Suggest Low Risk ALBUTEROL PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,IPRATROPIUM BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible ALBUTEROL BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,IH;INHL;,,,,,
YCIM,polysiloxanes,Cimeosil scar gel 14gm,TDER,,,,,,,,,,,,,,,,,,,
OANL,Lactobacillus + Bifidobacterium,Anlorin 5's/pk,ALIM,,適應症: Symptomatic treatment of mild diarrhea & abdominal pain.,,2-8℃,1 CAP TID,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OARI1,Donepezil,Aricept 10mg,CNEU,,適應症: Treatment of mild to moderate dementia of the Alzheimer's type. 副作用:Nausea， diarrhea， insomnia， vomiting， muscle cramp， fatigue & anorexia. Syncopal episodes have been reported. Cardiovascular: Hypertension (3% )， Syncope (2% ) Endocrine metabolic: Weight decreased (3% to 5% ) Gastrointestinal: Diarrhea (5% to 15% )， Loss of appetite (2% to 8% )， Nausea (3% to 19% )， Vomiting (3% to 9% ) Hematologic: Contusion (2% )， Ecchymosis (4% to 5% ) Musculoskeletal: Cramp (3% to 8% )， Increased creatine kinase level (3% ) Neurologic: Asthenia (1% to 2% )， Dizziness (2% to 8% )， Headache (3% to 4% )， Insomnia (2% to 14% )， Somnolence (1% to 2% ) Psychiatric: Depression (2% to 3% )， Dream disorder (3% ) Renal: Urinary incontinence (1% to 3% ) Other: Fatigue (1% to 8% ) 禁忌:Patients with a known hypersensitivity to donepezil HCl， piperidine derivatives or to any excipients used in Aricept. Use in children: Aricept is not recommended for use in children.,,室溫,Adult 5 mg once daily in the evening just prior to retiring. Dose may be increased to 10 mg once daily following 4-6 weeks of clinical assessment.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IGCS,Filgrastim,Gcsf 150mcg/0.6mL (Filgrastim),HEMT,Mobilization of hematopoietic progenitor cells to peripheral blood， Acceleration of an increase in the number of neutrophils following hematopoietic progenitor cells transplantation， Neutropenia caused by cancer chemotherapy， Neutropenia accompanying MDS， Congenital idiopathic neutropenia.,Hypersensitivity to any component of the formulation.,Mainly bone pain， fever， redness， nausea & vomiting， headache. Gastrointestinal: Nausea and vomiting (57% ) Musculoskeletal: Bone pain (22% to 33% ),避光冷藏 (<10℃),Mobilization of hematopoietic progenitor cells to peripheral blood: Adult & children Administer 400 mcg/m2 once daily or 200mcg/m2 twice daily SC.Acceleration of an increase in the number of neutrophils following hematopoietic progenitor cells transplantation:Adult & children Administer 300 mcg/m2 once daily IV. Neutropenia caused by cancer chemotherapy:Acute leukemia: Adult & children Administer 200 mcg/m2 once daily IV.Malignant lymphoma， Small Cell Lung Cancer， Germ cell tumors， Neuroblastoma and Pediatric cancer: 50 mcg/m2 SC or 100 mcg/m2 IV once daily after the next day of chemotherapy.Other cancer: Neutrophil count ≦ 1000/mm3 and fever， or Neutrophil count ≦ 500/mm3， 50 mcg/m2 SC or 100 mcg/m2 IV once daily.When neutrophil count ≧ 5000/mm3， consideration monitor and discontinue therapy.Neutropenia accompanying myelodysplastic syndrome: Neutrophil count ≦ 1000/mm3， 100 mcg/m2 once daily IV.Congenital idiopathic neutropenia:Adult & children: Neutrophil count ≦ 1000/mm3， 50 mcg/m2 SC once daily. When neutrophil count ≧ 5000/mm3， close observation is needed & consideration should be made to either decrease dosage or discontinue therapy.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;SC;,,【D5W】可選 。【N/S】可選 。,,IV輸注時可使用 D5W稀釋，濃度勿低於 5 mcg/mL。,1. IV輸注時可使用 D5W稀釋，濃度勿低於 5 mcg/mL。
IMIT1,Mitomycin C,Mitomycin-C inj 10mg,RACA,Treatment of disseminated adenocarcinoma of the stomach (in combination with other chemotherapy agents) and disseminated adenocarcinoma of the pancreas (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.,Hypersensitivity to mitomycin or any component of the formulation; thrombocytopenia; coagulation disorders， or other increased bleeding tendency,Leukopenia， thrombocytopenia， anorexia， nausea/vomiting， malaise， weight loss， bleeding tendency & anemia. Haemolytic-uremic syndrome， microangiopathic hemolytic anemia， nephropathy， bone marrow depression， interstitial pneumonia， liver & biliary tract disorders.,25°C以下,Intermittent therapy Adult 4-6 mg IV once or twice weekly. Consecutive therapy Adult 2 mg IV once daily. Large dose intermittent therapyAdult 10-30 mg IV at 1-3 (or more) weeks intervals. Combined use with other antineoplastic agent Adult 2-4 mg once or twice weekly. Bladder cancer Prophylaxis of recurrence: 4-10 mg intravesically once daily or every 2 days. Treatment: 10-40 mg intravesically once daily.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest high risk,,Contraindicated 哺乳期使用禁忌,,EXT;IRR;IVD;,以25mL無菌注射用水溶解,【N/S】可選 。,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、腎功能。
EMYDP,Tropicamide + Phenylephrine,Mydrin-P 10mL,TOPH,Mydriasis & cycloplegia for diagnosis,Narrow-angle glaucoma.,Transient stinging， dry mouth， Allergic reactions,1-30℃,For pupil dilation， usually 1-2 drops per time， or 1 drop each time at an interval of 3 to 5 minutes and 2 attempts in total. For cycloplegia， usually 1 drop each time at an interval of 3 to 5 minutes and 2 to 3 attempts in total. The dosage may be increased or decreased as appropriate depending on the symptoms.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
OANTI,Lactobacillus Casei,Antibiophilus 250mg,ALIM,Temporary relief of mild diarrhea， abdominal pain， constipation. Regulate bowel movement & soften stool.,When used for self-medication， do not use if sensitive to milk protein (product specific).,Bloating (intestinal)， flatulence.,25℃以下,Adult & children >12 years: PO 1~2 CAP TID-QID. (Better to take between meals) 6-12 years: one half dose of Adult. 3-6 years: one quarter dose of Adult.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
IINFE,Interferon alfacon-1,Infergen 9mcg,QANB,,適應症: Chronic hepatitis C. 副作用: Insomnia， nervousness， depression， dizziness， anxiety， emotional lability; alopecia， pruritus， rash; hot flushes; GI disturbances; blood dyscrasia; inj site reactions; myalgia， arthralgia， pain， paraesthesia; flu-like symptoms; upper respiratory tract infection; chest pain， arrhythmia， MI; hypersensitivity reaction; blurred or loss of vision; hepatomegaly， liver tenderness. 禁忌: Hypersensitivity. Hepatic decompensation， autoimmune hepatitis.,,2-8°C,SC 9 mcg 3 times/wk for 24 wk， then 15 mcg 3 times/wk for up to 48 wk if needed.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OKET,Ketorolac,Keto 10mg,CNEU,For the short-term management of moderate-severe acute pain， including pain following major abdominal， orthopedic & gynecological operative procedures.,Hypersensitivity to aspirin or other NSAIDs.,Nausea， abdominal discomfort， peptic ulceration， GI bleeding， drowsiness， dizziness. Cardiovascular: Edema (1% to 10% )， Hypertension (1% to 10% ) Dermatologic: Injection site pain (injection， 1% to 10% )， Pruritus (1% to 10% )， Rash (1% to 10% )， Sweating (1% to 10% ) Gastrointestinal: Abdominal pain (1% to 10% )， Diarrhea， Indigestion (1% to 10% )， Nausea (greater than 10% ) Hematologic: Anemia (1% to 10% )， Purpura (1% to 10% ) Neurologic: Dizziness (1% to 10% )， Headache (greater than 10% )， Somnolence (1% to 10% ) Ophthalmic: Burning sensation in eye， Transient (ophthalmic， 20% to 40% )， Corneal edema (ophthalmic， 1% to 10% )， Eye irritation (ophthalmic， 1% to 10% )， Iritis (ophthalmic， 1% to 10% )， Keratitis (ophthalmic， 1% to 10% ) Respiratory: Nasal irritation (nasal， 15% )， Pain， Rhinalgia (nasal， 13% ),25℃以下避光,10mg(1 capsule) every 4-6 hours,無需調整劑量,,需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為腸溶膠囊，可拆膠囊後服用。但不可將膠囊內的腸溶微粒研磨或壓碎。
OFERS,Ferrous Fumarate,Ferall soft cap 460mg，100's,NUTR,,I: Treatment all anemias responsive to oral iron therapy.,,RT,1-2 cap daily.,,,,,,,,,,,,,,
ESILK,Calcitriol,Silkis oint 30gm,TDER,,適應症:乾癬、尋常性痤瘡(B023403343),,RT,Apply bid. A maxium of 30 g of ointment is applied per day to up to 35% body surface.,,,,沒有資料,,,,,,,,,,
EDAIV,Calcipotriol + Betamethasone,Daivobet ointment 30gm,TDER,Psoriasis vulgaris.,Disorders of Ca metabolism， viral， fungal or bacterial skin infections， parasitic infections， skin manifestations in relation to TB or syphilis， rosacea， acne rosacea， perioral dermatitis， acne vulgaris， skin atrophy， striae atrophicae， fragility of skin veins， ichthyosis， ulcers， wounds， perianal & genital pruritus; guttate， erythrodermic， exfoliative & pustular psoriasis， severe renal insufficiency or severe hepatic disorders.,Pruritus， local transient irritation， dermatitis， erythema， aggravation of psoriasis， photosensitivity & hypersensitivity reactions. Dermatologic: Atrophic condition of skin (1.9% )， Pruritus (3.1% to 7.2% )， Psoriasis (1.2 to 3.4% )， Rash， scaly (1.2% ) Neurologic: Headache (2.8% ),30℃以下,Psoriasis Apply to the affected area once daily for 4 weeks. After this period， repeated treatment can be initiated under medical supervision. Maximum daily dose: 15 g. Maximum weekly dose: 100 g. Maximum treated area: 30% of the body surface.,無需調整劑量,,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;SKIN;TOPI;,,,,,
IPEG1,Peginterferon alfa-2b,PEG-INTRON 100mcg,QANB,,適應症:Treatment of chronic hepatitis C in patients ? 18 years with compensated liver disease. 副作用:Headache， myalgia， pain/inflammation at inj site， fatigue， rigors， fever， depression， arthralgia， nausea， alopecia， musculoskeletal pain， irritability， flu-like symptoms， insomnia， diarrhea， abdominal pain， asthenia， pharyngitis， weight decrease， anorexia， anxiety， impaired concentration， dizziness， local reactions at inj site. 禁忌:Hypersensitivity to interferon. Pregnancy. Men whose female partners are pregnant. Autoimmune hepatitis or a history of autoimmune disease. Decompensated liver disease or severe renal dysfunction.,,2-8℃,Adult≧18 years Monotherapy 0.5 or 1 mcg/kg SC once weekly for at least 6 months. Combination therapy 1.5 mcg/kg SC once weekly in combination with ribavirin,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,
EPRO,Tacrolimus,Protopic 0.03%軟膏，10gm,TDER,,適應症: Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis. 副作用: Burning sensation， pruritus， flu-like symptoms & headache. 禁忌: Patients with a history of hypersensitivity to tacrolimus or any other component of Protopic.,,15 ~ 30 °C,Adult & children 2-15 years Apply thinly & rub in bid， continue for 1 week after signs & symptoms clear.,,,,沒有資料,,,,,,,,,,
ODOR,Mephenoxalone,Dorsiflex 200mg,CNEU,,適應症: 為肌肉鬆弛劑Muscle spasms(A044318100)(B022801100) 副作用: Drowsiness; GI disturbances， paraesthesia， weakness; headache， dizziness， ataxia， paradoxical excitement; visual disturbances; arrhythmias， hypotension; hypersensitivity reactions; blood dyscrasias. 禁忌: Porphyria; pregnancy and lactation,,室溫,Adult: 1-2 tab. tid. Child 6-15 yr: 1/2 tab tid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OEFE,Venlafaxine,Efexor 37.5mg,CNEU,,適應症:解除憂鬱焦慮狀態(B022328100) ADR: Dizziness， dry mouth， insomnia， nervousness， somnolence， anorexia， constipation， nausea， abnormal ejaculation/orgasm， sweating， asthenia. CI: Concomitant use in patient taking MAOIs. Pregnancy， lactation. Children < 18 yr.,,室溫,75 mg once daily. After 2 weeks， the dose may be increased to 150 mg once daily & further to 225 mg once daily if needed.,,,,除非治療上需要,,,,,,,,,,
OEUC,Nicametate,Euclidan 50mg,CAVS,,Peripheral vascular disorders， cerebral insufficiency.,,,50-100 mg tid.,,,,,,,,,,,,,,
OHEA,Dihydroergotoxine Mesylate,Headgen 1.5mg,CAVS,,Cerebral arteriosclerosis and other cerebral vascular disorders.,,,1 tab tid.,,,,,,,,,,,,,,
OIMD,Isosorbide 5-Mononitrate,Imdur 60mg,CAVS,Prophylaxis of angina pectoris.,Cardiogenic shock， head trauma， cerebral hemorrhage， severe hypotension & severe hypovolemia.,Headache， dizziness， nausea. Neurologic: Dizziness (8% to 11% )， Headache (38% to 57% ),室溫,60 mg in the morning. Dose may be increased to 120 mg QD. Start from 30 mg QD in the initial 2-4 days to prevent headache occur.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ICLI2,TPN Solution,CLINOLEIC 20% 250mL emulsion,NUTR,,,,,,,,,,,,,,,,,,,
ICLI1,TPN Solution,Clinoleic 20% 100mL emulsion,NUTR,,,,,,,,,,,,,,,,,,,
OKAL,Calcium Polystyrene Sulfonate,Kalimate powder 5 gm/pk,ZADT,,,,,,,,,,,,,,,,,,,
OSTR4,Atomoxetine,STRATTERA 40MG,CNEU,Treatment of attention-deficit/hyperactivity disorder (ADHD).,with a MAOI or within 2 weeks after discontinuing a MAOI， narrow-Angle Glaucoma.,Nausea， vomiting， fatigue， decreased appetite， abdominal pain， somnolence. Endocrine metabolic: Weight loss (pediatrics， 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults， 7%; pediatrics， 17% to 18% )， Constipation (adults， 9%; pediatric， 1% to 2%)， Decrease in appetite (adult， 11%; pediatrics， 16% ，)， Nausea (adults， 21%; pediatrics， 7% to 13% )， Vomiting (adults， 3%; pediatrics， 11%)， Xerostomia (adults， 21% ) Neurologic: Headache (pediatrics， 19% )， Insomnia (adults， 16%; pediatrics， at least 2%; )， Somnolence (adult， 4%; pediatrics， 11% ) Renal: Delay when starting to pass urine (adults， 5.6% )， Urinary retention (adults， 1.7% ) Reproductive: Dysmenorrhea (adults， 6% )， Erectile dysfunction (adults， 9% ) Other: Menopausal flushing (adults， 8% ),25℃以下,Adult， adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg， whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult， adolescent & children>70 kg maximum dose is 100 mg total daily .,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,[磨粉/管灌註記]本藥請整顆膠囊吞服。若有磨粉需求請使用前自行磨粉並注意本藥粉末具有眼部刺激性。
OSTR6,Atomoxetine,Strattera 60mg,CNEU,Treatment of attention-deficit/hyperactivity disorder (ADHD).,with a MAOI or within 2 weeks after discontinuing a MAOI， narrow-Angle Glaucoma.,Nausea， vomiting， fatigue， decreased appetite， abdominal pain， somnolence.,室溫,Adult， adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg， whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult， adolescent & children>70 kg maximum dose is 100 mg total daily .,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
YDER,Polysiloxane,Dermatix gel 15gm,TDER,,,,,,,,,,,,,,,,,,,
YORI,噢立喜樂蜂膠,噢立喜樂蜂膠240'S,NUTR,,,,,,,,,,,,,,,,,,,
EATRI,Ipratropium,Atrovent MDI 200pff/10mL,ERSP,,適應症: Chronic obstructive bronchitis， bronchial asthma. Assisted respiration in patients with bronchospasm in intensive care & anaesthesiology. 副作用: GI motility disorders， dry mouth， headache， tachycardia， palpitations， supraventricular tachycardia， atrial fibrillation， ocular accomodation disturbances， nausea， urinary retention， cough， local irritation， inhalation-induced bronchospasm， allergic reactions. 禁忌: Hypersensitivity to atropine or its derivatives.,,室溫,Metered inhaler Intermittent & long-term treatment 2-6 puffs several times daily (ave: 4 puffs 3-4 times daily). Treatment of attacks 2-3 metered doses， may be repeated after 2 hr.,,,,可能安全,,,,,,,,,,
OEXE1,Rivastigmine,Exelon 1.5mg,CNEU,改善認知及記憶症(B022861100),,,,Initially 1.5 mg BID for 2 weeks. If well tolerated， increase in increments of 1.5 mg orally twice daily at minimum of every 2 weeks. Maintenance: 3-12 mg daily. Maximun: 12 mg/day.,無需調整劑量,,無需調整劑量,,,,,,,,,,,
OINDO2,Indomethacin,Indoy 25mg,CNEU,Inflammation， pain in the musculoskeletal system， swelling after dental surgery,1. Disabled for active gastric ulcers; should also be used with caution in patients with past gastric ulcers. 2. Patients with asthma caused by allergic to Aspirin are banned. 3. Disabled for children under the age of fourteen; use caution for patients who are pregnant or breastfeeding. 4. Patients with epilepsy， Parkinson's disease and mental illness should also pay attention to use. 5. The drug was banned within 14 days after the Coronary artery bypass graft (CABG).,>10%:Headache (12% to 16%)， Vomiting (<=12%)， Postoperative hemorrhage (<=11%) 1% to 10%:Presyncope (<=3%)， syncope (<=2%)， Dizziness (3% to 9%)， depression (1% to 3%)， drowsiness (1% to 3%)， fatigue (1% to 3%)， malaise (1% to 3%)， vertigo (1% to 3%)， Pruritus (1% to 4%)， hyperhidrosis (2%)， skin rash (1% to 2%)， Hot flash (2%)， Epigastric pain (3% to 9%)， heartburn (3% to 9%)， nausea (3% to 9%)， dyspepsia (2% to 9%)， constipation (?6%)， abdominal distress (1% to 3%)， abdominal pain (<3%)， diarrhea (<3%)， decreased appetite (>=2%)， Tinnitus (>1%)， Swelling (3%; postprocedural),25℃以下,Depending on the patient's response and tolerance， 25mg(1 capsule) twice or three times a day for adults， with or after meal.,無需調整劑量,,需調整劑量,,Human data suggest risk in 1st and 3 rd trimesters,Indomethacin use during the latter part of pregnancy may cause severe fetal toxicity. Short-term use， such as 24–48 hours， lessens the risk. Based on animal data， prostaglandin synthesis inhibitors， including indomethacin， might block blastocyst implantation. Nonsteroidal anti-inflammatory agents (NSAIDs) also have been associated with spontaneous abortions (SABs) and congenital malformations， but the absolute risk appears to be low. [20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;WM;,,,,,
INOVO,Insulin Aspart,NovoRapid 100u/mL， 3mL,META,,適應症:Treatment of patients with diabetes mellitus. 副作用:Hypoglycaemia， edema， refraction anomalies， hypersensitivity reactions， lipodystrophy. 禁忌: Hypoglycaemia.,,2-8℃,Individualised dosage. Administered by SC inj. Normally combined with basal insulins (intermediate or long acting insulins). Penfill should be used with NovoPen 4 & NovoFine Needles,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
IINS,Insulin Monocomponent Isophane (NPH),Insulatard HM penfill 3mL(100IU/mL),META,,適應症:Insulin-requiring diabetes mellitus. 副作用:Rare incidence of allergy & lipoatrophy. 禁忌:Hypoglycaemia， insulinoma.,,2-8℃,Administer once or twice daily by SC inj. Duration of action: Onset after 1 1/2 hr， peak between 4th-12th hr， terminates after approximately 24 hr. Penfill should be used with NovoPen 4 & NovoFine Needles.,,,,沒有資料,,,,,,,,,,
OYAS,Drospirenone + Ethinylestradiol,Yasmin 21's/box,HM,,適應症: Oral Contraceptives 副作用: Breast tenderness， pain， secretion; headache; migraine; changes in libido; depressive moods; contact lens intolerance; nausea; vomiting; changes in vaginal secretion; various skin disorders; fluid retention; change in body weight; hypersensitivity reaction. Rarely， benign or malignant liver tumors which may lead to life-threatening intra-abdominal hemorrhage have been observed. 禁忌: Venous or arterial thromboembolic events including MI & CVA. Prodromi of thrombosis (transient ischemic attack， angina pectoris)， diabetes mellitus with vascular involvement. Severe or multiple risk factors for venous or arterial thrombosis. Severe hepatic disease， benign or malignant liver tumours. Malignant conditions of the genital organs or breasts， if sex steroid-influenced. Undiagnosed vag bleeding. Pregnancy.,,室溫,1 tab daily for 21 consecuive days， starting on the 1st day of the cycle， then 7 tab-free days.,,,,不可使用,,,Compatible 哺乳時可使用,,,,,,,
ODEN,Desloratadine,Denosin 5mg,HIMM,,適應症:Symptomatic relief of seasonal allergic rhinitis & chronic idiopathic urticaria. 副作用: Pharyngitis， dry mouth， myalgia， fatigue， somnolence， dysmenorrhea， headache， nausea， dizziness， dyspepsia.,,室溫,Adult & children > 12 years 5 mg once daily,需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OCARD,Sotalol,Cardol 160mg,CAVS,,適應症: Management of ventricular & supraventricular arrhythmias; hypertension; angina pectoris. 副作用: Fatigue， bradycardia， dyspnoea， proarrhythmia， asthenia， dizziness. Cardiovascular: Bradyarrhythmia ( 12.3% to 16% )， Chest pain (2.5% to 16% )， Lightheadedness (12% )， Palpitations (14% ) Dermatologic: Rash (5% ) Gastrointestinal: Nausea (5.7% to 10% ) Neurologic: Disturbance of consciousness (4% )， Dizziness ( 13.1% to 20% )， Headache (3.3% to 11.5% ) Respiratory: Dyspnea (9.2% to 21% ) Other: Fatigue (18.9% to 20% ) 禁忌:Sick sinus syndrome; 2nd or 3rd degree AV heart block (unless a functioning pacemaker is present); congenital or acquired long QT syndromes; symptomatic sinus bradycardia; uncontrolled CHF; cardiogenic shock;history of COPD or bronchial asthma.,,室溫,Initial dose is 80 mg bid. This dose may be increased if necessary， after appropriate evaluation， to 240 or 320 mg/day. In most patients， a therapeutic response is obtained at total daily dose of 160 to 320 mg/day， given in two or three divided doses. Because of the long terminal elimination half-life of sotalol， dosing on more than a twice-daily regimen is usually not nessary.,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OINF,Lactobacillus + Bifidobacterium,Infloran 250mg (20 capsules/box),ALIM,Restoration of the eubiotic intestinal flora. Prophylaxis against antibiotic-induced enterocolitis. Acute non-specific enterocolitis after treatment with antibiotics.Digestive disorders in infants on an artificial diet. Chronic constipation.,Hypersensitivity,No significant side effects in normal dosage.,2-8℃,Adult & children >12 years: PO 1 CAP TID-QID 6-12 years: PO 0.5 CAP TID-QID 3-6 years: PO 0.25 CAP TID-QID,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥成份不宜遇熱，故不宜使用磨粉分包機。可自行拆膠囊使用。
OINH,Isoniazid,Duracrin (INH) 100mg,QANB,,適應症: TB. 副作用: Peripheral neuropathy， elevated hepatic enzyme levels， bilirubinemia， bilirubinuria， jaundice， hepatitis， GI disturbances， hematologic reactions， hypersensitivity reactions. 禁忌: Drug-induced hepatitis.,,,Adult 3-5 mg/kg/day in divided doses for 4-16 weeks. Infants and Children: Treatment of active infection: 10-15 mg/kg/day given once daily as part of a multidrug regimen; maximum dose: 300 mg/day Treatment of latent infection: 10-20 mg/kg/day given once daily， not to exceed 300 mg/day,需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IRI,Insulin Regular,Insulin actrapid (RI) HM Penfill,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,,According to individual requirements.,,,,,,,,,,,,,,
IGENT,Gentamicin,Gentamicin inj 80mg/2mL,QANB,,適應症: Susceptible infections， Surgical prophylaxis. 副作用: Dizziness or vertigo; acute renal failure， interstitial nephritis， acute tubular necrosis; electrolyte imbalances; transient elevation of serum bilirubin and aminotransferases; purpura; nausea， vomiting; convulsions， mental depression， hallucinations. Atrophy or rat necrosis at inj sites. 禁忌: History of hypersensitivity to aminoglycoside; pregnancy; perforated ear drum.,,,Adult: 3-5 mg/kg/day in 3 equal dose q8h. Child: 6-7.5 mg/kg/day q8h. Infant and neonate: 7.5 mg/kg/day q8h. 1 wk of age or less: 5 mg/kg/day q12h. *****NEONATE ANTIBIOTICS DOSE***** Gentamicin: Draw peak 30 min after completion infusion; draw trough just before the next dose (於第4個dose給藥前) PMA <=29 week Postnatal 0 to 7 days dose : 5mg/kg Q48h PMA <=29 week Postnatal 8 to 28 days dose : 4mg/kg Q36 h PMA <=29 week Postnatal >=29 days dose : 4mg/kg Q24 h PMA 30 – 34 week Postnatal 0 to 7 days dose : 4.5mg/kg Q36 h PMA 30 – 34 week Postnatal >= 8 days dose : 4mg/kg Q24 h PMA 35 - 44 week Postnatal all dose : 4mg/kg Q24 h,無需調整劑量,,需調整劑量,盡量避免,Human data suggest low risk,,Compatible 哺乳時可使用,,IH;IM;IMP;IRR;IVD;IVI;SCI;SUBCI;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【L/R】可選 。,,給藥濃度< 1 mg/mL (IV infuse over 30 minutes to 2 hours)。 NeoFax建議：Infuse over a period of 30 to 120 minutes using a concentration of 2 mg/mL or 10 mg/mL.,1. 監測體溫、CBC、肝腎功能、血鈣、血鉀、血鈉、血鎂、聽覺功能。 2. 建議監測藥物血中濃度。
ESWI,Sterile Water,Sterile water for irrigation 2000mL,MSIV,Wound cleansing， irrigation & flushing.,,,室溫25℃勿冷凍,For Irrigation Only. Not for Injection. As sterile irrigation of tissues or wounds， and for washing， rinsing medical device.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,EXT;G;GAR;IH;INHL;IRR;IRRI;NA;ORO;RT;SKIN;TOPI;,,,,,
YALDA,Imiquimod,Aldara cream 5%,TDER,Topical treatment of external genital & perianal warts.,Known allergy to imiquimod or to any of the excipients of Aldara.,Local skin reactions including erythema， erosion， excoriation， flaking & edema.,存放在陰涼且乾爽的地方，溫度保持25℃以下，但切勿冷凍,Molluscum contagiosum infection， Condyloma acuminatum of the anogenital region Apply 3 times weekly before sleep. Leave on skin for 6-10 hr， then wash off with mild soap & water.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,Limited Human Data Suggest Low Risk The animal reproduction data suggest that the risk of embryo–fetal harm is low. Moreover， an in vitro study with cultured human placental trophoblasts found that the systemic imiquimod concentrations obtained clinically should not alter normal placental function. The human pregnancy experience， however， is limited. Although the combined data suggest that the potential for human developmental toxicity is low， the data are too limited for a better assessment of the embryo–fetal risk. Until such data are available， the safest course is to avoid imiquimod in pregnancy， but if exposure does occur， the risk to the embryo and/or fetus appears to be low.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;SKIN;TOPI;,,,,,
OCONC,Methylphenidate,Concerta 18mg,CNEU,,適應症:For treatment of attention deficit hyperactivity disorder. 副作用:Headache， stomach ache， loss of appetite， insomnia， aggravation reaction， asthenia， hypertension， nausea &/or vomiting， dyspepsia， weight loss， twitching (tics)， dizziness， emotional lability， somnolence， anxiety， depression， nervousness， hostility， rash. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )， Loss of appetite (5% )， Nausea (12% )， Vomiting (10% ) Neurologic: Headache， Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )， Nasopharyngitis (5% ) 禁忌: Patients with marked anxiety， tension & agitation， glaucoma， Tourette's syndrome， & patients on MAOI therapy.,,室溫,Attention deficit disorder: Child over 6 yrs: Initial， 18 mg qd， max. 54 mg/day.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IVIN,Vinblastin,Vinblastin 10mg/10mL,RACA,,適應症: Histiocytic lymphoma; Hodgkin's disease; Kaposi's sarcoma; Letterer-Siwe disease; Lymphocytic lymphoma; Mycosis fungoides; Testicular cancer. 副作用: Alopecia， constipation， malaise， stomatitis， dose-limiting bone marrow suppression (e.g. granulocytopenia， thrombocytopenia， anaemia)， hypertension， central and peripheral neurotoxicity， 8th cranial nerve damage resulting in vestibular and auditory toxicity， ischaemic cardiac toxicity， breathlessness， bone， tumour or jaw pain. Nausea， vomiting， GI bleed， syndrome of inappropriate antidiuretic hormone. Necrosis， cellulitis if extravasation occurs. 禁忌: Severe bone marrow suppression; presence of bacterial infection; maglignant cell infiltration of bone marrow; Inj into extremity with poor circulation; porphyria; granulocytopenia. Elderly with cachexia or extreme skin ulcerations. Pregnancy; lactation. Intrathecal use may result in death.,,2-8°C.,IV Histiocytic lymphoma; Hodgkin's disease; Kaposi's sarcoma; Letterer-Siwe disease; Lymphocytic lymphoma; Mycosis fungoides; Testicular cancer Initial: 3.7 mg/m2， increase dose wkly in increments based on WBC counts until leukocyte count decreases to about 3，000/mm3， or max dose of 18.5 mg/m2/wk is reached. Usual dose: 5.5-7.4 mg/m2/wk.,需調整劑量,,無需調整劑量,盡量避免,,,,,IVD;,,,,,
Indocin,Indomethacin,Indocin IV 1mg,CNEU,,,,,,,,,,,,,,,,,,,
ENIC,Nicotine,Smokfree Nicotine TDDS 15,ZADT,To aid smoking cessation.,Non-somkers， children & occasional smokers. Acute MI， unstable or worsening angina pectoris， severe cardiac arrhythmias， recent CVA， skin diseases， pregnancy， lactation.,Withdrawal symptoms with smoking cessation. Frequently: Reaction at application site ( usually erythema or pruitus )， headache， cold & flu-like symptoms， insomnia， nausea， myalgia， & dizziness. Less common: BP changes， other CNS effects & GI disturbances.,室溫,1 patch/day. Treatment =/<3 months. Smokfree Nicotine TDDS 15 for those smoking >20 cigarettes/day. Smokfree Nicotine TDDS 10 for those smoking <20 cigarettes/day. Smokfree Nicotine TDDS 5 is designed to reduce nicotine replacement towards the end of therapy.,無需調整劑量,,無需調整劑量,盡量避免,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,EXT;SKIN;,,,,,
ENOG,NO Gravid IUD,NO Gravid IUD,HM,,intrauterine contraception.,,RT,Inserted into uterus.,,,,不可使用,,,Compatible 哺乳時可使用,,,,,,,
EINTD,Cromolyn,Intal eye drop 10mL,TOPH,,I: Allergic conjunctivitis. AR: Ocular stinging. CI: Soft contact lenses.,,,1-2 gtt qid.,,,,可能安全,,,,,,,,,,
ENOV,NOVA T,NOVA T,HM,,Intrauterine contraception.,,,Inserted into uterus.,,,,,,,,,,,,,,
ENTG,Nitroglycerin,Nitrolingual spray 0.4mg/dose,CAVS,,適應症:心絞痛之治療或預防(B020941153)(B020941153) CI: Severe hypotension， hypotensive shock， severe anemia， constrictive pericarditis， extreme bradycardia， G6PD deficiency， cerebral hemorrhage & brain trauma， aortic &/or mitral stenosis & angina caused by hypertrophic obstructive cardiomyopathy， circulatory collapse， cardiogenic shock， toxic pulmonary edema. Avoid coadministration with sildenafil.,,RT,Spray: Acute attack 1-2 doses. Max: 3 doses at any one time. Prevention of exercise-induced angina 1-2 doses before exercise.,,,,除非治療上需要,,,,,,,,,,
EOES,Estradiol,Oestrogel gel 30gm,HM,,適應症: Natural or surgical menopause， estrogen deficiencies; vasomotor disorders associated with menopause; tropic disorders caused by disturbances in ovarian secretions as in vag atrophy， kraurosis vulvae， female hypogonadism， castration in women， primary ovarian deficiency. 禁忌: Malignant tumors of the breast or uterus. Pituitary tumors. 副作用： Cardiovascular: Edema (transdermal system， 0.5% to 13% ) Dermatologic: Application site irritation (transdermal spray， 1.3% ; transdermal system， 5.7% to 56.7% )， Chloasma， Hirsutism， Persistent erythema of skin (transdermal patch， 17% )， Pruritus (topical emulsion， 4% ; topical gel， 4.8% ) Endocrine metabolic: Weight change finding Gastrointestinal: Bloating symptom， Nausea， Vomiting Neurologic: Migraine Psychiatric: Depression (transdermal system， 1% to 8% )， Disturbance in mood Reproductive: Breast tenderness (topical gel， 2.5% to 8.8% ; transdermal spray， 5% to 7% ; transdermal system， 6.5% to 17.0% )， Disorder of menstruation， Leukorrhea， Swelling of breast， Vaginal discomfort (vaginal cream， 5% ; vaginal ring， 5% )， Withdrawal bleeding,,室溫,Apply 2.5 g daily (preferably on the abdomen) for 24 successive days， stop for 1 week (25th-end of the months)， then combine therapy with an oral progesterone from 13th-24th day of the cycle. A depletion in bleeding is generally seen during the weeks of interruption.,,,,不可使用,,,Compatible 哺乳時可使用,,,,,,,
EOTO,Polymyxin B + Neomycin + Lidocaine.,Otozambon ear drops 8mL,TENT,,適應症: Otitis externa & media， furunculosis of auricular tube， allergic dermatoses of exudative， seborrheic & eczematous type， suppurative complications following ear & mastoid surgery， otalgia. 禁忌: Infected TB lesions of ear; chickenpox; live vaccine; herpes simplex.,,室溫,4-5 drop bid-qid.,,,,沒有資料,,,,,,,,,,
EOVEC,Estriol,Ovestin cream 0.1%， 15gm,SGU,,適應症:萎縮性陰道炎及相關症狀(B020830535) AR: Initially local irritation or itching. Occasional mastodynia. CI: Pregnancy， thrombosis， known or suspected estrogen-dependent tumors， undiagnosis vag bleeding.,,RT,Cream: 1 application/day for 2-3 wks.,,,,不可使用,,,,,,,,,,
EPAN,Benzoyl Peroxide,Panoxyl 5 acne gel,TDER,,Acne vulgaris.,,,Apply once daily initially. Increase strength as required.,,,,除非治療上需要,,,,,,,,,,
INOV,Prochlorperazine,Novamin inj 5mg/1mL,CNEU,Pyschosis， nausea， vomiting.,CNS depression， comatose patients. Bone marrow depression， phaechromocytoma， prolactin-dependent tumours， hypersensitivity. Childn <2 yr. Pregnancy and lactation.,Cholestatic jaundice， cardiac arrhythmias， orthostatic hypotension， leucopaenia， thrombocytopaenia， dry mouth， blurring of vision， glaucoma， urinary retention， constipation， galactorrhoea， gynaecomastia， amenorrhoea and impotence. Buccal: Transient numbness of gum and tongue. Potentially Fatal: Bone-marrow suppression. Cardiac arrhythmias or aspiration,25℃以下避光,Usual dose: IM， 5 to 10 mg (1 to 2 mL)， may repeat every 3 to 4 hours as needed; maxium daily dose: 40 mg. surgery: IM， 5 to 10 mg (1 to 2 mL) 1 to 2 hours prior to anesthesia; may repeat after 30 minutes.,無需調整劑量,[仿單]哺餵母乳之婦女，應避免給與本劑。,無需調整劑量,除非治療上需要,Compatible,[仿單]孕婦或可能懷孕之婦女請勿給藥。動物試驗( 小鼠、大鼠)，有催畸胎作用( 唇顎裂增加) 之報告),No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]哺餵母乳之婦女，應避免給與本劑。,IM;,,,,,
INPHI,Insulin NPH,Insulin Protaphane 100IU/mL,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,,According to individual requirements.,,,,,,,,,,,,,,
OPRA1,Multivitamins + Minerals,Pramet F.A 100'S/BOT,NUTR,,Pregnancy nutrition supplement.,,,1 Tab daily,,,,,,,,,,,,,,
IPRO5,Oxacillin,Prostaphlin inj 500mg,QANB,,適應症:細菌性感染(B017520277),,RT,IM， slow IV or IV infusion. Adult: 250 mg-1g q4-6h， (max. 20 g/day). Child under 40 kg: 12.5-25 mg/kg q4-6h， 300 mg/kg/day. Neonate: 25 mg/kg q6-12h.,,,,可能安全,,,,,,,,,,
EPOSU,Epinephrine,Posumin (外用),CAVS,,適應症: Open-angle glaucoma; Ocular HTN， Inhalation Asthmatic attacks， hemorrhage， nasal decongestants. 副作用: CNS effects; GI disturbances; epigastric pain; CV disorders; difficulty in micturition with urinary retention; dyspnoea; hyperglycaemia; sweating; hypersalivation; weakness， tremors; coldness of extremities; hypokalaemia. Gangrene， tissue necrosis and sloughing (extravasation) when used in addition to local anaesthetics. Eye drops: Severe smarting， blurred vision， photophobia; naso-lachrymal ducts obstruction. Oedema， hyperaemia and inflammation of the eyes with repeated administration. 禁忌: Preexisting hypertension; occlusive vascular disease; angle-closure glaucoma (eye drops); hypersensitivity; cardiac arrhythmias or tachycardia. When used in addition to local anaesthetics: Procedures involving digits， ears， nose， penis or scrotum.,,室溫,As hemostatic agent in surgery Apply as original concentration or 5 times more concentrated soln with cotton or gauze to the skin. Add 2-5 drops when use as local anesth. Ophthalmology Apply as 5-10 times more concentrated soln as eye drops.ENT Apply as original concentration or 5 times more concentrated soln as ear/nose drops. Asthma， whooping cough Add 2-3 mL to 100 mL salt water. Inhale daily in 2-3 divided dose.Coughing spasm 1-3 drops.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
TEST,TEST_PHR_NAME,test,AD-01-00,適應症,禁忌,副作用,,,需調整劑量,,需調整劑量,,,,,,,,,,,
YCON,Heparin Na， allantoin,Contractubex gel 20gm,TDER,,,,,,,,,,,,,,,,,,,
IKYT,Granisetron,Kytril 針劑 3mg/3mL,CNEU,,適應症: Prevention or treatment of nausea & vomiting induced by cytostatic therapy & radiation. 副作用: Headache， constipation. 禁忌: Hypersensitivity to granisetron or related substances.,,室溫,Prevention & treatment of nausea & vomiting due to cytostatic therapy & radiation Adult 3 mg either in 15 mL infusion fluid as IV bolus over not less than 30 seconds or diluted in 20-50 mL infusion fluid & administered over 5 mins. Max dose over 24 hr: 9 mg. Children 10-40 mcg/kg body weight (up to 3 mg) diluted in 10-30 mL infusion fluid & administered over 5 mins. Max dose: 1 additional dose of 40 mcg/kg (up to 3 mg) within 24 hr if necessary. Max: 9 mg/day. For prevention， administration should be completed prior to the start of cytostatic therapy and anesth induction.,,,,可能安全,,,,,,,,,,
EVORS,Diclofenac,Voren 栓劑 12.5mg,CNEU,Rheumatism， acute musculoskeletal disorders， post-traumatic & post-op inflammation & swelling.,Patients sensitive to aspirin or other NSAIDs.,GI disturbances. Peptic ulceration. GI bleeding. Headache， dizziness， nervousness， skin rash， pruritus， tinnitus， edema， depression， drowsiness， insomnia， & blurred vision. Hypersensitivity. Impairment of liver & kidney function. Agranulocytosis & thrombopenia. Dermatologic: Application site reaction (gel: all reactions， 7%; dermatitis， 4% to 11% ) Hematologic: Blood coagulation disorder (1% to 10% ) Ophthalmic: Burning sensation in eye (15% )， Keratitis (up to 28% )， Lacrimation and lacrimal drainage - finding (up to 30% )， Raised intraocular pressure (up to 15% ),25℃以下陰涼處,Adult: 75-100mg/day in 2 or 3 divided doses. Children >1year old: 0.5-2mg/kg/day in 2 or 3 divided doses. Juvenile rheumatoid arthritis(JRA) can increase to 3 mg/kg/day in divided doses.,無需調整劑量,,需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,RECT;,,,,,
EXAL,Latanoprost,Xalatan 0.005%， 2.5mL ophthalmic solution,TOPH,Reduction of elevated intraocular pressure in patients with glaucoma & ocular hypertension.,Known hypersensitivity to any component of Xalatan.,Slight discomfort， mild to moderate conjunctival hyperaemia， transient punctate epithelial erosions， increased pigmentation of iris， rash.,2-8℃,1 drop in affected eye once daily in the evening.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
EXYL41,Xylocaine,Xylocaine 4% 30mL,ZANE,,適應症: Local anesth in bronchoscopy， bronchography， laryngoscopy， oesophagoscopy， endotracheal intubation， & biopsy in the mouth & throat. 副作用: Rarely， allergic reactions， CNS excitation or depression， hypotension， bradycardia. 禁忌: Previously known hypersensitivity to local anaesthetics of amide type.,,室溫,Adult 2-7.5 mL (80-300 mg lidocaine); up to 400 mg may be administered during prolonged (> 5 mins) procedures. With applications mainly to the larynx， trachea & bronchi， the dose should not exceed 5 mL (200 mg lidocaine). When inhaled from a nebulizer， 5-10 mL (200-400 mg lidocaine HCl) may be used.,,,,可能安全,,,,,,,,,,
OMIND,Glipizide,Minidiab 5mg,META,,NIDDM.,,,2.5 mg-20 mg daily; in divided doses.,,,,除非治療上需要,,,,,,,,,,
OMOB,Meloxicam,Mobic 7.5mg,CNEU,,適應症:為止痛消炎藥(A041913100),,RT,Rheumatoid arthritis:15mg/day.According to the therapeutic response， the dose may be reduced to 7.5 mg/day. Osteoarthritis:7.5 mg/day.If necessary， the dose may be increase to 15 mg/day. In patient with increase risks of adverse reaction: Start treatment at the dose of 7.5 mg/day. In dialysis patients with severe renal failure：the dose should not exceed 7.5 mg/day.Max:15 mg.,,,,除非治療上需要,,,,,,,,,,
LGEL,Colloidal Aluminum Phosphate,Gelfos 20gm/pk,ALIM,,適應症:胃酸過多、胃或十二指腸潰瘍(B018641138),,,20-40gm bid-tid,,,,,,,,,,,,,,
OMOR,Morphine,Morphine 10mg,CNEU,,適應症: Relief of moderate to severe pain. Pre-op anesth. 副作用: Nausea， vomiting， constipation， drowsiness， palpitations， headache， disorientation， vertigo， mood changes， decreased libido， ureteric spasm， urinary retention， rash， sweating， facial flushing， miosis. Cardiovascular: Peripheral edema (5% to 10% ) Dermatologic: Pruritus (up to 80% )， Rash (5% to 10% )， Sweating (5% to 10% ) Gastrointestinal: Abdominal pain (5% to 10% )， Constipation (> 10% )， Diarrhea (5% to 10% )， Loss of appetite (5% to 10% )， Nausea and vomiting (7% to 70% )， Xerostomia (5% to 10% ) Hepatic: Liver function tests abnormal (< 5% ) Musculoskeletal: Backache (5% to 10% ) Neurologic: Asthenia (5% to 10% )， Dizziness (6% )， Headache (>10% )， Insomnia (5% to 10% )， Lightheadedness， Paresthesia (5% to 10% )， Somnolence (> 10% ) Ophthalmic: Amblyopia (< 5% )， Miosis Psychiatric: Anxiety (6% )， Depression (5% to 10% ) Renal: Urinary retention (oral: < 5% ; epidural/intrathecal: 15% to 70% ) Other: Fever (5% to 10% )， Hiccoughs (< 5% ) 禁忌: Respiratory depression， head injury， obstructive airways disease， paralytic ileus， GI obstruction， delayed gastric emptying， acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children < 3 years.,,室溫,5-20 mg every 4 hr.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OMORBAD,Morphine,Morphine 10mg 殘餘銷燬,CNEU,,Relief of visceral pain， preanesthetic medication， sedation and hypnosis when pain is present， dyspneic seizures of acute left ventricular failure and pulmonary edema.,,,Adult: PO: Initial， 10-30 mg q4h. IM or SC:5-20 mg (usually 10 mg) q4h as needed. IV (only rarely): 2.5-10 mg diluted in 4-5 ml of water for injection， administered slowly over 4-5 mins. Child: SC:0.1-0.2 mg/kg， not to exceed 15 mg/dose.,,,,除非治療上需要,,,,,,,,,,
IDOP,Dopamine,Dopamine 200mg(DBL),CAVS,,適應症:休克症候群及心衰竭等(B021687221) CI: Phaeochromocytoma; uncorrected hypovolaemia; uncorrected tachyarrhythmia or ventricular fibrillation.,,RT,IV infusion， initially 1-5 mcg/kg/min， increased by 5-10 mcg/kg/min， up to 20-50 mcg/kg/min.,,,,除非治療上需要,,,,,,,,,,
IEPH,Ephedrine,Ephedrine inj 40mg/1mL,CAVS,Diabetic neuropathic oedema ， Reversal of spinal or epidural anesth-induced hypotension,Hypersensitivity. Hypertension， thyrotoxicosis， BPH. Lactation.,Anxiety， tachycardia， tremor， dry mouth， hypertension， cardiac arrhythmias， impaired circulation to the extremities， nervousness， insomnia， palpitations. Difficulty in micturition in patients with prostatic enlargement. Nasal drops: Local irritation， rebound nasal congestion and drug-induced rhinitis on prolonged use. Potentially Fatal: Delusions， hallucinations. Seen with hypersensitivity and overdosage. Acute CNS and CVS stimulation presenting as vomiting， fever， hypertension， psychosis. Cardiac arrhythmias.,15-30℃避光避免冷凍,Adult usual dosage: IM/SC 25-50mg， repeat if necessary. IV 5-25mg slowly inject， repeat after 5-10 minutes if necessary. Maximum: 150mg/24 hours. Children usual dosage: IM/SC 500 mcg/kg (0.5 mg/kg) Q4H-Q6H.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;IVP;IVPUSH;SC;,,【D5NS】可選 。【D5W】可選 。【N/S】可選 。,稀釋到5-10mg/mL，緩慢靜脈推注,,1.IV: 稀釋到 5 - 10 mg/mL，緩慢靜脈推注。 2. 監測血壓、心跳變化。
IEUD,Clindamycin,Eudamycin inj 300mg/2mL,QANB,,適應症: Infections caused by susceptible strains of strep， staph， pneumococci， anaerobic bacteria. 副作用: Abdominal pain， nausea， vomiting， diarrhoea， urticaria， maculopapular reactions， jaundice， blood disorders. 禁忌: Hypersensitivity， meningitis.,,室溫,Adult 600-1200 mg IM daily in 2-4 doses. Severe infections: 1200-2700 mg daily in 2-4 doses. Children > 1 month 15-25 mg/kg/day in 3-4 doses. Severe infections: 25-40 mg/kg/day in 3-4 doses.,,,,可能安全,,,,,,,,,,
IEUJ,Prostaglandin F2 Alpha,Eujum 5mg/mL(PGF2),SGU,,適應症: Induction of labour. Therapeutic termination of pregnancy. 副作用: Nausea， vomiting， diarrhoea， local tissue reaction， flushing， shivering， headache， dizziness， temporary pyrexia & elevated WBC. Foetal distress， uterine hypertonus， tetonic contractions. Bronchoconstriction (in asthmatic patients). Rarely， uterine rupture. 禁忌: Acute pelvic inflammation， history of major uterine surgery; previous caesarean section. Patients with active cardiac， pulmonary， renal or hepatic disease. Difficult labour or traumatic delivery; significant cephalopelvic disproportion; grand multiparity; preexisting foetal distress; foetal malpresentation. History of previous difficult labor &/or traumatic delivery; unexplained vag bleeding during the 2nd or 3rd trimester of the present pregnancy.,,2-8℃,Induction of labour Initially 2.5 mcg/min for 30 min. May be increased to 10 mcg/min if needed. Foetal death in utero Initially 5 mcg/min. May increase to 40 mcg/min. Therapeutic termination of pregnancy IV Initially 50 mcg/min for 30 min. May increase up to 100 mcg/min. Intra-amniotic route Initially 40 mg administered intra-amniotically by slowly injecting 8 mL of a solution containing 5 mg/mL into the amniotic sac. A further dose of 10-40 mg after 24 hr may be given.,,,,除非治療上需要,,,,,,,,,,
OIMO,Loperamide,Ufunin (Imodium) 2mg,ALIM,,適應症: Acute & chronic diarrhea 副作用: Flatulence， constipation， nausea， abdominal pain， dry mouth; giddiness. 禁忌: Diarrhea associated with organisms which penetrate the mucosa; pseudomembranous colitis or diarrhea associated with broad spectrum antibiotics.,,室溫,Acute & chronic diarrhea Adult Initially 4 mg then 2 mg after each loose stool. Usual daily dose: 6-8 mg. Max: 16 mg daily. Initial dose: Children 8-12 years 6 mg， 5-8 years 4 mg， 2-5 years 3 mg. To be given in divided doses， followed by 1 mg/10 kg body wt， administered only after a loose stool. Chronic diarrhea Adult Initially 4-8 mg daily in divided doses， subsequently adjusted as necessary. Usual daily dose: 4-8 mg.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OMACA,1，25-Dihydroxycholecalciferol,Macalol 0.25mcg,META,Management of vit D deficiency states & hypocalcaemia associated with disorders such as hypoparathyroidism & secondary hyperparathyroidism.,Hypercalcemia or evidence of vit D toxicity.,Hypercalcemia.,25℃以下陰涼乾燥處,Initial 1 capsule daily， dosage may be gradually increased to 2-4 capsule daily.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為軟膠囊應整粒吞服， 切勿咬嚼或壓碎，無法吞服患者可以溫水溶解後服用。
IFRAX,Nadroparin,Fraxiparine inj 3800u/0.4mL,HEMT,,適應症:預防血栓(B016271218),,冷藏,Prophylaxis: 0.3 mL or 0.4 mL SC/day. General surgery: 0.3 mL or 0.4 mL SC 2-4 hr prior to operation， duration of treatment is at least 7 days. Treatment: 0.1 mL/10 kg bid for 7-10 days.,,,,可能安全,,,,,,,,,,
OCLIM,Estradiol Valerate + Cyproterone Acetate,Climen 21 tab/pk,HM,,適應症:更年期後之賀爾蒙補充(B022443100),,RT,1 tab. daily from the 5th to the 25th day of the cycle， then 7 tab-free days.,,,,不可使用,,,,,,,,,,
IDDA,Desmopressin,Minirin inj 4mcg/1mL (DDAVP),HM,Central Diabetes Insipidus， Primary Nocturnal Enuresis， Renal Concentrating Capacity Test，Symptomatic treatment of nocturia in adults associated with nocturnal polyuria ie， nocturnal urine production exceeding bladder capacity. Hemophilia A and von Willebrand's Disease,Habitual & psychogenic polydipsia， syndrome of inappropriate ADH secretion (SIADH)， known hyponatremia， known or suspected cardiac decompensation & other conditions that require diuretics， moderate & severe renal impairment.,Nausea， abdominal pain， headache， nasal congestion/rhinitis， nose bleeds. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl. Dermatologic: Flushing Gastrointestinal: Nausea， Will respond to dosage decrease Neurologic: Fatigue (10% )， Headache (22.5% ),冰箱2-8℃冷藏，室溫(25℃)以下可4週，超過4週須丟棄，一經室溫存放後則不可再放回冰箱,Central diabetes insipidus: Adult: 1-4mcg(0.25-1mL) ; Children > 1 year 0.4-1mcg(0.1-0.25mL) ; Children < 1 year 0.2-0.4mcg(0.05-0.1mL)， 1-2 times per day .Patients with mild to severe hemophilia or drug-induced platelet dysfunction: 0.3mcg/kg diluted with normal saline to 50-100mL， IV infusion for over 15-30 minutes， could repeat after 6-12 hours.,無需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,Compatible 哺乳時可使用,,IVD;,,【N/S】可選 。,,Infuse over 15-30 min. Adult: IV: 0.3 mcg/kg by slow infusion， Maximum IV dose: 20 mcg.,Adminisration (Intravenous) 1.dilute in sterile physiological saline (diluent); use 10 mL diluent if patient 10 kg or less; use 50 mL diluent if patient more than 10 kg 2.infuse over 15-30 min 3.give 30 min prior to surgical procedures if need to give preoperatively 4.fluid restriction recommended 須於冰箱2-8℃冷藏儲存，如果儲存於室溫25℃以下儲存，最多可保存4週，超過4週須丟棄，一經室溫存放後則不可再放回冰箱冷藏儲存。
ODEXA,Dexamethasone,Dexamethasone 0.5mg,HM,,適應症:氣喘、關節炎、過敏性疾病等(A014183100),,RT,Adul: Initial daily dose: 1.5-3 mg in 2-4 divided doses. Maintenance dose: 0.5-0.75 mg/day. Child: According to age.,,,,除非治療上需要,,,,,,,,,,
INS2,Sodium Chloride,Isotonic NaCl inj 20mL,NUTR,為生理食鹽水(N009997238),,,室溫,20-1000 mL SC/IV/IV infusion. May use as diluent.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;IH;IM;IRR;IVD;IVI;IVPUSH;LI;SC;,,,,,
INS250,Sodium Chloride,0.9% NaCl inj 250mL(硬瓶),MSIV,為生理食鹽水注射液(A001085265),,,室溫,Individualized dosage.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IRR;IRRI;IVD;,,,,,
INS3,Sodium Chloride,3% NaCl inj 500mL,NUTR,■Corneal edema ■Hyponatremia ■Hypovolemic shock,Hypersensitivity to sodium chloride or any component of the formulation; hypertonic uterus， hypernatremia， fluid retention,common ■Cardiovascular: Phlebitis ■Dermatologic: Injection site extravasation， Injection site reaction ■Endocrine metabolic: Hypervolemia serious ■Cardiovascular: Congestive heart failure ■Endocrine metabolic: Hypernatremia， Overhydration ■Hematologic: Disseminated intravascular coagulation ■Respiratory: Respiratory distress,25℃以下,Adult Parenteral nutrition: Sodium maintenance electrolyte requirement: IV: 1 to 2 mEq/kg/24 hours; customize amounts based on individual patient needs. Acute hyponatremia (serum sodium <130 mEq/L): Asymptomatic: IV 50 mL bolus over at least 5 minutes; monitor serum sodium every 1-2 hrs to assess need for additional treatment. Symptomatic: IV 100 mL over 10 minutes; if symptoms persist， may repeat up to a total of 3 doses over a period of 30 minutes; monitor serum sodium hourly to assess need for repeat treatment. Chronic hyponatremia Asymptomatic or mild to moderate symptoms， severe hyponatremia (serum sodium <120 mEq/L): IV Initial: 15 to 30 mL/hr with frequent (eg， every 2 to 4 hrs) serum sodium monitoring; or alternatively， 1 mL/kg bolus (maximum bolus: 100 mL) over 10 minutes every 6 hrs as needed. Severe symptoms (eg， seizures， obtundation， coma， respiratory arrest) or known intracranial pathology: IV 100 mL over 10 minutes; if symptoms persist， may repeat up to a total of 3 doses over a period of 30 minutes， Alternatively， some experts recommend 150 mL over 20 minutes， up to a total of 2 doses while measuring serum sodium between infusions. Hyponatremia in neonate: 3%NaCl infusion rate about 0.1-1 ml/kg/hour (max infusion rate 1 ml/kg/hour) and a central line is preferred for administration for 3% NaCl.,無需調整劑量,micromedex: Pregnancy category:C,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,micromedex: Pregnancy category:C,IH;IVD;LI;,,,,,1. 本藥品為高張輸注液，須特別注意給藥速率。
IOCT,Human Immunoglobulin,Octagam Human 2.5gm/50mL,HIMM,,Immunoglobulin deficiency， bacterial infections， idiopathic thrombocytopenic purpura， Kawasaki disease.,,,IV infusion (not exceeding 20 drops/min). Immunoglobulin deficiency: Adult: 0.1-0.15 g/kg; child: 0.15 g/kg; Infant: 0.2 g/kg， (max. 0.4 g/kg); repeated every 3-4 wks. Serious bacterial infections including sepsis: As above， repeated every 1-2 days if needed. Idiopathic thrombocytopenic purpura & Kawasaki disease: 0.4 g/kg/day for 5 consecutive days.,,,,除非治療上需要,,,,,,,,,,
IORA,Dexamethasone,Oradexon inj 5mg/1mL,HM,,適應症:Treatment in immuno-allergology， rheumatology， endocrinology， dermatology， ophthalmology， gastroenterology， cardiology， pulmonology， hematology & oncology， neurology; prevention of inflammatory edema & adhesions in surgery; tuberculous meningitis， pericarditis， peritonitis & pleuritis; severe trichinosis， hypercalcemia associated with neoplastic diseases， hypervitaminosis-D， idiopathic infantile hypercalcemia， dexamethasone suppression test; prevention of neonatal respiratory distress syndrome. 副作用:GI disorders; skin atrophy， acne; psychic disturbances， convulsions; glaucoma， increased intraocular pressure， posterior subcapsular cataracts; fluid & electrolyte disturbances; Cushing-like syndrome， premature epiphyseal closure， menstrual irregularities; myopathy， abdominal distension， osteoporosis， aseptic necrosis of femoral & humeral heads; following IV inj of large doses， transient burning or tingling sensation. 禁忌:Systemic therapy: peptic ulcers; systemic fungal infection; varicella & herpes genitalia infection; glaucoma. Local therapy: septic arthritis from gonorrhea or TB， instability of the joints. Hypersensitivity to glucocorticoids,,rt,IV or IM: 0.5-9 mg/day (max. 80 mg/day). Cerebral edema: IV 10 mg， then IM 4 mg q6h. Shock: 2-6 mg/kg as a single IV inj. Intra-articular or soft-tissue inj: 0.2-6 mg.,,,,盡量避免,,,,,,,,,,
IPAN,Cefotiam,Pansporin inj 0.5gm,QANB,,Active against E. coli， Klebsiella， Proteus， P. mirabilis， Citrobacter， Indole (+) proteus， H. influenza.,,,IV， IV infusion or IM (with Lidocaine) Adult: 0.5-2 g/day in 2-4 divided doses， (max. 4 g/day). Child: 40-80 mg/kg/day in 3-4 divided doses， (max. 160 mg/kg/day).,,,,,,,,,,,,,,
IURO6,Urokinase,Urokinase-GCC 6000 IU,HEMT,,適應症: Acute coronary embolism， clearance of occluded catheters & shunts， acute pulmonary embolism， peripheral arterial or venous thromboembolism. 副作用: Bleeding tendency. Fever， chills， headache & malaise may occur. Rarely， shock， sweating， disturbed pulse & dyspnea; rash， urticaria;nausea; vomiting & anorexia; abnormal liver function test; hematuria. Hematologic: Decreased hematocrit level (37%) 禁忌: Intracranial hemorrhage， hemoptysis， difficulty in hemostatic management; undergone intracranial or spinal surgery or with such injury (in the last 2 months); aneurysm; serious disturbance of consciousness.,,室溫,Cerebral thrombosis (within 5 days after onset of symptoms & without hemorrhage) 60，000 iu once daily for 7 days. Peripheral arterial/venous occlusion 60，000 to 240，000 iu on first day of treatment followed by tapered doses for about 7 days. Acute coronary embolism 26，000-52，000 iu daily for 7 days. Deep vein thrombosis or acute pulmonary embolism IV loading 250，000 iu/hr， then 1，000 iu/kg/hr (or 60，000 -100，000 iu/hr) for 72 hr.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. Total dose diluted to the recommended final volume of 195 mL 2. (loading dose) 90 mL/hr over 10 minutes (continuous infusion) 15 mL/hr for a period of 12 hr
EZOVC,Acyclovir,Zovirax cream 5%， 2gm,TDER,,適應症: Herpes simplex virus infection of the skin including initial & recurrent genital herpes & herpes labialis. 副作用: Transient burning or stinging. Mild drying & flaking. Erythema & itching. Dermatologic: Application site reaction， Topical Preparation (5% )， Contact dermatitis， Topical Preparation (2% ) Gastrointestinal: Diarrhea (2.4% to 3.2% )， Nausea (2.4% to 4.8% )， Vomiting Neurologic: Headache (2.2% ) Other: Malaise (11.5% ) 禁忌: Patients known to be hypersensitive to acyclovir or propylene glycol.,,室溫,Adult & children Apply 5 times daily at approximately 4 hr interval for 5-10 days.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
IABM,B. Multicinctus antivenin + N. Naja atra antivenin,抗雨傘節及飯匙倩蛇毒血清,HIMM,,適應症:Therapy for the bite of B. multicintus and N.atra snakes. 副作用:allergic phenomena including anaphylaxis， hypotension， serum sickness. 禁忌: Hypersensitivity to antivenin.,,2-8℃,Adult 1 dose.(SC: 0.5 dose near bite; 0.5 dose IV or IM),,,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 稀釋法：取稀釋溶液10 mL注入凍晶製劑中，避免用力振搖，應於2小時內用完。 2. 宜儘早注射，被咬傷後4小時內注射最有效。 3. 注射部位：咬傷時間二小時內，可將一半劑量注射在咬傷部位周圍皮下，另一半則IV或IM。 4. 注射速率：IV: 第1 mL數分鐘注完，以後每1 mL不快於一分鐘 (30-60分鐘內打完)。IVD: 一劑抗蛇毒血清稀釋於300mL N/S。 5. 注射劑量：成人為一劑量，10歲以下兒童加倍。如症狀繼續惡化隔30分鐘至一小時後可再打一劑。 6. 蛇毒血清為馬的血清製劑，為防過敏反應，可先做皮膚試驗並準備1:1000 Epinephrine備用。
IADR1,Epinephrine,Adrenalin inj 1mg/mL,CAVS,Anaphylactic shock， respiratory tract spasm， laryngeal edema， cardiac arrest， bronchial asthma.,Hypersensitivity to other sympathomimetics eg. Amphetamine， ephedrine， isoproterenol， metaproterenol， norepinephrine， levarterenol， phenylephedrine， phenylpropanolamine， pseudoephrine， terbutaline. Labor， lactation.,Chest pain， arrhythmia; headache， nervousness， restlessness， palpitation， dizziness， face flush， nausea， vomiting， tremor， insomnia， dysnea， increased adnormal perspiration， adnormal pallor & debilitation.,15~30℃,Adult Hypersensitivity reactions: 0.2-0.5 mg IM/SC at 10-15 minute-interval if necessary. Maximum: 1 mg/dose. Relief of bronchospasm: 0.2-0.5 mg SC at 20 minutes to 4 hours interval if necessary. Maximum: 1 mg/dose. Cardiac arrest: 0.1-1 mg intracardiac/IV at 5 minutes interval. As vasoconstrictor: Administer 0.2-0.4 mg with anesthetic spinal fluid mixture. Administration with local anesthetics 0.1-0.2 mg as 1:200000-1:20000 solution. Anaphylactic shock: Initially 0.5 mg IM/SC at a rate of 25-50 mcg per 5-15 minutes; 0.1-0.25 mg slow IV at 5-15 minutes interval if necessary. Children dosage: Hypersensitivity reactions or to relieve bronchospasm: 0.01 mg/kg or 0.3 mg/m2 SC. Maximum: 0.5 mg. Administer at 15 minutes interval， repeat twice. May be given every 4 hours. Cardiac arrest: 0.005-0.01 mg/kg or 0.15-0.3 mg/m2 intracardiac/IV. As vasoconstrictor as per adult dose. Anaphylactic shock: Initially 0.3 mg IM/SC at 15 minutes interval， repeated 3-4 times if necessary.,無需調整劑量,,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,EXT;IH;IM;IRR;IVD;IVPUSH;LI;SC;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【L/R】可選 。,IV push for cardiac resuscitation management.,IVD: 1-15 mcg/min,1. 治療Anaphylaxis反應: 0.2 to 0.5 mg IM 或 SC，可視情況每 5 分鐘投予。 2. 治療Anaphylaxis反應: : (IV infusion) 稀釋1 mg in 250 mL D5W (4 mcg/mL) ，給藥速率 1 mcg/min (15 mL/hr) 至 10 mcg/min ，或稀釋為 1 mg in 100 mL NS (10 mcg/mL) ，給藥速率 5 to 15 mcg/min (30 to 100 mL/hr)。
IALBB,Albumin,Albumin 25% 50mL(Buminate),HEMT,,適應症:低白蛋白血症(K000271248),,,IV infusion. Hypoproteinemia: 1 ml/lb/day， the rate should not exceed 2-3 ml/min. Burns: Depend on extent of burn. Shock: If initial dose is a inadequate， additional case give 15- 30' later， in normal blood volume not exceeding 1ml/min.,,,,除非治療上需要,,,,,,,,,,
IALI,TTFD + B12,Alinamin F-B12 inj 20mg/2mL,NUTR,,Vit. B1 deficiency， alinamin supplement.,,,Inj.: 1 amp qd SC， IM or IV for 5-10 days,,,,安全,,,,,,,,,,
ITEM,Buprenorphine,Temgesic inj 0.3mg/mL,CNEU,,Moderate to severe pain.,,,Adult 300-600ug IM or slow IV 6-8 hrly.,,,,除非治療上需要,,,,,,,,,,
ITIE5,Imipenem + Cilastatin Sodium,Tienam inj 500mg,QANB,,適應症: Intra-abdominal， lower respiratory tract， gynecological， GUT， bone & joint， skin & soft tissue & mixed infections， endocarditis， septicemia. Prophylaxis of post-op infections. 副作用: Thrombophlebitis， pain， induration， erythema & tenderness following inj. Rash， urticaria， pruritus， GI disturbances， pseudomembranous colitis， haematological disturbances， increase in liver enzymes， taste perversion. Myoclonic activity， seizures， psychic disturbances， confusional states. Dermatologic: Injection site pain Gastrointestinal: Diarrhea (1.8% )， Nausea (2% )， Vomiting (1.5% ) Hematologic: Thrombophlebitis (3.1% ) 禁忌: Hypersensitivity to amide-type local anaesth， severe shock or heart block.,,,IV infusion Adult with normal renal function & body weight >= 70 kg 1-2 g imipenem daily in 3-4 divided doses. Moderate infection 1 g imipenem bid. Infections due to less susceptible organisms Max: 4 g imipenem daily or 50 mg/kg/day (whichever is lower). Post-op prophylaxis 1 g imipenem IV on induction of anesth & 1 g 3 hr later. High-risk surgery: 2 additional 500 mg doses may be given at 8 & 16 hr after induction. Children >= 40 kg Administer adult dose. Children & infant < 40 kg & >= 3 months 15 mg/kg every 6 hr. Max: 2 g imipenem daily. IM inj 500-750 mg imipenem every 12 hr. Max: 1.5 g imipenem daily. Urethritis or cervicitis due to non-penicillinase producing Neisseria gonorrhoeae Single dose of 500 mg imipenem.,無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,N/S， D5W， D10W， D5NS,【D10W】可選 仿單建議。【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,劑量≦500 mg時，滴注時間約20 ~ 30分鐘，更大劑量的滴注時間約40 ~ 60分鐘。,1. 若病患有噁心感時應減慢滴注速率。 2. 監測體溫、CBC、肝腎功能，注意是否有肌肉震顫或癲癇發作徵狀。
ITIG1,Tetanus Immune Globulin Human,BayTet 250 IU,HIMM,,Passive immunization tetanus， treatment of active tetanus infection.,,,Deep IM， Prophylaxis: Adult & child: 250 U as a single dose. Treatment: Adult: 3000-5000 U. Child: 500-3000 U,,,,除非治療上需要,,,,,,,,,,
景收縮,Hexoprenaline,Ipradol inj 5mcg/2mL,ERSP,,,,,,,,,,,,,,,,,,,
IKET,Ketamine,Ketalar inj 500mg/10mL,ZANE,,For diagnostic and surgical procedures that do not require skeletal muscle relaxation， induction of anesthesia prior to the administration of other general anesthetics.,,,Induction: IV (over 1 min)， 1-4.5 mg/kg or IV infusion， at a rate of 0.5 mg/kg/min; IM， 6.5-13 mg/kg. Maintenance: 1/2 of the full induction dose， repeated as needed.,,,,,,,,,,,,,,
IKETO,Ketorolac,Keto針劑 30mg/1mL,CNEU,For the short-term management of moderate-severe acute pain， including pain following major abdominal， orthopedic & gynecological operative procedures.,Hypersensitivity to aspirin or other NSAIDs.,Nausea， abdominal discomfort， peptic ulceration， GI bleeding， drowsiness， dizziness. Cardiovascular: Edema (1% to 10% )， Hypertension (1% to 10% ) Dermatologic: Injection site pain (injection， 1% to 10% )， Pruritus (1% to 10% )， Rash (1% to 10% )， Sweating (1% to 10% ) Gastrointestinal: Abdominal pain (1% to 10% )， Diarrhea， Indigestion (1% to 10% )， Nausea (greater than 10% ) Hematologic: Anemia (1% to 10% )， Purpura (1% to 10% ) Neurologic: Dizziness (1% to 10% )， Headache (greater than 10% )， Somnolence (1% to 10% ) Ophthalmic: Burning sensation in eye， Transient (ophthalmic， 20% to 40% )， Corneal edema (ophthalmic， 1% to 10% )， Eye irritation (ophthalmic， 1% to 10% )， Iritis (ophthalmic， 1% to 10% )， Keratitis (ophthalmic， 1% to 10% ) Respiratory: Nasal irritation (nasal， 15% )， Pain， Rhinalgia (nasal， 13% ),室溫,Single dose: IM: deep inject slowly， < 65 years old: 60mg，>= 65 years old:30mg IV: inject > 15 seconds， < 65 years old: 30mg， >=65 years old:15mg Continuous dose， IV/IM: < 65 years old: 30mg q6h (maximum:120mg/day)， >= 65 years old， renal dysfunction and body weight <50kg: 15mg q6h(maximum:60mg/day),無需調整劑量,,需調整劑量,除非治療上需要,Human data suggest risk in 1st and 3 rd trimesters,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,Contraindicated 哺乳期使用禁忌,,IM;IV;IVD;IVP;IVPUSH;,,【D5NS】可選 。【D5W】可選 。【L/R】可選 。【N/S】可選 。,推注時間至少 15秒,,1. IM: 緩慢及深部投予 2. 仿單警語：（1）Ketorolac不可用於退燒，且禁止使用於產科相關止痛。（2）臺灣曾有病患使用Ketorolac導致過敏性休克，甚至死亡之案例發生，應小心使用本藥品。（3）使用注射劑型之Ketorolac成分藥品時，需有急救設備備用，注射後半小時內應有人監控病患之安全性。
ILIPO,Soyean oil + MCT+ Egg Yolk Phospholipids+ Glycerol,Lipofundin 10% 250mL,NUTR,In parenteral nutrition for energy & essential fatty acids.,Disturbances in fat metabolism; ketoacidosis， hypoxia， thromboembolism & acute shock states.,Adverse reactions directly related to fat emulsions in general are of 2 types: Immediate (Acute) Reactions: Dyspnea， cyanosis， allergic reactions， hyperlipaemia， hypercoagulability， nausea， vomiting， headache， flushing， hyperthermia， sweating， chills， sleepiness， chest and back pain. Delayed Reactions: Hepatomegaly， jaundice due to central lobular cholestasis， splenomegaly， thrombocytopenia， leucopenia， transient increases in liver function tests and overloading syndrome. The deposition of a brown pigmentation in the reticuloendothelial system， the so-called "IV Fat Pigment"， has also been reported. The cause and the significance of this phenomenon are unknown.,25℃以下避光避免冷凍,Dosage Adult: 0.7-1.5g lipids/kg body weight/day， maximum: 2g lipids/kg body weight/day. For home TPN apply>6 months or Short Bowel Syndrome: < 1g lipids/kg body weight/day. Children and adolescents: 2-3g lipids/kg body weight/day. Preterm neonatal infants， term newborn infants， infants and toddlers: <3g lipids/kg body weight/day. (Maximum: 4g lipids/kg body weight/day). Maximum infusion rate Adults: Up to 0.15 g lipids/kg body weight/hr. Children and adolescents: Up to 0.13 g lipids/kg body weight/hr. Preterm neonatal infants， term newborn infants， infants and toddlers: Up to 0.17 g lipids/kg body weight/hr.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,輸注前15分鐘，輸注速率: 0.5 - 1 mL/kg/hr，最大輸注速率: 1.5 mL/kg/hr,1. 本脂肪乳劑可經由週邊靜脈或中央靜脈導管輸注，若使用含過濾器之輸注套，必須選擇適合脂肪乳劑者。 2. 脂肪乳劑應以慢速輸注為原則，尤其輸注開始的十五分鐘，每小時每公斤體重0.5-1mL。 3. 最大輸注速度每小時每公斤體重1.5mL。
ILIS,Cephradine,Licef-A 1gm inj,QANB,,適應症:細菌性感染(A035929209) Infection of the respiratory tract， GUT， skin & skin structure， bone & joints; septicemia. 副作用:GI disturbances， hypersensitivity reactions. 禁忌:Hypersensitivity to cephalosporins.,,RT,Adult: 0.5-1 g q4-6h， (max. 8 g/day). Child over 1 yr: 50-100 mg/kg/day in 4 divided doses; max. daily dose should not exceed the recommended adult dose.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,1. 監測體溫、CBC、肝腎功能。
IMAR5,Bupivacaine,Marcaine 0.5% inj 100mg/20mL,ZANE,,適應症:為局部麻醉劑(B017201238),,RT,Marcaine: Caudal， epidural or peripheral nerve block: 25-175 mg (5-35 ml)as a 0.5% soln， repeated q3h as needed， (max. 175 mg (35 ml)/dose or 400 mg (80 ml)/day). Marcaine Spinal Heavy: Obstetrical: Vaginal delivery， 6 mg; cesarean section， 7.5-10.5 mg. Surgical: Lower extremity and perineal procedures， 7.5 mg; lower abdominal procedures， 12 mg. (Max. 400 mg/day)， dosing intervals>= 3 hrs.,,,,除非治療上需要,,,,,,,,,,
ICEF,Cefazolin,Cefamezin inj 1gm,QANB,,G(+) (not enterococci， methicillin-resistant staph.)， G(-)(esp. E. coli， proteus， Klebsiella， H. influenzae， not indole positive proteus， enterobacter， pseudomonas， seriatia， acinetobacter).,,,Adult: Antibacterial: IM or IV 250 mg-1 g q6-8h. Acute uncomplicated UTI: IM， IV 1 g q12h. Pneumococcal pneumonia: IM， IV 500 mg q12h. Perioperative prophylaxis: IM， IV 1 g 30 mins-1hr prior to the start of surgery， 500 mg-1 g during surgery， and 500mg-1 g q6-8h following surgery. Infant and child: IM， IV 6.25-25 mg/kg q6h.,,,,可能安全,,,,,,,,,,
ICEFO,Cefoperazone,Cefobid 0.5gm,QANB,,,,,,,,,,,,,,,,,,,
ICHL,Chlorpromazine,Chlorpromazine 50mg/2mL,CNEU,,適應症:鎮靜、止吐等作用(N000662212),,RT,Deep IM: 10-50 mg， repeated 3-4 times in 24 hrs if necessary. Child over 6 months. IM: 0.5 mg/kg q6-8h as needed.,,,,除非治療上需要,,,,,,,,,,
IHIK,Sodium Hyaluronate,Hikamilon Dispo syringe,CNEU,,適應症:Treatment of pain in osteoarthritis in knee in patients who have failed simple analgesics (e.g. acetaminophen) & nonpharmacologic treatment. 副作用:Transient swelling， pain， heat & redness may occur sporadically at the injection site. 禁忌:1. Hypersensitivity to the product components. 2. Infections or skin diseases at injection site.,,室溫,Inject 1 syringe once weekly for 5 weeks.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,IS;,,,,,
IOVI,Choriogonadotropin alfa,Ovidrel inj 250mcg,HM,Women undergoing superovulation prior to assisted reproductive techniques such as in-vitro fertilisation (IVF) ，Anovulatory or oligo-ovulatory women,Hypothalamic & pituitary tumours; ovarian enlargement or cyst due to reasons other than polycystic ovarian disease; gynaecological haemorrhage of unknown aetiology; ovarian， uterine or mammary carcinoma; extrauterine pregnancy in the previous 3 months; active thromboembolic disorders; primary ovarian failure， sexual organ malformations incompatible with pregnancy; fibroid uterine tumours incompatible with pregnancy; postmenopausal women. Pregnancy & lactation.,Local inj site reactions， headache， fatigue， GI disturbances， mild or moderate ovarian hyperstimulation syndrome. Ectopic pregnancy， ovarian torsion & other complications in some patients after hCG administration. Uncommonly， depression， irritability， restlessness， diarrhoea， severe ovarian hyperstimulation syndrome， breast pain. Rarely， thromboembolism.,原包裝保存於2-8℃;在藥品有效期限內可以放在25℃以下30天，但超過30天應將藥品丟棄,Women undergoing superovulation prior to assisted reproductive techniques such as in-vitro fertilisation (IVF) 250 mcg SC 24-48 hr after the last administration of an FSH or hMG prep， when optimal stimulation of follicular growth is achieved Anovulatory or oligo-ovulatory women 250 mcg SC 24-48 hr after optimal stimulation of follicular growth is achieved. The patient is recommended to have coitus on the day of， & the day after inj.,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,SC;,使用廠商所附稀釋溶液溶解,,,,
YMEP,Mepiform,MEPIFORM 4x30cm,ZOTH,,,,,,無需調整劑量,,無需調整劑量,沒有資料,Compatible,,Compatible 哺乳時可使用,,EXT;SKIN;,,,,,
OPROT,Pancrelipase,Protase 280mg enteric coated,ALIM,Cystic fibrosis， post-pancreatectomy， total gastrectomy， or chronic pancreatitis， ductal obstruction from neoplasm.,Early stages of acute pancreatitis.,Nausea， vomiting， bloating， cramping， constipation or diarrhea.,25℃以下,Adult & children >6 years: Initially 1 CAP with meals. Fibrocyst:1500-3000 USP Lipase Units/kg， with every meals.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,WM;,,,,,[磨粉/管灌註記]本藥為腸溶微粒膠囊，應整粒吞服， 切勿咬嚼或壓碎。無法吞服病患可拆膠囊後服用。但不可將膠囊內的腸溶微粒研磨或壓碎。
YMEP5,Mepiform,Mepiform 5x7.5cm,ZOTH,,,,,,無需調整劑量,,無需調整劑量,沒有資料,Compatible,,Compatible 哺乳時可使用,,EXT;SKIN;,,,,,
OMED4,Methylprednisolone,Mednin 4mg,HM,,適應症: RA， acute & subacute bursitis， exfoliative dermatitis， allergic rhinitis， bronchial asthma， contact dermatitis & allergic conjunctivitis. 副作用:Fluid & electrolyte disturbances; muscle weakness， aseptic osteonecrosis， osteoporosis; peptic ulcer with perforation， hemorrhage， abdominal distention， impaired wound healing; increased intraocular pressure; Cushingoid state， growth suppression， menstrual irregularities， posterior subcapsular cataracts. 禁忌: Systemic fungal infection; immunization. Lactation,,室溫,Should be taken with food 4-48 mg once-qid.,,,,除非治療上需要,,,,,,,,,,
OCLOX,Cloxacillin,Cloxacillin 250 mg,QANB,,適應症: Treatment of infections due to staphylococci resistant to benzylpenicillin including skin & soft tissue infections， bone & joint infections， endocarditis， pneumonia， septicemia 副作用: GI disturbances， rash， urticaria， purpura. Rarely， hepatitis， cholestatic jaundice， Stevens-Johnson syndrome， interstitial nephritis. 禁忌: Hypersensitivity; history of cloxacillin-associated jaundice/hepatic dysfunction.,,室溫,Adult 250-500 mg every 6 hr. Children over 40 kg Use adult dose， <40 kg 25-50 mg/kg/day in divided doses every 6 hr.,,,,可能安全,,,,,,,,,,
ODIF,Fluconazole,Diflucan 150mg,QANB,Dermatomycosis including tinea pedis， tinea corporis， tinea cruris， tinea versicolor and candidal infections.,Patients with known hypersensitivity to fluconazole or to related azole compounds.,Nausea， abdominal pain， diarrhoea; rash.,30℃以下,Adult: Cryptococcal meningitis: 400 mg on day 1， followed by 200 mg once daily for 10-12 weeks after the cerebrospinal fluid becomes culture negative. For suppression of relapse of cryptococcal meningitis in patients with AIDS: 100-200 mg once daily. Oropharyngeal candidiasis: 100 mg on day 1， followed by 50 mg once daily for at least 2-3 weeks; 150 mg once weekly for oropharyngeal candidiasis prophylxis in patients with HIV. Esophageal candidiasis: 200 mg on day 1， followed by 100 mg once daily for a 2-3 weeks. Candidiasis， life-threatening: 400 mg on day 1， followed by 200-400 mg once daily for at least 4 weeks. Vaginal/vulvovaginal candidiasis: 150 mg as a single dose. Tinea corporis or cruris/Tinea pedis: 150 mg once weekly for 4 weeks. Children: 6-12 mg/kg/dose on day 1， followed by 3-12 mg/kg/dose once daily.,無需調整劑量,,需調整劑量,盡量避免,Human (and animal) data suggest risk,PREGNANCY RECOMMENDATION: Human Data Suggest Risk (大於400 mg/day),Compatible 哺乳時可使用,,PO;,,,,,
ODIL,Phenytoin,Dilantin 100mg,CNEU,Control of generalized tonic-clonic (grand mal) and complex partial (psychomotor， temporal lobe) seizures. Prevention and treatment of seizures occurring during or following neurosurgery.,Sinus bradycardia， sino-atrial block， 2nd and 3rd degree AV block or in patients with Adams-Stokes sybdrome.,GI disturbances; ataxia， slurred speech; diplopia， nystagmus and mental confusion with headache， dizziness， gingival hyperplasia， hirsutism， hyperglycemia， osteomalacia.,25℃以下,Seizure， During and following neurosurgery; Treatment and Prophylaxis Oral: Adult: 100 mg BID or TID， adjusted as needed; (maximum loading dose: 1000 mg/day in 3 divided doses). Child: Initial， 5 mg/kg/day in 2-3 divided doses; maintenance， 4-8 mg/kg/day; (maximum: 300 mg/day).,無需調整劑量,Phenytoin is excreted in breast milk; however， the amount to which the infant is exposed is considered small. The manufacturers of phenytoin do not recommend breast-feeding during therapy.,無需調整劑量,盡量避免,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,Phenytoin is excreted in breast milk; however， the amount to which the infant is exposed is considered small. The manufacturers of phenytoin do not recommend breast-feeding during therapy.,PC;PO;WM;,,,,,
ODIM,Gestrinone,Dimetriose 2.5mg， 8's/box,HM,,適應症: 主治子宮內膜異位Endometriosis(B021526100) 副作用: Spotting， mild acne， oily skin， fluid retention， weight gain; hirsutism， voice changes. Transient increases in liver transaminases， headache， GI disturbances， libido changes， hot flushes， breast size reduction， nervousness & depression， cramp & appetite changes， arthralgia & isolated cases of benign intra-cranial hypertension. 禁忌: Pregnancy， lactation; severe cardiac， renal or hepatic insufficiency; metabolic &/or vascular disorders during previous oestrogen &/or progestogen therapy.,,室溫,2 cap/wk. Initial dose must be taken on day 1 of the menstrual cycle， 2nd dose on day 4. Continue treatment for 6 months.,,,,沒有資料,,,,,,,,,,
ODIV,Estradiol + Medroxyprogesterone,Divina 21's/pk,HM,,適應症:停經症候群荷爾蒙之補充(B019190100),,RT,1 tab. daily in 21 days cycle.,,,,不可使用,,,,,,,,,,
ODMP,Domperidone,Domperidone (D.M.P) 10mg,ALIM,,適應症:主治腸胃蠕動異常及胃腸脹氣(A030619100),,RT,Adult: 1-2 tab tid-qid. Child: 0.3-0.6 mg/kg tid-qid.,,,,沒有資料,,,,,,,,,,
ODOG5,Sulpiride,Dogmatyl 50mg,CNEU,Treatment of psychotic disorders. Management of gastric and duodenal ulcers.,Pheochromocytoma. Acute involuntary porphyria. prolactin-dependent tumors， such as pituitary prolactinoma and breast cancer.,Neuroleptic malignant syndrome. Extrapyramidal symptoms， parkinsonism and endocrine side effects. Perspiration， nausea， dry mouth， lowered BP， agitated state， difficulty in falling asleep， sexual stimulation， dysopia， profuse salivation， increase in weight and allergy.,遮光密封室溫25℃下儲存,Adults: Schizophrenia: 300-600mg/day oral in divided doses. Adjust according to age and symptoms. maximum: 1200mg/day. Depression: 150-300mg/day oral in divided doses. Adjust according to age and symptoms. maximum: 600mg/day. Gastric ulcer: 150/day， in 3 divided doses. Adjust according to symptoms.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
IAZA,Aztreonam,Azactam inj 1gm,QANB,,適應症:UTI， lower respiratory tract， skin & soft tissue， intra-abdominal， bone & joint， gynecological infections， septicemia. 副作用:Thrombophlebitis， GI disturbances， haematologic disorders， hepatitis. Rarely， anaphylaxis 禁忌:Hypersensitivity to β-lactams.,,室溫,UTI 500 mg-1 g 8-12 hrly. Moderately severe systemic infection 1-2 g 8-12 hrly. Life threatening infection 2 g 6-8 hrly. Children >1 weeks 30 mg/kg/dose 6 or 8 hrly.,,,,可能安全,,,,,,,,,,
ODOXA,Doxazosin,Doxaben 2mg,CAVS,,I: Hypertension or Benign prostatic hyperplasia.,,,Hypertension: 1-16mg qd. or qhs. initially 1mg qhs， increase every1 or 2 wk of therapy to 2mg & thereafter at similar intervals to 4，8 & 16mg as determined by patient's response to achieve the desired BP reduction. Benign prostatic hyperplasia: Initially 1 mg once daily， may be increased to 2 mg & thereafter to 4 mg & 8 mg once daily. Recommened titration interval is 1-2WK.,,,,除非治療上需要,,,,,,,,,,
OTRAC,Mepenzolate,Trancolon 7.5mg,ALIM,,Adjunctive therapy of peptic ulcer， visceral spasms， spasmodic condition of the colon.,,,Adult: 15 mg tid ac， increased if needed. Child 6-12 yrs: 12.5 mg in 3-4 divided doses.,,,,除非治療上需要,,,,,,,,,,
ITNL,Tinidazole,TNL inj 500mg/100mL,QANB,,Prophylaxis and treatment of infections due to anaerobes.,,,IV infusion 100 ml q8h， infusion rate: 5 ml/min.,,,,,,,,,,,,,,
ITPN1,TPN Solution,TPN-1 Solution,NUTR,,適應症:為10%靜脈營養輸注液(TPN0501209),,,,需調整劑量,,需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
ITPN3,TPN Solution,TPN-3 Solution,NUTR,,適應症:為30%靜脈營養輸注液(TPN05032CS),,,,需調整劑量,,需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
ITPNH,TPN Solution,TPN-H Solution,NUTR,,適應症:為靜脈營養輸注液(TPN0505297),,,,,,,,,,,,,,,,,
ITPNP1,TPN Solution,TPN-P1 Solution (Ped.),NUTR,,適應症:為靜脈營養輸注液(TPN0506255),,,,需調整劑量,,需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
ITPNP2,TPN Solution,TPN-P2 Solution (Ped.),NUTR,,適應症:為靜脈營養輸注液(TPN0507255),,,,需調整劑量,,需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
ITPNP3,TPN Solution,TPN-P3 Solution (Ped.),NUTR,,適應症:為靜脈營養輸注液(TPN0508255),,,,需調整劑量,,需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
ITPNR,TPN Solution,TPN-R Solution,NUTR,,適應症:為靜脈營養輸注液(TPN05042CT),,,,需調整劑量,,需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
ITRA,Zn + Cu + Mn + Cr + Iodide,Trace Element inj 10mL,NUTR,,適應症: Supplement of trace elements， diluted in TPN soln. 副作用: Hypersensitivity reactions of iodide. 禁忌: Never be injected into peripheral veins with undiluted soln， hypersensitivity to trace elements especially iodide.,,2-8℃,Individualised dosage.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,IVA;,,,,,
ITRAD,Labetalol,Trandate 針劑 25mg/5mL,CAVS,Hypertension.,2nd or 3rd degree heart block， cardiogenic shock， severe & prolonged hypotension or severe bradycardia. Hypertensive episodes after acute MI when peripheral vasoconstriction suggests low cardiac output.,Pronounced postural hypotension， nasal congestion. Rarely hypersensitivity， rash， pruritus， angioedema & dyspnea; raised liver function tests， jaundice， hepatitis & hepatitis necrosis; bradycardia， heart block. Cardiovascular: Orthostatic hypotension (1%， oral ; 58%， IV ) Dermatologic: Has tingling sensation (7% .) Gastrointestinal: Nausea (14% ) Neurologic: Dizziness (9% to 20% ) Respiratory: Nasal congestion (3% ) Other: Fatigue (11% ),30℃以下避光,IV bolus: Given 50 mg over 1 minute and may repeat every 5 minutes until desired blood pressure is achieved or up to a total maximum of 200 mg. IV infusion: Diluted with saline or 5% Dextrose solution to 1 mg/mL， administered 2 mg/minute initially. Gestational hypertension: Initial， 20mg/hour as an IV infusion， then double the dose in every 30 minutes until desired blood pressure is achieved or up to 160mg/hours. May give higher dosage when necessary. Blood pressure management in acute myocardial infarction: Initially give 15 mg/hour via infusion then increase gradually to maximum 120 mg/hour adjusted by blood pressure. Hypertension due to other causes: Initially give 2 mg/minute via infusion then adjust infusion rate to blood pressure response. The effective dose usually around 50-200 mg. Higher dosage may be required in particular patients， especially with pheochromocytoma. The infusion rate can be adjusted by the doctor according to the reaction. Blood pressure management in operative procedure: Initially IV 10-20 mg， add supplemental dose 5-10 mg every 5 minutes until target blood pressure is reached. (use with halothane) Patients with contraindications for halothane usually need the higher initial dose (25-30 mg).,需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,【L/R】可選 。【N/S】可選 。【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【D2.5HS】可選 。,Administer IV over 1 minutes,Micromedex Adult Dosing :Add 40 mL of labetalol (200 mg) to 250 mL of a compatible IV fluid for a final concentration of approximately 2 mg/3 mL. Pediatric Dosing: 1.General Dosage Information:Safety and efficacy not established in pediatric patients. 2.Hypertension: (1 year or older) (1 year or older) Infusion: 0.25 to 3 mg/kg/hour IV infusion (guideline dosage).,1. Do not dilute in 5% sodium bicarbonate. 2. Patient should remain supine during and for up to 3 hours following injection.
OINDO,Indomethacin,Indocid 25mg,CNEU,,Analgesia， antipyresis， anti-inflammatory， actue gout.,,,Antirheumatic and antipyretic: Oral， 25-50 mg bid-tid. Rectal， 50-100 mg qd-bid. Acute gout: 100 mg initially， then 50 mg tid until pain is relieved. For patent ductus arteriosus closure in neonate: Oral(via a nasogastric tube)， 0.2 mg/kg initially. If necessary， 1-2 additional doses of 0.1-0.25 mg/kg may be given at 12 hrs intervals.,,,,,,,,,,,,,,
ICIT,Thiamylal,Citosol inj 0.5gm,ZANE,,適應症: Anaesth for diagnostic & surgical procedures; induction of anaesth or to supplement low potency agent 副作用:Induced-asthma. 禁忌: Liver disease.,,室溫,IV test dose 3 mL， if no problems， then 1 mL/5 sec or by continuous infusion titrated to response.,,,,沒有資料,,,,,,,,,,1. 本藥品為麻醉誘導藥品，限由醫師使用。 2. 500mg 粉劑加入所附溶解液20 mL，稀釋後藥物濃度 2.5 % (大於5 % 會引起靜脈炎)。 3. 本藥品之最大量為一次 1 gm靜脈內投與。
ICLA1,Cefotaxime,Claforan inj 1gm,QANB,Respiratory tract， ENT， skin & soft tissue， bone & joints， genital organs， abdominal infections， UTI; septicemia， endocarditis， meningitis.,Hypersensitivity to cephalosporins.,Thrombocytopenia， eosinophilia， leukopenia; hypersensitivity reactions; GI effects; anaphylactic shock (rare). Dermatologic: Injection site pain， Injection site phlebitis， Rash (2.2% ) Gastrointestinal: Diarrhea， Vomiting,25℃以下避光,Adults and children > 50 kg: 1-2 g IV/IM Q8-12H; serious infection: 2 g IV Q6-8H (maximum 12 g/day); gonorrhea: 0.5-1 g IM as single dose. Children < 50 kg: 50-100 mg/kg/day IV/IM (divided Q6-12H); 150-200 mg/kg/day for severe infections. Preterm infants: 50 mg/kg/day (divided Q12H). *****NEONATE ANTIBIOTICS DOSE***** Cefotaxime (Claforan): General infection: total dose : 100-150 mg/kg/day Body weight <1kg ge<=7day 50mg/kg Q12H  Age 8-14 day 0mg/kg Q12H  Age 15-28 day 0 mg/kg Q8H Body weight 1-2kg ge<=7day 0mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age<=7day 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50mg/kg Q8H meningitis; total dose : 200 mg/kg/day ; interval 比照上述表格所示 (參考馬偕)。 Neofax: But if Body weight <2kg Age<=7days total dose : 100-150mg/kg/day Q12-Q8H Age 8-28 days total dose: 150-200mg/kg/day Q8H-Q6H,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,"IM: 4 mL D/W;IV: 10mL D/W",【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。,推注時間至少3 ~ 5分鐘,建議以20~60分鐘緩慢滴注。 NeoFax建議：For IV push， a concentration of 50 to 100 mg/mL may be used. For intermittent IV infusion， dilute to a concentration of 10 to 40 mg/mL and infuse over 10 to 30 minutes.,1. 注射前詢問病患是否有β-醯胺類抗生素過敏史。 2. 監測體溫、CBC (尤其使用超過10天)、肝腎功能、PT值，注意是否發生抗生素引起的腹瀉。 3. (IM) 1 gm/vial 乾粉加入4 mL D/W泡製。 4. (IV bolus) 1 gm/vial 乾粉加入10 mL D/W泡製，兒童使用的藥液濃度 < 50 mg/mL，推注至少3 ~ 5分鐘。 5. (IV infusion) 1 - 2gm 乾粉稀釋成40 ~ 100 mL，以20 ~ 60分鐘緩慢滴注 小兒給藥建議：IV push，200 mg/mL via central catheter and 60 mg/mL via peripheral vein over3-5 minutes. Intermittent infusion，10-60 mg/mL over10-30 minutes.
ICLE,Clindamycin,Cleocin inj 300mg/2mL,QANB,,,,,,,,,,,,,,,,,,,
ICOD,Codeine,Codeine phosphate inj 15mg/1mL,CNEU,,Relief of mild to moderate pain and cough.,,,Adult: Analgesia: 15-60 mg q4h. Antitussive: 10-20 mg q4-6h.(max. 120 mg ). Child:Analgesia: 3 mg/kg/day in 6 divided dose. Antitussive: 2.5-10 mg q4-6h. (max. 60 mg ).,,,,除非治療上需要,,,,,,,,,,
ICODBAD,Codeine,Codeine inj 15mg/1mL殘餘銷燬,CNEU,,,,,,,,,,,,,,,,,,,
ICOR,A.C.T.H.,Cortrosyn depot,HM,,Collagen diseases， chronic skin disorders， GI diseases， nephrotic syndrome， acute neurological conditions; palliative therapy in terminal stage of cancer; exceptional cases of asthma.,,,Adult: 0.5-1 mg 2 times/week & for acute cases 1 mg daily for 3 days. Child 6-12 yrs: 1/2 adult dose. Child < 6 yrs: 1/4 adult dose.,,,,除非治療上需要,,,,,,,,,,
IBON,Clodronate,Bonefos inj 300mg/5mL,META,,適應症:Treatment of osteolysis of malignant origin & malignant hypercalcaemia 副作用: Mild GI irritation， asymptomatic hypocalcemia， elevations of aminotransferases. Rarely， respiratory disorders， renal impairment. 禁忌: Coadministration with other bisphosphonates.,,,Infusion concentrate 3-5 mg/kg by IV infusion during 3-5 consecutive days. To be given in 300-500ml normal saline(0.9%)in slow infusion(in 2-3 hr daily),,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,IVD;,,【D5W】可選 。【N/S】可選 。,,Slow infusion 300 mg over at least 2 hours once daily.,Multiple infusions: 300 mg over at least 2 hours once daily; continue until plasma calcium levels return to normal (usually 2 to 5 days); treatment duration should not exceed 7 days. 不可使用含鈣溶液或兩價陽離子
IDES,Deferoxamine Methansulphonate,DesFERAL inj 500mg,ZADT,Transfusional hemosiderosis especially in thalassemia major; idiopathic hemochromatosis; porphyria cutanea tarda. Acute Fe poisoning. Chronic Al overload with Al-related disease &/or encephalopathy. Test for Fe & Al overload.,Known hypersensitivity to the active substance， except where desensitisation proves possible.,Rarely， allergic skin reactions， anaphylactic reactions; local irritation at inj site; audiovisual disturbances， lens opacities; GI disturbances; leg cramps; renal or hepatic impairment; reddish brown urine discoloration; thrombocytopenia; CV & neurological disturbances.,無特別指示,If the patient is normotensive， Desferal is usually given in a single IM dose: 2 g for an adult and 1 g for a child. If the patient is hypotensive， the IV route is recommended. The maximum rate for administration IV is 15 mg/kg/hr and is reduced after 4-6 hrs so that the total IV dose in general does not exceed 80 mg/kg/24 hrs. In an adult patient with severe iron poisoning even infusion of 37.1 g Desferal over 52 hrs has been tolerated without apparent unwanted effects. Therapy should be continued until the serum iron levels are less than the total iron-binding capacity.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;SC;,需先以5ml注射用水稀釋成10% Desferal，方可使用。,【D5W】可選 。【L/R】可選 。【N/S】可選 。,,注射速率 < 15mg/kg/hr,1.限用5mL注射用水溶解乾粉， 不可用 0.9% N/S作為乾粉藥劑之溶劑 2.溶解後可用0.9% N/S做進一步的稀釋
LHAL,Haloperidol,Haldol drops 2mg/mL， 15 mL,CNEU,,適應症:噁心嘔吐或精神障礙之治療(B019337135),,,Antipsychotic: Oral: Adult:0.5-5 mg bid-tid initially， adjusted as needed. Child: 3-12 yrs， 0.05-0.15 mg/kg/day in 2-3 divided doses. Mental retardation with hyperactivity: 10-15 mg/day in divided doses up to 60 mg/day.,,,,除非治療上需要,,,,,,,,,,
LKEF,Cefaclor Monohydrate,Keflor syr 25mg/mL， 60mL,QANB,,Active against some beta-lactamase producing Haemophilus influenza.,,,Adult: 250-500 mg q8h， (max. 4 g/day). Child: 6.7-13.4 mg/kg q8h， (max. 1 g/day).,,,,可能安全,,,,,,,,,,
LKI,Potassium Iodide,3% KI solution,ERSP,,適應症: Pre-op reduction of the vascularity of the thyroid gland， Thyrotoxicosis， Cutaneous or lymphocutaneous sporotrichosis， Cough. 副作用: Hypersensitivity reactions， gastric irritation， diarrhoea. Iodism (large doses). Potentially Fatal: Periarteritis. 禁忌: Hypersensitivity. Acute bronchitis.,,室溫,Pre-op reduction of the vascularity of the thyroid gland: 250 mg 3 times/day for 10-14 days pre-op. Thyrotoxicosis: 500 mg 4 hrly. Given 1 hr after an antithyroid agent. Cutaneous or lymphocutaneous sporotrichosis: As 1 g/mL soln: 1 mL 3 times/day. Duration: >=1 mth after the disappearance or stabilisation of the lesions. Cough 300-650 mg 3-4 times/day.,,,,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IMAG2,Magnesium Sulfate,Mg Sulfate inj 10%， 200mL,NUTR,Hypomagnesemia; emergency treatment of life-threatening arrhythmias; prevention of recurrent seizures in eclampsia or pre-eclampsia.,Patients with heart block， myocardial damage or severe renal impairment.,Hypermagnesaemia characterized by loss of tendon reflexes & respiratory depression， flushing， thirst， hypotension， drowsiness， nausea， vomiting， confusion， muscle weakness， cardiac arrhythmias， coma & cardiac arrest.,室溫,Each mL contains: 0.1g magnesium sulfate salt=0.81mEq of elemental magnesium=0.405 mmol of elemental magnesium. Eclampsia、Preeclampsia: 1-10gm/day IV or IM， Initial 4 gm and follow with 5mL (0.5gm) every half hour. Hypomagnesemia: only for TPN， not to injection via peripheral intravenous directly. [UpToDate 20210731] Eclampsia/preeclampsia， seizure prophylaxis and treatment: IV: Initial: 4 to 6 g loading dose over 15 to 30 minutes at onset of labor or induction/cesarean delivery， followed by 1 to 2 g/hour continuous infusion for at least 24 hours after delivery; maximum infusion rate: 3 g/hour. If seizure occurs while receiving magnesium， an additional bolus of 2 to 4 g may be administered over ?5 minutes with frequent monitoring for toxicity (ACOG 2020; Eclampsia Trial Collaborative Group 1995; Kraft 2005; Norwitz 2020). IM (50% concentration): Initial: 10 g loading dose administered as 5 g in each buttock at onset of labor or induction/cesarean delivery， followed by 5 g every 4 hours for at least 24 hours after delivery. Note: Use IM route when unable to establish venous access (ACOG 2020; Altman 2002; Norwitz 2020).,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IH;IM;IVD;IVP;IVPUSH;,D5W， N/S， L/R,,輸注速率: < 1.5 mL/min，Severe hypomagnesemia (<1 mg/dL) with polymorphic VT (including torsade de pointes): IV push 1 to 2 g (10-20 mL),輸注速率: < 1.5 mL/min,1.有腎功能障害之患者；高鎂血症患者；腸內有寄生蟲之小孩患者及有心臟疾病患者必須審慎投與，以免造成危險。 2.妊娠婦投與時，由於硫酸鎂很容易通過胎盤，曾經有引起極少數新生兒之高鎂血症，故應小心投與。 3.本劑與含有磺胺劑、鹼性碳酸鹽、碳酸氫鹽、酒石酸鹽、可溶性磷酸鹽、砷酸鹽、溴化鉀、溴化銨等製劑一起混合使用時會有沉澱產生，配合時必須注意。 4.本劑若與其他全靜脈營養輸注液調配混合後，請儘速使用。 5.硫酸鎂中毒時常引起呼吸停止，應隨時注意血中濃度並給予鈣劑注射解毒。
IINF6,DTaP-IPV-HIB-HBV,INFANRIX Hexa (六合一疫苗) 0.5 mL/dose,HIMM,,適應症:Primary immunisation against diphtheria， tetanus， pertussis， hepatitis B， poliomyelitis & Haemophilus influenzae type b in infants from the age of 6 week & in infants who received a 1st dose of hepatitis B vaccine at birth. 副作用:Pain， redness， swelling， loss of appetite， fever， drowsiness， irritability. 禁忌: Hypersensitivity. Encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine.,,2-8℃,Deep IM inj Primary immunisation: 3 doses of 0.5 mL with an interval of at least 1 mth between doses. If it is intended to administer according to the EPI schedule (Expanded Program on Immunisation: 6， 10， 14 weeks)， then the vaccinee must receive a dose of hepatitis B vaccine at birth. Booster dose at 15-18 months.,,,,沒有資料,,,,,,,,,,
OBET,Betahistine,Betaserc 8mg,CNEU,,Meniere's disease & Meniere-like syndrome & peripheral vertigo.,,,1 or 2 tab tid .,,,,,,,,,,,,,,
OBRI2,Terbutaline,Bricanyl 2.5mg,ERSP,,Bronchial asthma， bronchitis， emphysema.,,,Oral: Adult: 5 mg tid， Child 12-15 yrs: 2.5 mg tid. Nebulizing soln: Adult & child over 20 kg: 5 mg， Child under 20 kg: 2.5 mg， qid. Turbuhaler: Adult & childn > 12yr: 1 inhalation 6 hrly， may be increased to 3 inhalations. Max: 12 inhalation/24 hr. Childn 5-12 yr 1 inhalation 6 hrly， may be increased to 2 inhalation to 2 inhalations. Max: 8 inhalation/24 hr.,,,,可能安全,,,,,,,,,,
OADA3,Nifedipine,Adalat OROS 30mg,CAVS,,適應症: Hypertension， chronic stable angina pectoris 副作用: Initially mild & transient vasodilatation， hypotension， rarely GI， skin & other reactions. Very rarely: transient visual change; chest discomfort (if relation established， discontinue therapy). Extremely rare: on prolonged use gingival hyperplasia， gynaecomastia (both regressing on discontinuation); hepatobiliary disorders. Cardiovascular: Hypotension (up to 5% )， Palpitations (up to 7% )， Peripheral edema (7% to 29% ) Dermatologic: Flushing (4% to 25%) Gastrointestinal: Nausea (up to 10% ) Neurologic: Dizziness (4% to 10% )， Headache (19% to 23%) Psychiatric: Feeling nervous Respiratory: Cough， Dyspnea 禁忌: CV shock; pregnancy & lactation. Unstable angina & after recent MI (immediate release).,,室溫,30-60 mg once daily. Max 120 mg/day.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OATI5,Lorazepam,Ativan 0.5mg,CNEU,Relief of anxiety. Insomnia due to anxiety or transient situational stress. Pre-surgical medication.,Sleep apnoea， severe respiratory insufficiency. Pregnancy， lactation.,Daytime drowsiness， dizziness， muscle weakness， ataxia， confusion， depression， appetite changes， headache， sleep disturbance， agitation， dermatological symptoms， libido changes， decreased alertness， numbed emotions， eye function disturbance， GI symptoms， blood dyscrasias， elevated liver enzymes. Paradoxical reactions eg stimulation & rage (rare). Hypotension. Neurologic: Asthenia (4.2% )， Dizziness (6.9% )， Sedated (15.9% )， Unsteadiness present (3.4% )， Vertigo Psychiatric: Depression,25℃以下避光且避熱,Anxiety:1-3mg/day in 2~3 divided doses. Insomnia:2-4mg HS. Elderly or frail patients:1-2mg in divided doses. Medication before surgery:2-4mg one or two hours before surgery， or the night before surgery.,無需調整劑量,Potential toxicity if combined with other CNS depressants,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Potential toxicity if combined with other CNS depressants,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OCIP,Citalopram,Cipram 20mg,CNEU,,Depression. Panic disorders.,,,Initially 20mg once a day. Max: 60mg daily. Elderly > 65 yr 20，g daily， increased to max of 40mg qd.,,,,除非治療上需要,,,,,,,,,,
OTRAZ,Trazodone,Mesyrel 50mg,CNEU,Depression.,Serious hepatic impairment.,Dry mouth， constipation， nausea & vomiting， blurred vision， fatigue， restlessness， dizziness， hypotension. Gastrointestinal: Constipation (7% to 8% )， Diarrhea (up to 9% )， Nausea (21% )， Vomiting (at least 1% )， Xerostomia (14% to 33.8% ) Musculoskeletal: Backache (5% ) Neurologic: Confusion (up to 5.7% )， Dizziness (25% )， Headache (9.9% to 33% )， Insomnia (6.4% to 9.9% )， Somnolence (23.9% to 46% ) Ophthalmic: Blurred vision (5% to 14.7% ) Psychiatric: Dream disorder (up to 5.1% )， Feeling nervous (6.4% to 14.8% ) Other: Fatigue (5.7% to 15% ),25℃以下,Initial dose: 150 mg/day. Dose may be gradually increased by 50mg/day at adjustment interval of 3-4 days. maximum dose(in divided doses): Out-patient 400 mg/day， in-patient 600 mg/day.,無需調整劑量,[仿單]由於缺乏經驗，本品不推薦使用在哺乳中婦女。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,[仿單]由於缺乏經驗，本品不推薦使用在懷孕婦女。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]由於缺乏經驗，本品不推薦使用在哺乳中婦女。,PC;PO;WM;,,,,,
OTRE4,Pentoxifylline,Trental 400mg,CAVS,,適應症:末梢血管循環障礙(A028470100) CI: Severe cerebral hemorrhage; recent MI; massive retinal hemorrhage.,,RT,Cerebrovascular disease:Initial， 200 mg tid; maintenance， 100 mg tid， pc. Peripheral vascular disorders: Initial 400 mg tid; maintenance 400 mg bid， pc; swallowed whole.,,,,除非治療上需要,,,,,,,,,,
OTRYN,Amitriptyline,Trynol 10mg,CNEU,Endogenic depression， manic depressive psychosis， involution melancholia， climacteric & reactive melancholia， melancholia senilis， nervous depression， depressive state， depression due to neurasthenia & psychosis.,Concomitant use with MAOI. Immediate recovery phase after MI， heart block. Mania.,Dry mouth， sour or metallic taste; constipation occasionally leading to paralytic ileus; urinary retention; blurred vision & disturbances in accommodation; palpitations， tachycardia & impotence.,陰涼(15-30℃) 乾燥的緊密容器，避光保存,Adults: Outpatient initial dose: 75mg/day in divided doses. If necessary， the dose can be gradually increased to 150mg/day. Inpatient initial dose: 100mg/day. If necessary， the dose can be gradually increased to 200-300mg/day. The elderly: 50mg/day in divided doses. Single dose should be at night or before bed. Maintenance dose: 50-100mg/day Children with enuresis: under 6 years old:10mg HS 6-10 years old: 10-20mg/day 11-16 years old: 25-50mg/day,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OUCE,Cefadroxil,Ucefa 500mg,QANB,,適應症:細菌性感染(A025083100),,RT,Adult: 1-2 g/day in 1-2 divided doses， (max. 6 g/day). Child: 15 mg/kg q12h.,,,,可能安全,,,,,,,,,,
OUROC,Potassium Citrate,Urocit K 5meq,SGU,,Renal tubular acidosis (RTA) with calcium stones， hypocitraturic calcium oxalate nephrolithiasis of any etiology， and uric acid lithiasis with or without calcium stones.,,,Mild to moderate hypocitraturia: 2 tab tid. Do not exceed 100 mEq/day. Severe hypocitraturia: 4 tab tid or 3 tab qid with meals.,,,,除非治療上需要,,,,,,,,,,
OUROP,Phenazopyridine,Uroprin 100mg,SGU,,適應症: Symptomatic relief of pain， burning and urinary urgency and/or frequency caused by irritation of the lower urinary tract mucosa. 副作用: GI disturbances， headache; rash; hepatotoxicity; haemolytic anaemia， methaemoglobinaemia; discolouration of urine and other body fluids; staining of contact lens; crystal deposits in urinary tract. Potentially Fatal: Acute renal failure. Common: Neurologic - Headache Serious: Hematologic: Hemolytic anemia Hepatic: Hepatotoxicity Immunologic: Anaphylactoid reaction Renal: Nephrotoxicity 禁忌: Hypersensitivity to phenazopyridine products，renal insufficiency.,,室溫,Urinary analgesic: Adult: 200 mg tid， pc. Child: 4 mg/kg tid. - Micromedex 2.0 ■ Dysuria， Symptomatic relief: 200 mg ORALLY 3 times a day after meals; use should not exceed 2 days when used concomitantly with an antibiotic ■ renal impairment: mild renal failure (GFR greater than 50 mL/min)， increase dosing interval to every 8 to 16 hours; do not use if GFR less than 50 mL/min ■ geriatrics: increased risk of accumulation and toxicity; age-related renal function impairment,無需調整劑量,Infant risk cannot be ruled out,需調整劑量,可能安全,Compatible,,Contraindicated 哺乳期使用禁忌,Infant risk cannot be ruled out,,,,,,
OURS,Ursodeoxycholic Acid,Ursolic tab 100 mg,ALIM,,Dissolution of radiolucent cholesterol gallstones.,,,8-10 mg/kg/day in 2-3 divided doses.,,,,可能安全,,,,,,,,,,
OVB1,Thiamine,Vitamin B1 100mg,NUTR,,Vit. B1 deficiency or beriberi disease.,,,Oral， 10 mg tid.,,,,安全,,,,,,,,,,
OVC,Ascorbic Acid,Vitamin C 200mg,NUTR,,適應症: Prevention & treatment of vit C deficiency.,,室溫,Usual dose: 40-1000 mg/day.,,,,安全,,,,,,,,,,
EGENV,Gentian Violet,Gentian violet soln,TDER,,Skin disinfection.,,RT,Apply directly or on a dressing as often as needed.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OJOL,Iodized Lecithin,Jolethin 0.75mg (Iodine 0.05mg),META,,適應症: Pre-op management of hyperthyroidism. 副作用: Hypersensitivity reaction.,,室溫,Adult 6-12 tab daily. Children 1-6 tab daily.,,,,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OJUM,Selegiline,Jumexal 5mg,CNEU,,適應症:輔助治療帕金森氏症(B021941100),,RT,5 ~ 10 mg. ( max: 10 mg/day ),,,,除非治療上需要,,,,,,,,,,
OKAY,Sodium polystyrene sulfonate,Resonium-A powder 5gm/PK,ZADT,,適應症: Hyperkalemia. 副作用: Gastric irritation， anorexia， nausea， vomiting， constipation， occasional diarrhea; hypokalemia， hypocalcemia， Na retention. 禁忌: Patients with hypokalemia or those who are hypersensitive to Resonium-A.,,室溫,Adult: 15 g ORALLY 1 to 4 times daily as a slurry in water or syrup. Or 30 to 50 g RECTALLY every 6 hr as a warm emulsion in 100 mL aqueous vehicle (sorbitol)， retain 30-60 min and follow with a cleansing enema. Smaller children & infant: Use lower dose at a rate of 1 g/kg body wt.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OKEF,Cephalexin,Keflex 250mg,QANB,,適應症:細菌性感染(B023139100)(N003905100) G(+) (not enterococci， variable against beta-lactamase + staph. & Neissria， not methicillin-resistant staphylococcus aureus) G(-)(urinary infections due to most E. coli， Pr. mirabilis， & some klebsiella， variable against samonella and shigella， not enterobacter， pseudomonas， acinetobacter),,RT,Adult: 250 mg q6h， (max. 4g/day). Child: 6.25-12.5 mg/kg q6h， up to 25 mg/kg q6h.,,,,可能安全,,,,,,,,,,
OKLE,Polyethylene Glycol,Klean-Prep powder,ALIM,,適應症: Bowel prep before colonoscopy， colonic surgery， radiological exam & other related procedures. 副作用: Nausea， bloatedness， abdominal pain， vomiting. Rarely rectal irritation. 禁忌: GI obstruction or perforation， ileus， gastric retention， acute intestinal or gastric ulceration， toxic colitis or megacolon.,,室溫,Adult including elderly & renal insufficiency patient 1 sachet In 1 L water . 250ml to be drunk rapidly every 10-15 mins until all soln has been consumed. Repeat procedure with 2-4 sachets or until the rectal effuent is clear. 用藥前2小時以流體食物為主,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OKLI,Estradiol 2 mg/tab + Norethisterone 1mg/tab,Kliogest (28tab/box),HM,,,,,,,,,,,,,,,,,,,
OKNO,Piracetam,Knowful 400mg,CNEU,,適應症:為腦代謝改善劑(A017508100) CI: Severe renal insufficiency， creatinine clearance < 20 ml/min.,,RT,Initial， 800 mg tid; maintenance， 400 mg tid.,,,,沒有資料,,,,,,,,,,
OSUR2,Sulpiride,Surin 200mg,CNEU,,Acute or chronic schizophrenia.,,,Neurosis， migraine， function intestinal spasm: 100-200 mg/day. Gastric and duodenal ulcers:150-300 mg/day. Anxiety with depression: 150-300mg/day in divided doses， up to 600mg/day. Psychotic disorder: Adult: initially， 200-400mg bid; maintenance， 600-1200mg/day in 2-3 doses; max. 1200mg bid. Child: 3-5mg/kg/day.,,,,,,,,,,,,,,
LLUG,Strong Iodine Solution,Lugol's soln 10%,META,,Thyroid disorder due to iodine deficiency.,,,0.1-0.3 ml tid,,,,盡量避免,,,,,,,,,,
LMAC,Ibuprofen,Mac safe susp 60mL,CNEU,,,,,,,,,,,,,,,,,,,
LMAG,Magnesium Citrate,Magvac solution 250mL,ALIM,,,,,,,,,,,,,,,,,,,
LMEP6,Procaterol,Meptin liquid 5mcg/mL， 60mL,ERSP,Bronchial asthma， chronic bronchitis & pulmonary emphysema.,Hypersensitivity to any component of the formulation.,Infrequent palpitations & tremors.,30℃以下避光,Adult: 10 mL HS or 10 mL BID (in the morning and bedtime). Age >6 years: 5 mL HS or 5 mL BID (in the morning and bedtime). Age <6 years 0.25 mL/kg BID (in the morning and bedtime) or TID (morning， evening and bedtime.),無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
LOPV,Poliovirus Vaccine,沙賓疫苗(免費),HIMM,,適應症: Active immunization against poliomyelitis. 副作用: Rarely， allergic & anaphylactic reactions & vaccine-associated poliomyelitis. 禁忌: Immunosuppressed & immunodeficient patients; during acute feverish illnesses， hypersensitivity to neomycin. Vomiting & diarrhea. Debilitated states.,,冷凍,3 oral doses， (1 dose=2 drops). Separated by 2 months. Oral， 0.5 ml/dose. Primary immunization: 3 doses given at 8 wks intervals and a reinforcing 4th dose given 1 yr later. Booster dose: Given at 4-6 yrs.,,,,沒有資料,,,,,,,,,,
LPEA,Triprolidine + Pseudoephedrine,Peace syrup 60mL,HIMM,Nasal congestion， allergic rhinitis.,Hypersensitivity to any component of the formulation.,Insomnia.,25℃以下避光,TID-QID， Adult and children >12 years 10 mL， Children 6-12 years 5 mL， < 6 years as doctors' order.,無需調整劑量,Triprolidine- Limited Human Data—Probably Compatible Pseudoephedrine -Limited Human Data—Probably Compatible,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,Triprolidine- Compatible Pseudoephedrine Human Data Suggest Risk,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Triprolidine- Limited Human Data—Probably Compatible Pseudoephedrine -Limited Human Data—Probably Compatible,AC;AC15;PC;PO;WM;,,,,,
ODILA,Carvedilol,Dilatrend 25mg,CAVS,Hypertention， congestive heart failure.,Hypersensitivity to any component of the formulation.,Dizziness， headaches， fatigue， bradycardia， postural hypotension， hypotension， GI disturbances， flu-like symptoms， respiratory effects. Cardiovascular: Bradyarrhythmia (3% to 10% )， Hypotension (1.8% to 20.2% )， Peripheral edema (1% to 7% ) Endocrine metabolic: Abnormal weight gain (10% to 12% )， Hyperglycemia (5% to 12% ) Gastrointestinal: Diarrhea (2% to 12% ) Neurologic: Dizziness (6% to 33% ) Reproductive: Erectile dysfunction (13.5% ) Other: Fatigue (24% ) CI: Decompensated heart failure requiring IV inotropic support; asthma; COPD with bronchospastic component; clinically manifested liver dysfunction; 2nd & 3rd degree AV block; severe bradycardia; cardiogenic shock; sick sinus syndrome; severe hypotension.,30℃以下避光,Essential hypertension: Initially 12.5mg QD for 2 days， then 25 mg QD， and over the interval of 2 weeks to maximum 50 mg QD (may divide to 2 doses). Symptomatic， stable， chronic heart failure: Initially 3.125mg BID for 2 weeks， then increase to 6.25 mg， 12.5 mg， and 25 mg BID over successive intervals of at least 2 weeks if the initial dose is well-tolerated titration. Sever chronic heart failure and mild to moderate chronic heart failure < 85 kg: Maximum 25 mg BID. Mild to moderate chronic heart failure > 85 kg: Maximum 50mg BID.,需調整劑量,No reports describing the use of carvedilol during human lactation have been located. The molecular weight (about 407) and long terminal elimination half-life (7–10 hours) suggest that the drug will be excreted into breast milk， but the high plasma protein binding (>98%) should limit the amount. The potential effects of this exposure on a nursing infant include bradycardia， hypotension， and other symptoms of α/β-blockade. However， in 2001， a similar agent was classified by the American Academy of Pediatrics as compatible with breastfeeding.,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,Only one report describing the use of carvedilol in human pregnancy has been located. The animal data and the experience with other， similar agents suggest that the risk of teratogenicity is low. Intrauterine growth restriction (IUGR)， however， has been reported in the case below and is known to occur with other α/β-blockers (see Labetalol). Moreover， some β-blockers have caused IUGR and reduced placental weight， especially those lacking intrinsic sympathomimetic activity (ISA) (i.e.， partial agonist). Treatment beginning early in the 2nd trimester results in the greatest weight reductions， whereas treatment restricted to the 3rd trimester primarily affects only placental weight. Carvedilol does not possess ISA. IUGR and reduced placental weight may potentially occur with all agents within this class. Although growth restriction is a serious concern， the benefits of maternal therapy with carvedilol (or other α/β-blockers)， in some cases， might outweigh the risks to the fetus and must be judged on a case-by-case basis.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,No reports describing the use of carvedilol during human lactation have been located. The molecular weight (about 407) and long terminal elimination half-life (7–10 hours) suggest that the drug will be excreted into breast milk， but the high plasma protein binding (>98%) should limit the amount. The potential effects of this exposure on a nursing infant include bradycardia， hypotension， and other symptoms of α/β-blockade. However， in 2001， a similar agent was classified by the American Academy of Pediatrics as compatible with breastfeeding.,AC;AC15;PC;PO;WM;,,,,,
LPRE,Cisapride,Prepulsid susp 1mg/mL， 100mL,ALIM,,,,,,,,,,,,,,,,,,,
OCOUM,Warfarin,Coumadin 5 MG,HEMT,,I: Thrombolic conditions. CI: Pregnancy; haemorrhagic tendency or blood dyscrasias; recent or contemplated surgery of CNS， eye; traumatic surgery resulting in large open surfaces; bleeding tendencies associated with active ulceration or overt bleeding; threatened abortion; spinal puncture.,,,Initial: 40-60 mg/day. Maintenance: 2-10 mg/day,,,,不可使用,,,,,,,,,,
ODEX,Simethicone,Dexicone 40mg,ALIM,,適應症: Abdominal distension caused by GI disorders. Elimination of gas in GI tract prior to radiography.,,室溫,Adult: 40 mg qid， Child: Individualized by physician.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OTHA,Thalidomide,Thado 50mg,HIMM,,I: Erythema nodosum leprosum.,,,D: Initial dose is 100-300 mg hs， max.dose is 400 mg/day.,,,,不可使用,,,,,,,,,,
EPEN,NovoPen,NovoPen 3,ZOTH,,非藥品,,RT,非藥品,,,,,,,,,,,,,,
IIG3,Human Immunoglobulin,Human Immunoglobulin 3gm/50mL,HIMM,Replacement IgG therapy in primary immunodeficiency， myeloma & chronic lymphatic leukamia with severe secondary hypogammaglobulinemia & recurrent infections， congenital or AIDS with recurrent infections. Immunomodulatory therapy in idiopathic thrombocytopenic purpura (ITP) in adults or children at high risk of bleeding or prior to surgery， allogeneic bone marrow transplantation， Kawasaki disease.,Hypersensitivity to human Ig.,Malaise， abdominal pain， headache， chest tightness， facial flushing or pallor， erythema， hot sensations， dyspnea or respiratory difficulty， non-urticarial skin rash， cutaneous vasculitis， pompholyx on hands/palms， itching， tissue swelling， change in BP， nausea， vomiting.,2-8℃,IVD， Replacement therapy 0.2-0.6 g/kg/month as a single dose or 2 divided doses at fortnightly intervals. Idiopathic Thrombocytopenic Purpura (ITP) Up to max total cumulative dose of 2 g/kg over 2-5 days. Kawasaki disease 1.6-2 g/kg in divided doses over 2-5 days or 2 g/kg as single dose. Allogeneic bone marrow transplantation Initially 0.5 g/kg/week. Guillain Barre Syndrome (GBS) 0.4 g/kg/day for 5 days.,無需調整劑量,[仿單]目前還沒有針對懷孕婦女、哺乳期間之對照臨床試驗，因此對孕婦、哺乳婦女 施用時要特別小心。,無需調整劑量,除非治療上需要,Compatible,[仿單]目前還沒有針對懷孕婦女、哺乳期間之對照臨床試驗，因此對孕婦、哺乳婦女 施用時要特別小心。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前還沒有針對懷孕婦女、哺乳期間之對照臨床試驗，因此對孕婦、哺乳婦女 施用時要特別小心。,IVD;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,輸注速率< 4 mL/min;剛開始以1 mL/min，持續15分鐘以上，之後速率可漸增，最高 3-4 mL/min。,1. 本注射液可不稀釋直接靜脈輸注，也可用N/S或D5W稀釋後注射。 2. 注射速率從 1 mL/min開始，持續15分鐘以上，之後速率可漸增，最高 3-4 mL/min。 3. 高齡病人及腎臟病病患應考慮使用較低速率給藥。 4. 如發現注射液有混濁或沉澱，或是曾被冷凍過，切勿使用。
EELI,Pimecrolimus,Elidel cream 1%， 15gm,TDER,Second-line therapy for the short- term & non-continuous chronic treatment of mild to moderate atopic dermatitis in non- immunocompromised adults & children > 2 years.,Hypersensitivity to pimecrolimus or to any of the excipients of Elidel.,Feeling of warmth &/or burning sensation， irritation， pruritus & erythema， folliculitis. Dermatologic: Sensation of burning of skin Immunologic: At risk for infection， Viral Neurologic: Headache (7% to 25.4% ) Other: Fever,25°C以下,Apply thin layer to affected area twice daily.,無需調整劑量,局部使用Elidel1%乳膏對於哺乳中的動物試驗尚未進行過，因此仍未知使用pimecrolimus後會不會分泌至乳汁中。已知許多藥物均會分泌至人體乳汁中，因此哺乳婦女使用Elidel 1%乳膏時必須十分小心。然而，由於局部使用Elidel 1%乳膏後(請見“藥物動力學”部份) 其主成份pimecrolimus的吸收率極小，對人體造成的危險性亦有限。 哺乳婦女不應使用於Elidel 1%乳膏於乳房上。,無需調整劑量,沒有資料,,迄今Elidel 1%乳膏使用於孕婦的經驗仍有限。以動物皮膚使用Elidel 1%乳膏的試驗中，並無顯示Elidel 1%乳膏會直接或間接對懷孕、胚胎/胎兒發育、分娩或產後造成傷害(請見“臨床前體外試驗之安全性資料”部份)。 當使用Flidel 1%乳膏於孕婦時，必須十分小心；然而，由於pimecrolimus在局部使用後的吸收性極小(請見“藥物動力學”部份)，因此對於人體可能發生的危險性有限。,Contraindicated 哺乳期使用禁忌,局部使用Elidel1%乳膏對於哺乳中的動物試驗尚未進行過，因此仍未知使用pimecrolimus後會不會分泌至乳汁中。已知許多藥物均會分泌至人體乳汁中，因此哺乳婦女使用Elidel 1%乳膏時必須十分小心。然而，由於局部使用Elidel 1%乳膏後(請見“藥物動力學”部份) 其主成份pimecrolimus的吸收率極小，對人體造成的危險性亦有限。 哺乳婦女不應使用於Elidel 1%乳膏於乳房上。,EXT;SKIN;TOPI;,,,,,
IGON6,Follitropin,Gonal-F 1200iu/val,HM,,,,,,,,,,,,,,,,,,,
EGLYC,Glycerin,Glycerin liquid (mL),TDER,As a moisturizer to prevent dry skin and minor skin irritations.,Hypersensitivity to any component of the formulation.,,室溫,60 mL， 120 mL/BOT.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;SKIN;TOPI;,,,,,
EILO,Erythromycin,Erythromycin oph oint 0.5%， 3.5gm,TOPH,,適應症: Treatment of bacterial infections of the eye involving the conjunctiva &/or cornea caused by susceptible organisms. 副作用: Rarely， hypersensitivity reactions， ocular irritation or redness. 禁忌: Hypersensitivity.,,室溫,Apply up to 6 times daily.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
EINT5,Sod Cromoglycate,Intal 5 inhaler門診限一支,ERSP,,I: Prophylaxis & treatment of bronchial asthma due to allergy， exercise， cold air or chemical & occupational irritants. AR: Mild throat irritation， coughing & transient brochospasm. Very rarely， severe bronchospasm necessitating withdrowal of treatment may occur.,,,1-2 puffs qid.,,,,可能安全,,,,,,,,,,
EINTS,Indomethacin,Intocin supp 100mg,CNEU,,適應症:解熱、消炎、鎮痛(A005949500),,RT,Antirheumatic and antipyretic: Oral， 25-50 mg bid-tid. Rectal， 50-100 mg qd-bid. Acute gout: 100 mg initially， then 50 mg tid until pain is relieved. For patent ductus arteriosus closure in neonate: Oral(via a nasogastric tube)， 0.2 mg/kg initially. If necessary， 1-2 additional doses of 0.1-0.25 mg/kg may be given at 12 hrs intervals.,,,,沒有資料,,,,,,,,,,
EISA,Iodine + Salicylic Acid Alcohol,I.S.A spirit 30mL,TDER,,A keratolytics and a slight antiseptics.,,室溫,Topical use when necessary.,,,,除非治療上需要,,,,,,,,,,
EISO1,Pilocarpine,Isopto carpine 1%， 15mL,TOPH,,適應症:控制慢性青光眼之眼壓(B016354435) AR: Slight ciliary spasm， conjunctival vascular congestion， temporal or supraorbital headache， myopia. CI: Where constriction is undesirable eg in acute iritis， pupillary block glaucoma.,,RT,2 drops tid-qid.,,,,除非治療上需要,,,,,,,,,,
EISO4,Pilocarpine,Isopto carpine 4% 15mL,TOPH,,I: Control of intraocular pressure. AR: Slight ciliary spasm， conjunctival vascular congestion， temporal or supraorbital headache， myopia. CI: Where constriction is undesirable eg in acute iritis， pupillary block glaucoma.,,,2 drops tid-qid.,,,,除非治療上需要,,,,,,,,,,
EKIN,N6-furfuryladerine,Kinerase cream 0.1%,TDER,,Skin condition improvement,,,Apply to face and neck twice daily.,,,,,,,,,,,,,,
EKLA,Phenyl Mercuric Acetate,Klargine soln 20mL,TENT,,Bacteriostatic and antifungal.,,室溫,1-2 drops qd-qid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ELAT,Tetracycline,Latycin eye oint 5gm,TOPH,,I: External ocular infections such as acute，chronic or purulent conjunctiveitis， nordeolum， acute and chronic lepharitis，blepharo-conjunctivitis，corneal ulcers， secondary infections in patients with herpes corneae and trachoma.It is also useful for preventing infections in patients undergoing ophthalmic surgery. AR: Superinfection. CI: Photodermatosis.,,,Apply into the lower conjunctival sac every 2 hours. Treatment should be continued for 2 to 3 days after symptoms have subsided.,,,,可能安全,,,,,,,,,,
ELOC,Flumethasone + Salicylic Acid,Locasalen oint 5gm,TDER,,適應症: Seborrheic eczema， contact eczema， atopic dermatitis， localized neurodermatitis， psoriasis vulgaris， lichen planus， hyperkeratosis of the palms & soles. 副作用: Mild transient burning sensation， itching; in isolated cases， mild skin atrophy; changes in skin pigmentation， telangiectasia， purpura， steroid acne particularly after prolonged application. 禁忌: Tuberculous， syphilitic & fresh viral skin affections， vaccination reactions. Perioral dermatitis， acne vulgaris.,,室溫,Apply the ointment to the affected areas in a thin film once or twice daily and gently rubbed-in. An occlusive dressing may also be used.,,,,沒有資料,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OFLU,Trichlormethiazide,Fluitran 2mg,CAVS,As diuretics， antihypertensive.,Anuria， hypersensitivity to sulfonamides.,Arrhythmias， orthostatic hypotension， dizziness， headache， paresthesias， vertigo， xanthopsia， hyperglycemia， hyperuricemia， hypercalcemia， hypokalemia， hyponatremia， anorexia， cramping， constipation， diarrhea， gastric irritation， jaundice， pancreatitis， nausea & vomiting， glycosuria， muscle weakness， muscle spasm， necrotizing angiitis， photosensitivity， purpura， rash， urticaria， agranulocytosis， aplastic anemia， leukopenia， thrombocytopenia.,30°C以下避光,Antihypertensive: 2-4 mg once daily. Initial dose: 2-4 mg BID. Maintenance: 2 mg once daily. Diuretic: 4 mg once daily. Initial dose: 4 mg BID. Maintenance: 2 mg BID.,無需調整劑量,比照 Chlorothiazide。 Chlorothiazide is excreted into breast milk in low concentrations. Thiazide diuretics have been used to suppress lactation. However， in 2001 the American Academy of Pediatrics classified bendroflumethiazide， chlorothiazide， chlorthalidone， and hydrochlorothiazide as compatible with breastfeeding.,無需調整劑量,盡量避免,Compatible,無資料，比照 Chlorothiazide，如下： The published experience with 1st trimester use of thiazides and related diuretics does not indicate these agents are teratogenic. One large study (the Collaborative Perinatal Project) did find an increased risk of defects when diuretics were used during the 1st trimester in women with cardiovascular disorders， but causal relationships cannot be inferred from these data without independent confirmation. Diuretics are not recommended for the treatment of gestational hypertension or preeclampsia because of the maternal hypovolemia characteristic of this disease. Other risks to the fetus or newborn include hypoglycemia， thrombocytopenia， hyponatremia， hypokalemia， and death from maternal complications. Moreover， thiazide diuretics may have a direct effect on smooth muscle and inhibit labor.,Compatible 哺乳時可使用,比照 Chlorothiazide。 Chlorothiazide is excreted into breast milk in low concentrations. Thiazide diuretics have been used to suppress lactation. However， in 2001 the American Academy of Pediatrics classified bendroflumethiazide， chlorothiazide， chlorthalidone， and hydrochlorothiazide as compatible with breastfeeding.,AC;AC15;PC;PO;WM;,,,,,
ISHI,Triamcinolone,Shincort 40mg/1mL,HM,,適應症:具抗發炎作用(A011475209) ADR: Local atrophy (temporary). IA: post-inj flare， pigmentation changes， sterile abscess， charcot-like arthropathy. Systemically: Na and fluid retention， peptic ulcer with possible perforation， decreaswd carbohydrate tolerance， impaired wound healing， thin fragile skin， purpura， striae， muscle weakness， steroid myopathy， osteoporosis， aseptic necrosis， cataracts， increased intraocular or intracranial pressure， protein catabolism， Cushingoid state， growth retardation， aggravation of preexisting psychiatric conditions. CI: Systemic fungal infection， unstable or infected joints， lactation,,RT,Intra-articular: 2.5-15 mg. Intradermal or intralesional: less than 1 mg/site.,,,,除非治療上需要,,,,,,,,,,
ORES,Testosterone,Restandol 40mg,HM,,,,,,,,,,,,,,,,,,,
EMIR,Levonorgestrel Implants,Mirena 20mcg/24hours intrauterine system,HM,Contraception， idiopathic menorrhagia， Protection from endometrial hyperplasia during ERT.,Known or suspected pregnancy; genital infection; confirmed or suspected uterine or cervical malignancy; Undiagnosed abnormal uterine bleeding; Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity; acute liver disease or liver tumor; active thrombophlebitis or thromboembolic disorder.,Menstrual changes， lower abdominal pain， acne or other skin problems， back pain， mastalgia， headache， vag discharge， mood changes， nausea， edema， weight gain， decreased libido， sweating， hair loss， greasy hair. Ectopic pregnancy， pelvic inflammatory disease， perforation of the uterine wall， enlarged follicles (functional ovarian cysts) may develop.,30℃以下,1 unit inserted into the uterine cavity within 7 days of the onset of menstruation or immediately after first trimester abortion. Postpartum insertions should be postponed until 6 weeks after delivery.,無需調整劑量,•Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding,無需調整劑量,不可使用,Contraindicated,Levonorgestrel •Evidence has demonstrated fetal abnormalities or risks,Contraindicated 哺乳期使用禁忌,•Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding,INU;IUS;,,,,,
EMYD1,Tropicamide,Mydriacyl 1% 5mL,TOPH,,I: Mydriasis and cycloplegia for diagnostic purposes. AR: Increased intraocular pressure. Psychotic reactions， behavioral disturbances， cardioresp collapse in children & some adults; transient stinging， dry mouth， blurred vision， photophobia with or without corneal staining， tachycardia， headache， parasympathetic stimulation， allergic reactions. CI: Primary glaucoma or a tendency toward glaucoma.,,,For refraction: 1 drop followed by a second drop 5 mins later. If examination can't be performed within 20-35 mins， a third drop must be instilled.,,,,,,,,,,,,,,
EULT,Sevoflurane,Ultane 250mL,ZANE,,適應症: Induction & maintenance of general anesth. 副作用: Dose-dependent cardio-respiratory depression， nausea， vomiting， hypotension. 禁忌: Known or suspected genetic susceptibility to malignant hyperthermia.,,15-30°C,Individualized dosage. Adult Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6%. MAC values for surgical levels of anesthesia: (25 years) Sevoflurane in oxygen: 2.6%， Sevoflurane in 65% N20/35% oxygen: 1.4% (40 years) Sevoflurane in oxygen: 2.1%， Sevoflurane in 65% N20/35% oxygen: 1.1% (60 years) Sevoflurane in oxygen: 1.7%， Sevoflurane in 65% N20/35% oxygen: 0.9% (80 years) Sevoflurane in oxygen: 1.4%， Sevoflurane in 65% N20/35% oxygen: 0.7% Pediatric Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6%. MAC values for surgical levels of anesthesia: (0 to 1 month old full-term neonates) Sevoflurane in oxygen: 3.3% (1 to <6 months) Sevoflurane in oxygen: 3% (6 months to <1 year) Sevoflurane in oxygen: 2.8%， Sevoflurane in 65% N20/35% oxygen: 2% (1 to <3 years) Sevoflurane in oxygen: 2.8%， Sevoflurane in 60% N20/40% oxygen: 2% (3-12 years) Sevoflurane in oxygen: 2.5%,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,1. 只有受過全身麻醉操作訓練者才可施用sevoflurane。維持氣道通暢的設備、人工呼吸器、氧氣筒、及循環復甦器必須隨時備用。 2. 應精確地知道自麻醉揮發器釋出的sevoflurane 的濃度。因為揮發性麻醉劑的物性皆不相同，只可使用特別為sevoflurane定量校正的麻醉揮發器。應依據病患的反應來個案調整全身麻醉劑的使用量。當麻醉深度愈深時，低血壓和呼吸抑制會增加。
EURE,Urea,Urea cream 10%， 20gm,TDER,Ichthyosis and hyperkeratotic skin disorders.,Hypersensitivity to any component of the formulation.,Occasionally local stinging， pain， redness and itch.,25℃以下,Apply QD-TID.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
EXYLS,Lidocaine,Xylocaine spray 80mg/gm,ZANE,,適應症:為局部麻醉劑(B003456353),,,Infiltration， caudal， epidural or peripheral nerve block: Up to 30 ml as a 1% soln or 15 ml as a 2% soln. Surface anesthesia: Nose， nasopharynx and respiratory tract: 1-5 ml of 1%-4% soln is sprayed， 8% spray may be needed. Mouth， pharynx and upper digestive tract: 5-15 ml of 2% viscous soln. Urethral catheterization: Men， 5-10 ml; women， 3-5 ml of 2% jelly.,,,,可能安全,,,,,,,,,,
EXYSP,Lidocaine,Xylocaine spray 10%， 50mL,ZANE,Surface anaesth.,Hypersensitivity to amide type local anesth.,Local irritation， allergic reactions， acute systemic toxicity.,25℃以下。,Each spray of metered dose contains 10mg Lidocaine. Otorhinolaryngology: 3 metered doses for puncture of the maxillary sinus or other minor surgical procedures. Paracentesis: 3 metered doses. During delivery: Up to 20 metered doses. Introduction of instruments， tubes and catheters into the respiratory or digestive tract: Up to 20 metered doses for procedures in the pharynx， larynx and trachea. During prolonged procedures， up to 400 mg of lidocaine may be administered. In addition， when combined with other lidocaine products， the total dose should not exceed 400 mg. With applications mainly to the larynx， trachea and bronchi， the dose should not exceed 20 metered doses. Dental practice: 1-5 metered doses to the mucous membranes.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;LA;SKIN;TOPI;,,,,,
ETAR,Ofloxacin,Tarivid otic solution 0.3%， 5mL,TENT,Otitis media， otitis externa caused by ofloxacin-susceptible pathogen: Staph， Strep， Proteus sp， Pseudomonas aeruginosa， & haemophilus influenzae.,Hypersensitivity to quinolones; pregnancy and lactation; prolongation of the QT interval; uncorrected hypokalaemia.,Infrequently， earache， superinfection. Dermatologic: Pruritus， Rash Gastrointestinal: Diarrhea， Nausea (up to 3.5% )， Vomiting Neurologic: Dizziness (up to 8% )， Headache (up to 8% )， Insomnia (up to 13% ) Ophthalmic: Burning sensation in eye， Pain in eye,室溫,Otitis media， chronic suppurative (with perforated tympanic membranes): Otic: Instill 6-10 drops into affected ear(s) twice daily for 14 days,無需調整劑量,,無需調整劑量,沒有資料,Contraindicated,PREGNANCY RECOMMENDATION: Contraindicated (Use only if no other alternatives),No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AD;AS;AU;,,,,,
OMUS,Tolperisone,MusCalm S 50mg,CNEU,,適應症: Spastic paralysis due to sequelae to stroke， cerebral palsy， subacute myelo-opticoneuropathy， spastic spinal paralysis， amyotrophic lateral sclerosis， cerebrospinal degeneration， multiple sclerosis， cervical spondylosis， ossification of the posterior longitudinal ligament， sequelae to injury， sequelae to operation. For improvement of increased muscular tension in cervical syndrome， lumbago. 副作用: Shock， hepatic disorder， rashes; chest distress， respiratory disorders; lightheadedness， weakness， lassitude， dizziness， dull headache， drowsiness; anorexia， abdominal pain， nausea， vomiting， diarrhea & thirst; rarely， constipation， meteorism， gastric oppression & pyrosis; itching， sensation of weakness of lower extremity.,,室溫,Adult Usually 300 mg daily in 3 divided doses.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OMYK,Metolazone,Mykrox 0.5mg,CAVS,,適應症: Hypertension. 副作用: Dizziness， headache， muscle cramps， fatigue， joint pain， swelling， chest pain. 禁忌: Anuria， hepatic coma or pre-coma; allergy or hypersensitivity to metolazone.,,室溫,1 tab once daily， usually in the morning. may be increased to 2 tab once daily.,,,,盡量避免,,,,,,,,,,
OMYL,Busulphan,Myleran (Busulphan) 2mg,RACA,,,,,,,,,,,,,,,,,,,
ONAT,Indapamide,Natrilix SR 1.5mg,CAVS,Hypertension.,Hypersensitivity to sulfonamides; severe hepatic or renal failure， hypokalemia & hepatic encephalopathy.,Fatigue， orthostatic hypotension， hypokalemia， hyponatremia， allergic manifestations. Cardiovascular: Orthostatic hypotension， Vasculitis Dermatologic: Flushing， Hives， Pruritus， Rash Endocrine metabolic: Hyperuricemia， Hypochloremia (less than 5% )， Hypokalemia (3% to 7% )， Hyponatremia (less than 5% ) Neurologic: Dizziness， Fatigue， Headache， Paresthesia,30℃以下,1.5 mg once daily in the morning.,無需調整劑量,,需調整劑量,盡量避免,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效膜衣錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。
ONEG,Nalidixic Acid,Negram 500mg,QANB,,Acute and chronic urinary tract infection.,,,Adult: Initial， 1 g q6h for 1-2 wks; maintenance， 500 mg q6h(max. 4 g/day). Child over 3 months: Initial， 13.75 mg/kg q6h for 1-2 wks; maintenance， 8.25 mg/kg q6h.,,,,可能安全,,,,,,,,,,
ONEO,Neomycin,Neomycin 250mg,QANB,Bowel sterilisation before surgery; to reduce the bacterial population of the colon in hepatic failure.,Intestinal obstruction; myasthenia gravis.,Vestibular & auditory damage， nephrotoxicity， GI disturbances.,25℃以下，避光密封保存,(仿單) Adults: Intestinal infection: 500 mg orally Q6H. Bowel preparation， pre-GI surgery: 1 g orally Q6H for 1-3 days. (熱病) Hepatic encephalopathy: 500-2000 mg Q6-8H for 5-6 days; seek safer alternative for longer use.,無需調整劑量,以上懷孕分級參考micromedex,需調整劑量,盡量避免,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,以上懷孕分級參考micromedex,AC;AC15;PC;PO;WM;,,,,,
ONEW,Multivitamins + Minerals + Fe,New Prenatal 30's/bot,NUTR,,適應症: Nutritional supplement for vits & minerals during pregnancy & lactation.,,室溫,1 tab daily or as directed by the physician.,,,,安全,,,,,,,,,,
IIG5,Human Immunoglobulin,Gammar-P 5gm,HIMM,,I: Primary defective antibody synthesis such as hypogammaglobulinemia or gammaglobulinemia. Unlabeled use: Bacterial infections， idiopathic thrombocytopenic purpura， Kawasaki disease. ADR: Headache， myalgia， hypotension， nausea， abdominal pain， chills， pyrexia， palpitation， edema， flushing， diaphoresis， rash， pruritus， wheezing are often related to infusion rate. Increases in creatinine and BUN， oligouria or other types of severe renal adverse reactions has been observed. CI: Isolated IgA deficiency. Allergic to Ig or human albumin.,,< 25°C,Primary defective antibody synthesis: 100 ~ 200 mg/kg， up to 400 mg/kg. To be repeated every 3 ~ 4 wk at a level titrated to the individual， but in case of acute illness， it may be given as frequently as once a week or even daily. Serious bacterial infections including sepsis: As above， repeated every 1-2 days if needed. Idiopathic thrombocytopenic purpura & Kawasaki disease: 0.4 g/kg/day for 5 consecutive days.,,,,除非治療上需要,,,,,,,,,,
ILIP2,Soyean Oil + MCT+ Egg Yolk Phospholipids+ Glycerol,Lipofundin 20%， 250ml(成人),NUTR,,適應症: In parenteral nutrition for energy & essential fatty acids. 副作用: Adverse reactions directly related to fat emulsions in general are of 2 types: Immediate (Acute) Reactions: Dyspnea， cyanosis， allergic reactions， hyperlipaemia， hypercoagulability， nausea， vomiting， headache， flushing， hyperthermia， sweating， chills， sleepiness， chest and back pain. Delayed Reactions: Hepatomegaly， jaundice due to central lobular cholestasis， splenomegaly， thrombocytopenia， leucopenia， transient increases in liver function tests and overloading syndrome. The deposition of a brown pigmentation in the reticuloendothelial system， the so-called "IV Fat Pigment"， has also been reported. The cause and the significance of this phenomenon are unknown. 禁忌: Disturbances in fat metabolism; ketoacidosis， hypoxia， thromboembolism & acute shock states.,,室溫,Adult 1-2 g of fat/kg/day by IV infusion. Infusion rate of 1st 15 mins should not exceed 0.05-1.0 g/kg/hr. Max infusion rate up to 0.15 g/kg/hr.,,,,沒有資料,,,,,,,,,,
IOXA,Oxaliplatin,Oxalip inj 50mg/10mL,RACA,,適應症:Treatment of metastatic colorectal cancer that has been used with fluoropyrimidine failure. 副作用:Nausea， vomiting， diarrhea; anemia， leucopenia， granulocytopenia， thrombocytopenia; peripheral neuropathies; fever， rash， anorexia. Gastrointestinal: Abdominal pain (monotherapy， 31%; combination therapy， up to 39% )， Constipation (combination therapy， up to 32% )， Diarrhea (monotherapy， 46%; combination therapy， up to 76% )， Loss of appetite (monotherapy， 20%; combination therapy， up to 35% )， Nausea (monotherapy， 64%; combination therapy， up to 83% )， Stomatitis (monotherapy， 14%; combination therapy， up to 42% )， Vomiting (monotherapy， 4%; combination therapy， up to 64% ) Hematologic: Anemia (monotherapy， 64%; combination therapy， up to 81% )， Neutropenia， All grades (monotherapy， 7%; combination therapy， up to 81% ) Musculoskeletal: Backache Respiratory: Cough (monotherapy， 11%; combination therapy， up to 35% ) Other: Fatigue (monotherapy， 61%; combination therapy， up to 70% )， Fever (monotherapy， 25%; combination therapy， up to 29% ) 禁忌:Pregnancy， lactation,,室溫,Ovarian cancer: 130 mg/m2 every 3 weeks as single agent or in combination chemotherapy. Adult Adjuvant therapy 85 mg/m2 IV every 2 wk for 6 mth (12 cycles). Metastatic colorectal cancer 85 mg/m2 IV every 2 wk.,,Micromedex:Infant risk cannot be ruled out. No reports describing the use of oxaliplatin during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if oxaliplatin affects the quantity and composition of breast milk. Breastfeeding is not recommended while taking oxaliplatin due to the potential risk to the nursing infant. The manufacturer recommends making a decision to discontinue nursing or delay use of oxaliplatin in breastfeeding women.,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex:Infant risk cannot be ruled out. No reports describing the use of oxaliplatin during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if oxaliplatin affects the quantity and composition of breast milk. Breastfeeding is not recommended while taking oxaliplatin due to the potential risk to the nursing infant. The manufacturer recommends making a decision to discontinue nursing or delay use of oxaliplatin in breastfeeding women.,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 調配與注射cisplatin的器具不可含有鋁。本藥品不可使用含有氯的稀釋溶液 (例如：N/S)，給藥時避免和鹼性藥物(例如：5-FU)使用相同管路。 3. 稀釋後的輸注溶液在室溫下安定性維持6小時。 4. 監測CBC、腎功能，注意病人是否有呼吸方面的異常症狀。 5. 定期神經學檢測。
OHYP1,Barnidipine,Hypoca 10mg,CAVS,,適應症:高血壓(B023235100),,RT,【D】Initially 5-10 mg daily， may be increased to 10-15 mg daily.,,,,沒有資料,,,,,,,,,,
ILIPD1,Doxorubicin,Lipo-Dox inj 20mg (健保用),RACA,Treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 (< 200 CD4 lymphocytes/mm3) & diseases in mucosa， skin & internal organs. Treatment of metastasis carcinoma of the ovary in patients with disease that is recurrent to both 1st-line platinum- & paclitaxel-based chemotherapy regimens. As monotherapy for patients with metastatic breast cancer， where there is an increased cardiac risk.,Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal， conventional doxorubicin， or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic α-interferon,Infusion-associated acute reactions， stomatitis， Palmar-plantar erythrodysesthesia， cardiac toxicity. Nausea， leukopenia， neutropenia， anemia & thrombocytopenia. Asthenia， alopecia， fever， diarrhea. Resp infections， laboratory abnormalities. Dermatologic: Alopecia， Hand-foot syndrome due to cytotoxic therapy (ovarian cancer， 50.6% AIDS-related Kaposi's sarcoma， 3.4% multiple myeloma， 19% )， Rash (ovarian cancer， 28.5%AIDS-related Kaposi's sarcoma， 1% to 5% multiple myeloma， 22% ) Gastrointestinal: Constipation (multiple myeloma， 31% )， Diarrhea (ovarian cancer， 20.9%AIDS-related Kaposi's sarcoma， 7.8%multiple myeloma， 46% )， Loss of appetite (ovarian cancer， 20.1% AIDS-related Kaposi's sarcoma， 1% to 5%multiple myeloma， 19% )， Nausea (ovarian cancer， 46% AIDS-related Kaposi's sarcoma， 16.9%multiple myeloma， 48% )， Stomatitis (ovarian cancer， 41.4% AIDS-related Kaposi's sarcoma， 6.8%multiple myeloma， 20% )， Vomiting (ovarian cancer， 32.6%AIDS-related Kaposi's sarcoma， 7.8%multiple myeloma， 32%) Hematologic: Decreased platelet count (ovarian cancer， 13% to 24.2%; AIDS-related Kaposi's sarcoma， 60.9%; multiple myeloma， 33%)， Hemoglobin low (ovarian cancer， 40.2% to 52.6%; AIDS-related Kaposi's sarcoma， 55.4%; multiple myeloma， 25% )， Neutrophil count abnormal (ovarian cancer， 19% to 35.1%; AIDS-related Kaposi's sarcoma， 48.9%; multiple myeloma， 36%) Neurologic: Asthenia (ovarian cancer， 40.2% AIDS-related Kaposi's sarcoma， 9.9% multiple myeloma， 22% ) Psychiatric: Fatigue (multiple myeloma， 36%; ) Other: Drug fever (ovarian cancer， 21.3%AIDS-related Kaposi's sarcoma， 9.1%multiple myeloma， 31% ),2-8℃避免冷凍,[Breast cancer/Ovarian cancer] 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment. [Multiple myeloma] 30 mg/m2 on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m2 on days 1， 4， 8， and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart. [AIDS-related Kaposi sarcoma (AIDS-KS)] 20 mg/m2 once every 2-3 weeks for 2-3 months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response. Avoid intervals shorter than 10 days.,需調整劑量,,無需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能、尿酸與血中電解質濃度。 3.Pegylatedliposomal doxorubicin的累計劑量到450mg/m2時，需作左心室功能評估，並且在每增加100mg/m2給藥前再次評估. 450-600mg/m2並不會增加心臟毒性的危險性.
ETOBO,Tobramycin + Dexamethasone,Tobradex 眼藥膏 3.5gm,TOPH,Steroid-responsive inflammatory ocular conditions.,Epithelial herpes simplex keratitis (dendritic keratitis)， vaccinia， varicella & many other viral diseases of the cornea & conjunctiva. Mycobacterial eye infection. Fungal diseases of ocular structures. After uncomplicated removal of a corneal foreign body.,Localized ocular toxicity & hypersensitivity including lid itching & swelling & conjunctival erythema. Secondary infection.,8-27℃勿冷藏,Apply a 1-1.5 cm into the conjunctival sac up to three or four times daily or may be used adjunctively with drops at bedtime.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;OD;OL;OU;SKIN;TOPI;,,,,,
IENL,Edrophonium,Enlon inj 150mg/15mL,CNEU,,Enlon is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action， it is not recommended for maintenance therapy in myasthenia gravis.,,RT,Enlon Test for Evaluation of Treatment Requirements in Myasthenia Gravis: The recommended dose is 0.1 mL to 0.2 mL (1 mg to 2 mg) of EnlonR， administered intravenously one hour after oral intake of the drug being used in treatment. 1-5 Response will be myasthenic in the undertreated patient， adequate in the controlled patient， and cholinergic in the overtreated patient.,,,,沒有資料,,,,,,,,,,
ESIL,Silver Sulphadiazine,Siliverzine cream 1%， 20gm,TDER,Adjunct for the prevention & treatment of wound sepsis in patients with 2nd & 3rd degree burns.,Pregnancy， premature & newborn infants during 1st months of life.,Burning， rash， itching， interstitial nephritis.,避光,Burn treatment: Topical: Apply to a thickness of 1/16 inch QD -BID; reapply as needed to areas where the cream is removed by patient activity as the burned area should be covered with cream at all times. Continue use until healing has occurred.,無需調整劑量,參照 Sulfonamide,無需調整劑量,沒有資料,Human data suggest risk in 3 rd trimester,參照 Sulfonamide： Taken in sum， sulfonamides， as single agents， do not appear to pose a significant teratogenic risk. One study has found associations with birth defects， but a causative association cannot be determined with this type of study， and they may have been due to other factors， particularly if trimethoprim was combined with the sulfonamide. Confirmation is required. Because of the potential toxicity to the newborn， these agents should be avoided near term.,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,參照 Sulfonamide,EXT;SKIN;TOPI;,,,,,
IPAP1,Papaverine,Paparin inj 30mg/mL,CAVS,,適應症:緩解腦血管和末稍缺血ˋ緩解平滑肌痙攣等(A029287209),,,,,,,,,,,,,,,,,
IAMISA,Procainamide,Amisalin 200mg/2mL,CAVS,,Ventricular arrhythmia， atrial arrhythmia， atrial fibrilation.,,,Loading dose: 1 g over 2 hrs in 2 divided doses. Maintenance dose: 1-9 g/day in 4-6 divided doses. Child: 15-50 mg/kg/day， (max. 4 g/day).,,,,除非治療上需要,,,,,,,,,,
IPARB,Electrolyte + Dextrose,Paramental B inj 400mL,NUTR,,適應症: Fluid， electrolytes & calories supplement， especially for those who are poor-oral absorption or malnutrition 副作用:Hyperglycemia. At high dose or rapid administration: pulmonary & peripheral edema， acidosis. 禁忌:Hyperkalemia， hyperphosphatemia， hypermagnesemia， hypocalcemia， hepatic coma，severe renal insufficiency， disturbances in amino acid metabolism， peripheral parenteral administration.,,室溫,Mixed with 10-12% amino acid 200ml. Adult 1200-2400 mL daily IV infusion.,,,,沒有資料,,,Compatible 哺乳時可使用,,,,,,,1. 高張輸注液，限由中央靜脈導管給藥。 2. 本品專供藥劑科調配TPN製劑使用。
IPAV,Pancuronium,Pavulon inj 4mg/2mL,CNEU,,Adjunct to anesthesia to induce skeletal muscle relaxation， to facilitate the management of patients undergoing mechanical ventilation.,,,Adult and child: 0.04-0.1 mg/kg， later incremental doses starting at 0.01 mg/kg may be used. Neonate: 30-40 mcg/kg， then 10-20 mcg/kg.,,,,,,,,,,,,,,
IPCN3,Penicillin G,Penicillin G Sod inj 3百萬單位,QANB,,適應症:Bacterial endocarditis，Intrapartum prophylaxis against group B Streptoccocal infection in neonates， Meningococcal meningitis，Pneumococcal meningitis，Susceptible infection 副作用:Hypersensitivity reactions including uticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis. Potentially Fatal: Anaphylaxis. 禁忌:Hypersensitivity to penicillins,,,Staphylococcal/Streptococcal Endocarditis: Usual dosage: 5 to 24 million units/day IM in equally divided doses every 4 to 6 hours. Erysipeloid Endocarditis: Usual dosage: 12 to 20 million units/day IM in equally divided doses every 4 to 6 hours for 4 to 6 weeks. Listeria Endocarditis: Usual dosage: 15 to 20 million units/day IM in equally divided doses every 4 to 6 hours for 4 weeks. Sepsis: Meningococcal/Neisseria meningitidis: 2 million units IM every 2 hours; Streptococcus or Staphylococcus: 5 to 24 million units/day IM in equally divided doses every 4 to 6 hours. Actinomycotic infection: For abdominal or thoracic actinomycosis in adults， the recommended dose of penicillin G sodium 10 million to 20 million units IM per day， in divided doses every 4 to 6 hours. For cervicofacial infections， the recommended dose is 1 to 6 million units IM per day in divided doses every 4 to 6 hours. Anthrax: The recommended dose of penicillin G sodium for the treatment of anthrax in adults is a minimum of 8 million units IM daily in divided doses every 6 hours. Higher doses may be required based on the susceptibility of the pathogen. Diphtheria: Treatment and Prophylaxis - The recommended dosage of penicillin G sodium is 2 to 3 million units/day IM in divided doses every 4 to 6 hours for 10 to 12 days. Clostridial infection: The recommended dose of penicillin G sodium as adjunctive treatment for clostridial infection in adults is 20 million units per day IM in divided doses every 4 to 6 hours. Fusospirochetosis: For the treatment of susceptible strains of Fusospirochetosis in adults， the recommended dosage of penicillin G sodium is 5 to 10 million units IM daily in divided doses every 4 to 6 hours. Pasteurella infection: For the treatment of susceptible strains of Pasteurella infection， including bacteremia or meningitis in adults， the recommended dose of penicillin G sodium is 4 to 6 million units/day IM in divided doses every 4 to 6 hours for 2 weeks. Rat bite fever: For the treatment of rat-bite fever in adults， the recommended dose of penicillin G sodium is 12 million to 20 million units IM per day in divided doses every 4 to 6 hours for 3 to 4 weeks. Neurosyphilis: Usual dosage: 2 to 4 million units IM every 4 hours for 10 to 14 days. NEONATE ANTIBIOTICS DOSE Penicillin G: General infection ( IU/kg/dose) Body weight <1kg Age <=7 day 5萬IU/kg Q12H      Age 8-14 day 5萬IU/kg Q12H   Age 15-28 day 5萬IU/kg Q8H Body weight 1-2kg Age<=7 day 5萬IU/kg Q12H  Age 8-14 day 5萬IU/kg Q8H   Age 15-28 day 5萬IU/kg Q8H Body weight >2kg Age<=7 day 5萬IU/kg Q8H  Age 8-14 day 5萬IU/kg Q6H  Age 15-28 day 5萬IU/kg Q6H Meningitis: Body weight <1kg ge<=7 day 2.5萬IU/kg Q12H  Age 8-14 day 2.5萬IU/kg Q12H  Age 15-28 day 2.5萬IU/kg Q12H Body weight 1-2kg ge<=7 day 2.5萬IU/kg Q12H  Age 8-14 day 2.5萬IU/kg Q8H  Age 15-28 day 2.5萬IU/kg Q8H Body weight >2kg ge <=7 day  2.5萬IU/kg Q8H  Age 8-14 day 2.5萬IU/kg Q6H  Age 15-28 day 2.5萬IU/kg Q6H Congenital Syphilis: 5萬IU/kg/dose Q12H during the first 7 days of life， and thereafter 5萬IU/kg/dose Q8H， for a total of 10 days GBS meningitis: 50-60萬IU/kg/day (參考馬偕) Age<= 7 days: 25- 45萬IU/kg/day divided Q8H; Age 8-28 days : 45-50萬IU/kg/day divided Q6H (參考 NeoFax),無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,ID;IM;IVD;,IM: 3 mL D/W， N/S IV: 3 mL D/W， N/S,【N/S】可選 仿單建議。【D5W】可選 。,,建議以15 ~ 30分鐘緩慢滴注,1. 注射前檢查病患是否有PCN過敏史。 2. 注射高劑量 (每日大於1千萬單位) 時，應減慢注射速率並監測電解質狀態。 3. Penicillin G sodium 含鈉量：1.68 mEq/100萬單位 (每瓶含有5.04 mEq 鈉)。 4. (IV infusion) 以適當輸注液稀釋成 50，000-100，000 unit/mL，緩慢滴注15 ~ 30分鐘。 5. 滲透壓與周邊靜脈給藥最大稀釋濃度：154000 units/mL in D/W，76000 units/mL in N/S，85000 units/mL in D5W。
IPED,Haemophilus b Conjugate Vaccine,培定冒,HIMM,,Routine immunization against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age.,,,IM only. 2 to 14 months of age: 0.5 ml dose of vaccine ideally beginning at 2 months of age followed by a 0.5 ml dose 2 months later. When the primary 2-dose egimen is completed before 12 monthsof age， a booster dose is required. 15 months of age and older: Children 15 months of age and older previously unvaccinated against Haemophilus B disease should receive a single 0.5ml dose of vaccine. Booster dose: In infants completing the primary 2-dose regimen before 12 months of age ， a booster dose (0.5ml) should be administered at 12 to 15 months of age but not earlier than 2 months after the second dose.,,,,,,,,,,,,,,
IPEN0,Thiopental,Pentothal inj 0.5mg,ZANE,,,,,,,,,,,,,,,,,,,
IPENV,Thiopental,Pentothal 2.5gm,ZANE,,適應症:Anaesth for brief surgical procedures， induction of anaesth prior to administration of other anaesth agents， control of convulsive states， supplement to regional anaesth or low potency agents， aid in diagnosis & treatment of psychiatric disorders. 副作用:Drowsiness; tolerance， dependence， withdrawal effects including seizures. 禁忌:Absence of suitable veins; status asthmaticus; porphyria,,RT,Induction of anesthesia & induce hypnosis Adult test dose 25-75 mg， then 50-75 mg at 20-40 sec intervals IV. Children IV 3-5 mg/kg initially， followed by 1 mg/kg if needed Convulsions Adult IV 75-125 mg. Narcoanalysis IV 100 mg/min until confusion occurs.,,,,除非治療上需要,,,,,,,,,,
IPETBAD,Meperidine,Pethidine inj 50mg/1mL殘餘銷燬,CNEU,Relief of pain， preoperative medication anesthesia support.,,,,Analgesic: Adult: IM or SC 50-150 mg q3-4h. Child: 1.1-1.76 mg/kg q3-4h. Obstetrical analgesia: IM or SC， 50-100 mg， administered when pains become regular， may be repeated at 1-3 hrs intervals. Preoperative: Adult: IM or SC， 50-100 mg 30'-90' prior to anesthesia. Child: 1-2.2 mg/kg. Adjunct to anesthesia: IV: Slow injection of fractional doses of a soln diluted to 10 mg/ml. IVF: As a soln diluted to 1 mg/ml.,無需調整劑量,,需調整劑量,可能安全,Human data suggest low risk,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,,,,,
IPHA,Epirubicin,Pharmorubicin inj 10mg,RACA,,適應症:Adjuvant therapy component for primary breast cancer in patients with evidence of axillary node involvement following tumor resection. 副作用:Myelosuppression， cardiotoxicity， alopecia， mucositis， GI disturbances， hyperpyrexia. 禁忌:Hypersensitivity to epirubicin， other anthracyclines， anthracenediones， or any component of the formulation; cardiomyopathy and/or heart failure， recent myocardial infarction， severe arrhythmias; previous treatment with anthracyclines up to the maximum cumulative dose. Marked persistent myelosuppression induced by prior treatment with other chemotherapy agents or by radiotherapy; severe hepatic impairment.,,室溫,Breast cancer， adjuvant treatment: IV: Usual dose: 100 to 120 mg/m2 per 3- or 4-week treatment cycle as follows: 60 mg/m2 on days 1， 8 every 28 days for 6 cycles in combination with cyclophosphamide and fluorouracil or 100 mg/m2 on day 1 every 21 days for 6 cycles in combination with cyclophosphamide and fluorouracil.,需調整劑量,,無需調整劑量,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,IA;IRR;IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能、尿酸與血中電解質濃度。
IPHA1,Epirubicin,Pharmorubicin inj 1mg,RACA,,,,,,,,,,,,,,IVD;,,,,,
ETES,Testosterone + K-Y,Testoviron K-Y,HM,,,,,,,,,,,,,,,,,,,
EINTC,Indomethacin,InteBan cream 1%， 25gm,CNEU,,適應症: Alleviation of pain. 副作用: GI upsets， headache， dizziness， tinnitus， lightheadedness， depression， insomnia， psychiatric disturbances， peripheral neuropathy， blurred vision， confusion; hyperglycaemia， hyperkalaemia. Gastrointestinal: Abdominal pain (1% to 3% )， Constipation (1% to 3% )， Diarrhea (1% to 3% )， Indigestion (3% to 9% )， Nausea (3% to 9% ) Neurologic: Dizziness， Headache， Somnolence Otic: Tinnitus Psychiatric: Depression Other: Fatigue 禁忌: Active peptic ulcer; pregnancy (3rd trimester)， hypersensitivity to aspirin and other NSAIDs; treatment of perioperative pain in CABG surgery; severe renal impairment; rectal admin in patients with proctitis and haemorrhoids; neonates with necrotizing enterocolitis， active bleeding， thrombocytopenia， coagulation defects and untreated infections.,,室溫,Antirheumatic and antipyretic: Oral， 25-50 mg bid-tid. Rectal， 50-100 mg qd-bid. Acute gout: 100 mg initially， then 50 mg tid until pain is relieved. For patent ductus arteriosus closure in neonate: Oral(via a nasogastric tube)， 0.2 mg/kg initially. If necessary， 1-2 additional doses of 0.1-0.25 mg/kg may be given at 12 hrs intervals.,,,,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ETIM2,Timolol,Timoptol 0.25% 5mL,TOPH,,適應症:青光眼(B019247421),,RT,Initial: 1 gtt bid Maintenance: 1 gtt qd.,,,,除非治療上需要,,,,,,,,,,
ETIM5,Timolol,Timoptol 0.5% 5mL,TOPH,Glucoma.,Bronchial asthma or a history of bronchial asthma， severe COPD. Sinus bradycardia， 2nd and 3rd degree AV block， overt cardiac failure， cardiogenic shock.,Transient blurred vision， burning and stinging， conjunctival infection， discharge， foreign body sensation， itching. Ocular irritation and visual disturbances. Bradycardia， arrhythmia， hypotension， syncope， heart block， CVA， cerebral ischaemia， CHF， palpitation， cardiac arrest， oedema， claudication， Raynaud's syndrome， cold hands and feet. Bronchospasm， respiratory failure， dyspnoea， cough. Headache， asthenia， fatigue， chest pain. Alopecia， psoriasiform rash or exacerbation of psoriasis. Allergic reactions. Dizziness， depression， insomnia， nightmares， memory loss， paraesthesia. Increase in signs and symptoms of myasthenia gravis. Nausea， diarrhoea， dyspepsia， dry mouth. Decreased libido， Peyronie's disease. SLE. Ocular irritation， visual disturbances， bradycardia， arrhythmia， hypotension， syncope， heart block， CVA， cerebral ischemia， CHF; palpitation， cardiac arrest， bronchospasm in patients with pre-existing bronchospastic disease; respiratory failure， dyspnea， hypersensitivity reactions.,避光且30℃以下,Adult: Initial: 0.25% Timoptol 1 drop BID then titrate to 0.5% Timoptol 1 drop BID with poor efficacy. Maintenance: 1 drop QD. Child: Initial: 0.25% Timoptol 1 drop Q12H then titrate to 0.5% Timoptol 1 drop Q12H when necessary. Do not suggest using Timoptol to premature Infant or infant.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;OD;OL;OU;,,,,,
ETRU,Dorzolamide,Trusopt 2%， 5mL ophthalmic solution,TOPH,Raised intraocular pressure， open-angle glaucoma,Hypersensitivity to dorzolamide or any product component. CrCl < 30 mL/min.,Bitter taste in mouth， hypersensitivity reaction (ocular)， burning sensation in eye， superficial punctate keratitis， visual discomfort. Stevens-Johnson syndrome， toxic epidermal necrolysis， metabolic acidosis， aplastic anemia， thrombocytopenia， choroidal detachment， corneal decompensation， urolithiasis， angioedema.,30℃以下避光,Raised intraocular pressure， In patients with ocular hypertension or open-angle glaucoma: 1 drop into affected eye(s) 3 times daily. As an adjuvant therapy with an ophthalmic beta-blocker: 1 drop into affected eye(s) 2 times daily.,無需調整劑量,[仿單]目前並不清楚TRUSOPT是否會分泌至人類的乳汁中。於哺乳大鼠中， 發現子鼠的體重增加幅度減少。如果必須以TRUSOPT進行治療，則不建議哺乳。,需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]懷孕期間不可使用TRUSOPT。目前無懷孕女性使用藥物的臨床資料。 在兔子體內，投予具母體毒性劑量的TRUSOPT會產生致畸胎作用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並不清楚TRUSOPT是否會分泌至人類的乳汁中。於哺乳大鼠中， 發現子鼠的體重增加幅度減少。如果必須以TRUSOPT進行治療，則不建議哺乳。,OD;OL;OU;,,,,,1. 含benzalkonium chloride防腐劑，可能會造成眼睛刺激。點藥前應先摘除隱形眼鏡並至少等待15分鐘才可重新配戴。Benzalkonium chloride已知會造成軟性隱形眼鏡變色。
EVENN,Salbutamol,Ventolin Nebule 5mg/2.5mL,ERSP,,適應症: Routine management of bronchospasm unresponsive to conventional therapy; acute severe asthma. 副作用: Fine tremor of skeletal muscle， feelings of tension， peripheral vasodilation， a compensatory small increase in heart rate， headaches， transient muscle cramps， hypersensitivity reactions， potentially serious hypokalaemia， hyperactivity in children， tachycardia， cardiac arrhythmias. Mouth & throat irritations (inhalers). 禁忌: Threatened abortion. Inhaled prep not appropriate for managing premature labour.,,室溫,Initially 2.5-5 mg， may be repeated up to qid via a nebuliser.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
EVENR,Salbutamol,Ventolin respirator soln 1mL,ERSP,,適應症: Routine management of bronchospasm unresponsive to conventional therapy; acute severe asthma. 副作用: Fine tremor of skeletal muscle， feelings of tension， peripheral vasodilation， a compensatory small increase in heart rate， headaches， transient muscle cramps， hypersensitivity reactions， potentially serious hypokalaemia， hyperactivity in children， tachycardia， cardiac arrhythmias. Mouth & throat irritations (inhalers). 禁忌: Threatened abortion. Inhaled prep not appropriate for managing premature labour.,,室溫,Intermittent administration Adult 0.5-1 mL diluted to a final vol of 2-2.5 mL nebulised & administered over 10 mins. Or 2 mL of undiluted soln over 3-5 mins. Children <12 years 0.5 mL diluted to a final vol of 2-2.5 mL. Some children may require higher doses up to 1 mL. Continuous administration Dilute soln to contain 50-100 mcg salbutamol/mL & administer as an aerosol at rate of 1-2 mg/hr.,,,,除非治療上需要,,,,,,,,,,
EVOR,Diclofenac,Voren-G gel 10mg/gm 30gm,CNEU,,An analgesic， antipyretic， anti-inflammatory agents used in RA. and other rheumatic disorders.,,,Adult: 50 mg qd-bid. Child: 0.5-1 mg/kg qd-bid.,,,,,,,,,,,,,,
ITRI,Nitroglycerin,Tridil inj 25mg/5mL,CAVS,,I: Treatment and prophylaxis of angina pectoris. CI: Severe hypotension， severe anemia， constrictive pericarditis， extreme bradycardia， G6PD deficiency， cerebral hemorrhage & brain trauma， circulatory collapse， cardiogenic shock， toxic pulmonary edema. Avoid coadministration with sildenafil.,,,IV infusion: Initially， 5 mcg/min; may be increased by 5 mcg/min q3-5 mins until a response is noted.,,,,除非治療上需要,,,,,,,,,,
IXYL10,Lidocaine,Xylocaine 10% inj 10mL,ZANE,,Ventricular arrhythmias in connection with myocardial infarction.,,,Antiarrhythmic: IV (loading dose): 1 mg/kg at a rate of 25-50 mg/min， repeated after 5 mins if necessary， up to 300 mg/hr. IV continuous infusion: Diluted with 5% dextrose， at a rate of 1-4 mg/min. IM: 4.3 mg/kg， repeated after 60-90 mins if necessary. Anticonvulsant (status epilepticus): IV continuous infusion: 1-3 mg/min following a usual loading dose.,,,,可能安全,,,,,,,,,,
IZIN2,Cefuroxime,Zinacef 250mg,QANB,,Respiratory tract and soft tissue infections， serious infections pending bacteriology， Meningitis， Prophylaxis against infection in surgical procedures， UTI and gonorrhoea.,,,IV， IV infusion or IM， Adult: 0.75-1.5 g q8h， up to 1.5 g q6h. For bacterial meningitis: Max. 3-6 g/day in 3-4 divided doses. Child & infant over 3 Months: 30-100 mg/kg/day in 3-4 divided doses. For bacterial meningitis: 150-250 mg/kg/day in 3-4 divided doses.,,,,可能安全,,,,,,,,,,
LUPE,Ibuprofen,U-Pedia 20mg/mL， 60mL,CNEU,,Analgesic， antipyretic & anti-inflammatory.,,,Adult:20-30ml tid. Child: 0.75-2ml / kg / day,,,,,,,,,,,,,,
LXYLV,Lidocaine,Xylocaine viscous 2%， 100mL,ZANE,,適應症: Oropharynx， larynx， esophageal， bronchial & gastric exam. Local anaesth. 副作用: Intoxication， cutaneous & hypersensitivity symptoms. Drowsiness， anxiety， excitement， blurred vision， nausea， dizziness & vomiting. 禁忌: Known history of hypersensitivity to local anaesthetics of the amide type or other components of Xylocaine Viscous， eg methyl and propyl parahydroxybenzoate.,,室溫,Adult 5-15 mL once-tid.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ORIV5,Clonazepam,Rivotril 0.5mg,CNEU,Majority of clinical forms of epileptic disease in infants & children especially typical or atypical petit mal epilepsy， tonic-clonic seizures， status epilepticus. Adult epilepsies & in focal seizures.,,Tiredness， sleepiness， lassitude， muscular hypotonia， muscle weakness， dizziness， lightheadedness， ataxia， slowed reaction， poor conc.， restlessness， confusion， disorientation; anterograde amnesia， depression. Increased production of saliva or of bronchial secretions in infants & young children.,於30℃以下。避免光照。,Adult 4-8 mg. Children >6 years 3-6 mg， Small children 1.5-3 mg. Infant 0.5-1 mg. Divided into 3 or 4 doses daily.,無需調整劑量,[仿單]雖然已發現Rivotril的活性成分只有小部分會進入母乳中，進行此藥治療的母親仍不應該授乳。如果必須要使用Rivotril，則應停止授乳。,無需調整劑量,沒有資料,Human data suggest low risk,[仿單]從臨床前研究中，並不能排除clonazepam具有產生先天性畸形的可能性。從流行病學的資料評估，亦顯示抗痙攣藥可能為致畸胎原；然而，從發表的流行病學報告中，很難去決定是那一個藥物或那一群併用藥物造成新生兒的缺陷。其他因素如遺傳因子或癲癇狀況本身可能在導致先天缺陷的過程中較藥物扮演更重要角色的可能性也仍然存在。在這些前提下，只有當可能的效益勝過對胎兒的危險性時，才可給予孕婦此藥。在懷孕期，只有當必需要使用Rivotril時，才可給予。在懷孕的最後三個月或分娩時給予高劑量Rivotril，可能造成未出生兒的心跳不規則，新生兒的體溫過低、肌張力過低、輕度呼吸抑制和餵食困難。此外，亦應切記懷孕本身和突然停藥兩者皆可能加重癲癇的病情。Benzodiazepines造成新生兒發生戒斷症狀偶爾會被通報。,Compatible 哺乳時可使用,[仿單]雖然已發現Rivotril的活性成分只有小部分會進入母乳中，進行此藥治療的母親仍不應該授乳。如果必須要使用Rivotril，則應停止授乳。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
ODIC1,Diclofenac,Diclofenac 100mg S.R. F.C.,CNEU,Rheumatism， acute musculoskeletal disorders， post-traumatic & post-op inflammation & swelling.,Patients sensitive to aspirin or other NSAIDs.,GI disturbances. Peptic ulceration. GI bleeding. Headache， dizziness， nervousness， skin rash， pruritus， tinnitus， edema， depression， drowsiness， insomnia， & blurred vision. Hypersensitivity. Impairment of liver & kidney function. Agranulocytosis & thrombopenia. Dermatologic: Application site reaction (gel: all reactions， 7%; dermatitis， 4% to 11% ) Hematologic: Blood coagulation disorder (1% to 10% ) Ophthalmic: Burning sensation in eye (15% )， Keratitis (up to 28% )， Lacrimation and lacrimal drainage - finding (up to 30% )， Raised intraocular pressure (up to 15% ),25℃以下避光,100 mg QD， swallowed whole,無需調整劑量,,需調整劑量,除非治療上需要,Human data suggest risk in 1st and 3 rd trimesters,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為緩釋錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。若有磨粉管灌需求可改用院內同成分Cataflam 25mg。
IDIG,Digoxin,Digosin 針劑 0.25mg/1mL,CAVS,,I: CHF， artrial fibrilation， atrial flutter， paroxysmal atrial tachycardia. CI: AV block， SA block， digitalis intoxication， obstructive cardiomyopathy.,,,Adult and child over 10 yrs: IV slowly: Digitalization: 0.25-0.5 mg followed by 0.25 mg q4-6h as needed， not exceeding 1 mg/day. Maintenance: 0.125-0.5 mg/day. Infant and child under 10 yrs: IV slowly: Digitialization: 1/4-1/2 of the total digitalizing dose given initially， followed by 1/4 dose q6h for 2-3 doses. 2-10 yrs: 0.025-0.04 mg/kg. 2 wks-2 yrs: 0.035-0.05 mg/kg. Under 2 wks: 0.025-0.04 mg/kg. Maintenance: 1/5-1/3 of the total digitalizing dose， qd.,,,,除非治療上需要,,,,,,,,,,
IANX,Lorazepam,Anxicam inj 2mg/1mL,CNEU,Insomnia， anxiety & tension.,Sleep apnea; severe respiratory insufficiency; not for primary treatment of psychosis or depressive disorders,Sedation; dizziness; muscle weakness; ataxia; disorientation; depression; change in appetite; headache; sleep disturbance; agitation; dermatological symptoms， eye function disturbance; minor GI symptoms; autonomic manifestations; blood dyscrasias; elevated liver enzymes. Paradoxical reactions eg stimulation & rage (rare). Hypotension. Neurologic: Asthenia (4.2% )， Dizziness (6.9% )， Sedated (15.9% )， Unsteadiness present (3.4% )， Vertigo Psychiatric: Depression,2-8℃,Adults: IM: 0.05mg/kg， maximum dose: 4mg. 2 hours before surgery. Direct deep intramuscular injection without dilution. IV: 0.044mg/kg or totally 2mg， 15-20 minutes before surgery. Dilute with an equal volume of saline or water for injection. Slow injection， limited to a rate of 2 mg/min. Excluding those over 50 years old. Children: Dose not determined.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;IVP;IVPUSH;,,【N/S】可選 。,IV注射速率應2mg/分鐘以下，用等體積生理食鹽水或注射用水稀釋。,應使用non-PVC材質，用等體積生理食鹽水或注射用水稀釋。,1.未稀釋可deep IM。 2.IV常用劑量:0.044mg/kg或總量2mg。 3.應使用non-PVC材質。 4.dilute with an equal volume of compatible solution immediately prior to use; mix thoroughly by gently inverting the container until homogenous; do not shake vigorously. 5.diluted solution may be injected directly into a vein or into the tubing of an existing IV infusion.
EZOR,Tazarotene,Zorac cream 0.1%， 30gm,TDER,,適應症: Stable plaque psoriasis， acne vulgaris. 副作用: Pruritus， burning/stinging， erythema， worsening of psoriasis， irritation， pain， rash， desquamation， irritation， contact dermatitis. 禁忌: Pregnancy.,,室溫,Apply once daily at night.,,,,不可使用,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OAMO2,Amoxicillin,Amoxicillin 250mg,QANB,G(+) & G(-) infections,Hypersensitivity to penicillins.,Nausea， vomiting， diarrhea， glossitis， stomatitis， black hairy tongue; skin rashes， urticaria， exfoliative dermatitis， erythema multiforme; anemia， thrombocytopenia， eosinophilia， leukopenia， agranulocytosis.,室溫避光,Infection of upper respiratory tract， genitourinary tract and skin/soft tissue: Adult: 250-500 mg orally once every 8 hours; children: 20-40 mg/kg/day in divided doses every 8 hours. Lower respiratory tract infection: Adult: 500 mg every 8 hours; children: 40 mg/kg/day in divided doses every 8 hours. Children > 20 kg should be dosed according to the adult recommendations. Gonorrhea， acute uncomplicated genitourinary tract infections caused by N. gonorrhoeae in males and females: Adult: 3 g as single oral dose. All patients with gonorrhea should be evaluated for syphilis. The following Pediatric dose recommendation is from Sanford Guide to Antimicrobial Therapy.(2022/11/08): Age>28 days: 25-100mg/kg/day divided Q8-12H.,無需調整劑量,,需調整劑量,可能安全,Human data suggest risk in 1st and 3 rd trimesters,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
ILIPO2,Soybean Oil,Lipovenoes 20% 100mL(小兒TPN用),NUTR,,,,,,,,,,,,,,IVD;,,,,,
OISM,Isosorbide 5-Mononitrate,Ismo 20mg,CAVS,,適應症: Prophylaxis of angina pectoris. 副作用: Transient headache， nausea， dizziness， weakness， vomiting， tachycardia， decreased BP， possible formation of methemoglobin， rarely allergic skin reactions. Neurologic: Dizziness (8% to 11% )， Headache (38% to 57% ) 禁忌: Marked hypotension， hypertrophic obstructive cardiomyopathy， constrictive pericarditis， aortic & mitral stenosis， increased intracranial pressure， MI with low filling pressure. Avoid sildenafil， tadalafil， vardenafil.,,室溫,20 mg bid. Dose may be increased to 20 mg tid.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IPHA5,Epirubicin,PHARMORUBICIN inj 50mg,RACA,,適應症:Adjuvant therapy component for primary breast cancer in patients with evidence of axillary node involvement following tumor resection. 副作用:Myelosuppression， cardiotoxicity， alopecia， mucositis， GI disturbances， hyperpyrexia. 禁忌:Hypersensitivity to epirubicin， other anthracyclines， anthracenediones， or any component of the formulation; cardiomyopathy and/or heart failure， recent myocardial infarction， severe arrhythmias; previous treatment with anthracyclines up to the maximum cumulative dose. Marked persistent myelosuppression induced by prior treatment with other chemotherapy agents or by radiotherapy; severe hepatic impairment.,,室溫,Breast cancer， adjuvant treatment: IV: Usual dose: 100 to 120 mg/m2 per 3- or 4-week treatment cycle as follows: 60 mg/m2 on days 1， 8 every 28 days for 6 cycles in combination with cyclophosphamide and fluorouracil or 100 mg/m2 on day 1 every 21 days for 6 cycles in combination with cyclophosphamide and fluorouracil.,需調整劑量,,無需調整劑量,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,IA;IRR;IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能、尿酸與血中電解質濃度。
IPITA,Piperacillin,Pitamycin inj 2gm,QANB,,Systemic and local infections caused by G(+) (NOT resistant staphy. and enterococci)， G(-) (includes klebsiella， enterobacter， Pseudomonas anaerobes cluding B. fragilis.,,,IV or IM (under 2g per injection site). Max. 24 g/day. Severe Infection: IM or IV， 200-300 mg/kg/day in 4-6 divided doses. Complicated UTI: IV， 125-200 mg/kg/day in 3-4 divided doses. Uncomplicated UTI: IM or IV， 100-125 mg/kg/day in 2-4 divided doses.,,,,可能安全,,,,,,,,,,
ODOXY,Doxycycline,Doxymycin 100mg enteric coated,QANB,Rickettsial， chlamydial， mycoplasmal infection.,Pregnancy. Children <12 years. SLE.,Gastrointestinal effects; photosensitivity; enamel hypoplasia， tooth discoloration; hypersensitivity reactions. Rarely， bone marrow depression; oesophagitis & oesophageal ulceration.,25℃以下避光,(仿單) Adults: 200 mg in 1-2 divided doses on day 1， followed by 100-200 mg/day since day 2. (熱病) Pediatric: usual dose: 2-4.4 mg/kg/day， divided Q12H (maximum: 200 mg/day; maximum duration : 21 days),無需調整劑量,,無需調整劑量,盡量避免,Contraindicated – 2nd and 3 rd trimesters,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為腸溶膠囊，可拆膠囊後服用。但不可將膠囊內的腸溶微粒研磨或壓碎。
ODUP,Dydrogesterone,Duphaston 5mg,HM,,適應症: Infertility ，endometriosis ，amenorrhea ，uterine bleeding ，Postmenopausal complaints 副作用: During the clinical use of Duphaston， side effects eg， virilization were never seen. However， breakthrough bleeding does occur occasionally. 禁忌:None known.,,RT,Dysmenorrhoea: 10 mg twice daily from day 5 to day 25 of the cycle. Endometriosis: 10 mg 2 or 3 times daily from day 5 to day 25 of the cycle or continuously. Dysfunctional Bleeding: To Arrest bleeding: 10 mg twice daily with an oestrogen once daily for 5-7 days. Tto Regulate Bleeding: 10 mg twice daily together with an oestrogen once daily from day 11 to day 25 of the cycle， together with 10 mg dydrogesterone twice daily from day 11 to day 25 of the cycle. Premenstrual Syndrome: 10 mg twice daily from day 11 to day 25 of the cycle. Infertility or Irregular Cycles: 10 mg twice daily from day 11 to day 25 of the cycle. Threatened Abortion: 40 mg at once， then 10 mg every 8 hrs until symptoms remit. Habitual Abortion: 10 mg twice daily until the 20th week of pregnancy. Postmenopausal Complaints (HRT): In combination with continuous oestrogen therapy， 10-20 mg dydrogesterone daily during the last 12-14 days of each cycle. In combination with cyclical oestrogen therapy， 10-20 mg dydrogesterone daily during the last 12-14 days of oestrogen therapy.,,,,沒有資料,,,,,,,,,,
OERGO,Ergometrine,Ergometrine 0.2mg,SGU,Postpartum haemorrhage caused by uterine atony.,Threatened spontaneous abortion， vascular diseases， impaired renal or hepatic function， pregnancy， induction of labor.,Nausea， vomiting， headache， dizziness， abdominal pain， hypertension， bradycardia， dyspnea， ergotism.,25℃以下避光,Adult 1 tablet TID. the maximum dose: 2 mg/day. [Micromedex 2021/08/04] Postpartum hemorrhage; Treatment and Prophylaxis: Minimization of late postpartum hemorrhage， 0.2 to 0.4 mg (1 or 2 tablets ) orally or sublingually every 6 to 12 hours until the danger of uterine atony has passed， usually 48 hours.,無需調整劑量,Micromedex: Infant risk has been demonstrated. METHYLERGONOVINE MALEATE BREASTFEEDING RECOMMENDATION: Compatible,無需調整劑量,不可使用,Uknown 沒有資料,Micromedex: Fetal risk cannot be ruled out. METHYLERGONOVINE MALEATE PREGNANCY RECOMMENDATION: Contraindicated,Unknown 沒有資料,Micromedex: Infant risk has been demonstrated. METHYLERGONOVINE MALEATE BREASTFEEDING RECOMMENDATION: Compatible,AC;AC15;PC;PO;WM;,,,,,
OERI,Fludiazepam,Erispan 0.25mg,CNEU,,適應症: Anxiety， insomnia & muscle spasm. 副作用:Dependence， irritability， excitation， confusion， dizziness， dull headache， tremor， ataxia， visual disturbances， dizziness on standing up， delirium， amnesia， insomnia， vivid dreams， dyslalia， increased AST/ALT， dry mouth， anorexia， GI discomfort， rash， pruritus， fatigue， malaise， muscle weakness， decreased libido， dysuria， yawning， closed pharynx sensation， numbness of tongue & hands， diaphoresis， slight fever， enlarged axillary glands， urinary incontinence， premenstrual tension， alopecia. 禁忌: Acute narrow angle glaucoma， serious myasthenia,,室溫,May be taken with or without food Adult 0.75 mg in 3 divided doses， adjusted according to age & symptoms.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OEUG,Glibenclamide,Euglucon 5mg(Glibenclamide),META,,I: Diabetes mellitus. (NIDDM) ADR: Hypoglycaemia， temporary visual impairment esp at the start of treatment， GI disturbance. Rarely， mild to severe thrombocytopenia. Isolated cases of haemolytic anemia， hypersensitivity reactions. CI: Type I IDDM， diabetic ketoacidosis， diabetic precoma or coma. Severe renal or hepatic dysfunction. Pregnancy & lactation.,,RT,Initial， 2.5-5 mg/day with breakfast， increased as needed; (max daily dose: 20 mg ).,,,,可能安全,,,,,,,,,,
OEUR,Estazolam,Eurodin 2mg,CNEU,Insomnia.,Myasthenia gravis. Pregnancy， lactation.,Dependence， somnolence， confusion， dizziness， coordination abnormal， headache， dull headache & other psychotic disturbances. Respiratory depression. Anemia， leukopenia. Hypotension. Nausea， dry mouth. Fatigue， edema.,15-30℃緊密容器,2mg-4mg(1- 2 TAB) at bedtime. Increase or decrease according to age and medical condition.,無需調整劑量,,無需調整劑量,不可使用,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
ITT2,Electrolytes + Water,台大 No.2 500mL,MSIV,Fluid， electrolytes & calories supplement.,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30℃以下,Central vein or peripheral vein infusion， as needed. Taita No.1: Na 25mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 20mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 38g/L， 500mL/Bot， 300mOsm/L. Taita No.2: Na 40mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 26mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 33g/L， 500mL/Bot， 287mOsm/L. Taita No.3: Na 75mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 61mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 20g/L， 500mL/Bot， 285mOsm/L. Taita No.4: Na 110mEq/L， K 20mEq/L， Mg 0mEq/L， Cl 102mEq/L， Acetate 16mEq/L， Phosphate 12mM/L， Glucose 8g/L， 500mL/Bot， 300mOsm/L. Taita No.5: Na 36mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 17mEq/L， Acetate 28mEq/L， Phosphate 12mM/L， Glucose 100g/L， 400mL/Bot， 669mOsm/L.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,特點及適應症 Taita No.1: Na、Cl 是各台大電解質輸液中含量最低；小兒用維持液、電解質、水份、養份補充 Taita No.2: 成分與Taita No.1相似但Na、Cl較多;熱量及K含量較低，可作為小兒或成人用維持液 Taita No.3: NaCl含量似0.45 %N/S，可用於等張性脫水、糖尿病性酸中毒 Taita No.4: Na、K、Cl是各台大電解質輸液中含量最高，可用於低張性脫水、低磷血症 Taita No.5: 台大電解質輸液系列中，含Acetate及熱量最高，可用於高熱量電解質補充液、低磷血症
ITT3,Electrolytes + Water,台大 No.3 500mL,MSIV,Supplement of water， electrolytes and nutrition,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30℃以下,Central vein or peripheral vein infusion， as needed. Taita No.1: Na 25mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 20mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 38g/L， 500mL/Bot， 300mOsm/L. Taita No.2: Na 40mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 26mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 33g/L， 500mL/Bot， 287mOsm/L. Taita No.3: Na 75mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 61mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 20g/L， 500mL/Bot， 285mOsm/L. Taita No.4: Na 110mEq/L， K 20mEq/L， Mg 0mEq/L， Cl 102mEq/L， Acetate 16mEq/L， Phosphate 12mM/L， Glucose 8g/L， 500mL/Bot， 300mOsm/L. Taita No.5: Na 36mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 17mEq/L， Acetate 28mEq/L， Phosphate 12mM/L， Glucose 100g/L， 400mL/Bot， 669mOsm/L.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,特點及適應症 Taita No.1: Na、Cl 是各台大電解質輸液中含量最低；小兒用維持液、電解質、水份、養份補充 Taita No.2: 成分與Taita No.1相似但Na、Cl較多;熱量及K含量較低，可作為小兒或成人用維持液 Taita No.3: NaCl含量似0.45 %N/S，可用於等張性脫水、糖尿病性酸中毒 Taita No.4: Na、K、Cl是各台大電解質輸液中含量最高，可用於低張性脫水、低磷血症 Taita No.5: 台大電解質輸液系列中，含Acetate及熱量最高，可用於高熱量電解質補充液、低磷血症
IV2112Z,Insulin Syringe,1mL 胰島素空針,ZOTH,,適應症:為胰島素空針(NCS030510NBD),,,,,,,,,,,,,,,,,
IVAL,Diazepam,Valium inj 10mg/2mL,CNEU,,Anxiety， acute alcohol withdrawal， anticonvulsant.,,RT,IM or IV， 2-10 mg may be repeated after 4 hrs.,,,,盡量避免,,,,,,,,,,
IVAR1,Varicella Virus Vaccine,免費水痘疫苗(北市),HIMM,,適應症: Active immunisation against varicella of healthy infants from 12 months onwards， susceptible high-risk patients & their susceptible healthy close contacts. 副作用: Fever. Occasionally， papulovesicular eruptions. 禁忌: Pregnancy. Acute febrile illness. Total lymphocyte count < 1200/mm3. Hypersensitivity to neomycin.,,2-8℃,intradermal， 0.5ml / dose (children > 12 months， < 12 yrs),,,,除非治療上需要,,,,,,,,,,
IVC5,Ascorbic Acid,Vitamin C (Vitacicol) inj 100mg/2mL,NUTR,Scurvy， adjunct in treatment of wounds and infections.,Hypersensitivity to any component of the preparation. (Vitacicol contains Benzyl Alcohol 10mg per mL),Common Dermatologic: Injection site pain， Swelling at injection site Serious Hematologic: Hemolysis Renal: Oxalate nephropathy,25℃以下，避免光線照射,1-2mL per day. Maybe more times a day in severe cases. [Uptodate 20210731] Ascorbic acid deficiency: IM， IV， SC: 70 to 150 mg daily is an average protective dose; doses 3 to 5 times the recommended dietary allowance may be adequate for conditions with increased requirements. Burns: IM， IV， SC: 1 to 2 g daily for severe burns; dose may be determined by extent of tissue injury. Parenteral nutrition， maintenance requirement: IV: 200 mg/day (ASPEN 2019). Scurvy: IM， IV， SC: 300 to 1，000 mg daily; dose and duration of therapy should be individualized; doses up to 6 g per day have been administered. Ascor: IV: 200 mg once daily for up to a maximum of 7 days. If no improvement after one week of treatment， retreat until resolution of symptoms is observed. Wound healing: IM， IV， SC: 300 to 500 mg daily for 7 to 10 days pre-and post-operatively; larger doses have also been used.,無需調整劑量,[仿單]未有說明。,需調整劑量,除非治療上需要,Compatible,[仿單]未有說明。,Compatible 哺乳時可使用,[仿單]未有說明。,IM;IVD;SC;,,【D5W】可選 。【N/S】可選 。,,以最少等量體積的輸注液稀釋後，緩慢輸注超過10分鐘,1. 本藥劑會影響各種尿糖檢查值，可能造成假陰性反應。 2. IV注射太快可能引起暈眩不良反應。靜脈注射時，建議以最少等量體積的輸注液稀釋後，緩慢輸注超過10分鐘。 3. 稀釋後的注射溶液建議避光存放並盡快使用完畢。 4. 本藥劑含Benzyl Alcohol，不建議用於新生兒。
IDIL,Diphenylhydantoin,Dilantin inj 100mg/2mL,CNEU,,I: Status epilepticus of the grand mal type， prevention and treatment of seizure occuring during neurosurgery， arrhythmia. CI: Sinus bradycardia， sino-atrial block， 2nd and 3rd degree AV block or in patients with Adams-Stokes sybdrome.,,,Oral: Adult: 100 mg tid， adjusted as needed; (max. 600 mg/day). Child: Initial， 5 mg/kg/day in 2-3 divided doses; maintenance， 4-8 mg/kg/day;(max. 300 mg/day). Slow IV (not exceeding 50 mg/min): Anticonvulsant (for status epilepticus): Adult & child， loading dose， 15 mg/kg then 5 mg/kg given after 12hrs. Alternatively， 20 mg/kg as a full loading dose. Antiarrhythmic: 100 mg q5mins as needed; (max.1g).,,,,盡量避免,,,,,,,,,,
IDIP,Propofol,Diprivan 200mg/20mL,ZANE,,,,,,,,,,,,,,,,,,,
IDIPI,Propofol,Diprivan inj 200mg/20mL,ZANE,,,,,,,,,,,,,,,,,,,
IDOB,Dobutamine,Dobuject inj 250mg/5mL,CAVS,,適應症: Short-term treatment of cardiac decompensation due to depressed contractility resulting from heart disease or cardiac surgery. 副作用: Tachycardia， nausea， non-specific chest pain & palpitation. 禁忌: Obstructive cardiomyopathy.,,室溫,Usually 2.5-10 mcg/kg/min as IV infusion.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1.勿加入鹼性藥品
IDPT,Diphtheria + Tetanus + Pertussis,DPT vaccine 免費 0.5 mL/dose,HIMM,,Active immunization against diphtheria， tetanus and pertussis.,,2-8,IM， for child 6 wks-6 yrs， 0.5 ml/dose. Primary immunization: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months-1yr later. Booster dose: Given at 4-6 yrs.,,,,沒有資料,,,,,,,,,,
IDPT0,Diphtheria + Tetanus + Pertussis,白喉、百日咳、破傷風疫苗(自費),HIMM,,Active immunization against diphtheria， tetanus and pertussis.,,,IM， for child 6 wks-6 yrs， 0.5 ml/dose. Primary immunization: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months-1yr later. Booster dose: Given at 4-6 yrs.,,,,,,,,,,,,,,
IDT2,Diphtheria + Tetanus,DT vaccine (child),HIMM,,Active immunization against diphtheria and tetanus.,,,IM， for child 6 wks-6 yrs， 0.5 ml/dose. Primary immunization: Child 6 wks-1 yrs: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months 1 yr later. Child over 1 yrs: 2 doses given at 4-8 wks intervals and a reinforcing 3th dose given 6 months-1 yr later. Booster dose: Given at 4-6 yrs.,,,,,,,,,,,,,,
IDW5,Water for injection,Water for inj 500mL (TPN調配使用),NUTR,Solvent for parenteral preparations.,,,無特別指示,As TPN material.,無需調整劑量,,無需調整劑量,安全,,,Compatible 哺乳時可使用,,IRR;IVD;,,,,,
IEPO,Recombinant Human Erythropoietin,Eprex (EPO 4000IU),HEMT,,適應症:Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy 副作用:Increased BP， thrombotic or vascular events. Flu-like symptoms， bone pain & chills after inj. Seizures. Skin reactions， palpebral edema. Rarely， erythroblastopenia. 禁忌:Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.,,2-8℃,Chronic renal failure Adult patients Correction phase: 50 iu/kg 3 times/week IV. When necessary， dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 iu/kg. Pediatric patients Correction phase: 50 iu/kg 3 times/week IV. When necessary， dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally， children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 iu/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 iu/kg for an additional 4 weeks.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,1. 本藥品為預先充填的針筒，限單次使用，給藥前須先檢查確定溶液無雜質或變色。 2. 皮下注射每次體積不可超過1 mL。如需注射較大量，應於不同部位給藥。 3. 靜脈注射時間至少須超過 1-5 分鐘。血液透析病人在透析期間，可經由透析線內一個適當的靜脈入口進行大量注射。 4. 本藥品「不可以」靜脈點滴輸注或與其他藥物混用。
IEPO10,Erythropoietin,EPO 1000 IU (洗腎室用),HEMT,,適應症:Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy 副作用:Increased BP， thrombotic or vascular events. Flu-like symptoms， bone pain & chills after inj. Seizures. Skin reactions， palpebral edema. Rarely， erythroblastopenia. 禁忌:Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.,,2-8℃,Chronic renal failure Adult patients Correction phase: 50 iu/kg 3 times/week IV. When necessary， dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 iu/kg. Pediatric patients Correction phase: 50 iu/kg 3 times/week IV. When necessary， dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally， children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 iu/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 iu/kg for an additional 4 weeks.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,1. 本品限單次使用，給藥前須先檢查確定溶液無雜質或變色。 2. 皮下注射每次體積不可超過1 mL。如需注射較大量，應於不同部位給藥。 3. 靜脈注射時間至少須超過 1-5 分鐘。血液透析病人在透析期間，可經由透析線內一個適當的靜脈入口進行大量注射。 4. 本藥品「不可以」靜脈點滴輸注或與其他藥物混用。
LPRE1,Cisapride,Prepulsid susp 1mg/mL,ALIM,,,,,,,,,,,,,,,,,,,
OWIN,Cefadroxil,Wincef 500mg,QANB,,適應症: Susceptible infections. 副作用: Nausea， vomiting， diarrhoea， abdominal discomfort; skin rash， angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida. Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis. 禁忌: Hypersensitivity to cephalosporins.,,室溫,Adult: 1-2 g/day in 1-2 divided doses， (max. 6 g/day). Child: 15 mg/kg q12h.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
IFOR1,Paclitaxel,Formoxol inj 102mg/17mL,RACA,,適應症: After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma. 副作用: Bone marrow suppression， peripheral neuropathy， GI disturbances， alopecia， hypersensitivity. 禁忌: Baseline neutropenia， severe hepatic impairment.,,室溫,135-175 mg/m2 IV over 3 hr every 3 weeks. Patients must be premedicated dexamethasone， diphenhydramine & cimetidine prior to administration.,,,,盡量避免,,,,,,,,,,
OULE,Cephalexin,Ulex 250mg,QANB,,G(+) (not enterococci， variable against beta-lactamase + staph. & Neissria， not methicillin-resistant staphylococcus aureus) G(-)(urinary infections due to most E. coli， Pr. mirabilis， & some klebsiella， variable against samonella and shigella， not enterobacter， pseudomonas， acinetobacter),,RT,Adult: 250 mg q6h， (max. 4g/day). Child: 6.25-12.5 mg/kg q6h， up to 25 mg/kg q6h.,,,,可能安全,,,,,,,,,,
IINT3,Leucovorin,Antrex inj 30mg/10mL,ZADT,,,,,,,,,,,,,,,,,,,
ORED,Sibutramine,Reductil 10mg 28's/box,META,,適應症: Adjunctive therapy within a weight management programme for obese patients with BMI >= 30 kg/m2， overweight patients with BMI >= 27 kg/m2 or above who have obesity-related risk factors like type 2 diabetes or dyslipidemia. 副作用: Loss of appetite， constipation; dry mouth， insomnia; tachycardia， palpitations， hypertension; dizziness， paresthesia， headache， anxiety; sweating; taste disturbances. 禁忌: Bulimia nervosa， psychiatric illness， Gilles de la Tourette's syndrome， coronary artery disease， CHF， tachycardia， occlusive artery disease， heart rhythm disorder， cerebrovascular disease， inadequately controlled hypertension， hyperthyroidism， severely hepatic/renal impairment， benign prostatic hyperplasia， pheochromocytoma， narrow angle glaucoma， pregnancy， lactation， children < 16， elderly ? 65. Concomitant use of MAOIs or other CNS active drugs for the treatment of mental disorders (such as antidepressants or antipsychotics)， for sleep disorders (tryptophan) or for weight reduction. Misuse of drugs， medicines or alcohol.,,室溫,D: Initial dose is 10 mg qd; if weight loss < 2 kg in 4 weeks and well-toleranted patients can increased to 15 mg qd.,,,,除非治療上需要,,,,,,,,,,
ETAZ,Tazarotene,Zorac gel 0.1%， 30gm,TDER,,I: Stable plaque psoriasis， acne vulgaris. AR: Prurtus， burning/stinging， erythema， worsening of psoriasis， irritation， pain， rash， desquamation， contact dermatitis. CI: Pregnancy.,,,D: Apply once daily at night.,,,,不可使用,,,,,,,,,,
OFA,Folic Acid,Folic acid 5mg,NUTR,Pernicious anemia， pregnancy， megaloblastic anemia， aplastic anemia.,Hypersensitivity to any component of the formulation.,GI upset at high doses.,室溫藥品，仿單無特別指示儲存溫度條件,1 TAB contains 5 mg folic acid. Adult: Initially 1 TAB TID for 14 days. Maintenance: 1 TAB daily for 1-7 days. Children 6-12 years: Initially 2 TAB/day. Maintenance: As half of initial dose. Children 1-5 years: Initially 1 TAB /day. Maintenance: As half of initial dose. Children <1 years: 0.5 mg/kg body weight/day. Maintenance: As half of initial dose.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OVEN,Coumarin + Troxerutin,Venalot depot,HEMT,,適應症: Congestive symptoms due to venous (chronic venous insufficiency) & lymphatic lymphedema) flow impairments such as edemas， skin & tissue changes( dermatosiderosis， dematoliposclerosis)， ulcus cruris venosum. Superficial phlebitis. Hemorrhoids. Swelling after sports & accidental injuries (e.g. contusions & sprains) & after operations. Drug- or radiation-induced xerostomia. 副作用: Elevations of liver enzymes. Rarely， hepatitis with or without jaundice. 禁忌: Liver disease or a past history of liver diseases.,,室溫,1-2 tab tid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OWEL,Aluminum Hydroxide,Wellpin,ALIM,,I:Hyperacidity， flatulence， indigestion， abdominal pain. AR:Nausea， vomiting.,,,Adult (>12 yr) : 2 tab. tid ~ qid. Children (6 ~12 yr): 1 tab. tid ~ qid.,,,,,,,,,,,,,,
OXAN,Alprazolam,Xanax 0.5mg,CNEU,Anxiety states， Anxiety with symptoms of depression.,Acute narrow angle glaucoma.,Drowsiness. Less commonly lightheadedness， blurred vision， coordination disorders; GI effects; autonomic effects; dependence， withdrawal syndrome. Rarely， paradoxical agitation， confusion.,25℃以下,Adults: General dose: 0.25-0.5mg TID， dosage range:0.5-4mg/day. Slowly reduce the dose when stopping the drug. The reduction should not exceed 0.5mg every three days. Elderly or frail patients: Elderly patients who have not used psychotropic drugs should be treated with the lowest effective dose. Children: Safety and efficacy have not been established.,需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OXAT1,Alfuzosin,Xatral XL 10mg,SGU,,適應症:良性前列腺肥大。(B022917100),,RT,1 tab after dinner.,,,,沒有資料,,,,,,,,,,
OKRE,PSK,Krestin 1gm,RACA,Cancer chemotherapy adjunct， used in neoplastic diseases as immunomodulator.,Hypersensitivity to Coriolus versicolor,Dark colored stools， nail pigmentation， diarrhea， abnormal liver functions,室溫藥品，仿單無特別指示儲存溫度條件,3 g daily administered in 1 to 3 divided doses.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
IIPR,Hexoprenaline,Ipradol inj 5mcg/2mL,ERSP,,適應症:預防支氣管痙攣(B000656212),,RT,IM， slow IV. Adult: Acute asthmatic 1 amp; severe dyspnea 1.5-2 amp; status asthmaticus 1 amp tid-qid. Child: 1-3 mcg qd-tid.,,,,沒有資料,,,,,,,,,,
IHBV1,Hepatitis B Vaccine,Engerix-B (B肝疫苗，政府提供) 0.5mL/dose,HIMM,Active immunisation against hepatitis B virus infection,Hypersensitivity.,Redness， pain， swelling at inj site. Rarely， fatigue， fever， malaise， influenza-like symptoms， dizziness， headache， paresthesia， nausea， vomiting， diarrhea， abdominal pain， abnormal liver function tests， arthralgia， myalgia， rash， pruritus， urticaria.,2-8℃避光避免冷凍,IM， > or = 20 years 20 mcg/1mL/dose， < or = 19 years 10 mcg/0.5 mL/dose， 3 doses at 0， 1， and 6 months or 4 doses at 0， 1， 2， and 12 months. > or = 20 years rapid immunization 3 doses at 0， 7， and 21 days with a booster at 12 months. Renal insufficiency > or = 16 years 4 double doses (20 mcg x 2) at 0， 1， 2， and 6 months. 11-15 years 2 doses (20 mcg) at 0 and 6 months.,無需調整劑量,[仿單]並無足夠授乳期間使用之資料及動物生殖研究，尚未確認有任何禁忌。,無需調整劑量,可能安全,Compatible,[仿單]並無足夠人類懷孕期間使用之資料及動物生殖研究，只有在明確必要且潛在效益超越對胎兒 的潛在危險性時，才可在懷孕期間使用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]並無足夠授乳期間使用之資料及動物生殖研究，尚未確認有任何禁忌。,IM;,,,,,1. 以肌肉注射於成人或兒童的手臂三角肌部位，或新生兒、嬰兒、幼童的大腿前外側。 2. 血小板減少症或出血性疾病患者可以皮下注射方式投與。
OLAD,Danazol,Ladogal 200mg,HM,,適應症:主治子宮內膜異位(B022413100),,RT,Endometriosis: 400 mg bid for 3-6 months up to 9 months. Hereditary angioedema: 1-2 cap bid-tid. Fibrocystic breast cancer: 100-400 mg bid.,,,,不可使用,,,,,,,,,,
OLAMC,Lamotrigine,Lamictal 50mg,CNEU,Monotherapy in adult and children >12 year or as add-on therapy in adult and children > 2 year for the treatment of epilepsy (partial seizures and generalised seizures)， including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. Prevention of depressive episodes in patients with bipolar disorder.,Hypersensitivity to any component of the formulation.,Skin rash， irritability， headache， drowsiness， insomnia， dizziness， tremor， nystagmus， ataxia， diplopia， blurred vision， nausea， vomiting， diarrhoea， tiredness， arthralgia， pain， back pain. Dermatologic: Rash (immediate-release， 10% or less (adult); 14% (pediatric) ) Gastrointestinal: Abdominal pain (immediate-release， 5% to 10% )， Diarrhea (immediate-release， 6% to 11%; extended-release， 5% )， Indigestion (immediate-release， 2% to 7% )， Nausea (immediate-release， 7% to 25%; extended-release， 7% )， Vomiting (immediate-release， 5% to 20%; extended-release， 6%)) Neurologic: Asthenia (immediate-release， 2% to 8%; extended-release， 6% )， Ataxia (immediate-release， 2% to 11% )， Coordination problem (immediate-release， 6% to 7%; extended-release， 3% )， Dizziness (immediate-release， 7% to 54% ; extended release， 14% )， Headache (immediate-release， 29% )， Insomnia (immediate-release， 5% to 10% )， Somnolence (immediate-release， 9% to 17%; extended-release， 5% )， Tremor (immediate-release， 4% to 10%; extended-release， 6% )， Vertigo (immediate-release， 2%; extended-release， 3% ) Ophthalmic: Blurred vision (immediate-release， 11% to 25% (adults) and 4% (children); extended-release， 3%)， Diplopia (immediate-release， 24% to 49% (adults) and 5% (children); extended-release， 5%) Psychiatric: Anxiety (immediate-release， 4%; extended-release， 3%)， Depression (immediate-release， 4%; extended-release， 3% ) Reproductive: Dysmenorrhea (immediate-release， 5% to 7% ) Respiratory: Rhinitis (immediate-release， 7% to 14% ) Other: Pain (immediate-release， 5%),30℃以下，避光且保持乾燥,Adult & childn > 12yrs for mono therapy: Initially 25 mg once a day for 2 weeks， and 50 mg once a day for next 2 weeks， then increasing up to 50-100 mg every 1-2 weeks to achieve the desired effect. Maitenance: 100-500 mg/day in 1-2 divided doses. With valproate or without other antiepileptic drugs: the initial dose of Lamictal is 25 mg every other day for 2 weeks; then 25 mg daily for the next 2 weeks. Then increase 25-50 mg at most every 1-2 weeks to achieve an appropriate response. Maintenance: 100-200 mg/day QD or BID. With other Antiepileptic drugs or other drugs that induce lamotrigine aldose: Initially 50 mg QD for 2weeks， and 100 mg BID for the next 2 weeks. then increasing to 100 mg every 1-2 weeks to achieve the desired effect. Maintenance: 200-700 mg/day in 1-2 divided doses. With other drugs that do not significantly inhibit or induce lamotrigine aldose: Initially 25 mg QD for 2weeks， and 50 mg BID for the next 2 weeks. then increasing to 50-100 mg every 1-2 weeks to achieve the desired effect. Maintenance: 100-200 mg/day in 1-2 divided doses.,需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議須整粒吞服，不要咀嚼。因廠商無相關安定性測試。
OLE15,Folinic Acid,Leucovorin 15mg,ZADT,,An antidote or rescue after treatment with high dose of methotrexate. To diminish oxicity and counteract effect of overdosage of folic acid antagonist. For treatment of megaloblastic anemias.,,,For megaloblastic anemia: 1-15mg/day.,,,,除非治療上需要,,,,,,,,,,
OLEUC,Leucomycin,Leucomycin 250mg,QANB,,Tonsillitis， pharyngitis， pertussis， bronchitis， pneumonia， pyothorax， mastitis， osteomyelitis， gonorrhea， urethritis， syphilis， otitis media， septicemia， bacteria endocarditis， scarlet fever， scrub typhus & diphtheria.,,,1-2 cap every 6 hrs.,,,,,,,,,,,,,,
OLIB,Chlordiazepoxide,Librium 5mg,CNEU,,適應症: Tension， fear & anxiety. Muscular spasm of psychogenic， neurogenic or myogenic origin， acute alcohol withdrawal. 副作用: May affect psychomotor performances. Ataxia & drowsiness.,,室溫,Adult 20-40 mg daily; severe cases: 50-100 mg daily. Elderly or debilitated patient 5-10 mg daily & only in exceptional cases more. Children 5-10 mg daily， may be increased to 20-30 mg or in special cases more， daily.,,,,盡量避免,,,,,,,,,,
OLIM,Tramadol,Limadol 50mg,CNEU,,safety and efficacy <16 y/o have not been established FDA label use: Cancer pain， chronic pain: moderate to moderately severe contraindication: a)Rasagiline (theoretical); Selegiline (theoretical) b)situations where opioids are contraindicated，( including intoxication with alcohol， hypnotics， narcotics， centrally acting analgesics， opioids， or psychotropic drugs; may worsen CNS and respiratory depression) Commen side effect: a)Dermatologic: Flushing (7.7% to 15.8% )， Pruritus (6.2% to 11.9% ) b)Gastrointestinal: Constipation (12.2% to 29.7% )， Diarrhea (3.7% to 8.5% )， Nausea (15.1% to 26.2% )， Vomiting (5% to 9.4% )， Xerostomia (5% to 9.8% ) c)Neurologic: Asthenia (3.5% to 6.5% )， Dizziness (15.9% to 28.2% )， Headache (11.5% to 15.8% )， Insomnia (6.5% to 10.9% )， Somnolence (7.3% to 20.3% ) severe side effect: a)Cardiovascular: Myocardial infarction (0.5% to less than 1% )， Palpitations (0.5% to less than 1% ) b)Gastrointestinal: Pancreatitis (0.5% to less than 1% ) c)Hepatic: Liver function tests abnormal (0.5% to less than 1% ) d)Immunologic: Anaphylactoid reaction Neurologic: Seizure Respiratory: Dyspnea (1% to less than 5%,,,safety and efficacy <16 y/o have not been established Usual dose: 50-100mg q 4-6 h， max 400mg/day Dosage in renal impairment: Clcr< 30 ml/min， increase dosing interval to 12 h ; max. 200 mg/day dose for patients with cirrhosis: 50 mg q 12 h Thomson: Infant risk cannot be ruled out,,,,除非治療上需要,,,,,,,,,,
OLIP,Etofibrate,Lipo-Merz retard 500mg,CAVS,,適應症:為降血脂藥(B010330100) CI: Liver diseases， gallbladder diseases， severe renal insufficiency， decompensated heart failure， acute cardiac infarct， acute bleedings. Pregnancy & lactation.,,RT,1 cap daily.,,,,沒有資料,,,,,,,,,,
LSEC,Chlorpheniramine + Guaifenesin + Methylephedrine,Secorine syrup 120mL,ERSP,Relief of cold symptoms (runny nose， nasal congestion， sneezing and phlegm).,Hypersensitivity to any component of the formulation.,Dizziness， palpitations， nausea， vomiting， skin rash,25℃以下，不需冰存,Adult and >12 years children 20 mL TID. Children 9-12 years 10 mL(1/2 adult dose) TID. Children 6-9 years 6.7 mL(1/3 adult dose ) TID. Children < 6 years depended on doctor.,無需調整劑量,CHLORPHENIRAMINE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible GUAIFENESIN BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible Methylephedrine沒有資料,無需調整劑量,沒有資料,Uknown 沒有資料,CHLORPHENIRAMINE PREGNANCY RECOMMENDATION: Compatible GUAIFENESIN PREGNANCY RECOMMENDATION: Compatible Methylephedrine沒有資料,Unknown 沒有資料,CHLORPHENIRAMINE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible GUAIFENESIN BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible Methylephedrine沒有資料,AC;AC15;PC;PO;WM;,,,,,
LTRIM,Sulfamethoxazole + Trimethoprim,Trimerin syr 60mL,QANB,,,,,Antimicrobial: Adult: 2 tab q12h. Child over 2 months under 40 kg: 20 mg/kg syr & 4 mg/kg tab q12h. Antiprotozoal (Pneumocystis carinii pneumonia): Adult & child over 2 months: 18.75-25 mg/kg syr. & 3.75-5 mg/kg tab q6h for 2 wks.,,,,除非治療上需要,,,,,,,,,,
LULO,Erythromycin,Ulosina(Erythromycin) susp 25mg/mL， 60mL,QANB,,適應症: Prophylaxis of endocarditis; syphilis; otitis media; diphtheria; pertussis; Legionnaires' disease; enteritis， chancroid， severe acne vulgaris; M pneumoniae & chlamydia trachomatis infections. 副作用: Abdominal discomfort; Allergic reactions; hepatotoxicity; reversible hearing loss. 禁忌: Liver impairment.,,室溫,Adult 1 g daily in 2-4 divided doses; 2-4 g daily in severe infection. Children 30-50 mg/kg body weight daily， may be doubled in severe infection.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
LZIT,Azithromycin,Zithromax 200mg/5mL suspension,QANB,Upper & lower respiratory tract infections; skin & soft tissue infections; otitis media; uncomplicated genital infections due to Chlamydia trachomatis & Neisseria gonorrheae.,Hypersensitivity to macrolides.,Nausea， abdominal discomfort， vomiting， flatulence， diarrhoea & loose stools. Hearing impairment， interstitial nephritis， acute renal failure， abnormal liver function， dizziness/vertigo， convulsions， headache， somnolence.,30℃以下,Adults and children weighing > or = 45 kg: 500 mg orally once daily with or without food for 3 days. Sexually transmitted diseases caused by Chlamydia trachomatis: 1 g as single oral dose. Children 10 mg/kg once daily for 3 days.,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,AC;PC;PO;WM;,,,,,
MS0330,Alcohol,Alcohol 1mL 酒精,ZOTH,,,,,,,,,,,,,,,,,,,
MS2200,,3x12cm Silicone Gel Sheet安膚適疤痕矽膠片,ZOTH,,,,,,,,,,,,,,,,,,,
MS2201,,4x15cm Silicone Gel Sheet安膚適疤痕矽膠片,ZOTH,,,,,,,,,,,,,,,,,,,
MS2202,,4x12 Silk 矽膠片,ZOTH,,,,,,,,,,,,,,,,,,,
MS2203,,4x18 Silk 矽膠片,ZOTH,,,,,,,,,,,,,,,,,,,
OROB,Ribavirin,Robatrol 200mg,QANB,,適應症: In combination with interferon α for the treatment of chronic hepatitis C in adult patients who are α-interferon-naive or who have relapsed following α-interferon therapy. 副作用: Haemolysis， anaemia， neutropenia， dry mouth， hyperhidrosis， asthenia， chest pain， fatigue， fever， headache， flu-like symptoms， malaise， rigors， weight loss， dizziness， paresthesia， GI disturbances， arthralgia， myalgia， CNS effects， viral infection， cough， dyspnoea， pharyngitis， rhinitis， alopecia， pruritus， rash， dry skin， parageusia， blurred vision. Dermatologic: Pruritus， Rash Gastrointestinal: Indigestion， Loss of appetite， Nausea Hematologic: Neutropenia (8% to 40% ) Neurologic: Headache Other: Fatigue 禁忌: History of severe pre-existing cardiac disease; haemoglobinopathies; severe， debilitating medical conditions; severe hepatic dysfunction or decompensated liver cirrhosis; autoimmune hepatitis or a history of autoimmune disease; pre-existing thyroid disease. Pregnancy & lactation.,,室溫,Adult >= 18 years 1000-1200 mg daily in 2 divided doses， in combination with interferon α soln for inj administered SC at a dose of 3MIU 3 times/wk.,,,,不可使用,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OLIP2,Fenofibrate,LIPANTHYL 200M,CAVS,,I: Endogenous hypercholesterolaemia (type IIa) & hypertriglyceridaemia， either in isolation (type IV) or in association (type IIb & III). AR: GI disturbances， allergic skin reactions， elevation of transaminases， muscular pains. CI: Serious hepatic & renal insufficiency， children.,,Room Temperature,200 mg qd with meal.,,,,除非治療上需要,,,,,,,,,,
OZYP,Olanzapine,Zyprexa 5mg,CNEU,,適應症：Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment， olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. 副作用: Somnolence， weight gain， dizziness， akathisia， parkinsonism， dyskinesia， increased appetite， elevated glucose & triglyceride levels， asthenia， edema， orthostatic hypotension， dry mouth， constipation， eosinophilia， elevated prolactin levels (but clinical manifestations rare). May affect ability to operate machinery or drive motor vehicles. Elderly patients with dementia: a higher incidence of death and cerebrovascular adverse events; abnormal gait and falls; Pneumonia and urinary incontinence. Cardiovascular: Orthostatic hypotension (1% to 5% )， Peripheral edema (3% to 6% ) Endocrine metabolic: Hypercholesterolemia (up to 24% )， Hyperglycemia (0.1% to 17.4% )， Increased appetite (3% to 24% )， Increased prolactin level (31.2% to 61.1% )， Serum triglycerides raised (up to 40% )， Weight gain (up to 57% ) Gastrointestinal: Constipation (4% to 11% )， Xerostomia (3% to 32% ) Neurologic: Akathisia (3% to 27% )， Asthenia (2% to 20% )， Dizziness (1.6% to 18% )， Somnolence (6% to 52% )， Tremor (1% to 23% ) Psychiatric: Personality disorder (8% ) Other: Accidental injury (4% to 12% )， Fever (up to 4% ) 禁忌: Patients with known risk of narrow-angle glaucoma. Neuroleptic malignant syndrome.,,室溫,Adult Schizophrenia Starting dose: 10 mg/day. Manic episodes Starting dose: 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy. Preventing recurrence in patients whose manic episodes have responded previously to olanzapine Starting dose: 10 mg daily. Dose range for all indications: 5-20 mg daily. A lower starting dose (5 mg/day) should be considered for elderly patients (> 65 years) & in renal or hepatic impairment.,,,,除非治療上需要,,,,,,,,,,
OPRE5,Estrogen + Medroxyprogesterone,Premelle cycle 5,HM,,I: Moderate-to-severe vasomotor symptoms associated with estrogen deficiency. Prevention & management of osteoporosis associated with estrogen deficiency. Atrophic vaginitis & atrophic urethritis. AR: Increased risk of breast cancer， gallbladder disease， thrombophlebitis and/or thromboembolic disease. Increase in BP， fluid retention， changes in glucose tolerance， vag. bleeding， breast pain， tenderness & enlargement. GI effects， alopecia， rash， hirsutism， pruritus， visual disturbances， headache， nervousness. CI: Konwn or suspected cancer of the breast， estrogen-dependent neoplasia， pregnency. Undiagnosed abnormal genital bleeding. Active thrombophlebitis or thromboembolic disorders. Liver dysfunction or disease.,,,D: 1 maroon tab daily for the 1st 14 days， followed 1 blue tab daily for the next 14 days.,,,,不可使用,,,,,,,,,,
IMIXT,Human Insulin Regular/NPH 30/70,Mixtard insulin 30/70 10mL,META,,Insulin-requiring diabetes mellitus.,,,Administer SC once or bid.Duration of action:Onset 1/2 hr， peak between 2nd-8th hr，terminates after approx 24 hr. Vial:Soluble human monocomponent insulin 30% & Isophane human monocomponent insulin 70% ，100 IU/ml x10ml.,,,,可能安全,,,,,,,,,,
EPULN,Budesonide,Pulmicort 鼻噴劑 64mcg/dose,TENT,,適應症: Seasonal & perennial rhinitis， vasomotor rhinitis. Prevention of nasal polyps after polypectomy. 副作用: Local irritation， slight hemorrhagic secretion， epistaxis. Hypersensitivity reactions. Gastrointestinal: Diarrhea (inhalation， 4%; oral， 10% )， Nausea (inhalation， 1.8% to 6%; oral， 11% ) Musculoskeletal: Arthralgia (inhalation， 6%; oral， 5% ) Neurologic: Headache (inhalation， 3%; oral， 21% ) Respiratory: Epistaxis (intranasal， 8%; inhalation， 2% to 4% )， Nasal stinging/burning (intranasal， greater than 1% )， Respiratory tract infection (inhalation， 3% to 38%; oral， 11% )， Sinusitis (inhalation， 3% to 16%; oral， 8% ) 禁忌: Hypersensitivity to budesonide or any of the ingredients.,,室溫,Rhinitis Adult & children >= 6 years Initially 256 mcg daily as single (2 sprays of 64 mcg in each nostril) or in 2 divided doses (1 spray of 64 mcg in each nostril). Maintenance: 32 mcg in each nostril once daily in the morning. Treatment or prevention of nasal polyps 256 mcg daily as single or in 2 divided doses.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IMAX,Sulbactam,Maxtam inj 500mg,QANB,,適應症: To be combined with ampicillin to treat the moderate to severe bacterial infection. 副作用: Blood disorders， hypersensitivity， GI disturbances， chronic nephritis， dizziness， headache. 禁忌: Hypersensitivity to β-lactam antibiotics.,,室溫,Adult 0.5-1 g 6， 8 or 12 hrly IM/IV. Max: 4 g/day. Children 50 mg/kg/day given 6，8 or 12 hrly. Max: 80 mg/kg/day.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,1. IM: 給藥後3 ~ 5分鐘，注射併用抗生素。 2. IVF: 本藥可於注射併用抗生素前3 ~ 5分鐘施打，或與併用之ampicillin混合後緩慢滴注。
ODIA3,Gliclazide,Diamicron MR 30mg,META,,適應症: 第二型糖尿病(B023503100) 副作用: Hypoglycaemia， nausea， dyspepsia， diarrhoea， constipation. 禁忌: Type 1 diabetes， diabetic keto-acidosis or diabetic pre-coma， severe renal or hepatic insufficiency， co-administration with miconazole， pregnancy， lactation. Avoid coadministration with phenylbutazone or danazol.,,室溫,1-4 tab taken once daily at breakfast. Max : 120 mg daily.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OXEN1,Orlistat,Xenical 120mg,META,,,,,,,,,,,,,,,,,,,
EPOD,Podophylline,Podophylline extract,TDER,,,,,,,,,,,,,,,,,,,
EPOL,Tar + Cade Oil + Coal Tar Soln,Polytar liquid 1% 150mL,TDER,,適應症: Seborrhea， psoriasis. Dandruff & itching scalp. 副作用: Skin irritation， rash， mild photosensitivity.,,室溫,Use as scalp cleanser once or twice weekly.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EPOS,Hydrocortisone + Polyvalent Colibacilli,Posterisan forte oint 10gm,ALIM,,適應症:主治痣瘡(B012133329),,RT,Apply to affected areas several times daily.,,,,沒有資料,,,,,,,,,,
EPP,Potassium Permanganate,Pot permanganate 1gm,AGENT,,,,,,,,,,,,,,,,,,,
EPRE4,Conjugated Estrogen,Premarin vag cream 42.5gm(大劑量),SGU,,適應症: Atrophic vaginitis. Post-menopausal atrophic urethritis. 副作用: Rarely nausea， vomiting. Breakthrough bleeding， spotting， change in menstrual flow， amenorrhea. Breast tenderness， enlargement， secretion. GI effects， cholestatic jaundice. Chloasma or melasma. Steepening of the corneal curvature; intolerance to contact lenses. Headache， migraine， dizziness; chorea. Wt changes; edema; changes in libido. Cardiovascular: Edema， Vasodilatation (vaginal cream， 21 days on/7 off regimen， 3.5%; 2 times/wk regimen， 5% ) Dermatologic: Chloasma， Hirsutism， Injection site reaction， Pruritus (5% ) Endocrine metabolic: Weight change finding Gastrointestinal: Abdominal pain (vaginal cream， 21 days on/7 off regimen， 7.7%; 2 times/wk regimen， 6.4% )， Bloating symptom， Diarrhea (vaginal cream， 21 days on/7 off regimen， 2.8%; 2 times/wk regimen， 7.1% )， Flatulence (7% )， Nausea (oral， 9% ; vaginal cream， 21 days on/7 off regimen， 3.5%; 2 times/wk regimen， 2.1% )， Stomach cramps， Vomiting Musculoskeletal: Backache (vaginal cream， 21 days on/7 off regimen， 4.9%; 2 times/wk regimen， 9.3% )， Leg cramp Neurologic: Asthenia (vaginal cream， 21 days on/7 off regimen， 5.6%; 2 times/wk regimen， 1.4% )， Headache (vaginal cream， 21 days on/7 off regimen， 11.2%; 2 times/wk regimen， 17.9% )， Migraine Psychiatric: Depression， Disturbance in mood Reproductive: Disorder of menstruation， Pain of breast (oral， 12% ; vaginal cream， 21 days on/7 off regimen， 5.6%; 2 times/wk regimen， 2.9% )， Swelling of breast， Vaginitis (vaginal cream， 21 days on/7 off regimen， 5.6%; 2 times/wk regimen， 5% )， Withdrawal bleeding Respiratory: Increasing frequency of cough (vaginal cream， 21 days on/7 off regimen， 0%; 2 times/wk regimen， 5% )， Pharyngitis (vaginal cream， 21 days on/7 off regimen， 2.1%; 2 times/wk regimen， 5% ) Other: Accidental injury (vaginal cream， 21 days on/7 off regimen， 2.8%; 2 times/wk regimen， 6.4% )， Disorder of skin appendage (vaginal cream， 21 days on/7 off regimen， 8.4%; 2 times/wk regimen， 11.4% )， Infectious disease (vaginal cream， 21 days on/7 off regimen， 4.9%; 2 times/wk regimen， 11.4% )， Pain (vaginal cream， 21 days on/7 off regimen， 7%; 2 times/wk regimen， 2.9% ) 禁忌: Known or suspected breast cancer， estrogen-dependent neoplasia， active thromboembolic disease， undiagnosed abnormal genital bleeding. Pregnancy.,,室溫,Intravaginally or topically， 0.5-2 g daily depending on severity of condition. Max: 4 g/day. Cyclic administration (3 weeks on & 1 week off) should be used.,,,,不可使用,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EPROO,Hydrocortisone + Cinchocaine,Proctosedyl oint 15gm,ALIM,,,,RT,Rectal or applied topically， bid & after each stool.,,,,沒有資料,,,,,,,,,,
EQUI,Azapentacene Polysulfonate Sodium,Quinax 15mL,TOPH,,適應症: Senile cataract， traumatic cataract.,,冷藏2-8℃,Instill 2 gtt 3-5 times daily.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EREG,Minoxidil,Regain(Minoxidil) 5%， 60mL,TDER,,I: Alopecia androgenetica. AR: Scaling， dry skin， burning sensation， rash， erythema/flushing， dermaitis， hypertrichosis， infrequent allergic reactions， dizziness， tingling reaction，headache， weakness， neuritis， edema， eye irritation， altered taste， eye infection， visual disturbances， rarely alopecia， hair abnormalities， chest pain， BP changes， hepatitis， kidney calculi. CI: Pregnancy， lactation.,,RT,Applied bid,,,,除非治療上需要,,,,,,,,,,
INAHCO3,Sodium Bicarbonate,Sod. Bicarbonate inj 7% 20mL,NUTR,,適應症:Metabolic acidosis arising from a variety of disorders， eg diabetic ketoacidosis， diarrhoea， kidney disturbances & shock. To correct hyperkalaemia. Acute poisoning from weakly acidic drugs， eg phenobarbitone & salicylates. 副作用:Metabolic alkalosis; shortness of breath & muscle weakness; muscle hypertonicity， twitching & tetany; Na overloading & hyperosmolality. Stomach cramps & flatulence. Tissue necrosis at inj site. 禁忌:Metabolic or respiratory alkalosis， hypocalcaemia， hypochlorhydria. Avoid overtreatment.,,室溫,Metabolic acidosis IV 2-5 mEq/kg over 4-8 hr. Cardiac arrest IV 1 mEq initially， then 0.5 mEq/kg every 10 min if needed.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,1.未稀釋亦可使用
IPEN2,Penicillin G Benzathine,Penadur LA (Retarpen)2.4MIU,QANB,,適應症:Treatment & prophylaxis of infections caused by highly penicillin-sensitive organisms 副作用:Allergic reactions， stomatitis， glossitis， hemolytic anaemia， leucopenia， thrombocytopenia， agranulocytosis， neuropathy， nephropathy， Jarisch-Herxheimer reactions secondary to bacteriolysis. 禁忌:Hypersensitivity to penicillins & cephalosporins. Severe pneumonia， empyema， sepsis， pericarditis， meningitis， peritonitis or arthritis requiring high penicillin levels， allergic diathesis， bronchial asthma.,,室溫,Retarpen 2.4 MIU is intended for use in adults only. Therapy: Syphilis: Primary Stage: 1 x 1 Retarpen 2.4 MIU given at 2 injection sites. Secondary Stage: 1 x 2 Retarpen 2.4 MIU given at 2 injection sites. Treatment should be repeated if clinical symptoms recur or if laboratory values remain highly positive. Late Syphilis: 1-2 x Retarpen 2.4 MIU at weekly intervals over 3-5 weeks. Therapy of Streptococcal Infections， eg Tonsillitis， Scarlet Fever， Erysipelas: Treatment is commenced in the acute phase of infection with a rapidly absorbed penicillin preparation (eg， penicillin G) and continued with Retarpen. 1 x 1 Retarpen 2.4 MIU at weekly intervals. Prophylaxis: Rheumatic Fever: 1 x 1 Retarpen 2.4 MIU every 4 weeks.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,1. 注射前檢查病患是否有PCN過敏史。 2. 本藥品限肌肉注射！
IPENT,Thiopental,Pentothal inj 0.5gm,ZANE,,Control of convulsive states， narcoanalysis and narcosynthesis in psychiatrist disorders， induction of anesthesia， supplementation of other anesthetic agents.,,,IV only Anesthesia: 50-75 mg (2.5% soln) at interval of 20'-40'， additional injection of 20-25mg can be given whenever the patient moves. Convulsive states: 75-250 mg (2.5% soln) over a period of 10'. Induction: 3~5mg/kg,,,,除非治療上需要,,,,,,,,,,
IPITS,Oxytocin,Piton-S inj 10iu/mL,SGU,,適應症:促進子宮收縮ˋ 催產之用(B022279229),,2-8,Induction of labor & oxytocin challenge test: IV infusion: 5 U in 500 ml of normal saline or 5% dextrose (10 mU/ml)， initial， 0.5-2 mU/min， increased by 1-2 mU/min q 15-30 mins; (max. 20 mU/min)， Control of postpartum uterine bleeding: IV infusion: 10-20 U in 500 ml (20-40 mU/ml) given at a rate of 20-40 mU/min. IM: 3-10 U.,,,,不可使用,,,,,,,,,,
OSERE,Haloperidol,Serenace 0.5mg,CNEU,,Antidyskinetic (in Gilles de la Tourette's disease)， antipsychotic.,,,Antipsychotic: Oral: Adult:0.5-5 mg bid-tid initially， adjusted as needed. Child: 3-12 yrs， 0.05-0.15 mg/kg/day in 2-3 divided doses. Mental retardation with hyperactivity: 10-15 mg/day in divided doses up to 60 mg/day.,,,,除非治療上需要,,,,,,,,,,
OTIC,Ticlopidine,PanalDine 100mg,HEMT,,適應症: To reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors or who have had a completed thrombotic stroke， & are intolerant or allergic to or who have failed aspirin therapy. As adjunctive therapy with aspirin to reduce incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation. 副作用: GI disturbances; skin rashes. Blood dyscrasias; vertigo; jaundice. 禁忌: Hemorrhagic diathesis， GI ulcers， severe liver dysfunction， leukopenia.,,室溫,200 - 300 mg daily.,,,,可能安全,,,,,,,,,,
OVIA,Glucosamine Sulphate,Viartril-S 250mg,CNEU,,Vertebral artrosis， coxofemoral， scapulo-humeral， gonarthrosis， periarthritis， lumbosciatalgies， arthrosis of any etiology.,,RT,4-6 cap daily for 30-60 days.,,,,,,,,,,,,,,
OXEN2,Orlistat,Xenical 120mg 21'S/BOX,META,,I: Long-term treatment of obese & overweight patients w/ risk factors associated w/ obesity， in conjunction w/ a mildly hypocaloric diet. ADR: Oily spotting， flatus with discharge， fecal urgency， fatty/oily stool， oily evacuation， increased defecation， fecal incontinence (incidence of these increases the higher the fat content of the diet). CI: Chronic malabsorption syndrome.,,RT,1 cap 3 times daily w/ meals,,,,除非治療上需要,,,,,,,,,,
IDES1,Iron-Dextran,DesMAN inj 100mg/2mL,NUTR,,適應症: Treatment of Fe-deficiency anemia， where oral Fe is intolerable or ineffective. 副作用: Dyspnea， nausea & vomiting， abdominal pain， flushing， puritus， rash， blurred vision， feeling hot， cramps， numbness. 禁忌: Non-Fe deficiency anemia; Fe overload or disturbances in utilization of Fe; patients with a history of asthma， eczema or other atopic allergy (IV inj only); decompensated liver cirrhosis， hepatitis; acute or chronic infection; active RA; acute renal failure.,,室溫,Individualized dosage based on patients body wt & iron deficit. Slow IV or deep IM， Adult : not exceed 100 mg / day. Children < 10 kg : not exceed 50 mg / day. Infants < 5 kg : not exceed 25 mg / day.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ONORE,Ethinylestradiol + Levonorgestrel,Nordette 21's/pk,HM,,Oral contraceptive & treatment of dysmenorrhea & menstrual irregularities.,,,1 tab daily for 21 days， followed by 7 tab-free days.,,,,,,,,,,,,,,
ONORM,Sterculia + Frangula,Normacol plus granules 7gm/pack,ALIM,Treatment of constipation. The initiating and maintenance of bowel action after rectal surgery and haemorrhoidectomy.,Intestinal obstruction. Faecal impaction. Total atony of the colon. Hypersensitivity to the active substances or to any of the excipients. Pregnancy and lactation. Children under 12 years of age.,Abdominal distension， intestinal obstruction if overdosage or inadequate fluid intake.,25℃陰涼處,1 pack= 7g granules (62% w/w Sterculia and 8% w/w Frangula). Adult: 1-2 sachets QD-BID. After meal. (Put the granules directly into your mouth， do not chew or crush， and swallow with plenty of water or cold drinks),無需調整劑量,[仿單]無證據顯示Sterculia會分泌至乳汁；Frangula或其代謝物是否會分泌進入人體乳汁亦未知， 但有研究顯示其他Anthranoids之活性代謝物會分泌至乳汁， 故無法排除未斷奶小孩的風險，婦女哺乳期禁止使用。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]尚無Sterculia與Frangula併用於懷孕婦女的資料，目前已知Frangula會通過胎盤， 且非臨床資料顯示數個與Frangula相關之Anthranoids可能具有基因毒性，因此懷孕期禁止使用。,Unknown 沒有資料,[仿單]無證據顯示Sterculia會分泌至乳汁；Frangula或其代謝物是否會分泌進入人體乳汁亦未知， 但有研究顯示其他Anthranoids之活性代謝物會分泌至乳汁， 故無法排除未斷奶小孩的風險，婦女哺乳期禁止使用。,PC;,,,,,
ONORV,Amlodipine,Norvasc 5mg,CAVS,Hypertension & angina pectoris.,Known hypersensitivity to dihydropyridines.,Headache， edema， fatigue， somnolence， nausea， abdominal pain， flushing， palpitations， dizziness. Cardiovascular: Flushing (0.7% to 2.6% )， Palpitations (Up to 4.5% )， Peripheral edema (Up to 10.8% ) Gastrointestinal: Abdominal pain (1.6% )， Nausea (2.9% .) Neurologic: Dizziness (Up to 3.4% )， Headache (7.3% )， Somnolence (1.4% ) Other: Fatigue (4.5% ),25℃以下,Initially 5 mg once daily which may be increased to a maximum dose of 10 mg depending on the patient's response.,需調整劑量,藥品仿單：利用脈優進行治療時應停止授乳。 人體使用經驗表明amlodipine可分泌至人乳中。在31名發生妊娠高血壓的授乳女性中，施用amlodipine (初始劑量為每天一次每次5毫克) 後，乳汁與血漿中amlodipine濃度比中位數為0.85。該劑量會視需要做相應調整，平均每日劑量及依體重校正後的每日劑量分別為6毫克 和98.7微克/公斤。估計經由乳汁進入嬰兒體內的amlodipine每日劑量約為4.17微克/公斤。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,藥品仿單：分級C 鈣離子通道阻斷劑有可能使得母體血壓過低而導致胎兒缺氧，因此除了預期效益比胎兒風險還高時，孕婦不應使用本藥物。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,藥品仿單：利用脈優進行治療時應停止授乳。 人體使用經驗表明amlodipine可分泌至人乳中。在31名發生妊娠高血壓的授乳女性中，施用amlodipine (初始劑量為每天一次每次5毫克) 後，乳汁與血漿中amlodipine濃度比中位數為0.85。該劑量會視需要做相應調整，平均每日劑量及依體重校正後的每日劑量分別為6毫克 和98.7微克/公斤。估計經由乳汁進入嬰兒體內的amlodipine每日劑量約為4.17微克/公斤。,AC;AC15;PC;PO;WM;,,,,,
ONOVO,Repaglinide,NovoNorm (Repaglinide) 1mg,META,,I: Type 2 diabetes(NIDDM) whose hyperglycaemia is not controlled satisfactorily by diet， wt reduction & exercise. ADR: (>10 %) Headache， hypoglycemia. (1 ~ 10 %) Cheast pain， nausea， heartburn， vomiting， constipation， diarrhea， tooth disorder， arthralgia， back pain， paresthesia， allergy. (<1 %) Alopecia， anaphylactoid reaction， hemolytic anemia， hepatic dysfunction， leukopenia， liver function tests increased， pancreatitis， Stevens-Johnson sundrome， thrombocytopenia. CI: Type 1 diabetes. Diabetic ketoacidosis with or without coma. Pregnancy， lactation. Childn < 12 yr. Severe renal or hepatic function disorders. Concomitant therapy with medicinal products which are CYP3A4 inhibitors or inducers.,,RT,Initially 0.5mg， max single dose: 4mg with main meals. Max: 16mg/day.,,,,除非治療上需要,,,,,,,,,,
OOLB,Acipimox,Olbetam 250mg,CAVS,,hyperlipoproteinemia.,,,Treatment of type IV hyperlipoproteinemia 1 cap bid. Type Ⅱa，Ⅱb，Ⅲ，V 1 cap tid. Daily dose should be adjusted according to plasma triglyceride & cholesterol levels.,,,,,,,,,,,,,,
OONE,Alfacalcidol,Onealfa 0.5mcg,META,,適應症:為維他命D3製劑(B018274100)(B023031100),,RT,Osteoporosis: Adult: 0.5-1 mcg qd. Child: 0.01-0.03 mcg/kg qd. Hypoparathyroidism: 1-4 mcg qd.,,,,安全,,,,,,,,,,
OOVE,Estriol,Ovestin 1mg,HM,,適應症:為女性賀爾蒙補充劑(B019326100),,RT,Tab: Climacteric symptoms & complaints: 4-8 mg/day for 7 days， Maintance dose: 1-2 mg day. Supportive therapy of vag or cervical infection & Inflammation :0.5-2mg/day until regeneration.,,,,不可使用,,,,,,,,,,
OPAN,Acetaminophen,Panamax 500mg,CNEU,,適應症: Relief of painful disorders such as headache， dysmenorrhea， conditions involving musculoskeletal pain， myalgias & neuralgias. After dental work， tooth extractions & in teething. As an analgesic & antipyretic in conditions accompanied by discomfort & fever， such as common cold & viral infections. 副作用: Acetaminophen has rarely been found to produce any side effects. It is usually well tolerated by aspirin-sensitive patients. Severe recurrent pain or high continued fever may indicate a serious conditions. Under these circumstances consult a physician.,,室溫,Adult:500 mg q4h as needed， (max. 4 g/day). For long term therapy， not exceeding 2.6 g/day. Child: 10-15 mg/kg q4h as needed， (max. 65 mg/kg/day) not more than 5 doses in each 24 hrs period. 6-10 yrs.:20 ml qid.,需調整劑量,,需調整劑量,可能安全,,,Compatible 哺乳時可使用,,,,,,,
OPANA,Acetaminophen,Panadol for Children 80mg,CNEU,,適應症:具解熱、鎮痛作用(A028474100)(B023602100),,RT,Adult:500 mg q4h as needed， (max. 4 g/day). For long term therapy， not exceeding 2.6 g/day. Child: 10-15 mg/kg q4h as needed， (max. 65 mg/kg/day) not more than 5 doses in each 24 hrs period. Syrup: 3 months-1 yr.:2.5-5 ml qid. 1-6 yrs.:5-10 ml qid. 6-10 yrs.:20 ml qid.,,,,可能安全,,,,,,,,,,
OPANT,Terfenadine,Pantadin 60mg,HIMM,,,,,,,,,,,,,,,,,,,
OANTA,Magaldrate,Antashin(愛克胃新) 400mg,ALIM,,I : Hyperacidity,,,1-2 tab qid,,,,除非治療上需要,,,,,,,,,,
LEUF,Dimemorfan Phosphate,Eufan 2.5mg/mL， 120mL,ERSP,,適應症:鎮咳(A044509157) SP: Diabetes mellitus AP: Infrequently， change in glucose tolerance; dizziness， drowsiness; dry mouth， nausea， vomiting. Rarely， malaise; tachycardia， palpitations， hot flushes.,,,D: children 7-14 yr: 12-14 ml 6-4 yr: 8-11 ml 2-3 yr: 5-8 ml <2 yr: 3-4.5 ml tid,,,,,,,,,,,,,,
EPAR,Chlorhexidine gluconate,Parmason gargle 0.2%， 200mL,TENT,Cleansing & disinfection of mouth infections， eg gingivitis & oral candidiasis.,Hypersensitivity to any component of the formulation.,Conjunctival irritation. Discolouration of the tongue & teeth. Taste disturbances， burning sensation of the tongue. Oral desquamation.,25℃以下,Oral infection; Prophylaxis 10-20 mL BID rinse for 30-60 sec then spit it out,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,GAR;,,,,,
OLIV,Tibolone,Livial 2.5mg (28 tablets/box),HM,Complaints resulting from natural or surgical menopause.,Pregnancy. Known or suspected hormone dependent tumours. CV or cerebrovascular disorders， vag bleeding of unknown etiology; severe liver disorders.,Change in body wt， dizziness， seborrhoeic dermatosis， vaginal bleeding， headache， GI upset， changes in liver parameters， increased facial hair growth， pretibial edema.,2-25℃,1 tablet QD.,無需調整劑量,It is not known if tibolone or its metabolites are present in breast milk. Use is contraindicated in women who are breastfeeding.(UpToDate)2021/0125,無需調整劑量,沒有資料,Uknown 沒有資料,Tibolone is approved for use in postmenopausal women; use is contraindicated during pregnancy. Discontinue immediately if pregnancy occurs.(UpToDate)2021/0125,Unknown 沒有資料,It is not known if tibolone or its metabolites are present in breast milk. Use is contraindicated in women who are breastfeeding.(UpToDate)2021/0125,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉。
OQUE,Cholestyramine,Questran 4gm/pk,CAVS,,適應症: Hypercholesterolemia， Pruritus associated with partial biliary obstruction， Intractable diarrhea， Acute diarrhea. 副作用: Commonly， GI disturbances. Constipation may be accompanied by fecal impaction &/or hemorrhoids. 禁忌: Complete biliary obstruction.,,室溫,Hypercholesterolemia: 12-16 g/day， (max. 16-32 g/day)， ac. Pruritis of cholestasis: 4 g tid-qid. Diarrhea: Infant and child: 2-8 g/day in 3-4 divided doses. Adult: 4 g tid.,,,,除非治療上需要,,,,,,,,,,
ORIT,Methylphenidate,Ritalin 10mg,CNEU,,適應症: Attention-deficit hyperactivity disorder; narcolepsy. 副作用: Frequent: nervousness， insomnia， decreased appetite. Occasional: headache， drowsiness， dizziness， dry mouth， tachycardia， palpitations， arrhythmias， changes in BP & heart rate; GI disturbances， skin reactions， fever， arthralgia. Rare: blurred vision， moderately reduced weight gain & minor growth retardation in children. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )， Loss of appetite (5% )， Nausea (12% )， Vomiting (10% ) Neurologic: Headache， Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )， Nasopharyngitis (5% ) 禁忌: Anxiety & tension states， agitation， tics， tics in siblings， family history or diagnosis of Tourette's syndrome; glaucoma; hyperthyroidism; cardiac arrhythmias， severe angina pectoris.,,室溫,20-30 mg daily. Children >= 6 years Initially 5 mg once-bid with gradual increments of 5-10 mg weekly. Max: 60 mg/day.,,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,,,,,,
OSOT,Sotalol,Sotalex 80mg,CAVS,,I: Ventricular arrhythmias. CI: Bronchial asthma， sinus bradycardia; 2nd and 3rd degree AV block; congenital or acquired long QT syndromes; cardiogenic shock; uncontrolled CHF; concurrent use of cisapride， gatifloxacin， moxifloxacin， or sparfloxacin.,,RT,Initial dose is 80 mg bid. This dose may be increased if necessary， after appropriate evaluation， to 240 or 320 mg/day. In most patients， a therapeutic response is obtained at total daily dose of 160 to 320 mg/day， given in two or three divided doses.Because of the long terminal elimination half-life of sotalol， dosing on more than a twice-daily regimen is usually not nessary.,,,,可能安全,,,,,,,,,,
OTAM,Tamoxifen,Nolvadex 10mg,RACA,Breast cancer.,Pregnancy， concomitant coumarin-type anticoagulant therapy; when used for the reduction in breast cancer incidence in high risk women， deep vein thrombosis， history; when used for the reduction in breast cancer incidence in high risk women， hypersensitivity to tamoxifen citrate or any component of the product， pulmonary embolus， history; when used for the reduction in breast cancer incidence in high risk women.,Hot flushes， vag bleeding， vag discharge & pruritus vulvae; GI intolerance， tumour flare， light-headedness; fluid retention， skin rash， alopecia. A small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy. Falls in platelet count. Visual disturbance including corneal changes， cataracts & retinopathy. Cystic ovarian swellings occasionally in pre-menopausal women. Infrequently， thromboembolic events. An increased incidence of endometrial changes， including hyperplasia， polyps & cancer have been reported. Dermatologic: Menopausal flushing (33% to 64% ) Reproductive: Amenorrhea， Disorder of menstruation， Irregular periods， Vaginal discharge,儲存請勿超過30℃,20-40 mg once daily (with doses >20 mg administered in 2 divided doses),無需調整劑量,,無需調整劑量,盡量避免,Contraindicated,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
ERET,Tretinoin,Retin-A cream 20gm,TDER,,,,,,,,,,,,,,,,,,,
ERHE,Etofenamate,Rheumon gel 20gm,CNEU,,,,,,,,,,,,,,,,,,,
ERIN5,Betamethasone,Rinderon eye soln 0.1%， 5mL,TOPH,,適應症: Short-term treatment of steroid responsive inflammatory conditions of the eye. 副作用: Local burning & irritation， raised intraocular pressure， thinning of cornea (possibly perforation); rarely， cataracts (prolonged use). 禁忌: Bacterial， viral， fungal， tuberculous or purulent conditions of the eye; glaucoma; herpetic keratitis.,,室溫,1-2 drops tid-qid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ERINO,Betamethasone + Fradiomycin,Rinderon-A 眼藥膏3gm,TOPH,,適應症: Inflammatory conditions of the eye when secondary bacteria infection is present. 副作用: Allergic reactions， superinfection， delayed wound healing， raised intraocular pressure， thinning of cornea (possible perforation). 禁忌: Viral， fungal or TB conditions; glaucoma， herpetic keratitis.,,室溫,3-5 times daily.,,,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IPLA1,Cisplatin,Platinex inj 10mg/20mL,RACA,,Testicular cancer， ovarian cancer， head and neck， Hogkin's and non-Hogkin's lymphoma， sarcomas， bladder， gastric， lung， esophageal， cervical， prostate， myeloma， breast， melanoma， mesothelioma， and osteosarcoma.,,RT,IV infusion over 6-8 hrs， As a single agent: 50-100 mg/ml once every 4 wks. Metastatic testicular tumors: combined with vinblastine & bleomycin， 20/mL/day for 5 days every 3 wks for 3 courses. Metastatic ovarian tumors: combined with doxorubicin， 50 mg/mL once every 3 wks.,,,,盡量避免,,,,,,,,,,
IPPD,Tuberculin purified protein derivative,Tuberculin PPD (結核菌素試劑) 0.1mL/dose,HIMM,Skin test as an aid in the diagnosis of tuberculosis.,Hypersensitivity to any component of the formulation.,Injection site reactions (pain， pruritus， redness， ulceration， scarring),2-8℃避光避免冷凍,ID， 0.1 mL， in the middle third of the forearm.,無需調整劑量,WHO:Compatible with breastfeeding.,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,WHO:Compatible with breastfeeding.,ID;,,,,,
IPRE,Estrogen + Medroxyprogesterone,Premarin inj 25mg,HM,,Menopausal and post-menopausal oestrogen replacement， postmenopausal osteoporosis， atrophic vaginitis or urethritis.,,,IM， IV: 25 mg， repeated in 6-12hrs if needed.,,,,不可使用,,,,,,,,,,
IPROS,Oxacillin,Prostaphlin inj 250mg,QANB,,,,,,,,,,,,,,,,,,,
IPUR,Follitropin beta,Puregon 100 IU/0.5mL,HM,,適應症:Treatment of female infertility due to anovulation in women who have been unresponsive to treatment with clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs. 副作用:Ovarian hyperstimulation， bruising， pain， redness， swelling & itching， ectopic pregnancy， multiple gestations， arterio-thromboembolisms 禁忌:Ovarian， breast， uterine， pituitary or hypothalamic tumours. Pregnancy or lactation. Undiagnosed vag bleeding. Primary ovarian failure. Ovarian cysts or enlarged ovaries， not related to polycystic ovarian disease (PCOD). Sexual organ malformations incompatible with pregnancy. Uterine fibroid tumours incompatible with pregnancy,,2-8℃,Anovulation 50 iu daily， maintained for at least 7 days. Controlled ovarian hyperstimulation in medically assisted reproduction programs Starting dose of 100-225 iu for at least the 1st 4 days.,無需調整劑量,,無需調整劑量,不可使用,,,Contraindicated 哺乳期使用禁忌,,SC;,,,,,
IPROA,Protamine,Protamine sulphate 50mg/5mL,ZADT,Heparin antidote.,Hypersensitivity to any component of the formulation.,If administered by rapid IV; hypotension， bradycardia， dyspnea. Transitory flushing.,30℃以下,"If given within 15 min of the heparin injection， 10 mg of protamine will neutralize 1400 iu of heparin. The quantity of protamine required for neutralization falls rapidly with the lapse of time after the administration of heparin. If more time has elapsed after the administration of heparin， the dose of protamine sulfate required for neutralization should be determined accurately by titrating with the patient's plasma.",無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D5W】可選 。【N/S】可選 。,,投予protamine sulphate應緩慢靜脈注射超過10分鐘，最大單一注射劑量不應超過50mg/5mL。若要緩慢靜脈輸注，應使用生理食鹽水稀釋。,1. IVD易發生低血壓 2. 每10 mg protamine sulphate可中和1440國際單位的 Heparin。 3. 投予protamine sulphate應緩慢靜脈注射超過10分鐘，最大單一注射劑量不應超過50mg/5mL。若要緩慢靜脈輸注，應使用生理食鹽水稀釋。
IROB,Glycopyrrolate,Robinul inj 0.2mg/mL,ALIM,,適應症:Preoperatively to inhibit salivation & excessive secretions of the respiratory tract; reversal of neuromuscular blockade; control of upper airway secretions; adjunct in treatment of peptic ulcer. 副作用:Dry mouth; urinary hesitancy & retention; blurred vision. Increased ocular tension; tachycardia; palpitations; decreased sweating， loss of taste， headache， nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; severe allergic reaction， drug idiosyncrasies; urticaria; mental confusion. 禁忌:In management of peptic ulcer， may be C/I in glaucoma; obstructive uropathy; achalasia; pyloroduodenal stenosis; paralytic ileus; intestinal atony in the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Inj Newborn infant <1 mth.,,,Preoperative Adult & children 1 month-12 years 0.002 mg/pound body weight (0.01 mL) IM 30-60 mins before procedure or to be administered with pre-anesth narcotic & sedative. Intraoperative Adult 0.1 mg (0.5 mL) IV. May repeat at intervals of 2-3 mins. Children 0.002 mg/pound body weight (0.01 mL) IV. Max: 0.1 mg (0.5 mL)/dose. May repeat at intervals of 2-3 mins. Reversal of neuromuscular blockade Adult & children 0.2 mg (1 mL) IV for each 1 mg of neostigmine or 5 mg of pyridostigmine.,,,,可能安全,,,,,,,,,,
IALL,Allergy Skin Test,Allergy skin test,ZOTH,,,,,,,,,,,,,,,,,,,
IAMH,Amino Acids,Aminopoly-H 500 mL,NUTR,,,,,,,,,,,,,,,,,,,
IAMIK,Amino Acids + Xylitol,Aminol-K inj 500mL,NUTR,,適應症:為成人胺基酸補充液(A011723277),,RT,IV infusion 500-2000 ml/daily.,,,,沒有資料,,,,,,,,,,
IAMIL,Aminophylline,Aminophylline針劑250mg/10mL,ERSP,,適應症: Bronchospasm. 副作用: GI disturbances， visual disturbances， insomnia， nervousness， psychotic disturbances， dizziness. 禁忌: Hypersensitivity to xanthines.,,室溫,Amp Adult 250-500 mg 6 hrly， children 5 mg/kg 6 hrly.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
IAMIN,Amino Acids Infusion Soln,Aminosteril N Hepa 8% 500mL,NUTR,,適應症: Parenteral amino acid supply in severe forms of hepatic failure with & without encephalopathy， therapy of hepatic coma. 副作用: May lead to an increased production of gastric acid & to stress ulcer. 禁忌: Disturbed amino acid metabolism， conditions following hyperhydration， hyponatremia， hypokalemia， renal insufficiency， severe cardiac insufficiency.,,室溫,1.3-1.5 mL/kg body weight/hr. Max: 1.5 g amino acids/kg body weight/day.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,1. 輸注速率： 1.3-1.5mL/kg BW/Hour，最大劑量：1.5 公克胺基酸/kg BW/天。
IAMIO,Amiodarone,Amiodarone (Cordarone) inj 150mg/3mL,CAVS,Wolff-Parkinson-White syndrome， supraventricular & ventricular tachycardia， atrial & ventricular fibrillation.,AV or SA block， sinus bradycardia， sick sinus syndrome except when used in conjunction with a pacemaker; history of thyroid dysfunction; iodine intolerance， severe arterial hypotension， CV collapse， acute cardiac insufficiency. Combined therapy with drugs which may induce torsades de pointes. Pregnancy， lactation.,Hot flushes， sweating， nausea， moderate transient hypotension， moderate bradycardia， arrhythmia， elevation of transaminases. May impair hepatic function. Cardiovascular: Bradyarrhythmia， Hypotension (oral， less than 1%; intravenous， 15.6% ) Dermatologic: Photodermatitis (2% to 24% )， Photosensitivity (3% to 10% ) Endocrine metabolic: Thyroid dysfunction Gastrointestinal: Constipation (4% to 9% )， Loss of appetite (4% to 9% )， Nausea (10% to 33% )， Vomiting (10% to 33% ) Hepatic: Increased liver enzymes (4% to 9% ) Neurologic: Abnormal gait (4% to 9% )， Coordination problem (4% to 9% )， Dizziness (4% to 9% )， Involuntary movement (4% to 9% )， Movement disorder (4% to 9% )， Paresthesia (4% to 9% )， Peripheral neuropathy Ophthalmic: Corneal deposit， Microdeposits， Visual disturbance (4% to 9% ) Other: Malaise and fatigue (4% to 9% ),25℃以下,Must be administered using a volumetric infusion pump preferably via a central venous catheter. Initially 5 mg/kg in 250 mL of dextrose 5% IV infusion for 20 minutes to 2 hours. May repeat 2-3 times in 24 hours. Maintenance dose: 10-20 mg/kg (usually 600-800 mg/24 hours， maximum: 1.2 gm/24 hours) in 250 mL dextrose IV infusion. Cardiopulmonary resuscitation， Ventricular fibrillation/pulseless ventricular tachycardia: 300 mg IV by rapid infusion; a single dose of 150 mg IV may be repeated if Ventricular fibrillation/pulseless ventricular tachycardia recurs.,無需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,Contraindicated 哺乳期使用禁忌,,IVD;IVP;IVPUSH;,,【D5W】可選 。,administer according the ACLS guidelines for ventricular fibrillation/pulseless ventricular tachycardia (300mg 以20mL的5%葡萄糖溶液稀釋後快速注射),稀釋濃度不可低於 600mg/L(2 Amp in 500 mL D5W)，儘可能從中央靜脈導管點滴給藥(濃度大於2mg/mL需由CVP給藥)，注射時間超過2小時應使用玻璃或非PVC容器稀釋液,1.稀釋濃度不可低於 600mg/L(2 Amp in 500 mL D5W)，稀釋液只能使用等張的葡萄糖溶液。請勿將任何其他的產品加入此輸注溶液中。 2.儘可能從中央靜脈導管點滴給藥，濃度大於2mg/mL須由CVP給藥。 3.注射時間超過2小時應使用玻璃或非PVC容器稀釋液(否則會有10%藥物被吸附)。 4.不可混入Sodium Bicarbonate，會沉澱。 5.建議使用0.22micron fillter過濾。
IAMIP,Amikacin,Amikin inj 500mg/2mL,QANB,,適應症:細菌性感染(A034956212)(B017767212),,RT,IM or intermittent infusion over 30-60 mins (preferred)， Adult and child: 7.5 mg/kg q12h or 5 mg/kg q8h， (max.15mg/kg/day not to exceed 1.5 g/day). Neonate: 10 mg/kg initially， then 7.5 mg/kg q12h.,,,,除非治療上需要,,,,,,,,,,
OGIN,Ginkgo Biloba,Gina'ex F.C. 40mg,CAVS,,Peripheral circulatory or cerebrovascular disorders,,,1 Tab tid ~ qid,,,,沒有資料,,,,,,,,,,
OUFU,Tegafur + Uracil,UFUR 100/224mg,RACA,Colorectal cancer， gastric cancer， breast cancer， head & neck cancer， lung cancer.,Hypersensitivity to 5-fluorouracil. Pregnancy， lactation. Severe hepatic impairment or impairment of the cytochrome P450 3A system. Bone marrow suppression. Severe diarrhia. Severe infection.,Anorexia， diarrhea， nausea， vomiting， itch.,室溫 30℃以下保存,(1 UFUR capsule = tegafur 100 mg and uracil 224 mg)300-600 mg/day (300 mg/m2/day) tegafur administered in 2-3 doses one hour before or one hour after meals for 28 consecutive days. If the total number of UFUR capsules cannot be evenly divided， the highest dose should be given in the morning and lower doses in the afternoon or evening. Courses may be repeated every 35 days.,無需調整劑量,,無需調整劑量,沒有資料,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,AC;PO;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
EFLIN,Fluticasone,Flixonase nasal spray 0.05%,TENT,,適應症:過敏性鼻炎(B021477423) ADR: Nasal irritation， burning， dryness， mild naso-pharyngeal irritation， rhinorrhea， dry mucous membranes， nasal septum perforation， localized infections of the nose and pharynx with Candida albicans， alterations in taste and smell. CI: Hypersensitivity to any components of this product.,,< 30 ℃,D: Adult & childn > 12 yr : 2 sprays into each nostril once daily in the morning， in some severe cases， 2 sprays each nostril bid may be required. (Max : 4 sprays / nostril / day) Childn 4 - 11 yr : 1 spray into each nostril qd. (Max : 2 sprays / nostril / day),,,,除非治療上需要,,,,,,,,,,
ONIC,Nitroxoline,Nice 100mg,QANB,,適應症: Infection of the lower urinary tract. Infection related to urinary tract malformations & lithiasis.,,室溫,Adult : 100 mg tid ~ qid. Childn : 5 ~ 7 mg / kg / day divided into 4 doses.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OTRIO,Ethinylestradiol + Levonorgestrel,Trinordiol 21's/pk,HM,,I: Oral contraceptive. ADR: Chloasma， melasma， headache， nausea， vomiting， weight gain， breast pain， changes in menstrual flow， changes in libido， spotting， depression. CI: 1. History of thrombophlebitis 2. Cerebral vessel or coronary artery disease 3. Severe hepatic function impairment 4. Breast cancer 5. Estrogen-dependent neoplasia 6. Undiagnosed abnormal genital bleeding 7. Pregnancy,,RT,1 tab daily for 21 days beginning on Day 5 of menstruation， fallowed by 7 tab-free days.,,,,不可使用,,,,,,,,,,
IATO,Ferric Chloride Hexahydrate,Atofen inj 40mg/10mL,NUTR,,,,,,,,,,,,,,,,,,,
ENAC,Diclofenac,Naclof 0.1%， 5mL,TOPH,,適應症:白內障手術後之眼部發炎用(B019625429) AR: Mild transient burning sensation. CI: Hypersensitivity.,,RT,Pre-operation: Up to 5 drops over the 3 hrs preceding surgery. Post-operation: 3 drops immediately after surgery， thereafter 3-5 drops daily. Other indication: 4-5 drops daily.,,,,沒有資料,,,,,,,,,,
OBAS,Methimazole,Based 5mg,META,,適應症: Hyperthyroidism. 副作用:Skin rash， urticaria， nausea， vomiting， epigastric distress， hair loss， myalgia， edema， jaundice， sialadenopathy， lymphadenopathy & much less frequency of inhibition of myelopoiesis. 禁忌: Pregnancy， lactation.,,室溫,Adult: Initial， 5-10 mg q8h; maintenance， 5-15 mg/day. Child: Initial， 0.4 mg/kg/day， maintenance， 0.2 mg/kg/day.,,,,盡量避免,,,Compatible 哺乳時可使用,,,,,,,
OATR,Atropine,Atropine 1mg (Tromine),ALIM,,Cycloplegia and mydriasis， reduce salivation and bronchial secretion， spastic conditions of the GI tract.,,,0.4-0.6mg.,,,,除非治療上需要,,,,,,,,,,
EALC4,Alcohol,75% Alcohol 4000mL/bot,TDER,,,,,,,,,,,,,,,,,,,
ECRI,Progesterone,Crinone vaginal gel 8%,SGU,Treatment of disorders associated with progesterone deficiency， such as infertility due to inadequate luteal phase; for use during IVF， where infertility is mainly due to tubal， idiopathic or endometriosis linked sterility associated with normal ovulatory cycles.,Undiagnosed vag bleeding， breast or genital organ malignancy， acute porphyria， thrombophlebitis， thromboembolic disorder， cerebral apoplexy， missed abortion. Lactation.,Abdominal pain， perineal pain， headache， constipation， diarrhea， nausea， joint pain， depression， decreased libido， nervousness， somnolence， breast tenderness & pain， dyspareunia， nocturia， allergy， bloating， cramps， fatigue， pain， dizziness， vomiting， genital moniliasis & pruritus， aggressive reactions， forgetfulness， vag dryness， cystitis， UTI， vag discharge. Gastrointestinal: Abdominal pain (oral， 10% to 20%; vaginal gel， 5% to 12%; vaginal insert， 12% )， Constipation (vaginal gel， 27%; vaginal insert， 2% to 3% )， Nausea (oral， 8%; vaginal gel， 6% to 22%; vaginal insert; 7% to 8% ) Immunologic: Viral disease (oral， 7% to 12% ) Musculoskeletal: Cramp (vaginal gel， 15% to 26% ) Neurologic: Dizziness (oral， 15% to 24%; vaginal gel， 5% )， Headache (oral， 10% to 31%; vaginal gel， 13% to 19%， vaginal insert， 3% to 4% )， Sleep disorder (vaginal gel， 18% )， Somnolence (vaginal gel， 27% ) Psychiatric: Depression (oral， 19%; vaginal gel， 11% to 19% )， Feeling nervous (vaginal gel， 16% )， Mood swings (oral， 6%; vaginal gel， 22% to 23% ) Reproductive: Breast tenderness (oral， 16% to 27% )， Large breast (vaginal gel， 40% )， Pain， Post-oocyte retrieval (vaginal insert， 25% to 28% )， Pain of breast (oral， 6% to 16%; vaginal gel， 13% )， Perineal pain (vaginal gel， 17% ) Other: Fatigue (oral， 8% to 9%; vaginal gel， 21% to 22%; vaginal insert， 2% to 3% ),25℃以下,Treatment of infertility due to inadequate luteal phase : one application (1.125 g 8 % gel) every day， starting after documented ovulation or arbitrarily on the day18 to day21 of the cycle. When used during in-vitro fertilisation， daily application of CrinoneR 8 % gel should be continued for 30 days if there is laboratory evidence of pregnancy.,無需調整劑量,HYDROXYPROGESTERONE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,可能安全,Human data suggest risk in 1st trimester,HYDROXYPROGESTERONE PREGNANCY RECOMMENDATION: Human Data Suggest Risk (0–16 weeks) Compatible (after 16 weeks),No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,HYDROXYPROGESTERONE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,VAG;,,,,,
EEFE,Fluorometholone + Tetryzoline,Efemoline eye drops 0.1%， 5mL,TOPH,,適應症:Acute & chronic allergic non-infectious conjunctivitis & keratitis with severe swelling & intravascular inj. Non-infectious inflammation of the anterior segment of the eye. Post-op states after strabotomy; cataract & glaucoma operations. 副作用:Mild burning sensation; reversible increase in intraocular pressure， reactive hyperemia/rebound effect， cataract & corneal defects， glaucoma， systemic effects (chronic use). 禁忌:Herpes corneal superficialis， mycosis of the cornea & conjunctiva， tuberculous affections， ulcerous processes of the cornea.,,室溫,1 drop bid-tid. Increasing to 1 drop hrly in the 1st 24-48 hr if required.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OFER4,Ferrous Fumarate,Ferall 軟膠囊 460mg,NUTR,,Treatment all anemias responsive to oral iron therapy.,,RT,1-2 cap daily.,,,,除非治療上需要,,,,,,,,,,
ECLOC,Clobetasol,Clobetasol cream 0.05%， 5gm,TDER,,適應症:主治乾癬、扁平苔癬、皮膚搔癢等過敏症狀(A028562321),,RT,Apply bid.,,,,沒有資料,,,,,,,,,,
IANT,Folinic Acid,Antrex inj 30mg/10mL,ZADT,,適應症: Megaloblastic anemia due to folic acid deficiency， Intoxication & side-effects of folic acid antagonists， associated with high-dose methotrexate. 副作用:Occasionally Allergic reactions. Pyrexia may occur after inj 禁忌: Untreated vit B12 deficiency. Never given alone or in conjunction with inadequate amounts of hydroxocobalamin.,,2-8℃,Megaloblastic anemia due to folic acid deficiency Initially， 9-12 mg IM or 1 tab daily for 10-15 days. Then adjust dose according to clinical response. Intoxication & side-effects of folic acid antagonists 3-6 mg 1-2 times daily IM. Associated with high-dose methotrexate Individualised dosage,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
LROT3,Human Rotavirus,RotaTeq (MSD 輪狀病毒疫苗) 2mL/dose,HIMM,Prevention of rotavirus gastroenteritis in infant & children caused by the serotypes G1， G2， G3， G4 & G-serotypes that contain P1 (such as G9).,Hypersensitivity.,Diarrhea， vomiting， irritability， fever.,2-8℃避光,2 mL， 3 doses administered orally starting at 6-12 weeks of age， the subsequent doses administered at 4- to 10-weeks intervals. The third dose should be given before 32 weeks of age.,無需調整劑量,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料。 此疫苗不適用於成人。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料。 此疫苗不適用於成人。,Unknown 沒有資料,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料。 此疫苗不適用於成人。,PO;,,,,,
EENT,Tyrothricin,ENT oint 5gm,TENT,,適應症: Acute & chronic forms of rhinitis & treatment of bacterial infection of the nasal mucosa. 副作用: Rarely， hypersensitivity reactions. 禁忌: Acute & congestive glaucoma. Children <= 2 years.,,室溫,Apply to the nasal mucosa several times daily.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IREC,Epoetin-B 5000 I.U.,Recormon 5000 inj,HEMT,,,,,,,,,,,,,,,,,,,
IRECO,Propofol,Recofol inj 10mg/mL， 20mL,ZANE,,A short-acting intravenous anaesthetic agent suitable for induction and maintenance of general anesthesia.,,,Induction: IV， 2-2.5 mg/kg. Maintenance: IV infusion， 6-12 mg/kg/hr or intermittent IV bolus， 25-50 mg.,,,,可能安全,,,,,,,,,,
IREL,Succinylcholine,Relaxin inj 500mg,CNEU,Muscle relaxation.,Genetically determined disorders of plasma pseudocholinesterase; history of malignant hyperthermia; penetrating eye injuries.,Bronchial spasm; arrhythmia; hypotension; myotonia， raised intraocular pressure & hypersensitivity,25℃以下,IV injection for endotracheal intubation: 10-60 mg. Continuous IV infusion: dilute with normal saline or 5% dextrose to 0.1-0.2% solution， with rate of 2.5 mg/min. Infants and children: 1 mg/kg/dose intravenously or 2 to 3 mg/kg/dose intramuscularly.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;IVPUSH;,N/S or D5W， 250mL or 500mL. Final concentration of 1 or 2 mg/mL. (0.1% or 0.2% solution),【D5W】可選 仿單建議。【N/S】可選 仿單建議。,for Intubation: Adult dose - 0.6 mg/kg (range: 0.3 to 1.1 mg/kg),IVD: (continuous infusion) a solution diluted to 1 mg/mL in D5W or N/S may be administered at a rate of 0.5 to 10 mg/min depending on patient specific factors.,Do not mix with alkaline solutions having a pH greater than 8.5 (eg， barbiturate solutions). Add 1 g succinylcholine to 1000 or 500 mL sterile solution (eg， D5W or NS) for a final concentration of 1 or 2 mg/mL. (0.1% or 0.2% solution)
IRHO,Rho D Immune Globulin,Rho (D) Immune Globulin [HyperRHO],HIMM,Prevention of Rh haemolytic disease of the newborn by its administration to the Rho (D)-ve mother， within 72 hr after birth of her 1st Rho (D)+ve infant or after an abortion.,Rho (D)+ve mother.,Pain at inj site. Slight temp elevation. Hypersensitivity (rare),2-8℃避免冷凍,IM， full dose， Postpartum prophylaxis within 72 hours. Antenatal prophylaxis 1 full dose at 28 weeks gestation， followed by 1 more full dose within 72 hours postpartum. Threatened abortion at any stage of gestation 1 full dose.,無需調整劑量,[UpToDate2021/01/25]Adverse events in the breastfeeding infant have not been observed when administered to women for the suppression of RhD isoimmunization.,無需調整劑量,除非治療上需要,Uknown 沒有資料,[UpToDate2021/01/25]Available evidence suggests that Rho(D) immune globulin administration during pregnancy does not harm the fetus or affect future pregnancies.(UpToDate)2021/01/25 [仿單]使否影響生殖能力、或孕婦使用後是否會傷害胎兒不清楚，唯有明確需要時才 可對孕婦投予。,Unknown 沒有資料,[UpToDate2021/01/25]Adverse events in the breastfeeding infant have not been observed when administered to women for the suppression of RhD isoimmunization.,IM;,,,,,
IRII,Insulin Regular,Insalin Actrapid (R) 100IU/mL,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,,According to individual requirements.,,,,,,,,,,,,,,
OFAR,Medroxyprogesterone,Farlutal 500mg,RACA,,適應症:Palliative treatment of breast cancer; endometrial carcinoma， hypernephroma， prostate carcinoma; prostate hypertrophy. Anorexia cachexia. 副作用:Mastodynia， galactorrhea， vag bleeding， amenorrhea; modification to cervical erosions & secretions; changes in menstrual flow; edema; weight variation; cholestatic jaundice; rash; mental depression. 禁忌:Thrombophlebitis; thromboembolic disorders; severe hepatic impairment; hypercalcemia; pregnancy; missed abortion.,,室溫,Breast CA: 1 g / day. Other hormone dependent CA: 200 ~ 500 mg / day.,,,,不可使用,,,,,,,,,,
OFLAM,Diclofenac,Flamquit 50mg,CNEU,,An analgesic， antipyretic， anti-inflammatory agents used in RA. and other rheumatic disorders.,,,Oral: 25mg tid-qid， "Adefuronic". 100 mg qd， swallowed whole， "Grofenac Retard".,,,,,,,,,,,,,,
OFT207,Futraful,FT 207 200mg,RACA,,Malignant neoplasms of the breast and G-I tract.,,,800-1200 mg/day in 2-4 divided doses. 750mg-2g rectally once or in 2 divided dose daily.,,,,盡量避免,,,,,,,,,,
OFYB,Ispaghula Husk,Fybogel,ALIM,,Diverticular disease，spastic & irritable colon. Constipation due to insufficient fibre.,,,Adult 1 sachet bid.Childn 2.5-5 ml bid.,,,,,,,,,,,,,,
IANP,Ritodrine,Anpo 針劑 50mg/5mL,SGU,Prevention of preterm labour， Acute fetal distress， Prevention of preterm labour after operation.,Antepartum haemorrhage due to any cause but particularly placenta previa & abruptio placentae. Eclampsia & severe pre-eclampsia. Intra-uterine foetal death. Chorioamnionitis. Maternal cardiac disorder. Hyperthyroidism. Uncontrolled hypertension. Any other condition which can endanger cardiac function. Parenteral: Asthmatics (due to sulfite component).,Pulmonary oedema (several cases reported with fatal results). Maternal & foetal heart rate can increase. Frequently: Tremor， nausea， vomiting， headache or erythema， nervousness， restlessness， jitteriness， emotional upset， anxiety or malaise. Infrequently cardiac symptoms， eg chest pain or tightness with or without ECG abnormalities & cardiac arrhythmias. Hepatic impairment.,25℃以下，避免冷凍,Uncomplicated premature labour: IV infusion， initially 0.05 mg/min. Increase by 0.05 mg/minute every 10 min until patient responds. Usual rate: 0.15-0.35 mg/minute. Maintain for 12-48 hour after the contractions have stopped. As IM injection: initially 10 mg for 1 hour. then 10-20mg every 2-6 hours maintain for 12-48 hours. Increase or decrease the dose depending on the response.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,IM;IVD;,,【D5W】可選 。【L/R】可選 。【N/S】可選 。,,起始: 0.05 mg/min，維持:0.15~0.35 mg/min，輸注液建議使用D5W，若使用N/S稀釋，將增加發生肺水腫之可能性。,1. 輸注液建議使用D5W。若使用N/S稀釋，將增加發生肺水腫之可能性。(衛生署公文：FDA藥字第1001409159號)
IART,Sodium Hyaluronate,ARTZDispo 2.5mL,CNEU,,Degenerative osteoarthritis failed to common analgesics.,,,25mg weekly for 5 weeks intraarticular use.,,,,除非治療上需要,,,,,,,,,,
IVFDRUG,誘發排卵藥物費,誘發排卵藥物費,PHR,,,,,,,,,,,,,,,,,,,
IWAT,Water for injection,Water for injection 20mL,NUTR,Solvent for parenteral preparations.,,,室溫藥品，仿單無特別指示儲存溫度條件,It is for use only as a sterile solvent or diluent vehicle for drugs or solutions suitable for parenteral administration.,無需調整劑量,,無需調整劑量,沒有資料,Compatible,,Compatible 哺乳時可使用,,ID;IH;IM;IRR;IVD;IVPUSH;,,,,,
IXYL1,Lidocaine,Xylocaine 1% inj 20mL,ZANE,,1%/20 ml/vial: For local anesthesia， acute management of cardiac rrhythmia.,,,Infiltration， caudal， epidural or peripheral nerve block: Up to 30 ml as a 1% soln or 15 ml as a 2% soln. Surface anesthesia: Nose， nasopharynx and respiratory tract: 1-5 ml of 1%-4% soln is sprayed， 8% spray may be needed. Mouth， pharynx and upper digestive tract: 5-15 ml of 2% viscous soln. Urethral catheterization: Men， 5-10 ml; women， 3-5 ml of 2% jelly.,,,,可能安全,,,,,,,,,,
IXYL1E1,Lidocaine + Epinephrine,Xylocaine 1% + E inj 1mL,ZANE,,,,,,,,,,,,,,,,,,,
IXYL21,Lidocaine,Xylocaine 2% inj 1mL局麻,ZANE,For the production of local or regional anesth by infiltration， IV regional anesth， minor & major nerve blocks， epidural block & subarachnoid block.,Epidural or spinal anesth in patients with uncorrected hypotension or with coagulation disorders or receiving anti-coagulation treatment; inflammation &/or sepsis in the region of proposed inj or in the presence of septicemia; general contraindications related to epidural anesth should also be taken into account.,CNS reactions， either excitatory or depressant. CV reactions， mainly depressant. Maternal hypotension. Rarely allergic reactions.,室溫,Maximum recommended single dose of lidocaine is 3 mg/kg (plain solution) or 7 mg/kg (solution with adrenaline). Adult， 70 kg: Retrobulbar or peribulbar: 4 mL of 2% solution (80 mg). Sciatic nerve block: 15-20 mL of 2% solution (300-400 mg). Epidural anesthesia， Lumbar: 15-25 mL of 2% solution (300-500 mg). Epidural anesthesia， Thoracic: 15-20 mL of 2% solution (300-400 mg).,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,LA;LI;,,,,,
IXYL2E1,Lidocaine + Epinephrine,Xylocaine 2% + E inj 1mL,ZANE,,Local anesthesia.,,,Infiltration， caudal， epidural or peripheral nerve block: As needed， up to 50 ml.,,,,除非治療上需要,,,,,,,,,,
IXYL2V,Lidocaine,Xylocaine IV 2% 100mg/5mL,ZANE,Emergency treatment of ventricular arrhythmia.,Complete AV block. Amide local anesthetic hypersensitivity.,Conduction block， shock. Rarely malignant hyperthermia. Confusion， dizziness， drowsiness， nervousness， euphoria， vomiting， numbness.,25℃以下,Adult IV 50-100 mg (1-2 mg/kg) slow IV within 1-2 mins. If no effect is observed after the 1st inj， the same dose may be repeated after 5 mins. May repeat at 10-20 min intervals but not > 300 mg during a 1 hr period. IV infusion 1-2 mg/min.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,,Slow IV 50~100 mg/1~2 min (一小時內最高基準給藥量300mg),I.V. infusion: 1000 mg in 250 mL (concentration: 4 mg/mL) or 2000 mg in 250 mL (concentration: 8 mg/mL) of D5W,Usual Infusion Concentrations: Adult I.V. infusion: 1000 mg in 250 mL (concentration: 4 mg/mL) or 2000 mg in 250 mL (concentration: 8 mg/mL) of D5W 不可與鹼性藥品混合，會有沉澱析出。 Usual Infusion Concentrations: Pediatric Note: Premixed solutions available I.V. infusion: 8000 mcg/mL Compatibility Stable in D5LR， D51/2NS， D5NS， D5W， LR， 1/4NS， NS.
IEPO4,Recombinant Human Erythropoiet,Eprex (EPO 4000 IU),HEMT,,適應症:Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy 副作用:Increased BP， thrombotic or vascular events. Flu-like symptoms， bone pain & chills after inj. Seizures. Skin reactions， palpebral edema. Rarely， erythroblastopenia. 禁忌:Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.,,2-8℃,Chronic renal failure Adult patients Correction phase: 50 iu/kg 3 times/week IV. When necessary， dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 iu/kg. Pediatric patients Correction phase: 50 iu/kg 3 times/week IV. When necessary， dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally， children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 iu/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 iu/kg for an additional 4 weeks.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,1. 本藥品為預先充填的針筒，限單次使用，給藥前須先檢查確定溶液無雜質或變色。 2. 皮下注射每次體積不可超過1 mL。如需注射較大量，應於不同部位給藥。 3. 靜脈注射時間至少須超過 1-5 分鐘。血液透析病人在透析期間，可經由透析線內一個適當的靜脈入口進行大量注射。 4. 本藥品「不可以」靜脈點滴輸注或與其他藥物混用。
IEPOC,Ceftizoxime,Epocelin 0.5gm,QANB,,Useful in the treatment of meningitis due to susceptible G(-) bacilli， including betalactamase positive H. influenzae， active against Enterobacteriaceae and modest activity vs. Ps. aeruginosa.,,,IV， IV infusion or IM. Adult: 0.5-2g/day in 2-4 divided doses. increased up to 4g/day. Childn 40-80mg/kg/day in 2-4 divided doses; max. 120mg/kg/day.,,,,可能安全,,,,,,,,,,
IFEN1,Fentanyl,Fentanyl inj 0.05mg/1mL,CNEU,,適應症: Premed prior to surgery， Adjunct to general anesth induction， Adjunct to regional anesth， Post-operatively . 副作用: Respiratory depression， apnoea， muscle rigidity & bradycardia. 禁忌: Children <2 years， bronchial asthma， respiratory depression & head injury. Patients who received MAOIs within previous 14 days.,,室溫,Premed 50-100 mcg IM 30-60 mins prior to surgery. Adjunct to general anesth induction 50-100 mcg IV & repeated at 2-3 mins intervals until the desired effect is achieved. Adjunct to regional anesth 50-100 mcg IM or slow IV inj. Post-operatively 50-100 mcg IM repeated in 1-2 hr as needed. Induction & maintenance of anaesth Children 2-12 years 20-30 mcg/10 kg body wt.,,,,盡量避免,,,Compatible 哺乳時可使用,,,,,,,
IFENBAD,Fentanyl,Fentanyl inj 0.05mg/mL殘餘銷燬,CNEU,,1. For analgesic action of short duration during the anesthetic period， premedication， induction， maintenance， and in the immediate post-operative period. 2. It is also as the only agent in diagnostic procedure such as arteriograms， and pneumonence-phalograms.,,,Adult dosage: 1.Premedication:50 -100mcg im. 2.Adjunct to general anaesthesia induction:50-100mcg iv and repeated at 2-3min intervals， until the desired effect is achieved. 3.Adjunct to regional anaesthesia:50-100mcg im or slow iv injection. 4.Postoperatively:50-100mcg im repeated in 1-2 hours as needed.,,,,,,,,,,,,,,
IATI,Lorazepam,Ativan inj 2mg/mL,CNEU,,Insomnia associated with anxiety， neurosis and transiet situational disturbance.,,,Anxiolytic:1-3 mg bid-tid， (max. 10 mg/day). Sedative-hypnotic:2-4 mg hs. For elderly or debilitated patients: Initial， 0.5-2 mg/day in divided doses. Inj Premed IV: 44μg/kg (max 2mg)15-20 mins before procedure.Premed IM:50μg/kg(max 4 mg)≧2 hr before procedure.,,,,盡量避免,,,,,,,,,,
IFLU,Acetylcysteine,Fluimucil inj 300mg/3mL,ZADT,,Reduce the viscosity of pulmonary secretions in cystic fibrosis of the pancreas， paracetamol poisoning.,,,IM 1 Amp. Qd~bid.,,,,可能安全,,,,,,,,,,
IFOY,Gabexate Mesilate,FOY 100mg,HEMT,,Acute pancreatitis， chronic recurrent pancreatitis with acute exacerbation， postoperative acute pancreatitis.,,,Pancreatitis: 100-300mg in 500-1500ml soln/day Disseminated intravascular coagulation: 20-39 mg/kg/day IV drip in 24 hrs.,,,,,,,,,,,,,,
IFRA,Dalteparin,FRAGMIN 10000 IU(Anti-Xa)/4mL(洗腎室專用),HEMT,Treatment of acute deep venous thrombosis. Prevention of clotting in the extracorporeal system during hemodialysis & hemofiltration.,Confirmed or suspected history of immunologically-mediated heparin-induced thrombocytopenia. Active， clinically significant bleeding (eg. GI ulceration or bleeding or cerebral hemorrhage). Severe coagulation disorders， septic endocarditis. Recent injury to， or surgical procedures of， the CNS， eyes &/or ears.,Reversible non-immunologically-mediated thrombocytopenia (type 1)， transient elevation of liver transaminases， bleeding， hematoma at inj site， allergic reactions， pain at inj site. Dermatologic: Hematoma， Injection site (7% to 35%)， Injection site pain (4.5% to 12% ) Hematologic: Hematoma Other: Irritation symptom， Local,25℃以下,Thrombolysis or treatment of acute deep vein thrombosis and pulmonary embolism not suitable for surgical treatment: SC once daily 200 IU/kg or twice daily 100 IU/kg， up to 18000 IU. Prophylaxis of coagulation during hemodialysis and hemofiltration， IV initial dose of 30-40 IU/kg then 10-15 IU/kg every hour. Prophylaxis to patients with substantially increased risk of venous thromboembolism & that are temporarily immobilized due to acute illness such as cardiac/respiratory insufficiency， severe infections 5000 IU SC once daily for 12-14 days or longer in patients with restricted mobility. Treatment of acute deep venous thrombosis & pulmonary embolism & extended thromboprophylaxis in cancer patients 200 IU/kg SC once daily for first month of treatment. Maximum daily dose: 18，000 IU . 150 IU/kg SC once daily for months 2-6.,需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IVD;SC;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,,1. Dalteparin 不可經由肌肉注射給藥。 2. 以溶解血栓或手術治療不適合之急性深部靜脈血栓與肺栓塞治療，Dalteparin可採每天一次或每天兩次的方式，經由皮下注射(SC)給藥。 3. 預防血液透析(hemodialysis)與血液滲析(hemofiltration)期間的凝血，經由靜脈注射(IV)投與dalteparin。 4. 本注射液可與裝於玻璃或塑膠容器中的生理食鹽水溶液(0.9% NaCl)或等張葡萄糖溶液(5%)混合。Fragmin與其他藥物的相容性至今尚未進行研究，因此不可與其他藥物混合使用。
IFUN,Amphotericin B,Fungizone inj 50mg,QANB,,Treatment of cryptococcosis， North American blastomycosis， disseminated moniliasis， coccidioidomycosis， histoplasmosis， mucormycosis， sporotrichosis and spergillosis.,,室溫,IV infusion over 6 hrs with a conc. of 0.1 mg/ml， Initially: 0.25 mg/kg/day. Gradually increased: by 5-10 mg/day or q2d to 0.4-0.6mg/kg/day (max. 1 mg/kg qd or 1.5 mg/kg q2d).,,,,可能安全,,,,,,,,,,
IGAS,Famotidine,Gaster 針劑 20mg/2mL,ALIM,,適應症: Upper GI hemorrhage， Zollinger-Ellison syndrome. 副作用: Infrequently， rash; constipation， diarrhea; dry mouth， nausea. Rarely， leukopenia， thrombocytopenia; tinnitus， increased pulse & BP; reversible mental confusion. Gastrointestinal: Constipation (1.2% )， Diarrhea (1.7% ),,室溫,Upper GI hemorrhage， Zollinger-Ellison syndrome Adult 20 mg dissolved in 20 mL physiological saline or glucose soln by slow IV. Premed Adult 20 mg dissolved in 1-1.5 mL distilled water for inj IM or dissolved in 20 mL physiological saline or glucose soln by slow IV， 1 hr before anesthetization.,,Famotidine is excreted into breast milk with peak concentrations occurring ~6 hours after the maternal dose. According to the manufacturer， the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Famotidine is excreted into breast milk with peak concentrations occurring ~6 hours after the maternal dose. According to the manufacturer， the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.,,,,,,I.V. push: Inject over at least 2 minutes. Solution for infusion: Administer over 15-30 minutes.
IGCSF75,Filgrastim,GCSF 75mcg(FILGRASTIM),HEMT,,Increase in absolute neutrophil count after bone marrow transplantation; Neutropenia induced by cancer chemotherapy; Neutropenia accompanying MDS; Neutropenia accompanying aplastic anemia; Congenital idiopathic neutropenia:,,,Increase in absolute neutrophil count after bone marrow transplantation : Adult & childn administer 1 or 5 days after BMT; 300 mcg/m2 once daily IV. Neutropenia induced by cancer chemotherapy: Adult: Neutrophil count <= 1000/mml after chemotherapy 50 mcg/m2 once daily SC. Child: Neutrophil count <= 500/mml after chemotherapy 50 mcg/m2 once daily SC. When SC inj is not possible， 400 mcg/m2 once daily can be given IV. Neutropenia accompanying MDS: Adult， Neutrophil count <= 1000/mml， 200 mcg/m2 IV once daily. Neutropenia accompanying aplastic anemia: Adult & childn， Neutrophil count <=1000/mml 100 mcg/m2 IV once daily. Congenital idiopathic neutropenia: Adult & childn， Neutrophil count <=1000/mml， 50 mcg/m2 SC once daily. When neutrophil count >= 5000/mml， close observation is needed & consideration should be made to either decrease dosage or discontinue therapy.,,,,除非治療上需要,,,,,,,,,,
ODIMR,Metoclopramide + Pancreatin,Dimotil Repe-Tab 5/212mg,ALIM,,適應症: Digestant， improve digestive tract function Management of GI disorders (e.g. nausea， vomiting， bloatedness). 副作用: Rarely， extrapyramidal reactions， tardive dyskinesia， raised serum prolactin levels， sedation. 禁忌: Whenever stimulation of GI motility might be dangerous (e.g. in the presence of mechanical obstruction or perforation); pheochromocytoma; seizure disorders; children < 14 years,,室溫,1-2 tab tid.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IROL,Cephalexin,Roles inj 1gm,QANB,,適應症:Respiratory tract infections， skin & soft tissue infections， bone & joint infections 副作用:GI disturbances， hypersensitivity reactions， superinfection. Rarely， pseudomembranous colitis. 禁忌:Hypersensitivity to cephalosporins.,,室溫,IM/IV inj. Adult 2-8 g/day in divided doses， children 50-100 mg/kg/day.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,1. 靜脈大量投與會引起血管痛、血栓靜脈炎。 2. 監測體溫、CBC、腎功能。
IDPT2,Diphtheria + Tetanus + Pertussis,Tripacel 0.5mL/dose,HIMM,,Active immunization against diphtheria， tetanus and pertussis.,,2-8,IM， for child 6 wks-6 yrs， 0.5 ml/dose. Primary immunization: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months-1yr later. Booster dose: Given at 4-6 yrs.,,,,沒有資料,,,,,,,,,,
IDPTA,,Tripacel+Act-Hib (四合一),HIMM,,,,,,,,,,,,,,,,,,,
LROT2,Human Rotavirus,Rotarix (gsk 輪狀病毒疫苗) 1.5mL/dose,HIMM,Prevention of gastroenteritis caused by rotavirus， G1 & certain non-G1 serotypes.,Hypersensitivity， uncorrected congenital malformation of the GIT， known or suspected immunodeficiency.,Irritability， loss of appetite， diarrhoea， vomiting， flatulence， abdominal pain， regurgitation of food， fever， fatigue.,2-8℃避光避免冷凍,1.5 mL， 2 doses administered orally starting at 6 weeks of age， the subsequent doses administered at intervals of at least 4 weeks. Th second dose should be given before 24 weeks of age.,無需調整劑量,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料。 此疫苗不適用於成人。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料。 此疫苗不適用於成人。,Unknown 沒有資料,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料。 此疫苗不適用於成人。,PO;,,,,,
OCEL2,Celecoxib,Celebrex 200mg,CNEU,Relief of the signs and symptoms of osteoarthritis and RA. Management of acute pain and treatment of primary dysmenorrhea. To reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP)， as an adjunct to usual care. Ankylosing spondylitis.,Hypersensitivity to sulfonamides. Patients in whom aspirin or other NSAIDs induce symptoms of asthma， urticaria or allergic-type reactions.,Abdominal pain， diarrhea， dyspepsia， flatulence， peripheral edema， dizziness， pharyngitis， rhinitis， sinusitis， upper respiratory tract infection， rash. Cardiovascular: Hypertension (arthritis， 2.4% ; familial adenomatous polyposis， 12.5% ) Gastrointestinal: Diarrhea (arthritis， 5.6%; familial adenomatous polyposis， 10.5%; juvenile rheumatoid arthritis， 4% to 5% )， Nausea (arthritis， 3.5%; familial adenomatous polyposis， 6.8%; juvenile rheumatoid arthritis， 4% to 7% ) Neurologic: Headache (arthritis， 15.8%; juvenile rheumatoid arthritis， 10% to 13% ),25℃以下,Osteoarthritis: 200mg QD， or 100mg BID Rheumatoid arthritis: 100-200mg BID Ankylosing Spondylitis (AS):200mg/day in single (once a day) or divided (twice a day) dose. If it doesn't work after six weeks， try 400 mg/day. If there is no effect after another 6 weeks， there will be no therapeutic response， and other treatments should be considered. Relieve acute pain and treat primary dysmenorrhea: initial dose: 400mg， then 200 mg twice a day when needed.,需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 1st and 3 rd trimesters,[仿單] 避免讓懷孕30週及更晚的孕婦使用。在約此懷孕週數使用會增加胎兒動脈導管過早閉合風險。 懷孕20週以上孕婦使用可能會導致胎兒腎功能異常，造成羊水過少，導致新生兒腎功能不全。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
EEMA,Emedastine,Emadine 0.05%， 5mL oph soln,TOPH,,適應症:Symptomatic relief of allergic conjunctivitis. 副作用:Headache， abnormal dreams， asthenia， dysgeusia， blurred vision， burning or stinging， corneal infiltrates， corneal staining， dermatitis， discomfort， dry eye， foreign body sensation， hyperemia， keratitis， pruritus， rhinitis， sinusitis， tearing. 禁忌: hypersensitivity,,室溫,Allergic conjunctivitis As 0.05% soln: Instill 1 drop twice daily. If needed， up to qid.,無需調整劑量,以上懷孕分級參考UpToDate Pregnancy Risk Factor: B,無需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,以上懷孕分級參考UpToDate Pregnancy Risk Factor: B,,,,,,
OFERC,Iron (III) hydroxide polymaltose complex,Ferrum Hausmann 100mg Chewable,NUTR,,適應症: Treatment or prevention of iron deficiency and/or anemia 副作用:GI irritation， nausea， constipation， diarrhea. 禁忌:All cases of Fe overload or disturbances in utilization of Fe.,,室溫,Chewable tab: May be taken with food or immediately after a meal. PO Doses equivalent to 100 mg elemental Fe/day， up to 300 mg/day.,無需調整劑量,,無需調整劑量,沒有資料,,,Unknown 沒有資料,,,,,,,
OGLUB,Acarbose,Glucobay 50mg,META,,適應症: NIDDM. 副作用: Flatulence， diarrhea， GI & abdominal pains. Gastrointestinal: Abdominal pain (19% )， Diarrhea (31% )， Flatulence (74% ) 禁忌: Chronic intestinal disorders associated with distinct disturbances of digestion & absorption. States which may deteriorate as a result of increased gas formation in the intestine (eg. Roemheld's syndome， major hernias， intestinal obstructions， & intestinal ulcers). Severe renal impairment (CrCl < 25 mL/min).,,室溫,Diabetes mellitus type 2: initial， 25 mg ORALLY 3 times a day with the first bite of each main meal; may initiate at 25 mg ORALLY once daily with gradual dose titration to 25 mg ORALLY 3 times a day in some patients to minimize gastrointestinal side effects Diabetes mellitus type 2: maintenance， dose may be increased at 4- to 8-week intervals to 50 to 100 mg ORALLY 3 times a day with the first bite of each main meal; MAX 50 mg three times daily for patients weighing 60 kg or less and MAX 100 mg three times daily for those weighing more than 60 kg,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OGLUR,Gliquidone,Glurenorm 30mg,META,,,,,,,,,,,,,,,,,,,
OMOM,Magnisum Hydroxide,Mag Mag 500mg,ALIM,,,,,,,,,,,,,,,,,,,
OYUT,Ritodrine,Yutopar 10mg,SGU,,適應症: Prevention of preterm labour， Acute fetal distress， Prevention of preterm labour after operation Follow treatment for preterm labour. 副作用: Pulmonary oedema (several cases reported with fatal results). Maternal & foetal heart rate can increase. Frequently: Tremor， nausea， vomiting， headache or erythema， nervousness， restlessness， jitteriness， emotional upset， anxiety or malaise. Infrequently cardiac symptoms， eg chest pain or tightness with or without ECG abnormalities & cardiac arrhythmias. Hepatic impairment. 禁忌: Antepartum haemorrhage due to any cause but particularly placenta previa & abruptio placentae. Eclampsia & severe pre-eclampsia. Intra-uterine foetal death. Chorioamnionitis. Maternal cardiac disorder. Hyperthyroidism. Uncontrolled hypertension. Any other condition which can endanger cardiac function. Parenteral: Asthmatics (due to sulfite component).,,室溫,Tab 1-2 tab 2-6 hrly. Max: 120 mg daily. Usually 80-120 mg equally divided over the day.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OZAD,Ketotifen,Zaditen 1mg,HIMM,,適應症: Long-term prevention of bronchial asthma， allergic bronchitis， asthmatic symptoms associated with hay fever. Treatment of multi-system allergies， allergic rhinitis & skin conditions. 副作用: Sedation， dry mouth & slight dizziness; weight gain. Neurologic: Headache (10%-25%) Ophthalmic: Dry eyes， Eye irritation， Conjunctival (10%-25%)， Pain in eye Respiratory: Pharyngitis， Rhinitis (10%-25%) Other: Influenza,,室溫,Adult 1-2 mg， in susceptible patients start with 0.5 mg. Children over 3 years 1 mg， 6 months-3 years 0.5 mg. To be taken bid.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OZEF,Lamivudine,Zeffix 100mg,QANB,,適應症: Treatment of patients with chronic hepatitis B & evidence of hepatitis B virus replication. 副作用: Malaise， fatigue， respiratory tract infections， headache， abdominal discomfort， pain， nausea， vomiting， diarrhoea. Pancreatitis & peripheral neuropathy in patients with HIV infection. Lactic acidosis associated with severe hepatomegaly & hepatic steatosis. 禁忌: Patients with known hypersensitivity to lamivudine or to any ingredient of Zeffix.,,室溫,Adult & children <= 12 years 100 mg once daily. Childn 2-11 yr 3 mg/kg once daily， up to max 100 mg daily.,,,,除非治療上需要,,,,,,,,,,
OZIT,Azithromycin,Zithromax 250mg,QANB,Upper & lower respiratory tract infections; skin & soft tissue infections; otitis media; uncomplicated genital infections due to Chlamydia trachomatis & Neisseria gonorrheae.,Hypersensitivity to macrolides.,Nausea， abdominal discomfort， vomiting， flatulence， diarrhoea & loose stools. Hearing impairment， interstitial nephritis， acute renal failure， abnormal liver function， dizziness/vertigo， convulsions， headache， somnolence.,30℃以下,Adults: usual dose: 500 mg orally once daily + or - food for 3 days or 500 mg on day 1 then 250 mg on days 2-5; Chlamydia trachomatis infection of the cervix， urethra: 1 g as single oral dose; conjunctivitis or trachoma due to Chlamydia trachomatis infection: 1 g once weekly for ? 3 weeks; community-acquired pneumonia following IV therapy: 500 mg once daily for 7-10 days; primary prophylaxis for disseminated disease due to Mycobacterium avium complex (MAC) infection in patients with HIV: 1.2 g once weekly.,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OZOC2,Simvastatin,Zocor 20mg,CAVS,,I: Reduction of elevated total & LDL-cholesterol levels in patients primary hypercholesterloemia. Reduction of elevated cholesterol levels in patients hypercholesterolemia & hypertriglyceridemia. CI: Active liver disease or unexplained persistent elevations of serum transaminases. Pregnancy & lactation.,,RT,Patient should be placed on standard cholesterol-lowering diet before & during treatment. Usual starting dose: 10mg daily. Max: 40mg. Adjusted at 4wk intervals as required.,,,,不可使用,,,,,,,,,,
IXYL3,Lidocaine,Xylocaine 3% inj 3.5mL,ZANE,,適應症:為局部麻醉劑(B013896217),,RT,Infiltration， caudal， epidural or peripheral nerve block: Up to 30 ml as a 1% soln or 15 ml as a 2% soln. Surface anesthesia: Nose， nasopharynx and respiratory tract: 1-5 ml of 1%-4% soln is sprayed， 8% spray may be needed. Mouth， pharynx and upper digestive tract: 5-15 ml of 2% viscous soln. Urethral catheterization: Men， 5-10 ml; women， 3-5 ml of 2% jelly.,,,,可能安全,,,,,,,,,,
IZIN7,Cefuroxime,Zinacef inj 750mg,QANB,,適應症: Infections of resp tract， ENT， GUT， skin & soft tissue， bone & joint， gonorrhoea， septicaemia， meningitis， peritonitis. Prophylaxis against infections in abdominal， pelvic， orthopaedic， cardiac， pulmonary， oesophageal & vascular surgery. 副作用: Hypersensitivity， GI disturbances including very rarely pseudomembranous colitis. Haematological changes. Superinfection. Transient pain at IM inj site. Occasionally， thrombophlebitis (IV inj). 禁忌: Hypersensitivity to cephalosporins.,,室溫,Adult 750 mg tid IM or IV. Severe infections: 1.5 g tid IV. Total dose: 3-6 g/day. Infants & children 30-100 mg/kg/day in 3-4 divided doses. Neonates 30-100 mg/kg/day in 2-3 divided doses. Gonorrhoea 1.5 g as a single dose (as 2 x 750 mg IM with different sites eg each buttock). Meningitis Adult 3g IV 8 hrly. Infants & children 150-250 mg/kg/day IV in 3-4 divided doses. Neonates 100 mg/kg/day IV. Prophylaxis Abdominal， pelvic & orthopaedic operations 1.5 g IV with induction of anaeth， may be supplemented with two 750 mg IM doses 8 & 16 hrs later. Cardiac， pulmonary， oesophageal & vascular operations 1.5 g IV with induction of anaesth， continuing with 750 mg IM tid for a further 24-48 hrs. Total joint replacement 1.5 g cefuroxime powder may be mixed dry with each pack of methyl methacrylate cement polymer before adding the liquid monomer.,,,,可能安全,,,,,,,,,,
IZOL,Goserelin,Zoladex Depot 3.6mg,RACA,Breast cancer， advanced. Endometrial thinning. Endometriosis. Prostate cancer， advanced. Prostate cancer， stage B2 to C (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy): Males. Artificial assisted reproduction.,Hypersensitivity to goserelin， gonadotropin releasing hormone (GnRH)， GnRH agonist analogues， or any component of the product. Pregnancy in females with endometriosis or endometrial thinning， as drug may cause fetal harm and has increased risk of pregnancy loss; must exclude pregnancy prior to therapy and use nonhormonal contraception during therapy and 12 weeks after discontinuation.,Common Cardiovascular: Peripheral edema (21% ) Dermatologic: Acne (42% )， Seborrhea (26% )， Sweating (1% to 45% ) Endocrine metabolic: Atrophy of breast (33% ) Neurologic: Headache (men， greater than 1% to less than 5%; women， 32% to 75% ) Psychiatric: Depression (men， greater than 1% to less than 5%; women， 54% )， Mood swings (60% ) Reproductive: Erectile dysfunction (18% )， Flushing (46% to 96% )， Reduced libido (47.7% to 61% )， Sexual dysfunction (21% )， Vaginitis (5% to 75% ) Other: Pain (8% to 17% ) Serious Cardiovascular: Cardiovascular event risk， Congestive heart failure (5% )， Hemorrhagic shock， Myocardial infarction (greater than 1% to less than 5% )， Prolonged QT interval Dermatologic: Injection site hemorrhage Endocrine metabolic: Diabetes mellitus (10.9% to 22.2% )， Pituitary apoplexy (rare )， Pituitary tumor (rare )， Tumor flare (23% ) Hematologic: Hemorrhage Immunologic: Anaphylaxis， Hypersensitivity reaction (1% or greater ) Neurologic: Cerebrovascular accident (greater than 1% to less than 5% ) Renal: Renal impairment (greater than 1% to less than 5% ) Respiratory: Chronic obstructive pulmonary disease (5% ) Other: Tumor flare (23% ),25℃以下,3.6 mg SC every 28 days [Endometriosis] 3.6 mg SC every 28 days for up to 6 months [Endometrial thinning] Two 3.6 mg SC injections given 4 weeks apart with endometrial ablation surgery performed within 2 weeks of the second injection [Uterine fibroid with anemia] 3.6 mg SC with supplementary iron for up to 3 months before surgery,無需調整劑量,[仿單]不推薦使用在哺乳期間使用。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]雖然在動物之生殖毒性實驗中並未有造成畸胎之證據，但理論上LHRH協同有造成流？或胎兒不正常的風險， 故 Zoladex3.6mg不應使用於懷孕中的婦女。 可能懷孕的？女在使用本藥前應仔細檢職，以排除已懷孕的可能。 以 Zoladex3.6mg治療膜異位症之病例則須避孕至月經恢復為止。時，應採取荷爾蒙以外之避孕方法；對於子宮內 Zoladex3.6mg在用於人工協助生殖前，應先排除妊娠之狀況。雖然來自這個背景之臨床資料有 限，但目前所有的資料示 Zoladex3.6mg與卵子發育或妊娠及結果之任何繼起的不正常，沒有因果係。,Unknown 沒有資料,[仿單]不推薦使用在哺乳期間使用。,SC;,,,,,
OLAT,Lurasidone,Latuda 40mg,CNEU,Schizophrenia.,Hypersensitivity. Concomitant w/ strong CYP3A4 inhibitors (eg， ketoconazole， clarithromycin， ritonavir， voriconazole) & inducers (eg， rifampin， St. John's wort， phenytoin， carbamazepine).,Akathisia， somnolence. Hypersensitivity; increased wt; insomnia， agitation， anxiety， restlessness; parkinsonism， dizziness， dystonia， dyskinesia; nausea， vomiting， dyspepsia， salivary hypersecretion， upper abdominal pain， stomach discomfort; rash， pruritus; musculoskeletal stiffness， increased blood creatine phoshokinase; increased serum creatinine; fatigue.,25℃以下,Should be taken with food (at least 350 kcal). Schizophrenia: 40mg QD. maximum: 160mg/day. Depressive episodes of type 1 bipolar disorder: 20mg QD， the dose can be increased based on clinical response after one week of treatment. maximum: 80mg/day.,需調整劑量,,需調整劑量,,Human data suggest risk in 3 rd trimester,No Human Data—Potential Risk in 3rd Trimester,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IZOV,Acyclovir,Zovirax inj 250mg,QANB,Herpes simplex (except Herpes encephalitis) or Varicella zoster infections， Immuno-compromised patient with Varicella zoster infections or patient with Herpes encephalitis， Prophylaxis of CMV infection in bone marrow transplant recipients.,Hypersensitivity to valaciclovir or aciclovir.,GI disturbances， rashes including photosensitivty， urticaria， pruritus， headaches， reversible neurological reactions， fatigue. Phlebitis (Inj). Dermatologic: Application site reaction， Topical Preparation (5% )， Contact dermatitis， Topical Preparation (2% ) Gastrointestinal: Diarrhea (2.4% to 3.2% )， Nausea (2.4% to 4.8% )， Vomiting Neurologic: Headache (2.2% ) Other: Malaise (11.5% ) Dermatologic: Application site reaction， Topical Preparation (5% )， Contact dermatitis， Topical Preparation (2% ) Gastrointestinal: Diarrhea (2.4% to 3.2% )， Nausea (2.4% to 4.8% )， Vomiting Neurologic: Headache (2.2% ) Other: Malaise (11.5% ),25℃以下,Zovirax should be administered by slow IV infusion over 1 hour period. Usual treatment course: 5-10 days. Use ideal body weight for obese patients. Adults: 5-10 mg/kg every 8 hours; children aged between 3 months to 12 years: 250-500 mg/m2 every 8 hours; neonates: 20 mg/kg every 8 hours for 14 or 21 days. *****NEONATE ANTIBIOTICS DOSE***** Acyclovir: this dosage for herpes simplex virus infection Treat localized infections for 14 days; disseminated or CNS infections for 21 days. Dilute to a final concentration<=7 mg /mL; IV infusion over 60 minutes Body weight <1kg ge<=7day 20mg/kg Q12H  Age 8-14 day 20mg/kg Q12H  Age 15-28 day  20 mg/kg Q8H Body weight 1-2kg ge<=7day 20mg/kg Q12H  Age 8-14 day 20 mg/kg Q8H  Age 15-28 day 20 mg/kg Q8H Body weight >2kg Age<=7day 20 mg/kg Q8H  Age 8-14 day 20mg/kg Q8H  Age 15-28 d ay 20mg/kg Q8H PMA (postmenstrual age ) = gestational age plus postnatal age,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IVD;,IVD: 10mL D/W， N/S,【H/S】可選 仿單建議。【N/S】可選 仿單建議。【D5NS】可選 。【L/R】可選 。,,> 60分鐘以上時間緩慢滴注。 加入適當輸注液稀釋，濃度不可超過 5 mg/mL。,1. 本品不含抗菌劑，稀釋後應立即使用。 2.以1小時的時間緩慢靜脈輸注。 3.稀釋方法：每小瓶 250 mg 乾粉加入 10 mL 注射用水或0.9%注射用生理食鹽水溶解。取出醫囑所需劑量，加入適當輸注液稀釋，濃度不可超過 5 mg/mL。 4. 依照指示配製後的Zovirax靜脈輸注液 pH值約 11，不可冷藏，應儲存於 25 ℃以下。室溫下(15-25℃)保持12小時穩定性 5. 若於輸注前、輸注中發現藥液出現結晶或混濁，應立即拋棄不可使用。 6. 監測病人體溫、CBC、腎功能。
OLISA,Cephradine,Lisacef 500mg,QANB,,適應症: Infection of the respiratory tract， GUT， skin & skin structure， bone & joints; septicemia. 副作用: GI disturbances， hypersensitivity reactions. 禁忌: Hypersensitivity to cephalosporins.,,室溫,Adult: 0.5-1 g q4-6h， (max. 8 g/day). Child over 1 yr: 50-100 mg/kg/day in 4 divided doses; max. daily dose should not exceed the recommended adult dose.,,,,可能安全,,,,,,,,,,
OLISE,Metergoline,Liserdol 4mg (限自費),HM,,,,,,,,,,,,,,,,,,,
OLIT,Lithium,Lithonate 300mg,CNEU,,Treatment of manic episodes of manic depressive illness.,,,Acute mania: Initial 600 mg tid， Mintenance: 300 mg tid.,,,,盡量避免,,,,,,,,,,
OLOS,Omeprazole,Losec 20mg,ALIM,,Gastric and peptic ulcer， gastroesophageal reflex.,,,Active ulcer: 20 mg qd. Pathological hypersecretory conditions: Initial， 60 mg qd. Zollinger-Ellison syndrome: 20~40mg qd. S/P: 1. In elderly patients， the daily dose usually should not exceed 20 mg. 2. Swallow capsule whole.,,,,除非治療上需要,,,,,,,,,,
OLUVO,Fluvoxamine,Luvox 50mg,CNEU,Treatment of symptoms of depressive illness. Obsessive compulsive disorder in children & adolescents.,None.,Nausea， vomiting， asthenia， headache， malaise， palpitations/tachycardia， abdominal pain， anorexia， constipation， diarrhoea， dry mouth， dyspepsia， agitation， anxiety， dizziness， insomnia， nervousness， somnolence， tremor， sweating， (postural) hypotension， arthralgia， myalgia， ataxia， confusion， extrapyramidal symptoms， hallucinations， abnormal (delayed) ejaculation， cutaneous hypersensitivity reactions (including rash， pruritus， angioedema)， liver dysfunction， convulsions， mania， galactorrhoea， photosensitivity， weight gain/loss， serotonin syndrome， neuroleptic malignant syndrome-like events， hyponatremia & SIADH， withdrawal reactions， haemorrhage， paresthesia， anorgasmy & taste perversion. Dermatologic: Sweating (immediate-release， 7%; extended-release (social anxiety disorder)， 6%; extended-release (obsessive-compulsive disorder)， 7% ) Gastrointestinal: Diarrhea (immediate-release， 11%; extended-release (social anxiety disorder)， 14%; extended-release (obsessive-compulsive disorder)， 18% )， Indigestion (immediate-release， 10%; extended-release (social anxiety disorder)， 10%; extended-release (obsessive-compulsive disorder)， 8% )， Loss of appetite (immediate-release， 6%; extended-release (social anxiety disorder)， 14%; extended-release (obsessive-compulsive disorder)， 13% )， Nausea (immediate-release， 40%; extended-release (social anxiety disorder)， 39%; extended-release (obsessive-compulsive disorder)， 34% )， Xerostomia (immediate-release， 14%; extended-release (social anxiety disorder)， 11%; extended-release (obsessive-compulsive disorder)， 10% ) Neurologic: Asthenia (immediate-release， 14%; extended-release (social anxiety disorder)， 24%; extended-release (obsessive-compulsive disorder)， 26% )， Dizziness (immediate-release， 11%; extended-release (social anxiety disorder)， 15%; extended-release (obsessive-compulsive disorder)， 12% )， Insomnia (immediate-release， 21%; extended-release (social anxiety disorder)， 32%; extended-release (obsessive-compulsive disorder)， 35% )， Somnolence (immediate-release， 22%; extended-release (social anxiety disorder)， 26%; extended-release (obsessive-compulsive disorder)， 27% )， Tremor (immediate-release， 5%; extended-release (social anxiety disorder)， 8%; extended-release (obsessive-compulsive disorder)， 6% ) Psychiatric: Agitation (immediate-release， 2%; extended-release (social anxiety disorder)， 3%; extended-release (obsessive-compulsive disorder)， 2% )， Anxiety (immediate-release， 5%; extended-release (social anxiety disorder)， 8%; extended-release (obsessive-compulsive disorder)， 6% )， Feeling nervous (immediate-release， 12%; extended-release (social anxiety disorder)， 10% ) Reproductive: Abnormal ejaculation (immediate-release， 8%; extended-release (social anxiety disorder)， 11%; extended-release (obsessive-compulsive disorder)， 10% )， Orgasm incapacity (immediate-release， 2%; extended-release， 5% ),25℃以下,May be taken with or without food 100-200 mg daily. Maximum: 300 mg daily. The minimum recommended starting dose is 100 mg/day and can be given as a single dose; preferably in the evening.It is advisable that a total daily dose over 150 mg be given in 2 or 3 divided doses.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OMAC,Mag Hydroxide + Alum Hydroxide,Macgel,ALIM,,Hyperacidity， peptic and doudenal ulcer， gastritis， flatulence.,,RT,2-4 tab qid pc 1hr.,,,,可能安全,,,,,,,,,,
OACC,Zafirlukast,Accolate 20mg,ERSP,,適應症:主治支氣管哮喘(B022398100),,室溫,20mg twice daily in adults and children 12 years and older. Since food reduces the bioavailability of zafirlukast，Accolate should be taken at least 1 hour before or 2 hours after meals.,,,,可能安全,,,,,,,,,,
OACE,Perindopril,Acertil 4mg,CAVS,,,,RT,Hypertension 4mg daily as single dose， may be increased to a single 8mg dose. Elderly Start treatment 2mg dose. In renal insufficiency， dose has to be adapted according to creatinine clearance.,,,,盡量避免,,,,,,,,,,
OACT,Acetylcysteine,Actein 100mg/pk 顆粒劑,ERSP,,適應症: Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis， emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms. 副作用: Bronchospasm， GI upsets， stomatitis; rhinorrhea， fever， hemoptysis; rarely anaphylactic reactions. Dermatologic: Pruritus (1% to 4.3% )， Rash (4% to 5% )， Urticaria Gastrointestinal: Diarrhea， Nausea (2% to 7% )， Vomiting (9% to 12% ) 禁忌: Effervescent tab Phenylketonuria.,,室溫,Effervescent tab Adult & children > 6 years 1 effervescent tab daily. Granules Adult 200 mg. Children 100 mg. To be taken tid.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OAKI,Biperiden,Akineton 2mg,CNEU,,適應症: Parkinsonism. 副作用: Fatigue， dizziness， drowsiness. Restlessness， confusion at higher doses. Occasionally， impairment of memory. In rare cases， hallucinations. Dry mouth， accommodation impairment， hypohydrosis， constipation， gastric discomfort， tachycardia. Very rarely， bradycardia. Skin allergy， dyskinesia. Rarely， urine retention. 禁忌: Untreated narrow-angle glaucoma， intestinal stenoses or obstruction， megacolon， prostatic hypertrophy， life-threatening tachycardia.,,室溫,Initially， 1 mg bid. Maintenance: 3-16 mg/day(or 1-4 mg tid-qid) Max: 16 mg/day,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OALDA,Spironolactone,Aldactone 25mg,CAVS,,適應症: Edematous disorders， Congestive cardiac failure， Liver cirrhosis， Nephrotic syndrome， Hypertension 副作用: GI symptoms; drowsiness; lethargy; headache; cutaneous eruptions; urticaria; mental confusion; drug fever; ataxia; impotence; amenorrhea; post-menopausal bleeding; gynecomastia; rarely agranulocytosis. 禁忌: Acute renal insufficiency; significant impairment of renal function; anuria; hyperkalaemia; hypersensitivity.,,室溫,Edematous disorders: Daily dose given in divided doses or as single dose. Congestive cardiac failure: Initially， 100 mg/day; gradually increased up to 200 mg/day; usual maintenance dose， 25-200 mg/day. Liver cirrhosis Urinary Na/K ratio >1: recommended dose 100 mg/day， ratio <1: recommended dose 200-400 mg/day; maintenance dose individually determined. Nephrotic syndrome 100-200 mg/day. Idiopathic edema Usual dose 100 mg/day. Children Initial daily dose approximately 3.3 mg/kg body wt. Hypertension 50-100 mg/day given in divided doses or as a single daily dose. For difficult or severe casses， gradually increased at 2-wkly intervals up to 200 mg/day.,,,,盡量避免,,,,,,,,,,
OALDO,Methyldopa,Aldomet 250mg,CAVS,,I: Moderate to severe hypertension. CI: Active hepatic disease.,,,Adult: Initial: 250 mg bid-tid. Maintenance: 500 mg-2g/day in 2-4 divided doses， Max. 3 g/day Child: Initial: 10 mg/kg/day in 2-4 divided doses， up to 65 mg/kg/day.,,,,可能安全,,,,,,,,,,
OALK,Melphalan,Alkeran(Melphalan) 2mg,RACA,,Multiple myeloma， advanced ovarian aderocarcinoma， advanced breast carcinoma， polycythemia vera.,,,Multiple myeloma: 0.15 mg/kg/day with 40mg prednisolone daily in divided doses for 4 days. Repeat 6 weekly. Ovarian adenocarcinoma: 0.2 mg/kg/day for 5 days. Repeat 4-8 weekly. Advanced breast carcinoma: 0.15/kg/day for 5 weekly. Polycythemia vera: Induction: 6-10 mg daily for 5-7 days. Maintenance: 2-6 mg/week.,,,,盡量避免,,,,,,,,,,
OALM,Diclofenac,Almiral 100mg(Voren),CNEU,,An analgesic， antipyretic， anti-inflammatory agents used in RA. and other rheumatic disorders.,,,100 mg qd， swallowed whole，,,,,,,,,,,,,,,
EZAL,Sertaconazole,Zalain cream 2%， 15gm,TDER,Topical treatment of skin mycoses eg dermophytosis， tinea pedis， tinea cruris， tinea corporis， tinea barbae， tinea manus， candidiasis & Pityriasis versicolor.,Hypersensitivity to any component of the formulation.,Slight local & transient erythematous reaction.,25°C 以下,Apply to affected area once-bid. Clinical improvement within 2-4 weeks of treatment.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
ESYM,Budesonide + Formoterol,Symbicort Turbuhaler 160/4.5mcg,ERSP,Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β2-agonist) is appropriate. Symptomatic treatment of severe COPD & history of repeated exacerbation symptoms despite regular therapy with long-acting bronchodilators.,Hypersensitivity to any component of the formulation.,Palpitation， oral candidiasis， headache， tremor， mild throat irritation， cough， hoarseness.,30℃以下蓋緊瓶蓋,Anti-Inflammatory Reliever Therapy (patients with mild persistent asthma)， Adults and adolescents (12 years and older): 1 inhalation as needed in response to symptoms to control asthma. If symptoms persist after a few minutes， 1 additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion. The maximum recommended total daily dose is 8 inhalations. Anti-inflammatory Reliever plus Maintenance Therapy (patients with moderate or severe asthma)， Adults and adolescents (12 years and older): 1 or 2 inhalations twice daily or 2 inhalations once daily. Additional doses can be used as needed to provide rapid symptom relief and improved asthma control. Patients should take 1 additional inhalation as needed in response to symptoms to control asthma. If symptoms persist after a few minutes， 1 additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion. The maximum recommended total daily dose is 8 inhalations. Maintenance Therapy (patients with moderate or severe asthma)， Adults and adolescents (12 years and older): 1 or 2 inhalations once or twice daily. The maximum recommended daily maintenance dose is 4 inhalations.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
ITARI,Ofloxacin,Tarivid IV 200mg,QANB,,I: UTI including sexually transmitted diseases， biliary tract， GIT， ENT， phthalmological， resp. tract， gynaecological， skin & soft tissue infections. AR: GI disturbances， headache， giddiness， sleep disorders， hypersensitivty reactions. CI: Hypersensitivty. Pregnancy & lactation. Epileptics with pre-existing CNS lesions involving a lowered threshold. Children or adolescents in the growth phase.,,,D: UTI: 200 mg once daily or 200 mg bid. Infections of the kidneys & reproductive organs: 200 mg bid. RTI， infections of ENT， infections of the skin & soft tissues， abdominal cavity or septicaemia: 200 mg bid， maybe increased to 400 mg bid in severe cases. IV infusion rate < 200 mg / 30 mins.,,,,除非治療上需要,,,,,,,,,,
ETRA,Travoprost,Travatan 0.004%， 2.5mL,TOPH,,適應症: Reduction of intraocular pressure in patients with open-angle glaucoma or ocular HTN. 副作用: Ocular hyperemia， decreased visual acuity， eye discomfort， itch & pain， blepharitis， blurred vision， conjunctivitis， dry eye， foreign body sensation， iris discoloration， keratitis， photophobia & tearing. Neurologic: Foreign body sensation (5%-10%) Ophthalmic: Blepharitis， Blurred vision， Itching of eye (5%-10%)， Ocular hyperemia (35%-50%)， Pain in eye， Reduced visual acuity 禁忌: Hypersensitivity to travoprost， benzalkonium chloride. Pregnancy & women who are attempting to get pregnant.,,室溫,1 drop in the affected eye(s) once every evening.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OBUW,Hyoscyamine,Buwecon 0.125mg,ALIM,,適應症: Control gastric secretion， visceral spasm & hypermotility in spastic colitis， spastic bladder， cystitis， pylorospasm & associated abdominal cramps 副作用: Dry mouth， urinary hesitancy & retention， blur vision， tachycardia. 禁忌: Glaucoma， obstructive uropathy， GI obstruction， paralytic ileus， severe ulcerative colitis， myasthenia gravis.,,室溫,Adult & children > 12 years 1-2 tab 4 hrly. Max: 12 tab/day. Children 2-12 years 1/2-1 tab 4 hrly. Max: 6 tab/day.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OFAR6,Toremifene,Fareston 60mg,RACA,,適應症:Metastatic breast cancer in postmenopausal patients. 副作用:Hot flush， sweating， nausea， leukorrhea， dizziness， edema， pain， vomiting， vag bleeding， fatigue， skin discoloration， insomnia， dyspnea， pruritus， anorexia， reversible cornea， verticillata， asthenia. Thromboembolic events， endometrial hypertrophy. 禁忌:Pre-existing endometrial hyperplasia， severe hepatic failure.,,室溫,D : 60 mg daily,,,,沒有資料,,,,,,,,,,
IJEV1,Japanese Encephalitis Vaccine,JEV (自費日本腦炎疫苗) 0.5-1mL/dose,HIMM,,適應症: Active immunisation against encephalitis due to Japanese encephalitis virus. 副作用: Local reactions eg redness， swelling， tenderness or systemic reactions eg fever， chill， headache， lassitude. Rarely， severe adverse reactions manifesting as generalized urticaria or angioedema may occur. 禁忌: Avoid use in the following unless absolutely necessary: patients with fever or severe malnutrition; CV， renal or hepatic diseases in acute， exacerbating or active phases; history of abnormal adverse reactions caused by this vaccine; history of spasmodic symptoms within 1 yr; pregnancy.,,2-8℃,Adult Initially 2 inj of 1 mL SC at an interval of 7-14 days， with an additional 1 mL after 1 yr. Children <3 yr 3 doses of 0.5 mL.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OZOV,Acyclovir,Zovirax 200mg,QANB,,適應症:病毒感染(B012736100),,RT,Oral: 200 mg 5 times daily at 4 hrs intervals for 5days. Adult or child with impaired renal function: 200 mg q12h.,,,,除非治療上需要,,,,,,,,,,
SK1002,,妊娠細紋袪除霜,TDER,,,,,,,,,,,,,,,,,,,
SK1004,,胸部特別護持霜,TDER,,,,,,,,,,,,,,,,,,,
SK1006,,腿部疲勞速解霜,TDER,,,,,,,,,,,,,,,,,,,
ESA,Salicylic Acid,Salicylic Acid 5% 20mL,TDER,,適應症: Hyperkeratotic and scaling skin conditions， Warts and calluses . 副作用: Irritation， sensitivity， excessive drying; systemic effects on prolonged use.,,室溫,Hyperkeratotic and scaling skin conditions As 2-6% preparation: Apply <=3 times/day. Warts and calluses As 60% preparation: Apply as directed.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ESAN,Cyanocobalamin,Sancoba 0.02%， 5mL ophthalmic solution,TOPH,Relief of fatigue of ocular muscle.,Hypersensitivity to cyanocobalamin or any component of the formulation.,Transient stinging & burning， ocular irritation， allergic reactions.,避光及30℃以下,Instill 1-2 drops TID-QID.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,OD;OL;OU;,,,,,
ESER,Salmeterol,Serevent Accuhaler 50mcg(單方),ERSP,,I: Adult long-term regular treatment of reversible airways obstruction， in asthma & chronic bronchitis， emphyema. Childn≧4 yr regular treatment of reversible airway obstruction in asthma including long lasting prevention of exercise-induced bronchospasm. AR: Tremor， paradoxical brochospasm， headache， palpitations， muscle cramps， tachycardia， hypersensitiviy reactions.,,,Accuhaler:adult 1 rotadisk blister bid. In patients with more severe airways obstruction， up to 2 rotadisk blister bid. Inhaler:adult: 2 inhalation bid. Child ≧4 yr: 2 inhalation bid.,,,,除非治療上需要,,,,,,,,,,
ESERI,Salmeterol,Serevent inhaler 25mcg/dose,ERSP,,I: Adult long-term regular treatment of reversible airways obstruction， in asthma & chronic bronchitis， emphyema. Childn≧4 yr regular treatment of reversible airway obstruction in asthma including long lasting prevention of exercise-induced bronchospasm. AR: Tremor， paradoxical brochospasm， headache， palpitations， muscle cramps， tachycardia， hypersensitiviy reactions.,,,Accuhaler:adult 1 rotadisk blister bid. In patients with more severe airways obstruction， up to 2 rotadisk blister bid. Inhaler:adult: 2 inhalation bid. Child ≧4 yr: 2 inhalation bid.,,,,除非治療上需要,,,,,,,,,,
ESIL1,Silver Sulphadiazine,Silvazine cream 1gm,TDER,,I: Prevention of infectios in burns. CI: Pregnancy， premature & newborn infants.,,RT,Apply topically once daily,,,,可能安全,,,,,,,,,,
ESKI,Azelaic Acid,Skinoren cream 30gm,TDER,Acne vulgaris.,Hypersensitivity to azelaic acid or any component of the formulation,Occasionally， local skin irritation.,30℃以下,Acne vulgaris adult， apply BID. In the event of excessive skin irritation， reduce amount of cream/application or reduce application to once a day until irritation ceases or interrupt treatment temporarily for a few days.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
ESOFT,Framycetin + Lanoparaffin Gauz,Sofra-tulle 10x10,TDER,,I: Wounds， burns， ulcers and other infected skin conditions. AR: Possible ototoxicity ( open wounds， large areas， renal impairment on prolonged use ). CI: Known allergy to framycetin or where organisms are known to be resistant to framycetin.,,Room Temp,Apply the paraffin gauze dressing directly to the cleaned wound qd-bid.,,,,沒有資料,,,,,,,,,,
OMEDA,Dextromethorphan+Lysozyme+K Cresolsulfonate,Medicon-A 20/20/90mg,ERSP,,適應症: Symptomatic relief of coughs caused by the common cold or inhaled irritants. 副作用: Central nervous system: Confusion， excitement， irritability， nervousness， serotonin syndrome. 禁忌: Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor.,,室溫,Adult :10-20 mg ORALLY every 4hrs or 30 mg ORALLY every 6-8hrs maximum dose， 120 mg/day Pediatric : (6-12yrs) 5-10 mg ORALLY every 4hrs or 15 mg ORALLY every 6-8hrs; maximum dose: 60 mg/day (2-6yrs) 2.5-5 mg ORALLY every 4hrs or 7.5 mg ORALLY every 6-8hrs; maximum dose: 30 mg/day,無需調整劑量,,無需調整劑量,沒有資料,,,Compatible 哺乳時可使用,,,,,,,
OMEG,Magestrol,Megace 20mg,RACA,,,,,,,,,,,,,,,,,,,
OMEL,Thioridazine,Melleril 25mg,CNEU,,Anxiolytic & antidepressants; Neuroleptic.,,,Anxiolytic & antidepressants: Adult 10-75 mg daily. Childn 0.5-2 mg/kg body weight daily. Neuroleptic: Adult: 25-600 mg daily .Max:800mg daily. Childn: 1-4 mg/kg body weight daily.To be taken in divided doses.,,,,除非治療上需要,,,,,,,,,,
OMEL1,Thioridazine,Melleril 100mg,CNEU,,Anxiolytic & antidepressants; Neuroleptic.,,,Anxiolytic & antidepressants: Adult 10-75 mg daily. Childn 0.5-2 mg/kg body weight daily. Neuroleptic: Adult: 25-600 mg daily .Max:800mg daily. Childn: 1-4 mg/kg body weight daily.To be taken in divided doses.,,,,除非治療上需要,,,,,,,,,,
OSELA,Naproxen,Seladin 250mg,CNEU,RA， osteoarthritis， ankylosing spondylitis， acute gout， musculoskeletal disorders.,Hypersensitivity to aspirin or other NSAID， bleeding tendencies， peptic ulcer.,GI disturbances & bleeding， peptic ulceration. Headache， dizziness， nervousness， drowsiness; skin rash， blurred vision; hypersensitivity， hepatic & renal impairment， hematological reactions. Cardiovascular: Edema (3% to 9% ) Dermatologic: Pruritus (3% to 9% )， Rash (3% to 9% ) Gastrointestinal: Abdominal pain (3% to 9% )， Constipation (3% to 9% )， Diarrhea (1% to 10% )， Heartburn (3% to 9% )， Indigestion (1% to 10% )， Nausea (3% to 9% )， Stomatitis (less than 1% to 10% ) Neurologic: Dizziness (3% to 9% )， Headache (3% to 9% )， Lightheadedness (less than 3% )， Somnolence (3% to 9% )， Vertigo (less than 3% ) Otic: Tinnitus (3% to 9% ) Respiratory: Dyspnea (3% to 9% ),25℃以下避光,250mg(1 Tablet) BID for adult. Adjust the dose according to the patient's clinical response.,無需調整劑量,,需調整劑量,除非治療上需要,Human data suggest risk in 1st and 3 rd trimesters,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;,,,,,
OISOR,Isosorbide,Isordil 10mg (Sorbitrate),CAVS,,適應症:主要預防狹心症之發作(B018987100) CI: Cardiogenic shock; circulatory collapse; severe hypotension; marked anemia; head trauma; cerebral hemorrhage; severe hypovolemia.,,RT,Oral: 2.5-10 mg tid-qid， ac,,,,除非治療上需要,,,,,,,,,,
LOPV0,Oral Poliovirus Vaccine,Polio Sabin (自費),HIMM,,適應症: Active immunization against poliomyelitis. 副作用: Rarely， allergic & anaphylactic reactions & vaccine-associated poliomyelitis. 禁忌: Immunosuppressed & immunodeficient patients; during acute feverish illnesses， hypersensitivity to neomycin. Vomiting & diarrhea. Debilitated states.,,冷凍,3 oral doses， (1 dose=2 drops). Separated by 2 months. Oral， 0.5 ml/dose. Primary immunization: 3 doses given at 8 wks intervals and a reinforcing 4th dose given 1 yr later. Booster dose: Given at 4-6 yrs.,,,,沒有資料,,,,,,,,,,
IKET1,Ketamine,Ketalar inj 50mg/mL,ZANE,Induction & maintenance of anaesth.,Patients at risk of complications of hypertension.,Respiratory depression; hypotension， bradycardia， arrhythmia; emergent reactions. Occasionally， laryngospasms; diplopia， nystagmus; tonic/clonic movement.,25℃以下避光,Induction of general anesthesia: Adult: IV: Initial， 1-4.5 mg/kg as a single dose. The average amount required to produce 5-10 minutes of surgical anesthesia is 2 mg/kg， administer slowly (over 60 seconds); dose may be administered as an IV infusion at a rate of 0.5 mg/kg/minutes. In addition， diazepam in 2-5 mg doses， administered in a separate syringe over 60 seconds， may be used. In most cases， 15 mg or less of diazepam IV is enough. Adult: IM: initially 6.5-13 mg/kg as a single dose. Dosage of 10 mg/kg usually produce the surgical anesthetic effect lasting 12-25 minutes. Maintenance of anesthesia: Increments of 1/2 to the full induction dose may be repeated for maintenance of anesthesia. Adult patients induced with ketamine augmented with intravenous diazepam， may be maintanined with slow microdrip infusion ketamine at a dose of 0.1-0.5 mg/minute， and augmented with diazepam 2 to 5 mg administered intravenously as needed. In many cases 20 mg or less of intravenous diazepam total for combined induction and maintenance will suffice. For pediatric procedural sedation: Initial dose: 1-2mg/kg. When given with propofol: reduce to 0.5mg/kg. Repeat dose:0.5-1mg/kg repeat every 5-10 minutes， titrating to desired level of sedation.,需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;IVP;IVPUSH;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,推注時間至少 60秒,稀釋於適當輸注液，給藥濃度1-2 mg/mL，以輸注速率 0.1 - 0.5 mg/min 滴注,1. IV infusion: 稀釋於適當輸注液，濃度1-2 mg/mL，速率 0.1 - 0.5 mg/min 。
IKETBAD,Ketamine,Ketalar 50mg/mL 殘餘銷燬,ZANE,,,,,,,,,,,,,,IM;IV;IVD;IVP;IVPUSH;,,,,,
OAMA,Glimepiride,AmaRyl 2mg,META,Type 2 diabetes mellitus.,Insulin-dependent (type 1) diabetes mellitus; diabetic ketoacidosis; diabetic precoma or coma; serious renal or hepatic dysfunction. Pregnancy， lactation.,Hypoglycaemia; adrenergic counter-regulation; temporary visual impairment; GI symptoms. Rarely thrombopenia， haemolytic anaemia， erythrocytopenia， leucopenia， agranulocytosis. Endocrine metabolic: Hypoglycemia [0.9% to 1.7% (adults); 4% (pediatrics) ] Gastrointestinal: Nausea (1.1% ) Neurologic: Asthenia (1.6% )， Dizziness (1.7% )， Headache (1.5% ),30℃以下,1-2 mg once daily at breakfast， maximum: 8 mg/day.,無需調整劑量,藥品仿單: 懷孕及授乳婦女不可使用。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,藥品仿單: 懷孕及授乳婦女不可使用。,AC;AC15;PO;,,,,,[磨粉/管灌註記]仿單建議不可咀嚼或壓碎。廠商亦無相關安定性試驗。
OPCN,Penicillin V,Penicillin V 240mg,QANB,,適應症: Treatment of mild to moderate respiratory tract infections， otitis media， sinusitis， skin & UTI; prophylaxis in rheumatic fever. 副作用: Diarrhea， nausea， vomiting， hypersensitivity reactions. 禁忌: Hypersensitivity.,,室溫,Adult: 125-500 mg q6-8h. (max. 7.2 g/day). Child under 12 yrs: 15-56 mg/kg/day in 3-4 divided doses. To prevent recurrences of rheumatic fever 1 tab bid.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
OPEA,Triprolidine + Pseudoephedrine,Peace 2.5/60mg,HIMM,Nasal congestion， allergic rhinitis.,Hypersensitivity to any component of the formulation.,Cardiovascular: Tachycardia Central nervous system: Dizziness， drowsiness， fatigue， headache， insomnia， nervousness， transient stimulation Gastrointestinal: Abdominal pain， appetite increase， diarrhea， nausea， weight gain， xerostomia Genitourinary: Dysuria Neuromuscular & skeletal: Arthralgia， weakness Respiratory: Pharyngitis， thickening of bronchial secretions Miscellaneous: Diaphoresis,25℃以下避光,TID-QID， Adult and children >12 years 1 TAB， Children 6-12 years 0.5 TAB， 3-6 years 0.25 TAB， < 3 years as doctors' order.,無需調整劑量,Triprolidine- Limited Human Data—Probably Compatible Pseudoephedrine -Limited Human Data—Probably Compatible,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,Triprolidine- Compatible Pseudoephedrine Human Data Suggest Risk,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Triprolidine- Limited Human Data—Probably Compatible Pseudoephedrine -Limited Human Data—Probably Compatible,AC;AC15;PC;PO;WM;,,,,,
OPER2,Dipyridamole,Persantin 25mg,HEMT,,,,,,,,,,,,,,,,,,,
OPERD,Nicardipine,Perdipine 20mg,CAVS,,適應症:Cerebral blood flow disturbances， Essential hypertension. 副作用: Infrequently， anorexia， nausea， vomiting; flushing; palpitation; headache. Rarely， granulocytopenia; dry mouth， constipation， diarrhea; peripheral edema; rash. Cardiovascular: Hypotension (5.6% )， Peripheral edema (5.9% )， Tachyarrhythmia (3.5% ) Gastrointestinal: Nausea (1.9% to 4.9% )， Vomiting (0.6% to 4.9%) Neurologic: Headache (6.2% to 14.6% ) 禁忌: Incomplete hemostasis following intracranial hemorrhage; acute cerebral apoplexy， elevated intracranial pressure.,,室溫,Cerebral blood flow disturbances Adult 20 mg tid. Essential hypertension Adult 10-20 mg tid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OPHE,Phenobarbital,Phenobarbital 30mg,CNEU,Generalised tonic-clonic seizures， Partial seizures， Sedation， Hypnotic.,Severe renal and hepatic disorders. Severe respiratory depression， dyspnoea or airway obstruction; porphyria. Pregnancy.,Bradycardia， hypotension， syncope; drowsiness， lethargy， CNS excitation or depression， impaired judgment， hangover effect， confusion， somnolence， agitation， hyperkinesia， ataxia， nervousness， headache， insomnia， nightmares， hallucinations， anxiety， dizziness; rash， exfoliative dermatitis; nausea， vomiting， constipation; agranulocytosis， thrombocytopenia， megaloblastic anaemia; pain at inj site， thrombophlebitis (IV); oliguria: laryngospasm， respiratory depression， apnoea (especially with rapid IV admin)， hypoventilation. Potentially Fatal: Stevens-Johnson syndrome. Neurologic: Somnolence (1% to 3% ),陰涼(15-30℃) 乾燥處所,Adult: For anticonvulsant or ataxia: Oral: 100-200 mg HS or TID. For hypnotic: 100-200 mg HS. For CYP450 inducer: 30-60 mg TID. For sedative: 15-32 mg BID-TID. Child:For anticonvulsant or ataxia: Oral: 3-5 mg/kg HS or TID. For hypnotic: following doctor instruction. For CYP450 inducer，neonatel: 5-10 mg/kg. For CYP450 inducer， Child under 12 years : 1-4 mg/kg TID. For sedative: 2mg/kg or 60mg/BSA(m2) TID.,無需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;P1;P2;P3;P4;PC;PO;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OPIM,Pimozied,Pimozide(Orap)4mg,CNEU,,Chronic psychotics， responsive specific antipsychotic effects of neuroleptics. Borderline psychosis.,,,Adult initally 1-2mg once daily. Optimum daily maintenance dose:2-6 mg in one intake.,,,,除非治療上需要,,,,,,,,,,
OPLA,Hydroxychloroquine,Plaquenil 200mg,QANP,RA， Juvenile chronic arthritis， Systemic or discoid lupus erythematosus， Light-sensitive disease， Suppression of malaria.,Retinal or visual field changes. Long-term therapy in children.,Headache， GI complaints; skin reactions; psychic stimulation， bleaching of hair， alopecia， blurred vision， difficulty in focusing or accommodation， corneal changes， retinal changes; blood dyscrasias.,避濕，儲存於25℃以下,Other indications except malaria:Adults:Generally treated with lowest effective dose. 200mg or 400mg daily， maximum dose:6.5mg/kg/day(calculated with ideal body weight).Children:Should be treated with lowest effective dose， maximum dose:6.5mg/kg/day(calculated with ideal body weight).For children ideal body weight < 31kg， should avoid dose of 200mg tablet each time.Suppression of malaria:Adult 400 mg on the same day of each weeks. Children & infant 6.5 mg/kg body weight. Maximum: Adult dose regardless of wt. Suppressive therapy should begin 2 weeks prior to exposure. Failing this， in adults an initial double (loading) dose of 800 mg， or in children 12.9 mg/kg (maximum: 800 mg)， may be taken in 2 divided doses， 6 hr apart. The suppressive therapy should be continued for 8 weeks after leaving the endemic area. Treatment of acute attack of malaria: Adult Initially 800 mg followed by 400 mg in 6-8 hours & 400 mg on each of 2 consecutive days. Alternatively， 800 mg as single dose. Infant & children first dose: 12.9 mg/kg (but not exceeding a single dose of 800 mg); 2nd dose: 6.5 mg/kg (but not exceeding 400 mg) 6 hours after first dose; 3rd dose: 6.5 mg/kg (but not exceeding 400 mg) 18 hours after 2nd dose; 4th dose: 6.5 mg/kg (but not exceeding 400 mg) 24 hours after 3rd dose. Total dose of 32 mg/kg body weight (not exceeding 2 g) over 3 days,無需調整劑量,,需調整劑量,盡量避免,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;WM;,,,,,
OPOL2,Chlorpheniramine,Polaramine 2mg,HIMM,,i: Allergic and vasomotor rhinitis， allergic conjunctivitis， mild and uncomplicated allergic skin manifestations of urticaria and angioedema. ADR: Drowsiness， urticaria， drug rash， anaphylactic shock， photosensitivity， excessive perspiration， chills， dry mouth， nose & throat. CI: Newborn & premature infants. MAOI therapy.,,RT,Adult: 2mg tid-qid. Child: 1mg tid-qid.,,,,可能安全,,,,,,,,,,
OPLET,Cilostazol,Pletaal 50mg,HEMT,,適應症: Reduction of symptoms of intermittent claudication， as indicated by an increased walking distance. 副作用: Abdominal pain， back pain， headache， infection， palpitation， tachycardia， GI effects， peripheral edema， myalgia， dizziness， vertigo， cough， pharyngitis， rhinitis. Cardiovascular: Palpitations (5% to 10% )， Peripheral edema (7% to 9% )， Tachyarrhythmia (4% ) Gastrointestinal: Abdominal pain (4% to 5% )， Diarrhea (12% to 19% )， Feces contents abnormal (12% to 15% )， Indigestion (6% ) Hematologic: Decreased platelet aggregation Musculoskeletal: Backache (6% to 7% )， Myalgia (2% to 3% ) Neurologic: Dizziness (9% to 10% )， Headache (27% to 34% ) Respiratory: Increasing frequency of cough (3% to 4% )， Pharyngitis (7% to 12% )， Rhinitis (7% to 12% ) Other: Infectious disease (10% to 14% ) 禁忌: Patients with CHF of any severity.,,室溫,100 mg BID,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OSOL,Amisulpride,Solian 200mg,CNEU,,適應症:Treatment of psychoses， particularly acute or chronic schizophrenic disorders， characterized by +ve symptoms (e.g. delirium， hallucinations， thought disorders) &/or -ve symptoms (eg blunted emotions， emotional & social withdrawal)， including when the -ve symptoms predominate. 副作用:Insomnia， anxiety， agitation， extrapyramidal symptoms; galactorrhea， amenorrhea， gynecomastia， swollen breasts， impotence， frigidity， weight gain; GI disturbances. Occasionally， daytime drowsiness. 禁忌:Known or suspected pheochromocytoma carriers. Children < 15 years. Lactation. Known or suspected prolactin-dependent tumour， eg prolactin-secreting pituitary adenoma & breast cancer. Severe renal insufficiency. Congenital galactosemia， glucose or galactose malabsorption syndrome or lactase deficiency (due to lactose content). In combination with sultopride; dopaminergic agonists except L-dopa (amantadine， apomorphine， bromocriptine， cabergoline， entacapone， lisuride， pergolide， piribedil， pramipexole， quinagolide， ropinirole， selegiline)， except in the case of patients with Parkinson's disease.,,室溫,<=400 mg daily dose， single intake. >400 mg， in 2 divided doses. Predominant -ve episode 50-300 mg/day as individualized dosage. Optimum dosage: 100 mg/day. Mixed episodes w/ +ve & -ve symptoms 400-800 mg/day as individualized dosage to maintain min effective dose. Acute psychotic episodes Initiate with max 400 mg/day IM， replaced thereafter with 400-800 mg orally， max dosage: 1200 mg. Renal insufficiency CrCl 30-60 mL/min: reduce dose by 1/2. CrCl 10-30 mL/min: reduce dose to 1/3.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ENS5,Sodium Chloride,0.9%NaCl irrigation (Normal Saline) 500mL(沖洗用),MSIV,Wound cleansing， irrigation & flushing.,Not to be used to induce emesis.,,室溫,For Irrigation Only. Not for Injection. As sterile irrigation of tissues or wounds， and for washing， rinsing medical device.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,EXT;G;GAR;IH;IN;INHL;IRR;IRRI;NA;ORO;RT;SKIN;TOPI;,,,,,
ENS1,Sodium Chloride,Normal Saline irrigation 1000mL,NUTR,,適應症: Wound cleansing， irrigation & flushing. 禁忌: Not to be used to induce emesis.,,,,,,,,,,,,IRR;IRRI;,,,,,
EULE,Crotamiton,Ulex 擦液 10%， 30gm,TDER,Non-atopic allergy， urticaria， eczema.,Hypersensitivity to any component of the formulation.,Local skin irritations.,25℃以下,Scabies， Apply several times daily for 5 days Pruritus， Apply several times daily,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
OZYB,Bupropion,Zyban SR 150 mg,ZADT,,適應症:煙癮輔助戒治劑(B023941100),,RT,Adult Start treatment while patient is still smoking & set a "target stop date" w/in 1st 2 wk of treatment. Initially 150 mg daily for 3 days increasing to 150 mg bid， at least 8 hr between successive dose. Max: 150 mg/dose， 300 mg/day. Treat for at least 7 wk.,,,,可能安全,,,,,,,,,,
IGLYT,Nitroglycerin,Glyceryl trinitrate inj 50mg/10mL,CAVS,,,,RT,IV infusion: Initially， 5 mcg/min; may be increased by 5 mcg/min q3-5 mins until a response is noted.,,,,除非治療上需要,,,,,,,,,,
ICHL1,Chloramphenicol,Chloramphenicol inj 1gm,QANB,,適應症:Streptococcal， pneumococcal， H. influenzae infection， whooping cough， pneumonia， brucellosis， UTI， enteritis， peritonitis， salmonellosis， rickettsiosis， granuloma inguinale， typhus， cholera， actinomycetes. 副作用:Reversible bone marrow depression， leukopenia， reticulocytopenia， thrombopenia & anemia. 禁忌: Pregnancy & lactation， hypersensitivity， anemia.,,室溫,Adult 1g 12 hrly by IM or IV.,,,,除非治療上需要,Compatible,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,1. 監測體溫、CBC、血球分化計數、肝腎功能。 2. 新生兒或早產兒使用需注意”gray syndrome”。 3. 稀釋濃度：100 mg/mL
EGLYQ,Hydroquinon,Glyquin XM cream 4% ，1oz,TDER,,Chloasma， melasma， freckles， senile lentigines， & other unwanted areas of melanin hyperpigmentation.,,RT,Apply to the affected area bid.,,,,沒有資料,,,,,,,,,,
ESPED,Antazoline + Tetryzoline,Spersallerg eye drop 10mL,TOPH,,適應症: Irritant conjunctivitis， allergic inflammatory conditions of the conjunctiva， particularly hay fever conjunctivitis & vernal conjunctivitis. 副作用: Mild burning sensation; headache， sleepiness， tachycardia. 禁忌: Narrow-angle glaucoma.,,室溫,Acute stage: 1 drop 3 hrly. Continuous use: 1 drop 2-3 times daily. Severe cases: Use hrly. Infant Max: 1-2 drop daily.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EGEND,Gentamicin,Garamycin eye drop 5mL,TOPH,,I: Treatment of superficial bacterial infection of the conjunctive， cornea， eyelids， tear ducts， and skin adjacent to the eyes. CI: Garamycin solution should never be injected subconjunctivally， nor directly introduced into the anterior chamber of the eye.,,RT,Oph. oint.: tid-qid. Oph. soln: 1-2 gtt tid-qid.,,,,除非治療上需要,,,,,,,,,,
ESUP,Desflurane,Suprane 240mL,ZANE,Inhalation agent for induction & maintenance of general anesth.,Patient in whom general anaesth is contraindicated. Sensitivity to halogenated agents. Genetic susceptibility to malignant hyperthermia.,Dose-dependent hypotension & respiratory depression. Cough， breath holding， salivation， apnoea & laryngospasm. Post-op nausea & vomiting. Transient increase of WBC count， malignant hyperthermia.,15-30℃,Induction: Adult Initially 3%， increased by 0.5-1% every 2-3 breaths. Inspired concentration of 4-11% produces surgical anesthesia in 2-4 minutes. Maintenance: Adult whether mix nitrous oxide or not， 2.5-8.5% Suprane. Children 5.2-10% Suprane.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,1.Suprane (desflurane) should be administered only by persons trained in the administration of general anesthesia. It should only be administered using a vaporizer specifically designed and designated for use with Suprane. 2.The administration of general anesthesia must be individualized based on the patient’s response， including cardiovascular and pulmonary changes. 3.Suprane (desflurane) should not be used as the sole agent for anesthetic induction in patients with coronary artery disease
ETAL,Tetracycline + Amphotericin B,Talsutin VT 100/50mg,SGU,,適應症:念珠菌、滴蟲或細菌感染所引起之陰道炎(A034794500),,RT,Intravaginal， 1-2 vag. tab/day for 2 wks.,,,,沒有資料,,,,,,,,,,
IRIN,Betamethasone Disodium Phosphate,Rinderon inj 2mg/0.5mL,HM,,Emergency use in conditions or situations where a rapid and intense hormonal effect is necessary or desirable.,,,Initial: 1-2 ml to be repeated at 3 or 4 hrs interval. Maintenance: 0.5-1 ml.,,,,,,,,,,,,,,
OGLU,Metformin,Glucomine F.C. 500mg,META,,,,RT,250 - 1000 mg tid pc ( max: 3 g/day ).,,,,可能安全,,,,,,,,,,
EALC9,Alcohol,95% Alcohol,TDER,Antiseptics and disinfectants.,Hypersensitivity to any component of the formulation.,Mild local discomfort.,貯存在陰涼、乾燥、隔離且通風良好的地區， 遠離熱、引燃源及不相容物。,95% Alcohol contains 95% ethyl alcohol， can be diluted with purified water to the effective disinfecting strength of 70%.,無需調整劑量,,無需調整劑量,盡量避免,Contraindicated,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,EXT;,,,,,
ISAN1,Octreotide,Sandostatin inj 0.1mg/1mL,HM,Symptomatic control & reduction of growth hormone & somatomedin C plasma levels in acromegaly; relief of symptoms associated with gastroenteropancreatic endocrine (GEP) tumors & carcinoid tumors including VIPomas， glucagonomas， gastrinomas/Zollinger-Ellison syndrome， insulinomas， GRFomas. Prevention of complications following pancreatic surgery. Bleeding gastro-oesophageal varices.,Known hypersensitivity to octreotide or one of the excipients (see Description) of Sandostatin,Anorexia， nausea， vomiting， crampy abdominal pain， abdominal bloating， flatulence， loose stools， steatorrhea， rarely progressive abdominal distension， severe epigastric pain， gallstones. Dermatologic: Injection site pain Endocrine metabolic: Hyperglycemia (1.5% to 16%)， Hypoglycemia (1.5% to 3%)， Hypothyroidism Gastrointestinal: Abdominal discomfort， Cholelithiasis (22% to 33% )， Constipation， Diarrhea， Flatulence， Nausea， Pancreatitis Hepatic: Disorder of biliary tract Neurologic: Dizziness， Headache,2-8℃,Acromegaly: Initially IM 0.05-0.1mg every 8-12 hour， could increased up to 1.5mg. Functional gastrointestinal pancreatic endocrine tumor: Initially IM 0.05mg 1-2 times per day， followed by 0.1-0.2mg three times per day. Complications after pancreatic surgery: IM 0.1mg three times per day for 7 days. Bleeding esophageal varices: diluted in normal saline and IV infusion 25mcg per hour for 5 days.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;SC;,,【N/S】可選 仿單建議。,,Bleeding gastro-oesophageal varices 50 mcg/hr by IV infusion for max 5 days.,
ISAN2,Octreotide,Sandostatin LAR 20mg,HM,,Symptomatic control and reduction of growth hormone and somatomedin C plasma levels， gastroenteropancreatic endocrine tumors & carcinoid tumors. Acute pancreatitis， enteric fistula.,,,Adult: (max. 750 mcg/day). Carcinoid tumors: SC， 100-600 mcg/day in 2-4 divided doses. VIPomas & acromegaly: SC， 200-300 mcg/day in 2-4 divided doses. Initial: 100 mcg. Maintenance: 25 mcg/hr for 24 hrs. Acute pancreatitis: SC， 100 mcg q6h for 3-7 days. Child over 1 month: SC， 1-10 mcg/kg/day.,,,,可能安全,,,,,,,,,,
ISEP,Sulfamethoxazole + Trimethoprim,Septrin 400/80 for infusion,QANB,,Acute exacerbation of chronic obstructive pulmonary disease Acute otitis media Pneumocystis carinii pneumonia Pneumocystis carinii pneumonia; Prophylaxis Shigellosis Traveler's diarrhea Urinary tract infectious disease,,RT,Adult: Acute exacerbation of chronic obstructive pulmonary disease: 1 double-strength tablet or 2 single-strength tablets or 20 mL suspension ORALLY every 12 hr for 14 days Granuloma inguinale: 1 double-strength tablet ORALLY twice a day for at least 3 weeks and lesions are healed completely Pneumocystis carinii pneumonia: 15-20 mg/kg TMP component/day ORALLY or IV divided every 6 hr for 14-21 days Pneumocystis carinii pneumonia; Prophylaxis: 1 double-strength tablet ORALLY once a day; alternative regimens， 1 double-strength tablet ORALLY 3 times a week or 1 single-strength tablet ORALLY once a day Shigellosis: 1 double-strength tablet or 2 single-strength tablets or 20 mL suspension ORALLY every 12 hr for 5 days Toxoplasma encephalitis; Prophylaxis: 1 double-strength tablet or 1 single-strength tablet ORALLY once a day Traveler's diarrhea: 1 double-strength tablet or 2 single-strength tablets or 20 mL suspension ORALLY every 12 hr for 5 days Urinary tract infectious disease: 1 double-strength tablet or 2 single-strength tablets or 20 mL suspension ORALLY every 12 hr for 10-14 days Pediatric: Acute otitis media: (2 months of age and older) 8 mg/kg TMP component/day ORALLY divided every 12 hr for 10 days Pneumocystis carinii pneumonia: (2 months of age and older) 15-20 mg/kg TMP component/day ORALLY or IV divided every 6 hr for 14-21 days Pneumocystis carinii pneumonia; Prophylaxis: (1 month of age and older) 150 mg/m(2) TMP component/day in 2 divided doses 3 times a week on consecutive days; alternative regimens， 150 mg/m(2) TMP component once daily 3 times a week on consecutive days or 150 mg/m(2) TMP component/day in 2 divided doses every day or 3 times a week on alternate days Shigellosis: 8-10 mg/kg TMP component/day IV divided every 6-12 hr for up to 5 days Toxoplasma encephalitis; Prophylaxis: (2 months of age and older) 150 mg/m(2) TMP component/day in 2 divided doses Urinary tract infectious disease: (2 months of age and older) 8 mg/kg TMP component/day ORALLY divided every 12 hr for 10 days,,,,除非治療上需要,,,,,,,,,,
ISOLC,Hydrocortisone,Solu-Cortef inj 100mg,HM,,適應症:Endocrine， rheumatic & hematologic disorders; collagen， dermatologic， ophth， GI， respiratory & neoplastic diseases; allergic & edematous states; acute exacerbation of multiple sclerosis; tuberculous meningitis with subarachnoid block; trichinosis with neurologic or myocardial involvement. 副作用:Fluid & electrolyte disturbances; decreased carbohydrate tolerance; impaired wound healing， thin fragile skin; muscle weakness， steroid myopathy， osteoporosis， aseptic necrosis; peptic ulceration with possible perforation; cataracts， increased intraocular & intracranial pressure; growth retardation; Cushingoid state; protein catabolism; psychic derangements. 禁忌:Systemic fungal infection. Lactation,,20-25℃,Initially 100-500 mg depending on severity of condition， repeated at interval of 2， 4 or 6 hr.,,,,盡量避免,,,,,,,,,,
ODET,Tolterodine,Detrusitol 2mg,SGU,Overactive bladder， With symptoms of urinary frequency， urgency， or urge incontinence.,Hypersensitivity to the drug， tolterodine， or its ingredients. Uncontrolled narrow-angle glaucoma. Urinary retention.,Common Gastrointestinal: Abdominal pain (3% to 5% )， Constipation (6% to 7% )， Xerostomia (23% to 35% ) Neurologic: Headache (immediate-release， 7%) Serious Immunologic: Anaphylaxis Other: Angioedema,室溫，低於25℃,Adult: Initial， 2 mg BID; may decreasing to 1 mg BID depending on tolerability and response. Children: Safety and efficacy in pediatric patients has not been established on label. Pediatric Dosing recommedion from micromedex: 4 to 12 years: 1 mg twice daily(study dosage). Or younger than 5 years: 0.1 mg/kg/day， divided into 2 doses(study dosage).,需調整劑量,[仿單]使用tolterodine 時必須避免授乳，因為尚不知tolterodine 是否會分泌至人類的乳汁中。,需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]尚無孕婦的臨床試驗。因此懷孕期間，tolterodine 應只用於對母體的益處大於對胎兒可能 之危險的臨床狀況。,Human Data Suggest Potential Toxicity,[仿單]使用tolterodine 時必須避免授乳，因為尚不知tolterodine 是否會分泌至人類的乳汁中。,AC;AC15;PC;PO;WM;,,,,,1. 本藥對於開車及機械操作能力可能有負面的影響。應警告病人應避免從事相關活動。 2. 併用其他強效CYP3A4 抑制劑之患者，如巨環類抗生素（Erythromycin 和Clarithromycin）或Azole 類抗黴菌劑（Ketoconazole， Itraconazole 和Miconazole）時，Tolterodine 每日建議總劑量為2 毫克。
ECOM,Ipratropium + Salbutamol,Combivent Metered Aerosol,ERSP,,適應症: Management of reversible bronchospasm associated with obstructive airways diseases in patients who require more than a single bronchodilator. 副作用: Headache， dizziness， nervousness， tachycardia， fine tremor， palpitations. Potentially serious hypokalaemia may result from β2 agonist therapy. Dry mouth， dysphonia， ocular complications， allergic-type reactions. 禁忌: Hypertrophic obstructive cardiomyopathy or tachyarrhythmia,,室溫,Shake well before use. Adult 2 inhalations qid. Max: 12 inhalations in 24 hr.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OLIP10,Atorvastatin,Lipitor 10mg,CAVS,,適應症: Hyperlipidemia. 副作用: Constipation， flatulence， dyspepsia， abdominal pain， headache， nausea， myalgia， asthenia， diarrhea， insomnia. Gastrointestinal: Diarrhea (up to 14.1% ) Musculoskeletal: Arthralgia (up to 11.7% ) Renal: Urinary tract infectious disease (up to 8% ) Respiratory: Nasopharyngitis (8.3% ) Other: Pain， In extremity (up to 9.3% ) 禁忌: Active liver disease or persistent elevations of serum transaminases > 3 times the upper limit of normal. Pregnancy & lactation.,,室溫,Initial dose: 10 mg / day Dose range: 10 ~ 80 mg / day， atorvastatin can be administered as a single dose at any time of the day， with or without food.,,,,不可使用,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,
IATR,Atropine,Atropine sulfate 針劑1mg/1mL,ALIM,Bradycardia， Organophosphorus poisoning， Premed in anesth， Poisoning or overdosage w/ compd having muscarinic actions.,Glaucoma， chronic respiratory disease， sick sinus syndrome， thyrotoxicosis， cardiac failure， pyloric stenosis， prostatic hypertrophy.,Dry mouth， dysphagia， constipation， flushing and dryness of skin， tachycardia， palpitations， arrhythmias， mydriasis， photophobia， cycloplegia， raised intraocular pressure. Toxic doses cause tachycardia， hyperpyrexia， restlessness， confusion， excitement， hallucinations， delirium and may progress to circulatory failure and resp depression. Eye drops: Systemic toxicity esp in children， on prolonged use may lead to irritation， hyperaemia， oedema and conjunctivitis. Increased intraocular pressure. Inhalation: Dryness of mouth， throat.,15-30℃避免冰凍,Adult : IV/IM/SC Antimuscarinic 400-600mcg every 4-6 hours. IV Anti-arrhythmia 400 mcg-1mg every 1-2 hours. Maximum: 2 mg. IM Premedication in anesthesia 200-600 mcg 30-60 minutes before anesthesia. IM Gastrointestinal endoscopy: 1 mg. IV/IM Organophosphorus poisoning: 1-2 mg every 20-30 minutes until cyanosis disappear or atropine toxicity appears. IV/IM Poisoning or overdosage with compound having muscarinic actions 1-2 mg， repeat 1 hourly until the breathing effect occurs. Children: SC Antimuscarinic 10mcg/kg or 0.3mg/m2 (Body surface area) every 4-6 hours. Maximum: 400mcg. IV Anti-arrhythmia 10-30mcg/kg. SC before anesthesia: <3 kg: 100mcg， 7-9 kg: 200mcg， 12-16 kg: 300mcg， 20-27 kg: 400mcg， 32 kg: 500mcg， 41 kg: 600mcg.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;IVP;IVPUSH;SC;,,【N/S】可選 。,Administer undiluted by rapid IV injection.,1. 不建議加在大型靜脈注射液內。,1. 不建議加在大型靜脈注射液內。 2. UpToDate:IV: Administer undiluted by rapid IV injection; slow injection may result in paradoxical bradycardia. In bradycardia， atropine administration should not delay treatment with external pacing.
IATRA,Atracurium Besylate,Atracurium inj 25mg,CNEU,,Used in anesthesia to relax skeletal muscles during surgical procedures and to facilitate controlled ventilation， endotracheal intubation.,,,IV: Initial dose: 0.4-0.5 mg/kg. Subsequent doses: 0.08-0.1 mg/kg as needed.,,,,除非治療上需要,,,,,,,,,,
IAUG,Amoxicillin + Clavulanic Acid,Augmentin針劑 600mg,QANB,,適應症:Treatment of infections due to Staph， Strep， pneumococcus， meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract， GUT， skin & soft tissue， bone & joint. Dental infections， septic abortion， puerperal sepsis， intra-abdominal sepsis. Vial Also indicated for prophylaxis against infection which may be associated with major surgical procedures such as GI， pelvic， head & neck， cardiac， renal， joint replacement & biliary tract. 副作用:Diarrhea， indigestion， nausea， vomiting， pseudomembranous colitis and candidiasis have been reported. Nausea， although uncommon， is more often associated with higher oral dosages. If gastrointestinal side effects occur with oral therapy， they may be reduced by taking Augmentin at the start of meals. 禁忌:Hypersensitivity to penicillins， possible cross sensitivity with other β-lactam antibiotics. History of penicillin-associated cholestatic jaundice/hepatic dysfunction,,室溫,Treatment of infections Adult & children >12 years 1.2 g 8 hrly， increasing to 6 hrly in more serious infections. Children 3 months-12 years 30 mg/kg 8 hrly， increasing to 6 hrly in more serious infections， 0-3 months 30 mg/kg 12 hrly in premature infants & in full-term infants during the perinatal period， increasing to 8 hrly thereafter. Surgical prophylaxis Adult 1.2 g at the induction of anesth. Where there is a high risk of infection， 3-4 doses of 1.2 g may be needed in a 24-hr period. Continue regimen for several days if procedure has significantly increased risk of infection,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 注射前檢查病患是否有 penicillin 過敏史。 2. 稀釋後應儘快使用，安定性與稀釋濃度與保存條件有關。
EFLU,Halothane,Fluothane 250mL,ZANE,,適應症: Induction and maintenance of general anesth. 副作用: Bradycardia， hypotension， cardiac arrhythmias， respiratory depression， shivering during recovery (occasional)， hepatitis (multiple exposure). 禁忌: Obstetrics; malignant hyperthermia; porphyria.,,15-25°C.,Inhalation Induction: 2-4% v/v in O2 or mixtures of nitrous oxide and O2. Maintenance: 0.5-2% v/v depending on the flow rate used.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IBAY1,Hepatitis B Immune Globulin,HyperHep B 1mL,HIMM,,適應症: Post-exposure prophylaxis of hepatitis. Acute exposure to blood containing HBsAg， perinatal exposure of infants born to HBsAg +ve mothers， sexual exposure to an HBsAg +ve person， household exposure to persons with acute HBV infection. 副作用: Local pain & tenderness at the inj site， urticaria & angioedema， anaphylactic reactions.,,2-8℃,Prophylaxis of infants born to HBsAg and HBeAg +ve mothers: 0.5ml to be given w/in 12 hr of birth. Sexual exposure to an HBsAg +ve person: 0.06ml/mg of HBIG IM as a single dose w/in 14 days of sexual contact.Give together with 1st dose of 1mL IM of vaccine. Household exposure to persons w/ acute HBV infection: infants<12mth 0.5mL.,,,,除非治療上需要,,,,,,,,,,
IBCG,BCG Vaccine,BCG vaccine 2.5mg/mL,HIMM,,Persons who have negative tubercullin skin test.,,,Neonate against tuberculosis:0.1 ml intrademally， 0.05 ml may be given to newborn infants.,,,,除非治療上需要,,,,,,,,,,
OPOLI0,B1+ B12 + FA + Fe + Cu + Mg + Lysine,Polichinon,NUTR,,Aplastic anemias， iron deficiency anemias， macrocytic hyperchromic anemias.,,,1-3 cap daily， after meals.,,,,,,,,,,,,,,
EAAS,Sodium Oleate,Alcos-Anal 栓劑,ALIM,Hemorrhoids,Hypersensitivity to any component of the formulation.,Local irritation,存放在陰涼處,Insert 1 suppository in the morning， evening and after defecations,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,RECT;,,,,,
EACN,Sulfur Precipitated,Acne lotion 4% 100mL,TDER,,適應症: Acne， subacute & chronic dermatitis.,,室溫,Apply tid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EAGNO3,Silver Nitrate,Silver nitrate 10%， 10mL,TDER,,I: An astringent and caustic.,,室溫,Topcial use when necessary.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,EXT;,,,,,
EAIR,Tretinoin,Airol cream 0.05% 20gm,TDER,,I: Acne vulgaris esp. forms with comedones. AR: Transient skin irritation.,,,Apply qd-bid.,,,,除非治療上需要,,,,,,,,,,
EAL0C9,95% Alcohol,95% Alcohol,TDER,,,,,,,,,,,,,,,,,,,
EALB,Policresulen,Albothyl vag supp 90mg,SGU,,適應症: Local treatment of cervical & vag inflammatory & concomitant discharge. Vaginitis & cervicitis， cervical erosion; trichomoniasis & moniliasis. To stop bleeding after biopsy & removal of cervical polyps. Decubital ulcers caused by pessaries. After electrocoagulation to activate regeneration. 副作用: Occasionally， mild local discomfort at beginning of treatment which disappears on discontinuation. 禁忌: Concomitant use of other topical agents in treating the affected areas.,,室溫,1 to be inserted on alternate days.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EALC5,Alcohol,75% Alcohol 500mL,TDER,,,,,,,,,,,,,,,,,,,
EALCA,Proparacaine,Alcaine 0.5%， 15mL,TOPH,,適應症: Procedures in which a rapid & short-acting topical ophth anesth is indicated eg tonometry， gonioscopic exam， removal of foreign bodies & sutures from the cornea， conjunctival scraping in diagnosis， cataract extraction or other surgical procedures. 副作用: Transient stinging & burning， conjunctival redness.,,2-8 °C,Tonometry & other exam of short duration Instill 1-2 drops prior to evaluation. Minor surgical procedures eg foreign body or suture removal Instill 1-2 drops every 5-10 mins for 1-3 doses. Prolonged anesth Instill 1-2 drops every 5-10 mins for 3-5 times.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EALD,Beclomethason Dipronate,Aldecin Inhaler(50mcg/puff),ERSP,,,,,,,,,除非治療上需要,,,,,,,,,,
EART1,Carteolol,Arteoptic 1% oph sol 5mL,TOPH,,適應症: Glaucoma & ocular hypertension. 禁忌: Unsatisfactorily controlled cardiac insufficiency; risk of bronchial asthma & bronchospasm; sinus bradycardia; AV block (II & III); cardiogenic shock; right ventricular insufficiency due to pulmonary hypertension & CHF.,,室溫,1 gtt qd-bid.,,,,盡量避免,,,,,,,,,,
OMOD,Hydrochlorothiazide + Amiloride,Moduretic 50/5mg,CAVS,,適應症: Hypertension， edema of cardiac origin & hepatic cirrhosis with ascites & edema. 副作用: Headache， weakness， nausea， anorexia， rash & dizziness; orthostatic effects. Dermatologic: Rash (3% to 8% ) Gastrointestinal: Nausea Neurologic: Asthenia (3% to 8% )， Dizziness (3% to 8% )， Headache (3% to 8% ) 禁忌: Hyperkalemia， other concomitant antikaliuretic therapy or K supplementation， renal insufficiency.,,室溫,Initially 1-2 tab daily.Max: 4 tab.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OGLU2,Glimepiride,Glusafe 2mg,META,,適應症: Type 2 diabetes mellitus. 副作用: Hypoglycaemia; adrenergic counter-regulation; temporary visual impairment; GI symptoms. Rarely thrombopenia， haemolytic anaemia， erythrocytopenia， leucopenia， agranulocytosis. Endocrine metabolic: Hypoglycemia [0.9% to 1.7% (adults); 4% (pediatrics) ] Gastrointestinal: Nausea (1.1% ) Neurologic: Asthenia (1.6% )， Dizziness (1.7% )， Headache (1.5% ) 禁忌: Insulin-dependent (type 1) diabetes mellitus; diabetic ketoacidosis; diabetic precoma or coma; serious renal or hepatic dysfunction. Pregnancy， lactation.,,室溫,Starting dose: 1 mg/day. Dosage may be adjusted at 1-2 wk interval to 2， 3 or 4 mg/day. Max: 8 mg/day.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OHIC,Ca Carbonate from Oyst,Hi-Cal 250mg( 限自費),NUTR,,Calcium supplement.,,RT,1-2 tab tid.,,,,沒有資料,,,,,,,,,,
ODIO,Valsartan,Diovan 80mg,CAVS,Hypertension， heart failure and heart disease.,Pregnancy.,Headache， dizziness， viral infection， upper respiratory tract infection， diarrhea， coughing， fatigue， rhinitis， sinusitis， back pain， abdominal pain， nausea， pharyngitis， arthralgia. Cardiovascular: Hypotension Neurologic: Dizziness， Headache Renal: Serum blood urea nitrogen raised (heart failure， 16.6%; hypertension and post-myocardial infarction， not reported )， Serum creatinine raised (hypertension， 0.8%; heart failure， 3.9%; post-myocardial infarction， 4.2% ) Respiratory: Cough Other: Fatigue,30℃以下乾燥處,HTN Initial: 80 -160 mg QD; slowly titrate up to maximum 320 mg QD CHF with reduced ejection fraction 20 -40 mg BID; doubling dose， every 1 to 2 weeks to 160mg BID Acute coronary syndromes: initial: 20mg BID may tolerance up to 160mg BID.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
ECUS2,Timolol,Cusimolol 0.25%， 5mL,TOPH,,適應症: Reduction of increased intraocular pressure in conditions such as ocular hypertension， chronic open-angle glaucoma (including aphakic patients) & certain instances of secondary glaucoma. 副作用: Conjunctivitis， blepharitis， keratitis. Rarely hypersensitivity， urticaria， local or general eruptions. Mild bradycardia， hypotension， bronchospasm， congestive cardiac insufficiency & masking of hypoglycemic symptoms of IDDM patients. Cardiovascular: Angina， Bradyarrhythmia (9%)， Heart failure， Hypotension Dermatologic: Pruritus， Rash， Urticaria Gastrointestinal: Abdominal pain， Diarrhea， Indigestion， Nausea， Vomiting Musculoskeletal: Cramp Neurologic: Confusion (13%)， Dizziness (2%-10%)， Headache (2%-12%) Ophthalmic: Blurred vision， Burning sensation in eye (15%-20%)， Cataract， Conjunctival hyperemia， Corneal anesthesia (15%-20%)， Dry eyes (15%-20%)， Reduced visual acuity， Ophthalmic Psychiatric: Depression (12%)， Hallucinations (11%)， Psychotic disorder (3%) Respiratory: Cough， Dyspnea Other: Fatigue (3%-11%)， Infectious disease,,室溫,1 drop of 0.25 % soln in affected eye bid. If responseis not satisfactory， use 1 drop of 0.5 % soln in the affected eye bid.,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ODANZ,Serratiopeptidase,Danzen 5mg,CNEU,,適應症:化痰、消腫之用(A001001100),,RT,1-2 tab tid-qid， to be swallowed whole with warm drinking water， pc.,,,,沒有資料,,,,,,,,,,
ODAR,Sotalol,Darobb 80mg,CAVS,,,,,,,,,,,,,,,,,,,
ODEA,Flupentixol + Melitracen,Deanxit 0.5/10mg,CNEU,,適應症: 焦慮症、憂鬱症(B011315100) Anxiety， depression， asthenia. 副作用: Transient restlessness， insomnia. 禁忌:Immediate recovery phase after MI. Defects in bundle-branch conduction. Untreated narrow-angle glaucoma. Acute alcohol， barbiturates & opiate intoxications. Patients who have received MAOIs within 2 weeks. Excitable or overactive patients.,,室溫,2 tab bid. Maintenance: 1 tab qd. Max: 6 tab/daily.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ISOLM,Methylprednisolone,Solu-Medrol inj 40mg,HM,Adjunctive therapy in life-threatening conditions ，Rheumatic disorders ， Multiple sclerosis ，Glomerulonephritis， lupus nephritis，SLE,Systemic fungal infection,GI upsets， aseptic necrosis of femoral & humeral heads; peptic ulceration with possible perforation & hemorrhage; manifestations of latent diabetes mellitus; anaphylactic reactions with or without circulatory collapse， cardiac arrest or arrhythmias， bronchospasm. Fluid & electrolyte disturbances. Also see lit.,25℃以下,For large dose， IV 30mg/kg for 10-20 minutes， could repeat every 4-6 hours in 48 hours. In other indication， 10-40mg for the first dose， adjusted by patient's condition from second dose. For multiple sclerosis， 160mg daily for one week， then 80mg every two days for one month.,無需調整劑量,Corticosteroids are generally considered acceptable in breastfeeding women when used in usual doses; however， monitoring of the breastfeeding infant is recommended (WHO 2002). Methylprednisolone is classified as a nonfluorinated corticosteroid; when systemic corticosteroids are needed in a lactating woman for rheumatic disorders， low doses of nonfluorinated corticosteroids are preferred (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,無需調整劑量,除非治療上需要,Uknown 沒有資料,Methylprednisolone is classified as a nonfluorinated corticosteroid. When systemic corticosteroids are needed in pregnancy for rheumatic disorders， nonfluorinated corticosteroids are preferred. Chronic high doses should be avoided (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,Unknown 沒有資料,Corticosteroids are generally considered acceptable in breastfeeding women when used in usual doses; however， monitoring of the breastfeeding infant is recommended (WHO 2002). Methylprednisolone is classified as a nonfluorinated corticosteroid; when systemic corticosteroids are needed in a lactating woman for rheumatic disorders， low doses of nonfluorinated corticosteroids are preferred (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,IM;IVD;IVP;IVPUSH;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,IV push over 1 minute,Low dose (eg， <1.8 mg/kg or <125 mg/dose): Administer over 3 to 15 minutes Moderate dose (eg， >2 mg/kg or 250 mg/dose): Administer over 15 to 30 minutes High dose (eg， >15 mg/kg or >500 mg/dose): Administer over 30 to 60 minutes,UpToDate:Do not administer moderate- or high-dose IV push; severe adverse effects， including hypotension， cardiac arrhythmia， and sudden death， have been reported in patients receiving high-dose methylprednisolone IV push over <20 minutes. 稀釋後溶液若存放於20-25℃須於3小時內使用，2-8℃須於24小時內使用.
ISOMA,Somatostatin,Somatosan 3mg,HM,,適應症: Severe acute hemorrhage from esophageal varices. Severe acute hemorrhage from gastric or duodenal ulcers or accompanying acute erosive or hemorrhagic gastritis. Prophylaxis & treatment of post-op complications following pancreatic surgery. Adjuvant treatment of intestinal & pancreatic fistule. 副作用: GI symptoms (nausea， vomiting， diarrhea)， rarely skin rash. 禁忌: Pregnancy， peri & postnatal period， lactation. Spurting arterial bleeding must be treated by surgery.,,室溫,250 mcg IV in initial 3 mins， then continue with 250 mcg/hr by IV infusion.,,,,可能安全,,,,,,,,,,
ISPAR,Sparteine Sulfate (JP),Sparteine inj 100mg/1mL,SGU,,,,,,,,,,,,,,,,,,,
OGAST,Famotidine,Gaster 20mg,ALIM,,1. Duodenal and benign gastric ulcer. 2. Prevention of relapse of duodenal ulceration. 3. Zollinger-Ellison syndrome.,,,Oral: Adult: Benign gastric and duodenal ulcer: 40 mg at night for 6-8 wks. Prophylaxis of duodenal ulcer relapse: 20 mg at night. Zollinger-Ellison syndrome: Initially 20 mg q6h， adjust as necessary (max. 480 mg/day). Inj: Slow IV: 20 mg q12h， IV inj must be diluted to 20 ml and given over 2 mins. IV infusion: 20 mg q12h over 15-30 mins.,,,,可能安全,,,,,,,,,,
ISUN25,5% Dextrose in 0.9% Sodium,Suntose 2.5% 500mL,NUTR,,,,,,,,,,,,,,,,,,,
ITAX,Paclitaxel,Taxol inj 30mg/5mL,RACA,,After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast cancer.,,,135 mg/ m^2 IV over 24 hr every 3 wk. Patients must be premedicated prior to administration eg dexamehtasone 20 mg orally (or its equiv) 12 & 6 hr before Taxol， diphenhydramine (or its equiv) 50 mg IV 30-60 mins before Taxol.,,,,盡量避免,,,,,,,,,,
OHARN,Tamsulosin,Harnalidge 0.2mg,SGU,,適應症:主治良性前列腺肥大(B022095100),,RT,0.2mg once daily.,,,,可能安全,,,,,,,,,,
OHER,Diltiazem,Herbesser 30mg,CAVS,Angina pectoris， mild to moderate essential hypertension.,Sick-sinus syndrome; 2nd or 3rd AV block; porphyria. Severe congestive cardiac failure; marked bradycardia. Pregnancy & lactation. Serious Cardiovascular: Congestive heart failure (less than 2% )， Heart block， Myocardial infarction Hepatic: Hepatotoxicity,Dizziness， bradycardia， facial flushing， AV block. Fatigue， headache， lightheadedness. Skin rash; GI disturbances， constipation， abdominal pain， heartburn， dyspepsia. Cardiovascular: Bradyarrhythmia (1.7% to 3.6% )， Peripheral edema (4.6% to 8% ) Neurologic: Dizziness (3.5% to 6.4% )， Headache (4.6% ) Respiratory: Cough (2% ) Other: Fatigue (4.8% ),25℃以下,Angina: 30 mg TID. May be increased to 60 mg TID. HTN: (mild to moderate): 30-60 mg TID. Maximum dose: 360mg.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OHYT,Terazosin,Hytrin 2mg,CAVS,,適應症:Hypertension， benign prostatic hyperplasia (BPH). 副作用: Dizziness， nasal congestion， drowsiness， nausea， peripheral edema， asthenia， postural hypotension. Cardiovascular: Edema (3%)， Hypotension (3%-7%)， Lightheadedness， Palpitations (4%)， Syncope (1%)， Tachyarrhythmia (2%) Gastrointestinal: Nausea (2%-4%) Neurologic: Asthenia (2%-13%)， Dizziness (4%-26%)， Headache (2.5%)， Somnolence (3%-5%) Reproductive: Impotence (1%-2%) Respiratory: Dyspnea (2%-3%)， Nasal congestion (6%-12%)， Rhinitis (2%)， Sinusitis (3%) Other: Fatigue 禁忌: Pregnancy.,,室溫,BPH initially 1 mg at bedtime， increase dose in a stepwise fasion to 2 mg， 5 mg or 10 mg once daily to achieve desired improvement. Hypertension initially 1 mg at bedtime. Recommended dose range: 1~ 5 mg once daily.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OILO2,Erythromycin,Ilosone 250mg,QANB,,Active against Mycoplasma pneumonia， Legionella pneumophilia.,,,Oral: Take on an empty stomach. Adult: 250 mg q6h， (max. 4 g/day). Child: 30-50 mg/kg/day in 3-4 divided doses; dosage may be doubled in severe infections.,,,,可能安全,,,,,,,,,,
IBER,Immune Globulin,Beriglobin P 320mg/2mL,HIMM,,Immunoglobulin deficiency， Hepatitis A measles， Hepatitis B， other viral diseases.,,2-8,IM，Immunoglobulin deficiency: 0.66 ml/kg monthly， using multiple inj sites (max. 5 ml/site). Hepatitis A: Prophylaxis， 0.02 ml/kg; for travel longer than 3 months， 0.06 ml/kg. Measles: Prevention or modification， 0.25 ml/kg; max. 15 ml given within 6 days after exposure.,,,,除非治療上需要,,,,,,,,,,
IBLT,Dextrose,Bluton 500mL (50% glucose),NUTR,,適應症:Treatment of carbohydrate & fluid depletion; hypoglycaemia. 副作用: Fever， phlebitis， thrombosis， pain at inj site. 禁忌:Anuria， intracranial or intraspinal haemorrhage.,,室溫,Individualised dosage， depending on the deficit or the daily maintenance requirements.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,50 % Glucose Solution，高張葡萄糖液，限藥劑科調配TPN使用
IBRE,Esmolol,Brevibloc 100mg,CAVS,,適應症: Rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in peri-op， post-op or other emergent circumstances. Noncompensatory sinus tachycardia. Treatment of tachycardia & hypertension that occur during induction， tracheal intubation， during surgery， on emergence from anesth & in the post-op period. 副作用: Hypotension， dizziness， somnolence， confusion， headache， agitation， fatigue; nausea， vomiting. 禁忌: Sinus bradycardia， heart block > 1st degree， cardiogenic shock or overt heart failure.,,室溫,Supraventricular tachycardia 50-200 mcg/kg/min. Intra-op & post-op tachycardia &/or hypertension Immediate control: 80 mg bolus dose over 30 seconds followed by a 150 mcg/kg/min infusion. Gradual control: Initially 50 mcg/kg/min for 1 min followed by a 4-min maintenance infusion of 500 mcg/kg/min.,,,,除非治療上需要,,,,,,,,,,
IBRI,Methohexital,Brietal inj 500mg,ZANE,,適應症: Anesth. 副作用: Cardiorespiratory depression， tachycardia， hypotension， myocardial depression， bronchospasm， hiccups， laryngeal spasm， hypersensitivity reactions， inj-site reactions， skeletal muscle hyperactivity， convulsions， nausea， abdominal pain， abnormal liver function tests. 禁忌: Porphyria.,,20-25°C,IV Induction: 50-120 mg at rate of 10 mg every 5 sec. Maintenance: 20-40 mg via inj every 4-7 min or via continuous infusion using a 0.2% soln at 3 mL/min.,,,,可能安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IBUS,Hyoscin-Butylbromide,Buscopan inj 20mg/1mL,ALIM,,,,室溫,,,,,除非治療上需要,,,,,,,,,,
L,Liq Dispensing,Liq Dispensing,PHR,,,,,,,,,,,,,,,,,,,
LANT,Acetaminophen,Anti-phen 24mg/mL， 60mL,CNEU,Analgesic & antipyretic.,When used for self-medication， do not use with other drug products containing acetaminophen or if allergic to acetaminophen or any of the inactive ingredients.,Allergic reactions， hematological reactions.,25℃以下，不需冰存,＞12 years old:20-30mL(480mg-720mg) Q4H-Q6H， 6-12 years old: 10-15mL(240mg-360mg) Q4H-Q6H， 3-6 years old: 5-7.5mL(120mg-180mg) Q4H-Q6H，,需調整劑量,,需調整劑量,可能安全,Human data suggest low risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
LAUG,Amoxicillin + Clavulanic Acid,Augmentin syr 100mL,QANB,,,,,,,,,,,,,,,,,,,
LAUG1,Amoxicillin + Clavulanic Acid,Augmentin syr 100mL,QANB,,Respiratory tract infections， skin and soft tissue infections， genito-urinary tract infections， osteomyelitis.,,,Adult & child over 40 kg: 250-500 mg q8h. Child under 40 kg: 20-40 mg/kg/day in 3 divided doses.,,,,可能安全,,,,,,,,,,
LBER,Fenoterol,Berotec liq 0.5 mg/mL,ERSP,,Bronchospasm， bronchitis， emphysema.,,,Oral: Adult: 2.5-5 mg tid. Child: Up to 1 yr: 1.25 mg bid-tid. 1-6 yrs: 1.25 mg-2.5 mg tid. 6-14 yrs: 2.5 mg tid.,,,,可能安全,,,,,,,,,,
LBM,Opium Tincture + Glycyrrhiza + Antimony K tartrate,Brown mixture 200mL,ERSP,,適應症: Expectorant & antitussive.,,室溫,Adult 5 mL tid-qid.,,藥品仿單:懷孕及哺乳不建議使用,,沒有資料,,,Contraindicated 哺乳期使用禁忌,藥品仿單:懷孕及哺乳不建議使用,,,,,,
OCYM,Duloxetine,Cymbalta 30mg,CNEU,Treatment of major depressive disorder.,Coadministration with MAOIs; uncontrolled narrow-angle glaucoma.,Nausea， dry mouth， constipation， diarrhea， vomiting， decreased appetite， wt loss， fatigue， dizziness， somnolence， tremor， increased sweating， hot flushes， blurred vision， insomnia， anxiety， sexual dysfunction. Infrequently， urinary hesitation. Dermatologic: Diaphoresis (6% to 8% ) Gastrointestinal: Constipation (5% to 15% )， Decrease in appetite， Diarrhea (7% to 13% )， Nausea (14% to 30% )， Xerostomia (5% to 18% ) Neurologic: Dizziness (6% to 17% )， Insomnia (8% to 16% )， Somnolence (7% to 21% ) Other: Fatigue (2% to 15% ),30℃以下,Major Depression: Initial dose:40-60mg/day. Maintenance dose: 60mg/day. maximum dose: 120mg/day. Generalized Anxiety Disorder: Initial dose:30mg/day. Maintenance dose: 60mg/day. maximum dose: 120mg/day. Diabetic peripheral neuropathy: 60mg/day. maximum dose: 60mg/day. Fibromyalgia: Initial dose:30mg/day. Maintenance dose: 60mg/day. maximum dose: 60mg/day.",無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議應整錠吞服，不可咬碎或拆開膠囊。
ISOO,Amoxicillin + Clavulanic Acid,Soonmelt inj 600mg,QANB,Treatment of infections due to Staph， Strep， pneumococcus， meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract， GUT， skin & soft tissue， bone & joint. Dental infections， septic abortion， puerperal sepsis， intra-abdominal sepsis. Vial Also indicated for prophylaxis against infection which may be associated with major surgical procedures such as GI， pelvic， head & neck， cardiac， renal， joint replacement & biliary tract.,Hypersensitivity to penicillins， possible cross sensitivity with other β-lactam antibiotics. History of penicillin-associated cholestatic jaundice/hepatic dysfunction,Diarrhea， indigestion， nausea， vomiting， pseudomembranous colitis and candidiasis have been reported. Nausea， although uncommon， is more often associated with higher oral dosages. If gastrointestinal side effects occur with oral therapy， they may be reduced by taking Augmentin at the start of meals.,陰涼處儲存，需低於25℃,Adults and children > 12 years: 1.2 g IV every 6-8 hours for 30-40 minutes; children 3 months to 12 years: 30 mg/kg IV every 6-8 hours; infants 0-3 months: 30 mg/kg IV every 8-12 hours. Surgical prophylaxis: 1.2 g at induction of anesthesia then 1.2 g 3-4 times within 24 hours.,無需調整劑量,AMOXICILLIN BREASTFEEDING RECOMMENDATION: Compatible CLAVULANATE， POTASSIUM BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,需調整劑量,可能安全,Human data suggest risk in 1st and 3 rd trimesters,AMOXICILLIN PREGNANCY RECOMMENDATION: Human Data Suggest Risk in 1st and 3rd Trimesters CLAVULANATE， POTASSIUM PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,AMOXICILLIN BREASTFEEDING RECOMMENDATION: Compatible CLAVULANATE， POTASSIUM BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,IVD;IVP;IVPUSH;,10 mL D/W (稀釋液需在20分鐘內使用),【L/R】可選 仿單建議。【N/S】可選 仿單建議。,推注時間至少3 ~ 4分鐘,以30 ~ 40分鐘緩慢滴注,1. 注射前檢查病患是否有 penicillin 過敏史。 2. 稀釋後應儘快使用，安定性與稀釋濃度與保存條件有關。 3. 每小瓶的Soonmelt inj. 600mg中，含有0.5 mmol 的鉀與 1.55 mmol 的鈉 (估計值)。 4. 本產品不適用於肌肉注射給藥。 5.不可以血液製劑、其他蛋白液或靜脈注射用脂肪乳劑混合使用。 5. IV bolus: Amoxycillin 500mg + Clavulanic acid 100mg/vial 乾粉加入10 mL D/W泡製。 6. IV infusion: 每小瓶以50 mL適當輸注液稀釋，以30 ~ 40分鐘緩慢滴注。 本藥品不可加入含有葡萄糖、聚葡萄糖或重碳酸鹽的輸注溶液。
IPEGI,Peginterferon alfa-2b,Peg-Intron inj 80mcg,QANB,,適應症:Treatment of chronic hepatitis C in patients ? 18 years with compensated liver disease. 副作用:Headache， myalgia， pain/inflammation at inj site， fatigue， rigors， fever， depression， arthralgia， nausea， alopecia， musculoskeletal pain， irritability， flu-like symptoms， insomnia， diarrhea， abdominal pain， asthenia， pharyngitis， weight decrease， anorexia， anxiety， impaired concentration， dizziness， local reactions at inj site. 禁忌:Hypersensitivity to interferon. Pregnancy. Men whose female partners are pregnant. Autoimmune hepatitis or a history of autoimmune disease. Decompensated liver disease or severe renal dysfunction.,,2-8℃,Adult≧18 years Monotherapy 0.5 or 1 mcg/kg SC once weekly for at least 6 months. Combination therapy 1.5 mcg/kg SC once weekly in combination with ribavirin,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,
IARI,Fondaparinux,Arixtra 2.5mg/0.5mL pre-filled syringe,HEMT,Deep venous thrombosis， acute， In conjunction with warfarin sodium •Postoperative deep vein thrombosis， Hip repair or replacement， knee replacement， or abdominal surgery; Prophylaxis •Pulmonary embolism， acute， In conjunction with warfarin sodium when initial therapy is administered in a hospital,•Active major bleeding •Bacterial endocarditis •Body weight less than 50 kg in patients requiring prophylaxis for venous thromboembolism •History of serious hypersensitivity reaction (eg， angioedema， anaphylactoid or anaphylactic reactions) •Severe renal impairment (ie， CrCl less than 30 mL/minute) •Thrombocytopenia associated with positive in vitro test for antiplatelet antibody in the presence of fondaparinux sodium,Common •Dermatologic: Injection site reaction， Rash (7.5% ) •Other: Fever (13.6% ) Serious •Hematologic: Anemia (perioperative prophylaxis， 19.6%; extended prophylaxis， 1.5% )， Hemorrhage (2.2% to 3.4% )， Thrombocytopenia (0.04% to 0.2% (less than 50，000/mm(3)); 0.5% to 3% (50，000 to 100，000/mm(3)) ) •Immunologic: Anaphylaxis， Hypersensitivity reaction •Neurologic: Extradural intracranial hematoma， Non-traumatic spinal subdural hematoma,25℃以下。切勿冷凍,For patients undergoing lower extremity surgery or abdominal surgery， SC 2.5mg once daily for 5-9 days. The first dose must be gievn 6 hours after surgery and stop bleeding. For UA/NSTEMI， SC 2.5mg daily for 8 days or discharge. Maximum 8 days. For STEMI， IV 2.5mg as first dose， followed by SC 2.5mg once daily to 8 days or dischrage. Maximum 8 daysFor DVT and PE， SC once daily with dose of 5mg for weight < 50kg， 7.5mg for weight between 50-100 kg and 10mg for weight beyond 100 kg， combination with warfarin sodium within 72 hours， for at least 5 days， up to 9 days.,需調整劑量,,需調整劑量,可能安全,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;SC;,,【N/S】可選 。,,成人:當首次劑量使用IVD方式投予時，將藥品加入25~50毫升的0.9%生理食鹽水，靜脈注射需超過2分鐘。,1.當血小板數值低於100，000/mm，不可使用本藥 2.本藥不可用於肌肉注射
IDOR,Midazolam,Dormicum inj 5mg/1mL,CNEU,Conscious sedation before diagnostic therapeutic procedures with or without local anesthesia (IV administration). Premedication before induction of anesthesia (IM or rectal administration in children). Induction and maintenance of anesthesia. As an induction agent in inhalation anesthesia or a sedative component in combined anesthesia， including total IV anesthesia (IV injection and infusion). Ataralgesia in combination with ketamine in children (IM administration). Long-term sedation in intensive care units (IV administration as bolus injection or continuous infusion).,Hypersensitivity to benzodiazepines.,Drowsiness， numbed emotions， reduced alertness， confusion， fatigue， headache， dizziness， muscle weakness， ataxia or double vision. GI disturbances， changes in libido， skin reactions. Anterograde amnesia， depression， psychiatric & 'paradoxical' reactions (eg restlessness， agitation， irritability)， physical dependence. Gastrointestinal: Nausea (2.8%)， Vomiting (2.6%) Neurologic: Excessive somnolence (1.6%)， Headache (1.5%)， Somnolence (1.2%) Respiratory: Cough (1.3%) Other: Hiccoughs (3.9%),避光,Conscious sedation: Adult < 60 years old: IV: Initial dose: 2-2.5 mg， titration dose: 1mg， total dose: 3.5-7.5mg Adult >= 60 years old: IV: Initial dose: 0.5-1 mg， titration dose: 0.5-1mg， total dose: <3.5mg Pediatrics: IV: 6 months - 5 years: Initial dose: 0.05-0.1 mg/kg， repeat after 2-5 minutes and titrating to disired level of sedation as 0.2mg/kg/dose， total dose: <6mg. IV: 6-12 years: Initial dose: 0.025-0.05 mg/kg， repeat after 2-5 minutes and titrating to disired level of sedation as 0.1mg/kg/dose， total dose: <10mg. IV:13-16 years: As adults. Rectal:>6 montHS: 0.3-0.5 mg/kg IM: 1-15 years: 0.05-0.15 mg/kg Anaesthesia premedication: Adult < 60 years old: IV: 1-2 mg repeated， IM: 0.07-0.1mg/kg Adult >= 60 years old: IV: Initial dose:0.5mg slow uptitration as need， IM: 0.025-0.05 mg/kg Paediatrics:Rectal:>6 montHS: 0.3-0.5 mg/kg， IM: 1-15 years: 0.08-0.2 mg/kg Anaesthesia induction: Adult < 60 years old: IV: 0.2mg/kg(0.2-0.35 mg/kg without premedication) Adult >= 60 years old: IV: 0.05-0.15 mg/kg(0.15-0.2 mg/kg without premedication) Sedative component in combined anaesthesia: Adult < 60 years old: IV: Intermittent doses of 0.03-0.1 mg/kg or continuous infusion of 0.03-0.1 mg/kg/hr Adult >= 60 years old: IV: Lower doses than recommended for adults < 60 years old Sedation in ICUs: Adult: IV: Loading dose:0.03-0.3 mg/kg in increment of 1-2.5mg. Maintenance dose: 0.03-0.2 mg/kg/hr. <=32 weeks gestational age: IV 0.03mg/kg/hr >32 weeks gestational age up to 6 montHS: IV 0.06 mg/kg/hr >6 montHS of age: IV: Loading dose: 0.05-0.2 mg/kg. Maintenance dose: 0.06-0.12 mg/kg/hr.,需調整劑量,Potential Toxicity If Combined With Other CNS Depressants,需調整劑量,盡量避免,No (limited) human data – animal data suggest low risk,,Compatible 哺乳時可使用,Potential Toxicity If Combined With Other CNS Depressants,IM;IVD;IVP;IVPUSH;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【H/S】可選 。,緩慢推注，成人注射20-30 秒，孩童注射>2-3分鐘。下次投藥前至少等待 2 分鐘，觀察是否已發揮足夠藥效。,成人0.03-0.1 mg/kg/hour，孩童0.06-0.12 mg/kg/hour，>32週新生兒0.06 mg/kg/hour，<32週新生兒0.03 mg/kg/hour。,1. IM: 注射於大型肌肉之深部。 2. IV: 緩慢推注，成人注射20-30 秒，孩童注射>2-3分鐘。下次投藥前至少等待 2 分鐘，觀察是否已發揮足夠藥效。 3. 持續 IV infusion: 成人0.03-0.1 mg/kg/hour，孩童0.06-0.12 mg/kg/hour，>32週新生兒0.06 mg/kg/hour，<32週新生兒0.03 mg/kg/hour。 4. Dormicum inj 5mg/1mL可使用適當溶液稀釋為0.015-0.15mg/mL濃度。 5. Dormicum inj 5mg/1mL不可與鹼性溶液混合，會產生沉澱。
OAVA,Rosiglitazone,Avandia F.C. 4mg,META,,適應症:第二型糖尿病(B022818100) 禁忌:.Patients with known "NYHA"Class III or Class IV cardiac status. Patients with known hypersensitivity to this product or any of its components. 副作用: Anaemia and edema have been reported as adverse events of mild to moderate in severity. Cardiovascular: Edema (4.8% to 14.7% ) Endocrine metabolic: Weight gain 衛生署公告(99.10.14) 1.不建議該成分(rosiglitazone)使用於缺血性心臟病之病人。 2.不建議該成分使用於心臟衰竭之病人。 3.禁用於心衰竭第3級或第4級(NYHA Class III or IV cardiac status )病人,,室溫,Monotherapy or combination therapy with metformin:4mg once daily or in 2 divided doses， may be increased to 8mg in 1 or 2 divided doses after 12 wk. Combination therapy with sulfonylurea:4mg once daily or in 2 divided doses， may be increased to 8mg in 1 or 2 divided doses after 8-12 wk.,,,,除非治療上需要,,,,,,,,,,
ONEX,Esomeprazole,Nexium 40mg (耐適恩),ALIM,Erosive reflux esophagitis， Long-term management of patients with healed esophagitis， Symptomatic treatment of GERD， Treatment and prevention of H. pylori associated ulcers with amoxicillin and clarithromycin.,Hypersensitivity to benzimidadazoles.,Headache， abdominal pain， diarrhea， flatulence， nausea， vomiting， constipation. Rarely， dermatitis， pruritus， urticaria， dizziness， dry mouth. Dermatologic: Injection site reaction (1.7%) Gastrointestinal: Abdominal pain (5.8%%)， Constipation (2.5%)， Diarrhea (3.9%)， Flatulence (10.3%)， Indigestion (6.4%)， Nausea (6.4%)， Xerostomia (3.9%) Neurologic: Dizziness (2.5%)， Headache (10.9%),30℃以下避免潮濕,Erosive esophagitis - Gastroesophageal reflux disease treatment， 20 to 40 mg ORALLY once daily for 4 to 8 weeks; an additional 4 to 8 weeks may be considered if healing is not complete maintenance， 20 mg ORALLY once daily Gastroesophageal reflux disease - Heartburn 20 mg orally once daily for 4 weeks; an additional 4 weeks may be considered if symptoms do not completely resolve Helicobacter pylori gastrointestinal tract infection - Ulcer of duodenum Triple therapy， 40 mg orally once daily in combination with amoxicillin 1000 mg twice daily plus clarithromycin 500 mg twice daily for 10 days Gastric ulcer; Prophylaxis - NSAID-associated gastropathy; Prophylaxis 20 mg once daily 4-8 weeks Zollinger-Ellison syndrome 40 mg twice daily,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;PO;,,,,,[磨粉/管灌註記]本錠劑應整粒以液體吞服，不可嚼破或壓破本錠劑。無法吞服的病人，可將藥錠置入半杯非碳酸類的水中，攪拌直到藥錠崩散，將水連同小藥球喝下或管灌。再將半杯水加入杯中沖洗並服用，但小藥球不可咬碎或壓碎。
IV2113Z,Insulin Syringe,0.5mL 胰島素空針,ZOTH,為胰島素空針(NCS030510NBD),,,避免極端的溫度與濕度,,無需調整劑量,,無需調整劑量,,,,,,,,,,,
ETIMX,Timolol,Timoptol-XE 0.5% 2.5mL,TOPH,,I:Reduction of elevated intraocular pressure. AR:Transient blurred vision， burning， stinging， conjunctival infection， discharge， foreign body sensation， itching. Ocular irritation & visual disturbances. Bradycardia， arrhythmia， hypotension， syncope， heart block， CVA， cereral ischemia， CHF， palpitation， cardiac arrest， edema， bronchospasm， resp. failure etc. CI:Bronchial assthma or a hisory of bronchial asthma， severe COPD.Sinus bradycardia， 2nd & 3rd degree AV block， overt cardiac failure， cardiogenic shock.,,,1 drop once daily.,,,,,,,,,,,,,,
ODEC,Levamisole,Decaris 50mg,QANP,,適應症: 用於增強免疫力(B005827100) Ascariasis & ankylostomiasis. 副作用: Headache， vertigo， palpitation & GI disturbances. 禁忌: Patients with a known hypersensitivity to Decaris or its components. There are no absolute contraindications to the use of Decaris.,,室溫,Anthelmintic: 2.5 mg/kg as a single dose. Immunostimulant: 2.5 mg/kg/day in 1-3 divided doses， for 2 consecutive days every week or 3 consecutive days every 2 wks.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ODEU,Benzbromarone,Deuron 50mg,CNEU,,適應症:Hyperuricemia. 副作用:Rarely， diarrhoea， mild GI disturbances 禁忌:Severe renal disease， nephrolithiasis; pregnancy & lactation,,室溫,1 tab qd to tid,,,,沒有資料,,,,,,,,,,
ODIAM,Acetazolamide,Diamox 250mg,CAVS,,I: Edema， open angle glaucoma. CI: Depressed Na or K blood serum levels; marked kidney or liver disease; suprarenal gland failure; hyperchloremic acidosis; cirrhosis. Long-term administration in patients with chronic non-congestive angle-closure glaucoma.,,,0.25-1.5 g/day in divided doses.,,,,除非治療上需要,,,,,,,,,,
ODIAN,Cyproterone Acetate + Ethinylestradiol,Diane 35 (21 tablets/box),HM,Treatment of androgen dependent diseases in women， such as acne， especially pronounced forms & those which are accompanied by seborrhea or by inflammation or formation of nodes (acne papulopustulosa， acne nodulocystica)， mild forms of hirsutism. As OC.,Presence or a history of venous or arterial thrombotic/thromboembolic events (e.g. deep venous thrombosis， pulmonary embolism， MI) angina pectoris). History of migraine with focal neurological symptoms. DM with vascular involvement. Presence of a severe or multiple risk factor(s) for venous or arterial thrombosis may also constitute a contraindication. Pancreatitis or a history thereof if associated with severe hypertriglyceridemia. Presence or history of severe hepatic disease. Presence or history of liver tumors (benign or malignant). Known or suspected sex-steroid influenced malignancies (eg. of the genital organs or the breasts). Undiagnosed vag bleeding. Known or suspected pregnancy. Lactation.,Nausea， abdominal pain; weight increased; headache; depressed mood， mood altered; breast pain， breast tenderness.,陰涼(15-30℃) 乾燥處所,1 tablet daily for 21 days， starting on the 1st day of the cycle， then 7 tablet-free days.,無需調整劑量,Cyproterone Acetate [8] Micromedex Lactation Rating: Infant risk cannot be ruled out Ethinylestradil [8] Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding,無需調整劑量,不可使用,Contraindicated,Cyproterone Acetate [18] Micromedex Pregnancy Rating: Fetal risk cannot be ruled out Ethinylestradil [18] by book . micromedex : Teratogenicity/Effects in Pregnancy,Contraindicated 哺乳期使用禁忌,Cyproterone Acetate [8] Micromedex Lactation Rating: Infant risk cannot be ruled out Ethinylestradil [8] Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於懷孕或準備懷孕婦女。
OSUR,Tiaprofenic Acid,Surgam 200mg,CNEU,,適應症:為止痛消炎藥(B022728100),,RT,Initial: 600 mg/day in 2-3 divided doses. Maintenance: 300-400 mg/day.,,,,沒有資料,,,,,,,,,,
OSYN,Allopurinol,Synorid 100mg,CNEU,,,,,,,,,,,,,,,,,,,
OTAG4,Cimetidine,Tagamet 400mg,ALIM,,Active duodenal ulcer， pathological hypersecretory conditions， enhance pancreatic replacemant by reducing peptic acid deactivation， benign gastric ulcer， reflux esophagitis， upper GI bleeding.,,,,,,,可能安全,,,,,,,,,,
OTAPL,Acetylsalicylic Acid,Tapal 100mg (Aspirin),HEMT,,Fever， pain， rheumatic arthritis.,,RT,Antipyretic & analgesic: Adult: 325-650 mg q4h as needed. Child:10-15 mg/kg q4h. Arthritis:Adult:3.6-5.4 g/day. Child: 65 mg/kg/day in divided doses q6h. Acute rheumatic fever: Up to 7.8 g/day. Transient ischemic attacks: 1300 mg/day.,,,,可能安全,,,,,,,,,,
OIMIN,Methisoprinol,Imin 500mg,QANB,Viral disease， immunomodulator.,Hypersensitivity to any component of the formulation.,GI discomfort. Transient rise in serum & uric acid levels.,25℃以下避光,Adult: 500 mg q3-4h. Children: 50 mg/kg/day in divided doses.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
EAZO,Brinzolamide,Azopt 1%， 5mL ophthalmic suspension,TOPH,Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.,Hypersensitivity to sulphonamides. Severe renal impairment， hyperchloremic acidosis.,Taste perversion， temporary blurred vision， ocular discomfort， foreign body sensation， ocular hyperemia. Gastrointestinal: Abnormal taste in mouth， Bitter (5-10%) Neurologic: Headache (5-10%) Ophthalmic: Blurred vision (5-10%),儲存於4℃ -30℃,Instill 1 drop BID-TID into the conjunctival sac. Age <18 years: Not recommend use. Shake well before using.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
OIMP,Lacatol Monohydrate,Importal powder,ALIM,,,,,,,,,,,,,,,,,,,
OIMU,Azathioprine,Imuran 50mg,HIMM,As an adjunct for the prevention of rejection in renal homotransplantation. Treatment of SLE， severe RA， acute & chronic leukemia.,Hypersensitivity to 6-mercaptopurine. Pregnancy or patients who are likely to become pregnant in the near future.,Hypersensitivity reactions; dose-related， reversible bone marrow depression expressed as leucopenia， anemia or thrombocytopenia. Susceptibility to infection especially in transplant recipients. GI reactions， nausea， colitis， diverticulitis， bowel perforation， cholestasis， deterioration of liver function， reversible pneumonitis. Alopecia.,25℃以下避光,Adult Transplantation initial dose 5 mg/kg/day， maintenance dose 1-4 mg/kg/day. Other conditions 1-3 mg/kg/day.,無需調整劑量,,需調整劑量,盡量避免,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為免疫抑制劑，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
EBSS5,Balanced Salt Soln,BSS plus 500mL,TOPH,,適應症: B.S.S. Irrigation during various surgical procedures of the eyes， ears， nose &/or throat. BSS Plus Intraocular irrigating soln during intraocular surgical procedures involving perfusion of the eye. 副作用: When the corneal endothelium is abnormal， irrigation or any other trauma may result in bullous keratopathy.,,室溫,For irrigation during operations of the eyes， ears， nose and throat.,,,,沒有資料,,,,,,,,,,
IPOL,Inactivated poliovirus vaccine,Imovax polio 0.5mL (自費),HIMM,,Prophylaxis of poliomyelitis,,,SC/IM inj Primary immunization At least 2 inj of 0.5ml min 1mth apart.Boosters 1 yr after the last inj， then every 10 yr.,,,,,,,,,,,,,,
OALL6,Fexofenadine,Allegra 60mg,HIMM,Symptomatic relief of seasonal allergic rhinitis & uncomplicated skin manifestations of chronic idiopathic urticaria in adult & children over 6 years.,Patients with known hypersensitivity to any of the ingredients of Allegra,Viral infection， nausea， dysmenorrhoea， drowsiness， dyspepsia， fatigue， headache， back pain， coughing， fever， pain， otitis media， upper respiratory tract infection. Central nervous system: Headache (5% to 11%) Gastrointestinal: Vomiting (children 6 months to 5 years: 4% to 12%),20-25℃避免過高濕氣,Seasonal allergic rhinitis Adult & children > 12 years 60 mg BID or 180 mg QD. 6-11 years 30 mg BID. Chronic idiopathic urticaria Adult & children > 12 years 60 mg BID. 6-11 years 30-60 mg BID.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
LCOFS,Platycodon Fluid Extract,Cough mixture 120mL,ERSP,Antitussive， expectorant.,Hypersensitivity to any component of the formulation.,Poor appetite， GI disturbance,25℃以下,May be taken with or without food 5-15 mL TID.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
LDEP,Valproate Sodium,Depakine oral solution 200mg/mL， 40mL,CNEU,Epilepsy particularly of grand mal combined with petit mal & myoclonic petit mal types.,Acute or chronic hepatitis， personal or family history of severe hepatitis， hepatic porphyria.,GI disturbances， ataxia， tremor， increased appetite & weight gain， edema， thrombocytopenia， inhibition of platelet aggregation; impaired hepatic function， rashes， sedation. Rarely， pancreatitis (discontinue).,25℃以下避免陽光直射,Giving with food to decrease gastrointestinal irritation. Children 6 years and below: syrup or oral liquid is recommended for administration. DEPAKINE 500mg Chrono Tablet is only recommended for adult and children > 17 kg. Average daily dose (per 24 hours): Adult and adolescents: 20-30 mg/kg/day in 2 or 3 divided doses. Children: 30 mg/kg/day in 2 or 3 divided doses. (< 1 year old: in 2 divided doses),無需調整劑量,[仿單]valproate 分泌到乳汁中的量很低，濃度大約是母體血清濃度的 1%至 10%之間。 根據文獻和臨床經驗，若要哺乳，需考慮本品藥物安全性，特別是血液相關的疾病。 然而，懷孕期間暴露於 sodium valproate 的幼兒，可能降低語言能力，建議治療時不要授乳。,無需調整劑量,盡量避免,Human data suggest low risk,[仿單]懷孕期間禁止使用 valproate 治療躁鬱症。 除非癲癇治療沒有合適的替代藥物，否則懷孕期間禁止使用 valproate 治療癲癇。 除非能確實執行避孕計畫，否則具生育能力的婦女禁用 valproate。 使用本品可能會導致重大的先天性畸形，特別是神經管畸形（如：脊柱裂， spina bifida）， 且可能會導致胎兒智商下降，故本品應僅限用於無法以其他藥物控制症狀， 或有其它原因無法使用其他藥物治療之孕婦。 考量使用本品可能會有使孩童智商降低、發生神經管缺陷及其他嚴重先天性畸形之風險， 且該等風險可能發生於懷孕早期，故除非必要使用，否則不應使用於具生育能力或有懷孕可能之婦女。 避孕計畫： Valproate有高度的致畸性，且胎兒在子宮中曝露於valproate有導致先天性畸形和神經發育缺陷的高 度風險。 本品禁用於以下情況： 治療癲癇 • 在懷孕狀態下，除非沒有適合的替代療法 • 具有生育能力的婦女，除非能確實履行避孕計畫 治療躁鬱症 • 在懷孕狀態下 • 具有生育能力的婦女，除非能確實履行避孕計畫 避孕計畫條件： 處方醫師應確保 • 依病人個別狀況進行評估並與之討論。這是為了保證病人能確實配合並了解治療選擇及其風險， 以及為了降低風險而採取的措施。 • 所有女性病人都應針對懷孕的可能性進行評估。 • 病人應了解並認知先天性畸形和神經發育缺陷的風險，包括胎兒在子宮中曝露於valproate的風險程度。 • 病人應了解，治療前及治療期間(必要時)必須進行懷孕檢測。 • 應告訴病人必須避孕，且病人在整個valproate治療期間必須不間斷地採取有效的避孕措施 • 病人應了解，讓有癲癇或躁鬱症治療經驗的專科醫師定期(至少每年一次)評估治療結果有其必要性。 • 女性病人應了解，當其計畫懷孕時，應盡快諮詢醫師，以確保能及時討論並在懷孕前及停止避孕前更換治療藥物。 • 病人應了解，當發現懷孕時應緊急通知醫師。 • 病人已收到病人用藥指南。 • 女性病人已確認了解，使用valproate之相關風險和應注意事項 (年度風險確認表)。 這些條件亦適用於目前無性行為的婦女，除非處方醫師充分之理由認為其無懷孕風險。 藥師或其他醫療專業人員應確保 • 每次調配valproate時都有交付病人卡，讓病人了解其內容。 • 告知病人當計畫懷孕或疑似懷孕時，valproate不應擅自停藥，應立刻連絡專科醫師。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]valproate 分泌到乳汁中的量很低，濃度大約是母體血清濃度的 1%至 10%之間。 根據文獻和臨床經驗，若要哺乳，需考慮本品藥物安全性，特別是血液相關的疾病。 然而，懷孕期間暴露於 sodium valproate 的幼兒，可能降低語言能力，建議治療時不要授乳。,AC;AC15;PC;PO;WM;,,,,,
LDIG,Digoxin,Digosin 酏劑 0.05mg/mL,CAVS,,I: CHF， artrial fibrilation， atrial flutter， paroxysmal atrial tachycardia. CI: AV block， SA block， digitalis intoxication， obstructive cardiomyopathy.,,,Adult and child over 10 yrs: Oral: Rapid digitalization: A total of 1-1.5 mg divided into 2 or more doses given q6-8h. Slow digitalization: 0.125-0.5 mg qd for 7 days. Maintenance: 0.125-0.5 mg qd. Infant and child under 10 yrs: Oral: Digitalization: The following amounts divided into 2 or more doses given q6-8h. 2-10 yrs: 0.04-0.06 mg/kg. 1 month-2 yrs: 0.06-0.08 mg/kg. Under 1 month: 0.04-0.06 mg/kg. Maintenance: 1/5-1/3 of the total digitalizing dose， qd.,,,,除非治療上需要,,,,,,,,,,
LDUP,Lactulose,Duphalac 300mL(667mg/mL) oral solution,ALIM,,適應症: Chronic portal systemic encephalopathy， hepatic pre coma， hepatic coma 副作用: Flatulence， nausea， vomiting， abdominal pain & diarrhea occasionally with electrolyte imbalance (high doses only). 禁忌: Galactosemia， bowel obstruction.,,室溫,Chronic constipation: adult: Initial: 10-45 mL; Maintain dose: 10-25 mL. 7-14 years: Initial: 15 mL; Maintain dose: 10-15 mL. 1-6 years: Initial: 5-10 mL; Maintain dose: 5-10 mL. infant: Initial: 5 mL; Maintain dose: 5 mL. Orally once daily in the morning. It takes about 48 hours for a normal bowel movement if there is no response after taking the medicine for two days， should consider increasing the dose. Hepatic encephalopathy: adult: Initial dosage: 30-50 mL orally 3 times daily. Maintenance dosage: Adjust every day to achieve 2 to 3 soft formed stools daily. <6years old Children & infant: Initial: 5ml orally 4 times daily for10-12 days. The second and third course of treatment will adjust the dose according to individual conditions. [Micromedex 20210101] Rectal route: Treatment and Prophylaxis of Hepatic encephalopathy: Usual dosage: Mix lactulose 300 mL with 700 mL water or NS and administer rectally via rectal balloon catheter; retain for 30 to 60 minutes. Repeat dosages: Enema may be repeated every 4 to 6 hours for reversal of coma stage; if inadvertently evacuated too promptly， repeat immediately. Conversion to oral: When the oral route is viable， initiate oral administration before rectal administration is terminated.,無需調整劑量,Excretion in breast milk unknown/use caution,無需調整劑量,可能安全,,,,Excretion in breast milk unknown/use caution,AC;AC15;PC;PO;R;RECT;WM;,,,,,
LGAS0,Simethicone,Gascon drop 20mg/mL,ALIM,,,,,,,,,,,,,,,,,,,
OMES,Pyridostigmine,Mestinon 60mg,CNEU,Myasthenia gravis.,Mechanical intestinal or urinary obstruction.,Muscarinic: Nausea， vomiting， diarrhea， abdominal cramps， increased peristalsis， increased salivation， increased bronchial secretions， headache， miosis and diaphoresis. Nicotinic: Muscle cramps， fasciculation and weakness.,25℃以下,Myasthenia gravis: 60-180 mg BID-QID. Severe cases may require up to 1500 mg daily. (MicroMedex),無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OMET,Penicillamine,Metalcaptase 300mg,ZADT,,適應症: Chelating agent in treatment of Wilson's disease， cystinuria where high fluid regimens are not adequate or in conjunction with them. 副作用: Anorexia， nausea & vomiting; oral ulceration & stomatitis; pruritus， urticaria & fever. Glomerulonephritis or nephrotic syndrome. Rarely， hematuria; myasthenia gravis. 禁忌: Lupus erythematosus; history of penicillamine-induced agranulocytosis， aplastic anemia or severe thrombocytopenia. History of hepatic encephalopathy or bleeding varices.,,室溫,Adult Initially 150-300 mg daily for 2 weeks. Max: 1.8 g daily. Maintenance: 300-600 mg daily.,,,,盡量避免,,,,,,,,,,
OMETY,Mecobalamin,Methycobal 250mcg,CNEU,Megaloblastic anemia due to vit B12 deficiency & peripheral neuropathies.,Hypersensitivity to any component of the formulation.,Infrequently: Anorexia， nausea， diarrhea， pain & induration at IM inj site. Rarely: Skin rash， headache， sweating or hot sensation.,30℃以下,Adult: 1500 mcg daily in 3 divided doses. May adjust dosage according to patient's age and synptoms.,無需調整劑量,,無需調整劑量,安全,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
YPOL,,Saugella poligyn 250mL,SGU,,,,,,,,,,,,,,,,,,,
YATT,,Saugella attiva 250mL,SGU,,,,,,,,,,,,,,,,,,,
YINT,,Saugella intilac 7支/box,SGU,,,,,,,,,,,,,,,,,,,
INAV,Vinorelbine,Navelbine inj 50mg/5mL,RACA,,適應症:為抗腫瘤藥(B022215221) CI: Patients with pretreatment granulocyte counts < 1000 cells/mm3. Adverse Reactions: Chest pain (5%)， paresthesia， loss of deep tendon reflexes (< 5 %)， severe peripheral neuropathy (< 1 %)， alopecia (12 %)， injection site irritation， chemical phlebitis， mild or moderate nausea (34 %)， constipation (29 %)， paralytic ileus (1 %)， vomiting diarrhea， anorexia， stomatitis (< 20 %)， granulocytopenia ( the major dose-limiting toxicity)， grade 3 and 4 anemia (1 %)， transient liver enzyme elevation， shortness of breath (3 %)， fatigue (27 %)， jaw pain， myalgia， arthralgia， rash (< 5 %)， hemorrhagic cystitis， syndrome of inappropriate ADH secretion (< 1 %).,,2 ~ 8 ℃，,Dilute Navelbine to a concentration to 0.5 ~ 2 mg / ml with 5 % Dextrose or 0.9 % NaCl bofore administration. The recommemded method of administration is an IV injection over 6 ~ 10 minutes. The usual initial dose is 30 mg / m2 administered weekly， and the single-agent vinorelbine can be continued until progression or dose-limited toxicity. When Navelbine is used in combination wuth 120 mg / m2 of cisplatin， it can be used at the same dose and given on days 1 and 29， then every 6 weeks.,,,,盡量避免,,,,,,,,,,
OCOM,Lipase + Protease + Amylase,Combizym,ALIM,,適應症:幫助消化(B014461100) CI: Peptic ulcer.,,RT,2 tab during meals,,,,除非治療上需要,,,,,,,,,,
OACTI,Estradiol Hemihydrate + Norethisterone,Activelle,HM,,,,,,,,,,,,,,,,,,,
IALE,Phenytoin,Aleviatin inj 250mg/5mL,CNEU,Control of status epilepticus of the tonic-clonic (grand mal) type; prevention & treatment of seizures which occur during or following neurosurgery &/or severe head injury,Sinus bradycardia， heart block， Stokes-Adams syndrome.,Nystagmus， ataxia， slurred speech， decreased coordination， mental confusion， paraesthesia， drowsiness， vertigo; severe cardiotoxic reactions & fatalities; GI disturbances， scarlatiniform or measles-like rashes; pain & inflammation at inj site; gingival hypertrophy， coarse facies， acne & hirsutism， fever & hepatitis. Rarely， haematological effects， including megaloblastic anaemia， thrombocytopenia， leucopenia， granulocytopenia， agranulocytosis & aplastic anaemia.,30℃以下,Continuous epileptic state: The initial dose for adults (loading dose) is 10-15 mg/kg， and slowly intravenous injection at a rate of no more than 50 mg/min. Then use a maintenance dose of 100 mg orally or intravenously every 6-8 hours. Newborns and children: After an initial dose of 15-20 mg/kg body weight intravenously， the usual therapeutic concentration (10-20 mcg/mL) is usually reached.,無需調整劑量,,無需調整劑量,盡量避免,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,IVD;,,【N/S】可選 。,緩慢注射，每分鐘不超過50毫克。(不超過1mL/minute),1.以50到100毫升的生理食鹽水將Phenytoin注射劑濃度稀釋到不超過10 mg/mL的輸注液。 2.成人的靜脈注射速度每分鐘不可超過50毫克，新生兒及孩童每分鐘不可超過每公斤體重1-3毫克。 3.應使用0.22-0.50 micron fillter過濾。 4.Dilute in normal saline， to a final concentration no less than 5 mg/mL. [Micromedex 20211206],1.本品為強鹼性，故無法與其他藥品配合，與酸性藥品混合會產生不相容性。PH值降低會析出結晶。 2.配製完成後應立即開始給藥，且必須在一小時內輸注完畢（輸注混合液不可冷藏）。 3.應使用0.22-0.50 microns的線內（in-line）濾器。 4.每次靜脈注射Phenytoin前，應先以生理食鹽水沖洗；給藥後，再以同一注射針或靜脈導管注射無菌生理食鹽水，以幫助減少溶液的鹼性所造成的局部靜脈刺激。
IDPTH,Infanrix + Hiberix,Infanrix+Hiberix(四合一),HIMM,,I: Active immunization against diphtheria， tetanus， pertussis and Haemophilus influenzae type b caused diseases. CI: Children > 7 yr， adult. ADR: Erythema & swelling at the inj. site， Fever， irritability， drowsiness， decreased feeding， diarrhea. Vomiting， pallor， listlessness.,,2 ~ 8 °C,IM or SC. Primary immunization: complete all 3 doses before the first 6 mth of life， start from the age of 2 mth， subsequent doses at intervals of 1 ~ 2 mth. A reinforcing 4th dose is recommended to be given 1 yr after the 3rd dose.,,,,不可使用,,,,,,,,,,
IMIX3,Insulin RI 30 NPH 70,Mixtard 30 HM Penfill,META,,I: Insulin-requiring diabetes mellitus. CI: Hypoglycemia. ADR : Lipodistrophy， local and generalized allergic reactions.,,2 ~ 8 °C,Administer SC once or bid.Duration of action:Onset 1/2 hr， peak between 2nd-8th hr，terminates after approx 24 hr. Vial:Soluble human monocomponent insulin 30% & Isophane human monocomponent insulin 70% ，100 IU/ml x10ml.,,,,可能安全,,,,,,,,,,
OTAPZ,Methimazole,Tapazole 5mg,META,,Hyperthyroidism.,,,Adult: Initial， 5-10 mg q8h; maintenance， 5-15 mg/day. Child: Initial， 0.4 mg/kg/day， maintenance， 0.2 mg/kg/day.,,,,盡量避免,,,,,,,,,,
OTEG1,Carbamazepine,Tegretol 100mg ''Chewable'',CNEU,,Relief of pain associated with trigeminal neuralgia and used to control grand mal and psychomotor or partial seizure.,,,Anticonvulsant: Adult: Initial， 200 mg bid; maintenance， 800 mg-1.2 g/day;(max. 2 g/day). Child 6-12 yrs: Initial， 100 mg bid; Maintenance， 400-800 mg/day， (max. 1 g/day). Analgesic (for trigeminal neuralgia): Initial: 100 mg bid， increased by 100 mg q12h until pain is relieved. Maintenance: 400-800 mg/day， (max. 1.2 g/day).,,,,除非治療上需要,,,,,,,,,,
OTEG2,Carbamazepine,Tegretol 200mg,CNEU,,Relief of pain associated with trigeminal neuralgia and used to control grand mal and psychomotor or partial seizure.,,RT,Anticonvulsant: Adult: Initial， 200 mg bid; maintenance， 800 mg-1.2 g/day;(max. 2 g/day). Child 6-12 yrs: Initial， 100 mg bid; Maintenance， 400-800 mg/day， (max. 1 g/day). Analgesic (for trigeminal neuralgia): Initial: 100 mg bid， increased by 100 mg q12h until pain is relieved. Maintenance: 400-800 mg/day， (max. 1.2 g/day).,,,,除非治療上需要,,,,,,,,,,
OTENO,Atenolol,Tenormin 100mg,CAVS,,適應症: Antihypertension， anti angina. 副作用: Cold extremities， fatigue， GI disturbances， bradycardia. Occasionally， headache， mood changes， dizziness & deterioration of heart failure. Rarely， sleep disturbances， alopecia， thrombocytopenia， purpura， psoriasiform skin reactions， exacerbation of psoriasis， visual disturbances， psychoses， hallucinations， heart block， postural hypotension which may be associated with syncope. Intermittent claudication. Raynaud's phenomenon. Bronchospasm. Rashes & dry eyes， paraesthesia. Cardiovascular: Bradyarrhythmia (3% to 18% )， Cold extremities (12% )， Hypotension (4% to 25% ) Neurologic: Dizziness (13% ) Psychiatric: Depression (up to 12% ) Other: Fatigue (up to 26% ) 禁忌: Presence of 2nd or 3rd degree heart block; cardiogenic shock. Bradycardia， hypotension， metabolic acidosis， severe peripheral circulatory disturbances， sick sinus syndrome， untreated phaeochromocytoma， uncontrolled heart failure.,,室溫,50-100 mg daily.,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OTRA2,Tranexamic Acid,Transamin 250mg,HEMT,Hemorrhage， abnormal bleeding， genital & renal bleeding， bleeding due to prostatectomy.,Hypersensitivity to any component of the formulation.,GI disturbances. Gastrointestinal: Abdominal pain (oral， 19.8% ) Hematologic: Anemia (oral， 5.6% ) Musculoskeletal: Arthralgia (oral， 6.9% )， Backache (oral， 20.7% )， Cramp (oral， 6.5% )， Musculoskeletal pain (oral， 11.2% ) Neurologic: Headache (oral， 50.4% )， Migraine (oral， 6% ) Respiratory: Nasal sinus problem (oral， 25.4% ) Other: Fatigue (oral， 5.2% ),25℃以下,750-2000 mg/day divide 3-4 times a day.,無需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
EMET,Metronidazole,Metrogel 0.75%， 15gm,TDER,,適應症: Topical treatment of inflammatory papules， pustules & erythema of rosacea. 副作用: Transient redness， mild dryness， burning & skin irritation. Watery (tearing) eyes if applied too near the eyes Gastrointestinal: Abdominal discomfort (7%)， Loss of appetite， Metallic taste， Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )， Headache (tablets， 15% to 18%; vaginal gel， 5% )， Peripheral neuropathy Reproductive: Candida infection of genital region， Symptomatic cervicitis/vaginitis (10%)， Vaginal discharge (12%) Other: Drug interaction with alcohol， Disulfiram-like reaction 禁忌: Hypersensitivity to metronidazole.,,室溫,Apply and rub a thin film of Metrogel topical gel twice daily， morning and evening， to the entire affected areas after washing. Significant therapeutic results should be noticed within 3 weeks. Clinical studies have demonstrated continuing improvement through 9 weeks of therapy. Areas to be treated should be cleansed before application of Metrogel. Patients may use cosmetics after application of Metrogel.,無需調整劑量,Hold Breastfeeding (Single Dose) Limited Human Data—Potential Toxicity (Divided Dose),無需調整劑量,沒有資料,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Hold Breastfeeding (Single Dose) Limited Human Data—Potential Toxicity (Divided Dose),,,,,,
EMIN,Liquid Paraffin,Mineral oil,TDER,,Stool softeners,,室溫,Adult: 15-45 ml hs， up to 90 ml/day. 6 yrs and over: 10-15 ml hs.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
EMYDM,Tropicamide,Mydrin-M oph soln 5mL,TOPH,,,,,,,,,,,,,,,,,,,
EMYDPO,Tropicamide + Phenylephrine,Mydrin-P oph soln,TOPH,,I: Mydriasis & cycloplegia for diagnosis， pseudomyopia. AR: Transient stinging， dry mouth， allergic reactions. CI: Narrow-angle glaucoma.,,,Ophthalmoscopy: 1-2 gtt 15-20 mins prior to examination. Pseudomyopia: 1-2 gtt hs.,,,,,,,,,,,,,,
INEP,Amino Acids (Essential & Nonessential ),Nephrosteril inj 250mL， 7%,NUTR,Supply of protein elements in acute & chronic renal insufficiency as well as during peritoneal & hemodialysis treatment.,Disturbances in amino acid metabolism; liver failure， cardiac insufficiency; hyperhydration; hypokalemia; hyponatremia,Nausea， chills & vomiting (when rate of infusion is too rapid).,25℃以下避光,Acute & chronic renal insufficiency without dialysis. 0.5 g amino acids/kg body weight/day (= 500 mL/day at 70 kg body weight). Acute & chronic renal insufficiency under hemodialysis， hemofiltration or peritoneal dialysis. 1 g amino acids/kg body weight/day (= 1000 mL/day at 70 kg body weight). Maximum: 1.5 g amino acids/kg body weight/day (= 1500 mL/day at 70 kg body weight). Duration of Application: In case of acute renal insufficiency， the duration of use should be a few days to a maximum of 2 weeks. In chronic renal insufficiency not treated by hemodialysis， Nephrosteril can be used until a sufficient oral administration of protein is possible again.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,1. 每日每公斤體重最高1.5公克胺基酸，滴速不能超過每分鐘20滴。滴速過快可能造成噁心、寒顫和嘔吐的症狀。 2. 未接受血液透析治療的急性和慢性腎功能不足病人，每日每公斤體重最高0.5公克胺基酸。
INIM,Nimodipine,Nimotop針劑10mg/ 50mL,CAVS,Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasms following subarachnoid haemorrhage.,Must not be administered to patients with severely impaired liver function,Hypotension， GI disturbances.,避光,Subarachnoid hemorrhage， From ruptured intracranial berry aneurysms prophylaxis: initial， 0.5 mg/hr (hemadynamics unstable patient) to 1mg/hr (15mcg/kg/hr) for 2hr， then slowly titrate to 2mg/hr. (usually start drug within 4 days， then keep therapy for10-14days. if Craniotomy: continue IVD for at least 5 days after craniotomy. Then switch to orally 60mg Q4H for 7 days. treatment: initial， 1mg/hr (15mcg/kg/hr) for 2hr， then slowly titrate to 2mg/hr for 5-14days. after that， switch to orally 60mg Q4H for 7 days.,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,CVC;IVD;,,【D5W】可選 。【L/R】可選 。【N/S】可選 。,,起始速率:15 mcg/kg/hr輸注速率 < 2mg/hr (本藥應與下列相容溶液以一比四比例經由三向活塞給予，包括D5W、0.9% NaCl、Lactated Ringer’s solution、含有鎂的乳酸鹽林格氏液、dextran40 solution、HAESR poly (O-2-hydroxyethyl) starch 6%、甘露醇(mannitol)、人類白蛋白(human albumin)以及血液。),1. Nimotop輸注液需使用輸注幫浦以連續靜脈輸注經由中央靜脈導管(central catheter) 注入體內。 2. 由於藥品的有效成分會被聚氯乙烯(PVC)吸附，因此只能使用聚乙烯(PE)的輸注管。 3. 藥品勿直接加入點滴，應由三向活塞(three-way stopcock)與相容溶液以一比四的比例一同給予。
OCLOP,Clozapine,Clopine 100mg,CNEU,,適應症：精神科用藥。(A042448100) Treatment-resistant schizophrenic patients. 副作用:Initially drowsiness， hypersalivation， granulocytopenia & agranulocytosis， palpitation， fatigue. Dry mouth， blurred vision， orthostatic hypotension， disturbance in temp regulation. Tachycardia， ECG changes. Rarely: delirium， extrapyramidal reactions. Cardiovascular: Hypotension， Tachyarrhythmia (25%) Dermatologic: Rash (2%)， Sweating symptom (6%) Endocrine metabolic: Excessive salivation (31% )， Weight gain (4%) Gastrointestinal: Constipation (14% )， Excessive salivation (31% )， Nausea (5% )， Xerostomia (6% ) Musculoskeletal: Motor function behavior finding (4%)， Muscle rigidity (3%) Neurologic: Akathisia (3%)， Confusion (3%)， Dizziness (19%)， Headache (7%)， Insomnia (2%)， Somnolence (39%)， Tremor (6%)， Vertigo (19%) Ophthalmic: Visual disturbance (5%) Psychiatric: Agitation (4%)， Dyssomnia， Nightmares (4%)， Restlessness (4%) Other: Fatigue (2%)， Fever (5%) Tachycardia， ECG changes. Rarely: delirium， extrapyramidal reactions. 禁忌:History of drug-induced granulocytopenia， agranulocytosis. Impaired bone marrow function， comatose， severe hepatic & renal disease.,,室溫,300-450 mg daily in divided doses. Max: 900 mg daily.,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OCOC,Cocaine,Cocaine HCl Powder,ZANE,,,,,,,,,,,,,,,,,,,
OCODI,Codeine,Codeine 30mg,CNEU,Symptomatic relief of mild to moderate severe pain， suppress hyperactive or nonproductive cough.,Hypersensitivity to opiates， acute respiratory depression， acute asthma， increased intracranial pressure， COPD， head injury， paralytic ileus， acute alcoholism， hepatic or renal dysfunction， phaeochromocytoma.,Nausea & vomiting， constipation， drowsiness; respiratory depression & hypotension; difficulty with micturition， ureteric or biliary spasm， dry mouth， sweating， headache， facial flushing， vertigo， bradycardia， tachycardia， palpitations， postural hypotension， hypothermia， hallucinations， dysphoria， mood changes， dependence， miosis， decreased libido or potency， rashes， urticaria & pruritus.,25℃以下避光,Analgesic: Adult 15-60 mg qid. Children and Adolescents: Pain management; analgesia: 0.5-1 mg/kg/dose every 4-6 hours as needed; maximum single dose: 60 mg. Note: Do not use for postoperative tonsillectomy and/or adenoidectomy pain management. Antitussive: Adult Oral: 7.5 to 120 mg/day as a single dose or in divided doses; Note: The American College of Chest Physicians does not recommend the routine use of codeine as an antitussive in patients with upper respiratory infections.,無需調整劑量,,需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,Human Data Suggest Potential Toxicity,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。 The FDA is currently investigating the safety of using codeine-containing medicines to treat coughs and colds in children younger than 18 years.
OCODIBAD,Codeine,Codeine 30mg 殘餘銷燬,CNEU,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
OCOLC,Colchicine,Colchicine 0.5mg,CNEU,Gout.,Serious GI， renal/cardiac disorders， blood dyscrasias.,Diarrhea， N/V， abdominal pain， bone marrow depression， peripheral neuritis， myopathy， alopecia， rashes， reversible azoospermia. Gastrointestinal: Diarrhea (high dose， 77%; low-dose， 23% )， Nausea (high dose， 17%; low-dose， 4% )， Vomiting (17% ),30℃以下避光,Not recommended for use in children and adolescents Adults(>16 years old): Prevent gout:0.5mg QD or BID. maximum:1mg/day. Treat gout: Initial dose:1mg， take another 0.5 mg one hour later， or 0.5mg TID. maximum:1.5mg/day. After the next day， 0.5 mg 1-2 times a day until the onset of symptoms is relieved. Repeat courses of treatment should be separated by at least 3 days. For patients who have used the preventive dose， if necessary， 1 mg colchicine can be used to treat gout attacks， and then 0.5 mg one hour later. Wait 12 hours and then resume the preventive dose.,無需調整劑量,,需調整劑量,盡量避免,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OCOR,Cortisone,Cortisone acetate 25mg,HM,,,,,,,,,,,,,,,,,,,
OCOUG,Bromhexine,Coughxin 8mg,ERSP,,Tracheobronchitis， emphysema with bronchitis， pneumoconiosis， chronic inflammatory pulmonary conditions， bronchiectasis， bronchitis with bronchospasm， asthma.,,,Adult: 8-16 mg tid-qid. 5-10 yrs: 4mg qid. Under 5 yrs: 4 mg bid.,,,,,,,,,,,,,,
OCOV,Estradiol + Norethisterone,Covina 28tab/pk,HM,,Estrogen deficiency.,,,1 tab qd.,,,,不可使用,,,,,,,,,,
IDPT3,Diphtheria + Tetanus + Pertussis,Adacel (三合一補追疫苗) 0.5mL/dose,HIMM,Active booster immunization for the prevention of tetanus diphtheria & pertussis in children， adolescents & adults 4-64 years.,Hypersensitivity. Progressive neurological disorders， uncontrolled epilepsy or progressive encephalopathy. Encephalopathy not attributable to identifiable cause. Pregnancy.,Pain， swelling， erythema at inj site. Tiredness， headache， fever (> 38°C). Axillary lymph node swelling， rash， body ache or muscle weakness， sore or swollen joints. Nausea， diarrhea， vomiting. Demyelinating CNS diseases， peripheral mononeuropathies， cranial mononeuropathies & EEG disturbances with encephalopathy (with or without permanent intellectual &/or motor function impairment).,2-8℃避免冷凍,IM， 0.5mL， > or = 4 years as a single dose.,無需調整劑量,Up to date: Pregnancy Risk Factor B/C [仿單]授乳期間接種的影響尚未做過評估。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]第二、三孕期可使用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Up to date: Pregnancy Risk Factor B/C [仿單]授乳期間接種的影響尚未做過評估。,IM;,,,,,
EDUOT,Travoprost + Timolol,Duotrav eye drops 2.5mL,TOPH,Decrease of intraocular pressure in patient with open-angle glaucoma or ocular HTN who are insufficiently responsive to topical β-blockers or prostaglandin analogues.,Bronchial asthma， a history of bronchial asthma or severe COPD. Sinus bradycardia， 2nd or 3rd degree AV block， overt cardiac failure or cardiogenic shock. Severe allergic rhinitis & bronchial hypersensitivity; corneal dystrophies; hypersensitivity to other β-blockers. Pregnancy or women who may become pregnant.,Nervousness， dizziness， headache， eye irritation， ocular hyperemia， punctate keratitis， anterior chamber cells， anterior chamber flare， eye pain， photophobia， eye swelling， conjunctival hemorrhage， corneal staining， ocular discomfort， abnormal sensation in the eye， reduced visual acuity， visual disturbance， blurred vision， dry eye， eye pruritus， allergic conjunctivitis， increased lacrimation， eyelid irritation， eyelid erythema， eyelid dermatitis， asthenopia， growth of eyelashes， irregular or decreased heart rate， increased or decreased BP， bronchospasm， urticaria， skin hyperpigmentation (periocular)， pain in extremity. Neurologic: Foreign body sensation (5%-10%) Ophthalmic: Blepharitis， Blurred vision， Itching of eye (5%-10%)， Ocular hyperemia (35%-50%)， Pain in eye， Reduced visual acuity,25℃以下,Adult including the elderly: 1 drop in the conjunctival sac of the affected eye(s) once daily in the morning or evening. Age <18 years: Not recommend use.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
LCEN,Theophylline,Centertheo 60mL (5.34mg/mL) liquid,ERSP,Treatment of reversible airways obstruction associated with asthma， chronic bronchitis & related conditions,Allergy to theophylline， aminophylline or other xanthines.,GI disturbances， nervousness， headache， palpitations， insomnia， agitation， tachycardia， CNS stimulation,25℃以下，不需冰存並避免陽光直射,Theophylline 5.34mg/ml Adult 200-250 mg Children 6-12 years 125-250 mg. To be taken every 6 hr.,需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OIMI5,Sumatriptan,Imigran FDT 50mg,CNEU,Acute relief of migraine attacks with or without aura.,Previous MI， ischaemic heart disease (IHD)， Prinzmetal's angina/coronary vasospasm， peripheral vascular disease or patients who have symptoms or signs consistent with IHD; history of previous CVA or transient ischaemic attack (TIA); uncontrolled HTN; severe hepatic impairment. Concomitant use of ergotamine or its derivatives (including methysergide)， MAOIs or use within 2 wk of MAOI therapy.,Tingling， dizziness， drowsiness; transient increase in BP， flushing， nausea & vomiting; sensations of heaviness， heat， pressure or tightness; pain， feelings of weakness， fatigue.,30℃以下乾燥處,Migraine， acute:Adult: 50-100 mg as single dose. Further doses at 2 hours interval may be given in the next 24 hours. Maximum: 300 mg/24 hours.,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,[磨粉/管灌註記]本藥為速溶錠，仿單建議須整粒以水吞服，不要咀嚼。
OSUZ,Flunarizine,Suzin 5mg,CAVS,Prophylaxis of migraine， maintenance treatment of cerebral circulation disorders.,Hypersensitivity to flunarizine or any component of the formulation; history of depression; preexisting symptoms of Parkinson disease， or other extrapyramidal disorders.,Occasionally， transient fatigue & somnolence; weight gain. Exceptionally， depression or extrapyramidal reactions.,25℃以下避光,5-10 mg once daily in the evening (at bedtime),無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
OGES,Gestrinone,Gestrin 2.5mg (8 capsules/box),HM,Endometriosis.,Pregnancy， lactation; cardiac， renal or hepatic diseases. Experience adverse reactions during previous hormonal therapy,Menstrual disturbances. Acne， oily skin， fluid retention， wt gain， hirsutism， voice change， headache， GI disturbances， altered libido， hot flushes， breast size reduction， nervousness， change in appetite， muscle cramp， depression， arthralgia， isolated cases of benign intracranial hypertension.,25℃以下密封避光,2 capsule every week. First capsule must be taken on day 1 of the menstrual cycle， 2nd dose after 3 days. From then， take on the same 2 days per week.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PO;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於懷孕或準備懷孕婦女。
OELT1,Levothyroxine,100mcg ELTROXIN,META,,適應症: Hypothyroidism. 副作用: Following excessive dosage: Anginal pain， cardiac arrhythmias， palpitation & cramps in skeletal muscle， tachycardia， diarrhoea， vomiting， tremors， restlessness， excitability， insomnia， headache， flushing， sweating， excessive weight loss & muscular weakness 禁忌: Thyrotoxicosis.,,室溫,Adult Initially 50-100 mcg daily， adjusted 3-4 weekly by 50 mcg until normal metabolism is maintained. This may require doses of 100-200 mcg daily. Adult >50 yr <50 mcg/day， with cardiac disease 25 mcg/day or 50 mcg on alternate days. This may be increased by 25 mcg at intervals of 4 week. Congenital hypothyroidism Infant Initially 25 mcg， increase by 25 mcg 2-4 weekly until mild toxic symptoms appear. Juvenile myxoedema Children >1 yr 2.5-5 mcg/kg/day.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,AC;PO;,,,,,
OFLUV,Fluvoxamine,Fluvoxin 50mg,CNEU,,適應症: Treatment of symptoms of depressive illness. Obsessive compulsive disorder in children & adolescents. 副作用: Nausea， vomiting， asthenia， headache， malaise， palpitations/tachycardia， abdominal pain， anorexia， constipation， diarrhoea， dry mouth， dyspepsia， agitation， anxiety， dizziness， insomnia， nervousness， somnolence， tremor， sweating， (postural) hypotension， arthralgia， myalgia， ataxia， confusion， extrapyramidal symptoms， hallucinations， abnormal (delayed) ejaculation， cutaneous hypersensitivity reactions (including rash， pruritus， angioedema)， liver dysfunction， convulsions， mania， galactorrhoea， photosensitivity， weight gain/loss， serotonin syndrome， neuroleptic malignant syndrome-like events， hyponatremia & SIADH， withdrawal reactions， haemorrhage， paresthesia， anorgasmy & taste perversion. Dermatologic: Sweating (immediate-release， 7%; extended-release (social anxiety disorder)， 6%; extended-release (obsessive-compulsive disorder)， 7% ) Gastrointestinal: Diarrhea (immediate-release， 11%; extended-release (social anxiety disorder)， 14%; extended-release (obsessive-compulsive disorder)， 18% )， Indigestion (immediate-release， 10%; extended-release (social anxiety disorder)， 10%; extended-release (obsessive-compulsive disorder)， 8% )， Loss of appetite (immediate-release， 6%; extended-release (social anxiety disorder)， 14%; extended-release (obsessive-compulsive disorder)， 13% )， Nausea (immediate-release， 40%; extended-release (social anxiety disorder)， 39%; extended-release (obsessive-compulsive disorder)， 34% )， Xerostomia (immediate-release， 14%; extended-release (social anxiety disorder)， 11%; extended-release (obsessive-compulsive disorder)， 10% ) Neurologic: Asthenia (immediate-release， 14%; extended-release (social anxiety disorder)， 24%; extended-release (obsessive-compulsive disorder)， 26% )， Dizziness (immediate-release， 11%; extended-release (social anxiety disorder)， 15%; extended-release (obsessive-compulsive disorder)， 12% )， Insomnia (immediate-release， 21%; extended-release (social anxiety disorder)， 32%; extended-release (obsessive-compulsive disorder)， 35% )， Somnolence (immediate-release， 22%; extended-release (social anxiety disorder)， 26%; extended-release (obsessive-compulsive disorder)， 27% )， Tremor (immediate-release， 5%; extended-release (social anxiety disorder)， 8%; extended-release (obsessive-compulsive disorder)， 6% ) Psychiatric: Agitation (immediate-release， 2%; extended-release (social anxiety disorder)， 3%; extended-release (obsessive-compulsive disorder)， 2% )， Anxiety (immediate-release， 5%; extended-release (social anxiety disorder)， 8%; extended-release (obsessive-compulsive disorder)， 6% )， Feeling nervous (immediate-release， 12%; extended-release (social anxiety disorder)， 10% ) Reproductive: Abnormal ejaculation (immediate-release， 8%; extended-release (social anxiety disorder)， 11%; extended-release (obsessive-compulsive disorder)， 10% )， Orgasm incapacity (immediate-release， 2%; extended-release， 5% ),,室溫,May be taken with or without food 100-200 mg daily. Max: 300 mg daily. The minimum recommended starting dose is 100 mg/day and can be given as a single dose; preferably in the evening.It is advisable that a total daily dose over 150 mg be given in 2 or 3 divided doses.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IVAX9,Purified Split Inactivated Influenza Virus,免費小兒流感疫苗(4~10歲),HIMM,,I: Prophylaxis against influenza. ADR: Erythema (rash)， swelling， pain， ecchymosis， induration， fever， dizziness， shivering， tiredness， headaches， sweating， muscle pain， joint pains. CI: Allergy to eggs， chicken protein or any constituents of the vaccine. Febrile illness or acute infection.,,2 ~ 8 °C,本劑為成人劑型，若用於小兒劑量需減半 Adult & Children >= 36 mth 0.5ml IV or deep SC. Chidren <= 8 yr who have not been vaccinated previously， the 2nd dose can be given at an interval of at least 4 wk.,,,,除非治療上需要,,,,,,,,,,
LFERH,Ferric Hydroxide Polymaltose Complex,Ferrum hausmann 50mg/20drops/mL，30mL,NUTR,Treatment of latent Fe deficiency & Fe deficiency anaemia (manifest iron deficiency). Prophylactic therapy of Fe deficiency during pregnancy,Fe overload (eg haemochromatosis， hemosiderosis) or disturbances in Fe utilisation (eg lead anaemia， sideroachrestic anaemia， thalassaemia) & anaemia not caused by Fe deficiency (eg haemolytic anaemia).,GI irritations such as a sensation of repletion， pressure in the epigastric region， nausea， constipation or diarrhoea.,30℃以下避免照光,1 mL = 20 drops = 50 mg Iron as Iron(lll)-Hydroxide polymaltose complex. Iron deficiency anemia Pregnant women: 80-120 drops daily with meal. Adult & children > 12 years: 40-120 drops daily with meal. Children 1-12 years: 20-40 drops daily with meal. Infants < 1 year: 10-20 drops daily with meal. Premature infants: 1-2 drops/kg of body weight/day with meal. Iron deficiency Pregnant women: 40 drops daily with meal. Adult and children > 12 years: 20-40 drops daily with meal. Children 1-12 years: 10-20 drops daily with meal. Infants < 1 year: 6-10 drops daily with meal.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
LPEC,Kaolin + Pectin,Pecolin 200/10 mg/mL， 120mL suspension,ALIM,,適應症: Diarrhea. 副作用: Constipation. 禁忌: Intestinal obstruction.,,室溫,Adult 30 mL qid， Children > 6 years 15 mL qid， 2-5 years 7.5 mL qid.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;PO;,,,,,
LSUR,Beractant,Survanta 25mg/mL， 8mL,ERSP,Prevention & treatment of respiratory distress syndrome in premature infants.,Hypersensitivity to any component of the formulation.,Transient bradycardia. O2 desaturation.,2-8℃需避光,4 mL/kg (100 mg phospholipids/kg) as soon as possible after birth， preferably within 15 minutes; as many as 4 doses may be administered during the first 48 hours of life， no more frequently than 6 hours apart. following is the recommended doses according body weight: 600-650g: 2.6mL， 651-700g: 2.8mL， 701-750g: 3.0mL， 751-800g: 3.2mL， 801-850g: 3.4mL， 851-900g: 3.6mL， 901-950g: 3.8mL， 951-1000g: 4.0mL， 1001-1050g: 4.2mL， 1051-1100g: 4.4mL， 1101-1150g: 4.6mL， 1151-1200g: 4.8mL， 1201-1250g: 5.0mL， 1251-1300g: 5.2mL， 1301-1350g: 5.4mL， 1351-1400g: 5.6mL， 1401-1450g: 5.8mL， 1451-1500g: 6.0mL， 1501-1550g: 6.2mL， 1551-1600g: 6.4mL， 1601-1650g: 6.6mL， 1651-1700g: 6.8mL， 1701-1750g: 7.0mL， 1751-1800g: 7.2mL， 1801-1850g: 7.4mL， 1851-1900g: 7.6mL， 1901-1950g: 7.8mL， 1951-2000g: 8.0mL.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,INHL;,,,,,
ECER,Sod Bicarbonate + Glycerin,Cerum water 4%/20%， 20mL,TENT,To soften earwax,Hypersensitivity to any component of the formulation.,Local irritation,,Ear Drop: 3-4 drops twice a day for 5 days for each affected ear to soften dry or hardened earwax.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AD;AS;AU;,,,,,
OART2,Trihexyphenidyl,Artane 2mg,CNEU,,適應症: Parkinsonism. 副作用: GI disturbances; glaucoma， mydriasis; urinary retention， mental disturbances， excitement. 禁忌: Closed-angle glaucoma， paralytic ileus， prostatic hypertrophy.,,室溫,1-2 mg the first day， the dosage being increased by an additional 2 mg at 3-4days intervals until the desired response is obtained or until the dose reaches 10-15 mg/day， usually in 3-4 doses.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OASA,Mesalazine,Asacol 400mg,ALIM,,適應症:主治潰瘍性結腸炎(B017428100)(B023232100) Tab: Treatment & maintenance of remission of ulcerative colitis. Supp: Ulcerative colitis， mild to moderate proctitis， proctosigmoiditis. 副作用:Nausea， diarrhea， abdominal pain， headache， exacerbation of symptoms of colitis; rarely， blood disorders， pancreatitis， hepatitis. Gastrointestinal: Diarrhea (up to 8% )， Flatulence (0.7% to 4% )， Nausea (2.8% to 4% )， Upper abdominal pain (5%) Neurologic: Headache (3.4% to 11% ) Respiratory: Nasopharyngitis (1.4% to 4% ) 禁忌: Infant <2 years. Severe renal impairment.,,室溫,1-2 tab tid.,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OPRA,Multivitamins + Minerals,Pramet F.A 30's/bot,NUTR,,適應症: Nutritional supplement for vit & mineral deficiency. 副作用: Hypersensitivity reactions reported with folic acid.,,室溫,1 Tab daily,,,,安全,,,Compatible 哺乳時可使用,,,,,,,
OPRED,Prednisolone,Prednisolone 5mg,HM,,適應症: RA， lupus erythematosus， periarthritis nodosum， allergic & inflammatory skin disorders. 副作用: Fluid & salt retention， edema， hypertension; amenorrhea， hyperhidrosis， mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; local atrophy; increased appetite; growth retardation. 禁忌: Peptic ulcer， osteoporosis， psychoses or severe neuropsychosis; active or doubtfully quiescent TB; acute infection; live vaccines.,,室溫,Allergic and inflammatory disorders 5-60 mg/day， in 2-4 divided doses. Rheumatoid arthritis Initial: 5-7.5 mg/day， adjust dose if needed. Multiple sclerosis 200 mg/day for 1 wk， then 80 mg every other day for 1 mth.,,,,盡量避免,,,,,,,,,,
OPREM,Estrogen + Medroxyprogesterone,Premelle 2.5， 28's/pk,HM,,適應症: Moderate-to-severe vasomotor symptoms associated with estrogen deficiency. Prevention & treatment osteoporosis associated with estrogen deficiency. Atrophic vaginitis & atrophic urethritis. 副作用: Increased risk of breast cancer， gallbladder disease， thrombophlebitis &/or thromboembolic disease. Increase in BP， fluid retention， changes in glucose tolerance， vag bleeding， breast pain， tenderness & enlargement. GI effects， alopecia， rash， hirsutism， pruritus， visual disturbances， headache， nervousness. 禁忌: Known or suspected cancer of the breast， estrogen-dependent neoplasia， pregnancy. Undiagnosed abnormal genital bleeding. Active thrombophlebitis or thromboembolic disorders. Liver dysfunction or disease.,,室溫,1 tab qd.,,,,不可使用,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OPRIN,Norethisterone,Primolut-Nor 5mg,HM,,適應症: Dysfunctional bleeding， primary & secondary amenorrhea， premenstrual syndrome， mastopathy， timing of menstruation， endometriosis， progressive breast carcinoma. 副作用: Rarely， nausea. 禁忌: Pregnancy; severe liver dysfunction; Dubin-Johnson syndrome & Rotor syndrome; previous or existing liver tumors; history of jaundice or severe pruritus during pregnancy， history of herpes of pregnancy; thromboembolic processes.,,室溫,Dysfunctional bleeding 5 mg/day for 10 day. Primary & secondary amenorrhea Estrogen first， then 1 tab bid from day 19-26 of the cycle. Premenstrual syndrome & mastopathy 1 tab qd-bid from day 19-26 of the cycle. Endometriosis 1 tab bid from day 5 of the cycle. Duration: 4-6 months.,,,,不可使用,,,,,,,,,,
OPRIP,Metoclopramide,Primperan 5mg,ALIM,Prevention of nausea & vomiting， GERD & diabetic gastroparesis.,GI hemorrhage， mechanical obstruction or digestive perforation; Pheochromocytoma; previous history of tardive dyskinesia with neuroleptics. Epilepsy.,Syndrome malin. Occasionally GI disturbances， headache， lightheadedness， drowsiness. Rarely， endocrinal disorders eg. amenorrhea， hyperprolactinemia， gynecomastia in males， breast enlargement in women; extrapyrimidal symptoms， hypotension， tachycardia， arrhythmia. Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )， Vomiting (1.4% to 2.1% ) Neurologic: Asthenia (10% )， Headache (4.2% to 5.2% .)， Somnolence (oral， 2.1% to 10%; IV， 70%) Other: Fatigue (2.1% to 2.8% ),25℃以下,Adult: 10-30 mg daily in 2-3 divided doses， AC.,需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,,,,,,
OCOZ,Losartan,Cozaar 50mg,CAVS,,Hypertension,,,Initial & maintence dose : 50 mg once daily. May increase to 100mg once daily.,,,,,,,,,,,,,,
IKAN,Kanamycin,Kanamycin 1g inj (政府提供),QANB,,適應症: Susceptible infections. 副作用: Pain， inflammation， bruising， haematoma at inj site; GI disturbances; malabsorption of fat. 禁忌: Hypersensitivity.,,室溫,IV/IM Susceptible infections 15 mg/kg/day. Max: 1.5 g/day in 2-4 divided doses. Max cumulative dose: 10 g. IM Penicillin-resistant gonorrhoea 2 g as a single dose. Irrigation Irrigation of body cavities As 0.25% soln: Instill into abscess cavities， pleural space， or peritoneal or ventricular cavities as directed. Intraperitoneal Peritonitis or peritoneal contamination during surgery Instill 500 mg into the peritoneal cavity. Inhalation Susceptible infections 250 mg 2-4 times/day.,,,,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OGIN9,Ginkgo Biloba,Gincare 9.6mg film coated,CAVS,Peripheral circulatory disorders,Caution should be exercised with ginkgo in patients with bleeding disorders or those who take anticoagulant drugs.,GI disturbance， headache， skin rash， dizzy， palpitation.,25℃以下避光,1 TAB TID.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
EREL,Zanamivir,Relenza inhalation 5mg/dose (政府提供),QANB,Treatment of influenza A and B in adults and children >=5 year.,Hypersensitivity to any of the ingredients of Relenza.,Very rarely， allergic-type reactions， including oropharyngeal edema， bronchospasm， dyspnea， rash， urticaria. Central nervous system: Headache (prophylaxis 13% to 24%; treatment 2%) Respiratory: Cough (influenza prophylaxis in pediatric patients， 16% )， Nasal symptom (influenza prophylaxis in pediatric patients， 20% )， Pain in throat (influenza prophylaxis in pediatric patients， 11%)， Respiratory depression Other: Fever with chills (influenza prophylaxis， 5% ),30℃以下,(仿單+熱病) Zanamivir is used for treatment of influenza A or B in patients age > or = 7 years or for prophylaxis in patients age > or = 5 years. Treatment: 2 oral inhalations (10 mg) twice daily for 5 days; therapy should begin within 48 hours from onset of signs or symptoms. Prophylaxis: 2 oral inhalations (10 mg) once daily for 10 days or up to 28 days.,無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;INHL;,,,,,
HE5004,Dianeal 1500cc 4.25% (PD 2 雙袋),Dianeal 1500mL 4.25% (PD 2 雙袋),NUTR,,,,,Select mode of therapy， frequency of treatment， formulation， fill volume， duration of dwell， and length of dialysis based on the patient’s clinical condition， fluid， electrolyte and specific needs. The fill volume depends on body size， usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5010,Dianeal 2000cc 1.5% (PD 2雙袋),Dianeal 2000mL 1.5% (PD 2雙袋),NUTR,,,,,Select mode of therapy， frequency of treatment， formulation， fill volume， duration of dwell， and length of dialysis based on the patient’s clinical condition， fluid， electrolyte and specific needs. The fill volume depends on body size， usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5011,Dianeal 2L 1.5% (PD 4 雙袋),Dianeal 2L 1.5% (PD 4 雙袋),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
IALB,Albumin,Albumin 25% 50mL(Albutein),HEMT,,適應症: Hypovolemic shock， conditions when there is severe hypoalbuminemia， as an adjunct in hemodialysis & in cardiopulmonary bypass procedures. In conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia. 副作用: Allergic reactions， nausea， vomiting， increased salivation， fever and chills; vascular overload， haemodilution and pulmonary oedema. Potentially Fatal: Anaphylactic shock. 禁忌:Cardiac failure， severe anaemia， history of hypersensitivity， parenteral nutrition.,,,Adult: IV Acute hypovolaemic shock Initial: 25 g， adjust according to response. Usual rate: Up to 5 mL/min using 5% soln. Hypoproteinaemia Up to 2 g/kg/day. Usual rate: Up to 5 mL/min using 5% soln.,無需調整劑量,,無需調整劑量,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,IVD;,,【D5W】可選 。【N/S】可選 。,,1.如果是用於治療有嚴重血量減少的休克病人時，應儘可能地採高流速使用。 2.對於血量正常或稍減的病人，輸注速率約為 1 mL/min。 3.輸注速率過快會造成肺水腫情形，須注意病人靜脈壓是否升高,1.未稀釋亦可使用
ICEFA,Cefazolin,Cefazolin inj 1gm,QANB,,適應症: Susceptible infections， Surgical prophylaxis. 副作用: Superinfection; nausea， vomiting， abdominal pain， anorexia， diarrhoea; rash， leukopenia， thrombocytopaenia， haemorrhage， elevated transaminases. 禁忌: Hypersensitivity.,,室溫,Adult: IV/IM Susceptible infections 0.5-1 g 6-12 hrly. Max: 6 g/day， up to 12 g/day in severe infections. Surgical prophylaxis 1 g 30-60 mins pre-op， followed by 0.5-1 g during surgery for lengthy procedures. Continue w/ 0.5-1 g 6-8 hrly post-op for 24 hr. Children: (1 month of age and older): 25-50 mg/kg/day IV/IM divided into 3 or 4 equal doses， depending on severity of infection; dose may be increased to 100 mg/kg/day for severe infections.,,AAP: Maternal medication usually compatible with breastfeeding. WHO: Compatible with breastfeeding. Micromedex: Infant risk is minimal.,,可能安全,,,Compatible 哺乳時可使用,AAP: Maternal medication usually compatible with breastfeeding. WHO: Compatible with breastfeeding. Micromedex: Infant risk is minimal.,,,,,,1. 監測體溫、CBC、肝腎功能、PT值。 2. 注意是否發生抗生素引起的腹瀉。 3. (IM) 1gm/vial 乾粉加入2.5 mL D/W 泡製。 4. (IV bolus) 1gm/vial 乾粉加入2.5 mL D/W 泡製，再加入5 mL稀釋液，緩慢推注至少3 ~ 5分鐘。
IKAB,Glucose + Amino Acid + lipid,Kabiven PI inj 1440mL,NUTR,,,,,,,,,,,,,,,,,,,
OINV6,Paliperidone,INVEGA ER 6mg (臨床試驗用),CNEU,,Indication: schizophrenia. Contraindication: Hypersensitivity to paliperidone or risperidone.,,室溫,3-12 mg daily， max. dose: 12mg / day.,,,,除非治療上需要,,,,,,,,,,
ONAV2,Vinorelbine,Navelbine 20mg (臨採),RACA,Non-small cell lung cancer. Metastatic breast cancer.,Disease significantly affecting absorption; previous significant surgical resection of stomach or small bowel. Severe hepatic impairment; pregnancy & lactation; patients requiring long-term O2 therapy. Coadministration with meningocococal conjugate vaccine or other live virus vaccines， phenytoin & itraconazole. Pretreatment granulocyte counts <1000/mm3,Neutropenia， anemia， thrombocytopenia; nausea & vomiting， diarrhea， anorexia， stomatitis， esophagitis; loss of tendon reflexes， neuromotor disorders， neuroconstipation (rarely progressing to paralytic ileus); alopecia; fatigue， fever， arthralgia including jaw pain， myalgia， pain including pain at tumor site. Vial Ischemic cardiac disease (rare)， abnormal liver function tests， dyspnea， bronchospasm， generalized cutaneous reactions (rare).,2-8℃,As a single agent， first three administrations: 60 mg/m2 once weekly. Beyond the third administration， it is recommended to increase the dose to 80mg/m2 once weekly except in those patients for whom the neutrophil count dropped once < 500/mm3 or 500-1000/mm3 during the first three administrations at 60mg/m2,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為軟膠囊需以水整顆吞服。
ISEV,Sulfamethoxazole + Trimethoprim,Sevatrim inj(400mg+80mg),QANB,Infections of respiratory tract， GIT due to gm+ve & gm-ve bacteria.,Liver parenchymal damage， blood dyscrasias; severe renal insufficiency. Pregnancy， lactation. Porphyria.,Allergic skin reactions; hallucinations， depression， apathy， nervousness. Arthralgia， myalgia. Neurologic reactions.,25℃以下,Trimethoprim-sulfamethoxazole (TMP-SMX)Adult and children > 12 years: 160/800-240/1200 mg (10-15 mL) twice daily. Children (6-12 years): 80/400 mg (5 mL) twice daily. Children (6 months-6 years): 40/200 mg (2.5 mL) twice daily. Children (6 weeks-5 months): 20/100 mg (1.25 mL) twice daily. Pediatric dose is calculated based on TPM 6 mg/kg/day and SMX 30 mg/kg/day.,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,【D10W】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,,
OINV3,Paliperidone,Invega ER 3mg (臨床試驗用),CNEU,,Indication: schizophrenia. Contraindication: Hypersensitivity to paliperidone or risperidone.,,室溫,3-12 mg daily， max. dose: 12mg / day.,,,,除非治療上需要,,,,,,,,,,
ROHER,當歸/川芎/芍藥/熟地黃/甘胺酸亞鐵,Herbiron 50ml/bot(臨床試驗),NUTR,,,,,,,,,,,,,,,,,,,
OAMT,Amlodipine + Benazepril,AmTrel 5/10mg,CAVS,Hypertension,Concomitant use with aliskiren in patients with diabetes mellitus. Hypersensitivity to olmesartan or any component of the formulation; concomitant use with aliskiren in patients with moderate to severe renal impairment (GFR <60 mL/minute/1.73 m2),Cough， edema， headache， dizziness. Other effects include angioedema， asthenia & fatigue; Insomnia， nervousness， anxiety， tremor & decreased libido; flushing， hot flashes， rash， skin nodule， & dermatitis; GI disturbances; hypokalemia; musculoskeletal pain & cramps; pharyngitis; impotence， polyuria. Cardiovascular: Edema Neurologic: Dizziness， Headache Respiratory: Cough (3.3%),25℃以下避光,HTN initial: 1tablet QD， amlodipine 2.5-10 mg daily， benazepril 10-80 mg daily.,需調整劑量,Amlodipine: Limited Human Data—Probably Compatible Benazepril: No Human Data—Probably Compatible,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,Amlodipine: Limited Human Data—Animal Data Suggest Moderate Risk Benazepril: Human Data Suggest Risk in 2nd and 3rd Trimesters,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Amlodipine: Limited Human Data—Probably Compatible Benazepril: No Human Data—Probably Compatible,AC;AC15;PC;PO;WM;,,,,,
ICLEX,Enoxaparin,Clexane inj 60mg/0.6mL,HEMT,Prophylactic treatment of venous thromboembolic disease， particularly in orthopaedic & general surgery. Treatment of established DVT. Unstable angina， Non-Q-wave myocardial infarction.,History of thrombocytopenia during enoxaparin therapy. Hemorrhagic tendencies， organic lesion with tendency to bleed， major blood clotting disorder. Acute infectious endocarditis， hemorrhagic stroke syndrome， acute GI ulcer.,Hemorrhagic symptoms， thrombocytopenia (rare)， hematomas & skin necrosis at inj site; skin allergies or systemic allergic reactions. Gastrointestinal: Diarrhea (2.2% )， Nausea (2.5% to 3% ) Hematologic: Anemia (up to 16% )， Bleeding， Major (up to 4% )， Thrombocytopenia (less than 3% ) Hepatic: Increased liver function test (5.9% to 6.1% ) Other: Fever (up to 8% ),室溫25℃以下,For non-severe symptom DVT， SC 100 IU/kg twice daily， for less than 10 days. For unstable angina/ non-Q-wave MI， SC 100 IU/kg twice daily， for 2-8 days until stable， combination with aspirin (loading dose160mg then 75~325mg) could be considerated. For elevated ST-wave AMI， (only for patient < 75 years old， Clcr >60 mL/min) IV 3000 IU and SC 100 IU/kg within 15 minutes， then SC every 12 hours for 8 days or discharge. (stay at hospital less then 8 days)， combined with aspirin 75-325mg. The total dose of two initial injection should be less than 10000 IU. If patient > 75 years old ， SC 75 IU/kg every 12 hours， (first 2 doses can't exceed 7500IU.),需調整劑量,,需調整劑量,可能安全,,,Compatible 哺乳時可使用,,IVP;IVPUSH;SC;,,,ST-波段升高的急性心肌梗塞患者及進行血液透析治療的患者才建議施以靜脈注射，以30 IU/kg給予,,1. 皮下注射給藥（ST-波段升高的急性心肌梗塞患者及進行血液透析治療的患者除外，這些患者應施以靜脈注射）。 2. 本藥物不可以肌肉注射給藥。
IPRO,Progesterone,Progesterone inj 50mg/1mL,HM,,適應症:Amenorrhoea; Dysfunctional uterine bleeding，Recurrent miscarriage w/ progesterone deficiency， 副作用:GI disturbances， appetite/wt change， fluid retention， oedema， acne， skin rash， urticaria， depression， headache， fever， fatigue， breast changes， hirsutism， changes in libido， altered menstrual cycles or irregular menstrual bleeding (rare). Gastrointestinal: Abdominal pain (oral， 10% to 20%; vaginal gel， 5% to 12%; vaginal insert， 12% )， Constipation (vaginal gel， 27%; vaginal insert， 2% to 3% )， Nausea (oral， 8%; vaginal gel， 6% to 22%; vaginal insert; 7% to 8% ) Immunologic: Viral disease (oral， 7% to 12% ) Musculoskeletal: Cramp (vaginal gel， 15% to 26% ) Neurologic: Dizziness (oral， 15% to 24%; vaginal gel， 5% )， Headache (oral， 10% to 31%; vaginal gel， 13% to 19%， vaginal insert， 3% to 4% )， Sleep disorder (vaginal gel， 18% )， Somnolence (vaginal gel， 27% ) Psychiatric: Depression (oral， 19%; vaginal gel， 11% to 19% )， Feeling nervous (vaginal gel， 16% )， Mood swings (oral， 6%; vaginal gel， 22% to 23% ) Reproductive: Breast tenderness (oral， 16% to 27% )， Large breast (vaginal gel， 40% )， Pain， Post-oocyte retrieval (vaginal insert， 25% to 28% )， Pain of breast (oral， 6% to 16%; vaginal gel， 13% )， Perineal pain (vaginal gel， 17% ) Other: Fatigue (oral， 8% to 9%; vaginal gel， 21% to 22%; vaginal insert， 2% to 3% ) 禁忌:Hypersensitivity; thrombophloebitis; cerebral apoplexy; severe hepatic impairment; undiagnosed vag bleeding， incomplete abortion， hormone-dependent carcinoma， as a diagnostic test for pregnancy; pregnancy. History or current high risk of arterial disease.,,室溫,IM Amenorrhoea; Dysfunctional uterine bleeding 5-10 mg/day for 5-10 days until 2 days before expected onset of menstruation Recurrent miscarriage w/ progesterone deficiency 25-100 mg twice wkly from the 15th day of pregnancy until 8-16 wk. May increase to daily inj if needed. Vag Amenorrhoea; Dysfunctional uterine bleeding 45 mg every other day from the 15th-25th day of the cycle. Rectal/Vag Premenstrual syndrome 200 mg/day， up to 400 mg twice daily. Start on days 12-14 of the cycle and continue till onset of menstruation. Intrauterine Contraception As device containing progesterone 38 mg: Insert into the uterine cavity,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ICRA2,Levofloxacin,Cravit 針劑 250mg/50mL,QANB,Respiratory tract， ENT， GUT infection. Intrauterine infections， cervicitis， uterine adnesxitis， folliculitis. GIT infections， lymphangitis， mild to moderate skin & skin tissue infections.,Hypersensitivity to quinolones. Pregnancy & lactation. Children & growing adolescents < 18 years. Tendinitis or tendon rupture.,Dizziness， GI disturbances， rash， pruritus， vaginitis， genital moniliasis， taste perversion， insomnia， tendinitis. Rarely， anaphylactic reactions， Lyell's syndrome， Stevens-Johnson's syndrome. Gastrointestinal: Diarrhea (ophthalmic， 1% to 2%; oral or intravenous， 5% )， Nausea (ophthalmic， 1% to 2%; oral or intravenous， 7% ) Neurologic: Headache (ophthalmic， 8% to 10% ; oral and intravenous， 6% ),30℃以下避光,(仿單) Adult: 250-500 mg po/IV 1-2 times daily. Administer 250 mg injection over 30 minutes， 500 mg injection over 60 minutes. (熱病) Adult: 250-750 mg po/IV Q24H (depends on indication). For most indications， in patients with normal renal function， the 750 mg dose is preferred. Pediatric (age > 28 days): 16-20 mg/kg/day (divided Q12H) (maximum 750 mg/day) For oral therapy， avoid concomitant exposure to multivalent cations (Ca， Fe， Al， Mg， Zn) in dairy products， multivitamins and antacids. Cations chelate the drug and prevent absorption.,無需調整劑量,,需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D5W】可選 。【N/S】可選 。,,Infuse 250 mg IV solution over 30 minutes; infuse 500 mg IV solution over 60 minutes; infuse 750 mg IV solution over 90 minutes. Too rapid of infusion can lead to hypotension.,1. 需避光儲存，光照下藥效只能維持3天。 2. 輸注時監測BP，輸注過快可能發生低血壓。 3. 管路避免與含鈣、鎂離子溶液接觸。 4. 依2016年第2次ADR會議決議: 因Quinolones類藥物常見引起靜脈炎，建議輸注時間應超過60分鐘。
OONG,Saxagliptin,Onglyza 5mg,META,,適應症: Type 2 DM. 副作用: Upper respiratory tract infection， UTI， headache， sinusitis， abdominal pain， gastroenteritis， vomiting， hypersensitivity. 禁忌: Treatment of type 1 diabetes mellitus or diabetic ketoacidosis,,below 30°C.,2.5-5 mg once daily as monotherapy or as combination therapy with metformin， a sulfonylurea， a PPARγ agonist.,,Micromedex: Infant risk cannot be ruled out.,,可能安全,,,Contraindicated 哺乳期使用禁忌,Micromedex: Infant risk cannot be ruled out.,,,,,,
IGLYP,Terlipressin,Glypressin inj 1mg,HM,Treatment of bleeding esophageal varices， and type 1 hepatorenal syndrome， characterised by spontaneous acute renal insufficiency， in patients suffering from severe cirrhosis with ascites.,Pregnancy.,Infrequently， acrocyanosis， diarrhea， abdominal cramps， headache.,25℃以下避光,Bleeding oesophageal varices: Adults: Initially an IV injection of 2 ampoules of GLYPRESSINR solution for injection (2 mg terlipressin acetate， equivalent to 1.7 mg terlipressin) is given every 4 hours. The treatment should be maintained until bleeding has been controlled but up to a maximum of 48 hours. The dose can be adjusted to 1 ampoule of GLYPRESSINR solution for injection (1 mg terlipressin acetate， equivalent to 0.85 mg terlipressin) IV every 4 hours in patients with body weight < 50 kg. For maintenance dosage (if necessary)， bolus injection of 1 ampoule of GLYPRESSINR solution for injection every 4 hours for a maximum of 3 days. Duration of treatment must not exceed 5 days. In type 1 hepatorenal syndrome: 3 to 4 ampoules of GLYPRESSINR solution for injection (3 to 4 mg terlipressin acetate， equivalent to 2.55 to 3.4 mg terlipressin) every 24 hours as 3 or 4 administrations. In the absence of any reduction of the serum creatinine after 3 days of treatment， cessation of GLYPRESSINR treatment is advised. In the other cases， GLYPRESSINR treatment is to be pursued until the obtaining either of a serum creatinine less than 130 mmol/L or of a drop of at least 30 % in the serum creatinine with respect to the value measured at the time of diagnosis of hepatorenal syndrome. The standard average duration of treatment is 10 days.,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,IVP;IVPUSH;,使用廠商內附稀釋溶液,,2 mg 推注時間須超過 1 分鐘,,
OPROA,Cloxacillin,Prostaphlin-A 250mg,QANB,,適應症:細菌性感染(N006998100) Infections caused by penicillinase producing bacterias， upper and lower respiratory tract infection， skin and soft-tissue infections， G(+) infections， except Staphylococcus.,,RT,Adult: 250-500 mg q6h up to 6 g/day. Child: 12.5-25 mg/kg q6h.,,,,可能安全,,,,,,,,,,
OPROP,Finasteride,Propecia 1mg (28 tablets/box),TDER,Treatment of male pattern hair loss (androgenetic alopecia) in men only. Not indicated in women & children.,Pregnancy (or may potentially be pregnant). Hypersensitivity to any component of this product.,Decreased libido (placebo 1.3% vs Propecia 1.8%); erectile dysfunction (placebo 0.7% vs Propecia 1.3%); decreased vol of ejaculate (placebo 0.4% vs Propecia 0.8%).,30℃以下,Androgenetic alopecia (male pattern hair loss): Males: Oral: 1 mg once daily. Continue for at least 12 months to assess the full effect,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥應整粒吞服， 切勿咬嚼、壓碎。本藥僅用於男性，具致畸胎性，請注意相關暴露風險，尤其是婦女及小孩。錠劑覆有膜衣，若無破損可防止平常觸摸時直接接觸有效成份。
OPROS,Dinoprostone,Prostarmon-E 0.5mg,SGU,,適應症: Induction & augmentation of labor near term. 副作用: Hypercontractions & fetal distress; nausea， vomiting， diarrhea， facial flush， heaviness in the head， headache， dizziness & slight elevation or fall of BP may occasionally occur. Gastrointestinal: Diarrhea (vaginal insert， less than 1%; vaginal suppository， approximately 40% )， Nausea (vaginal insert， less than 1%; vaginal suppository， 33% )， Vomiting (vaginal insert， less than 1%; vaginal suppository， approximately 66% ) Musculoskeletal: Backache (cervical gel， 3.1% ) Neurologic: Headache (vaginal suppository， approximately 10% ) Reproductive: Irregular uterine contractions (cervical gel， 6.6% ) Other: Fever (cervical gel， 1.4%; vaginal insert， less than 1% )， Shivering (vaginal suppository， approximately 10% ) 禁忌: Contracted pelvis， cephalopelvic disproportion & fetal malpresentation; obstet complications which may threaten the life of the fetus; early or mid-pregnancy.,,室溫,1 tab hrly. If no effect is observed after 6 tab refrain from further dosing & resume the administration on the next day or later. Discontinue the administration when onset of uterine contractions or progression of parturition is observed.,無需調整劑量,,無需調整劑量,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EBSS2,Balanced Salt Soln,BSS sterile irrigation solusion 500ml/Bottle,TOPH,B.S.S. Irrigation during various surgical procedures of the eyes， ears， nose or throat. BSS Plus Intraocular irrigating soln during intraocular surgical procedures involving perfusion of the eye.,Hypersensitivity to any component of the formulation.,When the corneal endothelium is abnormal， irrigation or any other trauma may result in bullous keratopathy.,室溫,For irrigation during operations of the eyes， ears， nose and throat.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AD;AL;AS;AU;EXT;G;GAR;IN;IRR;IRRI;LI;NA;OD;OL;ORO;OU;SKIN;TOPI;,,,,,
ECAN,Clotrimazole,Canesten 20gm,TDER,,I: Dermatomycoses， pityriasis versicolor， erythrasma， Candidal vulvitis. AR: Skin reactions.,,,1-2 times daily.,,,,可能安全,,,,,,,,,,
ECH4,Chloral hydrate,Chloral hydrate 4%,CNEU,,,,,,,,,,,,,,,,,,,
ECHL,Chloramphenicol,Chloramphenicol 0.25% 10mL,TOPH,,適應症:Superficial bacterial eye infections 副作用: Transient stinging.,,2-8 °C,Apply 1 drop every 2 hr & reduce frequency as infection is controlled; continue for 48 hr after healing.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ECLI,Estradiol 17B,Climara 50 patch,HM,,適應症:補充女性賀爾蒙(B022702318),,,,,,,,,,,,,,,,,
HE5012,Dianeal 2000cc 2.5% (PD 2雙袋),Dianeal 2000mL 2.5% (PD 2雙袋),NUTR,,,,,Select mode of therapy， frequency of treatment， formulation， fill volume， duration of dwell， and length of dialysis based on the patient’s clinical condition， fluid， electrolyte and specific needs. The fill volume depends on body size， usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5013,Dianeal 2L 2.5% (PD 4雙袋),Dianeal 2L 2.5% (PD 4雙袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy， frequency of treatment， formulation， exchange volume， duration of dwell， and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
HE5014,Dianeal 2000cc 4.25%(PD 2雙袋),Dianeal 2000mL 4.25% (PD 2雙袋),NUTR,,,,,Select mode of therapy， frequency of treatment， formulation， fill volume， duration of dwell， and length of dialysis based on the patient’s clinical condition， fluid， electrolyte and specific needs. The fill volume depends on body size， usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5015,Dianeal 2000cc 4.25% (PD 4雙袋),Dianeal 2000mL 4.25% (PD 4雙袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy， frequency of treatment， formulation， exchange volume， duration of dwell， and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
HE5020,Dianeal 2500cc 1.5% (PD 2 單袋),Dianeal 2500mL 1.5% (PD 2 單袋),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD， the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period， the access device is opened， the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night， the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
HE5021,Dianeal 2500cc 1.5% (PD 2 雙袋),Dianeal 2500mL 1.5% (PD 2 雙袋),NUTR,,,,,Select mode of therapy， frequency of treatment， formulation， fill volume， duration of dwell， and length of dialysis based on the patient’s clinical condition， fluid， electrolyte and specific needs. The fill volume depends on body size， usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5022,Dianeal 2.5L 1.5% (PD 4 單袋),Dianeal 2.5L 1.5% (PD 4 單袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
ESPI,Tiotropium,Spiriva inhaler 18mcg 30's/set,ERSP,,適應症: Maintenance treatment of patients with COPD (including chronic bronchitis & emphysema). 副作用: GI disturbances， cough & local irritation， dysuria， urinary retention (in men)， tachycardia， allergic reactions. Gastrointestinal: Constipation (4% )， Xerostomia (12% to 16% ) Respiratory: Pharyngitis (7% to 9% )， Sinusitis (3% to 11% )， Upper respiratory infection (41% to 43% ) 禁忌: Patients with a history of hypersensitivity to atropine or its derivatives eg， ipratropium or oxitropium， or to any component of Spiriva.,,室溫,Inhale the contents of 1 cap once daily with the HandiHaler inhalation device at the same time of day.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
RIMMR,Measles & Mumps & Rubella & Varicella,Priorix-Tetra (臨床試驗藥),HIMM,,,,,,,,,,,,,,,,,,,
HE5023,Dianeal 2500cc 1.5% (PD 4 雙袋),Dianeal 2500mL 1.5% (PD 4 雙袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy， frequency of treatment， formulation， exchange volume， duration of dwell， and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
ROFER,Ferrous sulfate,Ferrous sulfate 324mg(臨床試驗),NUTR,,,,,,,,,,,,,,,,,,,
EAAO,Sod Oleate + Poldocanol + Chlorocarvacrol,Alcos-Anal oint 20gm,ALIM,,適應症: Hemorrhoids. 副作用: Local irritation.,,室溫,Apply once-bid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,RECT;,,,,,
OIXE,Milnacipran,Ixel 50mg,CNEU,,適應症: Treatment of major depressive episodes in adults. 副作用: Dizziness， increased sweating， anxiety， hot flushes， dysuria， GI disturbances， dry mouth， constipation， tremors， palpitations. 禁忌: Children < 15 years; concomitant administration with non-selective MAOI， MAO-B inhibitors， digoxin or 5-HT1 agonists (e.g. sumatriptan); use with parenteral adrenaline or noradrenaline， clonidine & related substances， MAO-A inhibitors; prostatic hypertrophy or urinary retention; pregnancy & lactation.,,室溫,50 mg bid.,,,,沒有資料,,,,,,,,,,
YSLJ2,water， propylene glycol， methycelluose,舒摩兒潤澤凝露 2 Oz (57gm),MSGO,,,,,,,,,,,,,,,,,,,
OGLUM,Glyburide + Metformin,GlucoMET 5/500mg(鋁箔/錫箔),META,As initial or 2nd-line therapy in the treatment of type 2 diabetes.,Renal disease or renal dysfunction， CHF requiring pharmacologic treatment， acute or chronic metabolic acidosis， including diabetic ketoacidosis with or without coma. Treatment should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials.,GI disturbances， headache， abdominal pain， dizziness. Rarely， lactic acidosis. Endocrine metabolic: Cobalamin deficiency (7% )， Hypoglycemia Gastrointestinal: Abdominal pain (6.9% )， Diarrhea (17% )， Nausea and vomiting (7.6% ) Neurologic: Dizziness (5.5% )， Headache (8.9% ) Respiratory: Upper respiratory infection (17.3% ),25℃以下，不透光容器內,Initial 0.5-1 TAB once daily， max 4 TAB (20 mg glyburide and 2000 mg metformin).,無需調整劑量,,需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PO;WM;,,,,,
ELOCO,Hydrocortisone,Locoid cream 0.1%， 5gm,TDER,,適應症: Treatment of all conditions for which corticosteroid therapy is indicated. 副作用: Electrolyte imbalance with edema & hypertension， increased insulin requirements in diabetic patients， delayed wound healing. Cushingoid symptoms， amenorrhoea， hyperhidrosis， skin thinning， ocular changes， mental & neurological disturbances， intracranial hypertension， acute pancreatitis， aseptic necrosis of the bone， muscle weakness & wasting， hypersensitivity reactions. 禁忌: Peptic ulcer， osteoporosis， psychoses， severe psychoneuroses， acute infections， concurrent administration with live vaccines.,,室溫,Apply several times a day.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IKCL1A,Potassium Chloride,子醫令 KCl inj 15% 10mL,NUTR,,,,,子醫令,無需調整劑量,,無需調整劑量,,Compatible,,Compatible 哺乳時可使用,,IVD;,,,,,調配製劑之子醫令，計價用。
IFEN2BAD,Fentanyl,Fentanyl inj 0.1mg/2mL殘餘銷毀,CNEU,,,,,,,,,,,,,,IM;IV;IVD;,,【D5W】可選 。【N/S】可選 。,推注時間成人 > 1-2分鐘，兒童 > 2-5分鐘,,
IFEN2,Fentanyl,Fentanyl inj 0.1mg/2mL,CNEU,Premed prior to surgery， Adjunct to general anesth induction， Adjunct to regional anesth， Post-operatively .,Children <2 years， bronchial asthma， respiratory depression & head injury. Patients who received MAOIs within previous 14 days.,Respiratory depression， apnoea， muscle rigidity & bradycardia.,25℃以下避光,As a general anesthesia analgesic aid: Low dose: 2 mcg/kg IV (Minor surgery) Medium dose: 2-20 mcg/kg IV (Complex surgery) High dose: 20-50 mcg/kg IV (Prolonged major surgery. Use with Oxygen， Nitrous Oxide to avoid body's stress response) IV injection 25-250 mcg/kg (0.5-5mL) can be given to extend the action time until the completion of the operation. As an anesthetic: When it is important to reduce the stress response during surgery， fentanyl can be administered intravenously 50-100 mcg/kg， combined with Oxygen and Muscle Relaxants without adding additional anesthetics. This method is often used for heart surgery and other needs to protect the myocardium from hypoxia. As an analgesic for acute severe pain: Epidural injection: single dose 5-100 mcg; continuous infusion: 25-100 mcg per hour. Elderly patients: similar to other opioids， the dose of the elderly and frail patients should be lowered. Children: The induction and maintenance of anesthesia for children between 2-12 years old， the dose should be reduced to 2-3 mcg/kg IV.,無需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,,【D5W】可選 。【N/S】可選 。,推注時間成人 > 1-2分鐘，兒童 > 2-5分鐘,,
OSWI,Trihexyphenidyl,Switane 2mg,CNEU,Parkinsonism.,Closed-angle glaucoma， paralytic ileus， prostatic hypertrophy.,GI disturbances; glaucoma， mydriasis; urinary retention， mental disturbances， excitement.,25℃以下,Parkinsonism: 1 mg on the 1st day， increment of 2 mg every 3-5 days until 6-10 mg/day in 3 divided doses. Medication induced parkinsonism: 5-15 mg/day， start from 1 mg/day. Postencephalitic parkinsonism: 12-15 mg/day.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
EACUL,Ketorolac,Acular 0.5%， 5mL ophthalmic solution,TOPH,Temporary relief of ocular itching due to seasonal allergic conjunctivitis. Treatment of postop inflammation in patients who have undergone cataract extraction.,Patients who have previously demonstrated hypersensitivity to any of the ingredients of Acular.,Transient stinging & burning， ocular irritation， allergic reactions， superficial ocular infections， superficial keratitis. Cardiovascular: Edema (1% to 10% )， Hypertension (1% to 10% ) Dermatologic: Injection site pain (injection， 1% to 10% )， Pruritus (1% to 10% )， Rash (1% to 10% )， Sweating (1% to 10% ) Gastrointestinal: Abdominal pain (1% to 10% )， Diarrhea， Indigestion (1% to 10% )， Nausea (greater than 10% ) Hematologic: Anemia (1% to 10% )， Purpura (1% to 10% ) Neurologic: Dizziness (1% to 10% )， Headache (greater than 10% )， Somnolence (1% to 10% ) Ophthalmic: Burning sensation in eye， Transient (ophthalmic， 20% to 40% )， Corneal edema (ophthalmic， 1% to 10% )， Eye irritation (ophthalmic， 1% to 10% )， Iritis (ophthalmic， 1% to 10% )， Keratitis (ophthalmic， 1% to 10% ) Respiratory: Nasal irritation (nasal， 15% )， Pain， Rhinalgia (nasal， 13% ),避光儲存於15℃- 25℃,Relief of ocular itching due to seasonal allergic conjunctivitis: Instill 1 drop QID. Treatment of inflammation in patients who have undergone cataract extraction: Instill 1 drop QID (above 24 hrs post-operation)， and use constantly until 2 weeks after surgery.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
OALI,Thiaine Tetrahydrofurfuryl Disulfide + Riboflavin,Alinamin-F 50mg,NUTR,Neuralgia， neuritis， eye's fatigue， nervous cystitis; post-op intestinal paralysis， vit B1 deficiency.,Hypersensitivity,Rarely， nausea， vomiting & rumbling; shock， hypersensitivity， headache or pollakiuria (decrease dose or stop use).,保存於乾燥陰涼且避免陽光直射,Oral: 1 tab QD-TID PC.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OAMI,Aminophylline,Aminophylline 100mg,ERSP,,適應症:Bronchospasm. 副作用:Nausea， vomiting， abdominal pain， diarrhoea， headache， insomnia， dizziness， anxiety， restlessness; tremor， palpitations. 禁忌: Hypersensitivity to xanthines.,,室溫,Oral: Adult: 100-300 mg tid-qid. Child: 13-24 mg/kg/day.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
ECLO,Clotrimazole,Clomazole VT 100mg,SGU,,Fungal and G(+) bacterial infection of the skin and nails.,,,1-2 times daily.,,,,可能安全,,,,,,,,,,
ECLT,Clindamycin,Cleocin T gel 1% 30gm,TDER,Acne vulgaris.,Individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin， a history of regional enteritis or ulcerative colitis， or a history of antibiotic-associated colitis.,Skin dryness， skin irritation， oiliness， contact dermatitis， gm-ve folliculitis， stinging of the eye.,儲存於20℃ -25℃,Apply a thin film of Cleocin T twice daily to affected area. More than one pledget may be used. Each pledget should be used only once and then be discarded.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,EXT;SKIN;TOPI;,,,,,
ECU375,Cu375,Cu 375,HM,,適應症: Intrauterine contraception 副作用: Uterine cramps &/or abdominal pain; syncope， bradycardia， other neurovascular episodes during or immediately after insertion or removal of IUDs; breakthrough bleeding， prolongation of menstruation， dysmenorrhea; back & leg pain， dyspareunia; pelvic inflammatory disease; abnormal vag discharge; perforated uterus or cervix; spontaneous abortion; septicemia; ectopic pregnancy. Urticarial allergic skin reactions. 禁忌: Pregnancy; ectopic pregnancy or predisposing factors; malformations or distortions of uterus or cervix; active pelvic inflammatory disease， presence or history of venereal disease， infected abortion within 3 months; undiagnosed vag bleeding; coagulopathy， treatment with anticoagulant; disorders of copper metabolism; severe anemia. Large or multiple uterine fibromyomata with heavy menstrual periods.,,室溫,Individualised dosage. Inserted into uterus.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EDAI,Calcipotriol,Daivonex ointment,TDER,,,,,,,,,,,,,,,,,,,
EDAIS,Calcipotriol,Daivonex scalp soln 30mL,TDER,,適應症: Scalp psoriasis. 副作用: Transient local irritation & very rarely， facial dermatitis may occur. Scalp soln Transient burning， stinging， rash， dry skin， skin irritation， worsening of psoriasis. 禁忌: Known disorder of Ca metabolism.,,室溫,Oint Apply bid. Maintenance therapy may be achieved with less frequent application. Weekly dose should not exceed 100 g. Scalp soln Apply bid. Weekly dose should not exceed 60 mL. When used together with oint/cream， the total dose of calcipotriol should not exceed 5 mg/week corresponding to 100 g of oint/cream.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IHBVA,Hepatitis B Vaccine,Engerix-B vaccine 20mcg/mL/DOS,HIMM,,Prevention of hepatitis B in healthy individuals exposed to risk of contamination.,,,IM (preferred) or SC， 20 mcg purified antigen protein. Standard 3-dose schedule: Given at 1 and 6 months after 1st dose. Alternative 4-dose schedule:Given at 1，2 and 12 months after 1st dose.,,,,除非治療上需要,,,,,,,,,,
IHCG1,Chorionic Gonadotropin,Gona Hormon(Pregnyl)1500U,HM,,,,,,,,,,,,,,,,,,,
IHCG2,Human Chorionic Gonadotrophin,Profasi (HCG) 2000IU,HM,,適應症:為不孕症用藥(B022773212),,2-8,Prepubertal cryptorchidism: 5000U every second day for 4 injections. Hypogonadism in males: 500-1000U 3 times/week for 3 wks， then twice/week for 3 wks. Induction of ovulation: 5000-10000U one day following the last dose of menotropins.,,,,不可使用,,,,,,,,,,
IHD10,House Dust Mite,HD 10,ZOTH,,,,,,,,,,,,,,,,,,,
HE5024,Dianeal 2500cc 2.5% (PD 2 單袋),Dianeal 2500mL 2.5% (PD 2 單袋),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD， the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period， the access device is opened， the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night， the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
HE5025,Dianeal 2500cc 2.5% (PD 2 雙袋),Dianeal 2500mL 2.5% (PD 2 雙袋),NUTR,,,,,Select mode of therapy， frequency of treatment， formulation， fill volume， duration of dwell， and length of dialysis based on the patient’s clinical condition， fluid， electrolyte and specific needs. The fill volume depends on body size， usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5026,Dianeal 2.5L 2.5% (PD 4 單袋),Dianeal 2.5L 2.5% (PD 4 單袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
HE5027,Dianeal 2500cc 2.5% (PD 4 雙袋),Dianeal 2500mL 2.5% (PD 4 雙袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy， frequency of treatment， formulation， exchange volume， duration of dwell， and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
HE5028,Dianeal 2500cc 4.25% (PD 4 單袋),Dianeal 2500mL 4.25% (PD 4 單袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
HE5029,Dianeal 2500cc 4.25% (PD 4雙袋),Dianeal 2500mL 4.25% (PD 4雙袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy， frequency of treatment， formulation， exchange volume， duration of dwell， and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
HE5040,Dianeal 5000cc 1.5% (PD2單袋),Dianeal 5000mL 1.5% (PD2單袋),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD， the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period， the access device is opened， the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night， the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
HE5041,Dianeal 5L1.5% (PD 4單袋),Dianeal 5L1.5% (PD 4單袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
HE5042,Dianeal 5000cc 2.5% (PD 2單袋),Dianeal 5000mL 2.5% (PD 2單袋),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD， the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period， the access device is opened， the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night， the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
HE5043,Dianeal 5L 2.5% (PD 4單袋),Dianeal 5L 2.5% (PD 4單袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
ETOP1,Fluocinonide,Topsym 乳膏0.05%， 10gm,TDER,Eczema; dermatitis; psoriasis; vitiligo; alopecia; pustulosis; prurigo.,Vaccinia & varicella.,urning， itching， irritation， dryness; perioral dermatitis; allergic contact dermatitis; skin atrophy. Dermatologic: Dry skin， Pruritus， Sensation of burning of skin Neurologic: Headache， with 0.1% cream (4%) Other: Irritation symptom,儲存於陰涼處,Apply QD-TID.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,EXT;,,,,,
IDEXA,Dexamethasone,Dexamethasone inj 5mg/1mL,HM,Conditions where the anti-inflammatory & immunosuppressive effects of the corticosteroids are desirable， especially for intensive treatment during shorter periods.,Systemic fungal infection， hypersensitivity. Administration of live virus vaccine， unstable or infected joint， diagnosed sepsis.,Fluid & electrolyte disturbances. CV， musculoskeletal， GI， dermatologic， neurologic， endocrine， ophth & metabolic effects. Thromboembolism， psychic disturbances. Joint tissue damage (frequent IA inj). Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin， Finding of skin healing， Impaired Endocrine metabolic: Cushing's syndrome， Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )， Raised intraocular pressure (25% ) Psychiatric: Depression， Euphoria Respiratory: Pulmonary tuberculosis,無特別指示,IM and IV: 2-10 mg (0.4-2 mL). INS : 4-6 mg (0.8-1.2 mL) on large joint and 0.8-1 mg (0.16-0.2 mL) for smaller joint. Soft tissue: 2-6 mg (0.4-1.2 mL). Subconjectival or retrobulbar injection: 0.4-2 mg (0.08-0.4 mL). ID: diluted 1/5 of Dexamethasone with normal saline， then inject 0.1mL. Eye drops: diluted 1/25 of Dexamethasone with normal saline.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,ID;IM;INS;IRR;IS;IVD;IVI;IVP;IVPUSH;LI;SCI;SUBCI;,,【D5W】可選 。【N/S】可選 。,靜脈推注需大於一分鐘,Consider further dilution and administration by IV intermittent infusion over 5 to 15 minutes. (UpToDate),一日總投與量不可超過80mg;用於皮內通常將之用生理食鹽水稀釋5倍後取約0.1mL;點眼通常稀釋25倍後來使用 Adult: May administer 4 mg/mL or 10 mg/mL concentration undiluted over >1 minute. (UpToDate)
IMTX1,Methotrexate,Abitrexate inj 50mg/2mL,RACA,,適應症: Gestational choriocarcinoma， acute lymphocytic leukemia， meningeal leukemia， chorioadenoma destruens， hydatidiform mole， epidermoid cancers of the head & neck， lung cancer， bladder cancer & lymphosarcoma. 副作用: Ulcerative stomatitis， leukopenia， nausea & abdominal distress. malaise， fatigue， chills & fever， dizziness & decreased resistance to infection. Erythematous rashes， pruritus， urticaria， photosensitivity， depigmentation， alopecia， ecchymosis， telangiectasia， acne & furunculosis. Hematologic disorders. GI disturbances. CNS effects. Metabolic changes， precipitating diabetes， osteoporosis， conjunctivitis， abnormal tissue cell changes， anaphylaxis. 禁忌: Pregnant psoriatic patients. Psoriatic patients with severe renal or hepatic disorders， preexisting blood dyscrasias.,,室溫,Choriocarcinoma: Oral or IM， 15-30 mg/day for a 5 day course. Acute leukemia: Induction， oral or IV， 3.3 mg/m2/day with prednisolone; maintenance， oral or IM， 30 mg/mL twice a week， or IV， 2.5 mg/kg every 14 days. Meningeal leukemia: Intrathecal， 0.2-0.5 mg/kg or 12 mg/mL (max. 15mg) every 2-5 days until the cell count of cerebrospinal fluid returns to normal. Burkitt's lymphoma (stage I & II): Oral， 10-25 mg/day for 4-8 days. Psoriasis: Oral， IM or IV， 10-25 mg/week. Rheumatoid arthritis: Oral， 2.5 mg q12h for 3 doses every week. Mycosis fungoides: Oral， 2.5-10 mg/day for weeks or months; IM， 50mg/week.,,,,不可使用,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能。 3. Methotrexate以靜脈方式給藥需緩慢推注，也可以短時間靜脈輸注或靜脈持續輸注給藥。依治療組合與醫囑決定。
IERB,Cetuximab,Erbitux inj 100mg/50mL,RACA,,適應症：Treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Treatment of locally advanced oropharyngeal cancer， hypopharyngeal cancer， laryngeal cancer in combination with radiation therapy. 副作用：Mild or moderate infusion-related reactions eg fever， chills， nausea， vomiting， headache， dizziness or dyspnoea; mild to moderate mucositis. Severe infusion-related reactions eg rapid onset of airway obstruction， urticaria， hypotension， loss of consciousness &/or stenocardia may occur during or within 1 hr of initial infusion. Skin reactions， mainy as acne-like rash. Renal impairment. Conjunctivitis. Mild to moderate increase in liver enzyme levels. Dermatologic: Acneiform eruption， Any grade (76% to 88% )， Application site reaction (squamous cell carcinoma of the head and neck (with radiation)， 18% )， Dry skin (metastatic colorectal cancer (monotherapy)， 49% )， Nail changes (colorectal cancer (monotherapy)， 21% )， Pruritus (squamous cell carcinoma of the head and neck (with radiation)， 16%; colorectal cancer (monotherapy)， 40% )， Radiation dermatitis， Any grade (squamous cell carcinoma of the head and neck (with radiation)， 86% )， Rash (squamous cell carcinoma of the head and neck (with radiation)， 87%; colorectal cancer (monotherapy)， 89% ) Endocrine metabolic: Dehydration (squamous cell carcinoma of the head and neck (with radiation)， 25% )， Hypomagnesemia， Any grade (55% )， Weight loss (squamous cell carcinoma of the head and neck (with radiation)， 84% ) Gastrointestinal: Abdominal pain (colorectal cancer (monotherapy)， 59% )， Constipation (colorectal cancer (monotherapy)， 46% )， Diarrhea (squamous cell carcinoma of the head and neck (with radiation)， 19%; colorectal cancer (monotherapy)， 39%; colorectal cancer (with irinotecan)， 72% )， Nausea (squamous cell carcinoma of the head and neck (with radiation)， 49%; colorectal cancer (with irinotecan)， 55% )， Stomatitis (colorectal cancer (monotherapy)， 25% )， Vomiting (squamous cell carcinoma of the head and neck (with radiation)， 29%; colorectal cancer (monotherapy)， 37% ) Immunologic: Infectious disease (squamous cell carcinoma of the head and neck (with radiation)， 13%; colorectal cancer (monotherapy)， 35% ) Neurologic: Asthenia， Any grade (squamous cell carcinoma of the head and neck (with radiation)， 56%; colorectal carcinoma (with irinotecan)， 73% )， Confusion (colorectal cancer， 15% )， Headache (squamous cell carcinoma of the head and neck (with radiation)， 19%; colorectal cancer (monotherapy)， 33% )， Insomnia (colorectal cancer (monotherapy)， 30% ) Psychiatric: Anxiety (colorectal cancer (monotherapy)， 14% )， Depression (colorectal cancer (monotherapy)， 13% ) Respiratory: Cough (colorectal cancer (monotherapy)， 29% )， Dyspnea (colorectal cancer (monotherapy)， 48% )， Pharyngitis (squamous cell carcinoma of the head and neck (with radiation)， 26% ) Other: Complication of infusion， Any grade (15% to 21% )， Fatigue (colorectal cancer (monotherapy)， 89% )， Fever (squamous cell carcinoma of the head and neck (with radiation)， 29%; colorectal cancer (monotherapy)， 30% )， Late effect of radiation， Pain (colorectal cancer (monotherapy)， 51% ),,2-8℃,Prior to infusion， patients must receive premedication with an antihistamine. Initial dose: 400 mg/m2 once weekly. Subsequent doses: 250 mg/m2 once weekly. Colorectal cancer Same dose of irinotecan is administered in the last cycles of the prior irinotecan-containing regimen. Irinotecan must not be administered earlier than 1 hr after the end of Erbitux infusion. Oropharyngeal cancer， hypopharyngeal cancer， laryngeal cancer Start therapy 1 week before the radiotherapy & continue until the end of the radiotherapy period.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
LMUS2,Ambroxol,Musco solution 3mg/mL， 120mL,ERSP,Expectorant.,Hypersensitivity to any component of the formulation.,Mild GI effects & Allergic reactions.,25℃以下,Adult & children >10 years 10 mL TID. 5-10 years 5 mL TID. 2-5 years 2.5 mL TID. < 2 years 2.5 mL BID. Reduce dose in long-term therapy. Recommended doses of Children: 1.2-1.6mg/Kg/day.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
LLAC6,Lactulose,Lacoly soln 60mL(667mg/mL),ALIM,,適應症: Chronic portal systemic encephalopathy， hepatic pre coma， hepatic coma 副作用: Flatulence， nausea， vomiting， abdominal pain & diarrhea occasionally with electrolyte imbalance (high doses only). 禁忌: Galactosemia， bowel obstruction.,,室溫,Chronic constipation:  Starting dose(for 3 days) aintenance -------------------- ---------------------------------- --------------------- Severe cases 0-45 ml 15-25 ml Moderate cases 5-30 ml 10-15 ml Mild cases 5ml 10 ml 6-14yr 15 ml 10 ml 1-6yr 5-10 ml 5-10 ml Infant 1-12mth 5 ml 5 ml All doses to be taken daily preferably as single doses. Precoma & hepatic coma: Starting doses: approx 30-50 ml tid. In acute cases a retention enema is given in a proportion of 300ml Duphalac to 700 ml water.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
INEB,Testosterone,Nebido inj 1000mg/4mL,HM,Testosterone replacement therapy for primary or secondary male hypogonadism < 65 years.,Androgen-dependent carcinoma of the prostate or male mammary gland; hypercalcemia accompanying malignant tumors; past or present liver tumors. Women.,Diarrhea， leg pain， arthralgia， dizziness， increased sweating， headache， dyspnea， acne， breast pain， gynecomastia， pruritus， skin reactions， testicular pain， inj site pain， SC hematoma at inj site. Dermatologic: Acne (up to 8% ) Endocrine metabolic: Gynecomastia (up to 3% ) Gastrointestinal: Oral irritation， Buccal system (9.2% ) Neurologic: Headache (up to 4% ) Reproductive: Large prostate (11.7% ),30℃以下,1000 mg every 10-12 weeks.,無需調整劑量,Testosterone is present in breast milk. Some products are specifically contraindicated while breastfeeding. (UpToDate)2021/0125,無需調整劑量,不可使用,Uknown 沒有資料,Use is contraindicated during pregnancy.(UpToDate)2021/0125,Unknown 沒有資料,Testosterone is present in breast milk. Some products are specifically contraindicated while breastfeeding. (UpToDate)2021/0125,IM;,,,,,1. 本藥品限肌肉注射，須以極緩慢速度施打，並小心避免注射入血管內。
OSPAS,Alverine,Spasmonal 60mg,ALIM,,適應症: Irritable bowel syndrome. 副作用: Rarely fatigue， dizziness， headache， allergic reactions， rash， itch. 禁忌: Paralytic ileus. Pregnancy， lactation.,,室溫,Adult & elderly 60-120 mg once-tid.,,,,沒有資料,,,,,,,,,,
OAMIO,Amiodarone,Cordarone 200mg,CAVS,Wolff-Parkinson-White syndrome， supraventricular & ventricular tachycardia， atrial & ventricular fibrillation.,AV or SA block， sinus bradycardia， sick sinus syndrome except when used in conjunction with a pacemaker; history of thyroid dysfunction; iodine intolerance， severe arterial hypotension， CV collapse， acute cardiac insufficiency. Combined therapy with drugs which may induce torsades de pointes. Pregnancy， lactation.,Hypersensitivity， headache， joint pain， bradycardia， pigmentation， photosensitization， transient hypotension， face flush， sweating & transient nausea. Cardiovascular: Bradyarrhythmia， Hypotension (oral， less than 1%; intravenous， 15.6% ) Dermatologic: Photodermatitis (2% to 24% )， Photosensitivity (3% to 10% ) Endocrine metabolic: Thyroid dysfunction Gastrointestinal: Constipation (4% to 9% )， Loss of appetite (4% to 9% )， Nausea (10% to 33% )， Vomiting (10% to 33% ) Hepatic: Increased liver enzymes (4% to 9% ) Neurologic: Abnormal gait (4% to 9% )， Coordination problem (4% to 9% )， Dizziness (4% to 9% )， Involuntary movement (4% to 9% )， Movement disorder (4% to 9% )， Paresthesia (4% to 9% )， Peripheral neuropathy Ophthalmic: Corneal deposit， Microdeposits， Visual disturbance (4% to 9% ) Other: Malaise and fatigue (4% to 9% ),30℃以下,Initial dose: 600mg/day in divided doses for 8-10 days. Maintenance dose: dosage range from 100mg daily (200 mg every other day) to 400 mg/day.,無需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,Contraindicated 哺乳期使用禁忌,,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥具有苦味，不建議磨粉口服。
IADIF,Purified Split Inactivated Influenza Virus,4價自費流感 AdimFlu-S 0.5mL/dose,HIMM,,適應症: Active immunisation against influenza. 副作用: Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome. 禁忌: Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,,2 ~ 8 °C,Adult & Children >= 36 mth 0.5ml IM Chidren(>= 3yr， < 9 yr who have not been vaccinated previously， the 2nd dose can be given at an interval of at least 4 wk.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;,,,,,
OARIM,Anastrozole,Arimidex 1mg,RACA,Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. Treatment of advanced breast cancer in postmenopausal women. Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2-3 years of adjuvant tamoxifen.,Hypersensitivity to anastrozole or any component of the formulation; use in women who are or may become pregnant. Lactating women.,Hot flushes， asthenia， joint pain/stiffness， headache， nausea， rash. Hair thinning， diarrhea， vomiting， somnolence， carpal tunnel syndrome， elevated liver enzymes， vag dryness，vag bleeding， loss of appetite， hyperlipidemia. Cardiovascular: Hypertension (2% to 13% )， Peripheral edema (5% to 10% )， Vasodilatation (25% to 36% ) Dermatologic: Rash (6% to 11% ) Gastrointestinal: Nausea (11% to 20% )， Vomiting (8% to 11% ) Hepatic: ALT/SGPT level raised (1% to 10% )， AST/SGOT level raised (1% to 10% ) Immunologic: Lymphedema (10% ) Musculoskeletal: Arthralgia (2% to 15% )， Arthritis (17% )， Backache (10% to 12% )， Bone pain (6% to 12% )， Osteoporosis (11% ) Neurologic: Asthenia (13% to 19% )， Headache (9% to 18% )， Insomnia (2% to 10% ) Psychiatric: Depression (2% to 13% )， Disturbance in mood (19% ) Reproductive: Menopausal flushing (11% to 36% ) Respiratory: Dyspnea (8% to 11% )， Increasing frequency of cough (7% to 11% )， Pharyngitis (6% to 14% ) Other: Fatigue， Pain (11% to 17% ),25℃以下,1 mg once daily,需調整劑量,,需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OARO,Exemestane,Aromasin 25mg,RACA,Adjuvant treatment of postmenopausal women with oestrogen receptor +ve invasive early breast cancer， following at least 2 year of initial adjuvant tamoxifen therapy. Treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.,Pregnancy， lactation. Women with premenopausal endocrine status.,Anorexia， insomnia， depression， headache， dizziness， carpal tunnel syndrome， hot flushes， nausea， abdominal pain， vomiting， constipation， dyspepsia， diarrhea， increased sweating， rash， alopecia， joint & musculoskeletal pain， fatigue， pain， peripheral oedema. Rarely， hepatitis including cholestatic hepatitis. Endocrine metabolic: Diaphoresis (6% to 17.8% )， Hot sweats (13% to 32.9% ) Gastrointestinal: Nausea (8.5% to 18% ) Musculoskeletal: Arthralgia (14.6% to 28.8% ) Neurologic: Headache (6.9% to 13.1% )， Insomnia (11% to 13.7% ) Psychiatric: Fatigue (11% to 22% ),30℃以下,25 mg administered orally once daily after a meal.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,PC;PO;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OBAM,Bambuterol,Bambec 10mg,ERSP,,適應症:預防及治療支氣管痙攣(B020058100) Bronchial asthma， chronic bronchitis， emphysema. 副作用: Tremor， headache， tonic muscle cramps， palpitations. 禁忌: Hypersensitivity to any of the ingredients of Bambec or to terbutaline.,,室溫,10 mg once daily at night， may be increased to 20 mg once daily after 1-2 wk.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OBENS,Benzonatate,Bensau 100mg,ERSP,,適應症:止咳作用(A042435100) Symptomatic relief of cough. 副作用: Sedation， headache， dizziness， itch， skin eruption， nasal congestion， constipation， GI upset， chills， chest tightness， allergy. 禁忌: Children < 14 yr.,,室溫,Adult 1-2 cap tid MAX dose is 600 mg/day,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IHD100,House Dust Mite,HD 100,ZOTH,,,,,,,,,,,,,,,,,,,
IHD1000,House Dust Mite,HD 1000,ZOTH,,,,,,,,,,,,,,,,,,,
IHEA,Amino Acids,8% Hepatamine 500mL,NUTR,,,,,,,,,,,,,,,,,,,
IHEP1,Heparin,Heparin inj 1KIU/0.2mL,HEMT,,適應症: Unstable angina; Venous thromboembolism; Peripheral arterial embolism， Prevention of re-occlusion of the coronary arteries following thrombolytic therapy ， Venous thromboembolism ，Prophylaxis of post-op venous thromboembolism， Prevention of mural thrombosis 副作用:Slight fever， headache， chills， nausea， vomiting， constipation， epistaxis， bruising， slight haematuria， skin necrosis (SC inj)， osteoporosis， alopecia. Hypersensitivity reactions include urticaria， conjunctivitis， rhinitis， asthma， angioedema and anaphylactic shock. Priapism. Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding 禁忌: Patients predisposed to active bleeding including thrombocytopenia， peptic ulcer disease， cerebrovascular disorders， haemorrhagic blood disorders， bacterial endocarditis， severe hypertension， oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage， abdominal or thoracic bleeding into closed space， severe traumatic bleed， hepatic， renal， splenic or arterial injury， severe haemostatic defect， arterial thrombosis with heparin-associated thrombocytopenia. IM admin.,,15-30℃,IV Unstable angina; Venous thromboembolism; Peripheral arterial embolism Loading dose: 5，000 u， then 1，000-2，000 u/hr. Prevention of re-occlusion of the coronary arteries following thrombolytic therapy in MI 5，000 u， then 1，000 u/hr w/ alteplase. SC Venous thromboembolism 15，000 u 12 hrly. Prophylaxis of post-op venous thromboembolism 5，000 u 2 hr before surgery， then 8-12 hrly for 7 days or until patient is ambulant. Prevention of mural thrombosis 12，500 u 12 hrly for at least 10 days,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,1.未稀釋亦可使用
IHMG,FSH75IU + LH75IU,Humegon,HM,,,,,,,,,,,,,,,,,,,
IHUMN,Insulin NPH Human,Humulin N inj100IU/mL 10mL,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,2-8,According to individual requirements.,,,,安全,,,,,,,,,,
OASV,Tipepidine,Asverin 20mg,ERSP,Relief of cough and difficulty in expectoration of sputum accompanying common cold， pharyngitis， laryngitis， acute bronchitis， chronic bronchitis， bronchiectasis.,Hypersensitivity to any component of the formulation.,Dizziness， insomnia; GI disturbances; skin itch.,25℃以下,Adult & children >12 years: 20mg TID. Children 6-12 years: 10mg TID. Children 3-6 years: 5 mg TID. Children < 3 years old: reduce dose depended on doctor.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
OATO,Formoterol,Atock 40 mcg,ERSP,,Alleviation of various symptoms egdyspnea due to airway obstructive disturbances in bronchial asthma， acute/chronic bronchitis， asthmatic bronchitis， pulmonary emphysema.,,,Adult 160 mg bid. Childn 4 mg/kg daily bid~tid.,,,,,,,,,,,,,,
OAUG,Amoxicillin + Clavulanic Acid,Augmentin 375mg,QANB,,Respiratory tract infections， skin and soft tissue infections， genito-urinary tract infections， osteomyelitis.,,,Adult & child over 40 kg: 250-500 mg q8h. Child under 40 kg: 20-40 mg/kg/day in 3 divided doses.,,,,可能安全,,,,,,,,,,
OAUR,Moclobemide,Aurorix 150mg,CNEU,,適應症:為抗憂鬱劑，緩解社交畏懼(B019040100),,RT,300-600mg /day， depending on severity of depression， in 2-3 divided doses， taken after meal.,,,,可能安全,,,,,,,,,,
OBACC,Norfloxacin,Baccidal 100mg,QANB,,All G(+) and G(-) pathogens sensitive to norfloxacin such as urinary tract infections， gastrointestinal infection & gonorrhoea.,,,Urinary tract infection: Adult: 400-800 mg/day in 2-4 divided doses， (max. 800 mg/day). Gastrointestinal infection: 400 mg bid-tid. Gonorrhoea: 800 mg single dose.,,,,除非治療上需要,,,,,,,,,,
OLEV5,Levofloxacin,Levofloxacin 500mg (政府提供),QANB,,適應症:Respiratory tract， ENT， GUT infection. Intrauterine infections， cervicitis， uterine adnesxitis， folliculitis. GIT infections， lymphangitis， mild to moderate skin & skin tissue infections 副作用:Dizziness， GI disturbances， rash， pruritus， vaginitis， genital moniliasis， taste perversion， insomnia， tendinitis. Rarely， anaphylactic reactions， Lyell's syndrome， Stevens-Johnson's syndrome. 禁忌:Hypersensitivity to quinolones. Pregnancy & lactation. Children & growing adolescents < 18 years. Tendinitis or tendon rupture.,,室溫,100 mg tab Adult 100 mg bid-tid. Severe case: 200 mg tid. 500 mg tab Adult Skin & soft tissue infections 250 mg once daily or 500 mg once-bid for 7-14 days. Chronic bacterial prostatitis 500 mg once daily for 28 days. Complicated UTI including pyelonephritis 250 mg once daily for 7-10 days. Community-acquired pneumonia 500 mg once-bid for 7-14 days. Acute exacerbations of chronic bronchitis 250-500 mg once daily for 7-10 days. Acute sinusitis 500 mg once daily for 10-14 days. Infusion Adult By slow IV infusion. Community-acquired pneumonia 500 mg once-bid. Complicated UTI 250 mg once daily. Skin & soft tissue infections 500 mg bid. Dosage may be increased if necessary in severe infections. Max treatment duration: 14 days.,,,,除非治療上需要,,,,,,,,,,
ISM1,Streptomycin,SM inj 1gm (政府提供),QANB,,適應症:Tuberculosis. Bacterial endocarditis. Plague， tularemia & brucellosis. Mycetoma & Whipple's disease. 副作用:Vestibular & auditory damage， nephrotoxicity， paraesthesia of face， rash， fever， urticaria， angioneurotic edema， eosinophilia. 禁忌:Hypersensitivity.,,室溫,TB Adult 15-20 mg/kg body weight/day. Max: 1 g/day. Adult > 40 years & < 50 kg Max: 500-750 mg/day. May be given as part of intermittent regimen 2 or 3 times weekly. Children 15-20 mg/kg/day. Max: 1 g/day. Non-tuberculous infections Adult 1-2 g/day in divided doses. Children Up to 40 mg/kg daily in divided doses. Max: 1 g/day. Course of treatment (except TB) should be limited to 7-14 days,,,,盡量避免,,,,,,,,,,
OGLIV,Imatinib,Glivec 100mg,RACA,,適應症: Adult & pediatrics with newly diagnosed chronic myeloid leukemia (CML)， CML in blast crisis， accelerated phase or chronic phase after failure of interferon-α therapy. Adult with newly diagnosed Philadelphia chromosome +ve acute lymphoblastic leukemia (Ph+ALL) integrated with chemotherapy; with relapsed or refractory Ph+ALL as montherapy; myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements; systemic mastocytosis (SM) without D816V c-Kit mutation or with c-Kit mutation status unknown; hypereosinophilic syndrome (HES) &/or chronic eosinophilic leukemia (CEL); unresectable &/or metastatic， malignant GI stromal tumors (GIST); unresectable， recurrent &/or dermatofibrosarcoma protuberans (DFSP). 副作用: GI disturbances， anorexia， gastro-esophageal reflux， mouth ulceration， myalgia， muscle cramps， joint swelling， headache， dizziness， taste disturbance， paraesthesia， insomnia， conjunctivitis， increased lacrimation， blurred vision， epistaxis， dyspnea， weight gain， periorbital edema， dermatitis， rash， face & eyelid edema， pruritus， erythema， dry skin， alopecia， night sweats， fluid retention & edema， fatigue; pyrexia， weakness， rigors; neutropenia & febrile neutropenia， thrombocytopenia， anemia. Cardiovascular: Edema (1.1% to 86.1% ) Dermatologic: Night sweats (13% to 17% )， Rash (up to 49.8% ) Endocrine metabolic: Weight gain (up to 32% ) Gastrointestinal: Diarrhea (3% to 58.2% )， Nausea (3% to 73% )， Vomiting (2% to 58% ) Musculoskeletal: Arthralgia (12.3% to 40% )， Cramp (up to 62% )， Musculoskeletal pain (up to 49% )， Myalgia (9% to 32.2% ) Neurologic: Asthenia (15% to 21% )， Dizziness (12% to 16% )， Headache (up to 36% )， Insomnia (10% to 14% ) Respiratory: Cough (14% to 27% )， Nasopharyngitis (10% to 30.5% )， Pain， Pharyngolaryngeal (18.1% )， Pharyngitis (10% to 15% ) Other: Fatigue (25% to 48% )， Fever (16.7% to 41% )， Influenza (0.8% to 13.8% )， Rigor (10% to 12% ) 禁忌: Hypersensitivity to imatinib or any component of the formulation,,室溫,Ph+ CML chronic phase 400mg qd， may be increase to 600mg qd Accelerated phase or blast crisis: 600mg qd increase to 800mg daily divided in two Ph+ ALL : 600mg once daily Kit+ GIST: adjuvant therapy， 400 mg qd; unresectable/metastatic， 400 mg qd; may increase up to 400 mg bid Dosage adjustment for hepatic impairment: Mild to moderate impairment : 400mg/day Severe impairment: 300mg/day 【Lactation】Infant risk cannot be ruled out,需調整劑量,,需調整劑量,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,
INOV6,Eptacog alfa,Novo Seven for inj 60K IU,HEMT,,適應症:Treatment of bleeding episodes & prevention of excessive bleeding in those undergoing surgery or invasive procedure in patients with congenital hemophilia with inhibitors， acquired hemophilia， Factor VII (FVII) deficiency， Glanzmann's thrombathenia. 副作用:Rarely rash， itching， fever， nausea， headache， general discomfort， perspiration or changes in BP 禁忌:Hypersensitivity to mouse， hamsters or bovine protein.,,2-8℃,Hemophilia with inhibitors or acquired hemophilia 90 mcg/kg 2-3 hrly or 270 mcg/kg as single IV bolus. May increase dosing frequency to 4， 6， 8 or 12 hrly. FVII deficiency 15-30 mcg/kg 4-6 hrly by IV bolus. Glanzmann's thrombasthenia 90 mcg/kg body wt (80-120 mcg/kg body wt) 2 hrly (1.5-2.5 hr) at least 3 doses.,,,,除非治療上需要,,,,,,,,,,
IVAR0,Varicella Vaccine,水痘疫苗(員工用) 0.5mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
IADA0,Diphtheria + Tetanus + Pertussis,Adacel 0.5mL (專案),HIMM,,,,,,,,,,,,,,,,,,,
HE5044,Dianeal 5000cc 4.25% (PD 2單袋),Dianeal 5000mL 4.25%(PD 2單袋),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD， the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period， the access device is opened， the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night， the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
HE5045,Dianeal 5000cc 4.25%(PD 4單袋),Dianeal 5000mL 4.25% (PD 4單袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients， the cycle of instillation， dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function， maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,無需調整劑量,,,,,,,,,,,,,
HE5050,Nutrineal 2000cc 1.1% (PD 4雙袋),Nutrineal 2000mL 1.1% (PD 4雙袋),NUTR,,,,,The mode of therapy， frequency of treatment， formulation， exchange volume， duration of dwell， and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Note that the recommended daily total intake of proteins is greater than or equal to 1.2-1.3 g/kg body weight for adult dialysis patients. A 2.0L bag of Nutrineal contains 22 g of amino acids which corresponds to 0.30 g/kg body weight/24 h (approximately 25% of the daily protein requirements) for an adult dialysis patient of 70 kg body weight.,無需調整劑量,,,,,,,,,,,,,
ECOS,Dorzolamide + Timolol,Cosopt 2/0.5%， 5ml ophthalmic solution,TOPH,Treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension， open-angle glaucoma， pseudoexfoliative glaucoma or other secondary open-angle glaucomas when concomitant therapy is appropriate.,Bronchial asthma or a history of bronchial asthma， or severe COPD， sinus bradycardia， 2nd or 3rd degree AV block， overt cardiac failure， cardiogenic shock.,Taste perversion， ocular burning &/or stinging， conjunctival hyperemia， blurred vision， superficial punctate keratitis or eye itching. Cardiovascular: Angina， Bradyarrhythmia， Heart failure， Hypertension， Hypotension Gastrointestinal: Nausea (less than 5%)， Taste sense altered (8%-42%)， Vomiting (less than 5%)， Xerostomia (less than 5%) Neurologic: Dizziness (less than 5%)， Headache (less than 5%) Ophthalmic: Blepharitis (5%)， Blurred vision (5% to 15%)， Burning sensation in eye (12%-30%)， Conjunctival hyperemia (5% to 15%)， Excessive tear production (15%)， Itching of eye (5% to 15%)， Light intolerance (5% to 15%)， Pain in eye (1%-14%) Psychiatric: Depression (less than 5%) Respiratory: Bronchitis， Dyspnea， Nasal congestion (less than 5%)， Upper respiratory infection (less than 5%),30℃以下儲存,Instill 1 drop BID into the conjunctival sac. Limited data available with child under 2 years old. Shake well before using.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
EPER,Test Strips,Performa test strips， 50strips(羅氏),ZOTH,,,,2-30℃,,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,,,,,,
EULTR,Test Strips,Ultra test strips(壯生),ZOTH,,,,,,,,,,,,,,,,,,,
INES,Darbepoetin alfa,NESP inj 20mcg(限自費-洗腎用),HEMT,,適應症: Treatment of anemia associated with chronic renal failure (CRF)， including patients either on or not on dialysis. Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. 副作用: Vascular thrombosis， CHF， sepsis， cardiac arrhythmia， infections， HTN， hypotension， myalgia， headache， diarrhea， fever， nausea， chest pain. 禁忌: Uncontrolled HTN.,,2-8℃,CRF patients Administered either IV/SC as a single weekly injection. Dose should be started & slowly adjusted to achieve & maintain a target Hb 10-12 g/dL. Reduce dose by 25% if rise in Hb is > 1 g/dL in 2 weeks. Correction of anemia Adult Initially 0.45 mcg/kg as single SC/IV once weekly. Maintain a target Hb 10-12 g/dL. Conversion From epoetin α to NESP Starting weekly dose should be estimated on the basis of the weekly epoetin α dose at the time of substitution. Administer once weekly if a patient was receiving epoetin α 2-3 times weekly. Administer once every 2 weeks if a patient was receiving epoetin α once weekly. Cancer patients receiving chemotherapy 2.25 mcg/kg once weekly. Increase dose to 4.5 mcg/kg if the rise in Hb is > 1 g/dL after 6 weeks. Refer full prescribing information for dosage adjustment.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IADEN,Adenosine,Adenozer inj 6mg/2mL,CAVS,,適應症: Treatment of paroxysmal supraventricular tachycardias. Diagnostic in narrow & broad-complex tachycardias 副作用: >10%: Cardiovascular: Cardiac arrhythmia (transient and new arrhythmia after cardioversion; eg， atrial premature contractions， atrial fibrillation， premature ventricular contractions; 55%)， chest pressure (and discomfort; 7% to 40%) Central nervous system: Headache (2% to 18%)， dizziness (?12%) Dermatologic: Facial flushing (18% to 44%) Gastrointestinal: Gastrointestinal distress (13%) Neuromuscular & skeletal: Neck discomfort (includes throat， jaw; <1% to 15%) Respiratory: Dyspnea (12% to 28%) 1% to 10%: Cardiovascular: Atrioventricular block (infusion 6%; third-degree <1%)， depression of ST segment on ECG (3%)， hypotension (<1% to 2%)， chest pain， palpitations Central nervous system: Nervousness (2%)， paresthesia (?2%)， numbness (1%)， apprehension Dermatologic: Diaphoresis Gastrointestinal: Nausea (3%) Neuromuscular & skeletal: Upper extremity discomfort (?4%) Respiratory: Hyperventilation <1%， postmarketing， and/or case reports: Asystole (prolonged)， atrial fibrillation， blurred vision， bradycardia， bronchospasm， burning sensation， cardiac arrest (fatal and nonfatal)， increased intracranial pressure， injection site reaction， loss of consciousness， metallic taste， myocardial infarction， respiratory arrest， seizure， torsades de pointes， transient hypertension， ventricular arrhythmia， ventricular fibrillation， ventricular tachycardia 禁忌: Hypersensitivity to adenosine or any component of the formulation; second- or third-degree AV block， sick sinus syndrome， or symptomatic bradycardia; known or suspected bronchoconstrictive or bronchospastic lung disease， asthma.,,室溫,Initially 3 mg by rapid IV bolus inj over 2 seconds. If required， a 2nd dose of 6 mg & 3rd dose of 12 mg at 1-2 min intervals may be given.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVP;,,,快速靜脈注射 (3mg > 2秒)。,,
EAVA,Fluticasone,Avamys 27.5mcg/dose， 120dose nasal spray,TENT,Treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older.,Hypersensitivity to any ingredients of Avamys.,Headache，dizziness， epistaxis， pharyngitis， nausea， vomiting， asthma symptoms， nasal ulceration. Neurologic: Headache (8% to 9% ) Respiratory: Epistaxis (4% to 20% ),30℃以下儲存,Allergic rhinitis (fluticasone furoate): Intranasal adult， two sprays (27.5 mcg/spray) per nostril once daily (110 mcg/day). Total daily dosage should not exceed 2 sprays in each nostril (110 mcg/day). Children 2 to 11 years: Initial: 1 spray per nostril once daily (total daily dose: 55 mcg/day),無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IN;,,,,,
ILUC,Ranibizumab,Lucentis inj 3mg/0.3mL,TOPH,,Treatment of neovascular (wet) age-related macular degeneration (AMD). 禁忌: Patients with active or suspected ocular or periocular infections. Patients with active intraocular inflammation. 不良反應:Nasopharyngitis， influenza; anemia; anxiety; headache， stroke; intraocular inflammation， vitritis， vitreous detachment， retinal hemorrhage， visual disturbance， eye pain， vitreous floaters， conjunctival hemorrhage， eye irritation， foreign body sensation in eyes， lacrimation increased， blepharitis， dry eye， ocular hyperemia， eye pruritus; retinal degeneration， retinal disorder， retinal detachment， retinal tear， detachment of retinal pigment epithelium， retinal pigment epithelium tear， visual acuity reduced， vitreous hemorrhage， vitreous disorder， uveitis， iritis， iridacyclitis， cataract， calaract subcapsular， posterior capsule opacification， punctuate keratitis， corneal abrasion， anterior chamber flare， vision blurred， inj site hemorrhage， eye hemorrhage， conjunctivitis， conjunctivitis allergic， eye discharge， photopsia， photophobia， ocular discomfort， eyelid edema， eyelid pain， conjunctival hyperemia; cough; nausea; allergic reactions; arthralgia; intraocular pressure increased.,,,0.5 mg (0.05 mL) by intravitreous inj， initiated with a loading phase of 1 inj/mth for 3 consecutive months followed by a maintenance phase in which patients should be monitored for visual acuity on a monthly basis. Interval between 2 doses should not be < 1 month.,,,,除非治療上需要,,,,,,,,,,
OMYC,Metolazone,Mycros 0.5mg,CAVS,,適應症: Hypertension. 副作用: Dizziness， headache， muscle cramps， fatigue， joint pain， swelling， chest pain. 禁忌: Anuria， hepatic coma or pre-coma; allergy or hypersensitivity to metolazone.,,,1 tab once daily， usually in the morning. may be increased to 2 tab once daily.,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ODUL,Bisacodyl,Dulcolax 5mg,ALIM,,適應症: 為瀉劑(A028503100) Constipation. Preparation of diagnostic procedures， in pre- & post-op treatment & in conditions which require defecation to be facilitated. 副作用: Rarely， abdominal cramps， abdominal pain & diarrhea. 禁忌: Ileus， intestinal obstruction， acute abdominal conditions including appendicitis， acute inflammatory bowel diseases & severe abdominal pain associated with nausea & vomiting. Severe dehydration. Rare hereditary conditions of galactose intolerance eg. galactosemia or fructose intolerance.,,室溫,Oral: Adult: 10-15 mg qn. Child Over 4 yrs: 5 mg， as one dose only.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OEBI,Memantine,Ebixa 10mg,CNEU,Treatment of adult patients with moderate to severe Alzheimer’s disease.,Hypersensitivity to the active substance or to any of the excipients.,Common Gastrointestinal: Constipation (3% to 5% )， Diarrhea (5% )， Vomiting (2% to 3% ) Neurologic: Confusion (6% )， Dizziness (5% to 7% )， Headache (adults， 6% ; pediatrics， 8% ) Serious Neurologic: Cerebrovascular accident， Seizure (up to 0.3% ) Renal: Acute renal failure Respiratory: Pneumonia,室溫,Initial， 5 mg orally once daily; titrate in 5-mg increments at intervals of at least 1 week to 10 mg/day (5 mg twice daily)， 15 mg/day (5 mg and 10 mg in separate doses)， and 20 mg/day (10 mg twice daily); target daily dose is 20 mg/day.,需調整劑量,[仿單]並未知memantine是否會排泄至乳汁，但考慮到本品的親脂性，此情況可能發生。因此服用memantine之婦女不應授乳。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]無memantine用於孕婦之臨床資料。動物實驗指出，暴露於合人體一致或稍高的濃度下，會延減緩胎兒之子宮內生長。使用於人體之潛在性風險未知，除非明確需要，否則memantine不應用於孕婦。,Unknown 沒有資料,[仿單]並未知memantine是否會排泄至乳汁，但考慮到本品的親脂性，此情況可能發生。因此服用memantine之婦女不應授乳。,AC;AC15;PC;PO;WM;,,,,,
OCAD,Amlodipine + Atorvastatin,Caduet 5/20mg,CAVS,Primary prevention of cardiovascular disease (high-risk for cardiovascular disease [CVD]): To reduce the risk of MI， stroke， and revascularization procedures and angina in adults without clinically evident coronary heart disease (CHD).,Active liver disease; unexplained persistent elevations of serum transaminases; pregnancy or women who may become pregnant; breastfeeding. Hypersensitivity to amlodipine， atorvastatin， or to other dihydropyridine calcium channel blockers; severe hypotension (systolic <90 mm Hg).,Amlodipine: Headache， dizziness， fatigue， somnolence， peripheral oedema， flushing， palpitations， nausea， abdominal pain; rarely pruritus， rash， dyspnoea， asthenia and muscle cramps. Atorvastatin: Nasopharyngitis， arthralgia， diarrhoea， pain in extremity， UTI， dyspepsia， nausea， musculoskeletal pain， muscle spasms， myalgia， insomnia， increased transaminases， abnormal liver function test， increased creatinine phosphokinase， thrombocytopenia， malaise， hepatitis， cholestasis， bullous rashes. Potentially Fatal: Rhabdomyolysis with acute renal failure.,15-30℃,Amlodipine: Initial， 5-10 mg orally once daily， titrate after 7-14 days to clinical response; if needed， titration may proceed more rapidly; Atorvastatin: Initial， 10-20 mg orally once daily; titrate within 2-4 weeks according to laboratory values; maintenance， 10-80 mg once daily.,需調整劑量,Amlodipine - Limited Human Data—Probably Compatible Atorvastatin - Contraindicated,無需調整劑量,不可使用,Contraindicated – 1st trimester,Amlodipine - Limited Human Data—Animal Data Suggest Moderate Risk Atorvastatin - Contraindicated 1st Trimester,Contraindicated 哺乳期使用禁忌,Amlodipine - Limited Human Data—Probably Compatible Atorvastatin - Contraindicated,AC;AC15;PC;PO;WM;,,,,,
OENZ,Serratiopeptidase,Enzdase EC 5mg,CNEU,,適應症: Inflammation after operation & traumatic injury， inadequate expectoration of sputum in respiratory disease. 副作用:Skin rash; diarrhoea， anorexia， GI disturbances， epistaxis (rare). 禁忌: Blood coagulation disorders.,,室溫,15-30 mg/day.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OERY,Erythromycin,Erythromycin 250mg,QANB,Susceptible infections ，Prophylaxis against pneumococcal infections; Prevention of streptococcal infections in patients w/ rheumatic fever or heart disease.,Hypersensitivity. Patient receiving astemizole， terfenadine， cisapride， pimozide， ergotamine or dihydroergotamine.,Rash， urticaria; nausea， vomiting， GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis. Potentially Fatal: Hepatotoxicity， cholestatic jaundice; raised serum transaminases; eosinophilia.,25℃以下,Adult 250-500 mg orally Q6H. Children 20-40 mg/pound/day， divided Q6H. (熱病) Pediatric dose: 40-50 mg/kg/day， divided Q6H.,需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,Drugs in Pregnancy and Lactation 無孕婦使用 estolate salt資料。 (2020.12.02更新),Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OBACL,Baclofen,Baclon 10mg,CNEU,,適應症:為肌肉鬆弛劑(B019346100)(B020226100),,RT,5 mg tid for 3 days， 10 mg tid for 3 days， 15 mg tid for 3 days， 20 mg tid for 3 days. Max daily dose: 80 mg.,,,,除非治療上需要,,,,,,,,,,
OBAE,Methylcobalamin,Baesukang 500mcg,CNEU,,適應症:末稍性神經障礙(A029759100) Peripheral neuropathies， megaloblastic anaemia caused by vit B12 deficiency. 副作用:Anorexia， nausea， vomiting and diarrhoea. Parenteral: Rash， headache， hot sensation.,,室溫,Adult: PO Peripheral neuropathies 1，500 mcg/day in 3 divided doses. IV/IM Peripheral neuropathies 500 mcg/day 3 times/wk. Megaloblastic anaemia caused by vit B12 deficiency 500 mcg/day 3 times/wk for about 2 mth. Maintenance: 500 mcg 1-3 mthly.,,,,安全,,,Compatible 哺乳時可使用,,,,,,,
OBAK,Sulfamethoxazole + Trimethoprim,Baktar(Trimerin) 400 / 80,QANB,,,,RT,Antimicrobial: Adult: 2 tab q12h. Child over 2 months under 40 kg: 20 mg/kg syr & 4 mg/kg tab q12h. Antiprotozoal (Pneumocystis carinii pneumonia): Adult & child over 2 months: 18.75-25 mg/kg syr. & 3.75-5 mg/kg tab q6h for 2 wks.,,,,除非治療上需要,,,,,,,,,,
OBEC,Sodium Dibunate,Becantex S.C. 30mg,ERSP,,適應症:止咳作用(A035817100) Cough. 副作用: GI discomfort.,,室溫,1 tab tid-qid.Childn:4~8mg/kg. Adult 90-240 mg/day. Children 7-15 years 60-120 mg/day， 2-7 years 60-90 mg/day， < 2 years 22-38 mg/day. Divided in 3 or 4 doses.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OPRS,Finasteride,Proscar 5mg,SGU,Treatment & control of benign prostatic hyperplasia (BPH) to cause regression of enlarged prostate， improve urine flow & improve the symptoms of BPH.,Women & paediatric patients.,Impotence， decreased libido & volume of ejaculate.,30℃以下避光,5mg daily.,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥具致畸胎性，請注意相關暴露風險，尤其是婦女及小孩。錠劑覆有膜衣，若無破損可防止平常觸摸時直接接觸有效成份。
OPTU,Propylthiouracil,Procil 50mg,META,,適應症: Adjunctive therapy in patients intolerant of methimazole to ameliorate hyperthyroidism symptoms in preparation for surgical treatment or radioactive iodine therapy; treatment of hyperthyroidism in patients intolerant of methimazole and not candidates for surgical/radiotherapy 副作用: Cardiovascular: Periarteritis， vasculitis (ANCA-positive， cutaneous， leukocytoclastic) Central nervous system: Drowsiness， drug fever， fever， headache， neuritis， vertigo Dermatologic: Alopecia， erythema nodosum， exfoliative dermatitis， pruritus， skin pigmentation， skin rash， skin ulcers， urticaria Endocrine & metabolic: Goiter， weight gain Gastrointestinal: Constipation， loss of taste， nausea， sialoadenopathy， splenomegaly， stomach pain， taste perversion， vomiting Hematologic: Agranulocytosis， aplastic anemia， bleeding， granulopenia， hypoprothrombinemia， leukopenia， thrombocytopenia Hepatic: Acute liver failure， cholestatic jaundice， hepatitis Neuromuscular & skeletal: Arthralgia， myalgia， paresthesia Renal: Acute renal failure， glomerulonephritis， nephritis Respiratory: Alveolar hemorrhage， interstitial pneumonitis Miscellaneous: Lymphadenopathy， SLE-like syndrome 禁忌:Hypersensitivity to propylthiouracil or any component of the formulation,,RT,Dosing: Adult --Hyperthyroidism: Oral: Initial: 300 mg/day in 3 divided doses， usual maintenance: 100-150 mg/day --Graves’ disease (off-label use): Oral: Initial: 50-150 mg (depending on severity) 3 times daily to restore euthyroidism; maintenance: 50 mg 2-3 times daily for a total of 12-18 months， then tapered or discontinued if TSH is normal at that time Thyrotoxic crisis/thyroid storm (off-label use): Oral: Typical dosing is 800-1200 mg/day given as 200-300 mg every 4-6 hours; maintenance dosage (100-600 mg/day in divided doses) Dosing: Pediatric --Hyperthyroidism: Oral: Children: Initial: 5-7 mg/kg/day or 150-200 mg/m2/day in divided doses every 8 hours or 6-10 years: 50-150 mg/day >10 years: 150-300 mg/day,,,,盡量避免,,,Compatible 哺乳時可使用,,,,,,,
OREL,Buspirone,Relac 5mg,CNEU,,適應症: Anxiety. 副作用: Dizziness， nausea， headache， nervousness， lightheadedness， excitement; rarely tachycardia， palpitations， chest pain， drowsiness， tinnitus. Gastrointestinal: Nausea (3%) Neurologic: Asthenia (2%)， Confusion (2%)， Dizziness (9%)， Excitement (2%)， Headache (3%)， Numbness (2%) Ophthalmic: Blurred vision (2%) Psychiatric: Feeling angry (2%)， Feeling nervous (4%)， Hostile behavior (2%) 禁忌: Epilepsy， severe hepatic or renal impairment， pregnancy & lactation. Breast feeding.,,室溫,Initially 5 mg bid-tid， increase as necessary every 2-3 days; usual range 15-30 mg daily in divided doses; max: 60 mg daily.,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OREN2,Enalapril,Renitec 20mg,CAVS,,,,,,,,,,,,,,,,,,,
HE5060,Extraneal 2L 7.5% 3.5meq/L雙袋,Extraneal 2L 7.5% 3.5meq/L雙袋,NUTR,,,,,Adults By intraperitoneal administration limited to a single exchange in each 24 hour-period， as part of a CAPD or APD regimen. The volume to be instilled should be given over a period of approximately 10 to 20 minutes at a rate which the patient finds comfortable. For adult patients of normal body size the instilled volume should not exceed 2.0 L. If the instilled volume causes discomfort due to abdominal tension the instilled volume should be reduced to 1.5 L. The recommended dwell time is between 6 and 12 hours in CAPD and 14-16 hours in APD. Drainage of the fluid is by gravity at a rate comfortable for the patient.,無需調整劑量,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
HE5061,Extraneal 2L 7.5% 3.5meq/L單袋,Extraneal 2L 7.5% 3.5meq/L單袋,NUTR,,,,,Adults By intraperitoneal administration limited to a single exchange in each 24 hour-period， as part of a CAPD or APD regimen. The volume to be instilled should be given over a period of approximately 10 to 20 minutes at a rate which the patient finds comfortable. For adult patients of normal body size the instilled volume should not exceed 2.0 L. If the instilled volume causes discomfort due to abdominal tension the instilled volume should be reduced to 1.5 L. The recommended dwell time is between 6 and 12 hours in CAPD and 14-16 hours in APD. Drainage of the fluid is by gravity at a rate comfortable for the patient.,無需調整劑量,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ELID4,Lidocaine,Lidocaine solution 4% 30mL,ZANE,,適應症: Local anesth in bronchoscopy， bronchography， laryngoscopy， oesophagoscopy， endotracheal intubation， & biopsy in the mouth & throat. 副作用: Rarely， allergic reactions， CNS excitation or depression， hypotension， bradycardia. 禁忌: Previously known hypersensitivity to local anaesthetics of amide type.,,室溫,Adult 2-7.5 mL (80-300 mg lidocaine); up to 400 mg may be administered during prolonged (> 5 mins) procedures. With applications mainly to the larynx， trachea & bronchi， the dose should not exceed 5 mL (200 mg lidocaine). When inhaled from a nebulizer， 5-10 mL (200-400 mg lidocaine HCl) may be used.,,,,可能安全,,,,,,,,,,
IMIL,Nitroglycerin,Millisrol inj 5mg/10mL,CAVS,Control of peri-op hypertension; CHF associated with acute MI. Treatment of angina pectoris unresponsive to recommended doses of organic nitrates &/or a β- blocker. Production of controlled hypotension during neurosurgical & orthopedic surgical procedures.,Glaucoma， severe anemia.,Tachycardia， arrhythmia， sudden drop of BP， deterioration of cardiac output， methemoglobinemia， headache， nausea， vomiting. Cardiovascular: Hypotension Dermatologic: Erythroderma， Flushing， Rash Neurologic: Headache (63% )， Lightheadedness (6% ),避光，室溫儲存,Diluted to 0.005-0.05% (50-500 mcg/mL)， IV infusion rate: 0.05-5 mcg/kg/minute according to indications and responses. Maintenance of reduced blood pressure during surgery: 1-5 mcg/kg/minute. Emergent treatment for hypertension during surgery: 0.5-5 mcg/kg/minute. Acute heart failure (including the acute exacerbation period of chronic heart failure): Initially 0.05-0.1 mcg/kg/minute， then increase drip rate to 0.1-0.2 mcg/kg/minute every 5-15 minutes until desired response is obtained.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。【D5NS】可選 。,,稀釋成0.005 ~ 0.05% (50 ~ 500 mcg/mL)，IV infusion rate: 0.05 - 5 mcg/kg/min依適應症不同，應使用玻璃或non-PVC材質。,1. 應使用玻璃或non-PVC材質 2. 點滴速度較低及輸注管較長，皆會增加輸注時藥品被吸附的比率。 3. 使用本劑應監測血壓。
ICIT3,Thiamylal,Citosol inj 300mg,ZANE,Anaesth for diagnostic & surgical procedures; induction of anaesth or to supplement low potency agent,Shock & circulatory insufficiency due to severe hemorrhage， severe cardiac insufficiency， acute & intermittent porphyria， Addison's disease， severe bronchial asthma. Hypersensitivity to barbiturates.,During anesth: respiratory arrest or depression， laryngospasm， hypotensin， arrhythmia， rash. After anesth: nausea， vomiting， headache， dizziness， tearing eyes， tremor， spasm， excitation， face flush， diplopia， numbness， urinary retention， drowsiness.,25℃以下,Use 2.5% solution for IV injection. Induction of general anesthesia: 50-100mg (2.5% solution， 2-4 mL) Anesthesia of short duration: 50-75mg (2.5% solution， 2-3mL) IV over 10-15 seconds initially， monitor the reaction for 30 seconds， if necessary， may readminister 50-75mg to produce anesthesia state. For maintaining the depth of anesthesia when the operation is not completed， give 25-100mg (2.5% solution， 1-4 mL). Maximum: 1000 mg for each time. Anesthesia for psychological electroconvulsive therapy: 300mg over 25-35 seconds (2.5% solution， 12 mL). Combine use with local or inhaled anesthetics: 50-100mg IV drip intermittently (2.5% solution， 2-4mL). Seizure: 50-200mg IV slowly (2.5% solution， 2-8mL).,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;IVP;IVPUSH;,使用廠商所附稀釋液(300mg powder + 12mL稀釋液，使用濃度為2.5%，大於5%會引起靜脈炎),,IV test dose: 3mL，沒問題後以1mL/5 sec速率給藥，Max:1g/次 (300mg 粉劑加入所附溶解液12 mL，稀釋後藥物濃度 2.5 %),IV test dose: 3mL，沒問題後以1mL/5 sec速率給藥，Max:1g/次 (300mg 粉劑加入所附溶解液12 mL，稀釋後藥物濃度 2.5 %),1. 本藥品為麻醉誘導藥品，限由醫師使用。 2. 300mg 粉劑加入所附溶解液12 mL，稀釋後藥物濃度 2.5 % (大於5 % 會引起靜脈炎)。 3. 本藥品之最大量為一次 1 gm靜脈內投與。
OSYNS,Estradiol + Medroxyprogesterone,Synseq (28 tablets/box),HM,Treat menopause symptoms such as hot flashes and vaginal changes， and to prevent osteoporosis (bone loss) in menopausal women.,Unusual vaginal bleeding that has not been checked by a doctor; liver disease; a history of heart attack， stroke， or blood clot; an increased risk of having blood clots due to a heart problem or a hereditary blood disorder; or a history of hormone-related cancer， or cancer of the breast， uterus/cervix， or vagina.,Heart attack symptoms: chest pain or pressure， pain spreading to your jaw or shoulder， nausea， sweating; signs of a stroke: sudden numbness or weakness (especially on one side of the body)， sudden severe headache， slurred speech， problems with vision or balance; signs of a blood clot: sudden vision loss， stabbing chest pain， feeling short of breath， coughing up blood， pain or warmth in one or both legs; swelling or tenderness in your stomach; jaundice (yellowing of the skin or eyes); memory problems， confusion， unusual behavior; unusual vaginal bleeding， pelvic pain; a lump in your breast; or high levels of calcium in your blood: nausea， vomiting， constipation， increased thirst or urination， muscle weakness， bone pain， lack of energy. Common side effects may include: nausea， gas， stomach pain; headache， back pain; depression， weakness; breast pain; itching， thinning scalp hair; or vaginal itching or discharge， changes in your menstrual periods， breakthrough bleeding.,25℃以下陰涼乾燥的地方,1 tablet daily.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於懷孕或準備懷孕婦女。
ONIL2,Betahistine,Nilasen 24mg,CNEU,Vertigo & hearing impairment associated with Meniere's syndrome. Treatment of vestibular vertigo.,Hypersensitivity to any component of the formulation.,Mild gastric complaints. Very rarely， rash， pruritus， urticaria.,25℃以下乾燥場所,Adult: 24mg BID. It is recommended that the drug be taken with meals.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
IKCL2,Potassium Chloride,20mEq KCl in 0.9%NaCl 500mL,NUTR,Hypokalaemia,Hyperkalemia.,Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg， heart block， ventricular arrhythmias， asystole).,30℃以下避光避免冷凍,Adult: Initial loading dose: 40~60 mEq， with ECG monitoring then based on serum potassium levels， Serum K>2.5 mEq/L: concentration < 30 mEq/L， with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia， treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
YHYA,Hyaluronic acid,Hyalofemme Lubricant 30gm,MSGO,主治陰道萎縮症，乾澀.,對產品過敏,,,Use applicator scale 2.5gm gel to apply vagina BIW for vaginal atrophy. No need to stop medication during menstrual cycle.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,VAG;,,,,,
ONIC4,Nicotine,Nicorette 咀嚼錠 4mg (薄荷味),ZADT,,,,,(Uptodate) Gum: If strong or frequent cravings are present after 1 piece of gum， may use a second piece within the hour (do not continuously use one piece after the other). Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. The 12-week dosing schedule (max 24 pieces/day): Weeks 1-6: Chew 1 piece of gum Q1-2H; chew at least 9 pieces/day during the first 6 weeks. Weeks 7-9: Chew 1 piece of gum Q2-4H. Weeks 10-12: Chew 1 piece of gum Q4-8H.,無需調整劑量,,無需調整劑量,,,,,,,,,,,
ONIC2,Nicotine,Nicorette 咀嚼錠 2mg (薄荷味),ZADT,,,,,(Uptodate) Gum: If strong or frequent cravings are present after 1 piece of gum， may use a second piece within the hour (do not continuously use one piece after the other). Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. The 12-week dosing schedule (maximum: 24 pieces/day): Weeks 1-6: Chew 1 piece of gum Q1-2H; chew at least 9 pieces/day during the first 6 weeks. Weeks 7-9: Chew 1 piece of gum Q2-4H. Weeks 10-12: Chew 1 piece of gum Q4-8H.,無需調整劑量,,無需調整劑量,,,,,,,,,,,
ONIQ2,Nicotine,NiQuitin 戒菸口含錠 2mg,ZADT,,,,,,,,,,,,,,,,,,,
ONIQ4,Nicotine,NiQuitin 戒菸口含錠4mg (24's/Bot),ZADT,,,,,,,,,,,,,,,,,,,
OJANM,Sitagliptin + Metformin,JanuMET 50/500mg,META,,適應症: Diabetes mellitus type 2 副作用: Diarrhea， nausea， vomiting， flatulence， abdominal discomfort， indigestion， asthenia & headache. Hypoglycemia. Hypersensitivity reactions. Musculoskeletal: Asthenia (greater than 5% ) Neurologic: Headache (greater than 5% ) Respiratory: Nasopharyngitis (greater than 5% ) 禁忌: Renal disease or dysfunction， abnormal CrCl which may result from CV collapse， acute MI & septicemia. Acute or chronic metabolic acidosis including diabetic ketoacidosis， with or without coma. Temporarily discontinue treatment in patients undergoing radiologic studies. Type 1 diabetes， diabetic ketoacidosis.,,室溫,should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis Diabetes mellitus type 2: dosage should be individualized based on patient's current regimen， effectiveness， and tolerability; MAX sitagliptin 100 mg and metformin 2000 mg per day (given twice a day in divided doses with meals) Diabetes mellitus type 2: (inadequately controlled on metformin monotherapy) initial， sitagliptin 50 mg plus current dose of metformin ORALLY twice daily Diabetes mellitus type 2: (inadequately controlled on metformin 850 mg twice daily) initial， sitagliptin 50 mg/metformin 1000 mg ORALLY twice daily Diabetes mellitus type 2: (inadequately controlled on sitagliptin monotherapy) initial， sitagliptin 50 mg/metformin 500 mg ORALLY twice daily Diabetes mellitus type 2: (switching from sitagliptin co-administered with metformin) initial， same as current doses of sitagliptin and metformin Diabetes mellitus type 2: when administered with a sulfonylurea or with insulin， a lower dose of sulfonylurea or insulin may be required,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IAMIF,Amino Acid + Glucose,Aminofluid 1000mL,NUTR,,適應症:Provision of electrolytes， glucose & amino acids in inadequate oral intake before & after surgery. 禁忌:Hepatic coma or risk of hepatic coma; severe renal disorder or azotemia; CHF; severe acidosis; abnormal electrolyte metabolism， hyperpotassemia， hyperphosphatemia， hypermagnesemia， hypercalcemia; reduced urine output; abnormal amino acid metabolism 副作用: Rash， chest discomfort， palpitation， cerebral， pulmonary & peripheral edema， hyperpotassemia， acidosis， water intoxication， vascular pain， phlebitis， chills， fever， feeling of warmth， headache.,,室溫,Adult Usual dose: 500 mL infused via peripheral vein. Max: 2500 mL/day. Infusion rate: 500 mL/120 min， slowed in elderly & critically ill patients,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,1. 每日最大投與劑量 2500mL 2. 使用前，用雙手壓上室或下室以打通兩室間的連結處，使二室溶液完全混合。 3.成人標準輸注速度為120分鐘內注射500mL。老人及重症患者應減緩輸注速度。
OIND1,Propranolol,Inderal 10mg,CAVS,Adult HTN， Angina， migraine & essential tremor， Arrhythmias， anxiety tachycardia， thyrotoxicosis， Pheochromocytoma.,History of bronchial asthma or bronchospasm， bradycardia， cardiogenic shock， hypotension， metabolic acidosis， after prolonged fasting， severe peripheral arterial circulatory disturbances， 2nd or 3rd degree heart block， sick sinus syndrome， untreated (with an alpha adrenoceptor antagonist) phaeochromocytoma， uncontrolled heart failure， Prinzmetal's angina.,Cold extremities， GI & sleep disturbances， fatigue， lassitude. Deterioration in heart failure， mood changes. Isolated cases of paresthesia. Rarely bradycardia， dizziness， postural hypotension which may be associated with syncope， heart block， alopecia， thrombocytopenia， purpura， psoriasiform skin reactions， exacerbation of psoriasis， visual disturbances， CNS symptoms including hallucinations & psychoses; hypoglycaemia in children. Rashes & dry eyes (discontinue drug). Intermittent claudication， Raynaud's phenomenon， bronchospasm， increased antinuclear antibodies. Dermatologic: Dermatitis， Pruritus， Urticaria Neurologic: Dizziness (4% to 7% ) Other: Fatigue (5% to 7% ),儲存於緊密容器，陰涼15-30℃乾燥避光,Adult: Angina: Initially 10-20 mg TID-QID， may titrate every 3 to 7 days gradually to 320 mg/day. Arrhythmia: 10-30mg TID-QID. Migraine prophylaxis: Initially 20mg QID; then up to 160-240 mg/day in divided doses. Hypertension: 120-240 mg/day， may increase to 640mg based on response and tolerability. Thyrotoxicosis: 10-40mg TID-QID. Pheochromocytoma: 20mg TID for 3 days prior to surgery， with alpha-adrenergic blocker. (Do not start propranolol before the effect of the alpha-blocker is established) Child: Limited data available. Supraventricular tachycardia: 0.5 to 1 mg/kg/day in 3-4 divided doses.,無需調整劑量,1) American Academy of Pediatrics Rating: Maternal medication usually compatible with breastfeeding. 2) World Health Organization Rating: Compatible with breastfeeding. 3) Micromedex Lactation Rating: Infant risk is minimal. 4) Clinical Management a) Propranolol is excreted in human milk and the manufacturer advises caution if propranolol is administered to a nursing woman. However， propranolol is considered compatible with breastfeeding by the American Academy of Pediatrics and the World Health Organization (WHO) [888][889]. Although propranolol appears in breast milk， the concentration is too low to be pharmacologically significant to the infant. WHO recommends monitoring the infant for bradycardia， hypoglycemia， and cyanosis,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,1) American Academy of Pediatrics Rating: Maternal medication usually compatible with breastfeeding. 2) World Health Organization Rating: Compatible with breastfeeding. 3) Micromedex Lactation Rating: Infant risk is minimal. 4) Clinical Management a) Propranolol is excreted in human milk and the manufacturer advises caution if propranolol is administered to a nursing woman. However， propranolol is considered compatible with breastfeeding by the American Academy of Pediatrics and the World Health Organization (WHO) [888][889]. Although propranolol appears in breast milk， the concentration is too low to be pharmacologically significant to the infant. WHO recommends monitoring the infant for bradycardia， hypoglycemia， and cyanosis,AC;AC15;PC;PO;WM;,,,,,
OISO2,Verapamil,Isoptin SR 240mg,CAVS,HTN.,CV shock， complicated acute MI， severe conduction disorders (2nd & 3rd degree AV block， SA block)， sick-sinus syndrome， heart failure， atrial fibrillation/flutter & simultaneous pre-excitation syndrome. Myasthenia gravis.,Bradycardiac arrhythmias eg. sinus bradycardia， asystole， 2nd/3rd degree AV blockade， hypotension， heart failure. Constipation. Rarely nausea， vomiting， dizziness， headache， flushing， fatigue， nervousness， ankle edema， inflammation of extremities， paresthesia， myalgia， rheumatism. Cardiovascular: Edema (up to 3.7% )， Hypotension (1.5% to 3% ) Gastrointestinal: Constipation (7.3% to 13% ) Neurologic: Dizziness (3% to 5.9% )， Headache (2.2% to 12.1% ) Respiratory: Pharyngitis (3% )， Sinusitis (3% ) Other: Influenza-like symptoms (3.7% ),25℃以下避光,HTN: 120-240mg/day with food in the morning.,需調整劑量,,需調整劑量,除非治療上需要,Compatible,The use of verapamil in any stage of pregnancy appears to be low risk. The drug was not teratogenic in two animal species， but did cause death and growth restriction in one species.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性膜衣錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。
OKIN,Sertraline,Kinloft 50mg,CNEU,,適應症: Depression， obsessive-compulsive disorder (OCD)， panic disorder. 副作用: Nausea， diarrhoea， dyspepsia， tremor， dizziness， insomnia， drowsiness， increased sweating， dry mouth， delay in ejaculation (males).,,室溫,50 mg daily. Dosage may be increased in 50 mg increments to max 200 mg over a period of 2-4 wks.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OMEX,Mexiletine,Mexitil 100mg,CAVS,,適應症: Ventricular arrhythmia. 副作用: Indigestion; hiccups; unpleasant taste， nausea， vomiting; joint pains; drowsiness， dizziness; confusion; disarticulated speech; blurred vision; nystagmus; tremor; paresthesia， ataxia; convulsions; hypotension， sinus bradycardia， atrial fibrillation， palpitations. Gastrointestinal: Heartburn， Nausea， Vomiting Neurologic: Coordination problem (approximately 10% )， Dizziness， Lightheadedness， Tremor (13.2% ) Ophthalmic: Blurred vision， Visual disturbance Psychiatric: Feeling nervous (5% to 11.3% ),,室溫,Initially， 400 mg. Maintenance， should be given 2-6 hr after initial dose: 400-800 mg in divided doses; max: 1200 mg daily in divided doses.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OMGO,Magnesium Oxide,MgO 250mg,ALIM,,適應症: Treatment of various GI problems associated with hyperacidity; as a laxative. 副作用: Diarrhea， abdominal cramps， nausea， hypermagnesemia， renal stones,,室溫,Antacids 250-1500 mg with water or milk， qid. Laxative 2-4 g with water or milk hs. Magnesium supplement 500-1200 mg/day.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
OMIDO,Midodrine,Midorine 2.5mg,CAVS,Treatment of symptomatic orthostatic hypotension. Adjunct in the management of urinary incontinence.,Severe organic heart disease， acute renal disease， urinary retention， pheochromocytoma， thyrotoxicosis.,Supine hypertension (discontinue)， paresthesia， pruritus， goosebumps， chills， dysuria.,25℃以下避光,Hypotensive states Adult & children > 12 years: Initially 1 tab BID-TID Urinary incontinence Adult 1-2 tablet BID to TID,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OREN5,Enalapril,Renitec 5mg,CAVS,,I: All grades of essential hypertension， renovascular hypertension， congestive heart failure. CI: History of angioneurotic edema related to previous treatment with an ACE inhibitor.,,,Initial: Patients without diuretic therapy: 5 mg qd. Patients with diuretic therapy: An initial dose of 2.5 mg should be used to determine the magnitude of hypotensive effect. Maintenance: 10-40 mg/day in 1-2 divided doses.(max. 40 mg/day).,,,,除非治療上需要,,,,,,,,,,
ORIF3,Rifampicin,Rifampicin 300mg,QANB,,適應症: TB & meningococcal carriers. 副作用: Skin reactions; GI discomfort; hepatitis; thrombopenia; flu-syndrome; reddish discoloration of urine， sputum & tears; stains soft contact lenses. 禁忌: Jaundice. Hypersensitivity to rifampicin.,,,Adult 8-12 mg/kg body weight daily; children 10-20 mg/kg to a max daily dose of 600 mg.,需調整劑量,,需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,,,,,,
ORIFA,Isoniazid + Pyrazinamide + Rifampicin,(複方) RifaTER 80/250/120mg,QANB,Initial intensive phase treatment (usually 2 months) for short course chemotherapy of TB. When indicated other anti-TB drugs may be added. After the intensive phase treatment， therapy should be continue with Rifinah for a further 4 months min.,Hypersensitivity; presence of jaundice.,Staining of contact lenses， reddish coloration of urine， sputum & lachrymal fluid. Irregular dosing may result in immunological side effects eg 'flu syndrome'.,30℃以下,Take Rifater tablet 1-2 hours before one meal. Weight > or = 50 kg: 5 tablets; weight < 50 kg: 4 tablets. Alternative dosing: weight > or = 50 kg: 5 tablets; weight 40-49 kg: 4 tablets; weight 30-39 kg: 3 tablets.,需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OROCH,Calcitriol,Rocaltrol 0.25mcg(Hemodialysis,META,,I: Hypoparathyroidism & rickets; Renal osteodystroghy; Postmenopausal osteoporosis. ADR: Hypercalcemia syndrome， Ca intoxication. CI: Hypercalcemia. Vit D containing prep.,,,Initially 0.25 mcg/day Adults: 0.5-3 mcg/day or more. Childn: 0.5-2 mcg/day. Hypoparathyroidism: Adults: 0.25-207 mcg/day. Childn: 0.04-0.08 mcg/kg/day. Renal osteodystroghy: Adults: 0.25 mcg qod to 3 mcg/day or more. Childn: 0.014-0.041 mcg/kg/day.,,,,,,,,,,,,,,
EATR5,Atropine,Atropine oph soln 0.5%,TOPH,,Long acting mydriatic and cycloplegic for use in uveitis and for use in treatment of myopia,,,1 gtt hs:for treatment of myopia.(0.1%， 0.25% and 0.5%) 1 gtt qid :for use in uveitis.(1.0%),,,,除非治療上需要,,,,,,,,,,
EATRC,Atropine,Colircusi ATROPINE 0.5%，10mL,TOPH,,適應症: Mydriasis & cycloplegia for ocular refraction examination. Acute inflammatory conditions of the anterior uveal tract. Treatment of iritis， iridocyclitis， corneal ulcer conditions， suppurated ulcers with hypopyon & accommodative spasm. Post-op treatment of extra or intracapsular lens extraction where an anticholinergic effect is required. 副作用: Dryness of the mouth， blurred vision， sensitivity to light， local irritation， hypotension with progressive respiratory depression. 禁忌: Primary glaucoma or narrow-angle glaucoma.,,室溫,Sustained anticholinergic effect Adult 2 drops tid. Children 1 drop tid. Refraction exam 1-2 drops to each eye bid， 1-3 days prior to exam.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EATRD,Atropine,Atropine 1% 點眼液， 5mL,TOPH,,適應症: Topical mydriatic & cycloplegic; uveitis. 副作用: Stinging， increased intraocular pressure， conjunctivitis. May precipitate glaucoma. 禁忌: Closed- & narrow-angle glaucoma.,,室溫,1 gtt hs: for treatment of myopia. (0.1 %， 0.25 % and 0.5%) 1 gtt qid: for use in uveitis. (1.0 %),,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IDT1,Diphtheria + Tetanus,Td Adult (自費成人破傷風白喉混合疫苗) 0.5mL/dose,HIMM,,Active immunization against diphtheria and tetanus.,,2-8℃,IM， for child 6 wks-6 yrs， 0.5 ml/dose. Primary immunization: Child 6 wks-1 yrs: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months 1 yr later. Child over 1 yrs: 2 doses given at 4-8 wks intervals and a reinforcing 3th dose given 6 months-1 yr later. Booster dose: Given at 4-6 yrs.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,
ITTA,Tetanus Toxid Alum Precipitate,Tetanus Toxoid (破傷風類毒素) 0.5mL/dose， 3mL/vial,HIMM,,適應症: Active immunization of tetanus. 副作用: Drowsiness， malaise， hypersensitivity. 禁忌：Hypersensitivity to tetanus toxoid or any component of the formulation,,2-8℃,IM， 0.5 mL/dose. Primary immunization: I.M.: 0.5 mL; repeat 0.5 mL at 4-8 weeks after first dose and at 6-12 months after second dose Routine booster dose: Recommended every 10 years Tetanus prophylaxis in wound management: Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated， the immunization status of the patient， proper use of tetanus toxoid and/or tetanus immune globulin (TIG)， wound cleaning， and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until >10 years after the most recent dose even if they have a wound that is neither clean nor minor.,,Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules.,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules.,,,,,,
RIMEN,Meningococcal vaccine,腦膜炎疫苗(臨床試驗),HIMM,,,,,,,,,,,,,,,,,,,
RIPRE,Pneumococcal vaccine,肺炎鏈球菌疫苗(臨床試驗),HIMM,,,,,,,,,,,,,,,,,,,
RIPED,DTaP5-IPV-HIB,五合一疫苗(臨床試驗),HIMM,,,,,,,,,,,,,,,,,,,
IH1N1,Inactivated H1N1 Influenza Virus,H1N1新型流感(>3歲) 0.5mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
OACE5,Perindopril,Acertil 5mg,CAVS,Hypertension， CHF， stable coronary artery disease.,Pregnancy， lactation; children. Bilateral or unilateral renal artery stenosis.,GI disorders; dizziness， headaches， mood &/or sleep disorders， asthenia; taste disorder; cramps， localized rash; dry cough; angioneurotic edema. Gastrointestinal: Intestinal angioedema Hepatic: Liver failure (rare) Other: Angioedema， More frequent in black patients (0.1%)， Angioedema of lips， More frequent in black patients (0.1%)， Angioedema of throat， More frequent in black patients (0.1%),30℃以下,HTN Initial: 5 mg QD before meal， maximum 16mg/day CHF: Initial: 2.5 mg QD before meal slow titrate up， maximum to 8-16mg QD Stable coronary artery disease: Initial: 5 mg QD before meal for 2 weeks; titrate up to10 mg QD if needed.,無需調整劑量,,需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;PO;,,,,,
OKNO1,Piracetam,KNOWFUL 1200mg,CNEU,,I: Treatment of cerebrovascular insufficiency & age-related cognitive impairment. CI: Hepatic & severe renal impairment.,,室溫,Adult: initially 800 mg tid. Maintenance: 400mg tid. Children: 30-50 mg / kg / day,,,,沒有資料,,,,,,,,,,
LMEG,Megestrol,Megest 40mg/mL，120mL suspension,HM,Cachexia associated with AIDS or cancer.,Known or suspected pregnancy. History of hypersensitivity to megestrol acetate or any component of the formulation.,Common Cardiovascular: Hypertension Dermatologic: Rash， Sweating symptom Endocrine metabolic: Hot sweats， Weight gain Gastrointestinal: Diarrhea， Flatulence， Indigestion， Nausea， Vomiting Neurologic: Insomnia Psychiatric: Mood swings Reproductive: Erectile dysfunction Serious Endocrine metabolic: Adrenal insufficiency Hematologic: Anemia， Deep venous thrombosis， Thrombophlebitis Respiratory: Pulmonary embolism,室溫,Initial， 400-800 mg (10-20 mL) orally daily.,無需調整劑量,,無需調整劑量,不可使用,,[仿單],Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,
YCYS,Hyaluronate,Cystistat 40mg/50mL,MEDD,Temporary replacement of the glycosaminoglycan layer in the bladder.,Hypersensitivity to sodium hyaluronate or avian proteins.,Hypersensitivity,25℃以下,[MIMS 2021/08/05] Instill the entire vol into the bladder after any residual urine has been removed. Alleviation of cystitis Instill into the bladder each week for 4-12 treatments & then mthly until symptoms resolve.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IRRI;,,,,,
ISYNA,Palivizumab,Synagis inj 50mg,HIMM,,適應症: Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease， including infants with bronchopulmonary dysplasia， a history of premature birth (<=35 weeks gestational age)， & children with hemodynamically significant congenital heart disease. 副作用: Upper respiratory infections， otitis media， rhinitis， rash， pain， hernia， increased SGOT， pharyngitis. 禁忌: Hypersensitivity to palivizumab or humanized monoclonal antibodies.,,2-8 C,Recommended Dose: 15 mg/kg IM (preferably in anterolateral thigh)， given once a month during anticipated periods of RSV risk in the community,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,IM;,,,,,1.調配前，先移除瓶蓋拉環部份，以70%酒精或等效品清潔橡膠瓶塞 2.緩慢加入0.6毫升無菌注射用水於50毫克之小瓶，輕輕旋轉30秒，避免產生泡沫。切勿搖晃瓶體 3.調配後的palivizumab應於室溫下靜置至少20分鐘，直至溶液澄清。 4.調配後的palivizumab未含有防腐劑，應於調配後六小時內使用。 5.此小瓶僅供單次使用。未使用部份請丟棄。
OMET4,Methylprednisolone,Metisone 4mg,HM,,適應症: RA， acute & subacute bursitis， exfoliative dermatitis， allergic rhinitis， bronchial asthma， contact dermatitis & allergic conjunctivitis. 副作用:Fluid & electrolyte disturbances; muscle weakness， aseptic osteonecrosis， osteoporosis; peptic ulcer with perforation， hemorrhage， abdominal distention， impaired wound healing; increased intraocular pressure; Cushingoid state， growth suppression， menstrual irregularities， posterior subcapsular cataracts. 禁忌: Systemic fungal infection; immunization. Lactation,,室溫,Should be taken with food 4-48 mg once-qid.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
ODIA6,Gliclazide,DIAMICRON MR 60mg,META,,適應症: 第二型糖尿病(B023503100) 副作用: Hypoglycaemia， nausea， dyspepsia， diarrhoea， constipation. 禁忌: Type 1 diabetes， diabetic keto-acidosis or diabetic pre-coma， severe renal or hepatic insufficiency， co-administration with miconazole， pregnancy， lactation. Avoid coadministration with phenylbutazone or danazol.,,室溫,1-4 tab taken once daily at breakfast. Max : 120 mg daily.,,,,除非治療上需要,,,,,,,,,,
ECAR,Carbenoxolone,Carboxe orabase 100mg/5gm,TENT,,適應症: Aphthous， herpes inflammation & traumatic mucosal lesions of the lips & oral cavity.,,室溫,Apply about 1 mm thick to affected areas after meals & before bedtime.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EMYC,Triamcinolone + Neomycin + Gramicidin + Nystatin,Mycomb otic drops 5mL,TENT,Inflammation of the outer and middle ear.,Acute herpes simplex， vaccinia， varicella; perforated eardrum.,Long term use: acne or oily skin; increased hair growth， especially on the face.,25℃以下,Instill2-3 drops into affected ear(s) TID to QID,無需調整劑量,Triamcinolone - No Human Data—Probably Compatible Neomycin - No Human Data—Probably Compatible Gramicidin - Unknown Nystatin - Compatible,無需調整劑量,沒有資料,Uknown 沒有資料,Triamcinolone - Compatible (Inhaled) Neomycin - Human Data Suggest Low Risk Gramicidin - Unknown Nystatin - Compatible,Unknown 沒有資料,Triamcinolone - No Human Data—Probably Compatible Neomycin - No Human Data—Probably Compatible Gramicidin - Unknown Nystatin - Compatible,AD;AS;AU;,,,,,
IDOBU,Dobutamine,DOBUha inj 250mg/20mL,CAVS,,適應症: Short-term treatment of cardiac decompensation due to depressed contractility resulting from heart disease or cardiac surgery. 副作用: Tachycardia， nausea， non-specific chest pain & palpitation. Cardiovascular: Angina (1% to 3% )， Hypertension (7.5% )， Tachyarrhythmia (approximately 10% ) Neurologic: Headache (1% to 3% ) 禁忌: Obstructive cardiomyopathy.,,室溫,Usually 2.5-10 mcg/kg/min as IV infusion.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1.勿加入鹼性藥品
LLAC3,Lactulose,LACOLY soln 300mL(667mg/mL),ALIM,,適應症: Chronic portal systemic encephalopathy， hepatic pre coma， hepatic coma 副作用: Flatulence， nausea， vomiting， abdominal pain & diarrhea occasionally with electrolyte imbalance (high doses only). 禁忌: Galactosemia， bowel obstruction.,,室溫,Chronic constipation:  Starting dose(for 3 days) aintenance -------------------- ---------------------------------- --------------------- Severe cases 0-45 ml 15-25 ml Moderate cases 5-30 ml 10-15 ml Mild cases 5ml 10 ml 6-14yr 15 ml 10 ml 1-6yr 5-10 ml 5-10 ml Infant 1-12mth 5 ml 5 ml All doses to be taken daily preferably as single doses. Precoma & hepatic coma: Starting doses: approx 30-50 ml tid. In acute cases a retention enema is given in a proportion of 300ml Duphalac to 700 ml water.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IGLUC,Glucagon,Glucagen inj 1mg/1mL,META,Treatment of severe hypoglycemia. Use as a diagnostic aid. Assessing of beta cell function.,Hypersensitivity to glucagon or any components of the product. Insulinoma. Pheochromocytoma. Glucagonoma when used as a diagnostic aid.,Common Gastrointestinal: Nausea， Vomiting Serious Dermatologic: Necrolytic migratory erythema Immunologic: Anaphylaxis,2-8℃避光,IM， SC， IVP， Hypoglycemia(severe) 1 mg IM， SC， child < 25 kg or < 8 years 0.5 mg IM， SC. Diagnostic aid: Radiologic examinations of gastrointestinal tract 0.2-0.5 mg IVP 1 min before procedure， 1-2 mg IM 5-15 min before procedure. βcell secretion function test 1 mg IVP.,無需調整劑量,[仿單]昇糖素在血流中清除的速率非常的快速，主要由肝臟liver (半衰期t？= 3-6分鐘)； 因此對於那些因嚴重低血糖而給予治療的哺乳婦女來說，分泌到乳汁的量是非常少的。 由於昇糖素會在消化道中被分解，而且無法以其原形形式被吸收，因此不會對兒童有任何代謝上的影響。 GlucaGenR可在哺乳時使用。,無需調整劑量,可能安全,Compatible – maternal benefit >> embryo-fetal risk,[仿單]昇糖素不會穿透人類胎盤屏障。 有報告指出患有糖尿病的孕婦使用昇糖素，對於懷孕過程以及新生兒未知有任何有害的影響。 GlucaGenR可在懷孕時使用。,Compatible 哺乳時可使用,[仿單]昇糖素在血流中清除的速率非常的快速，主要由肝臟liver (半衰期t？= 3-6分鐘)； 因此對於那些因嚴重低血糖而給予治療的哺乳婦女來說，分泌到乳汁的量是非常少的。 由於昇糖素會在消化道中被分解，而且無法以其原形形式被吸收，因此不會對兒童有任何代謝上的影響。 GlucaGenR可在哺乳時使用。,IM;IVP;IVPUSH;SC;,,,使用在Hypoglycemia: 1 mg (1 unit)，Children BW < 25 Kg: 0.5 mg (0.5 unit),,1. 配製好的溶液應立即使用，若有黏著狀或不容物質出現，應丟棄不用。 2. 嚴重低血糖症病人若在給予Glucagon十分鐘內沒有反應，須以靜脈注射方式給予葡萄糖。 3. Glucagon於診斷用途由IV給予，常見噁心、嘔吐的副作用。 4. 若大量投予造成藥物過量，可能降低血鉀，必須加以監測，必要時給予校正治療。
OBLO,Candesartan,Blopress 8mg,CAVS,Heart failure， (NYHA class II to IV， ejection fraction 40% or less) to reduce cardiovascular mortality and hospitalizations. Hypertension.,Concomitant use with aliskiren in diabetic patients. Hypersensitivity to candesartan. Severe hepatic impairment &/or cholestasis. Lactating women and women in the second and third trimesters of pregnancy. Children under one year old.,Common Cardiovascular: Hypotension (18.8% ) Musculoskeletal: Backache (3% .) Neurologic: Dizziness (less than 5% ) Respiratory: Pharyngitis (2% )， Rhinitis (2% )， Upper respiratory infection (6% ),25℃以下,HTN:initial: 8mg QD， may titrate up to 16mg， maximum 32mg.,需調整劑量,[仿單]由於缺乏哺乳期間使用Blopress的資訊，故哺乳時不建議使用 ， 建議改用其他安全性較確立的藥物，尤其是為新生兒或早產兒哺乳期間。,需調整劑量,沒有資料,Human data suggest risk in 2nd and 3 rd trimesters,[仿單]流行病學資料尚未能證實懷孕初期暴露於ACEI可能增加畸胎的風險；但無法排除有輕微提升的可能。 雖未有AIIRAs在流行病學的資料，但因屬同類產品，仍有相同的風險。 除非繼續使用AIIRA藥品是必要的，否則當病人有計畫要懷孕，就應改成其他對於使用在懷孕病人身上有安全療效的降血壓藥品。 一旦診斷懷孕，則應立即停止使用AIIRA藥品並開始使用其他合適的治療方式。 已知若懷孕第二及第三期間暴露在AIIRA治療將導致畸胎。(腎功能降低，羊水過少，顱骨發育遲致)及胎兒毒血症(腎衰竭，低血壓，高血鉀) 當發生AIIRA使用於懷孕第二期，建議使用超音波確認腎功能及顱部。嚴密觀察母親使用了AIIRA的嬰兒期低血壓情形。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]由於缺乏哺乳期間使用Blopress的資訊，故哺乳時不建議使用 ， 建議改用其他安全性較確立的藥物，尤其是為新生兒或早產兒哺乳期間。,AC;AC15;PC;PO;WM;,,,,,
OCAL,Calcium Carbonate + Vit D3,Caltrate chewable 28's,NUTR,,適應症:補充鈣質(A031828100) ADR: Constipation. CI: Hypercalcaemia & hypercalciuria， severe renal failure.,,室溫,Adult: 2 Tab bid ~ tid Children: 1 Tab bid ~ tid,,,,安全,,,Compatible 哺乳時可使用,,,,,,,
OCAR4,Metergoline,Carry 4mg,HM,,適應症: Hyperprolactinaemia高泌乳素症(A044600100) 副作用: Nausea， vomiting， insomnia， drowsiness， anxiety， dizziness， weakness. 禁忌: Lactation (discontinue from the 1st day of treatment).,,室溫,1 tab once-tid， increased gradually at meals.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EBBL,Benzyl benzoate,B.B. lotion 25%，100mL,TDER,,適應症: Treatment of scabies， head lice. 副作用: Skin irritation， burning sensation.,,室溫,Scabies Apply over the whole body; repeat without bathing on the following day & wash off 24 hr later. A repeat application may be required in some cases. Head lice Apply 10 mL to the affected area & repeat as often as necessary.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EBEC,Beclomethason,Beclomet nasal aqua 100mcg/dose,TENT,,Seasonal & perennial obstinate allergic rhinitis. Vasomotoric rhinitis require corticosteroids.,,,Adult: 1 spray qid into both nostrils. Max: 10 sprays. Child: 1 spray bid-qid daily into both nostrils. Max: 5 sprays.,,,,除非治療上需要,,,,,,,,,,
EBIAQ,Povidone-iodine,Povidone-Iodine solution 200mL,TDER,Post-op infections， bacterial or fungal skin infections. surgical scrub Antiseptic cleanser for pre-op scrubbing & washing by surgeons & theatre staff， & pre-op preparation of patients' skin.,Hypersensitivity to any component of the formulation.,Local irritation (discontinue).,25℃以下儲存,Aqueous soln As directed. Surgical disinfection Use 5 mL undiluted & allow to work for 5 mins， rinse off & repeat. Pre-op antiseptic skin cleanser Use undiluted.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,Four studies have shown the potential hazard resulting from the use of povidone–iodine during pregnancy. In each case， significant absorption of iodine occurred in the mother and fetus following topical， vaginal， or perineal use before delivery. Transient hypothyroidism was demonstrated in some newborns.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
EBOR,Boric Acid,Boric acid 2% 20mL,TDER,,適應症: Relief of chapped skin， chafed skin， diaper rash， dry skin， abrasion， sunburn， windburn， insect bites and other skin irritations.,,室溫,Apply directly or on a dressing as often as needed.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EBRIT,Terbutaline,Bricanyl Turbuhaler 0.5mg/dose,ERSP,,I: Relief of bronchospasm in bronchial asthma， chronic brochitis， emphysema & other bronchopulmonary conditions when bronchoconstriction is a complicating factor. AR: Tremor， tonic cramp & palpitations. Tachycardia， arrhythmia. Urticaria & exanthema may occur. CI: Thyrotoxicosis.,,,Oral: Adult: 5 mg tid， Child 12-15 yrs: 2.5 mg tid. Nebulizing soln: Adult & child over 20 kg: 5 mg， Child under 20 kg: 2.5 mg， qid. Turbuhaler: Adult & childn > 12yr: 1 inhalation 6 hrly， may be increased to 3 inhalations. Max: 12 inhalation/24 hr. Childn 5-12 yr 1 inhalation 6 hrly， may be increased to 2 inhalation to 2 inhalations. Max: 8 inhalation/24 hr.,,,,可能安全,,,,,,,,,,
EBSM,Boric Acid + NaHCO3 + Menthol,Boric acid+NaHCO3+Menthol,TDER,Antiseptics,Hypersensitivity to any component of the formulation.,Local irritation,室溫,1pk boric acid + 1pk NaHCO3 + few Methol to some warm water for topical infection.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
IHUMR,Insulin Regular Human,Humulin R inj100IU/mL 10mL,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,2-8,According to individual requirements.,,,,安全,,,,,,,,,,
IINT,Interferon alfa,Intron A inj 3MIU,QANB,,Multiple myeloma， hairy cell leukaemia， chronic myelogenous leukaemia， AIDS-related kaposi's sarcoma， condyloma acuminatum， chronic hepatitis B， chronic non-A， non-B hepatitis (hepatitis C) & non-Hodgkin's lymphoma.,,,Hairly cell leukemia: 3 million iu SC or IM daily for 16-24 wk. Maintenance: 3 million IU 3 times wkly. AIDS-related Kaposi's sarcoma: 36 million IU SC or IM daily for 4-10 wk. Maintenance: 36 million iu 3 times wkly.,,,,除非治療上需要,,,,,,,,,,
IISOK,Isosorbide Dinitrate,Isoket inj 10mg/10mL,CAVS,,I: Unresponsive left ventricular failure secondary to acute MI， unresponsive left ventricular failure of various etiology & severe or unstable angina pectoris. CI: Cardiogenic shock; circulatory collapse; severe hypotension; marked anemia; head trauma; cerebral hemorrhage; severe hypovolemia.,,,2-10 mg/hr by IV infusion after dilution.,,,,除非治療上需要,,,,,,,,,,
IJEV,Japanese Encephalitis Vaccine,JEV (日本腦炎，政府提供) 0.5-1mL/dose,HIMM,Active immunisation against encephalitis due to Japanese encephalitis virus,Avoid use in the following unless absolutely necessary: patients with fever or severe malnutrition; CV， renal or hepatic diseases in acute， exacerbating or active phases; history of abnormal adverse reactions caused by this vaccine; history of spasmodic symptoms within 1 yr; pregnancy.,Local reactions eg redness， swelling， tenderness or systemic reactions eg fever， chill， headache， lassitude. Rarely， severe adverse reactions manifesting as generalized urticaria or angioedema may occur.,2-8℃避光避免冷凍,IM， 2 months - < 3 years 0.25 mL， > 3 years 0.5 mL， 2 doses primary immunization at intervals of 28 days. A booster dose: Age > or = 18 years: after primary immunization 6 months， Age < 18 years: after primary immunization 1 year.,無需調整劑量,,無需調整劑量,不可使用,,,,,,,,,,
IBLE1,Bleomycin,BLEOCIN inj 15mg,RACA,Carcinoma of the skin， head & neck， lung， oesophagus， uterine cervix & thyroid， malignant lymphomas， glioma.,Severe pulmonary， renal or cardiac dysfunction.,Severe interstitial pneumonia & pulmonary fibrosis， hypersensitivity， fever， haemorrhage， scleroderma-like changes in skin， anorexia， diarrhea， GI upsets; renal， urinary & neuropsychic disturbances， hypertrophy of venous wall， narrowing of venous lumen & induration around administration site. Phlebalgia with IV administration. Dermatologic: Alopecia (1-10%)， Skin reaction - finding， Erythema， rash， striae， vesiculation， hyperpigmentation， skin tenderness (50%) Endocrine metabolic: Shivering Gastrointestinal: Nausea and vomiting， Stomatitis Psychiatric: Confusion Other: Fever,2-8℃,15-30 mg IV， IM or SC twice weekly; 5-15 mg IA twice weekly.May adjust dosing frequency to once daily to once weekly.,無需調整劑量,,需調整劑量,盡量避免,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,,,,1. 勿使用D5W或其他含有dextrose的稀釋液。 2. IM、SQ給藥：15 mg溶於1 mL到 5 mL的NS或注射用水。 3. IV 給藥：15 mg溶於 5 mL的NS，緩慢靜脈注射超過10分鐘。 4. Intrapleural給藥：溶於50 到100 mL 的NS ，經由thoracostomy tube投藥。 5. 監測項目：Pulmonary function tests (total lung volume， forced vital capacity， carbon monoxide diffusion)， renal function， liver function， chest x-ray， temperature initially; check body weight at regular intervals
OEST6,Conjugated Estrogen,Estromon 0.625mg,HM,Primary ovarian failure， primary amenorrhea， management of menopause syndrome.,Malignant neoplastic disease of the breast or genital tract (unless indicated for the treatment of the neoplasm); previous thromboembolic disorders， CV disease， thrombophlebitis; undiagnosed vag bleeding; liver impairment; pregnancy.,Fluid & salt retention， edema; weight gain; breast tenderness， gynecomastia; altered liver function， jaundice; depression; GI upsets， dizziness， chloasma， rash， urticaria， erythema multiforme; endometrial hyperplasia.,緊密保存於25℃以下乾燥處,Continue administetion or cyclic administration (3 weeks on & 1 week off) should be used.Atrophic vaginitis and atrophic urethritis caused by lack of estrogen: 0.3-1.25mg daily. Osteoporosis: 0.625mg daily. Protection of the cardiovascular system: 0.625-1.25mg daily. Low of feminine estrogen: 0.3-1.25mg daily. Promote the development of secondary sexual characteristics: 0.15mg.,無需調整劑量,Estrogens can be detected in breast milk. Estrogen has been shown to decrease the quantity and quality of human milk. The manufacturer recommends that caution be used if administered to a breastfeeding woman. (UpToDate)2021/0125,無需調整劑量,不可使用,Uknown 沒有資料,Use is contraindicated during pregnancy.(UpToDate)2021/0125,Unknown 沒有資料,Estrogens can be detected in breast milk. Estrogen has been shown to decrease the quantity and quality of human milk. The manufacturer recommends that caution be used if administered to a breastfeeding woman. (UpToDate)2021/0125,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於懷孕或準備懷孕婦女。
OSE200,Quetiapine,SEROQUEL XR 200mg,CNEU,Schizophrenia， manic episodes associated with bipolar disorder.,,Dry mouth， somnolence， dizziness ， & dyspepsia. Heart rate increased， hypotension， weight increased， tremor， akathisia， increased appetite， blurred vision， postural dizziness， pyrexia， dysarthria， dystonia， drooling， syncope， tardive dyskinesia， dysphagia， leukopenia & rash. Anaphylactic reaction， peripheral edema， rhinitis， eosinophilia， hypersensitivity， elevations in γ- GT levels & restless legs syndrome have also been reported. Cardiovascular: Hypertension (1% to 2% (adults); 15.2 to 40.6% (children and adolescents) )， Orthostatic hypotension (4% to 7% (adults); less than 1% (children and adolescents) )， Tachycardia (0.5% to 7% ) Endocrine metabolic: Serum cholesterol raised (7% to 18% )， Serum triglycerides raised (8% to 22% )， Weight gain (3% to 23% ) Gastrointestinal: Abdominal pain (4% to 7% )， Constipation (2% to 11% )， Increased appetite (2% to 12% )， Indigestion (2% to 7% )， Vomiting (1% to 11% )， Xerostomia (4.1% to 44% ) Hepatic: Increased liver enzymes (1% to 6% ) Musculoskeletal: Backache (3% to 5% ) Neurologic: Asthenia (2% to 10% )， Dizziness (9% to 18% )， Extrapyramidal disease (3% to 12.9% )， Headache (7.4% to 21% )， Insomnia (8% to 12% )， Lethargy (1% to 5% )， Somnolence (16% to 57% )， Tremor (2% to 8% ) Psychiatric: Agitation (6% to 20% ) Respiratory: Nasal congestion (3% to 5% )， Pharyngitis (4% to 6% ) Other: Fatigue (3% to 14% )， Pain (1% to 7% ),室溫,Seroquel XR Schizophrenia Initially 300 mg once daily preferably in the evening. Patients should be titrated within a dose range of 400-800 mg daily. Dose increases can be made at intervals as short as 1 day & in increments of up to 300 mg daily.,需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OLOX,Ambroxol,Loxol SR 75mg,ERSP,Expectorant.,Hypersensitivity to any component of the formulation.,Mild GI effects & Allergic reactions.,室溫,Adult 1 TAB once daily.,無需調整劑量,[仿單] 藥物會進入母乳內，而醫療劑量的使用至目前為止，尚未發現對嬰兒有造成傷害的情形出現。,無需調整劑量,可能安全,Uknown 沒有資料,[仿單] 動物試驗及廣泛的臨床實驗所得，任娠期間服食Ambroxol hydrochloride，在第28週後證實並無不良副作用。 然而，在懷孕期間服食任何藥物都應小心，特別在懷孕初期三個月內，應給予小心觀察。,Unknown 沒有資料,[仿單] 藥物會進入母乳內，而醫療劑量的使用至目前為止，尚未發現對嬰兒有造成傷害的情形出現。,PC;PO;,,,,,[磨粉/管灌註記]本藥為長效錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。院內另有同成份Musco solution可使用。
IMID1,Midazolam,Midazo inj 5mg/1mL,CNEU,,適應症: Sedation with amnesia; sedation in intensive care; premed， induction of anaesth. 副作用: Rarely cardio-resp adverse events， nausea， vomiting， headache， hiccoughs， laryngospasm， dyspnoea， hallucination， oversedation drowsiness， ataxia， paradoxical reactions， amnesic episodes. 禁忌: Premature infants. Myasthenia gravis.,,室溫,Premed before an operation 20-30 mins before induction of anaesth， alone or in combination with anticholinergics. Adult 0.07-0.1 mg/kg IM. Children 0.15-0.2 mg/kg body weight by IM. Sedation in interventions under local anaesth 2.5-5 mg IV 5-10 mins before start of operation. Elderly > 60 years 1-3.5 mg IV slowly. Induction agent in inhalation anesth or sleep-inducing component in combined anesth 10-15 mg IV in combination with analgesics. Maintenance of anesth Further small doses should be injected IV or by continuous infusion. Sedation in ICU Dosage should be individualised & titrated to the desired state of sedation. Loading dose: 0.03-0.3 mg/kg. Maintenance dose: 0.03-0.2 mg/kg/hr.,,,,盡量避免,,,,,,,,,,
ETRI3,Fluocinolone + Hydroquinone + Tretinoin,Tri-Luma cream 3gm,TDER,,適應症: Short-term treatment of moderate to severe melasma of the face， in the presence of measures for sun avoidance， including the use of sunscreens. 副作用: Erythema， desquamation， burning， dryness & pruritus at the site of application. 禁忌: Individuals with a history of hypersensitivity， allergy， or intolerance to Tri-Luma or any of its components.,,室溫,Apply a thin film of cream to hyperpigmented areas of melasma including about 0.5 inch of normal appearing skin surrounding each lesion. Rub lightly & uniformly into the skin. Apply once daily at night 30 minutes before bedtime.,,,,沒有資料,,,,,,,,,,
OEXJ,Deferasirox,Exjade 125mg,HEMT,,適應症:Treatment of chronic ion overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (?2 years). 副作用:Headache， diarrhoea， constipation， vomiting， nausea， abdominal pain， abdominal distension， dyspepsia， elevated transaminases， rash， pruritus， proteinuria， increased serum creatinine.,,,initial daily dose: 20 mg/kg once daily. Dose adjustments should be made in steps 5-10 mg/kg. Max daily dose: 30 mg/kg. Should be taken on an empty stomach (Take on an empty stomach at least 30 mins before meals， preferably at the same time daily. Disperse the tab by stirring in 100-200 mL of water or orange juice until a fine susp is obtained.,,,,可能安全,,,,,,,,,,
EVIM,Clobetasol,Vimax foaming solution 25mL,TDER,Psoriasis， recalcitrant eczema.,Bacterial infections (eg. impetigo， furuncle， boils， cellulitis)， candidiasis， dermatophytes infection， herpes simplex or herpes zoster infections. Avoid application near the eyes. Rosacea， perioral dermatitis & acne.,Local skin reactions: burning sensation， itch， rash， folliculitis， hypertrichosis， hypopigmentation， perioral dermatitis， allergic dermatitis， wrinkles， miliaria. HPA axis suppression， Cushing syndrome， hyperglycemia， DM. Cataract & glaucoma， skin atrophy， telangiectasia & purpura on prolonged use.,25℃以下陰涼乾燥處,Plaque psoriasis Apply sparingly to the affected area once or BID. Treatment should be stopped if the condition improves after treatment for more than four weeks.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
ODON5,Prednisolone,DONIson 5mg,HM,,適應症: RA， lupus erythematosus， periarthritis nodosum， allergic & inflammatory skin disorders. 副作用: Fluid & salt retention， edema， hypertension; amenorrhea， hyperhidrosis， mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; local atrophy; increased appetite; growth retardation. 禁忌: Peptic ulcer， osteoporosis， psychoses or severe neuropsychosis; active or doubtfully quiescent TB; acute infection; live vaccines.,,室溫,Allergic and inflammatory disorders 5-60 mg/day， in 2-4 divided doses. Rheumatoid arthritis Initial: 5-7.5 mg/day， adjust dose if needed. Multiple sclerosis 200 mg/day for 1 wk， then 80 mg every other day for 1 mth.,,,,盡量避免,,,Compatible 哺乳時可使用,,,,,,,
OVIRO,Tenofovir,Viread 300mg (勿用),QANB,,適應症： Management of HIV infections in combination with at least two other antiretroviral agents; treatment of chronic hepatitis B virus (HBV) in patients with compensated or decompensated liver disease 副作用：Diarrhoea， nausea， vomiting， abdominal pain， flatulence， dyspepsia， anorexia， skin rash， peripheral neuropathy， headache， dizziness， insomnia， depression， dyspnoea， asthenia， sweating， myalgia， myopathy， body fat redistribution， osteomalacia. Hypophosphataemia， raised amylase and liver enzymes， hepatitis， hypertriglyceridaemia， hyperglycaemia， neutropenia， nephritis， nephrogenic diabetes insipidus， renal impairment， proximal tubulopathy， Fanconi syndrome， immune reconstitution syndrome. Potentially Fatal: Lactic acidosis with severe hepatomegaly with steatosis; severe acute exacerbations of hepatitis B. Acute renal failure. 禁忌：Lactation. Not for treatment for chronic hepatitis B virus infection. Do not co-administer with fixed dose combinations containing tenofovir.,,室溫,Adult: PO HIV infection; Chronic hepatitis B over18 yr: 300 mg once daily. Click to view tenofovir disoproxil fumarate Dosage by Indications,,,,可能安全,,,,,,,,,,
IKCL3,Potassium Chloride,10mEq KCl in 5% D/W 500mL,NUTR,,適應症: Hypokalaemia. 副作用: Hyperkalemia， pain or phlebitis at injection site. 禁忌: Hyperkalemia.,,2-8度C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr， with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
ROVIR,Tenofovir,Viread 300mg(臨床試驗),QANB,,適應症： Management of HIV infections in combination with at least two other antiretroviral agents; treatment of chronic hepatitis B virus (HBV) in patients with compensated or decompensated liver disease 副作用：Diarrhoea， nausea， vomiting， abdominal pain， flatulence， dyspepsia， anorexia， skin rash， peripheral neuropathy， headache， dizziness， insomnia， depression， dyspnoea， asthenia， sweating， myalgia， myopathy， body fat redistribution， osteomalacia. Hypophosphataemia， raised amylase and liver enzymes， hepatitis， hypertriglyceridaemia， hyperglycaemia， neutropenia， nephritis， nephrogenic diabetes insipidus， renal impairment， proximal tubulopathy， Fanconi syndrome， immune reconstitution syndrome. Potentially Fatal: Lactic acidosis with severe hepatomegaly with steatosis; severe acute exacerbations of hepatitis B. Acute renal failure. 禁忌：Lactation. Not for treatment for chronic hepatitis B virus infection. Do not co-administer with fixed dose combinations containing tenofovir.,,30℃以下,Adults and children > 12 years (> 35 kg): 300 mg orally once daily. (熱病) Pediatric: age 2 to < 12 years: 8 mg/kg (maximum: 300 mg) Q24H. Weight based tablet recommendations: 17 to <22 kg: 150 mg Q24H; 22 to <28 kg: 200 mg Q24H; 28 to <35 kg: 250 mg Q24H; > or = 35 kg: 300 mg Q24H.,無需調整劑量,,需調整劑量,可能安全,Compatible – maternal benefit >> embryo-fetal risk,,Contraindicated 哺乳期使用禁忌,,,,,,,
OZYPZ,Olanzapine,ZYPREXA Zydis 5mg,CNEU,,適應症：Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment， olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. 副作用: Somnolence， weight gain， dizziness， akathisia， parkinsonism， dyskinesia， increased appetite， elevated glucose & triglyceride levels， asthenia， edema， orthostatic hypotension， dry mouth， constipation， eosinophilia， elevated prolactin levels (but clinical manifestations rare). May affect ability to operate machinery or drive motor vehicles. Elderly patients with dementia: a higher incidence of death and cerebrovascular adverse events; abnormal gait and falls; Pneumonia and urinary incontinence. Cardiovascular: Orthostatic hypotension (1% to 5% )， Peripheral edema (3% to 6% ) Endocrine metabolic: Hypercholesterolemia (up to 24% )， Hyperglycemia (0.1% to 17.4% )， Increased appetite (3% to 24% )， Increased prolactin level (31.2% to 61.1% )， Serum triglycerides raised (up to 40% )， Weight gain (up to 57% ) Gastrointestinal: Constipation (4% to 11% )， Xerostomia (3% to 32% ) Neurologic: Akathisia (3% to 27% )， Asthenia (2% to 20% )， Dizziness (1.6% to 18% )， Somnolence (6% to 52% )， Tremor (1% to 23% ) Psychiatric: Personality disorder (8% ) Other: Accidental injury (4% to 12% )， Fever (up to 4% ) 禁忌: Patients with known risk of narrow-angle glaucoma. Neuroleptic malignant syndrome.,,室溫,Adult Schizophrenia Starting dose: 10 mg/day. Manic episodes Starting dose: 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy. Preventing recurrence in patients whose manic episodes have responded previously to olanzapine Starting dose: 10 mg daily. Dose range for all indications: 5-20 mg daily. A lower starting dose (5 mg/day) should be considered for elderly patients (> 65 years) & in renal or hepatic impairment.,,,,除非治療上需要,,,,,,,,,,
IMAB1,Rituximab,Mabthera inj 100mg/10mL,RACA,Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment， after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.,Hypersensitivity to rituximab or murine proteins. Pregnancy， lactation. Active hepatits B disease,Fever， chills or rigor， flushing， angioedema， nausea， urticaria/rash， fatigue， headache， pruritus， dyspnea， throat irritation， rhinitis， vomiting. Cardiovascular: Hypertension (all grades， 6%; grades 3 and 4， 1% )， Hypotension (all grades， 10%; grades 3 and 4， 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% )， Diarrhea (10% )， Nausea (23% )， Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma， all grades， 26%; grades 3 and 4， 1%; rheumatoid arthritis， 2% )， Dizziness (all grades， 10%; grades 3 and 4， 1% )， Headache (all grades， 19%; grades 3 and 4， 1% )， Sensory neuropathy (30% ) Other: Fever (all grades， 53%; grades 3 and 4， 1% )， Shivering (all grades， 33%; grades 3 and 4， 3% ),2-8℃避光避免冷凍,Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction， increase the rate by 50 mg/hour increments every 30 minutes， to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion， start at 100 mg/hour; if there is no infusion-related reaction， increase the rate by 100 mg/hour increments every 30 minutes， to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin’s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide， doxorubicin， prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1， then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation)， but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,,,,1. 第一次使用：給藥速率建議從50 mg/小時開始，之後視病人耐受程度可每30 分鐘提高50 mg/小時，最大速率不可超過 400 mg/小時。 2. 第二次以後使用：給藥速率建議從100 mg/小時開始，之後可每30 分鐘提高100 mg/小時，最大速率不可超過 400 mg/小時。若病人耐受程度良好，快速給藥之給藥時間應 > 60 分鐘。 3. 配製好的輸注溶液濃度約 1 -4 mg/mL，室溫安定性維持 12 小時。 4.患有心律不整、心絞痛、肺疾患的病人， 輸注時加強監測心肺功能。 5. 監測CBC、腎功能。
IMAB5,Rituximab,MABTHERA infusion 500mg/50mL,RACA,Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment， after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.,Hypersensitivity to rituximab or murine proteins. Pregnancy， lactation. Active hepatits B disease.,Fever， chills or rigor， flushing， angioedema， nausea， urticaria/rash， fatigue， headache， pruritus， dyspnea， throat irritation， rhinitis， vomiting. Cardiovascular: Hypertension (all grades， 6%; grades 3 and 4， 1% )， Hypotension (all grades， 10%; grades 3 and 4， 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% )， Diarrhea (10% )， Nausea (23% )， Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma， all grades， 26%; grades 3 and 4， 1%; rheumatoid arthritis， 2% )， Dizziness (all grades， 10%; grades 3 and 4， 1% )， Headache (all grades， 19%; grades 3 and 4， 1% )， Sensory neuropathy (30% ) Other: Fever (all grades， 53%; grades 3 and 4， 1% )， Shivering (all grades， 33%; grades 3 and 4， 3% ),2-8℃避光避免冷凍,Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction， increase the rate by 50 mg/hour increments every 30 minutes， to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion， start at 100 mg/hour; if there is no infusion-related reaction， increase the rate by 100 mg/hour increments every 30 minutes， to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin’s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide， doxorubicin， prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1， then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation)， but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,,,,1. 第一次使用：給藥速率建議從50 mg/小時開始，之後視病人耐受程度可每30 分鐘提高50 mg/小時，最大速率不可超過 400 mg/小時。 2. 第二次以後使用：給藥速率建議從100 mg/小時開始，之後可每30 分鐘提高100 mg/小時，最大速率不可超過 400 mg/小時。若病人耐受程度良好，快速給藥之給藥時間應 > 60 分鐘。 3. 配製好的輸注溶液濃度約 1 -4 mg/mL，室溫安定性維持 12 小時。 4.患有心律不整、心絞痛、肺疾患的病人， 輸注時加強監測心肺功能。 5. 監測CBC、腎功能。
IMIR,Methoxy Polyethylene Glycol- Epoetin β,Mircera inj 50mcg/0.3mL,HEMT,Treatment of symptomatic anemia associated with chronic kidney disease (CKD). Not indicated for the treatment of anemia due to cancer chemotherapy.,Uncontrolled hypertension.Neonates: injections containing benzyl alcohol.,Hypertension， diarrhea， nasopharyngitis， headache & upper respiratory tract infections. Increased mortality， serious cardiovascular & thromboembolic events; Increased mortality and/or tumor progression; seizures; pure red cell aplasia.,2-8℃避光避免冷凍,Adult without treated with an ESA before， initially IV/SC 0.6 mcg/kg as a single dose every 2 weeks. Once Hb has been maintained between 10-12 g/dL， one time per month could be considerated， with double dose of initial dose. Adult currently treated with an ESA， IV/SC every 2 weeks or once monthly. Previous dose of Epoetin α or β < 4000 u/week or Darbepoetin α < 20 mcg/week: 80 mcg/month or 40 mcg every 2 weeks. Previous dose of Epoetin α or β 4000-< 8000 u/week or Darbepoetin α 20-< 40 mcg/week: 120 mcg/month or 60 mcg every 2 weeks. Previous dose of Epoetin α or β 8000-16000 u/week or Darbepoetin α 40-80 mcg/week: 200 mcg/month or 100 mcg every 2 weeks. Previous dose of Epoetin α or β > 16000 u/week or Darbepoetin α > 80 mcg/week: 360 mcg/month or 180 mcg every 2 weeks. Dose adjustments should not be made more than once per month.,無需調整劑量,仿單資訊： 目前並不確知Mircera是否會分泌進入人類的乳汁。一項大鼠的研究顯示，Mircera會分泌進入 母乳。由於許多藥物都會分泌進入人類的乳汁，因此，對授乳婦女投予Mircera時應謹慎。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest risk,仿單資訊：懷孕分級 C 對大鼠和兔子於懷孕期間以皮下注射的方式投予Mircera之後，兩種物種在每三天投予一次50 微公克/公斤的劑量下都有骨骼畸形的現象。所觀察到的影響為有一隻大鼠胎兒因尾椎骨缺失 而形成線狀尾巴，有一隻兔子胎兒因兩隻前腳的第一指沒有掌骨與趾骨而造成大拇指缺失，另 有兔子胎兒則是出現第四和第五頸椎中心融合的現象。大鼠與兔子的胎兒都有呈劑量相關性的 體重減輕現象。在每三天投予一次5微公克/公斤及更高的劑量下，Mircera在母獸中的藥效學作 用會更加擴大。 對懷孕母鼠每週投予一次最高達50微公克/公斤/劑之劑量的Mircera，並不會對懷孕參數、自然 生產或仔鼠觀察結果造成不良的影響。F1代仔鼠在哺乳及剛斷奶期間有死亡率升高及生長速率 明顯降低的現象。不過，在反射反應、身體和知能發展或生殖能力方面，各劑量組的F1代仔鼠 中皆未發現任何明顯的影響。 目前並無任何適當且控制良好的孕婦研究。只有在潛在效益超越胎兒可能面臨之風險的情況 下，才可於懷孕期間使用Mircera。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,仿單資訊： 目前並不確知Mircera是否會分泌進入人類的乳汁。一項大鼠的研究顯示，Mircera會分泌進入 母乳。由於許多藥物都會分泌進入人類的乳汁，因此，對授乳婦女投予Mircera時應謹慎。,IV;SC;,,,,,Intravenous: Inject into the venous port of the hemodialysis tubing. SC: Inject into the outer aspect of the upper arms， abdomen (except for 2 inches around the navel)， or front aspect of the middle thighs. Do not inject into an area that has scars or stretch marks or is tender， red， bruised， or hard. Rotate injection sites with each injection to prevent soreness.
LSIM,Simethicone,(限腸胃中心)Simethicone 20mg/mL suspension,ALIM,Relief of flatulence & abdominal discomfort due to excess GI gas.,Intestinal perforation or obstruction.,Mild diarrhea， nausea & vomiting， regurgitation.,25℃以下避光,Adult & children > 3 years : 2mL TID - QID， or when needed; Children < 3 years should consult with doctor.,需調整劑量,,需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
ILIP20,MCT + Omega-3-triglyceride + Soya Oil,Lipoplus inj 20% 250mL,NUTR,Supply of lipids， including essential omega-6 fatty acids and omega-3 fatty acids， as part of a parenteral nutrition regimen for adults， when oral or enteral nutrition is impossible， insufficient or contra-indicated.,Severe hyperlipidemia， severe blood coagulation disorders， intrahepatic cholestasis， severe liver failure， severe renal failure without access to hemofiltration or dialysis， acute phase of MI or stroke， acute thromboembolic disease， lipid embolism. Hypersensitivity to egg， fish， or soya-bean protein. General contraindications to infusion therapy include unstable hemodynamic status with compromised vital functions (conditions of collapse & shock)， unstable metabolic conditions (eg. severe post-traumatic conditions， uncompensated diabetes mellitus， severe sepsis， acidosis)， acute pulmonary edema， hyperhydration， decompensated cardiac insufficiency， hypotonic dehydration， hypokalemia.,Dyspnea， allergic reaction， hyperglycemia， nausea， vomiting,25℃以下避光避免冷凍,Dosage Adult: 0.7-1.5g lipids/kg body weight/day， maximum: 2g lipids/kg body weight/day. For home TPN apply > 6 months or short bowel syndrome: <1g lipids/kg body weight/day. Children and adolescents: 2-3g lipids/kg body weight/day. Preterm neonatal infants， term newborn infants， infants and toddlers: 2-3g lipids/kg body weight/day. Maximum infusion rate Adults: Up to 0.15 g lipids/kg body weight/hr. Children and adolescents: Up to 0.15 g lipids/kg body weight/hr. Preterm neonatal infants， term newborn infants， infants and toddlers: Up to 0.15 g lipids/kg body weight/hr.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,輸注速率: 0.25 - 0.5 mL/kg/hr,1. 本脂肪乳劑可經由週邊靜脈或中央靜脈導管輸注，若使用含過濾器之輸注套，必須選擇適合脂肪乳劑者。 2. 脂肪乳劑應以慢速輸注為原則，尤其輸注開始的十五分鐘，每小時每公斤體重不超過0.375mL。 3. 最大輸注速度每小時每公斤體重0.75mL。
OEST,Estradiol Valerate,Estrade 2mg,HM,Relief of menopausal symptoms including patients with ovariectomy,Sever hepatic dysfunction， thrombophlebitis， thromboembolic disorders， hormone-dependent tumors， undiagnosed vag bleeding， pregnancy.,Breast tenderness， nausea， weight change， edema， headache， dizziness， abdominal pain.,25℃以下,Initial dose as 2 mg once daily for 20-21 days and stop for at least 1 week， followed by decrease dose to 1mg.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於懷孕或準備懷孕婦女。
OFAM,Famciclovir,Famvir 250mg,QANB,Herpes zoster infections,Known hypersensitivity to famciclovir.,Headache， nausea. Gastrointestinal: Diarrhea (1.8% to 9% )， Flatulence (0.6% to 4.8% )， Nausea (2.2% to 12.5% )， Vomiting (1.2% to 4.8% ) Neurologic: Headache (9.7% to 39.3% ) Reproductive: Dysmenorrhea (0.9% to 7.6% ),30℃以下乾燥處,Adult: Herpes zoster (shingles): 250 mg orally TID for 7 days. Primary genital Herpes: 250 mg orally TID for 5 days. Recurrent genital Herpes: 125 mg orally BID for 5 days.,無需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
IKA+X1,Triamcinolone Acetonide,Kenacort-A + 1% Xylocaine,HM,,,,,,,,,,,,,,,,,,,
IKA+X2,Triamcinolone Acetonide,Kenacort-A + 2% Xylocaine,HM,,,,,,,,,,,,,,,,,,,
IKCL1,Potassium Chloride,KCl inj (限添加用) 15%，10mL,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia， pain or phlebitis at injection site.,避光,As TPN material. NOTE: Never give injectable potassium chloride undiluted. Standard daily potassium requirement: IV: 1 to 2 mEq/kg/day; adjust daily dose and selection of potassium additive (eg， chloride or acetate) based on serum potassium and clinical considerations; usual maximum: 10 mEq/hour (ASPEN 2019; Siparsky 2020).,無需調整劑量,,無需調整劑量,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,IVA;IVD;,,【D5W】可選 。【H/S】可選 。,,,1. 本品為高濃度鉀離子溶液，須稀釋後使用，限藥劑科用於製劑調配。 2. KCl製劑濃度 >= 0.1 mEq/mL時不可從周邊給藥。請確認病人有中央靜脈導管(Central venous catheter， CVC)，並在處方箋註明由中央靜脈導管給藥。
ILED,Triamcinolone Hexacetonide,Lederspan(Aristospan) 20mg/mL,HM,,Arthritis， severe dermatitis.,,,Adult: 2 ~ 40 mg IA,,,,除非治療上需要,,,,,,,,,,
ILEUP,Leuprolide,Leuplin Depot inj 3.75mg,RACA,,適應症: Palliative treatment of advanced prostatic cancer. Treatment of endometriosis (experience has been limited to women ≧18 years treated for 6 months). Treatment of uterine leiomyoma. Treatment of central precocious puberty. Palliative treatment of premenopausal breast cancer. 副作用: Hot flushes， anorexia， nausea. 禁忌: Women who are or may become pregnant while receiving the drug.,,室溫,1 vial monthly as a single SC inj. Central precocious puberty A dose of 30 mcg/kg， may be increased up to 90 mcg/kg.,,,,不可使用,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,
ILEUV,Folinic Acid,BW-Folin inj 1000mg/100mL,ZADT,,適應症: Megaloblastic anemia due to folic acid deficiency， Intoxication & side-effects of folic acid antagonists， associated with high-dose methotrexate. 副作用:Occasionally Allergic reactions. Pyrexia may occur after inj 禁忌: Untreated vit B12 deficiency. Never given alone or in conjunction with inadequate amounts of hydroxocobalamin.,,2-8 C,For large dose of methotrexate: IV 75 mg within 12hrs， followed by IM 12mg/6hrs for 4 doses. For less severe overdosage: IM 6-12mg/6hrs for 4 doses. For megaloblastic anemia: 1-15mg/day.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,配伍禁忌: 1. Droperidol與本藥混合在一起或共用Y-site會出現沉澱，不可共用。 2. Foscarnet與本藥混合在一起會出現混濁黃色溶液，不可共用。
OBER,Fenoterol,Berotec (Fenoterol) 2.5mg,ERSP,,適應症:預防及治療支氣管痙攣(A028501100),,RT,Oral: Adult: 2.5-5 mg tid. Child: Up to 1 yr: 1.25 mg bid-tid. 1-6 yrs: 1.25 mg-2.5 mg tid. 6-14 yrs: 2.5 mg tid.,,,,可能安全,,,,,,,,,,
OBIOC,Tricalcium phosphate + Cholecalciferol,Bio-Cal chewable,NUTR,,適應症:Osteoporosis， Ca deficiency. 禁忌: Hypercalcemia.,,室溫,2-4 tab daily.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
OBIOF,Lactobacillus Acidophilus,Biofermin,ALIM,,Digestant， antidiarrhea.,,,Adult: 8 tab tid， pc. Child 5-15 yrs: 4 tab tid. Under 5 yrs: reduced doses.,,,,,,,,,,,,,,
LSUL,Sulfamethoxazole + Trimethoprim,Sulfacotrim 40/8mg/mL， 60mL suspension,QANB,Acute exacerbations of chronic bronchitis， UTI & acute otitis media due to susceptible organisms; treatment & prophylaxis of P. carinii pneumonia; travelers?diarrhea due to susceptible strains of enterotoxigenic E. coli.,Hypersensitivity; megaloblastic anemia.,GI disturbances， allergic skin reactions (discontinue)， folic acid deficiency; mild & transient hematological abnormalities; rarely， megaloblastic anemia， purpura， agranulocytosis.,25℃以下，不需冰存並避免陽光直射,Adults: trimethoprim/sulfamethoxazole 160/800-240/1200 mg (20-30 mL) BID for 7 days or 80/400 mg (10 mL) BID for 14 days. Children 6 weeks to 5 months: 20/100 mg (2.5 mL) BID; 6 months to 5 years: 40/200 mg (5 mL) BID; 6 years to 12 years: 80/400 mg (10 mL) BID.,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
IHYC,Topotecan,Hycamtin inj 4mg,RACA,Metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. Small cell lung cancer sensitive disease after failure of 1st-line chemotherapy.,Severe hypersensitivity to topotecan or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Severe renal impairment (CrCl <20 mL/minute); pregnancy; breastfeeding; severe bone marrow depression,Neutropenia， leucopenia， thrombocytopenia， anemia， sepsis. GI disturbances， fatigue， fever， pain， asthenia， alopecia， rash， coughing， dyspnea， headache Dermatologic: Alopecia (IV， 49% ; oral， 10% to 20% )， Rash (IV， 16% ) Gastrointestinal: Abdominal pain (5% to 22% )， Constipation (5% to 29% )， Diarrhea (IV， 6% to 32% ; oral， 14% to 22% )， Nausea (IV， 8% to 64% ; oral， 27% to 33% )， Stomatitis (6% to 18% )， Vomiting (IV， 10% to 45% ; oral， 19% to 21% ) Hematologic: Anemia (IV， 89% to 94% ; oral， 94% to 98% )， Leukopenia (IV， 91% to 97% ; oral， 86% to 90% )， Neutropenia (IV， 89% to 97% ; oral， 83% to 91% )， Thrombocytopenia (IV， 69% to 74% ; oral， 81% ) Neurologic: Asthenia (IV， 25% ; oral， 3% to 7% )， Headache (IV， 18% )， Pain (23% ) Respiratory: Cough (15% )， Dyspnea (6% to 22% ) Other: Fatigue (IV， 29% ; oral， 11% to 19% )， Fever (28%， intravenous ; 5% to 7%， oral ),30℃以下,Baseline neutrophil count should be ?1，500/mm3 (1.5 x 10^9/L)， platelets should be ?100，000/mm3 (100 x 10^9/L) and hemoglobin ?9 g/dL prior to treatment; for re-treatment， neutrophil count should be >1，000/mm3 (1 x 10^9/L); platelets >100，000/mm3 and hemoglobin ?9 g/dL. [Ovarian Cancer and Small Cell Lung Cancer] 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days， starting on day 1 of a 21-day course. In the absence of tumor progression， a minimum of 4 courses is recommended because tumor response may be delayed. The median time to response in 3 ovarian clinical trials was 9-12 weeks， and median time to response in 4 small cell lung cancer trials was 5-7 weeks.  [Cervical Cancer] 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1， 2， and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).,無需調整劑量,,需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,1. Topotecan 4 mg 粉末須以4 mL D/W泡製，泡製後之溶液濃度 1mg/mL。泡製後溶液需以適當體積N/S或D5W進一步稀釋，最終濃度 25 - 50 mcg/mL。 2. 監測CBC、肝腎功能，注意是否出現間質性肺病症狀 (咳嗽、發燒、呼吸困難或缺氧)。
ENOV4,NovoPen 4,NovoPen 4,ZOTH,,,,,,,,,,,,,,,,,,,
OINV,Paliperidone,Invega 3mg extended release,CNEU,Treatment of schizophrenia.,Hypersensitivity to risperidone. Congenital long QT syndrome， cardiac arrhythmias. Pre-existing severe GI narrowing. Lactation.,Cardiac disturbances， arrhythmia， GI disturbances， upper abdominal pain， extrapyramidal disorder， weight increase. Rarely edema， hypersensitivity reactions， dystonia， hypotension， venous thromboembolism. Cardiovascular: Tachycardia (16% geriatric ) Endocrine metabolic: Hyperprolactinemia (geriatric， 45% to 49% )， Weight gain (4% to 9% ) Gastrointestinal: Constipation (4% to 5% )， Indigestion (5% to 6% ) Neurologic: Akathisia (3% to 10% )， Extrapyramidal disease (2% to 20% )， Somnolence (6% to 12% ) Respiratory: Nasopharyngitis (2% to 5% ),25℃以下,Schizophrenia: Adults: 3-12mg QD. When the dose >6 mg/day， increased by 3 mg/day at intervals of more than 5 days. maximum: 12mg/day. 12-17 years old: initial dose: 3mg QD. The dose should be increased by 3 mg/day at intervals of more than 5 days. maximum dose:<51kg:6mg/day; >=51kg:12mg/day Schizoaffective Disorder: 6mg QD， increase by 3 mg/day at intervals of more than 4 days. maximum: 12mg/day.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。
OPROV,Modafinil,Provigil 200mg,CNEU,,,,,,,,,,,,,,,,,,,
OAVE4,Moxifloxacin,Avelox 400mg (政府提供),QANB,,適應症:Treatment of adults ? 18 years with upper & lower respiratory tract infections such as acute sinusitis， acute exacerbation of chronic bronchitis， community acquired pneumonia; skin & soft tissue infections; complicated intra-abdominal infection 副作用:GI disturbances (eg nausea， vomiting， dyspepsia， abdominal pain); headache， dizziness; taste perversion; musculoskeletal effects (eg back pain， arthralgia); CVS effects (eg tachycardia， hypertension); hematological changes; CNS disturbances eg (insomnia， convulsion); skin reactions (eg rash， pruritus); visual disturbances. 禁忌:Hypersensitivity. Children， growing adolescent. Pregnancy， lactation,,室溫,1 tab/bot (400 mg) once daily. Duration: Acute exacerbation of chronic bronchitis 5 days. Community acquired pneumonia 10 days (IV 7-14 days). Acute sinusitis 7 days. Skin & soft tissue infection 7-21 days. Complicated intra-abdominal infection 5-14 days,,,,除非治療上需要,,,,,,,,,,
OALU,Aluminium Hydroxide,Aluminum 324mg,ALIM,As an antacid. Phosphate-binding agent (but not TFDA indication).,Hypophosphatemia.,Constipation.,置於25℃以下避光防潮的容器中,Adult 1-2 tablets 3-6 times daily.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
OCEPO,Captopril,Ceporin 25mg,CAVS,Hypertension， chronic heart failure.,Pregnancy,Dysgeusia， skin rash， cough,30℃以下，謹防濕氣,HTN initial 25mg TIDAC slow titrate up Maximum 450mg/day (Take one hour before meals ) CHF: initial dose of 6.25 or 12.5 mg TID in patients with normal or low blood pressure; maintence dose: -50mg TIDAC,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,Compatible 哺乳時可使用,,AC;AC15;PO;,,,,,
ODIG,Digoxin,Digoxin 0.25mg,CAVS,Heart failure， atrial fibrillation &/or flutter & supraventricular tachycardia.,Intermittent complete heart block or 2nd-degree AV block， especially if there is a history of Stokes-Adams attacks; arrhythmias caused by cardiac glycoside intoxication; supraventricular arrhythmias associated with an accessory AV pathway， as in the Wolff-Parkinson-White syndrome， unless the electrophysiological characteristics of the accessory pathway & any possible deleterious effect of digoxin on these characteristics has been evaluated. If an accessory pathway is known or suspected to be present & there is no history of previous supraventricular arrhythmias. Hypertrophic obstructive cardiomyopathy unless with concomitant atrial fibrillation & heart failure. Hypersensitivity to other digitalis glycosides.,Arrhythmias; anorexia， nausea， vomiting; lower abdominal pain， abnormal fatigue or weakness; abnormal bradycardia; visual disturbances; diarrhea; depression & psychosis， drowsiness， headache， malaise. Gynecomastia in prolonged use.,25℃以下,Adults and children over 10 years: Oral: Rapid digitalization: A total of 0.75-1.5 mg. if necessary， eg.， elderly or high sensitivity patients to clinical response， drug levels， and toxicity， that should be administered in several portions at 6-hour intervals with roughly half the total dose given as the first dose. Slow digitalization: 0.25-0.75 mg QD for 7 days. Maintenance: 0.125-0.25 mg QD. 0.0625mg or lower dose daily might be used on patients who have side effects. Infants and children under 10 years: Oral: Digitalization: This dose should be administered in several portions， with roughly half the total given as the first dose. Additional fractions of this planned total dose may be given at 4 to 8-hour intervals. <1.5kg， <1 month infant: 0.025mg/kg/24hour 1.5-2.5kg， <1 month infants: 0.03mg/kg/24hour 1 month ~ 2 years old children: 0.045mg/kg/24hour 2 ~ 5 years old children: 0.035mg/kg/24hour 5 ~ 10 years old children: 0.025mg/kg/24hour Maintenance: <1 month infants: daily dose = loading dose*20% 1 month ~ 10 years children: daily dose = loading dose*25%,無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
IALI1,Pemetrexed,Alimta inj 100mg,RACA,In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer.,Severe hypersensitivity to pemetrexed or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Concomitant yellow fever vaccine.,Bone marrow depression with neutropenia， leukopenia， anemia & thrombocytopenia; fatigue; fever; GI toxicity with nausea & vomiting， constipation， anorexia， anorexia， stomatitis/pharyngitis， diarrhea; dyspnea; chest pain; infection; rash/desquamation.,25℃以下,500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.,無需調整劑量,,需調整劑量,盡量避免,Contraindicated – 1st trimester,,Hold Breast Feeding 暫停哺乳,,IVD;,,,,,
IALI5,Pemetrexed,ALIMTA inj 500mg,RACA,In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer.,Severe hypersensitivity to pemetrexed or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Concomitant yellow fever vaccine.,Bone marrow depression with neutropenia， leukopenia， anemia & thrombocytopenia; fatigue; fever; GI toxicity with nausea & vomiting， constipation， anorexia， anorexia， stomatitis/pharyngitis， diarrhea; dyspnea; chest pain; infection; rash/desquamation. Dermatologic: Itching， Itching (1% to 7% )， Peeling of skin Gastrointestinal: Constipation (1% to 21% )， Diarrhea (5% to 17% )， Loss of appetite (19% to 27% )， Nausea (19% to 82% )， Pharyngitis， Stomatitis， Vomiting (9% to 57% ) Hematologic: Anemia， All Grades (15% to 33% )， Leukopenia， All Grades (6% to 53% )， Neutropenia， All Grades (6% to 56% )， Thrombocytopenia， All Grades (1% to 23% ) Other: Fatigue (25% to 48% ),25℃以下,500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.,無需調整劑量,BREASTFEEDING RECOMMENDATION: Hold Breastfeeding Contraindicated (if Combined with Cisplatin),需調整劑量,盡量避免,Contraindicated – 1st trimester,PREGNANCY RECOMMENDATION: Contraindicated—1st Trimester Contraindicated (if Combined with Cisplatin),Hold Breast Feeding 暫停哺乳,BREASTFEEDING RECOMMENDATION: Hold Breastfeeding Contraindicated (if Combined with Cisplatin),,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 本藥品不可與含有鈣離子的溶液混合。 3. 監測CBC、肝腎功能。 4. 建議監測homocysteine血中濃度。
ONTG6,Nitroglycerin,Nitrostat (NTG) 0.6mg,CAVS,Treatment & prophylaxis of angina pectoris.,Severe anemia; raised intracranial pressure， early MI， patients taking sildenafil.,Headache， vertigo， weakness， palpitation & postural hypotension. Marked sensitivity to the hypotensive effects of nitrates (manifested by nausea， vomiting， weakness， diaphoresis， pallor & collapse). Flushing， drug rash & exfoliative dermatitis. Cardiovascular: Hypotension Dermatologic: Erythroderma， Flushing， Rash Neurologic: Headache (63% )， Lightheadedness (6% ),20-25℃避免潮濕,Angina pectoris， acute: 0.6 mg sublingually or buccally at 1st sign of acute attack， may be repeated every 5 minutes for 3 doses. If no relief after taking 3 doses within 15 minutes， seek medical attention promptly. Angina pectoris， prophylaxis: 0.6 mg sublingually or buccally 5-10 minutes prior to the activity which may precipitate an attack.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SL;,,,,,[磨粉/管灌註記]本藥為舌下錠，可直接置於舌下使用。
OWELX,Bupropion,Wellbutrin XL 150mg,CNEU,Treatment of depressive illnesses.,Seizure disorder， undergoing abrupt discontinuation of alcohol or sedatives， current or previous diagnosis of bulimia or anorexia nervosa. Concomitant with other MAOIs.,Very common: Insomnia， headache， dry mouth， GI disturbances eg nausea & vomiting. Common: Hypersensitivity reactions eg urticaria， anorexia， agitation， anxiety， tremor， dizziness， taste disorders， visual disturbances， tinnitus， hypertension， flushing， abdominal pain， constipation， rash， pruritus， sweating， fever， chest pain， asthenia. Cardiovascular: Hypertension (2.5% to 4.3% )， Tachyarrhythmia (10.8% ) Dermatologic: Pruritus (2% to 4% )， Rash (3% to 5% )， Urticaria (1% to 2% ) Gastrointestinal: Constipation (5% to 26% )， Nausea (9% to 24% ) Musculoskeletal: Arthralgia (1% to 5% )， Myalgia (2% to 6% ) Neurologic: Confusion (8.4% )， Dizziness (6% to 22.3% )， Headache (approximately 25% )， Insomnia (11% to 40% )， Tremor (2% to 21.1% ) Otic: Tinnitus (3% ) Psychiatric: Agitation (2% to 31.9% )， Anxiety (3.1% to 8% )， Hostile behavior (6% ) Reproductive: Disorder of menstruation (5% ) Respiratory: Pharyngitis (3% to 11% ) Other: Xerostomia (10% to 27.6% ),25℃以下，乾燥陰涼處,Adults， > 18 years old: Initial dose: 150mg QD. maximum: 300 mg QD. There must be a 24 hour interval between doses. Children and adolescents， <18 years old: Safety and effectiveness have not been established. Elderly: More sensitive to bupropion. It may be necessary to reduce the frequency and/or dose of the drug.,需調整劑量,,需調整劑量,除非治療上需要,Human data suggest low risk,Limited Human Data Suggest Low Risk,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠，需整顆吞服勿咀嚼、剝半或磨粉。
OLAC4,Lacidipine,LaciPIL 4mg,CAVS,,適應症: Treatment of hypertension either alone or in combination with other antihypertensive agents. 副作用: Headache， flushing， oedema， dizziness， palpitation. Infrequently， asthenia， skin rash， gastric upset， nausea， polyuria， chest pain， gingival hyperplasia， aggravation of underlying angina. 禁忌: Hypersensitivity to any component of the Lacipil.,,室溫,Initially 2 mg once dialy; dosage may be increased after 3-4 weeks to 4 mg daily， then if necessary to 6 mg daily.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OLAMS,Terbinafine,Lamisil 250mg (療黴舒),QANB,Tinea corporis， tinea cruris， tinea pedis & onychomycosis caused by dermatophyte & skin infections caused by Candida albicans.,Hypersensitivity to any of the ingredients of Lamisil.,GI symptoms， skin reactions. Gastrointestinal: Diarrhea (oral granules， 3% ; oral tablets， 5.6% ) Neurologic: Headache (oral granules， 7% ; oral tablet， 12.9% ),30℃以下,Adults: 250 mg orally once daily. Children > 2 years: < 20 kg: 62.5 mg once daily; 20-40 kg: 125 mg once daily; > 40 kg: 250 mg once daily. Treatment duration varies from 2 to 12 weeks.,需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OLAS,Furosemide,Lasix 40mg,CAVS,Cardiac， renal & hepatic edema; edema due to burns; mild to moderate hypertension,Acute renal failure with anuria， hepatic coma， hypokalemia， hyponatremia， hypovolemia with or without hypotension. Impaired renal or hepatic function.,Minor GI upset; Ca， K & Na depletion， nephrocalcinosis in premature infants; aggravation of metabolic alkalosis; diabetes. Rarely， anaphylactic shock， allergic reactions， bone marrow depression; acute pancreatitis， auditory disorders. Endocrine metabolic: Hyperuricemia (40%)， Hypomagnesemia Gastrointestinal: Loss of appetite Renal: Spasm of bladder,避光,Cardiac， renal and hepatic edema; edema due to burns; mild to moderate hypertension: Adult: Initially 20-80 mg daily; maintenance 20-40 mg daily. Children: 2 mg/kg daily. Maximum: 40 mg daily. [Micromidex 2021/07/20] Maximum adult daily oral dose: 600mg/day.,無需調整劑量,[仿單] Furosemide 會移行進入乳汁中，並抑制乳汁分泌，因此，不可於餵哺母乳期間使用 Lasix。,無需調整劑量,除非治療上需要,Human data suggest low risk,[仿單] Furosemide 會通過胎盤障壁，因此，除非有強制性的醫學理由， 否則不可於懷孕期間使用 Lasix。 若於懷孕期間使用Lasix，則須監測胎兒的發育情形。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] Furosemide 會移行進入乳汁中，並抑制乳汁分泌，因此，不可於餵哺母乳期間使用 Lasix。,AC;AC15;PO;,,,,,
OMEL5,Minocycline,Melicin 50mg,QANB,,適應症: Respiratory tract， GUT， soft tissue， ENT， ophthalmologic infection， periodontitis. 副作用: GI disorders. Maculopapular & erythematous rashes， photosensitivity， tooth discoloration， hypersensitivity reactions. Neurologic: Dizziness (9% )， Vertigo 禁忌: Hypersensitivity to tetracyclines. Last half of pregnancy， infants， children ? 8 years.,,室溫,Acne vulgaris 100 mg daily as a single dose or in divided dose. Non gonococcal urethritis 200 mg daily as a single or in divided dose for 10-14 days. Gonorrhea Adult male 200 mg initially followed by 100 mg 12 hrly for min of 4 days. Adult female Same dosage as male for 10-14 days. Systemic infection 100 mg 12 hrly. Prophylaxis of asymptomatic meningococcal carriers 100 mg bid for 5 days. Children >8 years 50 mg 12 hrly.,,,,盡量避免,,,Compatible 哺乳時可使用,,,,,,,
OMIR,Mirtazapine,pms-Mirtazapine 30mg,CNEU,,適應症: Depression. 副作用: Increase in appetite and wt， oedema; drowsiness or sedation; dizziness， headache， increased liver enzyme levels; jaundice. Orthostatic hypotension， rash， nightmares， agitation， mania， hallucinations， paraesthesia， convulsions， tremor， myoclonus， akathisia， restless legs syndrome， arthralgia， myalgia， reversible agranulocytosis， leucopenia， granulocytopenia， hyponatraemia. Endocrine metabolic: Increased appetite (17% )， Serum triglycerides raised (increases to 500 mg/dL or greater: 6% )， Weight gain (body weight increase of 7% or greater: adults 7.5%; pediatrics 49% ) Gastrointestinal: Constipation (13% )， Xerostomia (25% ) Hepatic: ALT/SGPT level raised (2% ) Neurologic: Asthenia (8% )， Dizziness (7% )， Somnolence (54% ) Psychiatric: Disturbance in thinking (3% ),,室溫,PO Initial: 15 mg/day; may increase gradually based on response. Usual range: 15-45 mg/day as 1-2 divided doses.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OBOK,Acetylsalicylic Acid,Bokey 100mg,HEMT,Reducing the risk of mortality in patients with a suspected acute MI or a history of MI; secondary prevention of stroke; reducing the risk of transient ischaemic attacks (TIA) & stroke in patients with TIA; reducing the risk of morbidity & death in patients with stable & unstable angina pectoris; prevention of thromboembolism after vascular surgery or interventions; prophylaxis of deep vein thrombosis & lung embolism after longer-term immobilisation; reducing the risk of first MI in patients with CV risk factors.,Active peptic ulcers; haemorrhagic diathesis; a history of asthma induced by acetylsalicylic acid or other NSAIDs; combination with methotrexate at doses of ? 15 mg/week; last trimester of pregnancy.,Hypersensitivity reactions; GI disturbances; GI bleeding， ulceration or perforation; bleeding; dizziness & tinnitus.,25℃以下,Take 100-200 mg every day or 300 mg every other day: Reduce the mortality of patients who may have acute myocardial infarction， Prevent deep vein thrombosis and pulmonary embolism caused by long-term immobility， Reduce the risk of first myocardial infarction in patients with cardiovascular risk factors， such as diabetes， hyperlipidemia， hypertension， obesity， smoking， and the elderly. Take 100-300 mg every day: Reduce the recurrence rate and mortality of patients with myocardial infarction， Prevent secondary-stroke， Reduce the recurrence of transient ischemic attack and stroke in patients with transient ischemic attack， Reduce the incidence and mortality of patients with stable and unstable angina， Prevent thromboembolism caused by vascular surgery or invasive treatment， such as percutaneous coronary angioplasty， coronary artery separation， flow transplantation， carotid endarterectomy， arteriovenous catheter.,需調整劑量,,需調整劑量,除非治療上需要,Compatible,1.Compatible (Low Dose) 40~150mg/day 2.PREGNANCY RECOMMENDATION: Human Data Suggest Risk in 1st and 3rd Trimesters (Full Dose),No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,PO;,,,,,[磨粉/管灌註記]本藥為腸溶膠囊，可拆膠囊後服用。但不可將膠囊內的腸溶微粒研磨或壓碎。
OBON,Meclizine,Bonamine 25mg,CNEU,,Management of nausea， vomiting， and dizziness associated with motion sickness.,,,Antivertigo: 25-100 mg/day. Motion sickness: 25-50mg 1 hr before travel.,,,,可能安全,,,,,,,,,,
OBONE,Clodronate,Bonefos 400mg,META,Treatment of osteolysis due to malignancy and malignant hypercalcemia.,Coadministration with other bisphosphonates.,Mild GI irritation， asymptomatic hypocalcemia， elevations of aminotransferases. Rarely， respiratory disorders， renal impairment.,15-25℃,1600 mg daily， maximum 3200mg daily.,無需調整劑量,,需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PO;,,,,,
OBUS,Hyoscin-Butylbromide,Buscopan 10mg,ALIM,,Gastric and duodenal ulcer， intestinal colic， cholelithic colic， spasmodic dysmenorrhea， visceral spasms.,,,Oral: 10-20 mg tid-qid. IM， IV， SC: 10-20 mg qd， repeated as needed.,,,,除非治療上需要,,,,,,,,,,
OCACO3,Calcium Carbonate,Ca. Carbonate 500mg,NUTR,,適應症: Relief of the symptoms of gastric hyperacidity. 副作用: Mild GI disturbances. 禁忌: Hypercalcaemia due to myeloma， bone metastases or other malignant bone disease， sarcoidosis; primary hyperparathyroidism， vitamin D overdosage; severe renal failure.,,室溫,1-2 tab before meals & at bedtime. Max: 8 tab/day.,,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,,沒有資料,,,Compatible 哺乳時可使用,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,,,,,,
OCAP,Calcium Acetate,Caphos 667mg,NUTR,,適應症: Control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. 副作用: Hypercalemia， nausea， constipation， allergy reaction 禁忌: Hypercalemia,,室溫,Initial dose for the adult dialysis pt's is 2 tablets with each meal. The dosage may be increased gradually to bring serum phosphate value below 6 mg/ml， as long as hypercalcemia does not develop. Most pt's require 3-4 tablets with each meal.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
OROX,Roxatidine Acetate,Roxane 75mg,ALIM,,Duodenal ulcers， benign gastric ulcers. Prophylasix of recurrent gastric & duodenal ulcers.,,,Adult 1 cap in the morning and at night or 2 cap at night.,,,,,,,,,,,,,,
ORYT,Propafenone,Rytmonorm 150mg,CAVS,,適應症: Ventricular & supraventricular tachyarrhythmias， Wolff-Parkinson-White syndrome. 副作用: May induce arrhythmia eg. bradycardia， induction disorder， tachycardia. Rarely ventricular fibrillation. May increase severity of heart failure. Hypotension. GI disturbances. Paresthesia， visual disturbances， dizziness. Rarely fatigue， headache， psychotic disorders. Blood disorders. Rarely， skin allergy， bronchospasm. Cardiovascular: Chest pain (1.8% )， Edema (5% to 13% )， Palpitations (3.4% ) Gastrointestinal: Constipation (8% to 14% )， Nausea (9% to 17% )， Taste sense altered (6% to 22% )， Vomiting (0% to 6% ) Neurologic: Dizziness (21% to 23% ) Psychiatric: Anxiety (10% to 13% ) Respiratory: Dyspnea (13% to 17% )， Upper respiratory infection (8% to 12% ) Other: Fatigue (11% to 13% ) 禁忌: Manifest heart failure; cardiogenic shock (except for shock induced by arrhythmia); severe bradycardia within 3 months after MI; pre-existing high degree SA， AV & intraventricular disorders of impulse conduction; sick sinus syndrome; manifest disorders of electrolyte balance; severe obstructive pulmonary disease; marked hypotension， myasthenia gravis.,,室溫,Adult 70 kg Initial & maintenance dose: 450-600 mg daily. May be increased to 900 mg daily.,需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OMUB,Ambroxol,Mubroxol 30mg,ERSP,,適應症: Expectorant. 副作用: Mild GI effects， allergic reactions.,,室溫,Adult & children > 10 years 1 tab tid. (Adult Dosage:most studies have used of 60 to 180 milligrams/day in 2 or 3 divided doses) Children 5-10 years 1/2 tab tid. In long-term therapy the dose may be reduced to bid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OCAT4,Otilonium,Catilon 40mg,ALIM,Relief of abdominal pain due to irritable bowel syndrome.,Glaucoma,Mild nausea， vomiting， upper abdominal pain， dizziness & headache.,25℃以下,Oral， 40 mg BID-TID. Adult: Up to 120 mg daily.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,,,,,,
OJAN,Sitagliptin,Januvia 100mg,META,,適應症: Type 2 DM. 副作用: Upper respiratory tract infection， nasopharyngitis & headache. Hypoglycemia. Endocrine metabolic: Hypoglycemia (0.6% to 12.2% ) Neurologic: Headache (1.1% to 5.9% ) Respiratory: Nasopharyngitis (5.2% to 6.3% )， Upper respiratory infection (4.5% to 6.3% ) 禁忌: Type 1 DM， diabetic ketoacidosis.,,室溫,usually dose :100 mg once daily with or without food Dosage in renal impairment: CrCl < 50 ml/min 50mg qd CrCl < 30 ml/min 25mg qd,無需調整劑量,,需調整劑量,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OVAL,Valaciclovir,Valtrex 500mg,QANB,Treatment of herpes zoster & herpes labialis. Treatment & prevention of recurrent herpes simplex infections of the skin & mucous membranes including initial & recurrent genital herpes. Prophylaxis of cytomegalovirus (CMV) infection & disease， following renal transplantation.,Hypersensitivity to valacyclovir or acyclovir.,Headache， rash， GI disturbances. Uncommonly， reversible neurological reactions such as dizziness， confusion， hallucinations， decreased consciousness (rare) in patients with renal impairment or on high dose therapy. Rarely， renal insufficiency， microangiopathic hemolytic anemia & thrombocytopenia in severely immunocompromised patients with high doses & prolonged periods but these have also been observed in patients not on valacyclovir having the same underlying conditions.,30℃以下,(仿單) Adult: Herpes zoster (shingles): 1000 mg orally 3 times daily for 7 days. Herpes simplex virus infection: 500 mg orally 2 times daily for 5-10 days. Herpes simplex virus， prevention: 500 mg/day divided Q12-24H; 500 mg twice daily for immunocompromised patients. (熱病) Pediatric: Oral herpes (> or = 12 years) 2 g twice daily for 1 day. Varicella zoster virus (Chickenpox) (2-18 years): 60 mg/kg/day， divided Q8H for 5 days,無需調整劑量,Breastfeeding 1) Thomson Lactation Rating: Infant risk is minimal.,需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,Breastfeeding 1) Thomson Lactation Rating: Infant risk is minimal.,AC;AC15;PC;PO;WM;,,,,,
OLEUK,Chlorambucil,Leukeran 2mg,RACA,Management of chronic lymphocytic leukemia (CLL)， Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHL).,Hypersensitivity to chlorambucil or any component of the formulation; hypersensitivity to other alkylating agents (may have cross-hypersensitivity); prior (demonstrated) resistance to chlorambucil. Canadian labeling: Additional contraindications (not in US labeling): Use within 4 weeks of a full course of radiation or chemotherapy.,Bone marrow suppression; GI disturbances. Occasionally: severe interstitial pulmonary fibrosis; hepatotoxicity & jaundice. Fever， skin hypersensitivity， peripheral neuropathy， interstitial pneumonia & sterile cystitis. Seizures.,2-8°C,Take daily on an empty stomach (at least 1 hour before meals or 3 hours after meals). May be used in the management of Hodgkin's disease and non- Hodgkin's lymphomas in children. The dosage regimens are similar to those used in adults.  [Hodgkin's disease] 0.2 mg/kg/day for 4-8 weeks as a single agent in the palliative treatment of advanced disease[Non-Hodgkin's lymphoma] 0.1-0.2 mg/kg/day as a single agent for 4-8 weeks initially; maintenance therapy is then given either by a reduced daily dosage or intermittent courses of treatment.  [Chronic lymphocytic leukaemia] 0.15 mg/kg/day initially until the total leukocyte count has fallen to 10，000/mL. Treatment may be resumed 4 weeks after the end of the first course and continued at a dosage of 0.1 mg/kg/day. [Waldenstrom's macroglobulinaema] Starting doses of 6-12 mg daily until leucopenia occurs are recommended followed by 2-8 mg daily indefinitely.,需調整劑量,,需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,AC;PO;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OPROGY,Estradiol Valerate + Norgestrel,Progyluton 21's/box,HM,,適應症:月經停止後的更年期症候群 Pre- & postmenopausal symptoms， primary & secondary amenorrhea; menstrual irregularities; deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases 副作用:Rarely， breast tension， gastric upsets， nausea， headache， influence on body weight & libido， unscheduled bleeding. 禁忌:Pregnancy; severe liver dysfunction; jaundice or severe pruritus during a previous pregnancy; previous or existing liver tumours; existing or suspected hormone-dependent tumours of uterus or mammae. Severe diabetes with vascular changes， previous or existing thromboembolic processes; endometriosis; disturbances of lipometabolism， a history of herpes gestationis， otosclerosis with deterioration during previous pregnancies， Dubin-Johnson syndrome， Rotor syndrome， sickle-cell anemia,,室溫,1 tab daily for 21 days beginning on the 5th day of the cycle， pause for 7 days,,,,不可使用,,,Compatible 哺乳時可使用,,,,,,,
IDOR3,Midazolam,Dormicum inj 15mg/3mL,ZANE,,,,,,,,,,,,,,,,,,,
EPRO3,Tacrolimus,Protopic 0.03% oint 5gm,TDER,,適應症: Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis. 副作用: Burning sensation， pruritus， flu-like symptoms & headache. Dermatologic: Alopecia (systemic formulations: up to 28.9% topical: 1% )， Persistent erythema of skin (topical: 7% to 28% )， Persistent erythema of skin (20% to 58% )， Pruritus (systemic formulations: 15% to 36% ; topical: 19% to 46% ) Gastrointestinal: Constipation (systemic formulations: 23% to 35% ; topical: between 0.2% and 1% )， Diarrhea (systemic formulations: 37% to 72% ; topical: 3% to 5% )， Nausea (systemic formulations: 32% to 46% ; topical: 1% to 3% )， Vomiting (systemic formulations: 14% to 29% ; topical: 1% to 6% ) Hematologic: Anemia (systemic formulations: 5% to 65.4% ; topical: between 0.2% and less than 1% )， Leukocytosis (8% to 32% )， Thrombocytopenia (14% to 24% ) Neurologic: Headache (systemic formulations: 37% to 64% ; topical: 5% to 20% )， Insomnia (systemic formulations: 32% to 64% ; topical: 1% to 4% )， Paresthesia (systemic formulations: 17% to 40% ; topical: 2% to 3% )， Tremor (15% to 56% ) 禁忌: Patients with a history of hypersensitivity to tacrolimus or any other component of Protopic.,,15 ~ 30 °C,Adult & children 2-15 years Apply thinly & rub in bid， continue for 1 week after signs & symptoms clear.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EPROT,Tacrolimus,Protopic 0.1% oint 5gm,TDER,,適應症: Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis. 副作用: Burning sensation， pruritus， flu-like symptoms & headache. Dermatologic: Alopecia (systemic formulations: up to 28.9% topical: 1% )， Persistent erythema of skin (topical: 7% to 28% )， Persistent erythema of skin (20% to 58% )， Pruritus (systemic formulations: 15% to 36% ; topical: 19% to 46% ) Gastrointestinal: Constipation (systemic formulations: 23% to 35% ; topical: between 0.2% and 1% )， Diarrhea (systemic formulations: 37% to 72% ; topical: 3% to 5% )， Nausea (systemic formulations: 32% to 46% ; topical: 1% to 3% )， Vomiting (systemic formulations: 14% to 29% ; topical: 1% to 6% ) Hematologic: Anemia (systemic formulations: 5% to 65.4% ; topical: between 0.2% and less than 1% )， Leukocytosis (8% to 32% )， Thrombocytopenia (14% to 24% ) Neurologic: Headache (systemic formulations: 37% to 64% ; topical: 5% to 20% )， Insomnia (systemic formulations: 32% to 64% ; topical: 1% to 4% )， Paresthesia (systemic formulations: 17% to 40% ; topical: 2% to 3% )， Tremor (15% to 56% ) 禁忌: Patients with a history of hypersensitivity to tacrolimus or any other component of Protopic.,,15-30℃,Adult & children 2-15 years Apply thinly & rub in bid， continue for 1 week after signs & symptoms clear.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
EDEV,Acyclovir,Devirus 4.5gm ophthalmic ointment,TOPH,Herpes simplex virus infection of the eyes including initial & recurrent genital herpes & herpes labialis.,Patients known to be hypersensitive to acyclovir or propylene glycol.,Transient burning or stinging. Mild drying & flaking. Erythema & itching. Dermatologic: Application site reaction， Topical Preparation (5% )， Contact dermatitis， Topical Preparation (2% ) Gastrointestinal: Diarrhea (2.4% to 3.2% )， Nausea (2.4% to 4.8% )， Vomiting Neurologic: Headache (2.2% ) Other: Malaise (11.5% ),25℃以下,Apply 1 cm ribbon of the ointment should be placed inside the lower conjunctival sac five times a day at approximately four hourly intervals. Treatment should continue for at least three days after ending.",無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,OD;OL;OU;,,,,,
EALC8,Alcohol,95% Alcohol 4000mL,TDER,,,,,,,,,,,,,,,,,,,
ENACL,Sodium Chloride,Sodium Chloride eye drop 3%， 5mL,TOPH,To reduce swelling of the cornea.,Hypersensitivity to any component of the formulation.,Ocular irritation,2-8℃,Corneal edema: Instill 1 to 2 drops in affected eye(s) every 3 to 4 hours. [Micromedex 2021/08/02] 2% solution Instill 1 to 2 drops in affected eye(s) every 3 to 4 hours. [UpToDate 2021/08/02] Infants， Children， and Adolescents: Ophthalmic solution (5%): Instill 1 to 2 drops into affected eye(s) every 3 to 4 hours as needed.,無需調整劑量,,無需調整劑量,安全,Uknown 沒有資料,,Compatible 哺乳時可使用,,OD;OL;OU;,,,,,
ICLI,Clindamycin,Clindamycin inj 300mg/2mL,QANB,,適應症: Infections caused by susceptible strains of strep， staph， pneumococci， anaerobic bacteria. 副作用: Abdominal pain， nausea， vomiting， diarrhea， urticaria， maculopapular reactions， jaundice， blood disorders. 禁忌: Hypersensitivity， meningitis.,,室溫,Adult 600-1200 mg IM daily in 2-4 doses. Severe infections: 1200-2700 mg daily in 2-4 doses. Children > 1 month 15-25 mg/kg/day in 3-4 doses. Severe infections: 25-40 mg/kg/day in 3-4 doses.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,1. 靜脈給藥前『必需』要稀釋。 2. 監測體溫、CBC、肝腎功能，注意是否發生腹瀉。
OANT,Cyproheptadine,Antisemin 4mg,HIMM,,適應症: Allergic rhinitis， vasomotor rhinitis， urticaria， allergic skin & blood disorders. Pruritus due to chicken pox. 副作用: Sedation; drowsiness; dry mouth， nose & throat; Increase thickness of bronchial secretion， dizziness， upper abdominal discomfort. 禁忌: Acute asthmatic attack. Premature infants,,室溫,Allergy: Adult: 4mg tid (max. 32mg/day). Child: 2-6yrs: 2mg tid (max. 12mg/day). Child: 6-14yrs: 4mg tid (max: 16mg/day). Stimulation of appetite: Adult: 2-4mg tid-qid. Child: 2-6yrs: Max. of 8mg/day. Migraine: Initially 4mg， not to exceed 8mg within 4-6hrs.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OSPA6,Alverine,SpasMOL 60mg,ALIM,,適應症: Dysmenorrhoea; GI tract spasm. 副作用: Nausea， headache; pruritus， rash; dizziness; allergic reactions. 禁忌: Paralytic ileus. Pregnancy， lactation， intestinal obstruction.,,室溫,60-120 mg 1-3 times/day.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IUVAN,Vancomycin,U-Vanco inj 500mg,QANB,,適應症: Serious staphylococcal or other gm+ve infections. Brain abscess， staphylococcal meningitis， peritonitis associated with continuous ambulatory peritoneal dialysis & septicaemia. Treatment & prophylaxis of endocarditis， prophylaxis of surgical infection & in intensive care， management of immunocompromised patients. Treatment of antibiotic-associated colitis. 副作用: 'Red-neck' or 'red-man' syndrome characterised by erythema， flushing， rash over the face & upper torso， hypotension， shock-like symptoms. Hypersensitivity reactions， eg rashes， fever， chills， anaphylactoid reactions. Reversible neutropenia， eosinophilia & thrombocytopenia. Nephrotoxicity， ototoxicity， tinnitus， hearing loss. Thrombophlebitis. Tissue necrosis. 禁忌: Known hypersensitivity.,,室溫,Adult 500 mg 6 hrly or 1 g 12 hrly by intermittent infusion. Duration: At least 3 weeks in staphylococcal endocarditis. Prophylaxis of endocarditis in high-risk penicillin-allergic patients undergoing dental or other procedures 1 g by IV infusion as a single dose before the procedure together with gentamicin IV. Repeat doses 8 hrly for patients undergoing GI or GU procedures. Children 10 mg/kg body weight 6 hrly. Neonates initial 15 mg/kg followed by 10 mg/kg 12 hrly in 1st weeks of life & 8 hrly up to 1 month of age.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 監測體溫、CBC、腎功能、聽覺功能。 2. 注意輸注過快時的不良反應：低血壓、呼吸困難、蕁麻疹。 3. 建議監測藥物血中濃度。
OZIE,Dicloxacillin,Ziefmycin 250mg,QANB,Respiratory tract， skin & soft tissue infections caused by penicillinase-producing Staph.,Hypersensitivity to penicillins.,Allergic reactions; angioedema; bronchospasm.,25℃以下避光儲存,Adults and children > 40 kg: 125-250 mg orally Q6H 1-2 hours before meals. Children < 40 kg: 12.5-25 mg/kg/day divided Q6H 1-2 hours before meals. [Micromedex 20210920] Methicillin-susceptible Staphylococcus aureus: 500 mg orally 4 times daily. [Sanford Guide to Antimicrobial Therapy 2021] Usual Dose: 125-500mg Q6H before meals.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,AC;PO;,,,,,
OCEN,Calcium Citrate,Cenca 950mg,NUTR,,適應症: Ca supplement， renal osteodystrophy.,,室溫,Adult & children > 4 years 2-5 tabs daily.,,,,沒有資料,,,Compatible 哺乳時可使用,,,,,,,
OCAT2,Diclofenac,Cataflam 25mg,CNEU,Relief of pain & inflammation in RA， osteoarthritis， ankylosing spondylitis， migraine attacks， low back pain， painful syndromes of the vertebral column， non-articular rheumatism， painful post-traumatic & post-op inflammation.,Peptic ulcer; known hypersensitivity to diclofenac or other NSAIDs; patients in whom attacks of asthma， urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs.,Epigastric pain， nausea， vomiting， diarrhea， abdominal cramps， dyspepsia， flatulence， anorexia， headache， dizziness， vertigo， rashes or skin eruptions， elevation of serum aminotransferase. Rarely， GI bleeding， fatigue， urticaria， gastric or intestinal ulcer， drowsiness， edema， hepatitis with or without jaundice. Dermatologic: Application site reaction (gel: all reactions， 7%; dermatitis， 4% to 11% ) Hematologic: Blood coagulation disorder (1% to 10% ) Ophthalmic: Burning sensation in eye (15% )， Keratitis (up to 28% )， Lacrimation and lacrimal drainage - finding (up to 30% )， Raised intraocular pressure (up to 15% ),30℃以下防潮與避光儲存,>14 years old: 75-100mg/day in 2-3 divided doses. Children: Recommend drops or suppositories for treatment. Elders: Treat with caution.,無需調整劑量,,需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;,,,,,
OCHA5,Varenicline,Champix 0.5mg,ZADT,Aid to smoking cessation treatment.,,Nausea， sleep disturbance， constipation， flatulence， vomiting. Diarrhea， gingivitis， chest pain， flu-like illness， edema， thirst， abnormal liver function test， increased weight， arthralgia， back pain， muscle cramp， musculoskeletal pain， myalgia， attention disturbance， dizziness， sensory disturbance， anxiety， depression， emotional disorder， irritability， restlessness， polyuria， menstrual disorder， epistaxis， respiratory disorders， hyperhidrosis， hot flush， HTN. Gastrointestinal: Constipation (5% to 8% )， Flatulence (6% to 9% )， Nausea (16% to 40% )， Vomiting (1% to 5% ) Neurologic: Dream disorder (9% to 13% )， Headache (15% to 19% )， Insomnia (18% to 19% ),25℃,"Days 1-3: 0.5 mg once daily.Days 4-7: 0.5 mg twice daily.Days 8 and later (maintenance): 1 mg twice daily. Continue maintenance dose for at least 11 weeks to 1 year (for a total of at least 12 weeks of treatment).Approaches to selecting a tobacco quit date: May either choose a fixed quit date (ie， start varenicline， then quit on day 8) or a flexible quit date (ie， start varenicline， then quit between days 8-35). Alternatively， consider a gradual quit date (ie， start varenicline and reduce smoking 50% by week 4， reduce an additional 50% by week 8， and continue reducing with a goal of complete abstinence by week 12) followed by a maintenance dose for 12 weeks (for a total of at least 24 weeks of treatment).",無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OCRAS,Potassium Citrate Monohydrate + Citric Acid,Crashtone Granules 5gm,SGU,,適應症: Prevention of uric acid nephrolithiasis; prevention of Ca renal stones in patients with hypocitraturia; avoidance of the complication of Ca stone formation in uric lithiasis. 副作用: Abdominal pain; dyspepsia; gastroenteritis; hyperkinesia; nervousness. 禁忌: Hyperkalemia， peptic ulcer， abnormal renal function， anuria.,,室溫,5 gm Qd-qid.,,,,安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OSCA,Acetaminophen,Scanol 500mg,CNEU,,Analgesic and antipyretic actions， no anti-inflammatory properties.,,RT,Adult:500 mg q4h as needed， (max. 4 g/day). For long term therapy， not exceeding 2.6 g/day. Child: 10-15 mg/kg q4h as needed， (max. 65 mg/kg/day) not more than 5 doses in each 24 hrs period. Syrup: 3 months-1 yr.:2.5-5 ml qid. 1-6 yrs.:5-10 ml qid. 6-10 yrs.:20 ml qid.,,,,可能安全,,,,,,,,,,
OSCAN,Hydrochlorothiazide + Amiloride,Scanduretic,CAVS,,I: Hypertension， CHF， hepatic cirrhosis with ascites. CI: Hyperkalemia， other concomitant antikaliuretic therapy or K supplementation， renal insufficiency.,,,1-2 tab/day， pc， up to 4 tab/day.,,,,可能安全,,,,,,,,,,
OPLAV,Clopidogrel,Plavix 75mg,HEMT,,適應症: Prevention of atherothrombotic events in patients suffering from MI， ischemic stroke or established peripheral arterial disease; in patients suffering from non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) in combination with aspirin. ST segment elevation acute MI in combination with aspirin in patients eligible for thrombolytic therapy. 副作用: GI bleeding， purpura， bruising， haematoma， epistaxis， haematuria， ocular haemorrhage， intracranial bleeding， abdominal pain， dyspepsia， gastritis & diarrhoea， rash， pruritus. Cardiovascular: Chest pain， Hypertension (4.3% ) Dermatologic: Pruritus (3.3% )， Purpuric disorder (5.3% )， Rash (4.2% ) Endocrine metabolic: Hypercholesterolemia Gastrointestinal: Abdominal pain， Constipation， Diarrhea， Gastritis， Indigestion Hematologic: Epistaxis (2.9% )， Purpura (5.3% ) Musculoskeletal: Arthralgia (6.3% )， Backache (5.8% ) Neurologic: Headache (7.6% ) 禁忌: Severe liver impairment. Peptic ulcer & intracranial haemorrhage. Lactation.,,室溫,Adult & elderly 75 mg once daily. Patients with non-ST segment elevation acute coronary syndrome Initially 300 mg as single loading dose & then continued at 75 mg once daily (with 75-325 mg aspirin daily). Recommended dose of aspirin should not be >100 mg. ST segment elevation acute MI Initially 75 mg daily as single loading dose in combination with aspirin & with or without thrombolytics.,無需調整劑量,,無需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EDUA,Budesonide,Duasma MDI 200mcg/puff,ERSP,,I: Chronic control of bronchial asthma. ADR: Mild irritation of the throat， coughing， reversible hoarseness of voice， bad taste， dryness of the throat. Candidiasis of the mouth & throat. Paradoxical bronchoconstriction. CI: Moderate to severe bronchiectasis.,,RT,Adult & Children > 12 yr: initially 400 ~ 1600 mcg daily divided into 2 ~ 4 administrations. Maintenance: 200 ~ 400 mcg bid， up to 1600 mcg/day Children 6 ~ 12 yr initially 200 ~ 400 mcg daily in divided doses.,,,,除非治療上需要,,,,,,,,,,
OSEL,Naproxen,Seladin 250mg,CNEU,,RA， osteoarthritis， ankylosing spondylitis， acute gout， musculoskeletal disorders.,,,1 cap bid.,,,,除非治療上需要,,,,,,,,,,
OSENN,Sennosides,Sennapur 12.5mg,ALIM,,Relief of functional constipation， chronic geriatric， antepartum， postpartum， drug induced， pediatric & concurrent with heart disease or anorectal surgery.,,,Adult: 2-4 tab， at bedtime. Childn: 1-2 tab at bedtime,,,,,,,,,,,,,,
OSER,Oxazolam,Serenal 10mg,CNEU,,適應症: Anxiety-tension-depression-sleep disorders in neurosis; somatic symptoms & anxiety-tension-depression in psychosomatic diseases， Pre-anaesth. 副作用: Drowsiness， dizziness; headache; insomnia; anorexia， impaired tongue movement， dry mouth; fatigue; rarely， impatience; skin eruption; tachycardia (pre-anesth medication); drug dependence (massive dose). 禁忌: Acute narrow-angle glaucoma; myasthenia gravis.,,室溫,Anxiety-tension-depression-sleep disorders in neurosis; somatic symptoms & anxiety-tension-depression in psychosomatic diseases Adult 10-20 mg tid. Pre-anaesth medication 1-2 mg/kg body weight before operation. Dosage varies according to age & intensity of symptoms.,,,,沒有資料,,,,,,,,,,
EDERC,Clobetasol,Dermovate cream 5gm,TDER,,適應症: Psoriasis; recalcitrant eczema; lichen planus; discoid lupus erythematosus & other skin conditions which do not respond satisfactorily to less active steroids. 副作用: Features of hypercorticism， local atrophic changes， pigmentation changes & hypertrichosis. Exacerbation of symptoms may occur. 禁忌: Rosacea; acne vulgaris; perioral dermatitis; perianal & genital pruritus; primary cutaneous viral infection; bacterial， fungal infected skin lesions; perianal & genital pruritus; dermatoses in infant < 1 year including dermatitis & napkin eruptions. 是一種強效的類固醇藥膏，強效類固醇是較不適合「用在肛門及生殖器」，是因為此部位表皮層很薄，若有發炎現象可採用弱效或中效類固醇，以免吸收強效藥品，產生不良副作用,,室溫,Apply sparingly to the affected area once or bid.,,,,沒有資料,,,,,,,,,,
IFAS,Fulvestrant,Faslodex inj 250mg/5mL,RACA,Breast cancer， metastatic， breast cancer， advanced or metastatic (second-line endocrine-based combination therapy),a) hypersensitivity to fulvestrant or to any of its components b) suspected or known pregnancy Precautions A) hepatic impairment Serious Adverse Effects: a) Anemia b) Angioedema,>10%: Central nervous system: Fatigue (8% to 29%)， headache (8% to 20%) Gastrointestinal: Nausea (10% to 28%)， diarrhea (19%)， constipation (5% to 16%)， stomatitis (13%) Hematologic & oncologic: Anemia (13% to 40%; grade 3: 2%) Hepatic: Increased liver enzymes (>15%; grades 3/4: 1% to 2%) Infection: Infection (31%; including nasopharyngitis， upper respiratory infection， urinary tract infection， influenza， bronchitis， rhinitis， conjunctivitis， pneumonia， sinusitis， cystitis， oral herpes， respiratory tract infection) Local: Pain at injection site (12%; including neuralgia， peripheral neuropathy， sciatica) 1% to 10%: Dermatologic: Alopecia (6%)， skin rash (6%)， xeroderma (1%) Endocrine & metabolic: Hot flash (7%) Gastrointestinal: Decreased appetite (8%)， anorexia (6%)， vomiting (6%)， dysgeusia (3%) Hematologic & oncologic: Decreased platelet count (10%)， leukopenia (5%; grade 3: 1%; grade 4: 1%)， neutropenia (4%; grade 3: 1%)， febrile neutropenia (1%; grade 4: 1%) Neuromuscular & skeletal: Ostealgia (9%)， arthralgia (8%)， back pain (8%)， limb pain (7%)， musculoskeletal pain (6%)， weakness (5% to 6%) Ophthalmic: Blurred vision (2%)， dry eye syndrome (2%)， increased lacrimation (1%) Respiratory: Cough (5%)， dyspnea (4%)， epistaxis (2%),2-8℃避光,500 mg administered intramuscularly into the buttocks (gluteal area) slowly (1 -2 minutes per injection) as two 5 mL injections， one in each buttock， on Days 1， 15， 29， and once monthly thereafter.,需調整劑量,,需調整劑量,盡量避免,Contraindicated,,Contraindicated 哺乳期使用禁忌,,IM;,,,,,投與Faslodex應以兩次連續的5毫升在臀部肌肉處緩慢注射(1-2分鐘注射)，一邊一次。
OLAF,Ferric Hydroxide,La Ferrum Chewable 100mg,NUTR,,適應症: Fe-deficiency anaemia. 副作用: GI irritation， epigastric pain， stomach cramping， constipation， nausea， vomiting， diarrhoea， dark stools， heart burn， discoloured urine， teeth staining. IM: pain at inj site， abdominal pain at lower quadrant and local inflammation with inguinal lymphadenopathy. IV: Joint and muscle pain， bronchospasm， hypotension， tachycardia， flushing， sweating， dizziness. 禁忌: Hypersensitivity or intolerance to iron and overloading of iron in the body. Anaemia not caused by iron deficiency. Disturbances in iron utilisation， thalassemia. Patients receiving repeated blood transfusion. Parenteral: Iron overload， Ostler-Rendu-Weber syndrome， chronic polyarthritis， bronchial asthma， inflammation or infection of kidney or liver， uncontrolled hyperparathyroidism， decompensated liver cirrhosis. Pregnancy (1st trimester).,,室溫,1 tab qd-tid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ONAV3,Vinorelbine,NAVELBINE 30mg,RACA,Non-small cell lung cancer. Metastatic breast cancer.,Disease significantly affecting absorption; previous significant surgical resection of stomach or small bowel. Severe hepatic impairment; pregnancy & lactation; patients requiring long-term O2 therapy. Coadministration with meningocococal conjugate vaccine or other live virus vaccines， phenytoin & itraconazole. Pretreatment granulocyte counts <1000/mm3,Neutropenia， anemia， thrombocytopenia; nausea & vomiting， diarrhea， anorexia， stomatitis， esophagitis; loss of tendon reflexes， neuromotor disorders， neuroconstipation (rarely progressing to paralytic ileus); alopecia; fatigue， fever， arthralgia including jaw pain， myalgia， pain including pain at tumor site. Vial Ischemic cardiac disease (rare)， abnormal liver function tests， dyspnea， bronchospasm， generalized cutaneous reactions (rare).,2-8℃,As a single agent， first three administrations: 60 mg/m2 once weekly. Beyond the third administration， it is recommended to increase the dose to 80mg/m2 once weekly except in those patients for whom the neutrophil count dropped once < 500/mm3 or 500-1000/mm3 during the first three administrations at 60mg/m2.,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為軟膠囊需以水整顆吞服。
IZOM,Zoledronic Acid,Zometa infusion 4mg,META,,適應症: Prevention of skeletal related events (pathological fractures， spinal compression， radiation or surgery to bone， or tumor-induced hypercalcemia) in patients with advanced malignancies involving bone. Treatment of hypercalcemia of malignancy (HCM). 副作用: Very common: Hypophosphatemia. Common: Anemia， headache， conjunctivitis， nausea， vomiting， anorexia， bone pain， myalgia， arthralgia， renal impairment， fever， flu-like syndrome， blood creatinine & blood urea increase， hypocalcemia. Cardiovascular: Peripheral edema (Paget's Disease， 3%; osteoporosis， 4.6% to 5.5%; bone metastasis， 21% ) Endocrine metabolic: Weight decreased (bone metastasis， 16% ) Gastrointestinal: Abdominal pain (osteoporosis (female)， 0.9% to 4.6%; osteoporosis (male)， 7.9%; Paget's disease， 2%; hypercalcemia of malignancy， 16%; bone metastasis， 14% )， Constipation (Paget's disease， 6%; hypercalcemia of malignancy， 27%; bone metastasis， 31% )， Diarrhea (osteoporosis， 5.2% to 6%; Paget's disease， 6%; hypercalcemia of malignancy， 17%; bone metastasis， 24% )， Loss of appetite (osteoporosis， 1% to 2%; Paget's disease， 2%; hypercalcemia of malignancy， 9%; bone metastasis， 22% )， Nausea (osteoporosis， 4.5% to 8.5%; Paget's disease， 9%; hypercalcemia of malignancy， 29%; bone metastasis， 46% )， Vomiting (Paget's disease， 2%; osteoporosis， 3.4% to 4.6%; hypercalcemia of malignancy， 14%; bone metastasis， 32% ) Musculoskeletal: Arthralgia (osteoporosis (female)， 17.9% to 23.8%; osteoporosis (male)， 11.1%; hypercalcemia of malignancy， 5% to less than 10%; Paget's disease， 9%; bone metastasis， 21% )， Backache (Paget's disease， 4%; bone metastasis， 15% ) Neurologic: Asthenia (osteoporosis， 3.2 to 5.3%; Paget's disease， 2%; bone metastasis， 24% )， Dizziness (osteoporosis， 2% to 7.6%; Paget's disease， 9%; bone metastasis， 18% )， Headache (osteoporosis (female)， 3.9% to 12.4%; osteoporosis (male)， 15%; Paget's disease， 11%; hypercalcemia of malignancy， 5% to less than 10%; bone metastasis， 19% )， Insomnia (hypercalcemia of malignancy， 15%; bone metastasis， 16% )， Paresthesia (Paget's disease， 2%; bone metastasis， 15% .) Renal: Nephrotoxicity (bone metastasis， 11% to 17% ) Other: Fatigue (osteoporosis (female)， 2.1% to 5.4%; osteoporosis (male)， 17.6%; Paget's disease， 8%; bone metastasis， 39% )， Fever (osteoporosis (female)， 7% to 18%; osteoporosis (male)， 15.7%; Paget's disease， 3% to 11%; hypercalcemia of malignancy， 44%; bone metastasis， 32% ) 禁忌: Known hypersensitivity to zoledronic acid or other bisphosphonates.,,室溫,Prevention of skeletal related events in patients with advanced malignancies involving bone 4 mg reconstituted & further diluted， given as a single 15-min IV infusion every 3-4 weeks. Treatment of HCM 4 mg reconstituted & further diluted， given as a single 15-min IV infusion. Retreatment may be given with 8 mg IV for patients with relapse or those refractory to initial treatment. Allow at least 1 week before retreatment.,,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management It is not known whether zoledronic acid is excreted into human breast milk and the potential for adverse effects in the nursing infant from exposure to the drug are unknown. However， as zoledronic acid binds to bone long-term， it is recommended that it should not be administered to a nursing woman.,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management It is not known whether zoledronic acid is excreted into human breast milk and the potential for adverse effects in the nursing infant from exposure to the drug are unknown. However， as zoledronic acid binds to bone long-term， it is recommended that it should not be administered to a nursing woman.,,,,,,1. patients should be adequately hydrated prior to administration 2. If previously refrigerated， allow solution to reach room temperature before administration 3. administer as a single-dose IV infusion in a vented line separate from other drugs; infuse over no less than 15 minutes， over a constant infusion rate 4. Do not allow solution to come in contact with calcium-containing solutions or other divalent cation-containing infusion solutions (eg， lactated Ringer)
OTRE,Pentoxifylline,Trenfylline 400mg,CAVS,,適應症: Peripheral circulatory disorders， chronic occlusive arterial disease. 副作用: Cardiac arrhythmias， headache， nausea， GI effects， dizziness， flushing. 禁忌: Cerebral or retinal hemorrhage， intolerance to xanthine derivatives.,,室溫,1 tab bid or tid.,,Pentoxifylline and its metabolites are excreted into human breast milk. Because of the potential for tumorigenicity demonstrated in rat studies of pentoxifylline， it is recommended to discontinue nursing or discontinue the drug， taking into consideration the importance of the drug to the mother.,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Pentoxifylline and its metabolites are excreted into human breast milk. Because of the potential for tumorigenicity demonstrated in rat studies of pentoxifylline， it is recommended to discontinue nursing or discontinue the drug， taking into consideration the importance of the drug to the mother.,,,,,,
ICLI15,Amino Acid + Glucose,Clinimix inj 1500mL,NUTR,Parenteral nutrition when oral or enteral alimentation is impossible， insufficient or contraindicated.,Renal failure in the absence of haemodialysis， haemofiltration or haemo-diafiltration. Severe liver disease. Amino acid metabolism disorder. Metabolic acidosis， hyperlactataemia. Adrenal insufficiency. Hyperosmolar coma.,Hypertonic solutions may cause venous irritation if infused into a peripheral vein. Hyperglycaemia， glycosuria & hyperosmolar syndrome may occur.,室溫勿冷凍,Adult: 1-2 g amino acids/kg/day， 25-40 kcal/kg/day. Maximum daily dose: 30 mL/kg body weight. Maximum infusion rate: 1.4mL/kg body weight/hr. Children: 2-3g amino acids/kg/day.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,本藥品限藥劑科調劑TPN使用
HE5003,Dianeal 1500cc 2.5% (PD4雙袋),Dianeal 1500mL 2.5% (PD4雙袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy， frequency of treatment， formulation， exchange volume， duration of dwell， and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
OEFE3,Venlafaxine,Efexor XR 37.5mg,CNEU,,適應症: Major depressive disorder; generalized anxiety disorder; social anxiety disorder; panic disorder. 副作用: Dizziness， sedation， dry mouth， insomnia， nervousness， tremor， somnolence， anorexia， constipation， nausea， vomiting， abnormal ejaculation/orgasm (males)， erectile dysfunction， urinary hesitancy， sweating， asthenia， hypertension， hot flushes， ecchymosis， mucous membrane bleeding， thrombocytopenia， hypercholesterolaemia， yawning， fatigue， nausea， appetite & weight loss， decreased libido， sweating， anorexia， visual disturbances. 禁忌:Concomitant or within 14 days of MAOIs. Efexor XR must be discontinued for at least 7 days before starting treatment with MAOI. Severe renal or hepatic impairment. Pregnancy & lactation. Children < 18 years.,,室溫,75 mg once daily. After 2 weeks， the dose may be increased to 150 mg once daily & further to 225 mg once daily if needed.,,,,除非治療上需要,,,,,,,,,,
ILUC2,Ranibizumab,Lucentis inj 0.23mL,TOPH,,適應症: Treatment of neovascular (wet) age-related macular degeneration (AMD). 副作用: Nasopharyngitis， influenza; anemia; anxiety; headache， stroke; intraocular inflammation， vitritis， vitreous detachment， retinal hemorrhage， visual disturbance， eye pain， vitreous floaters， conjunctival hemorrhage， eye irritation， foreign body sensation in eyes， lacrimation increased， blepharitis， dry eye， ocular hyperemia， eye pruritus; retinal degeneration， retinal disorder， retinal detachment， retinal tear， detachment of retinal pigment epithelium， retinal pigment epithelium tear， visual acuity reduced， vitreous hemorrhage， vitreous disorder， uveitis， iritis， iridacyclitis， cataract， calaract subcapsular， posterior capsule opacification， punctuate keratitis， corneal abrasion， anterior chamber flare， vision blurred， inj site hemorrhage， eye hemorrhage， conjunctivitis， conjunctivitis allergic， eye discharge， photopsia， photophobia， ocular discomfort， eyelid edema， eyelid pain， conjunctival hyperemia; cough; nausea; allergic reactions; arthralgia; intraocular pressure increased. Common Ophthalmic: Cataract ( eovascular(wet) age-related macular degeneration 11% to 17%;macular edema following retinal vein occlusion，2%) ， conjunctival hemorrhage (neovascular (wet) age- related macular degeneration 64% to 74%; macular edema following retinal vein occlusion， 48%) ， Eye irritation (neovascular (wet) age- related macular degeneration 13% to 15% ; macular edema following retinal vein occlusion，7%) ， Foreign body sensation， in the eyes (neovascular (wet) age- related macular degeneration 13% to 16%; macular edema following retinal vein occlusion， 7% to 16%) ，Inflammatory disorder of the eye (neovascular (wet) age- related macular degeneration 13% to 18% )， Pain in eye (neovascular (wet) age- related macular degeneration 26 % to 35% ; macular edema following retinal vein occlusion， 17% )， Raised intraocular pressure (neovascular (wet) age- related macular degeneration 17% to 24% ; macular edema following retinal vein occlusion，7% ) ，Visual disturbance (neovascular (wet) age- related macular degeneration 13% to 18% ; macular edema following retinal vein occlusion，5% )， Vitreous detachment (neovascular (wet) age- related macular degeneration 15% to 21% ; macular edema following retinal vein occlusion，4% ) ， Vitreous floaters (neovascular (wet) age- related macular degeneration19 % to 27% ; macular edema following retinal vein occlusion， 7 %) 禁忌: Active or suspected ocular or periocular infections， active intraocular inflammation.,,2-8℃,0.5 mg (0.05 mL) by intravitreous inj， initiated with a loading phase of 1 inj/mth for 3 consecutive months followed by a maintenance phase in which patients should be monitored for visual acuity on a monthly basis. Interval between 2 doses should not be < 1 month.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVI;,,,,,僅供玻璃體內注射，限由醫師使用
OCAS,Bicalutamide,Casodex 50mg,RACA,Treatment of advanced prostate cancer in combination with LHRH analogue therapy or surgical castration.castration.,Females. Pregnancy and lactation. Hypersensitivity to bicalutamide or any component of the formulation; use in women. Patients with localized prostate cancer undergoing watchful waiting; children,Hot flushes， pruritus， diarrhea， nausea， vomiting， asthenia， dry skin， breast tenderness， gynecomastia， hot flushes， raised liver transaminases， jaundice， fatigue. Cardiovascular: Peripheral edema (13% ) Dermatologic: Hot sweats (53% ) Gastrointestinal: Abdominal pain (11% )， Constipation (22% )， Diarrhea (12% )， Nausea (15% ) Immunologic: Infectious disease (18% ) Musculoskeletal: Backache (25% )， Pain in pelvis (21% ) Neurologic: Asthenia (22% ) Renal: Hematuria (12% )， Nocturia (12% ) Respiratory: Dyspnea (13% ) Other: Pain (35% ),勿超過30℃以上,50 mg once daily in conjunction with a gonadotropin-releasing hormone analog (luteinizing hormone-releasing hormone).,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OCLOM,Clomiphene,Clomiphene 50mg,HM,Induction of ovulation in patients with persistent ovulatory dysfunction as the cause of infertility.,Hepatic impairment， endometrial carcinoma or ovarian cysts， polycystic ovary， pregnancy.,Ovarian enlargement (reversible)， vasomotor flushes resembling menopausal symptoms， abdominal or pelvic discomfort or pain， nausea， vomiting， blurring of vision. Cardiovascular: Syncope Dermatologic: Acne， Dermatitis (less than 1% )， Dry hair (less than 1% )， Erythema， Erythema multiforme， Erythema nodosum， Flushing， Vasomotor (10.4% )， Hypertrichosis， Loss of hair (less than 1% )， Pruritus， Rash (less than 1% )， Urticaria Endocrine metabolic: Disorder of thyroid gland， Weight gain (less than 1% )， Weight loss (less than 1% ) Gastrointestinal: Abdominal discomfort (5.5% )， Abdominal pain， Acute (less than 1% )， Constipation (less than 1% )， Diarrhea (less than 1% )， Gastrointestinal tract finding (2.2% )， Increased appetite (less than 1% ) Hepatic: Increased liver enzymes Musculoskeletal: Arthralgia， Backache， Myalgia Neurologic: Asthenia， Dizziness (less than 1% )， Headache (1.3% )， Insomnia (less than 1% )， Lightheadedness (less than 1% )， Migraine， Paresthesia， Unsteady when walking， Vertigo (less than 1% ) Ophthalmic: Eye / vision finding (1.5% )， Functional visual loss， Temporary， Pain in eye， Photopsia Otic: Tinnitus Psychiatric: Anxiety， Depression (less than 1% )， Fatigue (less than 1% )， Feeling nervous (less than 1% )， Irritability， Mood disorder Renal: Polyuria (less than 1% ) Reproductive: Cyst of ovary， Endometriosis， Hyperstimulation of ovaries， Pain of breast (2.1% )， Urogenital finding， Vaginal dryness (less than 1% ) Other: Fever,25℃以下避光,First treatment regimen: 50mg daily for 5 days， starting from the 5th day of the menstrual cycle. Second treatment regimen: 100mg daily for 5 days， starting from the 5th day of the next menstrual cycle if the first regimen failed. Third treatment regimen: same as second regimen.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OCON,Bisoprolol,CONCOR 5mg,CAVS,1.25 mg & 2.5 mg tab Stable chronic moderate to severe heart failure. 5 mg & 10 mg tab Management of hypertension， angina pectoris & stable， chronic moderate to severe heart failure (NYHA class III， IV).,Acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy， cardiogenic shock， AV block of grades II & III (without pacemaker)， sick sinus syndrome， SA block， bradycardia with < 60 beats/min; severe bronchial asthma or severe COPD， hypotension (systolic BP < 100 mmHg)， advanced stages of peripheral arterial circulatory disturbance & Raynaud's syndrome， untreated pheochromocytoma， metabolic acidosis.,Feeling of coldness or numbness in the extremities， nausea， vomiting， diarrhea， constipation. Tiredness， exhaustion， dizziness， headache (occur at the beginning of the therapy & usually disappear within 1-2 weeks). Gastrointestinal: Diarrhea (2.6% to 3.5% ) Neurologic: Headache (8.8% to 10.9% ) Respiratory: Rhinitis (2.9% to 4% )， Upper respiratory infection (4.8% to 5% .) Other: Fatigue (6.6% to 8.2%),30℃以下,Hypertension， angina: Initially 5mg QD， may up to 10mg QD if needed. Maximum: 20mg QD. Stable mild to server chronic heart failure: Patient must be treated at an optimal dose with an ACE inhibitor， a diuretic， & optionally cardiac glycosides， prior to the administration of bisoprolol. Titrate gradually as follows: Week 1: 1.25 mg QD. Week 2: 2.5 mg QD. Week 3: 3.75 mg QD. Week 4-7: 5 mg QD. Week 8-11: 7.5 mg QD. Week 12 and beyond: 10 mg QD as maintenance therapy. Maximum: 10 mg daily.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
ODEP2,Valproate Sodium,Depakine 200mg,CNEU,Treatment of generalized or partial epilepsy; mania.,Acute or chronic hepatitis， personal or family history of severe hepatitis， hepatic porphyria. Combination with mefloquine.,GI disturbances， ataxia， tremor， increased appetite & weight gain， edema， thrombocytopenia， inhibition of platelet aggregation; impaired hepatic function， rashes， sedation. Rarely， pancreatitis (discontinue). Cardiovascular: Peripheral edema (3% to 8% ) Dermatologic: Alopecia (6% to 24% )， Rash (6% ) Endocrine metabolic: Increased appetite (6% )， Weight increased (4% to 9% ) Gastrointestinal: Abdominal pain (9% to 23% )， Constipation (5% )， Diarrhea (12% to 23% )， Indigestion (8% to 13% )， Loss of appetite (4% to 12% )， Nausea (22% to 48% )， Vomiting (11% to 27% ) Hematologic: Ecchymosis (4% to 5% ) Musculoskeletal: Asthenia (10% to 27% )， Backache (8% ) Neurologic: Amnesia (4% to 7% )， Ataxia (8% )， Dizziness (12% to 25% )， Headache (5% to 31% )， Insomnia (9% to 15% )， Somnolence (17% to 30% )， Tremor (9% to 57% ) Ophthalmic: Amblyopia， Blurred vision， Diplopia (16% )， Nystagmus (1% to 8% ) Otic: Tinnitus (1% to 7% ) Psychiatric: Depression (4% to 5% )， Disturbance in thinking (6% )， Feeling nervous (7% to 11% )， Mood swings (6% ) Respiratory: Bronchitis (5% )， Dyspnea (5% )， Pharyngitis (8% )， Respiratory tract infection (12% to 20% )， Rhinitis (5% ) Other: Fever (2% )， Influenza (12% ),低於25℃,Giving with food to decrease gastrointestinal irritation. Children 6 years and below: syrup or oral liquid is recommended for administration. DEPAKINE 500mg Chrono Tablet is only recommended for adult and children > 17 kg. Average daily dose (per 24 hours): Adult and adolescents: 20-30 mg/kg/day in 2 or 3 divided doses. Children: 30 mg/kg/day in 2 or 3 divided doses. (< 1 year old: in 2 divided doses),需調整劑量,[仿單]valproate 分泌到乳汁中的量很低，濃度大約是母體血清濃度的 1%至 10%之間。 根據文獻和臨床經驗，若要哺乳，需考慮本品藥物安全性，特別是血液相關的疾病。 然而，懷孕期間暴露於 sodium valproate 的幼兒，可能降低語言能力，建議治療時不要授乳。,無需調整劑量,盡量避免,Human data suggest low risk,[仿單]懷孕期間禁止使用 valproate 治療躁鬱症。 除非癲癇治療沒有合適的替代藥物，否則懷孕期間禁止使用 valproate 治療癲癇。 除非能確實執行避孕計畫，否則具生育能力的婦女禁用 valproate。 使用本品可能會導致重大的先天性畸形，特別是神經管畸形（如：脊柱裂， spina bifida）， 且可能會導致胎兒智商下降，故本品應僅限用於無法以其他藥物控制症狀， 或有其它原因無法使用其他藥物治療之孕婦。 考量使用本品可能會有使孩童智商降低、發生神經管缺陷及其他嚴重先天性畸形之風險， 且該等風險可能發生於懷孕早期，故除非必要使用，否則不應使用於具生育能力或有懷孕可能之婦女。 避孕計畫： Valproate有高度的致畸性，且胎兒在子宮中曝露於valproate有導致先天性畸形和神經發育缺陷的高 度風險。 本品禁用於以下情況： 治療癲癇 • 在懷孕狀態下，除非沒有適合的替代療法 • 具有生育能力的婦女，除非能確實履行避孕計畫 治療躁鬱症 • 在懷孕狀態下 • 具有生育能力的婦女，除非能確實履行避孕計畫 避孕計畫條件： 處方醫師應確保 • 依病人個別狀況進行評估並與之討論。這是為了保證病人能確實配合並了解治療選擇及其風險， 以及為了降低風險而採取的措施。 • 所有女性病人都應針對懷孕的可能性進行評估。 • 病人應了解並認知先天性畸形和神經發育缺陷的風險，包括胎兒在子宮中曝露於valproate的風險程度。 • 病人應了解，治療前及治療期間(必要時)必須進行懷孕檢測。 • 應告訴病人必須避孕，且病人在整個valproate治療期間必須不間斷地採取有效的避孕措施 • 病人應了解，讓有癲癇或躁鬱症治療經驗的專科醫師定期(至少每年一次)評估治療結果有其必要性。 • 女性病人應了解，當其計畫懷孕時，應盡快諮詢醫師，以確保能及時討論並在懷孕前及停止避孕前更換治療藥物。 • 病人應了解，當發現懷孕時應緊急通知醫師。 • 病人已收到病人用藥指南。 • 女性病人已確認了解，使用valproate之相關風險和應注意事項 (年度風險確認表)。 這些條件亦適用於目前無性行為的婦女，除非處方醫師充分之理由認為其無懷孕風險。 藥師或其他醫療專業人員應確保 • 每次調配valproate時都有交付病人卡，讓病人了解其內容。 • 告知病人當計畫懷孕或疑似懷孕時，valproate不應擅自停藥，應立刻連絡專科醫師。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]valproate 分泌到乳汁中的量很低，濃度大約是母體血清濃度的 1%至 10%之間。 根據文獻和臨床經驗，若要哺乳，需考慮本品藥物安全性，特別是血液相關的疾病。 然而，懷孕期間暴露於 sodium valproate 的幼兒，可能降低語言能力，建議治療時不要授乳。,PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議應整錠吞服，不可咬碎。院內備有同成份藥水Depakin solution可供無法吞服病患使用。
ODOG2,Sulpiride,DOGMATYL 200mg,CNEU,,適應症: 抗潰瘍及情緒安定劑(A026976100) Treatment of psychotic disorders. Management of gastric & duodenal ulcers. 副作用: Neuroleptic malignant syndrome. Extrapyramidal symptoms， parkinsonism & endocrine side effects. Perspiration， nausea， dry mouth， lowered BP， agitated state， difficulty in falling asleep， sexual stimulation， dysopia， profuse salivation， increase in wt & allergy. 禁忌: Pheochromocytoma. Infants.,,室溫,Gastric & duodenal ulcers： -Adult 150 mg daily in 3 divided doses. Schizophrenia ： -300-600 mg daily in divided doses. -May increase to 1200 mg daily. Depression or depressive state： -150-300 mg daily in divided doses. -May increase to 600 mg daily.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OGOU,Benzbromarone,Goutil 50mg,CNEU,Hyperuricemia.,Severe renal disease， nephrolithiasis; pregnancy & lactation,Rarely， diarrhoea， mild GI disturbances,遮光保存(25℃以下),50mg QD to BID.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
EFUBO,Polycresolfonate,Fubodyl vag supp 90mg,SGU,,適應症: Local treatment of cervical & vag inflammatory & concomitant discharge. Vaginitis & cervicitis， cervical erosion; trichomoniasis & moniliasis. To stop bleeding after biopsy & removal of cervical polyps. Decubital ulcers caused by pessaries. After electrocoagulation to activate regeneration. 副作用: Occasionally， mild local discomfort at beginning of treatment which disappears on discontinuation. 禁忌: Concomitant use of other topical agents in treating the affected areas.,,2-8度C,1 to be inserted on alternate days. 泌乳: 未有資料,,,,除非治療上需要,,,,,,,,,,
OPHY,Aminophylline,Phyllocontin 225mg,ERSP,Treatment & prophylaxis of bronchospasm associated with asthma， emphysema & chronic bronchitis. Treatment of cardiac asthma & left ventricular or congestive cardiac failure.,Phyllocontin should not be given concomitantly with ephedrine in children.,nausea， gastric irritation， headache， palpitations and CNS stimulation， tachycardia， arrhythmias and convulsions.,25℃以下,Elderly: 1 TAB BID in the initial week， then adjust the dose depends on clinical response. Adult & adolescent: 1 TAB BID in the initial week， then 2 TAB BID. Age >3 years Child: Maintenance dose: 12mg/kg BID. The dosage may up to 125mg. If the patient has not taken xanthine preparations before， it is recommended that treat with half of maintenance dose during the first week. Some patient with chronic asthma may require 13-20mg/kg BID.,需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠整粒吞服，不可咀嚼或磨碎。院內另有Theophylline成份藥水Centertheo 60mL (5.34mg/mL) liquid及持續性藥效膠囊Xanthium 200mg。
OPRO5,Medroxyprogesterone,Provera 5mg,HM,Primary & secondary amenorrhea， Dysfunctional bleeding， Endometriosis.,Thrombophlebitis， thromboembolic disorders， cerebral apoplexy; liver dysfunction or disease; known or suspected malignancy of breast or genital organs; undiagnosed vag bleeding; pregnancy， missed abortion.,Nausea; fatigue， depression; acne， hirsutism; breast tenderness， galactorrhea， amenorrhea & anovulation; decreased glucose tolerance; thromboembolic phenomena; anaphylaxis; corticoid-like activity (high doses). Endocrine metabolic: Weight change finding (>5% ) Gastrointestinal: Abdominal pain ( >5% ) Neurologic: Asthenia ( >5% )， Dizziness ( >5% )， Headache ( >5% ) Psychiatric: Feeling nervous ( >5% ) Reproductive: Amenorrhea (>5% )， Break-through bleeding， Disorder of menstruation ( >5% )， Scanty vaginal bleeding,20-25℃,Secondary menopause: 5-10mg daily for 5-10 days. Abnormal bleeding in the uterus due to hormonal imbalance: 5-10mg daily for 5-10 days from day 16 or day 21 of menstrual cycle.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於懷孕或準備懷孕婦女。
OUCA,Calcium Carbonate,U-Cal 500mg,NUTR,,適應症: Relief of the symptoms of gastric hyperacidity. 副作用: Mild GI disturbances. 禁忌: Hypercalcaemia due to myeloma， bone metastases or other malignant bone disease， sarcoidosis; primary hyperparathyroidism， vitamin D overdosage; severe renal failure.,,室溫,1-2 tab before meals & at bedtime. Max: 6 tab/day.,,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,,沒有資料,,,Compatible 哺乳時可使用,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,,,,,,
OZES,Lisinopril,Zestril 10mg,CAVS,,適應症: Hypertension， CHF， AMI， Renal complications of diabetes mellitus. 副作用: Dizziness， headache， diarrhoea， fatigue， cough， nausea， rash， orthostatic effects， asthenia. Rarely， angioedema， MI， CVA possibly secondary to excessive hypotension in high risk patients， palpitations， tachycardia， abdominal pain and indigestion， dry mouth， hepatitis， jaundice， vomiting， mood alterations， mental confusion， vertigo， urticaria， diaphoresis， uraemia， oliguria/anuria， renal dysfunction， acute renal failure， impotence， a symptom complex which may include fever， vasculitis， myalgia， arthralgia/arthritis， positive ANA， elevated ESR， eosinophilia & leukocytosis. Rash， photosensitivity or other dermatological manifestations. Increases (usually reversible) in blood urea， serum creatinine， liver enzymes & serum bilirubin. Small decreases in hemoglobin & hematocrit. Hyperkalemia， hyponatremia， leucopenia， thrombocytopenia， bone marrow depression， manifest as anaemia， paraesthesia， pancreatitis. Rarely， haemolytic anaemia. 禁忌: Angioedema associated with ACE inhibitors & in patients with hereditary or idiopathic angioedema.,,室溫,Hypertension Usual maintenance dose: 20 mg once daily. Starting dose: 10 mg once daily. Lower starting dose required in renal impairment， renovascular hypertension， vol or salt depletion when diuretics cannot be discontinued. Max: 80 mg/day. CHF 5-20 mg once daily. Starting dose: 2.5 mg. AMI 1st dose of 5 mg followed by 5 mg after 24 hr， 10 mg after 48 hr & then 10 mg once daily thereafter. Renal complications of diabetes mellitus 10-20 mg once daily.,,,,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ITAX8,Docetaxel,TAXOTERE inj 80mg/4mL,RACA,Breast cancer， non-small cell lung cancer， prostate cancer， gastric adenocarcinoma， head & neck cancer.,Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count <1，500/mm3. Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding,Hematologic reactions especially neutropenia， fever， hypersensitivity reactions， fluid retention， GI disturbances， cutaneous reactions， neurologic symptoms， asthenia， alopecia. Cardiovascular: Edema (47% to 64.1% )， Vasodilatation (27% ) Dermatologic: Alopecia (56.3% to 97.8% )， Disorder of nail (11.4% to 18.5% )， Disorder of skin AND/OR subcutaneous tissue， Nail changes (8.1% to 30.6% )， Pruritus， Rash Gastrointestinal: Diarrhea (32.8% to 42.6% )， Nausea (38.8% to 80.5% )， Stomatitis (41.7% to 69.4% )， Vomiting (22.3% to 44.5% ) Hematologic: Anemia (89.1% to 93.6% )， Leukopenia (95.6% to 98.6% )， Neutropenia (71.4% to 99.5% ) Neurologic: Asthenia (61.8% to 80.8% )， Neuropathy Reproductive: Amenorrhea (61.7% ) Other: Fever of unknown origin (31.2% to 46.5% ),25℃以下避光,[Breast cancer] Operable (adjuvant treatment): TAC regimen: 75 mg/m2 every 3 weeks for 6 courses in combination with doxorubicin 50mg/m2 and cyclophosphamide 500 mg/m2; Locally advanced or metastatic: 100 mg/m2 every 3 weeks as a single agent; 75 mg/m2 every 3 weeks in combination with doxorubicin 50 mg/m2 as first-line therapy; In combination with weekly trastuzumab: 100 mg/m2 every 3 weeks; In combination with capecitabine: 75 mg/m2 every 3 weeks.  [Non-small cell lung cancer] Chemotherapy-naive patients: 75 mg/m2 every 3 weeks in combination with cisplatin 75 mg/m2 or carboplatin with a target AUC of 6 mg/mL•min; Patients with prior failure of platinum?based chemotherapy: 75 mg/m2 every 3 weeks as a single agent.  [Prostate cancer] 75 mg/m2 every 3 weeks in combination with oral prednisone or prednisolone 5 mg twice daily. [Gastric adenocarcinoma] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil. [Head and neck cancer] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil for 3 or 4 cycles， followed by radiation therapy.,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 稀釋溶液與器具應使用玻璃、聚丙烯(polypropylene)、聚烯(polyolefin)材質，不可使用含PVC塑膠材質。給藥時應使用 polyethylene 材質的輸液套。 3. 配製好的輸注溶液濃度避免超過 0.74 mg/mL，配置好6小時內以靜脈輸注方式使用 (包含輸注時間)，在低於25℃以下給予病患。使用前應再次目視檢查，若有沉澱物或結晶應予以丟棄。 4. 注射前應先給予預防過敏的藥物。 5. 監測CBC、肝功能。
EDOB,Sod Borate + Glycerin + Liq Phenol,Dobell's soln,TENT,,Antiseptic for oral hygiene.,,,Appropriate as much as necessary.,,,,,,,,,,,,,,
EDUL,Bisacodyl,Dulcolax 栓劑 10mg,ALIM,,適應症: Constipation. Preparation of diagnostic procedures， in pre- & post-op treatment & in conditions which require defecation to be facilitated. 副作用: Rarely， abdominal cramps， abdominal pain & diarrhea. Allergic reactions. 禁忌: Ileus， intestinal obstruction， acute surgical abdominal conditions including appendicitis， acute inflammatory bowel diseases & severe dehydration. Rare hereditary conditions of galactose intolerance eg. galactosemia or fructose intolerance. Lactation.,,室溫,Constipation Adult & children > 10 years 5-10 mg at bedtime or 1 supp. Children 4-10 years 5 mg at bedtime or 0.5 supp， < 4 years Pediatric supp recommended. Preparation of diagnostic procedures & preoperatively Adult 10-20 mg the night before the exam， followed by 1 supp in the morning of the exam. Children >= 4 years 5 mg in the evening & 1 pediatric supp on the following morning.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EDUO,Salicylic Acid + Lactic Acid,Duofilm 15mL,TDER,,禁忌：Hypersensitivity to salicylic acid or any component of the formulation. Impaired circulation (eg， diabetes， peripheral vascular disease); moles， birthmarks; warts with hair growth or on face. 適應症: Removal of warts. 副作用: Local irritation.,,室溫,Soak lesion in hot water for 5 mins & dry thoroughly. Rub surface with pumice stone or emery board & apply to affected area 2-4 drops once daily.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EDUR,Petrolatum + Lanolin + Mineral Oil,Duratears ointment 3.5gm,TOPH,Temporary relief of ocular irritation due to eye dryness.,Hypersensitivity to any ingredients of the ointment.,Transient blurring in vision， allergic reaction.,25℃以下,Apply a small amount of cream (approximately 1 cm) to the pouch whitch formed by pull the lower eyelid away from the eye when needed.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,OD;OL;OU;,,,,,
EELD,Hydroquinone,Eldopague Forte 4% cream,TDER,,I: Chloasma，melasma，freckles，senile lentigines，& other unwanted areas of melanin hyperpigmentation. AR: Hypersensitivity.,,,Apply to the affected area bid.,,,,除非治療上需要,,,,,,,,,,
EESP,Desoximetasone,Esperson oint 0.25%， 5gm,TDER,,I: Eczema， neurodermatitis， dermatitis， psoriasis， 1st degree burns， sunburn. AR: Folliculitis， acne， changes in skin pigmentation， telangiectasis， striae distensae， skin atrophy. CI: Skin changes due to chickenpox， syphilis， TB， vaccinations， rosacea or perioral dermatitis. Treatment of extensive areas in pregnant & lactating mothers.,,,Initially apply bid-tid， then once daily.,,,,,,,,,,,,,,
EESTT,Estradiol 17B,Estraderm MX 50,HM,,I: Signs & symptoms of natural or surgically induced estrogen deficiency due to menopause. AR: Skin irritation at application site， estrogen-treatment related reactions， eg. breast discomfort， migraine. Isolated cases; generalised pruritus & exanthema， thromboembolic disorders， anaphylactoid reactions， jaundice. CI: Breast or endometrial carcinoma; endometrosis， vag bleeding of unknown origin; severe liver damage; a history of， or active， thrombophlebitis， thrombosis or thromboembolic disorders; pregnancy & lactation.,,,Continuous therapy: Apply every 3-4 days. Cyclic administration: 3 wk treatment followed by 1 wk without treatment. In patients with intactuterus， supplement without progestogen.,,,,不可使用,,,,,,,,,,
EETH,Enflurane,Ethrane 250mL,ZANE,,適應症: Induction and maintenance of general anesth. 副作用: Convulsions; liver damage; shivering; nausea; vomiting; involuntary muscle movements; hiccup; coughing; bronchospasm; laryngospasm; hypotension; cardiac arrhythmias; resp depression; mild hypothermia; malignant hyperthermia; uterine relaxation (high concentrations); resp depression; hypotension; asthma. 禁忌: Known or suspected susceptibility to malignant hyperthermia. Porphyria.,,室溫,Inhalation Induction: 0.4% v/v in air， O2 or nitrous oxide-oxygen mixtures， increase in steps of 0.5% v/v every few breaths. Max: 4.5%. Maintenance: 0.5-3% v/v. Not to exceed 3% v/v during spontaneous resp.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EEURL,Crotamiton,Eurax lotion 10%,TDER,,I: Symptomatic treatment of pruritus， scabies， pediculosis capitis. AR: Local skin irritation. CI: Do not apply on nipples when breastfeeding.,,,Apply bid-tid; occlusive dressings not to be used.,,,,,,,,,,,,,,
EEXO,Naftifine,Exoderil cream 15gm,TDER,,I: Tinea corporis，Tinea inguinalis，Tinea manuum，Tinea pedum，Onychomycoses， Candida infections of the skin， Pityriasis versicolor，inflammatory dermatomycoses（ with and without pruritus）. AR: Dryness， reddening & burning.,,RT,Apply once daily to the affected skin area and its vicinity after thorough cleaning and drying. To prevent recurrent infection continue treatment for at least 2 weeks after clinical healing.,,,,可能安全,,,,,,,,,,
ILIP1,Soybean Oil,Lipovenos 10% 100mL(小兒TPN用),NUTR,,適應症:為幼兒脂質營養補給液(B020726255),,RT,Adult， neonate， infant & childn 1-2 g fat/kg body wt/day. Max infusion rate: 26 drrops/min.,,,,沒有資料,,,,,,,,,,
OGLI8,Gliclazide,Glicalin 80mg,META,,適應症: Type 2 DM 副作用: GI disturbances. Skin allergy (rare). 禁忌: Diabetes complicated by ketosis， acidosis， surgery， infection， severe trauma， severe diarrhea or nausea & vomiting; pregnancy. Severe renal or hepatic impairment.,,室溫,PO Initial: 40-80 mg/day， increase slowly if needed. Doses >160 mg/day may be given in 2 divided doses.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IAVA,Bevacizumab,Avastin inj 100mg/4mL,RACA,In combination with irinotecan/5-fluorouracil/leucovorin or 5-fluorouracil/leucovorin as 1st-line treatment of metastatic carcinoma of the colon or rectum,Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanised antibodies; untreated CNS metastases.,Asthenia， pain， abdominal pain， headache， hypertension， diarrhea， nausea， vomiting， anorexia， stomatitis， constipation， upper respiratory infection， epistaxis， dyspnea， exfoliative dermatitis， proteinuria. Rarely， GI perforation， hemorrhage， arterial thromboembolism， wound healing complications， hypertensive crises， nephrotic syndrome， CHF.,2-8℃避光,Infuse the initial dose over 90 minutes. The second infusion may be administered over 60 minutes if the initial infusion is well tolerated. The third and subsequent infusions may be administered over 30 minutes if the 60-minute infusion is well tolerated. Continue treatment until disease progression or unacceptable toxicity.  [Metastatic Colorectal Cancer (mCRC)]- 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination withfluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line Avastin-containing regimen.- 10 mg/kg every 2 weeks or 15 mg/kg every 2 weeks for Avastin-naive patients as second-line therapy.  [Metastatic Breast Cancer (mBC)] 10 mg/kg every 2 weeks  [Glioblastoma] 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks  [Non-Squamous Non-Small Cell Lung Cancer (NSCLC)] 15 mg/kg every 3 weeks  [Ovarian (epithelial)， fallopian tube， or primary peritoneal cancer] - Stage III/IV disease following initial surgical resection: 15 mg/kg every 3 weeks (in combination with carboplatin and paclitaxel) for up to 6 cycles， followed by bevacizumab 15 mg/kg every 3 weeks (monotherapy)， for a total of up to 22 cycles (=15 months) or until disease progression (whichever occurs earlier)- Platinum-sensitive recurrent: 15 mg/kg every 3 weeks (in combination with carboplatin and gemcitabine for 6-10 cycles or with carboplatin and paclitaxel for 6 to 8 cycles) then continue with bevacizumab (monotherapy) until disease progression or unacceptable toxicity- Platinum-resistant recurrent: 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks (in combination with paclitaxel， doxorubicin [liposomal]， or topotecan)  [Cervical cancer] 15 mg/kg every 3 weeks (in combination with paclitaxel and either cisplatin or topotecan),無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,【N/S】可選 。,,,1. 輸注溶液不可含葡萄糖。 2. 稀釋後輸注溶液應擺放於2-8度C儲存，超過8小時未使用應丟棄。 3. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至30-60分鐘。 4. 監測蛋白尿。 5. 每2-3週監測血壓變化。
IPITR,Vasopressin,Pitressin inj 20 Units/1mL,HM,Esophageal varices bleeding. Diabetes insipidus.,Anaphylaxis or hypersensitivity to the drug or its components,Tremor; sweating; vertigo; circumoral pallor; `pounding' in the head; abdominal cramps; urticaria; vomiting; bronchial constriction; MI， cardiac arrest; water intoxication.,25℃以下勿冷凍,Abdominal swelling caused by surgery: IV or IM 5 units (0.25mL)， up to 10 units (0.5mL)， repeated every 3-4 hour if needed. Abdominal radiography: IM 10 units (0.5mL) for two times， two hours and an half hour before radiography. Diabetes insipidus: IM or SC 5-10 units (0.25-0.5mL) or IV 0.1 units， repeated every 4-12 hours if needed. Bleeding from esophageal varices: Diluted 20 units of Pitressin into 100-200mL of 5% D5NS， infusion for 10-20 minutes， repeated every 1-2 hour， if needed， up to 4 doses.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IM;IN;IVD;SC;,,【D5W】可選 仿單建議。,,輸注速率 < 0.4 U/min,
OICO,Itraconazole,Icomein 100mg,QANB,Vulvovag candidiasis， Dermatomycosis， Plantar tinea pedis & palmar tinea manus， Pityriasis versicolor， Oral candidiasis， Fungal keratitis， Onychomycosis， Aspergillosis， Candidosis， Non-meningeal cryptococcosis， Cryptococcal meningitis ， Histoplasmosis， Blastomycosis， Lymphocutaneous & cutaneous sporotrichosis， Paracoccidioidomycosis， Chromomycosis.,Pregnancy & lactation.,Dyspepsia， nausea， abdominal pain & constipation. Less frequently， headache， reversible increases in hepatic enzymes， menstrual disorders， dizziness， allergic reactions (e.g. pruritus， rash， urticaria， angio-edema).,15-30℃乾燥處,(仿單) Adult: 100-200 mg 1-2 times daily after meals.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OFEM,Letrozole,Femara 2.5mg,RACA,Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status， who have previously been treated with antioestrogens. 1st-line treatment in postmenopausal women with hormone-dependent advanced breast cancer. Extended adjuvant treatment of hormone receptor +ve & LN metastasis +ve breast cancer patient who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor +ve invasive early breast cancer.,Hypersensitivity to letrozole or any component of the formulation; pregnancy. Use in patients <18 years of age; premenopausal endocrine status; breastfeeding.,Headache， nausea， peripheral edema， fatigue， hot flushes. Cardiovascular: Edema (7.2% to 18.4% ) Dermatologic: Hot sweats (5% to 49.7% )， Sweating (up to 24.2% ) Gastrointestinal: Constipation (1.5% to 11.3% )， Diarrhea (5% to 8% )， Loss of appetite (3% to 5% )， Nausea (8.6% to 17% )， Vomiting (2.7% to 7% ) Musculoskeletal: Arthralgia (8% to 22% )， Arthritis (6.7% to 21.1%)， Backache (5% to 18% )， Bone pain (22% )， Myalgia (6.4% to 6.7% ) Neurologic: Asthenia (4% to 33.6% )， Dizziness (2.4% to 14.2% .)， Headache (3.5% to 20.1% )， Insomnia (5.8% to 7% .)， Somnolence (2% to 3% .) Respiratory: Dyspnea (5.5% to 18% ) Other: Fatigue (6% to 13% ),30℃以下乾燥處,2.5 mg orally once a day， without regard to meals for a planned duration of 5 years; discontinue at relapse， disease progression or unacceptable toxicity. In patients with advanced disease， treatment with Femara should continue until tumor progression is evident.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OHAL2,Haloperidol,Apo-Haloperidol 2mg,CNEU,,適應症: Acute & chronic psychotic disorders including schizophrenia & manic states， Tourette's syndrome. Severe behavioral problems & hyperactivity in children. Nausea & vomiting associated with antineoplastic therapy & surgery. 副作用: Occasionally， depression， anxiety， agitation， confusion， vertigo， exacerbation of psychotic symptoms & seizures. Hyperprolactinaemia， gynaecomastia， menstrual irregularities， impotence. Rarely， tachycardia， orthostatic hypotension. 禁忌: Endogenous depression without agitation， comatose conditions， severe CNS depression. Pregnancy， children.,,室溫,Initially 1-2 mg bid-tid & gradually increase up to 4-6 mg tid if required. Severely disturbed patients Up to 100 mg/day. Maintenance: 1-2 mg tid-qid.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OIMOV,Zopiclone,Imovane 7.5mg,CNEU,Insomnia.,Myasthenia gravis. Respiratory failure， severe sleep apnea syndrome. Severe hepatic insufficiency.,Bitter-taste; dizziness， headache， residual somnolence; GI disturbances; allergic reactions; psychiatric & paradoxical reactions; rebound insomnia & withdrawal phenomena. Gastrointestinal: Disorder of taste (8% to 34% )， Vomiting (3% ) Neurologic: Dizziness (1% to 7% )， Headache (13% to 21% )， Migraine (1% or greater ) Respiratory: Respiratory tract infection (5% to 10% ),25℃以下,Adult 7.5mg(1 TAB) at bedtime. Elderly Initially 1/2 TAB at bedtime & if necessary increase to 1 TAB. In hepatic or renal function or non-decompensated respiratory insufficiency 1/2 TAB at bedtime.,無需調整劑量,,無需調整劑量,沒有資料,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
LKID,Prednisolone,Kidsolone solution 1mg/mL， 60mL,HM,Allergic and inflammatory disorders， Rheumatoid arthritis， Multiple sclerosis.,Hypersensitivity; live vaccines; herpes simplex keratitis， systemic infections.,Cushing's syndrome and growth retardation in childn; osteoporosis， fractures. Peptic ulceration; glaucoma， cataracts; hyperglycaemia， pancreatitis; increased appetite， obesity.,25℃以下，不需冰存並避免陽光直射,Adult: 5-60mL daily. Child: 0.14-2mg/kg/day devided into 3-4 times.,無需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
LUCE,Cefadroxil,Ucefa susp 25mg/mL， 60mL,QANB,,適應症: Infection of the GUT， respiratory tract， skin & soft tissue by susceptible organisms. 副作用: Nausea， vomiting， diarrhea， abdominal discomfort; Allergic reactions， eosinophilia， angioedema， anaphylaxis， neutropenia， superinfection， pseudomembranous colitis， genital pruritus. 禁忌: Hypersensitivity to cephalosporins.,,室溫,Children 30 mg/kg body wt， divided twice daily up to a maximum of 2 g/day,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
ORELA,Carisoprodol + Acetaminophen,RelaX 175/350mg,CNEU,,適應症: Symptomatic relief of mild to moderate pain of acute musculoskeletal disorders e.g. stiff shoulder， sprains， strains， lumbago， arthralgia & myalgia. 副作用: Drowsiness， dizziness， vertigo， ataxia， idiosyncratic reactions， hypersensitivity reactions， hypotension， tachycardia， cardiac arrhythmias， GI disturbances. Neurologic: Dizziness (7% to 8% )， Headache (3% to 5% )， Somnolence (13% to 17% ) 禁忌: Acute intermittent porphyria， lactation.,,室溫,Adult : 1 ~ 2 Tablets qid.,需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ORIS,Risperidone,Risperdal 2mg,CNEU,,適應症: Treatment of schizophrenia， including 1st episode psychoses， acute schizophrenic exacerbations， chronic schizophrenia， & other psychotic conditions. Alleviates affective symptoms (eg. depression， guilt feelings， anxiety) associated with schizophrenia. Long-term therapy for the prevention of relapse in chronic schizophrenia. Treatment of behavioral disturbances in patients with dementia. As adjunctive therapy to mood stabilizers or monotherapy in the treatment of manic episodes associated with bipolar disorder. Treatment of conduct & other disruptive behavioral disorders in children， adolescents & adults with subaverage intellectual functioning or mental retardation. 副作用: Common: insomnia， agitation， anxiety， headache. Less common: somnolence， fatigue， dizziness， impaired concentration， constipation， dyspepsia， nausea/vomiting， abdominal pain， blurred vision， priapism， erectile dysfunction， ejaculatory dysfunction， urinary incontinence， rhinitis， rash & other allergic reactions. Occasionally， orthostatic hypotension， reflex tachycardia or hypertension. Cardiovascular: Peripheral edema (adults， up to 3%; children， less than 5% .)， Tachycardia (oral， adults， up to 5%; children， up to 7% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% ) Dermatologic: Rash (oral， adults， 2% to 4%; children， up to 11% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% ) Endocrine metabolic: Hyperprolactinemia (oral， adults， less than 1%; children， 49% to 87% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Weight gain (oral， adults， up to 18%; children， up to 14%; intramuscular， schizophrenia， 4% to 5%; bipolar I disorder， 5% to 7% ) Gastrointestinal: Abdominal pain (oral， adults， 2% to 4%; children， 15% to 18% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Constipation (oral， adults， 5% to 9%; children， 21% ; intramuscular， schizophrenia， 5% to 7% )， Diarrhea (oral， adults， up to 6%; children， 7% to 8% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Excessive salivation (oral， adults， 1% to 4%; children， up to 22% ; intramuscular， schizophrenia， 1% to 4% )， Increased appetite (oral， children， 4 to 49% ; intramuscular， bipolar I disorder， 4% )， Indigestion (oral， adults， 4% to 10%; children， 5% to 16% ; intramuscular， schizophrenia， 6% )， Nausea (oral， adults， 4% to 9%; children， 8% to 16% ; intramuscular， schizophrenia， 3% to 4% )， Vomiting (oral， children， 10% to 12% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Xerostomia (oral， adults， up to 4%; children， up to 13% ; intramuscular， schizophrenia， 0% to 7%) Musculoskeletal: Pain， in Extremity (intramuscular， schizophrenia， 2% to 6% ) Neurologic: Akathisia (oral， adults， 5% to 9%; children， up to 10% ; intramuscular， schizophrenic adults， 4% to 11% )， Dizziness (oral， adults， 4% to 11%; children， 7% to 16% ; intramuscular， schizophrenia， 7% to 11%; bipolar I disorder， 3% )， Extrapyramidal disease (adults， 7% to 31% )， Headache (intramuscular， 15% to 21% )， Insomnia (oral， adults， less than 1%; children， less than 5% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Parkinsonism (oral， adults， 0.6% to 20%; children， 2% to 16% ; intramuscular， schizophrenia， 8% to 15%; bipolar I disorder， 15% )， Somnolence (oral， adults， 5% to 14%; children， 12% to 67% ; intramuscular， schizophrenia， 5% to 6%; bipolar I disorder， 7% )， Tremor (oral， adults， up to 5% to 6%; children， 10% to 12% ; intramuscular， schizophrenia， 0% to 3%; bipolar I disorder， 24% ),,室溫,Adult May be given once or bid. Initially 2 mg/day. Usual dose: 2-6 mg/day. Elderly or patient with renal or liver disease Initially 0.5 mg bid， increasing to 1-2 mg bid.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
YSTR,Polydimethylsiloxanes， siloxanes,Strataderm gel 10gm,TDER,,,,,,,,,,,,,,,,,,,
YPOLY,Polysiloxane,Polyxal silicone gel 15gm,TDER,,,,儲存在陰涼燥處,,無需調整劑量,,無需調整劑量,沒有資料,,,Unknown 沒有資料,,EXT;SKIN;TOPI;,,,,,
OMTX,Methotrexate,Methotrexate 2.5mg,RACA,Oncology uses: Acute lymphoblastic leukemia (ALL) maintenance treatment， ALL meningeal leukemia (preservative-free only; prophylaxis and treatment); treatment of trophoblastic neoplasms (gestational choriocarcinoma， chorioadenoma destruens and hydatidiform mole)， breast cancer， head and neck cancer (epidermoid)， cutaneous T-Cell lymphoma (advanced mycosis fungoides)， lung cancer (squamous cell and small cell)， advanced non-Hodgkin lymphomas (NHL)， osteosarcoma (preservative-free only). Nononcology uses: Treatment of psoriasis (severe， recalcitrant， disabling) that is unresponsive to other therapies; severe， active rheumatoid arthritis (RA) that is unresponsive to or intolerant of first-line therapy including full dose nonsteroidal anti-inflammatory agents (NSAIDs); active polyarticular-course juvenile idiopathic arthritis (pJIA) that is unresponsive to or intolerant of first-line therapy including full dose nonsteroidal anti-inflammatory agents (NSAIDs). Off-Label: Abortion (medical management); Acute graft-versus-host disease (prophylaxis); Acute promyelocytic leukemia (APL) maintenance (adults); Bladder cancer; CNS lymphoma; Crohn disease (maintenance of remission); Dermatomyositis/polymyositis; Ectopic pregnancy; Multiple sclerosis; Nonleukemic meningeal cancer; Soft tissue sarcoma (desmoid tumors， aggressive fibromatosis)， advanced; Systemic lupus erythematosus， moderate-to-severe; Takayasu arteritis， refractory or relapsing disease; Uveitis (adults),Known hypersensitivity to methotrexate or any component of the formulation; breast-feeding. Additional contraindications for patients with psoriasis， rheumatoid arthritis or polyarticular-course juvenile idiopathic arthritis: Pregnancy， alcoholism， alcoholic liver disease or other chronic liver disease， immunodeficiency syndromes (overt or laboratory evidence); preexisting blood dyscrasias (eg， bone marrow hypoplasia， leukopenia， thrombocytopenia， significant anemia).,Ulcerative stomatitis， leukopenia， nausea & abdominal distress. malaise， fatigue， chills & fever， dizziness & decreased resistance to infection. Erythematous rashes， pruritus， urticaria， photosensitivity， depigmentation， alopecia， ecchymosis， telangiectasia， acne & furunculosis. Hematologic disorders. GI disturbances. CNS effects. Metabolic changes， precipitating diabetes， osteoporosis， conjunctivitis， abnormal tissue cell changes， anaphylaxis.,避光儲存於25℃以下,[Choriocarcinoma and similar trophoblastic diseases] 15-30 mg orally or IM daily for a 5-day course. Repeat 3-5 times as required with rest periods of 1 or more weeks interposed between courses， until any manifesting toxic symptoms subside. [Leukemia] Induction: 3.3 mg/m2 in combination with prednisone 60 mg/m2 daily for 4-6 weeks. Maintenance therapy: orally or IM 2 times weekly intotal weekly doses of 30 mg/m2 or 2.5 mg/kg intravenously every 14 days. If and when relapse occurs， repeat the initial induction regimen. [Lymphomas] 10-25 mg/day orally for 4-8 days. Treatment in all stages usually consists of several courses interposed with 7-10 day rest periods. Lymphosarcomas in Stage III may respond to combined drug therapy with 0.625-2.5 mg/kg daily. [Psoriasis] 10-25 mg orally， IM or IV once weekly or 2.5 mg orally at 12-hour intervals for 3 doses every 1 week until adequate response is achieved. 30 mg/week should not ordinarily be exceeded.,無需調整劑量,,需調整劑量,不可使用,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
ONAHCO3,Sodium Bicarbonate,NaHCO3 300mg,ALIM,Relief of dyspepsia， Urinary alkalinization， Antacid.,Metabolic or respiratory alkalosis， hypocalcaemia， hypochlorhydria. Avoid overtreatment.,Metabolic alkalosis; shortness of breath & muscle weakness; muscle hypertonicity， twitching & tetany; Na overloading & hyperosmolality. Stomach cramps & flatulence. Tissue necrosis at inj site.,25℃以下避光,Metabolic acidosis， Chronic initial， 600 mg 3 times daily; increase to 4.8g/day (16 tablets). Severe Metabolic acidosis: used IV Sodium Bicarbonate. Urinary alkalinization: 3g every 2 hours， until urine pH>7 .maintain dose 5-10g/day (仿單),無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
ONIM,Nimodipine,Nimotop F.C 30mg,CAVS,Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasms following subarachnoid haemorrhage.,Patients with severely impaired liver function (eg， cirrhosis of the liver). In view of its indication area， Nimotop tablet is not used during pregnancy or lactation.,Hypotension， GI disturbances.,室溫藥品，仿單無特別指示儲存溫度條件,Subarachnoid hemorrhage， From ruptured intracranial berry aneurysms: treatment or prophylaxis: 60mg Q4H for 7 days (1 hour before or 2 hours after meals)， after IV infusion Nimotop for 5-14 days.,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OORF5,Warfarin,ORFARIN 5mg,HEMT,,適應症: Treatment & prophylaxis of thromboembolic disorders. 副作用: Alopecia， skin rashes of various kinds， hemorrhagic skin necrosis. Cardiovascular: Cholesterol embolus syndrome Dermatologic: Tissue necrosis Hematologic: Hemorrhage Immunologic: Hypersensitivity reaction (infrequent ) Ophthalmic: Intraocular hemorrhage (5% to 11% ) 禁忌: Severe hepatic or renal disease， actual or potential haemorrhagic conditions， severe hypertension， endocarditis， ulceration of the GI & urinary tract， visceral carcinoma， endocarditis， neurosurgery， recent surgery on the eye， brain or spinal cord. Pregnancy.,,室溫,Initially， 10-15 mg daily， adjusted with relation to the result of control tests. Maintenance dosage adjusted according to INR.,,WHO:Compatible with breast-feeding.,,不可使用,,,Compatible 哺乳時可使用,WHO:Compatible with breast-feeding.,,,,,,
ILOS,Omeprazole,Losec 40mg inf,ALIM,,適應症: Duodenal & gastric ulcer， reflux esophagitis， Zollinger-Ellison syndrome. 副作用: Headache， diarrhea， constipation， abdominal pain， nausea/vomiting， flatulence. Rarely fatigue， rash &/or pruritus， dizziness， paresthesia， somnolence， insomnia， increased liver enzymes.,,室溫,Duodenal & gastric ulcer， reflux esophagitis 40 mg IV once daily. Zollinger-Ellison syndrome Dose should be adjusted individually. Higher doses &/or several doses daily may be required.,,,,除非治療上需要,,,,,,,,,,
ILUM,Phenobarbital,Lumian inj,CNEU,,Insomnia， anxiety， excitement， epilepsy， tetanus， preanesthetic medication， cardiac and gastric neurosis.,,,Adult:For anticonvulsant: Oral: 50-100 mg bid-tid. IM， slow IV: 100-300 mg may be repeated in 6hrs as needed. For hypnotic: 100-200 mg qN. For sedative: 15-30 mg bid-tid. Child:Oral: 3-6 mg/kg in divided doses. IM， IV: 3-5 mg/kg q3-4h as needed.,,,,盡量避免,,,,,,,,,,
IMART,Maltose,Maltose-10 inj 10% 500mL,NUTR,,適應症:醣類補給液,,室溫,Adult: 500-1000 ml at rate of 500 ml/120 mins.,,,,沒有資料,,,,,,,,,,
IMEA,Measles Vaccine,麻疹自費疫苗,HIMM,,Active immunization against measles.,,,SC， children over 1 yr， 1 vial (0.5 ml after reconstitution).,,,,除非治療上需要,,,,,,,,,,
IMEAA,Measles Vaccine,Rimevax inj( MEASLES )(衛生署),HIMM,,Active immunization against measles.,,,SC， children over 1 yr， 1 vial (0.5 ml after reconstitution).,,,,除非治療上需要,,,,,,,,,,
IMETY,Mecobalamin,Methycobal inj 500mcg/1mL,CNEU,Megaloblastic anemia due to vit B12 deficiency & peripheral neuropathies.,Hypersensitivity to any component of the formulation.,Infrequently: Anorexia， nausea， diarrhea， pain & induration at IM inj site. Rarely: Skin rash， headache， sweating or hot sensation. Dermatologic: Injection site pain Musculoskeletal: Arthralgia (12% ) Neurologic: Dizziness (12% )， Headache (12% ) Respiratory: Nasopharyngitis (12% ),室溫,Peripheral neuropathies: 500 mcg IM/IV 3 times/week.Megaloblastic anemia due to vit B12 deficiency: 500 mcg IM/IV 3 times/week for 2 months， then 500 mcg every 1-3 months as maintenance therapy.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,IM;IVP;IVPUSH;,,,,,1.IM is the preferred route of administration. IV administration is not recommended because the drug is excreted more rapidly and almost all of the cyanocobalamin is lost in the urine. 2.The medicine is light sensitive， so protection from light is recommended.
IMF1000,Mix Fungus,MF 1000,ZOTH,,,,,,,,,,,,,,,,,,,
IMGSO4,Magnesium Sulfate,Magnesium Sulfate inj 10%， 20mL,NUTR,Hypomagnesemia; emergency treatment of life-threatening arrhythmias; prevention of recurrent seizures in eclampsia or pre-eclampsia.,Patients with heart block， myocardial damage or severe renal impairment.,Hypermagnesaemia characterized by loss of tendon reflexes & respiratory depression， flushing， thirst， hypotension， drowsiness， nausea， vomiting， confusion， muscle weakness， cardiac arrhythmias， coma & cardiac arrest.,25℃以下,As TPN material only. Each mL contains: 0.1g magnesium sulfate salt=0.81mEq of elemental magnesium=0.405 mmol of elemental magnesium. [Uptodate 20210731] Standard daily magnesium requirement: IV: Elemental magnesium 8 to 20 mEq (4 to 10 mmol) daily as component of parenteral nutrition; adjust daily dose based on serum magnesium and clinical considerations (ASPEN 2019).,無需調整劑量,,需調整劑量,沒有資料,,,,,,,,,,
IMIA,Salmon Calcitonin,Miacalcic inj 50 IU/1mL,META,Hypercalcemia， Paget's disease of bone， postmenopausal osteoporosis.,Hypersensitivity to Miacalcic.,Inj Nausea， vomiting， dizziness， flushing accompanied by heat， arthralgia， polyuria， chills， hypersensitivity reactions. Dermatologic: Flushing， Face or hands (approximately 2% to 5% )， Injection site reaction (about 10% ) Gastrointestinal: Nausea (approximately 10% ) Respiratory: Rhinitis (12% )， Sinusitis (2.3% ),2-8℃避免冷凍,IM， SC， IVD， Paget's disease 100 IU IM or SC once daily or every alternate day. Emergency treatment of hypercalcemic crisis 5-10 IU/kg daily by IV infusion over at least 6 hours or by slow IV inj in 2-4 divided doses. Chronic hypercalcemic states 5-10 IU/kg IM or SC daily as a single dose or in 2 divided doses. If the volume to be injected is >2 mL， use IM administration.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;SC;,,【N/S】可選 仿單建議。,,高血鈣危象時可能採用靜脈輸注，劑量 5-10 U/Kg/day 加入500 mL N/S，作6小時以上靜脈輸注，或將日劑量均分成2-4次慢速靜脈注射。,1. 注射量 >2 mL建議採肌肉注射，並於不同部位施打。。 2. 高血鈣危象時可能採用靜脈輸注，劑量 5-10 U/Kg/day 加入500 mL N/S，作6小時以上靜脈輸注，或將日劑量均分成2-4次慢速靜脈注射。
IMIN,Minocycline,Minocin 100mg,QANB,,Resp. tract， GUT，soft tissue， ENT， ophthalmologic infection，periodonitis.,,,Acne vulgaris : 100 mg qd or 50mg bid. Non-gonococcal urethritis: 200 mg qd or 100mg bid for 10-14 days. Gonorrhea : Adult male 200 mg initially followed by 100 mg 12 hrly for min of 4 days. Adult female Same dosage as male for 10-14 days. Systemic infection: 100 mg q12h. Prophylaxis of asymptomatic meningococcal carriers:100 mg bid for 5 days.,,,,盡量避免,,,,,,,,,,
IMIO,Carbachol,Miostat inj 0.01% 1.5mL,TOPH,Intraocular use for miosis during surgery.,Hypersensitivity to carbachol or any component of the formulation. Use with caution in patients with asthma， peptic ulcer disease or gastrointestinal spasm， acute heart failure， hyperthyroidism， Parkinson's disease， and urinary tract obstruction.,Ophthalmic: Blurred vision， corneal edema， corneal opacity， epithelial keratopathy (bullous)， eye pain， increased intraocular pressure， iritis (postoperative)， ocular hyperemia， ophthalmic inflammation， retinal detachment， visual impairment.,攝氏15-30度室溫,Ophthalmic surgery， miosis: Intraocular: 0.5 mL instilled into the anterior chamber before or after securing sutures.,無需調整劑量,[仿單] 本品是否會由乳脂分泌未知。授乳婦使用本品應予以警告。,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,[仿單] 孕婦類別C.本品尚未有對孕婦作適當及控制量老之研究報告。 只有在權衡益處大於對胎兒之危險性時才得以使用本品。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 本品是否會由乳脂分泌未知。授乳婦使用本品應予以警告。,LI;TOPI;,,,,,Intraocular route 1) It is recommended that no more than 0.5 milliliter of a 0.01% carbachol solution be instilled into the anterior chamber of the eye to obtain miosis before or after securing sutures.
OLACS,Etodolac,Lacoxa SR 400mg,CNEU,,適應症: RA & osteoarthritis. 副作用: GI discomfort， hypersensitivity reactions， bronchospasm， headache， dizziness， nervousness， depression， drowsiness， insomnia， vertigo， hearing disturbances， photosensitivity， haematuria. Cardiovascular: Edema (1% to 10% ) Gastrointestinal: Abdominal pain (3% to 9% )， Diarrhea (3% to 9% )， Flatulence (3% to 9% )， Indigestion (10% )， Nausea (3% to 9% ) Hepatic: Increased liver function test (up to 15% ) Neurologic: Dizziness (3% to 9% )， Headache (3% to 4% ) Other: Malaise (3% to 9% ) 禁忌: Patients in whom aspirin & other NSAIDs precipitate attacks of asthma， angioedema， urticaria or rhinitis; active peptic ulceration.,,室溫,Initially 600-1200 mg daily in divided doses adjusted according to response to a max of 1200mg daily,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IKAB1,Glucose + Amino Acid + lipid,Kabiven 中心靜脈輸注1540mL,NUTR,,,,,,,,,,,,,,,,,,,
EVIG,Moxifloxacin,Vigamox 0.5%， 5mL ophthalmic solution,TOPH,The treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-positive microorganisms (Corynebacterium species， Micrococcus luteus， Staphylococcus aureus， Staphylococcus epidermidis， Staphylococcus haemolyticus， Staphylococcus hominis， Staphylococcus warneri， Streptococcus pneumoniae， Streptococcus viridans group)， Aerobic Gram-negative microorganisms (Acinetobacter lwoffii， Haemophilus influenzae， Haemophilus parainfluenzae)， Other microorganisms (Chlamydia trachomatis).,History of hypersensitivity to moxifloxacin， to other quinolones， or to any of the components in this medication.,Conjunctivitis， decreased visual acuity， dry eye， keratitis， ocular discomfort， ocular hyperemia， ocular pain， ocular pruritus， subconjunctival hemorrhage， and tearing.(1-6%) Fever， increased cough， infection， otitis media， pharyngitis， rash， and rhinitis.(1-4%),30°C以下,instill 1 drop in the affected eye TID for 7 days.,無需調整劑量,[仿單]雖然可以假設moxifloxacin會分泌至人類乳汁中，但是並無法在人類乳汁中偵測出moxifloxacin。 Vigamox點眼液用於哺乳婦女應謹慎使用。,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,[仿單]懷孕的大鼠在器官形成期，口服moxifloxacin最高達500 mg/kg/day的劑量（約為人類眼部每日最高建議總量之21700倍）並不具致畸胎性；然而卻發現會造成胎兒體重減輕及胎兒骨骼發展略為延遲。懷孕的Cynomogus猴口服moxifloxacin高達100 mg/kg/day的劑量（約為人類眼部每日最高建議總量之4300倍）並未發現致畸胎的證據；在100 mg/kg/day的劑量下，胎兒較小的發生率增高。 由於用於懷孕婦女並無適當的對照研究，只有在潛在效益高於對胎兒的潛在傷害時，方可將Vigamox點眼液用於懷孕婦女。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]雖然可以假設moxifloxacin會分泌至人類乳汁中，但是並無法在人類乳汁中偵測出moxifloxacin。 Vigamox點眼液用於哺乳婦女應謹慎使用。,OD;OL;OU;,,,,,1. 不可作為注射劑使用。 2. 不可於結膜下注射Vigamox，也不可直接注入眼睛前房。
IFUC,Hyoscin-Butylbromide,Fucon inj 20mg/1mL,ALIM,Spasm & hyperkinesia of the GIT， spasm & dyskinesia of the biliary tract， urinary tract & female genital tracts.,Myasthenia gravis， toxic megacolon， narrow angle glaucoma， tachycardia， prostatic enlargement with urinary retention， pyloric stenosis & paralytic ileus.,Dry mouth， dyshidrosis， visual accommodation disturbances， tachycardia， dizziness， constipation， urinary retention， hypotension， allergic reactions， inj site pain.,25℃以下,Adult 20 mg 3-5 times daily IM/IV/SC.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;IVP;IVPUSH;SC;,,【N/S】可選 。,推注時間至少>1分鐘 (兒童：至少2-3分鐘),Intravenous routes， at a slow injection rate of 1 mL/min. No dilution of the solution is necessary prior to administration.,
OGLI5,Metformin,Glibudon 500mg,META,,適應症: Type 2 diabetes mellitus. 副作用: GI disturbances; skin rash or dermatitis (rare). Endocrine metabolic: Cobalamin deficiency (up to 9.9% ) Gastrointestinal: Diarrhea (53.2% (immediate-release) ; 9.6% to 12.5% (extended-release) )， Flatulence (12.1% )， Indigestion (7.1% )， Malabsorption syndrome (up to 9.9% )， Nausea (up to 25.5% (immediate-release); ; 6.7% (extended-release) )， Vomiting (up to 25.5% ) 禁忌: Patients with ketoacidosis， severe infections， stress， trauma. Severe renal impairment. Heart failure， dehydration， acute or chronic alcoholism， predisposition to lactic acidosis.,,室溫,1 tab tid.,,,,可能安全,,,,,,,,,,
OWIL,Dicyclomine + Alumium Hydroxide + Magnesium Oxide,Wilcon-U,ALIM,,適應症: Acute & chronic gastritis， indigestion， hyperacidity & symptomatic relief of pain due to peptic or duodenal ulceration. 副作用: Constipation， transient bradycardia (followed by tachycardia)， reduced bronchial secretions， urinary urgency & retention， dilatation of the pupils with loss of accommodation， photophobia， dry mouth， flushing & dryness of skin. 禁忌: Angle-closure glaucoma， myasthenia gravis， paralytic ileus， pyloric stenosis， prostatic enlargement.,,室溫,Adult 1-2 tab tid & at bedtime.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EMIK,Carteolol,Mikelan LA 2%， 2.5mL ophthalmic solution,TOPH,Glaucoma & ocular hypertension.,Unsatisfactorily controlled cardiac insufficiency; risk of bronchial asthma & bronchospasm; sinus bradycardia; AV block (II & III); cardiogenic shock; right ventricular insufficiency due to pulmonary hypertension & CHF.,Cardiovascular: Angina Neurologic: Asthenia (7% .)， Dizziness (4% to 15% .)， Headache (4% to 17% .)， Insomnia (2% to 12%.) Ophthalmic: Blurred vision， Burning sensation in eye (25% )， Conjunctival edema (25% )， Conjunctival hyperemia (25% )， Epiphora (25% )， Eye irritation (25% ),25℃以下,Instill 1 drop QD into the conjunctival sac.,無需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
OKBT,Kaolin + (BiO)2CO3 + Al. Tannate,KBT,ALIM,,適應症: Diarrhea. 禁忌: Intestinal obstruction.,,室溫,Adult 1-2 tab 4 hrly.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OLEX3,Bromazepam,Lexotan 3mg,CNEU,Functional disturbances of the CV & respiratory systems， GIT & GUT. Emotional disturbances & reactions to chronic organic diseases. Psychosomatic disorders & adjuvant to psychotherapy in psychoneurosis.,Early pregnancy， lactation. Myasthenia gravis.,Fatigue， drowsiness; rarely， muscle weakness (high doses). May impair ability to drive or operate machinery.,30℃以下,Outpatient 1.5-3 mg TID. Severe case， esp in hospital 6-12 mg BID or TID.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OLON,Etodolac,Lonine 200mg,CNEU,Osteoarthritis. Pain. Rheumatoid arthritis.,Asthma， urticaria， or allergic-type reaction following aspirin or other NSAID administration; severe， even fatal anaphylactic-like reactions have been reported. hypersensitivity to etodolac. CABG surgery within 14 days， treatment of perioperative pain.,Common Cardiovascular: Edema (1% to 10% ) Gastrointestinal: Abdominal pain (3% to 9% )， Diarrhea (3% to 9% )， Flatulence (3% to 9% )， Indigestion (10% )， Nausea (3% to 9% ) Hepatic: Increased liver function test (up to 15% ) Neurologic: Dizziness (3% to 9% )， Headache (3% to 4% ) Other: Malaise (3% to 9% ) Serious Cardiovascular: Congestive heart failure (less than 1% )， Hypertension (less than 1% )， Myocardial infarction (less than 1% )， Thrombotic tendency observations Dermatologic: Erythroderma， Stevens-Johnson syndrome (less than 1% )， Toxic epidermal necrolysis (less than 1% ) Gastrointestinal: Gastrointestinal hemorrhage， Gastrointestinal perforation， Gastrointestinal ulcer， Inflammatory disorder of digestive tract Hematologic: Thrombocytopenia (less than 1% ) Hepatic: Hepatic necrosis， Hepatitis (less than 1% )， Liver failure (less than 1% ) Immunologic: Anaphylactoid reaction (less than 1% ) Neurologic: Cerebrovascular accident Renal: Acute renal failure (less than 1% )， Papillary necrosis (less than 1% ) Respiratory: Bronchospasm,25℃以下,Pain: 200 to 400 mg orally every 6 to 8 hours; maximum 1200 mg/day. Rheumatoid arthritis or osteoarthritis: 300 mg orally BID to TID; or 500mg BID,無需調整劑量,[仿單]用於授乳婦:授乳期間使用LONINE之安全性尚未建立.致癌性，致突變性以及對生育力的損害: 為了評估LONINE的致癌性，會進行一項長達2年的大鼠實驗，以及另一項？期18個月的小鼠實驗; 結果並沒有發現任何致癌性. LONINE亦經Ames氏致突變性測驗證明無致變性.,無需調整劑量,沒有資料,Human data suggest risk in 1st and 3 rd trimesters,[仿單]用於孕婦:由動物實驗顯示，在2~10mg/kg的每日劑量下，此藥對大鼠或家免均無致胎性或胚胎毒性. 在3~15mg/kg的每日劑量下，對於雄鼠及雄鼠的生育力和全面的生殖表現，以及這些雌鼠所產下的後代，都只有很小的影響. 據實驗證明，若懷孕動物使用抑制前列腺素生物合成的藥物，可能會導致難產或延遲生產. 由針對每天服用LONINE 3~15 mg/kg的大鼠於產前產後的情況所進行的研究，發現在每天服用15mg/kg的一組裡，發生難產或孕期延長的母鼠數目，以及每一產的死胎數目，都比平常多. 至於孕婦，目前未有足夠且控制嚴謹的研究結果可循. 因此，對於孕婦，也只有在經過衡量後確定患者可能獲得的利益重於胎兒可能遭受的危害時，才可以使用LONINE，有一部份前列腺素生物合成抑制劑據證實會妨礙動脈導管的閉合; 所以，在懷孕末期三個月裡並不推薦使用LONINE. [20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]用於授乳婦:授乳期間使用LONINE之安全性尚未建立.致癌性，致突變性以及對生育力的損害: 為了評估LONINE的致癌性，會進行一項長達2年的大鼠實驗，以及另一項？期18個月的小鼠實驗; 結果並沒有發現任何致癌性. LONINE亦經Ames氏致突變性測驗證明無致變性.,AC;AC15;PC;PO;WM;,,,,,
OMEP,Procaterol,Meptin - Mini 25mcg,ERSP,Bronchial asthma， chronic bronchitis & pulmonary emphysema.,Hypersensitivity to any component of the formulation.,Infrequent palpitations & tremors.,30℃以下避光防潮儲存,Adult: 50 mcg HS or 50 mcg BID (in the morning and bedtime). Age >6 years: 25 mcg HS or 25 mcg BID (in the morning and bedtime). The dose may decrease or increase depends on patient’s age and symptoms.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
ONEOT,Acitretin,Neotigason 10mg,TDER,Severe forms of psoriasis & disorders of keratinization.,Hepatic or renal impairment. Elevated blood lipid levels. Pregnancy， lactation. Women of childbearing potential.,Dry lips & mouth， cheilitis， rhagades around mouth， dry mucous membranes. Thirst. Conjunctivitis， impaired night vision. Headache. Thinning of skin. Arthralgia， ostealgia， myalgia. Hyperostosis & extraskeletal calcification. Reversible increase of liver enzymes. Dermatologic: Alopecia (50-75%)， Cheilitis， Dry skin， Mucous membrane dryness， Skin peeling disorder Ophthalmic: Night blindness,25℃以下,Psoriasis Adult Initial daily dosage， 25mg or 30 mg for 2-4 weeks. Maintenance: 25-50mg for 6-8 weeks. Maximum: 75mg/day. Keratinization disorders the lowest dose treatment is required. Less than 20 mg/day， but not more than 50 mg/day. Child: Safety and efficacy for pediatric patients have not been established. use with caution， 0.5 mg/kg. Maximum: 35mg/day.,無需調整劑量,懷孕禁用:停藥後需再避孕3年。,無需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,懷孕禁用:停藥後需再避孕3年。,PO;WM;,,,,,[磨粉/管灌註記]本藥應整粒吞服， 切勿咬嚼、壓碎或打開膠囊。本藥具致畸胎性，請注意相關暴露風險，尤其是婦女及小孩。
ONUX,Piracetam,Nuxitam 1200mg,CNEU,,適應症: Treatment of cerebrovascular insufficiency & age-related cognitive impairment; adjunct in the treatment of myoclonus of cortical origin. 副作用: Hyperkinesia， wt gain， nervousness， somnolence， depression， asthenia. 禁忌: Cerebral hemorrhage; severe renal impairment.,,室溫,Cerebrovascular insufficiency & age-related cognitive impairment Loading dose: 4.8 g daily during initial weeks of treatment. Maintenance: 1.2-2.4 g daily. Cortical myoclonus Initially 7.2 g daily， increasing by 4.8 g/day every 3-4 days to a max of 24 g/day in divided doses.,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,,,,,,
OCHL5,Chlordiazepoxide,Chlordiazepoxide 5mg,CNEU,Neurosis， anxiety & tension， depression especially agitated depression.,Acute narrow-angle glaucoma; myasthenia gravis， shock; severe psychoses.,Drowsiness， ataxia， confusion; skin eruptions， edema; menstrual irregularities; nausea & constipation; extrapyramidal symptoms & decreased libido; blood dyscrasias; jaundice & hepatic dysfunction. Skin rashes; nausea; headache; decreased tolerance to alcohol.,室溫藥品，仿單無特別指示儲存溫度條件,Adult 10mg (2 tablets) BID-TID， may be increased to 60mg-90mg (12-18 tablets) daily in 3-4 divided doses.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OCYT,Misoprostol,Cytotec 200mcg,ALIM,Healing of duodenal & gastric ulcer & NSAID-induced peptic ulcer; Prophylaxis of NSAID-induced peptic ulcer.,Pregnancy， women planning a pregnancy， premenopausal women， lactation. Known allergy to prostaglandins.,GI disturbances including diarrhea， abdominal pain with or without dyspepsia， flatulence， nausea & vomiting， menorrhagia， vag bleeding & intermenstrual bleeding， rashes， dizziness. Gastrointestinal: Abdominal pain (7% to 20% )， Diarrhea (13% to 40% ),30℃以下避免受潮,Duodenal ulcer & Gastric ulcer: 800 mcg/day in 2-4 divided doses for 4-8 weeks.Prophylaxis of NSAID-induced ulcer: 200 mcg BID， TID or QID.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,PREGNANCY RECOMMENDATION: Contraindicated (Oral) Human Data Suggest Low Risk (Term Cervical Ripening),No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;PO;SL;VAG;,,,,,
ODAM,Bethanechol Chloride,Dampurine 25mg,SGU,Treatment of acute post-op & postpartum non-obstructive urinary retention & neurogenic atony of the urinary bladder with retention.,Intestinal or urinary obstruction， hyperthyroidism， peptic ulcer disease， epilepsy， obstructive pulmonary disease， bradycardia， vasomotor instability， AV conduction defects， hypotension， parkinsonism.,Nausea， vomiting， sweating， intestinal colic.,25℃以下,Urinary retention， neurogenic bladder: To determine minimal effective dose: 5 to 10 mg; repeat the same dose hourly until effective response or a maximum of 50 mg is reached; usual dose: 10 to 50 mg 3 to 4 times daily. Cholinergic effects at higher oral dosages may be cumulative.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;PO;,,,,,
ODEF,Cimetidine,Defense 300mg,ALIM,,適應症: Treatment of duodenal & gastric ulcer， GERD， persistent dyspepsia & pathological hypersecretory states eg Zollinger-Ellison syndrome. 副作用: Altered bowel habits， diarrhoea， headache， tiredness， dizziness， somnolence， rash， reversible impotence， gynaecomastia， reversible confusional states， reversible hepatic damage. 禁忌: Exclude gastric malignancy before treatment.,,室溫,Tab 300mg tid & at bedtime for 4-6 weeks. The dosage may be increased to 600mg qid if necessary. Max: 2400mg/day,需調整劑量,,需調整劑量,可能安全,,,Compatible 哺乳時可使用,,,,,,,
ODET4,Tolterodine,DETRUSITOL SR 4mg prolonged-release,SGU,Treatment of overactive bladder with symptoms of urinary urgency， frequency，or urge incontinence.,Urinary retention， uncontrolled narrow angle glaucoma， myasthenia gravis， severe ulcerative colitis， toxic megacolon.,Dry mouth， dyspepsia， dry eyes， fatigue， constipation， abdominal pain， dizziness， headache， somnolence， flatulence， vomiting， paresthesia， nervousness， dry skin. Gastrointestinal: Constipation (6% to 7% )， Xerostomia (15% to 30% ) Neurologic: Headache [7% (immediate release); 6% (extended release)],25℃以下,2-4 mg once daily depending on response & tolerability.,需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續釋放膠囊，需整顆吞服，勿拆開膠囊、咬碎、壓碎、剝半或磨粉。廠商未能提供破壞劑型後的有效性及安定性。
ODOLC,Pipemidic Acid,Dolcol 250mg,QANB,UTI， Bacillary dysentery， enteritis， otitis media and sinusitis,Hypersensitivity to any component of the formulation.,GI symptoms. CNS， skin reactions. Muscular weakness， myalgia. CI: Hypersensitivity， children， pregnancy and lactation. infants < 3 months.,室溫25℃存放,Adult: 500-2000 mg/day， divided Q6-8H. For adults with pyelonephritis， pyelitis， cystitis， urethritis， and prostatitis: 2-8 tablets (500-2000mg) daily， divided into 3-4 doses. For adults with otitis media， sinusitis， enteritis， and bacterial dysentery: 6-8 tablets (1500-2000mg)， divided into 3-4 doses.,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;PO;,,,,,
OCAR,Activated Charcoal,Carbomix 61.5gm,ZADT,Emergency treatment of acute oral poisoning or drug overdose. Also binding of bacteriotoxins & other diarrhea-inducing substances in the gastrointestinal tract.,Corrosive substance intoxication.,Diarrhea or constipation (occasionally).,室溫藥，避免濕氣,Acute poisoning -Adult 50-100 g in susp immediately followed by 20 g Q4-6H for a few days. -Children 1 g/kg body weight. Diarrhea -Adult 1 sachet/time several times daily. -Children 1 sachet in several divided doses.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PO;,,,,,
OCAT,Clonidine,CataPRES 75mcg,CAVS,All grades of hypertension except when due to pheochromocytoma.,Sick-sinus syndrome. 2nd or 3rd degree AV block.,Initially， dry mouth & fatigue; orthostatic complaints especially with IV. Dermatologic: Contact dermatitis (5% to 47% )， Erythema (26% )， Pruritus Gastrointestinal: Xerostomia (25% ) Neurologic: Dizziness (2% )， Headache (5% )， Sedated (3% )， Somnolence (12% ) Other: Fatigue (6% ),25℃以下,HTN: Mild to moderate HTN: initial 0.075mg -0.15mg BID， may up to 0.3mg/day severe HTN: initial 0.3mg TID (0.9mg/day),無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OCEF5,Cefixime,Cefspan 50mg,QANB,,Otitis media， pharyngitis， bronchitis and UTI.,,,Adult & child over 30 kg: 50-100 mg q12h， up to 200 mg q12h. Child: 1.5-3 mg/kg q12h， up to 6 mg/kg q12h.,,,,可能安全,,,,,,,,,,
OCEL,Pergolide,Celance 0.05mg,CNEU,,,,,,,,,,,,,,,,,,,
OCEP,Diphenidol,Cephadol 25mg,CNEU,,Peripheral (labyrinthine) vertigo， Meniere's disease， middle and inner ear surgery (labyrinthitis)， nausea， vomiting.,,,Adult: 25-50mg qid (max. 300mg/day). Child over 6 months or over 12kg: 0.9mg/kg， may be repeated in 1hr with subsequent doses of q4h as needed， (max. 5.5mg/kg/day).,,,,,,,,,,,,,,
OCIPR,Ciprofloxacin,Ciproxin tab 250mg,QANB,,適應症: 細菌性感染 UTI .Respiratory tract， bone & joint & biliary tract infection.GI (infectious diarrhea). Gonorrhea. 副作用:Nausea， diarrhoea， vomiting， dyspepsia， abdominal pain， flatulence， anorexia， dizziness， headache， tiredness， agitation， trembling. Very rarely， insomnia， peripheral paralgesia， sweating， unsteady gait， convulsions， increase in intracranial pressure， anxiety states， nightmares， confusion， depression， hallucinations， impaired taste & smell， visual disturbances， tinnitus， transitory impairment of hearing， especially at high frequencies， skin reactions. 禁忌:Hypersensitivity to ciprofloxacin or other quinolones. Children， adolescents， pregnancy & lactation.,,室溫,UTI Uncomplicated:250mg bid. UTI Complicated: 500mg bid. Resp tract， bone&joint，skin&biliary tract infection Moderate infection:500mg bid. Severe infection:750mg bid. GI (infectious diarrhea): 500mg bid for 5 days. Gonorrhea 250mg as a single dose.,無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OCLAR,Loratadine + Pseudoephedrine,Clarinase 5/120mg,HIMM,,適應症: Relief of symptoms associated with allergic rhinitis & common cold including nasal congestion， sneezing， rhinorrhea， pruritus & lacrimation. 副作用: Insomnia， dry mouth. 禁忌: Patients receiving MAOI therapy or within 14 days of discontinuing such treatment. Narrow-angle glaucoma， urinary retention， severe hypertension， severe coronary artery disease， hyperthyroidism.,,室溫,1 tab bid.,,,,可能安全,,,,,,,,,,
OCLO,Clomiphene,Clomid 50mg,HM,,,,,,,,,,,,,,,,,,,
OCLO2,Clomipramine,Clopran 25mg,CNEU,,適應症: Depression 副作用: Thirst， reduced appetite， hypotension， frequent pulse， difficulty with micturition， intraocular pressure， blurred vision， constipation. 禁忌: Recent MI， hypersensitive to tricyclic antidepressants， glaucoma.,,室溫,50-100 mg daily in divided doses.,,,,除非治療上需要,,,,,,,,,,
IFOR7,Teriparatide,Forteo 750mcg/3mL， 28dose,META,Treatment of postmenopausal women with osteoporosis who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.,Paget's disease of bone， unexplained elevations of alkaline phosphatase， prior history of radiation therapy involving the skeleton， bone metastases or a history of skeletal malignancies， metabolic bone diseases (other than osteoporosis)， pre-existing hypercalcemia， children or adolescents with open epiphyses.,GI disturbances， asthenia， hypotension， arthralgia， leg cramps， dizziness， depression， insomnia， vertigo， rhinitis， cough， pharyngitis， dyspnea， rash， increased sweating， hypercalcemia. Cardiovascular: Hypotension， Syncope Dermatologic: Rash， Sweating symptom Endocrine metabolic: Hyperuricemia Gastrointestinal: Constipation， Diarrhea， Indigestion， Nausea， Vomiting Musculoskeletal: Arthralgia (10.1% )， Spasm (1% to 10% ) Neurologic: Asthenia， Dizziness Respiratory: Increasing frequency of cough， Pharyngitis， Rhinitis,2-8℃避光避免冷凍,SC， 20 mcg once daily.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,SC;,,,,,2020/10/30:詢問廠商後告知25度C以下可保24小時安定.
IABI1,Cisplatin,Abiplatin inj 10mg/20mL,RACA,,適應症: Metastatic testicular tumors， Metastatic ovarian tumors， Advanced bladder cancer. 副作用: Nausea & vomiting， renal toxicity， bone-marrow depression， ototoxicity， serum electrolyte disturbances， peripheral neuropathy， retinal toxicity， anaphylactic reactions， cardiac abnormalities. 禁忌: Hearing or renal impairment， myelosuppression， dehydration.,,室溫,IV infusion over 6-8 hrs， As a single agent: 50-100 mg/ml once every 4 wks. Metastatic testicular tumors: combined with vinblastine & bleomycin， 20/mL/day for 5 days every 3 wks for 3 courses. Metastatic ovarian tumors: combined with doxorubicin， 50 mg/mL once every 3 wks.,,,,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 調配與注射cisplatin的器具不可含有鋁。 3. 稀釋後的輸注溶液應避光保存。 4. 給藥前後應給予病人適當水分補充。 5. 監測CBC、肝腎功能。 6. 定期神經學、聽力檢測。
OCHE,Sulfamethoxazole + Trimethoprim,Chemix (Baktar) 400/80mg,QANB,Acute infective exacerbation of chronic obstructive pulmonary disease， pneumocystis pneumonia， shigellosis， traveler's diarrhea， urinary tract infectious， acute otitis.,Liver parenchymal damage， blood dyscrasias; severe renal insufficiency. Pregnancy， lactation. Porphyria.,GI disturbances; allergic skin reactions; hallucinations， depression， apathy， nervousness. Arthralgia， myalgia. Neurologic reactions.,25℃以下避光,Trimethoprim-sulfamethoxazole (TMP-SMX)Adult and children > 12 years: 80/400-240/1200 mg (1-3 tablets) twice daily. Children (6-12 years): 80/400 mg (1 tablet) twice daily. Children (6 months-5 years): 40/200 mg (0.5 tablet) twice daily. Children (6 weeks-5 months): 20/100 mg (0.25 tablet) twice daily. Pediatric dose is calculated based on TPM 6 mg/kg/day and SMX 30 mg/kg/day.,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
ICLA,Cefotaxime,Claforan iInj 500mg,QANB,,,,,,,,,,,,,,,,,,,
OPRO2,Estradiol Valerate,Progynova 2mg 21's/pk,HM,,適應症: Climacteric complaints after cessation of monthly bleeding， or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases. 副作用: Breast tension， gastric upsets， nausea， headache， increase in body wt， uterine bleeding. 禁忌: Pregnancy; severe disturbance of liver function; jaundice or persistent itching during a previous pregnancy; Dubin-Johnson syndrome， Rotor syndrome; previous or existing liver tumours; existing or previous thromboembolic processes; sickle-cell anaemia; existing or suspected hormone-dependent tumours of the uterus or mammae; endometriosis; severe diabetes with vascular changes; congenital disturbances of lipometabolism; otosclerosis with deterioration during pregnancy.,,室溫,1 tab. daily.Pause for at least 1 week after each 21-day regimen. Dose may be reduced to 1 tab every other day.,,,,不可使用,,,,,,,,,,
EFLUC,Fluorometholone,Flucason oph soln 0.02%， 5mL,TOPH,,適應症: Acute & chronic iritis， iridocyclitis， scleritis， episcleritis， conjunctivitis， keratitis， resistant ocular allergy & inflammation following surgery 副作用: Glaucoma with optic nerve damage， visual acuity or field defects， raised intraocular pressure， secondary infection (persistent corneal ulceration， possibly fungal invasion)， perforation of globe， posterior subcapsular cataract formation 禁忌: Acute superficial herpes simplex keratitis， fungal diseases of ocular structure; vaccinia， varicella & other viral diseases of the cornea & conjunctiva， eye TB,,室溫,Instill 1-2 drops bid-qid,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EHUM,Humapen Luxura,Humapen Luxura,ZOTH,,,,,,,,,,,,,,,,,,,
INEX,Esomeprazole,Nexium 針劑 40mg,ALIM,,適應症:As an alternative to oral therapy when oral intake is not appropriate for GERD in patients with esophagitis &/or severe symptoms of reflux & for healing of gastric ulcers associated with NSAID therapy. 副作用:Headache， abdominal pain， diarrhea， flatulence， nausea/vomiting， constipation. Uncommonly， dermatitis， pruritus， urticaria， dizziness， dry mouth， blurred vision. Rarely hypersensitivity reactions， elevation of liver enzymes， Steven-Johnson syndrome， erythema multiforme， myalgia. Dermatologic: Injection site reaction (1.7%) Gastrointestinal: Abdominal pain (5.8%%)， Constipation (2.5%)， Diarrhea (3.9%)， Flatulence (10.3%)， Indigestion (6.4%)， Nausea (6.4%)， Xerostomia (3.9%) Neurologic: Dizziness (2.5%)， Headache (10.9%) 禁忌:Hypersensitivity to benzimidadazoles.,,,20-40 mg IV once daily over > 3 min or infusion over 10-30 min. Reflux esophagitis 40 mg once daily. Symptomatic treatment for reflux disease 20 mg once daily.,需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IV;IVD;IVP;,IV:5 mL N/S,【N/S】可選 仿單建議。,注射速率 > 3 min (40mg),IV infusion， pediatrics: Give as IV infusion over 10 to 30 minutes. 80 mg loading dose， adults: Give IV infusion over 30 minutes.,調配完成之溶液的降解對於pH有高度依賴性，因此本品只能以0.9%氯化鈉溶液調配後用於靜脈注射。調配完成之溶液不應在同一靜脈輸液管中，與其他藥品混合或同時給藥。 調配完成之溶液應與其他藥品分開給藥。
OFIN,Loratadine + Pseudoephedrine,Finska-LP SR 10/240mg,HIMM,,適應症:Relief of symptoms associated with allergic rhinitis & common cold. 副作用:Insomnia， dry mouth， headache， drowsiness. 禁忌:Patients receiving MAOI therapy or within 14 days of discontinuing such treatment. Narrow-angle glaucoma， urinary retention， severe hypertension， severe coronary artery disease， hyperthyroidism.,,室溫,Adult & children > 12 years 1 tab qd.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ISYN,Pneumococcal Vaccine Polyvalent,Synflorix (10價肺炎疫苗) 0.5mL/dose,HIMM,,適應症:active immunization of infants and children from 6 weeks up to 2 years of age against Streptococcus pneumoniae serotypes 1， 4， 5， 6B， 7F， 9V， 14， 18C， 19F and 23F and invasive disease caused by these serotypes (including sepsis， meningitis， bacteraemic pneumonia， pleural empyema and bacteraemia). 副作用: Very common (≧ 1/10) drowsiness， appetite loss， pain， redness， swelling at the injection site， fever (≧ 38°C rectally)，irritability -------------------------------------------------------------------------------------------------------------- Common (≧ 1/100 to < 1/10) injection site induration， fever (> 39°C rectally) -------------------------------------------------------------------------------------------------------------- Uncommon (≧ 1/1，000 to < 1/100) diarrhoea， vomiting， injection site haematoma， haemorrhage and nodule， fever (> 40°C rectally)*， crying abnormal， apnoea in very premature infants (? 28 weeks of gestation) -------------------------------------------------------------------------------------------------------------- Rare (≧ 1/10，000 to < 1/1，000) febrile and non-febrile convulsions， rash， urticaria， allergic reactions (such as allergic dermatitis， atopic dermatitis， eczema),,2-8℃,Infants from 6 weeks to 6 months of age: The primary vaccination schedule consists of three doses of 0.5 mL with an interval of at least 1 month between doses A booster dose is recommended at least 6 months after the last priming dose and preferably between 12 and 18 months of age. ----------------------------------------------------------------------------------------- Infants aged 7-11 months: The vaccination schedule consists of two doses of 0.5 mL with an interval of at least 1 month between doses. A third dose is recommended in the second year of life with an interval of at least 2 months between doses. ------------------------------------------------------------------------------------------ Children aged 12-23 months: The vaccination schedule consists of two doses of 0.5 mL with an interval of at least 2 months between doses.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OPLE,Felodipine,Plendil 5mg,CAVS,Hypertension， angina pectoris.,Pregnancy， uncompensated heart failure， acute MI， unstable angina pectoris.,Flushing， headache， palpitations， dizziness， fatigue， peripheral oedema. Cardiovascular: Peripheral edema (2% to 17.4% ) Dermatologic: Flushing (3.9% to 6.9% ) Gastrointestinal: Indigestion (0.5% to 3.9% ) Neurologic: Headache (10.6% to 14.7% ) Respiratory: Upper respiratory infection (0.7% to 3.9% ),30℃以下,HTN: Initially 5 mg QD. Maintenance: 5-10 mg QD. Angina pectoris :5 mg QD， may increase to 10 mg QD. Elderly: Initially 2.5 mg daily.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OSINM,Carbidopa + Levodopa,Sinemet 25/100mg,CNEU,Symptomatic treatment of Parkinsonism.,Narrow-angle glaucoma. Undiagnosed skin lesions or history of melanoma. Hypersensitivity to any component of this product.,Dyskinesia including choreiform， dystonic & other involuntary movements. Mental changes including paranoid ideation & psychotic episodes; depression with or without development of suicidal tendencies; dementia; & GI disturbances. Gastrointestinal: Nausea (5.5% to 5.7% ),30℃以下，避光，防潮,Initial， 1 tablet TID. Maximum : 8 tablets/day.,無需調整劑量,levodopa - probably compatible Carbidopa probably compatible,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,levodopa human data suggest low risk Carbidopa- animal data suggest low risk,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,levodopa - probably compatible Carbidopa probably compatible,AC;PO;,,,,,[磨粉/管灌註記]本藥錠劑上的刻痕，是便於剝半吞嚥，而非用於分成相等的劑量。錠劑經剝半後，應服用完整劑量。
OSON,Nicametate,Songora 50mg,CAVS,Peripheral vascular circulation disorders & cerebral insufficiency.,Arterial bleeding.,GI disturbances， anorexia， palpitations， cutaneous flushing， heat sensation， tiredness， rarely dizziness， vertigo， headache. Rashes， dry skin， pruritus， hyperpigmentation. Amblyopia， jaundice， decreased glucose tolerance， hyperglycaemia， hyperuricaemia.,室溫藥品，避光保存,50-100 mg TID.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PC;PO;,,,,,
OTRIL,Oxcarbazepine,Trileptal 300mg,CNEU,Monotherapy & adjunctive treatment of partial seizures in adult. Adjunctive treatment of partial seizure in children <1 month.,Hypersensitivity.,Frequent: Fatigue， dizziness， headache， somnolence， nausea， vomiting， diplopia. Common: Asthenia， agitation， amnesia， apathy， ataxia， impaired concentration， confusion， depression， emotional lability， nystagmus， tremor， constipation， diarrhea， abdominal pain， asymptomatic hyponatremia， acne， alopecia， rash， vertigo， vision disorders. Uncommon: Leucopenia， increase in liver enzyme， urticaria. Very rare: Angioedema， multi-organ hypersensitivity disorders， arrhythmia， thrombocytopenia， hepatitis， symptomatic hyponatremia， Stevens-Johnson syndrome， SLE.,30℃以下,Adult 600-2400 mg/day in 2 divided doses. Children Initially 8-10 mg/kg/day in 2 divided doses. Dosage may be increased according to response in steps of up to 10 mg/kg daily at weekly intervals. maximum: 46 mg/kg daily in divided doses.,需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OTAR,Erlotinib,Tarceva 150mg,RACA,Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least 1 prior chemotherapy regimen.,Hypersensitivity to any component of the formulation.,Rash， diarrhea， anorexia， fatigue， dyspnea， cough， nausea， vomiting， stomatitis， pruritus， dry skin， conjunctivitis， keratoconjunctivitis sicca， abdominal pain. Rarely， elevated liver enzymes， GI bleeding (in association with concomitant administration of warfarin or NSAIDs). Cardiovascular: Edema (37% ) Dermatologic: Alopecia (14% )， Pruritus (7.4% to 13% )， Rash， Any grade (49.2% to 75% ) Endocrine metabolic: Weight decreased (3.9% to 39% ) Gastrointestinal: Abdominal pain (11% to 46% )， Diarrhea， Any grade (20.3% to 54% )， Flatulence (13% )， Indigestion (17% )， Inflammatory disease of mucous membrane (17% to 22% )， Loss of appetite (9.2% to 52% )， Nausea (33% to 60% )， Vomiting (23% to 42% ) Hepatic: Hyperbilirubinemia， Increased liver enzymes Immunologic: Infectious disease (39% ) Musculoskeletal: Bone pain (25% )， Myalgia (21% ) Neurologic: Headache (15% ) Ophthalmic: Conjunctivitis (12% )， Keratoconjunctivitis sicca (12% ) Psychiatric: Anxiety (13% )， Depression (19% ) Respiratory: Cough (16% to 33% )， Dyspnea (24% to 41% ) Other: Fatigue (9% to 73% )， Fever (36% ),請儲存於30℃的溫度下,[Non–small cell lung cancer (NSCLC) (as first-line therapy， maintenance treatment， or for progressive disease)] 150 mg taken on an empty stomach at least 1 hour before or 2 hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.,需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
EART2,Carteolol,Arteoptic 2% oph sol 5mL,TOPH,,適應症: Glaucoma & ocular hypertension. 副作用：Local irritation， visual disturbances， foreign body sensation， orbital fat， conjunctivitis， blepharitis， photophobia. Bradycardia. Headache， discomfort， fatigue， dizziness. Asthma， syncope， myasthenia gravis. 禁忌: Unsatisfactorily controlled cardiac insufficiency; risk of bronchial asthma & bronchospasm; sinus bradycardia; AV block (II & III); cardiogenic shock; right ventricular insufficiency due to pulmonary hypertension & CHF.,,室溫,1 gtt qd-bid.,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OULT,Tramadol + Acetaminophen,Ultracet 37.5/325mg,CNEU,Management of moderate to severe pain,Acute intoxication with alcohol， hypnotics， narcotics， centrally acting analgesics， opioids or psychotropic drugs.,Nausea， dizziness， somnolence， asthenia， fatigue， hot flushes， headache， tremor， GI disturbances， anorexia， anxiety， confusion， euphoria， insomnia， nervousness， pruritus， rash， increased sweating.,貯於25°C以下,Adult & children > 16 years 1-2 TAB every 4-6 hr. Maximum: 8 TAB /day.,無需調整劑量,,需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OGEM,Gemfibrozil,Gemnpid 300mg,CAVS,,適應症: Dyslipidemia type IIa， IIb， III， IV & V. Reduces risk of CHD. 副作用: GI upset， rash， pruritus， headache， dizziness， hematopoietic disorders. Gastrointestinal: Abdominal pain (9.8% )， Acute appendicitis (1.2% )， Indigestion (19.6% .) 禁忌: Gallbladder disease， hepatic， renal dysfunction including primary cirrhosis.,,室溫,1200 mg daily in 2 divided doses.(Should be taken on an empty stomach ),,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OHARD,Tamsulosin,Harnalidge D 0.2mg,SGU,,適應症: Urinary dysfunction caused by benign prostatic hyperplasia. 副作用: Dizziness， GI discomfort， allergy， impaired hepatic function， nasal congestion， peripheral edema， asthenia. Immunologic: Infectious disease (9% to 10.8% ) Musculoskeletal: Backache (7% to 8.3% ) Neurologic: Asthenia (7.8% to 8.5% )， Dizziness (14.9% to 17.1% )， Headache (19.3% to 21.1% )， Insomnia (1.4% to 2.4% )， Somnolence (3% to 4.3% ) Reproductive: Abnormal ejaculation (8.4% to 18.1% ) Respiratory: Rhinitis (13.1% to 17.9% ),,室溫,0.2mg once daily. May increase dose to 0.4mg once daily. (Micromedex 2.0，非衛生署仿單建議劑量) Benign prostatic hyperplasia: initial， 0.4 mg ORALLY once daily; if no response after 2 to 4 weeks， may increase dose to 0.8 mg ORALLY once daily,,,,可能安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OSERO,Paroxetine,Seroxat 20mg,CNEU,For adults: Treatment of symptoms and prevention of recurrence of major depressive disorder. Treatment of symptoms of obsessive-compulsive disorder. Treatment of symptoms and prevention of recurrence of panic disorder. Treatment of social anxiety disorder (social phobia). Treatment of symptoms and prevention of recurrence of generalized anxiety disorder. Treatment of posttraumatic stress disorder (PTSD).,Hypersensitivity to paroxetine or any component of the product. Concomitant use with an MAOI， including linezolid or IV methylene blue， or use of paroxetine hydrochloride within 14 days of discontinuing an MAOI used to treat psychiatric disorders， or use of an MAOI used to treat psychiatric disorders within 14 days of discontinuing paroxetine hydrochloride; increased risk of serotonin syndrome. Concomitant use with drugs that prolong the QT interval and are also metabolized by CYP450 2D6 (such as thioridazine or pimozide).,[Common] Palpitations (2-3% )， Vasodilatation (1-5% )， Diaphoresis (5-14% )， Constipation (2-16% )， Diarrhea (6-18% )， Loss of appetite (1-12% )， Nausea (4-26% )， Xerostomia (1-18% )， Asthenia (12-22% )， Dizziness (6-14% )， Headache (17-27% )， Insomnia (7-24% )， Somnolence (3-24%)， Tremor (4-11% )， Blurred vision (Up to 5% )， Abnormal ejaculation (13-28% )， Erectile dysfunction (2-10% )， Orgasm disorder (2-10% )， Reduced libido (0-15%)， Yawning (2-4% ) [Serious] Stevens-Johnson syndrome， Toxic epidermal necrolysis， Hyponatremia (<0.1% ; elderly， 12% )， Hemorrhage， Acute hepatitis， Seizure (0.1% )， Depression， Exacerbation (1-5% )， Mania (0.1-1% )， Suicidal thoughts， Suicide， Serotonin syndrome， Withdrawal symptom (11-66% ),不超過30°C,Adults: May increase/reduce dosage by 10mg per week if needed. Elderly: Max: 40mg/day. -Major Depression: 20mg once daily. Max: 50mg/day. -Obsessive-Compulsive Disorder (OCD): 20-40mg once daily. Max: 60mg/day. -Panic disorder: 10-40mg once daily. Max: 50mg/day. -Social Anxiety Disorder (Social Phobia): 20mg once daily. Max: 50mg/day. -Generalized Anxiety Disorder: 20mg once daily. Max: 50mg/day. -Post-Traumatic Stress Disorder (PTSD): 20mg once daily. Max: 50mg/day.,需調整劑量,[仿單] 有少量的paroxetine會分泌到乳汁。在已發表的研究中，母乳餵養的嬰兒， 血濃度是偵測不到的(<2 ng/mL)或非常低(<4 ng/mL)。在這些嬰兒並無藥物作用的徵狀。 然而仍不建議在哺乳期間使用SEROXAT。除非證明在母親之期待利益超過嬰兒的潛在風險。,需調整劑量,沒有資料,Human (and animal) data suggest risk,[仿單] 動物研究並未顯示有任何的致畸性或選擇性的胎兒毒性。 針對在懷孕前三個月母親使用抗憂鬱劑後其懷孕之結果之流行學報告指出，會增加先天性畸形的風險， 特別是心血管方面(例如心室與心房隔膜缺陷)，與paroxetine的使用有關。 數據指出母親使用paroxetine造成嬰兒心血管缺陷的風險約是1/50，一般族群嬰兒是1/100。 對於懷孕或是計畫懷孕的婦女，醫師必須考慮替代治療的選擇方案，只能在潛在利益大於潛在風險時才能使用。 有些報告是關於孕婦使用paroxetine或其他SSRIs而有早產情形，但尚未建立其因果關係。 因此，不應於懷孕期間使用，除非其潛在效益超越其可能的危險性。 觀察性研究數據指出於生產前一個月暴露於SSRI及SNRI類藥品會增加產後出血風險(小於2倍)。 曾有報告指出嬰兒會因為至懷孕的第三期仍使用SEROXAT或是其他SSRIs而產生併發症， 且藥物治療的因果關係仍未建立，故母親持續使用到懷孕後期則必須觀察嬰兒情形。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 有少量的paroxetine會分泌到乳汁。在已發表的研究中，母乳餵養的嬰兒， 血濃度是偵測不到的(<2 ng/mL)或非常低(<4 ng/mL)。在這些嬰兒並無藥物作用的徵狀。 然而仍不建議在哺乳期間使用SEROXAT。除非證明在母親之期待利益超過嬰兒的潛在風險。,AC;AC15;PC;PO;WM;,,,,,
OSIB,Flunarizine,Sibelium (Flunarizine) 5mg,CAVS,,適應症:主治噁心、眩暈、暈動病、末梢血管循環障礙等(A028955100)(B022622100) CI: History of depressive illness， history of extrapyramidal syndrome or Parkinsonism.,,RT,1 cap bid， 2 cap qn.,,,,沒有資料,,,,,,,,,,
OSLOF,Dried FeSO4 + Folic Acid,Slow-Fe Folic160mg/400mcg,NUTR,,During the second and third trimesters of pregnancy for prophylaxis of iron and folic acid deficiency. Prevent the occurrence of megaloblastic anaemia due to folate deficiency.,,,1~2 tab daily.,,,,,,,,,,,,,,
OSLOK,Potassium Chloride,Slow-K 600mg/8mEq,NUTR,,適應症: Hypokalemia. 副作用: GI upsets. 禁忌: Hyperkalemia; marked renal failure; concomitant treatment with K-sparing diuretics & patients in whom there is cause for arrest or delay in tab passage through the GI.,,室溫,Prophylaxis: 2-3 tab daily. Treatment: 5-6 tab， up to 12 tab daily.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
OSMA,Captopril,Smarten 25mg,CAVS,,,,,,,,,,,,,,,,,,,
OSOR,Isosorbide Dinitrate,Sorbitrate 10mg,CAVS,,Angina pectoris.,,,Oral: 2.5-10 mg tid-qid， ac.,,,,除非治療上需要,,,,,,,,,,
OSPAE,Sulfacarbamide + Phenazopyridine,SPASMO-Euvernil 500/50,QANB,,適應症: Treatment of UTI eg cystitis， prostatitis， urethritis. 副作用: GI disturbances， hypersensitivity reactions， blood disorders， hypoglycaemia， hypothyroidism， neurological reactions， kernicterus in premature neonates， abnormal coloration of body tissues or fluids. 禁忌: Impaired renal function or severe hepatitis， blood disorders. Hypersensitivity.,,室溫,Adult & school children 2 tab tid. Pre-school children 1 tab tid. Max: 10 tab daily. Initial infection 2 tab tid for 10 days.,,,,沒有資料,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OSTE,Trifluoperazine,Stelazine 5mg,CNEU,,Symptomatic treatment of psychotic disorders， short-term management of nonpsychotic anxiety.,,,Adult: Initially 0.5-1 tab bid. Maintenance: 3-4 tab/day. Max: 6 tab/day.,,,,,,,,,,,,,,
OSUL,Sulindac,Sulindec 200mg,CNEU,,適應症: Osteoarthritis， RA， ankylosing spondylitis， acute painfull shoulder， acute gouty arthritis. 副作用:GI disturbances， headache， dizziness. GI ulceration & bleeding. Depression， drowsiness， tinnitus， confusion， lightheadedness， insomnia， psychiatric disturbances， syncope， convulsions， coma， peripheral neuropathy， blurred vision & other ocular effects. Edema， weight gain， hypertension， hematuria， skin rashes， stomatitis， alopecia. Hypersensitivity reactions. Blood disorders. Hepatitis， jaundice or renal failure. 禁忌:Peptic ulcer. History of GI lesion. Sensitivity to aspirin.,,室溫,Antirheumatic: 150-200 mg bid with meals， (max. 400 mg/day). Acute gout: 200 mg bid.,無需調整劑量,,需調整劑量,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IVIN1,Vincristine,Vincristine inj 1mg/1mL,RACA,Acute leukemia & for Hodgkin's disease & non-Hodgkin's malignant lymphomas， rhabdomyosarcoma， neuroblastoma. Wilms' tumor， reticulum cell sarcoma， lymphosarcoma.,Demyelinating form of Charcot-Marie-Tooth syndrome; avoid use in patients receiving radiation therapy through ports that include the liver.,Neurotoxicity， hypertension & hypotension， ataxia， foot drop， depression， agitation， insomnia， hallucinations， episodes of altered consciousness， anemia， thrombocytopenia， constipation， paralytic ileus， hyperuricemia， bladder atony， alopecia， hypersecretion of ADH， fever & headache， abnormal Valsalva response， impotence. Rarely， allergic-type reactions such as anaphylaxis.,2-8℃避光,(Micromedex) [Acute leukemia] 1.4-2 mg/m2/week IVD. [AIDS-related Kaposi's sarcoma] 0.03-1.4 mg/m2/week. Maximum: 2 mg/m2. Dosing and frequency may vary by protocol and/or treatment phase.,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest high risk,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,
OSTU,Cinnarizine,Stugeron 25mg,CAVS,,適應症：噁心、眩暈、迷路障礙、暈動病、末梢血管循環障礙。 副作用：Extrapyramidal symptoms sometimes associated with severe depression. Drowsiness， headache， GI upsets， unsteadiness， headache; rarely skin and hypersensitivity reactions， dry mouth， blurred vision， urinary difficulty or retention， constipation and increased gastric reflux， fatigue. Hypolipidaemic effect. 禁忌：Proven hypersensitivity to the drug. Parkinson's disease. Childn and neonates.,,室溫,PO Peripheral vascular diseases 75 mg 2-3 times/day. Motion sickness 30 mg 2 hr before travel and 15 mg 8 hrly during travel if needed. Cerebrovascular disorders 75 mg 1-3 times/day. Vertigo and vestibular disorders 30 mg 3 times/day.,,,,除非治療上需要,,,,,,,,,,
OAVO,Dutasteride,Avodart 0.5mg,SGU,,適應症:Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms， reduce the risk of acute urinary retention & reduce the need for BPH-related surgery. 副作用:Impotence， decreased libido， ejaculation disorder， gynecomastia. Endocrine & metabolic: Impotence (1% to 5%)， libido decreased (?3%)， ejaculation disorders (?1%)， gynecomastia (including breast tenderness， breast enlargement; ?1%) 禁忌:Use in women & children.,,室溫,Benign prostatic hyperplasia: 0.5 mg ORALLY once a day,,,,不可使用,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OTRAM,Tramadol,Tramtor 50mg,CNEU,,適應症: Moderate to severe acute or chronic pain. 副作用: Nausea， vomiting， constipation， drowsiness & confusion. Difficulty in micturition & biliary spasm. Dry mouth， sweating， facial flushing， vertigo， bradycardia， palpitations， orthostatic hypotension， hypothermia， restlessness， changes of mood， hallucinations， miosis. Raised intracranial pressure. Muscle rigidity in high doses. Dermatologic: Flushing (1% to 15.8% )， Pruritus (3% to 11.9% ) Gastrointestinal: Constipation (10% to 29.7% )， Nausea (13% to 26.2% )， Vomiting (3% to 9.4% )， Xerostomia (1% to 9.8% ) Neurologic: Dizziness (7% to 28.2% )， Headache (3% to 15.8% )， Insomnia (1% to 10.9% )， Somnolence (4% to 20.3% ) 禁忌: Acute alcoholism， head injuries & conditions in which intraocular pressure is raised. Attack of bronchial asthma or in heart failure secondary to lung disease.,,室溫,safety and efficacy <16 y/o have not been established Usual dose: 50-100mg q 4-6 h， max 400mg/day Dosage in renal impairment: Clcr< 30 ml/min， increase dosing interval to 12 h ; max. 200 mg/day dose for patients with cirrhosis: 50 mg q 12 h Thomson: Infant risk cannot be ruled out,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OSIN1,Montelukast,SINGULAIR 10mg,ERSP,SINGULAIR is indicated in adult & pediatric patients 6 months of age & older for the prophylaxis & chronic treatment of asthma， including the prevention of day- & nighttime symptoms， the treatment of aspirin-sensitive asthmatic patients， & the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated in adults & pediatric patients 2 years of age & older for the relief of day- & nighttime symptoms of seasonal allergic rhinitis.,Hypersensitivity to any component of Singulair.,Abdominal pain， headache， thirst， diarrhea， hyperkinesia， asthma， eczematous dermatitis， rash. Neurologic: Headache (Adult and adolescent; 18.4%; pediatric， 2% and greater ),30℃以下，避免潮濕與光線照射,Should be taken once daily. For asthma， the dose should be taken in the evening. For seasonal allergic rhinitis， the time of administration may be individualized. Patients with both asthma & seasonal allergic rhinitis should take only 1 TAB daily in the evening. Asthma and/or seasonal allergic rhinitis- Age > or = 15 years: 10 mg QD. Age 6-14 years: One 5 mg chewable TAB QD. Age 2-5 years: One 4 mg chewable TAB QD or one packet of 4 mg oral granules QD. Age 6 months-2 years with asthma: One packet of 4 mg oral granules QD.,需調整劑量,,無需調整劑量,可能安全,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OZAN,Lercanidipine,Zanidip 10mg,CAVS,Treatment of essential hypertension.,Known sensitivity to dihydropyridines. Pregnancy & lactation.,Flushing， peripheral edema， palpitation， headache， dizziness.,室溫藥品，仿單無特別指示儲存溫度條件,HTN: initial 10mg QD， May increase to 20 mg.,需調整劑量,[仿單]目前不清楚 lercanidipine 代謝物是否會分泌至人類乳汁中。 因無法排除對新生兒/嬰兒造成的風險，哺餵母乳期間不可使用 lercanidipine。,需調整劑量,除非治療上需要,Uknown 沒有資料,[仿單]目前沒有 lercanidipine 用於懷孕女性的相關資料。 無證據顯示對動物有致畸胎作用。 但過去曾有其他 dihydropyridine 類化合物中觀察到致畸胎作用， 故 lercanidipine 不應用於懷孕期間以及未實施避孕的具生育能力女性。,Unknown 沒有資料,[仿單]目前不清楚 lercanidipine 代謝物是否會分泌至人類乳汁中。 因無法排除對新生兒/嬰兒造成的風險，哺餵母乳期間不可使用 lercanidipine。,AC;PO;,,,,,過去在使用 lercanidipine 時，曾在腹膜透析病人身上出現混濁的腹膜透析流出液。此混濁現象肇因於腹膜透析流出液中較高的三酸甘油酯濃度。雖然機制不明，但此混濁現象往往在停用lercanidipne 後迅速消失。這是一個應辨認的重要相伴現象，因為有可能將混濁的腹膜透析流出液誤認為感染性腹膜炎，進而造成不必要的住院及經驗性抗生素施用。
ELIDP,Lidocaine,Lidopat patch 5% (3片/包),ZANE,Relief of post-herpetic neuralgia.,Known history of sensitivity to local anesth of the amide type. Avoid in cardiac disease patients: 2nd & 3rd degree AV block (without pacemaker)， severe SA block (without pacemaker)， current administration of Class I antiarrhythmic agents (quinidine， flecainide， disopyramide， procainamide) to patients previously on amiodarone therapy， hypotension due to arrhythmia， bradycardia， ventricular arrhythmia.,Severe hepatic disease. Avoid application to broken or inflamed skin or contact with eyes.,30℃以下,Apply to intact skin once daily up to 12 hours within a 24-hours period. Maximum: 3 patches/24 hours. When needed， the patches may be cut into smaller sizes with scissors prior to removal of the release liner.,無需調整劑量,lactation: 無資料;但lidocain 會進入乳汁,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,lactation: 無資料;但lidocain 會進入乳汁,EXT;,,,,,
OLIC,Ticlopidine,Licodin 100mg,HEMT,To reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors or who have had a completed thrombotic stroke， & are intolerant or allergic to or who have failed aspirin therapy. As adjunctive therapy with aspirin to reduce incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation.,Hemorrhagic diathesis， GI ulcers， severe liver dysfunction， leukopenia.,GI disturbances; skin rashes. Blood dyscrasias; vertigo; jaundice.,室溫,200-500mg daily devided into 2-3 times.,需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IGW5A,Glucose,配藥用Glucose inj 5% 500mL,NUTR,,,,,配藥用子醫令,無需調整劑量,,無需調整劑量,沒有資料,,,Compatible 哺乳時可使用,,IVD;,,,於靜脈注射時應盡可能減慢速率，以免引起注射部位疼痛或靜脈炎,,1.高張液於靜脈注射時應盡可能減慢速率，以免引起注射部位疼痛或靜脈炎。 2.每支20mL含有10g Dextrose。
OVGR,Sildenafil,Viagra 50mg (4 tablets/box),SGU,,適應症: Treatment of erectile dysfunction. 副作用: Headache， flushing， dizziness， dyspepsia， nasal congestion， altered vision. 禁忌: Patients who use nitric oxide donors or nitrates. Viagra should not be used in men for whom sexual activity is inadvisable (patients with severe CV disorders eg unstable angina or severe cardiac failure). Severe hepatic impairment， hypotension (< 90/50 mm Hg) or hypertension (> 170/100 mm Hg)， recent history of stroke or MI， known hereditary degenerative retinal disorders such as retinitis pigmentosa. Not indicated for women.,,室溫,Adult 50-100 mg once daily， taken approximately 25-60 min before sexual activity. Max: 100 mg once daily. Hepatic impairment (eg. cirrhosis， 80%)， severe renal impairment (creatinine clearance < 30 mL/min， 100%)， and concomitant of potent cytochrome P450 3A4 inhibitors; Starting dose of 25 mg should be considered， may increase to 50-100 mg based on efficacy & toleration. Max dosing frequency is once per day. Pulmonary hypertension:(高山症) 20mg tid or 本院 50mg qd as needed,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OWIN1,Chlorpromazine,Winsumin 12.5mg,CNEU,,適應症: Nausea， vomiting， spasm， severe insomnia， nightmares， frequent micturition， nocturnal enuresis， pain， visceral neurosis， premed for anaesth， artificial hibernation， nausea & vomiting in pregnancy， eclampsia， psychoneurosis. 副作用: Drowsiness; hypotension; dry mouth; blurred vision; constipation; palpitations. 禁忌: Comatose patients & those with bone marrow depression， blood dyscrasias; Parkinsonism; severe cardiac insufficiency; renal or liver damage; marked cerebral atherosclerosis.,,室溫,Adult: Oral: Antiemetic: 10-25 mg q4-6h. Antipsychotic: 25-50 mg tid， (max. 1 g/day). Deep IM: 10-50 mg， repeated 3-4 times in 24 hrs if necessary. Child over 6 months. Oral: 0.5 mg/kg qid. IM: 0.5 mg/kg q6-8h as needed.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OXEN,Orlistat,Xenical 120mg (42 capsules/box),META,Obesity management.,Chronic malabsorption syndrome， cholestasis.,Common Gastrointestinal: Abdominal discomfort， Abdominal pain (Up to 41.1% )， Defecation urgency (For up to 1 year， 22.1% to 38.9% ; for up to 2 years， 2.8% )， Discharge from anus， Oily (2.3% to 11.9% )， Flatulence (For up to 1 year， 23.9% to 43.9%; for up to 2 years， 2.1% )， Increased frequency of defecation (2.6% to 10.8% )， Soiling， Oily (For up to 1 year， 26.6% to 37.2% ; for up to 2 years， 4.4% )， Steatorrhea (For up to 1 year， 20%; for up to 2 years， 5.5% ) Musculoskeletal: Backache (13.9% )， Pain in lower limb (10.8% ) Neurologic: Headache (30.6% ) Respiratory: Upper respiratory infection (26.1% to 38.1% ) Other: Influenza (39.7% ) Serious Hepatic: Liver failure Renal: Nephrolithiasis， oxalate， Oxalate nephropathy， with renal failure,25°C 以下,120 mg 3 times daily with each main meal containing fat (during or up to 1 hour after the meal).,無需調整劑量,[仿單] 尚無對 orlistat 是否會分泌至人類乳汁中的研究。哺乳時不應服用Xenical。,無需調整劑量,不可使用,Contraindicated,[仿單] 於動物生殖實驗中並未發現orlistat有胚胎毒性或致畸胎效應。 在無動物之致畸胎效應下，於人類中亦不預期有致畸胎的反應。 然而，在缺少臨床數據下，並不建議懷孕時服用Xenical。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 尚無對 orlistat 是否會分泌至人類乳汁中的研究。哺乳時不應服用Xenical。,PC;PO;WM;,,,,,
ECH10,Chloral hydrate,Chloral hydrate 10%,CNEU,,適應症: Insomnia，Sedation 副作用: Gastric irritation， abdominal distention and flatulence， vertigo， ataxia， staggering gait， rashes， malaise， lightheadedness， headache， ketonuria， excitement， nightmares， delirium (especially in elderly)， eosinophilia， reduction in white blood cell count; dependence on prolonged use. 禁忌: Hepatic or renal impairment， cardiac disease， hypersensitivity， porphyria， oesophagitis， gastritis. Pregnancy and lactation.,,,Chloral hydrate 10% = 100 mg/mL Dosing: Adult Sedation， anxiety: Oral: 250 mg 3 times/day Hypnotic: Oral: 500-1000 mg at bedtime or 30 minutes prior to procedure， not to exceed 2 g/24 hours Discontinuation: Withdraw gradually over 2 weeks if patient has been maintained on high doses for prolonged period of time. Do not stop drug abruptly; sudden withdrawal may result in delirium. Dosing: Pediatric Sedation， anxiety: Oral， rectal: 5-15 mg/kg/dose every 8 hours， maximum: 500 mg/dose Prior to EEG: Oral， rectal: 20-25 mg/kg/dose， 30-60 minutes prior to EEG; may repeat in 30 minutes to maximum of 100 mg/kg or 2 g total Hypnotic: Oral， rectal: 20-40 mg/kg/dose up to a maximum of 50 mg/kg/24 hours or 1 g/dose or 2 g/24 hours Conscious sedation: Oral: 50-75 mg/kg/dose 30-60 minutes prior to procedure; may repeat 30 minutes after initial dose if needed， to a total maximum dose of 120 mg/kg or 1 g total Discontinuation: Withdraw gradually over 2 weeks if patient has been maintained on high doses for prolonged period of time. Do not stop drug abruptly; sudden withdrawal may result in delirium.,,,,除非治療上需要,,,,,,,,,,
EATR2,Atropine,Atropine 0.25%， 10mL,TOPH,,適應症: Topical mydriatic & cycloplegic; uveitis. 副作用: Stinging， increased intraocular pressure， conjunctivitis. May precipitate glaucoma. 禁忌: Closed- & narrow-angle glaucoma.,,2-8 °C,1 gtt hs: for treatment of myopia. (0.1 %， 0.25 % and 0.5%) 1 gtt qid: for use in uveitis. (1.0 %),,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IGLY5,Glycerin + Fructose + NaCl,Glyceol 10% 500mL,CAVS,,適應症: Treatment of increased intracranial pressure & intracranial edema， improvement of impaired consciousness & neurologic deficits in cerebral infarct， intracerebral & subarachnoid hemorrhages， head injury， brain tumor， cerebromeningitis. Post-op therapy following brain surgery; reduction of brain vol at time of brain surgery. 副作用: Lactic acidosis; hemoglobinuria; headache， thirst， nausea; hypernatremia. 禁忌: Hereditary fructose intolerance.,,室溫,Adult 200-500 mL once or bid IV drip in 2-3 hr/500 mL.,,,,除非治療上需要,,,,,,,,,,
IGON,Follitropin Alpha,Gonal-F 75 IU inj,HM,Anovulation including polycystic ovarian disease (PCOD) in women who have not responded to clomiphene citrate therapy. Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART).,Pregnancy & lactation， ovarian enlargement or cyst not due to polycystic ovarian disease， gynaecological haemorrhages of unknown aetiology， ovarian， uterine or mammary carcinoma， case of tumours of the hypothalamus & pituitary gland， hypersensitivity to follitropin α， FSH or to any of the excipients. When an effective response cannot be obtained， such as primary ovarian failure， malformation of sexual organs incompatible with pregnancy， fibroid tumours of the uterus incompatible with pregnancy.,Local reactions at the inj site. Fever， arthralgia， pain in the lower abdominal region， nausea， vomiting， weight gain.,25℃以下避光,Women with anovulation (including PCOD) 75-150 IU daily & increased by 37.5 or 75 IU at 7 or 14 day intervals. Maximum daily dose: 225 IU. When an optimal response is obtained a single injection of up to 5，000 IU， up to 10，000 IU hCG should be given 24-48 hr after the last Gonal-F injection. The patient is recommended to have coitus on the day of， & the day after hCG administration. Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilization or other ART 150-225 IU of Gonal-F daily， commencing on day 2 or 3 of the cycle. When an optimal response is obtained a single injection of up to 5，000 IU， up to 10，000 IU hCG should be given 24-48 hour after the last Gonal-F injection. Dose adjustment should not exceed 450 IU daily. A single inj of up to 10，000 IU hCG is administered 24-48 hour after the last Gonal-f inj to induce final follicular maturation. Women with anovulation resulting from severe LH and FSH deficiency usually is starting as dose of GONAL-f 75-150 IU together with 75 IU of lutropin alfa， dose increased should be after 7-14 day intervals and preferablt by 37.5-75 IU. When an optimal response is obtained a single injection of up to 5，000 IU， up to 10，000 IU hCG should be given 24-48 hr after the last Gonal-F injection. Men with hypogonadotrophic hypogonadism should be given at a dose of 150 IU three times a week， together with hCG， for minimum of 4 months.,無需調整劑量,Micromedex: Infant risk cannot be ruled out.,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,Micromedex: Infant risk cannot be ruled out.,SC;,,,,,
IGON1,Follitropin(r-hFSH),Gonal-F 150IU,HM,,,,,,,,,,,,,,,,,,,
IGS25,Dextrose + Sodium Chloride,2.5 % Dextrose in 0.45% NaCl 500mL,MSIV,Replacement & maintenance of fluid & electrolytes.,,,無特別指示,Individualized dosage. Each Dextrose 2.5% and Sodium chloride 0.45% solution mL contains: Dextrose 25mg， Sodium chloride 4.5mg.,無需調整劑量,,無需調整劑量,沒有資料,Compatible,,Compatible 哺乳時可使用,,IVD;,,,,,
IGS33,Dextrose + Sodium Chloride,5% Dextrose in 0.33% NaCl 500mL,MSIV,為葡萄糖與食鹽水注射液化(A022666277),,,陰涼避光,Individualized dosage. Each Dextrose 5% and Sodium chloride 0.33% solution mL contains: Dextrose 50mg， Sodium chloride 3.3mg.,無需調整劑量,,無需調整劑量,沒有資料,Compatible,,Compatible 哺乳時可使用,,IVD;,,,,,
IGW10,Glucose,10% Dextrose inj 500mL,MSIV,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,室溫避光,Individualise dosage. Adult 20-500 mL， maximun infusion rate: 0.5g/kg/hr.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;IVPUSH;,,,,,
IGW20,Dextrose,20% Vitagen inj (Glucose) 20mL,NUTR,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,避光,Only for Postpartum Nursing Care Center using. [UpToDate 20270731] Hypoglycemia: IV: 10 to 25 g (50 to 125 mL of 20% solution); repeat as needed in severe cases. Oral: 15 to 20 g as a single dose; repeat in 15 minutes if self-monitoring of blood glucose (SMBG) shows continued hypoglycemia. Once the SMBG returns to normal， a meal or snack should be consumed to prevent recurrence of hypoglycemia (ADA 2020).,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,,,,,,
IGW250,Glucose,Glucose inj 5% 250mL,MSIV,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,無特別指示,Individualized dosage. Adult 500-1000 mL each time IV drip.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,
EEXT,Nystatin+Neomycin+Gramicidin+Triamcinolone,Extracomb cream 12gm,TDER,,Allergic and inflammatary skin disorders. Candida and yeast infection of the skin.,,,Apply bid ~ tid.,,,,,,,,,,,,,,
EFEM,Butoconazole,Femstat VS 100mg,SGU,,適應症:黴菌引起之陰道炎(A032378500) AR: Vulvar itching， burning & swelling， vag burning; headache， rash. CI: Hypersensitivity. 1st trimester of pregnancy.,,RT,Non-pregnant patients 1 vag supp at bedtime for 3 days. Pregnant patients (2nd & 3rd trimesters only) 1 vag supp at bedtime for 6 days.,,,,除非治療上需要,,,,,,,,,,
EFEN,Fentanyl,Fentanyl patch 25mcg/hr,CNEU,Intractable cancer pain,Hypersensitivity.,Nausea， vomiting; bradycardia， oedema， CNS depression， confusion， dizziness，drowsiness， headache， sedation， transient hypotension， peripheral vasodilation; increased intracranial pressure. High IV dose may cause chest wall rigidity. Transdermal: Rash， erythema and itching.,25℃以下,Adults: Initial dose:12 mcg/hr or 25mcg/hr. Maintenance dose: Increase and decrease by 12 mcg/hr or 25 mcg/hr to lowest appropriate dose. Renew every 72 hours. Children， 2-16 years old: Fentanyl transdermal patch can only be used on children have drug tolerance to opioids. Before use fentanyl transdermal patch， the child must be receiving opioids potency are equal to 30 mg oral morphine. The dose of fentanyl transdermal patch can be calculated from the 24-hour morphine dose with the same analgesic effect.(The conversion ratio of oral morphine to fentanyl transdermal patch is about 150:1) If fentanyl transdermal patches have to be discontinued， they should be replaced with other opioids (start with a low dose and slowly increase the dose).,需調整劑量,,需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,Compatible 哺乳時可使用,,EXT;,,,,,
EFLA,Silver Sulfadiazine,Flamazine cream 1% 50gm,TDER,,I: Treatment of skin graft donor sites， wounds， burns， infected leg ulcers and pressure sores. CI: Pregnancy at term， premature infants.,,,Apply topically once daily,,,,可能安全,,,,,,,,,,
EFLE,Sod Chloride,Atomic enema 20mL,ALIM,Constipation.,GI obstruction， abdominal pain， nausea， vomiting. Children <3 years.,Diarrhea， rectal irritation， abdominal discomfort.,25℃以下,Adult & children >6 years Insert 1-2 ball and retain for 15 mins. 3-6 years 0.5 adult dose.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,RECT;,,,,,
EFLI,Fluticasone,Flixotide Accuhaler 50mcg/dose,ERSP,,,,,,,,,,,,,,,,,,,
EFLIA,Fluticasone,Flixotide Accuhaler 250mcg/dos,ERSP,,I: Prophylaxis of asthma. AR: Mouth & throat candidiasis， hoarseness， paradoxical bronchospasm， cutaneous hypersensitivity reactions.,,RT,Adult& childn> 16 yr Mild asthma:100-250μg， Moderate asthma:250-500μg Severe asthma:500-1000μg. To be inhaled bid. Childn > 4 yr :50-200μg bid.,,,,除非治療上需要,,,,,,,,,,
EFLII,Fluticasone,Flixotide 50 Inhaler 50mcg/dose,ERSP,,I: Prophylaxis of asthma. AR: Mouth & throat candidiasis， hoarseness， paradoxical bronchospasm， cutaneous hypersensitivity reactions.,,,Adult& childn> 16 yr Mild asthma:100-250μg， Moderate asthma:250-500μg Severe asthma:500-1000μg. To be inhaled bid. Childn > 4 yr :50-200μg bid.,,,,除非治療上需要,,,,,,,,,,
EFML,Fluorometholone,Flumetholon oph drop 0.1%， 5mL(限自費),TOPH,,適應症: Ocular inflammation. 副作用: Glaucoma with optic nerve damage， visual acuity or field defects， raised intraocular pressure， secondary infection (persistent corneal ulceration， possibly fungal invasion)， perforation of globe， posterior subcapsular cataract formation. 禁忌: Hypersensitivity to fluorometholone or any component of the formulation; viral diseases of the cornea and conjunctiva (including epithelial herpes simplex keratitis， vaccinia， and varicella); mycobacterial or fungal infections of the eye; untreated eye infections which may be masked/enhanced by a steroid.,,室溫,Instill 1-2 drop 2-4 times daily.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EFOR,Isoflurane,Forane 100mL,ZANE,,適應症: Inhalation anesth for induction & maintenance of general anesth. 副作用: Dose-dependent respiratory depression， hypotension， arrhythmias; transient rise in CSF pressure; jaundice; malignant hyperthermia. Hepatic injury. Post-op shivering， GI upset， ileus. 禁忌: Genetic susceptibility to malignant hyperthermia.,,室溫,Induction: 1.5-3%， maintenance: 1-2.5%.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EFUT,Futraful,Futraful zupo 200mg,RACA,,,,,,,,,,,,,,,,,,,
OFAX,Venlafaxine,Faxine 37.5mg,CNEU,Treatment of depression， including melancholia.,Coadministration with MAOIs.,Dizziness， sedation， dry mouth， insomnia， nervousness， tremor， somnolence， anorexia， constipation， nausea， vomiting， abnormal ejaculation/orgasm (males)， erectile dysfunction， urinary hesitancy， sweating， asthenia， hypertension， hot flushes， ecchymosis， mucus membrane bleeding， thrombocytopenia， hypercholesterolemia， yawning， fatigue， nausea， appetite & wt loss， decreased libido， sweating， anorexia， visual disturbances Cardiovascular: Hypertension (3% to 13%) Dermatologic: Sweating symptom (6.7% to 25% ) Endocrine metabolic: Weight loss (3% to 47% ) Gastrointestinal: Constipation (8% to 15% )， Loss of appetite (8% to 22% )， Nausea (21% to 58% )， Xerostomia (12% to 22% ) Neurologic: Asthenia (8% to 19% )， Dizziness (11% to 23.9% )， Dream disorder (3% to 7% )， Headache (25% to 38% )， Insomnia (14% to 24% )， Somnolence (14% to 26% )， Tremor (1.1% to 10.2% ) Ophthalmic: Blurred vision (4% to 6% ) Psychiatric: Feeling nervous (4% to 21.3% ) Reproductive: Abnormal ejaculation (2.2% to 19% )， Impotence (2.1% to 6% )， Orgasm disorder (2% to 5% ),儲存於乾燥的25℃以下,Adult Initially 75 mg/day in 2-3 divided doses， can be increased in increments of up to 75 mg/day at intervals of ＞﹦ 4 days. Dose can be titrated up to 225 mg/day in moderate depression & 375 mg/day for severe depression,需調整劑量,,需調整劑量,除非治療上需要,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,PO;WM;,,,,,
OMIY,Clostridium Butyricum Miyairi 588,Miyarisan BM 1gm,ALIM,Intestinal disorders (prepare the bowel movement)， loose stools， constipation， abdominal bloating.,Hypersensitivity to any component of the formulation.,Flatulence,25℃以下避光乾燥處,Adult & children >12 years: PO， 1 Pack， TID-QID. 6-12 years: PO， 0.5 Pack， TID-QID. 3-6 years: PO， 0.25 Pack， TID-QID.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
ICOL,Colistin Methanesulfonate,Colimycin inj 2MU,QANB,GI infections; Bowel sterilisation.,Hypersensitivity. Anuria; porphyria; myasthenia gravis. Pregnancy and lactation.,Superinfection; renal damage; visual disturbances; GI disturbances， dizziness， nausea， vomiting; confusion， peripheral neuropathy; respiratory insufficiency and muscle weakness.,室溫25℃,Colimycin 2MU: colistin base 66.8 mg/2mL/vial. All doses are expressed as colistin base activity (CBA). Adults: IV 2.5-5 mg/kg/day divided Q12H (slowly inject for over 3-5 minutes or infuse over 1-2 hours at a rate of 5-6 mg/hours) or IM 2.5-5 mg/kg/day divided Q6-12H. (熱病) Adult: For severe systemic infection: give loading dose (4x body weight in kg using lower of ideal or actual weight)， then begin daily maintenance dosing 12 hours later. Inhalation therapy: 50-75 mg CBA in 3-4 mL saline via vibrating mesh nebulizer 2-3 times/day. Meningitis (intraventricular or intrathecal dose): 10 mg/day x several weeks; intrathecal dose often combined with IV dosing. Pediatric dose: systemic Infection: 2.5-5 mg/kg/day in 2-4 divided doses (based on ideal body weight). Cystic fibrosis: 3-8 mg/kg/day in 3 divided doses (based on ideal body weight).,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;IM;IVD;,"IM: 2 mL D/W， N/S; IV: 2mL D/W， N/S， D5W",【L/R】可選 。【D5NS】可選 。【D5W】可選 。【N/S】可選 。,推注時間至少3 ~ 5分鐘,開始的1~2小時，以5-6mg/hr緩慢滴注,1. 輸注液需新鮮配製，室溫下只能擺放24小時 2. 腎功能不全病患需減慢注射速率。
EZOVO,Acyclovir,Zovirax 眼用藥膏 3%， 4.5gm,TOPH,,適應症: Herpes simplex virus infection of the eyes including initial & recurrent genital herpes & herpes labialis. 副作用: Transient burning or stinging. Mild drying & flaking. Erythema & itching. Dermatologic: Application site reaction， Topical Preparation (5% )， Contact dermatitis， Topical Preparation (2% ) Gastrointestinal: Diarrhea (2.4% to 3.2% )， Nausea (2.4% to 4.8% )， Vomiting Neurologic: Headache (2.2% ) Other: Malaise (11.5% ) 禁忌: Patients known to be hypersensitive to acyclovir or propylene glycol.,,室溫,Adult & children Apply 5 times daily at approximately 4 hr interval for 5-10 days.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
OSONI,Zaleplon,Sonimax 10mg,CNEU,,適應症:Insomnia 副作用:Headache， light headedness， asthenia， dizziness， nausea， somnolence， rash， myalgia， back pain， chest pain， taste perversion， fever， migraine， constipation， dry mouth， dyspepsia， arthralgia， anxiety， depression， difficulty concentrating， amnesia， confusion， hallucinations. Transient impairment of memory and psychomotor function. Decreased inhibition， behavioural changes (e.g. bizarre behaviour， depersonalisation)， complex sleep related behaviour (e.g. sleep driving). Neurologic: Dizziness (7% to 9% )， Headache (30% to 42% ) 禁忌:嚴重肝功能不全，睡眠停止呼吸症候群，重症肌無力，嚴重呼吸功能不全， 兒童(十八歲以下),,室溫,PO 10 mg/day at bedtime. Max: 20 mg/day 成年人:10mg 老年人:5mg 肝功能不全:輕至中度肝功能不全之病人使用5mg,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
HE5000,,Dianeal 1500mL 1.5% (PD2雙袋),NUTR,,,,,,,,,,,,,,,,,,,
HE5001,,Dianeal 1500mL 1.5% (PD4雙袋),NUTR,,,,,,,,,,,,,,,,,,,
HE5002,,Dianeal 1500mL 2.5% (PD2雙袋),NUTR,,,,,,,,,,,,,,,,,,,
EFEN5,Fentanyl,DUROGESIC 50mcg/hr,CNEU,,適應症: Management of chronic pain & intractable pain requiring opioid analgesia. 副作用: Hypoventilation， nausea， vomiting， constipation， somnolence， confusion， hallucination， euphoria， pruritus & urinary retention. 禁忌: Patients with known hypersensitivity to fentanyl or to the adhesives present in the system.,,室溫,Opioid-naive patients: 25 mcg/hr as initial dose. Opioid-tolerant patients: Convert from oral or parenteral opioids to Durogesic according to suggested equianalgesic potency conversion. May be worn continuously for 72 hr.,,,,除非治療上需要,,,,,,,,,,
EDEX,Dexamethasone,Dexaltin(口內膏)0.1% 5gm,TENT,,適應症: Intractable stomatitis or glossitis associated with erosion or ulceration. 副作用: Fungal or bacterial infection of the oral cavity; hypersensitivity; hypofunction of pituitary-adrenocortical system (prolonged use). Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin， Finding of skin healing， Impaired Endocrine metabolic: Cushing's syndrome， Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )， Raised intraocular pressure (25% ) Psychiatric: Depression， Euphoria Respiratory: Pulmonary tuberculosis 禁忌: Patients with tuberculotic， viral or other purulent infections of the oral cavity.,,室溫,Apply adequate amount to the affected area once to several times daily.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EELOO,Mometasone,Elomet oint 0.1%， 5gm,TDER,,適應症: Inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses. 副作用: Very rarely， paresthesia， pruritus， burning， tingling/stinging， signs of skin atrophy. Dermatologic: Atrophic condition of skin， Topical， Pruritus， Topical Gastrointestinal: Abdominal pain (2%-3%， oral inhalation)， Indigestion (3%-5%， oral inhalation)， Nausea (1%-3%， oral inhalation) Musculoskeletal: Backache (3%-6%， oral inhalation)， Musculoskeletal pain (4%-8%， oral inhalation)， Myalgia unspecified (2%-3%， oral inhalation) Neurologic: Headache (4%， intranasal; 17%-22%， oral inhalation) Reproductive: Dysmenorrhea (4%-9%， oral inhalation) Respiratory: Allergic rhinitis (11%-15%， oral inhalation)， Candidiasis， oral (4%-6%， oral inhalation)， Epistaxis， Intranasal (5%)， Pharyngitis (8%-13%， oral inhalation)， Upper respiratory infection (8%-15%， oral inhalation) Other: Burning sensation， Topical， Fatigue (13%， oral inhalation)， Viral disease， Intranasal (3%),,室溫,Children >= 2 years Apply once daily.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EFLIE,Fluticasone,Flixotide 50mcg evohaler 120dose,ERSP,Prophylactic management in mild， moderate & severe asthma for adult & childn.,Patients with a history of hypersensitivity to any of the components of Flixotide.,Mouth & throat candidiasis， hoarseness， paradoxical bronchospasm. Cutaneous hypersensitivity reactions. Neurologic: Headache (8% to 9% ) Respiratory: Epistaxis (4% to 20% ),30℃以下,Adult & children >16 years:100-1000 mcg BID. Mild asthma 100-250 mcg BID. Moderate asthma 250-500 mcg BID. Severe asthma 500-1000 mcg BID. Children >4 years: 50-200 mcg BID. Children 1-4 years: 500-100 mcg BID.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
ETOP,Fluocinonide,Topsym lotion 0.05%， 10gm,TDER,Eczema; dermatitis; psoriasis; vitiligo; alopecia; pustulosis; prurigo.,Vaccinia & varicella.,Burning， itching， irritation， dryness; perioral dermatitis; allergic contact dermatitis; skin atrophy. Dermatologic: Dry skin， Pruritus， Sensation of burning of skin Neurologic: Headache， with 0.1% cream (4%) Other: Irritation symptom,25℃以下,Apply QD-TID.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,EXT;,,,,,
IHUMA,Insulin Lispro 50% + Insulin Protamine 50%,Humalog Mix 50， 100 IU/mL， 3 mL,META,,適應症:type 1， type 2 DM 副作用:Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj 禁忌:Hypoglycaemia.,,2-8 ℃,Should be taken with food. (Administer w/in 15 mins before or immediately after meals.) Subcutaneous Diabetes mellitus Adult: Dosing regimen should be individualised and adjusted based on patient's glycaemic response. Administer 15 min before or immediately after a meal. Renal impairment: Decreased dose may be necessary. Hepatic impairment: Decreased dose may be necessary.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
IGW50,Dextrose,50% GW inj (Vitagen) 20mL,NUTR,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,25℃以下,[UpToDate 20270731] Hypoglycemia: IV: 10 to 25 g (20 to 50 mL of 50% solution); repeat as needed in severe cases. Oral: 15 to 20 g as a single dose; repeat in 15 minutes if self-monitoring of blood glucose (SMBG) shows continued hypoglycemia. Once the SMBG returns to normal， a meal or snack should be consumed to prevent recurrence of hypoglycemia (ADA 2020). Glucose tolerance test (Glutol): Oral: One-step (ADA 2020): 75 g as single dose to a fasting patient; assess plasma glucose 2 hours after dose in nonpregnant adults or 1 and 2 hours after dose in pregnant women.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;IVP;IVPUSH;LI;PO;,,,於靜脈注射時應盡可能減慢速率，以免引起注射部位疼痛或靜脈炎,,1.高張液於靜脈注射時應盡可能減慢速率，以免引起注射部位疼痛或靜脈炎。 2.每支20mL含有10g Dextrose。
IHAE,Gelatine Polypeptides,Haemaccel inj 500mL,HEMT,,Hypovolemic shock， loss of blood or plasma， exsiccosis， wt. Loss during & after surgery.,,,Adult: 500-1500 ml (Max: 2000 ml).,,,,,,,,,,,,,,
IASP,Lysine Acetylsalicylate,Aspegic inj 0.5gm,CNEU,,適應症:解熱ˋ鎮痛ˋ風濕性疼痛(B0215282B9),,RT,Slow IV or deep IM: Adult: 1-4 vials/day. Child: 10-25 mg/kg/day (claculated as aspirin) in 2 divided doses.,,,,沒有資料,,,,,,,,,,
IHAL,Haloperidol,Haloperidol(Binison)50mg/mL,CNEU,,Antidyskinetic (in Gilles de la Tourette's disease)， antipsychotic.,,,Antipsychotic: Oral: Adult:0.5-5 mg bid-tid initially， adjusted as needed. Child: 3-12 yrs， 0.05-0.15 mg/kg/day in 2-3 divided doses. Mental retardation with hyperactivity: 10-15 mg/day in divided doses up to 60 mg/day.,,,,除非治療上需要,,,,,,,,,,
OAMIY,Amino Acids + Histidine,Amiyu granules 2.5mg,NUTR,,適應症: 慢性腎不全時胺基酸之補給劑(A025449114) 副作用: Rash， general urticaria， itching， GI upsets. Rare temporary increase of GOT， GPT， palpitation， acidosis. 禁忌: Patients with possibility of hepatic coma,,RT,Adult: one pack three times a day，after meals.,,,,沒有資料,,,,,,,,,,
OAMO5,Amoxicillin,AMOXICILLIN 500mg,QANB,,適應症: G(+) & G(-) infections 副作用: Nausea， vomiting， diarrhea， glossitis， stomatitis， black hairy tongue; skin rashes， urticaria， exfoliative dermatitis， erythema multiforme; anemia， thrombocytopenia， eosinophilia， leukopenia， agranulocytosis. 禁忌: Hypersensitivity to penicillins.,,室溫,Adult : 250-500 mg q8h，(max. 4.5 g/day) Child under 20 kg: 20-40 mg/kg/day in 3 divided doses. Acute uncomplicated gonorrhea: Adult: 3 g once. Child over 2 yrs: 50mg/kg with 25 mg/kg probenecid once.,無需調整劑量,,需調整劑量,可能安全,Human data suggest risk in 1st and 3 rd trimesters,,Compatible 哺乳時可使用,,,,,,,
OAMP5,Ampicillin,Ampicillin 500mg(Pentrexyl),QANB,,Active against G(-) organism， generally less active against G(+) organism， except enterococci.,,,Adult & child over 20kg: Oral: 250-500 mg q6h， (max. 6 g/day). IM， slow IV or IV infusion: 250-500 mg q6h. For bacterial meningitis or septicemia: 1-2 g q3-4h，(max.16 g/day or 300 mg/kg/day). Child under 20 kg: Oral: 12.5-25 mg/kg q6h， (max. 200 mg/kg/day). IM， slow IV or IV infusion: 6.25-25 mg/kg q6h. For bacterial meningitis or septicemia: 16.7-41.7 mg/kg q4h，(max. 400 mg/kg/day ).,,,,可能安全,,,,,,,,,,
OAND,Cyproterone,Androcur 50mg,RACA,Antiandrogen with progestogenic activity,Hypersensitivity to cyproterone or any component of the formulation; liver disease or hepatic dysfunction; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumors (if not due to metastases from prostate cancer); presence or history of meningioma; wasting diseases (except inoperable prostate cancer); severe chronic depression; existing thromboembolic processes,Decreased libido， erectile dysfunction， inhibition of ovulation， reversible inhibition of spermatogenesis， weight increase/decrease， mood depression， restlessness， breast tenderness， gynecomastia， fatigue， hot flushes， sweating.,室溫藥品，仿單無特別指示儲存溫度條件,Dosage in females [For severe signs of androgenisation]100 mg are to be taken with some liquid after a meal from the 5th to the14th day of the cycle (i.e. for ten days). Every 28 days (the usual duration of a menstrual cycle)， the above dosage regimen is to be followed. Seven inactive tablets are taken once daily after 21 days， during which time a withdrawal bleeding occurs. Exactly 4 weeks after the first course of treatment was started， i.e. on the same day of the week， the next cyclical course of combined treatment is started， regardless of whether bleeding has stopped or not. Following clinical improvement， the daily dose of Androcur 50 mg during the 10 days of the combined treatment with a combined oral contraceptive can be reduced to one or half a tablet of Androcur 50 mg. Dosage in males [Reduction of drive in sexual deviations] 50 mg twice daily initially; may be increased to 100 mg 2-3 time daily. Quite often 25 mg twice daily (50 mg daily) is sufficient. When establishing the maintenance dose or when discontinuing the preparation， dosage should not be reduced abruptly， but gradually. [Antiandrogen treatment in inoperable carcinoma of the prostate] 100 mg 2-3 times daily (= 200-300 mg/day)- To reduce the initial increase of male sex hormones in treatment with GnRH agonists: 100 mg twice daily alone for 5-7 days， followed by 100 mg twice daily for 3-4 weeks together with a GnRH agonist in the dosage recommended by the manufacturer.- To treat hot flushes in patients under treatment with GnRH analogues or who have had orchidectomy: 50-150 mg daily; may be increased to 300 mg/day as needed.,需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PC;PO;,,,,,[磨粉/管灌註記]本藥為抗雄性激素製劑，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於小孩及懷孕或準備懷孕婦女。
OAPR5,Hydralazine,Apresoline 50mg,CAVS,Hypertension.,Idiopathic SLE and related diseases. Severe tachycardia and heart failure with high cardiac output. Myocardial insufficiency due to mechanical obstruction. Right ventricular heart failure due to pulmonary HTN. Dissecting aortic aneurysm.,Tachycardia， palpitation， anginal symptoms， flushing， headache， dizziness， nasal congestion， GI disturbances.,置於陰涼處15-30℃且避免潮濕,HTN Adult: 10-50 mg QID slowly titrate up (Maximum dose 300 mg/day). Child: 0.75 mg/kg/day in 4 divided doses， up to 7.5 mg/kg/day. (Maximum dose 300mg/day).,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 3 rd trimester,No reports linking the use of hydralazine with congenital defects have been located. However， fetal toxicity has been associated with use of the drug in the 3rd trimester.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
EGARO,Gentamicin Sulfate + Betamethasone,Garasone eye oint,TOPH,,I: Ocular inflammation when concurrent use of an antibiotic is necessary. AR: Increased intraocular pressure， glaucoma， infrequent optic nerve damage， cataract， acute anterior uveitis， perforation of the globe. CI: Epithelial herpes simplex keratitis， dendritic keratitis， viral disease of the cornea & conjunctiva， mycobacterial or fungal infectoin， trachoma.,,,Apply tid-qid.,,,,,,,,,,,,,,
IMIV,Mivacurium,Mivacron,CNEU,,適應症: Adjunct to general anesth， Endotracheal intubation， Maintenance of neuromuscular block. 副作用: Cutaneous flushing， mild hypotension， moderate wheezing; tachycardia， bradycardia， phlebitis; bronchospasm， hypoxaemia; rash， inj site reaction; dizziness; prolonged drug effect; muscle spasms. 禁忌: Patients known or suspected to be homozygous for the atypical plasma cholinesterase gene.,,室溫,IV Adjunct to general anesth Initial: 70-250 mcg/kg via inj. Maintenance: 100 mcg/kg at 15-min intervals. Patients w/ asthma/CV disease: ≦150 mcg/kg. Endotracheal intubation Initial: 150 mcg/kg， then 100 mcg/kg 30 sec later. Maintenance of neuromuscular block Infuse 8-10 mcg/kg/min， adjusted every 3 mins， if needed， up to a usual rate of 6-7 mcg/kg/min.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IAMIX1,Amino Acid + Glucose,Aminomix 1500mL,NUTR,,Complete parenteral nutrition & electrolyte & fluid subsitution in catabolic situation. In the post-aggressive phase.,,,20-30 ml/kg/day (approx 1400-2100 ml/day for 70 kg body weight).Max： 40ml/kg/day.Infusion：1000ml/pack.,,,,,,,,,,,,,,
IMMRA,Measles + Mumps + Rubella,Pluserix inj ( MMR )(衛生署),HIMM,,Measles， mumps and rubella immunisation in adults and children over 15 months.,,,SC， child 15 months and over， 1 vial (0.5 ml after reconstitution).,,,,除非治療上需要,,,,,,,,,,
IMORI,Amino Acids,Moriamin-SN inj 200mL,NUTR,,適應症:為成人氨基酸補充液(A024029263),,RT,Peripheral infusion: Adult: 200-400 ml slow infusion. Central venous infusion: Adult: 400-800 ml daily,,,,除非治療上需要,,,,,,,,,,
IMORP,Morphine,Morphine inj 10mg/1mL,CNEU,Relief of moderate to severe pain. Pre-op anesth.,Respiratory depression， head injury， obstructive airways disease， paralytic ileus， GI obstruction， delayed gastric emptying， acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children < 3 years.,Nausea， vomiting， constipation， drowsiness， palpitations， headache， disorientation， vertigo， mood changes， decreased libido， ureteric spasm， urinary retention， rash， sweating， facial flushing， miosis.,室溫避光,SC/IV Opiate agonist naive patients Initially 2-5 mg every 3-4 hours. Higher dose may be used for patients used before. 0.8-10 mg/hr by continuous infusion. Patient with assisted ventilation (for 70 kg body weight) 0.7-10 mg IV per 1-2 hour or 5-35 mg/hr as continuous infusion. Epidural: 1-5 mg as single dose. Continuous infusion: Initially 1-5 mg at rate of 0.1-1 mg/hr. Subarachnoid injection: Opiate agonist naive patients 0.1-0.3 mg each time to provide 24 hours relief. Not recommended to repeat dose. Pain relief of surgical anesthesia: adjust dose according to age & symptoms.,無需調整劑量,,需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;IVD;IVP;IVPUSH;SC;,,【D5W】可選 。【N/S】可選 。,推注時間至少4-5分鐘,起始劑量: 每3-4小時2.0-5mg，持續輸注: 0.8-10mg/hr；用呼吸器的病患(以70kg計)起始劑量:每1-2小時0.7-10mg，持續輸注:5-35mg/hr,1. IV給藥濃度0.5-3mg/mL，緩慢注射4-5分鐘。
IMORPBAD,Morphine,Morphine inj 10mg/1mL殘餘銷燬,CNEU,Relief of visceral pain， preanesthetic medication， sedation and hypnosis when pain is present， dyspneic seizures of acute left ventricular failure and pulmonary edema.,,,,Adult: PO: Initial， 10-30 mg q4h. IM or SC:5-20 mg (usually 10 mg) q4h as needed. IV (only rarely): 2.5-10 mg diluted in 4-5 ml of water for injection， administered slowly over 4-5 mins. Child: SC:0.1-0.2 mg/kg， not to exceed 15 mg/dose.,無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;IVP;IVPUSH;,,,,,
INAA,Sodium Acetate Anhydrous,Sodium acetate inj 20mL (4mEq/mL),NUTR,Electrolyte imbalance or severe Na depletion.,Hypernatremia. Fluid retention.,Serious Endocrine metabolic: Hypervolemia， Metabolic alkalosis Other: Aluminum poisoning， Hypernatremia,25℃以下,As TPN material. Each mL contains: Sodium Acetate anhydrous 328.16mg = 4mEq Sodium Acetate. Parenteral nutrition; maintenance sodium requirement: Note: A combination of salt forms may be necessary to fulfill sodium requirement. Neonatal: 2 - 5 mEq/kg/day of sodium as an additive to parenteral nutrition solution. Infants and Children < or = 50 kg: IV: 2 - 5 mEq/kg/day of sodium as an additive to parenteral nutrition solution. Children > 50 kg and Adolescents: IV: 1 - 2 mEq/kg/day of sodium as an additive to parenteral nutrition solution. [Uptodate 20210731] Sodium maintenance electrolyte requirement (combination of chloride and acetate， where applicable): IV: 1 to 2 mEq/kg/24 hours; customize amounts based on individual patient needs (Mirtallo 2004). General maximum sodium acetate: 100 to 150 mEq/24 hours.,無需調整劑量,,無需調整劑量,除非治療上需要,,,Compatible 哺乳時可使用,,IVA;,,,,,1. 每mL含Sodium Acetate Anhydrous 328.16 mg，相當於 4 mEq/mL，使用前須稀釋。 2. 添加於靜脈輸注液，濃度>154 mEq/L須經由中央靜脈給予。最大輸注速率 1 mEq/kg/hour 3. 本藥品為藥劑科配置TPN製劑專用。
INAN,Nitroprusside,Sodium Nitroprusside 50mg,CAVS,,適應症:危急性高血壓(B021879248),,RT,Only be used as IV infusion Adult: 0.5 mcg/kg/min， adjusted slowly in increments of 0.5 mcg according to response， usual dose is 3 mcg/kg/min， up to 10mcg/kg/min. Child: 1.4 mcg/kg/min.,,,,除非治療上需要,,,,,,,,,,
INAR,Naloxone,Narcan inj 0.4mg/1mL,ZADT,,適應症:麻醉藥品解毒劑(B021318209),,RT,IV ， IM or SC.The IV dose may be repeated at 2-3 mins intervals as needed. Opioid overdose: Adult: 0.4-2 mg. Child: 0.01 mg/kg. Postoperative opioid depression: 0.1-0.2 mg every 2-3 min Opioid-induced respiratory depression : 0.01 mg/kg.,,,,可能安全,,,,,,,,,,
INEO,Phenylephedrine,Neo-synesin 1mg,CAVS,,適應症:為血管收縮劑 禁忌: Pregnancy.,,室溫,SC & IM: Adult 2-5 mg. Max: 10 mg. IV: Adult 0.2 mg. Dose range: 0.1-0.5 mg. IV infusion: 0.5-1 mg/100ml blood.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OCAL9,Calcium Citrate,Callate 950mg,NUTR,,適應症: Ca supplement， renal osteodystrophy.,,室溫,Adult & children > 4 years 2-5 tabs daily.,,,,沒有資料,,,Compatible 哺乳時可使用,,,,,,,
IAVA0,Bevacizumab,Avastin inj 100mg/4mL (Sample),RACA,In combination with irinotecan/5-fluorouracil/leucovorin or 5-fluorouracil/leucovorin as 1st-line treatment of metastatic carcinoma of the colon or rectum,Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanised antibodies; untreated CNS metastases.,Asthenia， pain， abdominal pain， headache， hypertension， diarrhea， nausea， vomiting， anorexia， stomatitis， constipation， upper respiratory infection， epistaxis， dyspnea， exfoliative dermatitis， proteinuria. Rarely， GI perforation， hemorrhage， arterial thromboembolism， wound healing complications， hypertensive crises， nephrotic syndrome， CHF.,2-8℃避光,Infuse the initial dose over 90 minutes. The second infusion may be administered over 60 minutes if the initial infusion is well tolerated. The third and subsequent infusions may be administered over 30 minutes if the 60-minute infusion is well tolerated. Continue treatment until disease progression or unacceptable toxicity.  [Metastatic Colorectal Cancer (mCRC)]- 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination withfluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line Avastin-containing regimen.- 10 mg/kg every 2 weeks or 15 mg/kg every 2 weeks for Avastin-naive patients as second-line therapy.  [Metastatic Breast Cancer (mBC)] 10 mg/kg every 2 weeks  [Glioblastoma] 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks  [Non-Squamous Non-Small Cell Lung Cancer (NSCLC)] 15 mg/kg every 3 weeks  [Ovarian (epithelial)， fallopian tube， or primary peritoneal cancer] - Stage III/IV disease following initial surgical resection: 15 mg/kg every 3 weeks (in combination with carboplatin and paclitaxel) for up to 6 cycles， followed by bevacizumab 15 mg/kg every 3 weeks (monotherapy)， for a total of up to 22 cycles (=15 months) or until disease progression (whichever occurs earlier)- Platinum-sensitive recurrent: 15 mg/kg every 3 weeks (in combination with carboplatin and gemcitabine for 6-10 cycles or with carboplatin and paclitaxel for 6 to 8 cycles) then continue with bevacizumab (monotherapy) until disease progression or unacceptable toxicity- Platinum-resistant recurrent: 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks (in combination with paclitaxel， doxorubicin [liposomal]， or topotecan)  [Cervical cancer] 15 mg/kg every 3 weeks (in combination with paclitaxel and either cisplatin or topotecan),無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,【N/S】可選 。,,,1. 輸注溶液不可含葡萄糖。 2. 稀釋後輸注溶液應擺放於2-8度C儲存，超過8小時未使用應丟棄。 3. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至30-60分鐘。 4. 監測蛋白尿。 5. 每2-3週監測血壓變化。
OSINE,Doxepin,Sinequan 25mg,CNEU,,適應症:Anxiety or depression. 副作用:Dry mouth， blurred vision， constipation， drowsiness， confusion， paresthesias， extrapyramidal effects， seizures， hypotension， tachycardia; skin rash. 禁忌:Glaucoma; urinary retention.,,室溫,Mild to moderate: 75 mg daily. Optimum dose: 75-150 mg/day. Severe: Higher doses with subsequent gradual increase to 300 mg/day.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IPRO125,Hydroxyprogesterone caproate,Progeston Depot-S 125mg/1mL inj,HM,,禁忌: Undiagnosed vaginal bleeding， breast cancer， pregnancy， lactation. Thrombophlebitis， thromboembolic disorders， cerebral apoplexy or a history of these conditions. Markedly impaired liver function. 副作用: GI disturbances， increased appetite， wt gain or loss， oedema， acne， allergic skin rashes， urticaria， mental depression， discomfort in breast; cough， dyspnoea， circulatory disturbances. Pain at site of inj. 適應症: Recurrent miscarriage， Amenorrhoea， Abnormal uterine bleeding， Palliative treatment of advanced， inoperable endometrial carcinoma,,室溫,Adult: IM Recurrent miscarriage 65-125 mg/wk during the 1st half of pregnancy. To reduce the risk of preterm birth: Pregnant females > OR = 16 years: I.M.: 250 mg once weekly. Treatment may begin between 16 weeks 0 days and 20 weeks 6 days of gestation. Continue weekly administration until 37 weeks gestation or until delivery， whichever comes first. Amenorrhoea or abnormal uterine bleeding 375 mg as a single dose; may repeat at 4-wkly intervals if needed. After 4 days of desquamation， or if there is no bleeding w/in 21 days after administration of the drug， may initiate cyclic therapy that includes an oestrogen.,,,,可能安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,
LPS45,Sodium Phosphate,Phospho-Soda 45mL,ALIM,,適應症: Relief of occasional constipation. For use as part of a bowel cleansing regimen in preparing the patient for surgery or for preparing the colon for X-ray or endoscopic exam. 副作用: Nausea， vomiting， bloating. 禁忌: Congenital megacolon， intestinal obstruction or CHF. Children < 5 years.,,室溫,Prep for diagnostic procedures & pre-op 45 mL the evening before & repeat on the morning of the procedure. Constipation Adult & children >= 12 years Dilute 15 mL in 240 mL liqd & drink at least 240 mL. Max: 45 mL/24 hr. Children 10-11 yearsDilute 15 mL in 240 mL liqd & drink at least 240 mL. Max: 15 mL/24 hr. 5-9 years Dilute 7.5 mL in 240 mL liqd & drink at least 240 mL. Max: 7.5 mL/24 hr. Take 120 ml cool water with 45 ml of the Fleet phospho-soda to drink， and follow up more than 240 ml of cool water. Twice a day.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
LSHO,Cyproheptadine,Showmin 0.4mg/mL， 60mL,HIMM,,適應症: Symptomatic relief of allergic conditions， eg urticaria， angioedema， rhinitis， conjunctivitis， pruritic skin disorders. Vascular headaches， migraine. 副作用: Increased appetite & weight gain. CNS depression， drowsiness， lassitude， dizziness， incoordination， sedation. Headache， psychomotor impairment， dry mouth， thickened respiratory tract secretions， blurred vision， urinary difficulty & retention， constipation， increased gastric reflux. Rashes， hypersensitivity reactions. Convulsion， sweating， myalgia， paresthesia， extrapyramidal effects， tremor， sleep disturbances， depression， tinnitus， hypotension， hair loss. 禁忌: Pregnancy & lactation. Neonates. Debilitated patients， elderly.,,室溫,Allergic conditions & pruritus Adult Initial: 4 mg tid. Maintenance: 12-16 mg/day in 3 or 4 divided doses. Max: 32 mg/day. Children 7-14 years 4 mg bid-tid (max: 16 mg/day)， 2-6 years 2 mg bid-tid (max: 12 mg/day). Vascular headache & migraine 4-8 mg 4-6 hrly.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EACU,Adapalene,Acure gel 0.1% 15gm,TDER,,適應症: Treatment of acne vulgaris. 副作用: Skin irritation such as redness & sensation of heat. Dermatologic: Dry skin (36.1% or less )， Erythema (0.2% to 21.8% )， Scaly skin (25.3% or less),,室溫,Apply once daily at bedtime.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
EALC2,Alcohol,75% Alcohol 20mL/bottle,TDER,Antiseptics and disinfectants.,Hypersensitivity to any component of the formulation.,Mild local discomfort.,25℃以下儲存,Use appropriate amount for disinfection.,無需調整劑量,,無需調整劑量,盡量避免,Contraindicated,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,EXT;,,,,,
EAND,Testosterone,Androgel 50mg,HM,Testosterone replacement therapy in male hypogonadal disorders.,Prostatic or mammary carcinoma.,Acne， alopecia， application site reaction， asthenia， depression， emotional lability， gynecomastia， headache， hypertension， abnormal lab tests (e.g. elevated hemoglobin or hematocrit， hyperlipidemia， elevated triglycerides， hypokalemia， decreased HDL， elevated glucose， elevated creatinine， or elevated total bilirubin)， libido decreased， nervousness， breast pain， prostate disorder， testis disorder. Dermatologic: Acne (up to 8% ) Endocrine metabolic: Gynecomastia (up to 3% ) Gastrointestinal: Oral irritation， Buccal system (9.2% ) Neurologic: Headache (up to 4% ) Reproductive: Large prostate (11.7% ),仿單無指示,Adult and elders: 5 g (50mg testosterone) of gel once daily， best in the morning， Maximum dose 10g /day.,無需調整劑量,Testosterone is present in breast milk. Some products are specifically contraindicated while breastfeeding. (UpToDate)2021/0125,無需調整劑量,不可使用,Uknown 沒有資料,Use is contraindicated during pregnancy.(UpToDate)2021/0125,Unknown 沒有資料,Testosterone is present in breast milk. Some products are specifically contraindicated while breastfeeding. (UpToDate)2021/0125,EXT;,,,,,
EBRIS,Terbutaline,Bricanyl solution 5mg/2mL,ERSP,Relief of bronchospasm in bronchial asthma， chronic bronchitis， emphysema & other bronchopulmonary conditions when bronchoconstriction is a complicating factor.,Hypersensitivity to any of the ingredients of Bricanyl.,Tremor， tonic cramp & palpitations. Tachycardia， arrhythmia. Urticaria & exanthema may occur.,30℃以下儲存,Single dose 5mg QID. If a single dose is not used up， it can be stored in the storage tank of the nebulizer within 24 hours.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;INHL;,,,,,
IPCA3,PCA-3 inj 300mL (自費),PCA-3 inj 300mL (自費),CNEU,,,,,,無需調整劑量,Fentanyl BREASTFEEDING RECOMMENDATION: Compatible Ropivacaine BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,,Human (and animal) data suggest risk,Fentanyl PREGNANCY RECOMMENDATION: Human Data Suggest Risk Ropivacaine PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Fentanyl BREASTFEEDING RECOMMENDATION: Compatible Ropivacaine BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,IVD;,,,,,成份：Fentanyl 0.5mg/10mL+ Ropica 400mg/40mL， in N/S 250 mL
ECIL,Ciprofloxacin,Ciloxan 0.3%， 5mL ophthalmic solution,TOPH,Corneal ulcer ，Conjunctivitis.,Hypersensitivity to quinolones.,Local burning or discomfort， itching， lid edema， tearing， white crystalline precipitates which will resolve.,30℃以下儲存,Corneal ulcer: Instill 2 drops into affected eye every 15 minutes for the first 6 hours， then 2 drops into the affected eye every 30 minutes for the remainder of the first day. On day 2， instill 2 drops into the affected eye hourly. On days 3-14， instill 2 drops into affected eye every 4 hours. Treatment may continue after day 14 if re-epithelialization has not occurred. Bacterial conjunctivitis: Instill 1 to 2 drops into the conjunctival sac every 2 hours while awake for 2 days and 1 to 2 drops every 4 hours while awake for the next 5 days.,無需調整劑量,,無需調整劑量,除非治療上需要,Contraindicated,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,OD;OL;OU;,,,,,
ECOMB,Brimonidine + Timolol,Combigan 5mL ophthalmic solution,TOPH,Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension.,Bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; in patients receiving MAOIs therapy.,Conjunctival hyperemia， ocular burning & stinging.,25℃以下儲存,Instill 1 drop in the affected eye(s) Q12H.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
ECUS5,Timolol,CUSIMOLOL 0.5%， 5mL,TOPH,,適應症: Reduction of increased intraocular pressure in conditions such as ocular hypertension， chronic open-angle glaucoma (including aphakic patients) & certain instances of secondary glaucoma. 副作用: Conjunctivitis， blepharitis， keratitis. Rarely hypersensitivity， urticaria， local or general eruptions. Mild bradycardia， hypotension， bronchospasm， congestive cardiac insufficiency & masking of hypoglycemic symptoms of IDDM patients. Cardiovascular: Angina， Bradyarrhythmia (9%)， Heart failure， Hypotension Dermatologic: Pruritus， Rash， Urticaria Gastrointestinal: Abdominal pain， Diarrhea， Indigestion， Nausea， Vomiting Musculoskeletal: Cramp Neurologic: Confusion (13%)， Dizziness (2%-10%)， Headache (2%-12%) Ophthalmic: Blurred vision， Burning sensation in eye (15%-20%)， Cataract， Conjunctival hyperemia， Corneal anesthesia (15%-20%)， Dry eyes (15%-20%)， Reduced visual acuity， Ophthalmic Psychiatric: Depression (12%)， Hallucinations (11%)， Psychotic disorder (3%) Respiratory: Cough， Dyspnea Other: Fatigue (3%-11%)， Infectious disease,,室溫,1 drop of 0.25 % soln in affected eye bid. If responseis not satisfactory， use 1 drop of 0.5 % soln in the affected eye bid.,,,,沒有資料,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
EDDA,Desmopressin,Minirin 0.01%， 2.5mL Nasal Spray,HM,,適應症: Central diabetes insipidus， Renal concentrating capacity test. 副作用: Headache， abdominal pain， nausea， hyponatraemia， dizziness， peripheral edema， daytime polyuria， stomach pain， dry mouth， weight gain. Rarely， emotional disturbances in children， allergic skin reactions. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl. Dermatologic: Flushing Gastrointestinal: Nausea， Will respond to dosage decrease Neurologic: Fatigue (10% )， Headache (22.5% ) 禁忌: Habitual or psychogenic polydipsia， history of known or suspected cardiac insufficiency & other conditions requiring diuretic treatment， moderate to severe renal insufficiency， syndrome of inappropriate ADH secretion， known hyponatraemia.,,25°C 以下,Central diabetes insipidus: Adult 10-20 mcg 1-2 times daily. children 5-10 mcg 1-2 times daily. Renal concentrating capacity test Nasal spray Adult 40 mcg， Children >1 years 20 mcg， Infant <1 years 10 mcg.,無需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,Compatible 哺乳時可使用,,IN;,,,,,
EDERO,Clobetasol,Dermovate ointment 0.05% 5gm,TDER,,適應症: Psoriasis; recalcitrant eczema; lichen planus; discoid lupus erythematosus & other skin conditions which do not respond satisfactorily to less active steroids. 副作用: Features of hypercorticism， local atrophic changes， pigmentation changes & hypertrichosis. Exacerbation of symptoms may occur. 禁忌: Rosacea; acne vulgaris; perioral dermatitis; perianal & genital pruritus; primary cutaneous viral infection; bacterial， fungal infected skin lesions; perianal & genital pruritus; dermatoses in infant < 1 year including dermatitis & napkin eruptions. 是一種強效的類固醇藥膏，強效類固醇是較不適合「用在肛門及生殖器」，是因為此部位表皮層很薄，若有發炎現象可採用弱效或中效類固醇，以免吸收強效藥品，產生不良副作用,,室溫,Apply sparingly to the affected area once or bid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EEML,Lidocaine + Prilocaine,Emla cream 5%， 5gm,TDER,Topical anesth of the skin in connection with insertion of IV catheters， blood sampling & superficial surgical procedures.,Hypersensitivity to local anaesthetics of the amide type or to any other component of Emla.,Rarely， mild local reactions eg edema， itching， erythema; corneal irritation， methemoglobinemia (rare).,30℃以下,Apply a thick layer to intact skin and cover with an occlusive dressing. Dermal analgesia can be expected to increase for up to 3 hours under occlusive dressing and persist for 1 to 2 hours after removal of the cream. adult， minor dermal procedures (eg， IV cannulation or venipuncture): Apply 2.5 g (1/2 of the 5 g tube) over 20 to 25 cm2 of skin surface area) for at least 1 hour pediatrics Minor dermal procedures (eg， IV access， venipuncture， IM injection); anesthetic <5 kg: Apply < or = 1 g per 10 cm2 area; cover with an occlusive dressing for the usual duration of application of 60 minutes prior to the procedure. maximum total dose (for all sites combined): 1 g; maximum application area: 10 cm2; maximum application time: 1 hour. 5 kg to 10 kg: Apply 1 to 2 g per 10 cm2 area; cover with an occlusive dressing for at least 60 minutes. Max total dose (for all sites combined): 2 g; maximum application area: 20 cm2; maximum application time: 4 hours. >10 kg to 20 kg: Apply 1 to 2 g per 10 cm2 area; cover with an occlusive dressing for at least 60 minutes. maximum total dose (for all sites combined): 10 g; maximum application area: 100 cm2; maximum application time: 4 hours. >20 kg: Apply 1 to 2 g per 10 cm2 area; cover with an occlusive dressing for at least 60 minutes. maximum total dose (for all sites combined): 20 g; maximum application area: 200 cm2; maximum application time: 4 hours.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
IPCA1,PCA-1 inj 100mL (自費),PCA-1 inj 100mL (自費),CNEU,,,,,,無需調整劑量,,無需調整劑量,,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,,,,成份：Morphine 100mg/10mL in N/S 89 mL
IPCA2,PCA-2 inj 125mL (自費),PCA-2 inj 125mL (自費),CNEU,,,,,,,,,,,,,,,,,,,成份：Fentanyl 0.25mg/5mL+Chirocaine**0.5%， 20mL， in N/S 100 mL
EONMD,Neostigmine Methylsulfate,ONSD 0.01%， 10mL,TOPH,Relief of fatigue of ocular muscle.,Hypersensitivity to any component of the formulation.,Transient stinging,30℃以下,Instill 2 drops TID .The dosage may be increased or decreased moderately.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
ETEI,Etofenamate,Teiria gel 5%， 40gm,CNEU,,適應症: Relief of pain & inflammation associated with musculoskeletal， joint & soft tissue disorders e.g. stiff shoulder， sprains， strains， lumbago， arthralgia & myalgia. 副作用: Rarely， allergic skin reactions.,,室溫,Apply tid-qid to the affected area.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EZNO,Zinc Oxide,Zin ointment 20%， 1oz (28.4gm),TDER,,適應症:Eczema， scalp dermatoses.,,室溫,Apply several times as need.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OGLI3,Gliclazide,Gliclax SR 30mg,META,,適應症: 第二型糖尿病(B023503100) Type 2 DM. 副作用: Hypoglycaemia， nausea， dyspepsia， diarrhoea， constipation. 禁忌: Type 1 diabetes， diabetic keto-acidosis or diabetic pre-coma， severe renal or hepatic insufficiency， co-administration with miconazole， pregnancy， lactation. Avoid coadministration with phenylbutazone or danazol.,,室溫,1-4 tab taken once daily at breakfast. Max : 120 mg daily.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OREQ,Ropinirole,ReQuip PD 2mg PR,CNEU,,適應症:Treatment of idiopathic Parkinson's disease. 副作用:Hallucinations， confusion， somnolence， syncope， dizziness (including vertigo)， dyskinesia， nausea， abdominal pain， vomiting， dyspepsia， constipation， peripheral edema (including leg edema)， nervousness， fatigue， postural hypotension， hypotension.,,室溫,Adult Parkinson's disease: The starting dose is 2mg taken once daily for 1-2 weeks， followed by increases of 2mg/day at 1 week or longer intervals as appropriate， depending on therapeutic response and tolerability， up to a maximally recommended dose of 24mg/day.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
EEXEP,Rivastigmine,Exelon patch 5,CNEU,Mild to moderate Alzheimer's disease.,Hypersensitivity to rivastigmine， other carbamate derivatives or any other components of the product.,More frequent: diarrhea; weight loss; Iindigestion; loss of strength ; nausea; vomiting; loss of appetite; abdominal pain; confusion; constipation; depression; dizziness; fatigue ; headache; insomnia Less frequent: high blood pressure; fainting; general feeling of discomfort or illness; increased sweating; runny nose. Rare: aggression; seizures; trembling and shaking of hands and fingers; trouble in urinating,30℃以下,Mild-to-moderate Alzheimer’s dementia: Initial， 4.6 mg/24 hours patch (Exelon patch 5) topically once daily; after a minimum of 4 weeks and good tolerability， may titrate dose to 9.5 mg/24 hours patch (Exelon patch 10) topically once daily. Conversion from oral therapy: If oral daily dose <6 mg， switch to 4.6 mg/24 hours patch. Apply patch on the next day following last oral dose.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,EXT;,,,,,
IPUL,Metoclopramide hydrochloride,Pulin inj 10mg/2mL,ALIM,Prophylaxis of nausea and vomiting， Gastroesophageal reflux disease， Gastroparesis due to diabetes mellitus.,Preexisting pheochromocytoma or other catecholamine-releasing paragangliomas; increased risk of hypertensive crisis. Sensitivity or intolerance to metoclopramide products.,Common Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )， Taste sense altered (Nasal route， 15% )， Vomiting (1.4% to 2.1% ) Neurologic: Asthenia， Headache (4.2% to 5.2% )， Somnolence (Oral， 2.1% to 2.8% ; IV， 70% ) Serious Neurologic: Neuroleptic malignant syndrome， Tardive dyskinesia,25℃以下,Adult: 1AMP(10mg) BID-QD IM， IVPUSH or IVD. Pediatric: QD IM， IVPUSH or IVD. Child>6 years-old: 0.2mg/kg or 1/2-2/3AMP(5-6.6mg) or 1-1.3mL. Age 3-6 years: 0.2-0.25mg/kg or 1/3-1/2AMP(3.3-5mg) or 0.7-1.0mL. Age1-3 years: 0.25mg/kg or 1/4-1/3AMP(2.5-3.3mg) or 0.5-0.7mL. Age 6-12 months: 0.3mg/kg or 1/4AMP(2.5mg) or 0.5mL. Newborn: QD 0.25mL(0.4mg/kg)， Age < 6 months: 0.3-0.4mL(0.4-0.35mg/kg) IM.,無需調整劑量,[仿單]無相關說明。,需調整劑量,可能安全,Compatible,[仿單]懷孕用藥分級B: 動物實驗證實對胎兒無害但缺乏足夠的孕婦實驗; 或動物實驗有副作用報告，但孕婦實驗無法證明對懷孕初期及後期之胎兒有害。,Compatible 哺乳時可使用,[仿單]無相關說明。,IM;IVD;IVPUSH;,,【D5W】可選 。【L/R】可選 。【N/S】可選 。,over 1 to 2 minutes,The following Administration of Recommended is according to UpToDate(20221206): Adult， higher doses (>10 mg) are to be diluted in 50 mL of compatible solution (preferably N/S) and at least 15 minutes.,1. The following Administration of Recommended is according to UpToDate(20221206): lower doses (< or =10 mg) of metoclopramide can be given IV push undiluted over 1 to 2 minutes. 2. 遲發性運動障礙(Tarddive dyskinesia)發生的風險與總累積劑量有正相關性，分析後有20%病患使用超過12週，故不建議長期(>12週)使用，除非經過評估其治療效益高於Tarddive dyskinesia之風險。 3. 出現錐體外副作用症狀時請停止給藥，尤其是小兒族群比成人更容易發生。
EEXE,Sulconazole Nitrate,Exelderm solution 10mL,TDER,Tinea pedis， tinea cruris， tinea corporis， candidiasis， tinea versicolor.,Hypersensitivity to any component of the formulation.,Local itch， stinging， burning sensation， contact dermatitis， inflammation.,25℃以下，避光密閉容器儲存,Apply BID-TID.,無需調整劑量,,無需調整劑量,沒有資料,Contraindicated – 1st trimester,No Human Data—Potential Toxicity No reports describing the use of sulconazole in human pregnancy have been located. When given orally， sulconazole was embryotoxic and prolonged gestation in one animal species， but the systemic exposures appeared to be far higher than those that could possibly be obtained after topical use. Sulconazole is partially absorbed with the amount reaching the plasma dependent on the dose and application site. The effects of this exposure are unknown. One study did find a significant increase (relative risk 1.4) in the risk of spontaneous abortion after vaginitis therapy with the imidazole antifungals clotrimazole and miconazole (1). A later study speculated that this effect might have been due to inhibition of the critical placental enzyme aromatase (2). There is no other evidence suggesting that similar topical imidazole-derivative antifungal agents cause embryo–fetal harm. However， sulconazole was a more potent inhibitor of aromatase than either of the two agents associated with the abortions (2). Until additional data are available， the best course is to avoid the use of sulconazole in the 1st trimester or the application of the antifungal to large areas of skin at any time in pregnancy.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;SKIN;TOPI;,,,,,
ESERT,Salmeterol + Fluticasone,Seretide 250 Accuhaler,ERSP,,I: Regular treatment of reversible obstructive airways disease， including asthma in childn and adults. ADR : (salmeterol) tremor， subjective palpitations， headache. Cardiac arrhythmias may occur in susceptible patients. (fluticasone) hoarseness， candidiasis of the mouth and throat. CI : Hypersensitivity to any component of this product.,,< 30 ℃,Adult & Childn > 12 yr : 1 inhalation twice daily.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OUTA,Quetiapine,Utapine 200mg,CNEU,Bipolar I disorder， Acute manic episode of Bipolar disorder， Schizophrenia.,Hypersensitivity to quetiapine.,Common Cardiovascular: Increased diastolic arterial pressure (Pediatric， 40.6% )， Increased systolic arterial pressure (Pediatric， 15.2% )， Orthostatic hypotension (Up to 7% )， Tachycardia (Up to 6% ) Endocrine metabolic: Serum cholesterol raised (7% to 18% )， Serum triglycerides raised (8% to 28% )， Weight gain (3% to 28% ) Gastrointestinal: Abdominal pain (3% to 7% )， Constipation (2% to 11% )， Increased appetite (2% to 12% )， Indigestion (2% to 7% )， Nausea (Pediatric， 6% to 10% )， Vomiting (Pediatric， 7% to 8% )， Xerostomia (Adult， 9% to 44%; pediatric， 4% to 10% ) Hepatic: Increased liver enzymes (1% to 6% ) Musculoskeletal: Backache (3% to 5% ) Neurologic: Asthenia (Up to 10% )， Dizziness (8% to 19% )， Extrapyramidal disease (1.1% to 12.9% )， Headache (17% to 21% )， Insomnia (8% to 12% )， Lethargy (1% to 5% )， Somnolence (18% to 57% )， Tremor (2% to 8% ) Psychiatric: Agitation (6% to 20% ) Respiratory: Nasal congestion (3% to 5% )， Pharyngitis (4% to 6% ) Other: Fatigue (3% to 14% )， Pain (7% ) Serious Cardiovascular: Prolonged QT interval (0.1% to less than 1% )， Sudden cardiac death， Syncope (0.3% to 2% ) Endocrine metabolic: Diabetic ketoacidosis Gastrointestinal: Bowel obstruction， Pancreatitis Hematologic: Agranulocytosis， Leukopenia， Neutropenia (0.3% to 1.5% ) Immunologic: Anaphylaxis Neurologic: Seizure (0.05% to 0.5% )， Tardive dyskinesia Psychiatric: Suicidal thoughts Reproductive: Priapism Other: Neuroleptic malignant syndrome,勿超過25℃,Schizophrenia: Initial: 50mg/day on Day1， 100mg/day on Day 2， 200mg/day on Day 3 and 300mg/day on Day 4. Increase further to a target dose of 300 to 450 mg/day and adjust dose based on response and tolerability. Usual dosage range: 150 to 750 mg/day. Bipolar I disorder: Initial: 100mg /day on day 1， 200mg/day on day 2， 300mg/day on day 3， 400mg/day on day 4. Increase further to a target dose of 200 to 800 mg/day and adjust dose based on response and tolerability. Usual effective dose is 400 to 800 mg/day.,需調整劑量,[仿單]Quetiapine會分泌到人類乳汁中，因此建議婦女在服用Quetiapine期間不要餵母奶。在出版的病例報告中，Quetiapine在乳汁中的濃度從檢測不到的程度到170μg/L。估計的嬰兒劑量是經體重校正的母親劑量的0.09%至0.43%。根據有限的母親/嬰兒配對數(N=8)，算出嬰兒每日劑量從小於0.01mg/kg(母親繼量高達每天400mg)至0.01mg/kg(母親繼量高達每天400mg)。,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,[仿單節錄]目前對於Quetiapine使用於孕婦，還沒有適當且控制良好的研究。在有限的出版文獻中，沒有重大畸形與懷孕期間暴露於quetiazine有關。 非致畸作用：在妊娠第三期暴露於抗精神病藥物(包括Quetiapine)，新生兒出生後有發生錐體外徑和/或戒斷症狀的風險。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Quetiapine會分泌到人類乳汁中，因此建議婦女在服用Quetiapine期間不要餵母奶。在出版的病例報告中，Quetiapine在乳汁中的濃度從檢測不到的程度到170μg/L。估計的嬰兒劑量是經體重校正的母親劑量的0.09%至0.43%。根據有限的母親/嬰兒配對數(N=8)，算出嬰兒每日劑量從小於0.01mg/kg(母親繼量高達每天400mg)至0.01mg/kg(母親繼量高達每天400mg)。,AC;AC15;PC;PO;WM;,,,,,
IACT,Human Plasminogen Activator,Actilyse inj 50mg,HEMT,Thrombolytic treatment in acute myocardial infarction， acute massive pulmonary embolism with haemodynamic instability & acute ischaemic stroke,Patients with known hypersensitivity to the active substance alteplase， gentamicin (a trace residue from the manufacturing process) or to any of the excipients listed in Description. Contraindications in acute myocardial infarction， acute massive pulmonary embolism and acute ischaemic stroke: high risk of haemorrhage such as: significant bleeding disorder at present or within the past 6 months; known haemorrhagic diathesis; patients receiving effective oral anticoagulant treatment， e.g. warfarin sodium (INR > 1.3); manifest or recent severe or dangerous bleeding; known history of or suspected intracranial haemorrhage; suspected subarachnoid haemorrhage or condition after subarachnoid haemorrhage from aneurysm; any history of central nervous system damage (i.e. neoplasm， aneurysm， intracranial or spinal surgery); recent (less than 10 days) traumatic external heart massage， obstetrical delivery， recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture); severe uncontrolled arterial hypertension; bacterial endocarditis， pericarditis; acute pancreatitis; documented ulcerative gastrointestinal disease during the last 3 months， oesophageal varices， arterial-aneurysm， arterial/venous malformations; neoplasm with increased bleeding risk; severe liver disease， including hepatic failure， cirrhosis， portal hypertension (oesophageal varices) and active hepatitis; major surgery or significant trauma in past 3 months. Additional contraindications in acute myocardial infarction: any known history of haemorrhagic stroke or stroke of unknown origin; known history of ischaemic stroke or transient ischaemic attack (TIA) in the preceding 6 months except current acute ischaemic stroke within 4.5 hours. Additional contraindications in acute massive pulmonary embolism: any known history of haemorrhagic stroke or stroke of unknown origin; known history of ischaemic stroke or transient ischaemic attack (TIA) in the preceding 6 months except current acute ischaemic stroke within 4.5 hours. Additional contraindications in acute ischaemic stroke: symptoms of ischaemic attack beginning more than 4.5 hours prior to infusion start or symptoms for which the onset time is unknown and could potentially be more than 4.5 hours ago (see Pharmacology: Pharmacodynamics under Actions); minor neurological deficit or symptoms rapidly improving before start of infusion; severe stroke as assessed clinically (e.g. NIHSS>25) and/or by appropriate imaging techniques; seizure at onset of stroke; evidence of intracranial haemorrhage (ICH) on the CT-scan; symptoms suggestive of subarachnoid haemorrhage， even if CT-scan is normal; administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory; patients with any history of prior stroke and concomitant diabetes; prior stroke within the last 3 months; platelet count of below 100，000/mm3; systolic blood pressure > 185 mm Hg or diastolic BP > 110 mm Hg， or aggressive management (intravenous pharmacotherapy) necessary to reduce BP to these limits; blood glucose < 50 mg/dl or > 400 mg/dl (< 2.8mM or > 22.2mM).,Serious Cardiovascular: Cardiac dysrhythmia， Cardiac tamponade， Laceration - injury， Myocardial rupture， Pericardial effusion， Pericarditis Gastrointestinal: Gastrointestinal hemorrhage (5% ) Hematologic: Hemorrhage Immunologic: Anaphylaxis， Hypersensitivity reaction Neurologic: Cerebral herniation， Cerebrovascular accident (1.6% )， Intracranial hemorrhage (0.4 to 1.3% )， Ischemic stroke， Seizure Respiratory: Pleural effusion， Pulmonary edema Other: Angioedema， Orolingual,30℃以下,Myocardial infarction: a)90 mins (accelerated) dose regimen and patients with body weight > 65 kg， started within 6 hr after symptom onset: 15 mg as an IV bolus， 50 mg as an infusion over the 1st 30 mins， followed by an infusion of 35 mg over 60 mins until the max dose of 100 mg. Patients with body weight < 65 kg: 15 mg as an IV bolus & 0.75 mg/kg over 30 mins (max 50 mg)， followed by an infusion of 0.5 mg/kg over 60 mins (max 35 mg). MI: b)3 hr dose regimen for patients in whom treatment can be started between 6 & 12 hr after symptom onset: 10 mg as an IV bolus， then 50 mg as an IV infusion over 1st hr， followed by infusions of 40 mg over 120 mins， until the max dose of 100 mg . Patient < 65 kg Max total dose: 1.5 mg/kg. Pulmonary embolism 10 mg as an IV bolus over 1-2 mins， followed by 90 mg as an IV infusion over 2 hr， until the max dose of 100 mg. Patients with body weight < 65 kg.Max total dose: 1.5 mg/kg . Acute ischemic stroke: Activase: IV: Within 3 hours of the onset of symptom onset (labeled use) or within 3 to 4.5 hours of symptom onset: Note: Perform non-contrast-enhanced CT or MRI prior to administration. Aspirin initiation is generally delayed ?24 hours after administration of alteplase; use of antiplatelet agents (eg， aspirin) or therapeutic-dose anticoagulants (eg， heparin) within 24 hours of alteplase administration is not recommended.Recommended total dose: 0.9 mg/kg (maximum total dose: 90 mg)Load with 0.09 mg/kg (10% of 0.9 mg/kg dose) as an IV bolus， followed by 0.81 mg/kg (90% of 0.9 mg/kg dose) as a continuous infusion over 60 minutes.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,IVD;,使用所附稀釋溶液 (50mL)調配好的Actilyse 1 mg/mL,【N/S】可選 。,X,Acute ischaemic stroke: 0.9 mg/kg via infusion over 60 min. MI: 15 mg as bolus， then 50 mg (0.75 mg/kg in patients <65 kg) via infusion over 30 min， followed by 35 mg (0.5 mg/kg in patients <65 kg) via infusion over 1 hr. Max total: 100mg.,1. 使用所附稀釋溶液 (50mL)調配好的Actilyse 1 mg/mL，可用N/S進一步稀釋，最低濃度 0.2 mg/mL。不可使用其他輸注液稀釋，也不可與其他藥物混合。 2. 注射速率依照醫囑指示，不同適應症有不同的給藥時程表。
IBCGI8,BCG Immunotherapeutic,BCG 81mg Immucyst,RACA,,適應症: Treatment & prophylaxis of primary or recurrent carcinoma in-situ (CIS) of the urinary bladder & prophylaxis following transurethral resection of primary or recurrent stage Ta &/or T1 papillary tumours， regardless of antecedent intravesical treatment. 副作用:Hematuria， urinary frequency， dysuria， bacterial UTI. Local irritative symptoms， fever， prostatitis， ureteral obstruction， systemic BCG infection. 禁忌: Patients on immunosuppressive therapy or with compromised immune systems. Patients who had a transurethral resection or traumatic bladder catheterization in the previous weeks. Active TB， evidence of systemic BCG reaction， fever， UTI.,,2-8℃,81 mg intravesically once weekly for 6-8 weeks (induction therapy). Therapy is resumed after 6 weeks rest with a weekly installation for its 1-3 weeks. Repeat every 6 months until 36 months.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IHER,Trastuzumab,Herceptin inj 440mg,RACA,Treatment of metastatic breast cancer who have tumours that overexpress Human Epidermal Growth Factor Receptor 2 protein (HER2). As single agent or in combination with paclitaxel or docetaxel. Treatment of HER2 +ve early breast cancer patients (EBC) following surgery， chemotherapy (neoadjuvant or adjuvant)& radiotherapy (if applicable).,Patients with known hypersensitivity to trastuzumab or to any other component of Herceptin,Abdominal pain， accidental injury， asthenia， back pain， chest pain， chills， fever， flu syndrome， headache， infection， neck pain， vasodilation， GI disturbances， peripheral edema， edema， arthralgia， myalgia， anxiety， depression， dizziness， insomnia， paresthesia， somnolence， asthma， cough increased， dyspnea， epistaxis， lung disorders， pleural effusion， pharyngitis， rhinitis， sinusitis， pruritus， rash. Cardiovascular: Edema (8% monotherapy )， Peripheral edema (5% to 10% )， Tachycardia (5% monotherapy ) Dermatologic: Rash (4% to 18% ) Gastrointestinal: Abdominal pain (2% to 22% )， Diarrhea (7% to 25% monotherapy; 1.6% grade 3/5 adjuvant therapy )， Loss of appetite (14% monotherapy )， Nausea (6% to 33% )， Vomiting (3.5% to 23% ) Hematologic: Anemia (4% )， Febrile neutropenia (23% adjuvant therapy )， Leukopenia (3% )， Neutropenia (32% grade 3/4; 2% grade 4/5 ) Immunologic: Infectious disease (20% monotherapy; 22% grade 2/5 adjuvant therapy ) Musculoskeletal: Backache (5% to 22% )， Myalgia (4% to 10% ) Neurologic: Asthenia (4.5% to 42% )， Dizziness (4% to 13% )， Headache (6% to 26% )， Insomnia (14% monotherapy; 3.7% grade 2/5 adjuvant therapy ) Respiratory: Cough (2% to 26% )， Dyspnea (3% to 22% )， Pharyngitis (12% monotherapy )， Rhinitis (2% to 14% ) Other: Fever (6% to 36% ),2-8℃,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion， then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks， or initial dose of 8 mg/kg over 90 minutes IV infusion， then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion， followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,【N/S】可選 仿單建議。,,,1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。 3. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 4. 監測CBC、肝腎功能。
IINT2,Eptifibatide,Integrilin inj 20mg/10mL,HEMT,,適應症: Unstable angina， Angioplasty 副作用: Bleeding， hypotension; localised Inj site reaction; thrombocytopaenia; back pain; anaphylaxis; GI， intracranial or pulmonary haemorrhage. Cardiovascular: Hypotension Hematologic: Bleeding， Minor (3 -12%) 禁忌: Active bleeding， increased risk of haemorrhage including hemorrhagic disorders， cerebrovascular disorders， history of stroke， uncontrolled hypertension， severe trauma， severe renal impairment， recent major surgery. Lactation.,,2-8 °C,IV Unstable angina 180 mcg/kg followed by 2 mcg/kg/min for up to 72 hr. If percutaneous coronary procedure is performed during therapy， continue infusion for 18-24 hr after procedure， up to a max total of 96 hr. Angioplasty Initial: 180 mcg/kg immediately pre-op， followed by 2 mcg/kg/min. A 2nd dose of 180 mcg/kg should be given 10 mins later. Continue infusion until discharge or up to 18-24 hr. Min treatment duration: 12 hr.,,,,可能安全,,,Hold Breast Feeding 暫停哺乳,,,,,,,
IMV,Multivitamin,Multivita inj 2mL,NUTR,,適應症:Multivit deficiency.,,2-8℃,2-5 mL as a single dose IV. Per mL Vit A 2，000 iu， vit B1 10 mg， vit B2 2 mg， vit B6 3 mg， nicotinamide 20 mg， pantothenol 5 mg， vit C 100 mg， vit D 200 iu， vit E 1 mg,,,,安全,,,Compatible 哺乳時可使用,,,,,,,
ITRA5,Atosiban,Tractocile inj 5mL (7.5mg/mL) infusion,SGU,Delay imminent preterm birth in pregnant women with regular uterine contractions of at least 30 seconds duration at a rate of >=4 per 30 mins; cervical dilation of 1-3 cm (0-3 for nulliparas) & effacement of >=50%， age >=18 years; gestational age of 24-33 weeks， normal fetal heart rate.,Gestation ages <24 weeks or >33 weeks premature rupture of the membranes > 30 weeks of gestation， intrauterine growth retardation & abnormal fetal heart rate， antepartum uterine hemorrhage requiring immediate delivery， eclampsia & severe pre-eclampsia requiring delivery， intrauterine fetal death， suspected intrauterine infection， placenta praevia， abruptio placenta， abnormal or high-risk pregnancy.,Very common (>10%): nausea. Common (1-10%): headache， dizziness， hot flushes， vomiting， tachycardia， hypotension， inj site reactions， hyperglycemia. Uncommon (0.1%-1%): fever， insomnia， pruritus， rash. Rare (<0.1%): incidental cases of uterine haemorrhage/uterine atony and one case of allergic reaction were reported.,2-8℃,Premature labour: Adult: Initially， 6.75 mg bolus (as 7.5 mg/mL solution) over 1 minute， immediately followed by continuous infusion (as 0.75 mg/mL solution) of 0.3 mg/min for 3 hr， then 0.1 mg/min for up to 45 hr. Total duration: < or = 48 hr. the maximum dose: 330.75 mg. Stage 1: 0.9mL IV bolus， over 1 minute， total 6.75mg. Stage 2: IV infusion over 3 hours， 24mL/hour， 18mg/hour. Stage 3: IV infusion， 8mL/hour， 6mg/hour. Reconstitution: for infusion: Withdraw 10 mL from a 100-mL bag of NaCl 0.9%， glucose 5% or Ringer’s lactate solution and replace with 10 mL of atosiban concentrate (using 2 vials of 37.5 mg/5 mL solution) to produce a final concentration of 0.75 mg/mL.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;IVP;IVPUSH;,,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,初始劑量：6.75mg/0.9mL 推注1分鐘,維持劑量:100~300 mcg/min,1.不可與其他藥物混合 2.維持劑量:100~300 mcg/min 3.起始劑量:7.5mg/mL，推注時間至少1分鐘
LIDO1,Ibuprofen,Idofen 20mg/mL， 120mL suspension,CNEU,Relief of pain， inflammation & fever.,Peptic ulceration; patients in whom attacks of asthma， angioedema， urticaria or rhinitis are precipitated by aspirin & other NSAIDs.,GI effects including ulceration; rashes; bronchospasm. Rarely， thrombocytopenia.,25℃以下避免陽光直射,Children: Antipyretic: For children aged 6 months to 12 years old， if the body temperature is lower than 102.5 °F (about 39.2 ° C)， the recommended dose is 0.25 mL/kg; if the body temperature is 102.5 ° F (about 39.2 ° C) or higher， the recommended dose is 0.5 mL/kg. The duration is generally maintained for 6 to 8 hours. maximum dose: 2 mL/kg/day. Analgesic: For children from 6 months to 12 years of age to relieve mild to moderate pain， the recommended dose is 0.5 mL/kg Q6H-Q8H. maximum daily dose: 2 mL/kg/day Juvenile arthritis: 1.5-2 mL/kg/day in 3-4 divided doses. Children with mild symptoms 1 mL/kg/day. Adults: Antipyretic:20mL Q4-6H. Primary menstrual pain:20mL Q4H Rheumatoid arthritis and osteoarthritis， chronic diseases including sudden symptoms :60 mL-160 mL per day (15 mL QID; 20 mL-40 mL， TID-QID),無需調整劑量,,需調整劑量,可能安全,Human data suggest risk in 1st and 3 rd trimesters,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
IGLY1,Glycerin + Fructose + Sodium chloride,GLYCETOSE inj 10%， 500mL,CAVS,Treatment of increased intracranial pressure & intracranial edema， improvement of impaired consciousness & neurologic deficits in cerebral infarct， intracerebral & subarachnoid hemorrhages， head injury， brain tumor， cerebromeningitis. Post-op therapy following brain surgery; reduction of brain vol at time of brain surgery.,Hereditary fructose intolerance.,Lactic acidosis; hemoglobinuria; headache， thirst， nausea; hypernatremia.,無特別指示,Adult usual dosage: 200-500 mL QD-BID IV infusion (rate: 500 mL over 2-3 hours). Duration of treatment usually is about 1-2 weeks， the dosage may be adjusted according to age and symptoms. Reduction of the brain volume during brain surgery: IV bolus of 500 mL over 30 minutes.,無需調整劑量,Glycerin: No Human Data—Probably Compatible Fructose: no data,需調整劑量,除非治療上需要,No (limited) human data – probably compatible,Glycerin: Limited Human Data—Probably Compatible Fructose: no data,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Glycerin: No Human Data—Probably Compatible Fructose: no data,IVD;,,,,以500mL/2~3 hours 速率滴注,1.未稀釋亦可使用
IART3,Sodium Hyaluronate,Arti Aid I-A inj 3mL,CNEU,,適應症: Treatment of pain in osteoarthritis in knee in patients who have failed simple analgesics (e.g. acetaminophen) & nonpharmacologic treatment. 副作用: Transient swelling， pain， heat & redness may occur sporadically at the injection site. 禁忌: 1. Hypersensitivity to the product components. 2. Infections or skin diseases at injection site.,,2-8℃,Inject 1 syringe once weekly for 5 weeks.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IDIF,Fluconazole,Diflucan 針劑 100mg/50mL,QANB,Candidemia， disseminated candidiasis & invasive candidiasis， Oropharyngeal candidiasis， Esophageal candidiasis， Vag candidiasis， Cryptococcal meningitis， Dermal infection (tinea corporis， cruris & dermal candidal infection)， tinea pedis， Prevention of fungal infection in patients with AIDS.,Patients with known hypersensitivity to fluconazole or to related azole compounds.,Nausea， abdominal pain， diarrhea; rash.,30℃以下,Adult: Cryptococcal meningitis and cryptococcosis: 400 mg on day 1， then 200-400 mg once daily for 6-8 weeks; cryptococcal meningitis prophylaxis in patients with AIDS: 100 mg once daily. Candidiasis: 400 mg on day 1， followed by 200-400 mg once daily. Oropharyngeal candidiasis: 50-100 mg once daily. Vaginal candidiasis: 150 mg as a single dose. Children (> 1 year): 1-2 mg/kg/day for superficial fungal infection; 3-6 mg/kg/day for systemic fungal infection. *****NEONATE ANTIBIOTICS DOSE***** Fluconazole: Invasive Candidiasis Duration of therapy for candidemia: 2 weeks after documented clearance of Candida from the bloodstream and resolution of symptoms (without metastatic complications) Prophylaxis: 3 mg/kg/dose， twice weekly， duration up to 6 weeks Treatment: loading dose 25 mg/kg GA <= 29 week Postnatal 0-14 days: maintenance dose 12mg/kg Q48H GA <= 29 week Postnatal >=15days : maintenance dose 12mg/kg Q24H GA 30-44 week Postnatal 0-7 days: maintenance dose 12mg/kg Q48H GA 30-44 week Postnatal >=8 days: maintenance dose 12mg/kg Q24H,無需調整劑量,,需調整劑量,盡量避免,Human (and animal) data suggest risk,PREGNANCY RECOMMENDATION: Human Data Suggest Risk (大於400 mg/day),Compatible 哺乳時可使用,,IVD;,,,,以10mL/分鐘速率緩慢滴注 (每小瓶至少滴注超過30分鐘)，給藥速率 < 200 mg/hr,1. 注意是否發生皮膚疹、腹痛症狀。 2. 監測肝腎功能與心電圖變化。
IEPO1,Recombinant Human Erythropoietin,EPO inj 1 IU (洗腎門診申報用),HEMT,Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy,Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.,Increased BP， thrombotic or vascular events. Flu-like symptoms， bone pain & chills after inj. Seizures. Skin reactions， palpebral edema. Rarely， erythroblastopenia.,2-8℃避光避免冷凍,Chronic renal failure Adult patients Correction phase: 50 IU/kg 3 times/week IV. When necessary， dose adjustments should be made in increments of 25 IU/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 IU/kg. Pediatric patients Correction phase: 50 IU/kg 3 times/week IV. When necessary， dose adjustments should be made in increments of 25 IU/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally， children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 IU/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 IU/kg for an additional 4 weeks.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,,,,,,1. 本藥品為預先充填的針筒，限單次使用，給藥前須先檢查確定溶液無雜質或變色。 2. 皮下注射每次體積不可超過1 mL。如需注射較大量，應於不同部位給藥。 3. 靜脈注射時間至少須超過 1-5 分鐘。血液透析病人在透析期間，可經由透析線內一個適當的靜脈入口進行大量注射。 4. 本藥品「不可以」靜脈點滴輸注或與其他藥物混用。
IFOR,Ceftazidime,Fortum 1gm,QANB,,適應症: Severe infections of resp tract， ENT， urinary tract， GI， biliary & abdominal. Skin & soft tissue infections， bone & joint infections. Infections associated with haemo- & peritoneal dialysis & with continuous ambulatory peritoneal dialysis (CAPD). 副作用: Phlebitis or thrombophlebitis at IV inj site， pain &/or inflammation after IM inj. Hypersensitivity reactions， maculopapular or urticarial rash， fever， pruritus. GI disturbances， candidiasis， vaginitis， headache， dizziness， parasthesia， bad taste. Transient hematological changes. Cardiovascular: Phlebitis (less than 2%) Dermatologic: Injection site pain Gastrointestinal: Diarrhea (less than 2%) Immunologic: Immune hypersensitivity reaction， Rash (2%) 禁忌: Hypersensitivity to cephalosporins.,,室溫,Adult Dose range: 1-6 g/day in 2-3 divided doses by IV/IM inj. Majority of infections: 1 g 8 hrly or 2 g 12 hrly. UTI 500-1，000 mg 12 hrly. Severe infections， especially immunocompromised patients， including those with neutropenia 2 g 8 or 12 hrly or 3 g 12 hrly. As a prophylactic agent in prostatic surgery 1 g at the induction of anaesth. A 2nd dose at the time of catheter removal. Fibrocystic adults with normal renal function who have pseudomonal lung infections 100-150mg/kg/day in 3 divided doses. Infant & children >2 month 30-100 mg/kg/day in 2-3 divided doses. Immunocompromised， fibrocystic or children w/ meningitis Up to 150 mg/kg/day (max 6 g/day) in 3 divided doses. Neonate & children up to 2 month 25-60 mg/kg/day given in 2 divided doses.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,1. 注射前詢問病患是否有β-醯胺類抗生素過敏史。 2. 監測體溫、CBC、肝腎功能、PT值，注意是否發生抗生素引起的腹瀉。
ISTE,Ustekinumab,Stelara inj 45mg/0.5mL,TDER,Treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Treatment of adult patients with active psoriatic arthritis. Can be used alone or in combination with methotrexate (MTX). Treatment of adult patients with moderately to severely active Crohn’s disease. Treatment of adult patients with moderately to severely active ulcerative colitis.,patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients. Clinically important， active infection .,Common Dermatologic: Erythema at injection site (1% to 5% )， Pruritus (1% to 4% ) Gastrointestinal: Abdominal pain (7% )， Diarrhea (2% to 4% )， Nausea (3% )， Vomiting (4% ) Neurologic: Headache (5% to 10% ) Renal: Urinary tract infectious disease (4% ) Reproductive: Mycosis (Crohn disease， 5% ) Respiratory: Bronchitis (5% )， Nasopharyngitis (7% to 24% )， Sinusitis (3% to 4% )， Upper respiratory infection (4% to 5% ) Other: Fatigue (3% to 4% )， Fever (5% )， Infectious disease (Psoriasis， 27% to 72.3% ) Serious Dermatologic: Skin cancer， Non-melanoma (Up to 1.5% ) Gastrointestinal: Diverticulitis (Less than 1% ) Immunologic: Anaphylaxis (Crohn disease， 0.1% )， Hypersensitivity reaction (Crohn disease， 0.08% ) Neurologic: Posterior reversible encephalopathy syndrome Ophthalmic: Herpes zoster with ophthalmic complication (Less than 1% ) Respiratory: Cryptogenic organizing pneumonia， Interstitial pneumonia， Pulmonary eosinophilia Other: Angioedema， Cancer (Up to 1.7% )， Infectious disease， Serious (Up to 2.8% ),2-8°C儲存且需避光，切勿冷凍與振搖,Plaque psoriasis (Moderate to Severe) (100 kg or less) 45 mg SC initially and 4 weeks later， followed by 45 mg every 12 weeks (Greater than 100 kg) 90 mg SC initially and 4 weeks later， followed by 90 mg every 12 weeks Psoriatic arthritis 45 mg SC initially and 4 weeks later， followed by 45 mg SC every 12 weeks Coexistent moderate to severe plaque psoriasis and weight greater than 100 kg， 90 mg SC initially and 4 weeks later， followed by 90 mg SC every 12 weeks Crohn's disease & Ulcerative colitis (Moderate to Severe) (55 kg or less) Induction， 260 mg (two 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance， 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 55 kg to 85 kg) Induction， 390 mg (three 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance， 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 85 kg) Induction， 520 mg (four 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance， 90 mg SC every 8 weeks beginning 8 weeks after induction dose,無需調整劑量,[仿單]應將餵哺母乳對發育與健康的好處和母親對STELARAR的臨床需求，以及STELARAR或母親的基礎疾病對餵哺母乳之嬰兒的任何可能不良影響放在一起考慮。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]目前並無任何關於ustekinumab是否會出現於人 乳汁、對餵哺母乳之嬰兒的影響、或對乳汁生成作用之影響方面的資料。 Ustekinumab會出現於投予ustekinumab之泌乳母猴的乳汁中。由於在泌乳生理學方面有具物種特異性的差異，因此，動物試驗的資料可能無法可靠地預測人類乳汁中的藥物含量。母體的IgG已知會出現於人類的乳汁。已發表的資料顯示，餵哺母乳之嬰兒的全身暴露量預期應該很低，因為ustekinumab是大分子，並且在胃腸道中會降解。然而，如果ustekinumab會轉移進入人類的乳汁，目前並不確知胃腸道中的局部暴露會造成何種影響。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]應將餵哺母乳對發育與健康的好處和母親對STELARAR的臨床需求，以及STELARAR或母親的基礎疾病對餵哺母乳之嬰兒的任何可能不良影響放在一起考慮。,SC;,,,,,1.建議每次注射都應施打於和上次不同部位，不可注入皮膚有觸痛、瘀傷、紅斑或硬化現象的區域。 2.需冷藏貯存於2-8°C。勿冷凍。勿振搖。若貯存於高達30°C，最長達單次30天。一旦已被貯存於室溫下，勿將其放回冰箱貯存，如果沒有在30天內使用請丟棄。
IGLYB,Glycerin + Fructose + NaCl,Glybrain inj 10%， 500mL,CAVS,,適應症: Treatment of increased intracranial pressure & intracranial edema， improvement of impaired consciousness & neurologic deficits in cerebral infarct， intracerebral & subarachnoid hemorrhages， head injury， brain tumor， cerebromeningitis. Post-op therapy following brain surgery; reduction of brain vol at time of brain surgery. 副作用: Lactic acidosis; hemoglobinuria; headache， thirst， nausea; hypernatremia. 禁忌: Hereditary fructose intolerance.,,室溫,Adult 200-500 mL once or bid IV drip in 2-3 hr/500 mL.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1.未稀釋亦可使用
IGW5,Glucose,Glucose inj 5% 500mL,MSIV,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,室溫,Individualized dosage. Adult 500-1000 mL each time IV drip.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IRR;IVD;PO;,,,,,
IHBIG0,Hepatitis B Immune Globulin,HyperHep B 0.5mL/dose(自費B肝免疫球蛋白),HIMM,Prophylaxis of hepatitis B.,Severe platelet deficiency or other coagulation disorders.,Occasionally temporary tenderness at inj site， skin reactions & elevations of temperature.,2-8℃避免冷凍,IM， acute exposure to blood containing HBsAg 0.06 mL/kg within 24 hours. Prophylaxis of infants born to HBsAg & HBeAg postive mothers 0.5 mL to be given within 12 hours of birth. Sexual exposure to an HBsAg postive person 0.06 mL/kg as a single dose within 14 days of sexual contact. Household exposure to persons with acute HBV infection Infants < 12 months 0.5 mL.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,[仿單]孕婦使用後是否會傷害胎兒、或影響生殖能力也不太清楚，唯有明確需要時才可投與。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,
OGEN,Ursodeoxycholic Acid,Genurso 100mg,ALIM,Dissolution of cholesterol-rich gallstones， Primary biliary cirrhosis， Prevention of gallstones in patients undergoing rapid wt loss.,Calcified and pigment gallstones， radio opaque gallstones. Nonfunctioning gall bladders; chronic liver and peptic ulcer disease. Inflammatory disease of colon and small intestine. Pregnancy.,Diarrhoea， pruritus， nausea， vomiting， gallstone calcification.,室溫藥品，仿單無特別指示儲存溫度條件,Adult 13-15mg/kg devided into four times a day.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OGUT,Midodrine,Gutron 2.5mg,CAVS,,I: Orthostatic circulatory regulation disturbances & dysregulation， constitutional & symptoms hypotension， constitutional Management of side effects produced by hypertensive. CI: Raised BP， severe organic heart diseases， acute nephritis， thyrotoxicosis， pheochromocytoma.,,,Adult & adolescent Tab 1/2 tab. To be taken once or bid.,,,,除非治療上需要,,,,,,,,,,
OLIG,Lithium Carbonate,Ligilin 300mg,CNEU,Treatment of manic episodes of manic depressive illness.,Significant renal or CV disease， severe debilitation， or dehydration， or Na depletion. Lactation.,Tremor， muscle hyperirritability， ataxia， choreoathetotic movements， hyperactive deep tendon reflexes; anorexia， nausea， vomiting， diarrhea， blurred vision， dry mouth; euthyroid goitre &/or hypothyroidism.,避光避熱，儲存於25℃以下,Acute mania: 900-1800mg/day in 3 divided doses. Adjust blood lithium concentration to about 1.0-1.5mEq/L. Check the blood lithium concentration twice a week until the effective blood concentration is reached and the clinical symptoms are stable. Long-term treatment: 900-1200mg in 3-4 divided doses to adjust the blood lithium concentration to 0.6-1.2mEq/L.,無需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OLIS0,Metergoline,Liserdol 4mg(自費),HM,,Amenorrhoea， galactorrhea， female infertility， lactational disorder， puerperal breast engorgement， Parkinson's disease， premenstrual mammary syndrojme， male infertility due to hyperprolactinemia spermacrasia， acromegalia.,,RT,1 tab once-tid， increased gradually at meals.,,,,沒有資料,,,,,,,,,,
OMAD2,Levodopa + Benserazide,Madopar 200/50mg,CNEU,Parkinsonism.,Severely decompensated endocrine， renal， hepatic function & cardiac disorders. Psychoses & severe psychoneuroses. Patients <25 years. Pregnancy. Combination with MAOIs (except selegiline， rasagiline， moclobemide).,Anorexia， GI upsets (rare); cardiac arrhythmias & orthostatic hypotension. Abnormal involuntary movements. Mild， transient leucopenia & thrombocytopenia (rare). Psychotic disturbances. Urine discoloration.,30℃以下,Should be taken on an empty stomach， and avoid high protein diets.Initially 1/2 tablet TID-QID. Optimal daily dosage: 300-800 mg levodopa and 75-200 mg benserazide， divided into 3 or more doses. Average maintenance dose: 1 tablet (levodopa 100 mg/benserazide 25 mg) 3-6 times daily.,無需調整劑量,Levodopa - probably compatible Benserazide-[8] no data,無需調整劑量,沒有資料,Uknown 沒有資料,Levodopa - human suggest low risk Benserazide- [18] no data,Unknown 沒有資料,Levodopa - probably compatible Benserazide-[8] no data,AC;PC;PO;,,,,,
OMOR3,Morphine,MORPHINE SR 30mg,CNEU,,適應症: Relief of mild to moderate pain especially associated with cancer， MI & surgery. Anxiety & sleeplessness associated with severe pain. Symptomatic treatment of diarrhoea. Relief of dyspnoea of left ventricular failure & pulmonary edema. Suppression of cough. Pre-op to anaesth. General anaesth in specialized procedures. 副作用: Respiratory depression， apnoea， circulatory depression， respiratory arrest， shock， cardiac arrest. Constipation， lightheadedness， dizziness， sedation， nausea， vomiting， sweating， dysphoria & euphoria. 禁忌: Acute or severe bronchial asthma; respiratory depression; biliary colic; GI obstruction， concurrent MAOI therapy.,,室溫,1 tab 12 hrly.,,,,除非治療上需要,,,,,,,,,,
ICOS,Dactinomycin,Cosmegen inj 0.5mg,RACA,,適應症:Treatment of cancers in children & testicular cancer. Wilms' tumor， rhabdomyosarcoma， palliative treatment of other types of cancer. 副作用:Malaise， fatigue， lethargy， fever， myalgia， proctitis， hypocalcemia， growth retardation， infection. Pneumonitis. Cheilitis， dysphagia， esophagitis， ulcerative stomatitis， pharyngitis. Anorexia， nausea， vomiting， abdominal pain， diarrhea， gastrointestinal ulceration. Liver toxicity including liver function test abnormalities， ascites， hepatomegaly， hepatitis， hepatic failure with reports of death， hepatic veno-occlusive disease which may be associated with intravascular clotting disorder & multi-organ failure. Anemia， agranulocytosis， leukopenia， neutropenia， febrile neutropenia， thrombocytopenia. Baldness， skin eruptions， acne， flare-up of erythema or darkening pigmentation of skin. 禁忌:Chicken pox or herpes zoster infections. Pregnancy， lactation.,,室溫,Adult 0.5 mg IV daily for max. 5 days. Children 15 mcg/kg IV for 5 days or total dosage of 2，500 mcg/m2 IV for 7 days. Adult & children 2nd cycle can only start 3 weeks later.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,1. 藥品稀釋成濃度10mcg/mL或以上時， 在玻璃或PVC輸注容器內， 室溫下可安定10小時.
OPER7,Dipyridamole,Persantin 75mg,HEMT,,Coronary insufficiency; Inhibition of platelet aggregation.,,,Adult: Coronary insufficiency : 150-225mg daily in divided doses. Inhibition of platelet aggregation : 300- 450mg daily in divided doses. Childn in general， 5-10mg/kg body weight.,,,,可能安全,,,,,,,,,,
OPRE6,Conjugated Estrogen,Premarin 0.625mg,HM,,適應症:女性賀爾蒙缺乏(B018977100),,RT,Osteoporosis: 1.25 mg/day cyclically. Moderate to severe vasomotor symptoms associated with the menopause: 1.25 mg/day if the patient is menstruating， begin administration on day 5 of bleeding.,,,,不可使用,,,,,,,,,,
OQUIN,Quinidine Gluconate,Quinaglute 324mg,CAVS,,Premature atrial & ventricular comtrctions， paroxysmal Superventricular tachycardia， atrial flutter， paroxysmal ventricular fibrillation. Maintenace of conversion of atrial fibrillation.,,,324-648 mg q6-12h， (max. 4 g/day).,,,,除非治療上需要,,,,,,,,,,
OQUIS,Quinidine,Quinidine sulfate 200mg,CAVS,,I: Premature atrial & ventricular comtrctions， paroxysmal Superventricular tachycardia， atrial flutter， paroxysmal ventricular fibrillation. Maintenace of conversion of atrial fibrillation. ADR: Headache， dizziness， visual disturbance， nausea， abdominal pain， skin itch. CI: Complete heart block.,,RT,Premature atrial & ventricular comtrctions: 1 ~ 1/2 tab tid ~ qid Sudden ventricular tachycaedia: 2 ~ 3 tab 2 ~ 3 hrly until tachycardia is terminated. Atrial fibrillation: individualised dosage.,,,,除非治療上需要,,,,,,,,,,
OREM,Mirtazapine,RemeRon 30mg Sol Tab,CNEU,,適應症: Major depressive disorder 副作用: Common ■Endocrine metabolic: Increased appetite (17% )， Serum triglycerides raised (increases to 500 mg/dL or greater: 6% )， Weight gain (body weight increase of 7% or greater: adults 7.5%; pediatrics 49% ) ■Gastrointestinal: Constipation (13% )， Xerostomia (25% ) ■Hepatic: ALT (SGPT) level raised (2% ) ■Neurologic: Asthenia (8% )， Dizziness (7% )， Somnolence (54% ) ■Psychiatric: Disturbance in thinking (2%)， Dream disorder (3%) Serious ■Hematologic: Agranulocytosis， Neutropenia ■Neurologic: Grand mal seizure (less than 0.1% )， Status epilepticus ■Psychiatric: Depression， exacerbation， Mania (0.2%)， Suicidal thoughts， Suicide (rare) 禁忌: hypersensitivity to mirtazapine,,室溫,15 mg/day ORALLY at bedtime; may increase in dose every 1-2 weeks to a max dose of 45 mg/day,,,,除非治療上需要,,,,,,,,,,
OSEC4,Acebutolol,Sectral 400mg,CAVS,,適應症: Hypertension， ventricular arrhythmia， angina pectoris. 副作用: Bradycardia， GI effects， cold extremities， lethargy. Rarely， central effects， dry eyes， rashes， bronchospasm， hypersensitivity， pneumonitis， myalgia， arthralgia. Neurologic: Dizziness (6% )， Headache (6% ) Other: Fatigue (11% ) 禁忌: Cardiogenic shock， bronchial asthma， obstructive lung disorders， uncontrolled heart failure， 2nd or 3rd degree intranodal AV block， severe bradycardia.,,室溫,Initially， 400mg daily as single or 2 divided doses. Dosage may be increased to 800mg daily or 400mg bid.,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OSULF,Sulfinpyrazone,Sulfin 100mg,CNEU,,I: Chronic gouty arthritis and intermittent gouty arthritis. AR: Nausea， vomiting， stomach pain， anemia， dermatitis， dizziness， flushing， geadache， hepatic necrosis， increased bleeding time ( decreased platelet aggregation )， leukopenia， nephrotic symdrome， polyuria， rash， uric acid stones. CI: Active peptic ulcers， hypersensitivity to sulfinpyrazone， phenylbutazone， or other pyrazoles， GI inflammation， blood dyscrasias.,,,D: Adult 100-200 mg twice daily; maximum daily dose: 800 mg.,,,,除非治療上需要,,,,,,,,,,
OVESI,Solifenacin,Vesicare 5mg,SGU,Treatment of overactive bladder with symptoms of urge urinary incontinence， urinary frequency & urgency.,Urinary retention， gastric retention， uncontrolled narrow angle glaucoma.,Dry mouth， GI disturbances including constipation， blurred vision， dry eyes， urinary retention， lower limb edema， fatigue， cough. <Common> Gastrointestinal: Constipation (5.4% to 13.4% )， Xerostomia (10.9% to 27.6% ) <Serious> Cardiovascular: Prolonged QT interval Gastrointestinal: Bowel obstruction， Fecal impaction， Obstruction of colon Immunologic: Anaphylaxis Neurologic: Confusion， Headache， Somnolence Psychiatric: Hallucinations Other: Angioedema,30℃以下,5-10 mg once a day.,需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議本藥需整顆以水吞服。
EBOS,Epinephrine,Bosmin soln 500mL,CAVS,,適應症:Vasoconstriction， circulatory dystonia， esporthostatic， constitutional & symptoms hypotension. 副作用:Whole body reactions such as pulmonary edema， severe hypokalemia (inhalation). Palpitation， BP fluctuation， face flushing， pallor， headache， tremor， sweating， paranoid. GI disturbances， rashes， resp disturbances. 禁忌:Patients receiving halothane or halogen-containing inhalation anesth， butyrophenone or phenothiazine antipsychotics， α-blockers， isoproterenol， sympathetic stimulants (except in emergency). Closed-angle glaucoma.,,室溫,As hemostatic agent in surgery Apply as original concentration or 5 times more concentrated soln with cotton or gauze to the skin. Add 2-5 drops when use as local anesth. ENT Apply as original concentration or 5 times more concentrated soln as ear/nose drops. Asthma， whooping cough Add 2-3 mL to 100 mL salt water as daily dose. Inhale 2-3 times/day. Coughing spasmUse 1-3 drops.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OEPI,Scopolam + Dicyclomine + Chlordiazepoxide,Epilon,ALIM,,適應症: Antacid plus antispasmodic & sedative. 副作用: Constipation， intestinal impaction; phosphate depletion; diarrhea， dehydration; sedation; accommodation disturbances; urinary incontinence; jaundice; dry mouth. 禁忌: Appendicitis; hypophosphatemia; closed-angle glaucoma; prostatic enlargement; paralytic ileus or pyloric stenosis.,,室溫,Adult 1-2 tab tid-qid. Each Tablet contains: Butylscopolamine Bromide 2mg + Dicyclomine HCl 2mg + Chlordiazepoxide 5mg + Magnesium Aluminum Hydroxide co-dried Gel 350mg + Magnesium Oxide 40mg + Chlorophyll Sodium Copper 3mg,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IDIAG,Indocyanine Green,Diagnogreen inj 25mg,ZOTH,Assessment of hepatic function， cardiac output.,Hypersensitivity to any component of the formulation.,Urticaria， pruritus， headache， discolouration of faeces， diaphoresis. Potentially Fatal: Anaphylaxis.,25℃以下避光,Adults Liver Function Test， for determination of Plasma Elimination Rate and Blood Retention Rate: 0.5 mg/kg of body weight as indocyanine green is diluted to a concentration of 5 mg/mL with water for injection and is injected IV gradually into the cubitus vein within 30 sec with careful observation of the symptoms. Liver Function Test， the measurement of hepatic blood flow: After 25mg as indocyanine green is dissolved in as small amount of water for injections as possible， the solution is diluted to a concentration of 2.5-5mg/ml with 0.9% sodium chloride and an amount of this solution equivalent to 3mg as indocyanine green is injected intravenously. Then， intravenous drip infusion is performed at a constant speed until blood collection for about 50 minutes at a rate of 0.27 ~ 0.49mg/minute is completed. Circulatory function test: Depending on the purpose， a solution of indocyanine green is injected at various vascular sites until it reaches the peripheral veins from inside the heart. Usually， the injection is via the forearm vein. The amount each time per adult is 5 ~ 10mg of indocyanine green (about 1 ~ 2mL). Doses for children are decreased in accordance with the body weight.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVP;IVPUSH;,使用廠商提供之10mL注射用水稀釋,,Max: 2 mg/kg/dose.,,
OEM125,Aprepitant,EMEND 125mg,CNEU,Prevention of acute & delayed nausea & vomiting associated with initial & repeat courses of highly & moderately emetogenic cancer chemotherapy.,Concurrent administration with pimozide， terfenadine， astemizole， or cisapride.,Hiccups， asthenia/fatigue， ALT increased， constipation， headache， anorexia. Central nervous system: Fatigue (?18%) Gastrointestinal: Nausea (6% to 13%)， constipation (9% to 10%) Neuromuscular & skeletal: Weakness (?18%) Miscellaneous: Hiccups (11%),30℃以下,Given as part of a 3-day regimen that includes a corticosteroid and a 5-HT3 antagonist. Recommended dose: 125 mg orally 1 hour prior to chemotherapy (day 1) and 80 mg once daily in the morning on day 2 and day 3.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OLOR,Loratadine + Pseudoephedrine,Lorapseudo SR 10/240mg,HIMM,Relief of symptoms associated with allergic rhinitis & common cold.,Patients receiving MAOI therapy or within 14 days of discontinuing such treatment. Narrow-angle glaucoma， urinary retention， severe hypertension， severe coronary artery disease， hyperthyroidism.,Insomnia， dry mouth， headache， drowsiness.,25℃以下，陰涼乾燥處,Adult & children > or = 12 years 1 TAB QD.,無需調整劑量,Loratadine- Limited Human Data—Probably Compatible Pseudoephedrine -Limited Human Data—Probably Compatible,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,Loratadine-Limited Human Data—Animal Data Suggest Low Risk Pseudoephedrine Human Data Suggest Risk,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Loratadine- Limited Human Data—Probably Compatible Pseudoephedrine -Limited Human Data—Probably Compatible,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為緩釋錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。
IPRIM,Gadoxetate,Primovist inj 2.5mmol/10mL,SCAN,MRI of liver,Specific contraindications have not been determined. Precautions: diabetes; elderly patients， renal insufficiency， asthma， allergy， previous contrast media reaction， or other hypersensitivity disorders.,Common Gastrointestinal: Nausea (1.1%) Neurologic: Headache (1.1%) Serious Cardiovascular: Bundle branch block (less than 0.1%)， Shock. Immunologic: Anaphylactoid reaction. Renal: Injury of kidney， Acute， Nephrogenic systemic fibrosis.,30℃以下,Adults: 0.1 mL / kg body weight. [Micromedex 2021/08/05] Usual dose: 0.1 mL/kg (0.025 millimoles/kg) given undiluted as a single IV bolus injection at a flow rate of approximately 2 mL/sec,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IV;,,,,,1. 一般成人使用劑量：0.1 mL/kg 2. 本藥品不應與其他藥品混合使用。 3. 本預填針筒限單次使用，未用完的顯影劑一律丟棄。 4. 本品為可馬上使用不需稀釋的靜脈注射水溶液，以大約 2 mL/秒的速度施打。本品使用後，靜脈留滯針應用生理食鹽水沖洗。
OVIR3,Tenofovir,Viread 300mg,QANB,Treatment of HIV-1 infection in combination with other antiretrovirals. Chronic hepatitis B.,Lactation. Not for treatment for chronic hepatitis B virus infection. Do not co-administer with fixed dose combinations containing tenofovir.,Asthenia， pain， headache， abdominal pain， back pain， chest pain， fever; diarrhea， nausea， vomiting， anorexia， dyspepsia， flatulence， pneumonia; depression， insomnia， peripheral neuropathy， dizziness; rash， sweating， myalgia; wt loss; allergic reaction; increased amylase， pancreatitis; increased liver enzymes， hepatitis; renal & urinary disorders.,30℃以下,Adults and children > 12 years (> 35 kg): 300 mg orally once daily. (熱病) Pediatric: age 2 to < 12 years: 8 mg/kg (maximum: 300 mg) Q24H. Weight based tablet recommendations: 17 to <22 kg: 150 mg Q24H; 22 to <28 kg: 200 mg Q24H; 28 to <35 kg: 250 mg Q24H; > or = 35 kg: 300 mg Q24H.,無需調整劑量,,需調整劑量,可能安全,Compatible – maternal benefit >> embryo-fetal risk,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,
OGEN5,Fluvoxamine,Genbou 50mg,CNEU,,適應症: Treatment of symptoms of depressive illness. Obsessive compulsive disorder in children & adolescents. 副作用: Nausea， vomiting， asthenia， headache， malaise， palpitations/tachycardia， abdominal pain， anorexia， constipation， diarrhoea， dry mouth， dyspepsia， agitation， anxiety， dizziness， insomnia， nervousness， somnolence， tremor， sweating， (postural) hypotension， arthralgia， myalgia， ataxia， confusion， extrapyramidal symptoms， hallucinations， abnormal (delayed) ejaculation， cutaneous hypersensitivity reactions (including rash， pruritus， angioedema)， liver dysfunction， convulsions， mania， galactorrhoea， photosensitivity， weight gain/loss， serotonin syndrome， neuroleptic malignant syndrome-like events， hyponatremia & SIADH， withdrawal reactions， haemorrhage， paresthesia， anorgasmy & taste perversion. Dermatologic: Sweating (immediate-release， 7%; extended-release (social anxiety disorder)， 6%; extended-release (obsessive-compulsive disorder)， 7% ) Gastrointestinal: Diarrhea (immediate-release， 11%; extended-release (social anxiety disorder)， 14%; extended-release (obsessive-compulsive disorder)， 18% )， Indigestion (immediate-release， 10%; extended-release (social anxiety disorder)， 10%; extended-release (obsessive-compulsive disorder)， 8% )， Loss of appetite (immediate-release， 6%; extended-release (social anxiety disorder)， 14%; extended-release (obsessive-compulsive disorder)， 13% )， Nausea (immediate-release， 40%; extended-release (social anxiety disorder)， 39%; extended-release (obsessive-compulsive disorder)， 34% )， Xerostomia (immediate-release， 14%; extended-release (social anxiety disorder)， 11%; extended-release (obsessive-compulsive disorder)， 10% ) Neurologic: Asthenia (immediate-release， 14%; extended-release (social anxiety disorder)， 24%; extended-release (obsessive-compulsive disorder)， 26% )， Dizziness (immediate-release， 11%; extended-release (social anxiety disorder)， 15%; extended-release (obsessive-compulsive disorder)， 12% )， Insomnia (immediate-release， 21%; extended-release (social anxiety disorder)， 32%; extended-release (obsessive-compulsive disorder)， 35% )， Somnolence (immediate-release， 22%; extended-release (social anxiety disorder)， 26%; extended-release (obsessive-compulsive disorder)， 27% )， Tremor (immediate-release， 5%; extended-release (social anxiety disorder)， 8%; extended-release (obsessive-compulsive disorder)， 6% ) Psychiatric: Agitation (immediate-release， 2%; extended-release (social anxiety disorder)， 3%; extended-release (obsessive-compulsive disorder)， 2% )， Anxiety (immediate-release， 5%; extended-release (social anxiety disorder)， 8%; extended-release (obsessive-compulsive disorder)， 6% )， Feeling nervous (immediate-release， 12%; extended-release (social anxiety disorder)， 10% ) Reproductive: Abnormal ejaculation (immediate-release， 8%; extended-release (social anxiety disorder)， 11%; extended-release (obsessive-compulsive disorder)， 10% )， Orgasm incapacity (immediate-release， 2%; extended-release， 5% ),,室溫,May be taken with or without food 100-200 mg daily. Max: 300 mg daily. The minimum recommended starting dose is 100 mg/day and can be given as a single dose; preferably in the evening.It is advisable that a total daily dose over 150 mg be given in 2 or 3 divided doses.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OEM80,Aprepitant,Emend 80mg,CNEU,,適應症:Prevention of acute & delayed nausea & vomiting associated with initial & repeat courses of highly & moderately emetogenic cancer chemotherapy. 副作用:Hiccups， asthenia/fatigue， ALT increased， constipation， headache， anorexia. Central nervous system: Fatigue (?18%) Gastrointestinal: Nausea (6% to 13%)， constipation (9% to 10%) Neuromuscular & skeletal: Weakness (?18%) Miscellaneous: Hiccups (11%) 禁忌:Concurrent administration with pimozide， terfenadine， astemizole， or cisapride.,,室溫,Given as part of a 3-day regimen that includes a corticosteroid & a 5-HT3 antagonist. Recommended dose: 125 mg orally 1 hr prior to chemotherapy (day 1) & 80 mg once daily in the morning on days 2 & 3.,無需調整劑量,,無需調整劑量,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IHAV0,Inactivated Hepatitis A Virus Vaccine,Havrix 720(小兒A肝，政府提供)0.5mL/dose,HIMM,Active immunisation against infections caused by hepatitis A virus.,Hypersensitivity.,Inj site soreness， mild redness & swelling， headache， malaise， vomiting， fever， nausea & loss of appetite.,2-8℃避光避免冷凍,IM， 0.5mL， 12 months-15 years primary immunization. A booster dose after 6-36 months.,無需調整劑量,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料，絕對需要時才給予。,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料，絕對需要時才給予。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料，絕對需要時才給予。,IM;,,,,,
IOMN5,Iohexol + Tromethamine,Omnipaque 350mg I/mL， 50mL,SCAN,脊髓造影， 血管造影， 電腦斷層掃描增強造影劑， 泌尿道造影 Intrathecal: Myelography; contrast enhancement for computerized tomography Intravascular: Angiocardiography， aortography， digital subtraction angiography， peripheral arteriography， excretory urography; contrast enhancement for computed tomographic imaging Oral/body cavity: Arthrography， GI tract examination， hysterosalpingography， pancreatography， cholangiopancreatography， herniography， cystourethrography; enhanced computed tomography of the abdomen,Hypersensitivity to iohexol or any component of the formulation.,全身溫熱感， 暫時性金屬味道， 腹部不適， 噁心， 嘔吐， 過敏性反應 Cardiovascular: Asystole， arrhythmia， bradycardia， cardiopulmonary collapse， edema， heart failure， hypertension (in patients with phenochromocytoma after intra-arterial injection)， hypotension， syncope， transient ischemic attacks， vasovagal attacks， venous thrombosis， ventricular fibrillation， ventricular tachycardia Central nervous system: Anxiety， confusion， dizziness， headache， loss of consciousness， seizure， vertigo Dermatologic: Pruritus， rash， urticaria Endocrine & metabolic: Thyrotoxicosis exacerbation Gastrointestinal: Cramping， diarrhea， nausea， salivary gland swelling， vomiting Local: Burning sensation， pain at injection site， thrombophlebitis Neuromuscular & skeletal: Parasthesia， polyarthropathy， tremor Ocular: Vision abnormalities Renal: Contrast-associated nephropathy， creatinine increased， renal dysfunction Respiratory: Bronchospasm， cough， dyspnea， pulmonary edema， rhinitis， sneezing Miscellaneous: Anaphylactoid reaction， diaphoresis， hypersensitivity reactions,無特別指示儲存溫度但可於使用前加熱至體溫的37℃,Dosing is based numerous variables including: type of examination， route of administration， patient age/weight and product. Consult specific product information for detailed dosing. Intrathecal route: Myelogram a) Lumbosacral:The usual recommended dose for use in lumbar myelography is 10 to 17 milliliters of iohexol 180 milligrams iodine/milliliter (mgI/mL) or 7 to 12.5 milliliters of iohexol 240 mgI/mL administered by lumbar injection. b) Thoracic:The usual recommended dose for thoracic myelography is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter (mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL administered by lumbar or cervical injection. c) Cervical:For cervial myelography given by lumbar injections， the following doses have been used: 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. If iohexol is administered by C1-2 injection， the recommended dose is 7 to 10 mL of iohexol 180 mgI/mL， 6 to 12.5 mL of iohexol 240 mgI/mL， or 4 to 10 mL of iohexol 300 mgI/mL. d) Spinal cord:The usual dose for total columnar myelography (lumbar injection) is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. Intravascular route: CT of head The recommended dose for HEAD IMAGING is 70 to 150 milliliters of iohexol 300 milligram iodine/milliliter (mgI/mL) or 80 mL of iohexol 350 mgI/mL by injection or 120 to 250 mL of iohexol 240 mgI/mL by infusion. For BODY IMAGING the dose is 50 to 200 mL of iohexol 300 mgI/mL or 60 to 100 mL of iohexol 350 mgI/mL by injection. Angiocardiography a) DOSAGE SUMMARY:Iohexol 350 milligrams iodine/milliliter is recommended for use in ANGIOCARDIOGRAPHY. b) VENTRICULOGRAPHY:The usual adult volume is a single injection of 40 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 30 mL to 60 mL). This may be repeated as necessary. When combined with selective coronary arteriography the total administered dose should not exceed 250 milliliters (87.5 grams iodine). c) SELECTIVE CORONARY ARTERIOGRAPHY:The usual adult dose for right or left coronary arteriography is 5 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 3 mL to 14 mL) per injection.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,IA;IRR;IT;IV;IVP;IVPUSH;PO;R;RECT;,,,,,1.體腔使用途徑以水稀釋， 成人兒童及部位不同依1:1~1:50不等比例稀釋 2.腎功能正常病患應立即停用Meformin 48小時，待腎功能恢復後再啟用;如腎功能不佳病患，請評估病患情況，提前48小時停用Meformin.
IOMN1,Iohexol + Tromethamine,Omnipaque 350mg I/mL， 100mL,SCAN,脊髓造影， 血管造影， 電腦斷層掃描增強造影劑， 泌尿道造影 Intrathecal: Myelography; contrast enhancement for computerized tomography Intravascular: Angiocardiography， aortography， digital subtraction angiography， peripheral arteriography， excretory urography; contrast enhancement for computed tomographic imaging Oral/body cavity: Arthrography， GI tract examination， hysterosalpingography， pancreatography， cholangiopancreatography， herniography， cystourethrography; enhanced computed tomography of the abdomen,Hypersensitivity to iohexol or any component of the formulation.,全身溫熱感， 暫時性金屬味道， 腹部不適， 噁心， 嘔吐， 過敏性反應 Cardiovascular: Asystole， arrhythmia， bradycardia， cardiopulmonary collapse， edema， heart failure， hypertension (in patients with phenochromocytoma after intra-arterial injection)， hypotension， syncope， transient ischemic attacks， vasovagal attacks， venous thrombosis， ventricular fibrillation， ventricular tachycardia Central nervous system: Anxiety， confusion， dizziness， headache， loss of consciousness， seizure， vertigo Dermatologic: Pruritus， rash， urticaria Endocrine & metabolic: Thyrotoxicosis exacerbation Gastrointestinal: Cramping， diarrhea， nausea， salivary gland swelling， vomiting Local: Burning sensation， pain at injection site， thrombophlebitis Neuromuscular & skeletal: Parasthesia， polyarthropathy， tremor Ocular: Vision abnormalities Renal: Contrast-associated nephropathy， creatinine increased， renal dysfunction Respiratory: Bronchospasm， cough， dyspnea， pulmonary edema， rhinitis， sneezing Miscellaneous: Anaphylactoid reaction， diaphoresis， hypersensitivity reactions,無特別指示儲存溫度但可於使用前加熱至體溫的37℃,Dosing is based numerous variables including: type of examination， route of administration， patient age/weight and product. Consult specific product information for detailed dosing. Intrathecal route: Myelogram a) Lumbosacral:The usual recommended dose for use in lumbar myelography is 10 to 17 milliliters of iohexol 180 milligrams iodine/milliliter (mgI/mL) or 7 to 12.5 milliliters of iohexol 240 mgI/mL administered by lumbar injection. b) Thoracic:The usual recommended dose for thoracic myelography is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter (mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL administered by lumbar or cervical injection. c) Cervical:For cervial myelography given by lumbar injections， the following doses have been used: 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. If iohexol is administered by C1-2 injection， the recommended dose is 7 to 10 mL of iohexol 180 mgI/mL， 6 to 12.5 mL of iohexol 240 mgI/mL， or 4 to 10 mL of iohexol 300 mgI/mL. d) Spinal cord:The usual dose for total columnar myelography (lumbar injection) is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. Intravascular route: CT of head The recommended dose for HEAD IMAGING is 70 to 150 milliliters of iohexol 300 milligram iodine/milliliter (mgI/mL) or 80 mL of iohexol 350 mgI/mL by injection or 120 to 250 mL of iohexol 240 mgI/mL by infusion. For BODY IMAGING the dose is 50 to 200 mL of iohexol 300 mgI/mL or 60 to 100 mL of iohexol 350 mgI/mL by injection. Angiocardiography a) DOSAGE SUMMARY:Iohexol 350 milligrams iodine/milliliter is recommended for use in ANGIOCARDIOGRAPHY. b) VENTRICULOGRAPHY:The usual adult volume is a single injection of 40 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 30 mL to 60 mL). This may be repeated as necessary. When combined with selective coronary arteriography the total administered dose should not exceed 250 milliliters (87.5 grams iodine). c) SELECTIVE CORONARY ARTERIOGRAPHY:The usual adult dose for right or left coronary arteriography is 5 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 3 mL to 14 mL) per injection.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,IA;IV;IVP;IVPUSH;PO;R;RECT;,,,,,1.體腔使用途徑以水稀釋， 成人兒童及部位不同依1:1~1:50不等比例稀釋 2.腎功能正常病患應立即停用Meformin 48小時，待腎功能恢復後再啟用;如腎功能不佳病患，請評估病患情況，提前48小時停用Meformin.
OEPB,Ethambutol,Epbutol (EMB) 400mg,QANB,TB.,Diabetes， alcohol poisoning. Patients who are unable to appreciate & report visual side effects or changes in vision (e.g. young children， unconscious patients); optic neuritis.,Decreased visual acuity， leukopenia， neutropenia， thrombocytopenia， hypersensitivity， anaphylactoid reactions， headache， mental confusion， disorientation & possible hallucinations， dizziness， hypoaesthesia， paraesthesia， peripheral neuropathy， pulmonary infiltrates with or without eosinophilia， GI disturbances， dermatitis， rash， pruritus， Stevens-Johnson syndrome， toxic epidermal necrolysis， gout， hyperuricemia， joint pain， fever， malaise.,室溫藥品，仿單無特別指示儲存溫度條件,15-25 mg/kg orally once daily.,無需調整劑量,,需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OFEL,Piroxicam,Feldene 10mg,CNEU,,An analgesic， anti-inflammatory agent， gout attacks.,,,Antirheumatic: 20 mg/day in single or divided doses (range 10-30 mg/day). Acute gout: 40 mg/day for 5-7 days.,,,,,,,,,,,,,,
IERB2,Cetuximab,Erbitux inj 100mg/20mL,RACA,Colorectal cancer， metastatic: Treatment of KRAS wild-type (without mutation)， epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer as determined by approved tests (in combination with FOLFIRI [irinotecan， fluorouracil， and leucovorin] as first-line treatment， in combination with irinotecan [in patients refractory to irinotecan-based chemotherapy]， or as a single agent in patients who have failed irinotecan- and oxaliplatin-based chemotherapy or who are intolerant to irinotecan). Limitation of use: Cetuximab is not indicated for the treatment of RAS-mutant colorectal cancer or when results of the RAS mutation tests are unknown. Head and neck cancer， squamous cell: Treatment of squamous cell cancer of the head and neck (as a single agent for recurrent or metastatic disease after platinum-based chemotherapy failure; in combination with radiation therapy as initial treatment of locally or regionally advanced disease; in combination with platinum and fluorouracil-based chemotherapy as first-line treatment of locoregional or metastatic disease).,Known severe hypersensitivity reactions to cetuximab.,Mild or moderate infusion-related reactions eg fever， chills， dizziness or dyspnea; mild to moderate mucositis， increase in liver enzyme levels; skin reactions mainly as acne-like rash; headache; conjunctivitis; diarrhea， nausea， vomiting; dehydration， hypocalcemia， anorexia; fatigue.,2-8°C,Weekly dosing: Initial loading dose: 400 mg/m2 infused over 120 minutes. Maintenance dose: 250 mg/m2 infused over 60 minutes once weekly until disease progression or unacceptable toxicity. Complete cetuximab dose 1 hour prior to chemotherapy.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,,,Administer through a low protein-binding 0.22 micrometer in-line filter. Administer via infusion pump or syringe pump at a rate not to exceed 10 mg/minute. Do not administer as IV push or bolus. Do not shake or dilute.,1. 輸注本藥品一定要單獨使用一條管線，輸注結束時一定要用無菌的生理食鹽水沖洗管線。
IFEB,Ferric-Hydroxide-Sucrose Complex,Fe-Back inj 2%， 5mL,NUTR,Rapid correction of Fe-deficiency anemia.,Evidence of iron overload. Severe hepatic or renal impairment. Potentially Fatal: Anaphylaxis.,Anaphylactoid reactions.,25℃，不可冷藏,Iron sucrose contains 20 mg elemental iron/mL slow IV or IV infusion only. Iron-deficiency anaemia < 5 kg: IVD 1.25mL， may repeat treatment if clinically indicated. 5-10 kg: IVD 2.5 mL， may repeat treatment if clinically indicated. Adult: 10 mL， may repeat treatment if clinically indicated. Slow IV injection rate: 1 mL/min. IV infusion rate: 2.5-5 mL via infusion over at least 15 min. 10 mL via infusion over at least 30 min.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,IVD;IVP;IVPUSH;,,【N/S】可選 。,緩慢注射，每分鐘1mL (20mg 元素鐵) 速率，每瓶5 mL 推注時間至少 5 分鐘。,建議 5 mL Fe-Back 稀釋成100 mL，以大約15分鐘時間滴注，若劑量 > 120mg 滴注需 2 小時。 (Fe-Back 每 mL 含有 400 mg Ferric-Hydroxide-Sucrose Complex，相當於20mg iron),1.本藥品需緩慢靜脈注射，建議速率：1 mL/分鐘，單次注射不要超過10 mL。 2.初次使用前應先用測試劑量1 mL，觀察30分鐘，確定無任何不良反應，？如頭？、臉水腫、呼吸困難 3.靜脈滴注建議使用0.9%生理食鹽水稀釋。5 mL Fe-Back inj 2%稀釋成100 mL，以大約15分鐘時間滴注。 4.？病人之前曾使用含鐵成分針劑藥品發生過敏反應，或患有免疫或發炎(？如？風溼性關節炎)相關疾病，或有氣喘、濕疹、過敏病史，應主動告知醫師。
IFOR10,Paclitaxel,FORMOXOL inj 60mg/10mL,RACA,After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma.,Hypersensitivity to paclitaxel， polyoxyl 35/polyoxyethylated castor oil (Cremophor EL)， or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts <1，500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts <1，000/mm3.,Bone marrow suppression， peripheral neuropathy， GI disturbances， alopecia， hypersensitivity. Dermatologic: Alopecia (55% to 96% ) Gastrointestinal: Diarrhea (16% to 90% )， Inflammatory disease of mucous membrane (5% to 45% )， Nausea and vomiting， Any grade (9% to 88% ) Hematologic: Anemia， Any grade (47% to 96% )， Leukopenia (90% )， Neutropenia， Any grade (78% to 100% )， Thrombocytopenia， Any grade (4% to 68% ) Immunologic: Immune hypersensitivity reaction， Any grade (2% to 45% ) Musculoskeletal: Arthralgia， Myalgia Neurologic: Peripheral neuropathy， Any grade (42% to 79% ),25℃以下避光,Premedication with dexamethasone 20 mg orally at 12 and 6 hours prior to paclitaxel， promethazine 25 or 50 mg or diphenhydromine 50 mg IV 30-60 minutes prior to paclitaxel， and cimetidine 300 mg， ranitidine 50 mg or famotidine 20 mg IV 30-60 minutes prior to paclitaxel is recommended.Baseline neutrophil count should be ?1，500 cells/mm3 (1.5 x 10^9 cells/L)， platelets should be ?100，000 cells/mm3 (100 x 10^9 cells/L) prior to treatment. [Ovarian Caner， advanced]- Previously untreated: 175 mg/m2 infused over 3 hours every 3 weeks in combination with cisplatin 75 mg/m2 or 135 mg/m2 over 24 hours administered every 3 weeks in combination with cisplatin 75 mg/m2.- Previously treated: 135 or 175 mg/m2 infused over 3 hours every 3 weeks.  [Breast Cancer]- Adjuvant treatment: 175 mg/m2 infused over 3 hours every 3 weeks for 4 cycles (administer sequentially following an anthracycline-containing regimen).- Breast cancer， metastatic or relapsed: 175 mg/m2 infused over 3 hours every 3 weeks. [Non-small cell lung cancer (NSCLC)] 135 mg/m2 infused over 24 hours every 3 weeks in combination with cisplatin 75 mg/m2. [Kaposi sarcoma， AIDS related] 135 mg/m2 over 3 hours every 3 weeks or 100 mg/m2 over 3 hours every 2 weeks (due to dose-related toxicity， the 100 mg/m2 dose should be used for patients with a lower performance status).,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 稀釋溶液與器具應使用玻璃、聚丙烯(polypropylene)、聚烯(polyolefin)材質，不可使用含DEHP的PVC塑膠材質。 3. 配製好的輸注溶液濃度在 0.3 - 1.2 mg/mL，室溫下安定性維持 27小時。 4. 注射前應先給予預防過敏的藥物。輸注開始的第一個小時應監測Vital Sign。 5. 曾使用 Paclitaxel發生心臟傳導異常的病人，之後使用Paclitaxel期間應進行連續心電圖監測。 6. 監測CBC。 7.含有蓖麻油成分，容易造成病患過敏反應，施打時應由低速率開始調整，並注意病人反應。
IFORM,Paclitaxel,Formoxol inj 30mg/5mL,RACA,After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma.,Hypersensitivity to paclitaxel， polyoxyl 35/polyoxyethylated castor oil (Cremophor EL)， or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts <1，500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts <1，000/mm3.,Bone marrow suppression， peripheral neuropathy， GI disturbances， alopecia， hypersensitivity. Dermatologic: Alopecia (55% to 96% ) Gastrointestinal: Diarrhea (16% to 90% )， Inflammatory disease of mucous membrane (5% to 45% )， Nausea and vomiting， Any grade (9% to 88% ) Hematologic: Anemia， Any grade (47% to 96% )， Leukopenia (90% )， Neutropenia， Any grade (78% to 100% )， Thrombocytopenia， Any grade (4% to 68% ) Immunologic: Immune hypersensitivity reaction， Any grade (2% to 45% ) Musculoskeletal: Arthralgia， Myalgia Neurologic: Peripheral neuropathy， Any grade (42% to 79% ),25℃以下避光,Premedication with dexamethasone 20 mg orally at 12 and 6 hours prior to paclitaxel， promethazine 25 or 50 mg or diphenhydromine 50 mg IV 30-60 minutes prior to paclitaxel， and cimetidine 300 mg， ranitidine 50 mg or famotidine 20 mg IV 30-60 minutes prior to paclitaxel is recommended.Baseline neutrophil count should be ?1，500 cells/mm3 (1.5 x 10^9 cells/L)， platelets should be ?100，000 cells/mm3 (100 x 10^9 cells/L) prior to treatment. [Ovarian Caner， advanced]- Previously untreated: 175 mg/m2 infused over 3 hours every 3 weeks in combination with cisplatin 75 mg/m2 or 135 mg/m2 over 24 hours administered every 3 weeks in combination with cisplatin 75 mg/m2.- Previously treated: 135 or 175 mg/m2 infused over 3 hours every 3 weeks.  [Breast Cancer]- Adjuvant treatment: 175 mg/m2 infused over 3 hours every 3 weeks for 4 cycles (administer sequentially following an anthracycline-containing regimen).- Breast cancer， metastatic or relapsed: 175 mg/m2 infused over 3 hours every 3 weeks. [Non-small cell lung cancer (NSCLC)] 135 mg/m2 infused over 24 hours every 3 weeks in combination with cisplatin 75 mg/m2. [Kaposi sarcoma， AIDS related] 135 mg/m2 over 3 hours every 3 weeks or 100 mg/m2 over 3 hours every 2 weeks (due to dose-related toxicity， the 100 mg/m2 dose should be used for patients with a lower performance status).,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 稀釋溶液與器具應使用玻璃、聚丙烯(polypropylene)、聚烯(polyolefin)材質，不可使用含DEHP的PVC塑膠材質。 3. 配製好的輸注溶液濃度在 0.3 - 1.2 mg/mL，室溫下安定性維持 27小時。 4. 注射前應先給予預防過敏的藥物。輸注開始的第一個小時應監測Vital Sign。 5. 曾使用 Paclitaxel發生心臟傳導異常的病人，之後使用Paclitaxel期間應進行連續心電圖監測。 6. 監測CBC。 含有蓖麻油成分，容易造成病患過敏反應，施打時應由低速率開始調整，並注意病人反應。
ISUB,Ampicillin + Sulbactam,SUBAcillin inj 1.5gm,QANB,Infections due to susceptible strains of Streptococcus， S. aureus， Enterococcus， Escherichia coli， Klebsiella spp.， Serratia， H. influenza， gm-ve bacteria， Citrobacter & anerobic bacterias (Bacteroides， Fusobacterium & Clostridium difficile)， Branhamella catarrhalis.,Hypersensitivity to penicillins.,Inj site reactions， hypersensitivity reactions， nausea， vomiting， diarrhea， pseudomembraneous colitis， hematological changes， elevated liver transaminases， rash， itch.,25℃以下,Subacillin may be administered by either IV or IM routes (following dilution). Adults: usual dose 1.5-3 g every 6-12 hours for 5-14 days (maximum: ampicillin/sulbactam 12 g/day; sulbactam 4 g/day). Surgical prophylaxis: 1.5-3 g at induction of anesthesia， may repeat the dose once every 6-8 hours， total duration should be ?24 hours. Gonorrhea， uncomplicated: 1.5 g IV/IM as single dose in combination with oral probenecid 1 g. For children and younger， 150 mg/kg/day IV/IM in 3-4 divided doses; neonates < 1 week， 75 mg/kg/day in 2 divided doses.,無需調整劑量,Subactam會分泌至乳汁 AMPICILLIN BREASTFEEDING RECOMMENDATION: Compatible SULBACTAM BREASTFEEDING RECOMMENDATION: Compatible,需調整劑量,可能安全,Human data suggest risk in 1st trimester,AMPICILLIN PREGNANCY RECOMMENDATION: Human Data Suggest Risk in 1st Trimester SULBACTAM PREGNANCY RECOMMENDATION: Compatible,Compatible 哺乳時可使用,Subactam會分泌至乳汁 AMPICILLIN BREASTFEEDING RECOMMENDATION: Compatible SULBACTAM BREASTFEEDING RECOMMENDATION: Compatible,IM;IVD;IVP;IVPUSH;,,,,,1.deep IM 疼痛時可用0.5%滅菌lidocaine hydrochloride anhydrous配製 2. 本品在含有葡萄糖或其他醣類溶液中較不穩定，也不可與血品、蛋白質水解物、胺基醣類混合。 3. 注射劑應於配置後1小時內使用。
IASI,Aminophylline,Asiphylline inj 250mg/10mL,ERSP,Relaxation of bronchial smooth muscle & stimulation of myocardium.,Hypersensitivity to xanthines.,Visual disorders; insomnia， headache， vertigo， hyperventilation， confusion; palpitations， hypotension (too rapid inj).,15-30℃避光避免冷凍,Bronchodilator- Adult: 250-500mg Q6H via IV. Child: 5mg/kg or 150mg/m2 Q6H via IV. Acute symptoms- Adult: Loading dose: 6mg/kg for over 20 min via IV infusion. Maintenance dose: Elderly or patient with cor pulmonale: 0.6mg/kg/hr for 12 hr via IV infusion， then 0.3mg/kg/hr. Healthy people who don't smoke: 0.7mg/kg/hr for 12 hr via IV infusion， then 0.5mg/kg/hr. CHF orlLiver failure: 0.5mg/ kg/hr for 12 hr via IV infusion， then 0.1-0.2mg/kg/hr. Child: Loading dose: Age < 6 months: Individually determined by the physician. Age 6 months -16 years: 6mg/kg for over 20 min via IV infusion. Maintenance dose: Age < 6 months: Individually determined by the physician. Age 6 months - 9 years: 1.2mg/kg/hr for 12 hr via IV infusion， then 1mg/kg/hr. Age 9- 16 years: 1mg/kg/hr for 12 hr via IV infusion， then 0.8mg/kg/hr. Cardiac stimulants- Adult: 500mg via slowly IV.,需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,INHL;IVD;,,【D5NS】可選 。【D5W】可選 。【L/R】可選 。【N/S】可選 。,,1.輸注時間應在20分鐘以上。 2.以靜脈注射投藥時只能使用25mg/mL之注射液，並且須以靜脈注射液稀釋。 3.應以每分鐘25mg的速度緩慢注射，最好事先稀釋。 4.Rate of IV infusion should not exceed 7.5 mg/kg over 30 minutes. For IV intermittent therapy， dilute the dose in 50 mL of fluid and infuse over 30 minutes. [Micromedex 20211207] 5.Usual Infusion Concentrations: Adult: IV infusion: 250mg in 250mL (concentration: 1mg/mL) of D5W or NS. [Uptodate(Lexicomp) 20211207] 6.Usual Infusion Concentrations: Pediatric: IV infusion: 1mg/mL. [Uptodate(Lexicomp) 20211207],1.單獨給藥，不得加入其他藥物共同輸注。 2.In healthy elderly adults (older than 60 years of age): The initial theophylline dose should not exceed 400 mg/day. [Micromedex 20211207]
OOTS,Aripiprazole,Otsuka Abilify 10mg,CNEU,,適應症: Schizophrenia in adults & adolescents 13-17 years. Monotherapy or adjunctive therapy to either lithium or valproate for the acute manic & mixed episodes associated with Bipolar I disorder in adults & pediatrics 10-17 years. Adjunctive treatment of major depressive disorders. Irritability associated with autistic disorder in pediatric patients 6-17 years. 副作用: Headache， asthenia， accidental injury， peripheral edema， hypertension， GI disturbances， myalgia， agitation， anxiety， insomnia， lightheadedness， somnolence， akathisia， extrapyramidal syndrome， tremor， increased salivation， rhinitis， pharyngitis， coughing， blurred vision. Endocrine metabolic: Weight increased (2% to 30% ) Gastrointestinal: Constipation (5% to 11% )， Nausea (8% to 15% )， Vomiting (3% to 11% ) Neurologic: Akathisia (2% to 25% )， Dizziness (4% to 10% )， Extrapyramidal disease (2% to 27.3% )， Headache (12% to 27% )， Insomnia (8% to 18% )， Sedated (1% to 8% )， Somnolence (5% to 26.3% )， Tremor (2% to 11.8% ) Ophthalmic: Blurred vision (3% to 8% ) Psychiatric: Anxiety (4% to 17% )， Restlessness (2% to 12% ) Other: Fatigue (2% to 11% ) 禁忌: Known hypersensitivity to aripiprazole.,,室溫,Schizophrenia Acute treatment: Adult Initially 10 mg or 15 mg once daily. Dose may be increased at intervals of not < 2 weeks. Effective dose range: 10-30 mg/day. Adolescent 13-17 years Initially 2 mg/day， titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Bipolar disorder Acute treatment: Adult Initially 15 mg once daily， may be increased to 30 mg/day. Children 10-17 years Initially 2 mg/day， titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Adjunctive treatment of major depressive disorder Acute treatment: Adult Initially 2-5 mg/day. Dose range: 2-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not < 1 week. Irritability associated with autistic disorder Children 6-17 years Initially 2 mg/day. Dose range: 5-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not < 1 week.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IHER0,Trastuzumab,Herceptin inj 440mg (Sample),RACA,Treatment of metastatic breast cancer who have tumours that overexpress Human Epidermal Growth Factor Receptor 2 protein (HER2). As single agent or in combination with paclitaxel or docetaxel. Treatment of HER2 +ve early breast cancer patients (EBC) following surgery， chemotherapy (neoadjuvant or adjuvant)& radiotherapy (if applicable).,Patients with known hypersensitivity to trastuzumab or to any other component of Herceptin,Abdominal pain， accidental injury， asthenia， back pain， chest pain， chills， fever， flu syndrome， headache， infection， neck pain， vasodilation， GI disturbances， peripheral edema， edema， arthralgia， myalgia， anxiety， depression， dizziness， insomnia， paresthesia， somnolence， asthma， cough increased， dyspnea， epistaxis， lung disorders， pleural effusion， pharyngitis， rhinitis， sinusitis， pruritus， rash. Cardiovascular: Edema (8% monotherapy )， Peripheral edema (5% to 10% )， Tachycardia (5% monotherapy ) Dermatologic: Rash (4% to 18% ) Gastrointestinal: Abdominal pain (2% to 22% )， Diarrhea (7% to 25% monotherapy; 1.6% grade 3/5 adjuvant therapy )， Loss of appetite (14% monotherapy )， Nausea (6% to 33% )， Vomiting (3.5% to 23% ) Hematologic: Anemia (4% )， Febrile neutropenia (23% adjuvant therapy )， Leukopenia (3% )， Neutropenia (32% grade 3/4; 2% grade 4/5 ) Immunologic: Infectious disease (20% monotherapy; 22% grade 2/5 adjuvant therapy ) Musculoskeletal: Backache (5% to 22% )， Myalgia (4% to 10% ) Neurologic: Asthenia (4.5% to 42% )， Dizziness (4% to 13% )， Headache (6% to 26% )， Insomnia (14% monotherapy; 3.7% grade 2/5 adjuvant therapy ) Respiratory: Cough (2% to 26% )， Dyspnea (3% to 22% )， Pharyngitis (12% monotherapy )， Rhinitis (2% to 14% ) Other: Fever (6% to 36% ),2-8℃避光避免冷凍,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion， then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks， or initial dose of 8 mg/kg over 90 minutes IV infusion， then 6 mg/kg over 30?90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion， followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,【N/S】可選 仿單建議。,,,1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。 3. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 4. 監測CBC、肝腎功能。
ICAG2,Calcium gluconate,Ca. gluconate 10% 200mL,NUTR,,適應症:Ca deficiency. 副作用: Cardiovascular (with rapid I.V. injection): Arrhythmia， bradycardia， cardiac arrest， hypotension， syncope， vasodilation Central nervous system: Sense of oppression (with rapid I.V. injection) Endocrine & metabolic: Hypercalcemia Gastrointestinal: Chalky taste Neuromuscular & skeletal: Tingling sensation (with rapid I.V. injection) Miscellaneous: Heat waves (with rapid I.V. injection) 禁忌：Ventricular fibrillation; hypercalcemia; concomitant use of I.V. calcium gluconate and ceftriaxone in neonates (risk of precipitation of calcium-ceftriaxone),,室溫,Calcium: 96.1mg/mL， equal to 0.465 meq/mL (200 mL/Bot) Calcium Gluconate: IV infusion not to exceed 0.5 mL/min. Adult: 0.5-2 g as required. Child: 0.5 g/kg/day in divided doses.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,本品為200 mL包裝，僅供TPN調配使用，禁止直接使用於靜脈注射。
EPROS,Dinoprostone,Prostin E2 Vaginal Tablet 3mg,SGU,Induction & augmentation of labor near term.,Hypersensitivity to Prostin E2 (dinoprostone)， prostaglandins， or any other component of the product. Do not use in patients in whom oxytocic drugs are generally contraindicated such as: - multiple gestation - grand multiparity (6 or more previous term pregnancies) - engagement of the head has not taken place - previous uterine surgery (e.g.， cesarean section， hysterotomy) - cephalopelvic disproportion - fetal heart rate pattern suggests incipient fetal compromise - obstetric conditions where either maternal or fetal benefit/risk ratio favors surgical intervention - unexplained vaginal discharge and/or abnormal uterine bleeding during current pregnancy - nonvertex presentation,Common: Diarrhea (Vaginal insert， <1%; vaginal suppository， approximately 40%)， Nausea (Vaginal insert， <1%; vaginal suppository， 33%)， Vomiting (Vaginal insert， <1%; vaginal suppository， approximately 66%)， Headache (Vaginal suppository， approximately 10%)， Fever (vaginal insert， <1%)， Shivering (Vaginal suppository， approximately 10%) Serious: Decreased diastolic arterial pressure (Vaginal suppository， 10%)， Myocardial infarction， Disseminated intravascular coagulation， Hypersensitivity reaction， Hypertonic uterine dysfunction (Vaginal insert， 2-4.7%)， Infection of amniotic cavity， Intrauterine sepsis of fetus， Non-allergic anaphylaxis， Premature rupture of membranes， Rupture of uterus， Vaginospasmm， Fetal distress (Vaginal insert， 2.9-3.8%),2-8°C冰箱,Initially， insert 1 vaginal tablet high into posterior fornix. Second tablet may be inserted after 6-8 hr if labor is not established. the maximum dose: 6 mg in 24 hr.,無需調整劑量,[仿單] 乳汁中僅含有微量前列腺素，而且在生下早產兒婦女及 足月生產之婦女所分泌乳汁中測得含量並沒有顯著差異。,無需調整劑量,除非治療上需要,Contraindicated,PREGNANCY RECOMMENDATION: First 28 Weeks of Pregnancy—Contraindicated Unless for Termination/Evacuation of Pregnancy Compatible—Near or at Term [仿單] 普洛舒定-益二型使用於預產期及接近預產期懷孕婦女。在老鼠與兔子的動物實驗中， 前列腺素E2的生成增加會造成骨骼異常。目前已有證據顯示在老鼠與兔子中普洛舒定-益二型 具有胚胎毒性，給予任一劑量都會造成子宮張力持續上升，而對胚胎或胎兒造成威脅。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 乳汁中僅含有微量前列腺素，而且在生下早產兒婦女及 足月生產之婦女所分泌乳汁中測得含量並沒有顯著差異。,VAG;,,,,,外源性前列腺素治療可能會加強催產素的作用。不建議同時併用其他的催產製劑。一般建議在使用Prostin E2後至少間隔六小時再使用催產素。
ILAS,Furosemide,Lasix 針劑 20mg/2mL,CAVS,Cardiac， renal & hepatic edema; edema due to burns; mild to moderate hypertension， Acute pulmonary edema， Forced diuresis.,Acute renal failure with anuria， hepatic coma， hypokalemia， hyponatremia， hypovolemia with or without hypotension. Impaired renal or hepatic function.,Minor GI upset; Ca， K & Na depletion， nephrocalcinosis in premature infants; aggravation of metabolic alkalosis; diabetes. Rarely， anaphylactic shock， allergic reactions， bone marrow depression; acute pancreatitis， auditory disorders. Endocrine metabolic: Hyperuricemia (40%)， Hypomagnesemia Gastrointestinal: Loss of appetite Renal: Spasm of bladder,30℃以下避光,Adult and children >15 years: Initially 20-40 mg IM or IV， may increase stepwise by 20 mg at 2-hour interval. Acute pulmonary edema: Initially 40 mg IV， then 20-40 mg after 20 minutes. Forced diuresis: 20-40 mg given in addition to infusion of electrolyte solution. Infant and children <15 years: 1 mg/kg body weight IM or IV up to daily maximum of 20 mg. Intravenous administration should be given slowly， not exceeding an injection rate of 4 mg/minute. In patients with severe impairment of renal function (serum creatinine > 5 mg/dl)， the infusion rate should not exceed 2.5 mg/minute. Intramuscular administration must be restricted to exceptional cases where neither oral nor intravenous administration is feasible. Intramuscular injection is not suitable for the treatment of acute conditions such as pulmonary oedema.,無需調整劑量,[仿單] Furosemide 會移行進入乳汁中，並抑制乳汁分泌，因此，不可於餵哺母乳期間使用 Lasix。,無需調整劑量,除非治療上需要,Human data suggest low risk,[仿單] Furosemide 會通過胎盤障壁，因此，除非有強制性的醫學理由， 否則不可於懷孕期間使用 Lasix。 若於懷孕期間使用Lasix，則須監測胎兒的發育情形。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] Furosemide 會移行進入乳汁中，並抑制乳汁分泌，因此，不可於餵哺母乳期間使用 Lasix。,IM;IVD;IVP;IVPUSH;,,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,推注時間至少 5分鐘,滴注速率 <4mg/min，稀釋後pH值須維持在弱鹼 (7-10之間),1.pH>5.5時IVD < 4mg/min 2.未稀釋亦可使用 3.避光使用，溶液變色即不可使用
ILIP21,Soybean Oil,Lipofundin (小兒TPN用100mL， 20%),NUTR,In parenteral nutrition for energy & essential fatty acids.,Disturbances in fat metabolism; ketoacidosis， hypoxia， thromboembolism & acute shock states.,Adverse reactions directly related to fat emulsions in general are of 2 types: Immediate (Acute) Reactions: Dyspnea， cyanosis， allergic reactions， hyperlipaemia， hypercoagulability， nausea， vomiting， headache， flushing， hyperthermia， sweating， chills， sleepiness， chest and back pain. Delayed Reactions: Hepatomegaly， jaundice due to central lobular cholestasis， splenomegaly， thrombocytopenia， leucopenia， transient increases in liver function tests and overloading syndrome. The deposition of a brown pigmentation in the reticuloendothelial system， the so-called "IV Fat Pigment"， has also been reported. The cause and the significance of this phenomenon are unknown.,25℃以下避光避免冷凍,Dosage Adult: 0.7-1.5g lipids/kg body weight/day， maximum: 2g lipids/kg body weight/day. For home TPN apply>6 months or Short Bowel Syndrome: < 1g lipids/kg body weight/day. Children and adolescents: 2-3g lipids/kg body weight/day. Preterm neonatal infants， term newborn infants， infants and toddlers: <3g lipids/kg body weight/day. (Maximum: 4g lipids/kg body weight/day). Maximum infusion rate Adults: Up to 0.15 g lipids/kg body weight/hr. Children and adolescents: Up to 0.13 g lipids/kg body weight/hr. Preterm neonatal infants， term newborn infants， infants and toddlers: Up to 0.17 g lipids/kg body weight/hr.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,輸注的最初15分鐘不宜超過每小時每公斤體重0.05 – 0.1 g 脂肪量，相當於0.25 – 0.5 ml/kg/hr。 最大輸注速率 ：每小時每公斤體重不大於 0.15 g 脂肪量，相當於0.75 mL/kg/hr 最大滴注速率 ：每分鐘每公斤體重不超過0.25滴。( 0.25 gtt/kg/min ) 以體重70公斤的病患為例，最大輸注速率為每小時50 ml或每分鐘18滴。 每日劑量的建議輸注速率不可少於16小時，較好的輸注時間為連續輸注24小時。,脂肪乳劑應以慢速輸注為原則。 營養不量患者及兒童應調降輸注速率。
IMEN,FSH 75 IU + LH 75 IU,Menopur 75/75 IU,HM,Infertility in male & female.,Pregnancy & lactation; enlargement of the ovaries or cysts not due to polycystic ovarian syndrome; gynaecological bleeding of unknown origin; tumors in the uterus， ovaries & breasts.,Ovarian hyperstimulation， ascites， hydrothorax， oliguria， hypotension， thromboembolism， hypersensitivity reactions， fever， nausea & vomiting， inj site reactions， unintentional multiple pregnancies.,30℃以下避光避免冷凍,PCOD: treatment should be started within the first 7 days of the menstrual cycle. The recommended initial dose is 75-150 IU daily， which should be maintained for at least 7 days. The recommended dose increment is 37.5 IU per adjustment， and should not exceed 75 IU. Maximum daily dose < 225 IU. When an optimal response is obtained， a single injection of 5000 - 10000 IU hCG should be given 1 day after the last Menopur injection .Women undergoing controlled ovarian hyperstimulation for multiple follicular development for assisted reproductive technologies (ART): Menopur therapy should start approximately 2 weeks after the start of agonist treatment. The recommended initial dose of Menopur is 150-225 IU daily for at least the first 5 days of treatment. Adjustment depending on clinical response， should not exceed more than 150 IU per adjustment. The maximum daily dose < 450 IU daily and in most cases dosing beyond 20 days is not recommended.Male infertility: 75-150IU Menopur combinded with hCG， 2-3 times/week， for 90 days.,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,SC;,使用廠商提供之1mL溶劑溶解之,,,,
IMETE,Methylergometrine,Methergin inj 0.2mg/1mL,SGU,Active management of the 3rd stage of labour， Uterine atony/hemorrhage， Subinvolution， lochiometra， puerperal bleeding.,Pregnancy; 1st & 2nd stage of labour & before crowning of the head; severe hypertension， hypertensive toxemia; occlusive vascular disease; sepsis.,Abdominal pain， hypertension， headache， skin eruptions， dizziness， nausea， vomiting， convulsions， sweating， chest pain， hypotension， bradycardia， tachycardia， palpitations， peripheral vasospastic reaction. Very rarely， hallucinations， anaphylactic reactions， MI.,2-8℃避光， 避免冷凍,Effective management of the third stage of labor: 0.5-1 mL (0.1-0.2 mg) intravenously slowly when the baby is delivered to the front shoulder or at least immediately after the baby is born. Usually， the first strong contraction after MetherginR is given， the placenta needs to be expelled by applying pressure at the base of the hand. The recommended dose for production under general anesthesia is 1 mL(0.2 mg). Treatment of uterine relaxation/bleeding: 1 mL (0.2 mg) intramuscularly or 0.5-1 mL (0.1-0.2 mg) intravenously slowly. If necessary， repeat every 2 to 4 hours， up to 5 times in 24 hours. Intramuscularly: 1 mL， 0.2 mg， after delivery of the anterior shoulder， after delivery of the placenta， or during the puerperium. May be repeated as required， at intervals of 2-4 hours. Intravenously: 1 mL， 0.2 mg， administered slowly over a period of no less than 60 seconds.,無需調整劑量,,無需調整劑量,沒有資料,Contraindicated,,Compatible 哺乳時可使用,,IM;IVPUSH;,,【N/S】可選 。,推注時間 > 60秒,,Administer slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. 請置於攝氏 2-8 度冰箱冷藏， 避光， 避免冷凍
OANS,Metformin,Ansures ER 500mg,META,,適應症:Type 2 diabetes mellitus 副作用:Diarrhea， nausea， vomiting Endocrine metabolic: Cobalamin deficiency (up to 9.9% ) Gastrointestinal: Diarrhea (53.2% (immediate-release) ; 9.6% to 12.5% (extended-release) )， Flatulence (12.1% )， Indigestion (7.1% )， Malabsorption syndrome (up to 9.9% )， Nausea (up to 25.5% (immediate-release); ; 6.7% (extended-release) )， Vomiting (up to 25.5% ) Neurologic: Asthenia (9.2% )， Headache (5.7% ) 禁忌:Renal/hepatic diseases， renal impairment， CHF， acute/chronic metabolic toxicity including ketoacidosis. Discontinue before administration of parenteral iodinated contrast media for radiological diagnosis & before surgery.,,室溫,Adult Initially 500 mg during dinner. May increase by 500 mg after 1 week. Max: 2000 mg in 1-2 divided doses,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
OCLIN,Clindamycin,Clincin 150mg,QANB,,適應症: 細菌性感染(A032065100) Treatment of infections caused by susceptible strains of Strep， staphylococcus， pneumococci & anaerobic bacteria. 副作用: Diarrhea occasionally with acute colitis， abdominal pain， GI upsets; skin reactions， jaundice， hematopoietic changes. 禁忌: Hypersensitivity to clindamycin or lincomycin. History of GI diseases， severe renal or liver impairment.,,室溫,Adult: 150-300 mg 6 hrly. Severe infection: 300-400 mg 6 hrly. Children: 8-16 mg/kg/day in 3-4 equal doses. Severe infection: 16-20 mg/kg/day in 3-4 equal doses.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
ITT5,Electrolytes + Water,台大 No.5 400mL,MSIV,Supplement of water， electrolytes & nutrition,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30℃以下,Central vein or peripheral vein infusion， as needed. Taita No.1: Na 25mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 20mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 38g/L， 500mL/Bot， 300mOsm/L. Taita No.2: Na 40mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 26mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 33g/L， 500mL/Bot， 287mOsm/L. Taita No.3: Na 75mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 61mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 20g/L， 500mL/Bot， 285mOsm/L. Taita No.4: Na 110mEq/L， K 20mEq/L， Mg 0mEq/L， Cl 102mEq/L， Acetate 16mEq/L， Phosphate 12mM/L， Glucose 8g/L， 500mL/Bot， 300mOsm/L. Taita No.5: Na 36mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 17mEq/L， Acetate 28mEq/L， Phosphate 12mM/L， Glucose 100g/L， 400mL/Bot， 669mOsm/L.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,特點及適應症 Taita No.1: Na、Cl 是各台大電解質輸液中含量最低；小兒用維持液、電解質、水份、養份補充 Taita No.2: 成分與Taita No.1相似但Na、Cl較多;熱量及K含量較低，可作為小兒或成人用維持液 Taita No.3: NaCl含量似0.45 %N/S，可用於等張性脫水、糖尿病性酸中毒 Taita No.4: Na、K、Cl是各台大電解質輸液中含量最高，可用於低張性脫水、低磷血症 Taita No.5: 台大電解質輸液系列中，含Acetate及熱量最高，可用於高熱量電解質補充液、低磷血症
OMETR,Metronidazole,Metrozole 250mg,QANB,Vaginitis caused by Trichomonas. Amebiasis & metronidazole-susceptible anaerobic infection.,Blood dyscrasias. Active CNS disease.,GI disturbances; peripheral neuropathy; drowsiness; leukopenia; rarely， skin reactions， darkening of urine， anaphylaxis， encephalopathy. Gastrointestinal: Abdominal discomfort (7%)， Loss of appetite， Metallic taste， Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )， Headache (tablets， 15% to 18%; vaginal gel， 5% )， Peripheral neuropathy Reproductive: Candida infection of genital region， Symptomatic cervicitis/vaginitis (10%)， Vaginal discharge (12%) Other: Drug interaction with alcohol， Disulfiram-like reaction,室溫藥品，仿單無特別指示儲存溫度條件,(仿單) Adults: Anaerobic infections: 7.5 mg/kg Q6H for 7 days (maximum 1 g/dose; 4 g/day).Helicobacter pylori: 500 mg orally Q8H in combination with bismuth and other antibiotics for 1-2 weeks. Amebiasis: 500-700 mg orally Q8H for 5-7 days. Trichomoniasis: 2 g orally as a single dose， 1 g Q12H for 1 day or 250 mg Q8H for 7 days. Dracunculiasis: 250 mg Q8H for 10 days. Children: Anaerobic infections:7.5 mg/kg Q6H or 10 mg/kg Q8H. Amebiasis: 11.6-16.7 mg/kg Q8H for 10 days. Trichomoniasis: 5 mg/kg Q8H for 7 days. Dracunculiasis: 8.3 mg/kg (max 250 mg/dose) Q8H for 10 days.,需調整劑量,Hold Breastfeeding (Oral/IV Single Dose) Limited Human Data—Potential Toxicity (Oral/IV Divided Dose),無需調整劑量,可能安全,Human data suggest low risk,,Hold Breast Feeding 暫停哺乳,Hold Breastfeeding (Oral/IV Single Dose) Limited Human Data—Potential Toxicity (Oral/IV Divided Dose),AC;AC15;PC;PO;WM;,,,,,
ITYG,Tigecycline,Tygacil inj 50mg,QANB,Treatment of complicated skin & skin structure infections， complicated intra-abdominal infections & community-acquired pneumonia caused by susceptible microorganisms sensitive to tigecycline.,Hypersensitivity.,Abdominal pain， abscess， asthenia， back pain， fever， headache， infection， pain; HTN， hypotension， phlebitis; constipation， diarrhea， dyspepsia， nausea， vomiting; anemia， leukocytosis， thrombocythemia; increased alkaline phosphatase/amylase/BUN/lactic dehydrogenase/SGOT/SGPT， bilirubinemia， abnormal healing， hyperglycemia， hypokalemia， hypoproteinemia， peripheral edema; dizziness， insomnia; increased cough， dyspnea， pulmonary physical finding; pruritus， rash， sweating; inj site reactions.,20-25℃,Adult: a single loading dose of 100 mg IV initially， then 50 mg IV Q12H over 30-60 minutes for 5-14 days.,需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,1.IVD: 5.3 mL N/S或D5W或L/R，調配成藥液濃度10mg/mL，只需取出5mL.,【D5W】可選 。【L/R】可選 。【N/S】可選 。,,給藥濃度≦ 1mg/mL，建議以 >30 ~ 60分鐘緩慢滴注,1. 稀釋於小瓶內的溶液室溫最多擺放6小時，稀釋好的輸注溶液室溫下最多擺放24小時 (包含原先在小瓶內的6小時)。因此，若使用方式為25mg Q12H，建議將小瓶內剩餘的藥液置於冰箱冷藏 (最多48小時)，下次給藥前再加於輸注溶液。 2. 藥液若變色則不可使用。(調配好的藥液應呈黃色或橙色) 3. Tygacil給藥時必須使用專用的輸注管路，或使用Y型輸注管路，以便與其他輸注藥液區別。 4. 監測體溫、CBC與感染症狀變化。 5. 監測肝功能。
IMAN1,D-Mannitol,Maniton inj 20% 100mL,CAVS,,適應症: Treatment of cerebral oedema; to increase urine flow in acute renal failure; reduce raised intracranial pressure; short-term management of glaucoma; promote excretion of toxic substances by forced diuresis. 副作用: Fluid & electrolyte imbalance， nausea & vomiting， thirst， headache， chills， fever， allergic reactions. 禁忌: Pulmonary oedema， intracranial bleeding (except during craniotomy)， heart failure & renal failure (unless a test dose has produced a diuretic response).,,,Adult 1-2 g/kg as a 20% soln given by rapid IV infusion.,無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【N/S】可選 。【D5NS】可選 。【D5W】可選 。【L/R】可選 。,,輸注速率: 0.5 - 1 g/kg/30~60min 建議使用0.22 micron fillter過濾,1.未稀釋亦可使用 2.IVD:建議使用0.22 micron fillter過濾
IPEGA,Peginterferon alfa-2a,Pegasys 180mcg/0.5mL,QANB,,適應症:Treatment of both HBeAg-positive & HBeAg-negative chronic hepatitis B in non-cirrhotic & cirrhotic patients with compensated liver disease & evidence of viral replication & liver inflammation. Treatment of chronic hepatitis C， alone or in combination with ribavirin， in non-cirrhotic patients & cirrhotic patients with compensated liver disease. 副作用:Fatigue， rigors， pyrexia， inj site reaction， pain， asthenia， GI disorders， anorexia， weight loss， myalgia， arthralgia， back pain， headache， insomnia， dizziness， concentration impairment， depression， irritability， anxiety， dyspnea， cough， alopecia， pruritus， dry skin. Dermatologic: Alopecia (18% to 28% )， Dermatitis (8% to 16% )， Dry skin (4% to 10% )， Injection site inflammation (10% to 31% )， Injection site reaction (22% to 23% )， Pruritus (12% to 19% )， Rash (5% to 8% ) Endocrine metabolic: Weight decreased (4% to 16% ) Gastrointestinal: Abdominal pain (8% to 26% )， Diarrhea (11% to 31% )， Loss of appetite (16% to 24% )， Nausea and vomiting (5% to 25% ) Hematologic: Lymphocyte count abnormal (3% to 14% )， Thrombocytopenia (5% to 8% ) Musculoskeletal: Arthralgia (22% to 28% )， Myalgia (26% to 51% ) Neurologic: Dizziness (13% to 23% )， Headache (27% to 54% )， Insomnia (19% to 30% )， Reduced concentration (8% to 10% ) Psychiatric: Anxiety (19% to 33% )， Feeling nervous (19% to 33% )， Irritability (19% to 33% ) Respiratory: Cough (4% to 10% )， Dyspnea (4% to 13% ) Other: Fatigue (24% to 67% )， Fever (24% to 54% )， Influenza-like illness， Rigor (25% to 47% ) 禁忌:Autoimmune hepatitis， decompensated cirrhosis， use in neonates & infants ? 3 years. Pegasys/ribavirin combination therapy must not be used during pregnancy,,2-8℃,HBeAg-positive & HBeAg-negative chronic hepatitis B 180 mcg SC once weekly for 48 weeks Chronic hepatitis C 180 mcg SC once weekly for 48 weeks in monotherapy & individualised based on the patient's viral genotype in combination therapy.,需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,
IROC,Ceftriaxone,Rocephin inj 500mg,QANB,,適應症:Infections caused by pathogens sensitive to Rocephin， eg sepsis; meningitis; infection in patients with impaired defence mechanisms; UTI; infection of respiratory tract， abdominal， bone， joint， soft tissue， skin， GUT， ENT; genital infection including gonorrhea. 副作用:GI upsets， hematological changes， skin reactions， coagulation disorders， phlebitis (IV administration). Rarely， agranulocytosis， renal precipitations. 禁忌:Known hypersensitivity to cephalosporins. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing soln or products.,,室溫,Adult & children >12 years 1-2 g IV infusion once daily. Severe infection: 2-4 g once daily. Infant & children 20-80 mg/kg/day; neonate 20-50 mg/kg/day.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,1. 本藥品勿與含鈣或其他抗生素溶液混合。 2. 注射前詢問病患是否有β-醯胺類抗生素過敏史。 3. 監測體溫、CBC、肝腎功能，抗生素引起的腹瀉。 4. Roche藥廠提供本藥僅IV或IVD給藥。
IMV13,Multivitamin,Lyo-Povigent inj 4mL (13種成份),NUTR,Nutritional supplementary for urgent situations induced by surgery， severe burns， fracture and trauma， severe infection， and coma.,Hypersensitivity to any component of the formulation; pre-existing hypervitaminosis,Cardiovascular: Angioedema， edema Central nervous system: Agitation， anxiety， dizziness， headache Dermatologic: Erythema， pruritus， rash， urticaria Ocular: Diplopia Respiratory: Dyspnea， wheezing Miscellaneous: Allergic reactions， anaphylaxis， hypervitaminosis,2-8℃避光,As TPN material. For TPN Adult: 4 mL/day. For TPN Pediatric: see [處方集附錄十五 早產兒靜脈營養中維生素與微量元素建議劑量表] Each Vial contains: (PART Ⅰ) Thiamine Hydrochloride 3.9mg， Riboflavin-5'-phosphate Sodium 4.6mg， Pyridoxine Hydrochloride 4.9mg， Cyanocobalamin 0.005mg， Niacinamide 40mg， Folic acid 0.4mg， Ascorbic acid 100mg， D-Panthenol 14mg， Biotin 0.06mg， Each Ampoule contains: (PART Ⅱ) Vitamin A palmitate 3300IU， Cholecalciferol 0.005mg(200IU)， dl-α-Tocopheryl Acetate 10mg， Phytonadione 2mg,無需調整劑量,Refer to individual vitamin monographs for requirements while breast-feeding,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,Refer to individual vitamin monographs for requirements while breast-feeding,IVA;,,【D5W】可選 。【N/S】可選 。,,本劑PARTⅠ、PARTⅡ混合溶解後，加入高熱量輸注液後稀釋使用,1.脂溶性維生素的滲透壓很高，仿單建議「本劑避免單獨投與，及末梢靜脈內投與」。廠商建議：如果需週邊施打 (滲透壓 < 300 mOsm/L)，每劑4mL請使用500-1000 mL以上的溶劑稀釋。溶劑可選用N/S或D5W。 2. 仿單建議「本劑PARTⅠ，PARTⅡ混合溶解後，應迅速加入高熱量輸液中稀釋後才能使用，通常應在12小時內使用完。為防止維他命被光分解，因此在貯存，溶解使用時，均應避光。」廠商建議： 混合後未使用完畢，冷藏3天。
EPER2,Minocycline,Periofeel Dental oint 2%,TENT,,,,,,,,,,,,,,,,,,,
IZYV,Linezolid,Zyvox inj 600mg/300mL,QANB,Vancomycin-resistant Enterococcus faecium infections， including cases with concurrent bacteremia ， Nosocomial pneumonia caused by Staphylococcus aureus ，Complicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains)， Streptococcus pyogenes， or Streptococcus agalactiae,Patients who have known hypersensitivity to linezolid or any of the other components of Zyvox.,Diarrhea (incidence across studies: 2.8-11%)， headache (incidence across studies: 0.5-11.3%) and nausea (incidence across studies: 3.4-9.6%).,25℃以下避光,Adult and children > 12 years: 600 mg PO/IV Q12H; uncomplicated skin/skin structure infections: 400-600 mg PO Q12H. Children (0-11 years): 10 mg/kg PO/IV Q8H; uncomplicated skin/skin structure infection: (5-11 years) 10 mg/kg PO Q12H， (< 5 years) 10 mg/kg PO Q8H. Administer IV infusion over 30-120 minutes. *****NEONATE ANTIBIOTICS DOSE***** Linezolid: Oral， IV. Bacteremia， community/ hospital-acquired pneumonia， skin infections. Vancomycin-resistant Enterococcus faecium (VREF) infection GA <34 week Postnatal 0-7 days， dose: 10mg/kg Q12H GA <34 week Postnatal >=8 days， dose: 10mg/kg Q8H GA 33-44 week Postnatal 0-28 days， dose: 10mg/kg Q8H,無需調整劑量,Linezolid和代謝物會分泌至授乳大鼠的乳汁,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Linezolid和代謝物會分泌至授乳大鼠的乳汁,IVD;,,【D5W】可選 。【L/R】可選 。【N/S】可選 。,,輸注時間建議以30至120分鐘,1. 靜脈投與Zyvox Inj. 時，輸注時間應為30至120分鐘。不得使用此靜脈輸注袋作一系列的聯結。添加物不得注入此輸注液中。當使用ZYVOX靜脈注射劑必須同時併用其他藥物時，應該根據每一個藥品的建議劑量和投與途徑分開投與。 2. Zyvox Inj.應避光儲存於25°C以下。瓶口應緊閉以避免潮濕。輸注袋在使用前，建議應保存在鋁箔外包裝內。輸注袋應預防結冰。藥物在投與之前應用眼睛檢查是否有微粒存在。 3. 注意副作用：乳酸性酸中毒、血清素症候群(併用血清素類製劑或酪胺酸食品)、週邊神經病變及視神經病變、痙攣。
IACL,Zoledronic Acid,Aclasta inj 5mg/100mL,META,Treatment and prevention of postmenopausal osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment and prevention of glucocorticoid-induced osteoporosis. Treatment of Paget’s disease of bone in men and women.,Hypocalcemia. Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment. Hypersensitivity to any component of Aclasta.,Common Cardiovascular: Peripheral edema (Paget disease， 3%; osteoporosis， 4.6% to 5.5%; osteopenia， 3.9% to 5.6%; hypercalcemia of malignancy， 5% to less than 10%; bone metastasis， 21% ) Endocrine metabolic: Weight decreased (bone metastasis， 16% ) Gastrointestinal: Abdominal pain (osteoporosis (female)， 0.9% to 4.6%; osteoporosis (male)， 7.9%; osteoporosis (male and female)， 7.5%; osteopenia， 6.6% to 8.6%; Paget disease， 2%; hypercalcemia of malignancy， 16%; bone metastasis， 14% )， Constipation (Paget disease， 6%; hypercalcemia of malignancy， 27% )， Diarrhea (osteoporosis， 5.2% to 6%; osteopenia， 6.6% to 8.1%; Paget disease， 6%; hypercalcemia of malignancy， 17%; bone metastasis， 24% )， Loss of appetite (osteoporosis， 1% to 2%; osteopenia， 0.6% to 2%; Paget disease， 2%; hypercalcemia of malignancy， 9%; bone metastasis， 22% )， Nausea (osteoporosis (female)， 4.5% to 8.5%; osteoporosis (male and female)， 9.6%; osteopenia， 11.6% to 17.7%; Paget disease， 9%; hypercalcemia of malignancy， 29%; bone metastasis， 46% )， Vomiting (Paget disease， 2%; osteoporosis， 3.4% to 4.6%; osteopenia， 5% to 7.6%; hypercalcemia of malignancy， 14%; bone metastasis， 32% ) Musculoskeletal: Arthralgia (Osteoporosis (female)， 17.9% to 23.8%， (acute phase， 3% to 7%); osteoporosis (male， acute phase)， 11.1%; osteopenia， 18.8% to 27.3%， (acute phase， 6.1%); hypercalcemia of malignancy， 5% to less than 10%; Paget disease， 9%; bone metastasis， 21% )， Backache (Osteoporosis (male and female)， 4.3%; osteoporosis (male， acute phase)， 3.3%; osteopenia， 16.6% to 18.2%， (acute phase， 1.7%); Paget disease， 4%; bone metastasis， 15% )， Pain in limb (Osteoporosis (female)， 5.9% to 11.3%; osteoporosis (male and female)， 3.1%; osteopenia， 11.1% to 16%， (acute phase， 3.9%); bone metastasis， 14% ) Neurologic: Asthenia (osteoporosis， 3.2 to 5.3%; osteopenia， 2.8% to 6.1%; Paget disease， 2%; hypercalcemia of malignancy， 5% to less than 10%; bone metastasis， 24% )， Dizziness (osteoporosis， 2% to 7.6%; osteopenia， 6.1% to 7.6%; Paget disease， 9%; bone metastasis， 18% )， Headache (osteoporosis (female)， 3.9% to 12.4%， (acute phase， 7%); osteoporosis (male)， 15%， (acute phase， 9.8%); osteopenia， 14.6% to 20.4%， (acute phase， 13.3%); Paget disease， 11%; hypercalcemia of malignancy， 5% to less than 10%; bone metastasis， 19% )， Insomnia (hypercalcemia of malignancy， 15%; bone metastasis， 16% )， Paresthesia (Paget disease， 2%; bone metastasis， 15% .) Renal: Nephrotoxicity (bone metastasis， 11% to 17% ) Other: Fatigue (osteoporosis (female)， 2.1% to 5.4%; osteoporosis (male)， 17.6%， (acute phase， 12.4%); osteopenia， 9.9% to 14.6%， (acute phase， 8.3%); Paget disease， 8%; bone metastasis， 39% )， Fever (osteoporosis (female， acute phase)， 7% to 18%; osteoporosis (male， acute phase)， 15.7%; osteopenia， 21% to 21.7% (acute phase， 19.3%); Paget disease， 3% to 11%; hypercalcemia of malignancy (acute phase)， 44%; bone metastasis， 32% ),15-30℃,IVD， 5 mg once every year.,無需調整劑量,,需調整劑量,不可使用,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,,,輸注時間 > 15 分鐘(輸注完應以10mL N/S沖管路),1.注射液不可接觸含有鈣離子或其他二價離子的溶液 (例如：lactated Ringer)，必須以單獨的輸注管路給藥。 2.若藥品已冷藏，輸注前先讓注射溶液回復到室溫。開瓶後的溶液在攝氏2-8度下可保存24小時。 3.病人接受Aclasta輸注前，必須保持水分充足的狀態(adequately hydrated)。
IBAY,Hepatitis B Immune Globulin,BayHep B 0.5mL,HIMM,,適應症:Post-exposure prophylaxis of hepatitis. Acute exposure to blood containing HBsAg， perinatal exposure of infants born to HBsAg +ve mothers， sexual exposure to an HBsAg +ve person， household exposure to persons with acute HBV infection. 副作用: Local pain & tenderness at the inj site， urticaria & angioedema， anaphylactic reactions.,,2-8,By IM inj only. Acute exposure to blood containing HBsAg 0.06 mL/kg body weight within 24 hr. Prophylaxis of infants born to HBsAg & HBeAg +ve mothers 0.5 mL to be given within 12 hr of birth. Sexual exposure to an HBsAg +ve person 0.06 mL/kg as a single dose within 14 days of sexual contact. Give together with 1st dose of 1 mL IM of vaccine. Household exposure to persons with acute HBV infection Infants < 12 months 0.5 mL.,,,,除非治療上需要,,,,,,,,,,
ICAR,Carboplatin,Carboplatin inj 150mg/15mL,RACA,,適應症: Treatment of advanced ovarian carcinoma in combination with other chemotherapeutic agents. Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy， including patients who have previously been treated with cisplatin. Metastatic small cell carcinoma of the lung. 副作用: Myelosuppression especially thrombocytopenia， leukopenia; nausea & vomiting， abdominal pain， diarrhea， constipation; nephrotoxicity; neurotoxicity including paresthesia & decreased deep tendon reflexes; transient visual disturbances， ototoxicity manifesting as tinnitus; abnormal liver function tests; hypersensitivity reactions. 禁忌: Severe bone marrow suppression or significant bleeding; severe pre-existing renal impairment (creatinine clearance <=20 mL/min).,,室溫,Advanced ovarian carcinoma Initial treatment: 300 mg/m2 IV on day 1 at 4-week intervals for 6 cycles. Secondary treatment: 360 mg/m2 IV on day 1 at 4-week intervals. Metastatic small cell carcinoma of the lung 400 mg/m2 IV over 15-60 mins at 4-week intervals.,,,,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 調配與注射cisplatin的器具不可含有鋁。 3. 稀釋後的輸注溶液若超過8小時未用完，應丟棄不用。 4. 監測CBC。
ICAV,Alprostadil,Caverject 20mcg inj,SGU,,適應症: Erectile dysfunction of neurogenic etiology， Erectile dysfunction of vasculogenic， psychogenic or mixed etiology， Diagnosis of erectile dysfunction. 副作用: Penile pain， haematoma at the site of inj， prolonged erection， priapism， ecchymosis， penile rash， itching， penile oedema & penile fibrosis. Cardiovascular: Bradyarrhythmia， Prostin VR(R) (7%)， Hypotension， Prostin VR(R) (4%)， Tachyarrhythmia， Prostin VR(R) (3%) Reproductive: Fibrosis of penis， Caverject(R) (3%)， Pain in penis， Caverject(R) (37%)， Pain in penis， MUSE(R)， Pain in testicle， MUSE(R)， Perineal pain， MUSE(R)， Urethral discomfort， Warmth or burning， MUSE (R) Other: Fever， Prostin VR(R) (14%) 禁忌: Predisposition to priapism eg sickle cell anemia or trait， multiple myeloma or leukaemia. Anatomical deformation of the penis eg angulation， cavernosal fibrosis or Peyronie's disease. Patients with penile implants， men for whom sexual activity is inadvisable or contraindicated.,,2-8°C,Erectile dysfunction of neurogenic etiology Starting dose: 1.25 mcg， 2nd dose: 2.5 mcg， 3rd dose: 5 mcg. Erectile dysfunction of vasculogenic， psychogenic or mixed etiology Starting dose: 2.5 mcg， 2nd dose: 5-7.5 mcg， 3rd dose: 5-10 mcg. The lowest effective dose to maintain an erection by direct intracavernosal inj is used. Maintenance therapy: once daily & not >3 times weekly. Diagnosis of erectile dysfunction A single dose that induces a firm erection is used.,無需調整劑量,,無需調整劑量,不可使用,,,Contraindicated 哺乳期使用禁忌,,LI;,使用廠商提供之注射用水稀釋,,,,
ETEA,Dextran70 + Hydromellose,Tears Naturale 15mL,TOPH,Temporary relief of ocular irritation due to eye dryness.,Wearing of soft contact lenses.,Occasionally ocular redness， swelling， burning sensation， pain， stinging.,30℃以下,Instill 1-2 drops TID-QID.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,OD;OL;OU;,,,,,
IHEP50,Heparin,Heparin for flushing 50IU/mL，100mL,HEMT,,適應症:Flush in central line only. 副作用:Hemorrhage， allergic reactions 禁忌:Patients predisposed to active bleeding including thrombocytopenia， peptic ulcer disease， cerebrovascular disorders， haemorrhagic blood disorders， bacterial endocarditis， severe hypertension， oesophageal varices. Hypersensitivity to heparin.,,20-25℃,Flush in central line only.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,IVD;,,,,,不可用於肌肉注射。
IHEP250,Heparin,Heparin inj 250IU/mL，250mL(for H/D),HEMT,,,,,,,,,,,,,,IVD;,,,,,
EALC1,Alcohol,75% Alcohol 10mL/bot,TDER,,,,,,,,,,,,,,,,,,,
IPERG,FSH 150IU + LH 75IU,Pergoveris 150 IU/75 IU,HM,,適應症: Infertility in male & female. 副作用: Ovarian hyperstimulation， ascites， hydrothorax， oliguria， hypotension， thromboembolism， hypersensitivity reactions， fever， nausea & vomiting， inj site reactions， unintentional multiple pregnancies. 禁忌: Pregnancy & lactation; enlargement of the ovaries or cysts not due to polycystic ovarian syndrome; gynaecological bleeding of unknown origin; tumors in the uterus， ovaries & breasts.,,,By IM or SC inj. Female Initially 75-150 iu of FSH (1-2 vials) daily & gradually adjusted if necessary until an adequate response is achieved. To induce ovulation， 5000-10，000 iu HCG should be administered by IM inj after the last dose of HMG. A 2nd HCG administration of 5000 iu may be given 7 days afterwards to improve luteal function. Male 1 vial of Pergoveris administered 3 times/week， along with 3000 iu of HCG/week. This dosage should be maintained for 10-12 wks， or until there is evidence of improvement in spermatogenesis.,無需調整劑量,,無需調整劑量,不可使用,,,Contraindicated 哺乳期使用禁忌,,SC;,使用廠商所附稀釋溶液溶解,,,,
IOCI,Oxacillin,Ocillina inj 500mg,QANB,Staphylococcal infections resistant to benzylpenicillin,Hypersensitivity to penicillins,Fever; rash; diarrhoea， nausea， vomiting; agranulocytosis， eosinophilia， leukopenia， neutropenia， thrombocytopenia; AST increased， hepatotoxicity; acute interstitial nephritis， haematuria; serum sickness-like reactions. Potentially Fatal: Anaphylaxis.,30℃以下避光,(仿單+熱病) Adults and children > 40 kg: 0.25-2 g IV/IM Q4-6H over 10 minutes. Children < 40 kg: 50-200 mg Q4-6H. *****NEONATE ANTIBIOTICS DOSE***** Oxacillin: General infection Body weight <1kg Age<=7 day 25 mg/kg Q12H  Age 8-14 day 25 mg/kg Q12H  Age 15-28 day 25 mg/kg Q8H Body weight 1-2kg Age<=7 day 25 mg/kg Q12H   Age 8-14 day 25 mg/kg Q8H   Age 15-28 day 25 mg/kg Q8H Body weight >2kg Age<=7 day 25 mg/kg Q8H  Age 8-14 day 25 mg/kg Q6H  Age 15-28 day 25 mg/kg Q6H Meningitis Body weight <1kg ge<=7 day 0mg/kg Q12H  Age 8-14 day 0mg/kg Q12H  Age 15-28 day 0 mg/kg Q8H Body weight 1-2kg ge<=7day 0mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age <=7day 50 mg/kg Q8H  Age 8-14 day 50 mg/kg Q6H  Age 15-28 day 50mg/kg Q6H,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,IM: 2.7 mL D/W IV: 5mL D/W， N/S,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。,推注速率 < 100 mg/分鐘，建議推注> 10分鐘,給藥濃度0.5~40 mg/mL，建議輸注> 30分鐘,注射前檢查病患是否有Penicillin過敏史 1.注射速率太快可能造成痙攣性癲癇。 2.老年人應減慢給藥速率，避免發生血栓性靜脈炎。 3.監測體溫、CBC、血球分化計數、肝腎功能。 4.特殊族群: 年長者、肝、腎功能受損者不需調整劑量。 5. 濃度0.5~2 mg/mL 的藥物安定性：在6小時會減少10%以下的活性。
OCON3,Methylphenidate,CONCERTA 36mg,CNEU,For treatment of attention deficit hyperactivity disorder.,Patients with marked anxiety， tension & agitation， glaucoma， Tourette's syndrome， & patients on MAOI therapy.,Headache， stomach ache， loss of appetite， insomnia， aggravation reaction， asthenia， hypertension， nausea &/or vomiting， dyspepsia， weight loss， twitching (tics)， dizziness， emotional lability， somnolence， anxiety， depression， nervousness， hostility， rash. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )， Loss of appetite (5% )， Nausea (12% )， Vomiting (10% ) Neurologic: Headache， Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )， Nasopharyngitis (5% ),25℃以下避免潮濕,Attention deficit disorder : (Child over 6 yrs and adult) Concerta: 36mg(1 TAB) QD. (maximum for Child: 54 mg/day; maximum for adult : 72 mg/day ),無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為長效錠，請整粒吞服，不可撥半或磨粉。
IOMNI,Gadodiamide + Caldiamide,OmniSCAN inj 0.5 mmol/mL， 20mL,SCAN,腦脊髓磁振顯影及全身磁振顯影 Magnetic resonance imaging， Brain， spine and associated tissues; Intrathoracic (noncardiac)， abdominal， pelvic， and retroperitoneal regions.,Kidney disease， chronic and severe (GFR less than 30 mL/min/1.73 m(2)); high risk for fatal or debilitating nephrogenic systemic fibrosis. Kidney injury， acute; high risk for fatal or debilitating nephrogenic systemic fibrosis. Hypersensitivity to gadodiamide or any component of the formulation.,溫、涼感所造成的不適， 注射部位疼痛(常見)， 暈眩， 噁心， 頭痛， 味覺及嗅覺改變， 嘔吐， 嗜睡， 感覺異常， 視覺模糊， 下痢， 焦躁不安， 呼吸困難， 胸痛， 心動過速， 顫抖， 關節疼痛 Dermatologic: Nephrogenic systemic fibrosis. Renal: Injury of kidney， Acute.,30℃以下避光,Magnetic resonance imaging， Brain， spine and associated tissues; Intrathoracic (noncardiac)， abdominal， pelvic， and retroperitoneal regions: CNS imaging， 0.2 mL/kg (0.1 mmol/kg) as an IV bolus injection. kidney imaging， 0.1 mL/kg (0.05 mmol/kg) IV. intrathoracic (noncardiac)， intra-abdominal， pelvic cavities imaging， 0.2 mL/kg (0.1 mmol/kg) IV.,無需調整劑量,GADODIAMIDE BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible Caldiamide無資料,無需調整劑量,除非治療上需要,Uknown 沒有資料,GADODIAMIDE PREGNANCY RECOMMENDATION: Limited Human Data—Animal Data Suggest Moderate Risk Caldiamide無資料,Human Data Suggest Potential Toxicity,GADODIAMIDE BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible Caldiamide無資料,IV;IVP;IVPUSH;,,,,,
OTS1,Tegafur + Gimeracil + Oteracil K,TS-1 20mg,RACA,Post-op adjuvant chemotherapy for locally advanced [stage II (excluding T1)， IIIA or IIIB) gastric cancer. Treatment for advanced Inoperable or recurrent gastric cancer.,Severe bone marrow depression， renal & hepatic disorder. Treatment with other fluoropyrimidine-group anticancer drugs (including combination therapies) & flucytosine. Pregnancy & lactation.,Leukopenia， decreased Hb， thrombocytopenia， decreased neutrophil count; increased AST/ALT， bilirubin & creatinine; glycosuria， stomatitis， anorexia， nausea， vomiting， diarrhea， abdominal pain， constipation， rash， pigmentation， lacrimation， taste abnormality， dizziness， decreased weight， pyrexia， nasopharyngitis & fatigue.,室溫25℃保存,In general， for adults， the initial dose is determined based on body surface area (BSA). BSA < 1.25 m2: 40 mg/dose (80 mg/day); BSA 1.25 to < 1.5 m2: 50 mg/dose (100 mg/day); BSA >= 1.5 m2: 60 mg/dose (120 mg/day). Administer TS-1 capsule orally twice daily， after breakfast and dinner， for 28 consecutive days (4 weeks)， followed by a 14-day (2 weeks) rest for a 6-week course. For colorectal cancer， TS-1 administered orally twice daily on days 1 through 14 of a 28-day cycle in combination with irinotecan 125 mg/m2 IVD once every 14 days on day 1 and 15. TS-1 must NOT be taken with other fluoropyrimidine-group anti-cancer drug.,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OHAL5,Haloperidol,Binin-U 5mg,CNEU,,適應症: Acute & chronic psychotic disorders including schizophrenia & manic states， Tourette's syndrome. Severe behavioral problems & hyperactivity in children. Nausea & vomiting associated with antineoplastic therapy & surgery. 副作用: Occasionally， depression， anxiety， agitation， confusion， vertigo， exacerbation of psychotic symptoms & seizures. Hyperprolactinaemia， gynaecomastia， menstrual irregularities， impotence. Rarely， tachycardia， orthostatic hypotension. 禁忌: Endogenous depression without agitation， comatose conditions， severe CNS depression. Pregnancy， children.,,室溫,Initially 1-2 mg bid-tid & gradually increase up to 4-6 mg tid if required. Severely disturbed patients Up to 100 mg/day. Maintenance: 1-2 mg tid-qid.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ISOBI,Sodium Bicarbonate,NaHCO3 (Rolikan) inj 7% 20mL,NUTR,Antacid. Treatment of metabolic acidosis & certain drug intoxications.,Metabolic or respiratory alkalosis， hypocalcemia， hypochlorhydria.,Excessive administration may cause hypokalaemia & metabolic alkalosis.,25℃以下避免冷凍,Each mL contains: 70 mg， this package contains: 16.67 mEq/20mL. Cardiac arrest， Due To Hyperkalemia: IV: 50 mEq over 5 minutes. [Uptodate 20210731] Cardiac arrest (ACLS 2010): IV: Initial: 1 mEq/kg/dose; repeat doses should be guided by arterial blood gases Metabolic acidosis: IV: Dosage should be based on the following formula if blood gases and pH measurements are available: HCO3-(mEq) = 0.5 x weight (kg) x [24 - serum HCO3-(mEq/L)] or HCO3-(mEq) = 0.5 x weight (kg) x [desired increase in serum HCO3-(mEq/L)] Administer 1/2 dose initially， then remaining 1/2 dose over the next 24 hours; monitor pH， serum HCO3-， and clinical status. If acid-base status is not available: 2 to 5 mEq/kg IV infusion over 4 to 8 hours; subsequent doses should be based on patient's acid-base status.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IH;IRR;IVD;IVP;IVPUSH;LI;SC;,,【D5W】可選 仿單建議。【D10W】可選 。【D5NS】可選 。【N/S】可選 。,Administer slowly (maximum rate in infants: 10 mEq/minute),IV infusion， dilute to a maximum concentration of 0.5 mEq/mL in dextrose solution and infuse over 2 hours (maximum rate of administration: 1 mEq/kg/hour) 未稀釋亦可使用，不可與含鈣製劑混合使用,1. 16.7 mEq / 20 mL / Amp 2. For I.V. administration to infants， use the 0.5 mEq/mL solution or dilute the 1 mEq/mL solution 1:1 with sterile water 3. Direct I.V. infusion in emergencies: administer slowly (maximum rate in infants: 10 mEq/minute) 4. IV infusion， dilute to a maximum concentration of 0.5 mEq/mL in dextrose solution and infuse over 2 hours (maximum rate of administration: 1 mEq/kg/hour) 5. Avoid extravasation， tissue necrosis can occur due to the hypertonicity of NaHCO3
ITAP,Piperacillin + Tazobactam,Tapimycin inj 2.25gm,QANB,Lower respiratory tract infections， complicated & uncomplicated UTI， intra-abdominal infections， skin & skin structure infections， bacterial septicaemia， polymicrobic infections， bacterial infections in neutropenic adults in combination with an aminoglycoside.,Hypersensitivity to penicillins， cephalosporins or β-lactamase inhibitors.,Diarrhea， constipation， nausea， headache， insomnia， rash， erythema， pruritus， vomiting， allergic reactions， urticaria & superinfection. Dermatologic: Pruritus (3.1% to 3.2% )， Rash (1.3% to 4.2% ) Gastrointestinal: Constipation (1.1% to 8.4% )， Diarrhea (4.4% to 20% )， Nausea (1.8% to 6.9% )， Oral candidiasis (1.8% 3.9% )， Vomiting (2.6% to 3.7% ) Neurologic: Headache (1.4% to 7.7% )， Insomnia (4.5% to 6.6% ) Psychiatric: Agitation (2.1% to 7.1% ) Other: Fever (2.4% to 4.8% )， Pain (1.7% to 3.2% ),25℃以下,Usual dose range: 4.5 g every 6-8 hr. Renal insufficiency， creatinine clearance > 40 mL/min 3.375 g every 6 hr， 20-40 mL/min 2.25 g every 6 hr， < 20 mL/min 2.25 g every 8 hr. Hemodialysis patients 2.25 g every 12 hr， Maximum dose: 2.25 g every 8 hr with additional 0.75 g following each dialysis period on hemodialysis days. Neutropenia 4.5 g every 6 hr in combination with an aminoglycoside. Hospital-acquired pneumonia : creatinine clearance > 40 mL/min 4.5 g every 6 hr， 20-40 mL/min 3.375 g every 6 hr， < 20 mL/min 2.25 g every 6 hr. Hemodialysis patients 2.25 g every 8 hr， Maximum dose: 2.25 g every 8 hr with additional 0.75 g following each dialysis period on hemodialysis days. *****NEONATE ANTIBIOTICS DOSE***** Piperacillin 2G+ Tazobactam 0.25G (Tapimycin): Dose base on piperacillin component Body weight <1kg ge<=7day 100mg/kg Q12H  Age 8-14 day 100mg/kg Q12H  Age 15-28 day 100mg/kg Q8H Body weight 1-2kg ge<=7day 100mg/kg Q12H  Age 8-14 day 100 mg/kg Q8H  Age 15-28 day 100mg/kg Q8H Body weight >2kg Age<=7day 100 mg/kg Q8H  Age 8-14 day 80 mg/kg Q6H  Age 15-28 day 80 mg/kg Q6H,無需調整劑量,PIPERACILLIN BREASTFEEDING RECOMMENDATION: Compatible TAZOBACTAM BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,PIPERACILLIN PREGNANCY RECOMMENDATION: Compatible TAZOBACTAM PREGNANCY RECOMMENDATION: Limited Human Data—Animal Data Suggest Low Risk,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,PIPERACILLIN BREASTFEEDING RECOMMENDATION: Compatible TAZOBACTAM BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible,IVD;,10 mL D/W,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,以 > 30分鐘速率緩慢滴注。(給本藥輸液時，需暫停原有之輸液給藥。),1. 注射前檢查病患是否有PCN過敏史。 2. 監測體溫、CBC、血球分化計數、血鉀、肝腎功能。
ITAR,Teicoplanin,Targocid inj 200mg,QANB,Potentially serious gm+ve infections including those which cannot be treated with other antimicrobial drugs.,Hypersensitivity.,Local pain， rash， pruritus， nausea， dizziness， headache， eosinophilia， leukopenia.,25℃以下,Adult: 6 mg/kg Q12H x 3 IV/IM doses (target trough: >15 μg/mL)， then 6 mg/kg IV/IM once daily (target trough: >15 μg/mL). Bone and joint infection: 12 mg/kg IV Q12H x 3-5 doses (target trough: >20 μg/mL)， then 12 mg/kg IV/IM Q24H (target trough: >20 μg/mL). Endocarditis: 12 mg/kg IV Q12H x 3-5 doses (target trough: 30-40 μg/mL)， then 12 mg/kg IV/IM Q24H (target trough: >30 μg/mL); a total treatment duration 21 days is recommended. Children (2 months-12 years): 10 mg/kg IV Q12H x 3 doses， then 6-10 mg/kg IV Q24H. Children (0-2 months): 16 mg/kg IV x 1 dose， then 8 mg/kg IV Q24H.NOTE: Target trough should measured by FPIA (Fluorescence Polarization Immunoassay). After loading dose， trough should be measured at day 3-5; during maintenance dose， trough should be measured weekly. Pediatric: Age 0 to <=2 months: 16mg/kg IVD x 1 dose on Day 1， then 8mg/kg IVD q24h since Day 2 Age 2 months to 16 years: 10mg/kg IV q12h x 3 doses， then 6-10mg/kg IV/IM q24h *****NEONATE ANTIBIOTICS DOSE***** Teicoplanin (Targocid): loading dose 16 mg/kg/dose， followed by 8 mg/kg/dose QD,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IM;IMP;IVD;IVP;IVPUSH;,IM， IV: 3mL D/W,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,推注時間至少3 ~ 5分鐘,建議以30分鐘緩慢滴注,1. 勿用力搖晃，若出現泡沫可靜置15分鐘。 2. 稀釋後應於24小時內使用。監測體溫、CBC，長期使用需注意聽力變化。 3.本品與aminoglycoside類抗生素不相容，不可混合或同時注射 。 4.對Vancomycine過敏者應小心使用，可能發生交叉過敏。
IURO,Urokinase,UROKINASE 60，000IU (綠十字),HEMT,Acute coronary embolism， clearance of occluded catheters & shunts， acute pulmonary embolism， peripheral arterial or venous thromboembolism.,Intracranial hemorrhage， hemoptysis， difficulty in hemostatic management; undergone intracranial or spinal surgery or with such injury (in the last 2 months); aneurysm; serious disturbance of consciousness.,Bleeding tendency. Fever， chills， headache & malaise may occur. Rarely， shock， sweating， disturbed pulse & dyspnea; rash， urticaria;nausea; vomiting & anorexia; abnormal liver function test; hematuria. Hematologic: Decreased hematocrit level (37%),室溫,Cerebral thrombosis (within 5 days after onset of symptoms & without hemorrhage) 60，000 iu once daily for 7 days. Peripheral arterial/venous occlusion 60，000 to 240，000 iu on first day of treatment followed by tapered doses for about 7 days. Acute coronary embolism 26，000-52，000 iu daily for 7 days. Deep vein thrombosis or acute pulmonary embolism IV loading 250，000 iu/hr， then 1，000 iu/kg/hr (or 60，000 -100，000 iu/hr) for 72 hr.,需調整劑量,,無需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IV;IVD;,,,,1. Total dose diluted to the recommended final volume of 195 mL 2. (loading dose) 90 mL/hr over 10 minutes (continuous infusion) 15 mL/hr for a period of 12 hr,1. Total dose diluted to the recommended final volume of 195 mL 2. (loading dose) 90 mL/hr over 10 minutes (continuous infusion) 15 mL/hr for a period of 12 hr
IYUT,Ritodrine,Yutopar針劑 50mg/5mL,SGU,,適應症: Prevention of preterm labour， Acute fetal distress， Prevention of preterm labour after operation. 副作用: Pulmonary oedema (several cases reported with fatal results). Maternal & foetal heart rate can increase. Frequently: Tremor， nausea， vomiting， headache or erythema， nervousness， restlessness， jitteriness， emotional upset， anxiety or malaise. Infrequently cardiac symptoms， eg chest pain or tightness with or without ECG abnormalities & cardiac arrhythmias. Hepatic impairment. 禁忌: Antepartum haemorrhage due to any cause but particularly placenta previa & abruptio placentae. Eclampsia & severe pre-eclampsia. Intra-uterine foetal death. Chorioamnionitis. Maternal cardiac disorder. Hyperthyroidism. Uncontrolled hypertension. Any other condition which can endanger cardiac function. Parenteral: Asthmatics (due to sulfite component).,,室溫,Prevention of preterm labour IV infusion Initially 0.05 mg/min， to be gradually increased by 0.05 mg/min every 10-15 mins. IM inj 10 mg 4-6 hrly. Continue treatment for 12-48 hr after ceased contraction. Oral maintenance Initiate oral therapy 30-60 mins before termination of parenteral therapy. Tab 1-2 tab 2-6 hrly. Max: 120 mg daily. Usually 80-120 mg equally divided over the day. Acute fetal distress Follow initial IV treatment for preterm labour. Prevention of preterm labour after operation Follow treatment for preterm labour.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 輸注液建議使用D5W。若使用N/S稀釋，將增加發生肺水腫之可能性。(衛生署公文：FDA藥字第1001409159號)
LCENZ,Sertraline,CenZoft solution 60mL，20mg/mL,CNEU,,適應症: Depression， obsessive-compulsive disorder (OCD)， panic disorder， post traumatic stress disorder (PTSD)， social phobia， premenstrual dysphoric disorder (PMDD). 副作用: Nausea， diarrhoea/loose stools， anorexia， dyspepsia; male sexual dysfunction (ejaculatory delay); tremor; dry mouth; increased sweating. Sertraline has been associated with PALPITATIONS， CHEST PAIN， HYPERTENSION， HYPOTENSION， EDEMA， SYNCOPE， and TACHYCARDIA 禁忌: Patients with known hypersensitivity to sertraline. Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs).,,室溫,Depression; Obsessive-compulsive disorder Initial: 2.5mL once daily， may increase slowly. Max: 10 mL/day. Panic disorder; Post-traumatic stress disorder; Social anxiety disorder Initial: 1.25 mL/day， increased to 2.5 mL/day after 1 wk. May increase slowly. Max: 10 mL/day. Premenstrual dysphoric disorder Initial: 2.5 mL/day throughout the menstrual cycle or only during luteal phase. May increase by 2.5 mL/cycle. Max: 7.5 mL/day for continuous dosing or 5 mL/day for luteal phase-only dosing.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IPKE5,Streptococus Pyogenes,Picibanil inj 5KE,RACA,Cancers of the digestive organs， head & neck， thyroid， lung.,History of anaphylactic reactions to benzylpenicillin. History of previous shock reactions to the drug.,Nausea， vomiting， anorexia; pyrexia， generalized fatigability， headache， arthralgia; pain， swelling at site of inj. Rarely， hypersensitivity reactions， shock， anemia.,10℃以下避免冷凍,For intravenous injection， starting at 0.2-1 KE 2-3 times weekly; may increase to 1-3 KE 2-3 times weekly as maintenance therapy. For local injection， 5-10 KE dissolved in 2 mL normal saline as a single dose administered locally once daily or once a few days. For administration into the serous cavity， a single dose of 5-10 KE in 2 mL normal saline 2-3 times weekly. For intramuscular or subcutaneous injection， starting at 0.2-0.5 KE in 2 mL normal saline once daily or once every other day. May consider increasing dose gradually after 3-5 doses. Maintenance dose: 1-5 KE 1-3 times weeekly.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IPLE;,靜脈注射:以2mL生理食鹽水或5%葡萄糖液溶解，做靜脈內注射，或與輸入液、補液等 混合而做靜脈點滴。 局部或漿膜腔內使用: 以2mL食鹽水溶解.,【D5W】可選 。【N/S】可選 。,,,1. 本劑含苯甲基青黴素，對青黴素過敏病患不宜使用。 2. 以2mL生理食鹽水溶解，混合輸液中
IVOR,Diclofenac,VOREN inj 75mg/3mL,CNEU,Rheumatism， acute musculoskeletal disorders， post-traumatic & post-op inflammation & swelling.,Patients sensitive to aspirin or other NSAIDs.,GI disturbances. Peptic ulceration. GI bleeding. Headache， dizziness， nervousness， skin rash， pruritus， tinnitus， edema， depression， drowsiness， insomnia， & blurred vision. Hypersensitivity. Impairment of liver & kidney function. Agranulocytosis & thrombopenia. Dermatologic: Application site reaction (gel: all reactions， 7%; dermatitis， 4% to 11% ) Hematologic: Blood coagulation disorder (1% to 10% ) Ophthalmic: Burning sensation in eye (15% )， Keratitis (up to 28% )， Lacrimation and lacrimal drainage - finding (up to 30% )， Raised intraocular pressure (up to 15% ),25℃以下,Adults: 75 mg(1 ampoule) IM once a day. Slow injection deep into the lateral buttock muscles.,無需調整劑量,,需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,仿單警語： （1）心血管事件：可能惡化高血壓，可能發生體液滯留或水腫（2）胃腸道作用：胃腸潰瘍、出血及穿孔之危險性（3）肝臟作用：肝指數升高 （4）腎臟作用：長期投與可能造成腎臟損傷 （5）皮膚反應：可能發生嚴重而致死性的不良反應，如：SJS、TENS（6）血液作用 ：注意貧血、血小板計數
EALL,Antazoline + Tetrahydrozoline,Allergopos Eye Drops 10mL,TOPH,,適應症:Irritant conjunctivitis， allergic inflammatory conditions of the conjunctiva， particularly hay fever conjunctivitis & vernal conjunctivitis. 副作用: Mild burning sensation; Blurred vision 禁忌: Narrow-angle glaucoma.,,室溫,instill 1 drop 3 to 4 times daily into the eye.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ICAL2,Calcitriol,Caltsue inj 4mcg/2mL,META,,適應症： Management of hypocalcemia in patients undergoing chronic renal dialysis. 副作用： Weakness， headache， somnolence; nausea， vomiting， dry mouth， constipation; muscle pain， bone pain & metallic taste. 禁忌： Hypercalcemia or evidence of vit D toxicity.,,室溫,Initially 1 mcg (0.02 mcg/kg) to 2 mcg 3 times weekly， approximately every other day. Dose may be increased by 0.5-1 mcg at 2- to 4-week intervals.,,,,盡量避免,,,,,,,,,,
IPRO6,Denosumab,Prolia inj 60mg,META,Treatment of postmenopausal women w/ osteoporosis at high risk for fracture; bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer; bone loss in men receiving androgen deprivation therapy for prostate cancer.,Hypocalcemia. Pregnancy & lactation. Severe renal impairment. Hypersensitivity to any component of the product; facial swelling and urticaria have been reported.,Facial swelling and urticaria have been reported. Influenza， hypocalcemia， headache， lethargy， dyspnea， diarrhea， nausea， dyspepsia， bone pain， arthralgia， myalgia， flu-like symptoms， pyrexia， rigors， fatigue， pain， asthenia. Local site reactions. Osteonecrosis of the jaw. Cardiovascular: Peripheral edema (Paget's Disease， 3%; osteoporosis， 4.6% to 5.5%; bone metastasis， 21% ) Endocrine metabolic: Weight decreased (bone metastasis， 16% ) Gastrointestinal: Abdominal pain (osteoporosis (female)， 0.9% to 4.6%; osteoporosis (male)， 7.9%; Paget's disease， 2%; hypercalcemia of malignancy， 16%; bone metastasis， 14% )， Constipation (Paget's disease， 6%; hypercalcemia of malignancy， 27%; bone metastasis， 31% )， Diarrhea (osteoporosis， 5.2% to 6%; Paget's disease， 6%; hypercalcemia of malignancy， 17%; bone metastasis， 24% )， Loss of appetite (osteoporosis， 1% to 2%; Paget's disease， 2%; hypercalcemia of malignancy， 9%; bone metastasis， 22% )， Nausea (osteoporosis， 4.5% to 8.5%; Paget's disease， 9%; hypercalcemia of malignancy， 29%; bone metastasis， 46% )， Vomiting (Paget's disease， 2%; osteoporosis， 3.4% to 4.6%; hypercalcemia of malignancy， 14%; bone metastasis， 32% ) Musculoskeletal: Arthralgia (osteoporosis (female)， 17.9% to 23.8%; osteoporosis (male)， 11.1%; hypercalcemia of malignancy， 5% to less than 10%; Paget's disease， 9%; bone metastasis， 21% )， Backache (Paget's disease， 4%; bone metastasis， 15% ) Neurologic: Asthenia (osteoporosis， 3.2 to 5.3%; Paget's disease， 2%; bone metastasis， 24% )， Dizziness (osteoporosis， 2% to 7.6%; Paget's disease， 9%; bone metastasis， 18% )， Headache (osteoporosis (female)， 3.9% to 12.4%; osteoporosis (male)， 15%; Paget's disease， 11%; hypercalcemia of malignancy， 5% to less than 10%; bone metastasis， 19% )， Insomnia (hypercalcemia of malignancy， 15%; bone metastasis， 16% )， Paresthesia (Paget's disease， 2%; bone metastasis， 15% .) Renal: Nephrotoxicity (bone metastasis， 11% to 17% ) Other: Fatigue (osteoporosis (female)， 2.1% to 5.4%; osteoporosis (male)， 17.6%; Paget's disease， 8%; bone metastasis， 39% )， Fever (osteoporosis (female)， 7% to 18%; osteoporosis (male)， 15.7%; Paget's disease， 3% to 11%; hypercalcemia of malignancy， 44%; bone metastasis， 32% ),2-8℃避光避免冷凍,SC， 60 mg every 6 months.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,[仿單]有生育能力之婦女於治療期間至最後一劑藥物後五個月內，應採有效的避孕措施.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,1. 注射前於冰箱取出，可於室溫擺放15-30分鐘回溫，本藥品不可加熱。 2. 皮下注射部位：上臂、上臀或腹部。
OPROZ,Fluoxetine,Prozac 20mg,CNEU,,適應症: Treatment of depression， obsessive-compulsive disorder & bulimia nervosa. 副作用: Hypersensitivity reactions including rash， anxiety， nervousness， insomnia， anorexia， weight loss， asthenia， GI disturbances， somnolence， tremor， pharyngitis， sweating， impotence， abnormal ejaculation， mania or hypomania. Dermatologic: Diaphoresis， Rash (7% ) Gastrointestinal: Loss of appetite (3.5% to 15% )， Nausea (20% to 30% .)， Xerostomia Neurologic: Asthenia (9% to 21% )， Dizziness (2% to 11% )， Insomnia (9% to 26% )， Somnolence (13% )， Tremor (12% ) Psychiatric: Anxiety (3% to 9% )， Feeling nervous (3% to 14% ) Respiratory: Pharyngitis (6% to 10% )， Rhinitis (16% to 23% ) 禁忌: Should not be used within a min of 14 days of discontinuation of MAOI. At least 5 weeks should elapse between discontinuation of fluoxetine & initiation of MAOI therapy. Concomitant use with thioridazine.,,室溫,Adult Depression Initially 20 mg/day in the morning， increase after several weeks if required to 20 mg morning & noon. Max: 80 mg/day. Maintenance: 20 mg/day. Obsessive-compulsive disorder 20-60 mg/day. Max: 80 mg/day. Bulimia 60 mg/day. Children Lower starting dose should be considered. Doses > 60 mg/day have not been systematically evaluated in children 7-18 years.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OROA,Isotretinoin,Roaccutane 10mg,TDER,Severe forms of acne resistant to therapy， especially cystic acne & acne conglobata.,Pregnancy & lactation. Hepatic or renal insufficiency. Hypervitaminosis A. Patients with excessively elevated blood lipid values. Supplementary treatment with tetracycline.,Dry mucosa; dermatitis facialis， pruritus， sweating. Occasionally， reversible alopecia， muscle & joint pain. Rarely， inflammatory bowel disease; hyperuricaemia; benign intracranial hypertension， visual disturbances & photosensitivity reactions. Hematuria/proteinuria， hirsutism， pancreatitis， lymphadenopathy. Rarely， depression. Dermatologic: Alopecia (6.4% )， Cheilitis (91.3% to 95.5% )， Dry skin (87.1% )， Pruritus (22.8% )， Retinoid dermatitis (68% ) Gastrointestinal: Xerostomia Musculoskeletal: Arthralgia， Backache Ophthalmic: Conjunctivitis Respiratory: Epistaxis,30℃以下,Acne (severe recalcitrant nodular): Initially， 0.5 mg/kg/day in 2 divided doses ， if Severe acnes then slowly adjust dose to 2mg/kg/day,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為軟膠囊應整粒吞服， 切勿咬嚼、壓碎或打開膠囊。本藥具致畸胎性，請注意相關暴露風險，尤其是婦女及小孩。
OROWA,Pipoxolan,Rowapraxin 10mg,ALIM,,適應症: Antispasmodic in the management of spasm & colic in the GI， biliary & renal-urogenital tracts. Treatment of vascular headache. 禁忌: Narrow-angle glaucoma， patients susceptible to intestinal or urinary outlet obstruction. Pregnancy.,,室溫,Adult Vascular headache 10 mg tid. Other indications 10-30 mg tid. Children > 6 years 10-30 mg once-bid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OSAB,Vigabatrin,Sabril 500mg,CNEU,Treatment of epilepsy which is not satisfactorily controlled by other antiepileptic drugs.,pregnancy & lactation.,Aggression & psychosis. Drowsiness， fatigue， dizziness， nervousness， irritability， depression， headache. Less commonly， confusion， memory disturbance， diplopia. Wt gain， minor GI side effects. Dermatologic: Rash (4% to 11% ) Endocrine metabolic: Weight increased (6% to 14% ) Gastrointestinal: Constipation (5% to 14% )， Diarrhea (7% to 16% )， Nausea (2% to 10% )， Vomiting (6% to 20% ) Immunologic: Viral disease (19% to 20% ) Musculoskeletal: Arthralgia (5% to 10% )， Muscle twitch (1% to 9% ) Neurologic: Confusion (4% to 14% )， Coordination problem (7% to 16% )， Dizziness (15% to 26% )， Headache (18% to 33% )， Insomnia (7% to 12% )， Memory impairment (7% to 16% )， Sedated (adults， 4%; children， 17% to 19% )， Somnolence (17% to 45% )， Tremor (7% to 16% ) Ophthalmic: Blurred vision (6% to 16% )， Diplopia (6% to 16% )， Nystagmus (7% to 19% ) Otic: Infection of ear (7% to 14% )， Otitis media (10% to 44% ) Psychiatric: Depression (6% to 14% )， Irritability (7% to 23% ) Renal: Urinary tract infectious disease (4% to 6% ) Reproductive: Dysmenorrhea (5% to 9% )， Erectile dysfunction (5% ) Respiratory: Bronchitis (adults， 5%; children， 30% )， Cough (2% to 14% )， Nasopharyngitis (9% to 14% )， Pain in throat (7% to 14% )， Pneumonia (11% to 13% )， Upper respiratory infection (adults， 7% to 9%; children 46% to 51% ) Other: Fatigue (16% to 40% )， Fever (adults， 4% to 7%; children， 19% to 29% )， Influenza (3% to 7% ),避光存放於30℃以下,Sabril 500mg film-coated tablet is not suitable for children under the age of 6 years， because of the risk of choking. Adult usual dose: 2000-3000 mg/day. Treatment should be initiated at 1000 mg/day (divided to 1-2 doses). Total daily dose may be increased in 500 mg increments at weekly intervals， depending on response. Maximum: 3000 mg/day. Children: recommended starting dose 40 mg/kg/day (divided to 1-2 doses)， maintenance dose in relation to bodyweight: > 50 kg， 2000-3000 mg/day， 30-50 kg， 1500-3000 mg/day， 15-30 kg， 1000-1500 mg/day， 10-15 kg， 500-1000 mg/day. Adjustment of dose or frequency of administration must be considered in elderly and patients with creatinine clearance less than 60 mL/min.,無需調整劑量,,需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Compatible 哺乳時可使用,,,,,,,
OSAL,Sulfasalazine,Salazopyrin EN 0.5gm,CNEU,,適應症: Inflammatory bowel disease including Crohn's disease， ulcerative colitis， Active RA， ankylosing spondylitis. 副作用: Nausea， anorexia， raised temp; erythema & pruritus; headache. Rarely， hematological， GI， CNS， renal， dermatological reactions. Dermatologic: Pruritus (3% to 4% )， Rash (3% to 13% ) Gastrointestinal: Abdominal pain (8% )， Indigestion (13% to 33% )， Loss of appetite (33% )， Nausea (19% to 33% )， Stomatitis (4% )， Vomiting (8% to 33% ) Neurologic: Dizziness (4% )， Headache (9% to 33% ) Renal: Discolored urine Reproductive: Oligozoospermia， Reversible (33% ) Other: Fever (3% to 5% ) 禁忌: Hypersensitivity to sulfonamides & salicylates. Acute intermittent porphyria. Infant < 2 years.,,室溫,Inflammatory bowel disease including Crohn's disease， ulcerative colitis Adult Mild to moderate attacks: 2 tab tid or qid. Severe attacks: 2-4 tab tid or qid. Children 40-60 mg/kg body weight/day in 3-6 doses. Maintenance: Adult 2 tab bid or tid. Children 20-30 mg/kg body weight/day in 3-6 divided doses. Active RA， ankylosing spondylitis 2 tab bid or tid.,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OSEB,Telbivudine,Sebivo 600mg,QANB,,適應症: Treatment of chronic hepatitis B with evidence of viral replication & active liver inflammation. 副作用: Headache， dizziness， diarrhea， nausea， rash， fatigue. Increased serum amylase， serum lipase， serum alanine aminotransferase， serum creatinine phosphokinase. Musculoskeletal: Finding of creatine kinase level (11% )， Finding of creatine kinase level， grade 3/4 (13%) Neurologic: Headache (10% ) Respiratory: Cough (6% to 16%) Other: Fatigue (13% to 18%)， Influenza (18% to 21%) 禁忌: Hypersensitivity to telbivudine or to any of the excipients of Sebivo.,,,Adult 600 mg once daily. Renal impairment: CrCl 30-49 mL/min 600 mg once every 48 hr. CrCl <30 mL/min (not requiring dialysis) 600 mg once every 72 hr. End stage renal disease 600 mg every 96 hr.,無需調整劑量,,需調整劑量,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IPED5,DTaP5-IPV-HIB,Pediacel (五合一疫苗， 自費) 0.5mL/dose,HIMM,,適應症:Active immunization of children from 2 months of age to 7 years against diphtheria， tetanus， pertussis， poliomyelitis & invasive Haemophilus influenzae type b disease. 副作用:Redness， tenderness & swelling at inj site; fever， crying， drowsiness; decreased feeding， vomiting， irritability. 禁忌:Hypersensitivity to neomycin， streptomycin or polymyxin B. Postpone vaccination in acute febrile illness. Children > 7 yr， adults.,,2-8℃,1 dose = 0.5 mL. Primary immunization with the following schedule is recommended: One 0.5-mL dose administered IM at 2， 4， 6 and 18 months. Where more rapid protection is preferred， the first 3 doses may be administered at intervals of 4 weeks,,,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,1. 注射前應充分搖勻。 2. 應以肌肉注射方式投予，最好注射於大腿中段的前外側 (股外側肌) 或手臂的三角肌。超過一歲的孩童，最好是注射在三角肌。
IPET,Meperidine,Pethidine HCl inj 50mg/1mL,CNEU,Analgesia.,Concurrent use with MAOIs or within 2 weeks of the therapy.,Respiratory depression. Lightheadednes， dizziness， sedation， nausea， vomiting， perspiration. CNS disturbances， muscle spasm， visual disturbances. Dry mouth， constipation， biliary spasm. Urinary retention. Pain at inj site,避光儲存於室溫,Adult 50-100 mg SC/IM， may be repeated every 3-4 hours. Children 1.1-1.76 mg/kg SC/IM， may be repeated every 3-4 hours.(Do not exceed adult dose) Pre-op sedation induction Adult 50-100 mg SC/IM 30-90 min before the beginning of anesthesia. Children 1-2.2 mg/kg SC/IM 30-90 min before the beginning of anesthesia.(Do not exceed adult dose). Obstetric analgesia 50-100 mg SC/IM. May repeat at 1-3 hours interval.,無需調整劑量,,需調整劑量,可能安全,Human (and animal) data suggest risk,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【D5NS】可選 。【H/S】可選 。【L/R】可選 。,緩慢推注,以適當輸注液稀釋成1 mg/mL，給藥速率依病人反應進行調整;不能連續超過48小時，或是累積劑量不能超過 600mg/24小時,1. IM: 注射於大的肌肉。 2. 給藥時最好讓病人躺下。 3. 對於腎功能正常的病人，Pethidine 連續使用不能超過48 小時，或是累積劑量不能超過600 mg/24 小時。
IPROM,Alprostadil,Promostan inj 20mcg,CAVS,Improvement of symptoms caused by peripheral arterial occlusive diseases. Maintenance of blood flow after vascular reconstructive surgery.,Patients with severe heart failure or pulmonary edema. Patients with bleeding disorders (such as intracranial bleeding， hemorrhagic eye diseases， gastrointestinal bleeding， hemoptysis， etc.， as it may increase the risk of bleeding). Pregnant women or women who may be pregnant (please refer to medication guidelines for pregnant women， postpartum women， breastfeeding women， etc.). Patients who have experienced allergic reactions to this medication.,Common: Bradyarrhythmia (Neonates， 7%)， Hypotension (Adult， up to 3% ; pediatric， 4%)， Tachycardia (Neonates， 3%)， Flushing (Neonates， 10%)， Urethral discomfort (Adult， 12-13%)， Pain in penis (Adult， 29-37%)， Pain in testicle (Adult， 1-5%)， Fever (Neonates， 14%) Serious: Cardiac arrest (Neonates， 1%)， Gastrointestinal obstruction (Neonates， 6.8%)， Disseminated intravascular coagulation (Neonates， 1%)， Infantile cortical hyperostosis， Seizure (Neonates， 4%)， Fibrosis of penis (Intracavernous， 3-7.8%)， Priapism (Adult， <1%)， Prolonged erection of penis (Adult， 0.3-4%)， Apnea (Neonates， 10-12%),避光、室溫保存,Peripheral artery occlusive disease (POAD) adult: IVD， 2-3 vial (40-60 mcg) in NS 500 mL IVD > 2 hr. ( infusion rate: 5-10 ng/kg/min) once or twice daily (maximum: 0.6 mcg/kg/hr),無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,[仿單] 孕婦及可能已懷孕的婦女禁止給藥。,Unknown 沒有資料,,IVD;LI;,IV:5 mL N/S,【N/S】可選 仿單建議。,,IVD: 5-10ng/kg/min,1.Max:20 mcg/mL 2.給藥速率體重每公斤2小時內不超過1.2mcg.
IRIN4,Betamethasone,Rinderon inj 4mg/1mL,HM,Shock， hypersensitivity disorders， bronchial asthma， severe infection,Peptic ulcer， osteoporosis， psychoses or severe psychoneuroses， active or quiescent TB; acute infection; live vaccines,Fluid & salt retention， edema， hypertension; amenorrhea， hyperhidrosis; mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; visual disturbances; local atrophy; increased appetite; growth retardation.,25℃以下避光,IV and IM: 4-12 mg (1-3 mL). IVD: 4-20 mg (1-5 mL). INS: 0.4-1 mL for large joint， 0.2-0.5 mL for middle joint， 0.1-0.2 mL for smaller joint. Intra soft tissue: 0.4-6 mg (0.1-1.5 mL). Subconjectival or retrobulbar injection: 0.4-2 mg (0.1-0.5mL). SPI: 1-4 mg(0.25-1 mL).,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;INS;IS;IVD;IVP;IVPUSH;LI;SPI;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,Slow intravenous injection over half to one minute.,1-5mL (4-20mg) daily diluted in Normal Saline or Dextrose Water.,1.未稀釋亦可使用 2.1-3 mL IV or IM slowly 3-4 hourly
ISUS,Testosterone,Sustanon inj (Testosterone250mg/1mL),HM,Testosterone replacement therapy in male hypogonadal disorders. Osteoporosis due to androgen deficiency.,Known or suspected prostatic or mammary carcinoma.,Priapism， signs of excessive sexual stimulation， oligospermia， decreased ejaculatory vol; fluid & salt retention. In prepubertal boys， precocious sexual development， increased frequency of erections， phallic enlargement， premature epiphyseal closure. Dermatologic: Acne (up to 8% ) Endocrine metabolic: Gynecomastia (up to 3% ) Gastrointestinal: Oral irritation， Buccal system (9.2% ) Neurologic: Headache (up to 4% ) Reproductive: Large prostate (11.7% ),8-30℃，不需冷藏或冷凍,1 mL every 3 weeks. Deep IM only.,無需調整劑量,Testosterone is present in breast milk. Some products are specifically contraindicated while breastfeeding. (UpToDate)2021/0125,無需調整劑量,不可使用,Uknown 沒有資料,Use is contraindicated during pregnancy.(UpToDate)2021/0125,Unknown 沒有資料,Testosterone is present in breast milk. Some products are specifically contraindicated while breastfeeding. (UpToDate)2021/0125,IM;,,,,,
OSER2,Quetiapine,Seroquel 25mg,CNEU,Schizophrenia， manic episodes associated with bipolar disorder.,Hypersensitivity to quetiapine or any component of the product. Anaphylactic reactions have been reported.,Dry mouth， somnolence， dizziness ， & dyspepsia. Heart rate increased， hypotension， weight increased， tremor， akathisia， increased appetite， blurred vision， postural dizziness， pyrexia， dysarthria， dystonia， drooling， syncope， tardive dyskinesia， dysphagia， leukopenia & rash. Anaphylactic reaction， peripheral edema， rhinitis， eosinophilia， hypersensitivity， elevations in γ- GT levels & restless legs syndrome have also been reported. Cardiovascular: Hypertension (1% to 2% (adults); 15.2 to 40.6% (children and adolescents) )， Orthostatic hypotension (4% to 7% (adults); less than 1% (children and adolescents) )， Tachycardia (0.5% to 7% ) Endocrine metabolic: Serum cholesterol raised (7% to 18% )， Serum triglycerides raised (8% to 22% )， Weight gain (3% to 23% ) Gastrointestinal: Abdominal pain (4% to 7% )， Constipation (2% to 11% )， Increased appetite (2% to 12% )， Indigestion (2% to 7% )， Vomiting (1% to 11% )， Xerostomia (4.1% to 44% ) Hepatic: Increased liver enzymes (1% to 6% ) Musculoskeletal: Backache (3% to 5% ) Neurologic: Asthenia (2% to 10% )， Dizziness (9% to 18% )， Extrapyramidal disease (3% to 12.9% )， Headache (7.4% to 21% )， Insomnia (8% to 12% )， Lethargy (1% to 5% )， Somnolence (16% to 57% )， Tremor (2% to 8% ) Psychiatric: Agitation (6% to 20% ) Respiratory: Nasal congestion (3% to 5% )， Pharyngitis (4% to 6% ) Other: Fatigue (3% to 14% )， Pain (1% to 7% ),25℃以下,Adults: Schizophrenia: initial dose:50 mg (Day 1)， 100 mg (Day 2)， 200 mg (Day 3)， 300 mg (Day 4)， then titrate to 300-450/day. Adjust dose within the range of 150-750 mg/day depending on clinical response & tolerability of the patient. Manic episodes associated with bipolar disorder: As monotherapy of as adjunct therapy to mood stabilizers， initial dose: 100 mg (Day 1)， 200 mg (Day 2)， 300 mg (Day 3)， 400 mg (Day 4). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of no > 200 mg/day. Adjust dose within the range of 200-800 mg/day depending on clinical response & tolerability of the patient. Usual effective dose range: 400-800 mg/day. Elders: Initial dose:25mg， increase by 25-50mg daily to the effective dose. Children: Not approved for use under 18 years of age.,需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OSIN4,Montelukast,Singulair 4mg,ERSP,SINGULAIR is indicated in adult & pediatric patients 6 months of age & older for the prophylaxis & chronic treatment of asthma， including the prevention of day- & nighttime symptoms， the treatment of aspirin-sensitive asthmatic patients， & the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated in adults & pediatric patients 2 years of age & older for the relief of day- & nighttime symptoms of seasonal allergic rhinitis.,Hypersensitivity to any component of Singulair.,Abdominal pain， headache， thirst， diarrhea， hyperkinesia， asthma， eczematous dermatitis， rash. Neurologic: Headache (Adult and adolescent; 18.4%; pediatric， 2% and greater ),30℃以下，避免潮濕與光線照射,Should be taken once daily. For asthma， the dose should be taken in the evening. For seasonal allergic rhinitis， the time of administration may be individualized. Patients with both asthma & seasonal allergic rhinitis should take only 1 TAB daily in the evening. Asthma and/or seasonal allergic rhinitis- Age > or = 15 years: 10 mg QD. Age 6-14 years: One 5 mg chewable TAB QD. Age 2-5 years: One 4 mg chewable TAB QD or one packet of 4 mg oral granules QD. Age 6 months-2 years with asthma: One packet of 4 mg oral granules QD.,需調整劑量,,無需調整劑量,可能安全,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OSTI,Zolpidem,Stilnox 10mg,CNEU,Insomnia.,Children < 15 years; pregnancy & lactation.,Occasional dizziness， drowsiness， nausea & headache. Gastrointestinal: Diarrhea (1% to 3% )， Nausea (1% to 7% ) Immunologic: Allergy (4% ) Neurologic: Dizziness (1% to 23.5% )， Drugged state (3% )， Headache (1% to 19% )， Somnolence (2% to 15% ) Ophthalmic: Visual disturbance (3% ),30℃以下,Oral Short-term management of insomnia Adult: Initial dose: woman : 5mg; man: 5 or 10mg immediately before bedtime; maximum: 10 mg/day. Elderly: 5mg before bedtime. Hepatic impairment: 5 mg before bedtime. In good tolerance or insufficient clinical response may be 10 mg. Severe: contraindicated.,需調整劑量,,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;VAG;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OTAMI,Oseltamivir,Tamiflu 75mg (政府提供),QANB,Prophylaxis & treatment of influenza in adult & children.,Hypersensitivity.,Nausea， vomiting， abdominal pain， headache. Insomnia， diarrhea. Gastrointestinal: Abdominal pain (2% to 5% )， Nausea (4% to 10% )， Vomiting (2% to 15% ),25℃以下,(仿單) Influenza: Treatment (for patients > 1 year): - Adult: Usual Dose for uncomplicated influenza of <48 hrs duration: 75 mg PO BID x 5 days; complicated influenza in immunocompromised patients even if ill over 48 hrs: 75 mg PO BID x 10 or more days. - Children > 40 kg: 75 mg BID x 5 days - Children > 23-40 kg: 60 mg BID x 5 days - Children > 15-23 kg: 45 mg BID x 5 days - Children < or = 15 kg: 30 mg BID x 5 days - Infant 0-12 months: 3 mg/kg BID x 5 days Prophylaxis (for patients > 1 year): - Adults: 75 mg orally once daily for 10 days to 6 weeks. - Children > 40 kg: 75 mg QD x 10 days - Children > 23-40 kg: 60 mg QD x 10 days - Children > 15-23 kg: 45 mg QD x 10 days - Children < or = 15 kg: 30 mg QD x 10 days - Infants 3-11 months: 3 mg/kg once daily (熱病),無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OTEGCR,Carbamazepine,Tegretol CR 200mg,CNEU,Epilepsy， trigeminal neuralgia， bipolar disorder， diabetes insipidus centralis， glossopharyngeal neuralgia.,AV block. History of bone marrow depression or acute intermittent porphyria.,Frequent: dizziness， ataxia， mild allergic skin reactions， mild leucopenia. Occasionally: diplopia， liver enzyme elevations， vomiting， thrombocytopenia， hyponatremia， accommodation disorders. Rare: exfoliative dermatitis， Stevens-Johnson syndrome， jaundice， hepatitis， delayed multi-organ hypersensitivity disorders， SLE-like syndrome. Isolated cases: neuritis， hallucinations， agitation， depression， Lyell's syndrome， blood dyscrasias， anaphylactic reaction， AV-block， congestive heart failure， thromboembolism， osteomalacia， renal dysfunction， interstitial nephritis， sexual disturbances.,30℃以下並防潮,Adult -Initially 100-200 mg QD or BID， may be gradually increased to 400mg BID or TID. Daily dosage may be 1600-2000 mg . Children (4 years or less)Initially 20-60 mg/kg body weight/day.Children (over 4 years) )Initially 100 mg/kg body weight/day，then weekly increased to 100mg . Maintenance dose of children: 10-20 mg/kg body weight/day in divided doses. Continuous treatment of bipolar disorder: 400-1600mg/day，usually 400-600mg in 2-3 times a day. Treatment of trigeminal neuralgia:Initially 200-400mg/day and then slowly increase until the pain disappears. (Usually 3 to 4 times a day， 200mg each time) Nephrogenic diabetes insipidus:adults 2 to 3 times a day， 200mg each time.,無需調整劑量,,無需調整劑量,盡量避免,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為長效錠，需整顆吞服勿咀嚼、剝半或磨粉。
OTEN5,Atenolol,Tenormin 50mg,CAVS,,適應症: Antihypertension， anti angina. 副作用: Cold extremities， fatigue， GI disturbances， bradycardia. Occasionally， headache， mood changes， dizziness & deterioration of heart failure. Rarely， sleep disturbances， alopecia， thrombocytopenia， purpura， psoriasiform skin reactions， exacerbation of psoriasis， visual disturbances， psychoses， hallucinations， heart block， postural hypotension which may be associated with syncope. Intermittent claudication. Raynaud's phenomenon. Bronchospasm. Rashes & dry eyes， paraesthesia. Cardiovascular: Bradyarrhythmia (3% to 18% )， Cold extremities (12% )， Hypotension (4% to 25% ) Neurologic: Dizziness (13% ) Psychiatric: Depression (up to 12% ) Other: Fatigue (up to 26% ) 禁忌: Presence of 2nd or 3rd degree heart block; cardiogenic shock. Bradycardia， hypotension， metabolic acidosis， severe peripheral circulatory disturbances， sick sinus syndrome， untreated phaeochromocytoma， uncontrolled heart failure.,,室溫,50-100 mg daily.,,,,盡量避免,,,,,,,,,,
INOC,Vecuronium,Norcuron 10mg,CNEU,,適應症: Facilitate endotracheal intubation; Muscle relaxant in general anesth 副作用: Muscle weakness， paralysis， muscle atrophy (after long term use)， hypersensitivity reactions e.g urticaria and erythema. 禁忌: Hypersensitivity to vecuronium or bromide.,,室溫,IV Facilitate endotracheal intubation; Muscle relaxant in general anesth Initial: 80-100 mcg/kg as inj. Maintenance: 20-30 mcg/kg， adjust according to response. Alternatively， as continuous infusion at 0.8-1.4 mcg/kg/min after initial IV dose of 40-100 mcg/kg.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IENB,Etanercept,Enbrel 25mg inj,HIMM,,適應症:Treatment of active RA in adults when the response to disease-modifying antirheumatic drugs， including methotrexate has been inadequate. Treatment of severe， active & progressive RA in adults not previously treated with methotrexate. Treatment of active polyarticular-course juvenile chronic arthritis in children 4-17 years who have had an inadequate response to， or who are intolerant of， methotrexate. Treatment of active & progressive psoriatic arthritis in adults when the response to DMARD therapy has been inadequate. Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Treatment of adults with moderate to severe plaque psoriasis who failed to respond to， or have a contraindication to， or are intolerant to other systemic therapy including cyclosporine， methotrexate or PUVA.Treatment of active polyarticular juvenile idiopathic arthritis in adolescents & childn ?4 yr w/ inadequate response or intolerant to methotrexate. Treatment of chronic severe plaque psoriasis in adolescents & childn ?8 yr inadequately controlled by or intolerant to other systemic therapies or phototherapies. 副作用:Inj site reactions， infections， allergic reactions， autoantibody formation， pruritus， fever. Rarely， serious infections including sepsis， CNS demyelinating disorders， worsening of CHF， pancytopenia (& very rarely aplastic anaemia). 禁忌:Sepsis or risk of sepsis; active infections including chronic or localized infections.,,2-8℃,SC Adult (18-64 years) RA 25 mg twice weekly or 50 mg once weekly. Psoriatic arthritis & ankylosing spondylitis 25 mg twice weekly or 50 mg once weekly. Plaque psoriasis Initially 25 mg twice weekly or 50 mg twice weekly for up to 12 weeks， then reduce to 25 mg twice weekly. Treatment should continue until remission is achieved， for up to 24 weeks; discontinue if no response after 12 weeks. Children >= 4 years Juvenile idiopathic arthritis 0.4 mg/kg (max: 25 mg/dose) twice weekly at 3-4 day intervals. Children >= 8 years Pediatric plaque psoriasis 0.8 mg/kg (max: 50 mg/dose) weekly for up to 24 weeks,,animal data suggest low risk.,,可能安全,,,Human Data Suggest Potential Toxicity,animal data suggest low risk.,,,,,,■(prefilled syringe and autoinjector) allow 15 to 30 minutes for syringe to reach room temperature before injecting; do not remove needle cover while allowing the syringe to come to room temperature ■do not shake vial or syringe ■visually inspect solution prior to administration; do not use if solution is cloudy， or if particulate matter is present ■inject into thigh， abdomen， or upper arm; rotate sites on subsequent doses; avoid tender， bruised， red or hard areas of the skin
OPR150,Dabigatran,Pradaxa 150mg,HEMT,reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation,Pathological bleeding,Gastrointestinal: Dyspepsia (11%; includes abdominal discomfort/pain， epigastric discomfort) GI hemorrhage (<6%)， gastritis-like symptom Hematologic: Bleeding (8% to 33%; major: <6%) Anemia (1% to 4%) hematoma (1% to 2%) hemoglobin decreased (1% to 2%) hemorrhage (postprocedural or wound: 1% to 2%) Hepatic: ALT increased (>3 x ULN: 2% to 3%) Renal: Hematuria (1%) Miscellaneous: Wound secretion (5%)， postprocedural discharge (1%),30℃以下，避免濕氣,Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation: adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily， with or without food. For prophylaxis of venous thrombosis of hip replacement surgery， starting 75mg within 1-4 hours after the operation， then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days， then 150mg twice a day for 6 months.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,WM;,,,,,[磨粉/管灌註記]本藥應整粒吞服， 切勿咬嚼或打開膠囊。若破壞劑型會造成生體可用率增加1.4倍而增加出血風險。
OTOP,Alginic Acid+Colloidal Al(OH)3+MgHCO3,Topaal chewable Tab,ALIM,,適應症: Reflux esophagitis， hiatal hernia， heartburn， peptic ulcer， gastric hyperacidity. 副作用: Diarrhea， constipation.,,室溫,2 tab bid-tid.,,,,沒有資料,,,Compatible 哺乳時可使用,,,,,,,
OTOPA,Topiramate,Topamax 25mg,CNEU,,適應症: Adjunctive therapy in adults & children >= 2 years with partial seizures， seizures associated with the Lennox-Gastaut Syndrome， as well as with tonic-clonic seizures. Monotherapy in patients with partial onset seizure. Migraine prophylaxis. 副作用: Ataxia， impaired conc， confusion， dizziness， fatigue， paresthesia， somnolence， abnormal thinking. Less commonly， agitation， amnesia， anorexia， aphasia， depression， diplopia， emotional lability， nausea， nystagmus， speech disorder， taste perversion， abnormal vision & weight decrease. Nephrolithiasis (rare). Gastrointestinal: Diarrhea (5% to 11% )， Loss of appetite (4% to 24% )， Nausea (6% to 14% )， Taste sense altered (3% to 15% )， Weight decreased (6% to 21% ) Neurologic: Confusion (3% to 14% )， Disorder of language (6% to 10% )， Dizziness (8% to 32% )， Feeling nervous (7% to 14% )， Headache， Impaired psychomotor performance (3% to 21% )， Memory impairment (5% to 14% )， Paresthesia (2% to 51% )， Reduced concentration span (4% to 14% )， Somnolence (9% to 29% )， Speech and language disorder Ophthalmic: Abnormal vision (2% to 13% )， Diplopia (1% to 10% )， Nystagmus (10% to 11% ) Other: Fatigue (14% to 30% ) 禁忌: Pregnancy.,,室溫,Adjunctive therapy Adult 200-600 mg/day in 2 doses. Children >= 2 years 6-9 mg/kg/day in 2 doses. Max: 1000mg/day. Monotherapy Adult Initial target dose 100mg/day in 2 doses. Children >= 2 years 3-6 mg/kg/day in 2 doses.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OUTR,Progesterone,Utrogestan 100mg,HM,,適應症：Pre-menstrual syndrome， dysmenorrhea， endometriosis， habitual abortion， infertility due to luteal insufficiency， secondary amenorrhea， uterine bleeding， threatened abortion. 副作用：Drowsiness， slight spotting before menstruation or a clear shortening of the cycle.,,室溫,Revention: 200-400 mg q8h on the 1st day， then 100-200 mg q8h afterward till 36th week of pregnancy. Supplement: 100-200 mg hs x 10-14 days (may give an extra 100 mg in the morning if needed) starting from the 12th day of the menstrual cycle.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OVEN2,Estradiol + Medroxyprogesterone,Venina 1/2.5mg (28 tablets/pack),HM,Hormone replacement therapy (HRT) for estrogen deficiency symptoms & prophylaxis of osteoporosis in women with an intact uterus.,Pregnancy & lactation. Known， suspected or past history of breast cancer or estrogen-dependent tumour， undiagnosed vag bleeding， confirmed active venous thromboembolism (VTE) within the last 2 years. History of recurrent VTE or known thrombophilic disease in patients not on anticoagulant， acute or chronic liver diseases or a history of liver disease.,Breast tenderness & enlargement， uterine bleeding， increase in size of uterine fibroids， headache， GI discomfort， weight changes， edema， mood changes including anxiety & depressive mood， changes in libido.,25℃以下,1 tablet (MPA 2.5mg) daily， Rule out the possibility of endometrial abnormalities may up to 5mg.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於懷孕或準備懷孕婦女。
OXANT,Theophylline,Xanthium 200mg,ERSP,Treatment & prevention of bronchospasm in asthma & COPD.,Allergy to theophylline， aminophylline or other xanthines.,GI discomfort (nausea， vomiting). CNS disturbances (palpitation， arrhythmia).,25℃以下,QD (in the morning or evening) or Q12H. Age 6-9 years: 20mg/kg/day， maximum dose: 400mg/day. Age 9-12 years: 18mg/kg/day， maximum dose: 400-600mg/day. Age 12-16 years: 16mg/kg/day， maximum dose: 600-800mg/day. Age >17 years: 10mg/kg/day， maximum dose: 600-1000mg/day. Elderly: 6-8mg/kg/day， maximum dose: 400-600mg/day. Patient with obesity should adjust by standard weight.,需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為腸溶膠囊，可拆膠囊後服用。但不可將膠囊內的腸溶微粒研磨或壓碎。院內另有Theophylline成份藥水Centertheo 60mL (5.34mg/mL) liquid。
OXEL,Capecitabine,Xeloda 500mg,RACA,,適應症:Colon cancer， Adjuvant therapy， Duke's Stage C， when treatment with a fluoropyrimidine alone is preferred. Metastatic breast cancer， metastatic colorectal cancer， 1-line therapy when treatment with a fluoropyrimidine alone is preferred. 副作用: GI disturbances; hand-foot syndrome， alopecia， pruritus， rash; fatigue， pyrexia， lethargy， asthenia; dizziness， taste disturbance; anorexia; conjunctivitis; neutropenia. Dermatologic: Dermatitis (27% to 37% ) Gastrointestinal: Abdominal pain， Constipation， Loss of appetite， Nausea， Stomatitis， Vomiting Other: Fatigue 禁忌:Known hypersensitivity to capecitabine， fluorouracil， or any component of the formulation; severe renal impairment (CrCl <30 mL/minute). Canadian labeling: Additional contraindications (not in the US labeling): Known complete absence of dihydropyrimidine dehydrogenase (DPD) activity; concomitant administration with sorivudine or chemically related analogues (eg， brivudine).,,室溫,Breast cancer， metastatic: Oral: 1，250 mg/m2 twice daily for 2 weeks， every 21 days (as either monotherapy or in combination with docetaxel). Colorectal cancer， metastatic: Oral: 1，250 mg/m2 twice daily for 2 weeks， every 21 days. Breast cancer， adjuvant therapy (off-label; in HER2-negative patients with residual disease after neoadjuvant therapy and surgery): Oral: 1，250 mg/m2 twice daily on days 1 to 14 of a 21-day treatment cycle for 6 to 8 cycles.,,,需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,,,,,,
OYAZ,Drospirenone + Ethinylestradiol,YAZ 悅姿錠 (28 tablets/box),HM,Treatment of moderate acne vulgaris in women at least 14 years of age， who have no known contraindications to OC therapy， & have achieved menarche,Renal insufficiency， hepatic dysfunction， adrenal Insufficiency， thrombophlebitis or thromboembolic disorders， past history of deep-vein thrombophlebitis or thromboembolic disorders， cerebrovascular or coronary-artery disease (current or history)， valvular heart disease with thrombogenic complications， severe hypertension， diabetes with vascular involvement， headaches with focal neurological symptoms， major surgery with prolonged immobilization， known or suspected carcinoma of the breast， carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia， undiagnosed abnormal genital bleeding， cholestatic jaundice of pregnancy or jaundice with prior pill use， known or suspected pregnancy， liver tumor (benign or malignant) or active liver disease， heavy smoking (> 15 cigarettes/day) & over age 35,Upper respiratory infection， headache， breast pain， vag moniliasis， leukorrhea， diarrhea， nausea， vomiting， vaginitis， abdominal pain， flu syndrome， dysmenorrhea， moniliasis， allergic reaction， UTI， accidental injury， cystitis， tooth disorder， sore throat， infection， fever， surgery， sinusitis， back pain， emotional lability， migraine， suspicious Papanicolaou smear， dyspepsia， rhinitis， acne， gastroenteritis， bronchitis， pharyngitis， skin disorder， intermenstrual bleeding， decreased libido， weight gain， pain， depression， increased cough， dizziness， menstrual disorder， pain in extremity， pelvic pain & asthenia,30℃以下,Start on day 1 of menstrual cycle， take one light pink tablet QD for 24 consecutive days followed by one white inert tablet QD for 4 days. If YAZ is first taken later than the first day of the menstrual cycle， other contraceptive methods must be used until after the first 7 consecutive days of product administration.,無需調整劑量,up to date: Enters breast milk/use caution Drospirenone [8] Micromedex Lactation Rating: Infant risk is minimal Ethinylestradiol Ethinylestradil [8] Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding,無需調整劑量,不可使用,Contraindicated,Drospirenone [18] micromedex : Teratogenicity/Effects in Pregnancy Ethinylestradiol Ethinylestradil [18] by book . micromedex : Teratogenicity/Effects in Pregnancy,Contraindicated 哺乳期使用禁忌,up to date: Enters breast milk/use caution Drospirenone [8] Micromedex Lactation Rating: Infant risk is minimal Ethinylestradiol Ethinylestradil [8] Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding,AC;PC;PO;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於懷孕或準備懷孕婦女。
OZOL,Sertraline,Zoloft 50mg,CNEU,Depression， obsessive-compulsive disorder (OCD)， panic disorder， post traumatic stress disorder (PTSD)， social phobia， premenstrual dysphoric disorder (PMDD).,Patients with known hypersensitivity to sertraline. Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs).,Nausea， diarrhoea/loose stools， anorexia， dyspepsia; male sexual dysfunction (ejaculatory delay); tremor; dry mouth; increased sweating. Sertraline has been associated with PALPITATIONS， CHEST PAIN， HYPERTENSION， HYPOTENSION， EDEMA， SYNCOPE， and TACHYCARDIA,30℃以下,50-200 mg daily. Dosage may be increased in 50 mg increments to maximum 200 mg over a period of weeks.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
LAMO,Amoxicillin,Amoxicillin syr 25mg/mL,QANB,,適應症: Gm+ve & gm-ve infections. 副作用: Nausea， vomiting， diarrhea， glossitis， stomatitis， black hairy tongue; skin rashes， urticaria， exfoliative dermatitis， erythema multiforme; anemia， thrombocytopenia， eosinophilia， leukopenia， agranulocytosis. 禁忌: Hypersensitivity to penicillins.,,室溫,Adult 250 mg 8 hrly. Children >= 20 kg Adult dose， < 20 kg 20 mg/kg/day 8 hrly. Severe infections or penicillin non-sensitive bacterial infections: Adult 500 mg 8 hrly. Children >= 20 kg Adult dose， < 20 kg 40 mg/kg/day 8 hrly. Gonorrhea Adult 3 g as a single dose.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,
OGLUF,Mitiglinide,GluFAST 10mg,META,,適應症：To improve the postprandial plasma glucose transition in patient with type 2 DM who do not sufficiently respond to dietary treatment & exercise therapy alone， use of α-glucosidase inhibitors， use of thiazolidinediones in addition to diet & physical exercise. 副作用：Hypoglycemic symptoms， weight increase， edema， abdominal distension， constipation. 禁忌：Severe ketosis， diabetic coma or pre-coma， or type 1 DM. Severe infections， before or after operation， or with serious trauma. Pregnancy.,,室溫,Adult 10 mg tid. Should be taken with food (Take immediately before meals.).,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ISCA3,Mepivacaine,Scandonest 3%(for Dental) 1.8mL,ZANE,Dental infiltration and dental nerve block.,Complete heart block. Porphyria. Do not inject through infected skin when using for epidural anaesthesia.,Restlessness， excitement， nervousness， paraesthesias; dizziness， tinnitus， blurred vision; nausea， vomiting; muscle twitching， tremors， convulsions; numbness of the tongue and perioral region; lightheadedness， drowsiness， respiratory failure， coma， hypotension.,室溫,3~6 years:maximum 1.8mL 6~14 years:usual dose:1.35mL; maximum 2.7mL,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,LI;,,,,,
OIND4,Propranolol,Inderal 40mg,CAVS,,適應症: Adult HTN， Angina， migraine & essential tremor， Arrhythmias， anxiety tachycardia， thyrotoxicosis， Pheochromocytoma. 副作用: Cold extremities， GI & sleep disturbances， fatigue， lassitude. Deterioration in heart failure， mood changes. Isolated cases of paresthesia. Rarely bradycardia， dizziness， postural hypotension which may be associated with syncope， heart block， alopecia， thrombocytopenia， purpura， psoriasiform skin reactions， exacerbation of psoriasis， visual disturbances， CNS symptoms including hallucinations & psychoses; hypoglycaemia in children. Rashes & dry eyes (discontinue drug). Intermittent claudication， Raynaud's phenomenon， bronchospasm， increased antinuclear antibodies. Dermatologic: Dermatitis， Pruritus， Urticaria Neurologic: Dizziness (4% to 7% ) Other: Fatigue (5% to 7% ) 禁忌: History of bronchial asthma or bronchospasm， bradycardia， cardiogenic shock， hypotension， metabolic acidosis， after prolonged fasting， severe peripheral arterial circulatory disturbances， 2nd or 3rd degree heart block， sick sinus syndrome， untreated (with an alpha adrenoceptor antagonist) phaeochromocytoma， uncontrolled heart failure， Prinzmetal's angina.,,室溫,Angina: PO， initially， 10-20mg tid-qid; maintenance， 160-240mg/day. Arrhythmia: Adult: PO， 10-30mg tid-qid ac. IV， 0.5-3mg; a second dose may be given 2 min later if necessary; additional doses may be given at intervals of no less than 4hr. Child: PO， initially， 1.5-2mg/kg/day， titrate up to a max. 16mg/kg/day in 4 doses. Essential tremor: PO， initially， 40mg bid; maintenance， 120-320mg/day in 3 doses. Hypertension: PO. Adult: Initially， 40mg bid; maintenance， 160-480mg/day. Child: Initially， 1mg/kg/day in 2 doses; maintenance， 1-5mg/kg/day in 2-4 doses. Migraine: PO， initially， 80mg/day in divided doses; maintenance，160-240 mg/day. Pheochromocytoma: PO， 60mg/day in divided doses for 3 days before surgery; 30 mg/day in divideddoses with an adrenergic blocker as an adjunct to prolonged treatment of intolerable pheochromocytoma. Post-MI: PO， 180-240mg/day in divided doses.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
EENT3,Tyrothricin,ENT oint 3.5gm,TENT,,適應症: Acute & chronic forms of rhinitis & treatment of bacterial infection of the nasal mucosa. 副作用: Rarely， hypersensitivity reactions. 禁忌: Acute & congestive glaucoma. Children <= 2 years.,,室溫,Apply to the nasal mucosa several times daily.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OSALA,Pilocarpine,Salagen 5mg,CNEU,Treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head & neck. Treatment of symptoms of dry mouth in patients with Sjogren's syndrome.,Uncontrolled asthma， acute iritis & angle closure glaucoma.,Sweating， nausea， diarrhea， chills， flushing， urinary frequency， dizziness， asthenia， headache， dyspepsia， lacrimation， edema， abdominal pain， amblyopia， vomiting， pharyngitis， hypertension.,15-30℃,Head & neck cancer - Radiation-induced xerostomia: Initially 5 mg TID. Usual dosage range: 15-30 mg daily (do not exceed 10 mg/dose). Sjogren's syndrome - Xerostomia: 5 mg QID.,需調整劑量,Infant risk cannot be ruled out: Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when Pilocarpine is used during breast-feeding. Weigh the potential benefits of treatment against potential risks before prescribing Pilocarpine during breast-feeding.,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Infant risk cannot be ruled out: Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when Pilocarpine is used during breast-feeding. Weigh the potential benefits of treatment against potential risks before prescribing Pilocarpine during breast-feeding.,AC;AC15;PC;PO;WM;,,,,,
OARH,Leflunomide,Arheuma 20毫克,HIMM,,適應症:Treatment of RA & psoriatic arthritis in adult. 副作用:Increase in BP; GI disturbances， anorexia， oral mucosal disorders， weight loss; headache， dizziness， asthenia， paraesthesia; tenosynovitis; alopecia， eczema， dry skin， rash， pruritus; hypersensitivity reactions， leucopenia. 禁忌:Stevens-Johnson syndrome， toxic epidermal necrolysis， multiforme epithelium. Hepatic dysfunction， severe immunodeficiency such as AIDS， bone-marrow dysplasia， severe infections， moderate to severe renal dysfunction， severe hypoproteinaemia. Pregnancy， lactation.,,室溫,Adult Initially 100 mg once daily for 3 days then maintenance， 10-20 mg once daily.,,,,不可使用,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OPOT2,Strontium Ranelate,Protos 2gm 28pk/box,META,,適應症: Treatment of postmenopausal osteoporosis to reduce the risk of vertebral & hip fractures. 副作用: Nausea， diarrhea， loose stools， headache， dermatitis， eczema， VTE， memory loss， seizures. 禁忌: Hypersensitivity to strontium ranelate or to any of the excipients of Protos.,,室溫,The recommended dose is 2 g daily 每日一包充分加水攪拌後服用， given preferably at night and at least 2 hours after food.(MICROMEDEX) Strontium ranelate should not be given with food， milk or antacids (2hours apart); Because of possible complex formation， strontium ranelate should not be given with oral tetracyclines or quinolones. 機轉: Strontium ranelate is claimed to stimulate bone formation as well as reduce bone resorption.,,,,盡量避免,,,Human Data Suggest Potential Toxicity,,,,,,,
OLIN,Clindamycin,Lindacin 150mg,QANB,Treatment of infections caused by susceptible strains of Strep， staphylococcus， pneumococci and anaerobic bacteria.,Hypersensitivity to clindamycin or lincomycin. History of GI diseases， severe renal or liver impairment.,GI disturbances， hypersensitivity reactions， pruritus.,15-30℃，避光處及緊密容器中,Adults: 150-450 mg orally Q6H; severe disease: 600 mg orally Q6-8H. Children > 1 month of age: 8-25 mg/kg/day， divided Q6-8H. (熱病) Adults: 150-450 mg orally Q6-8H (maximum: 1.8 gm/day). Pediatric dose for age > 28 days: Oral: 30-40 mg/kg/day， divided Q6-8H.,需調整劑量,Enters breast milk/not recommended (AAP rates “compatible”; AAP 2001 update pending) Breast-Feeding Considerations:Small amounts of clindamycin transfer to human milk. The manufacturer does not recommend the use of clindamycin during breast-feeding. Nondose-related effects could include modification of bowel flora. One case of bloody stools in an infant occurred after a mother received clindamycin while breast-feeding; however， a casual relationship was not confirmed.,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,Enters breast milk/not recommended (AAP rates “compatible”; AAP 2001 update pending) Breast-Feeding Considerations:Small amounts of clindamycin transfer to human milk. The manufacturer does not recommend the use of clindamycin during breast-feeding. Nondose-related effects could include modification of bowel flora. One case of bloody stools in an infant occurred after a mother received clindamycin while breast-feeding; however， a casual relationship was not confirmed.,AC;AC15;PC;PO;WM;,,,,,
OTOF,Imipramine,Tofranil 25mg,CNEU,Depressive states of varying etiology & symptomatology， panic attacks， chronic painful conditions， pavor nocturnus， nocturnal enuresis.,Acute stage of MI. Mania.,Anticholinergic effects are frequent. Rarely， liver disorders， CV effects.,室溫藥，避光避熱,Adults: Outpatient initial dose: 75mg/day. The dose can be increased to 150mg/day. maximum: 200mg/day. Maintenance dose: 50-150mg/day. Inpatient initial dose: 100mg/day in divided doses. If necessary， the dose can be gradually increased to 200mg/day. If there is no improvement after two weeks， increase to 250-300mg/day. Teenager and elderly: 30-40mg/day. maximum: 100mg/day. Children with enuresis: > 6 years old: 25mg 1 hour before bed. If there is no improvement after a week:<12 years old: 50mg， >12 years old:75mg. maximum:2.5mg/kg/day.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
LULE,Cephalexin,Ulexin 25mg/mL， 60mL suspension,QANB,Susceptible infections， Prophylaxis against recurrent UTI.,Hypersensitivity to cephalosporins.,Pain at inj site; hypersensitivity; GI disturbances; eosinophilia， neutropenia， leucopenia， thrombocytopenia. Potentially Fatal: Anaphylactic reactions; nephrotoxicity.,室溫藥品，加入冷開水至60cc溶解後2-8℃冷藏儲存，並於一星期內使用完畢,Adults: 0.25-1 g Q6H or 500 mg Q12H (maximum: 4 g/day). Children: 25-100 mg/kg/day divided Q6H.,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
ODIL9,Diltiazem,Diltelan 90mg,CAVS,,適應症: 主治高血壓、心絞痛(B021113100) Hypertension. 副作用: Bradycardia， 1st degree AV block， ankle edema， nausea， headache， skin rashes， finger swelling. Cardiovascular: Bradyarrhythmia (1.7% to 3.6% )， Peripheral edema (4.6% to 8% ) Neurologic: Dizziness (3.5% to 6.4% )， Headache (4.6% ) Respiratory: Cough (2% ) Other: Fatigue (4.8% ) CI: Pregnancy， lactation; sick sinus syndrome， AV block II or III， severe bradycardia.,,室溫,Intial: 30 mg qid ac. Maintenance: 180-360 mg/day.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
LCYP,Cyproheptadine,Cypromin solution 0.4mg/mL， 60mL,HIMM,Symptomatic relief of allergic conditions， eg urticaria， angioedema， rhinitis， conjunctivitis， pruritic skin disorders. Vascular headaches， migraine.,Pregnancy & lactation. Neonates. Debilitated patients， elderly.,Increased appetite & weight gain. CNS depression， drowsiness， lassitude， dizziness， incoordination， sedation. Headache， psychomotor impairment， dry mouth， thickened respiratory tract secretions， blurred vision， urinary difficulty & retention， constipation， increased gastric reflux. Rashes， hypersensitivity reactions. Convulsion， sweating， myalgia， paresthesia， extrapyramidal effects， tremor， sleep disturbances， depression， tinnitus， hypotension， hair loss.,密封儲存25℃以下，不需冰存並避免陽光直射,Allergic conditions & pruritus Adult Initial: 10~50mL/day. Maintenance: 30-40 mL/day in 3 divided doses. Maximum: 80 mL/day. Children: 7-14 years 10 mL BID-TID (Maximum: 40 mL/day)， 2-6 years 5 mL every 8 - 12 hours. (Maximum: 30 mL/day). Vascular headache & migraine 4-8 mg Q4-6H.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OURA,Trospium,Uracare 10mg,SGU,Antispasmodics of smooth muscle. Overactive bladder.,Urinary retention; gastric retention， toxic megacolon; uncontrolled narrow-angle glaucoma， hypersensitivity; myasthenia gravis; tachyarrhythmia; severe renal or hepatic impairment.,Dry mouth， dry eyes， blurred vision， flatulence， constipation， abdominal pain， nausea， vomiting， dyspepsia， urinary retention， tachycardia.,25℃以下,Bladder hyperactive disorder: 1-2 tablets BID before meals; Smooth muscle spasm & pain: 1-2 tablets TID before meals.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;PO;,,,,,
IFLU10,Fluorescein,Fluorescite 10% 5mL,ZOTH,Diagnostic fluorescein angiography or angioscopy of the fundus & iris vasculature.,Not for intrathecal administration. Care must be taken to avoid extravasation during injection. History of allergy or bronchial asthma. Pregnancy， especially in the 1st trimester. Lactation.,Nausea， headache， GI distress， syncope， vomiting， hypotension， hypersensitivity. Reported cardiac arrest， basilar artery ischemia， severe shock， convulsions & thrombophlebitis at inj site. Extravasation may cause severe pain & pain at inj site. Occasionally， urticaria， itch， bronchial spasm.,25℃以下避免冷凍,Use in adults， including the elderly: Inject 5 mL of Fluorescein 10% solution for injection rapidly into the antecubital vein after taking precautions to avoid extravasation. In cases when highly sensitive imaging systems， e.g.， scanning laser ophthalmoscope are used， the dose of this product should be reduced to 2 mL of Fluorescein 10% solution for injection. Use in paediatric patients: For children， the dose should be calculated on the basis of 35 mg for each 10 pounds of body weight (7.7 mg/kg body weight).,無需調整劑量,FLUORESCEIN SODIUM BREASTFEEDING RECOMMENDATION: Limited Human Data—Potential Toxicity (IV) Limited Human Data—Probably Compatible (Topical),無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,FLUORESCEIN SODIUM PREGNANCY RECOMMENDATION: Limited Human Data—Animal Data Suggest Low Risk,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,FLUORESCEIN SODIUM BREASTFEEDING RECOMMENDATION: Limited Human Data—Potential Toxicity (IV) Limited Human Data—Probably Compatible (Topical),IVP;IVPUSH;,,,Adult: 500 mg (as a 10% soln) over 5-10 sec into the antecubital vein. (1 mL/second),,1. Prior to injection， an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30-60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur. 2.IV: Inject into the antecubital vein at a rate of ~1 mL/second using a 23-gauge butterfly needle attached to a small syringe. Prior to turning off room light， ensure extravasation has not occurred.
OMOBI,Meloxicam,Mobicam 15mg,CNEU,Painful osteoarthritis， rheumatoid arthritis， ankylosing spondylitis.,Hypersensitivity to NSAIDs or aspirin. Active peptic ulceration， severe hepatic insufficiency， non-dialysed severe renal insufficiency. Children < 15 years. Pregnancy & lactation.,Dyspepsia， nausea， vomiting， abdominal pain， constipation， flatulence， diarrhoea， anaemia， pruritus， rash， lightheadedness， headache， oedema. Cardiovascular: Edema (0.6% to 4.5% ) Gastrointestinal: Abdominal pain (1.9% to 4.7% )， Constipation (0.8% to 2.6% )， Diarrhea (1.9% to 7.8% )， Flatulence (3.2% )， Indigestion (3.8% to 9.5% )， Nausea (2.4% to 7.2% )， Vomiting Neurologic: Dizziness (1.1% to 3.8% )， Headache (2.4% to 8.3% ) Respiratory: Upper respiratory infection (up to 8.3% ) Other: Fever,25℃以下,Adults: maximum:15mg/day Osteoarthritis: 7.5mg/day， the dose can be increased to 15mg/day if needed Rheumatoid arthritis: 15mg/day， can be reduced to 7.5mg/day based on clinical response. Ankylosing Spondylitis (AS):15mg/day Patients who are more likely to have adverse reactions: Should start from 7.5mg/day Severe renal failure: Don't exceed 7.5mg/day Children: Data has not been established.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OBIN2,Haloperidol,Binin-U 2mg,CNEU,,適應症: Acute & chronic psychotic disorders including schizophrenia & manic states， Tourette's syndrome. Severe behavioral problems & hyperactivity in children. Nausea & vomiting associated with antineoplastic therapy & surgery. 副作用: Occasionally， depression， anxiety， agitation， confusion， vertigo， exacerbation of psychotic symptoms & seizures. Hyperprolactinaemia， gynaecomastia， menstrual irregularities， impotence. Rarely， tachycardia， orthostatic hypotension. 禁忌: Endogenous depression without agitation， comatose conditions， severe CNS depression. Pregnancy， children.,,室溫,Initially 1-2 mg bid-tid & gradually increase up to 4-6 mg tid if required. Severely disturbed patients Up to 100 mg/day. Maintenance: 1-2 mg tid-qid.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
INOV1,Eptacog alfa,Novo Seven RT 1mg,HEMT,Treatment of bleeding episodes & prevention of excessive bleeding in those undergoing surgery or invasive procedure in patients with congenital hemophilia with inhibitors， acquired hemophilia， Factor VII (FVII) deficiency， Glanzmann's thrombathenia.,Hypersensitivity to mouse， hamsters or bovine protein.,Rarely rash， itching， fever， nausea， headache， general discomfort， perspiration or changes in BP.,25℃以下避光勿冷凍,1.Hemophilia with inhibitors or acquired hemophilia or severe bleeding: 90 mcg/kg 2-3 hourly as single IV bolus. May increase dosing frequency to 4， 6， 8 or 12 hourly. One single injection of 270 μg/kg body can be given to hemophilia patients with mild to moderate bleeding episodes. 2.FVII deficiency: 15-30 mcg/kg 4-6 hourly by IV bolus. 3.Glanzmann's thrombasthenia: 90 mcg/kg body weight (80-120 mcg/kg body weight ) 2 hourly (1.5-2.5 hr) at least 3 doses.4.off-labeled use:Post-partum haemorrhage (PPH) unresponsive to standard therapy: 90 mcg/kg assingle IV bolus (over 2-5 min). At 20 min if no response， check and optimise: temperature; acidemia; serum calcium; platelets， fibrinogen. May consider administer a second dose of 90 mcg/kg. Australian and New Zealand Journal of Obstetrics and Gynaecology 2008; 48: 12–16,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IVD;IVP;IVPUSH;,使用產品所附溶液稀釋,,緩慢地進行靜脈注射，注射時間2-5分鐘為宜,緩慢地進行靜脈注射，注射時間2-5分鐘為宜,1.限用專用注射溶劑， 不可與其他輸注液混合 2.緩慢地進行靜脈注射，注射時間2-5分鐘為宜，不可以點滴方式給藥。
LGASC,Simethicone,Gascon drop 20mg/mL,ALIM,,適應症: Elimination of foamy mucus for gastric endoscopy 副作用: Very rarely， soft stool & GI discomfort,,室溫,Should be taken with food (Take after meals & at bedtime.). 2-10 mL 10-40 mins prior to test by oral.,,,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OBIP2,Biperiden,Bipiden 2mg,CNEU,,適應症: Parkinsonism. 副作用: GI disturbances; dry mouth; visual disorders; drowsiness， dizziness; fatigue; urinary retention. 禁忌: Narrow-angle glaucoma; mechanical stenoses of the GIT， megacolon.,,室溫,1 tab tid-qid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EH2O2,Hydrogen Peroxide,H2O2 solution 3%,TDER,Wound cleansing,Inj or instillation of hydrogen peroxide into closed body cavities.,Irritating burns on the skin and mucous membranes (strong solutions); reversible hypertrophy of the papillae of the tongue with continued use as mouthwash; gas embolism， rupture of the colon， proctitis， ulcerative colitis and gangrene of the intestines have occurred following colonic lavage with hydrogen peroxide solution.,30℃以下,Mouth/throat Acute stomatitis As 1.5% solution: Use as mouthwash or gargle. Otic Earwax removal As 6% solution: Dilute and use as directed. Topical Wound cleansing As 6% solution or 1-1.5% cream: Use as directed.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
EGENT,Gentamicin,Gentamicin eye drops 5mL,TOPH,Blepharitis， conjunctivitis， keratitis， iridocyclitis， meibomianitis & dacryocystitis.,Hypersensitivity.,Rarely， transient stinging.,25℃以下,Instill 2 drops to the affected eye(s) TID-QID.,無需調整劑量,,無需調整劑量,,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;TOPI;,,,,,
ECALA,Calamine + Diphenhydramine + ZnO,Calamaum lotion 120mL,TDER,,適應症: Symptomatic relief of skin irritation & itch associated with urticaria， insect bites， nappy rash & other minor skin problems. 禁忌: Avoid use on broken or eczematous skin. May affect ability to drive or operate machinery.,,室溫,Apply 3-4 times daily on the affected area.,,,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OSYN2,Piracetam,Syntam granules 2400mg,CNEU,,適應症: Treatment of cerebrovascular insufficiency & age-related cognitive impairment; adjunct in the treatment of myoclonus of cortical origin. 副作用: Hyperkinesia， wt gain， nervousness， somnolence， depression， asthenia. 禁忌: Cerebral hemorrhage; severe renal impairment.,,室溫,Cerebrovascular insufficiency & age-related cognitive impairment Loading dose: 4.8 g daily during initial weeks of treatment. Maintenance: 1.2-2.4 g daily. Cortical myoclonus Initially 7.2 g daily， increasing by 4.8 g/day every 3-4 days to a max of 24 g/day in divided doses.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OSAN1,Ciclosporin,Sandimmun Neoral 100mg,HIMM,Immunosuppression in organ transplant， psoriasis， severe atopic dermatitis， rheumatoid arthritis， nephrotic syndrome， prevention of graft rejection in bone marrow transplantation.,Hypersensitivity; malignant neoplasms; uncontrolled hypertension; psoriasis; lactation.,Hypertension; hepatoxicity; tremor; paraesthesia， hypertrichosis， facial oedema， acne; gingival hypertrophy; hyperkalaemia， fluid retention; increased susceptibility to infections; GI symptoms. Potentially Fatal: Nephrotoxicity; convulsions.,勿儲存於30℃以上,Transplant rejection initial 10-15 mg/kg before transplant， then divided twice daily into 2 equal doses for 1 to 2 weeks， titrate subsequent doses to achieve predefined blood concentrations. Plaque psoriasis initial 2.5 mg/kg/day in divided doses twice daily. Maximum 5 mg/kg/day. Rheumatoid arthritis initial 3 mg/kg/day in divided doses twice daily. Maximum 5 mg/kg/day. Atopic dermatitis 2.5-5 mg/kg/day in divided doses twice daily. Nephrotic syndrome adult 5 mg/kg/day， children 6 mg/kg/day.,需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥軟膠囊，應整粒吞服， 切勿咬嚼或壓碎。本藥具致畸胎性，請注意相關暴露風險，尤其是婦女及小孩。
OYUB,Sodium Fluoride,Yubon 0.25mg， 100's/bot,TENT,,適應症:預防蛀牙 副作用:輕微刺激反應(紅疹) 禁忌:對NaF過敏,,室溫,2週~2歲: 0.25 mg/day 2~3歲: 0.5 mg/day 4~5歲: 0.75 mg/day 6歲以上: 1 mg/day 懷孕期: 1 mg/day,無需調整劑量,,無需調整劑量,可能安全,,,Compatible 哺乳時可使用,,,,,,,
IGLUB,Ca Gluconate+ Glucoheptonate+ Lactobionate+ Saccha,Glucal Black inj 4.5mEq/5mL,NUTR,,適應症:Ca deficiency,,室溫,2-5 mL IM or IV at 2 mL/min， 5-20 mL daily or every other day.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,1. 靜脈注射時，可用5%或20%葡萄糖注射液稀釋，且須每分鐘2 mL 之緩慢速度注射。 2. 本劑與乙醇(Alcohol)混合時會有沉澱析出，故注射筒如用酒精消毒時，須待其完全乾燥始可使用。 3. 小兒與嬰兒須作靜脈注射，除非技術上有困難。 4. 曾經使用或正在使用洋地黃或其類似製劑者，因鈣離子可增強其作用，所以使用本劑時，務請萬分小心。
IUBI,Articaine,Ubistesin 4%(for Dental) 1.7mL,ZANE,Dental infiltration and dental nerve block,對麻藥成分過敏、心臟有嚴重的傳導系統障礙、急性心衰竭、嚴重低血壓,Tinnitus， dizziness， nausea， vomiting， restlessness. Central nervous system: Headache (4%)， paresthesia (1%) Gastrointestinal: Gingivitis (1%) Miscellaneous: Pain (body as a whole 13%)， facial edema (1%),室溫,For submucosal infiltration and/or nerve block injection. Avoid intravascular injection. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection. Injection rate: <= 0.5 mL/15 seconds. Children 20-30 kg: 0.25-1 mL; maximum: 1.5 mL each time and 2.5 mL/24 hours. Children 30-45 kg: 0.5-2 mL; maximum: 2 mL each time and 5 mL/24 hours. Adult: 0.5-1.7 mL each time， total maximum: 500mg， equivalent to 12.5 mL (7mg/kg).,需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,LA;LI;,,,,,
IZIA,Lidocaine + Epinephrine,Ziacaine 2%(for Dental) 1.8mL,ZANE,Dental infiltration and dental nerve block.,Thyrotoxicosis， hypertension， severe heart disease (particularly when tachycardia is present)， diabetes; hypovolaemia， shock， heart block; when inflammation or sepsis is present in the region of the proposed inj. Soln containing epinephrine should not be used for local anesth inj in digits & appendages.,Nervousness， dizziness， blurred vision， tremor， drowsiness， tinnitus， numbness， disorientation， nausea & vomiting.,室溫,4~6 years:usual dose:0.9ml; maximum.1.8ml 6~14 years:usual dose:1.35ml; maximum.2.7ml >15 years:usual dose:1.8ml; maximum.3.6ml,無需調整劑量,,無需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,LA;LI;,,,,,
OCOT,Dextromethorphan+Lysozyme+K Cresolsulfonate,Cotazym 20/20/90mg,ERSP,,適應症: Antitussive， expectorant. 副作用: Rarely， dizziness; GI disturbances; drowsiness. 禁忌: MAOI therapy.,,室溫,Drug leaflet: Adult 1 cap tid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IOMN2,Iohexol + Tromethamine,Omnipaque 350mg I/mL， 200mL,SCAN,脊髓造影， 血管造影， 電腦斷層掃描增強造影劑， 泌尿道造影 Intrathecal: Myelography; contrast enhancement for computerized tomography Intravascular: Angiocardiography， aortography， digital subtraction angiography， peripheral arteriography， excretory urography; contrast enhancement for computed tomographic imaging Oral/body cavity: Arthrography， GI tract examination， hysterosalpingography， pancreatography， cholangiopancreatography， herniography， cystourethrography; enhanced computed tomography of the abdomen,Hypersensitivity to iohexol or any component of the formulation.,全身溫熱感， 暫時性金屬味道， 腹部不適， 噁心， 嘔吐， 過敏性反應 Cardiovascular: Asystole， arrhythmia， bradycardia， cardiopulmonary collapse， edema， heart failure， hypertension (in patients with phenochromocytoma after intra-arterial injection)， hypotension， syncope， transient ischemic attacks， vasovagal attacks， venous thrombosis， ventricular fibrillation， ventricular tachycardia Central nervous system: Anxiety， confusion， dizziness， headache， loss of consciousness， seizure， vertigo Dermatologic: Pruritus， rash， urticaria Endocrine & metabolic: Thyrotoxicosis exacerbation Gastrointestinal: Cramping， diarrhea， nausea， salivary gland swelling， vomiting Local: Burning sensation， pain at injection site， thrombophlebitis Neuromuscular & skeletal: Parasthesia， polyarthropathy， tremor Ocular: Vision abnormalities Renal: Contrast-associated nephropathy， creatinine increased， renal dysfunction Respiratory: Bronchospasm， cough， dyspnea， pulmonary edema， rhinitis， sneezing Miscellaneous: Anaphylactoid reaction， diaphoresis， hypersensitivity reactions,無特別指示儲存溫度但可於使用前加熱至體溫的37℃,Dosing is based numerous variables including: type of examination， route of administration， patient age/weight and product. Consult specific product information for detailed dosing. Intrathecal route: Myelogram a) Lumbosacral:The usual recommended dose for use in lumbar myelography is 10 to 17 milliliters of iohexol 180 milligrams iodine/milliliter (mgI/mL) or 7 to 12.5 milliliters of iohexol 240 mgI/mL administered by lumbar injection. b) Thoracic:The usual recommended dose for thoracic myelography is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter (mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL administered by lumbar or cervical injection. c) Cervical:For cervial myelography given by lumbar injections， the following doses have been used: 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. If iohexol is administered by C1-2 injection， the recommended dose is 7 to 10 mL of iohexol 180 mgI/mL， 6 to 12.5 mL of iohexol 240 mgI/mL， or 4 to 10 mL of iohexol 300 mgI/mL. d) Spinal cord:The usual dose for total columnar myelography (lumbar injection) is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. Intravascular route: CT of head The recommended dose for HEAD IMAGING is 70 to 150 milliliters of iohexol 300 milligram iodine/milliliter (mgI/mL) or 80 mL of iohexol 350 mgI/mL by injection or 120 to 250 mL of iohexol 240 mgI/mL by infusion. For BODY IMAGING the dose is 50 to 200 mL of iohexol 300 mgI/mL or 60 to 100 mL of iohexol 350 mgI/mL by injection. Angiocardiography a) DOSAGE SUMMARY:Iohexol 350 milligrams iodine/milliliter is recommended for use in ANGIOCARDIOGRAPHY. b) VENTRICULOGRAPHY:The usual adult volume is a single injection of 40 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 30 mL to 60 mL). This may be repeated as necessary. When combined with selective coronary arteriography the total administered dose should not exceed 250 milliliters (87.5 grams iodine). c) SELECTIVE CORONARY ARTERIOGRAPHY:The usual adult dose for right or left coronary arteriography is 5 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 3 mL to 14 mL) per injection.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,IA;IV;IVP;IVPUSH;R;RECT;,,,,,1.體腔使用途徑以水稀釋， 成人兒童及部位不同依1:1~1:50不等比例稀釋 2.腎功能正常病患應立即停用Meformin 48小時，待腎功能恢復後再啟用;如腎功能不佳病患，請評估病患情況，提前48小時停用Meformin.
IMV5,Multivitamin,Multivita inj 5mL,NUTR,,適應症:Multivit deficiency.,,2-8℃,2-5 mL as a single dose IV. Per mL Vit A 2，000 iu， vit B1 10 mg， vit B2 2 mg， vit B6 3 mg， nicotinamide 20 mg， pantothenol 5 mg， vit C 100 mg， vit D 200 iu， vit E 1 mg,,,,安全,,,Compatible 哺乳時可使用,,,,,,,
IAVE,Moxifloxacin,Avelox 針劑 400mg/250mL,QANB,Treatment of adults >= 18 years with upper & lower respiratory tract infections such as acute sinusitis， acute exacerbation of chronic bronchitis， community acquired pneumonia; skin & soft tissue infections; complicated intra-abdominal infection.,Hypersensitivity. Children， growing adolescent. Pregnancy， lactation.,GI disturbances (eg nausea， vomiting， dyspepsia， abdominal pain); headache， dizziness; taste perversion; musculoskeletal effects (eg back pain， arthralgia); CVS effects (eg tachycardia， hypertension); hematological changes; CNS disturbances eg (insomnia， convulsion); skin reactions (eg rash， pruritus); visual disturbances.,室溫15℃ -25℃,Adult: 400 IV over 60 minutes Q24H.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D10W】可選 。【D5W】可選 。【L/R】可選 。【N/S】可選 。,,以超過60分鐘緩慢滴注。不建議使用在pediatric patients,1. 監測體溫、CBC，注意是否有癲癇、心律不整徵狀。 2. 本品可直接輸注或透過T-tube與其他相容的輸注液一同輸注。 3. 依2016年第2次ADR會議決議: 因Quinolones類藥物常見引起靜脈炎，建議輸注時間應超過60分鐘。
ICEF7,Cefuroxime,Cefuroxime inj 750mg,QANB,,適應症: Infections due to Staphylococci， Streptococci， Pneumococci， Meningococci & other susceptible bacteria. 副作用: Allergic reactions， GI intolerance， superinfection， eosinophilia. Rarely， transient hematological abnormalities; pseudomembranous colitis， phlebitis. 禁忌: Hypersensitivity to cephalosporins.,,室溫,Adult 750 mg tid IM or IV. Severe infections: 1.5 g tid IV. Children 30-100 mg/kg/day in 3 or 4 divided doses. Neonate 30-100 mg/kg/day in 2 or 3 divided doses.,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,1. 監測體溫、CBC、腎功能、PT值。
ICIP,Ciprofloxacin,Ciproxin 針劑 100mg/50mL,QANB,,適應症: Complicated UTI， bone & joint， complicated intra-abdominal & lower respiratory tract infection. 副作用: Nausea， diarrhea， vomiting， dyspepsia， abdominal pain， flatulence， anorexia， dizziness， headache， tiredness， agitation， trembling. Very rarely， insomnia， peripheral paralgesia， sweating， unsteady gait， convulsions， increase in intracranial pressure， anxiety states， nightmares， confusion， depression， hallucinations， impaired taste & smell， visual disturbances， tinnitus， transitory impairment of hearing， especially at high frequencies， skin reactions. 禁忌: Hypersensitivity to ciprofloxacin or other quinolones. Children， adolescents， pregnancy & lactation.,,室溫,Complicated UTI， bone & joint， complicated intra-abdominal & lower respiratory tract infection 400 mg 12 hrly. Particularly severe， life threatening infections: septicemia， peritonitis， bone & joint infections， recurrent infections in cystic fibrosis 400 mg 8 hrly.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 需避光儲存，光照下(未開瓶)藥效只能維持3天。 2. 監測體溫、CBC，長期使用應監測肝腎功能。
IFUR,Cefuroxime,Furoxime inj 750mg,QANB,,適應症: Infections due to Staphylococci， Streptococci， Pneumococci， Meningococci & other susceptible bacteria. 副作用: Allergic reactions， GI intolerance， superinfection， eosinophilia. Rarely， transient hematological abnormalities; pseudomembranous colitis， phlebitis. 禁忌: Hypersensitivity to cephalosporins.,,室溫,Adult 750 mg tid IM or IV. Severe infections: 1.5 g tid IV. Children(above 3months of age) 50-100 mg/kg/day in 3 or 4 divided doses. Neonate 30-100 mg/kg/day in 2 or 3 divided doses.,,AAP: Maternal medication usually compatible with breastfeeding. Micromedex: Infant risk is minimal. Cefuroxime is excreted in breast milk. Manufacturer recommendations vary; caution is recommended if cefuroxime I.V. is given to a nursing woman and it is recommended to consider discontinuing nursing temporarily during treatment following oral cefuroxime. Nondose-related effects could include modification of bowel flora.,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,AAP: Maternal medication usually compatible with breastfeeding. Micromedex: Infant risk is minimal. Cefuroxime is excreted in breast milk. Manufacturer recommendations vary; caution is recommended if cefuroxime I.V. is given to a nursing woman and it is recommended to consider discontinuing nursing temporarily during treatment following oral cefuroxime. Nondose-related effects could include modification of bowel flora.,,,,,,1. 監測體溫、CBC、腎功能、PT值。 2. IM 給藥：1.5 gm/vial 乾粉以6 mL D/W溶解 IV bolus：1.5 gm/vial 乾粉以至少15 mL相容稀釋液溶解，推注時間至少3 ~ 5分鐘 IV infusion：1.5 gm/vial 乾粉稀釋成50-100 mL，滴注15 ~ 60分鐘
EEAR,Ofloxacin,Earflo otic solution 3mg/mL,TENT,,適應症: Otitis media， otitis externa caused by ofloxacin-susceptible pathogen: Staph， Strep， Proteus sp， Pseudomonas aeruginosa， & haemophilus influenzae. 副作用: Infrequently， earache， superinfection. Dermatologic: Pruritus， Rash Gastrointestinal: Diarrhea， Nausea (up to 3.5% )， Vomiting Neurologic: Dizziness (up to 8% )， Headache (up to 8% )， Insomnia (up to 13% ) Ophthalmic: Burning sensation in eye， Pain in eye 禁忌: Hypersensitivity to quinolones; pregnancy and lactation; prolongation of the QT interval; uncorrected hypokalaemia.,,室溫,Otic/Aural Otic infections Adult: Apply 10 drops of 0.3% solution in the affected ear once daily for 7 days. Lie with the affected ear upwards for 5 min to facilitate penetration into the ear canal. Child: 6 mth-13 yr: 5 drops of 0.3% solution in the affected ear once daily for 7 days. >13 yr: 10 drops of 0.3% solution in the affected ear once daily for 7 days. Lie with the affected ear upwards for 5 min to facilitate penetration into the ear canal.,,,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OFOL,Folinate,Folina 15mg,ZADT,Antidote for folic acid antagonists overdosage. In folinic acid rescue to reduce toxicity of methotrexate. To potentiate cytotoxic effects of fluorouracil in advanced colorectal cancer. Treatment of folate-deficient megaloblastic anaemia.,Untreated vit B12 deficiency. Never give alone or in conjunction with inadequate amounts of hydroxocobalamin; pernicious anaemia & other megaloblastic anaemia where vit B12 is deficient.,Occasional hypersensitivity reactions; rarely pyrexia after inj. GI complaints at high doses. Haematological remissions with simultaneous progression of neurological disturbances.,25℃以下,Methotrexate-rescue (high-dose): 15 mg (~10 mg/m2) orally; start 8-24 hours after beginning methotrexate infusion; continue every 6 hours for 10 doses， until methotrexate level is <0.05 micromolar. Monitor levels of serum creatinine and methotrexate， as well as urine alkalinization. Folate Deficiency: adults: 10-20 mg orally once daily. Children < 12 years: 0.25 mg/kg.day.,無需調整劑量,,需調整劑量,沒有資料,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OBIOT,Biodiastase + Lipase + Newlase,Biotase,ALIM,,適應症:Indigestion 副作用: Hypersensitivity reactions.,,室溫,Adult 2-3 tab tid， children 6-12 years 1/2 adult dose， 3-6 years 1/4 adult dose.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OTED,Fe (III) Hydroxide Polymaltose Complex,Tedalin 100mg Chewable,NUTR,Fe-deficiency anaemia.,Hypersensitivity or intolerance to iron and overloading of iron in the body. Anaemia not caused by iron deficiency. Disturbances in iron utilisation， thalassemia. Patients receiving repeated blood transfusion. Pregnancy (1st trimester).,GI irritation， epigastric pain， stomach cramping， constipation， nausea， vomiting， diarrhoea， dark stools， heart burn， discoloured urine， teeth staining.,25℃以下緊密容器保存,PO dose: 100mg QD-BID,無需調整劑量,[仿單]無相關記載,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]無相關記載,Unknown 沒有資料,[仿單]無相關記載,AC;AC15;PC;PO;WM;,,,,,
EPOL0,Tar + Cade Oil + Coal Tar Soln,Polytar Liquid 1% 150mL (限自費),TDER,,適應症: Seborrhea， psoriasis. Dandruff & itching scalp. 副作用: Skin irritation， rash， mild photosensitivity.,,室溫,Use as scalp cleanser once or twice weekly.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OTRAJ,Linagliptin,Trajenta 5mg,META,Management of type 2 diabetes mellitus (noninsulin dependent， NIDDM) as an adjunct to diet and exercise as monotherapy or in combination with other antidiabetic agents.,Hypersensitivity to linagliptin or any component of the formulation.,>10%: Endocrine & metabolic: Hypoglycemia (combined with metformin/sulfonylurea [15%]， metformin [<1%]， pioglitazone [<1%]; monotherapy [<1%]) Central nervous system: Headache (6%) Endocrine & metabolic: Hyperuricemia (3%)， lipids increased (3%)， triglycerides increased (2%)， weight gain (2%) Neuromuscular & skeletal: Arthralgia (6%)， back pain (6%) Respiratory: Nasopharyngitis (6%)， cough (2%) <1% (Limited to important or life-threatening): Angioedema， hypersensitivity， pancreatitis,30℃以下,5 mg once daily.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
ICET,Cefmetazole,CetaZONE inj 1gm,QANB,,適應症:Treatment and prophylaxis of anaerobic and mixed bacterial infections， gonorrhoea. 副作用:Hypersensitivity reactions; nephrotoxicity; neutropenia; thrombocytopenia; agranulocytosis; bleeding complications related to hypoprothrombinaemia or platelet dysfunction; GI effects; CNS toxicity; superinfection; pain at Inj site (IM); thrombophloebitis (IV infusion); hepatitis; cholestatic jaundice. Potentially Fatal: Pseudomembranous colitis. 禁忌:Hypersensitivity to cephalosporins.,,,(MICREMEDEX) Intravenous route a) Cefmetazole is generally dosed intravenously as 2 grams every 6 to 12 hours for 5 to 14 days， with severe or life-threatening infections requiring 8 grams/day. The drug can also be given as a single 2-gram dose 30 to 90 minutes before procedures as surgical prophylaxis to reduce the incidence of postoperative infections. An alternative regimen in this setting would be 1 gram intravenously 30 to 90 minutes before surgery or after clamping the umbilical cord in cesarean section， with 1 gram again 8 and 16 hours later. If surgery lasts longer than 4 hours， the preoperative dose should be repeated. b) Clinical trials have used daily intravenous doses of cefmetazole that ranged from 1 to 8 grams divided every 6 to 12 hours for urinary tract infections， respiratory tract infections， skin and soft tissue infections， abdominal infections， pelvic inflammatory disease， and surgical prophylaxis. c) Intravenous cefmetazole was given to patients who were undergoing appendectomies by infiltrating the layers of the abdominal wall. Peri-incisional infiltration was effective in preventing wound infections.,無需調整劑量,,需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IV;IVD;IVP;IVPUSH;,IV: 10mL D/W， N/S， D5W,【D5W】可選 。【N/S】可選 。,緩慢注射,建議以30 ~ 90分鐘緩慢滴注,1.仿單並無提及可以IM。
EVIT,Vitamin A,Vita A eye oint,TOPH,,適應症: Superficial diffuse keratitis， exfoliative epithelial keratitis， viral keratitis， vesicular keratitis & other types of keratitis. 副作用: Hypersensitivity reactions.,,室溫,Apply once to several times daily.,,,,安全,,,Compatible 哺乳時可使用,,,,,,,
IAPR,Hydralazine,Aprelazine inj 20mg/1mL,CAVS,,適應症: Treatment of hypertensive emergencies， including those associated with pre-eclampsia & toxaemia of pregnancy. 副作用:Tachycardia， palpitation， flushing， hypotension， anginal symptoms， headache， arthralgia， joint swelling， myalgia， GI disturbances. Rarely， SLE-like syndrome after long-term therapy with doses > 100 mg daily (or less in women & in slow acetylators). 禁忌: Idiopathic SLE & related disorders， severe tachycardia， high output heart failure， myocardial insufficiency due to mechanical obstruction， cor pulmonale， dissecting aortic aneurysm.,,室溫,Adult Initially 5-10 mg by IM or slow IV inj; if necessary， dosage may be repeated after 20-30 mins. Or by continuous IV infusion at an initial dose of 200-300 mcg/min. Maintenance dose: 50-150 mcg/min.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 靜脈注射應緩慢，避免平均動脈壓突然下降。 2. Apresoline不可與葡萄糖注射液混合，因主成分會迅速分解。
IDOPM,Dopamine,DOPmin inj 200mg/5mL,CAVS,,適應症: Correction of poor perfusion， low cardiac output， impending renal failure & shock associated with MI， trauma， endotoxic septicemia， open heart surgery， heart failure. 副作用: Most frequently: ectopic beats， nausea， vomiting， tachycardia， anginal pain， palpitations， dyspnoea， headache， hypotension & vasoconstriction. Other infrequent side effects include aberrant conduction， bradycardia， piloerection， widened QRS complex， azotaemia & hypertension. 禁忌: Phaeochromocytoma; uncorrected hypovolaemia; uncorrected tachyarrhythmia or ventricular fibrillation.,,室溫,Initial flow rate 2-4 mcg/kg body weight/min by IV infusion into medium to large veins. May be increased by 5-10 mcg/kg/min increment up to 20-50 mcg/kg/min if needed.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1.勿加入鹼性藥品
IIVIG,Human Immunoglobulin,Human Immunoglobulin 2.5gm/50mL,HIMM,,適應症:為人類免疫球蛋白製劑(K000215248)(K000215299)(K000672248),,2-8,IV infusion (not exceeding 20 drops/min). Immunoglobulin deficiency: Adult: 0.1-0.15 g/kg; child: 0.15 g/kg; Infant: 0.2 g/kg， (max. 0.4 g/kg); repeated every 3-4 wks. Serious bacterial infections including sepsis: As above， repeated every 1-2 days if needed. Idiopathic thrombocytopenic purpura & Kawasaki disease: 0.4 g/kg/day for 5 consecutive days.,,,,除非治療上需要,,,,,,,,,,
IKA,Triamcinolone,Kenacort-A inj 10mg/mL,HM,,Inflammatory dermatoses.,,,Intra-articular: 2.5-15 mg. Intradermal or intralesional: less than 1 mg/site. IM: 40-80 mg.,,,,除非治療上需要,,,,,,,,,,
IKCL4,Potassium Chloride,20mEq KCl in 5% D/W 500mL,NUTR,,適應症: Hypokalaemia. 副作用: Hyperkalemia， pain or phlebitis at injection site. 禁忌: Hyperkalemia.,,2-8度C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr， with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,IVD;,,,,,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
ILUP,Leuprolide,Leuprolide (Lupron) 5mg/mL， 2.8mL,RACA,,適應症: Palliative treatment of advanced prostatic cancer. 副作用: Hot flushes， anorexia， nausea. 禁忌: Women who are or may become pregnant while receiving the drug.,,2-8℃,1 mg SC as a single dose.,,,,不可使用,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,
INAL,Naloxone,Naloxone inj 0.4mg/1mL,ZADT,Complete or partial reversal of narcotic depression including respiratory depression， induced by opioids including natural & synthetic narcotics & narcotic-antagonist analgesics. Diagnosis of suspected acute opioid overdosage,Hypersensitivity to any component of the formulation.,Hypertension， hypotension， ventricular tachycardia， pulmonary oedema， tremulousness， nausea/vomiting， sweating.,室溫,(Micromedex) Overdose of opiate， known or suspected: (Injection solution) 0.4-2 mg IV， repeat every 2-3 minutes as needed; if no response after 10 mg， reconsider diagnosis of opioid toxicity; may administer IM or SC if IV route is unavailable.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,【D5W】可選 。【N/S】可選 。,IV push: Administer over 30 seconds as undiluted preparation or administer as diluted preparation slow IV push by diluting 0.4 mg (1 mL) ampul with 9 mL of normal saline for a total volume of 10 mL to achieve a concentration of 0.04 mg/mL.,2 mg naloxone以500mL N/S，D5W稀釋為0.004 mg/mL，依病人臨床反應調整給藥速率,1. IV infusion：2 mg naloxone以500 mL N/S 或 5% Dextrose solution稀釋為0.004 mg/mL，依病人臨床反應調整給藥速率。
IPROE,Isoproterenol,Proternol inj 0.2mg/1mL(Isoproterenol),CAVS,,適應症:心律不整(B012225209) CI: Tachyarrhythmias; tachycardia or heart block caused by digitalis intoxication; ventricular arrhythmias which require inotropic therapy; angina pectoris.,,RT,IM or SC: 0.2 mg. IV: 0.01-0.06 mg. IV infusion: 1-2 mg in 500 ml of 5% dextose， at a rate of 0.5-5 mcg/min or adjusted as needed.,,,,可能安全,,,,,,,,,,
OSEV,Amlodipine + Olmesartan,Sevikar 5/20mg(小劑量),CAVS,Treatment of HTN. Not indicated for the initial therapy.,Pregnancy.,Edema， dizziness， flushing， palpitation， somnolence.,25℃以下,HTN initial: 1 tablet QD， after 2 weeks may titrate up to 2 tablet QD (maximum 10/40mg),需調整劑量,[仿單] 目前並不確定SevikarR的amlodipine或olmesartanmedoxomil成份是否會分泌至人類乳汁，但已知泌乳大鼠的乳汁中會出現低濃度olmesartan。由於此藥物可能 導致接受哺乳的嬰兒產生不良反應，應考慮藥物對母親的重要性，決定是否停止哺乳或停用藥物。 Amlodipine: Limited Human Data—Probably Compatible Olmesartan: No Human Data—Probably Compatible,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,[仿單] 懷孕分級D，警語：胎兒毒性，若發現懷孕，應立即停用SevikarR，服用直接作用於腎素－血管收縮素系統的藥物，可能傷害發育中胎兒甚至 造成死亡。 Amlodipine: Limited Human Data—Animal Data Suggest Moderate Risk Olmesartan: Human Data Suggest Risk in 2nd and 3rd Trimesters,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 目前並不確定SevikarR的amlodipine或olmesartanmedoxomil成份是否會分泌至人類乳汁，但已知泌乳大鼠的乳汁中會出現低濃度olmesartan。由於此藥物可能 導致接受哺乳的嬰兒產生不良反應，應考慮藥物對母親的重要性，決定是否停止哺乳或停用藥物。 Amlodipine: Limited Human Data—Probably Compatible Olmesartan: No Human Data—Probably Compatible,AC;AC15;PC;PO;WM;,,,,,
ITEST,Testosterone,Testosterone inj 250mg/1mL,HM,,適應症:男性更年期障礙 女性停經後癌症之治療(A000138209)(A003006209),,RT,IM inj. only， Female: 250mg IM every 2 wks; cystic mastopathy: 100mg between the 15th and 18th days of the cycle. Male: 250mg IM every 2-3 wks; maintenance， 250mg IM every 3-6wks. Climacteric: 50-100mg q2-3 wks， repeated cures of 4-8 wks's at 4 wk's intervals are recommended.,,,,不可使用,,,,,,,,,,
EFLAR,Fluorometholone,Flarex 0.1%， 5mL,TOPH,,適應症: Treatment of steroid-responsive inflammation of the palpebral & bulbar conjunctiva， cornea & anterior segment of the eye. 副作用: Glaucoma with optic nerve damage， visual acuity & field defects， cataract formation， secondary ocular infection following suppression of host response & perforation of the globe may occur. 禁忌: Acute superficial herpes simplex keratitis， varicella & most viral diseases of the cornea & conjunctiva; TB; fungal diseases; acute purulent infections.,,室溫,Initially 2 drops 2 hrly for 1st 1-2 days， then 1-2 drops qid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EFUC,Fusidic Acid,Fucidin cream 2%， 5gm,TDER,,適應症: Skin infections caused by Staph， Strep & other organisms sensitive to fusidic acid. 副作用: Hypersensitivity (rare).,,室溫,Apply bid-tid.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,EXT;,,,,,
EGIN,Carbomer,Ginpol eye gel 10gm,TOPH,,適應症: Substitute for lacrimal fluid in deficiency of tear production or dry eye. 副作用: Transient blurring in vision. 禁忌: Hypersensitivity to cetrimide.,,室溫,Instill 1 drop into conjunctival sac 3-5 times daily or more frequently during the day & before retiring at night.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,OD;OL;OU;,,,,,
EICH,Doxepin,Ichderm cream 50mg/gm， 15gm,TDER,Temporary relief of moderate itch associated with eczematous dermatitis.,Hypersensitivity to any component of the formulation.,Local skin irritation， drowsiness. Gastrointestinal: Constipation (oral， 4% )， Nausea (topical， less than 1%; oral， 2% )， Xerostomia (topical， 1%; oral， 15% ) Neurologic: Dizziness (topical， 1% to 10% )， Somnolence (topical， 22%; oral， 6% to 9% ) Renal: Urinary retention Respiratory: Upper respiratory infection (oral， 2% to 4%),25℃以下,Apply QID,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,EXT;,,,,,
EJOY,Aluminum Hydroxychloride,Joyla liquid 30mL,TDER,,適應症: Hyperhidrosis.,,室溫,Apply to skin when necessary.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OAPR1,Hydralazine,Apresoline 10mg,CAVS,,適應症: Hypertension，為周邊血管擴張劑(A030879100) 副作用:Tachycardia， palpitation， anginal symptoms， flushing， headache， dizziness， nasal congestion， GI disturbances. 禁忌:Idiopathic SLE & related diseases. Severe tachycardia & heart failure with high cardiac output. Myocardial insufficiency due to mechanical obstruction. Right ventricular heart failure due to pulmonary HTN. Dissecting aortic aneurysm.,,室溫,Adult: 10-50 mg qid (max. dose 200-300 mg/day). Child: 0.75 mg/kg/day in 4 divided doses， up to 7.5 mg/kg/day.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OLOP,Loperamide,Loperam 2mg (Loperamide),ALIM,Acute & chronic diarrhea,Diarrhea associated with organisms which penetrate the mucosa; pseudomembranous colitis or diarrhea associated with broad spectrum antibiotics.,Flatulence， constipation， nausea， abdominal pain， dry mouth; giddiness.,室溫藥品，仿單無特別指示儲存溫度條件,Oral Adult: Initially， 4 mg followed by 2 mg after each loose stool. Maximum dose: 16 mg daily. Child: Initially， 2 mg followed by 2 mg after each loose stool. Maximum dose: 8-12 mg daily.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
ISTR,Streptomycin,Streptomycin inj 1gm,QANB,,適應症: Tuberculosis. Bacterial endocarditis. Plague， tularemia & brucellosis. Mycetoma & Whipple's disease. 副作用: Vestibular & auditory damage， nephrotoxicity， paraesthesia of face， rash， fever， urticaria， angioneurotic edema， eosinophilia. 禁忌: Hypersensitivity.,,室溫,TB Adult 15-20 mg/kg body weight/day. Max: 1 g/day. Adult > 40 years & < 50 kg Max: 500-750 mg/day. May be given as part of intermittent regimen 2 or 3 times weekly. Children 15-20 mg/kg/day. Max: 1 g/day. Non-tuberculous infections Adult 1-2 g/day in divided doses. Children Up to 40 mg/kg daily in divided doses. Max: 1 g/day. Course of treatment (except TB) should be limited to 7-14 days.,,,,盡量避免,,,Compatible 哺乳時可使用,,,,,,,1. 監測體溫、CBC、腎功能、聽覺功能。
ITRA2,Atracurium Besylate,Tracrium inj 25mg /2.5mL,CNEU,,適應症: Highly selective， nondepolarizing muscle relaxant. As an adjunct to general anaesth to enable tracheal intubation， to relax skeletal muscles during surgery or controlled ventilation & to facilitate control of mechanical ventilation in ICU patient. 副作用: Skin flushing， mild transient hypotension， bronchospasm. Rarely， anaphylactoid reactions. Dermatologic: Flushing (5%) 禁忌: Hypersensitivity to atracurium， cisatracurium or benzenesulfonic acid.,,2-8℃,Adult & children > 1 month 0.3-0.6 mg/kg. Endotracheal intubation 0.5 to 0.6 mg/kg IV. Supplementary dosage: 0.1-0.2 mg/kg. Maintenance: 0.3-0.6 mg/kg/hr by IV infusion. ICU patient initial dose: 0.3-0.6 mg/kg， maintenance rate: 0.65-0.78 mg/kg/hr.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,,1.未稀釋亦可使用
IVAG,Neostigmine Methylsulfate,Vagostin inj 0.5mg/1mL,CNEU,Paralytic ileus， myasthenia gravis， vascular spasm， ocular myasthenia gravis.,Mechanical GI or urinary tract obstruction， peritonitis.,Increased salivation & sweating， nausea & vomiting， abdominal cramps， diarrhea， allergic reactions， miosis， increased bronchial secretions， bradycardia， bronchospasm， weakness， muscle cramps， fasciculation， hypotension.,室溫藥品，仿單無特別指示儲存溫度條件,Adult: 0.5 mg IM QD， may adjust dosage to 1.5mg QD or 0.5mg several times a day， according to patient's age and symptom. Paralytic ileus: 0.5 mg Q4-5H. Ophthalmology: 0.25-1 mg SC.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;SC;,,,,,
IVENA,Diphenhydramine,Venan inj 30mg/1mL,HIMM,,適應症: Urticaria， dermatologic disease， pruritus， acute rhinitis & hay fever. 副作用: Drowsiness， dizziness， antimuscarinic effects. CV & CNS effects. Muscular weakness. Allergic reaction. Blood disorders. 禁忌: Acute asthmatic attack. Premature infants.,,室溫,1 mL tid. Adult: 10-50mg， (max. 400 mg/day). Child: 5 mg/kg/day or 150 mg/Kg/day， (max. 300mg/day).,,Diphenhydramine is excreted into breast milk; drowsiness has been reported in a breast-feeding infant. Premature infants and newborns have a higher risk of intolerance to antihistamines. Breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Diphenhydramine is excreted into breast milk; drowsiness has been reported in a breast-feeding infant. Premature infants and newborns have a higher risk of intolerance to antihistamines. Breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.,,,,,,102.02.25 衛生署公告 (一)1. 「嬰幼兒(premature infants及neonate)不建議使用」 2. 「老人宜以最低有效起始劑量開始治療」 3.「腎功能不全者應延長給藥間隔；輕度(GFR>50 mL/min)：間隔6小時；中度(GFR 10-50 mL/min)：間隔6-12小時；重度(GFR<10 mL/min)：間隔12-18小時」。 (二) 可供靜脈注射劑型之藥品，每次diphenhydramine之劑量以10-50mg為宜，且其注射速率不宜超過25mg/min。
YAMO,美甲組 for Amocoat,美甲組 for Amocoat,ZOTH,,,,室溫藥品，仿單無特別指示儲存溫度條件,,無需調整劑量,,無需調整劑量,,,,,,TOPI;,,,,,
IPNS1,Sodium Chloride,PREFILLED 0.9% Saline 10mL,NUTR,,,,,,,,,,,,,,,,,,,
IPROG,Progesterone,Progesterone inj 25mg/1mL,HM,Amenorrhoea; Dysfunctional uterine bleeding，Recurrent miscarriage w/ progesterone deficiency，,Hypersensitivity; thrombophloebitis; cerebral apoplexy; severe hepatic impairment; undiagnosed vag bleeding， incomplete abortion， hormone-dependent carcinoma， as a diagnostic test for pregnancy; pregnancy. History or current high risk of arterial disease.,GI disturbances， appetite/wt change， fluid retention， oedema， acne， skin rash， urticaria， depression， headache， fever， fatigue， breast changes， hirsutism， changes in libido， altered menstrual cycles or irregular menstrual bleeding (rare). Gastrointestinal: Abdominal pain (oral， 10% to 20%; vaginal gel， 5% to 12%; vaginal insert， 12% )， Constipation (vaginal gel， 27%; vaginal insert， 2% to 3% )， Nausea (oral， 8%; vaginal gel， 6% to 22%; vaginal insert; 7% to 8% ) Immunologic: Viral disease (oral， 7% to 12% ) Musculoskeletal: Cramp (vaginal gel， 15% to 26% ) Neurologic: Dizziness (oral， 15% to 24%; vaginal gel， 5% )， Headache (oral， 10% to 31%; vaginal gel， 13% to 19%， vaginal insert， 3% to 4% )， Sleep disorder (vaginal gel， 18% )， Somnolence (vaginal gel， 27% ) Psychiatric: Depression (oral， 19%; vaginal gel， 11% to 19% )， Feeling nervous (vaginal gel， 16% )， Mood swings (oral， 6%; vaginal gel， 22% to 23% ) Reproductive: Breast tenderness (oral， 16% to 27% )， Large breast (vaginal gel， 40% )， Pain， Post-oocyte retrieval (vaginal insert， 25% to 28% )， Pain of breast (oral， 6% to 16%; vaginal gel， 13% )， Perineal pain (vaginal gel， 17% ) Other: Fatigue (oral， 8% to 9%; vaginal gel， 21% to 22%; vaginal insert， 2% to 3% ),室溫藥品，仿單無特別指示儲存溫度條件,Pain and bleeding of habitual abortion: 10-25mg daily， then 10mg twice a week IM.Uterine bleeding in middle age and menopause: 5-10mg daily IM.,無需調整劑量,Breastfeeding recommendations vary by manufacturer; the decision to breastfeed during therapy should consider the risk of infant exposure， the benefits of breastfeeding to the infant， and the benefits of treatment to the mother. (UpToDate)2021/0125,無需調整劑量,可能安全,Uknown 沒有資料,It may also be used to prevent spontaneous preterm birth in women with a singleton pregnancy who have a cervix <20 mm before or at 24 weeks' gestation. Use is not recommended as an intervention for women with multiple gestations (ACOG 2012). (UpToDate)2021/0125,Unknown 沒有資料,Breastfeeding recommendations vary by manufacturer; the decision to breastfeed during therapy should consider the risk of infant exposure， the benefits of breastfeeding to the infant， and the benefits of treatment to the mother. (UpToDate)2021/0125,IM;,,,,,
OBLA,Flavoxate,Bladderon 200mg,SGU,,Symptoms relief of prostatitis， urinary frequency.,,,100-200 mg tid-qid， may be reduced when symptoms improve.,,,,可能安全,,,,,,,,,,
OCAR2,Activated Charcoal,Carbomix 2gm/pk,ZADT,,適應症: 為活性碳，解毒之用(B0215491CC) Emergency treatment of acute oral poisoning or drug overdose. Also binding of bacteriotoxins & other diarrhea-inducing substances in the GIT. 副作用: Diarrhea or constipation (occasionally). 禁忌: Corrosive substance intoxication.,,,Acute poisoning -Adult 50-100 g in susp immediately followed by 20 g 4-6 hrly for a few days. -Children 1 g/kg body wt. Diarrhea -Adult 1 sachet/time several times daily. -Children 1 sachet in several divided doses.,,,,,,,,,,,,,,
OCOMB,Vitamin B Complex,Combeplex S.C. Tab,NUTR,,I: Prevention & treatment of vit. B deficiency.,,RT,Oral: 1 tab tid.,,,,安全,,,,,,,,,,
ODAI,Gliclazide,Dail 80mg,META,,適應症:為降血糖藥，宜飯前15分鐘服用(A034350100),,RT,Initial 40-80mg/day then 320mg/day qd or 160 mg bid， use before meal.,,,,除非治療上需要,,,,,,,,,,
ODEP5,Valproate Sodium,DEPAKINE 500mg,CNEU,Treatment of generalized or partial epilepsy; mania.,Acute or chronic hepatitis， personal or family history of severe hepatitis， hepatic porphyria. Combination with mefloquine.,GI disturbances， ataxia， tremor， increased appetite and weight gain， edema， thrombocytopenia， inhibition of platelet aggregation; impaired hepatic function， rashes， sedation. Rarely， pancreatitis (discontinue). Cardiovascular: Peripheral edema (3% to 8% ) Dermatologic: Alopecia (6% to 24% )， Rash (6% ) Endocrine metabolic: Increased appetite (6% )， Weight increased (4% to 9% ) Gastrointestinal: Abdominal pain (9% to 23% )， Constipation (5% )， Diarrhea (12% to 23% )， Indigestion (8% to 13% )， Loss of appetite (4% to 12% )， Nausea (22% to 48% )， Vomiting (11% to 27% ) Hematologic: Ecchymosis (4% to 5% ) Musculoskeletal: Asthenia (10% to 27% )， Backache (8% ) Neurologic: Amnesia (4% to 7% )， Ataxia (8% )， Dizziness (12% to 25% )， Headache (5% to 31% )， Insomnia (9% to 15% )， Somnolence (17% to 30% )， Tremor (9% to 57% ) Ophthalmic: Amblyopia， Blurred vision， Diplopia (16% )， Nystagmus (1% to 8% ) Otic: Tinnitus (1% to 7% ) Psychiatric: Depression (4% to 5% )， Disturbance in thinking (6% )， Feeling nervous (7% to 11% )， Mood swings (6% ) Respiratory: Bronchitis (5% )， Dyspnea (5% )， Pharyngitis (8% )， Respiratory tract infection (12% to 20% )， Rhinitis (5% ) Other: Fever (2% )， Influenza (12% ),低於25℃,Epilepsy: Adult and children > 17 kg: Initially 10-15 mg/kg/day ，then increase to the appropriate dose: 20-30 mg/kg/day in 1-2 divided doses. When epilepsy is not controlled or side effects are suspected， the blood concentration of valproic acid can be used for clinical follow-up. The effective therapeutic concentration is usually between 40-100 mg/L (280 to 700 μmol/L). Mania: Initially 600 mg daily increasing by 200 mg/day every 3 days to reach desired clinical effect. Usual dose range: 1000-2000 mg/day (20-30 mg/kg/day) Dose may be further increased to maximum 2500 mg/day if necessary.,需調整劑量,[仿單]valproate 分泌到乳汁中的量很低，濃度大約是母體血清濃度的 1%至 10%之間。 根據文獻和臨床經驗，若要哺乳，需考慮本品藥物安全性，特別是血液相關的疾病。 然而，懷孕期間暴露於 sodium valproate 的幼兒，可能降低語言能力，建議治療時不要授乳。,無需調整劑量,盡量避免,Human (and animal) data suggest risk,[仿單]懷孕期間禁止使用 valproate 治療躁鬱症。 除非癲癇治療沒有合適的替代藥物，否則懷孕期間禁止使用 valproate 治療癲癇。 除非能確實執行避孕計畫，否則具生育能力的婦女禁用 valproate。 使用本品可能會導致重大的先天性畸形，特別是神經管畸形（如：脊柱裂， spina bifida）， 且可能會導致胎兒智商下降，故本品應僅限用於無法以其他藥物控制症狀， 或有其它原因無法使用其他藥物治療之孕婦。 考量使用本品可能會有使孩童智商降低、發生神經管缺陷及其他嚴重先天性畸形之風險， 且該等風險可能發生於懷孕早期，故除非必要使用，否則不應使用於具生育能力或有懷孕可能之婦女。 避孕計畫： Valproate有高度的致畸性，且胎兒在子宮中曝露於valproate有導致先天性畸形和神經發育缺陷的高 度風險。 本品禁用於以下情況： 治療癲癇 • 在懷孕狀態下，除非沒有適合的替代療法 • 具有生育能力的婦女，除非能確實履行避孕計畫 治療躁鬱症 • 在懷孕狀態下 • 具有生育能力的婦女，除非能確實履行避孕計畫 避孕計畫條件： 處方醫師應確保 • 依病人個別狀況進行評估並與之討論。這是為了保證病人能確實配合並了解治療選擇及其風險， 以及為了降低風險而採取的措施。 • 所有女性病人都應針對懷孕的可能性進行評估。 • 病人應了解並認知先天性畸形和神經發育缺陷的風險，包括胎兒在子宮中曝露於valproate的風險程度。 • 病人應了解，治療前及治療期間(必要時)必須進行懷孕檢測。 • 應告訴病人必須避孕，且病人在整個valproate治療期間必須不間斷地採取有效的避孕措施 • 病人應了解，讓有癲癇或躁鬱症治療經驗的專科醫師定期(至少每年一次)評估治療結果有其必要性。 • 女性病人應了解，當其計畫懷孕時，應盡快諮詢醫師，以確保能及時討論並在懷孕前及停止避孕前更換治療藥物。 • 病人應了解，當發現懷孕時應緊急通知醫師。 • 病人已收到病人用藥指南。 • 女性病人已確認了解，使用valproate之相關風險和應注意事項 (年度風險確認表)。 這些條件亦適用於目前無性行為的婦女，除非處方醫師充分之理由認為其無懷孕風險。 藥師或其他醫療專業人員應確保 • 每次調配valproate時都有交付病人卡，讓病人了解其內容。 • 告知病人當計畫懷孕或疑似懷孕時，valproate不應擅自停藥，應立刻連絡專科醫師。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]valproate 分泌到乳汁中的量很低，濃度大約是母體血清濃度的 1%至 10%之間。 根據文獻和臨床經驗，若要哺乳，需考慮本品藥物安全性，特別是血液相關的疾病。 然而，懷孕期間暴露於 sodium valproate 的幼兒，可能降低語言能力，建議治療時不要授乳。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠應整錠吞服，不可咬碎。院內備有同成份藥水Depakin solution可供無法吞服病患使用。
ODIZ5,Diazepam,Diazepam 5mg(VALIUM 5mg),CNEU,,Anxiety， acute alcohol withdrawal， anticonvulsant.,,,Adult: Antianxiety: 2-10 mg bid-qid. Sedative-hypnotic (acute alcohol withdrawal): 10 mg tid-qid during the first 24 hrs， then 5 mg tid-qid as needed. Anticonvulsant and skeletal muscle relaxant: 2-10 mg bid-qid. Child 6 months of age and over: 0.04-0.2 mg/kg tid-qid.,,,,盡量避免,,,,,,,,,,
OELT,Levothyroxine,Eltroxin 50mcg,META,Hypothyroidism.,Hypersensitivity to the active substance or to any of the excipients. Thyrotoxicosis. Acute myocardial infarction， Acute myocarditis， Acute pancarditis.,Following excessive dosage: Anginal pain， cardiac arrhythmias， palpitation & cramps in skeletal muscle， tachycardia， diarrhoea， vomiting， tremors， restlessness， excitability， insomnia， headache， flushing， sweating， excessive weight loss & muscular weakness,勿超過室溫25℃,Adult Initially 50-100 mcg daily， adjusted 4-6 weekly by 50 mcg until normal metabolism is maintained. This may require doses of 100-200 mcg daily. Adult >50 years <50 mcg/day， with cardiac disease 25 mcg/day or 50 mcg on alternate days， may be increased by 25 mcg at intervals of 4 week. Congenital hypothyroidism Infant Initially 25 mcg， increase by 25 mcg 2-4 weekly until mild toxic symptoms appear. Juvenile myxoedema Children >1 year 2.5-5 mcg/kg/day.,無需調整劑量,[仿單]分泌到乳汁的甲狀腺素(levothyroxine)濃度很低，但足以干擾新生兒甲狀腺機能不足症的篩檢。,無需調整劑量,安全,Compatible,[仿單]已有許多的孕婦及正值生育年齡的婦女服用過ELTROXIN；到目前為止，在懷孕生產過程中並未發現任何明確形式的干擾。然而，母親甲狀腺機能低落或亢進，可能對胎兒出生或健康有不利的影響。,Compatible 哺乳時可使用,[仿單]分泌到乳汁的甲狀腺素(levothyroxine)濃度很低，但足以干擾新生兒甲狀腺機能不足症的篩檢。,AC;PO;,,,,,
OFLUN,Flunarizine,Flunazon 5mg,CAVS,,適應症: Migraine prophylaxis; Prophylaxis of peripheral and cerebrovascular disorders; Prophylaxis of vertigo and vestibular disorders. 副作用: Drowsiness. Rarely wt gain， headache， depression， gastric pain， dry mouth， insomnia， extrapyramidal reactions， galactorrhoea. 禁忌: Pregnancy， lactation， GI or urinary tract obstruction， acute porphyrias.,,室溫,5-10 mg/day at bedtime.,,,,沒有資料,,,,,,,,,,
IANEG,Metronidazole,Anegyn inj 500mg/100mL,QANB,,適應症: Infections with anaerobic causative agents. Infections of the GIT， after colon surgery， in peritonitis， purulent diseases of the pelvic cavity， infections of the female genital tract as well as puerperal fever. 副作用: GI disturbances， somnolence， vertigo， headache， ataxia， darkening of urine， itch， cutaneous eruption， peripheral neuropathy. Gastrointestinal: Abdominal discomfort (7%)， Loss of appetite， Metallic taste， Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )， Headache (tablets， 15% to 18%; vaginal gel， 5% )， Peripheral neuropathy Reproductive: Candida infection of genital region， Symptomatic cervicitis/vaginitis (10%)， Vaginal discharge (12%) Other: Drug interaction with alcohol， Disulfiram-like reaction 禁忌: Hypersensitivity. Blood dyscrasias.,,室溫,Anaerobic infections: Max. 1 g/dose， 4 g/day. Oral: 7.5 mg/kg q6h for 7 days or longer. IV infusion only (over 1 hr): 15 mg/kg as a loading dose， then 7.5 mg/kg q6h for 7 days or longer. Amebiasis: oral: Adult: 500-750 mg tid for 10 days. Child: 11.6-16.7 mg/kg tid for 10 days. Trichomoniasis: oral: Adult: 2 g as a single dose; 1 g bid for 1 day; or 250mg tid for 7 days. Child: 5 mg/kg tid for 7 days. Giardiasis: Adult: 2 g qd x 3 days or 250-500 mg tid x 5-7 days. Child: 5 mg/kg tid x 5 days.,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,1. 監測體溫、CBC、血球分化計數，注意心智與神經功能變化。 2. 療程建議不超過10天。
EDUAC,Clindamycin + Benzoyl Peroxide,Duac gel 6gm,TDER,,適應症: Topical treatment of inflammatory acne vulgaris. 副作用: Stinging， burning or redness， peeling. Dermatologic: Dry skin (12% ) 禁忌: Patients suffering or with history of regional enteritis， ulcerative colitis or antibiotic-associated colitis.,,2-8℃,Apply once daily in the evening to the affected areas.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ENAS,Mometasone,Nasonex 50mcg/dose， 140dose nasal spray,TENT,Treatment of seasonal or perennial rhinitis & associated symptoms in adults， adolescents & children > 3 years. Treatment of mild to severe nasal polyps & associated symptoms in adults > 18 years.,Hypersensitivity to any ingredients of Nasonex,Headache， epistaxis， pharyngitis， nasal burning， nasal irritation & nasal ulceration.,25℃以下避開熱源,Allergic rhinitis， Seasonal and perennial adult， 2 sprays/nostril (50 mcg/spray) once daily (total daily dose， 200 mcg) maximum 4 sprays/nostril (50 mcg/spray) once daily (total daily dose， 400 mcg) 2 to 11 Years: Usual dosage: 1 spray (50 mcg/spray) in each nostril once daily (total daily dose， 100 mcg Polyp of the nasal cavity and/or nasal sinus Age >18 Years : 2 sprays/nostril (50 mcg/spray) twice daily (total daily dose， 400 mcg); some patients may respond to 2 sprays/nostril once daily.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IN;,,,,,
ESIN,Sulfamethoxazole,Sinomin oph soln 4%， 15mL,TOPH,,適應症: Trachoma or inclusion conjunctivitis. 副作用: Conjunctival or corneal scarring may occur.,,室溫,1-2 drop once-tid.,無需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – probably compatible,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ITAX1,Docetaxel,Taxotere inj 1mg(組套用),RACA,,,,,,,,,,,,,,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 稀釋溶液與器具應使用玻璃、聚丙烯(polypropylene)、聚烯(polyolefin)材質，不可使用含PVC塑膠材質。給藥時應使用 polyethylene 材質的輸液套。 3. 配製好的輸注溶液濃度在 0.3 - 0.74 mg/mL，室溫安定性維持 4 小時。使用前應再次目視檢查是否有結晶析出。 4. 注射前應先給予預防過敏的藥物。 5. 監測CBC、肝功能。
IPH1,Epirubicin,Pharmorubicin inj 1mg(組套用),RACA,,,,,,,,,,,,,,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能、尿酸與血中電解質濃度。
IFORM1,Paclitaxel,Formoxol Inj 1mg(組套用),RACA,,,,,,,,,,,,,,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 稀釋溶液與器具應使用玻璃、聚丙烯(polypropylene)、聚烯(polyolefin)材質，不可使用含DEHP的PVC塑膠材質。 3. 配製好的輸注溶液濃度在 0.3 - 1.2 mg/mL，室溫下安定性維持 27小時。 4. 注射前應先給予預防過敏的藥物。輸注開始的第一個小時應監測Vital Sign。 5. 曾使用 Paclitaxel發生心臟傳導異常的病人，之後使用Paclitaxel期間應進行連續心電圖監測。 6. 監測CBC。
IBCO,Vitamin B Complex,B-complex針劑1mL (Combeplex),NUTR,,適應症: Vit B-complex deficiency. 副作用:Nausea， vomiting， abdominal cramps， pruritus， flushing， sensation of heat， faintness， pounding in the head,,室溫,1 mL as a single dose. Max dose: 1-2 mL daily.,無需調整劑量,,無需調整劑量,安全,,,Compatible 哺乳時可使用,,IM;IV;IVD;SC;,,【D5NS】可選 。【D5W】可選 。【N/S】可選 。,,,
IBLE5,Bleomycin,Bleocin inj 5mg,RACA,,適應症:Carcinoma of the skin， head & neck， lung， oesophagus， uterine cervix & thyroid， malignant lymphomas， glioma. 副作用:Severe interstitial pneumonia & pulmonary fibrosis， hypersensitivity， fever， haemorrhage， scleroderma-like changes in skin， anorexia， diarrhea， GI upsets; renal， urinary & neuropsychic disturbances， hypertrophy of venous wall， narrowing of venous lumen & induration around administration site. Phlebalgia with IV administration. Dermatologic: Alopecia (1-10%)， Skin reaction - finding， Erythema， rash， striae， vesiculation， hyperpigmentation， skin tenderness (50%) Endocrine metabolic: Shivering Gastrointestinal: Nausea and vomiting， Stomatitis Psychiatric: Confusion Other: Fever 禁忌:Severe pulmonary， renal or cardiac dysfunction. Hypersensitivity to bleomycin or any component of the formulation.,,,15-30 mg IM or IV 2 times/wk. May be given once a day for consecutive days or once a weeks.,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,【N/S】可選 。,,,1. 勿使用D5W或其他含有dextrose的稀釋液。 2. IM、SQ給藥：15 mg溶於1 mL到 5 mL的NS或注射用水。 3. IV 給藥：15 mg溶於 5 mL的NS，緩慢靜脈注射超過10分鐘。 4. Intrapleural給藥：溶於50 到100 mL 的NS ，經由thoracostomy tube投藥。 5. 監測項目：Pulmonary function tests (total lung volume， forced vital capacity， carbon monoxide diffusion)， renal function， liver function， chest x-ray， temperature initially; check body weight at regular intervals
IDIA,Diazepam,Diazepam(Dianlin) 針劑 10mg/2mL,CNEU,,適應症: Insomnia， anxiety， muscle spasm， status epilepticus. 副作用: Drowsiness & lightheadedness; confusion & ataxia; amnesia; dependence; paradoxical increase in aggression; muscle weakness; headache， vertigo， hypotension， salivation changes， GI disturbances， visual disturbances， dysarthria， tremor， changes in libido， incontinence， urinary retention; thrombophlebitis. Cardiovascular: Hypotension Dermatologic: Rash (3%， rectal gel ) Gastrointestinal: Diarrhea (4%， rectal gel ) Musculoskeletal: Muscle weakness Neurologic: Ataxia， Incoordination (3%， rectal gel )， Somnolence Psychiatric: Euphoria (3%， rectal gel ) Respiratory: Respiratory depression Other: Fatigue 禁忌: Respiratory depression; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment.,,室溫,Adult Acute anxiety 2-5 mg IV， repeated if necessary after 4 hr. The dosage may be increased to 5-10 mg in severe anxiety. Management of agitation associated with acute alcohol withdrawal Initially 10 mg IV， repeated if necessary after>= 4 hr. Pre-op sedation 10 mg IV 1-2 hr before surgery. Facilitation of labour 10-20 mg IM (or IV in extreme excitation) when cervix dilation is 2-5 cm. Painful musculoskeletal conditions & spasticity Initially 5-10 mg IV， repeated after 3-4 hr if necessary. Tetanus Up to 20 mg every 2-8 hr parenterally. Status epilepticus Initially 10-20 mg IV， in the following hr: 20 mg IM or by IV drip infusion,,,,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;IV;IVD;,,,,,1. IM: inject deeply into muscle mass. 2. IV: inject slowly; do not administer faster than 5 mg/min. Do not use small veins for injection; if direct injection is not feasible， may inject through infusion tubing as close as possible to the vein insertion. 3. Do not mix or dilute with other solutions or drugs in syringe or infusion flask.
IFEN,Fentanyl,Fentanyl inj 0.5mg/10mL,CNEU,,適應症: Premed prior to surgery， Adjunct to general anesth induction， Adjunct to regional anesth， Post-operatively . 副作用: Respiratory depression， apnoea， muscle rigidity & bradycardia. 禁忌: Children <2 years， bronchial asthma， respiratory depression & head injury. Patients who received MAOIs within previous 14 days.,,25℃以下避光,Premed 50-100 mcg IM 30-60 mins prior to surgery. Adjunct to general anesth induction 50-100 mcg IV & repeated at 2-3 mins intervals until the desired effect is achieved. Adjunct to regional anesth 50-100 mcg IM or slow IV inj. Post-operatively 50-100 mcg IM repeated in 1-2 hr as needed. Induction & maintenance of anaesth Children 2-12 years 20-30 mcg/10 kg body wt.,無需調整劑量,,無需調整劑量,盡量避免,,,Compatible 哺乳時可使用,,,,,,,
IHAV7,Inactivated Hepatitis A Virus Vaccine,Havrix 720 (小兒A肝疫苗) 0.5mL/dose,HIMM,Active immunisation against infections caused by hepatitis A virus.,Hypersensitivity.,Inj site soreness， mild redness & swelling， headache， malaise， vomiting， fever， nausea & loss of appetite.,2-8℃,Children & adolescents 1-18 years Primary immunisation: A single IM dose. A booster dose at any time between 6 & 12 months after the single dose is recommended in order to ensure long-term protection.,無需調整劑量,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料，絕對需要時才給予。,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料，絕對需要時才給予。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料，絕對需要時才給予。,IM;,,,,,1. 肌肉注射於成人或孩童的三角肌部位，嬰兒則應注射於大腿前側部位。
IINT7,Eptifibatide,Integrilin inj 75mg/100mL,HEMT,,適應症: Unstable angina， Angioplasty 副作用: Bleeding， hypotension; localised Inj site reaction; thrombocytopaenia; back pain; anaphylaxis; GI， intracranial or pulmonary haemorrhage. Cardiovascular: Hypotension Hematologic: Bleeding， Minor (3 -12%) 禁忌: Active bleeding， increased risk of haemorrhage including hemorrhagic disorders， cerebrovascular disorders， history of stroke， uncontrolled hypertension， severe trauma， severe renal impairment， recent major surgery. Lactation.,,2-8 °C,IV Unstable angina 180 mcg/kg followed by 2 mcg/kg/min for up to 72 hr. If percutaneous coronary procedure is performed during therapy， continue infusion for 18-24 hr after procedure， up to a max total of 96 hr. Angioplasty Initial: 180 mcg/kg immediately pre-op， followed by 2 mcg/kg/min. A 2nd dose of 180 mcg/kg should be given 10 mins later. Continue infusion until discharge or up to 18-24 hr. Min treatment duration: 12 hr.,,,,可能安全,,,Hold Breast Feeding 暫停哺乳,,,,,,,
IIRI,Irinotecan,Irino IV infusion 100mg/5mL,RACA,Refractory colorectal malignancies ， 1st line treatment of metastatic colorectal cancer,Known hypersensitivity to irinotecan or any component of the formulation. Coadministraton with azole antifungals (ketoconazole， fluconazole， itraconazole); patients with hereditary fructose intolerance,Neutropenia， anemia， thrombocytopenia; acute diarrhoea， sweating， hypersalivation， abdominal cramps， lachrymation， miosis， weakness; nausea， vomiting， alopecia and skin reactions; cardiovascular toxicity. Potentially Fatal: Fatal sepsis due to myelosuppression; severe， chronic diarrhoea,25℃以下避光,Monotherapy (for previously treated patient): [Colorectal cancer， metastatic] 350 mg/m2 as a single agent infused over 90 minutes once every 3 weeks. [Gastric cancer， metastatic or locally advanced] 150 mg/m2 as a single agent infused over 30-90 minutes on days 1 and 15 of a 4-week treatment cycle. Combination therapy (for treatment naive patients):180 mg/m2 over 90 minutes on days 1， 15， and 29 in combination with infusional leucovorin and bolus/infusion fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin).,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 配製好的輸注溶液濃度在 0.12 - 2.8 mg/mL，室溫安定性維持 12 小時。 3. 監測CBC、肝功能。 4. 注意病人可能出現腹瀉的藥物副作用，尤其是65歲以上的老年人。 若病人注射Irinotecan後發生延遲性腹瀉，應盡快聯絡醫師，給予適當治療。
IFLU1,5-Fluorouracil,Fluorouracil inj 1000mg/20mL,RACA,,適應症: Palliative management of carcinoma of the colon， rectum， breast， stomach & pancreas. 副作用: Stomatitis， esophagopharyngitis， diarrhea， anorexia， nausea， vomiting， enteritis， cramps， abdominal pain & ulceration， glossitis， pharyngitis， leukopenia， alopecia， dermatitis， ocular irritation， central neurotoxicity (acute cerebellar syndrome)， myocardial ischemia & angina. 禁忌: Patients in a poor nutritional state; with depressed bone marrow function or potentially serious infections.,,室溫,IV inj Initial dosage 12 mg/kg once daily (to a max of 800 mg daily) for 4 days. If no toxicity is observed， this may be followed by 6 mg/kg on the 6th， 8th， 10th & 12th days， unless toxicity occurs. Poor risk patients or those in a poor nutritional state 6 mg/kg/day (to a max of 400 mg daily) for 3 days. If no toxicity is observed， 3 mg/kg is given on the 5th， 7th & 9th days， unless toxicity occurs. Maintenance therapy Repeat the dosage of the 1st course every 30 days after the last day of the previous course of treatment. Alternatively， administer a maintenance dose of 10-15 mg/kg/week (to a max of 1 g/week) as a single dose. IV infusion 15 mg/kg/day (to a max of 1 g daily) being infused in 500 mL of 5% dextrose or 0.9% NaCl over 4 hours & repeated on successive days until toxicity occurs or a total of 12-15 g has been given. Continuous infusion may also be used. The course may be repeated after 4-6 weeks.,,,,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、血糖變化 (DM病人)。
IKYT1,Granisetron,Kytron inj 1mg/1mL,CNEU,,適應症: Prevention or treatment of nausea & vomiting induced by cytostatic therapy & radiation. 副作用: Headache， constipation. Gastrointestinal: Constipation (5.4% ) 禁忌: Hypersensitivity to granisetron or related substances.,,,Prevention & treatment of nausea & vomiting due to cytostatic therapy & radiation Adult 3 mg either in 15 mL infusion fluid as IV bolus over not less than 30 seconds or diluted in 20-50 mL infusion fluid & administered over 5 mins. Max dose over 24 hr: 9 mg. Children 10-40 mcg/kg body weight (up to 3 mg) diluted in 10-30 mL infusion fluid & administered over 5 mins. Max dose: 1 additional dose of 40 mcg/kg (up to 3 mg) within 24 hr if necessary. Max: 9 mg/day. For prevention， administration should be completed prior to the start of cytostatic therapy and anesth induction.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVP;IVPUSH;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,推注時間至少 30秒,,
OPOLU,Propylthiouracil,Polupi 50mg (PTU),META,Adjunctive therapy in patients intolerant of methimazole to ameliorate hyperthyroidism symptoms in preparation for surgical treatment or radioactive iodine therapy; treatment of hyperthyroidism in patients intolerant of methimazole and not candidates for surgical/radiotherapy,Hypersensitivity to propylthiouracil or any component of the formulation,Cardiovascular: Periarteritis， vasculitis (ANCA-positive， cutaneous， leukocytoclastic) Central nervous system: Drowsiness， drug fever， fever， headache， neuritis， vertigo Dermatologic: Alopecia， erythema nodosum， exfoliative dermatitis， pruritus， skin pigmentation， skin rash， skin ulcers， urticaria Endocrine & metabolic: Goiter， weight gain Gastrointestinal: Constipation， loss of taste， nausea， sialoadenopathy， splenomegaly， stomach pain， taste perversion， vomiting Hematologic: Agranulocytosis， aplastic anemia， bleeding， granulopenia， hypoprothrombinemia， leukopenia， thrombocytopenia Hepatic: Acute liver failure， cholestatic jaundice， hepatitis Neuromuscular & skeletal: Arthralgia， myalgia， paresthesia Renal: Acute renal failure， glomerulonephritis， nephritis Respiratory: Alveolar hemorrhage， interstitial pneumonitis Miscellaneous: Lymphadenopathy， SLE-like syndrome,25℃以下避光,Adult initial 300 mg/day in 3-4 divided doses (severe condition 400-600 mg/day)， maintenance dose 50-100 mg/day. Children 10-14 years 200-300 mg/day， 5-9 years 100- 200 mg/day in 2-4 divided doses， maintenance dose 50-100 mg/day in 1-2 divided doses. Pregnancy initial 150-300 mg/day in 3-4 divided doses， maintenance dose 50-100 mg/day.,無需調整劑量,,無需調整劑量,盡量避免,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OCTC1,Levonorgestrel+Ethinyl Estradiol 0.15/0.03mg,家計1號口服避孕藥(28's),HM,,適應症: Oral Contraceptives 副作用: Breast tenderness， pain， secretion; headache; migraine; changes in libido; depressive moods; contact lens intolerance; nausea; vomiting; changes in vaginal secretion; various skin disorders; fluid retention; change in body weight; hypersensitivity reaction. Rarely， benign or malignant liver tumors which may lead to life-threatening intra-abdominal hemorrhage have been observed. 禁忌: Venous or arterial thromboembolic events including MI & CVA. Prodromi of thrombosis (transient ischemic attack， angina pectoris)， diabetes mellitus with vascular involvement. Severe or multiple risk factors for venous or arterial thrombosis. Severe hepatic disease， benign or malignant liver tumours. Malignant conditions of the genital organs or breasts， if sex steroid-influenced. Undiagnosed vag bleeding. Pregnancy.,,室溫,1 tab daily for 28 consecutive days. Levonorgestrel 0.15mg + Ethinyl estradiol 0.03mg x 21 顆、不含藥 x 7錠 (依包裝順序每日服用1顆),,,,不可使用,,,Compatible 哺乳時可使用,,,,,,,
EBAAG,Boric Acid + Alcohol Glycerin,BAAG soln 20mL,TENT,,適應症: Chronic otitis media， mastoidectomy.,,室溫,Apply topically as directed.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EPRE1,Conjugated Estrogen,Premarin Vaginal Cream 14gm,SGU,Atrophic vaginitis. Post-menopausal atrophic urethritis.,Known or suspected breast cancer， estrogen-dependent neoplasia， active thromboembolic disease， undiagnosed abnormal genital bleeding. Pregnancy.,Rarely nausea， vomiting. Breakthrough bleeding， spotting， change in menstrual flow， amenorrhea. Breast tenderness， enlargement， secretion. GI effects， cholestatic jaundice. Chloasma or melasma. Steepening of the corneal curvature; intolerance to contact lenses. Headache， migraine， dizziness; chorea. Wt changes; edema; changes in libido. Cardiovascular: Edema， Vasodilatation (vaginal cream， 21 days on/7 off regimen， 3.5%; 2 times/wk regimen， 5% ) Dermatologic: Chloasma， Hirsutism， Injection site reaction， Pruritus (5% ) Endocrine metabolic: Weight change finding Gastrointestinal: Abdominal pain (vaginal cream， 21 days on/7 off regimen， 7.7%; 2 times/wk regimen， 6.4% )， Bloating symptom， Diarrhea (vaginal cream， 21 days on/7 off regimen， 2.8%; 2 times/wk regimen， 7.1% )， Flatulence (7% )， Nausea (oral， 9% ; vaginal cream， 21 days on/7 off regimen， 3.5%; 2 times/wk regimen， 2.1% )， Stomach cramps， Vomiting Musculoskeletal: Backache (vaginal cream， 21 days on/7 off regimen， 4.9%; 2 times/wk regimen， 9.3% )， Leg cramp Neurologic: Asthenia (vaginal cream， 21 days on/7 off regimen， 5.6%; 2 times/wk regimen， 1.4% )， Headache (vaginal cream， 21 days on/7 off regimen， 11.2%; 2 times/wk regimen， 17.9% )， Migraine Psychiatric: Depression， Disturbance in mood Reproductive: Disorder of menstruation， Pain of breast (oral， 12% ; vaginal cream， 21 days on/7 off regimen， 5.6%; 2 times/wk regimen， 2.9% )， Swelling of breast， Vaginitis (vaginal cream， 21 days on/7 off regimen， 5.6%; 2 times/wk regimen， 5% )， Withdrawal bleeding Respiratory: Increasing frequency of cough (vaginal cream， 21 days on/7 off regimen， 0%; 2 times/wk regimen， 5% )， Pharyngitis (vaginal cream， 21 days on/7 off regimen， 2.1%; 2 times/wk regimen， 5% ) Other: Accidental injury (vaginal cream， 21 days on/7 off regimen， 2.8%; 2 times/wk regimen， 6.4% )， Disorder of skin appendage (vaginal cream， 21 days on/7 off regimen， 8.4%; 2 times/wk regimen， 11.4% )， Infectious disease (vaginal cream， 21 days on/7 off regimen， 4.9%; 2 times/wk regimen， 11.4% )， Pain (vaginal cream， 21 days on/7 off regimen， 7%; 2 times/wk regimen， 2.9% ),20 -25℃,Intravaginally or topically， 0.5-2 g daily depending on severity of condition. the maximum dose: 4 g/day. Cyclic administration (3 weeks on and 1 week off) should be used.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;VAG;,,,,,
EBUT,Butorphanol,Butaro Nasal Spray 10mg/mL,CNEU,Management of pain when the use of an opioid analgesic is appropriate.,Hypersensitivity to Butorphanol， benzenthonium chloride， or any component of the formulation.,Common: Nausea/vomiting， Dizziness (19-54%)， Insomnia (11%)， Sedated (30-40%)， Somnolence (43-88%)， Nasal congestion， Long-term use of intranasal product (13%) Serious: Respiratory depression,25℃以下儲存,Initially 1 mg (1 spray in 1 nostril); if adequate pain relief is not achieved within 60-90 mins， an additional 1 mg dose may be given; may repeat initial dose sequence in 3-4 hr as required after the 2nd dose of the sequence. Alternatively， an initial dose of 2 mg (1 spray in each nostril) may be used in patients who will be able to remain recumbent in the event drowsiness or dizziness occurs; additional 2 mg doses should not be given for 3-4 hr.,需調整劑量,[仿單] 使用butorphanol tartrate後在母乳中可檢測出butorphanol。 新生兒所接受的量在臨床上並不顯著 (推測為4μg/L milk，其母親接受肌肉注射2mg，一日四次)。 雖然沒有關於哺乳母親使用butorphanol NS的臨床報告，但是可預測的是， butorphanol應會以近乎相同的量排至母乳中。,需調整劑量,沒有資料,Human data suggest risk in 3 rd trimester,[仿單] 在老鼠及兔子的器官生成期生殖實驗顯示，butorphanol並無致畸胎的可能性。 然而，對懷孕大鼠施予皮下注射1mg/kg(5.9 mg/m2) butorphanol會造成較高的死產率。 經口給與30mg/kg(360 mg/m2)及60mg/kg(720 mg/m2)的butorphanol會使得兔子有較高的著床後損傷率。 目前對於butorphanol tartrate 使用於懷孕37周前的婦女並無明確的研究。 因此唯有當用藥好處多於新生兒可能發生之潛在風險之時才可施予。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 使用butorphanol tartrate後在母乳中可檢測出butorphanol。 新生兒所接受的量在臨床上並不顯著 (推測為4μg/L milk，其母親接受肌肉注射2mg，一日四次)。 雖然沒有關於哺乳母親使用butorphanol NS的臨床報告，但是可預測的是， butorphanol應會以近乎相同的量排至母乳中。,IN;,,,,,
OURI,Silodosin,Urief 4mg,SGU,,適應症:Treatment of signs and symptoms of benign prostatic hyperplasia (BPH). 副作用:Drowsiness， postural hypotension， syncope， asthenia， depression， headache， dry mouth， GI disturbances， edema， blurred vision， rhinitis， erectile disorders， tachycardia， palpitation， hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy. 禁忌:Severe hepatic impairment; severe renal insufficiency.,,室溫,Oral: 4 mg bid after meal.,需調整劑量,,需調整劑量,可能安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,
YEUR,Silicone Gel,Eurogel Plus 20gm,TDER,,,,室溫藥品，仿單無特別指示儲存溫度條件,,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,EXT;SKIN;TOPI;,,,,,
EBIA5,Povidone-iodine,Povidone-iodine soln 500mL,TDER,,適應症: Post-op infections， bacterial or fungal skin infections. surgical scrub Antiseptic cleanser for pre-op scrubbing & washing by surgeons & theatre staff， & pre-op preparation of patients' skin. 副作用: Local irritation (discontinue).,,室溫,Aqueous soln As directed. Surgical disinfection Use 5 mL undiluted & allow to work for 5 mins， rinse off & repeat. Pre-op antiseptic skin cleanser Use undiluted.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OTRAD,Labetalol,Trandate 200mg,CAVS,Mild to severe hypertension， hypertension in pregnancy， angina pectoris with coexisting hypertension.,2nd or 3rd degree heart block， cardiogenic shock， severe and prolonged hypotension or severe bradycardia. Hypertensive episodes after acute MI when peripheral vasoconstriction suggests low cardiac output.,Pronounced postural hypotension， nasal congestion. Rarely hypersensitivity， rash， pruritus， angioedema and dyspnea; raised liver function tests， jaundice， hepatitis and hepatitis necrosis; bradycardia， heart block. Cardiovascular: Orthostatic hypotension (1%， oral ; 58%， IV ) Dermatologic: Has tingling sensation (7% .) Gastrointestinal: Nausea (14% ) Neurologic: Dizziness (9% to 20% ) Respiratory: Nasal congestion (3% ) Other: Fatigue (11% ),30℃以下,Hypertension: Initially 100 mg BID. May increase in increments of 100 mg twice daily intermittently in every 2-14 days. Maximum: 800 mg/day in 2 divided doses. Patients with severe hypertension may require 2400 mg/day， in 3-4 divided doses. Gestational hypertension: Initially 100 mg BID. May increase in increments of 100 mg twice daily intermittently in 1-week interval. Total daily dose may be divided to 3 doses for patient with severe hypertension. Maximum: 2400mg/day.,需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IADE,Adenosine,Adenocor inj 6mg/2mL,CAVS,Treatment of paroxysmal supraventricular tachycardias. Diagnostic in narrow & broad-complex tachycardias,2nd or 3rd degree AV block (except in patients with a functioning artificial pacemaker). Sick sinus syndrome (except in patients with a functioning artificial pacemaker). Asthma.,Atrial fibrillation/flutter & an accessory bypass tract. Rapid saline flush needed if drug is injected into IV line,不要冷藏,Paroxysmal supraventricular tachycardia: IV (rapid， over 1 to 2 seconds， via peripheral line): Initial: 6 mg; if not effective within 1 to 2 minutes， 12 mg may be given; may repeat 12 mg bolus if needed (maximum single dose: 12 mg). Follow each dose with 20 mL N/S flush.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVP;IVPUSH;,,,快速靜脈注射 (over 1 to 2 seconds)。,,1.本藥品對年長者較具感受性。
IANE,Flumazenil,Anexate inj 0.5mg/5mL,ZADT,Reversal of centrally sedative effects of benzodiazepines,Patients with known hypersensitivity to flumazenil.,During anaesth， flushing & GI upsets occur rarely. After rapid inj， anxiety， palpitation， fear (occasionally).,30℃以下,Initial dose: 0.2 mg over 15 seconds. Repeat doses: If the desired level of consciousness is not obtained， 0.1 mg may be repeated at 1-minute intervals. Maximum total cumulative dose: 1 mg (usual total dose: 0.3-0.6 mg). Loss of Consciousness in intensive care units: 0.3 mg initially; repeat doses at 1-minute intervals， if the desired level of consciousness is not obtained. Maximum total cumulative dose: 2 mg.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,【D5W】可選 。【L/R】可選 。【N/S】可選 。,IV over 15~30 seconds,0.1-0.4 mg/hr IV infusion,
EACR,Ethacridine,Acrinol soln 450mL,TDER,,,,,,,,,,,,,,,,,,,
IENC,Acetylcysteine,Encore inj 300mg/3mL,ZADT,Acute & chronic affections of the respiratory tract with abundant mucous secretions in bronchitis， emphysema & bronchiectasis， prophylaxis & treatment of bronchopulmonary complications with mucostasis， bronchial catarrh， acetaminophen overdose.,Hypersensitivity to any component of the formulation.,Stomatitis， nausea， vomiting， fever， rhinorrhea; drowsiness; clamminess; chest tightness; bronchoconstriction Dermatologic: Pruritus (1% to 4.3% )， Rash (4% to 5% )， Urticaria Gastrointestinal: Diarrhea， Nausea (2% to 7% )， Vomiting (9% to 12% ),室溫避光保存,Adult: 300 mg deep IM 1-2 times daily; children: give half of the adult dose. Acetaminophen overdose: 21-hour regimen: Consists of 3 doses; total dose delivered: 300 mg/kg. Loading dose: 150 mg/kg infused over 15 minutes. Second dose: 50 mg/kg infused over 4 hours. Third dose: 100 mg/kg infused over 16 hours. For inhalation (nebulization)， 1 ampoule 1-2 times daily for 5-10 days. For intratracheal instillation， 1 ampoule 1-2 times daily.,無需調整劑量,,無需調整劑量,可能安全,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;IM;IVD;,,【D5W】可選 。【H/S】可選 。,,建議以>60分鐘緩慢滴注,1. IV用於Acetaminophen過量的成人劑量： loading dose， 150 mg/kg in 200 mL of compatible solution IV over 60 minutes， then 50 mg/kg in 500 mL of solution IV over 4 hours， followed by 100 mg/kg in 1000 mL of solution IV over 16 hours.
IEND,Cyclophosphamide,Endoxan Asta inj 200mg,RACA,Treatment of acute lymphoblastic leukemia (ALL)， acute myelocytic leukemia (AML)， breast cancer， chronic lymphocytic leukemia (CLL)， chronic myeloid leukemia (CML)， Hodgkin lymphoma， mycosis fungoides， multiple myeloma， neuroblastoma， non-Hodgkin lymphomas (including Burkitt lymphoma)， ovarian adenocarcinoma， retinoblastoma， and nephrotic syndrome.,Hypersensitivity to cyclophosphamide or its metabolites， urinary outflow obstructions， severe myelosuppression， severe renal or hepatic impairment， active infection (especially varicella zoster)， severe immunosuppression.,GI upsets; alopecia; reticulo-endothelial system depression; hematuria; reversible amenorrhea & azoospermia; myocardial damage with very high doses; pigmentation， macrocytosis， water retention; induction of hyperglycemia or hypoglycemia; risk of secondary malignancies.,25℃以下,The dosage must be adapted to each patient individually.Unless otherwise prescribed the following dosages are recommended: - for continuous treatment in adults and children: 3-6 mg/kg body weight daily (= 120-240 mg/m2 body surface) - for intermittent treatment: 10-15 mg/kg body weight (= 400-600 mg/m2 body surface) at intervals of 2-5 days - for high-dose intermittent treatment， e.g. 20-40 mg/kg body weight (= 800-1600 mg/m2 body surface) and higher doses (e.g. for conditioning prior to bone-marrow transplantation) at intervals of 21-28 days.,需調整劑量,,需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,IVD;,,【D5W】可選 。【N/S】可選 。,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC。 3. 定期尿液檢測，注意血尿。
IGLYC,Glycopyrrolate,Glycopyrodyn inj 0.2mg/1mL,ALIM,Preoperatively to inhibit salivation & excessive secretions of the respiratory tract; reversal of neuromuscular blockade; control of upper airway secretions; adjunct in treatment of peptic ulcer.,In management of peptic ulcer， may be C/I in glaucoma; obstructive uropathy; achalasia; pyloroduodenal stenosis; paralytic ileus; intestinal atony in the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Inj Newborn infant <1 mth.,Dry mouth; urinary hesitancy & retention; blurred vision. Increased ocular tension; tachycardia; palpitations; decreased sweating， loss of taste， headache， nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; severe allergic reaction， drug idiosyncrasies; urticaria; mental confusion.,25℃以下避光,Preoperative Adult & children 1 month-12 years 0.002 mg/pound body weight (0.01 mL) IM 30-60 mins before procedure or to be administered with preanesthetic narcotic & sedative. children 1 month-2 years may incresed 0.004 mg/pound body weight (0.02 mL).Intraoperative Adult 0.1 mg (0.5 mL) IV. May repeat at intervals of 2-3 mins. Children 0.002 mg/pound body weight (0.01 mL) IV. Maximum: 0.1 mg (0.5 mL)/dose. May repeat at intervals of 2-3 mins. Reversal of neuromuscular blockade Adult & children 0.2 mg (1 mL) IV for each 1 mg of neostigmine or 5 mg of pyridostigmine.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – no relevant animal data,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;IVP;IVPUSH;,,【D10W】可選 。【D5NS】可選 。【D5W】可選 。【N/S】可選 。,,,1. 使用前應先檢查病人是否有任何心搏過速的現象，因為使用本藥品後有可能增加心跳速率。
IHALD,Haloperidol,Haldol inj 5mg/1mL,CNEU,Acute psychosis ，Nausea and vomiting， Restlessness and confusion,Severe toxic CNS depression; preexisting coma; Parkinson's disease; lactation,Tardive dyskinesia; extrapyramidal reactions. Anxiety， drowsiness， depression， anorexia， transient tachycardia， postural hypotension， leukopenia; anticholinergic side effects.,15-30℃避光,Adults: Acute psychosis， acute excitement: 5mg IM. Can be repeated every hour until the symptoms are effectively controlled.maximum:20mg/day. Vomiting caused by the central nervous system: 5mg IM Prevent vomiting after surgery: 2.5-5mg IM at the end of the operation. Elders: Start with half of the adult dose， and adjust according to the needs of the result.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;,,,,,
ILIPD,Doxorubicin,Lipo-Dox inj 20mg (自費用),RACA,Treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 (< 200 CD4 lymphocytes/mm3) & diseases in mucosa， skin & internal organs. Treatment of metastasis carcinoma of the ovary in patients with disease that is recurrent to both 1st-line platinum- & paclitaxel-based chemotherapy regimens. As monotherapy for patients with metastatic breast cancer， where there is an increased cardiac risk.,Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal， conventional doxorubicin， or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic α-interferon,Infusion-associated acute reactions， stomatitis， Palmar-plantar erythrodysesthesia， cardiac toxicity. Nausea， leukopenia， neutropenia， anemia & thrombocytopenia. Asthenia， alopecia， fever， diarrhea. Resp infections， laboratory abnormalities.,2-8℃避免冷凍,[Breast cancer/Ovarian cancer] 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.[Multiple myeloma] 30 mg/m2 on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m2 on days 1， 4， 8， and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart. [AIDS-related Kaposi sarcoma (AIDS-KS)] 20 mg/m2 once every 2-3 weeks for 2-3 months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response. Avoid intervals shorter than 10 days.,需調整劑量,,無需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,IVD;,,【D5W】仿單建議。,,給藥劑量在90mg以下：以250 ml之5%葡萄糖溶液(Dextrose 5% in Water)稀釋 給藥劑量在90mg(含)以上：以500 ml之5%葡萄糖溶液稀釋。 起始劑量的輸注速率應不超過1 mg/min。若無輸注不良反應，剩餘藥物可以60分鐘輸注完畢。,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能、尿酸與血中電解質濃度。
IDOB2,Dobutamine,Gendobu inj 250mg/20mL,CAVS,Short-term treatment of cardiac decompensation due to depressed contractility resulting from heart disease or cardiac surgery.,Obstructive cardiomyopathy.,Tachycardia， nausea， non-specific chest pain & palpitation. Cardiovascular: Angina (1% to 3% )， Hypertension (7.5% )， Tachyarrhythmia (approximately 10% ) Neurologic: Headache (1% to 3% ),25℃以下,Must be diluted before infusion. Recommended dosage: usually 2.5-10 mcg/kg/minute as IV infusion. Infusion rate > 20 mcg/kg/minute for hemodynamic improvement. In rare cases， doses up to 40 mcg/kg/minute have been administered.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D10W】可選 。【D5NS】可選 。【D5W】可選 。【L/R】可選 。【N/S】可選 。,,2.5-10 mcg/kg/min as IV infusion,1.勿加入鹼性藥品 2.開封後請於24小時內用完 3.靜脈輸注部位之反應－偶而發生靜脈炎的報告，不小心的輸注滲漏引發局部發炎的變化。曾有皮膚壞死個案報告（破壞皮膚組織）。
OEVO,Cevimeline,Evoxac 30mg,CNEU,Treatment of symptoms of dry mouth in patients with Sjogren's Syndrome.,Uncontrolled asthma， when miosis is undesirable eg. in acute iritis & in narrow-angle glaucoma.,Excessive sweating， nausea， rhinitis， diarrhea， excessive salivation， urinary frequency， asthenia， flushing， palpitation， dyspepsia， abdominal pain， UTI， cough， vomiting. (Common) Dermatologic: Sweating symptom Gastrointestinal: Diarrhea， Excessive salivation， Indigestion， Nausea， Vomiting Renal: Urinary tract infectious disease Respiratory: Bronchitis， Cough， Rhinitis， Sinusitis， Upper respiratory infection (Serious) Cardiovascular: Chest pain (1-3%)， Edema (1-3%)， Palpitations (1-3%) Ophthalmic: Eye / vision finding (1-3%),25℃以下,Sjogren's syndrome - Xerostomia: 30 mg PO TID.,無需調整劑量,(1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) No reports describing the use of cevimeline during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if cevimeline is excreted into breast milk; therefore the manufacturer recommends that a decision should be made whether to discontinue nursing or discontinue the drug， taking into account the importance of the drug to the mother.,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,(1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) No reports describing the use of cevimeline during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if cevimeline is excreted into breast milk; therefore the manufacturer recommends that a decision should be made whether to discontinue nursing or discontinue the drug， taking into account the importance of the drug to the mother.,AC;AC15;PO;,,,,,
ONYS,Nystatin,Nystatin 50萬U,QANB,,適應症: Monilial infection of oral cavity， intestinal moniliasis. 副作用: Diarrhoea， GI distress， nausea and vomiting. vaginal pessaries/cream: May damage latex contraceptives (e.g. diaphragms， condoms)， additional contraceptive measures should be taken. 禁忌: History of hypersensitivity to nystatin.,,室溫,Adult: PO Intestinal or oropharyngeal candidiasis 500，000 or 1，000，000 u 3-4 times/day. Oral candidiasis As pastilles or oral susp: 100，000 u 4 times/day. Continue for 48 hr after lesions have healed. Prophylaxis of intestinal candidiasis 1，000，000 u/day in divided doses.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
OVBC,Vitamin B complex,Vitamin B complex,NUTR,Prevention & treatment of vit B deficiency.,Hypersensitivity to any component of the formulation; pre-existing hypervitaminosis,GI complaints at high doses.,室溫,Adult 2-3 capsules daily. the maxinum dose: 3 capsules/day. Each capsule contains: Thiamine HCl 5mg， Riboflavin 2mg， Nicotinamide 10.1mg， Pyridoxine HCl 0.25mg， Cyanocobalamine 1 mcg， Calcium Pantothenate 2.75mg， Folic Acid 0.1 mg.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,,,,,,
ICER1,HPV type16/18 L1 protein,Cervarix(gsk) inj 0.5mL(限專案員工用),HIMM,,適應症: Prevention of cervical cancer in females 10-25 years， by protecting against incident & persistent infections， cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) & cervical intraepithelial neoplasia (CIN)， CIN1 & pre-cancerous lesions (CIN2 & CIN3) caused by HPV Types 16 & 18. 副作用:Headache， GI disturbances， itch， rash， myalgia， arthralgia， inj site reactions， fatigue， fever. 禁忌: Subjects with known hypersensitivity to any component of Cervarix.,,2-8℃,3 separated doses given at baseline， 1， and 6 months by intramuscular injection,,,,可能安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,1. 使用前應先充分搖勻。 2. 應以肌肉注射的方式施打於上臂三角肌部位。
LAMO6,Amoxicillin,Amolin 25mg/mL， 60mL suspension,QANB,Infection of staphylococcus， streptococcus， pneumococcus， meningococcus， or other susceptibility bacteria.,Hypersensitivity to penicillins. Infectious mononucleosis.,Allergic reactions， GI disturbances， pseudomembranous colitis， hemolytic anemia， leukopenia.,25℃以下,Adult: 250 mg 3-4 times daily; children: 20-40 mg/kg in divided doses 3-4 times daily. Before administration， add water 60 mL into the bottle and shake until all the powder is thoroughly mixed.,無需調整劑量,,需調整劑量,可能安全,Human data suggest risk in 1st and 3 rd trimesters,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
LCAS,Castor Oil,Castor oil,ALIM,,適應症: As laxative. 副作用: Severe purgation， nausea & vomiting， abdominal cramps， flatus， rebound constipation， irritation of colon， dehydration， electrolyte imbalance. 禁忌: Dehydration， constipation， abdominal pain， nausea & vomiting， appendicitis， GI bleeding， ulceration， purgation， intestinal obstruction， pregnancy， menstruation.,,室溫,Adult 15-60 mL as single dose 16 hr before procedure. Children 2-12 years 5-15 mL， < 2 years 1-5 mL.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
LMYC,Nystatin,Mycostatin 10萬單位/mL suspension,QANB,Treatment of susceptible cutaneous， mucocutaneous， and oral cavity fungal infections normally caused by the Candida species,Hypersensitivity to nystatin or any component of the formulation,Diarrhea， nausea， stomach pain， vomiting,25℃以下,Oral candidiasis: (Suspension) Premature infants: 100，000 units 4 times/day; paint suspension into recesses of the mouth Infants: 200，000 units 4 times/day or 100，000 units to each side of mouth 4 times/day; paint suspension into recesses of the mouth Children: 400，000-600，000 units 4 times/day; swish in the mouth and retain for as long as possible (several minutes) before swallowing Adult: Suspension (swish and swallow): 400，000-600，000 units 4 times/day; swish in the mouth and retain for as long as possible (several minutes) before swallowing,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;TOPI;WM;,,,,,
EALV,Ciclesonide,Alvesco Inhaler 160mcg/puff， 60 puffs,ERSP,Persistent asthma in patients aged four and above.,Hypersensitivity to ciclesonide or any component of the product. Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive intervention.,Common: Arthralgia (oral inhalation， 0.9-3.5%)， Backache (oral inhalation， 0.6-3.1%)， Headache (intranasal， up to 3.1% ; oral inhalation， 4.9-11%)， Otalgia (intranasal， 2.2%)， Bleeding from nose (intranasal， 2.9-11.4%)， Nasal congestion (oral inhalation， 1.8-5.5%)， Nasopharyngitis (intranasal， 3.7%; oral inhalation， 7-10.5%)， Pain in throat (oral inhalation， 2.4-4.7%)， Sinusitis (oral inhalation， 3.1-5.5%)， Upper respiratory infection (intranasal， at least 2% ; oral inhalation， 4.1-8.7%)， Pain， In extremity (oral inhalation， 0.3-3.1%) Serious: Adrenal insufficiency， Type 2 diabetes mellitus， Hypersensitivity reaction (rare)， Cataract， Glaucoma， Raised intraocular pressure， Asthma， acute (6%)， Bronchospasm,室溫,Initial， 80 mcg oral inhalation twice daily; higher doses may provide additional control in patients who do no respond adequately after 4 weeks of treatment; MAX， 320 mcg twice daily.,無需調整劑量,,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
EOEKC,Estriol,OEKOLP creme 25gm,SGU,,適應症: Vag or cervical inflammation， atrophic vaginitis. 副作用: Local irritation or itch， breast tenderness， fluid retention.,,室溫,Apply 0.5 g daily.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EPULR,Budesonide,Pulmicort respules 1mg/2mL,ERSP,Patients with bronchial asthma not well controlled by bronchodilators &/or antiallergic agents.,Hypersensitivity to budesonide or any other ingredients.,Mild throat irritation & hoarseness. Candida infection in oropharynx.,30℃以下,The required dose can be administered at one time under 1mg， otherwise， divided in 2 times daily when the required dose above 1mg. Adult: Initial dose: 1-2 mg daily. Maintenance dose: 0.5-4mg daily. May increase the dosage with the very severe patient. Child > 6 months: Loading dose: 0.25-0.5mg daily. May up to 1mg daily if required. Maintenance dose: 0.25-2mg daily.,無需調整劑量,,無需調整劑量,可能安全,Compatible,PREGNANCY RECOMMENDATION: Compatible (Inhaled/Nasal) No Human Data—Animal Data Suggest Risk (Oral),No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;INHL;,,,,,
ESPEO,Bacitracin + Neomycin + Ploymyxin B,Spersin ointment 10gm,TDER,Infections caused by neomycin &/or bacitracin-susceptible organisms.,Hypersensitivity to any component of the formulation.,Allergic reactions like reddening & dryness of skin， skin rashes & pruritus.,25℃以下,Apply BID-QID.,無需調整劑量,[仿單]未有相關記載 Bacitracin - Compatible (Topical) Neomycin - No Human Data—Probably Compatible Ploymyxin B - Unknown,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]未有相關記載 Bacitracin - Compatible (Topical) Neomycin - Human Data Suggest Low Risk Ploymyxin B - Unknown,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]未有相關記載 Bacitracin - Compatible (Topical) Neomycin - No Human Data—Probably Compatible Ploymyxin B - Unknown,EXT;SKIN;TOPI;,,,,,
ESUT,Metronidazole,Sutrol gel-vaginal 7.5mg/gm， 25gm,SGU,Treatment of vag infections such as Hemophilus vaginitis， Gardnerealla vaginitis， nonspecific vaginitis， Corynebacterium vaginitis or anaerobic vaginosis.,Hypersensitivity to parabens or other nitroimidazole.,Vag discomfort， vag candidiasis， vag irritation， pelvic discomfort. GI disturbances， nausea， vomiting， unpleasant smell， diarrhea， loss of appetite， flatulence， dry mouth. Headache， dizziness， depression. Itch or rash. Skin irritation. Gastrointestinal: Abdominal discomfort (7%)， Loss of appetite， Metallic taste， Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )， Headache (tablets， 15% to 18%; vaginal gel， 5% )， Peripheral neuropathy Reproductive: Candida infection of genital region， Symptomatic cervicitis/vaginitis (10%)， Vaginal discharge (12%) Other: Drug interaction with alcohol， Disulfiram-like reaction,室溫,Apply 5 g QD-BID for 5 days. Apply before bedtime if to be used once daily.,無需調整劑量,METRONIDAZOLE BREASTFEEDING RECOMMENDATION: Hold Breastfeeding (Single Dose) Limited Human Data—Potential Toxicity (Divided Dose),無需調整劑量,可能安全,Human data suggest low risk,METRONIDAZOLE PREGNANCY RECOMMENDATION: Human Data Suggest Low Risk,Hold Breast Feeding 暫停哺乳,METRONIDAZOLE BREASTFEEDING RECOMMENDATION: Hold Breastfeeding (Single Dose) Limited Human Data—Potential Toxicity (Divided Dose),VAG;,,,,,
ETOB,Tobramycin + Dexamethasone,Tobradex 5mL ophthalmic suspension,TOPH,Steroid-responsive inflammatory ocular conditions.,Epithelial herpes simplex keratitis (dendritic keratitis)， vaccinia， varicella & many other viral diseases of the cornea & conjunctiva. Mycobacterial eye infection. Fungal diseases of ocular structures. After uncomplicated removal of a corneal foreign body.,Localized ocular toxicity & hypersensitivity including lid itching & swelling & conjunctival erythema. Secondary infection.,30℃以下勿冷凍,One to two drops instilled into the conjunctival sac every 4 to 6 hours. During the initial 24 to 48 hours， the dosage may be increased to 1 to 2 drops every 2 hours. Shake well before use.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
EVENI,Salbutamol,Ventolin inhaler 0.1mg/dose,ERSP,Relief of acute bronchospasm， Prevention of allergen or exercise-induced bronchospasm.,Threatened abortion. Inhaled prep not appropriate for managing premature labour.,Fine tremor of skeletal muscle， feelings of tension， peripheral vasodilation， a compensatory small increase in heart rate， headaches， transient muscle cramps， hypersensitivity reactions， potentially serious hypokalaemia， hyperactivity in children， tachycardia， cardiac arrhythmias. Mouth & throat irritations (inhalers).,避光避結霜且30℃以下,Relief of acute bronchospasm- Adult: 100-200 mcg. Children: 100 mcg， may be increased to 200 mcg if required. Prevention of allergen or exercise-induced bronchospasm- Adult: 200 mcg before contact challenge or exercise. Children 100 mcg before contact challenge or exercise， may be increased to 200 mcg if required. Chronic therapy- Adult: 200 mcg QID. Children: 200 mcg QID.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
IPKM,Amantadine,PK-Merz infusion 200mg/500mL,CNEU,,I: intensive & initial treatment of severe & life-threatening cases of Parkinsonism. CI: states of agitation & confusion， predelirious or delirious conditions & history of psychosis.,,室溫,1-2 * 500 ml daily may be increased to 3 *500 ml daily.(55 drops/min),,,,除非治療上需要,,,,,,,,,,
EXYLJ,Lidocaine,Xylocaine 凝膠 30gm， 2%,ZANE,Surface anaesth.,Known hypersensitivity to local anesth of the amide type.,Rarely， anaphylactic shock. Post-op sore throat following endotracheal tube lubrication. Acute systemic toxicity.,25℃以下，不可冷凍,Urethral anesthesia Men 20 mL is instilled slowly until the patient has a feeling of tension or until almost half the tube (10 mL) has been emptied. Apply a penile clamp for several mins， then instill the rest of the jelly. Women 5-10 mL in small portions to fill the whole urethra. Endoscopy 10-20 mL. Lubrication for endotracheal intubation 2 mL applied to the surface of the tube just prior to insertion. Children < 12 years Maximum: 6 mg/kg.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
ECOMS,Benzydamine,Comfflam spray 1.5mg/mL， 30mL/Bot,CNEU,,適應症:Relief of painful conditions of the mouth & throat including tonsillitis， sore throat， radiation mucositis， aphthous ulcers， post orosurgical & periodontal procedures. 副作用:Oral numbness; dryness or thirst， tingling， warm feeling in mouth， altered sense of taste. 禁忌:Hepatic or renal impairment. Pregnancy， children < 6 years. In bacterial infection， appropriate antibacterial therapy should be used in addition to product.,,室溫,Adult & children > 12 years 4-8 sprays onto the affected area， children 6-12 years 4 sprays onto the affected area. May be repeated every 1.5-3 hrly. Duration should not exceed 7 days.,,,,可能安全,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IHUM4,Adalimumab,Humira 40mg inj,HIMM,,適應症:Monotherapy or in combination with methotrexate or other DMARDs for reducing of the signs & symptoms & to inhibit the progression of structural damage in adult patients with moderately to severely active RA. Monotherapy or in combination with other DMARDs for reducing the signs & symptoms of active arthritis in patients with psoriatic arthritis. Reduction of signs & symptoms in patients with active ankylosing spondylitis. Reduction of signs & symptoms & inducing & maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy or if they have also lost response to or are intolerant to infliximab. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy & when other systemic therapies are medically less appropriate. Reduction of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients 13-17 years. 副作用:Resp tract infections， leucopenia， anemia， increased lipids， headache， abdominal pain， nausea & vomiting， elevated liver enzymes， rash， musculoskeletal pain， inj site reaction. 禁忌:Known hypersensitivity to adalimumab or any of the excipients of Humira.,,2-8℃,Adult RA， psoriatic arthritis， ankylosing spondylitis， polyarticular juvenile idiopathic arthritis Single dose of 40 mg SC every other week. If not taking concomitantly with methotrexate， increasing the dosing frequency to 40 mg weekly may derive additional benefit. Crohn's disease 160 mg initially at day 1 (as four 40-mg inj in 1 day or as two 40-mg inj/day for 2 consecutive days)， followed by 80 mg 2 weeks later (day 15). Another 2 weeks later (day 29) begin a maintenance dose of 40 mg every other week. Patients who experience decrease in their response may benefit from an increase in dose intensity to 40 mg every week. Plaque psoriasis Initially 80 mg， followed by 40 mg given every other week starting 1 week after the initial dose.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,
EKIN1,Atropine,Kintropine 0.125% 10mL,TOPH,,適應症: As a mydriatic & cycloplegic in various eye disorders. 副作用: May cause whole body reactions if used on long-term. Sensitivity to light， visual disturbances. 禁忌: Closed- & narrow-angle glaucoma.,,室溫,Cycloplegic refraction 1 drop once-bid. Uveitis 1 drop once-tid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EKIN2,Atropine,KINTROPINE 0.25% 10mL,TOPH,,適應症: As a mydriatic & cycloplegic in various eye disorders. 副作用: May cause whole body reactions if used on long-term. Sensitivity to light， visual disturbances. 禁忌: Closed- & narrow-angle glaucoma.,,室溫,Cycloplegic refraction 1 drop once-bid. Uveitis 1 drop once-tid.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IPANT,Vit B1+ B2 + B6 + C + Nicotinamide + Pantothenyl,Pantogen inj 500mL,META,Prevention & treatment of vit B & vit C deficiency.,Use of hypertonic glucose soln in patients with anuria; intracranial or intraspinal hemorrhage; delirium tremens with dehydration,Nausea， vomiting， abdominal cramps， pruritus， flushing， sensation of heat， faintness， pounding in the head.,無特別指示,Individualised dosage. Slow IV only， injection rate: 2 mL/min.,無需調整劑量,,無需調整劑量,安全,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,
IPERD,Nicardipine,Perdipine inj 10mg/10mL,CAVS,Cerebral blood flow disturbances ，Essential hypertension， Short-term therapy of hypertension or of unusual hypertension during surgery,Incomplete hemostasis following intracranial hemorrhage; acute cerebral apoplexy， elevated intracranial pressure， Hypersensitivity to nicardipine or any component of the formulation; advanced aortic stenosis,Infrequently， anorexia， nausea， vomiting; flushing; palpitation; headache. Rarely， granulocytopenia; dry mouth， constipation， diarrhea; peripheral edema; rash. Cardiovascular: Hypotension (5.6% )， Peripheral edema (5.9% )， Tachyarrhythmia (3.5% ) Gastrointestinal: Nausea (1.9% to 4.9% )， Vomiting (0.6% to 4.9%) Neurologic: Headache (6.2% to 14.6% ),30℃以下避光,adult， HTN: initial 3-5mg/hr ， titrate up 0.5-1 mg/hr every 15 minutes maximum 15mg/hr HTN emergency: Initial: 5 mg/hr; may increase by 2.5 mg/hr every 5 to 15 minutes maximum of 15 mg/hour. [Micromedex 20211013] Intracerebral hemorrhage / Subarachnoid hemorrhage blood pressure management (off-label use): 5 mg/hr; may increase by 2.5 mg/hr every 5 to 15 minutes (for gradual titration) up to a maximum of 15 mg/hr.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D5W】可選 。【N/S】可選 。,,靜脈輸注時，稀釋成0.1-0.2 mg/mL濃度，成人起始劑量:3-5 mg/hour，持續輸注15分鐘，但不可超過15 mg/hour;小兒起始劑量:0.5-5 mcg/kg/min，建議維持劑量為1-4mcg/kg/min。,依103年8月7日衛福部發佈於不良反應中心安全性評估結果。 1.IV infusion 成人起始劑量:3-5 mg/h，持續輸注15分鐘，但不可超過15 mg/hour 2.IV infusion 老人、孕婦及肝腎功能不良者起始劑量:1-5 mg/hour，不可超過15 mg/hour 3.IV infusion 小兒起始劑量:0.5-5 mcg/kg/min，建議維持劑量為1-4mcg/kg/min 4.本藥遇光會慢慢的變化。
IPROL,Propofol,Propofol 1% 20mL,ZANE,,適應症:Short-acting IV anesth for induction & maintenance of general anesth. Conscious sedation for surgical & diagnostic procedures. Sedation of ventilated patients receiving intensive care. 副作用:Hypotension， transient apnea， epileptiform movements， mild degree of local pain， post-op fever & discoloration of urine， anaphylaxis， edema， bronchospasm， erythema. Dermatologic: Injection site pain (up to 28.5% ) Gastrointestinal: Nausea and vomiting (2% to 2.5% ) Musculoskeletal: Involuntary movement， Muscle (17%) 禁忌:Pregnancy， lactation & obstetrics (except abortion). General anesth in children <1 month & for sedation of children <16 years in ICU.,,室溫,General anesth Adult <55 years Induction: 2-2.5 mg/kg IV. Maintenance by continuous IV infusion: 4-12 mg/kg/hr. Maintenance by repeat bolus inj: increments of 25-50 mg may be given according to clinical need. Children >=3 years Induction: 2.5 mg/kg IV. Maintenance: 9-15 mg/kg/hr. Sedation of ventilated patients receiving intensive care Adult Continuous infusion recommended; infusion rate should be determined by the desired depth of sedation. Rates at 0.3-4 mg/kg/hr should achieve satisfactory sedation Conscious sedation for surgical & diagnostic procedures Adult Induction: 0.5-1 mg/kg over 1-5 mins. Maintenance: 1.5-4.5 mg/kg/hr. In addition to the infusion， bolus administration of 10-20 mg may be used for rapid increase in the depth of sedation.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1.使用濃度勿低於2 mg/mL。(最大稀釋比例 1:4)) 2.輸注時不可使用含微生物過濾器之輸液套。輸注本品建議使用流速滴定或體積設定幫浦控制流速。 3.本品不含防腐劑，開瓶後應立即抽取至無菌針筒或輸液套，剩餘的殘量應丟棄不用。 4.輸注未經稀釋的Propofol 1% 20mL時，使用同一系統輸注時間不宜超過12小時。使用12小時後，輸注管路與剩餘的藥物應丟棄、更換。 5.輸注稀釋過的Propofol 1% 20mL時，應於投藥前以無菌操作立即調配，且務必於6小時內使用。
OCEPH,Cephalexin,Cephalexin 250mg,QANB,Infections caused by Staph， Strep， pneumococci & other susceptible bacteria.,Hypersensitivity to cephalosporins.,Diarrhea; superinfection; hypersensitivity reactions; eosinophilia; neutropenia， thrombopenia; rarely erythema multiforme， anaphylaxis; pseudomembranous colitis.,15-30℃緊密容器,(仿單) Adults: 250 mg Q6H. Children: 25-50 mg/kg/day. (Uptodate+Ulexin仿單) Adults: 0.25-1 g Q6H or 500 mg Q12H (maximum: 4 g/day). Children: 25-100 mg/kg/day divided Q6H.,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OFOL5,Folic Acid,Folacin FC 5mg(自費),NUTR,Pernicious anemia， pregnancy， megaloblastic anemia， aplastic anemia.,Hypersensitivity to any component of the formulation.,GI complaints at high doses.,25℃以下緊密容器,1 TAB contains 5 mg folic acid. Adult: Initially 1 TAB TID for 14 days. Maintenance: 1 TAB daily for 1-7 days. Children 6-12 years: Initially 2 TAB/day. Maintenance: As half of initial dose. Children 1-5 years: Initially 1 TAB /day. Maintenance: As half of initial dose. Children <1 years: 0.5 mg/kg body weight/day. Maintenance: As half of initial dose.,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
LCET,Cetirizine,Cetirizine 1mg/mL， 60mL oral solution,HIMM,Symptomatic treatment of seasonal rhinitis & conjunctivitis， perennial allergic rhinitis as well as pruritus & urticaria of allergic origin.,Lactation.,Headache， dizziness， drowsiness， agitation， dry mouth， GI discomfort， skin reactions & angioedema.,25℃以下，不需冰存並避免陽光直射,Adult & children >6 years : 10 mg once daily， taking with dinner and liquids. Children 3-6 years: initial dose: 5 mg once daily， taking with dinner， or 2.5mg every 12 hours.Patient with renal function impairment should reduce dosage to half.,無需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
IPNS3,Sodium Chloride,Prefilled 0.9% Saline 3mL,NUTR,,,,,,,,,,,,,,,,,,,
LCH10,Chloral hydrate,Chloral hydrate 10%， 10mL,CNEU,,適應症: Insomnia，Sedation 副作用: Gastric irritation， abdominal distention and flatulence， vertigo， ataxia， staggering gait， rashes， malaise， lightheadedness， headache， ketonuria， excitement， nightmares， delirium (especially in elderly)， eosinophilia， reduction in white blood cell count; dependence on prolonged use. 禁忌: Hepatic or renal impairment， cardiac disease， hypersensitivity， porphyria， oesophagitis， gastritis. Pregnancy and lactation.,,2-8 ℃,Chloral hydrate 10%= 100 mg/mL --Dosing: Adult Sedation， anxiety: Oral: 250 mg 3 times daily Hypnotic: Oral: 500-1000 mg 15-30 minutes before bedtime or 30 minutes prior to procedure， not to exceed 2000 mg per 24 hours --Dosing: Pediatric Hypnotic: Oral: 50 mg/kg/day in 1 or more divided doses; maximum single dose: 1000 mg Sedation or anxiety: Oral: 25 mg/kg/day in 1 or more divided doses; maximum single dose: 500 mg Procedural sedation: Oral: 25-50 mg/kg/dose， 30 minutes prior to procedure; may repeat in 30 minutes using half the dose,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EJAL,Benzyl benzoate,Jaline Lotion 25%， 150mL,TDER,Treatment of scabies， head lice.,Hypersensitivity to any component of the formulation.,Skin irritation， burning sensation.,25℃以下,Scabies Apply over the whole body; repeat without bathing on the following day & wash off 24 hr later. A repeat application may be required in some cases,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Contraindicated 哺乳期使用禁忌,,EXT;,,,,,
INESP,Darbepoetin alfa,NESP inj 20mcg(洗腎用),HEMT,Anemia: Treatment of anemia due to concurrent myelosuppressive chemotherapy in patients with cancer (nonmyeloid malignancies) receiving chemotherapy (palliative intent) for a planned minimum of 2 additional months of chemotherapy; treatment of anemia due to chronic kidney disease (including patients on dialysis and not on dialysis),Hypersensitivity to darbepoetin or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (due to darbepoetin or other erythropoietin protein drugs),Hypertension (31%)， peripheral edema (17%)， edema (6% to 13%)， Abdominal pain (10% to 13%)， Dyspnea (17%)， cough (12%),2-8℃避光勿冷凍勿搖,Initial dose as 0.45mcg/kg IV or SC every week for treatment of chronic renal failure patient with anemia， keeping Hb between 10-12g/dL. For patient with chemotherapy， 2.25mcg/kg SC as initial dose.,無需調整劑量,仿單資訊：尚不清楚Darbepoetin alfa是否會分泌到人體的乳汁中， 因為許多藥會分泌到人體的乳汁中，關於授乳婦女Darbepoetin alfa投與應謹慎。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,仿單資訊：懷孕分級C 尚未有足夠且控制良好的懷孕婦女的Darbepoetin alfa試驗。 動物的生殖及發育毒性試驗中，Darbepoetin alfa增加著床後的流產。 唯有治療的益處足以彌補對對胎兒造成潛在傷害的風險，才使用Darbepoetin alfa於懷孕病人。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,仿單資訊：尚不清楚Darbepoetin alfa是否會分泌到人體的乳汁中， 因為許多藥會分泌到人體的乳汁中，關於授乳婦女Darbepoetin alfa投與應謹慎。,IV;SC;,,,,,
ODOB,Mebeverine,Dobecon 100mg,ALIM,Diarrhea， abdominal pain & flatulence due to irritable colon， diverticulitis,1. Hypersensitivity to mebeverine 2.Severe hepatic impairment 3.Cystic fibrosis,Skin rash， hives， dizziness， headache,25℃以下,Adult: The usual oral adult dose of mebeverine hydrochloride for irritable bowel syndrome is one 100 mg tablet 3 times daily taken with fluids 20 minutes before a meal. The dosage of mebeverine may be reduced gradually after a few weeks of treatment， if the desired effect has been achieved.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PO;,,,,,
OPLEY,Cilostazol,Pleya 100mg,HEMT,,適應症: Reduction of symptoms of intermittent claudication， as indicated by an increased walking distance. 副作用: Abdominal pain， back pain， headache， infection， palpitation， tachycardia， GI effects， peripheral edema， myalgia， dizziness， vertigo， cough， pharyngitis， rhinitis. Cardiovascular: Palpitations (5% to 10% )， Peripheral edema (7% to 9% )， Tachyarrhythmia (4% ) Gastrointestinal: Abdominal pain (4% to 5% )， Diarrhea (12% to 19% )， Feces contents abnormal (12% to 15% )， Indigestion (6% ) Hematologic: Decreased platelet aggregation Musculoskeletal: Backache (6% to 7% )， Myalgia (2% to 3% ) Neurologic: Dizziness (9% to 10% )， Headache (27% to 34% ) Respiratory: Increasing frequency of cough (3% to 4% )， Pharyngitis (7% to 12% )， Rhinitis (7% to 12% ) Other: Infectious disease (10% to 14% ) 禁忌: Patients with CHF of any severity.,,室溫,100 mg BID,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ESPIR,Tiotropium,Spiriva Respimat 2.5mcg/puff,ERSP,Maintenance treatment of patients with COPD (including chronic bronchitis & emphysema).,Patients with a history of hypersensitivity to atropine or its derivatives eg， ipratropium or oxitropium， or to any component of Spiriva.,GI disturbances， cough & local irritation， dysuria， urinary retention (in men)， tachycardia， allergic reactions. Gastrointestinal: Constipation (4% )， Xerostomia (12% to 16% ) Respiratory: Pharyngitis (7% to 9% )， Sinusitis (3% to 11% )， Upper respiratory infection (41% to 43% ),30℃以下勿冷凍,Adult:Inhale 2 puffs once daily at the same time of day. Age 6-17 years with asthma: 2 puffs once daily at the same time of day. Age <6 years: Limited data available.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;INHL;,,,,,
IOLI3,Amino Acid + Glucose + Lipid,Oliclinomel N4-550E Emulsion 1500mL,NUTR,Parenteral nutrition when oral or enteral alimentation is impossible， insufficient or contraindicated.,Renal failure in the absence of haemodialysis， haemofiltration or haemo-diafiltration. Severe liver disease. Amino acid metabolism disorder. Metabolic acidosis， hyperlactataemia. Adrenal insufficiency. Hyperosmolar coma.,Hypertonic solutions may cause venous irritation if infused into a peripheral vein. Hyperglycaemia， glycosuria & hyperosmolar syndrome may occur.,25℃以下避光避免冷凍,Adult: 1-2 g amino acids/kg/day， 25-40 kcal/kg/day. Maximum daily dose: 40mL/kg body weight. Maximum infusion rate: 3mL of the emulsion for infusion/kg/hr. 12-18 years: 1-2g amino acids/kg/day， 30-75kcal/kg/day. Maximum daily dose: 100mL/kg body weight. Maximum infusion rate: 5.5mL of the emulsion for infusion/kg/hr. 2-11 years: 1-2g amino acids/kg/day (maximum: 3g amino acids/kg/day)， 60-90kcal/kg/day. Maximum daily dose: 100mL/kg body weight. Maximum infusion rate: 6.5mL of the emulsion for infusion/kg/hr.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,1.此輸注乳液最大輸注速率勿超過3毫升/公斤/小時。 2.若有任何症狀或跡象顯示過敏反應(如：發燒、顫抖、皮疹或呼吸困難)，應立即停止輸注。 3.本輸注乳液絕對不可於輸血時使用相同的輸注導管裝置，因為可能導致假性凝血跡象。 4.本產品需在三袋液體充分混合後方可使用，限單次使用。
ITRAN,Tranexamic Acid,Transamin inj 250mg/5mL,HEMT,Hemorrhage， abnormal bleeding， genital & renal bleeding， bleeding due to prostatectomy.,Hypersensitivity to any component of the formulation.,GI disturbances. Gastrointestinal: Abdominal pain (oral， 19.8% ) Hematologic: Anemia (oral， 5.6% ) Musculoskeletal: Arthralgia (oral， 6.9% )， Backache (oral， 20.7% )， Cramp (oral， 6.5% )， Musculoskeletal pain (oral， 11.2% ) Neurologic: Headache (oral， 50.4% )， Migraine (oral， 6% ) Respiratory: Nasal sinus problem (oral， 25.4% ) Other: Fatigue (oral， 5.2% ),25℃保存,Adult: 250-500mg divide 1-2 times， IV/IM.During or after surgery: 500-1000 mg IV or 500-2500 mg by IV infusion.,無需調整劑量,Micromedex Lactation Rating: Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. Clinical Management: There are limited data on nursing an infant while on tranexamic acid. Data have shown that only minimal amounts of the drug are excreted in breast milk. Breast milk concentrations were reported to be approximately 1% of peak serum levels 1 hour following the last dose of a 2-day treatment regimen. Tranexamic acid should only be used in a nursing mother only if clearly needed and use caution when tranexamic acid is administered to a nursing mother.,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Micromedex Lactation Rating: Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. Clinical Management: There are limited data on nursing an infant while on tranexamic acid. Data have shown that only minimal amounts of the drug are excreted in breast milk. Breast milk concentrations were reported to be approximately 1% of peak serum levels 1 hour following the last dose of a 2-day treatment regimen. Tranexamic acid should only be used in a nursing mother only if clearly needed and use caution when tranexamic acid is administered to a nursing mother.,IM;INS;IVD;IVP;IVPUSH;,,【D5W】可選 。【N/S】可選 。,1000 mg 推注時間至少 10 mins (速率 < 2 mL/min),1000 mg 推注時間至少 10 mins 輸注速率 < 2500mg/24hr,1. 靜脈內注射時應緩慢進行，急速給藥時，可能會出現噁心、胸部不適、心悸亢進或血壓下降。 2.不可與血品或含penicillin的藥物混合
IPAM2,Pralidoxime,Pampara inj 500mg/20mL,ZADT,Treatment of muscle weakness and/or respiratory depression secondary to poisoning due to organophosphate anticholinesterase pesticides and chemicals (eg， nerve agents); control of overdose of anticholinesterase medications used to treat myasthenia gravis (ambenonium， neostigmine， pyridostigmine),According to the manufacturer， relative contraindications include hypersensitivity to pralidoxime or any component of the formulation and other situations where the risk of administration clearly outweighs possible benefit.,Cardiovascular: Cardiac arrest， hypertension， tachycardia Central nervous system: Dizziness， drowsiness， headache， paralysis， seizure Dermatologic: Skin rash Gastrointestinal: Nausea Hepatic: Increased serum ALT (transient)， increased serum AST (transient) Local: Pain at injection site (IM) Neuromuscular & skeletal: Fasciculations， increased creatine phosphokinase， laryngospasm， muscle rigidity， weakness Ophthalmic: Accommodation disturbance， blurred vision， diplopia Renal: Renal insufficiency Respiratory: Apnea， hyperventilation,無特別指示,(仿單) Loading dose 1 g IV; may repeat bolus of 1 g after 30 minutes if symptoms have not been relieved.,無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,Hold Breast Feeding 暫停哺乳,,IVD;,,【N/S】可選 。,slow injection,以10~20 mg/mL 滴注 15~30 min，Max: 200 mg/min,Intravenous 1.dilute to a final concentration of 10 to 20 mg/mL in NS; infuse over 15 to 30 minutes 2.maximum infusion rate is 200 mg/min
OSEN,Sennosides,Sennoside 12mg,ALIM,,適應症: Treatment of constipation & for bowel evacuation before investigational procedures or surgery. 副作用: Mild abdominal discomfort， eg colic or cramps. Prolonged use or overdosage can result in diarrhoea with excessive loss of water & electrolytes， particularly K; possibility of developing an atonic non-functioning colon. May colour urine yellow-brown at acid pH， & red at alkaline pH. Reversible melanosis coli has been reported following chronic use. 禁忌: Patients with intestinal obstruction or with undiagnosed abdominal symptoms.,,室溫,Constipation Adult 12-50 mg. Bowel evacuation up to 158 mg.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
EDIP,Betamethasone + Gentamicin,Diprogenta cream 5gm,TDER,,適應症: Dermatoses complicated by infection in psoriasis， neurodermatitis， lichen planus， eczema， intertrigo， dyshidrosis， seborrhoeic， contact， atopic， exfoliative， solar， stasis dermatitis; anogenital & senile pruritus. 副作用: Burning， itching， irritation， dryness， folliculitis， hypertrichosis， perioral dermatitis， allergic contact dermatitis， acneiform eruption， hypopigmentation， maceration of the skin， skin atrophy， secondary infection， striae & miliaria. 禁忌: Hypersensitivity to any of the component of Diprogenta.,,室溫,Cover affected area completely bid.,,,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IMAR4,Bupivacaine,Marcaine Spinal 0.5% 4mL inj (麻醉科用),ZANE,Spinal anaesth for surgery.,Diseases of the cerebrospinal system; septicaemia; pernicious anemia with cord symptoms; cardiac decompensation; massive pleural effusions & markedly increased intra-abdominal pressure; pyogenic infection of skin.,Drowsiness， unconsciousness， respiratory arrest; hypotension， myocardial depression， bradycardia， possibly cardiac arrest; numbness of the tongue， light-headedness， dizziness， tremor followed by convulsions may rarely occur.,2-25℃避免冷凍,Marcaine Spinal 0.5% contains bupivacaine 5mg/mL， 4mL/ampoule. Intrapinal injection. Spinal injections should only be made after the subarachnoid space has been clearly identified by lumbar puncture. No drug should be injected until clear cerebrospinal fluid (CSF) is seen to escape from the spinal needle or it is detected by aspiration. The dose required for the most effective blocking (patient in the supine horizontal position): For lower limbs， urinary tract and perineum surgery: 10-15 mg inject into L3/4/5. For hip and lower abdomen surgery: 15-20 mg and inject into L2/3/4.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IT;,,,,,局部麻醉劑，限由醫師使用。
LPOL,Multivitamin,Poly Baby Multivitamin Drops 50mL,NUTR,,副作用: Allergic reactions， dizziness， hypervitaminosis 適應症: Vitamin and mineral supplement for infants.,,室溫,Infant(Age <3yr): 1mL，QD. Infant(Age <3 month): 0.6mL，QD.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ITPN1A,TPN-1 Solution,TPN-1A Solution (1000mL/bag),NUTR,,,,,,需調整劑量,,需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
IALBU,Albumin,Albumin 25% 50mL (Albuminar-25),HEMT,,適應症 (FDA-Labeled Indications ): ■Acute respiratory distress syndrome ■Ascites; Adjunct ■Burn - Hypovolemia ■Cardiopulmonary bypass operation ■Cellulitis， Extensive ■Hemodialysis; Adjunct ■Hypoalbuminemia ■Hypovolemic shock ■Liver failure (Acute) ■Mediastinitis ■Neonatal hyperbilirubinemia ■Nephropathy， acute; Adjunct ■Ovarian hyperstimulation syndrome ■Pancreatitis ■Peritonitis ■Transfusion of red blood cells 副作用Serious: Immunologic: Immune hypersensitivity reaction (rare) 禁忌: ■hypersensitivity to albumin ■patients at risk for acute circulatory overload (cardiac failure， pulmonary edema， severe anemia),,室溫,Adult Dosing ■Acute respiratory distress syndrome: 25 g (100 mL of 25% solution) IV over 30 minutes， repeated at 8 hours for 3 days if necessary ■Ascites; Adjunct: 6 to 8 g of 25% albumin for every 1000 mL of ascitic fluid removed ■Burn - Hypovolemia: after the first 24 hours， dose albumin 5% or 25% IV to achieve plasma albumin level of approximately 2.5g/100mL or a total plasma protein concentration of 5.2g/100mL; an initial dose of 25 g of albumin (500 mL of 5% solution) is recommended ■Cardiopulmonary bypass operation: (AlbuRx(R) 25， Plasbumin(R)-5%， Plasbumin(R)-25%) adjust albumin and crystalloid pump prime to achieve a hematocrit of 20% and a plasma albumin concentration of 2.5 g/100 mL ■Hemodialysis; Adjunct: (25% solution) 25 g (100 mL) IV ■Hypoalbuminemia: initial， 25 g (100 mL of 25% solution) IV， usual daily dose 50 to 75 g (200 to 300 mL of 25% solution ) IV， additional doses may be given as clinically indicated; MAX 2 g/kg/day ■Hypovolemic shock: initial， 12.5 to 25 g IV (250 to 500 mL of 5% solution， 50 to 100 mL of 25% solution)， may repeat in 15 to 30 minutes; further doses based on clinical response， blood pressure， and anemia assessment ■Liver failure (Acute): 10 to 20 g infusion in combination with octreotide 200 micrograms subcutaneous three times daily and midrodrine titrated to 12.5 mg by mouth three times daily for 20 days ■Nephropathy， acute; Adjunct: initial， 25 g (100 mL of 25% solution) IV daily for 7 to 10 days with loop diuretics ■Ovarian hyperstimulation syndrome: 50 to 100 g IV over 4 hours， repeat at 4 to 12 hour intervals as needed or 10 to 50 g as a single infusion ■Transfusion of red blood cells: 25 g (100 mL of 25% albumin) per liter of erythrocytes， added to washed red cell suspension immediately prior to transfusion [1][6] Pediatric Dosing ■Acute respiratory distress syndrome: (Kedbumin(TM)) 12 to 16 years， 25 g (100 mL of 25% solution) IV over 30 minutes， repeated at 8 hours for 3 days if necessary ■Burn - Hypovolemia: (Kedbumin(TM)) 12 to 16 years， dose should be determined by measurement of plasma oncotic pressure or protein content， or by direct observation of vital signs. Patients should be adequately hydrated while receiving Kedbumin(TM) ■Cardiopulmonary bypass operation: (Kedbumin(TM)) 12 to 16 years， estimate dose from difference between desired and actual total serum protein concentration， multiplied by the estimated plasma volume (40 mL/kg) times 2 ■Hemodialysis; Adjunct: (Kedbumin(TM)) 12 to 16 years， 25 g (100 mL) IV ■Hypoalbuminemia: (Kedbumin(TM)) 12 to 16 years， 50 to 75 g (200 to 300 mL of 25% solution) IV ■Hypovolemic shock: neonate， infants， and young children， 0.5 to 1 g/kg (10 to 20 mL/kg of 5% solution) IV; further doses based on clinical response， blood pressure， and anemia assessment ■Hypovolemic shock: (Buminate(TM) 5%) older children， initial， 12.5 to 25 g (250 to 500 mL) IV， may repeat at 30 minute intervals; further doses should be individualized ■Neonatal hyperbilirubinemia: 1 g/kg of 25% albumin 1 hour prior to or during exchange transfusion ■Ovarian hyperstimulation syndrome: 50 to 100 g IV over 4 hours， repeat at 4 to 12 hour intervals as needed or 10 to 50 g as a single infusion,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,1.未稀釋亦可使用
EELO,Mometasone,Elomet cream 0.1%， 5gm,TDER,Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid),Hypersensitivity to mometasone furoate， other corticosteroids， or any component of the formulation; untreated fungal， bacterial， and viral (ie， herpes simplex， chicken pox， and vaccinia) infections involving the skin.,Bacterial skin infection， burning， furunculosis， pruritus， skin atrophy， tingling/stinging,25℃以下,Topical: Apply sparingly， do not use occlusive dressings. Therapy should be discontinued when control is achieved; consider reassessment of diagnosis if no improvement is seen within 2 weeks. Cream， ointment: Apply a thin film to affected area once daily,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
EACR5,Acrinol,Acrinol solution 500mL,TDER,Topical agents and dressings for local wound care.,Hypersensitivity， pregnancy.,Hypersensitivity， prolonged use delays wound healing,儲存於25 ℃以下,Pre-op antiseptic skin cleanser Use undiluted.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
LHALD,Haloperidol,Haldomin 2mg/mL， 15mL oral solution,CNEU,,適應症: Mania， psychotic disorders， nausea， vomiting， combative & explosive type of behaviour problems， chorea. 副作用: Hypotension， tardive dyskinesia， extrapyramidal reactions. Blurred vision， blood disorders， GI disturbances. CV disorders， photosensitivity. CNS disorders. 禁忌: Coma， severe CNS depression， parkinsonism.,,室溫,May be taken with or without food (May be taken w/ meals to minimise GI irritation.). Antipsychotic: Oral: Adult:0.5-5 mg bid-tid initially， adjusted as needed. Child: 3-12 yrs， 0.05-0.15 mg/kg/day in 2-3 divided doses. Mental retardation with hyperactivity: 10-15 mg/day in divided doses up to 60 mg/day.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
LBM1,Opium Tincture + Glycyrrhiza + Antimony K tartrate,Brown mixture 120mL,ERSP,Expectorant & antitussive.,Hypersensitivity to any component of the formulation. Severe respiratory depression. Severe liver impairment. Acute alcoholic intoxication.,Constipation， Nausea， Vomiting， Dizziness， Lightheadedness， Sedated， Hypotension， Tachycardia， Seizure， Apnea， Respiratory depression， Drug withdrawal.,25℃以下，不需冰存並避免陽光直射,Adult: 5 mL TID-QID. Can titrate dose up or down if needed.,無需調整劑量,藥品仿單:懷孕及哺乳不建議使用 OPIUM BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible Glycyrrhiza + Antimony K tartrate無資料,無需調整劑量,沒有資料,Uknown 沒有資料,OPIUM PREGNANCY RECOMMENDATION: Human Data Suggest Risk in 3rd Trimester Glycyrrhiza + Antimony K tartrate無資料,Unknown 沒有資料,藥品仿單:懷孕及哺乳不建議使用 OPIUM BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible Glycyrrhiza + Antimony K tartrate無資料,AC;AC15;PC;PO;WM;,,,,,
OGLUS,Glucosamine Sulphate,Glustrong 250mg,CNEU,,Vertebral artrosis， coxofemoral， scapulo-humeral， gonarthrosis， periarthritis， lumbosciatalgies， arthrosis of any etiology.,,RT,4-6 cap daily for 30-60 days.,,,,沒有資料,,,,,,,,,,
IMID,Midazolam,Midatin inj 5mg/1mL,ZANE,,適應症: Sedation with amnesia; sedation in intensive care; premed， induction of anaesth. 副作用: Rarely cardio-resp adverse events， nausea， vomiting， headache， hiccoughs， laryngospasm， dyspnoea， hallucination， oversedation drowsiness， ataxia， paradoxical reactions， amnesic episodes. 禁忌: Premature infants. Myasthenia gravis.,,室溫,Premed before an operation 20-30 mins before induction of anaesth， alone or in combination with anticholinergics. Adult 0.07-0.1 mg/kg IM. Children 0.15-0.2 mg/kg body weight by IM. Sedation in interventions under local anaesth 2.5-5 mg IV 5-10 mins before start of operation. Elderly > 60 years 1-3.5 mg IV slowly. Induction agent in inhalation anesth or sleep-inducing component in combined anesth 10-15 mg IV in combination with analgesics. Maintenance of anesth Further small doses should be injected IV or by continuous infusion. Sedation in ICU Dosage should be individualised & titrated to the desired state of sedation. Loading dose: 0.03-0.3 mg/kg. Maintenance dose: 0.03-0.2 mg/kg/hr.,,,,盡量避免,,,,,,,,,,
OMELE,Mexiletine,Meletin 100mg,CAVS,Ventricular arrhythmia.,Gastrointestinal: Heartburn， Nausea， Vomiting Neurologic: Coordination problem (approximately 10% )， Dizziness， Lightheadedness， Tremor (13.2% ) Ophthalmic: Blurred vision， Visual disturbance Psychiatric: Feeling nervous (5% to 11.3% ),Indigestion; hiccups; unpleasant taste， nausea， vomiting; joint pains; drowsiness， dizziness; confusion; disarticulated speech; blurred vision; nystagmus; tremor; paresthesia， ataxia; convulsions; hypotension， sinus bradycardia， atrial fibrillation， palpitations.,15-30℃緊密容器,Initially， 400 mg as loading dose. Maintenance dose should be started 2-6 hours after initial dose. Usual daily dosage: 400-800 mg in 2-3 divided doses; maximum: 1200 mg/day.,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;,,,,,[磨粉/管灌註記]仿單建議本藥應併用足量液體且整粒吞服。
ONEU1,Gabapentin,Neurontin 100mg,CNEU,,,,15-30℃,Epilepsy: Adult & children > 12 years 900-1800 mg/day in 3 divided doses. May be increased to 1800 mg/day. On the other long term clinical trials，being increased to 2400 mg/day ，some patient may be in the good tolerance .Children 3-12 years Initially 10- 15 mg/kg/day in 3 divided doses， then titrated upward over a period of about 3 days to the effective dose of 25-35 mg/kg/day for children over 5 years. May require up to 40 mg/kg/day for children over 3-5 years.Not recommand that over 12 hrs of maximum interval when dosage up to 50 mg/kg/day.Post-herpetic neuralgia :Adult Initially 900 mg TID. May titrate dosage up to 1800 mg/day.,需調整劑量,,需調整劑量,,,,,,,,,,,
OPAR,Selegiline,Parkryl 5mg,CNEU,,適應症: Parkinson's disease. 副作用: Psychokinesia， insomnia， hallucination， GI disturbances. Gastrointestinal: Abdominal pain (4% )， Nausea (10 to 11% )， Oral irritation Neurologic: Dizziness (11% )， Headache (7% )， Insomnia (7% ) Psychiatric: Hallucinations (4% ) 禁忌: Active ulceration. Pregnancy and lactation.,,室溫,Parkinson's disease， in combination with levodopa/carbidopa; Adjunct: 5 mg ORALLY twice a day (with breakfast and lunch); MAX 10 mg/day Parkinson's disease， in combination with levodopa/carbidopa; Adjunct: (Zelapar(TM) orally disintegrating TAB) initial， 1.25 mg dissolved ORALLY on the tongue once daily (before breakfast) for at least 6 weeks Parkinson's disease， in combination with levodopa/carbidopa; Adjunct: (Zelapar(TM) orally disintegrating TAB) maintenance， may increase dose up to 2.5 mg dissolved ORALLY on the tongue once daily (before breakfast)， MAX 2.5 mg/day,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OLIVA,Pitavastatin,Livalo 2mg,CAVS,,禁忌: Hypersensitivity to pitavastatin or any component of the formulation; active liver disease including unexplained persistent elevations of hepatic transaminases; concurrent use with cyclosporine; pregnancy; breast-feeding 副作用: 2% to 10%: Gastrointestinal: Constipation (2% to 4%)， diarrhea (2% to 3%) Neuromuscular & skeletal: Back pain (1% to 4%)， myalgia (2% to 3%)， pain in extremities (1% to 2%) <2% (Limited to important or life-threatening): Alkaline phosphatase increased， amnesia (reversible)， arthralgia， bilirubin increased， blood glucose increased， cognitive impairment (reversible)， confusion (reversible)， CPK increased， glycosylated hemoglobin (Hb A1c) increased， headache， hyperglycemia， influenza， memory disturbance (reversible)， memory impairment (reversible)， nasopharyngitis， pruritus， rash， transaminases increased， urticaria 適應症:Primary hyperlipidemia and mixed dyslipidemia for Adult and 10 years older chindren.,,室溫,Dosing: Adult:Primary hyperlipidemia and mixed dyslipidemia: Oral: Initial: 2 mg once daily; may be increased to maximum 4 mg once daily 10 years older chindren: Oral: Initial: 1 mg once daily; may be increased to maximum 2 mg once daily Note: Doses should be individualized according to the baseline LDL-cholesterol levels， the recommended goal of therapy， and patient response; adjustments should be made at intervals of 4 weeks. Dosage adjustment with concomitant medications: Erythromycin: Pitavastatin dose should not exceed 1 mg once daily Rifampin: Pitavastatin dose should not exceed 2 mg once daily Dosing: Geriatric Refer to adult dosing. Safety and efficacy not established in pediatric patients,需調整劑量,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) No reports describing the use of pitavastatin during human lactation or measuring the amount， if any， of the drug excreted into milk have been located. Because of the potential for adverse events in nursing infants， pitavastatin use is contraindicated during lactation,需調整劑量,不可使用,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) No reports describing the use of pitavastatin during human lactation or measuring the amount， if any， of the drug excreted into milk have been located. Because of the potential for adverse events in nursing infants， pitavastatin use is contraindicated during lactation,,,,,,
INS1,Sodium Chloride,Sodium chloride 0.9% inj 1000mL,MSIV,為食鹽水沖洗液(A001085209),,,室溫,Individualized dosage.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IRR;IRRI;IVD;,,,,,
IMYC,Micafungin,Mycamine inj 50mg,QANB,Candidemia， acute disseminated candidiasis， and Candida peritonitis and abscesses， Esophageal candidiasis， Prophylaxis of Candida infection in hematopoietic stem cell transplantation,Hypersensitivity to micafungin， other echinocandins， or any component of the formulation,>10%: Cardiovascular: Tachycardia (3% to 26%)， localized phlebitis (with peripheral administration; 5% to 19%) Central nervous system: Headache (2% to 44%)， insomnia (4% to 37%)， anxiety (?23%)， dizziness (13%) Dermatologic: Pruritus (pediatric patients ages 3 days through 16 years: ?33%; adults 6%)， skin rash (2% to 30%)， urticaria (pediatric patients ages 3 days through 16 years: ?19%; adults <5%) Endocrine & metabolic: Hypokalemia (14% to 18%)， hypomagnesemia (6% to 13%) Gastrointestinal: Diarrhea (7% to 77%)， nausea (7% to 71%)， vomiting (7% to 66%)， abdominal pain (2% to 35%)， abdominal distension (pediatric patients ages 3 days through 16 years: 2% to 19%)， mucositis (14%)， constipation (11%) Genitourinary: Decreased urine output (pediatric patients ages 3 days through 16 years: ?23%)， hematuria (pediatric patients ages 3 days through 16 years: ?23%) Hematologic & oncologic: Neutropenia (5% to 75%)， thrombocytopenia (4% to 75%)， anemia (pediatric patients ages 3 days through 16 years: 13% to 51%; adults 3% to 10%)， febrile neutropenia (?16%) Hepatic: Increased serum ALT (pediatric patients ages 3 days through 16 years: ?16%; adults 5%)， abnormal hepatic function tests (pediatric patients ages 3 days through 16 years: <15%; adults 4%)， hyperbilirubinemia (pediatric patients ages 3 days through 16 years: <15%; adults <1%) Renal: Renal failure (pediatric patients ages 3 days through 16 years: <15%) Miscellaneous: Fever (pediatric patients ages 3 days through 16 years: 9% to 61%; adults 7% to 20%)， infusion related reaction (pediatric patients ages 3 days through 16 years: ?16%; adults <5%),15-30℃避光,Adult: Candida esophagitis: 150 mg IV Q24H; candidemia: 100 mg IV Q24H; prophylaxis， post transplant: 50 mg IV Q24H. Children > 4 months: Esophageal candidiasis: (weight< 30 kg) 3 mg/kg Q24H or (weight > 30 kg) 2.5 mg/kg Q24H (maximum 150 mg); candidiasis: 2 mg/kg Q24H (maximum 100 mg); prophylaxis in HSCT recipients: 1 mg/kg Q24H (maximum 50 mg).,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,IVD: 5mL N/S， D5W(需減少泡沫形成),【D5W】可選 。【N/S】可選 。,,給藥濃度0.5~1.5mg/mL，建議滴注1小時以上,本品配製後應避光，並可儲存在原小瓶內，室溫25℃(77℉)下最多保存24小時。
ITTA1,Tetanus Toxoid Alum Precipitate,Tetanus Toxoid 0.5mL/dose， 1mL/vial,HIMM,,適應症: Active immunization of tetanus. 副作用: Drowsiness， malaise， hypersensitivity. 禁忌：Hypersensitivity to tetanus toxoid or any component of the formulation,,2-8℃,IM， 0.5 mL/dose. Primary immunization: I.M.: 0.5 mL; repeat 0.5 mL at 4-8 weeks after first dose and at 6-12 months after second dose Routine booster dose: Recommended every 10 years Tetanus prophylaxis in wound management: Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated， the immunization status of the patient， proper use of tetanus toxoid and/or tetanus immune globulin (TIG)， wound cleaning， and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until >10 years after the most recent dose even if they have a wound that is neither clean nor minor.,無需調整劑量,Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules.,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules.,IM;,,,,,
IHALA,Eribulin,Halaven inj 1mg/2mL,RACA,Treatment of Breast cancer， metastatic.,Hypersensitivity to eribulin mesylate， halichondrin B， or its chemical derivatives.,>10%: Central nervous system: Fatigue (54%)， fever (21%)， headache (19%) Dermatologic: Alopecia (45%) Gastrointestinal: Nausea (35%)， constipation (25%)， weight loss (21%)， anorexia (20%)， diarrhea (18%)， stomatitis (5% to 18%)， vomiting (18%) Hematologic: Neutropenia (82%; grades 3: 28%; grade 4: 29%; nadir: 13 days; recovery: 8 days)， anemia (58%; grades 3/4: 2%) Hepatic: ALT increased (18%) Neuromuscular & skeletal: Weakness (54%)， peripheral neuropathy (35%; grades 3/4: ?8%)， arthralgia/myalgia (22%)， back pain (16%)， bone pain (12%)， limb pain (11%) Respiratory: Dyspnea (16%)， cough (14%) 1% to 10%: Cardiovascular: Peripheral edema Central nervous system: Depression， dizziness， insomnia Dermatologic: Rash Endocrine & metabolic: Hypokalemia Gastrointestinal: Mucosal inflammation (9%)， abdominal pain， dyspepsia， taste alteration， xerostomia Genitourinary: Urinary tract infection (10%) Hematologic: Neutropenic fever (5%)， thrombocytopenia (grades 3/4: 1%) Neuromuscular & skeletal: Muscle spasm Ocular: Lacrimation increased Respiratory: Upper respiratory infection <1% (Limited to important or life-threatening): Pancreatitis， pharyngolaryngeal pain， sepsis,25℃以下,1.4 mg/m2 on days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.,需調整劑量,廠商 懷孕分級建立: D,無需調整劑量,沒有資料,Contraindicated,,Contraindicated 哺乳期使用禁忌,廠商 懷孕分級建立: D,IVD;,,【N/S】仿單建議。,,可給予未稀釋或以100 mL 0.9% 氯化鈉溶液稀釋後的注射液。 靜脈注射給藥時間為2至5分鐘。,不可以葡萄糖溶液稀釋或含葡萄糖溶液之靜脈注射管線給藥。
OCEFA,Cefadroxil,賜福得修Cefadroxil 500mg,QANB,Susceptible infections.,Hypersensitivity to cephalosporins.,Nausea， vomiting， diarrhoea， abdominal discomfort; skin rash， angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida. Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.,25℃以下避光,(仿單) Adults: 1-2 g orally in 1-2 divided doses daily. (Uptodate) Children and adolescents: 15-30 mg/kg/dose every 12 hours (maximum daily dose: 2 g/day),無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OPKM,Amantadine,PK-Merz 100mg,CNEU,,適應症: Parkinsonism of various origin， senile Parkinsonism， residual symptoms & discomfort after stereotactic operations. 副作用: Occasional dry mouth; dizziness. Paranoid exogenous psychoses associated with visual hallucinations， visual disturbances; motor or mental restlessness， urinary retention in the case of prostatic hypertrophy， signs of cardiac insufficiency， cardiac dysrhythmia associated with tachycardia， nausea， sleep disturbances， orthostatic dysregulation; very rarely， myoclonus & symptoms of peripheral neuropathy; livedo reticularis (marble skin) & lower-leg & ankle oedema are common occurrences; very rarely， increased photosensitivity; very rarely haematological side effects， such as leukopenia & thrombocytopenia; very rarely， anaphylactic reactions after infusion therapy. Cardiovascular: Orthostatic hypotension (1% to 5% )， Peripheral edema (1% to 5% ) Gastrointestinal: Constipation (1% to 5% )， Diarrhea (1% to 5% )， Loss of appetite (1% to 5% )， Nausea (5% to 10% )， Xerostomia (1% to 5% ) Neurologic: Ataxia (1% to 5% )， Confusion (1% to 5% )， Dizziness (5% to 10% )， Headache (1% to 5% )， Insomnia (5% to 10% )， Somnolence (1% to 5% ) Psychiatric: Agitation (1% to 5% )， Anxiety (1% to 5% )， Depression (1% to 5% )， Dream disorder (1% to 5% )， Feeling nervous (1% to 5% )， Hallucinations (1% to 5% )， Irritability (1% to 5% ) Other: Fatigue (1% to 5% ) 禁忌: Severe CHF (NYHA class IV)， cardiomyopathies & myocarditis， 2nd or 3rd degree AV block， existing bradycardia under 55 beats/min， known prolonged QT interval (Bazett QTc > 420 ms) or discernible U-waves or congenital QT syndrome in the family anamnesis ， history of serious ventricular arrhythmias including torsade de pointes， simultaneous treatment with budipine or other drugs that prolong the QT interval， reduced levels of potassium or magnesium in the blood. Pregnancy & lactation.,,室溫,100 mg/day for the first 4-7 days， followed by a once-weekly increase in daily dose of 100 mg until the maintenance dose is reached. Usual effective dose: 200-600 mg/day.,無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OWELL,Bupropion,Wellbutrin SR 150mg (排裝),CNEU,,適應症: Treatment of depressive illnesses. 副作用: Very common: Insomnia， headache， dry mouth， GI disturbances eg nausea & vomiting. Common: Hypersensitivity reactions eg urticaria， anorexia， agitation， anxiety， tremor， dizziness， taste disorders， visual disturbances， tinnitus， hypertension， flushing， abdominal pain， constipation， rash， pruritus， sweating， fever， chest pain， asthenia. Cardiovascular: Hypertension (2.5% to 4.3% )， Tachyarrhythmia (10.8% ) Dermatologic: Pruritus (2% to 4% )， Rash (3% to 5% )， Urticaria (1% to 2% ) Gastrointestinal: Constipation (5% to 26% )， Nausea (9% to 24% ) Musculoskeletal: Arthralgia (1% to 5% )， Myalgia (2% to 6% ) Neurologic: Confusion (8.4% )， Dizziness (6% to 22.3% )， Headache (approximately 25% )， Insomnia (11% to 40% )， Tremor (2% to 21.1% ) Otic: Tinnitus (3% ) Psychiatric: Agitation (2% to 31.9% )， Anxiety (3.1% to 8% )， Hostile behavior (6% ) Reproductive: Disorder of menstruation (5% ) Respiratory: Pharyngitis (3% to 11% ) Other: Xerostomia (10% to 27.6% ) 禁忌: Seizure disorder， undergoing abrupt discontinuation of alcohol or sedatives， current or previous diagnosis of bulimia or anorexia nervosa. Concomitant with other MAOIs.,,室溫,Adult & adolescents > 18 years Initially 150 mg as a single daily dose. Max: 300 mg/day in 2 divided doses at least 8 hr apart.,,,,除非治療上需要,,,,,,,,,,
IKCL6,Potassium Chloride,冷藏20mEq KCl in【D5W 250mL】,NUTR,,,,2-8℃,Adult: Initial loading dose: 40~60 mEq， with ECG monitoring then based on serum potassium levels， Serum K>2.5 mEq/L: concentration < 30 mEq/L， with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia， treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,無需調整劑量,,無需調整劑量,除非治療上需要,,,Compatible 哺乳時可使用,,IVD;,,,,,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
ICEFT,Ceftazidime,Cetazine inj 1gm,QANB,Severe infections of resp tract， ENT， urinary tract， GI， biliary & abdominal. Skin & soft tissue infections， bone & joint infections. Infections associated with haemo- & peritoneal dialysis & with continuous ambulatory peritoneal dialysis (CAPD).,Hypersensitivity to cephalosporins.,Phlebitis or thrombophlebitis at IV inj site， pain &/or inflammation after IM inj. Hypersensitivity reactions， maculopapular or urticarial rash， fever， pruritus. GI disturbances， candidiasis， vaginitis， headache， dizziness， parasthesia， bad taste. Transient hematological changes. Cardiovascular: Phlebitis (less than 2%) Dermatologic: Injection site pain Gastrointestinal: Diarrhea (less than 2%) Immunologic: Immune hypersensitivity reaction， Rash (2%),25℃以下避光,Adults: 0.5-2 g IV/IM Q8-12H; cystic fibrosis: 100-150 mg/kg/day (divided Q8H). Children aged 2 months to 1 years: 25-50 mg/kg Q8-12H *****NEONATE ANTIBIOTICS DOSE***** Ceftazidime (Fortum): general infection Body weight <1kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50mg/kg Q12H  Age 15-28 day 50 mg/kg Q8H Body weight 1-2kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age<=7day 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50mg/kg Q8H Meningitis: use smaller doses and longer intervals for neonates <2 kg Age<=7days 100-150 mg/kg/day divided Q12-Q8H 8-28 days 150 mg/kg/day divided Q8H Body weight <1kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight 1-2kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age<=7day 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50mg/kg Q8H,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IM;IMP;IVD;IVI;IVP;IVPUSH;SCI;SUBCI;,"IM: 3.5 mL D/W; IV: 10mL D/W， N/S， D5W",【D5W】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【D5NS】可選 。【L/R】可選 。,推注時間至少3 ~ 5分鐘,給藥濃度20mg/mL，以20 ~ 30分鐘緩慢滴注,1. 注射前詢問病患是否有β-醯胺類抗生素過敏史。 2. 監測體溫、CBC、肝腎功能、PT值，注意是否發生抗生素引起的腹瀉。 3. 2020/11/26詢問廠商: 2-8度C保存，主成份安定性為4天。
EPRE2,Prednisolone,Pred Mild 0.12% 5mL oph susp,TOPH,,適應症: Steroid responsive inflammation of the palpebral & bulbar conjunctiva， cornea & anterior segment of the globe. 副作用: Increased intraocular pressure with optic nerve damage， visual field defects. Posterior subcapsular cataract formation (heavy or protracted use)， secondary ocular infection from fungi or viruses liberated from ocular tissues & perforation of the globe when there is thinning of the cornea or sclera. Systemic side effects may occur with extensive use of steroids. 禁忌: Acute untreated purulent ocular infections， acute superficial herpes simplex (dendritic keratitis)， vaccinia， varicella & most other viral diseases of the cornea & conjunctiva， ocular TB & fungal diseases of the eye.,,室溫,1-2 drop bid-qid; during the initial 24-48 hr the dosage may be increased to 2 drop hrly.,,,,盡量避免,,,Compatible 哺乳時可使用,,,,,,,
EETH7,Alcohol,75% Ethanol 200mL,TDER,,,,25℃以下,,無需調整劑量,,無需調整劑量,,,,,,EXT;,,,,,
OXELJ,Tofacitinib,Xeljanz 5mg,HIMM,Rheumatoid arthritis (Moderate to Severe)， Psoriatic arthritis， Ankylosing spondylitis， Ulcerative colitis (Moderate to Severe),Hypersensitivity to tofacitinib or any component of the formulation,Common: Increased HDL level (10-12%)， Low density lipoprotein cholesterol above reference range (15-19%)， Headache (3.4-9%)， Urinary tract infectious disease (2%)， Nasopharyngitis (2.8-14%)， Upper respiratory infection (3.8-6%) Serious: Cardiovascular morbidity， Major adverse cardiac events (MACE)， Death， Cardiovascular， Myocardial infarction， Skin cancer， Non-melanoma， Gastrointestinal perforation， Anemia (2-4%)， Arterial thrombosis， Decreased lymphocyte count (0.04%)， Deep venous thrombosis， Neutropenia (0.07%)， Hepatotoxicity， Infectious disease (20-22%)， Malignant lymphoma， Opportunistic infection， Post-transplant lymphoproliferative disorder， Epstein Barr virus associated (2.3%)， Tuberculosis， Cerebrovascular accident， Lung cancer， Pulmonary embolism， Cancer,30℃以下,Rheumatoid arthritis， psoriatic arthritis， ankylosing spondylitis: 5 mg orally twice daily. Ulcerative colitis induction dose 10 mg orally twice daily (8-16 weeks)， maintenance dose 5 mg orally twice daily.,需調整劑量,BREASTFEEDING RECOMMENDATION: Contraindicated if Combined with Methotrexate,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,PREGNANCY RECOMMENDATION: Contraindicated if Combined with Methotrexate,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,BREASTFEEDING RECOMMENDATION: Contraindicated if Combined with Methotrexate,,,,,,[磨粉/管灌註記]本藥為免疫抑制劑，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OPRAD,Dabigatran,Pradaxa 110mg,HEMT,Prevention of venous thromboembolic events in patients who have undergone elective total hip or knee replacement surgery; stroke & systemic embolism in patients w/ atrial fibrillation in whom anti-coagulation is appropriate.,Severe renal impairment (CrCl <30 mL/min)， haemorrhagic manifestations， bleeding diathesis or patients w/ spontaneous or pharmacological impairment of haemostasis， lesions at risk of clinically significant bleeding， concomitant treatment w/ strong p-glycoprotein (p-gp) inhibitors eg ketoconazole.,Anemia， GI haemorrhage， haematoma， hematuria， wound haemorrhage; wound secretion， postprocedural haematoma， postprocedural haemorrhage， post-op anemia， traumatic haematoma， postprocedural discharge; ALT ≧3 x ULN， decreased haemoglobin. Epistaxis， urogenital haemorrhage; abdominal pain， diarrhoea， dyspepsia， nausea.,30℃以下，避免濕氣,Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation:adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily， with or without food. For prophylaxis of venous thrombosis of hip replacement surgery， starting 75mg within 1-4 hours after the operation， then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days， then 150mg twice a day for 6 months.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,WM;,,,,,[磨粉/管灌註記]本藥應整粒吞服， 切勿咬嚼或打開膠囊。若破壞劑型會造成生體可用率增加1.4倍而增加出血風險。
IHEPA1,Heparin,Hepac inj 1KIU/0.2mL,HEMT,,Hypersensitivity to any component of the formulation.,,25℃以下,,無需調整劑量,,無需調整劑量,,Compatible,,Compatible 哺乳時可使用,,IRR;IVD;,,,,,
IABI5,Cisplatin,Abiplatin inj 50mg/100mL,RACA,,適應症: Metastatic testicular tumors， Metastatic ovarian tumors， Advanced bladder cancer. 副作用: Nausea & vomiting， renal toxicity， bone-marrow depression， ototoxicity， serum electrolyte disturbances， peripheral neuropathy， retinal toxicity， anaphylactic reactions， cardiac abnormalities. 禁忌: Hearing or renal impairment， myelosuppression， dehydration.,,室溫,IV infusion over 6-8 hrs， As a single agent: 50-100 mg/ml once every 4 wks. Metastatic testicular tumors: combined with vinblastine & bleomycin， 20/mL/day for 5 days every 3 wks for 3 courses. Metastatic ovarian tumors: combined with doxorubicin， 50 mg/mL once every 3 wks.,,,,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 調配與注射cisplatin的器具不可含有鋁。 3. 稀釋後的輸注溶液應避光保存。 4. 給藥前後應給予病人適當水分補充。 5. 監測CBC、肝腎功能。 6. 定期神經學、聽力檢測。
ECLOO,Clobetasol,Clobetasol ointment 0.05% 7gm,TDER,,適應症: Psoriasis; recalcitrant eczema; lichen planus; discoid lupus erythematosus & other skin conditions which do not respond satisfactorily to less active steroids. 副作用: Features of hypercorticism， local atrophic changes， pigmentation changes & hypertrichosis. Exacerbation of symptoms may occur. 禁忌: Rosacea; acne vulgaris; perioral dermatitis; perianal & genital pruritus; primary cutaneous viral infection; bacterial， fungal infected skin lesions; perianal & genital pruritus; dermatoses in infant < 1 year including dermatitis & napkin eruptions. 是一種強效的類固醇藥膏，強效類固醇是較不適合「用在肛門及生殖器」，是因為此部位表皮層很薄，若有發炎現象可採用弱效或中效類固醇，以免吸收強效藥品，產生不良副作用,,室溫,Apply sparingly to the affected area once or bid.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,EXT;SKIN;TOPI;,,,,,
OCOMT,Entacapone,Comtan 200mg,CNEU,Pregnancy & lactation. Liver impairment. Pheochromocytoma. Concomitant use w/ non-selective MAO-A & MAO-B inhibitors. Concomitant use w/ a selective MAO-A plus a selective MAO-B inhibitor. History of neuroleptic malignant syndrome (NMS) &/or non-traumatic rhabdomyolysis.,Management of Parkinson's disease as an adjunct to levodopa therapy.,Dyskinesia; GI symptoms; urine discoloration; fatigue， insomnia， paranoia， confusion， hallucinations; dizziness， postural hypotension， vertigo， headache; leg cramps， hyperkinesia， tremor， increased sweating; slight decrease in Hb， erythrocyte count， & hematocrit. Rarely， increases in liver enzymes.,30℃以下,Entacapone is used in combination with either levodopa/carbidopa or levodopa/benserazide. Other antiparkinsonian drugs may be used simultaneously. Give 200 mg orally with each dose of levodopa/dopa-decarboxylase inhibitor， up to a maximum of 10 times daily (maximum daily dose: 2000 mg); reductions in daily levodopa dose or extension of levodopa dosing intervals may be necessary to optimize patient's response. If entacapone treatment is discontinued， it is necessary to adjust the dosage of other antiparkinsonian treatments， especially levodopa， to achieve a sufficient level of control of the parkinsonian symptoms.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
EDIF,Benzydamine,Difflam forte 3mg/mL， 15mL,CNEU,Relief of painful conditions of the mouth & throat including tonsillitis， sore throat， radiation mucositis， aphthous ulcers， post orosurgical & periodontal procedures.,Hepatic or renal impairment. children < 6 years. In bacterial infection， appropriate antibacterial therapy should be used in addition to product.,Oral numbness; dryness or thirst， tingling， warm feeling in mouth， altered sense of taste.,25℃以下,Adult & children > 12 years: 2-4 sprays onto the affected area. Children 6-12 years: 2 sprays onto the affected area. May be repeated every 1.5-3 hourly. Duration should not exceed 7 days.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,ORO;,,,,,
IMTX,Methotrexate,Methotrexate 500mg/20mL inj,RACA,,適應症:Oncology uses: Acute lymphoblastic leukemia (ALL) maintenance treatment， ALL meningeal leukemia (preservative-free only; prophylaxis and treatment); treatment of trophoblastic neoplasms (gestational choriocarcinoma， chorioadenoma destruens and hydatidiform mole)， breast cancer， head and neck cancer (epidermoid)， cutaneous T-Cell lymphoma (advanced mycosis fungoides)， lung cancer (squamous cell and small cell)， advanced non-Hodgkin lymphomas (NHL)， osteosarcoma (preservative-free only). Nononcology uses: Treatment of psoriasis (severe， recalcitrant， disabling) that is unresponsive to other therapies; severe， active rheumatoid arthritis (RA) that is unresponsive to or intolerant of first-line therapy including full dose nonsteroidal anti-inflammatory agents (NSAIDs); active polyarticular-course juvenile idiopathic arthritis (pJIA) that is unresponsive to or intolerant of first-line therapy including full dose nonsteroidal anti-inflammatory agents (NSAIDs). Off-Label: Abortion (medical management); Acute graft-versus-host disease (prophylaxis); Acute promyelocytic leukemia (APL) maintenance (adults); Bladder cancer; CNS lymphoma; Crohn disease (maintenance of remission); Dermatomyositis/polymyositis; Ectopic pregnancy; Multiple sclerosis; Nonleukemic meningeal cancer; Soft tissue sarcoma (desmoid tumors， aggressive fibromatosis)， advanced; Systemic lupus erythematosus， moderate-to-severe; Takayasu arteritis， refractory or relapsing disease; Uveitis (adults) 副作用:Ulcerative stomatitis， leukopenia， nausea & abdominal distress. malaise， fatigue， chills & fever， dizziness & decreased resistance to infection. Erythematous rashes， pruritus， urticaria， photosensitivity， depigmentation， alopecia， ecchymosis， telangiectasia， acne & furunculosis. Hematologic disorders. GI disturbances. CNS effects. Metabolic changes， precipitating diabetes， osteoporosis， conjunctivitis， abnormal tissue cell changes， anaphylaxis. 禁忌:Known hypersensitivity to methotrexate or any component of the formulation; breast-feeding. Additional contraindications for patients with psoriasis， rheumatoid arthritis or polyarticular-course juvenile idiopathic arthritis: Pregnancy， alcoholism， alcoholic liver disease or other chronic liver disease， immunodeficiency syndromes (overt or laboratory evidence); preexisting blood dyscrasias (eg， bone marrow hypoplasia， leukopenia， thrombocytopenia， significant anemia).,,RT,Choriocarcinoma: Oral or IM， 15-30 mg/day for a 5 day course. Acute leukemia: Induction， oral or IV， 3.3 mg/m2/day with prednisolone; maintenance， oral or IM， 30 mg/mL twice a week， or IV， 2.5 mg/kg every 14 days. Meningeal leukemia: Intrathecal， 0.2-0.5 mg/kg or 12 mg/mL (max. 15mg) every 2-5 days until the cell count of cerebrospinal fluid returns to normal. Burkitt's lymphoma (stage I & II): Oral， 10-25 mg/day for 4-8 days. Psoriasis: Oral， IM or IV， 10-25 mg/week. Rheumatoid arthritis: Oral， 2.5 mg q12h for 3 doses every week. Mycosis fungoides: Oral， 2.5-10 mg/day for weeks or months; IM， 50mg/week.,,,,不可使用,,,,,,,,,,
OTAM7,Oseltamivir,Tamiflu 75mg (自費),QANB,Prophylaxis & treatment of influenza in adult & children.,Hypersensitivity.,Nausea， vomiting， abdominal pain， headache. Insomnia， diarrhea. Gastrointestinal: Abdominal pain (2% to 5% )， Nausea (4% to 10% )， Vomiting (2% to 15% ),25℃以下,(仿單) Influenza: Treatment (for patients > 1 year): - Adult: Usual Dose for uncomplicated influenza of <48 hrs duration: 75 mg PO BID x 5 days; complicated influenza in immunocompromised patients even if ill over 48 hrs: 75 mg PO BID x 10 or more days. - Children > 40 kg: 75 mg BID x 5 days - Children > 23-40 kg: 60 mg BID x 5 days - Children > 15-23 kg: 45 mg BID x 5 days - Children < or = 15 kg: 30 mg BID x 5 days - Infant 0-12 months: 3 mg/kg BID x 5 days Prophylaxis (for patients > 1 year): - Adults: 75 mg orally once daily for 10 days to 6 weeks. - Children > 40 kg: 75 mg QD x 10 days - Children > 23-40 kg: 60 mg QD x 10 days - Children > 15-23 kg: 45 mg QD x 10 days - Children < or = 15 kg: 30 mg QD x 10 days - Infants 3-11 months: 3 mg/kg once daily (熱病),無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
IOXA5,Oxacillin,Oxacillin Sod. inj 500mg,QANB,,適應症:Staphylococcal infections resistant to benzylpenicillin 副作用:Fever; rash; diarrhoea， nausea， vomiting; agranulocytosis， eosinophilia， leukopenia， neutropenia， thrombocytopenia; AST increased， hepatotoxicity; acute interstitial nephritis， haematuria; serum sickness-like reactions. Potentially Fatal: Anaphylaxis. 禁忌:Hypersensitivity to penicillins,,室溫,Infections due to staphylococci resistant to benzylpenicillin Adult: 0.5-1 g IM， slow IV over 10 minutes or by IV infusion every 4-6 hr. Doses may be increased in severe infections. Child: <40 kg: 50-100 mg/kg/day in divided doses. Elderly: Dosage adjustment recommended. Renal impairment: Dosage adjustment recommended,,,,可能安全,,,Compatible 哺乳時可使用,,,,,,,1. 注射前檢查病患是否有PCN過敏史。 2. 老年人應減慢給藥速率，避免發生血栓性靜脈炎 3. 監測體溫、CBC、血球分化計數、肝腎功能。
IPG2,Polysaccharides of Astragalus membranaceus,PG2 inj 500mg,RACA,As a complementary and palliative medicine for managing cancer-related fatigue.,1.Hypersensitivity to Astragalus. 2.Precautionary use in individuals with autoimmune disease 3.Discontinue prior to elective surgery to reduce risk of bleeding,Itching (2.38%)， skin rash (9.21%)， dizziness (2.38%)， Fever(7.24%)， feeling cold(5.26%)， chills(2.63%),25℃以下乾燥處避光,Adults: 500 mg infused intravenously for 2.5-3.5 hours 2-4 times/week for a total of 2-4 weeks. Reconstitute each vial of 500 mg of PG2 with 10 mL normal saline. Shake thoroughly until dissolved completely. Mix the dissolved solution with normal saline (490mL) for IV infusion.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,先抽10 mL N/S溶解乾粉，並注射回原500 mL點滴瓶,【N/S】可選 仿單建議。,,先抽10 mL N/S溶解乾粉，並注射回原500 mL點滴瓶 建議以2.5-3.5小時緩慢滴注，需使用0.22 micron fillter過濾,1.需使用需使用0.22 micron fillter過濾。 2.先抽10 mL N/S溶解乾粉，並注射回原500 mL點滴瓶。 3.每週2-4次使用，使用2-4週。 4.若需預防輸注反應，可延長滴注時間。經詢問廠商(20220518)本藥泡製後之安定性可達24小時，但此安定性資料不包含配製時的微生物變因。
IOLA5,Oxaliplatin,Olatin I.V. inj 50mg/10mL,RACA,,適應症:Adjuvant treatment of stage III colon cancer after complete resection of primary tumor and advanced colorectal cancer (in combination with infusional fluorouracil and leucovorin). 副作用:Nausea， vomiting， diarrhea; anemia， leucopenia， granulocytopenia， thrombocytopenia; peripheral neuropathies; fever， rash， anorexia. Gastrointestinal: Abdominal pain (monotherapy， 31%; combination therapy， up to 39% )， Constipation (combination therapy， up to 32% )， Diarrhea (monotherapy， 46%; combination therapy， up to 76% )， Loss of appetite (monotherapy， 20%; combination therapy， up to 35% )， Nausea (monotherapy， 64%; combination therapy， up to 83% )， Stomatitis (monotherapy， 14%; combination therapy， up to 42% )， Vomiting (monotherapy， 4%; combination therapy， up to 64% ) Hematologic: Anemia (monotherapy， 64%; combination therapy， up to 81% )， Neutropenia， All grades (monotherapy， 7%; combination therapy， up to 81% ) Musculoskeletal: Backache Respiratory: Cough (monotherapy， 11%; combination therapy， up to 35% ) Other: Fatigue (monotherapy， 61%; combination therapy， up to 70% )， Fever (monotherapy， 25%; combination therapy， up to 29% ) 禁忌:Hypersensitivity to oxaliplatin， other platinum-containing compounds， or any component of the formulation. Pregnancy， breast-feeding; severe renal impairment (CrCl <30 mL/minute),,室溫,Ovarian cancer: 130 mg/m2 every 3 weeks as single agent or in combination chemotherapy. Adult Adjuvant therapy 85 mg/m2 IV every 2 wk for 6 mth (12 cycles). Metastatic colorectal cancer 85 mg/m2 IV every 2 wk. Gastric cancer: usual dose is 65-85 mg/m2 IV infusion over 2 hours. Colon cancer or metastatic colorectal cancer， adjuvant， stage III or metastatic colorectal cancer: 85 mg/m2 every 2 wk in combination with infusional 5-fluorouracil/leucovorin. Colorectal cancer， advanced: 130 mg/m2 every 3 wk in combination with capecitabine.,無需調整劑量,Micromedex: Infant risk cannot be ruled out. No reports describing the use of oxaliplatin during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if oxaliplatin affects the quantity and composition of breast milk. Breastfeeding is not recommended while taking oxaliplatin due to the potential risk to the nursing infant. The manufacturer recommends making a decision to discontinue nursing or delay use of oxaliplatin in breastfeeding women.,需調整劑量,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex: Infant risk cannot be ruled out. No reports describing the use of oxaliplatin during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if oxaliplatin affects the quantity and composition of breast milk. Breastfeeding is not recommended while taking oxaliplatin due to the potential risk to the nursing infant. The manufacturer recommends making a decision to discontinue nursing or delay use of oxaliplatin in breastfeeding women.,IVD;,,【D5W】可選 仿單建議。,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 調配與注射的器具不可含有鋁。本藥品不可使用含有氯的稀釋溶液 (例如：N/S)，給藥時避免和鹼性藥物(例如：5-FU)使用相同管路。 3. 稀釋後的輸注溶液在室溫下安定性維持6小時。 4. 監測CBC、腎功能，注意病人是否有呼吸方面的異常症狀。 5. 定期神經學檢測。
LMEG4,Megestrol,Megatus 40mg/mL， 120mL suspension,HM,Treatment of anorexia， cachexia， or unexplained significant weight loss in patients with AIDS or cancer. Palliative treatment of breast and endometrial carcinoma.,1.Hypersensitivity to megestrol or any component of the formulation. 2.Known or suspected pregnancy.,Abdominal pain， chest pain， infections. Cardiomyopathy， palpitations. Constipation， dry mouth， liver enlargement， increased salivation， oral candida infections. Leukopenia， increased LDH， edema. CNS disturbances. Dysnea， cough， pharyngitis， lung disease. Hair loss， papule， pruritus & other skin disorders， poor vision， proteinuria， incontinence， UTI， gynecomastia. Cardiovascular: Hypertension (?8%)， cardiomyopathy (1% to 3%)， chest pain (1% to 3%)， edema (1% to 3%)， palpitation (1% to 3%)， peripheral edema (1% to 3%)， heart failure Central nervous system: Headache (?10%)， insomnia (?6%)， fever (1% to 6%)， pain (?6%， similar to placebo)， abnormal thinking (1% to 3%)， confusion (1% to 3%)， depression (1% to 3%)， hypoesthesia (1% to 3%)， seizure (1% to 3%)， mood changes， malaise， lethargy Dermatologic: Rash (2% to 12%)， alopecia (1% to 3%)， pruritus (1% to 3%)， vesiculobullous rash (1% to 3%) Endocrine & metabolic: Hyperglycemia (?6%)， gynecomastia (1% to 3%)， adrenal insufficiency， amenorrhea， breakthrough bleeding， cervical erosion and secretions (changes)， breast tenderness increased， Cushing's syndrome， diabetes， glucose intolerance， HPA axis suppression， hot flashes， hypercalcemia， menstrual flow changes， spotting， vaginal bleeding pattern changes Gastrointestinal: Diarrhea (6% to 15%， similar to placebo)， flatulence (?10%)， vomiting (?6%)， nausea (?5%)， dyspepsia (?4%)， abdominal pain (1% to 3%)， constipation (1% to 3%)， salivation increased (1% to 3%)， xerostomia (1% to 3%)， weight gain (not attributed to edema or fluid retention) Genitourinary: Impotence (4% to 14%)， decreased libido (?5%)， urinary incontinence (1% to 3%)， urinary tract infection (1% to 3%)， urinary frequency (?2%) Hematologic: Anemia (?5%)， leukopenia (1% to 3%) Hepatic: Hepatomegaly (1% to 3%)， LDH increased (1% to 3%)， cholestatic jaundice， hepatotoxicity Neuromuscular & skeletal: Weakness (2% to 6%)， neuropathy (1% to 3%)， paresthesia (1% to 3%)， carpal tunnel syndrome Ocular: Amblyopia (1% to 3%) Renal: Albuminuria (1% to 3%) Respiratory: Dyspnea (1% to 3%)， cough (1% to 3%)， pharyngitis (1% to 3%)， pneumonia (?2%)， hyperpnea Miscellaneous: Diaphoresis (1% to 3%)， herpes infection (1% to 3%)， infection (1% to 3%)， moniliasis (1% to 3%)， tumor flare Postmarketing and/or case reports: Thromboembolic phenomena (including deep vein thrombosis， pulmonary embolism， thrombophlebitis),25℃以下陰涼處,400-800mg(10-20mL)/day,無需調整劑量,Due to the potential for adverse reaction in the breastfed newborn， the manufacturer recommends discontinuing breastfeeding while receiving megestrol for the treatment of cancer. Due to the potential for HIV transmission， breastfeeding is not recommended when treating females for anorexia or cachexia associated with HIV infection. (UpToDate)2021/0125,無需調整劑量,不可使用,Uknown 沒有資料,Use is contraindicated for the treatment of anorexia or cachexia in pregnant females with HIV infection. Megestrol may cause fetal harm if administered during pregnancy.(UpToDate)2021/0125,Unknown 沒有資料,Due to the potential for adverse reaction in the breastfed newborn， the manufacturer recommends discontinuing breastfeeding while receiving megestrol for the treatment of cancer. Due to the potential for HIV transmission， breastfeeding is not recommended when treating females for anorexia or cachexia associated with HIV infection. (UpToDate)2021/0125,AC;AC15;PC;PO;WM;,,,,,
ICEF1,Cefazolin,Cefa inj 1gm,QANB,Susceptible infections， Surgical prophylaxis.,Hypersensitivity.,Superinfection; nausea， vomiting， abdominal pain， anorexia， diarrhoea; rash， leukopenia， thrombocytopaenia， haemorrhage， elevated transaminases.,避光,"(仿單) Usually， adult: 1 g/day; children: 25-50 mg/kg/day in 2 divided doses. For intravenous administration， inject directly over 3-5 minutes or infuse as an intermittent infusion over 30-60 minutes.(熱病) Adult 1-1.5 g IV/IM Q8H; 2 g IV Q8H for serious infection (maximum: 12 g/day). Pediatric 50-150 mg/kg/day (divided Q6-8H) (maximum: 6 g/day).(Uptodate) Surgical prophylaxis: 2 g for patients <120 kg or 3 g for patients > or =120 kg; administer within 60 minutes of surgical incision. " *****NEONATE ANTIBIOTICS DOSE***** Cefazolin: general infection Body weight <1kg ge<=7day 5 mg/kg Q12H  Age 8-14 day 5 mg/kg Q8H  Age 15-28 day 5 mg/kg Q8H Body weight 1-2kg ge<=7day 5 mg/kg Q12H  Age 8-14 day 25 mg/kg Q8H  Age 15-28 day 25 mg/kg Q8H Body weight >2kg Age<=7 day 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H,無需調整劑量,AAP: Maternal medication usually compatible with breastfeeding. WHO: Compatible with breastfeeding. Micromedex: Infant risk is minimal.,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,AAP: Maternal medication usually compatible with breastfeeding. WHO: Compatible with breastfeeding. Micromedex: Infant risk is minimal.,IM;INS;IRR;IRRI;IS;IVD;IVP;IVPUSH;,IM: 3.5 mL D/W; 4.5 mL N/S; 4.5mL D5W IV: 10mL D/W， N/S， D5W,【D5W】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【D5NS】可選 。【L/R】可選 。,推注時間至少 5分鐘,給藥濃度10-20 mg/mL，以30~60分鐘輸注。,1. 監測體溫、CBC、肝腎功能、PT值。 2. 注意是否發生抗生素引起的腹瀉。 3. (IM) 1gm/vial 乾粉加入3.5 mL D/W 泡製。 4. (IV bolus) 1gm/vial 乾粉加入5 mL D/W 泡製，再加入5 mL稀釋液，緩慢推注至少3 ~ 5分鐘。 小兒給藥建議： IV push， 50-100 mg/mL over 3-5 minutes. In fluid-restricted patients， 138mg/mL has been administered. Intermittent infusion， 5-20 mg/mL over 10-60 minutes.
OMET1,Methylphenidate,apo-Methylphenidate 10mg,CNEU,Attention-deficit hyperactivity disorder; narcolepsy.,Anxiety & tension states， agitation， tics， tics in siblings， family history or diagnosis of Tourette's syndrome; glaucoma; hyperthyroidism; cardiac arrhythmias， severe angina pectoris.,Frequent: nervousness， insomnia， decreased appetite. Occasional: headache， drowsiness， dizziness， dry mouth， tachycardia， palpitations， arrhythmias， changes in BP & heart rate; GI disturbances， skin reactions， fever， arthralgia. Rare: blurred vision， moderately reduced weight gain & minor growth retardation in children. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )， Loss of appetite (5% )， Nausea (12% )， Vomiting (10% ) Neurologic: Headache， Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )， Nasopharyngitis (5%),15-30℃，避免熱及潮濕,"Children >= 6 years: Initially 5 mg QD or BID with gradual increments of 5-10 mg weekly. maximum: 60 mg/day.Adult: 10 to 60 mg/day divided 2 to 3 times， preferably 30 to 45 minutes before meals. If the patient is unable to fall asleep due to taking the medicine late， the last dose should be taken before 6 pm. If no improvement in symptoms is seen after an appropriate dose adjustment for more than one month， the drug should be discontinued.",無需調整劑量,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OCUR,Amoxicillin + Clavulanic Acid,Curam 1000mg,QANB,Treatment of infections due to Staph， Strep， pneumococcus， meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract， GUT， skin & soft tissue， bone & joint. Dental infections， septic abortion， puerperal sepsis， intra-abdominal sepsis.,History of hypersensitivity to β-lactams. History of penicillin-associated jaundice/hepatic dysfunction.,Diarrhea， nausea， vomiting， mucocutaneous candidiasis. Dermatologic: Diaper rash (3.5% )， Rash (1.1% to 3% ) Gastrointestinal: Diarrhea (2.9% to 14.5% )， Loose stool (1.6% )， Nausea (2.1% to 3% )， Vomiting (1% to 2.2% ) Reproductive: Mycosis (3.3% )， Vaginitis (1% ) Other: Candidiasis (1.4% ),25℃以下,Adults and children > 12 years: Curam 1000 mg orally twice daily. Swallow whole tablets or in half. Curam 1000 mg is not recommended for children younger than 12 years.,無需調整劑量,AMOXICILLIN: Compatible CLAVULANATE， POTASSIUM: No Human Data - Probably Compatible. [仿單]在授乳的期間仍可使用amoxycillin+clavulanic acid，本藥用於母體時， 對於嬰兒並不會有所傷害，唯一的例外是當微量的藥物隨著母乳進入嬰兒體？時， 可能會有造成過敏的危險。,需調整劑量,可能安全,Human data suggest risk in 1st and 3 rd trimesters,AMOXICILLIN: Human Data Suggest Risk in 1st and 3rd Trimesters. CLAVULANATE， POTASSIUM: Compatible. [仿單]利用小老鼠及大白鼠所進行的動物試驗中，在經口及注射的方式投予amoxycillin + clavulanic acid 後顯示此藥並不會有畸胎的情形發生. 一針對孕婦早產和胚胎膜早熟破裂(premature rupture of the foetal membrane，pPROM)進行之單盲試驗指出， Amoxycillin+clavulanic acid之預防療法可能與新生兒壞死性腸炎的危險性增加有關。 如同所有其他藥品一樣，若非醫師認為有必要，在懷孕期間應避免使用， 尤其是在懷孕的前三個月。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,AMOXICILLIN: Compatible CLAVULANATE， POTASSIUM: No Human Data - Probably Compatible. [仿單]在授乳的期間仍可使用amoxycillin+clavulanic acid，本藥用於母體時， 對於嬰兒並不會有所傷害，唯一的例外是當微量的藥物隨著母乳進入嬰兒體？時， 可能會有造成過敏的危險。,PO;WM;,,,,,
EBIS,Bisacodyl,Bisacodyl suppository 10mg,ALIM,Constipation. Preparation of diagnostic procedures， in pre- & post-examination & in conditions which require defecation to be facilitated.,Ileus， intestinal obstruction， acute surgical abdominal conditions including appendicitis， acute inflammatory bowel diseases & severe dehydration. Rare hereditary conditions of galactose intolerance eg. galactosemia or fructose intolerance. Lactation.,Rarely， abdominal cramps， abdominal pain & diarrhea. Allergic reactions.,25℃以下儲存,Dosing: Adult & children > 10 years Relief of constipation: Rectal: Suppository: 5-10 mg as single dose Children: Rectal (suppository) 4-10 years: 5mg <4 years: 5 mg as a single dose,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,RECT;,,,,,
INUT1,Amino Acid + Glucose,Nutriflex peri 40/80 1000mL,NUTR,Parenteral nutrition when oral or enteral alimentation is impossible， insufficient or contraindicated.,Renal failure in the absence of haemodialysis， haemofiltration or haemo-diafiltration. Severe liver disease. Amino acid metabolism disorder. Metabolic acidosis， hyperlactataemia. Adrenal insufficiency. Hyperosmolar coma.,Hypertonic solutions may cause venous irritation if infused into a peripheral vein. Hyperglycaemia， glycosuria & hyperosmolar syndrome may occur.,15-25℃，混合後立即輸注並於24~48小時內輸注完畢,Adults Maximum daily dose: 40 ml /kg body weight/day， =1.6 g amino acids/kg body weight/day = 3.2 g glucose/kg body weight/day. Maximum infusion rate: 2.5 ml /kg body weight/hour， = 0.100 g amino acids/kg body weight /hour，=0.20 g glucose/kg body weight/hour. 2-17 years of age: Maximum daily dose: 50 ml/kg body weight/day， = 2.0 g amino acids/kg body weight/day =4.0 g glucose/kg body weight/day. 2 to 12 years of age: Maximum infusion rate: 2.5 ml /kg body weight/hour， =0.10 g amino acids/kg body weight/hour=0.20 g glucose/kg body weight/hour. 13 to 17 years of age Maximum infusion rate: 2.25 ml/kg body weight/hour， =0.09 g amino acids/kg body weight/hour=0.18 g glucose/body weight/hour. Nutrifex peri is contraindicated in newborn infants， infants and toddlers < 2 years of age.,無需調整劑量,,無需調整劑量,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,本藥品限藥劑科調劑TPN使用
OPREP,Cisapride,Prepulsid 5mg,ALIM,,Gastroparesis， gastro-oesophageal reflux disorders.,,,Adult: 5-10 mg bid-qid ， Child & infant: 0.2 mg/kg tid-qid.,,,,除非治療上需要,,,,,,,,,,
INSW,Sodium Chloride,Normal Saline irrigation 500mL(沖洗用),MSIV,,適應症:為生理食鹽水沖洗液,,室溫,Individualised dosage.,,,,安全,,,Compatible 哺乳時可使用,,,,,,,
ITRAS,Tranexamic Acid,Transamin S 針劑 10% 10mL,HEMT,,適應症: Hemorrhage， abnormal bleeding， genital & renal bleeding， bleeding due to prostatectomy. 副作用: GI disturbances. Gastrointestinal: Abdominal pain (oral， 19.8% ) Hematologic: Anemia (oral， 5.6% ) Musculoskeletal: Arthralgia (oral， 6.9% )， Backache (oral， 20.7% )， Cramp (oral， 6.5% )， Musculoskeletal pain (oral， 11.2% ) Neurologic: Headache (oral， 50.4% )， Migraine (oral， 6% ) Respiratory: Nasal sinus problem (oral， 25.4% ) Other: Fatigue (oral， 5.2% ),,室溫,Adult Cap/Tab 750-2000 mg/day tid-qid. Amp 250-500 mg/day in 1-2 divided doses IV/IM. During or after surgery: 500-1000 mg IV or 500-2500 mg by IV infusion.,,Micromedex Lactation Rating: Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. Clinical Management: There are limited data on nursing an infant while on tranexamic acid. Data have shown that only minimal amounts of the drug are excreted in breast milk. Breast milk concentrations were reported to be approximately 1% of peak serum levels 1 hour following the last dose of a 2-day treatment regimen. Tranexamic acid should only be used in a nursing mother only if clearly needed and use caution when tranexamic acid is administered to a nursing mother.,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Micromedex Lactation Rating: Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. Clinical Management: There are limited data on nursing an infant while on tranexamic acid. Data have shown that only minimal amounts of the drug are excreted in breast milk. Breast milk concentrations were reported to be approximately 1% of peak serum levels 1 hour following the last dose of a 2-day treatment regimen. Tranexamic acid should only be used in a nursing mother only if clearly needed and use caution when tranexamic acid is administered to a nursing mother.,,,,,,1. 靜脈內注射時應緩慢進行，急速給藥時，可能會出現噁心、胸部不適、心悸亢進或血壓下降。
IDEPP,Medroxyprogesterone,Depo-provera inj 150mg,HM,,I : Contraception.,,,150mg every 3 mth,,,,,,,,,,,,,,
OHAR4,Tamsulosin,Harnalidge OCAS 0.4mg prolonged release,SGU,Treatment of signs and symptoms of benign prostatic hyperplasia (BPH),Hypersensitivity to tamsulosin or any component of the formulation,Cardiovascular: Orthostatic hypotension (6% to 19%) Central nervous system: Headache (19% to 21%)， dizziness (15% to 17%) Genitourinary: Abnormal ejaculation (8% to 18%) Respiratory: Rhinitis (13% to 18%) Miscellaneous: Infection (9% to 11%),30℃以下,Benign prostatic hyperplasia: Oral， Initial and maintenance: 0.4 mg once daily， may increase to 0.8 mg once daily.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PO;,,,,,[磨粉/管灌註記]本藥為持續性藥效膜衣錠應整粒吞服，不可咀嚼或磨碎。
IOXO,Oxytocin,Oxocin inj 10 IU/1mL,SGU,,適應症:Induction of labor for medical reasons; stimulation or reinforcement of labor in hypotonic uterine inertia; during caesarean section， following delivery of the child; adjunctive therapy in the management of incomplete， inevitable， or missed abortion; prevention & treatment of postpartum uterine atony & haemorrhage. 副作用:Uterine spasm， uterine overstimulation (usually with excessive doses); water intoxication associated with maternal & neonatal hyponatraemia; nausea， vomiting， arrhythmias; rashes & anaphylactoid reactions. Rapid IV bolus inj may result in an acute short-lasting drop in BP. 禁忌:Significant cephalopelvic disproportion or unfavorable presentation of the fetus， placenta praevia or vasa praevia， cord presentation or prolapse， mechanical obstruction to delivery， fetal distress or hypertonic uterine contractions; multiple pregnancy or high parity， polyhydramnios， or the presence of a uterine scar from previous caesarean section. Avoid prolonged administration in patients with oxytocin-resistant uterine inertia， severe pre-eclampsia or severe CV disorders.,,室溫,Dosing: Adult Note: IV administration requires the use of an infusion pump. --Induction or enhancement of labor 1 iu oxytocin/100 mL by IV drip infusion --Prevention & treatment of post-partum haemorrhage; incomplete， inevitable or missed abortion 5-10 iu IM. Postpartum hemorrhage: 10 to 40 units of oxytocin added to running IV infusion (maximum 40 units to 1000 mL IV solution),,WHO: Compatible with breastfeeding. (micromedex) Pregnancy Category: C (micromedex),,沒有資料,,,Contraindicated 哺乳期使用禁忌,WHO: Compatible with breastfeeding. (micromedex) Pregnancy Category: C (micromedex),,,,,,
IPAR2,Electrolyte + Glucose,Paren-Aid N0.2 inj 400mL,NUTR,Fluid， electrolytes & calories supplement， especially for those who are poor-oral absorption or malnutrition,Hyperkalemia， hyperphosphatemia， hypermagnesemia， hypocalcemia， hepatic coma，severe renal insufficiency， disturbances in amino acid metabolism， peripheral parenteral administration.,Hyperglycemia. At high dose or rapid administration: pulmonary & peripheral edema， acidosis.,30℃以下,As TPN material.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,CVC;,,,,,1. 高張輸注液，限由中央靜脈導管給藥。 2. 本品專供藥劑科調配TPN製劑使用。
ISHI1,Triamcinolone acetonide,Shincort inj 10mg/mL， 5mL,HM,,禁忌: Acute psychoses， serious fungal or viral infection， untreated acute or chronic infection including TB. 副作用: Transient local discomfort， depigmentation & local atrophy， abscess formation; skeletal muscle wasting & weakness， impaired blood glucose control. Water & electrolyte imbalance， Cushing's syndrome. 適應症: RA; synovitis; allergic rhinitis， asthma & dermatitis; pemphigus; allergic & inflammatory ophth diseases.,,室溫,IA/ID 2.5-5 mg for smaller joints; 5-15 mg for larger joints.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IGLU5,Dextrose,(TPN調配使用) Glucose inj 50%， 500mL,NUTR,Treatment of hypoglycemia,Hypersensitivity to corn or corn products; hypertonic solutions in patients with intracranial or intraspinal hemorrhage， diabetic coma， or delirium tremens， especially if dehydrated; severe dehydration; glucose-galactose malabsorption syndrome,Cardiovascular: Edema， localized phlebitis， phlebitis， venous thrombosis Central nervous system: Confusion， loss of consciousness Endocrine & metabolic: Acidosis， dehydration， glycosuria， hyperglycemia， hyperosmolar syndrome， hypervolemia， hypokalemia， hypomagnesemia， hypophosphatemia， hypovolemia， ketonuria， polydipsia Gastrointestinal: nausea Local: Local pain， local tissue necrosis Renal: Polyuria Respiratory: Pulmonary edema， tachypnea Miscellaneous: Fever,30℃以下避光,As TPN material.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,50 % Glucose Solution，高張葡萄糖液，限藥劑科調配TPN使用
IKEP,Levetiracetam,Keppra inj 500mg/5mL,CNEU,Focal (partial) onset: Adjunctive therapy in the treatment of focal (partial) onset seizures in adults and children >=4 years of age and >20 kg with epilepsy. Generalized onset: Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years and older with juvenile myoclonic epilepsy. Primary generalized tonic-clonic seizures: Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and 16 years and older with idiopathic generalized epilepsy.,Hypersensitivity to levetiracetam.,Common Gastrointestinal: Loss of appetite (3% to 8% )， Vomiting (15% ) Immunologic: Infectious disease (13% ) Musculoskeletal: Decreased bone mineral density (70% )， Neck pain (2% to 8% ) Neurologic: Asthenia (15% )， Dizziness (5% to 9% )， Headache (14% to 19% ) Psychiatric: Abnormal behavior (7% to 37.6% )， Irritability (6% to 12% ) Respiratory: Cough (2% to 9% )， Nasopharyngitis (7% to 15% ) Other: Fatigue (10% to 11% ) Serious Dermatologic: Stevens-Johnson syndrome， Toxic epidermal necrolysis due to drug Hematologic: Decreased erythrocyte production， Decreased white blood cell count (2.4% to 3.2% )， Eosinophil count raised (8.6% )， Neutropenia ( 2.4% )， Pancytopenia， Thrombocytopenia Hepatic: Liver failure Immunologic: Anaphylaxis Neurologic: Somnolence (8% to 45% ) Psychiatric: Suicidal intent (0.5% )， Suicide Other: Angioedema,攝氏30度C以下,Monotherapy: Adults， 16 Years and Older: Initial， 250 mg twice daily IV/orally; titration， may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum 3000 mg/day. Adjunctive therapy: Adults， 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily， increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.,無需調整劑量,[仿單] Levetiracetam 會排泄至人類乳汁中，故不建議授乳。 但如果在授乳期間需要服用levetiracetam，須評估治療效益及風險與授乳的重要性。,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,[仿單]在一大量上市後資料中，接受 levetiracetam 單一治療的孕婦（超過 1800 例，其中超過 1500 例發生在懷孕的前三個月期間）主要先天性畸形的風險並未增加。 關於在子宮內接受 levetiracetam 單一治療的兒童神經發育，目前僅有有限的證據。但目前流行病學研究（約 100 名兒童）並未有神經發育障礙或延遲的風險增加。 Levetiracetam 如果在經仔細評估後認為它是臨床上所需要時，才可以在懷孕期間使用。 在這種情況下，建議使用最低有效劑量。懷孕期間的生理變化也可能會影響 levetiracetam 的濃度。 曾有在懷孕期間出現血漿中 levetiracetam 濃度降低現象的報告。這種濃度降低的現象在第三孕期會更為顯著(降低程度最高可達懷孕前之基礎濃度的 60%)。 請務必為接受治療的懷孕婦女進行適當的臨床處置。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] Levetiracetam 會排泄至人類乳汁中，故不建議授乳。 但如果在授乳期間需要服用levetiracetam，須評估治療效益及風險與授乳的重要性。,IVD;,,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,,必需稀釋到至少100 mL的相容稀釋液後，建議以15分鐘緩慢滴注。,1. Keppra Inj 500mg/5mL僅靜脈輸注使用，建議劑量必需稀釋到至少100 mL的相容稀釋液中，以15分鐘的靜脈輸注時間給藥。 2.本藥為單次使用，未用完的溶液不應保留。經稀釋後從微生物學的觀點應立即使用，若無法立即使用通常2-8°C不超過24小時，除非稀釋步驟以無菌環境下進行。經稀釋後的化學穩定與下列稀釋液(D5W，N/S，L/R)在室溫15-25°C下PVC袋中達24小時。
EILO1,Erythromycin,Erythromycin 0.5%， 3.5gm ophthalmic ointment,TOPH,Treatment of bacterial infections of the eye involving the conjunctiva &/or cornea caused by susceptible organisms.,Hypersensitivity to any component of the formulation.,Rarely， hypersensitivity reactions， ocular irritation or redness.,無特別指示,Instill 1 cm ribbon of the ointment into affected eye(s) up to 6 times daily， depending on the severity of the infection.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,EXT;OD;OL;OU;SKIN;,,,,,
OSMO4,Nicotine,Smokquit Mint Lozenges 4mg口含錠,ZADT,,,,,(Uptodate) Lozenge: Do not use more than 1 lozenge at a time. 4 mg for patients who smoke their first cigarette within 30 minutes of waking; 2 mg for others. The 12-week dosing schedule: Weeks 1-6: 1 lozenge every 1-2 hours (max: 5 lozenges Q6H; 20 lozenges/day); to increase chances of quitting， use at least 9 lozenges/day during the first 6 weeks. Weeks 7-9: 1 lozenge every 2-4 hours (max: 5 lozenges Q6H; 20 lozenges/day). Weeks 10-12: 1 lozenge Q4-8H (max: 5 lozenges Q6H; 20 lozenges/day).,無需調整劑量,,無需調整劑量,,,,,,,,,,,
OCER,Cefaclor,Cero 250mg,QANB,Otitis media， lower and upper respiratory tract infection， UTI， skin infection.,Hypersensitivity.,Hypersensitivity reactions. GI symptoms.,室溫藥品，仿單無特別指示儲存溫度條件,Adults: 250-500 mg orally every 8-12 hours. Children: 20-40 mg/kg/day in 2-3 divided doses.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OEFE7,Venlafaxine,Effexor XR 75mg,CNEU,Major depressive disorder; generalized anxiety disorder; social anxiety disorder; panic disorder.,Concomitant or within 14 days of MAOIs. Efexor XR must be discontinued for at least 7 days before starting treatment with MAOI. Severe renal or hepatic impairment. Pregnancy & lactation. Children < 18 years.,Dizziness， sedation， dry mouth， insomnia， nervousness， tremor， somnolence， anorexia， constipation， nausea， vomiting， abnormal ejaculation/orgasm (males)， erectile dysfunction， urinary hesitancy， sweating， asthenia， hypertension， hot flushes， ecchymosis， mucous membrane bleeding， thrombocytopenia， hypercholesterolaemia， yawning， fatigue， nausea， appetite & weight loss， decreased libido， sweating， anorexia， visual disturbances. Cardiovascular: Hypertension (3% to 13%) Dermatologic: Sweating symptom (6.7% to 25% ) Endocrine metabolic: Weight loss (3% to 47% ) Gastrointestinal: Constipation (8% to 15% )， Loss of appetite (8% to 22% )， Nausea (21% to 58% )， Xerostomia (12% to 22% ) Neurologic: Asthenia (8% to 19% )， Dizziness (11% to 23.9% )， Dream disorder (3% to 7% )， Headache (25% to 38% )， Insomnia (14% to 24% )， Somnolence (14% to 26% )， Tremor (1.1% to 10.2% ) Ophthalmic: Blurred vision (4% to 6% ) Psychiatric: Feeling nervous (4% to 21.3% ) Reproductive: Abnormal ejaculation (2.2% to 19% )， Impotence (2.1% to 6% )， Orgasm disorder (2% to 5% ),20-25℃的室溫下,Should be taken with food (XR cap: Swallow whole， do not chew/crush.). Dosage: 75 mg once daily. After 2 weeks， the dose may be increased to 150 mg once daily & further to 225 mg once daily if needed.,需調整劑量,,需調整劑量,除非治療上需要,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效膠囊應整粒吞服， 勿咬嚼或壓碎。若有管灌需求可拆開膠囊後使用，但不可將膠囊內微粒壓碎或磨粉。
ONEOV,TTFD,Neo-Vibon 50mg,NUTR,,,,,,,,,,,,,,,,,,,
EETO,Etofenamate,Eto gel 10%， 40gm,CNEU,Relief of pain & inflammation associated with musculoskeletal， joint & soft tissue disorders e.g. stiff shoulder， sprains， strains， lumbago， arthralgia & myalgia.,Hypersensitivity to any component of the formulation.,Rarely， allergic skin reactions.,30℃以下,Apply BID-TID to the affected area.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
ODOS,Cabergoline,Dostinex 0.5mg,HM,Treatment of hyperprolactinemic disorders， either idiopathic or caused by pituitary adenomas.,Known hypersensitivity to cabergoline， ergot derivatives， or any component of the formulation; uncontrolled hypertension; history of cardiac valvular disorders; history of pulmonary， pericardial， or retroperitoneal fibrotic disorders.,Headache (26%)， dizziness (15% to 17%)， Nausea (27% to 29%)， Orthostatic hypotension (4%)， hypotension (1%)， dependent edema (1%)， edema (peripheral 1%)， palpitation (1%)， syncope (1%)， Fatigue (5% to 7%)， vertigo (1% to 4%)， depression (3%)， somnolence (2% to 5%)， nervousness (1% to 2%)， anxiety (1%)， insomnia (1%)， concentration impaired (1%)， malaise (1%)， Acne (1%)， pruritus (1%)， Hot flashes (1% to 3%)， breast pain (1% to 2%)， dysmenorrhea (1%)， Constipation (7% to 10%)， abdominal pain (5%)， dyspepsia (2% to 5%)， vomiting (2% to 4%)， xerostomia (2%)， diarrhea (2%)， flatulence (2%)， anorexia (1%)， throat irritation (1%)， toothache (1%)， Weakness (6% to 9%)， pain (2%)， paresthesia (1% to 2%)， arthralgia (1%)， Abnormal vision (1%)， periorbital edema (1%)， Rhinitis (1%)， Flu-like syndrome (1%) <1% (Limited to important or life-threatening): Aggression， alopecia， cardiac fibrosis， duodenal ulcer (in PD patients)， gastric ulcer (in PD patients)， pleural effusion， psychosis， pulmonary fibrosis， valvular regurgitation， valvulopathy.,25℃以下,Inhibition of physiological lactation soon after parturition 1 mg as a single dose during the 1st postpartum day. Suppression of established lactation: 0.25 mg Q12H for 2 days. Hyperprolactinemic disorders: Initially 0.5 mg/week in 1 or 2 doses which should be increased gradually by adding 0.5 mg/week at monthly intervals. Therapeutic range: 0.25-2 mg/week.,無需調整劑量,,無需調整劑量,可能安全,Human data suggest low risk,,Contraindicated 哺乳期使用禁忌,,PO;WM;,,,,,
IVAN,Vancomycin,Vancomycin inj 500mg,QANB,,適應症: Treatment of severe infections caused by susceptible strains of methicillin-resistant staphylococci. For penicillin-allergic patients. Staphylococcal endocarditis. Infections due to staphylococci eg septicemia， bone infections， lower resp tract infections， skin & skin structure infections. Diphtheroid endocarditis. Oral treatment for antibiotic-associated pseudomembranous colitis. 副作用: Anaphylactoid reactions following rapid infusion. Nephrotoxicity， ototoxicity， reversible neutropenia， pseudomembranous colitis; chemical peritonitis following intraperitoneal administration. 禁忌:Hypersensitivity.,,室溫,Adult 500 mg 6 hrly or 1 g 12 hrly by intermittent infusion. Duration: At least 3 weeks in staphylococcal endocarditis. Prophylaxis of endocarditis in high-risk penicillin-allergic patients undergoing dental or other procedures 1 g by IV infusion as a single dose before the procedure together with gentamicin IV. Repeat doses 8 hrly for patients undergoing GI or GU procedures. Children 10 mg/kg body weight 6 hrly. Neonates initial 15 mg/kg followed by 10 mg/kg 12 hrly in 1st weeks of life & 8 hrly up to 1 month of age.,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,1. 監測體溫、CBC、腎功能、聽覺功能。 2. 注意輸注過快時的不良反應：低血壓、呼吸困難、蕁麻疹。 3. 建議監測藥物血中濃度。
OCOF5,Warfarin,COFARIN 5mg,HEMT,Treatment & prophylaxis of thromboembolic disorders.,Severe hepatic or renal disease， actual or potential haemorrhagic conditions， severe hypertension， endocarditis， ulceration of the GI & urinary tract， visceral carcinoma， endocarditis， neurosurgery， recent surgery on the eye， brain or spinal cord. Pregnancy.,Alopecia， skin rashes of various kinds， hemorrhagic skin necrosis. Cardiovascular: Cholesterol embolus syndrome Dermatologic: Tissue necrosis Hematologic: Hemorrhage Immunologic: Hypersensitivity reaction (infrequent ) Ophthalmic: Intraocular hemorrhage (5% to 11% ),15-30℃避光,Initial dose as 2-5mg once daily， depends on patient's PT/INR. Maintenance dose would be 2-10mg， adjusted by patient's PT/INR. Duration of the treatment should be kept until the risks have been excluded.,需調整劑量,WHO:Compatible with breast-feed,無需調整劑量,不可使用,Contraindicated – 1st trimester,,Compatible 哺乳時可使用,WHO:Compatible with breast-feed,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥與feeding nutrition有交互作用而影響吸收，可磨粉但需與nutrition間隔1小時，並密切監測INR值。
EDUR1,Fentanyl,Durogesic D-trans Patch 12mcg/h,CNEU,Management of chronic & intractable pain requiring opioid analgesia.,Hypersensitivity.,Hypoventilation. Nausea， vomiting， constipation; hypotension， somnolence， confusion， hallucinations， euphoria， pruritus， urinary retention; rash， erythema， itching.,30℃以下,Adults: Initial dose:12 mcg/hr or 25mcg/hr. Maintenance dose: Increase and drcrease by 12 mcg/hr or 25 mcg/hr to lowest appropriate dose. Renew every 72 hours. Children， 2-16 years old: Fentanyl transdermal patch can only be used on children have drug tolerance to opioids. Before use fentanyl transdermal patch， the child must be receiving opioids potency are equal to 30 mg oral morphine. The dose of fentanyl transdermal patch can be calculated from the 24-hour morphine dose with the same analgesic effect.(The conversion ratio of oral morphine to fentanyl transdermal patch is about 150:1) If fentanyl transdermal patches have to be discontinued， they should be replaced with other opioids (start with a low dose and slowly increase the dose).,需調整劑量,,需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,Compatible 哺乳時可使用,,EXT;,,,,,
OAMIZ,Hydrochlorothiazide + Amiloride,AmiZide 50/5mg,CAVS,Hypertension， edema of cardiac origin & hepatic cirrhosis with ascites & edema.,Hyperkalemia， other concomitant antikaliuretic therapy or K supplementation， renal insufficiency.,Headache， weakness， nausea， anorexia， rash & dizziness; orthostatic effects. Dermatologic: Rash (3% to 8% ) Gastrointestinal: Nausea Neurologic: Asthenia (3% to 8% )， Dizziness (3% to 8% )， Headache (3% to 8% ),25℃以下,Initially， 1-2 tablets daily. Maximum: 4 tablets/day.,無需調整劑量,Hydrochlorothiazide: 比照 Chlorothiazide - Compatible Amiloride: No Human Data—Probably Compatible,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,Hydrochlorothiazide: 比照 Chlorothiazide - Compatible Amiloride: Limited Human Data—Animal Data Suggest Low Risk,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Hydrochlorothiazide: 比照 Chlorothiazide - Compatible Amiloride: No Human Data—Probably Compatible,AC;AC15;PC;PO;WM;,,,,,
IUROK,Urokinase,UROKINASE 60，000IU (藥之鄉),HEMT,Acute coronary embolism， clearance of occluded catheters & shunts， acute pulmonary embolism， peripheral arterial or venous thromboembolism.,Intracranial hemorrhage， hemoptysis， difficulty in hemostatic management; undergone intracranial or spinal surgery or with such injury (in the last 2 months); aneurysm; serious disturbance of consciousness.,Bleeding tendency. Fever， chills， headache & malaise may occur. Rarely， shock， sweating， disturbed pulse & dyspnea; rash， urticaria;nausea; vomiting & anorexia; abnormal liver function test; hematuria. Hematologic: Decreased hematocrit level (37%),15-30℃,60000-240000 IU on the first day， then decrease the dose day by day for about 7 days.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IA;IPL;IRR;IVD;,10 mL N/S，D5W,【D5W】可選 。【N/S】可選 。,,稀釋到總體積為195 mL，起始劑量:90 mL/hr 輸注超過 10 minutes，維持劑量:15 mL/hr 持續12小時,1. Total dose diluted to the recommended final volume of 195 mL 2. (loading dose) 90 mL/hr over 10 minutes (continuous infusion) 15 mL/hr for a period of 12 hr
OJOH,Bisacodyl,Johnlax 5mg,ALIM,Treatment of constipation; colonic evacuation prior to procedures or examination.,Hypersensitivity to bisacodyl or any component of the formulation; abdominal pain or obstruction， nausea， or vomiting,Abdominal cramps (mild)， electrolyte disturbance (metabolic acidosis or alkalosis， hypocalcemia)， nausea， rectal irritation (burning)， vertigo， vomiting,25℃以下避光，緊密容器,Dosing: Adult & children >10 years Relief of constipation: Oral: 5-10 mg as single dose Dosing: Pediatric Relief of constipation: Oral: Children 4-10 years: 5 mg as single dose Oral: Children <4 years: recommend Rectal suppository,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為腸溶糖衣錠。須整粒吞服，勿咬嚼或壓碎。
ISUX,Succinylcholine,Suxamethonium inj 100mg/2mL,CNEU,,適應症: Production of skeletal muscle relaxation in anaesth; for procedures eg endotracheal intubation， endoscopic exam， orthopaedic manipulations， short surgical procedures & electroconvulsive therapy. 副作用: Post-op muscle pain or fasciculation， rhabdomyolisis， myoglobinuria， myoglobinaemia， elevated creatine phosphokinase， hypertonia， bradycardia， tachycardia， arrhythmia， cardiac arrest， HTN， hypotension， tachyphylaxis， ventricular fibrillation， resp or GI disorders， malignant hyperthermia， porphyria， hyperkalaemia， excessive salivation， increased intraocular & intracranial pressure， renal failure， precipitation or exacerbation of myasthenia gravis， hypersensitivity reactions. 禁忌: Familial history of malignant hyperthermia， disorders of pseudocholinesterase， myopathy， Duchenne's muscular dystrophy， severe hyperkalaemia， acute narrow-angle glaucoma， penetrating eye injuries. Major burns or multiple trauma， renal impairment w/ hyperkalaemia， extensive muscle degeneration， severe chronic sepsis.,,2-8°C,Individualised dosage. Adult Short procedures 0.6 mg/kg (range: 0.3-1.1 mg/kg) IV over 10-30 sec. Prolonged surgical procedures 2.5-4.3 mg/min by IV infusion. Childn 1-2 mg/kg IV. IM Adult & childn 2.5 mg/kg， max total dose: 150 mg.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IVD;IVP;IVPUSH;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,for Intubation: Adult dose - 0.6 mg/kg (range: 0.3 to 1.1 mg/kg),IVD: (continuous infusion) a solution diluted to 1 mg/mL in D5W or N/S may be administered at a rate of 0.5 to 10 mg/min depending on patient specific factors.,1. 成人深度肌肉鬆弛IM: 15mg-100 mg. 2. IVD: (continuous infusion) a solution diluted to 1 mg/mL in D5W or N/S may be administered at a rate of 0.5 to 10 mg/min depending on patient specific factors.
OSAM,Tolvaptan,Samsca 15mg,CAVS,Clinically significant hypervolemic & euvolemic hyponatremia including patients w/ heart failure & syndrome of inappropriate antidiuretic hormone (SIADH).,Urgent need to raise serum Na acutely; inability to sense or appropriately respond to thirst; hypovolemic hyponatremia; strong CYP3A inhibitors (eg clarithromycin， ketoconazole， itraconazole， ritonavir， indinavir， nelfinavir， saquinavir， nefazodone & telithromycin); anuric patients.,Thirst， dry mouth， pollakiuria or polyuria， asthenia， constipation， hyperglycemia， pyrexia & anorexia.,儲存於25℃,Adult: Initial， 15 mg QD; may increase to 30 mg QD， after at least 24 hours， to maximum of 60 mg QD; do not administer for more than 30 days. Patient should be hospitalized for initiation or reinitiation of tolvaptan therapy to evaluate therapeutic response and avoid too rapid correction of hyponatremia. Serum sodium levels should be monitored for prevention of too rapid correction of hyponatremia. (Correction of hyponatremia < 10-12 mEq/L in 24 hours， and < 18 mEq/L in 48 hours),無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
EMAD,Asiaticoside + Asiatic Acid + Madecassic Acid,Madecassol onit 10gm,TDER,,Burns， wound of surgical operation， skin transplantaion， ulcerated skin， bed sore.,,,Apply 1-3 times daily.,,,,,,,,,,,,,,
IXYL11,Lidocaine,Xylocaine 1% inj 1mL,ZANE,,,,,,,,,,,,,,,,,,,
OEMB,Ethambutol,EMB(Myambutol) 400mg,QANB,,適應症: Combination therapy of pulmonary TB. 副作用: Decreased visual acuity， leukopenia， neutropenia， thrombocytopenia， hypersensitivity， anaphylactoid reactions， headache， mental confusion， disorientation & possible hallucinations， dizziness， hypoaesthesia， paraesthesia， peripheral neuropathy， pulmonary infiltrates with or without eosinophilia， GI disturbances， dermatitis， rash， pruritus， Stevens-Johnson syndrome， toxic epidermal necrolysis， gout， hyperuricemia， joint pain， fever， malaise. 禁忌: 已知對乙胺丁醇(ethambutol)或對任何其他成分過敏者不得使用本劑。 孟表多禁止使用於無法正確評估視覺的副作用與變化的病人（例如幼童、失去意識的病人）。 對已知患有視神經炎之患者不得使用本劑，除非經臨床研討後決定可以使用。 對異菸鹼醯胼(Isoniazid)的使用尚無絕對禁忌之報告。,,室溫,Initial treatment (patients never on anti-TB therapy) 15 mg/kg as a single dose 24 hrly. Retreatment (patients previously on anti-TB therapy) 25 mg/kg as a single dose 24 hrly. Concurrently administer at least 1 other anti-TB drug to which the organisms have been demonstrated to be susceptible. After 60 days， decrease dose to 15 mg/kg body weight as a single dose 24 hrly. Intermittent therapy 15 or 25 mg/kg/day for 2 months， then 50 mg/kg twice weekly.,,,,可能安全,,,,,,,,,,
LRIS,Risperidone,Risperdal solution 1mg/mL， 30mL,CNEU,Treatment of schizophrenia， including 1st episode psychoses， acute schizophrenic exacerbations， chronic schizophrenia， & other psychotic conditions. Alleviates affective symptoms (eg. depression， guilt feelings， anxiety) associated with schizophrenia. Long-term therapy for the prevention of relapse in chronic schizophrenia. Treatment of behavioral disturbances in patients with dementia. As adjunctive therapy to mood stabilizers or monotherapy in the treatment of manic episodes associated with bipolar disorder. Treatment of conduct & other disruptive behavioral disorders in children， adolescents & adults with subaverage intellectual functioning or mental retardation.,Hypersensitivity.,Common: insomnia， agitation， anxiety， headache. Less common: somnolence， fatigue， dizziness， impaired concentration， constipation， dyspepsia， nausea/vomiting， abdominal pain， blurred vision， priapism， erectile dysfunction， ejaculatory dysfunction， urinary incontinence， rhinitis， rash & other allergic reactions. Occasionally， orthostatic hypotension， reflex tachycardia or hypertension.,15-30℃避免冷凍,Schizophrenia: Adults: Initial dose: 2 mg/day in a single dose or 2 divided doses. The dose can be increased to 4 mg the next day. Adjust according to individual when necessary. The general dosage is 4-6 mg/day. Dosage over 10 mg/day may cause extrapyramidal symptoms. maximum: 16mg/day Children(13-17 years old) :0.5mg QD. The dose is increased by 0.5 mg/day or 1 mg/day adjust to the recommended dose of 3 mg/day when necessary. (The adjustment interval cannot be less than 24 hours). maximum:6mg/day. Data for children under 13 years of age with schizophrenia are not esTABlished. Elderly (65 years old and above): Initial dose:0.5mg BID， increased by 0.5mg each dose adjust to 1-2 mg BID. Manic episodes of bipolar disorder: Adults:2mg or 3mg QD， increased by no more than 1 mg/day. Effective at 1mg-6mg/day. Children(10-17 years old):0.5mg QD， increased by 0.5 mg or 1mg/day adjust to 2.5mg/day.(The adjustment interval cannot be less than 24 hours). Effective at 0.5mg-6mg/day.If the patient has persistent sleepiness， adjust the frequency from QD to half of the original dose twice a day. Data for children under 10 years of age with bipolar manic episode are not established. Agitation， aggressive behavior， or psychotic symptoms in patients with Alzheimer's disease: 0.25mg BID， increased by 0.25mg each doses adjust to 0.5mg BID or 1mg BID. (The adjustment interval cannot be less than 2 days.) After determining the sTABle dose， dose frequency can be changed to QD. Behavioral Disorders and Other Disruptive Behavior Disorders(5-18 years old): >=50 kg:0.5mg/day. When necessary， it can be increased by 0.5 mg/day adjust to 1mg QD， or 1.5mg QD.(The adjustment interval cannot be less than 2 days.) <50kg:0.25mg/day.When necessary， dose can be increased by 0.25 mg/day adjust to 0.5mg QD， or 0.75mg QD.(The adjustment interval cannot be less than 2 days.) Data for children under 5 years of age are not esTABlished. Agitated symptoms in children and adolescents with autism(5-17 years old): Dose frequency:1-2times/day. <20kg:0.25mg/day(day1-3)， 0.5mg/day(day4-14)， dose can be increased by 0.25 mg/day adjust to 0.5-1.5mg/day.(The adjustment interval cannot be less than 2 weeks.) >=20kg:0.5mg/day(day1-3)， 1mg/day(day4-14)， dose can be increased by 0.5 mg/day adjust to 1-2.5mg/day.(The adjustment interval cannot be less than 2 weeks.) If the patient has persistent sleepiness， adjust the frequency from QD to HS， or half of the original dose twice a day. Data for children under 5 years of age are not established.,需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
ESHO,Chloramphenicol,Showen 0.25% eye drops， 5mL,TOPH,,適應症:Superficial bacterial eye infections 副作用: Transient stinging.,,室溫,Apply 1 drop every 2 hr & reduce frequency as infection is controlled; continue for 48 hr after healing.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IPER0,Pertuzumab,Perjeta inj 420mg/14mL (sample),RACA,PERJETA? (pertuzumab) is approved for use in combination with Herceptin? (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.,PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA.,The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are: Diarrhea Hair loss Low levels of white blood cells with or without a fever Nausea Feeling tired Rash Damage to the nerves (numbness， tingling， pain in hands/feet),2-8℃避光,Initial dose of 840 mg infused over 60 minutes followed by a maintenance dose of 420 mg infused over 30-60 minutes every 3 weeks.,無需調整劑量,,無需調整劑量,盡量避免,Contraindicated,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,僅可使用0.9%氯化鈉注射液稀釋。不可使用葡萄糖(5%)溶液。
IPERJ,Pertuzumab,Perjeta inj 420mg/14mL,RACA,PERJETA (pertuzumab) is approved for use in combination with Herceptin (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.,Treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.,The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are: Diarrhea Hair loss Low levels of white blood cells with or without a fever Nausea Feeling tired Rash Damage to the nerves (numbness， tingling， pain in hands/feet),2-8°C避光,Initial dose of 840 mg infused over 60 minutes followed by a maintenance dose of 420 mg infused over 30-60 minutes every 3 weeks.,無需調整劑量,,無需調整劑量,盡量避免,Contraindicated,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,僅可使用0.9%氯化鈉注射液稀釋。不可使用葡萄糖(5%)溶液。
IKAD0,Trastuzumab Emtansine,Kadcyla inj 100mg (sample),RACA,Metastatic breast cancer， HER2 overexpression， monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.,Specific contraindications have not been determined.,Common ■Gastrointestinal: Constipation (26.5% )， Nausea (39.8% ) ■Hematologic: Thrombocytopenia， All grades (31.2% ) ■Hepatic: Increased liver enzymes， All grades (28.8% ) ■Musculoskeletal: Musculoskeletal pain (36.1% ) ■Neurologic: Headache (28.2% ) ■Other: Fatigue (36.3% ) Serious ■Cardiovascular: Left ventricular cardiac dysfunction (1.8% ) ■Dermatologic: Injection site extravasation ■Hematologic: Anemia， Grade 3 and 4 (4.1% )， Neutropenia， Grade 3 and 4 (2% )， Thrombocytopenia， Grade 3 and 4 (14.5% ) ■Hepatic: Hepatotoxicity， Increased liver enzymes， Grades 3 and 4 (8% )， Injury of liver ■Immunologic: Anaphylactoid reaction ■Neurologic: Peripheral nerve disease， Grade 3 or 4 (2.2% ) ■Respiratory: Dyspnea (12% )， Interstitial lung disease， Pneumonitis (0.8% to 1.2% ),2-8℃,3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever， chills， or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.,無需調整劑量,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded， a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,無需調整劑量,盡量避免,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded， a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,IVD;,,,,,1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。請使用0.2-0.22微米、不吸附蛋白質的管線內 polyethersulfone (PES)過濾器。 3. 溶液配置後應立即使用，冷藏於2-8℃最多儲存24小時。 4. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 5. 監測CBC、肝腎功能。
INS45/20,Sodium Chloride,0.45% NaCl inj 20mL (限RT使用),MSIV,,,,,Only for respiratory treatment of in-patient.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IH;,,,,,
IERB0,Cetuximab,Erbitux inj 100mg/20mL (sample),RACA,Colorectal cancer， metastatic: Treatment of KRAS wild-type (without mutation)， epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer as determined by approved tests (in combination with FOLFIRI [irinotecan， fluorouracil， and leucovorin] as first-line treatment， in combination with irinotecan [in patients refractory to irinotecan-based chemotherapy]， or as a single agent in patients who have failed irinotecan- and oxaliplatin-based chemotherapy or who are intolerant to irinotecan). Limitation of use: Cetuximab is not indicated for the treatment of RAS-mutant colorectal cancer or when results of the RAS mutation tests are unknown. Head and neck cancer， squamous cell: Treatment of squamous cell cancer of the head and neck (as a single agent for recurrent or metastatic disease after platinum-based chemotherapy failure; in combination with radiation therapy as initial treatment of locally or regionally advanced disease; in combination with platinum and fluorouracil-based chemotherapy as first-line treatment of locoregional or metastatic disease).,Known severe hypersensitivity reactions to cetuximab.,Mild or moderate infusion-related reactions eg fever， chills， dizziness or dyspnea; mild to moderate mucositis， increase in liver enzyme levels; skin reactions mainly as acne-like rash; headache; conjunctivitis; diarrhea， nausea， vomiting; dehydration， hypocalcemia， anorexia; fatigue.,2-8°C,Weekly dosing: Initial loading dose: 400 mg/m2 infused over 120 minutes. Maintenance dose: 250 mg/m2 infused over 60 minutes once weekly until disease progression or unacceptable toxicity. Complete cetuximab dose 1 hour prior to chemotherapy.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,,,,1. 輸注本藥品一定要單獨使用一條管線，輸注結束時一定要用無菌的生理食鹽水沖洗管線。
ODIA,Diazepam,Diazepam 2mg,CNEU,,適應症: ■Anxiety ■Sedation， Premedication before surgery， endoscopic procedures and cardioversion ■Seizure， Refractory， increased frequency ■Seizure; Adjunct ■Skeletal muscle spasm; Adjunct ■Skeletal muscle spasm - Tetanus ■Status epilepticus 副作用: Common ■Cardiovascular: Hypotension ■Dermatologic: Rash (3%， rectal gel ) ■Gastrointestinal: Diarrhea (4%， rectal gel ) ■Musculoskeletal: Muscle weakness ■Neurologic: Ataxia， Incoordination (3%， rectal gel )， Somnolence ■Psychiatric: Euphoria (3%， rectal gel ) ■Respiratory: Respiratory depression ■Other: Fatigue Serious ■Hematologic: Neutropenia 禁忌: Contraindications ■hepatic insufficiency， severe ■hypersensitivity to diazepam ■myasthenia gravis ■narrow-angle glaucoma， acute ■pediatric patients less than 6 months of age ■respiratory insufficiency， severe ■sleep apnea syndrome,,室溫,,,AAP: Drugs for which the effect on nursing infants is unknown but may be of concern. ■WHO: Compatible with breastfeeding. Monitor infant for side effects. ■Micromedex: Infant risk has been demonstrated.,,盡量避免,,,Human Data Suggest Potential Toxicity,AAP: Drugs for which the effect on nursing infants is unknown but may be of concern. ■WHO: Compatible with breastfeeding. Monitor infant for side effects. ■Micromedex: Infant risk has been demonstrated.,,,,,,
IESM,Rocuronium Bromide,Esmeron inj 50mg/5mL,CNEU,,禁忌: Hypersensitivity. 副作用: Anaphylactic & anaphylactoid reactions， anaphylactic & anaphylactoid shock; flaccid paralysis; tachycardia; hypotension， circulatory collapse & shock， flushing; bronchospasm; angioneurotic edema， urticaria， rash， erythematous rash; muscular weakness， steroid myopathy; face oedema， injection site pain & reaction; airway complication of anaesth， delayed recovery from anaesth. 適應症: Adjunct to general anaesth to facilitate tracheal intubation， during routine & rapid sequence induction， & to provide skeletal muscle relaxation during surgery. Adjunct in ICU to facilitate intubation & mechanical ventilation.,,2-8℃,Tracheal intubation Intubating dose: 0.6 mg/kg body wt. Maintenance: 0.15 mg/kg body wt. Infusion rate: 0.3-0.6 mg/kg/hr. Rapid sequence induction 1 mg/kg body wt. Caesarean section 0.6 mg/kg body wt. Mechanical ventilation 0.6 mg/kg body wt followed by a continuous infusion as soon as twitch height recovers to 10% or upon reappearance of 1-2 twitches to train of 4 stimulation.,需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,IV bolus as an adjunct to facilitate tracheal intubation.,0.3~0.4mg/kg/h (濃度：0.5 mg/mL 或 2 mg/mL ),1.Esmeron以靜脈投藥採一次注入或連續輸注方式
OCOMP,Prednisolone,Compesolon 5mg,HM,RA， lupus erythematosus， periarthritis nodosum， allergic & inflammatory skin disorders.,Peptic ulcer， osteoporosis， psychoses or severe neuropsychosis; active or doubtfully quiescent TB; acute infection; live vaccines.,Fluid & salt retention， edema， hypertension; amenorrhea， hyperhidrosis， mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; local atrophy; increased appetite; growth retardation.,25℃以下,Asthma: 30-60mg daily in one week， from then decrease dosage to maintain as 10-30mg daily. Arthritis: 20mg daily， or 30mg daily in severe patient.,無需調整劑量,,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
IAAA,A. Acutus antivenin,抗百步蛇毒血清,HIMM,,適應症:Therapy for the bite of D. acutus snake. 副作用:allergic phenomena including anaphylaxis， hypotension， serum sickness. 禁忌: Hypersensitivity to antivenin.,,2-8℃,1000 or more units per dose. Adult 1 dose. (SC: 0.5 dose near bite; 0.5 dose IV or IM),,,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 稀釋法：取稀釋溶液10 mL注入凍晶製劑中，避免用力振搖，應於2小時內用完。 2. 宜儘早注射，被咬傷後4小時內注射最有效。 3. 注射部位：咬傷時間二小時內，可將一半劑量注射在咬傷部位周圍皮下，另一半則IV或IM。 4. 注射速率：IV: 第1 mL注射時間為5分鐘以上，之後每分鐘不可超過1 mL。IVD: 一劑抗蛇毒血清稀釋於300mL N/S。 5. 注射劑量：成人為一劑量，10歲以下兒童加倍。如症狀繼續惡化，隔30分鐘至一小時後可再打一劑。 6. 蛇毒血清為馬的血清製劑，可能有過敏反應，可先做皮膚試驗並準備1:1000 Epinephrine備用。
EULT1,Indacaterol + Glycopyrronium,Ultibro Breezhaler 110/50mcg,ERSP,Once-daily maintenance bronchodilator treatment to relieve symptoms & reduce exacerbations in patients with COPD.,hypersensitivity to glycopyrrolate， indacaterol maleate， or any excipients of the product,Cardiovascular: Chest pain (1% to less than 10% ) Endocrine metabolic: High glucose level in blood (4.1% ) Gastrointestinal: Indigestion (1% to less than 10% ) Neurologic: Dizziness (1% to less than 10% )， Headache (1% to less than 10% ) Respiratory: Cough (1% to less than 10% )， Nasopharyngitis (1% to less than 10% )， Pain in throat (1% to less than 10% .)， Rhinitis (1% to less than 10% )， Sinusitis (1% to less than 10% )， Throat irritation， Upper respiratory infection (10% or more ) Other: Fever (1% to less than 10% ),30℃以下,Adult Dosing Chronic obstructive pulmonary disease: 1 capsule via INHALATION once a day using Ultibro Breezhaler inhaler. Safety and efficacy not established in children<18years.,無需調整劑量,Micromedex Lactation Rating: Infant risk cannot be ruled out. It is not known if indacaterol is excreted into breast milk. The manufacturer recommends that caution be exercised when administering indacaterol to nursing women. The use of beta2-receptor agonists are not considered a contraindication to breast-feeding INDACATEROL BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible Glycopyrronium無資料,無需調整劑量,除非治療上需要,Uknown 沒有資料,INDACATEROL Respiratory (Bronchodilator) PREGNANCY RECOMMENDATION: No Human Data—Animal Data Suggest Low Risk Glycopyrronium無資料 BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,Unknown 沒有資料,Micromedex Lactation Rating: Infant risk cannot be ruled out. It is not known if indacaterol is excreted into breast milk. The manufacturer recommends that caution be exercised when administering indacaterol to nursing women. The use of beta2-receptor agonists are not considered a contraindication to breast-feeding INDACATEROL BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible Glycopyrronium無資料,IH;,,,,,1. 每個Ultibro Breezhaler 包裝含有: 一個Ultibro Breezhaler 吸入器 / 鋁箔片，內含有供Ultibro Breezhaler 吸入器使用的膠囊 2. 不可吞服Ultibro Breezhaler 膠囊: Ultibro Breezhaler 吸入器是一種器材，供您在吸入Ultibro Breezhaler 膠囊中的藥品時使用。 3. 只可使用包裝中的Ultibro Breezhaler 吸入器。 4. Ultibro Breezhaler 膠囊不可使用其他吸入器，其他膠囊藥品也不可使用Ultibro Breezhaler 吸入器。
IAMP5,Ampicillin,Ampicillin inj 0.5gm,QANB,,Active against G(-) organism， generally less active against G(+) organism， except enterococci.,,,Adult & child over 20kg: Oral: 250-500 mg q6h， (max. 6 g/day). IM， slow IV or IV infusion: 250-500 mg q6h. For bacterial meningitis or septicemia: 1-2 g q3-4h，(max.16 g/day or 300 mg/kg/day). Child under 20 kg: Oral: 12.5-25 mg/kg q6h， (max. 200 mg/kg/day). IM， slow IV or IV infusion: 6.25-25 mg/kg q6h. For bacterial meningitis or septicemia: 16.7-41.7 mg/kg q4h，(max. 400 mg/kg/day ).,,,,可能安全,,,,,,,,,,
OFLA,Metronidazole,Flagyl 250mg,QANB,,適應症:Vaginitis caused by Trichomonas. Amebiasis & metronidazole-susceptible anaerobic infection. 副作用:GI disturbances; peripheral neuropathy; drowsiness; leukopenia; rarely， skin reactions， darkening of urine， anaphylaxis， encephalopathy. Gastrointestinal: Abdominal discomfort (7%)， Loss of appetite， Metallic taste， Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )， Headache (tablets， 15% to 18%; vaginal gel， 5% )， Peripheral neuropathy Reproductive: Candida infection of genital region， Symptomatic cervicitis/vaginitis (10%)， Vaginal discharge (12%) Other: Drug interaction with alcohol， Disulfiram-like reaction 禁忌:Blood dyscrasias. Active CNS disease.,,室溫,Anaerobic infections: Max. 1 g/dose， 4 g/day. Oral: 7.5 mg/kg q6h for 7 days or longer. IV infusion only (over 1 hr): 15 mg/kg as a loading dose， then 7.5 mg/kg q6h for 7 days or longer. Amebiasis: oral: Adult: 500-750 mg tid for 10 days. Child: 11.6-16.7 mg/kg tid for 10 days. Trichomoniasis: oral: Adult: 2 g as a single dose; 1 g bid for 1 day; or 250mg tid for 7 days. Child: 5 mg/kg tid for 7 days. Giardiasis: Adult: 2 g qd x 3 days or 250-500 mg tid x 5-7 days. Child: 5 mg/kg tid x 5 days.,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OACAL,Calcium Carbonate,A-Cal 500mg,NUTR,,適應症: Relief of the symptoms of gastric hyperacidity. 副作用: Mild GI disturbances. 禁忌: Hypercalcaemia due to myeloma， bone metastases or other malignant bone disease， sarcoidosis; primary hyperparathyroidism， vitamin D overdosage; severe renal failure.,,室溫,1-2 tab before meals & at bedtime. Max: 8 tab/day.,,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,,沒有資料,,,Compatible 哺乳時可使用,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,,,,,,
ICIS,Cisplatin,Cisplatin 50mg/50mL,RACA,Bladder cancer， advanced. Ovarian cancer， metastatic. Testicular cancer， metastatic.,History of allergic reactions to cisplatin， other platinum-containing compounds， or any component of the formulation; preexisting renal impairment; myelosuppressed patients; hearing impairment.,Nausea & vomiting， renal toxicity， bone-marrow depression， ototoxicity， serum electrolyte disturbances， peripheral neuropathy， retinal toxicity， anaphylactic reactions， cardiac abnormalities.,15-25℃避光勿冷藏,50-100 mg/m2 every 3-4 weeks or 15-20 mg/m2 for 5 days every 3-4 weeks.,無需調整劑量,,需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,IVD;,,【N/S】可選 。,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 調配與注射cisplatin的器具不可含有鋁。 3. 稀釋後的輸注溶液應避光保存。 4. 給藥前後應給予病人適當水分補充。 5. 監測CBC、肝腎功能。 6. 定期神經學、聽力檢測。
HCVDA13,Glecaprevir + Pibrentasvir (1~6type/12週),HCVDAA0013(C肝全口服新藥健保計畫) 1-6型/12週,QANB,,,,,,,,,,,,,,,,,,,
OSUB,Buprenorphine + Naloxone,Suboxone 8/2mg,CNEU,Treatment of opioid dependence.,Hypersensitivity to buprenorphine， naloxone， or any component of the formulation,Central nervous system: Headache (36%)， withdrawal syndrome (25%; placebo 37%)， pain (22%) Dermatologic: Diaphoresis (14%) Gastrointestinal: Glossodynia (film)， oral hypoesthesia (film)， oral mucosa erythema (film),30℃以下,Adults and teenagers over 15 years old: Day 1 induction dose: Initial: Buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg sublingual; may increase the dose with buprenorphine 2 to 4 mg/naloxone 0.5 to 1 mg， based on control of acute withdrawal symptoms. Adjust and maintain dose: Titrate the dose with buprenorphine 2 to 8 mg based on patient's clinical and psychological status(Max:buprenorphine 24mg/day). Heroin or short-acting opioid dependency: Start treatment when withdrawal symptoms occur， but 6 hours after patient takes the last opiods. For patients taking methadone: Patients taking methadone > 30mg/day should start the treatment from Buprenorphine 2 mg/naloxone 0.5 mg and mind the half-life of methadone. Start treatment when withdrawal symptoms occur， but 24 hours after patient takes the last dose of methadone. Buprenorphine may increase withdrawal symptoms of methadone.,無需調整劑量,Buprenorphine BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible Naloxone BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,Buprenorphine PREGNANCY RECOMMENDATION: Limited Human Data—Probably Compatible Naloxone PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Buprenorphine BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible Naloxone BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,SL;,,,,,[磨粉/管灌註記]本藥為舌下錠，可直接置於病患舌下。
OCON2,Methylphenidate,Concerta ER 27mg,CNEU,For treatment of attention deficit hyperactivity disorder.,Patients with marked anxiety， tension & agitation， glaucoma， Tourette's syndrome， & patients on MAOI therapy.,Headache， stomach ache， loss of appetite， insomnia， aggravation reaction， asthenia， hypertension， nausea &/or vomiting， dyspepsia， weight loss， twitching (tics)， dizziness， emotional lability， somnolence， anxiety， depression， nervousness， hostility， rash. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )， Loss of appetite (5% )， Nausea (12% )， Vomiting (10% ) Neurologic: Headache， Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )， Nasopharyngitis (5% ),25℃以下避免潮濕,Attention deficit disorder : (Child over 6 years and adult) Concerta: 27mg(1 TAB) QD. ( maximum for Child: 54 mg/day; maximum for adult : 72 mg/day ),無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為長效錠，請整粒吞服，不可撥半或磨粉。
OGEMD,Gemfibrozil,Gemd 300mg,CAVS,,適應症: Dyslipidemia type IIa， IIb， III， IV & V. Reduces risk of CHD. 副作用: GI upset， rash， pruritus， headache， dizziness， hematopoietic disorders. Gastrointestinal: Abdominal pain (9.8% )， Acute appendicitis (1.2% )， Indigestion (19.6% .) 禁忌: Gallbladder disease， hepatic， renal dysfunction including primary cirrhosis.,,室溫,1200 mg daily in 2 divided doses.(Should be taken on an empty stomach ),,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
EBETA,Betamethasone + Gentamicin,Sinbeta derm cream 10gm,TDER,Dermatoses complicated by infection in psoriasis， neurodermatitis， lichen planus， eczema， intertrigo， dyshidrosis， seborrhoeic， contact， atopic， exfoliative， solar， stasis dermatitis; anogenital & senile pruritus.,Hypersensitivity to any of the component.,Burning， itching， irritation， dryness， folliculitis， hypertrichosis， perioral dermatitis， allergic contact dermatitis， acneiform eruption， hypopigmentation， maceration of the skin， skin atrophy， secondary infection， striae & miliaria.,25℃以下儲存,Cover affected area completely BID.,無需調整劑量,Betamethasone - No Human Data—Probably Compatible Gentamicin - Compatible,無需調整劑量,除非治療上需要,Human data suggest low risk,Betamethasone - Compatible—Maternal Benefit >> Embryo–Fetal Risk Gentamicin - Gentamicin,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Betamethasone - No Human Data—Probably Compatible Gentamicin - Compatible,EXT;,,,,,
ODIA2,Diazepam,當立平Diapin 2mg,CNEU,Management of anxiety disorders， ethanol withdrawal symptoms; skeletal muscle relaxant; treatment of convulsive disorders; preoperative or preprocedural sedation and amnesia,Hypersensitivity to diazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; acute narrow-angle glaucoma; not for use in infants <6 months of age (oral),Hypotension， localized phlebitis， vasodilatation， Amnesia， ataxia， confusion， depression， drowsiness， dysarthria， fatigue， headache， slurred speech， vertigo， Skin rash， Change in libido， Altered salivation (dry mouth or hypersalivation)， constipation， diarrhea， nausea， Urinary incontinence， urinary retention， Jaundice， Pain at injection site， Tremor， weakness， Blurred vision， diplopia， Apnea， asthma， bradypnea， Paradoxical reaction (eg， aggressiveness， agitation， anxiety， delusions， hallucinations， inappropriate behavior， increased muscle spasms， insomnia， irritability， psychoses， rage， restlessness， sleep disturbances， stimulation),30℃乾燥避光,Adults: Anxiety， Insomnia: 5-30mg HS， or in 2-4 divided doses. Acute alcohol withdrawal: Initial dose:10mg， then TID-QID as needed. Spasm: 2-10mg TID-QID Skeletal muscle relaxation: 2-10mg TID-QID. Elderly and frail patients: 2-2.5mg QD-BID， titrate the dose as needed and tolerability. Children: Not recommended for children under 6 years old. Children 6 years and older:1-2.5mg， or 0.04mg-0.2mg/kg， or 1.17∼6mg per square meter of body surface area TID-QID， titrate the dose as needed and tolerability.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OFOS,Alendronate,Fosamax 10mg,META,,Treatment of osteoporosis in postmenopausal women.,,,10 mg once daily.,,,,除非治療上需要,,,,,,,,,,
IGEN,Gentamicin,Garamycin 80mg/2mL,QANB,,THIS IS A TESTING,,,,,,,,,,,,,,,,,
SK1001,,妊娠細紋雙效霜,TDER,,,,,,,,,,,,,,,,,,,
ESTI,Erythromycin,Stiemycin solution 2% 25mL,TDER,,I: Topical treatment of acne vulgais， in particular， inflamed forms with papules & pustules. CI: Hypersensitivity.,,,Apply bid. Continue for ≧6-12weeks.,,,,可能安全,,,,,,,,,,
OSIN,Montelukast,SINGULAIR Chewable 5mg,ERSP,SINGULAIR is indicated in adult & pediatric patients 6 months of age & older for the prophylaxis & chronic treatment of asthma， including the prevention of day- & nighttime symptoms， the treatment of aspirin-sensitive asthmatic patients， & the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated in adults & pediatric patients 2 years of age & older for the relief of day- & nighttime symptoms of seasonal allergic rhinitis.,Hypersensitivity to any component of Singulair.,Abdominal pain， headache， thirst， diarrhea， hyperkinesia， asthma， eczematous dermatitis， rash. Neurologic: Headache (Adult and adolescent; 18.4%; pediatric， 2% and greater ),30℃以下，避免朝濕與光線照射,Should be taken once daily. For asthma， the dose should be taken in the evening. For seasonal allergic rhinitis， the time of administration may be individualized. Patients with both asthma & seasonal allergic rhinitis should take only 1 TAB daily in the evening. Asthma and/or seasonal allergic rhinitis- Age > or = 15 years: 10 mg QD. Age 6-14 years: One 5 mg chewable TAB QD. Age 2-5 years: One 4 mg chewable TAB QD or one packet of 4 mg oral granules QD. Age 6 months-2 years with asthma: One packet of 4 mg oral granules QD.,需調整劑量,,無需調整劑量,可能安全,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為咀嚼錠，咬碎後吞服即可。
OMERC,Desogestrel + Ethinylestradiol,Mercilon (21 tablets/box),HM,Oral Contraceptives,Thrombophlebitis， thromboembolic disorders， CV disease or past history of these conditions; severe hypertension; severe liver disorder， cholestatic jaundice， Rotor syndrome， Dubin-Johnson syndrome; known or suspected estrogen-dependent tumours; endometrial hyperplasia; undiagnosed vag bleeding; porphyria; hyperlipoproteinemia; history during pregnancy of severe pruritus or herpes gestationis. Pregnancy.,GI upsets， cholestatic jaundice; thrombosis， BP elevation; chloasma， erythema， nodosum， rash; headache， migraine， mood changes; breast tenderness， pain， enlargement， secretion; fluid retention， reduced glucose tolerance， change in body wt; intermenstrual bleeding， post-medication amenorrhea， changes in cervical secretion， increase in size of uterine fibromyomata， aggravation of endometriosis， vag infection.,30℃以下勿冷凍，避免光線與濕氣,1 tablet daily for 21 days， starting on the 1st day of the cycle， then 7 tablet-free days.,無需調整劑量,Desogestrel [8] •Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding lEthinylestradiol Ethinylestradil [8] Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding up to date: Lactation Enters breast milk/not recommended,無需調整劑量,不可使用,Contraindicated,Desogestrel [18] Ethinylestradiol Ethinylestradil [18] by book . micromedex : Teratogenicity/Effects in Pregnancy Rating Fetal risk cannot be ruled out.,Contraindicated 哺乳期使用禁忌,Desogestrel [8] •Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding lEthinylestradiol Ethinylestradil [8] Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding up to date: Lactation Enters breast milk/not recommended,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉並注意相關風險，尤其避免暴露於懷孕或準備懷孕婦女。
OTIN,Oxatomide,Tinset 30mg,HIMM,,Hay fever， chronic urticaria， pruritus， adjuvant in allergic asthma， prevention of food allergies， food and drug induced exanthema， allergic rhumitis.,,,Adult: Allergic asthma: 2 tab bid， Other indications: 1 tab. bid. Child: 0.5mg/kg bid.,,,,除非治療上需要,,,,,,,,,,
OCALW,Calcium Citrate,Calwell chewable 950mg,NUTR,,適應症: Ca supplement， renal osteodystrophy. 副作用: -Mild hypercalcemia (calcium: >10.5 mg/dL) may be asymptomatic or manifest itself as constipation， anorexia， nausea， and vomiting. -More severe hypercalcemia (calcium: >12 mg/dL) is associated with confusion， delirium， stupor， and coma -Central nervous system: Headache -Endocrine & metabolic: Hypophosphatemia， hypercalcemia -Gastrointestinal: Nausea， anorexia， vomiting， abdominal pain， constipation -Miscellaneous: Thirst 禁忌: Hypersensitivity to any component of the formulation,,室溫,Adult & children > 4 years 2-5 tabs daily.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,(UpToDate) 1 g calcium citrate = elemental calcium 211 mg = calcium 10.5 mEq = calcium 5.25 mmol
ICOL1,Colistin Methanesulfonate,Colomycin inj 1MU,QANB,,適應症: GI infections; Bowel sterilisation. 副作用: Superinfection; renal damage; visual disturbances; GI disturbances， dizziness， nausea， vomiting; confusion， peripheral neuropathy; respiratory insufficiency and muscle weakness. 禁忌: Hypersensitivity. Anuria; porphyria; myasthenia gravis. Pregnancy and lactation.,,室溫,IV/IM GI infections; Bowel sterilisation As colistimethate Na: 6 million units/day in 3 divided doses. Max: 6 million units/24 hr. (每小瓶100萬單位=80mg Colistimethate sodium=33.4mg colistin base activity ) Normal renal function: 2.5-5mg/kg/day divided in 2-4 doses Mild renal impairment: 2.8-3.8mg/kg/day divided in 2 doses Moderate renal impairment: 2.5mg/kg/day divided in 1-2 doses,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 輸注液需新鮮配製，室溫下只能擺放24小時 2. 腎功能不全病患需減慢注射速率。
EATR3,Atropine,0.3% ANTOL， 5mL,TOPH,,適應症: Topical mydriatic & cycloplegic; uveitis. 副作用: Stinging， increased intraocular pressure， conjunctivitis. May precipitate glaucoma. 禁忌: Closed- & narrow-angle glaucoma.,,室溫,1 gtt hs: for treatment of myopia. (0.1 %， 0.25 % and 0.5%) 1 gtt qid: for use in uveitis. (1.0 %),無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
ETET,Tetracycline,Tetracycline oph oint 1%， 5gm,TOPH,,禁忌: Hypersensitivity to doxycycline or other tetracyclines. 副作用: Local irritation 適應症: Local treatment of ophth infections due to gm+ve & gm-ve bacteria eg acute & chronic conjunctivitis， blepharoadenitis， acute keratitis & trachoma.,,室溫,For eye infections: Adults and children—Use every two to four hours， depending on severity of infection.,無需調整劑量,,無需調整劑量,盡量避免,,,Compatible 哺乳時可使用,,AD;AL;AS;AU;EXT;OD;OL;OU;SKIN;TOPI;,,,,,
OCHAL,Calcium polystyrene sulfonate,Chalian powder 5g/pk,ZADT,,適應症: Treatment of hyperkalemia 副作用: Endocrine & metabolic: Hypercalcemia， hypokalemia， hypomagnesemia Gastrointestinal: Anorexia， concretions (bezoars; oral administration)， constipation， diarrhea， fecal impaction (rectal administration)， gastric irritation， GI necrosis/ulceration， ischemic colitis， nausea， obstruction (rare)， rectal hemorrhage， vomiting Respiratory: Acute bronchitis， bronchopneumonia 禁忌: Hypersensitivity to polystyrene sulfonate resins or any component of the formulation; potassium <5 mmol/L (5 mEq/L); conditions associated with hypercalcemia (eg， metastatic carcinoma， hyperparathyroidism); obstructive bowel disease; oral administration in neonates; use in neonates with reduced gut motility (postoperative， drug induced),,室溫,Dosing: Adult Hyperkalemia: Initiate treatment if potassium level >6 mmol/L (6 mEq/L); discontinue when potassium < 5 mmol/L (5 mEq/L). Oral: 15 g 3-4 times/day Rectal: 30 g once daily,,(104.01.15)藥品廠商建議日極量 30 g.,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,(104.01.15)藥品廠商建議日極量 30 g.,,,,,,
OACT6,Acetylcysteine,Actein 600mg 發泡錠,ERSP,,適應症: Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis， emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms. 副作用: Bronchospasm， GI upsets， stomatitis; rhinorrhea， fever， hemoptysis; rarely anaphylactic reactions. Dermatologic: Pruritus (1% to 4.3% )， Rash (4% to 5% )， Urticaria Gastrointestinal: Diarrhea， Nausea (2% to 7% )， Vomiting (9% to 12% ) 禁忌: Effervescent tab Phenylketonuria.,,室溫,Effervescent tab Adult & children > 6 years 1 effervescent tab qd ~ bid.,無需調整劑量,,無需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OARI,Donepezil,Aricept 5mg,CNEU,Mild to moderate Alzheimer's disease.,,,,1 TAB daily.,無需調整劑量,,無需調整劑量,除非治療上需要,,,,,AC;AC15;PC;PO;WM;,,,,,
OCRA,Levofloxacin,Cravit F.C. 100mg,QANB,,Resp tract， ENT， GUT infection. Intracterine infections， cervicitis， uterine adnesxitis， folliculitis. GIT infections， lymphangitis， mild to moderate skin & skin tissue infections.,,,Adult 100mg bid-tid. Severe case: 200mg bid.,,,,除非治療上需要,,,,,,,,,,
HE5005,Dianeal 1500cc 4.25% (PD 4雙袋),Dianeal 1500mL 4.25% (PD 4雙袋),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy， frequency of treatment， formulation， exchange volume， duration of dwell， and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size， usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
ECIV,Heparinoid,Cividoid gel 20gm,TDER,Treatment of superficial thrombophlebitis & relief of superficial bruising & haematoma.,Hypersensitivity to this medicine. Not for oral or ophthalmic use.,Hypersensitivity reaction.,25℃以下儲存,superficial thrombophlebitis & hematoma Use 2-3 times a day， till symptom resolved,無需調整劑量,[仿單]兒童，孕婦，可能懷孕婦女及哺乳婦，使用前請先諮詢醫師藥師藥劑生.,無需調整劑量,除非治療上需要,Uknown 沒有資料,[仿單]兒童，孕婦，可能懷孕婦女及哺乳婦，使用前請先諮詢醫師藥師藥劑生.,Unknown 沒有資料,[仿單]兒童，孕婦，可能懷孕婦女及哺乳婦，使用前請先諮詢醫師藥師藥劑生.,EXT;SKIN;TOPI;,,,,,
IPRI,Metoclopramide hydrochloride,Primperan 針劑 10mg/2mL,ALIM,Prevention of nausea & vomiting， GERD & diabetic gastroparesis.,GI hemorrhage， mechanical obstruction or digestive perforation; Pheochromocytoma; previous history of tardive dyskinesia with neuroleptics. Epilepsy,Syndrome malin. Occasionally GI disturbances， headache， lightheadedness， drowsiness. Rarely， endocrinal disorders eg. amenorrhea， hyperprolactinemia， gynecomastia in males， breast enlargement in women; extrapyrimidal symptoms， hypotension， tachycardia， arrhythmia Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )， Vomiting (1.4% to 2.1% ) Neurologic: Asthenia (10% )， Headache (4.2% to 5.2% .)， Somnolence (oral， 2.1% to 10%; IV， 70%) Other: Fatigue (2.1% to 2.8% ),30℃以下，置於原包裝內避光貯存,Actute condition: Adult 10mg， may repeat if necessary; Children > 14 years: 10mg; 6-14 years: 2.5-5mg; Children 1-6 years: 0.1mg/kg/dose; Children < 1 year: 0.1mg/kg/dose with maximum 2 times per day. Recommended dosage: 0.1mg/kg/dose， maximum 3 times per day. Maximum dosage: 0.2mg/kg/dose. Daily maximum dosage: < 0.5mg/kg.,需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,,【D5NS】可選 。【N/S】可選 。【D10W】可選 。【L/R】可選 。,Primperan inj.請 slowly push (至少3 分鐘)，超過 1 amp 請 IV drip。,化療前靜脈注射：10 mg / 50 mL 緩慢輸注超過 15 分鐘。,1. 化療前靜脈注射：10 mg / 50 mL 緩慢輸注超過 15 分鐘。 2. Primperan 10 mg IV 請 slowly push (至少3 分鐘)，超過 1 amp 請 IV drip。(2008/03/11 藥物不良反應小組)
EZIN,Zinc Oxide,Zin ointment 20%， 28.4gm,TDER,Eczema， scalp dermatoses.,Hypersensitivity to any component of the formulation.,Drying or tightening of skin.,25℃以下,Apply several times as need.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
IVIT,Calcium chloride， Glucose,Vitacal inj 5.44mEq / 20mL,NUTR,,適應症: Treatment of hypocalcemia and conditions secondary to hypocalcemia (eg， tetany， seizures， arrhythmias); emergent treatment of severe hypermagnesemia. 副作用: Cardiovascular (following rapid IV injection): Bradycardia， cardiac arrest， cardiac arrhythmia， hypotension， syncope， vasodilatation Central nervous system: Feeling abnormal (sense of oppression; with rapid IV injection)， tingling sensation (with rapid IV injection) Endocrine & metabolic: Hot flash (with rapid IV injection)， hypercalcemia Gastrointestinal: Dysgeusia (chalky taste)， gastrointestinal irritation， increased serum amylase Local: Local tissue necrosis (following extravasation) Renal: Nephrolithiasis Postmarketing and/or case reports (Limited to important or life-threatening): Cutaneous calcification 禁忌: Known or suspected digoxin toxicity; not recommended as routine treatment in cardiac arrest (includes asystole， ventricular fibrillation， pulseless ventricular tachycardia， or pulseless electrical activity),,室溫,Vitacal inj (Calcium chloride 400mg + Glucose.H2O 2gm / 20mL) Adult Dosing --Hypocalcemia: 200 mg to 1 g calcium chloride (55 to 273 mg elemental calcium) IV every 1 to 3 days. --Cardiac arrest or cardiotoxicity in the presence of hyperkalemia， hypocalcemia， or hypermagnesemia: IV: 500-1000 mg over 2-5 minutes; may repeat as necessary. --Beta-blocker overdose， refractory to glucagon and high-dose vasopressors (off-label use): IV: 20 mg/kg over 5-10 minutes followed by an infusion of 20 mg/kg/hour titrated to adequate hemodynamic response. --Calcium channel blocker overdose (off-label use): IV: Initial: 1000-2000 mg over 5 minutes; may repeat every 10-20 minutes with 3-4 additional doses or 1000 mg every 2-3 minutes until clinical effect is achieved; if favorable response obtained， consider IV infusion. IV infusion: 20-40 mg/kg/hour.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,1. 1 g calcium chloride = elemental calcium 273 mg = calcium 13.6 mEq = calcium 6.8 mmol 2. For IV administration only and administration via central or deep vein is preferred. 3. stop the infusion if the patient complains of pain or discomfort. 4. Monitor ECG if calcium is infused faster than 2.5 mEq/minute 5. Do not infuse calcium chloride in the same IV line as phosphate-containing solutions. 6. Avoid rapid administration (do not exceed 100mg/minute).
IPAN5,Pantoprazole,Pantoprazole inj 40mg,ALIM,,適應症: - Reflux oesophagitis - Gastric and duodenal ulcer - Zollinger – Ellison Syndrome and other pathological hypersecretory conditions. 副作用:Headache， Diarrhea， Nausea， Abdominal pain， Vomiting， Flatulence， Dizziness， Arthralgia 禁忌:Hypersensitivity (eg， anaphylaxis， anaphylactic shock， angioedema， bronchospasm， acute interstitial nephritis， urticaria) to pantoprazole， other substituted benzimidazole proton pump inhibitors， or any component of the formulation,,,Dosing: Adult Erosive esophagitis associated with GERD: IV: 40 mg once daily for 7 to 10 days. Hypersecretory disorders (including Zollinger-Ellison):IV: 80 mg every 12 hours; adjust dose based on acid output measurements; 160 to 240 mg daily in divided doses has been used for a limited period (up to 7 days). Prevention of rebleeding in peptic ulcer bleed (off-label use): IV:Continuous infusion: Loading dose of 80 mg， followed by 8 mg/hour infusion for 72 hours. Dosing: Pediatric IV: Dosage not established,需調整劑量,,無需調整劑量,可能安全,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;,,【N/S】可選 仿單建議。【D5W】可選 。,推注時間> 2-15分鐘,本品輸注時間應超過2-15分鐘,本藥需先以10mL N/S溶解，配製後之溶液可直接注射投予或以100mL建議輸注液混合滴注。
IK2P,K2HPO4+KH2PO4,Potassium Phosphate inj 20mL,NUTR,For TPN preparation， Severe hypophosphataemia.,Severe renal impairment， hyperkalaemia， hypocalcaemia， infected phosphate renal calculi.,Hyperphosphataemia esp in renal failure which may lead to hypocalcaemia and ectopic calcification esp in hypercalcaemic patients. Hypotension and organ damage due to tissue calcification which may cause acute renal failure. Hyperphosphataemia， hypocalcaemia， tissue calcification; nausea， vomiting， diarrhoea， abdominal pain， flatulence; bradycardia; hyperkalaemia; weakness; dyspnoea.,25℃以下,As TPN material only. Each mL contains: Potassium 4.4 mEq and phosphorus 3 mmol = potassium 170 mg and elemental phosphorus 93 mg. Dose and rate of administration are dependent on individual patient needs.,無需調整劑量,,無需調整劑量,除非治療上需要,,,Compatible 哺乳時可使用,,IVD;,,【N/S】可選 。,,For adult patients with severe symptomatic hypophosphatemia (ie， <1.5 mg/dL)， may administer at rates up to 15 mmol phosphate/hour (this rate will deliver potassium at 22.5 mEq/hour). Potassium infusion rates >10 mEq/hour should be administered via central line (minimizes burning and phlebitis). ECG monitoring is recommended for potassium infusions >10 mEq/hour in adults or >0.5 mEq/kg/hour in children. In patients with renal dysfunction and/or less severe hypophosphatemia， slower administration rates (eg， over 4 to 6 hours) or oral repletion is recommended.,1. 本品為高濃度鉀離子溶液，須稀釋後使用，限藥劑科用於製劑調配。 2. 每 mL含phosphate : 3 mmole， potassium : 4.4 mEq
ONEW2,Multivitamins + Minerals + Fe,New Prenatal 200's/bot,NUTR,,適應症: Nutritional supplement for vits & minerals during pregnancy & lactation.,,室溫,1 tab daily or as directed by the physician.,,,,安全,,,,,,,,,,
EISO2,Pilocarpine,Isopto carpine 2% 15mL,TOPH,Control of intraocular pressure.,Acute iritis， anterior uveitis， acute inflammatory disease of the anterior segment.,Burning， itching & smarting of the eyes， blurred vision， conjunctival vascular congestion， myopia， lens changes (chronic use)， vitreous haemorrhage， pupillary block， headache. Dermatologic: Flushing， Oral formulation (8-13%)， Sweating symptom， Oral formulation (29-68%) Endocrine metabolic: Shivering， Oral formulation (3-15%) Gastrointestinal: Nausea， Oral formulation (6-15%) Neurologic: Dizziness， Oral formulation (5-12%) Ophthalmic: Blurred vision， Ophthalmic formulation， Burning sensation in eye， Ophthalmic formulation， Itching of eye， Ophthalmic formulation， Scotopic sensitivity， Difficulty， with ophthalmic formulation Renal: Increased frequency of urination， Oral formulation (9-12%) Respiratory: Rhinitis， Oral formulation (5-14%),8-30℃,Instill 2 drops TID.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
EAZA,Timolol + Brinzolamide,Azarga 0.5/1%， 5mL ophthalmic suspension,TOPH,Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma,Hypersensitivity to brinzolamide， timolol， other beta-blockers， sulfonamides， or any component of the formulation; current or history of bronchial asthma; severe chronic obstructive pulmonary disease (COPD); severe allergic rhinitis and bronchial hyper-reactivity; sinus bradycardia， second-/third degree atrioventricular (AV) block， overt cardiac failure， cardiogenic shock; hyperchloremic acidosis; severe renal impairment,Taste perversion (2%)， Blurred vision (6%)， eye irritation (4%)， eye pain (3%)， foreign body sensation in eyes (1%),30℃以下儲存,Instill 1 drop BID into the conjunctival sac. Age <18 years: Not recommend use.,無需調整劑量,(Up to date) Pregnancy Implications: There are no adequate and well-controlled studies in pregnant women with the combination product. Use only if benefit outweighs risk. Bradycardia and arrhythmia have been reported in an infant following ophthalmic administration of timolol during pregnancy. See individual agents. Lactation: Timolol enters breast milk/not recommended,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,(Up to date) Pregnancy Implications: There are no adequate and well-controlled studies in pregnant women with the combination product. Use only if benefit outweighs risk. Bradycardia and arrhythmia have been reported in an infant following ophthalmic administration of timolol during pregnancy. See individual agents. Lactation: Timolol enters breast milk/not recommended,OD;OL;OU;,,,,,
IVISI,Iodixanol,Visipaque inj 320mg I/mL， 100mL,SCAN,Intra-arterial: Digital subtraction angiography， angiocardiography， peripheral arteriography， visceral arteriography， cerebral arteriography Intravenous: Contrast enhanced computed tomography imaging， excretory urography， and peripheral venography,Hypersensitivity to iodixanol or any component of the formulation; not intended for intrathecal use In pediatric population: Prolonged fasting or laxative administration prior to iodixanol administration Refer to product labeling for procedure-specific contraindications.,Local: Injection site reactions (discomfort/pain/warmth 30%)， Angina/chest pain (2%)， Headache/migraine (3%)， vertigo (2%)， Nonurticarial rash/erythema (2%)， pruritus (2%)， Taste perversion (4%)， nausea (3%)， Paresthesia (1%)， Parosoma (1%),30℃以下避光,the Remencomended dose: Indication or investigation; Concentration; Volume per injection: Intra-arterial use: Selective Cerebral Aortgraphy; 320mg I/mL( Both strengths are documented， but 270mg I/mL is recommened in most case); 5-10mL. Aortography; 320mg I/mL; 40-60mL. Peropheral; 320mg I/mL; 30-60mL. Cardioangiography: Adults Left ventricle and aortic root; 320mg I/mL; 30-60mL. Adults Selevtive coronary arteriography; 320mg I/mL; 4-8mL. Children; 320mg I/mL; depending on age， weight， and pathology. Remencomended maximum total dose is 10mL/Kg. Intravenous use: Urography， Adults; 320mg I/mL; 40-80mL(higher doses can be used in some cases). Urography， Children <7kg; 320mg I/mL; 2-4mL/kg. Urography， Children >7kg; 320mg I/mL; 2-3mL/kg.(depending on age， weight， and pathology. Remencomended maximum total dose is 50mL.) Venography: CT-enhancement; 270mg I/mL; 50-150mL/leg. Adults CT of the head; 320mg I/mL; 50-150mL. Adults CT of the body; 320mg I/mL; 75-150mL. Children CT of the head and body; 320mg I/mL; 2-3mL/kg， the maximum dose is 50mL， but 150mL can be used in some cases. Intrathecal use: Lumbar and thoracic myelography (lumbar injection); 320mg I/mL; 10mL.(to minimize possible adverse reactions a total dose of 3.2g iodine should not be exceeded.) Cervical myelography (cervical or lumbar injection); 320mg I/mL; 10mL.(to minimize possible adverse reactions a total dose of 3.2g iodine should not be exceeded.),無需調整劑量,,需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,IA;IT;ITH;IV;IVP;IVPUSH;,,,,,
IGRA,Granisetron,Grantron inj 3mg/3mL,CNEU,Prevention or treatment of nausea & vomiting induced by cytostatic therapy & radiation.,Hypersensitivity to granisetron or related substances.,Headache， constipation. Gastrointestinal: Constipation (5.4% ),25℃以下避光,Prophylaxis or treatment of chemotherapy-induced nausea and vomiting: Prophylactic dose given before chemotherapy. Adult: 1-3 mg (10-40 mcg/kg) either as IV bolus over not less than 30 seconds or diluted in 20-50 mL infusion fluid and administered over >5 minutes. Maximum dose over 24 hours: 9 mg. Children: 10-40 mcg/kg body weight (up to 3 mg) diluted in 10-30 mL infusion fluid and administered over >5 minutes. One additional dose may be given within 24 hr if necessary. (Repeat infusions should be separated with each by at least 10-minute intervals.) Prevention & treatment of radiation-induced nausea and vomiting: Prophylactic dose given before radiation. Adult: 1-3 mg (10-40 mcg/kg) either as IV bolus over not less than 30 seconds or diluted in 20-50 mL infusion fluid and administered over >5 minutes. Maximum: 9 mg/24 hours. Postoperative nausea and vomiting: Adult: 1 mg (10 mcg/kg) either as IV bolus over not less than 30 seconds. Maximum: 3 mg/24 hours.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,【D5W】。【N/S】可選 。,推注時間至少超過30秒,稀釋於20-50mL輸注液，輸注時間>5分鐘,
IGS5,Dextrose + Sodium Chloride,5% Dextrose in 0.9% NaCl 500mL,MSIV,Replacement & maintenance of fluid & electrolytes.,,,30℃以下,Individualized dosage. Each Dextrose 5% and Sodium chloride 0.9% solution mL contains: Dextrose 50mg， Sodium chloride 9mg.,無需調整劑量,,無需調整劑量,沒有資料,Compatible,,Compatible 哺乳時可使用,,IVD;,,,,,
INS45,Sodium Chloride,0.45% Saline inj 500mL,MSIV,為0.45 % 食鹽水注射液(A036014277),,,室溫,IV infusion as needed.,無需調整劑量,,需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,
IHMGS,FSH75IU + LH75IU,Pergonal 75 IU,HM,,Stimulation of follicular maturation in anovulatory， infertile women & spermatogenesis in infertile males.,,,Individual-dependent.,,,,,,,,,,,,,,
OCONS,Bisacodyl + DSS + Sennoside,Conslife 2/20/10mg,ALIM,,適應症: Constipation. 副作用: Diarrhea， abdominal pain， discomfor or cramping， allergy， electrolye imbalance. 禁忌: Ileus， intestinal obstruction， acute abdominal conditions including appendicitis， acute inflammatory bowel diseases & severe abdominal pain associated with nausea & vomiting. Severe dehydration.,,室溫,Oral: Adult: 2-3 tablets once daily， taking before sleeping. Child over 6 y/o: 2 tablets once daily， taking before sleeping.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
LBAR,Barium sulfate,Baritop-120 300mL,SCAN,,適應症: ■Computerized axial tomography ■Endoscopy of esophagus ■Gastrointestinal investigation ■Radiography of intestine 副作用: ■Cardiovascular: Cardiorespiratory arrest， Edema ■Gastrointestinal: Impaction of intestine， Small bowel obstruction ■Immunologic: Immune hypersensitivity reaction (rare) 禁忌: ■colon obstruction， known or suspected ■distal small bowel obstruction， suspected ■duodenal or jejunal obstruction， complete， in newborns ■gastrointestinal tract leakage， possibility of (eg， necrotizing enterocolitis， unexplained pneumoperitoneum， gasless abdomen， other bowel perforation， esophageal perforation， or postoperative anastomosis)， in infants and young children ■gastrointestinal tract perforation， known or suspected ■hypersensitivity to barium sulfate or any product component ■latex allergy or hypersensitivity; balloon retention enema tips contain latex ■obstructing lesions of the small intestine ■procedures requiring small volumes of contrast media in very small preterm infants or young babies ■pyloric stenosis ■rectal biopsy， recent ■rectum inflammation or neoplastic lesions ■swallowing disorders in infants ■tracheoesophageal fistula， suspected,,室溫,Computerized axial tomography:Total bowel opacification: 300 milliliters (mL) orally the evening prior to examination， 300 mL orally the 2 hours prior to exam， and 300 mL orally 15 minutes prior to exam.,,micromedex (Pregnancy Category):Fetal risk is minimal. (TH) micromedex (Breastfeeding):Breastfeeding a) Micromedex Lactation Rating: Infant risk is minimal. 1) The weight of an adequate body of evidence and/or expert consensus suggests this drug poses minimal risk to the infant when used during breastfeeding. b) Clinical Management 1) Nursing mothers may use barium sulfate products,,沒有資料,,,Contraindicated 哺乳期使用禁忌,micromedex (Pregnancy Category):Fetal risk is minimal. (TH) micromedex (Breastfeeding):Breastfeeding a) Micromedex Lactation Rating: Infant risk is minimal. 1) The weight of an adequate body of evidence and/or expert consensus suggests this drug poses minimal risk to the infant when used during breastfeeding. b) Clinical Management 1) Nursing mothers may use barium sulfate products,PO;,,,,,
IHUM0,Adalimumab,Humira 40mg inj (sample),HIMM,,適應症:Monotherapy or in combination with methotrexate or other DMARDs for reducing of the signs & symptoms & to inhibit the progression of structural damage in adult patients with moderately to severely active RA. Monotherapy or in combination with other DMARDs for reducing the signs & symptoms of active arthritis in patients with psoriatic arthritis. Reduction of signs & symptoms in patients with active ankylosing spondylitis. Reduction of signs & symptoms & inducing & maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy or if they have also lost response to or are intolerant to infliximab. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy & when other systemic therapies are medically less appropriate. Reduction of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients 13-17 years. 副作用:Resp tract infections， leucopenia， anemia， increased lipids， headache， abdominal pain， nausea & vomiting， elevated liver enzymes， rash， musculoskeletal pain， inj site reaction. 禁忌:Known hypersensitivity to adalimumab or any of the excipients of Humira.,,2-8℃,Adult RA， psoriatic arthritis， ankylosing spondylitis， polyarticular juvenile idiopathic arthritis Single dose of 40 mg SC every other week. If not taking concomitantly with methotrexate， increasing the dosing frequency to 40 mg weekly may derive additional benefit. Crohn's disease 160 mg initially at day 1 (as four 40-mg inj in 1 day or as two 40-mg inj/day for 2 consecutive days)， followed by 80 mg 2 weeks later (day 15). Another 2 weeks later (day 29) begin a maintenance dose of 40 mg every other week. Patients who experience decrease in their response may benefit from an increase in dose intensity to 40 mg every week. Plaque psoriasis Initially 80 mg， followed by 40 mg given every other week starting 1 week after the initial dose.,,,,可能安全,Compatible,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,SC;,,,,,
IBOL,Zoledronic Acid,Bolenic IV infusion 4mg,META,Prevention of skeletal related events (pathological fractures， spinal compression， radiation or surgery to bone， or tumor-induced hypercalcemia) in patients with advanced malignancies involving bone. Treatment of hypercalcemia of malignancy (HCM).,Known hypersensitivity to zoledronic acid or other bisphosphonates.,Very common: Hypophosphatemia. Common: Anemia， headache， conjunctivitis， nausea， vomiting， anorexia， bone pain， myalgia， arthralgia， renal impairment， fever， flu-like syndrome， blood creatinine & blood urea increase， hypocalcemia. Cardiovascular: Peripheral edema (Paget's Disease， 3%; osteoporosis， 4.6% to 5.5%; bone metastasis， 21% ) Endocrine metabolic: Weight decreased (bone metastasis， 16% ) Gastrointestinal: Abdominal pain (osteoporosis (female)， 0.9% to 4.6%; osteoporosis (male)， 7.9%; Paget's disease， 2%; hypercalcemia of malignancy， 16%; bone metastasis， 14% )， Constipation (Paget's disease， 6%; hypercalcemia of malignancy， 27%; bone metastasis， 31% )， Diarrhea (osteoporosis， 5.2% to 6%; Paget's disease， 6%; hypercalcemia of malignancy， 17%; bone metastasis， 24% )， Loss of appetite (osteoporosis， 1% to 2%; Paget's disease， 2%; hypercalcemia of malignancy， 9%; bone metastasis， 22% )， Nausea (osteoporosis， 4.5% to 8.5%; Paget's disease， 9%; hypercalcemia of malignancy， 29%; bone metastasis， 46% )， Vomiting (Paget's disease， 2%; osteoporosis， 3.4% to 4.6%; hypercalcemia of malignancy， 14%; bone metastasis， 32% ) Musculoskeletal: Arthralgia (osteoporosis (female)， 17.9% to 23.8%; osteoporosis (male)， 11.1%; hypercalcemia of malignancy， 5% to less than 10%; Paget's disease， 9%; bone metastasis， 21% )， Backache (Paget's disease， 4%; bone metastasis， 15% ) Neurologic: Asthenia (osteoporosis， 3.2 to 5.3%; Paget's disease， 2%; bone metastasis， 24% )， Dizziness (osteoporosis， 2% to 7.6%; Paget's disease， 9%; bone metastasis， 18% )， Headache (osteoporosis (female)， 3.9% to 12.4%; osteoporosis (male)， 15%; Paget's disease， 11%; hypercalcemia of malignancy， 5% to less than 10%; bone metastasis， 19% )， Insomnia (hypercalcemia of malignancy， 15%; bone metastasis， 16% )， Paresthesia (Paget's disease， 2%; bone metastasis， 15% .) Renal: Nephrotoxicity (bone metastasis， 11% to 17% ) Other: Fatigue (osteoporosis (female)， 2.1% to 5.4%; osteoporosis (male)， 17.6%; Paget's disease， 8%; bone metastasis， 39% )， Fever (osteoporosis (female)， 7% to 18%; osteoporosis (male)， 15.7%; Paget's disease， 3% to 11%; hypercalcemia of malignancy， 44%; bone metastasis， 32% ),30℃以下,IVD， 4 mg once every 3-4 weeks.,無需調整劑量,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management It is not known whether zoledronic acid is excreted into human breast milk and the potential for adverse effects in the nursing infant from exposure to the drug are unknown. However， as zoledronic acid binds to bone long-term， it is recommended that it should not be administered to a nursing woman.,需調整劑量,不可使用,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management It is not known whether zoledronic acid is excreted into human breast milk and the potential for adverse effects in the nursing infant from exposure to the drug are unknown. However， as zoledronic acid binds to bone long-term， it is recommended that it should not be administered to a nursing woman.,IVD;,5mL注射用水稀釋,【D5W】可選 。【N/S】可選 。,,加入100mL相容輸注液中輸注，IVD > 15 mins，不可使用含鈣或兩價陽離子的溶液,1. patients should be adequately hydrated prior to administration 2. If previously refrigerated， allow solution to reach room temperature before administration 3. administer as a single-dose IV infusion in a vented line separate from other drugs; infuse over no less than 15 minutes， over a constant infusion rate 4. Do not allow solution to come in contact with calcium-containing solutions or other divalent cation-containing infusion solutions (eg， lactated Ringer)
EDIV,Estradiol,Divigel 0.1% gel,HM,,適應症:女性由於自然停經或手術引起之女性荷爾蒙缺乏症狀的荷爾蒙替代療法更年期的熱潮紅或生理不適、無法分泌女性荷爾蒙而引起的各種不適。Treatment of the climacteric syndrome associated with natural or artificial menopause (estro-genic deficiency， e.g. hot flushes， night sweatings， urogenital atrophy and prevention of postmenopausal (type 1) osteoporosis. 副作用: 頭痛，乳房漲痛，水腫，體重增加，噁心，嘔吐，不規則之陰道出血或點狀出血或皮膚刺激性等。Common side effects that may occur with Divigel? include headache; breast pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps， bloating; nausea and vomiting; hair loss; fluid retention and vaginal yeast infection. Serious but less common side effects include heart attack， stroke， blood clots， dementia， breast cancer， cancer of the uterus， ovarian cancer， high blood pressure， high blood sugar， gallbladder disease， liver problems， and enlargement of benign uterus tumors (“fibroids”). 禁忌: 不明原因陰道出血。過去兩年內患有靜脈血栓(例如:深部靜脈血栓或肺栓塞)。又復發性靜脈血栓病史或有血栓疾病而尚未接受抗凝血藥物治療者。嚴重肝疾病患者。已知或懷疑之惡性腫瘤，可能受類固醇影響者，特別是乳癌或子宮內膜癌。對該成分過敏unusual vaginal bleeding， currently have or have had certain cancers， including cancer of the breast or uterus， had a stroke or heart attack; currently have or have had blood clots， currently have or have had liver problems， have been diagnosed with a bleeding disorder， are allergic to Divigel?or any of its ingredients， or think you may be pregnant.,,,Divigel can be used for continuous or cyclical treatment. The dose can be adjusted individually from 0.5g-1.5g per day， corresponding to 0.5-1.5mg estradiol per day. The usual starting dose is 1.0mg estradiol daily and can be readjusted after 2 to 3 cycles. The Divigel gel is applied once daily， on the skin of the lower trunk or the right or left thighs， on alternate days. The application surface should be 1-2times the size of the hand. Divigel should not be applied on the breasts， on the face or irritated skin. After application the gel should be allowed to dry for a few minutes and the application site should not be washed within one hour.Hands should be washed after application.,,,,不可使用,,,Compatible 哺乳時可使用,,,,,,,
LCUR,Amoxicillin + Clavulanic Acid,Curam 懸浮液 312.5mg/5mL， 60mL,QANB,,適應症: Treatment of infections due to Staph， Strep， pneumococcus， meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract， GUT， skin & soft tissue， bone & joint. Dental infections， septic abortion， puerperal sepsis， intra-abdominal sepsis. Vial Also indicated for prophylaxis against infection which may be associated with major surgical procedures such as GI， pelvic， head & neck， cardiac， renal， joint replacement & biliary tract. 副作用: Diarrhea， nausea， vomiting， skin candidiasis. Uncommonly dizziness， headache， indigestion， rash， pruritus， urticaria. Rarely， reversible leucopenia， thrombocytopenia， erythema multiforme. 禁忌: Hypersensitivity to penicillins， possible cross sensitivity with other β-lactam antibiotics. History of penicillin-associated cholestatic jaundice/hepatic dysfunction.,,室溫,(Amoxicillin 250 mg and clavulanate 62.5 mg per 5mL) Pediatric drug Infants < 3 months: General dosing， susceptible infection: Oral: 30 mg amoxicillin/kg/day in divided doses every 12 hours using the 125 mg/5 mL oral suspension only Infants >= 3 months， Children， and Adolescents:General dosing， susceptible infection: Oral: Three times daily dosing: 20-40 mg amoxicillin/kg/day in divided doses 3 times daily using 125 mg/5 mL or 250 mg/5 mL oral suspension or 500 mg tablet formulations; maximum single dose: 500 mg amoxicillin,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IALO,Palonosetron,Aloxi inj 0.25mg/5mL,CNEU,Chemotherapy-induced nausea and vomiting,Hypersensitivity to palonosetron or any component of the formulation,1% to 10%: Cardiovascular: Prolonged Q-T interval on ECG (PONV 1% to 5%; chemotherapy-associated <1%)， bradycardia (chemotherapy-associated 1%)， sinus bradycardia (PONV: 1%)， tachycardia (may be nonsustained; 1%)， hypotension (<=1%) Central nervous system: Headache (chemotherapy-associated: Adults 9%; infants， children， and adolescents <1%)， anxiety (chemotherapy-associated: 1%)， dizziness (infants， children， adolescents， and adults ?1%) Dermatologic: Pruritus (PONV: 1%) Endocrine & metabolic: Hyperkalemia (chemotherapy-associated: 1%) Gastrointestinal: Constipation (chemotherapy-associated: 5%)， diarrhea (<=1%)， flatulence (<=1%) Genitourinary: Urinary retention (<=1%) Hepatic: Increased serum ALT (<=1%; may be transient)， increased serum AST (<=1%; may be transient) Neuromuscular & skeletal: Weakness (chemotherapy-associated: 1%),25℃以下，避免冷凍,Chemotherapy-induced nausea and vomiting， associated with emetogenic chemotherapy; Prophylaxis: Adult: 0.25 mg IV over 30 seconds approximately 30 minutes prior to starting chemotherapy. Children and Adolescents (1 month to 17 years old): 20 mcg/kg IV over 15 minutes approximately 30 minutes prior to starting chemotherapy; maximum dose: 1.5 mg.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,【D5W】可選 。【N/S】可選 。,成人:化學治療前30分鐘給藥，以靜脈注射需超過30秒。,1個月-17歲小孩小孩:在開始化療前30分鐘給藥，靜脈注射需超過15分鐘。,1.投與本藥前與後均需以生理食鹽水沖洗輸注管線，不應與其他藥物混合 2.仿單建議給藥方式:成人:化學治療前30分鐘給藥，以靜脈注射需超過30秒；1個月-17歲小孩:在開始化療前30分鐘給藥，靜脈注射需超過15分鐘。
ICETR,Cetrorelix,Cetrotide inj 0.25mg,HM,Prevention of premature ovulation in patients undergoing controlled ovarian stimulation， followed by oocyte pick-up & assisted reproduction techniques.,Hypersensitivity to extrinsic peptide hormones or mannitol. Postmenopausal women， moderate & severe renal or hepatic impairment. Pregnancy， lactation.,Reactions at inj site， nausea， headache， ovarian hyperstimulation syndrome.,2-8℃避光,SC inj Cetrotide 0.25 mg Administration in the morning 1 vial once daily commencing on day 5 or 6 of ovarian stimulation (approximately 96-120 hr after initiation of ovarian stimulation). Administration in the evening 1 vial once daily on day 5 of ovarian stimulation (approximately 96-108 hr) after initiation of ovarian stimulation. To be given w/ urinary or recombinant gonadotrophins & continued throughout gonadotrophin treatment until the evening prior to the day of ovulation induction.,無需調整劑量,,需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,H;SC;,使用廠商提供之注射用水稀釋，以溫和旋轉方式來溶解，避免劇烈搖晃產生氣泡,,,,
LALG,Alginate+Calcium Carbonate+NaHCO3,Alginos oral susp 210mL,ALIM,,適應症: Symptomatic relief of gastric distress， heartburn， hyperacidity & indigestion. 副作用: Flatulence. 禁忌或警語: Each 10 ml of Alginos contains Na 141 mg， so Na ingestion should be calculted for patients with renal or CV diseases & requiring limited Na diet.,,室溫,Adult (>12yr): 10-20 ml tid-qid. child(2-12yr): 5-10 ml tid-qid.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,Each 10 ml of Alginos contains Na 141 mg， so Na ingestion should be calculted for patients with renal or CV diseases & requiring limited Na diet.
OEXF,Amlodipine + Valsartan,Exforge 5/80mg,CAVS,Hypertension,■Severe hepatic impairment， biliary cirrhosis or cholestasis. Severe renal impairment (GFR <30 mL/min/1.73 m2) & dialysis patients. Pregnancy. ■hypersensitivity to amlodipine， valsartan， or any other component ■concomitant aliskiren use in diabetic patients,common ■Cardiovascular: Peripheral edema (5.4% ) ■Neurologic: Dizziness (2.1% ) ■Respiratory: Nasopharyngitis (4.3% )， Upper respiratory infection (2.9% ) serious Cardiovascular: Hypotension (0.4% ),30℃以下避光,HTN initial: 1tablet QD slowly titiate up to 2 tablet QD (maximum 10mg/160mg),需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OTYK,Lapatinib ditosylate,Tykerb 250mg,RACA,In combination w/ capecitabine for the treatment of patients w/ advanced/metastatic breast cancer whose tumours overexpress HER2 & who have received prior therapy including anthracycline， taxane & trastuzumab. In combination w/ letrozole for the treatment of post-menopausal women w/ hormone receptor positive metastatic breast cancer that overexpress HER2 receptor for whom hormonal therapy is indicated.,Hypersensitivity to lapatinib ditosylate or to any of the excipients of Tykerb,Anorexia， diarrhea， nausea， vomiting， rash， fatigue， dyspepsia， dry skin， stomatitis， constipation， abdominal pain， palmar-plantar erythrodysesthesia， mucosal inflammation， pain in extremity， back pain， insomnia， epistaxis， alopecia; decreased LVEF， nail disorders， headache.,貯存溫度切勿超過 30°C,Monitor left ventricular ejection fraction (baseline and periodic) before and during therapy. TYKERB should be taken at least one hour before or one hour after a meal. [Advanced/metastatic breast cancer] 1250 mg (5 tablets) once daily on Days 1-21 continuously in combination with capecitabine 2，000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. [Hormone receptor (+)， HER2 (+) metastatic breast cancer] 1500 mg (6 tablets) once daily continuously in combination with letrozole 2.5 mg once daily.,需調整劑量,,無需調整劑量,盡量避免,Contraindicated,,Contraindicated 哺乳期使用禁忌,,,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
IEP50,Epirubicin,EPICIN 50mg/25mL,RACA,Leukemia， lymphoma， breast cancer， sarcomas， small-cell lung carcinoma， ovarian cancer， gastric cancer. Liver cancer， head & neck cancer， pancreatic cancer.,Myelosuppression. Cardiac impairment. Previous full cumulative doses of anthracyclines. Pregnancy. Lactation.,Myelosuppression， cardiotoxicity， alopecia， mucositis， GI disturbances， hyperpyrexia.,2-8℃避光,(仿單) Epirubicin should be administered intravenously or intravesicularly. Do not administer epirubicin orally， intramuscularly or subcutaneously. A lifetime maximum cumulative dose >1000 mg/m2 should be avoided. Usual dose: 75-90 mg/m2 intravenously once every 3 weeks. Intravesicular: 50 mg once weekly for 8 weeks; dose range: 30-80 mg.,需調整劑量,,無需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,IRR;IVD;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能、尿酸與血中電解質濃度。 3.Epirubicin的累積劑量與心臟毒性相關，將累積劑量限制在1000mg/m2以下可以降低相關風險.
IIND,Indomethacin,Indocin IV 1mg,CNEU,,適應症: Patent ductus arteriosus in premature infants when after 48 hrs usual medication management. 禁忌: neonates are bleeding or with proven or suspected infection that is untreated，,,室溫,A course of therapy is defined as three IV doses given at 12-24 hr intervals， with careful attention to urinary output. AGE at 1st DOSE: Less than 48 hrs: 0.2 mg/kg (1st)， 0.1mg/kg (2nd)， 0.1 mg/kg (3rd) 2-7 days: 0.2 mg/kg (1st)， 0.2mg/kg (2nd)， 0.2 mg/kg (3rd) over 7 days: 0.2 mg/kg (1st)， 0.25mg/kg (2nd)， 0.25 mg/kg (3rd) If the ductus arteriosus closes or reduced in size after an interval of 48 hr， no further doses are necessary. RE-OPEN: A second course of 1-3 doses may be given， each separated 12-24 hrs interval UNRESPONSIVE: surgery may be necessary if unresponsive after 2 courses.,,,,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OBIO,Biodiastase + Vitamin B complex,Biogen,ALIM,,適應症:治療消化不良或消化障礙(A021755100),,室溫,Adult: 2-3 tab tid Child: reduced doses,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OBAL,NaAl(OH)2CO3,Baluna 350mg,ALIM,,Acute & chronic gastritis， gastric & duodenal ulcer.,,,1-2 tab tid-qid， chewed before swallowing.,,,,,,,,,,,,,,
IH1N13,Inactivated H1N1 Influenza Virus,H1N1新型流感(1-3歲) 0.25mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
EDEC,Salicylic Acid + Lactic Acid,Decorn solution 10mL， 16.7%,TDER,Removal of warts.,Hypersensitivity to salicylic acid or any component of the formulation. Impaired circulation (eg， diabetes， peripheral vascular disease); moles， birthmarks; warts with hair growth or on face.,Local irritation.,25℃以下,Soak lesion in hot water for 5 mins & dry thoroughly. Rub surface with pumice stone or emery board & apply to affected area 2-4 drops once daily.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;SKIN;TOPI;,,,,,大範圍及長期使用會造成水楊酸效應 (耳鳴、暈眩、噁心、嘔吐等) 禁忌：糖尿病患者及有血循障礙之病人不宜使用。亦不能使用於治療黑痣、胎記或生毛之疣。
OZYV,Linezolid,Zyvox 600mg,QANB,Vancomycin-resistant Enterococcus faecium infections， including cases with concurrent bacteremia ， Nosocomial pneumonia caused by Staphylococcus aureus ，Complicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains)， Streptococcus pyogenes， or Streptococcus agalactiae,Patients who have known hypersensitivity to linezolid or any of the other components of Zyvox.,Diarrhea (incidence across studies: 2.8-11%)， headache (incidence across studies: 0.5-11.3%) and nausea (incidence across studies: 3.4-9.6%).,25℃以下避光,Adult and children > 12 years: 600 mg po/IV Q12H; uncomplicated skin/skin structure infections: 400-600 mg po Q12H. Children (0-11 years): 10 mg/kg po/IV Q8H; uncomplicated skin/skin structure infection: (5-11 years) 10 mg/kg po Q12H， (< 5 years) 10 mg/kg po Q8H.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EALP,Brimonidine,Alphagan-P 0.15%， 5mL ophthalmic solution,TOPH,Lowering of ocular pressure in patients with open-angle glaucoma or ocular hypertension.,Patients on MAOI therapy.,Oral dryness， ocular hyperemia， burning & stinging， headache， blurring， foreign body sensation， fatigue/drowsiness， conjunctival follicles， ocular allergic reactions， & ocular pruritus.,25℃以下儲存,Instill 1 drop in the affected eye(s) 3 times daily， about 8 hours apart.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
OMAG,Magnesium Oxide,Magnesium Oxide 250mg,ALIM,Treatment of various GI problems associated with hyperacidity; as a laxative.,Hypersensitivity to any component of the formulation.,Diarrhea， abdominal cramps， nausea， hypermagnesemia， renal stones,25℃以下乾燥處所,Adult & children >12 years: Antacids 1 TAB TID-QID. Laxative 1-2 TAB QD-TID. 6-12 years: one half dose of Adult.3-6 years: one quarter dose of Adult.,無需調整劑量,[仿單]未說明 [Micromedex] AAP: Maternal medication usually compatible with breastfeeding. WHO: Compatible with breastfeeding. Micromedex: Infant risk is minimal.,無需調整劑量,盡量避免,Uknown 沒有資料,[仿單]未說明 [Micromedex]D級,Unknown 沒有資料,[仿單]未說明 [Micromedex] AAP: Maternal medication usually compatible with breastfeeding. WHO: Compatible with breastfeeding. Micromedex: Infant risk is minimal.,AC;AC15;P;P1;P2;P3;P4;PC;PO;WM;,,,,,
OKCIT,Potassium Citrate Monohydrate + Citric Acid,K-citrate granules 5gm,SGU,Prevention of uric acid nephrolithiasis; prevention of Ca renal stones in patients with hypocitraturia; avoidance of the complication of Ca stone formation in uric lithiasis.,Hyperkalemia， peptic ulcer， abnormal renal function， anuria.,Abdominal pain; dyspepsia; gastroenteritis; hyperkinesia; nervousness.,室溫藥品，仿單無特別指示儲存溫度條件,5 gm dissolved in water QD-QID; adjust dose to urinary pH. (Target urinary pH: 6.5-7.4),無需調整劑量,POTASSIUM CITRATE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,除非治療上需要,Uknown 沒有資料,POTASSIUM CITRATE PREGNANCY RECOMMENDATION: Limited Human Data—Probably Compatible,Unknown 沒有資料,POTASSIUM CITRATE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,PC;PO;,,,,,
EESA,Escin + Heparinoid + Diethylamine Salicylate,Esarin gel 20gm,TDER,,適應症:chronic venous insufficiency and relief of pain. 副作用:Rash， pruritus 禁忌:hypersensitivity to these drug,,室溫,Apply gently or massage once daily or more.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
ORIT2,Methylphenidate,Ritalin LA 20mg,CNEU,Attention-deficit hyperactivity disorder; narcolepsy.,Anxiety & tension states， agitation， tics， tics in siblings， family history or diagnosis of Tourette's syndrome; glaucoma; hyperthyroidism; cardiac arrhythmias， severe angina pectoris.,Frequent: nervousness， insomnia， decreased appetite. Occasional: headache， drowsiness， dizziness， dry mouth， tachycardia， palpitations， arrhythmias， changes in BP & heart rate; GI disturbances， skin reactions， fever， arthralgia. Rare: blurred vision， moderately reduced weight gain & minor growth retardation in children. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )， Loss of appetite (5% )， Nausea (12% )， Vomiting (10% ) Neurologic: Headache， Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )， Nasopharyngitis (5% ),30℃以下保持瓶蓋緊閉,Children >= 6 years (immediate-release Tablets) Initially 10mg. Dose adjustment can be based on the observed tolerance and therapeutic effect with gradual increments of 10 mg weekly. maximum: 40 mg/day. Adult: 20 mg QD initially.maximum: 60 mg/day.Ritalin LA sustained action capsules can be adjusted by increasing the dosage by 10 mg weekly. Immediate-release Tablets convert to extended-release Tablets: 5mg methylphenidate BID (immediate-release TABlets) is equivalent to 10mg methylphenidate(extended release Tablets) QD.10mg methylphenidate BID (immediate-release Tablets) is equivalent to 20mg methylphenidate(extended release Tablets) QD. 15mg methylphenidate BID (immediate-release TABlets) is equivalent to 30mg methylphenidate(extended release Tablets) QD. 20mg methylphenidate BID (immediate-release Tablets) is equivalent to 40mg methylphenidate(extended release Tablets) QD.,無需調整劑量,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效膠囊，請整粒吞服，不可撥半或磨粉。
IKCL,Potassium Chloride,10mEq KCl in 0.9%NaCl 500mL,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia， pain or phlebitis at injection site.,25℃以下避光避免冷凍,Adult: Initial loading dose: 40~60 mEq， with ECG monitoring then based on serum potassium levels， Serum K>2.5 mEq/L: concentration < 30 mEq/L， with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia， treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
EAMO,Amorolfine,Amocoat Nail Lacquer 5mL,TDER,Fungal nail infections.,Hypersensitvity.,Skin irritation with erythema and pruritus; slight transient burning sensation (rare); hypersensitivity reactions.,25℃以下儲存,Fungal nail infections Adult: Topical As 5% nail lacquer: Apply 1-2 times/week. Usual treatment duration: 6 months for fingernails and 9-12 months for toenails.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
OWIN5,Chlorpromazine,Winsumin 50mg (個案臨採),CNEU,Management of psychotic disorders (control of mania， treatment of schizophrenia); control of nausea and vomiting; relief of restlessness and apprehension before surgery; acute intermittent porphyria; adjunct in the treatment of tetanus; intractable hiccups; combativeness and/or explosive hyperexcitable behavior in children 1-12 years of age and in short-term treatment of hyperactive children.,Hypersensitivity to chlorpromazine or any component of the formulation (cross-reactivity between phenothiazines may occur). Comatose state. Concomitant use with large doses of CNS depressants (eg， barbiturates， alcohol， narcotics),Common: Orthostatic hypotension， Tachycardia， Ineffective thermoregulation， Heatstroke or Hypothermia， Constipation， Nausea， Xerostomia， Akathisia， Dizziness， Parkinsonism， Somnolence， Tardive dyskinesia Serious: Prolonged QT interval， Erythroderma， Obstipation， Paralytic ileus， Agranulocytosis， Aplastic anemia， Leukopenia， Jaundice， Non-allergic anaphylaxis， Systemic lupus erythematosus， Dystonia， Neuroleptic malignant syndrome， Seizure， Priapism,室溫,Dosing: Adult --Schizophrenia/psychoses: Oral: Range: 30-800 mg/day in 1-4 divided doses， initiate at lower doses and titrate as needed; usual dose: 200~600 mg/day; some patients may require 1-2 g/day --Intractable hiccups: Oral: 25-50 mg 3-4 times/day --Nausea and vomiting: Oral: 10-25 mg every 4-6 hours Dosing: Pediatric (Children >=6 months) --Schizophrenia/psychoses: Oral: 0.5-1 mg/kg/dose every 4-6 hours; older children may require 200 mg/day or higher. --Nausea and vomiting: Oral: 0.5-1 mg/kg/dose every 4-6 hours as needed,無需調整劑量,Lactation Enters breast milk/not recommended (up to date),無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Lactation Enters breast milk/not recommended (up to date),,,,,,
EFLUS,Flumethasone + Salicylic Acid,Flusalic ointment 15gm,TDER,Seborrheic eczema， contact eczema， atopic dermatitis， localized neurodermatitis， psoriasis vulgaris， lichen planus， hyperkeratosis of the palms & soles.,Tuberculous， syphilitic & fresh viral skin affections， vaccination reactions. Perioral dermatitis， acne vulgaris.,Mild transient burning sensation， itching; in isolated cases， mild skin atrophy; changes in skin pigmentation， telangiectasia， purpura， steroid acne particularly after prolonged application.,1 5℃- 30℃,Apply the ointment to the affected areas in a thin film once or twice daily and gently rubbed-in. An occlusive dressing may also be used.,無需調整劑量,Flumethasone - Unknown Salicylic Acid - Unknown,無需調整劑量,沒有資料,Uknown 沒有資料,Flumethasone - Unknown Salicylic Acid - Unknown,Unknown 沒有資料,Flumethasone - Unknown Salicylic Acid - Unknown,EXT;SKIN;TOPI;,,,,,
OSME,Dioctahedral Smectite,Smecta 3gm/pack,ALIM,Treatment of acute & chronic diarrhea.,Hypersensitivity to Dioctahedral Smectite.,Rarely， constipation.,30℃以下,Adult 3 sachet/day. Children > 2 years 2-3 sachet/day， To be administered in 2-3 divided doses. In acute diarrhea， the daily dose can be doubled at the beginning of treatment. Each sachet can be mixed with 50 mL of water or semi-liquid. Administer preferably after meals in oesophagitis， or in between meals in other indications.,無需調整劑量,[仿單]哺乳期間使用的資料有限.哺乳期間不建議使用,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]目前沒有懷孕婦或資料有限. 動物實驗的資料不足以判定是否有生殖毒性. 懷孕期間不建議使用,Unknown 沒有資料,[仿單]哺乳期間使用的資料有限.哺乳期間不建議使用,AC;AC15;PC;PO;WM;,,,,,
EFOX,Fluorometholone,Foxone 0.02% oph susp 5mL,TOPH,,適應症: Acute & chronic iritis， iridocyclitis， scleritis， episcleritis， conjunctivitis， keratitis， resistant ocular allergy & inflammation following surgery 副作用: Glaucoma with optic nerve damage， visual acuity or field defects， raised intraocular pressure， secondary infection (persistent corneal ulceration， possibly fungal invasion)， perforation of globe， posterior subcapsular cataract formation 禁忌: Acute superficial herpes simplex keratitis， fungal diseases of ocular structure; vaccinia， varicella & other viral diseases of the cornea & conjunctiva， eye TB,,室溫,Instill 1-2 drops bid-qid,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ISCA2,Epinephrine + Mepivacaine,Scandonest 2%(for Dental) 1.8mL,ZANE,Amide-type anesthetic used for local infiltration anesthesia; injection near nerve trunks to produce nerve block,Hypersensitivity to local anesthetics of the amide type or any component of the formulation,Degree of adverse effects in the CNS and cardiovascular system is directly related to the blood levels of local anesthetic. Cardiovascular: Myocardial effects include a decrease in contraction force as well as a decrease in electrical excitability and myocardial conduction rate resulting in bradycardia and reduction in cardiac output Central nervous system: High blood levels result in anxiety， restlessness， disorientation， confusion， dizziness， and seizure. This is followed by depression of CNS resulting in somnolence， unconsciousness and possible respiratory arrest. In some cases， symptoms of CNS stimulation may be absent and the primary CNS effects are somnolence and unconsciousness. Gastrointestinal: Nausea and vomiting may occur,室溫,Dental anesthesia， single site in upper or lower jaw: Infiltration: 54 mg (1.8 mL) as a 3% solution Infiltration and nerve block of entire oral cavity: 270 mg (9 mL) as a 3% solution; up to a maximum of 6.6 mg/kg of body weight but not to exceed 300 mg per appointment. Manufacturer's maximum recommended dose is not more than 400 mg to normal healthy adults. The effective anesthetic dose varies with procedure， intensity of anesthesia needed， duration of anesthesia required， and physical condition of the patient. Always use the lowest effective dose along with careful aspiration.,無需調整劑量,(Up to date) Pregnancy Risk Factor:C Lactation:Excretion in breast milk unknown/use caution,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,(Up to date) Pregnancy Risk Factor:C Lactation:Excretion in breast milk unknown/use caution,,,,,,Pharmacodynamics/Kinetics Onset of action: Upper jaw: 30-120 seconds; Lower jaw: 1-4 minutes Duration: Upper jaw: 20 minutes; Lower jaw: 40 minutes Half-life elimination， serum: 1.9 hours
ILEU1,Leuprorelin Acetate,LEUPLIN 3M inj 11.25mg (三個月),RACA,,適應症: Prostate Cancer， Endometriosis， Menorrhagia and anemia cause by uterine fibroids who intends to carry out surgical resection， Premenopausal breast cancer as postoperative supplementary treatment. 副作用: Increased LDH， Hot flashes， feeling of warmth， anorexia， nausea， Headache， facial hot flushes， dizziness， diaphoresis， decreased libido， erectile dysfunction， gyecomastia， testicular atrophy or discomfort in the perineal region， Pains， such as arthralgia， and bone pain. 禁忌: CONTRAINDICATIONS Leuplin Depot 3M is contraindicated in the following patients. 1) Patients with a history of hypersensitivity to any of the ingredients of this drug or synthetic LH-RH or LH-RH derivatives For Endometriosis and Uterine Leiomyomata (Fibroids) 2) Pregnant women or women having possibilities of being pregnant， or nursing mothers. 3) Patients with abnormal genital bleeding of indeterminable nature [There is a possibility of malignant disease.] For Premenopausal breast cancer as postoperative supplementary treatment 4) Pregnant women or women having possibilities of being pregnant， or nursing mothers.,,,Usually， for adults， 11.25 mg subcutaneously once every 12 weeks.  [Prostate Cancer] Monitor serum testosterone concentration periodically， at least once per 3 months， within 6 months treatment is required. [Endometriosis] therapy duration: 6 months. [Uterine Leiomyomata (Fibroids)] one Leuplin Depot 3M injection. The symptoms associated with uterine leiomyomata will recur following discontinuation of therapy. If additional treatment with Leuplin Depot 3M is contemplated， bone density should be assessed prior to initiation of therapy to ensure that values are within normal limits. [Central Precocious Puberty] Children with a body weight ? 20 kg: 1 ml (11.25 mg leuprorelin acetate) every 3 months as a single subcutaneous injection; children with a body weight < 20 kg: 0.5 ml (5.625 mg leuprorelin acetate) once every 3 months as a single subcutaneous injection. The bone age should be monitored during treatment at 6-12 month intervals.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,SC;,以廠商所添附的懸濁用溶解液稀釋,,,,
OCIA5,Tadalafil,Cialis 5mg (28 tablets/box),SGU,1.Treatment of erectile dysfunction. 2.Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH),1.Concomitant use of nitrates (any form) either regularly or intermittently. 2.Hypersensitivity to tadalafil; Stevens-Johnson syndrome and exfoliative dermatitis have been reported,headache， dyspepsia， back pain， myalgia， nasopharyngitis， cough， or flushing Common ■Dermatologic: Flushing (1% to 13% ) ■Gastrointestinal: Indigestion (1% to 13% )， Nausea (up to 11% ) ■Musculoskeletal: Backache (2.4% to 12% )， Myalgia (1% to 14% ) ■Neurologic: Headache (3% to 42% ) ■Respiratory: Nasopharyngitis (2% to 13% )， Respiratory tract infection (3% to 13% ) Serious ■Cardiovascular: Angina (less than 2% )， Chest pain (less than 2% )， Heart failure， Myocardial infarction (less than 2% )， Tachycardia (less than 2% ) ■Dermatologic: Stevens-Johnson syndrome ■Neurologic: Cerebral hemorrhage， Cerebrovascular accident， Seizure ■Ophthalmic: Non-arteritic ischemic optic neuropathy， Retinal artery occlusion， Thrombosis of retinal vein ■Otic: Decreased hearing， Sudden onset (less than 2% )， Sudden hearing loss (less than 2% ),30℃以下,Erectile Dysfunction: The recommended starting dose of CIALIS for once daily use is 2.5 mg， taken at approximately the same time every day， without regard to timing of sexual activity. The CIALIS dose for once daily use may be increased to 5 mg， based on individual efficacy and tolerability. Benign Prostatic Hyperplasia: The recommended dose of CIALIS for once daily use is 5 mg， taken at approximately the same time every day. The recommended dose of CIALIS for once daily use is 5 mg， taken at approximately the same time every day for up to 26 weeks.,需調整劑量,Micromedex: Infant risk cannot be ruled out. (1)Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. (2)Clinical Management:Tadalafil is not indicated for use in women and there are no reports describing the use of tadalafil during human lactation availableThe effects on the nursing infant from exposure to the drug in milk are unknown. Tadalafil is secreted into the milk of lactating rats at approximately 2.4 times the concentration found in plasma. No information is available on the secretion of tadalafil into human breast milk.,需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,Micromedex: Infant risk cannot be ruled out. (1)Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. (2)Clinical Management:Tadalafil is not indicated for use in women and there are no reports describing the use of tadalafil during human lactation availableThe effects on the nursing infant from exposure to the drug in milk are unknown. Tadalafil is secreted into the milk of lactating rats at approximately 2.4 times the concentration found in plasma. No information is available on the secretion of tadalafil into human breast milk.,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議本藥需整顆服用。
OTHR,Sennosides,Through (Sennosides) 12mg,ALIM,Treatment of constipation & for bowel evacuation before investigational procedures or surgery.,Patients with intestinal obstruction or with undiagnosed abdominal symptoms.,Mild abdominal discomfort， eg colic or cramps. Prolonged use or overdosage can result in diarrhoea with excessive loss of water & electrolytes， particularly K; possibility of developing an atonic non-functioning colon. May colour urine yellow-brown at acid pH， & red at alkaline pH. Reversible melanosis coli has been reported following chronic use.,25℃以下，避免陽光直射,Adult & children >12 years: PO 1-2 TAB HS. 6-12 years: one half dose of Adult. 3-6 years: one quarter dose of Adult.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,AC;PO;,,,,,
IHEPA,Heparin,HEPAC inj 25KIU/5mL,HEMT,Unstable angina; Venous thromboembolism; Peripheral arterial embolism， Prevention of re-occlusion of the coronary arteries following thrombolytic therapy ， Venous thromboembolism ，Prophylaxis of post-op venous thromboembolism， Prevention of mural thrombosis,Patients predisposed to active bleeding including thrombocytopenia， peptic ulcer disease， cerebrovascular disorders， haemorrhagic blood disorders， bacterial endocarditis， severe hypertension， oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage， abdominal or thoracic bleeding into closed space， severe traumatic bleed， hepatic， renal， splenic or arterial injury， severe haemostatic defect， arterial thrombosis with heparin-associated thrombocytopenia. IM admin.,Slight fever， headache， chills， nausea， vomiting， constipation， epistaxis， bruising， slight haematuria， skin necrosis (SC inj)， osteoporosis， alopecia. Hypersensitivity reactions include urticaria， conjunctivitis， rhinitis， asthma， angioedema and anaphylactic shock. Priapism. Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding Dermatologic: Erythema， Injection site ulcer， After deep subcutaneous injection Hematologic: Hematoma， Heparin-induced thrombocytopenia (up to 30% ) Neurologic: Pain (Mild) Other: Irritation symptom， Local,25℃以下,IV: 10000 IU as first dose， followed by 5000-10000 IU every 4-6 hours. IV infusion: 20000-40000 IU/day， adding in 1000mL solvent. Deep SC: 10000 IU every 8 hours or 15000-20000 IU every 12 hours.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IA;IRR;IV;IVD;,,【N/S】可選 仿單建議。【H/S】可選 。,,輸注速率 10~20 u/mL/min,1.未稀釋亦可使用 2.廠商建議使用稀釋亦為N/S
ISIM,Golimumab,Simponi inj 50mg/0.5mL,HIMM,In combination w/ methotrexate for the treatment of moderate to severe active RA. Alone or in combination w/ methotrexate for active psoriatic arthritis (PsA). Treatment of active ankylosing spondylitis (AS).,Canadian labeling: Hypersensitivity to golimumab， latex， or any other component of formulation or packaging; patients with severe infections (eg， sepsis， tuberculosis， opportunistic infections); moderate or severe heart failure (NYHA class III/IV),Serious infections， malignancies， autoimmune disorders & autoantibodies， inj site reactions， new onset & exacerbations of psoriasis， immunogenicity， upper resp tract infection， nasopharyngitis， sepsis， increased ALT & AST; HTN， bronchitis， dizziness， sinusitis， flu， pharyngitis， rhinitis， pyrexia， oral herpes， paraesthesia.,2-8℃避光避免冷凍,SC， rheumatoid arthritis， psoriatic arthritis and ankylosing spondylitis 50 mg once a month. Moderate to severe active ulcerative colitis( body weight<80 kg) 200 mg at week 0， then 100 mg at week 2， followed by 50-100 mg every 4 weeks.( body weight > or = 80kg) 200 mg at week 0， then 100 mg at week 2， followed by 100 mg every 4 weeks.,無需調整劑量,BREASTFEEDING RECOMMENDATION: Contraindicated if combined with methotrexate.,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,PREGNANCY RECOMMENDATION: Contraindicated if combined with methotrexate.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,BREASTFEEDING RECOMMENDATION: Contraindicated if combined with methotrexate.,SC;,,,,,安全注射須知與步驟: 必須由醫療專業人員施打。 1. 使用前，從冰箱取出預充針筒或預充SmartJect自動注射器，自包裝盒中取出，在室溫下放置至少30分鐘。勿以任何其它方式加熱。在等候回溫時不可移除針頭套或注射器護套。即將注射前才移除。 2. 總共會聽到兩次「喀嗒」聲，之後針頭會自動縮回。在針頭拉回之前，切勿將自動注射器自皮膚表面拉開。在第一個「喀嗒」聲之後，通常只要經過3至6秒就會聽到第二個「喀嗒」聲，但也可能會需要長達15秒。 3. 注射完成後，依照廢棄醫療尖銳物處理原則丟棄針具。
OEDA,Azilsartan medoxomil,Edarbi 40mg,CAVS,Treatment of hypertension; may be used alone or in combination with other antihypertensives.,Hypersensitivity to azilsartan medoxomil or any component of the formulation; concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment (GFR <60 mL/minute/1.73 m2).,Hypotension， orthostatic hypotension， Dizziness， fatigue， Diarrhea， nausea， Decreased hemoglobin， decreased hematocrit， decreased red blood cells， leukopenia (rare)， thrombocytopenia (rare)， Muscle spasm， weakness， Increased serum creatinine， Cough,30℃以下，避免光照及潮濕,HTN Initial: 20-40 mg QD; titrate up to maximum 80 mg QD,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,Human Data Suggest Potential Toxicity,,AC;AC15;PC;PO;WM;,,,,,
OKES,Amino Acids + Ketoanalogues,Ketosteril,NUTR,Chronic renal insufficiency amino acid supplement,hypersentivity，hypercalcinemia,hypercalcinemia,室溫藥品，仿單無特別指示儲存溫度條件,Take 4-8 tablets three times a day during meals. Swallow whole. This dosage applies to adults (70kg/BW). Health insurance regulations: eGFR <or = 15mL/min /1.73 m2 and have not received dialysis treatment， use up to six pills a day.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PC;PO;WM;,,,,,[磨粉/管灌註記]由於本品帶有臭味，若使用磨粉分包機會汙染難以清潔。廠商亦無相關資料。因此建議不要將藥錠磨粉使用。
IXGE,Denosumab,Xgeva inj 120mg,META,Bone metastases from solid tumors: Prevention of skeletal-related events (eg， fracture， spinal cord compression， bone pain requiring surgery/radiation therapy) in patients with bone metastases from solid tumors. Giant cell tumor of bone: Treatment of giant cell tumor of bone (in adults and skeletally mature adolescents) that is unresectable or where surgical resection is likely to result in severe morbidity. Hypercalcemia of malignancy: Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.,Hypersensitivity. Severe， symptomatic hypocalcaemia.,>10%: Cardiovascular: Hypertension (11%) Central nervous system: Fatigue (Xgeva: <45%)， headache (Xgeva: 13% to 24%)， peripheral edema (5%; Xgeva: 24%) Dermatologic: Dermatitis (4% to 11%)， eczema (4% to 11%)， skin rash (3% to 11%) Endocrine & metabolic: Hypophosphatemia (Xgeva: 32%)， hypocalcemia (2%; Xgeva: 3% to 18%) Gastrointestinal: Nausea (Xgeva: 31%)， decreased appetite (Xgeva: 24%)， vomiting (Xgeva: 24%)， constipation (Xgeva: 21%)， diarrhea (Xgeva: 20%) Hematologic & oncologic: Anemia (Xgeva: 21%) Infection: Influenza (11%) Neuromuscular & skeletal: Weakness (Xgeva: ?45%)， arthralgia (7% to 14%)， limb pain (10% to 12%)， back pain (8% to 12%) Respiratory: Dyspnea (Xgeva: 21% to 27%)， cough (Xgeva: 15%),2-8℃避光避免冷凍,SC， bone metastasis associated with solid tumors 120 mg every 4 weeks. Giant cell tumor of bone， hypercalcemia of malignancy 120 mg every 4 weeks， with additional 120 mg doses on days 8 and 15 of first month of therapy.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,皮下注射部位：上臂、上臀或腹部。
OXAR,Rivaroxaban,XARELTO 15mg,HEMT,Xarelto 10 mg Prevention of Venous Thrombosis(VTE) in adult patients undergoing elective hip or knee replacement surgery. Xarelto 15 mg & 20 mg Prevention of stroke & systemic embolism in adult patients w/ non-valvular atrial fibrillation w/ ≧1 risk factors eg CHF， HTN， age ≧75 yr， DM， prior stroke or transient ischaemic attack. Treatment of Deep Venous Thrombosis (DVT) & PE， & prevention of recurrent DVT & PE following an acute DVT in adults.,Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk including cirrhotic Child-Pugh B & C patients. Pregnancy & lactation.,Anemia， dizziness， headache， syncope， eye haemorrhage， tachycardia， hypotension， haematoma， epistaxis， GI disorders， pruritus， pain in extremity， urogenital tract haemorrhage， fever， peripheral oedema， decreased general strength & energy， increased transaminases， postprocedural haemorrhage.,儲存溫度不可超過30℃,Prevention of stroke and systemic embolism for patients with non-valvular atrial fibrillation: 15-20mg QD.(Clcr > 50 mL/min). Deep vein thrombosis(DVT)， pulmonary embolism(PE) treatment and prophylaxis: 15mg BID on day 1-21， followed by 20mg QD from day 22. Prophylaxis of VTE high risk patient: 10mg QD.,需調整劑量,[仿單]無授乳婦使用的安全性與有效性資料，動物實驗中顯現本藥可以分泌致乳汁中， 因此僅能在停止哺乳後使用.,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,[仿單]無孕婦使用的安全性與有效性資料，動物實驗中顯現生殖性毒性，且本藥可以通過胎盤， 懷孕婦女禁止使用. 具生育能力婦女應採取有效的避孕措施.,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]無授乳婦使用的安全性與有效性資料，動物實驗中顯現本藥可以分泌致乳汁中， 因此僅能在停止哺乳後使用.,PC;PO;WM;,,,,,
INEOP,Ibuprofen,Neoprofen 20mg/2mL,CNEU,,適應症: Treatment of Patent Ductus Arteriosus (PDA) in premature neonates. 副作用: Injection: Ibuprofen lysine (NeoProfen?): >10%: Cardiovascular: Intraventricular hemorrhage (29%; grade 3/4: 15%) Dermatologic: Skin irritation (16%) Endocrine & metabolic: Hypocalcemia (12%)， hypoglycemia (12%) Gastrointestinal: GI disorders， non NEC (22%) Hematologic: Anemia (32%) Respiratory: Apnea (28%)， respiratory infection (19%) Miscellaneous: Sepsis (43%) 1% to 10%: Cardiovascular: Edema (4%) Endocrine & metabolic: Adrenal insufficiency (7%)， hypernatremia (7%) Genitourinary: Urinary tract infection (9%) Renal: Urea increased (7%)， renal impairment (6%)， creatinine increased (3%)， urine output decreased (3%; small decrease reported on days 2-6 with compensatory increase in output on day 9)， renal failure (1%) Respiratory: Respiratory failure (10%)， atelectasis (4%) 禁忌: Hypersensitivity to ibuprofen; history of asthma， urticaria， or allergic-type reaction to aspirin or other NSAIDs; aspirin triad (eg， bronchial asthma， aspirin intolerance， rhinitis); perioperative pain in the setting of coronary artery bypass graft (CABG) surgery,,室溫,PDA: Each course of therapy consists of 3 doses administered at 24-hour intervals. First dose is 10 mg/kg; second and third doses are 5 mg/kg each， If anuria or oliguria (urine output <0.6 mL/kg per hour) withhold the dose until renal function has returned to normal. If ductus arteriosus fails to close or reopens， a second course of ibuprofen， may be needed,,,,盡量避免,,,Compatible 哺乳時可使用,,,,,,,NeoProfen (ibuprofen lysine): For I.V. administration only; administration via umbilical arterial line has not been evaluated. Infuse over 15 minutes through port closest to insertion site. Avoid extravasation. Do not administer simultaneously via same line with TPN. If needed， interrupt TPN for 15 minutes prior to and after ibuprofen administration， keeping line open with dextrose or saline.
OZCO,Benzonatate,Zcough 100mg,ERSP,Symptomatic relief of nonproductive cough,Hypersensitivity to benzonatate， related compounds (such as tetracaine)， or any component of the formulation， age < 14yr.,Sedation， headache， dizziness， itch， skin eruption， nasal congestion， constipation， GI upset， chills， chest tightness， allergy.,25℃下儲存,Adult 1-2 cap TID Maximum dose is 600 mg/day,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;,,,,,[磨粉/管灌註記]本藥為軟膠囊，仿單建議應整粒吞服，切勿咬嚼或壓碎。
OARH1,Leflunomide,Arheuma 10mg,HIMM,Treatment of RA & psoriatic arthritis in adult.,Stevens-Johnson syndrome， toxic epidermal necrolysis， multiforme epithelium. Hepatic dysfunction， severe immunodeficiency such as AIDS， bone-marrow dysplasia， severe infections， moderate to severe renal dysfunction， severe hypoproteinaemia. Pregnancy， lactation.,Increase in BP; GI disturbances， anorexia， oral mucosal disorders， weight loss; headache， dizziness， asthenia， paraesthesia; tenosynovitis; alopecia， eczema， dry skin， rash， pruritus; hypersensitivity reactions， leucopenia.,25℃以下避免光線直接照射,Adult loading dose 100 mg once daily for 3 days. Maintenance dose rheumatoid arthritis 10-20 mg once daily， psoriatic arthritis 20 mg once daily.,需調整劑量,,需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為免疫抑制劑，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
IDIPH,Diphenhydramine,Diphenhydramine inj 30mg/1mL,HIMM,Urticaria， dermatologic disease， pruritus， acute rhinitis & hay fever.,Acute asthmatic attack. Premature infants.,Drowsiness， dizziness， antimuscarinic effects. CV & CNS effects. Muscular weakness. Allergic reaction. Blood disorders.,15-30℃避光,Adult: 30mg QD， Child: half dose of adult. Do not recommended for use to premature infants and neonate. Patient with renal function impairment should prolong interval. Depend on eGFR.IV 10~50mg each time， injection rate does not exceed 25mg/min.,無需調整劑量,Diphenhydramine is excreted into breast milk; drowsiness has been reported in a breast-feeding infant. Premature infants and newborns have a higher risk of intolerance to antihistamines. Breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.,需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Diphenhydramine is excreted into breast milk; drowsiness has been reported in a breast-feeding infant. Premature infants and newborns have a higher risk of intolerance to antihistamines. Breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.,IM;IVD;IVP;IVPUSH;SC;,,【D10W】可選 。【D5NS】可選 。【D5W】可選 。【H/S】可選 。【L/R】可選 。【N/S】可選 。,,成人: 10-50mg(max. 400 mg/day);小孩: 5 mg/kg/day(max. 300mg/day),102.02.25 衛生署公告 1. 「嬰幼兒(premature infants及neonate)不建議使用」 2. 「老人宜以最低有效起始劑量開始治療」 3.「腎功能不全者應延長給藥間隔；輕度(GFR>50 mL/min)：間隔6小時；中度(GFR 10-50 mL/min)：間隔6-12小時；重度(GFR<10 mL/min)：間隔12-18小時」。
OZON1,Zonisamide,Zonegran 100mg,CNEU,Adjunctive treatment of partial seizures.,Hypersensitivity to zonisamide， sulfonamides， or any component of the formulation.,Frequencies noted in patients receiving other anticonvulsants: >10%: Central nervous system: Somnolence (17%)， dizziness (13%) Gastrointestinal: Anorexia (13%) 1% to 10%: Central nervous system: Headache (10%)， agitation/irritability (9%)， fatigue (8%)， tiredness (7%)， ataxia (6%)， confusion (6%)， concentration decreased (6%)， memory impairment (6%)， depression (6%)， insomnia (6%)， speech disorders (5%)， mental slowing (4%)， anxiety (3%)， nervousness (2%)， schizophrenic/schizophreniform behavior (2%)， difficulty in verbal expression (2%)， status epilepticus (1%)， seizure (1%)， hyperesthesia (1%)， incoordination (1%) Dermatologic: Rash (3%)， bruising (2%)， pruritus (1%) Gastrointestinal: Nausea (9%)， abdominal pain (6%)， diarrhea (5%)， dyspepsia (3%)， weight loss (3%)， constipation (2%)， taste perversion (2%)， xerostomia (2%)， vomiting (1%) Neuromuscular & skeletal: Paresthesia (4%)， abnormal gait (1%)， tremor (1%)， weakness (1%) Ocular: Diplopia (6%)， nystagmus (4%)， amblyopia (1%) Otic: Tinnitus (1%) Renal: Kidney stones (4%， children 3% to 8%) Respiratory: Rhinitis (2%)， pharyngitis (1%)， increased cough (1%) Miscellaneous: Flu-like syndrome (4%) accidental injury (1%) <1% (Limited to important or life threatening): Agranulocytosis， allergic reaction， alopecia， amenorrhea， aplastic anemia， apnea， arthritis， atrial fibrillation， bladder calculus， bradycardia， cerebrovascular accident， cholangitis， cholecystitis， cholestatic jaundice， colitis， deafness， duodenitis， encephalopathy， fecal incontinence， gingivitis， GI ulcer， glaucoma， heart failure， hematuria， hemoptysis， hirsutism， hyper-/hypotension， hyperthermia， hypoglycemia， hyponatremia， immunodeficiency， impotence， iritis， leukopenia， lupus erythematosus， lymphadenopathy， mastitis， menorrhagia， metabolic acidosis， neuropathy， oculogyric crisis， oligohidrosis (children)， pancreatitis， photophobia， pulmonary embolus， rectal hemorrhage， Stevens-Johnson syndrome， stroke， suicidal behavior/ideation， syncope， thrombocytopenia， thrombophlebitis， toxic epidermal necrolysis， urinary incontinence， ventricular extrasystoles,30℃以下,Partial seizure， Monotherapy: Adult， initially 100 mg daily， daily dose may be increased in 100mg increments every 2 weeks up to 300 mg or more. Maximum: 500 mg/day. Partial seizure， Adjunct: Adult， initially 100 mg daily， daily dose may be increased every 1-2 weeks up to 200-400 mg daily (in 1-3 divided doses). Maximum: 500 mg/day.,無需調整劑量,Zonisamide 停藥一個月後，方可繼續開始授乳。 (藥品仿單),無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest high risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Zonisamide 停藥一個月後，方可繼續開始授乳。 (藥品仿單),,,,,,
EBET,Betamethasone + Neomycin,Betason-N 眼藥膏3gm,TOPH,Inflammatory dermatoses responsive to topical corticosteroid therapy， where secondary bacterial infection is present or suspected or likely to occur. Management of insect bites， prickly heat， anal & genital intertrigo & otitis externa.,Rosacea; acne vulgaris; perioral dermatitis; perianal & genital pruritus. Primary cutaneous viral infection; treatment of primarily infected skin lesions caused by infection w/ fungi or bacteria; primary or secondary infections due to yeast; dermatoses in childn <1 yr. Otitis externa when tympanum is perforated. Secondary infections due to Pseudomonas or Proteus spp.,Local atrophic skin changes; hypercorticism; hypersensitivity.,25℃以下儲存,Apply 1-3 times a day on affected part.,無需調整劑量,,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AD;AL;AS;AU;EXT;NA;OD;OL;OU;SKIN;TOPI;,,,,,
OSOO,Amoxicillin + Clavulanic Acid,Soonmelt 625mg,QANB,,適應症:Treatment of infections due to Staph， Strep， pneumococcus， meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract， GUT， skin & soft tissue， bone & joint. Dental infections， septic abortion， puerperal sepsis， intra-abdominal sepsis. 副作用:Diarrhea， nausea， vomiting， mucocutaneous candidiasis. Dermatologic: Diaper rash (3.5% )， Rash (1.1% to 3% ) Gastrointestinal: Diarrhea (2.9% to 14.5% )， Loose stool (1.6% )， Nausea (2.1% to 3% )， Vomiting (1% to 2.2% ) Reproductive: Mycosis (3.3% )， Vaginitis (1% ) Other: Candidiasis (1.4% ) 禁忌:History of hypersensitivity to β-lactams. History of penicillin-associated jaundice/hepatic dysfunction.,,室溫,Adult & child over 40 kg: 250-500 mg q8h. Child under 40 kg: 20-40 mg/kg/day in 3 divided doses.,,WHO: Compatible with breastfeeding Micromedex: Infant,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,WHO: Compatible with breastfeeding Micromedex: Infant,,,,,,
ICAC,Calcitriol,Cacare inj 2mcg/1mL,META,Management of hypocalcemia in patients undergoing chronic renal dialysis.,Hypercalcemia or evidence of vit D toxicity.,Weakness， headache， somnolence; nausea， vomiting， dry mouth， constipation; muscle pain， bone pain & metallic taste.,25℃以下避光,Initially 0.5 mcg (0.01 mcg/kg) administered 3 times a week， approximately every other day. Dose may be increased by 0.25 ~ 0.5 mcg at 2 ~ 4 week intervals.,無需調整劑量,,無需調整劑量,除非治療上需要,,,Compatible 哺乳時可使用,,IVP;IVPUSH;,,【D5W】可選 。【N/S】可選 。,May be administered as a bolus dose IV through the catheter at the end of hemodialysis.,,May be administered as a bolus dose IV through the catheter at the end of hemodialysis.
EPROV,Methacholine,Provocholine Inhalation 100mg,ZOTH,Diagnosis of bronchial airway hyperactivity,Hypersensitivity to methacholine， other parasympathomimetic agents， or any component of the formulation; concomitant use of beta-blockers; repeat administration (other than day of challenge test with increasing doses),Central nervous system: Headache， lightheadedness Dermatologic: Itching Gastrointestinal: Throat irritation,未開封15-30℃,Age >5 years old and Adult: Use 0.03， 0.0625， 0.125， 0.25， 0.5， 1， 2， 4， 8， 16 mg/mL solution for inhalation only. Stop dosing if the FEV1 has fallen by 20% from the mean baseline， the FEV1 is 1.5 L， or the highest dose has been administered (whichever comes first).,無需調整劑量,,無需調整劑量,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,IH;,0.9%氯化鈉注射液(生理食鹽水)或含有0.4%酚的0.9%氯化鈉注射劑(含有0.4%酚之生理食鹽水)或含有0.9%苯甲醇的0.9%氯化鈉注射劑(含有0.9%苯甲醇的生理食鹽水),,,,以無菌技術配製的ProvocholineR溶液保存在冰箱內(2-8℃)可保存2星期。冷凍保存不會破壞稀釋液的穩定性。 因為溶液的溫度會影響噴霧器的噴出量，因此使用前(約30分鐘以前)應先將溶液從冰箱取出，使溶液溫度回復至與室溫相同。
OLINI,Niacin + Lovastatin,Linicor F.C.T. 500/20mg,CAVS,Primary hypercholesterolemia/mixed dyslipidemia: Treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb) in combination with a standard cholesterol-lowering diet.,Hypersensitivity to lovastatin， niacin， or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; active peptic ulcer disease; arterial bleeding; pregnancy; breast-feeding; concomitant use of strong CYP3A4 inhibitors (eg， clarithromycin， erythromycin， itraconazole， ketoconazole， nefazodone， posaconazole， voriconazole， protease inhibitors including boceprevir and telaprevir， telithromycin， and cobicistat-containing products),>10%: Cardiovascular: Flushing (53% to 83%) Infection: Infection (20%) 1% to 10%: Central nervous system: Headache (9%)， pain (8%) Dermatologic: Pruritus (7%)， skin rash (5%) Endocrine & metabolic: Hyperglycemia (4%)， hypophosphatemia Gastrointestinal: Nausea (7%)， diarrhea (6%)， abdominal pain (4%)， dyspepsia (3%)， vomiting (3%) Hematologic & oncologic: Increased prothrombin time (2%) Respiratory: Flu-like symptoms (6%),25℃以下,Hyperlipidemia adult， initial 1tab HS (niacin/lovastatin 500mg/20mg) slowly titrate up. maximum 2 tab /day (niacin/lovastatin 1000 mg/40mg),無需調整劑量,Niacin - Compatible Lovastatin - Contraindicated [仿單] 目前未曾有緩釋劑型niacin/lovastatin複方錠劑對於哺乳中婦女的研究。 因為niacin和lovastatin的劑量能造成血脂改變，對於哺乳中的胎兒有潛在的嚴重不良反應， 因此當母親正在哺乳時不應該服用緩釋劑型niacin/lovastatin複方錠劑。,無需調整劑量,沒有資料,Contraindicated – 1st trimester,Niacin - Compatible Lovastatin - Contraindicated 1st Trimester [仿單] 緩釋劑型niacin/lovastatin複方錠劑只能使用在極度不可能懷胎情況且已被告知其使用風險之婦女身上。 緩釋劑型niacin/lovastatin複方錠劑對於孕婦的安全性尚未建立且在懷孕期間接受治療並未出現顯著好處。 一旦懷孕確定時應立即中止此藥物治療。,Contraindicated 哺乳期使用禁忌,Niacin - Compatible Lovastatin - Contraindicated [仿單] 目前未曾有緩釋劑型niacin/lovastatin複方錠劑對於哺乳中婦女的研究。 因為niacin和lovastatin的劑量能造成血脂改變，對於哺乳中的胎兒有潛在的嚴重不良反應， 因此當母親正在哺乳時不應該服用緩釋劑型niacin/lovastatin複方錠劑。,PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為Lovastatin加緩釋劑型Niacin，需整顆吞服勿咀嚼、剝半或磨粉。無法吞服病患可改用院內同成份一般劑型藥物。
OVES,Ranitidine,VesYCA 150mg,ALIM,,適應症: Duodenal ulcer， benign gastrac ulcer， peptic ulcer， reflux esophagitis， Zollinger-Ellison Syndrome. 副作用: ■Gastrointestinal: Abdominal pain， Constipation， Diarrhea ■Neurologic: Headache 禁忌: ■hypersensitivity to ranitidine or any of its ingredients,,室溫,Adult Dosing ■Duodenal ulcer disease: 150 mg ORALLY twice daily OR 300 mg once daily after the evening meal or at bedtime， Maintenance: 150 mg ORALLY once daily at bedtime ■Erosive esophagitis: initial， 150 mg ORALLY 4 times daily， maintenance， 150 mg ORALLY twice daily ■Gastric hypersecretion: (oral) 150 mg ORALLY twice daily ■Gastric ulcer: 150 mg ORALLY twice daily， Maintenance: 150 mg ORALLY once daily at bedtime ■Gastroesophageal reflux disease: 150 mg ORALLY twice daily ■Indigestion， Non-ulcer: (treatment) 75 to 150 mg ORALLY once or twice daily， MAX 300 mg/day ■Stress ulcer; Prophylaxis: 150 mg NG or ORALLY twice daily ■Zollinger-Ellison syndrome: (oral) 150 mg ORALLY twice daily Pediatric Dosing ■Duodenal ulcer disease: (1 month to 16 yr) 2 to 4 mg/kg ORALLY twice daily， MAX 300 mg/day ■Erosive esophagitis: (1 month to 16 years) initial， 5 to 10 mg/kg/day ORALLY in 2 divided doses ■Gastric ulcer: (1 month to 16 years) 2 to 4 mg/kg ORALLY twice daily， MAX 300 mg/day ■Gastroesophageal reflux disease: (1 month to 16 yr) 5 to 10 mg/kg/day ORALLY in 2 divided doses ■Indigestion， Non-ulcer: (treatment) 12 yr of age and older， 75 to 150 mg ORALLY once or twice daily， MAX 300 mg/day,無需調整劑量,,需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ODEXI,Dexlansoprazole,Dexilant delay-release 60mg,ALIM,Treatment of erosive esophagitis (EE) in patients aged 12 and above for up to 8 weeks. Maintenance of healed erosive esophagitis in patients aged 12 and above who have already healed from EE; in adults for up to 6 months， and in patients aged 12-17 for up to 16 weeks. Symptomatic treatment of non-erosive gastroesophageal reflux disease (GERD) in patients aged 12 and above for a duration of 4 weeks.,Known hypersensitivity (eg， anaphylaxis， anaphylactic shock， angioedema， bronchospasm， acute tubulointerstitial nephritis， urticaria) to dexlansoprazole or any component of the formulation; concomitant use with products that contain rilpivirine.,Common: Abdominal pain (3.5-5%)， Diarrhea (4.7-5.1%)， Flatulence (1.4-2.6%)， Nausea (2.8-3.3%)， Vomiting (1.4-2.2%)， Nasopharyngitis (Pediatrics， >5%)， Pain， Oropharyngeal (Pediatrics， >5%)， Upper respiratory infection (1.7-2.9%) Serious: Cutaneous lupus erythematosus， acute generalized exanthematous pustulosis， Stevens-Johnson syndrome (SJS)， Toxic epidermal necrolysis (TEN)， Cobalamin deficiency (Rare)， Hypomagnesemia， Clostridium difficile diarrhea， Fundic gland polyposis of stomach， Anaphylaxis， Drug reaction with eosinophilia and systemic symptoms (DRESS)， Hypersensitivity reaction (<2%)， Systemic lupus erythematosus， Fracture of bone (<2%)， acute tubulointerstitial nephritis,30℃以下,Erosive esophagitis， Healing of all grades Age > 12 years-old， 60 mg orally once daily for up to 8 weeks. Erosive esophagitis， Maintenance of healing - Heartburn 30 mg orally once daily for up to 6 months. Gastroesophageal reflux disease， nonerosive 30 mg orally once daily for 4 weeks.,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為緩釋膠囊，需整顆吞服，勿咬碎、壓碎、剝半或磨粉。廠商提供之建議:對於不會吞膠囊之患者，可打開緩釋膠囊，並將藥粒灑在一湯匙蘋果醬(果泥)上，立刻吞服，不可咀嚼藥粉顆粒。對於管灌的病人，可打開緩釋膠囊，並將藥粉顆粒加入20 mL冷開水中，輕搖並反抽至針筒，打入鼻胃管中。(不要使藥粒溶解)
OSANC,Dipyridamole,Sancin F.C. 50mg,HEMT,Coronary insufficiency， Inhibition of platelet aggregation.,Hypersensitivity to dipyridamole or any other product component.,Worsening of angina， flushing， dizziness， palpitations. Lightheadedness， headache， asthenia， hypersensitivity reactions. GI disturbances. Cardiovascular: Electrocardiogram abnormal (15.9%)， Hypotension， IV (4.6%) Gastrointestinal: Abdominal discomfort， Oral (6.1%)， Nausea， IV (4.6%) Neurologic: Dizziness (12%)， Headache， IV (12.2%)， Headache， Oral (2.3%),室溫藥品，仿單無特別指示儲存溫度條件,25mg TID on empty stomach.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OASA8,Mesalazine,Asacol 800mg,ALIM,,適應症:Treatment of moderately active ulcerative colitis 副作用: >10%: Central nervous system: Headache (2% to 35%)， pain (?14%) Gastrointestinal: Abdominal pain (1% to 18%)， eructation (16%)， nausea (3% to 13%) Respiratory: Pharyngitis (11%) 禁忌: U.S. labeling: Hypersensitivity to mesalamine， aminosalicylates， salicylates， or any component of the formulation (including suppository vehicle of vegetable fatty acid esters) Canadian labeling: Hypersensitivity to mesalamine， salicylates， or any component of the formulation; severe renal impairment (GFR <30 mL/minute/1.73 m2); severe hepatic impairment Additional contraindications per specific Canadian product labeling: Existing gastric or duodenal ulcer， urinary tract obstruction， use in children <2 years of age (Asacol， Asacol 800， Mesasal， Pentasa， Salofalk); hemorrhagic diathesis (Mesasal); patients unable to swallow intact tablet (Asacol， Asacol 800); renal parenchymal disease (Pentasa),,室溫,800 mg to 3.2 g in divided doses daily; for severe active disease may increase to 4.8 g daily,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ILEU3,Leuprorelin Acetate,Leuplin Depot inj 3.75mg,RACA,Palliative treatment of advanced prostatic cancer. Treatment of endometriosis (experience has been limited to women ≧18 years treated for 6 months). Treatment of uterine leiomyoma. Treatment of central precocious puberty. Palliative treatment of premenopausal breast cancer.,Patients with a history of hypersensitivity to any of the ingredients of this drug or synthetic LH-RH or LH-RH derivatives， For Endometriosis and Uterine Leiomyomata (Fibroids)， pregnant women or women having possibilities of being pregnant， or nursing mothers， patients with abnormal genital bleeding of indeterminable nature， for Premenopausal breast cancer as postoperative supplementary treatment， pregnant women or women having possibilities of being pregnant， or breastfeeding mothers.,Hot flushes， anorexia， nausea.,25℃以下,[Endometriosis] 3.75 mg subcutaneously once every 4 weeks on the first to fifth day after the start of menstrual period for 6 months. [Uterine myoma] 1.88-3.75 mg subcutaneously once every 4 weeks on the first to fifth day after the start of menstrual period. [Prostate cancer and Premenopausal breast cancer] 3.75 mg subcutaneously once every 4 weeks. [Central precocious puberty] For body weight < 20 kg: 1.88-3.75 mg; for body weight >= 20 kg: 3.75-7.5 subcutaneously once every 4 weeks.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,SC;,以廠商所添附的懸濁用溶解液稀釋,,,,
OCOR5,Ivabradine,Coralan 5mg,CAVS,For adult patients with stable， symptomatic chronic heart failure to reduce the risk of hospitalization for worsening heart failure. It should only be used in patients with an ejection fraction of 35% or less who are in sinus rhythm， have a resting heart rate of at least 70 beats per minute， and are receiving the maximally tolerated beta-blocker dose (or have a contraindication to beta-blocker use),Acute decompensated heart failure; blood pressure <90/50 mm Hg; sick sinus syndrome， sinoatrial block， or third-degree AV block (unless a functioning demand pacemaker is present); resting heart rate <60 bpm prior to treatment; severe hepatic impairment; pacemaker dependence (heart rate maintained exclusively by the pacemaker); concomitant use with strong CYP3A4 inhibitors.,Cardiovascular: Bradycardia (6% to 10%)， hypertension (9%)， atrial fibrillation (5% to 8%)， heart block， sinoatrial arrest Central nervous system: Phosphene (3%) <1% (Limited to important or life-threatening): Angioedema， diplopia， erythema， hypotension， pruritus， skin rash， syncope， urticaria， vertigo， visual impairment.,30℃以下,Initial， 5 mg orally twice daily with food; after 2 weeks， adjust based on heart rate; for resting rate greater than 60 beats per minute (bpm)， increase dose by 2.5 mg twice daily; for 50 to 60 bpm， continue current dose; for less than 50 bpm or for signs or symptoms of bradycardia， decrease dose by 2.5 mg twice daily; Maximum dose: 7.5 mg twice daily.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,PO;WM;,,,,,
OGALM,Vildagliptin + Metformin,GalVUS Met 50/850mg,META,Type 2 diabetes mellitus,A) alcohol intoxication， acute， or alcoholism B) diabetic ketoacidosis or diabetic pre-coma C) hepatic impairment D) hypersensitivity to vildagliptin， metformin hydrochloride， or any components of the product E) hypoxic conditions， acute or chronic (eg， cardiac or respiratory failure， recent myocardial infarction， shock) F) lactation G) renal failure or renal impairment (CrCl less than 60 mL/min) H) renal function-altering acute conditions (eg， dehydration， severe infection， shock， intravascular administration of iodinated contrast agents),Endocrine metabolic: Hypoglycemia (1% to less than 10% ) Gastrointestinal: Nausea (1% to less than 10% ) Neurologic: Dizziness (1% to less than 10% )， Headache (1% to less than 10% )， Tremor (1% to less than 10% ),30℃儲存,1 TAB BID， not to exceed vildagliptin 100 mg/day or metformin 3000mg/day.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PC;PO;WM;,,,,,
OAKI2,Biperiden,Akinfree 2mg,CNEU,Parkinsonism.,Narrow-angle glaucoma; mechanical stenoses of the GIT， megacolon.,GI disturbances; dry mouth; visual disorders; drowsiness， dizziness; fatigue; urinary retention.,25℃以下儲存,2mg TID-QID. Maximum: 16 mg/day (MicroMedex).,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
IONC5,BCG Immunotherapeutic,OncoTICE 2-8×10^8 CFU (專案進口),RACA,Bladder cancer， Stage Ta and/or T1 papillary tumors following transurethral resection.,1. immunocompromised status including HIV infection (percutaneous and intravesical) 2. urinary tract infection or hematuria (intravesical) 3.acute febrile illness (intravesical) 4. 7 to 14 days following biopsy， transurethral resection， or traumatic catheterization; increased risk for systemic BCG infection (intravesical) 5. active tuberculosis (intravesical) 6. hypersensitivity to BCG products,Hematuria， urinary frequency， dysuria， bacterial UTI. Local irritative symptoms， fever， prostatitis， ureteral obstruction， systemic BCG infection.,2-8℃避光,TICE BCG: One dose instilled into the bladder (retain for 2 hours) once weekly for 6 weeks (may repeat cycle 1 time) followed by approximately once monthly for at least 6-12 months. Have patient avoid fluid intake for 4 hours prior to treatment and empty bladder prior to instillation. Slowly instill via catheter into the bladder by gravity flow; do not force by depressing plunger. Retain suspension for up to 2 hours， repositioning the patient every 15 minutes from left side to right side， and supine to prone. After 2 hours， have patient void in a seated position. Have patient increase fluid intake to flush bladder; dispose of all urine voided for 6 hours after instillation with an equal volume of household bleach (this should be done for the first 6 hours after therapy). After administration， patients should drink plenty of water in order to flush the bladder.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IRR;,以1mL N/S配製，輕輕搖勻,【N/S】可選 仿單建議。,,以1mL NS配製，輕輕搖勻，取出後以NS稀釋至50mL,ONCOTICE (CONTAINING 2-8×10^8 CFU TICE BCG) 為膀胱灌洗用溶液。
IKCL5A,KCl + D5W,申報用代碼 KCl 10mEq in D5W 250mL,NUTR,,,,,,,,,,,,,,,,,,,
IKCL6A,KCl + D5W,申報用代碼 KCl 20mEq in D5W 250mL,NUTR,,,,,計價用子醫令,無需調整劑量,,無需調整劑量,,,,,,IVD;,,,,,
IKCL7A,KCl + D5S,申報用代碼 KCl 20mEq in D5NS 500mL,NUTR,,,,,,,,,,,,,,,,,,,
EPERI,Minocycline,Periocline periodontal oint 10mg/0.5g/syringe,TENT,Adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. May be used as part of a periodontal maintenance program which includes good oral hygiene， scaling， and root planing.,Known hypersensitivity to minocycline， tetracyclines， or any component of the formulation; children <8 years of age,>10%: Gastrointestinal: Tooth disorder (12%) 1% to 10%: Central nervous system: Headache (9%)， pain (4%) Gastrointestinal: Dental caries (10%)， dental pain (10%)， gingivitis (9%)， mouth ulceration (5%)， dyspepsia (4%)， mucous membrane disorder (3%) Respiratory: Pharyngitis (4%) Miscellaneous: Infection (8%)， flu-like syndrome (5%) Postmarketing and/or case reports: Anaphylaxis， angioneurotic edema， erythema multiforme (oral minocycline)， pruritus， rash， Stevens-Johnson syndrome (oral minocylcine)， swelling of face， urticaria,2-8度 冷藏及避光,Once a week. Adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. May be used as part of a periodontal maintenance program which includes good oral hygiene， scaling， and root planing.,無需調整劑量,Up to date: Pregnancy Risk Factor: D Lactation: Enters breast milk/not recommended,無需調整劑量,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Up to date: Pregnancy Risk Factor: D Lactation: Enters breast milk/not recommended,,,,,,
OPRI,Dapoxetine,Priligy 30mg (3 tablets/box),SGU,Treatment of premature ejaculation (PE) in men,Hypersensitivity. Significant pathological cardiac conditions eg heart failure (NYHA class II-IV)， conduction abnormalities (2nd- or 3rd-degree AV block or sick sinus syndrome) not treated w/ a permanent pacemaker， ischemic heart disease， valvular disease. Concomitant w/ MAOIs， thioridazine， selective serotonin re-uptake inhibitors (SSRIs)， serotonin-norepinephrine re-uptake inhibitors (SNRIs)， TCAs or other medicinal/herbal products w/ serotonergic effects (including recreational drugs)， CYP3A4 inhibitors. Moderate & severe hepatic impairment (Child-Pugh class B & C). Childn <18 yr.,Dizziness， headache， nausea， insomnia， anxiety， agitation， restlessness， decreased libido， abnormal dreams， somnolence， attention disturbance， tremor， paraesthesia， blurred vision， tinnitus， flushing， sinus congestion， yawning， GI disturbances， hyperhidrosis， erectile dysfunction， fatigue， irritability， increased BP,25℃以下,30 mg 1-3 hours prior to sexual activity. The recommended dose: 30mg/day.,無需調整劑量,,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥應整粒吞服， 切勿咬嚼或剝半。廠商亦無相關的安定性及療效數據。
OPRO6,Calcium Acetate,Procal 667mg(醋酸鈣),NUTR,Control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption.,Hypercalemia,Hypercalemia， nausea， constipation， allergy reaction,25℃以下,Initial dose for the adult dialysis patient is 2 TAB with each meal. The dosage may be increased gradually to bring serum phosphate value below 6 mg/dL， as long as hypercalcemia does not develop. Most patient require 3-4 TAB with each meal. 1 TAB contains: 667 mg calcium acetate = 169 mg elemental calcium.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC15;PO;WM;,,,,,Calcium acetate 667 mg = elemental calcium 169 mg = calcium 8.45 mEq = calcium 4.23 mmol
IMEP2,Meropenem,Mepem inj 0.25gm(美平),QANB,Bacterial meningitis: Treatment of bacterial meningitis in pediatric patients 3 months and older caused by Streptococcus pneumoniae， Haemophilus influenzae， and Neisseria meningitidis Complicated skin and skin structure infections: Treatment of complicated skin and skin structure infections in adults and pediatric patients 3 months and older caused by Staphylococcus aureus (methicillin-susceptible isolates only)， Streptococcus pyogenes， S. agalactiae， viridans group streptococci， Enterococcus faecalis (vancomycin-susceptible isolates only)， Pseudomonas aeruginosa， Escherichia coli， Proteus mirabilis， Bacteroides fragilis， and Peptostreptococcus species Intra-abdominal infections: Treatment of complicated appendicitis and peritonitis in adult and pediatric patients caused by viridans group streptococci， E. coli， Klebsiella pneumoniae， P. aeruginosa， B. fragilis， B. thetaiotaomicron， and Peptostreptococcus species Canadian labeling: Additional indications (not in U.S. labeling): Treatment of lower respiratory tract infections (community-acquired and nosocomial pneumonias)， uncomplicated skin and skin structure infections， complicated urinary tract infections， gynecologic infections (excluding chlamydia)， and septicemia; treatment of bacterial meningitis in adults caused by S. pneumoniae， H. influenzae， and N. meningitidis (use in adult meningitis based on pediatric data),Hypersensitivity to meropenem， other drugs in the same class， or any component of the formulation; patients who have experienced anaphylactic reactions to beta-lactams,Shock， serious renal disorders including acute renal failure， serious colitis accompanied with bloody stool， pseudomembranous colitis， interstitial pneumonia & PIE syndrome. CNS convulsion e.g. seizures， consciousness disorders. Lyell syndrome， Steven-Johnson syndrome， pancytopenia， agranulocytosis， leucopenia， hepatic disorders， jaundice， rash， urticaria， feeling of warmth， erythema， pruritus， fever & redness. Granulocytopenia， eosinophilia， thrombocytopenia or thrombocytosis & lymphocytosis increased GOT/GPT/LDH/A1-P/LAP/γ-GTP/bilirubin/urinary urobilinogen， decreased cholinesterase， increased urinary β2-microglobulin/BUN/creatinine， abdominal pain， diarrhea， nausea， vomiting & anorexia， stomatitis， candidiasis， vit K deficiency symptoms， vit B complex deficiency symptoms， headache， malaise. Dermatologic: Injection site inflammation (2.4% ) Gastrointestinal: Constipation (1.4% to 7% )， Diarrhea (3.5% to 7% )， Nausea and vomiting (3.6% adults; 0.8% children ) Neurologic: Headache (2.3% to 7.8% ),25℃以下,Adults: 0.5-2 g in 2-3 divided doses IV infused over 30 minutes. Children: 30-120 mg/kg in 2-3 divided doses IV infused over 30 minutes (max. 2 g/day). *****NEONATE ANTIBIOTICS DOSE***** Meropenem: general infection Body weight <1kg ge<=7day 20mg/kg Q12H  Age 8-14 day 20mg/kg Q12H  Age 15-28 day 20 mg/kg Q8H Body weight 1-2kg ge<=7day 20mg/kg Q12H  Age 8-14 day 20 mg/kg Q8H  Age 15-28 day 20 mg/kg Q8H Body weight >2kg Age<=7day 20 mg/kg Q8H  Age 8-14 day 30 mg/kg Q8H  Age 15-28 day 30mg/kg Q8H meningitis Body weight <1kg ge<=7day 40mg/kg Q12H  Age 8-14 day 40mg/kg Q12H  Age 15-28 day 40 mg/kg Q8H Body weight 1-2kg ge<=7day 40mg/kg Q12H  Age 8-14 day 40 mg/kg Q8H  Age 15-28 day 40 mg/kg Q8H Body weight >2kg Age <=7ayd 40 mg/kg Q8H  Age 8-14 d ay 40 mg/kg Q8H  Age 15-28 day 40mg/kg Q8H,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,IVD: 5mL N/S,【N/S】可選 。,,通常0.25g-2g用100mL以上的生理食鹽水溶解後使用，即2.5-20mg/mL或更小濃度，建議以>30分鐘緩慢滴注。,1. 監測體溫、CBC、肝腎功能，注意是否有肌肉震顫或癲癇發作徵狀。 2. 給藥後第3 ~ 5天應特別觀察皮疹等不良反應。 3. 溶解後應立即使用。以等張食鹽水溶解後，室溫25℃可保存6小時，5℃可保存24小時。詳細安定性數據請參見藥物仿單。
IATM,Tr.mucrosquamatus antivenin+Tr.gramineus antivenin,抗龜殼花及赤尾鮐蛇毒血清,HIMM,,適應症:Therapy for the bite of Tr. mucrosquamatus and Tr. stejneteri snakes. 副作用:allergic phenomena including anaphylaxis， hypotension， serum sickness. 禁忌: Hypersensitivity to antivenin.,,2-8℃,Adult 1 dose.,,,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 稀釋法：取稀釋溶液10 mL注入凍晶製劑中，避免用力振搖，應於2小時內用完。 2. 宜儘早注射，被咬傷後4小時內注射最有效。 3. 注射部位：咬傷時間二小時內，可將一半劑量注射在咬傷部位周圍皮下，另一半則IV或IM。 4. 注射速率：IV: 第1 mL數分鐘注完，以後每1 mL不快於一分鐘 (30-60分鐘內打完)。IVD: 一劑抗蛇毒血清稀釋於300mL N/S。 5. 注射劑量：成人為一劑量，10歲以下兒童加倍。如症狀繼續惡化隔30分鐘至一小時後可再打一劑。 6. 蛇毒血清為馬的血清製劑，為防過敏反應，可先做皮膚試驗並準備1:1000 Epinephrine備用。
OALA,Nifedipine,Alat 10mg,CAVS,Hypertension， chronic stable angina pectoris,CV shock; pregnancy & lactation. Unstable angina & after recent MI (immediate release).,Initially mild & transient vasodilatation， hypotension， rarely GI， skin & other reactions. Very rarely: transient visual change; chest discomfort (if relation established， discontinue therapy). Extremely rare: on prolonged use gingival hyperplasia， gynaecomastia (both regressing on discontinuation); hepatobiliary disorders. Cardiovascular: Hypotension (up to 5% )， Palpitations (up to 7% )， Peripheral edema (7% to 29% ) Dermatologic: Flushing (4% to 25%) Gastrointestinal: Nausea (up to 10% ) Neurologic: Dizziness (4% to 10% )， Headache (19% to 23%) Psychiatric: Feeling nervous Respiratory: Cough， Dyspnea,25℃以下避光且乾燥處儲存,HTN， angina 10-20mg TID， maximum 180mg.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PO;,,,,,[磨粉/管灌註記]本藥為微粒膠囊，可拆膠囊後服用。但不可將膠囊內的微粒研磨或壓碎。管灌時建議分次使用，注意沾黏及堵塞管路。
OLICA,Methimazole,利甲 Lica 5mg,META,Hyperthyroidism.,Pregnancy， lactation.,Skin rash， urticaria， nausea， vomiting， epigastric distress， hair loss， myalgia， edema， jaundice， sialadenopathy， lymphadenopathy & much less frequency of inhibition of myelopoiesis.,25℃以下,Mild hyperthyroidism 15mg daily， moderate hyperthyroidism 30-40 mg daily， severe hyperthyroidism 60 mg daily， > 60 mg should be taken in 3 divided doses.Maintenance dose 5-15 mg in3 divided doses.,無需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
IJET,Ocriplasmin,Jetrea inj 0.5mg/0.2mL,TOPH,,適應症:Vitreomacular adhesion: Treatment of symptomatic vitreomacular adhesion (VMA) 副作用: >10%: Ocular: Blurred vision (5% to 20%)， conjunctival hemorrhage (5% to 20%)， eye pain (5% to 20%)， macular hole (5% to 20%)， photopsia (5% to 20%)， retinal edema (5% to 20%)， visual acuity decreased (5% to 20%)， visual impairment (5% to 20%)， vitreous floaters (5% to 20%) 1% to 10%: Ocular: Intraocular inflammation (7%)， anterior chamber cell (2% to 5%)， cataract (2% to 5%)， conjunctival hyperemia (2% to 5%)， dry eyes (2% to 5%)， intraocular pressure increased (2% to 5%)， iritis (2% to 5%)， macular edema (2% to 5%)， metamorphopsia (2% to 5%)， ocular discomfort (2% to 5%)， photophobia (2% to 5%)， retinal degeneration (2% to 5%)， vitreous detachment (2% to 5%)， dyschromatopsia (2%)， a-wave and b-wave amplitude decreased (1%) <1% (Limited to important or life-threatening): Lens subluxation (high dose; 0.175 mg)， retinal detachment 禁忌:Hypersensitivity to ocriplasmin or any component of the formulation; active or suspected ocular or periocular infections.,,store in -20°C,Adult: Vitreomacular adhesion: Intravitreal: 0.125 mg once (as a single dose to the affected eye) Dosing: Renal Impairment There are no dosage adjustments provided in the manufacturer's labeling. However， dosage adjustment unlikely due to low systemic absorption.,無需調整劑量,,無需調整劑量,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,IVI;,,,,,
IKCL8,Potassium Chloride,20mEq KCl in N/S 100mL,NUTR,,適應症: Hypokalaemia. 副作用: Hyperkalemia， pain or phlebitis at injection site. 禁忌: Hyperkalemia.,,2-8度C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr， with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
IMET4,Methylprednisolone,Methylprednisolone inj 40mg,HM,Primarily as an anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of dermatologic， endocrine， GI， hematologic， allergic， inflammatory， neoplastic， neurologic， ophthalmic， renal， respiratory， and autoimmune origin. Prevention and treatment of graft-versus-host disease following allogeneic bone marrow transplantation.,Hypersensitivity to methylprednisolone or any component of the formulation; systemic fungal infection; administration of live virus vaccines; methylprednisolone formulations containing benzyl alcohol preservative are contraindicated in premature infants; IM administration in idiopathic thrombocytopenic purpura; intrathecal administration,Common Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin， Impaired wound healing Endocrine metabolic: Body fluid retention， Decreased body growth， Hypernatremia， Hypokalemia Gastrointestinal: Disorder of gastrointestinal tract， Peptic ulcer disease Hepatic: Liver function tests abnormal (Mild) Immunologic: At risk for infection Musculoskeletal: Muscle weakness Psychiatric: Depression， Euphoria Serious Cardiovascular: Cardiac dysrhythmia， Congestive heart failure Endocrine metabolic: Adrenal insufficiency， Cushing's syndrome， Hyperglycemia Hepatic: Hepatotoxicity Musculoskeletal: Osteoporosis Neurologic: Cerebrovascular accident， Infarction of spinal cord， Nerve injury， Paraplegia， Raised intracranial pressure， Seizure， Tetraplegia Ophthalmic: Cataract， Cortical blindness， Glaucoma Renal: Acute scleroderma renal crisis Respiratory: Pulmonary tuberculosis,25℃以下,--Anti-inflammatory or immunosuppressive: IM (sodium succinate): 10 to 80 mg/day once daily IV (sodium succinate): 10 to 40 mg over a period of several minutes and repeated IV or IM at intervals depending on clinical response; when high dosages are needed， give 30 mg/kg over a period >=30 minutes and may be repeated every 4 to 6 hours for 48 hours. --Dermatomyositis/polymyositis: IV (sodium succinate): 1 g/day for 3 to 5 days for severe muscle weakness， followed by conversion to oral prednisone. --Asthma exacerbations， including status asthmaticus (emergency medical care or hospital doses): IV: 40 to 80 mg/day in 1 to 2 divided doses until peak expiratory flow is 70% of predicted or personal best --Acute spinal cord injury: 30 mg/kg IV bolus followed by a continuous infusion of 5.4 mg/kg/hr for 24 hours if treatment is started within 3 hours of the injury or 48 hours if treatment is started between 3 and 8 hours after the injury.,無需調整劑量,UpToDate哺乳建議:Corticosteroids are excreted in human milk. The manufacturer notes that when used systemically， maternal use of corticosteroids have the potential to cause adverse events in a nursing infant (eg， growth suppression， interfere with endogenous corticosteroid production) and therefore recommends a decision be made whether to discontinue nursing or to discontinue the drug， taking into account the importance of treatment to the mother. If there is concern about exposure to the infant， some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breast-feeding in order to decrease potential exposure to the nursing infant (based on a study using prednisolone).,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,UpToDate哺乳建議:Corticosteroids are excreted in human milk. The manufacturer notes that when used systemically， maternal use of corticosteroids have the potential to cause adverse events in a nursing infant (eg， growth suppression， interfere with endogenous corticosteroid production) and therefore recommends a decision be made whether to discontinue nursing or to discontinue the drug， taking into account the importance of treatment to the mother. If there is concern about exposure to the infant， some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breast-feeding in order to decrease potential exposure to the nursing infant (based on a study using prednisolone).,IM;IVD;IVP;IVPUSH;,無菌注射用水2mL. 依廠商提供安定性資訊亦可用1mL的5% glucose及0.9% Sodium Chloride.,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,注射時間60秒至數分鐘以上.,30mg/kg，靜脈注射10-20分鐘.48小時內可4-6小時重複一次.,1.reconstitute with the accompanying diluent or bacteriostatic water for injection with benzyl alcohol only and use with 48 hours of mixing. 2.IVD:methylPREDNISolone solutions in D5W should be infused within 8 hours of mixing due to stability concerns. adult: high-dose therapy (30 mg/kg)， administer IV over at least 30 minutes. adult: (bolus) reconstituted solution may be given via direct IV injection over several minutes without further dilution.
IMV9,Multivitamin,Lyo-Povigen inj 5mL (9種成份),NUTR,,適應症: Nutritional supplementary for urgent situations induced by surgery， severe burns， fracture and trauma， severe infection， and coma. 副作用： Cardiovascular: Angioedema， edema Central nervous system: Agitation， anxiety， dizziness， headache Dermatologic: Erythema， pruritus， rash， urticaria Ocular: Diplopia Respiratory: Dyspnea， wheezing Miscellaneous: Allergic reactions， anaphylaxis， hypervitaminosis 禁忌：Hypersensitivity to any component of the formulation; pre-existing hypervitaminosis,,2-8℃,Adult: I.V. (not for direct infusion， solution must be diluted prior to administration): 1-5 mL/day added to TPN or > 500 mL of appropriate solution Each 5 mL reconstituted solution contains:Vitamin A 10，000 I.U.， Vitamin D2 (Ergocalciferol) 1，000 I.U.， dl-α-Tocopheryl Acetate(Vit. E) 5 I.U.， Ascorbic Acid (Vit.C) 500mg， Thiamine Hydrochloride (Vit.B1) 50mg， Riboflavin 10mg， Niacinamide 100mg， Pyridoxine Hydrochloride (Vit.B6) 15mg， d-Panthenol 25mg,,Refer to individual vitamin monographs for requirements while breast-feeding,,沒有資料,,,Contraindicated 哺乳期使用禁忌,Refer to individual vitamin monographs for requirements while breast-feeding,,,,,,1.本劑水溶性維他命群經凍結乾燥，形成多孔易溶的安定性結晶。另一安瓿內則為脂溶性維他命的無菌水溶液，係作凍結乾燥成分之溶釋用。使用時，先將溶釋液導入凍結乾燥瓶內，反覆輕搖不使生氣泡，作成均一溶液。溶解後之pH值為2.5-4 2.由於本劑含有Thiamine成分，敏感病患有過敏性的報告。 3.本劑不得以未稀釋方式投與，可能產生眩暈，昏倒現象。
IPRE1,Pneumococcal Vaccine Polyvalent,Prevenar (政府提供，13價肺炎) 0.5mL/dose,HIMM,Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1， 3， 4， 5， 6A， 6B， 7F， 9V， 14， 18C， 19A， 19F and 23F in infants and children from 2 month-5 years.,Hypersensitivity.,Decreased appetite， irritability， drowsiness/increased sleep， restless sleep/decreased sleep， fever， inj site erythema， induration/swelling or pain/tenderness， rash.,2-8℃避免冷凍,IM， 0.5mL， children 2-6 months 3 doses primary immunization at intervals of 1 month (the 1st dose can be given at 6 weeks of age)， a booster dose at 12-15 months. 7-11 months 2 doses primary immunization at intervals of 1 month ， a booster dose at 12 months. 12-23 months 2 doses at intervals of 2 months. > or = 2 years a single dose.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,1. 應以肌肉注射方式投予，最好注射在嬰兒大腿前外側的股外側肌，或是幼童上臂的三角肌。
OFLUP,Fludiazepam,FluPINE 0.25mg,CNEU,Anxiety， insomnia & muscle spasm.,Acute narrow angle glaucoma， serious myasthenia,Dependence， irritability， excitation， confusion， dizziness， dull headache， tremor， ataxia， visual disturbances， dizziness on standing up， delirium， amnesia， insomnia， vivid dreams， dyslalia， increased AST/ALT， dry mouth， anorexia， GI discomfort， rash， pruritus， fatigue， malaise， muscle weakness， decreased libido， dysuria， yawning， closed pharynx sensation， numbness of tongue & hands， diaphoresis， slight fever， enlarged axillary glands， urinary incontinence， premenstrual tension， alopecia.,25℃以下緊密容器,Adult 0.25 mg TID， adjusted according to age & symptoms.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
ITAXO,Docetaxel,Taxotere inj 20mg/1mL,RACA,Breast cancer， non-small cell lung cancer， prostate cancer， gastric adenocarcinoma， head & neck cancer.,Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count <1，500/mm3. Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding,Hematologic reactions especially neutropenia， fever， hypersensitivity reactions， fluid retention， GI disturbances， cutaneous reactions， neurologic symptoms， asthenia， alopecia. Cardiovascular: Edema (47% to 64.1% )， Vasodilatation (27% ) Dermatologic: Alopecia (56.3% to 97.8% )， Disorder of nail (11.4% to 18.5% )， Disorder of skin AND/OR subcutaneous tissue， Nail changes (8.1% to 30.6% )， Pruritus， Rash Gastrointestinal: Diarrhea (32.8% to 42.6% )， Nausea (38.8% to 80.5% )， Stomatitis (41.7% to 69.4% )， Vomiting (22.3% to 44.5% ) Hematologic: Anemia (89.1% to 93.6% )， Leukopenia (95.6% to 98.6% )， Neutropenia (71.4% to 99.5% ) Neurologic: Asthenia (61.8% to 80.8% )， Neuropathy Reproductive: Amenorrhea (61.7% ) Other: Fever of unknown origin (31.2% to 46.5% ),25℃以下避光,[Breast cancer] Operable (adjuvant treatment): TAC regimen: 75 mg/m2 every 3 weeks for 6 courses in combination with doxorubicin 50mg/m2 and cyclophosphamide 500 mg/m2; Locally advanced or metastatic: 100 mg/m2 every 3 weeks as a single agent; 75 mg/m2 every 3 weeks in combination with doxorubicin 50 mg/m2 as first-line therapy; In combination with weekly trastuzumab: 100 mg/m2 every 3 weeks; In combination with capecitabine: 75 mg/m2 every 3 weeks.  [Non-small cell lung cancer] Chemotherapy-naive patients: 75 mg/m2 every 3 weeks in combination with cisplatin 75 mg/m2 or carboplatin with a target AUC of 6 mg/mL•min; Patients with prior failure of platinum?based chemotherapy: 75 mg/m2 every 3 weeks as a single agent.  [Prostate cancer] 75 mg/m2 every 3 weeks in combination with oral prednisone or prednisolone 5 mg twice daily. [Gastric adenocarcinoma] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil. [Head and neck cancer] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil for 3 or 4 cycles， followed by radiation therapy.,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 稀釋溶液與器具應使用玻璃、聚丙烯(polypropylene)、聚烯(polyolefin)材質，不可使用含PVC塑膠材質。給藥時應使用 polyethylene 材質的輸液套。 3. 配製好的輸注溶液濃度避免超過 0.74 mg/mL，配置好6小時內以靜脈輸注方式使用 (包含輸注時間)，在低於25℃以下給予病患。使用前應再次目視檢查，若有沉澱物或結晶應予以丟棄。 4. 注射前應先給予預防過敏的藥物。 5. 監測CBC、肝功能。
IROP,Ropivacaine,Ropica inj 200mg/20mL,ZANE,Acute pain management: For acute pain management administered as an epidural continuous infusion， intermittent bolus (eg， postoperative or labor)， or local infiltration. Surgical anesthesia: For the production of local or regional anesthesia for surgery administered as an epidural block， including cesarean section， major nerve block， or local infiltration.,Hypersensitivity to ropivacaine， amide-type local anesthetics (eg， bupivacaine， mepivacaine， lidocaine)， or any component of the formulation,>10%: Cardiovascular: Hypotension (32% to 69%)， bradycardia (6% to 20%); Gastrointestinal: Nausea (13% to 25%)， vomiting (7% to 12%); Neuromuscular & skeletal: Back pain (4% to 16%) 1% to 10%: Cardiovascular: Chest pain (1% to 5%)， hypertension (1% to 5%)， tachycardia (1% to 5%); Central nervous system: Headache (5% to 8%)， pain (4% to 8%)， paresthesia (2% to 6%)， dizziness (3%)， chills (<=3%)， rigors (<=3%)， hypoesthesia (2%)， anxiety (1%); Dermatologic: Pruritus (1% to 5%); Endocrine & metabolic: Hypokalemia (1% to 5%); Genitourinary: Oliguria (1% to 5%)， urinary retention (1% to 5%)， urinary tract infection (1% to 5%)， disorder of breast milk secretion (1%)， poor progression of labor (1%); Hematologic & oncologic: Anemia (6%); Neuromuscular & skeletal: Muscle cramps (1% to 5%); Respiratory: Dyspnea (1% to 5%)， rhinitis (1%); Miscellaneous: Fever (2% to 9%)， postoperative complication (3% to 7%) <1%， postmarketing， and/or case reports: Accidental injury， agitation， amnesia， angioedema， asthenia， atrial fibrillation， auditory disturbance， blepharoptosis， bronchospasm， cardiac arrhythmia， coma， confusion， cough， deep vein thrombosis， drowsiness， dyskinesia， ECG abnormality， emotional lability， extrasystoles， fecal incontinence， hallucination， Horner's syndrome， hypersensitivity reaction， hypokinesia， hypomagnesemia， hypothermia， hypotonia， insomnia， jaundice， malaise， myalgia， myocardial infarction， nervousness， neuropathy， nightmares， orthostatic hypotension， pain at injection site， paresis， phlebitis， pulmonary embolism， seizure， skin rash， ST segment changes on ECG， stupor， syncope， tenesmus， tinnitus， tremor， urinary incontinence， urination disorder， urticaria， uterine atony， vertigo， visual disturbance,25℃以下避免冷凍,Ropivacaine should only be used by， or under the supervision， of clinicians experienced in regional anaesthesia. Adults and children > 12 years of age: Lumbar epidural administration: Surgery: 15-20 mL of 10% solution (150-200 mg). Cesarean section: 15-20 mL of 7.5% solution (113-150 mg). Thoracic epidural administration: To establish block for post-operative pain relief: 5-15 mL of 7.5% solution (38-113 mg). Field block (minor nerve blocks and infiltration): 1-30 mL of 7.5% solution (7.5-225 mg). For acute pain management: Lumbar epidural administration: Bolus 10-20 mL of 2% solution (20-40 mg). Intermittent injections (top-up): 10-15 mL of 2% solution (20-30 mg)， minimum interval 30 minutes. Continuous infusion (labour pain): 6-10 mL/hour of 2% solution (12-20 mg/hour). Postoperative pain management: 6-14 mL/hour of 2% solution (12-28 mg/hour). Thoracic epidural administration: Continuous infusion (postoperative pain management): 6-14 mL/hour of 2% solution (12-28 mg/hour). Field block (minor nerve blocks and infiltration): 1-100 mL of 2% solution (2-200 mg). Post knee arthroscopy pain: Intra-articular， 20 mL of 7.5% solution (150 mg).,需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,INS;IS;LA;SPI;,,【N/S】可選 。,,,外科麻醉：硬膜外阻斷麻醉以進行外科手術，包括剖腹產及區域阻斷。 急性疼痛處理：持續性硬膜外輸注或間歇性之一次注射給藥，如：手術後或產後疼痛；區域阻斷及關節內注射。 1至12歲兒童之急性疼痛處理，限單一注射：尾部脊椎硬膜外(Caudal)阻斷，週邊神經阻斷，以解除手術期間或手術後疼痛。 本品僅供有麻醉經驗的臨床醫生或在其指導下使用。
OOLM,Olmesartan medoxomil,Olmetec 40mg,CAVS,Hypertension: Treatment of hypertension with or without concurrent use of other antihypertensive agents,Concomitant use with aliskiren in patients with diabetes mellitus Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to olmesartan or any component of the formulation; concomitant use with aliskiren in patients with moderate to severe renal impairment (GFR <60 mL/minute/1.73 m2),1% to 10%: Central nervous system: Dizziness， headache Endocrine & metabolic: Hyperglycemia， hypertriglyceridemia Gastrointestinal: Diarrhea Neuromuscular & skeletal: Back pain， CPK increased Renal: Hematuria Respiratory: Bronchitis， pharyngitis， rhinitis， sinusitis Miscellaneous: Flu-like syndrome,25℃以下,HTN: initial 20mg QD， after 2weeks may titrate up to 40mg QD.,無需調整劑量,[仿單] 尚無相關資訊顯示是否人類乳汁中存在Olmesartan，影響哺乳胎兒或影響乳汁產生，但泌乳大鼠會分泌低濃度olmesartan到乳汁中。 因為其對哺乳胎兒可能產生的副作用，應評估藥物對母親的重要性，以決定要停止哺乳或停止用藥。,無需調整劑量,沒有資料,Human data suggest risk in 2nd and 3 rd trimesters,[仿單] 懷孕婦女服用Olmetec會對胎兒造成傷害。在懷孕第2和第3期時，使用腎素－血管昇壓素系統的藥物使胎兒腎功能降低及增加胎兒和新生兒罹病率與死亡。 多數流行病學研究顯示，在懷孕第一期使用腎素－血管昇壓素系統藥物治療高血壓所產生的胎兒異常和使用其他種類的抗高血壓藥物並無分別。。 在動物生殖研究中，在器官形成過程中使用劑量低於母體毒性劑量的Olmetec進行治療，導致大鼠胚胎胎兒讀性增加。 一旦病患確定懷孕，需立即讓病患停用Olmetec。懷孕期間應考慮替代高血壓治療。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 尚無相關資訊顯示是否人類乳汁中存在Olmesartan，影響哺乳胎兒或影響乳汁產生，但泌乳大鼠會分泌低濃度olmesartan到乳汁中。 因為其對哺乳胎兒可能產生的副作用，應評估藥物對母親的重要性，以決定要停止哺乳或停止用藥。,AC;AC15;PC;PO;WM;,,,,,
ODALP,Flurazepam,Dalpam 30mg,CNEU,,適應症:Short-term treatment of insomnia 副作用: Cardiovascular: Chest pain， flushing， hypotension， palpitation Central nervous system: Apprehension， ataxia， confusion， depression， dizziness， drowsiness， euphoria， faintness， falling， hallucinations， hangover effect， headache， irritability， lightheadedness， memory impairment， nervousness， paradoxical reactions， restlessness， slurred speech， staggering， talkativeness Dermatologic: Pruritus， rash Gastrointestinal: Appetite increased/decreased， bitter taste， constipation， diarrhea， GI pain， heartburn， nausea， salivation increased/excessive， upset stomach， vomiting， weight gain/loss， xerostomia Hematologic: Granulocytopenia， leukopenia Hepatic: Alkaline phosphatase increased， ALT increased， AST increased， cholestatic jaundice， total bilirubin increased Neuromuscular & skeletal: Body/joint pain， dysarthria， reflex slowing， weakness Ocular: Blurred vision， burning eyes， difficulty focusing Respiratory: Apnea， dyspnea Miscellaneous: Diaphoresis， drug dependence 禁忌:Hypersensitivity to flurazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); narrow-angle glaucoma; pregnancy,,室溫,Dosing: Adult Insomnia (short-term treatment): Oral: 15-30 mg at bedtime Dosing: Geriatric Oral: 15 mg at bedtime. Avoid use if possible.,,,,不可使用,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ICAN,Caspofungin,Cancidas inj 50mg,QANB,,適應症: Empirical therapy for presumed fungal infections in febrile， neutropenic patients. Treatment of invasive candidiasis， including candidemia， esophageal candidiasis & invasive aspergillosis in patients refractory to or intolerant of other therapies. 副作用: Fever， headache， chills; nausea， diarrhea， vomiting; elevated liver enzyme levels; anemia; tachycardia; catheter site pain， flushing， hypotension; phlebitis/thrombophlebitis， infusion-site pruritus; arthralgia; dyspnea; rash， pruritus， sweating， erythema. 禁忌: Hypersensitivity.,,2-8 C,Dosing: Adult Aspergillosis (invasive): I.V.: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily. Duration of therapy should be a minimum of 6-12 weeks or throughout period of immunosuppression and until lesions have resolved. Salvage treatment with 70 mg once daily (unlabeled dosing) has been reported. Candidemia: I.V.: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily; generally continue for at least 14 days after the last positive culture or longer if neutropenia warrants. Higher doses (150 mg once daily infused over ~2 hours) compared to the standard adult dosing regimen (50 mg once daily) have not demonstrated additional benefit or toxicity in patients with invasive candidiasis. Esophageal candidiasis: I.V.: 50 mg once daily; continue for 7-14 days after symptom resolution. Note: The majority of patients studied for this indication also had oropharyngeal involvement. Empiric therapy: I.V.: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily; continue until resolution of neutropenia; if fungal infection confirmed， continue for a minimum of 14 days (continue for at least 7 days after resolution of both neutropenia and clinical symptoms); if clinical response inadequate， may increase up to 70 mg once daily if tolerated， but increased efficacy not demonstrated. Dosage adjustment with concomitant use of an enzyme inducer: Patients receiving rifampin: 70 mg caspofungin once daily Patients receiving carbamazepine， dexamethasone， efavirenz， nevirapine， or phenytoin (and possibly other enzyme inducers): May require an increased dose of caspofungin 70 mg once daily.,需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,10.5mL 0.9%生理食鹽水，無菌注射用水稀釋成5.2mg/mL,【H/S】可選 。【L/R】可選 。【N/S】可選 。,,,
ETIS,Thrombin+calcium chloride+aprotinin+protein clotta,Tisseel solution for sealant 2mL/set,HEMT,,適應症:Adjunct to hemostasis in cardiopulmonary bypass surgery (including fully heparinized patients) and splenic injury (due to blunt or penetrating trauma to the abdomen) when the control of bleeding by conventional surgical techniques is ineffective or impractical; adjunctive sealant for closure of colostomies. 副作用: May be related to aprotinin contained in some products. Frequency may vary by product. 1% to 10%: Cardiovascular: Bradycardia (?10%) Central nervous system: Fever (6%) Dermatologic: Pruritus (?1%) Gastrointestinal: Abdominal distension (4%) Hematologic & oncologic: Hematoma (Facial rhytidectomy: 1% to 4%)， hemorrhage (internal， postprocedural; 2%)， increased serum fibrinogen (2%) Immunologic: Antibody development (1% to 2%) Local: Skin graft failure (3%) Respiratory: Pulmonary embolism (<1% to 3%) 禁忌:Hypersensitivity to aprotinin; direct intravascular injection; severe or brisk arterial bleeding,,-18℃以下冷凍,Dosing: Adult Adjunct to hemostasis: Apply topically in an even Tisseel: Package size to be used is determined by the size of the surface to be covered. Apply in thick layer to completely cover the application area. Maximum area to be sealed: 8 cm2 Required package size of Tisseel: 2 mL Maximum area to be sealed: 16 cm2 Required package size of Tisseel: 4 mL Maximum area to be sealed: 40 cm2 Required package size of Tisseel: 10 mL,,Upper table Pregnancy Risk Factor: C (up to date),,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,Upper table Pregnancy Risk Factor: C (up to date),,,,,,
IFAM,Famotidine,Famodine inj 20mg/2mL,ALIM,,適應症: Upper GI hemorrhage， Zollinger-Ellison syndrome. 副作用: Infrequently， rash; constipation， diarrhea; dry mouth， nausea. Rarely， leukopenia， thrombocytopenia; tinnitus， increased pulse & BP; reversible mental confusion. Gastrointestinal: Constipation (1.2% )， Diarrhea (1.7% ),,,Upper GI hemorrhage， Zollinger-Ellison syndrome Adult 20 mg dissolved in 20 mL physiological saline or glucose soln by slow IV. Premed Adult 20 mg dissolved in 1-1.5 mL distilled water for inj IM or dissolved in 20 mL physiological saline or glucose soln by slow IV， 1 hr before anesthetization.,無需調整劑量,藥品仿單: 哺乳及懷孕不建議使用。,需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,藥品仿單: 哺乳及懷孕不建議使用。,IM;IVD;IVP;IVPUSH;,,【D5W】可選 。【L/R】可選 。【N/S】可選 。,須以5-10 mL適當溶液稀釋後，推注時間至少 2 mins,加入適當稀釋液100mL 後，以15 ~ 30分鐘緩慢滴注,I.V. push: Inject over at least 2 minutes. (加入適當稀釋液5-10mL) Solution for infusion: Administer over 15-30 minutes. (加入適當稀釋液100mL)
EMYC6,Triamcinolone + Neomycin + Gramicidin + Nystatin,Mycomb 乳膏 16gm,TDER,,適應症: Treatment of inflammatory skin lesions where bacterial or candidal infections are suspected. 副作用: Skin atrophy; ototoxicity; nephrotoxicity. 禁忌: Tuberculous & most viral lesions of skin， especially herpes simplex， vaccinia， varicella.,,室溫,apply bid or tid.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,EXT;,,,,,
OVALD,Agomelatine,Valdoxan 25mg,CNEU,Treatment for adult patients with major depression and generalized anxiety disorder.,Concomitant use of potent CYP1A2 inhibitors. Hepatic impairment (ie， cirrhosis or active liver disease) or transaminase levels greater than 3 times ULN. Hypersensitivity to agomelatine or any component of the product..,Common: Hyperhidrosis (0.1% to <1%)， Abdominal pain (1% to <10%)， Constipation (1% to <10%)， Diarrhea (1% to <10%)， Nausea (1% to <10%)， Vomiting (1% to <10%)， Backache (1% to <10%)， Dizziness (1% to <10%)， Headache (>=10%)， Insomnia (1% to <10%)， Migraine (0.1% to <1%)， Somnolence (1% to <10%)， Anxiety (1% to <10%)， Fatigue (1% to <10%) Serious: Hepatitis (0.01% to <0.1%)， Jaundice (0.01% to <0.1%)， Liver failure (0.01% to <0.1%)， Hallucinations (0.01% to <0.1%),30℃以下,Generally， take 25mg orally before bedtime. Treatment should last at least 6 months to ensure symptom resolution. Dose adjustment: If no improvement， increase the dose to 50mg at bedtime. 1) For depression: After 2 weeks of initial treatment. 2) For generalized anxiety disorder: After 4 weeks of initial treatment.,無需調整劑量,It is not known whether agomelatine is excreted into human milk. Agomelatine and/or its metabolites were excreted in the milk of lactating rats. There were no adverse effects on offspring following oral administration of agomelatine to rats from prior to mating until weaning， with systemic exposures (plasma AUC) of 100-fold human exposure at the maximal recommended clinical dose.The effects of agomelatine on the nursing infant have not been established. If treatment with agomelatine is considered necessary， breastfeeding should be discontinued.,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,It is not known whether agomelatine is excreted into human milk. Agomelatine and/or its metabolites were excreted in the milk of lactating rats. There were no adverse effects on offspring following oral administration of agomelatine to rats from prior to mating until weaning， with systemic exposures (plasma AUC) of 100-fold human exposure at the maximal recommended clinical dose.The effects of agomelatine on the nursing infant have not been established. If treatment with agomelatine is considered necessary， breastfeeding should be discontinued.,AC;AC15;PC;PO;WM;,,,,,
ECIN,Dexamethasone + Neomycin,Cindecason oph oint 3.5gm,TOPH,,適應症: Non-infectious forms of conjunctivitis， keratitis & blepharitis， especially of allergic origin， inflammation of the anterior uvea， scleritis， episcleritis & orbital myositis. Sympathetic ophthalmia. 副作用:Glaucoma， cataract， transient blurred vision. Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin， Finding of skin healing， Impaired Endocrine metabolic: Cushing's syndrome， Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )， Raised intraocular pressure (25% ) Psychiatric: Depression， Euphoria Respiratory: Pulmonary tuberculosis 禁忌: Herpes cornea superficialis; injuries & ulcerous processes of the cornea; ocular TB; ophth mycosis; ulcerous lesions of the cornea; narrow- & open-angle glaucoma.,,室溫,Once to several times daily.,,,,盡量避免,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IANG,Isosorbide Dinitrate,Angidil inj 0.1% 10mL,CAVS,Treatment of angina.,Severe hypotension， hypovolaemia， marked anaemia， heart failure due to obstruction， raised intracranial pressure due to head trauma or cerebral haemorrhage.,Flushing， dizziness， tachycardia， throbbing headache.,25℃以下,Diluted in saline or dextrose solution to 100 mcg/mL before use. Usual adult dosage: 2-7 mg/hour by IV infusion; some patients may require up to 10 mg/hour.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IA;IVD;,,【D5W】可選 。【N/S】可選 。,,一般稀釋濃度：100 mcg/mL，一般輸注速率2-7 mg/hr，最大輸注速率10 mg/hr，給藥管路與稀釋溶液應使用「非PVC之材質」。,1. 一般稀釋濃度：50 mL Angidil 0.1 % 以適當溶液稀釋至500 mL，每mL含有100 mcg isosorbide dinitrate。 2. 稀釋時應使用玻璃或非PVC之硬塑膠材質容器的稀釋溶液。 3. 注射時建議使用聚乙烯(PE)材質的輸注套或硬塑膠材質的針筒幫浦。 4. 投藥期間應嚴密監測脈搏與血壓。
IDEP4,Valproate Sodium,Depakine 針劑 400mg,CNEU,Absence seizure， Simple and complex. Complex partial epileptic seizure. Manic bipolar I disorder.Migraine; Prophylaxis.Seizure， Multiple seizure types.,Hypersensitivity to any component of the formulation.,Cardiovascular: Peripheral edema (3% to 8% ) Dermatologic: Alopecia (6% to 24% )， Rash (6% ) Endocrine metabolic: Increased appetite (6% )， Weight increased (4% to 9% ) Gastrointestinal: Abdominal pain (9% to 23% )， Constipation (5% )， Diarrhea (12% to 23% )， Indigestion (8% to 13% )， Loss of appetite (4% to 12% )， Nausea (22% to 48% )， Vomiting (11% to 27% ) Hematologic: Ecchymosis (4% to 5% ) Musculoskeletal: Asthenia (10% to 27% )， Backache (8% ) Neurologic: Amnesia (4% to 7% )， Ataxia (8% )， Dizziness (12% to 25% )， Headache (5% to 31% )， Insomnia (9% to 15% )， Somnolence (17% to 30% )， Tremor (9% to 57% ) Ophthalmic: Amblyopia， Blurred vision， Diplopia (16% )， Nystagmus (1% to 8% ) Otic: Tinnitus (1% to 7% ) Psychiatric: Depression (4% to 5% )， Disturbance in thinking (6% )， Feeling nervous (7% to 11% )， Mood swings (6% ) Respiratory: Bronchitis (5% )， Dyspnea (5% )， Pharyngitis (8% )， Respiratory tract infection (12% to 20% )， Rhinitis (5% ) Other: Fever (2% )， Influenza (12% ),30℃以下,Seizures unable to use oral form valproic acid: Total daily IV dose should be equivalent to the total daily oral valproate dose (expressed as valproic acid) and divided every 6 hours. Administer each dose as a 60-minute infusion (rate 20 mg/minute). Start intravenous administration 4 to 6 hours after the last oral administration. The original oral dose (usually an average dose of 20 to 30 mg/kg/day) can be administered by drip for 24 hours. To achieve therapeutic levels of valproic acid quickly: initially give 15 mg/kg by a slow intravenous injection (> 5 minutes)， followed by 1 mg/kg/hour intravenous continuous infusion， and adjust the dose according to target serum level and clinical symptoms.,無需調整劑量,[仿單]valproate 分泌到乳汁中的量很低，濃度大約是母體血清濃度的 1%至 10%之間。 根據文獻和臨床經驗，若要哺乳，需考慮本品藥物安全性，特別是血液相關的疾病。 然而，懷孕期間暴露於 sodium valproate 的幼兒，可能降低語言能力，建議治療時不要授乳。,無需調整劑量,盡量避免,Human data suggest low risk,[仿單]懷孕期間禁止使用 valproate 治療躁鬱症。 除非癲癇治療沒有合適的替代藥物，否則懷孕期間禁止使用 valproate 治療癲癇。 除非能確實執行避孕計畫，否則具生育能力的婦女禁用 valproate。 使用本品可能會導致重大的先天性畸形，特別是神經管畸形（如：脊柱裂， spina bifida）， 且可能會導致胎兒智商下降，故本品應僅限用於無法以其他藥物控制症狀， 或有其它原因無法使用其他藥物治療之孕婦。 考量使用本品可能會有使孩童智商降低、發生神經管缺陷及其他嚴重先天性畸形之風險， 且該等風險可能發生於懷孕早期，故除非必要使用，否則不應使用於具生育能力或有懷孕可能之婦女。 避孕計畫： Valproate有高度的致畸性，且胎兒在子宮中曝露於valproate有導致先天性畸形和神經發育缺陷的高 度風險。 本品禁用於以下情況： 治療癲癇 • 在懷孕狀態下，除非沒有適合的替代療法 • 具有生育能力的婦女，除非能確實履行避孕計畫 治療躁鬱症 • 在懷孕狀態下 • 具有生育能力的婦女，除非能確實履行避孕計畫 避孕計畫條件： 處方醫師應確保 • 依病人個別狀況進行評估並與之討論。這是為了保證病人能確實配合並了解治療選擇及其風險， 以及為了降低風險而採取的措施。 • 所有女性病人都應針對懷孕的可能性進行評估。 • 病人應了解並認知先天性畸形和神經發育缺陷的風險，包括胎兒在子宮中曝露於valproate的風險程度。 • 病人應了解，治療前及治療期間(必要時)必須進行懷孕檢測。 • 應告訴病人必須避孕，且病人在整個valproate治療期間必須不間斷地採取有效的避孕措施 • 病人應了解，讓有癲癇或躁鬱症治療經驗的專科醫師定期(至少每年一次)評估治療結果有其必要性。 • 女性病人應了解，當其計畫懷孕時，應盡快諮詢醫師，以確保能及時討論並在懷孕前及停止避孕前更換治療藥物。 • 病人應了解，當發現懷孕時應緊急通知醫師。 • 病人已收到病人用藥指南。 • 女性病人已確認了解，使用valproate之相關風險和應注意事項 (年度風險確認表)。 這些條件亦適用於目前無性行為的婦女，除非處方醫師充分之理由認為其無懷孕風險。 藥師或其他醫療專業人員應確保 • 每次調配valproate時都有交付病人卡，讓病人了解其內容。 • 告知病人當計畫懷孕或疑似懷孕時，valproate不應擅自停藥，應立刻連絡專科醫師。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]valproate 分泌到乳汁中的量很低，濃度大約是母體血清濃度的 1%至 10%之間。 根據文獻和臨床經驗，若要哺乳，需考慮本品藥物安全性，特別是血液相關的疾病。 然而，懷孕期間暴露於 sodium valproate 的幼兒，可能降低語言能力，建議治療時不要授乳。,IVD;,將4毫升注射用水注入小瓶中，藥粉溶解後再取出所需劑量加入點滴中。,【D5W】可選 。【N/S】可選 。,,注射速率 < 20mg/min;先15mg/kg slow IV >5mins， 再1mg/kg/hr,使用前應先調劑，將4毫升注射用水注入小瓶中，藥粉溶解後再取出所需劑量加入點滴中。
IKCL5,Potassium Chloride,10mEq KCl in 5% Glucose 250mL,NUTR,,適應症: Hypokalaemia. 副作用: Hyperkalemia， pain or phlebitis at injection site. 禁忌: Hyperkalemia.,,2-8度C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr， with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
IFYT,Etoposide,Fytosid inj 100mg/5mL,RACA,Small cell carcinoma of lung， In combination with other approved chemotherapeutic agents as first line， Testicular cancer， In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical， chemotherapeutic， and radiotherapeutic therapy,Hypersensitivity to etoposide or any component of the formulation. Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment,Alopecia， Shivering， Diarrhea， Inflammatory disease of mucous membrane， Loss of appetite， Nausea， Vomiting， Asthenia， Fever， Malaise,25℃以下避光,[Testicular cancer (combination chemotherapy)] Usual dose ranges from 50-100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1， 3 and 5. [Small cell lung cancer (combination chemotherapy)] Usual dose ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity.,無需調整劑量,,需調整劑量,盡量避免,Human (and animal) data suggest risk,,Contraindicated 哺乳期使用禁忌,,IVD;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,給藥濃度 0.2-0.4mg/ml (Max 0.4mg/ml) ; 建議以30 ~ 60分鐘緩慢滴注,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 配製好的輸注溶液濃度在 0.2 - 0.4 mg/mL，使用前應再次目視檢查是否有顆粒沉澱或變色。 3. 輸注過快可能發生低血壓。 4. 監測CBC、肝腎功能。
OALGI,Alginic Acid+Colloidal Al(OH)3+MgHCO3,Algitab chewable,ALIM,Reflux esophagitis， hiatal hernia， heartburn， peptic ulcer， gastric hyperacidity.,Hypersensitivity to any component of the formulation.,Diarrhea， constipation.,置於25℃陰涼處所，避免陽光直射,usual dose: 2 TAB TID. (Each tablet contains Sodium 0.4mEq),無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;P1;P2;P3;P4;PC;PO;WM;,,,,,
ICAL,Calcitriol,Calcijex inj 2mcg/1mL,META,,適應症： Management of hypocalcemia in patients undergoing chronic renal dialysis. 副作用： Weakness， headache， somnolence; nausea， vomiting， dry mouth， constipation; muscle pain， bone pain & metallic taste. 禁忌： Hypercalcemia or evidence of vit D toxicity.,,室溫,Initially 0.5 mcg (0.01 mcg/kg) administered 3 times wkly， approx every other day. Dose may be increased by 0.25 ~ 0.5 mcg at 2 ~ 4 wk intervals.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
I5FU,5-Fluorouracil,5-FU inj 1000mg/20mL,RACA,,適應症: Palliative management of carcinoma of the colon， rectum， breast， stomach & pancreas. 副作用: Stomatitis， esophagopharyngitis， diarrhea， anorexia， nausea， vomiting， enteritis， cramps， abdominal pain & ulceration， glossitis， pharyngitis， leukopenia， alopecia， dermatitis， ocular irritation， central neurotoxicity (acute cerebellar syndrome)， myocardial ischemia & angina. 禁忌: Patients in a poor nutritional state; with depressed bone marrow function or potentially serious infections.,,RT,IV inj Initial dosage 12 mg/kg once daily (to a max of 800 mg daily) for 4 days. If no toxicity is observed， this may be followed by 6 mg/kg on the 6th， 8th， 10th & 12th days， unless toxicity occurs. Poor risk patients or those in a poor nutritional state 6 mg/kg/day (to a max of 400 mg daily) for 3 days. If no toxicity is observed， 3 mg/kg is given on the 5th， 7th & 9th days， unless toxicity occurs. Maintenance therapy Repeat the dosage of the 1st course every 30 days after the last day of the previous course of treatment. Alternatively， administer a maintenance dose of 10-15 mg/kg/week (to a max of 1 g/week) as a single dose. IV infusion 15 mg/kg/day (to a max of 1 g daily) being infused in 500 mL of 5% dextrose or 0.9% NaCl over 4 hours & repeated on successive days until toxicity occurs or a total of 12-15 g has been given. Continuous infusion may also be used. The course may be repeated after 4-6 weeks.,,,,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、血糖變化 (DM病人)。
ICAG,Calcium gluconate,Calglon inj 10% 10mL,NUTR,Ca deficiency.,Ventricular fibrillation; hypercalcemia; concomitant use of I.V. calcium gluconate and ceftriaxone in neonates (risk of precipitation of calcium-ceftriaxone),Cardiovascular (with rapid I.V. injection): Arrhythmia， bradycardia， cardiac arrest， hypotension， syncope， vasodilation Central nervous system: Sense of oppression (with rapid I.V. injection) Endocrine & metabolic: Hypercalcemia Gastrointestinal: Chalky taste Neuromuscular & skeletal: Tingling sensation (with rapid I.V. injection) Miscellaneous: Heat waves (with rapid I.V. injection),30℃以下,Each mL contains: 100 mg calcium gluconate= 9.3 mg (0.465 mEq) of elemental calcium. Adult: The usual dose is 10 mL of Calcium Gluconate 10 % each time a day or every other day. Childen patients: 2~5 mL of Calcium Gluconate 10 % each time. [UpToDate 20210731] Cardiac arrest or cardiotoxicity in the presence of hyperkalemia， hypocalcemia， or hypermagnesemia: IV: 1.5 to 3 g over 2 to 5 minutes (Vanden Hoek 2010). Hypocalcemia: IV: Mild (ionized calcium: 4 to 5 mg/dL [1 to 1.2 mmol/L]): 1 to 2 g over 2 hours; asymptomatic patients may be given oral calcium (Ariyan 2004; French 2012). Moderate to severe (without seizure or tetany; ionized calcium: <4 mg/dL [<1 mmol/L]): 4 g over 4 hours (French 2012). Severe symptomatic (eg， seizure， tetany): 1 to 2 g over 10 minutes; repeat every 60 minutes until symptoms resolve (French 2012).,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;IVP;IVPUSH;PO;,,【D10W】可選 。【D5NS】可選 。【D5W】可選 。【N/S】可選 。,Slow IV < 1.8mEq/min (< 2 mL/min)，推注時間至少 3-5 分鐘 ; 在cardiac arrest 情況下 over 10-20 seconds,稀釋至50 mg/mL後，以120-240 mg/kg (0.6-1.2mEq calcium/kg) 輸注 > 1 hour,1. 鈣含量0.46 mEq/mL 2. I.V.: infuse slow IVP over 3-5 minutes or at a maximum rate of 50-100 mg calcium gluconate/minute; in situations of cardiac arrest， calcium gluconate may be administered over 10-20 seconds. 3. I.V. infusion: Dilute to 50 mg/mL and infuse at 120-240 mg/kg (0.6-1.2mEq calcium/kg) over 1 hour 4.不可 I.M. 或SubQ 給藥，IV注射不可外滲，以免發生嚴重組織壞死或脫屑。 5.若藥液內出現結晶沉澱，建議可以施壓製品容器，檢視製品是否漏液，出現漏液時，不應使用。若無漏液現象，可能因溫度變化或是因運送過程中，瓶內產生的氣泡，構成晶核，進而析出結晶沉澱。此時可置於65℃水浴內進行溫熱，使結晶溶解，藥液澄清後，方可安心使用。(20211126廠商建議)
ICAR1,Carboplatin,Carboplatin inj 150mg/15mL,RACA,,適應症: Treatment of advanced ovarian carcinoma in combination with other chemotherapeutic agents. Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy， including patients who have previously been treated with cisplatin. Metastatic small cell carcinoma of the lung. 副作用: Myelosuppression especially thrombocytopenia， leukopenia; nausea & vomiting， abdominal pain， diarrhea， constipation; nephrotoxicity; neurotoxicity including paresthesia & decreased deep tendon reflexes; transient visual disturbances， ototoxicity manifesting as tinnitus; abnormal liver function tests; hypersensitivity reactions. 禁忌: Severe bone marrow suppression or significant bleeding; severe pre-existing renal impairment (creatinine clearance <=20 mL/min).,,室溫,Advanced ovarian carcinoma Initial treatment: 300 mg/m2 IV on day 1 at 4-week intervals for 6 cycles. Secondary treatment: 360 mg/m2 IV on day 1 at 4-week intervals. Metastatic small cell carcinoma of the lung 400 mg/m2 IV over 15-60 mins at 4-week intervals.,,,,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,室溫，配製後安定性室溫8小時
ECOL2,Mesalazine,Colasa enema 2gm/100mL,ALIM,Treatment of active mild to moderate distal ulcerative colitis， proctosigmoiditis， or proctitis,Hypersensitivity to mesalazine or any component in the preparation. History of hypersensitivity to salicylate preparations. Severe liver impairment. Severe renal impairment (GFR less than 30 ml/minute/1.73m2).,Nausea， diarrhea， abdominal pain， headache,25℃以下儲存,Adults: 2gm-4gm once at night. Children: Dose is not determined.,需調整劑量,upper table (According to up to date of Pregnancy Risk Factor),需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,upper table (According to up to date of Pregnancy Risk Factor),RECT;,,,,,
OBUSR,Buspirone,Busron 10mg,CNEU,Anxiety.,Epilepsy， severe hepatic or renal impairment， pregnancy & lactation. Breast feeding.,Dizziness， nausea， headache， nervousness， lightheadedness， excitement; rarely tachycardia， palpitations， chest pain， drowsiness， tinnitus. Gastrointestinal: Nausea (3%) Neurologic: Asthenia (2%)， Confusion (2%)， Dizziness (9%)， Excitement (2%)， Headache (3%)， Numbness (2%) Ophthalmic: Blurred vision (2%) Psychiatric: Feeling angry (2%)， Feeling nervous (4%)， Hostile behavior (2%),室溫下儲存，避免暴露於高於40℃之下。避免陽光直射,Initial dose:15mg/day(5mg TID). If needed， increased by 5mg/day every 2~3 days. General dose:20-30mg/day in divided doses. maximum dose: 60mg/day.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,Limited Human Data—Animal Data Suggest Low Risk,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
IRL,NaCl + KCl + Calcium Chloride + Lactose,Ringer Lactate 500mL,MSIV,為電解質補充液(A002801277),,,室溫,Each time 500-1000 mL or 20-30 mL/kg IV infusion. [UpToDate 20210731] Irrigation: Dose dependent on area to be irrigated and the procedure. Septic shock or sepsis-induced hypoperfusion， fluid resuscitation (off-label use): IV: Minimum of 30 mL/kg to be given within the first 1 hour of identification of sepsis for initial resuscitation; following initial resuscitation， additional fluid administration guided by frequent reassessment of hemodynamic status.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
ITT1,Electrolytes + Water,台大 No.1 500mL,MSIV,Supplement of water、 electrolytes 、 nutrition,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30℃以下,Central vein or peripheral vein infusion， as needed. Taita No.1: Na 25mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 20mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 38g/L， 500mL/Bot， 300mOsm/L. Taita No.2: Na 40mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 26mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 33g/L， 500mL/Bot， 287mOsm/L. Taita No.3: Na 75mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 61mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 20g/L， 500mL/Bot， 285mOsm/L. Taita No.4: Na 110mEq/L， K 20mEq/L， Mg 0mEq/L， Cl 102mEq/L， Acetate 16mEq/L， Phosphate 12mM/L， Glucose 8g/L， 500mL/Bot， 300mOsm/L. Taita No.5: Na 36mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 17mEq/L， Acetate 28mEq/L， Phosphate 12mM/L， Glucose 100g/L， 400mL/Bot， 669mOsm/L.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,特點及適應症 Taita No.1: Na、Cl 是各台大電解質輸液中含量最低；小兒用維持液、電解質、水份、養份補充 Taita No.2: 成分與Taita No.1相似但Na、Cl較多;熱量及K含量較低，可作為小兒或成人用維持液 Taita No.3: NaCl含量似0.45 %N/S，可用於等張性脫水、糖尿病性酸中毒 Taita No.4: Na、K、Cl是各台大電解質輸液中含量最高，可用於低張性脫水、低磷血症 Taita No.5: 台大電解質輸液系列中，含Acetate及熱量最高，可用於高熱量電解質補充液、低磷血症
OPYR,Pyridoxine,Pyridoxine (B6) 50mg,NUTR,Prevention & treatment of vit B6 deficiency.,Hypersensitivity.,Severe peripheral neuropathies (long-term administration of large doses).,室溫且避光保存,50-100 mg/day. [Micromedex 20210731] Adverse reaction to drug - Vitamin B6 deficiency: (deficiency due to isoniazid) 100 mg/day IV or IM for 3 weeks， followed by 30 mg/day ORAL maintenance dose. [UpToDate 20210731] Nausea and vomiting of pregnancy (off-label use): Oral: 10 to 25 mg 3 to 4 times a day. May be given alone or in combination with doxylamine. Adjust dose based on severity of symptoms (ACOG 189 2018).,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OEND,Cyclophosphamide,Endoxan 50mg,RACA,Treatment of acute lymphoblastic leukemia (ALL)， acute myelocytic leukemia (AML)， breast cancer， chronic lymphocytic leukemia (CLL)， chronic myeloid leukemia (CML)， Hodgkin lymphoma， mycosis fungoides， multiple myeloma， neuroblastoma， non-Hodgkin lymphomas (including Burkitt lymphoma)， ovarian adenocarcinoma， retinoblastoma， and nephrotic syndrome.,Hypersensitivity to cyclophosphamide or its metabolites， urinary outflow obstructions， severe myelosuppression， severe renal or hepatic impairment， active infection (especially varicella zoster)， severe immunosuppression.,Nausea， vomiting; bone marrow depression， leukopenia; alopecia; mucosal ulceration; pigmentation; interstitial pulmonary fibrosis; fluid retention,25℃以下,For continuous therapy 1-4 tablets (50-200 mg) daily; if necessary， more tablets may be taken. The dose recommendations given mainly apply to the treatment with cyclophosphamide as a monotherapy. In combination with other cytostatics of similar toxicity， a dose reduction or extension of the therapy-free intervals may be necessary.,需調整劑量,,需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
IPEDE,Ibuprofen,Pedea inj 10mg/2mL (專案進口),CNEU,Treatment of Patent Ductus Arteriosus (PDA) in premature neonates (>34 weeks' gestational age),for Pedea: untreated infection， bleeding， thrombocytopenia; coagulation defects， necrotizing enterocolitis， renal impairment， congenital heart disease if patency of the ductus arteriosus is necessary for pulmonary or systemic blood flow (e.g.， pulmonary atresia， severe tetralogy of Fallot， severe coarctation of the aorta).,For Pedea sepsis， anemia， bleeding， apnea， adverse GI effects， renal impairment， respiratory tract infection， dermatologic effects， hypoglycemia， hypocalcemia， respiratory failure. Cardiovascular: Hypotension (intravenous， up to 10% ) Dermatologic: Rash (oral， 3% to 9% ) Endocrine metabolic: Hypernatremia (intravenous， up to 10% )， Hypoalbuminemia (intravenous， 3% to 10% )， Hypoproteinemia (intravenous， up to 13% )， Serum lactate dehydrogenase level elevated (intravenous， 3% to 10% ) Gastrointestinal: Flatulence (injection， 7% to 16% )， Heartburn (oral， 3% to 9% )， Nausea (oral， 3% to 9%; intravenous， 53% to 57% )， Vomiting (oral， 1% to 3%; intravenous， 15% to 22% ) Hematologic: Thrombocytosis (intravenous， 3% to 10% ) Immunologic: Bacteremia (injection， 13% ) Neurologic: Dizziness (oral， 3% to 9%; intravenous 4% to 6% )， Headache (oral， 1% to 3%; intravenous， 9% to 11% ) Renal: Serum blood urea nitrogen raised (intravenous， up to 10% )， Urinary retention (intravenous， 3% to 5% ) Respiratory: Bacterial pneumonia (intravenous， 3% to 10% ),仿單無特別指示,Micromedex: Patent ductus arteriosus (PDA): 10 mg/kg/dose IV followed by 5 mg/kg at 24 and 48 hours after treatment initiation.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,Compatible 哺乳時可使用,,IVD;,,【D5W】可選 。【N/S】可選 。,,輸注時間至少 15分鐘,Pedea should be administered as a short infusion over 15 minutes， preferably undiluted. To facilitate the administration an infusion pump may be used.
OBIO3,Calcium + Cholecalciferol,Bio-Cal plus 450mg/330IU,NUTR,Osteoporosis， Ca deficiency.,Hypercalcemia.,itch， rash， Nausea， vomiting， diarrhea， constipation,25℃以下,2-3 TAB daily. 1 TAB contains: Tribasic calcium phosphate equivalent to calcium 450 mg， and Cholecalciferol 330 IU.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PC;PO;,,,,,1. 本品一顆錠劑含量Tribasic calcium phosphate 1203mg + Cholecalciferol 330IU 2. Tribasic calcium phosphate 1203mg= Calcium 450mg
OFOSP,Alendronate + Colecalciferol,Fosamax Plus 70mg/5600IU,META,,適應症:Treatment of osteoporosis in postmenopausal women to increase bone mass & reduce incidence of fractures， including those of the hip & spine (vertebral compression fractures). Treatment of osteoporosis in men to increase bone mass. 副作用: Nausea， vomiting， black &/or bloody stool， oesophagitis， oesophageal ulcer， oesophageal erosions. 禁忌: Hypersensitivity. Abnormalities of the oesophagus eg stricture or achalasia. Inability to stand or sit upright for at least 30 min. Hypocalcaemia.,,室溫,1 tab once weekly.,無需調整劑量,,需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,服藥後，上半身需直立30分鐘以上。
ICERE,Cerebrolysin concentrate,Cerebrolysin 215.2mg/mL， 10mL,NUTR,Amino acid supplement for disturbances of protein digestion & malabsorption due to disorders， heavy protein loss due to wounds， burns， fractures， purulency or operation..,Severe renal impairment,Hypersensitivity reactions.,無特別指示,Initial IV/IM 2 mL/day， then extended interval to 2mL in 2-3 days. High dose: 5-40 mL/day slow IV or IV infusion. A treatment cycles needs 10-15 AMP， may take a series of cycles.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IM;IVD;,,【D5W】可選 。【N/S】可選 。,,1.建議以60 ~ 120分鐘緩慢滴注 2.10ml - 50ml Cerebrolysin diluted to at least 100ml total volume with Saline， Ringer solution or 5% glucose solution. Infuse within 15 minutes. [202004查詢廠商國外官網https://www.cerebrolysin.com/en/cerebrolysin/administration.html],
IFOLI,Folinate,Folina 針劑100mg/10mL,ZADT,Megaloblastic anemia due to folic acid deficiency， Intoxication & side-effects of folic acid antagonists， associated with high-dose methotrexate.,Hypersensitivity. Pernicious or other anaemia due to vit B12 deficiency.,Dermatologic: Rash， pruritus， erythema， urticaria Hematologic: Thrombocytosis Respiratory: Wheezing Miscellaneous: Allergic reactions， anaphylactoid reactions,2-8℃避光避免冷凍,Methotrexate-rescue (high-dose): 15 mg (~10 mg/m2) IV; start 24 hours after beginning methotrexate (12-15 mg/m2) infused > 4 hours; continue every 6 hours for 10 doses， until methotrexate level is <0.05 micromolar. Monitor levels of serum creatinine and methotrexate once daily. Methotrexate overdose (inadvertent) (begin as soon as possible after overdose): Oral， IM， IV: 10 mg/m2 Q6H until the methotrexate level is <0.01 micromolar. If serum creatinine is increased >50% above baseline 24 hours after methotrexate administration， if 24 hours methotrexate level is >5 micromolar， or if 48 hours methotrexate level is >0.9 micromolar， increase leucovorin dose to 100 mg/m2 IV Q3H until the methotrexate level is <0.01 micromolar. Megaloblastic anemia， folate-deficient: 1 mg IM/IV QD. Colorectal cancer， advanced: 200 mg/m2/day for 5 days every 4 weeks in combination with fluorouracil.,無需調整劑量,,需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,,【D5W】可選 。【N/S】可選 。,< 160mg/min,IV infusion over 15 minutes to 2 hours.,1. Due to calcium content， do not administer IV solutions at a rate >160 mg/minute. 2. Should be administered IM， IV push， or IV infusion (15 minutes to 2 hours). 3. Droperidol與本藥混合在一起或共用Y-site會出現沉澱，不可共用。
IMARS,Bupivacaine,Marcaine Spinal 0.5% Heavy inj 4mL,ZANE,Spinal anaesth for surgery.,Acute active disease of the CNS， such as meningitis， tumours， poliomyelitis & cranial haemorrhage， active TB or metastatic lesions in the vertebral column. Septicaemia. Pernicious anaemia with subacute combined degeneration of the spinal cord. Pyrogenic infection of the skin at or adjacent to the site of puncture. Cardiogenic or hypovolaemic shock. Coagulation disorders or ongoing anticoagulant treatment.,Hypotension， bradycardia， post-spinal headache. Rarely， high or total spinal blockade resulting in CV & respiratory depression， neurological complications.,2-25℃避免冷凍,Marcaine Spinal 0.5% Heavy contains bupivacaine 5mg/mL， 4mL/ampoule (with glucose monohydrate to adjust a specific gravity of 1.026 at 20°C). Intrapinal injection. Spinal injections should only be made after the subarachnoid space has been clearly identified by lumbar puncture. No drug should be injected until clear cerebrospinal fluid (CSF) is seen to escape from the spinal needle or it is detected by aspiration. The dose required for the most effective blocking: For lower limbs， urinary tract and perineum surgery (patient in the sitting position): 7.5-15 mg inject into L3/4/5. For lower abdomen surgery (patient in the supine horizontal position): 15-20 mg and inject into L2/3/4.,無需調整劑量,Bupivacaine [8],無需調整劑量,除非治療上需要,Uknown 沒有資料,Bupivacaine [18],Unknown 沒有資料,Bupivacaine [8],IT;,,,,,局部麻醉劑，限由醫師使用。
ODOF,Mephenoxalone,Doflex 200mg,CNEU,Muscle spasms.,Porphyria; pregnancy and lactation,Drowsiness; GI disturbances， paraesthesia， weakness; headache， dizziness， ataxia， paradoxical excitement; visual disturbances; arrhythmias， hypotension; hypersensitivity reactions; blood dyscrasias.,室溫藥品，仿單無特別指示儲存溫度條件,Adult: 200-400 mg TID. Maximum: 2000mg daily.Children 6-15 years: 100mg TID.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
ECLOB,Clobetasol propionate,Clobex Shampoo 60mL， 0.05%,TDER,Treatment of moderate to severe forms of scalp psoriasis in patient ≧18 yr.,Hypersensitivity to clobetasol or any ingredient in the preparation (gel， cream， ointment),Burning/stinging， pruritus， edema， folliculitis， acne， dry skin， irritant dermatitis， alopecia， urticaria， skin atrophy & telangiectasia.,30℃以下儲存,Scalp psoriasis (Moderate to Severe) (Shampoo) Apply topically onto dry scalp once daily in a thin film to affected areas only; leave in place 15 minutes before lathering and rinsing; maximum 50 mL/week for 2 consecutive weeks,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,EXT;SKIN;TOPI;,,,,,
IKAD1,Trastuzumab Emtansine,Kadcyla inj 100mg,RACA,Metastatic breast cancer， HER2 overexpression， monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.,Specific contraindications have not been determined.,Common ■Gastrointestinal: Constipation (26.5% )， Nausea (39.8% ) ■Hematologic: Thrombocytopenia， All grades (31.2% ) ■Hepatic: Increased liver enzymes， All grades (28.8% ) ■Musculoskeletal: Musculoskeletal pain (36.1% ) ■Neurologic: Headache (28.2% ) ■Other: Fatigue (36.3% ) Serious ■Cardiovascular: Left ventricular cardiac dysfunction (1.8% ) ■Dermatologic: Injection site extravasation ■Hematologic: Anemia， Grade 3 and 4 (4.1% )， Neutropenia， Grade 3 and 4 (2% )， Thrombocytopenia， Grade 3 and 4 (14.5% ) ■Hepatic: Hepatotoxicity， Increased liver enzymes， Grades 3 and 4 (8% )， Injury of liver ■Immunologic: Anaphylactoid reaction ■Neurologic: Peripheral nerve disease， Grade 3 or 4 (2.2% ) ■Respiratory: Dyspnea (12% )， Interstitial lung disease， Pneumonitis (0.8% to 1.2% ),2-8℃,3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever， chills， or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.,無需調整劑量,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded， a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,無需調整劑量,盡量避免,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded， a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,IVD;,,,,,1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。請使用0.2-0.22微米、不吸附蛋白質的管線內 polyethersulfone (PES)過濾器。 3. 溶液配置後應立即使用，冷藏於2-8℃最多儲存24小時。 4. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 5. 監測CBC、肝腎功能。
OFER,Ferrous Gluconate + Vit B1 + Vit C,Ferrous gluco-B 300/10/30,NUTR,Treatment & prevention of iron deficiency anemia， vit B1 & C deficiency.,Hypersensitivity to any component of the formulation.,Nausea & GI irritation， tachycardia(5%),室溫藥品，仿單無特別指示儲存溫度條件,1 TAB contains：Ferrous gluconte 300mg， Vitamin B1 10mg， Vitamin C 30mg. PO dose: 1 TAB TID.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PC;PO;,,,,,
OCOF1,Warfarin,Cofarin 1mg,HEMT,Treatment & prophylaxis of thromboembolic disorders.,Severe hepatic or renal disease， actual or potential haemorrhagic conditions， severe hypertension， endocarditis， ulceration of the GI & urinary tract， visceral carcinoma， endocarditis， neurosurgery， recent surgery on the eye， brain or spinal cord. Pregnancy.,Alopecia， skin rashes of various kinds， hemorrhagic skin necrosis. Cardiovascular: Cholesterol embolus syndrome Dermatologic: Tissue necrosis Hematologic: Hemorrhage Immunologic: Hypersensitivity reaction (infrequent ) Ophthalmic: Intraocular hemorrhage (5% to 11% ),室溫藥品，仿單無特別指示儲存溫度條件,Initial dose as 2-5mg once daily， depends on patient's PT/INR. Maintenance dose would be 2-10mg， adjusted by patient's PT/INR. Duration of the treatment should be kept until the risks have been excluded.,需調整劑量,WHO:Compatible with breast-feeding.,無需調整劑量,不可使用,Contraindicated – 1st trimester,,Compatible 哺乳時可使用,WHO:Compatible with breast-feeding.,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥與feeding nutrition有交互作用而影響吸收，可磨粉但需與nutrition間隔1小時，並密切監測INR值。
IBFL,Amino Acid + Glucose+ Vit B1,Bfluid inj 1000mL,NUTR,Provision of electrolytes， glucose & amino acids in inadequate oral intake before & after surgery.,Hepatic coma or risk of hepatic coma; severe renal disorder or azotemia; CHF; severe acidosis; abnormal electrolyte metabolism， hyperpotassemia， hyperphosphatemia， hypermagnesemia， hypercalcemia; reduced urine output; abnormal amino acid metabolism,Rash， chest discomfort， palpitation， cerebral， pulmonary & peripheral edema， hyperpotassemia， acidosis， water intoxication， vascular pain， phlebitis， chills， fever， feeling of warmth， headache.,25℃以下避光,Adult Usual dose: 500 mL infused via peripheral vein. Maximum dose: 2500 mL/day. Infusion rate: 500 mL/120 min， slowed in elderly & critically ill patients. The dosage should be adjusted according to the patient’s condition， body weight， and age.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,IVD: 150mL/60min，每日最大投與劑量 2500mL,1. 每日最大投與劑量 2500mL 2. 使用前，用雙手壓上室或下室以打通兩室間的連結處，使二室溶液完全混合。 3.成人標準輸注速度為60分鐘內注射150mL(廠商建議)。老人及重症患者應減緩輸注速度。 4.廠商建議可在外加K量 周邊靜脈:可再外加20mEq; 中央靜脈可再外加60mEq。 5.若有出現結晶請與廠商更換。
ODOR4,Dexamethasone,Dorison 4mg,HM,Conditions where the anti-inflammatory and immunosuppressive effects of the corticosteroids are desirable， especially for intensive treatment during shorter periods.,Systemic fungal infection， hypersensitivity. Administration of live virus vaccine， unstable or infected joint， diagnosed sepsis.,Fluid and electrolyte disturbances. CV， musculoskeletal， GI， dermatologic， neurologic， endocrine， ophth and metabolic effects. Thromboembolism， psychic disturbances.,室溫15-30℃避光，緊密容器儲存,Parkinson's disease: Adult: Monotherapy， 100 mg orally twice daily; may titrate up to 400 mg/day in divided doses. During a serious related disease or receiving high-dose anti-Parkinson's disease treatment， the initial dose of this agent is 100 mg once a day， After 1-7 weeks， if necessary， may titrate up to 100 mg twice a day; and additionally up to 400 mg/day in divided doses. Initiating levodopa and amantadine concurrently， hold amantadine at 100 mg once or twice daily while gradually increasing levodopa. Prophylaxis or treatment of Influenza A symptoms: (Due to high resistance rates， amantadine is no longer recommended by the CDC for the treatment or prophylaxis of influenza A.) Adult: 100-200mg/day. Children > 10 years old or > 45 kg: 100mg BID. Children > 5 years old: 100mg QD.,無需調整劑量,[仿單] 本劑會分泌於乳液，授乳婦使用時應注意.,需調整劑量,,,[仿單] 懷孕禁止使用,,[仿單] 本劑會分泌於乳液，授乳婦使用時應注意.,AC;AC15;PC;PO;WM;,,,,,
OVEP,Etoposide,Vepesid 50mg,RACA,,適應症:Small cell carcinoma of lung， In combination with other approved chemotherapeutic agents as first line， Testicular cancer， In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical， chemotherapeutic， and radiotherapeutic therapy 副作用:Alopecia， Shivering， Diarrhea， Inflammatory disease of mucous membrane， Loss of appetite， Nausea， Vomiting， Asthenia， Fever， Malaise 禁忌:Hypersensitivity to etoposide or any component of the formulation. Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment,,室溫,Non-Hodgkin lymphoma (in combination with other agents)， nonsmall cell lung cancer (alone or in combination)， small cell lung cancer (first-line in combination; second-line alone or in combination)， testicular cancer (in combination; oral therapy for refractory disease): Oral: 100-200 mg/m2/day for 5 days; administer daily doses >200 mg in 2 divided doses.,需調整劑量,,需調整劑量,盡量避免,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,
IDRO,Droperidol,Dropel inj 2.5mg/1mL,CNEU,Management of nausea & vomiting following surgical or diagnostic procedures.,Pre-existing CNS depression or coma， parkinsonism; known or suspected QT prolongation， including congenital long QT syndrome. Hypokalemia or hypomagnesiemia. Bradycardia.,Sedation， drowsiness， weight gain， dry mouth， constipation， difficulty with micturition， blurred vision， mydriasis， restlessness， anxiety， extrapyramidal symptoms， acute dystonia， pseudoparkinsonism， akathisia， tardive dyskinesia， seizure， impaired body temperature regulation， prolongation of the QT interval， gynecomastia， orthostatic hypotension， tachycardia， arrhythmia.,30℃以下避免冷凍,Nausea and vomiting， Associated with surgical or diagnostic procedures; Prophylaxis: Adult: 2.5 mg IM/IV， followed by additional doses of 1.25 mg if potential benefit outweighs potential risk. Children 2-12 years old: maximum initial dose: 0.1 mg/kg IM/IV， additional doses should be administered with caution and if pot.ential benefit outweighs potential risk. Psychosis: 2.5-15 mg IV. Maximum single dose: 10 mg IV. Second dose may be given at 4-6 hr interval IM/IV.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;IVD;IVP;IVPUSH;,,,IV push administration should be slow.,,緩慢注射，成人最大初始劑量2.5mg;小孩(2-12歲)最大初始劑量0.1mg/kg
IKCL7,Potassium Chloride,20mEq KCl in D5NS 500mL,NUTR,,適應症: Hypokalaemia. 副作用: Hyperkalemia， pain or phlebitis at injection site. 禁忌: Hyperkalemia.,,2-8度C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr， with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
OLYR,Pregabalin,Lyrica 75mg,CNEU,Diabetic peripheral neuropathy - neuropathic pain， fibromyalgia， neuropathic pain - spinal cord injury， partial seizure – adjunct， postherpetic neuralgia.,Hypersensitivity to pregabalin or any other component of the product.,(Common) Cardiovascular: Peripheral edema (5% to 12% ) Endocrine metabolic: Increased appetite (5% )， Weight gain (3.3% to 12% ) Gastrointestinal: Constipation (4% to 8.2% )， Xerostomia (2.3% to 11% ) Neurologic: Asthenia (5% to 10% )， Ataxia (3% to 15% )， Dizziness (9.1% to 42.7% )， Headache (5.6% to 9.3% )， Incoordination (2% to 10.1% )， Somnolence (10.2% to 35.7% )， Tremor (1% to 11.2% ) Ophthalmic: Blurred vision (3.4% to 10.1% )， Diplopia (2% to 9% ) Psychiatric: Disturbance in thinking (2% to 8% )， Euphoria (2% to 6% ) Respiratory: Nasopharyngitis (8.2% ) Other: Fatigue (7% to 11% ) (Serious) Hepatic: Jaundice Immunologic: Hypersensitivity reaction Musculoskeletal: Increased creatine kinase level (1.5% to 2.7% ) Psychiatric: Suicidal thoughts Other: Angioedema,25℃以下,Diabetic peripheral neuropathy - neuropathic pain: initial， 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (maximum 300 mg/day). Fibromyalgia: initial， 75 mg twice a day (150 mg/day)， may increase to 150 mg twice a day (300 mg/day) within 1 week and to 225 mg twice a day (maximum 450 mg/day). Neuropathic pain - spinal cord injury: initial， 75 mg two times a day; may increase to 150 mg two times a day within 1 week; may further increase to 300 mg two times a day for insufficient pain relief after 2 to 3 weeks of treatment. Partial seizure - adjunct: initial， no greater than 75 mg two times a day or 50 mg three times a day (150 mg/day) and increased to a maximum dose of 600 mg/day in divided doses (either two or three times a day) based on response and tolerability. Postherpetic neuralgia: initial， 75 mg two times a day or 50 mg three times a day; maintenance， 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day)， in patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and are tolerating pregabalin， may increase dosage up to 300 mg two times a day， or 200 mg three times a day (600 mg/day). Safety and efficacy have not been established in pediatric patients.,無需調整劑量,Micromedex Lactation Rating: Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex Lactation Rating: Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,AC;AC15;PC;PO;WM;,,,,,
EONB,Indacaterol,Onbrez Breezhaler 150mcg,ERSP,,適應症: Manitenance treatment of airflow obstruction in patients wih chronic obstructive pulmonary disease. 副作用: (Common) Headache (5.1%)， cough (6.5% to 24% )， nasopharyngitis (5.3% ) (Serious) Hypersensitivity reaction， paradoxical bronchospasm (Overdose) palpitation， headace， fatigue， hypokalemia， hyperglycemia 禁忌: Hypersensitivity to indacaterol or any of other components of Onbrez Breezhaler,,室溫,Adults: inhalation of the content of one 150 mcg capsule once a day， using the Onbrez Breezhaler inhaler. Safety and effectiveness not established in pediatric patients. (< 18 years),無需調整劑量,Micromedex Lactation Rating: Infant risk cannot be ruled out. It is not known if indacaterol is excreted into breast milk. The manufacturer recommends that caution be exercised when administering indacaterol to nursing women. The use of beta2-receptor agonists are not considered a contraindication to breast-feeding,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex Lactation Rating: Infant risk cannot be ruled out. It is not known if indacaterol is excreted into breast milk. The manufacturer recommends that caution be exercised when administering indacaterol to nursing women. The use of beta2-receptor agonists are not considered a contraindication to breast-feeding,IH;,,,,,1. 每個Onbrez Breezhaler 包裝含有: 一個Onbrez Breezhaler 吸入器 / 鋁箔片，內含有供Onbrez Breezhaler 吸入器使用的膠囊 2. 不可吞服Onbrez Breezhaler 膠囊: Onbrez Breezhaler 吸入器是一種器材，供您在吸入Onbrez Breezhaler 膠囊中的藥品時使用。 3. 只可使用包裝中的Onbrez Breezhaler 吸入器。 4. Onbrez Breezhaler 膠囊不可使用其他吸入器，其他膠囊藥品也不可使用Onbrez Breezhaler 吸入器。
IFUR1,Cefuroxime,FuroXime inj 1.5gm,QANB,Infections due to Staphylococci， Streptococci， Pneumococci， Meningococci & other susceptible bacteria.,Hypersensitivity to cephalosporins.,Allergic reactions， GI intolerance， superinfection， eosinophilia. Rarely， transient hematological abnormalities; pseudomembranous colitis， phlebitis.,避光保存,Adults: 0.75-1.5 g IV/IM Q6-12H (dose ranges from 1.5-6 g/day); surgical prophylaxis: 1.5 g at induction of anesthesia and 1.5 g IM 6-8 hours after; gonorrhea: a single IM dose of 1.5 g (administer two doses of 750 mg at seperate area). Children: 30-100 mg/kg/day divided Q6-8H. Newborn: 30-100 mg/kg/day divided Q8-12H.,無需調整劑量,AAP: Maternal medication usually compatible with breastfeeding. Micromedex: Infant risk is minimal. Cefuroxime is excreted in breast milk. Manufacturer recommendations vary; caution is recommended if cefuroxime I.V. is given to a nursing woman and it is recommended to consider discontinuing nursing temporarily during treatment following oral cefuroxime. Nondose-related effects could include modification of bowel flora.,需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,AAP: Maternal medication usually compatible with breastfeeding. Micromedex: Infant risk is minimal. Cefuroxime is excreted in breast milk. Manufacturer recommendations vary; caution is recommended if cefuroxime I.V. is given to a nursing woman and it is recommended to consider discontinuing nursing temporarily during treatment following oral cefuroxime. Nondose-related effects could include modification of bowel flora.,IM;IV;IVD;IVP;IVPUSH;,IV:15 mL D/W,【D10W】可選 仿單建議。【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,推注時間至少3 ~ 5分鐘,給藥濃度1~30mg/mL， 滴注時間 > 15~ 60分鐘,1. 監測體溫、CBC、腎功能、PT值。 2.IM用法:加入3mL注射用水於750mg Cefuroxime，1.5gm應給予2支750mg不同部位肌肉注射，如兩側臀部。 3.配製後於25°C以下可保存5小時，冷藏可保存48小時。
IHYA,Sodium Hyaluronate,Hyalubrix Intra-articular inj,CNEU,Treatment of pain in osteoarthritis in knee in patients who have failed simple analgesics (e.g. acetaminophen) & nonpharmacologic treatment.,1. Hypersensitivity to the product components. 2. Infections or skin diseases at injection site.,Transient swelling， pain， heat & redness may occur sporadically at the injection site.,25℃以下,Inject in the affected joint at weekly intervals for 3 weeks.,無需調整劑量,[8] unknow- by book,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,[8] unknow- by book,INS;IS;,,,,,
OCER4,Pentoxifylline,Ceretal S.C. 400mg,CAVS,Peripheral circulatory disorders， chronic occlusive arterial disease.,Cerebral or retinal hemorrhage， intolerance to xanthine derivatives.,Cardiac arrhythmias， headache， nausea， GI effects， dizziness， flushing.,室溫下，防濕與避光儲存,1 TAB TID with meal.,無需調整劑量,Pentoxifylline is excreted into human milk. Five healthy women who had been breastfeeding for at least 6 weeks were given a single 400-mg sustained-release tablet of pentoxifylline after a 4-hour fast. The mean milk:plasma ratio of unmetabolized pentoxifylline at 4 hours was 0.87. Mean milk:plasma ratios for the three major metabolites at 4 hours were 0.76， 0.54， and 1.13. Mean milk concentration of pentoxifylline at 2 hours (73.9 ng/mL) was approximately twice as much as that occurring at 4 hours (35.7 ng/mL) (3). Pentoxifylline and its metabolites are stable in breast milk for 3 weeks when stored at ?15°C. The effects of this exposure on a nursing infant are unknown.,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Pentoxifylline is excreted into human milk. Five healthy women who had been breastfeeding for at least 6 weeks were given a single 400-mg sustained-release tablet of pentoxifylline after a 4-hour fast. The mean milk:plasma ratio of unmetabolized pentoxifylline at 4 hours was 0.87. Mean milk:plasma ratios for the three major metabolites at 4 hours were 0.76， 0.54， and 1.13. Mean milk concentration of pentoxifylline at 2 hours (73.9 ng/mL) was approximately twice as much as that occurring at 4 hours (35.7 ng/mL) (3). Pentoxifylline and its metabolites are stable in breast milk for 3 weeks when stored at ?15°C. The effects of this exposure on a nursing infant are unknown.,PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性糖衣錠，應整粒吞服，切勿咬嚼或壓碎。
OTOP5,Topiramate,Topamax film-coated 50mg,CNEU,,適應症: Adjunctive therapy in adults & children >= 2 years with partial seizures， seizures associated with the Lennox-Gastaut Syndrome， as well as with tonic-clonic seizures. Monotherapy in patients with partial onset seizure. Migraine prophylaxis. 副作用: Ataxia， impaired conc， confusion， dizziness， fatigue， paresthesia， somnolence， abnormal thinking. Less commonly， agitation， amnesia， anorexia， aphasia， depression， diplopia， emotional lability， nausea， nystagmus， speech disorder， taste perversion， abnormal vision & weight decrease. Nephrolithiasis (rare). Gastrointestinal: Diarrhea (5% to 11% )， Loss of appetite (4% to 24% )， Nausea (6% to 14% )， Taste sense altered (3% to 15% )， Weight decreased (6% to 21% ) Neurologic: Confusion (3% to 14% )， Disorder of language (6% to 10% )， Dizziness (8% to 32% )， Feeling nervous (7% to 14% )， Headache， Impaired psychomotor performance (3% to 21% )， Memory impairment (5% to 14% )， Paresthesia (2% to 51% )， Reduced concentration span (4% to 14% )， Somnolence (9% to 29% )， Speech and language disorder Ophthalmic: Abnormal vision (2% to 13% )， Diplopia (1% to 10% )， Nystagmus (10% to 11% ) Other: Fatigue (14% to 30% ) 禁忌: Pregnancy.,,室溫,Adjunctive therapy Adult 200-600 mg/day in 2 doses. Children >= 2 years 6-9 mg/kg/day in 2 doses. Max: 1000mg/day. Monotherapy Adult Initial target dose 100mg/day in 2 doses. Children >= 2 years 3-6 mg/kg/day in 2 doses.,無需調整劑量,Micromedex: Infant risk cannot be ruled out.,需調整劑量,盡量避免,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex: Infant risk cannot be ruled out.,,,,,,May be taken with or without food: Swallow whole， do not chew/crush.
IVFEN,Voriconazole,Vfend inj 200mg,QANB,Treatment of invasive aspergillosis， candidemia in non-neutropenic patients， fluconazole-resistant serious invasive Candida infections (including C. krusei)， esophageal candidiasis， serious fungal infections caused by Scedosporium spp & Fusarium spp in patients w/ progressive， possibly life-threatening infections.,Co-administration w/ terfenadine， astemizole， cisapride， pimozide， quinidine， sirolimus， rifampicin， carbamazepine， long-acting barbiturates (eg phenobarb)， ritonavir， ergot alkaloids (eg ergotamine & dihydroergotamine)， St. John's wort,Headache， visual disturbances， nausea， vomiting， diarrhea， abdominal pain， rash， fever， peripheral edema.,25℃以下,(仿單+熱病) Loading dose is recommended. Adult and children (12-14 years and weighing > or = 50 kg， or 15-17 years): 6 mg/kg IV Q12H x 2 doses (loading)， then 3-4 mg/kg IV Q12H. Children (2-12 years， or 12-14 years and weighing < 50 kg): 9 mg/kg IV Q12H x 2 doses， then 4-8 mg/kg IV Q12H.,需調整劑量,,需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,IVD: 19 mL注射用水，配製成20 mL的透明溶液,【D5NS】可選 。【D5W】可選 。【N/S】可選 。,,給藥濃度0.5~5mg/mL，給藥速率最高 3mg/kg/hr,
IENB5,Etanercept,Enbrel 50mg prefilled pen,HIMM,In combination w/ methotrexate in the treatment of moderate to severe active RA in adults when response to disease-modifying antirheumatic drugs (DMARDs) has been inadequate. As monotherapy in case of intolerance to methotrexate or when continued treatment w/ methotrexate is inappropriate. Treatment of severe， active & progressive RA in adults not previously treated w/ methotrexate. As monotherapy or in combination w/ methotrexate to reduce progression rate of joint damage & improve physical function. Treatment of active & progressive psoriatic arthritis in adults when the response to previous DMARDs has been inadequate. Treatment of adults w/ severe active ankylosing spondylitis not responsive to conventional therapy. Treatment of adults w/ moderate to severe plaque psoriasis who failed to respond to， contraindicated to or intolerant of other systemic therapy including cyclosporine， methotrexate or PUVA. Treatment of chronic severe plaque psoriasis in childn & adolescents ≧8 yr inadequately controlled by or intolerant to other systemic therapies or phototherapies. Treatment of active polyarticular juvenile idiopathic arthritis in childn ≧4 yr w/ inadequate response or intolerant to methotrexate.,Sepsis,>10%: Headache (17% to 19%)， Skin rash (3% to 13%)， Abdominal pain (5%; children 19%)， diarrhea (3% to 16%)， vomiting (3%; children 13%)， Infection (50% to 81%; children 62%)， Injection site reaction (14% to 43%; bleeding， bruising， erythema， itching， pain， or swelling)， Upper respiratory tract infection (38% to 65%)， respiratory tract infection (21% to 54%)， rhinitis (12%)， Antibody development (positive antidouble-stranded DNA antibodies 15% by RIA， 3% by Crithidia luciliae assay)， positive ANA titer (11%),2-8℃避光避免冷凍,SC， ankylosing spondylitis， psoriatic arthritis， rheumatoid arthritis， plaque psoriasis 50 mg once weekly or 25 mg twice weekly. Alternatively， plaque psoriasis 50 mg twice weekly for 12 weeks， then 50 mg once weekly or 25 mg twice weekly for 12 weeks.,無需調整劑量,有皮下給予etanercept後，etanercept分泌於人類乳汁的報告。哺乳的大白鼠皮下給予恩博時，恩博會分泌到乳汁，且幼鼠的血漿能偵測到恩博的濃度。由於免疫球蛋白(常見於許多醫藥品) 會分泌於人類乳汁中，因此欲使用恩博於哺乳期間的婦女時，在衡量哺乳的好處與哺乳婦女治療的益處時，應考量是否停止哺乳或停藥。,無需調整劑量,可能安全,Human data suggest low risk,在大鼠及兔子的發育毒性實驗中，並未發現etanercept傷害大鼠胎兒或新生兒的證據。目前已在兩項觀察性世代研究中探討etanercept對懷孕結果的影響。在其中一項觀察性研究中發現，相較於在懷孕期間沒有暴露於etanercept 或其他 TNF 抗拮劑的懷孕婦女(n=164)，懷孕前三個月中暴露於etanercept 的懷孕婦女(n=370) 發生重大先天缺陷的比率較高(調整勝算比2.4，95% CI: 1.0-5.5)。重大先天缺陷的類型和一般族群最常報告的類型一致，且沒有異常的特定模式。自然流產、胎死腹中或輕微畸形的比率沒有觀察到變化。另一項觀察性多國登錄試驗比較在懷孕的前90 天中暴露於etanercept之婦女(n=425) 與暴露於非生物製劑藥物之婦女(n=3497) 的不良懷孕結果風險，並未觀察到重大先天缺陷風險上升情形(粗勝算比[OR]= 1.22， 95% CI: 0.79-1.90；在校正國別、母親疾病、胎次、母親年齡和懷孕早期吸菸因子後之調整勝算比= 0.96， 95% CI: 0.58-1.60)。此試驗也顯示在懷孕期間暴露於etanercept的婦女發生輕微先天缺陷、早產、胎死腹中或新生兒在出生後第一年內發生感染之風險並未增加。懷孕期間使用恩博應僅限於有明確需求時。 Etanercept 會通過胎盤，懷孕期間接受恩博治療的婦女，產下的嬰兒血清中曾測到etanercept。此部分的臨床影響未知，但可能提高嬰兒受到感染的風險。一般來說，母親投與最後一劑恩博後未滿16週前，建議不要為嬰兒接種活疫苗(live vaccines)。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,有皮下給予etanercept後，etanercept分泌於人類乳汁的報告。哺乳的大白鼠皮下給予恩博時，恩博會分泌到乳汁，且幼鼠的血漿能偵測到恩博的濃度。由於免疫球蛋白(常見於許多醫藥品) 會分泌於人類乳汁中，因此欲使用恩博於哺乳期間的婦女時，在衡量哺乳的好處與哺乳婦女治療的益處時，應考量是否停止哺乳或停藥。,SC;,,,,,回溫: 使用前保留白色針蓋，等候15-30分鐘左右，讓恩博中的溶液達到室溫。待溶液達到室溫後使注射時的感覺較為舒服再注射。切勿以任何其它方式加熱。 檢查藥物: 透過透明檢視窗口檢視注射劑或注射筆中的溶液。注射劑或注射筆中的溶液必須為澄清、無色至淡黃色或淡棕色的溶液，並且沒有任何肉眼可見的微粒，才可用於注射。 注射部位: 建議的注射部位為大腿前面的中段。也可以選擇注射在腹部區域，但請確定您所選擇的位置距離肚臍至少5公分以上。如果有其他人為您注射，亦可選擇注射在上臂外側。 忘記投藥: 如果忘記投藥，應在想起時立即投藥，除非下一次預定的投藥時間是在隔天；在這種情況下，應該跳過錯過的劑量，然後在平常的時間繼續投藥。如果直到下一次投藥時間才記得，請不要施用雙倍劑量。
OSAL5,Sulfasalazine,Salazine 500mg,CNEU,Inflammatory bowel disease including Crohn's disease， ulcerative colitis， Active RA， ankylosing spondylitis.,Hypersensitivity to sulfonamides & salicylates. Acute intermittent porphyria. Infant < 2 years.,Nausea， anorexia， raised temp; erythema & pruritus; headache. Rarely， hematological， GI， CNS， renal， dermatological reactions. Dermatologic: Pruritus (3% to 4% )， Rash (3% to 13% ) Gastrointestinal: Abdominal pain (8% )， Indigestion (13% to 33% )， Loss of appetite (33% )， Nausea (19% to 33% )， Stomatitis (4% )， Vomiting (8% to 33% ) Neurologic: Dizziness (4% )， Headache (9% to 33% ) Renal: Discolored urine Reproductive: Oligozoospermia， Reversible (33% ) Other: Fever (3% to 5% ),15-30℃密蓋容器,Inflammatory bowel disease including Crohn's disease， ulcerative colitis: Adult moderate attacks: 2 tables TID-QID. Severe attacks: 2-4 TABTID-QID. Children: 40-60 mg/kg/day in 3-6 doses. Maintenance: Adult 2 tablets BID-TID. Children 20-30 mg/kg/day in 3-6 divided doses. RA : 2 tablets BID. Child (Juvenile chronic arthritis)， no enough information.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為腸溶錠，應整粒吞服，不可咬碎或咀嚼。
IDEC,Triptorelin,Decapeptyl inj 0.1mg/1mL,RACA,Advanced prostate cancer: Palliative treatment of advanced prostate cancer Assisted reproductive technologies: Decapeptyl: Adjunctive therapy in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART),Hypersensitivity to triptorelin or any component of the formulation， other GnRH agonists or GnRH; pregnancy Canadian labeling: Additional contraindications (not in U.S. labeling): Breast-feeding women,>10%: Endocrine & metabolic: Hot flash， increased serum glucose， increased testosterone (peak: days 2-4; decline to low levels by weeks 3-4) Hematologic & oncologic: Decreased hemoglobin， decreased red blood cells Hepatic: Increased serum alkaline phosphatase， increased serum ALT， increased serum AST Neuromuscular & skeletal: Musculoskeletal pain Renal: Increased blood urea nitrogen,2-8℃避光避免冷凍,0.5 mg SC once daily for 7-10 days， followed by 0.1 mg SC once daily as maintenance therapy,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,SC;,,,,,
EFOX2,Fluorometholone,Foxone 0.02% 10mL ophthalmic suspension,TOPH,Acute & chronic iritis， iridocyclitis， scleritis， episcleritis， conjunctivitis， keratitis， resistant ocular allergy & inflammation following surgery,Acute superficial herpes simplex keratitis， fungal diseases of ocular structure; vaccinia， varicella & other viral diseases of the cornea & conjunctiva， eye TB,Glaucoma with optic nerve damage， visual acuity or field defects， raised intraocular pressure， secondary infection (persistent corneal ulceration， possibly fungal invasion)， perforation of globe， posterior subcapsular cataract formation,25℃以下,Instill 1 drop into conjunctival sac 2 to 4 times daily; may instill 1 drop every 4 hours during initial 24 to 48 hours. Shake well before use.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AD;AL;AS;AU;OD;OL;OU;,,,,,
IMTX5,Methotrexate,MTX inj 500mg/5mL,RACA,,適應症: Gestational choriocarcinoma， acute lymphocytic leukemia， meningeal leukemia， chorioadenoma destruens， hydatidiform mole， epidermoid cancers of the head & neck， lung cancer， bladder cancer & lymphosarcoma. 副作用: Ulcerative stomatitis， leukopenia， nausea & abdominal distress. malaise， fatigue， chills & fever， dizziness & decreased resistance to infection. Erythematous rashes， pruritus， urticaria， photosensitivity， depigmentation， alopecia， ecchymosis， telangiectasia， acne & furunculosis. Hematologic disorders. GI disturbances. CNS effects. Metabolic changes， precipitating diabetes， osteoporosis， conjunctivitis， abnormal tissue cell changes， anaphylaxis. 禁忌: Pregnant psoriatic patients. Psoriatic patients with severe renal or hepatic disorders， preexisting blood dyscrasias.,,室溫,Choriocarcinoma: Oral or IM， 15-30 mg/day for a 5 day course. Acute leukemia: Induction， oral or IV， 3.3 mg/m2/day with prednisolone; maintenance， oral or IM， 30 mg/mL twice a week， or IV， 2.5 mg/kg every 14 days. Meningeal leukemia: Intrathecal， 0.2-0.5 mg/kg or 12 mg/mL (max. 15mg) every 2-5 days until the cell count of cerebrospinal fluid returns to normal. Burkitt's lymphoma (stage I & II): Oral， 10-25 mg/day for 4-8 days. Psoriasis: Oral， IM or IV， 10-25 mg/week. Rheumatoid arthritis: Oral， 2.5 mg q12h for 3 doses every week. Mycosis fungoides: Oral， 2.5-10 mg/day for weeks or months; IM， 50mg/week.,,,,不可使用,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能。 3. Methotrexate以靜脈方式給藥需緩慢推注，也可以短時間靜脈輸注或靜脈持續輸注給藥。依治療組合與醫囑決定。
ISIV4,Triamcinolone,SIVKORT Suspension 400mg/10mL,HM,,適應症: Intra-articular Inflammatory joint disease 副作用: Common ■Cardiovascular: Hypertension ■Dermatologic: Atrophic condition of skin， Finding of skin healing， Impaired ■Endocrine metabolic: Cushing's syndrome， Decreased body growth ■Gastrointestinal: Disorder of gastrointestinal tract， Loss of appetite ■Musculoskeletal: Osteoporosis ■Psychiatric: Depression， Euphoria Serious ■Endocrine metabolic: Hyperglycemia， Primary adrenocortical insufficiency ■Ophthalmic: Cataract， Glaucoma ■Respiratory: Pulmonary tuberculosis 禁忌: ■hypersensitivity to triamcinolone ■systemic fungal infections,,室溫,,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
EBIO,Sulfur Precipitated,Biofur acne lotion 5% 30mL,TDER,,適應症: Acne vulgaris. 副作用: Skin dryness; less frequently， skin irritation 禁忌: hypersensitivity 注意事項: Topical: Avoid contact with the eyes; for external use only,,室溫,Apply a thin film of Biofur twice daily to affected area.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
OSTV,Regorafenib,Stivarga 40mg (28#/Bot),RACA,Colorectal cancer: Treatment of patients with metastatic colorectal cancer (mCRC) who have previously received the following therapies， including fluoropyrimidine-， oxaliplatin-， irinotecan-based chemotherapy， and anti-vascular endothelial growth factor (anti-VEGF) therapy; If KRAS is a wild type， the patient needs to have received anti-epidermal growth factor receptor (anti-EGFR) therapy. Gastrointestinal stromal tumors: Treatment of locally advanced， unresectable or metastatic gastrointestinal stromal tumors in patients who have previously received imatinib mesylate and sunitinib malate. Hepatocellular carcinoma: Treatment of hepatocellular carcinoma (HCC) patients who have received sorafenib treatment.,Hypersensitivity to regorafenib， any component of the formulation， or sorafenib.,Hypertension， Fatigue， dysphonia， pain， fever， headache， Palmar-plantar erythrodysesthesia， rash， alopecia， Hypocalcemia， hypophosphatemia， hyponatremia， hypokalemia， hypothyroidism， Appetite decreased， lipase increased， diarrhea， mucositis， weight loss， amylase increased， nausea， vomiting， Anemia， lymphopenia， thrombocytopenia， INR increased， hemorrhage， neutropenia， AST increased， ALT increased， hyperbilirubinemia， Stiffness， Proteinuria， Infection.,30℃以下,160 mg (four 40 mg tablets) taken orally once daily for the first 21 days of each 28-day cycle. Continue treatment until disease progression or unacceptable toxicity.Take Stivarga at the same time each day. Swallow tablet whole with a low-fat breakfast that contains less than 30% fat. Examples of a low-fat breakfast include 2 slices of white toast with 1 tablespoon of low-fat margarine and 1 tablespoon of jelly， and 8 ounces of skim milk (319 calories and 8.2 g fat); or 1 cup of cereal， 8 ounces of skim milk， 1 slice of toast with jam， apple juice， and 1 cup of coffee or tea (520 calories and 2 g fat).,需調整劑量,(UPp to date) Pregnancy Risk Factor: D 仿單: 懷孕分級D; 授乳:禁用,無需調整劑量,盡量避免,Contraindicated,,Contraindicated 哺乳期使用禁忌,(UPp to date) Pregnancy Risk Factor: D 仿單: 懷孕分級D; 授乳:禁用,,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OBECA,Entecavir,Becavir 0.5mg,QANB,,適應症:Treatment of chronic HBV infection in adults with evidence of active viral replication & either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. 副作用:Diarrhea， dyspepsia， nausea， vomiting. Fatigue. Headache， dizziness， somnolence. Insomnia. Gastrointestinal: Nausea (all grades， 3% or greater; grade 2 to 4， less than 1% ) Neurologic: Dizziness (all grades， 3% or greater; grade 2 to 4， less than 1% )， Headache (all grades， 3% or greater; grade 2 to 4， 2% to 4% ) Other: Fatigue (all grades， 3% or greater; grade 2 to 4， 1% to 3% ) 禁忌:Patients who previously demonstrated hypersensitivity to entecavir.,,,Active type B viral hepatitis， chronic: (nucleoside-treatment-naive patients) 0.5 mg ORALLY once daily Active type B viral hepatitis， chronic: (history of hepatitis B viremia while receiving lamivudine or known lamivudine resistant mutations) 1 mg ORALLY once daily,無需調整劑量,HIV: [U.S. Boxed Warning]: May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection. Determine HIV status prior to initiating treatment with entecavir. Not recommended for HIV/HBV coinfected patients unless also receiving highly active antiretroviral therapy (HAART).,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,HIV: [U.S. Boxed Warning]: May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection. Determine HIV status prior to initiating treatment with entecavir. Not recommended for HIV/HBV coinfected patients unless also receiving highly active antiretroviral therapy (HAART).,,,,,,
OZYD,Aripiprazole,Zydus Aripiprazole 10mg,CNEU,,適應症: Schizophrenia in adults & adolescents 13-17 years. Monotherapy or adjunctive therapy to either lithium or valproate for the acute manic & mixed episodes associated with Bipolar I disorder in adults & pediatrics 10-17 years. Adjunctive treatment of major depressive disorders. Irritability associated with autistic disorder in pediatric patients 6-17 years. 副作用: Headache， asthenia， accidental injury， peripheral edema， hypertension， GI disturbances， myalgia， agitation， anxiety， insomnia， lightheadedness， somnolence， akathisia， extrapyramidal syndrome， tremor， increased salivation， rhinitis， pharyngitis， coughing， blurred vision. Endocrine metabolic: Weight increased (2% to 30% ) Gastrointestinal: Constipation (5% to 11% )， Nausea (8% to 15% )， Vomiting (3% to 11% ) Neurologic: Akathisia (2% to 25% )， Dizziness (4% to 10% )， Extrapyramidal disease (2% to 27.3% )， Headache (12% to 27% )， Insomnia (8% to 18% )， Sedated (1% to 8% )， Somnolence (5% to 26.3% )， Tremor (2% to 11.8% ) Ophthalmic: Blurred vision (3% to 8% ) Psychiatric: Anxiety (4% to 17% )， Restlessness (2% to 12% ) Other: Fatigue (2% to 11% ) 禁忌: Known hypersensitivity to aripiprazole.,,室溫,Schizophrenia Acute treatment: Adult Initially 10 mg or 15 mg once daily. Dose may be increased at intervals of not < 2 weeks. Effective dose range: 10-30 mg/day. Adolescent 13-17 years Initially 2 mg/day， titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Bipolar disorder Acute treatment: Adult Initially 15 mg once daily， may be increased to 30 mg/day. Children 10-17 years Initially 2 mg/day， titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Adjunctive treatment of major depressive disorder Acute treatment: Adult Initially 2-5 mg/day. Dose range: 2-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not < 1 week. Irritability associated with autistic disorder Children 6-17 years Initially 2 mg/day. Dose range: 5-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not < 1 week.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OCOV7,Alendronate,Covaxin 70mg,META,,適應症: • Treatment of osteoporosis in postmenopausal women • Treatment to increase bone mass in men with osteoporosis 副作用Common: Common ■Gastrointestinal: Abdominal pain (2.1% to 6.6% )， Constipation (0.3% to 3.1% )， Diarrhea (0.6% to 3.1% )， Flatulence (2.6% to 4.1% )， Indigestion (1.7% to 3.6% )， Vomiting (pediatric patients， 29.4% ) ■Neurologic: Headache (2.6% ) ■Other: Fever (24% )， Influenza-like symptoms Serious ■Gastrointestinal: Duodenal ulcer disease， Esophageal erosions， Esophageal perforation， Esophageal stricture， Esophagitis (1.5% )， Gastric ulcer (up to 13.2% )， Ulcerative pharyngitis， acute， Ulcer of esophagus (1.5% ) ■Immunologic: Hypersensitivity reaction ■Musculoskeletal: Arthralgia， Aseptic necrosis of bone of jaw (0.017% to 0.03% )， Bone pain， Myalgia 禁忌: • Abnormalities of the esophagus which delay emptying such as stricture or achalasia • Inability to stand/sit upright for at least 30 minutes • Increased risk of aspiration • Hypocalcemia • Hypersensitivity to any component of this product,,室溫,1 tab once weekly.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OSER1,Paroxetine,Seroxat CR 12.5mg,CNEU,■Generalized anxiety disorder ■Major depressive disorder ■Obsessive-compulsive disorder ■Panic disorder ■Posttraumatic stress disorder ■Premenstrual dysphoric disorder ■Social phobia,■coadministration with an MAOI， including linezolid or IV methylene blue， or use of paroxetine hydrochloride within 14 days of discontinuing an MAOI used to treat psychiatric disorders， or use of an MAOI used to treat psychiatric disorders within 14 days of discontinuing paroxetine hydrochloride; increased risk of serotonin syndrome ■concomitant use with pimozide ■concomitant use with thioridazine ■hypersensitivity to paroxetine or any component of the product,Common ■Cardiovascular: Palpitations (up to 3% )， Vasodilatation (2% to 4% ) ■Dermatologic: Diaphoresis (5% to 14% ) ■Gastrointestinal: Constipation (up to 16% )， Diarrhea (up to 18% )， Loss of appetite (up to 9% )， Nausea (up to 26% )， Xerostomia (9% to 18% ) ■Neurologic: Asthenia (up to 22% )， Dizziness (6% to 14% )， Headache (17% to 27% )， Insomnia (up to 24% )， Somnolence (up to 24%)， Tremor (4% to 11% ) ■Ophthalmic: Blurred vision (up to 5% ) ■Reproductive: Abnormal ejaculation (13% to 28% )， Impotence (2% to 9% )， Orgasm disorder (females; 2% to 9% )， Reduced libido (males: 6% to 15%; females: 0% to 9%) ■Respiratory: Yawning (4% ) Serious ■Dermatologic: Stevens-Johnson syndrome， Toxic epidermal necrolysis ■Hepatic: Acute hepatitis (rare) ■Neurologic: Seizure (0.1% ) ■Psychiatric: Depression， exacerbation， Suicidal thoughts (rare)， Suicide (rare) ■Other: Serotonin syndrome,儲存溫度不超過25℃,Major depressive disorder: controlled-release， 25 mg/day orally in the morning; may increase dosage by 12.5-mg/day increments at intervals of at least 1 week to a maximum dose of 62.5 mg/day Panic disorder: controlled-release， 12.5 mg/day orally in the morning; may increase dosage by 12.5-mg/day increments at intervals of at least 1 week to a maximum dose of 75 mg/day Premenstrual dysphoric disorder: controlled-release， 12.5 mg/day orally in the morning; may increase to 25 mg/day at interval of at least 1 week; may be administered daily throughout the menstrual cycle or limited to daily administration during the luteal phase of the menstrual cycle Social phobia: controlled-release， 12.5 mg/day orally in the morning; may be increased by 12.5-mg/day increments at intervals of at least 1 week to a maximum dose of 37.5 mg/day,無需調整劑量,,無需調整劑量,不可使用,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠，需整顆吞服，勿咬碎、壓碎、剝半或磨粉。
IAET,Polidocanol,Aethoxysklerol 2% 2mL/amp (專案進口),CAVS,,適應症: Treatment of small， uncomplicated varicose veins of the lower extremities 副作用: >10%: Local: Hematoma (42%)， irritation (41%)， discoloration (38%)， pain (24%)， pruritus (19%)， warmth (16%) 1% to 10%: Local: Neovascularization (8%)， injection site thrombosis (6%) 禁忌: Hypersensitivity to polidocanol or any component of the formulation; acute thromboembolic diseases,,,Adult Varicose veins of lower extremity: initial， 0.5-1ml; depending on the outcome and the length of of the segment to be treated， several injections with up to 2ml per injection may be administered in subsequent treatment sessions. Max. 2mg/kg/day. Pediatric Safety and efficacy have not been established.,,,,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,For intravenous use only. Avoid extravasation. After injection， apply compression in the form of a stocking or bandage (maintain for 2-3 days [spider veins] and 5-7 days [reticular veins]). After applying compression， patient should walk for 15-20 minutes and be observed for anaphylactic or allergic reaction.
IHLF,Heparin,Hepac Lock Flush 1000 Unit/10mL,HEMT,Solution is intended for maintenance of patency of intravenous injection devices only. (central line use),Hypersensitivity to the drug， Bleeding disorders， Severe thrombocytopenia， Patients who can't undergo regular blood coagulation tests,Hemorrhage， allergic reactions,20-25℃,Adult dosing: Port-A flush only. Hepac Lock Flush Solution is intended for maintenance of patency of intravenous injection devices only and is not to be used for anticoagulant therapy.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IRR;IRRI;,,,,,不可用於肌肉注射。
IDOPA,Dopamine,Dopamin inj 200mg/5mL,CAVS,Correction of poor perfusion， low cardiac output， impending renal failure & shock associated with MI， trauma， endotoxic septicemia， open heart surgery， heart failure.,Phaeochromocytoma; uncorrected hypovolaemia; uncorrected tachyarrhythmia or ventricular fibrillation.,Most frequently: ectopic beats， nausea， vomiting， tachycardia， anginal pain， palpitations， dyspnoea， headache， hypotension & vasoconstriction. Other infrequent side effects include aberrant conduction， bradycardia， piloerection， widened QRS complex， azotaemia & hypertension.,15-30℃避光避免冷凍,Must be diluted before infusion. Adult usual dosage: Initially， 1-5 mcg/kg/minute， increased gradually by 1-4 mcg/kg/minute in every 10-15 minutes according to patient's cardiac and urine output， blood pressure. Chronic refractory congestive heart failure: Initially， 0.5-2 mcg/kg/minute and increased gradually until the desired response is obtained. Severely ill patients: Initially， 5 mcg/kg/min， increased gradually by 5-10 mcg/kg/minute until the desired response is obtained. Maximum: 20-50 mcg/kg/minute.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,,Initiate at a rate of 2~5 mcg/kg/min increment up to 20-50 mcg/kg/min if needed,1.勿加入鹼性藥品 2.注射時應選較大靜脈，最好是肘前窩，以防止外溢而引起組織壞死和環繞組織腐肉生成.如有必要需由手或足踝靜脈給藥時，注射部位仍應儘速改變到較大的靜脈. 如有劑量外溢發生時，立刻以含5-10mg Phentolamine Mesylate之0.9%Sodium Chloride注射液10-15mL浸潤患部以防止腐肉生城和壞死.
ORAK,Rasagiline,Rakinson 1mg,CNEU,■Parkinson's disease， Initial monotherapy ■Parkinson's disease， To levodopa; Adjunct,Concomitant use of cyclobenzaprine， dextromethorphan， methadone， propoxyphene， St John’s wort， or tramadol; concomitant use of meperidine or an MAO inhibitor (including selective MAO-B inhibitors) within 14 days of rasagiline,■Cardiovascular: Orthostatic hypotension (6% to 9%) ■Dermatologic: Rash (3% to 6% ) ■Endocrine metabolic: Weight loss (2% to 9% ) ■Gastrointestinal: Constipation (4% to 9% )， Indigestion (7% )， Nausea (10% to 12% )， Vomiting (4% to 7%)， Xerostomia (2% to 6% ) ■Musculoskeletal: Arthralgia (6% to 11% ) ■Neurologic: Ataxia (3% to 6% )， Dyskinesia (18% )， Headache (8% to 14% ) ■Psychiatric: Depression (5% ) ■Other: Falling injury (5% )， Influenza-like illness (5% ),25℃以下，毋需冰存並避免陽光直射,Monotherapy: 1 mg once daily Adjunctive therapy with levodopa: Initial: 0.5 mg once daily; may increase to 1 mg once daily based on response and tolerability,需調整劑量,1) Micromedex Lactation Rating: Milk effects are possible. a) Evidence suggests this drug may alter milk production or composition. If an alternative to this drug is not prescribed， monitor the infant for adverse effects and/or adequate milk intake. 2) Clinical Management a) Rasagiline inhibits prolactin secretion in rats， and may inhibit milk secretion in females. Data regarding use in lactating women are not available. Caution should be exercised when rasagiline is administered to a lactating woman.,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,1) Micromedex Lactation Rating: Milk effects are possible. a) Evidence suggests this drug may alter milk production or composition. If an alternative to this drug is not prescribed， monitor the infant for adverse effects and/or adequate milk intake. 2) Clinical Management a) Rasagiline inhibits prolactin secretion in rats， and may inhibit milk secretion in females. Data regarding use in lactating women are not available. Caution should be exercised when rasagiline is administered to a lactating woman.,AC;AC15;PC;PO;WM;,,,,,
EATR1,Atropine,Antol 0.125%， 5mL,TOPH,Topical mydriatic & cycloplegic; uveitis.,Closed- & narrow-angle glaucoma.,Stinging， increased intraocular pressure， conjunctivitis. May precipitate glaucoma.,25℃以下儲存,Ciliary muscle paralyzation: Instill 1 drop 1 to 2 times per day at conjunctiva. Age < 1 year: 0.125% or depending on the doctor’s instruction. Age 1-5 years: 0.25% or depending on the doctor’s instruction. Age > or = 5 years with blue iris: 0.25% or depending on the doctor’s instruction. Age > or = 5 years with dark iris: 0.5% or 1% or depending on the doctor’s instruction. Uveitis: Apply 1 drop in the conjunctival sac 1 to 3 times daily(0.125%-1%) For pupil dilation after operation: Instill 1 drop 1 to 3 times per day (or depending on the doctor’s instruction) at conjunctiva. (0.5% or 1%),無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
ISIV1,Triamcinolone,Sivkort Suspension 10mg/1mL,HM,,適應症: Intra-articular Inflammatory joint disease 副作用: HPA axis supression， intracranial hypertension， Cushing's syndrome， growth retardation in children; osteoporosis， fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas， broken skin or under occlusive dressing. 禁忌: Untreated systemic fungal， bacterial， viral or parasitic infection， hypersensitivity. Neonates (Parenteral),,室溫,Intra-articular Inflammatory joint disease As acetonide: Smaller joints: 2.5-5 mg (up to 10 mg)， larger joints: 5-15 mg (up to 40 mg). Max: 20-80 mg/treatment. As hexacetonide: Initial: 2-20 mg/day.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IS;,,,,,
INS5,Sodium Chloride,0.9% NaCl inj 500mL(硬瓶),MSIV,為生理食鹽水注射液(A001085277),,,室溫,IV infusion as needed.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IRR;IRRI;IV;IVD;,,,,,
ITT4,Electrolytes + Water,台大 No.4 500mL,MSIV,Supplement of water， electrolytes & nutrition,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30℃以下,Central vein or peripheral vein infusion， as needed. Taita No.1: Na 25mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 20mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 38g/L， 500mL/Bot， 300mOsm/L. Taita No.2: Na 40mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 26mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 33g/L， 500mL/Bot， 287mOsm/L. Taita No.3: Na 75mEq/L， K 12mEq/L， Mg 0mEq/L， Cl 61mEq/L， Acetate 20mEq/L， Phosphate 6mM/L， Glucose 20g/L， 500mL/Bot， 285mOsm/L. Taita No.4: Na 110mEq/L， K 20mEq/L， Mg 0mEq/L， Cl 102mEq/L， Acetate 16mEq/L， Phosphate 12mM/L， Glucose 8g/L， 500mL/Bot， 300mOsm/L. Taita No.5: Na 36mEq/L， K 18mEq/L， Mg 3mEq/L， Cl 17mEq/L， Acetate 28mEq/L， Phosphate 12mM/L， Glucose 100g/L， 400mL/Bot， 669mOsm/L.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,特點及適應症 Taita No.1: Na、Cl 是各台大電解質輸液中含量最低；小兒用維持液、電解質、水份、養份補充 Taita No.2: 成分與Taita No.1相似但Na、Cl較多;熱量及K含量較低，可作為小兒或成人用維持液 Taita No.3: NaCl含量似0.45 %N/S，可用於等張性脫水、糖尿病性酸中毒 Taita No.4: Na、K、Cl是各台大電解質輸液中含量最高，可用於低張性脫水、低磷血症 Taita No.5: 台大電解質輸液系列中，含Acetate及熱量最高，可用於高熱量電解質補充液、低磷血症
OANP,Ritodrine,Anpo 10mg,SGU,Prevention of preterm labour， Acute fetal distress， Prevention of preterm labour after operation Follow treatment for preterm labour.,Antepartum haemorrhage due to any cause but particularly placenta previa & abruptio placentae. Eclampsia & severe pre-eclampsia. Intra-uterine foetal death. Chorioamnionitis. Maternal cardiac disorder. Hyperthyroidism. Uncontrolled hypertension. Any other condition which can endanger cardiac function. Parenteral: Asthmatics (due to sulfite component).,Pulmonary oedema (several cases reported with fatal results). Maternal & foetal heart rate can increase. Frequently: Tremor， nausea， vomiting， headache or erythema， nervousness， restlessness， jitteriness， emotional upset， anxiety or malaise. Infrequently cardiac symptoms， eg chest pain or tightness with or without ECG abnormalities & cardiac arrhythmias. Hepatic impairment.,25℃以下乾燥避光,Uncomplicated premature labour Adult: Start oral therapy 30 minutes before termination of IV infusion at 10 mg every 2 hours for 24 hours. Subsequently， 10-20 mg every 4-6 hours according to patient's response. the maximum oral dose: 120 mg/day.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
IESC,Hyoscin-Butylbromide,Escopan inj 20mg/1mL,ALIM,,適應症: Spasm & hyperkinesia of the GIT， spasm & dyskinesia of the biliary tract， urinary tract & female genital tracts. 副作用: Dry mouth， dyshidrosis， visual accommodation disturbances， tachycardia， dizziness， constipation， urinary retention， hypotension， allergic reactions， inj site pain. 禁忌: Myasthenia gravis， toxic megacolon， narrow angle glaucoma， tachycardia， prostatic enlargement with urinary retention， pyloric stenosis & paralytic ileus.,,,Adult 20 mg 1-5 times daily IM/IV/SC.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IV;IVD;IVP;SC;,,【D5W】可選 。【N/S】可選 。,推注時間至少>1分鐘,,
IEP10,Epirubicin,Epicin 10mg/5mL,RACA,Leukemia， lymphoma， breast cancer， sarcomas， small-cell lung carcinoma， ovarian cancer， gastric cancer. Liver cancer， head & neck cancer， pancreatic cancer.,Myelosuppression. Cardiac impairment. Previous full cumulative doses of anthracyclines. Pregnancy. Lactation.,Myelosuppression， cardiotoxicity， alopecia， mucositis， GI disturbances， hyperpyrexia.,2-8℃避光,(仿單) Epirubicin should be administered intravenously or intravesicularly. Do not administer epirubicin orally， intramuscularly or subcutaneously. A lifetime maximum cumulative dose >1000 mg/m2 should be avoided. Usual dose: 75-90 mg/m2 intravenously once every 3 weeks. Intravesicular: 50 mg once weekly for 8 weeks; dose range: 30-80 mg.,需調整劑量,,無需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,IRR;IVD;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能、尿酸與血中電解質濃度。 3.Epirubicin的累積劑量與心臟毒性相關，將累積劑量限制在1000mg/m2以下可以降低相關風險.
OCAR90,Diltiazem,Cardizem Retard 90mg,CAVS,,適應症: 主治高血壓、心絞痛(B021113100) Hypertension. 副作用: Bradycardia， 1st degree AV block， ankle edema， nausea， headache， skin rashes， finger swelling. Cardiovascular: Bradyarrhythmia (1.7% to 3.6% )， Peripheral edema (4.6% to 8% ) Neurologic: Dizziness (3.5% to 6.4% )， Headache (4.6% ) Respiratory: Cough (2% ) Other: Fatigue (4.8% ) CI: Pregnancy， lactation; sick sinus syndrome， AV block II or III， severe bradycardia.,,室溫,Intial: 30 mg qid ac. Maintenance: 180-360 mg/day.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OCAF,Ergotamine tartrate + Caffeine,Cafergot 1/100mg,CNEU,,適應症: Acute attacks of migraine & related types of vascular headache. 副作用: Nausea and vomiting. Paraesthesia， pain and weakness in the extremities or peripheral vasoconstriction may occur in susceptible patients or following prolonged treatment. If ergotamine-containing drugs are used excessively over years， they may induce fibrotic changes， in particular of the pleura and the retroperitoneum. 禁忌: Impaired peripheral circulation， obliterative vascular disease， CHD; severe hypertension; renal or hepatic insufficiency， sepsis; pregnancy， lactation.,,室溫,2 tab at 1st attack.if no relief ，1 tab after 1/2hr. Subsequent attack initially: 3 Tab Max: 6 tab/daily and 10 tab/weekly,,,,不可使用,,,,,,,,,,
OKLU,Gliclazide,Kludone MR 60mg,META,Management of type 2 diabetes mellitus (noninsulin dependent， NIDDM),Hypersensitivity to gliclazide， other sulfonylureas or sulfonamides， or any component of the formulation; unstable and/or type 1 diabetes mellitus (insulin dependent， IDDM); diabetic ketoacidosis; diabetic pre-coma and coma; severe renal or hepatic impairment; stress conditions (eg， serious infection， trauma， surgery); concurrent use with miconazole (systemic or oromucosal gel); pregnancy; breast-feeding,Hypoglycemia， Hypertension， angina， peripheral edema， Headache， dizziness， depression， insomnia， Skin disorder， dermatitis， rash， pruritus，， hyperlipidemia， lipid metabolism disorder， Diarrhea， constipation， gastroenteritis， abdominal pain， gastritis， nausea， Urinary tract infection， Back pain， arthralgia， weakness， arthrosis， myalgia， arthritis， neuralgia， tendonitis， Conjunctivitis， Otitis media， Bronchitis， rhinitis， pharyngitis， upper respiratory infection， cough， pneumonia， sinusitis， Viral infection,25℃以下陰涼乾燥處,0.5-2 TAB once daily at breakfast. (30-120 mg/day),無需調整劑量,upper table (according to up to date) Pregnancy Implications: Use during pregnancy is contraindicated. Lactation: Excretion in breast milk unknown/contraindicated. Breast-Feeding Considerations: Potential for neonatal hypoglycemia in a nursing infant contraindicates use.,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,upper table (according to up to date) Pregnancy Implications: Use during pregnancy is contraindicated. Lactation: Excretion in breast milk unknown/contraindicated. Breast-Feeding Considerations: Potential for neonatal hypoglycemia in a nursing infant contraindicates use.,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。
EVIRL,Acyclovir,Virless cream 5%， 5gm,TDER,Herpes simplex virus infection of the skin including initial & recurrent genital herpes & herpes labialis.,Patients known to be hypersensitive to acyclovir or propylene glycol.,Transient burning or stinging. Mild drying & flaking. Erythema & itching. Dermatologic: Application site reaction， Topical Preparation (5% )， Contact dermatitis， Topical Preparation (2% ) Gastrointestinal: Diarrhea (2.4% to 3.2% )， Nausea (2.4% to 4.8% )， Vomiting Neurologic: Headache (2.2% ) Other: Malaise (11.5% ),25℃以下避光儲存,Herpes simplex: Initial therapy: Apply ointment topically every 3 hours (6 times per day) for 7 days in sufficient quantities to adequately cover lesion,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,EXT;,,,,,
OBAR1,Entecavir,1mg BARACLUDE,QANB,Treatment of chronic active type B viral hepatitis or reactivation of hepatitis B viral hepatitis in adults and children over 2 years of age.,Hypersensitivity to entecavir or any component of the formulation.,Common Gastrointestinal: Nausea (Adult， less than 1%; Pediatric， greater than 1% ) Neurologic: Dizziness (Less than 1% )， Headache (2% to 4% ) Other: Fatigue (1% to 3% ) Serious Endocrine metabolic: Lactic acidosis Hepatic: Hepatomegaly (Severe)， With steatosis， Recurrent hepatitis,30℃以下避光,Administer on an empty stomach (2 hours before or after a meal). Adults and adolescents > 16 years: nucleoside-treatment naive， compensated liver disease: 0.5 mg once daily; decompensated liver disease: 1 mg once daily. Children and adolescents 2 to <16 years: 10 to 11 kg: 0.15 mg oral solution once daily >11 to 14 kg: 0.2 mg oral solution once daily >14 to 17 kg: 0.25 mg oral solution once daily >17 to 20 kg: 0.3 mg oral solution once daily >20 to 23 kg: 0.35 mg oral solution once daily >23 to 26 kg: 0.4 mg oral solution once daily >26 to 30 kg: 0.45 mg oral solution once daily >30 kg: 0.5 mg oral solution or tablet once daily,無需調整劑量,Breastfeeding Recommendation: Contraindicated (HIV) ; No Human Data—Probably Compatible (Hepatitis B) [仿單]目前尚不清楚 BARACLUDE 是否會排入人類乳汁、影響母乳分泌，或對哺乳嬰兒造成影響。 在大鼠哺乳期施用時，entecavir 會出現在乳汁中 (請見資料)。在考量哺餵母乳對發育和健康效益時，應一併考量產婦對 BARACLUDE 的臨床需求，以及 BARACLUDE或產婦的身體狀況對餵哺母乳嬰兒的所有可能不良反應。在大鼠哺乳第7天口服單劑 entecavir 10 mg/kg 後，entecavir 會分泌至大鼠的乳汁 中。乳汁中的 entecavir 約為母體血漿中的 25% (根據 AUC)。,需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,[仿單]在孕婦中並無適當且具有良好對照的BARACLUDE研究。因為動物生殖研究未必能預測人體的反應，所以只有在潛在效益高於對胎兒的潛在風險時，方能於懷孕期間使用BARACLUDE (entecavir)。 在動物生殖研究中，entecavir 達到臨床意義暴露時，並未觀察到不良發育影響。全身暴露量 (AUC) 約為人類最大建議劑量 (MRHD) 每日1 mg的 25 倍 (大鼠) 與 200倍 (兔子) 時，並未觀察到發育毒性。在胎兒器官形成期間 (妊娠第 6 至 15 天 [大鼠] 與妊娠第 6 至 18 天 [兔子])，對懷孕的大鼠 (每日每公斤體重 2、20 及 200 毫克) 與兔子 (每日每公斤體重 1、4 及 16 毫克) 口服施用 entecavir。在大鼠中，當母體全身暴露 (AUC) 為 MRHD 的 3100 倍時，觀察到胚胎－胎兒毒性，包括著床後流產、胚胎再吸收、尾巴與脊椎畸形、骨骼變化，包括成骨不全 (脊椎、胸骨節與指骨)、多餘的腰椎與肋骨、胎兒體重較輕。在該劑量濃度也觀察到母體毒性。在兔子中，當母體全身暴露 (AUC) 為 MRHD的 883 倍時，觀察到胚胎－胎兒毒性，包括著床後流產、胚胎再吸收及骨骼變化，包括成骨不全 (舌骨)、第 13 肋骨的發生率增加。當懷孕動物口服施用的 entecavir約為 28 倍 (大鼠) 與 212 倍 (兔子) 之 MRHD 人體暴露量 (AUC) 時，並無胚胎－胎兒毒性的現象。在產前及產後發育試驗中，從妊娠第 6 天至哺乳期/產後 20 天，對懷孕大鼠口服施用 entecavir，劑量為每日每公斤體重 0.3、3 及 30 毫克。在評估的最高劑量下，暴露量 (AUC) 高於 MRHD 94 倍，並未對後代產生不良影響。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Breastfeeding Recommendation: Contraindicated (HIV) ; No Human Data—Probably Compatible (Hepatitis B) [仿單]目前尚不清楚 BARACLUDE 是否會排入人類乳汁、影響母乳分泌，或對哺乳嬰兒造成影響。 在大鼠哺乳期施用時，entecavir 會出現在乳汁中 (請見資料)。在考量哺餵母乳對發育和健康效益時，應一併考量產婦對 BARACLUDE 的臨床需求，以及 BARACLUDE或產婦的身體狀況對餵哺母乳嬰兒的所有可能不良反應。在大鼠哺乳第7天口服單劑 entecavir 10 mg/kg 後，entecavir 會分泌至大鼠的乳汁 中。乳汁中的 entecavir 約為母體血漿中的 25% (根據 AUC)。,AC;AC15;PO;,,,,,
EHYD,Hydrocortisone,Hydrocortisone cream 1%， 10gm,TDER,Relief of inflammation of corticosteroid-responsive dermatoses (low and medium potency topical corticosteroid); adjunctive treatment of ulcerative colitis; mild-to-moderate atopic dermatitis; inflamed hemorrhoids， postirradiation (factitial) proctitis， and other inflammatory conditions of anorectum and pruritus ani,Hypersensitivity to any component of the formulation.,Acneiform eruptions， burning， dryness， folliculitis， hypertrichosis， hypopigmentation， irritation， itching， maceration of skin， miliaria， perioral dermatitis， secondary infection， skin atrophy， striae,25℃以下,Apply thin film to affected area 2-4 times/day,無需調整劑量,,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;SKIN;TOPI;,,,,,
IMEP,Meropenem,Mepem inj 0.5gm,QANB,,適應症: Septicemia， phlegmon， lymphadenitis， tonsillar abscess， osteomyelitis， arthritis， periproctic abscess， traumatic wound infection， burn wound infection， operative wound infection， chronic bronchitis， bronchiectasis (with infection)， secondary infection in chronic respiratory disease， pneumonia， lung abscess & pyothorax， pyelonephritis， complicated cystitis， cholecystitis， cholangitis， & liver abscess， peritonitis， uterine adnexitis， intrauterine infection， inflammation of pelvic dead space， & parametritis， purulent meningitis， panophthalmitis， otitis media & sinusitis， gnathitis & phlegmon around the jaw. 副作用: Shock， serious renal disorders including acute renal failure， serious colitis accompanied with bloody stool， pseudomembranous colitis， interstitial pneumonia & PIE syndrome. CNS convulsion e.g. seizures， consciousness disorders. Lyell syndrome， Steven-Johnson syndrome， pancytopenia， agranulocytosis， leucopenia， hepatic disorders， jaundice， rash， urticaria， feeling of warmth， erythema， pruritus， fever & redness. Granulocytopenia， eosinophilia， thrombocytopenia or thrombocytosis & lymphocytosis increased GOT/GPT/LDH/A1-P/LAP/γ-GTP/bilirubin/urinary urobilinogen， decreased cholinesterase， increased urinary β2-microglobulin/BUN/creatinine， abdominal pain， diarrhea， nausea， vomiting & anorexia， stomatitis， candidiasis， vit K deficiency symptoms， vit B complex deficiency symptoms， headache， malaise. Dermatologic: Injection site inflammation (2.4% ) Gastrointestinal: Constipation (1.4% to 7% )， Diarrhea (3.5% to 7% )， Nausea and vomiting (3.6% adults; 0.8% children ) Neurologic: Headache (2.3% to 7.8% ) 禁忌: Hypersensitivity; coadministration with Na valproate.,,室溫,Adult 0.5-1 g IV infusion over > 30 min daily in 2-3 divided doses. Max: 2 g/day. Children 30-60 mg/kg IV infusion over > 30 min daily in 3 divided doses. May increase to 120 mg/kg but not exceeding the adult max daily dose of 2 g. Renal impairment: (Adults) Clcr 26-50 mL/minute: Administer recommended dose based on indication every 12 hours Clcr 10-25 mL/minute: Administer one-half recommended dose based on indication every 12 hours Clcr <10 mL/minute: Administer one-half recommended dose based on indication every 24 hours Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Meropenem and its metabolite are readily dialyzable: 500 mg every 24 hours.,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,1. 監測體溫、CBC、肝腎功能，注意是否有肌肉震顫或癲癇發作徵狀。 2. 給藥後第3 ~ 5天應特別觀察皮疹等不良反應。 3. Meropenem 0.5 gm/vial 乾粉使用100 mL適當輸注液稀釋，靜脈點滴輸注 > 30分鐘給藥。
ITPN2,TPN Solution,TPN-2 Solution,NUTR,,適應症:為20%靜脈營養輸注液(TPN0502297),,,,需調整劑量,,需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
OPIL,Cyproheptadine,Pilian 4mg,HIMM,Allergic rhinitis， vasomotor rhinitis， urticaria， allergic skin & blood disorders. Pruritus due to chicken pox.,Acute asthmatic attack. Premature infants,Sedation; drowsiness; dry mouth， nose & throat; Increase thickness of bronchial secretion， dizziness， upper abdominal discomfort.,25℃以下避光,Adult: 1 TAB TID-QID. Children: 7-14years 1/2 TAB， 2-6 years 1/4 TAB TID-QID.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
EKAR,Tazarotene,Karac cream 0.1%， 30gm,TDER,,適應症: Stable plaque psoriasis， acne vulgaris. 副作用: Pruritus， burning/stinging， erythema， worsening of psoriasis， irritation， pain， rash， desquamation， irritation， contact dermatitis. 禁忌: Pregnancy.,,室溫,Apply once daily at night.,,,,不可使用,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
OSMO2,Nicotine,Smokquit Mint Lozenges 2mg口含錠,ZADT,,,,,(Uptodate) Lozenge: Do not use more than 1 lozenge at a time. 4 mg for patients who smoke their first cigarette within 30 minutes of waking; 2 mg for others. The 12-week dosing schedule: Weeks 1-6: 1 lozenge every 1-2 hours (max: 5 lozenges Q6H; 20 lozenges/day); to increase chances of quitting， use at least 9 lozenges/day during the first 6 weeks. Weeks 7-9: 1 lozenge every 2-4 hours (max: 5 lozenges Q6H; 20 lozenges/day). Weeks 10-12: 1 lozenge Q4-8H (max: 5 lozenges Q6H; 20 lozenges/day).,無需調整劑量,,無需調整劑量,,,,,,,,,,,
IPROP,Propofol,Propofol-Lipuro 1% 20mL,ZANE,Induction of anesthesia in patients >=3 years of age; maintenance of anesthesia in patients >2 months of age; in adults， for monitored anesthesia care sedation during procedures; in adults， for sedation in intubated， mechanically-ventilated ICU patients.,Pregnancy， lactation & obstetrics (except abortion). General anesth in children <1 month & for sedation of children <16 years in ICU.,>10%:Cardiovascular: Hypotension (children 17%; adults 3% to 26%); Central nervous system: Movement (children 17%; adults 3% to 10%); Local: Injection site burning， stinging， or pain (children 10%; adults 18%); Respiratory: Apnea lasting 30-60 seconds (children 10%; adults 24%)， apnea lasting >60 seconds (children 5%; adults 12%) 1% to 10%: Cardiovascular: Hypertension (children 8%)， arrhythmia (1% to 3%)， bradycardia (1% to 3%)， cardiac output decreased (1% to 3%; concurrent opioid use increases incidence)， tachycardia (1% to 3%); Dermatologic: Pruritus (1% to 3%)， rash (children 5%; adults 1% to 3%); Endocrine & metabolic: Hypertriglyceridemia (3% to 10%); Respiratory: Respiratory acidosis during weaning (3% to 10%) <1% (Limited to important or life-threatening): Agitation， amblyopia， anaphylaxis， anaphylactoid reaction， anticholinergic syndrome， asystole， atrial arrhythmia， bigeminy， cardiac arrest， chills， cough， dizziness， delirium， discoloration (green [urine， hair， or nailbeds])， extremity pain， fever， flushing， hemorrhage， hypersalivation， hypertonia， hypomagnesemia， hypoxia， infusion site reactions (including pain， swelling， blisters and/or tissue necrosis following accidental extravasation); laryngospasm， leukocytosis， lung function decreased， myalgia， myoclonia (rarely including convulsions and opisthotonos)， nausea， pancreatitis， paresthesia， phlebitis， postoperative unconsciousness with or without increase in muscle tone， premature atrial contractions， premature ventricular contractions， pulmonary edema， propofol-related infusion syndrome， rhabdomyolysis， somnolence， syncope， thrombosis， urine cloudy， vision abnormality， wheezing,25℃以下避免冷凍,Given intravenously. Induction of general anesthesia: 20-40 mg every 10 seconds titrated against the patient's response. Adult < 55 years: 1.5-2.5 mg/kg IV. Patients > 55 years and of ASA (American society of anesthesiologists) grade III/IV may reduce dosage to 1 mg/kg and apply slower rate (20mg every 10 seconds). Children 1 month-3 years: 2.5-4 mg/kg. Children > 8 years: 2.5 mg/kg. Maintenance of general anesthesia: Adult: Continuous IV infusion: 4-12 mg/kg/hour. Adult: Repeat IV bolus: increments of 25-50 mg may be given according to clinical need. Children: 9-15 mg/kg/hour. Sedation of mechanically ventilated patients receiving intensive care: Continuous infusion: infusion rate should be determined by the desired depth of sedation. Rates at 0.3-4 mg/kg/hour should achieve satisfactory sedation. Do not use in sedation of ventilated ICU patients who is under 16 years. Procedural sedation for adults: Induction: 0.5-1 mg/kg over 1-5 minutes. Maintenance: 1.5-4.5 mg/kg/hour. In addition to the infusion， bolus administration of 10-20 mg may be used for rapid increase in the depth of sedation.Do not use in sedation for surgical & diagnostic procedures patients who is under 16 years.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,全麻用法 IVD:50~100mcg/kg/min，輸注時間不宜超過12小時，使用濃度勿低於2mg/mL。(最大稀釋比例 1:4),1.使用濃度勿低於2 mg/mL。(最大稀釋比例 1:4) 2.輸注時不可使用含微生物過濾器之輸液套。輸注本品建議使用流速滴定或體積設定幫浦控制流速。 3.本品不含防腐劑，開瓶後應立即抽取至無菌針筒或輸液套，剩餘的殘量應丟棄不用。 4.輸注未經稀釋的Propofol 1% 20mL時，使用同一系統輸注時間不宜超過12小時。使用12小時後，輸注管路與剩餘的藥物應丟棄、更換。 5.輸注稀釋過的Propofol 1% 20mL時，應於投藥前以無菌操作立即調配，且務必於6小時內使用。 6.可以藉由選擇前臂及肘前窩處較大靜脈血管進行注射來減低疼痛。
OMUCR,Iodopropylidene Glycerol,Mucora 30mg,ERSP,,Reduce the viscosity of sputum and expectorant.,,RT,Adult: 30-60 mg， tid-qid， Child: 30-60 mg/10kg， tid-qid.,,,,不可使用,,,,,,,,,,
IMEA1,Measles Vaccine,麻疹疫苗(免費),HIMM,,,,,,,,,,,,,,,,,,,
IXYL2,Lidocaine,Xylocaine 20mL 2% inj局麻,ZANE,For the production of local or regional anesth by infiltration， IV regional anesth， minor & major nerve blocks， epidural block & subarachnoid block.,Epidural or spinal anesth in patients with uncorrected hypotension or with coagulation disorders or receiving anti-coagulation treatment; inflammation &/or sepsis in the region of proposed inj or in the presence of septicemia; general contraindications related to epidural anesth should also be taken into account.,CNS reactions， either excitatory or depressant. CV reactions， mainly depressant. Maternal hypotension. Rarely allergic reactions.,25℃以下避免冷凍,Maximum recommended single dose of lidocaine is 3 mg/kg (plain solution) or 7 mg/kg (solution with adrenaline). Adult， 70 kg: Retrobulbar or peribulbar: 4 mL of 2% solution (80 mg). Sciatic nerve block: 15-20 mL of 2% solution (300-400 mg). Epidural anesthesia， Lumbar: 15-25 mL of 2% solution (300-500 mg). Epidural anesthesia， Thoracic: 15-20 mL of 2% solution (300-400 mg).,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IRR;LA;LI;,,,,,
OMUCA,Oxethazaine+Aluminum hydroxide+Magnesium oxide,Mucaine,ALIM,Symptomatic relief of gastric pain & heartburn due to gastric hyperacidity.,Hypophosphatemia; severe renal impairment; symptoms of appendicitis.,Hypersensitivity reactions， dermatitis， urticaria， pruritus， glossitis， angioedema & collapse. In large doses， dizziness， faintness or drowsiness. Diarrhea， constipation.,密閉置於冷暗處,2-4 TAB QID.,無需調整劑量,,無需調整劑量,盡量避免,Uknown 沒有資料,,Unknown 沒有資料,,AC15;PO;,,,,,
IPAR,Carboplatin,Paraplatin inj 150mg/15mL,RACA,Ovarian cancer， advanced: Initial treatment of advanced ovarian cancer in combination with other established chemotherapy agents; palliative treatment of recurrent ovarian cancer after prior chemotherapy， including cisplatin-based treatment.,History of severe allergic reaction to carboplatin， cisplatin， other platinum-containing formulations， mannitol， or any component of the formulation; should not be used in patients with severe bone marrow depression or significant bleeding.,Myelosuppression especially thrombocytopenia， leukopenia; nausea & vomiting， abdominal pain， diarrhea， constipation; nephrotoxicity; neurotoxicity including paresthesia & decreased deep tendon reflexes; transient visual disturbances， ototoxicity manifesting as tinnitus; abnormal liver function tests; hypersensitivity reactions.,15-25℃避光,CALVERT FORMULA FOR CARBOPLATIN DOSING: Total Dose (mg) = (target AUC mg/mL•min)) x (GFR mL/min + 25)Target AUC of 4-6 mg/mL•min using single-agent carboplatin appears to provide the most appropriate dose range in previously treated patients.  [Recurrent Ovarian Carcinoma] 360 mg/m2 as a single agent on day 1 every 4 weeks. Treatment course should not be repeated until the neutrophil count is > 2，000 and the platelet count is > 100，000.  [Advanced Ovarian Cancer， previously untreated] 300 mg/m2 in combination with cyclophosphamide 600 mg/m2 on day 1 every 4 weeks for 6 cycles. Treatment course should not be repeated until the neutrophil count is > 2，000 and the platelet count is > 100，000.,無需調整劑量,,需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,PARAPLATIN 通常輸注15 分鐘以上,1. 室溫，配製後安定性室溫8小時 2. 不可使用含鋁針頭或可能與藥品接觸部位含鋁的靜脈給藥器組。
ILAN,Insulin glargine,Lantus inj 100U/mL， 3mL pre-filled Pen,META,,適應症:Treatment of type 1 diabetes mellitus (insulin dependent， IDDM) and type 2 diabetes mellitus (noninsulin dependent， NIDDM) to improve glycemic control. 副作用:Primarily symptoms of hypoglycemia 禁忌:Hypersensitivity to insulin glargine or to any of the excipients.,,2-8 C,---Diabetes mellitus， type 2: SubQ: Initial basal insulin dose: 10 units (or 0.2 units/kg) once daily ---Conversion to insulin glargine from other insulin therapies: Converting from once-daily NPH insulin: May be substituted on an equivalent unit-per-unit basis Converting from twice-daily NPH insulin: Initial dose: Use 80% of the total daily dose of NPH (eg， 20% reduction); administer once daily; adjust dosage according to patient response,,,,除非治療上需要,,,Compatible 哺乳時可使用,,SC;,,,,,
OOXB,Oxybutynin,Oxbu 5mg extended-release,SGU,Relief of symptoms associated w/ voiding in patients w/ uninhibited neurogenic & reflex neurogenic bladder.,Myasthenia gravis， glaucoma; GI obstruction， paralytic ileus， intestinal atony， megacolon， severe colitis; acute haemorrhage.,Dry mouth， blurred vision， tachycardia， dizziness， impotence; allergic reactions.,25℃以下,Initially， 5 mg once daily increased by 5 mg every week if necessary to the maximum 30 mg daily.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為緩釋錠整粒吞服，不可咀嚼或磨碎。
ORAD,Potassium Gluconate,Radi-K (2.54 mEq K+/tab),NUTR,,適應症: Hypokalemia. 副作用: GI upsets. 禁忌: Hyperkalemia; marked renal failure; concomitant treatment with K-sparing diuretics & patients in whom there is cause for arrest or delay in tab passage through the GI.,,室溫,Prophylaxis: 3-9 tab daily. 1 g potassium gluconate = elemental potassium 167 mg = potassium 4.3 mEq = potassium 4.3 mmol,無需調整劑量,,無需調整劑量,除非治療上需要,,,Compatible 哺乳時可使用,,,,,,,
OLIP20,Atorvastatin,Lipitor 20mg,CAVS,Hyperlipidemia.,Active liver disease or persistent elevations of serum transaminases > 3 times the upper limit of normal. Pregnancy & lactation.,Constipation， flatulence， dyspepsia， abdominal pain， headache， nausea， myalgia， asthenia， diarrhea， insomnia. Gastrointestinal: Diarrhea (up to 14.1% ) Musculoskeletal: Arthralgia (up to 11.7% ) Renal: Urinary tract infectious disease (up to 8% ) Respiratory: Nasopharyngitis (8.3% ) Other: Pain， In extremity (up to 9.3% ),30℃以下,Adults: Initial 10 mg once daily at any time of the day， with or without food; dosage range: 10-80 mg/day. Children aged 10-17 years: 10-20 mg/day.,無需調整劑量,以上哺乳及懷孕分級參考來源為藥品仿單。,無需調整劑量,不可使用,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,以上哺乳及懷孕分級參考來源為藥品仿單。,AC;AC15;PC;PO;WM;,,,,,
OSYN3,Flurazepam,Syndoman 30mg,CNEU,Short-term treatment of insomnia,Hypersensitivity to flurazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); narrow-angle glaucoma; pregnancy,Cardiovascular: Chest pain， flushing， hypotension， palpitation Central nervous system: Apprehension， ataxia， confusion， depression， dizziness， drowsiness， euphoria， faintness， falling， hallucinations， hangover effect， headache， irritability， lightheadedness， memory impairment， nervousness， paradoxical reactions， restlessness， slurred speech， staggering， talkativeness Dermatologic: Pruritus， rash Gastrointestinal: Appetite increased/decreased， bitter taste， constipation， diarrhea， GI pain， heartburn， nausea， salivation increased/excessive， upset stomach， vomiting， weight gain/loss， xerostomia Hematologic: Granulocytopenia， leukopenia Hepatic: Alkaline phosphatase increased， ALT increased， AST increased， cholestatic jaundice， total bilirubin increased Neuromuscular & skeletal: Body/joint pain， dysarthria， reflex slowing， weakness Ocular: Blurred vision， burning eyes， difficulty focusing Respiratory: Apnea， dyspnea Miscellaneous: Diaphoresis， drug dependence,25℃以下乾燥且避光的處所,Adults: General dose: 30mg HS. Dosage range: 15-60mg. The elderly and the frail: Initial dose: 15mg， increase according to the individual response.,無需調整劑量,Potential toxicity if combined with other CNS depressants,無需調整劑量,不可使用,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Potential toxicity if combined with other CNS depressants,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
ITPN2A,TPN-2 Solution,TPN-2A Solution (1500mL/bag),NUTR,,,,,,需調整劑量,,需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,IV;IVD;,,,,,
IVIC,Liraglutide,Victoza inj 6mg/mL， 3mL,META,,適應症: Diabetes mellitus type 2 副作用: ■Hypoglycemia (monotherapy， 9.7%; combination therapy， 3.6% to 27.4% ) ■Constipation (9.9% )， Diarrhea (17.1% )， Nausea (28.4% )， Vomiting (10.9% ) ■Headache (9.1% ) ■Upper respiratory infection (9.5% ) ■C-cell hyperplasia of thyroid， Papillary thyroid carcinoma ■Gastrointestinal: Pancreatic cancer， Pancreatitis ■Renal: Acute renal failure 禁忌:Hypersensitivity to liraglutide or any component of the product;Medullary thyroid carcinoma (MTC); Multiple endocrine neoplasia syndrome type 2 (MEN 2),,2-8C,initial: 0.6 mg SC every day for 1 week. maintenance: 1.2 mg SC once daily; may increase to 1.8 mg/day if needed; MAX: 1.8 mg/day. If more than 3 days elapse between doses， reinitiate at 0.6 mg/day SUBQ,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,
OBRI,Ticagrelor,Brilinta 90mg,HEMT,Prevention of atherothrombotic events in patients w/ acute coronary syndromes (ACS) [unstable angina， non-ST elevation MI (NSTEMI) or ST elevation MI (STEMI)] including patients managed medically & managed w/ percutaneous coronary intervention (PCI) or CABG co-administered w/ acetylsalicylic acid (ASA).,Active pathological bleeding， history of intracranial haemorrhage， moderate to severe hepatic impairment， co-administration w/ strong CYP3A4 inhibitors.,Dyspnoea， epistaxis， GI haemorrhage， subcutaneous or dermal bleeding， bruising， procedural site haemorrhage.,30℃以下保持乾燥,Acute coronary heart disease: loading dose as 180mg and followed by 90mg BID for 12 months. Patient with MI history combined with high risk of arterial thrombosis， needed an extended treatment: 60mg BID.,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;PC;PO;,,,,,
OSERM,Nicergoline,Sermion 5mg,CAVS,,適應症: Acute or chronic vascular or metabolic cerebral insufficiency (cerebral arteriosclerosis， cerebral thrombosis and embolism， transient cerebral ischaemia). Acute or chronic peripheral vascular insufficiency (obliterative vascular diseases of the limbs， Raynaud's syndrome， other syndromes due to altered peripheral flow). Headache. As an adjuvant to the therapy of arterial hypertension and parenterally， of hypertensive crises. 副作用: Rare cases of mild side effects have been reported， which in general may be related to the vasoactive action of Sermion. These are hypotension and vertigo after parenteral administration， slight gastric disturbances， feeling of heat and flushing， drowsiness and insomnia. 禁忌: Hypersensitivity to nicergoline.,,室溫,Oral: 5-10 mg 3 times daily at regular intervals for prolonged periods. In order to improve absorption， the drug should be taken between meals. 60 mg a day in two administrations orally at regular intervals,,,,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,,,,,,
OFEB,Febuxostat,Feburic 80mg,CNEU,Chronic hyperuricaemia where urate deposition had occurred including history or presence of tophus &/or gouty arthritis.,Hypersensitivity. Concomitant use of azathioprine or mercaptopurine.,(common): ■Dermatologic: Rash (0.5% to 1.6% ) ■Gastrointestinal: Nausea (1.1% to 1.3% ) ■Hepatic: Liver enzymes abnormal (4.6% to 6.6% ) ■Musculoskeletal: Arthralgia (0.7% to 1.1% )， Gout， acute 副作用 (serious) ■Cardiovascular: Death， Cardiovascular， Myocardial infarction ■Dermatologic: Stevens-Johnson syndrome ■Hematologic: Idiopathic thrombocytopenic purpura (less than 1% ) ■Hepatic: Hepatitis (less than 1% )， Liver failure ■Immunologic: Anaphylaxis， Immune hypersensitivity reaction (less than 1% ) ■Musculoskeletal: Rhabdomyolysis ■Neurologic: Cerebrovascular accident (less than 1% )， Transient ischemic attack (less than 1% ) ■Renal: Renal failure (less than 1% )， Tubulointerstitial nephritis ■Other: Angioedema (less than 1% ),30℃以下,Gout: Initial dose: 40mg QD. If the serum uric acid concentration is not lower than 6mg/dL after taking the medicine for 2 weeks， change to 80mg QD. Tumor lysis syndrome: Two days before the start of cytotoxic drug treatment， 80 mg QD for 7 days. According to the clinical response during chemotherapy， it can be extended to 9 days.,無需調整劑量,,需調整劑量,,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
EDEH,Calamine + Diphenhydramine,Dehist lotion 100mL,TDER,,適應症: Symptomatic relief of skin irritation & itch associated with urticaria， insect bites， nappy rash & other minor skin problems. 禁忌: Avoid use on broken or eczematous skin. May affect ability to drive or operate machinery.,,室溫,Apply 3-4 times daily on the affected area.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IHAL0,Eribulin,Halaven inj 1mg/2mL (sample),RACA,Treatment of Breast cancer， metastatic.,Hypersensitivity to eribulin mesylate， halichondrin B， or its chemical derivatives.,>10%: Central nervous system: Fatigue (54%)， fever (21%)， headache (19%) Dermatologic: Alopecia (45%) Gastrointestinal: Nausea (35%)， constipation (25%)， weight loss (21%)， anorexia (20%)， diarrhea (18%)， stomatitis (5% to 18%)， vomiting (18%) Hematologic: Neutropenia (82%; grades 3: 28%; grade 4: 29%; nadir: 13 days; recovery: 8 days)， anemia (58%; grades 3/4: 2%) Hepatic: ALT increased (18%) Neuromuscular & skeletal: Weakness (54%)， peripheral neuropathy (35%; grades 3/4: ?8%)， arthralgia/myalgia (22%)， back pain (16%)， bone pain (12%)， limb pain (11%) Respiratory: Dyspnea (16%)， cough (14%) 1% to 10%: Cardiovascular: Peripheral edema Central nervous system: Depression， dizziness， insomnia Dermatologic: Rash Endocrine & metabolic: Hypokalemia Gastrointestinal: Mucosal inflammation (9%)， abdominal pain， dyspepsia， taste alteration， xerostomia Genitourinary: Urinary tract infection (10%) Hematologic: Neutropenic fever (5%)， thrombocytopenia (grades 3/4: 1%) Neuromuscular & skeletal: Muscle spasm Ocular: Lacrimation increased Respiratory: Upper respiratory infection <1% (Limited to important or life-threatening): Pancreatitis， pharyngolaryngeal pain， sepsis,25℃以下,1.4 mg/m2 on days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,不可以葡萄糖溶液稀釋或含葡萄糖溶液之靜脈注射管線給藥。
OUTRO,Progesterone,Utrogestan 100mg,HM,Oral: Prevention of endometrial hyperplasia in nonhysterectomized， postmenopausal women who are receiving conjugated estrogen tablets; secondary amenorrhea.,Hypersensitivity to progesterone or any component of the formulation; undiagnosed abnormal vaginal bleeding; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT， PE); active or history of arterial thromboembolic disease (eg， stroke， MI); history of or known or suspected carcinoma of the breast or genital organs; hepatic dysfunction or disease; missed abortion or ectopic pregnancy; diagnostic test for pregnancy; capsules are also contraindicated for use during pregnancy,Central nervous system: Headache (16% to 31%)， dizziness (15% to 24%)， depression (19%) Endocrine & metabolic: Breast tenderness (27%)， breast pain (6% to 16%) Gastrointestinal: Abdominal pain (10% to 20%)， abdominal bloating (8% to 12%) Genitourinary: Urinary problems (11%) Neuromuscular & skeletal: Joint pain (20%)， musculoskeletal pain (12%) Miscellaneous: Viral infection (12%),30℃以下,Oral: 200-300mg devided into 1-2 tims. Vaginal: 100mg two times daily.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;VAG;WM;,,,,,[磨粉/管灌註記]軟膠囊不可剝半或磨粉。無法吞服病患可以溫水溶解後服用。
IVAQ,Inactivated Hepatitis A Virus Vaccine,Vaqta(小兒A肝疫苗) 0.5mL/dose,HIMM,Vaccination against infection caused by hepatitis A virus.,Hypersensitivity to any component of the vaccine.,Pain， tenderness & swelling at inj site. Warmth， erythema， ecchymosis， abdominal pain， diarrhoea， vomiting， headache， pharyngitis.,2-8℃避免冷凍,IM， 0.5mL， 12 months-18 years primary immunization. A booster dose after 6-18 months.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,1. 肌肉注射於成人或孩童的三角肌部位，嬰兒則應注射於大腿前外側部位。
OLEN,Brotizolam,Lendormin 0.25mg,CNEU,Insomnia,Hypersensitivity to Brotizolam,Dizziness， headache， tiredness,25℃以下,Adults: Oral: 0.25 mg at bedtime. Elderly: 0.125 mg - 0.25 mg. Treatment should be started with the lowest recommended dose. The recommended dose of 0.25 mg should not be exceeded because of the increased risk of unacceptable CNS-adverse effects.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
IEYL,Aflibercept,Eylea aflibercept 2mg/0.05mL,TOPH,Treatment of neovascular (wet) age-related macular degeneration (AMD).,1.Ocular or periocular infection 2.Active intraocular inflammation 3.Hypersensitivity,>10%: Ocular: Conjunctival hemorrhage (12% to 25%)， eye pain (9% to 13%) 1% to 10%: Local: Injection site pain (3%)， injection site hemorrhage (1%) Ocular: Intraocular pressure increased (5% to 8%)， cataract (7%)， vitreous detachment (6%)， vitreous floaters (5% to 6%)， conjunctival hyperemia (4% to 5%)， corneal erosion (4% to 5%)， foreign body sensation (3%)， lacrimation increased (3%)， retinal pigment epithelium detachment (3%)， blurred vision (1% to 2%)， retinal pigment epithelium tear (2%)， eyelid edema (1%)， corneal edema (1%) Miscellaneous: Aflibercept antibodies (1% to 3%) <1% (Limited to important or life-threatening): Endophthalmitis， hypersensitivity， intraocular inflammation， retinal detachment， retinal tear， thromboembolic events， traumatic cataract,2-8℃避光避免冷凍,Wet type (Neovascular) of age-related macular degeneration (wAMD): 2 mg every 4 weeks for the first 3 injections then every 8 weeks thereafter. Macular edema following central retinal vein occlusion (CRVO): 2 mg every 4 weeks via IVIA. Diabetic macular edema: 2 mg every 4 weeks for the first 5 injections， followed by 2 mg every 8 weeks. Macular edema induced visual impairment following branch retinal vein occlusion (BRVO): 2 mg every 4 weeks for the first 6 injections， followed by 2 mg every 8 weeks. Choroidal neovascularization(CNV) following pathological myopia: 2 mg single dose via IVIA. May repeat 1 to 3 times a year with the 1 month- interval according to the doctor's judgment on vision and/or anatomy.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVI;,,,,,僅供眼科玻璃體內注射用。EYLEA 必須由合格醫師注射。
EXYL,Zinc Oxide+ Lidocaine+ Alu. Acetate+Hydrocortisone,Xylmol oint 15gm,ALIM,,適應症: Hemorrhoids， anal rhagades & inflammatory conditions， perianal abscess， proctoptosis.,,室溫,Apply tid-qid.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,EXT;RECT;,,,,,
OFLUC,Acetylcysteine,Flucil 100mg/PK,ERSP,,適應症: Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis， emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms. 副作用: Bronchospasm， GI upsets， stomatitis; rhinorrhea， fever， hemoptysis; rarely anaphylactic reactions. Dermatologic: Pruritus (1% to 4.3% )， Rash (4% to 5% )， Urticaria Gastrointestinal: Diarrhea， Nausea (2% to 7% )， Vomiting (9% to 12% ) 禁忌: Effervescent tab Phenylketonuria.,,室溫,Adult and 12 years older Children: 200 mg tid. 6Y-12Y Children:100 mg tid. 3Y-6Y Children: 50mg tid.,無需調整劑量,,無需調整劑量,可能安全,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ODUO,Dutasteride + Tamsulosin,Duodart 0.5/0.4mg,SGU,Benign prostatic hyperplasia: Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate,Hypersensitivity (clinically significant) to dutasteride， tamsulosin， other 5-alpha-reductase inhibitors (eg， finasteride)， or any component of the formulation; children; women of childbearing potential; pregnancy,1% to 10%: Central nervous system: Dizziness (2%) Endocrine & metabolic: Decreased libido (5% to 6%)， breast changes (3% to 5%， including enlargement， swelling， pain， tenderness， gynecomastia， nipple pain， nipple swelling) Genitourinary: Ejaculatory disorder (10% to 11%)， impotence (8% to 10%) <1% (Limited to important or life-threatening): Prostate cancer (high-grade),25℃的環境中,The recommended dose of Duodart is 1 capsule daily (0.5 mg / 0.4 mg). Duodart must always be taken with a glass of water， up to 30 minutes after a meal. It must never be taken on an empty stomach. Ideally， it should be taken at the same time of the day (this means with the same meal). The capsules should be swallowed whole and not chewed or opened， as contact with the capsule contents may result in irritation of the oropharyngeal mucosa.,無需調整劑量,Up-to date: Breast-Feeding Considerations:It is not known if dutasteride or tamsulosin are excreted in human milk. Use is contraindicated in women of childbearing potential. TAMSULOSIN BREASTFEEDING RECOMMENDATION: No Human Data—Potential Toxicity,無需調整劑量,不可使用,Uknown 沒有資料,TAMSULOSIN PREGNANCY RECOMMENDATION: No Human Data—Animal Data Suggest Low Risk BREASTFEEDING RECOMMENDATION: No Human Data—Potential Toxicity,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),Up-to date: Breast-Feeding Considerations:It is not known if dutasteride or tamsulosin are excreted in human milk. Use is contraindicated in women of childbearing potential. TAMSULOSIN BREASTFEEDING RECOMMENDATION: No Human Data—Potential Toxicity,PC;PO;,,,,,[磨粉/管灌註記]本藥應整粒吞服， 切勿咬嚼、壓碎或打開膠囊。本藥具致畸胎性，請注意相關暴露風險，尤其是婦女及小孩。
OAFI,Everolimus,Afinitor 5mg,RACA,Treatment of postmenopausal women w/ advanced hormone receptor positive & HER-2 negative breast cancer in combination w/ exemestane after failure of treatment w/ letrozole or anastrozole. Progressive neuroendocrine tumors of pancreatic origin (PNET) w/ unresectable， locally advanced or metastatic disease. Advanced renal cell carcinoma (RCC) after failure of treatment w/ sunitinib or sorafenib.,Hypersensitivity to everolimus or other rapamycin derivatives.,Stomatitis， infections， rash， fatigue， diarrhea， decreased appetite， hyperglycemia， dyspnea， pneumonitis， hypercholesterolemia， increased AST & ALT， anemia， leukopenia， thrombocytopenia， lymphopenia， hypertriglyceridemia， decreased K.,15-30℃避光及避免潮濕,[Advanced Breast cancer， hormone receptor-positive， HER2-negative; Advanced Neuroendocrine tumors (GI， lung， or pancreatic origin); Advanced Renal cell cancer (RCC)] 10 mg orally once daily， continue treatment until disease progression or unacceptable toxicity,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest moderate risk,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。不可咀嚼或咬碎錠劑。對無法吞服錠劑的病人，應將本藥以輕輕攪拌的方式完全溶散( 約7 分鐘) 於一杯水( 約30 毫升) 中，並立即喝下。再於杯中倒入等量的水洗滌，然後將洗滌液全部喝掉，以確保服下完整劑量。
OVEM,Tenofovir alafenamide,Vemlidy 25mg,QANB,Chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.,Hypersensitivity to tenofovir alafenamide or any component of the formulation.,Headache， abdominal pain， fatigue， cough， nausea， back pain.,30℃以下,Adutl: 25 mg orally once daily.,需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,
EDHEP,Acyclovir,Deherp cream 5%， 5gm,TDER,Herpes simplex virus infection of the skin.,Hypersensitivity to acyclovir or any other component of the product. Hypersensitivity to any component of this product with the topical ointment.,Common Dermatologic: Contact dermatitis (topical cream， 2% )，Application site reaction(5% )，Transient burning or stinging. Mild drying & flaking. Erythema & itching.,25℃以下乾燥處,Apply topically every 4 hours， 5 times per day for 5 days in sufficient quantities to adequately cover the lesion. Maybe prolong to 10 days if necessary.,無需調整劑量,[仿單]無充分資料指出使用本品對孕婦及胎兒之影響，以及使用本品後乳汁中Acyclovir之濃度。 因此孕婦及授乳婦女宜審慎評估利弊後再使用本品。,無需調整劑量,沒有資料,Compatible,[仿單]無充分資料指出使用本品對孕婦及胎兒之影響，以及使用本品後乳汁中Acyclovir之濃度。 因此孕婦及授乳婦女宜審慎評估利弊後再使用本品。,Compatible 哺乳時可使用,[仿單]無充分資料指出使用本品對孕婦及胎兒之影響，以及使用本品後乳汁中Acyclovir之濃度。 因此孕婦及授乳婦女宜審慎評估利弊後再使用本品。,EXT;,,,,,
IGLY3,Glycerin + Fructose + Sodium chloride,Glycetose inj 10%， 300mL,CAVS,Treatment of increased intracranial pressure and intracranial edema， improvement of impaired consciousness and neurologic deficits in cerebral infarct， intracerebral and subarachnoid hemorrhages， head injury， brain tumor， cerebromeningitis. Post operation therapy following brain surgery; reduction of brain volume at time of brain surgery.,Hypersensitivity to any component in the preparation.,Lactic acidosis; hemoglobinuria; headache， thirst， nausea; hypernatremia.,無特別指示,Adult usual dosage: 200-500 mL QD-BID IV infusion (rate: 500 mL over 2-3 hours). Duration of treatment usually is about 1-2 weeks， the dosage may be adjusted according to age and symptoms. Reduction of the brain volume during brain surgery: IV bolus of 500 mL over 30 minutes.,無需調整劑量,Glycerin: No Human Data - Probably Compatible [仿單]沒有相關說明,需調整劑量,沒有資料,No (limited) human data – probably compatible,Glycerin: Limited Human Data - Probably Compatible [仿單]沒有相關說明,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Glycerin: No Human Data - Probably Compatible [仿單]沒有相關說明,IVD;,,,,仿單建議500mL以2~3小時滴注，若為縮小腦容量為目的者500mL以30分鐘滴注,廠商建議本藥開封後僅供當次使用，不可保存。
ICOMDBA1,SARS-CoV-2 Spike glycoprotein [mRNA],BA1雙價Moderna(Covid19) 0.5mL/dose(2.5mL/vial),HIMM,Moderna COVID-19 Vaccine， for active immunization to prevent COVID-19 in individuals 18 years of age and older.,Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g.， anaphylaxis) to any component of the Moderna COVID-19 Vaccine.,erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.,-50℃至-15℃可保存9個月。2-8℃避免光照，可保存30天。離冷藏於8-25℃只可保存24小時,IM， 0.5 mL， > or = 18 years， As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine， bivalent Original/Omicron BA.1 which contains elasomeran and an additional mRNA molecule.,無需調整劑量,[仿單]由於哺乳婦女接種Spikevax原病毒株疫苗後之全身性暴露可被忽略，預期對於餵哺母乳之新生兒/嬰兒不具影響。 觀察性資料顯示哺乳婦女接種疫苗後，並未出現對餵哺母乳之新生兒/嬰兒有害的影響。 哺乳期間可以接種Spikevax原病毒株疫苗。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]大量的觀察性資料顯示，孕婦在第二與第三孕期接種Spikevax原病毒株疫苗並未增加不良懷孕結果。 雖然在第一孕期接種的懷孕結果資料有限，但是並未發現流產風險有上升的現象。 動物試驗並未顯示Spikevax原病毒株疫苗會對懷孕、胚胎／胎兒發育、分娩或產後發育會造成直接或間接有害的影響。 懷孕期間可以接種Spikevax原病毒株疫苗。,Unknown 沒有資料,[仿單]由於哺乳婦女接種Spikevax原病毒株疫苗後之全身性暴露可被忽略，預期對於餵哺母乳之新生兒/嬰兒不具影響。 觀察性資料顯示哺乳婦女接種疫苗後，並未出現對餵哺母乳之新生兒/嬰兒有害的影響。 哺乳期間可以接種Spikevax原病毒株疫苗。,IM;,,,,,1. 本藥為多劑量藥瓶。每瓶可抽取5劑，每劑0.5mL。 2. 未開封藥瓶，冷藏於2-8℃下可保存30天，室溫保存於8-25℃下可保存24小時。已抽液藥瓶，冷藏或室溫下可保存19小時，19小時後須丟棄。 3. 解凍後，請勿重新冷凍。使用前請先將藥瓶解凍，解凍方式：放置冷藏室(2-8℃)2小時30分鐘，並於施打前請將藥瓶放置室溫(15-25℃)15分鐘。或者放置室溫(15至25℃)1小時。 4. 本疫苗應以肌肉注射方式施打，理想注射部位為上臂三角肌。請勿以血管內注射、皮下注射或皮內注射方式施打本疫苗。
HE1806,,#8 血液透析液-3.8L A液,NUTR,,,,避光、室溫貯存，請勿冷凍。,"信東"血液透析液8號使用時配合"信東"腎臟透析液300號(乙)、R.O.水使用。透析時請遵照人工腎臟機操作說明、操作方法進行透析。透析液為: acid concentrate:bicarbonate concentrate:R.O. water = 1 1，83 34,無需調整劑量,,無需調整劑量,,,,,,,,,,,
IOPD,Nivolumab,Opdivo inj 100mg/10mL,RACA,Unresectable or Metastatic Melanoma. Adjuvant Treatment of Melanoma. Metastatic Non-Small Cell Lung Cancer. Advanced Renal Cell Carcinoma. Classical Hodgkin Lymphoma. Squamous Cell Carcinoma of the Head and Neck. Urothelial Carcinoma. Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient. Hepatocellular Carcinoma.,Specific contraindications have not been determined.,Common Hypertension (36% )， Hand-foot syndrome due to cytotoxic therapy (40% )， Pruritus (10% to 53% )， Rash (16% to 53% )， Hyperglycemia (6% to 19% )， Abdominal pain (10% to 34% )， Constipation (10% or greater )， Decrease in appetite (14% to 35% )， Nausea (16% to 34% )， Stomatitis (Up to 37% )， Vomiting (12% to 31% )， Arthralgia (10% to 23% )， Backache (Renal cell carcinoma， 21% )， Musculoskeletal pain (17% to 42% )， Headache (11% to 23% )， Neuropathy (Up to 12% )， Cough (10% to 37% )， Dyspnea (2% or greater )， Upper respiratory infection (9% to 44% )， Fatigue (12% or 62% ). Serious Myocarditis， Pericarditis， Shock， Vasculitis， Erythroderma， Stevens-Johnson syndrome， Toxic epidermal necrolysis， Adrenal insufficiency (0.6% to 18% )， Diabetic ketoacidosis (0.1% )， Hyperthyroidism (2.7% to 12% )， Hypophysitis (0.6% to 9% )， Hypopituitarism， Hypothyroidism (4.5% to 34% )， Thyroiditis (0.6% )， Type 1 diabetes mellitus (0.9% )， Colitis (1.9% to 26% )， Diarrhea (17% to 64% )， Duodenitis， Esophageal fistula， Fatal (0.5% )， Gastritis， Gastrointestinal hemorrhage， Fatal (0.5% )， Pancreatitis， Perforation of colon (Less than 10% )， Aplastic anemia， Autoimmune hemolytic anemia， Hemoptysis， Massive， Idiopathic thrombocytopenic purpura， Thrombocytopenia， Hepatitis (1.8% to 21% )， Hepatotoxicity (44% )， Veno-occlusive disease of the liver， Graft versus host disease， Histiocytic necrotizing lymphadenitis， Sarcoidosis， Transplanted organ rejection， Arthritis， Eaton-Lambert syndrome， Myasthenia gravis， Myositis， Polymyalgia rheumatica， Polymyositis， Rhabdomyolysis， Demyelination of spinal cord， Encephalitis， Guillain-Barre syndrome， Meningitis， Myelitis， Iritis， Myasthenia gravis， ocular， Unexplained visual loss， Uveitis (0.8% )， Vogt-Koyanagi-Harada disease， Nephritis， Renal impairment， Urinary tract infectious disease (Urothelial carcinoma， 17% )， Interstitial lung disease (16% )， Pleural effusion (2% or greater )， Pneumonia (2% or greater )， Pneumonitis (1.3% to 10% )， Pulmonary embolism (Non-small cell lung cancer， recurrent， 4.2% )， Respiratory failure (2% or greater )， Respiratory tract infection (2% or greater ) Other: Cytomegalovirus infection， Disorder characterized by fever， Steroid-requiring， Sepsis (2% or greater ),2-8℃勿冷凍,Monotherapy: [Melanoma， unresectable or metastatic; Non-small cell lung cancer， metastatic， progressive; Renal cell carcinoma， advanced; Hodgkin lymphoma， classical; Head and neck cancer， squamous cell; Urothelial carcinoma， locally advanced or metastatic; Gastric cancer or gastroesophageal junction cancer， advanced or metastatic; Hepatocellular carcinoma; Colorectal cancer， metastatic， microsatellite instability-high or mismatch repair deficient] 3 mg/kg infused over 30 minutes once every 2 weeks until disease progression or unacceptable toxicity. [Esophageal carcinoma， squamous cell， unresectable advanced， recurrent， or metastatic] 240 mg infused over 30 minutes once every 2 weeks until disease recurrence or unacceptable toxicity. [Melanoma， adjuvant treatment] 3 mg/kg infused over 30 minutes once every 2 weeks until disease recurrence or unacceptable toxicity for up to 1 year. Combination therapy: [Melanoma， unresectable or metastatic] 1 mg/kg once every 3 weeks in combination with ipilimumab 3 mg/kg over 90 minutes for a maximum of 4 combination doses or until unacceptable toxicity (whichever occurs earlier)， followed by nivolumab 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity. [Non-small cell lung cancer， metastatic， PD-L1-expressing] 3 mg/kg once every 2 weeks in combination with ipilimumab 1 mg/kg once every 6 weeks until disease progression， unacceptable toxicity or for up to 2 years in patients without disease progression. [Non-small cell lung cancer， metastatic or recurrent] 360 mg once every 3 weeks in combination with ipilimumab 1 mg/kg every 6 weeks and histology-based platinum-doublet chemotherapy every 3 weeks until disease progression， unacceptable toxicity or for up to 2 years in patients without disease progression. [Renal cell carcinoma， advanced， first-line treatment; intermediate or poor risk] 3 mg/kg once every 3 weeks in combination with ipilimumab 1 mg/kg over 30 minutes for 4 combination doses， followed by 3 mg/kg once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. [Colorectal cancer， metastatic， microsatellite instability-high or mismatch repair deficient] 3 mg/kg once every 3 weeks in combination with ipilimumab 1 mg/kg over 30 minutes for 4 combination doses， followed by 3 mg/kg once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity.,無需調整劑量,[仿單]目前不清楚 OPDIVO 是否會分泌至人體乳汁中。 由於許多藥物(包括抗體)會分泌至人體乳汁中， 且因為OPDIVO 對接受哺乳的嬰兒可能造成嚴重不良反應， 建議孕婦在接受 OPDIVO 治療期間停止哺乳。,無需調整劑量,沒有資料,Contraindicated,[仿單]根據其作用機轉和動物試驗資料，當對孕婦投予 OPDIVO，可能會對胎兒造成傷害。在動物生殖研究中，對馬來猴從器官形成開始到生產期間投予 nivolumab，導致流產和早產胎兒死亡情形增加。 已知人類 IgG4 會通過胎盤障壁，nivolumab 亦為一種免疫球蛋白 G4 (IgG4)；因此，nivolumab 可能會從母體傳遞到發育中的胎兒。 OPDIVO 對第二及第三孕期的影響可能較大。目前尚無可說明此藥物相關風險的人類研究資料。應告知孕婦本品對胎兒的潛在風險。 目前不清楚對適用族群之重大先天缺陷和流產的背景風險；不過，在美國一般族群中，臨床上確認懷孕的背景風險分別是重大先天缺陷為 2%-4%，以及流產為 15%-20%。 PD-1/ PD-L1 途徑的一項核心作用為透過維持母體對胎兒的免疫耐受性來持續孕期。已在懷孕鼠模型證明，阻斷 PD-L1 信號會破壞對胎兒的耐受性並導致流產的增加。 從器官形成開始到生產期間，對猴子每週投予兩次 nivolumab (其曝藥量比接受 nivolumab 3 mg/kg 臨床劑量所觀察到之曝藥量高出 9 至 42 倍[根據血中濃度時間曲線下面積，AUC])，以評估 nivolumab 對產前和產後發育的影響。 投予 nivolumab 會導致非劑量相關的自然流產和新生兒死亡增加。根據其作用機轉，胎兒暴露於 nivolumab 可能會使免疫調節性異常或正常免疫反應改變的風險增加，在 PD-1 基因剔除小鼠中曾發生免疫調節性異常。 接受nivolumab 治療的馬來猴存活子代中 (32 隻中有 18 隻相較於未給藥組 16 隻有 11 隻)，產後 6 個月期間並未出現明顯畸形且未對神經行為、免疫學和臨床病理學參數造成影響。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]目前不清楚 OPDIVO 是否會分泌至人體乳汁中。 由於許多藥物(包括抗體)會分泌至人體乳汁中， 且因為OPDIVO 對接受哺乳的嬰兒可能造成嚴重不良反應， 建議孕婦在接受 OPDIVO 治療期間停止哺乳。,IVD;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,抽取所需的OPDIVO容積，製備成最終濃度為1mg/mL至10mg/mL的輸注液。 對於體重≧30 kg 的病人給予 240 mg 或 360 mg 固定劑量(flat-dose)的總體積不得超過150mL 而體重<30 kg 的病人給予之總體積不得超過100mL。 輕輕翻轉混合稀釋液。 請勿振搖輸液袋。,1.從製備開始，置於室溫下的時間不得超過8小時。包括IV輸液袋內輸注液放置於室溫下2.透過含無菌、無熱原、低蛋白結合率過濾器(孔徑大小為0.2微米至1.2微米)的靜脈導管連續輸注30分鐘 3.請勿以相同的靜脈導管同時輸注其他藥物。輸注結束後應沖洗靜脈導管 4.併用ipilimumab時，同一天先給予OPDIVO後再給予ipilimumab。當併用ipilimumab和化學治療時，同一天應先給予OPDIVO接著給予ipilimumab，最後再給予化學治療 5.應使用個別的輸液袋和過濾器
IAJO,Fremanezumab,Ajovy inj 225mg/1.5mL,CNEU,For the preventive treatment of migraine in adults.,Patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.,Common Dermatologic: Injection site disorder (43% to 45% ) Serious Immunologic: Anaphylaxis， Hypersensitivity reaction Other: Angioedema,避光冷藏儲存於2-8°C,225 mg monthly， or 675 mg every 3 months (quarterly).,無需調整劑量,[仿單]目前並無數據顯示人體母乳中是否出現fremanezumab、是否影響哺乳中幼兒或是否影響母乳生產。應衡量哺乳對於發育和健康的利益，和母親對於AJOVY的臨床需求，以及AJOVY或潛在母體病況對於哺乳嬰兒的任何可能不良作用。,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]目前缺乏與懷孕女性使用AJOVY有關的發育風險數據。AJOVY半衰期較長。因此，懷孕或計畫懷孕的女性使用AJOVY時應將此風險納入考量。在大鼠及兔子器官形成期間或大鼠懷孕及哺乳期間，投予導致血漿濃度高於臨床預期濃度劑量的fremanezumab，未對發育造成不良反應。在美國一般族群中，根據臨床所觀察到的懷孕情形，重大先天缺陷和流產的預估背景風險分別為2 - 4%和15 - 20%。偏頭痛女性產下重大先天缺陷(2.2 - 2.9%)與流產(17%)的預估比例與無偏頭痛女性相近。 發表的數據指出偏頭痛女性於懷孕期間發生子葖e症的風險可能較高。 在公鼠與母鼠交配前及交配期間，以皮下注射方式投予每週一次之fremanezumab (0、50、100或 200 mg/kg)，並對胚胎器官形成期間之懷孕母鼠持續給藥，未觀察到胚胎胎兒不良反應。最高試驗劑量的血漿藥品暴露量(以AUC表示)約為人體接受675 mg劑量的2倍。在胚胎器官形成期間之懷孕兔子中，以皮下注射方式投予每週一次之fremanezumab (0、10、50或100 mg/kg) ，未觀察到對胚胎胎兒發育造成不良影響。最高試驗劑量的血漿藥品暴露量(以AUC表示)約為人體(675 mg)的3倍。在母鼠懷孕及哺乳期間，以皮下注射方式投予每週一次之fremanezumab (0、50、100或 200 mg/kg)，未觀察到對胎兒產前與產後發育造成不良影響。最高檢測劑量的血漿藥品暴露量(以AUC表示)約為人體(675 mg)的2倍。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並無數據顯示人體母乳中是否出現fremanezumab、是否影響哺乳中幼兒或是否影響母乳生產。應衡量哺乳對於發育和健康的利益，和母親對於AJOVY的臨床需求，以及AJOVY或潛在母體病況對於哺乳嬰兒的任何可能不良作用。,SC;,,,,,1. 本藥僅供皮下注射，需避光冷藏儲存於2-8°C。若置於室溫最高25°C下超過24小時，請勿使用。 2. 使用前，從冰箱中取出本藥，置於室溫下30分鐘，並避免光線直接照射。若已置於室溫下超過24小時，請勿使用。 3. 皮下注射於無觸痛、瘀血、發紅或硬結的腹部、大腿或上臂部位。多次注射可在相同身體部位進行注射，但不可使用與前次注射相同的位置。 4. 更換劑量時，於下次預定投藥日投予第一劑新的療程劑量。若漏打一劑，應儘快投藥，之後，以最後一次投藥日來排定後續的投藥時間。
IORG,Ganirelix,Orgalutran inj 0.25mg/0.5mL,HM,For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.,Known hypersensitivity to Ganirelix Acetate or to any of its components. Known hypersensitivity to GnRH or any other GnRH analog. Known or suspected pregnancy.,Common Neurologic: Headache (3% ) Reproductive: Abdominal pain， Gynecological (4.8% )， Vaginal bleeding (1.8% ) Serious Immunologic: Hypersensitivity reaction Reproductive: Ovarian hyperstimulation syndrome (2.4% ) Other: Undelivered in utero fetal death (3.7% ),勿冷凍。請避光保存在攝氏2-30℃。,250 mcg once daily during the mid-to-late phase after initiating follicle-stimulating hormone on day 2 or 3 of cycle. Treatment should be continued daily until the day of chorionic gonadotropin administration.,無需調整劑量,[仿單]目前不清楚ganirelix是否會分泌至乳汁中。 在懷孕與哺乳時使用Orgalutran是禁忌的。,無需調整劑量,不可使用,Uknown 沒有資料,[仿單]對於使用於孕婦，目前並無臨床資料。 動物中，在著床時暴露ganirelix會導致受精卵再吸收。 這些資料對於人類的關聯性則尚未得知。 在懷孕與哺乳時使用Orgalutran是禁忌的。,Unknown 沒有資料,[仿單]目前不清楚ganirelix是否會分泌至乳汁中。 在懷孕與哺乳時使用Orgalutran是禁忌的。,SC;,,,,,1. 本藥應該經由皮下注射給藥，最好是在大腿。每次注射應該取不同的部位，以預防皮下脂肪萎縮。 2. 本藥勿冷凍。請避光保存在攝氏2-30℃。 3. 在預充填針筒中可能會看到氣泡是可預期的，無須去除氣泡。
LAZI,Azithromycin,Azithrom 40mg/mL， 15mL suspension,QANB,Lower respiratory tract infections (including bronchitis and pneumonia) skin and soft tissue infections， otitis media， upper respiratory tract infections， and sexually transmitted infections caused by Gram-positive， negative and anaerobic bacteria.,Hypersensitivity to azithromycin， erythromycin， other macrolide antibiotics， or ketolide antibiotics. Hypersensitivity to any component of the formulation.,Common Dermatologic: Injection site disorder (3.1% to 6.5% ) Gastrointestinal: Abdominal pain (adult， 1.9% to 14%; pediatric， 2% to 4% )， Diarrhea (Adult， 4.3% to 12%; pediatric， 7% to 10% )， Flatulence (5% )， Nausea (Adult， 3% to 14%; pediatric， 4% )， Vomiting (Adult， up to 13%; pediatric， 11% to 14% ) Hepatic: Increased liver enzymes (less than 1% to 6% ) Neurologic: Headache (up to 5% ) Ophthalmic: Abnormal vision (5% ) Serious Cardiovascular: Prolonged QT interval， Torsades de pointes Dermatologic: Generalized exanthematous pustulosis， acute， Stevens-Johnson syndrome， Toxic epidermal necrolysis Gastrointestinal: Congenital hypertrophic pyloric stenosis Hepatic: Hepatic necrosis， Hepatitis (less than 1% )， Liver failure Immunologic: Drug reaction with eosinophilia and systemic symptoms， Hypersensitivity reaction Musculoskeletal: Eaton-Lambert syndrome， Myasthenia gravis， Exacerbation of， Myasthenic crisis Ophthalmic: Corneal erosion (less than 1% ),室溫25℃以下保存。泡製後室溫保存10天。,Adults and children weighing > or = 45 kg: 500 mg orally once daily with or without food for 3 days. Sexually transmitted diseases caused by Chlamydia trachomatis: 1 g as single oral dose. Children 10 mg/kg once daily for 3 days.,無需調整劑量,[仿單]報告指出， Azithromycin會泌入乳汁，但目前尚未針對授乳婦女進行良好的對照試驗，研究投予Azithromycin的人類乳汁分泌藥物動力學。因此，除非醫師判斷用藥效益大於對嬰兒的潛在風險，否則授乳婦女不得使用Azithromycin。,需調整劑量,可能安全,Compatible,[仿單] 研究人員曾以劑量逐漸遞增、最終達到母體毒性劑量的方式進行動物生殖研究。在這些研究中，病會發現任何顯示Azithromycin會對胎兒造成危險的證據。動物之生殖毒性試驗顯示Azithromycin會穿過胎盤，但未發現致畸胎性。不過，目前尚無適當且控制良好的孕婦研究。由於動物生殖研究的結果並不一定能預測人類的反應，因此，只有在絕對必要的情況下才可於懷孕期間使用Azithromycin。,Compatible 哺乳時可使用,[仿單]報告指出， Azithromycin會泌入乳汁，但目前尚未針對授乳婦女進行良好的對照試驗，研究投予Azithromycin的人類乳汁分泌藥物動力學。因此，除非醫師判斷用藥效益大於對嬰兒的潛在風險，否則授乳婦女不得使用Azithromycin。,AC;PC;PO;WM;,,,,,1. 請先將藥粉搖散， 加入冷開水9mL混合均勻後使用。 2. 泡製後可室溫保存10天。
OCAN,Canagliflozin,Canaglu 100mg,META,Type 2 diabetes.,History of serious hypersensitivity to canagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2); end-stage renal disease or patients on dialysis.,>10%: Increased serum potassium (>5.4 mEq/mL [eGFR 30 to 50]: 27%; >5.4 mEq/mL [eGFR 45 to 60]: 9%; ?6.5 mEq/mL [eGFR 30 to 50]: 2%)， Genitourinary fungal infection (females: 11% to 12%; males: 4%; patients who developed infections were more likely to experience recurrence)， Renal insufficiency (?30% decrease in eGFR from baseline: 1% to 23%; eGFR decline was more common in patients with moderate renal impairment) 1% to 10%: Falling (2%)， fatigue (2%)， Hypoglycemia (4%)， hypovolemia (2% to 3%)， increased thirst (2% to 3%)， Abdominal pain (2%)， constipation (2%)， nausea (2%)， Urinary tract infection (6%)， increased urine output (5%)， vulvovaginal pruritus (2% to 3%)， Increased hemoglobin (3% to 4%)， Hypersensitivity reaction (4%)， Asthenia (?1%) Frequency not defined: Hypermagnesemia， increased serum cholesterol (non-HDL)， increased serum phosphate， Bone fracture， decreased bone mineral density， Increased serum creatinine <1%， postmarketing， and/or case reports: Acute renal failure， anaphylaxis， angioedema， increased LDL cholesterol， ketoacidosis， necrotizing fasciitis (perineum)， pancreatitis， phimosis， pyelonephritis， skin photosensitivity， urinary tract infection with sepsis,25℃以下,100 mg once daily.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
IANO,D-Mannitol,Anol inj 200mg/mL，100mL/bag,CAVS,Treatment of cerebral oedema; to increase urine flow in acute renal failure; reduce raised intracranial pressure; short-term management of glaucoma; promote excretion of toxic substances by forced diuresis.,Children under 12 years old， Pulmonary oedema， intracranial bleeding (except during craniotomy)， heart failure & renal failure (unless a test dose has produced a diuretic response).,Fluid & electrolyte imbalance， nausea & vomiting， thirst， headache， chills， fever， allergic reactions.,20-30度C,Osmotic reduction of intracranial pressure: 0.5 to 2 gm/kg of a 15-25% solution IV infusion over 30-60 minutes. Diuresis: 50-100 gm of a 5-25% solution IV infusion to keep urine output 30-50 mL/hours. (Children dosage: 2 gm/kg or 60mg/m2) Determination of glomerular filtration rate: 20 gm (100 mL of 20% solution) in 180 mL saline diluted to 7.2% solution， IV infusion rate: 20 mL/minutes.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【N/S】仿單建議。【D5NS】可選 。【D5W】可選 。【L/R】可選 。,,滲透降壓作用:IVD， 0.5~2g/kg (as a 15~25% solution)， 30~60min 利尿作用:IVD， Adult: 50~100g， Children: 2g/kg， or 60mg/m2 body surface area (as a 5~25% solution)， 維持尿液流量30~50mL/hour.,1.冬季或冷藏時，可能產生結晶，可將其保溫於攝氏40-50度，待溶解後冷卻至體溫使用。 2.請使用附有過濾裝置之輸液套，導入針應以垂直方式插入橡皮塞，插入後勿扭轉，以免產生碎片。 3.使用前應再檢視，確定無異物方可使用。
IBOT,Botulinum Toxin type A,Botox 100 Unit/Vial,CNEU,For the treatment of strabismus & blepharospasm associated with dystonia， including benign essential blepharospasm or VII nerve disorders in patients >= 12 years. Treatment of spasmodic torticollis (cervical dystonia) in adults. Treatment of dynamic equinus foot deformity due to spasticity in pediatric cerebral palsy patients >= 2 years. Treatment of primary hyperhidrosis of the axilla. Treatment of glabellar lines associated with corrugator &/or procerus muscle activity. Management of focal spasticity， including treatment of upper limb spasticity associated with stroke in adults.,Myasthenia gravis or Eaton Lambert syndrome， infection at inj site.,Localized pain， tenderness &/or bruising， local weakness， ptosis， vertical deviation， irritation/tearing. Rarely， skin rash (including erythema multiforme， urticaria & psoriasiform eruption)， pruritus， allergic reactions， dysphagia， pneumonia. Dermatologic: Injection site reaction (cervical dystonia， 5% to 22%; glabellar lines， 3% ) Gastrointestinal: Xerostomia (cervical dystonia， 13% to 39% ) Musculoskeletal: Muscle weakness (cervical dystonia， 11% to 56% ) Neurologic: Difficulty speaking (cervical dystonia， 6% to 28% )， Headache (9% to 11% ) Ophthalmic: Disorder of eye (cervical dystonia， 6% to 17% ) Respiratory: Nasopharyngitis (glabellar lines， 10% ),2-8℃或-5~-20℃,Strabismus: Intramuscular. Vertical muscles and for horizontal strabismus of < 20 prism diopters: 1.25-2.5 units in any one muscle. Horizontal strabismus of 20-50 prism diopters: 2.5-5 units in any one muscle. Persistent VI nerve palsy of >= 1 month: 1.25-2.5 units in the medial rectus muscle. Maximum: 25 units as single injection for any one muscle. Blepharospasm: Intramuscular. Initially 1.25-2.5 units injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and into the lateral pretarsal orbicularis oculi of the lower lid. Maximum cumulative dose: 200 units in 2-month period. VII nerve disorders: Patients with hemifacial spasm or VII nerve disorder should be treated as for unilateral blepharospasm. Maximum cumulative dose: 200 units in 2-month period. Spastic torticollis (Cervical dystonia): Intramuscular. Individualised dosing. Maximum cumulative dose:<= 360 units in 2-month period and administer no more frequently than every 2 months. Spasticity (due to juvenile cerebral palsy) in patients 2 years of age and older: Intramuscular. 4 units/kg into each of 2 sites in the medial and lateral heads of the gastrocnemius muscle of the affected lower limb(s). Maximum total dose in 30-day period: 200 units. Primary axillary hyperhidrosis: 50 unit intradermally to each axilla evenly distributed in multiple sites about 1-2 cm apart. Administer no more frequently than every 2 months. Reduction of glabellar lines: Intramuscular. Inject 4 units into each of 5 sites， two in each corrugator muscle and one in the procerus muscle for a total dose of 20 units. Reduction of lateral canthus lines (Crow's feet): Intramuscular. Inject 2-6 units into 3 injection sites per side (6 total injection points) in the lateral orbicularis oculi muscle. Reduction of forehead lines: Intramuscular. Inject 2 to 6 units into each of four sites in the frontalis muscle every 1 to 2 cm along either side of forehead crease and 2 to 3 cm above eyebrows for total dose of 8-24 units. Stroke-related upper limb spasticity: Intramuscular. Inject into selected muscles (typically the flexor muscles of the elbow， wrist & fingers)， start with lowest dose， maximum: 50 units/site. Maximum dose per treatment session: 360 units. May be repeated when the effects have lessened， but generally no sooner than 12 weeks after the previous injection. Lower limb spasticity: Intramuscular. Total dose of 300 to 400 units IM divided among 5 muscles (gastrocnemius， soleus， posterior tibial， flexor pollicis longus and flexor digitorum longus). May be repeated when the effects have lessened， but generally no sooner than 12 weeks after the previous injection. Chronic migraine: Intramuscular. Total dose of 155 units as 5 units into each of 31 sites divided across 7 specific head/neck muscle areas. Usual retreatment every 12 weeks. Bladder dysfunction: Intradetrusor. Detrusor overactivity associated with neurologic condition: Total dose of 100 units/treatment initially， may increase to the maximum: 200 units/treatment， if necessary. Overactive bladder: Total dose of 100 units administered as twenty 10 units injections into the detrusor muscle; injections should be spaced approximately 1 cm apart. Median time to retreatment is approximately 24 weeks， but should be no sooner than 12 weeks.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;SC;,加入0.9% N/S 10mL稀釋後.每0.1 mL含有1 Unit,,,,
EZAL5,Sertaconazole,ZALAIN 陰道錠 500mg,SGU,Vulvovag candidiasis.,Hypersensitivity to any component of the formulation.,Slight local & transient erythematous reaction.,30℃以下,Insert 1 vaginal tablet at bedtime. Administer second dose 1-2 weeks later if symptoms not reside.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,VAG;,,,,,
ECLO5,Clotrimazole,Clomazole vaginal tablet 500mg,SGU,Vulvovaginal candidiasis,Hypersensitivity.,Erythema， stinging， irritation; hypersensitivity reactions.,儲存於陰涼15-30℃處,1 vaginal tablet every three days at bedtime. [Micromrdex 2021/06/15] 500 mg vaginal suppository intravaginally once weekly or 200 mg vaginal tablet intravaginally twice weekly for at least 6 months.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,VAG;,,,,,
ECLF,Hydroquinone + Tretinoin + Fluocinolone acetonide,Cleanfleck cream 5gm,TDER,For short-term treatment of moderate to severe melasma of the face.,Hypersensitivity to fluocinolone acetonide， hydroquinone， tretinoin， or any components of the product.,Common Dermatologic: Burning sensation (18% )， Dry skin (14% )， Erythema (41% )， Peeling of skin (38% )， Pruritus (11% ),2-8℃冷藏保存，開封後請保持密封。,Each gram contains Fluocinolone acetonide 0.1mg(0.01%) + Hydroquinone 40mg(4%) + Tretinoin 0.5mg(0.05%). For short-term treatment of moderate to severe melasma of the face， apply a thin film of the cream topically to affected areas once nightly at least 30 minutes prior to bedtime.,無需調整劑量,Hydroquinone of Breastfeeding Recommendation: No Human Data - Probably Compatible. Tretinoin(Topical) of Breastfeeding Recommendation: No Human Data - Probably Compatible. Fluocinolone(Topical) of Breastfeeding Recommendation: No Human Data—Potential Toxicity. [仿單]全身性使用皮質類固醇時，出現於人類乳汁，但未知局部塗擦本配方時，是否可能因全身性吸收，而於人類乳汁中產生可偵測量的Fluocinolone acetonide、Hydroquinone或Tretinoin； 由於許多藥物會分泌於人類乳汁，因此本配方投予哺乳婦時應審慎；應小心避免被哺乳的嬰兒接觸到本配方。,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,Hydroquinone of Pregnancy Recommendation: Limited Human Data - Probably Compatible. Tretinoin(Topical) of Pregnancy Recommendation: Human Data Suggest Low Risk. Fluocinolone(Topical) of Pregnancy Recommendation: Limited Human Data—Animal Data Suggest Risk. [仿單]本藥於懷孕期間使用的安全性及有效性尚未確立，懷孕期間除非無其他替代藥品，且臨床效益大於風險時方可考慮使用； 而育齡婦女使用期間應採行必要的避孕措施。因依據動物研究顯示含retinoids類口服劑型藥品用於懷孕婦女可能導致胎而具有先天性異常之風險，雖依目前臨床文獻資料，若依照仿單建議用法用量，外用劑型retinoids類藥品，因經皮吸收量微小，並未有明確證據顯示對於胎兒健康有害，但仍應經過審慎評估後使用。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Hydroquinone of Breastfeeding Recommendation: No Human Data - Probably Compatible. Tretinoin(Topical) of Breastfeeding Recommendation: No Human Data - Probably Compatible. Fluocinolone(Topical) of Breastfeeding Recommendation: No Human Data—Potential Toxicity. [仿單]全身性使用皮質類固醇時，出現於人類乳汁，但未知局部塗擦本配方時，是否可能因全身性吸收，而於人類乳汁中產生可偵測量的Fluocinolone acetonide、Hydroquinone或Tretinoin； 由於許多藥物會分泌於人類乳汁，因此本配方投予哺乳婦時應審慎；應小心避免被哺乳的嬰兒接觸到本配方。,EXT;SKIN;,,,,,
OSEV3,Amlodipine + Olmesartan,SEVIKAR 5/40mg,CAVS,Management of hypertension， not recommended for initial therapy.,Combined use of Sevikar and drugs containing aliskiren in patients with diabetes or renal insufficiency (GFR<60ml/min/1.73 m2). Known hypersensitivity to Sevikar or any of its components.,Peripheral edema (dose related: 18-26%)， anaphylaxis， hypotension， nocturia， orthostatic hypotension， palpitations， pruritus， skin rash， urinary frequency.,25°C以下,Initial: 5/20 mg q24h. After 2 weeks of treatment， the dose can be increased to 10/40 mg q24h as needed (Max: 10/40mg). If blood pressure control is still not ideal， alternative treatments can be considered， such as increasing the dose of one or both components.,需調整劑量,[仿單] 有關Sevikar是否會分泌至人類乳汁、對哺乳嬰兒影響或對乳汁分泌影響的資料有限。 Amlodipine會分泌至人類乳汁。Olmesartan會分泌至大鼠乳汁。 由於藥物對授乳嬰兒具有潛在不良作用，應告知授乳女性接受Sevikar治療期間不建議哺乳。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 對懷孕女性投予Sevikar可能會對胎兒造成傷害。在懷孕第2和第3期時， 使用腎素-血管昇壓素系統的藥物會使胎兒腎功能降低及增加胎兒和新生兒罹病率與死亡。 藥物造成的羊水過少則與胎兒肺部發育不良及胎兒四肢攣縮有關。潛在的新生兒副作用包括顱骨發育不全、無尿症、低血壓、腎臟衰竭及死亡。 一旦病人確定懷孕，需立即讓病人停用Sevikar。,Unknown 沒有資料,[仿單] 有關Sevikar是否會分泌至人類乳汁、對哺乳嬰兒影響或對乳汁分泌影響的資料有限。 Amlodipine會分泌至人類乳汁。Olmesartan會分泌至大鼠乳汁。 由於藥物對授乳嬰兒具有潛在不良作用，應告知授乳女性接受Sevikar治療期間不建議哺乳。,AC;AC15;PC;PO;WM;,,,,,
IVAB,Faricimab,Vabysmo intravitreal inj 6mg/0.05mL,TOPH,For intravitreal injection. Neovascular (wet) age-related macular degeneration (nAMD)， diabetic macular edema (DME),Ocular or periocular infection. Active intraocular inflammation. Known hypersensitivity to faricimab or any of its excipients (allergic reactions may manifest as rash， itching， urticaria， erythema， or severe intraocular inflammation).,Common: Conjunctival hemorrhage (7-8%) Serious: Arterial thromboembolism (1-5%)， Raised intraocular pressure (3-4%)， Retinal pigment epithelial detachment with tear of retinal pigment epithelium (3%),避光冷藏(2-8°C)儲存、不可冷凍。,Neovascular age-related macular degeneration (nAMD): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Maximum interval: Every 16 weeks (4 months)， but can be adjusted to every 12 weeks (3 months) or every 8 weeks (2 months). Limited safety data for intervals shorter than 8 weeks. Diabetic macular edema (DME): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Dosing intervals: Gradual extension of injection intervals， up to every 16 weeks (4 months). No clinical trial data available for intervals shorter than 4 weeks.,無需調整劑量,[仿單] 目前未知 Vabysmo 是否會分泌至人體乳汁內。目前尚未進行試驗評估 Vabysmo 對於乳汁製造的影響或其是否會進入乳汁裡。 由於許多藥物會分泌至人體乳汁中，存在吸收而傷害嬰兒生長與發育的潛在可能， 因此 Vabysmo 給予哺乳中女性時應特別小心。應同時考慮哺乳對於發育和健康的益處， 以及母親對於 Vabysmo 的臨床需要與 Vabysmo 對於接受哺乳孩童的任何潛在不良影響。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 目前並無 Vabysmo 用於懷孕女性的資料。 目前並不知道給予懷孕女性時， Vabysmo 是否會通過胎盤或傷害胎兒。根據 VEGF 與 Ang-2抑制劑的作用機轉， 存在對女性生殖能力以及胚胎胎兒發育的潛在風險。雖然眼部給藥後全身暴露非常低， 但除非對病人的潛在效益超過對胎兒的潛在風險，否則不應於懷孕期間使用Vabysmo。,Unknown 沒有資料,[仿單] 目前未知 Vabysmo 是否會分泌至人體乳汁內。目前尚未進行試驗評估 Vabysmo 對於乳汁製造的影響或其是否會進入乳汁裡。 由於許多藥物會分泌至人體乳汁中，存在吸收而傷害嬰兒生長與發育的潛在可能， 因此 Vabysmo 給予哺乳中女性時應特別小心。應同時考慮哺乳對於發育和健康的益處， 以及母親對於 Vabysmo 的臨床需要與 Vabysmo 對於接受哺乳孩童的任何潛在不良影響。,IVI;,,,,,1. 僅供玻璃體內注射使用。Vabysmo 必須由具備玻璃體內注射經驗的合格醫師給予。每小瓶僅應使用於治療單眼。
OMTCB,Mecobalamin,METHYCOBAL 500mcg,CNEU,Peripheral neuropathies， megaloblastic anaemia caused by vit B12 deficiency.,Hypersensitivity to mecobalamin， cobalt， vitamin B12， or any component of the product.,Common: Asthenia (4-16%)， Headache (4-20%)， Paresthesia (4%)， Stomach discomfort， Loss of appetite， Nausea， Diarrhea， Rash. Serious: Congestive heart failure， Pulmonary edema， Thrombosis， Anaphylaxis， Optic atrophy.,對光不安定，需避光保存,Adult: 500mcg TID PO. May adjust dosage according to patient's age and synptoms.,無需調整劑量,VITAMIN B12 Vitamin PREGNANCY RECOMMENDATION: Compatible BREASTFEEDING RECOMMENDATION: Compatible,無需調整劑量,沒有資料,Compatible,VITAMIN B12 Vitamin PREGNANCY RECOMMENDATION: Compatible BREASTFEEDING RECOMMENDATION: Compatible,Compatible 哺乳時可使用,VITAMIN B12 Vitamin PREGNANCY RECOMMENDATION: Compatible BREASTFEEDING RECOMMENDATION: Compatible,AC;AC15;PC;PO;WM;,,,,,
EPOLI,Policresulen,Polinin 90mg vaginal suppository,SGU,Local treatment of cervical & vag inflammatory & concomitant discharge. Vaginitis & cervicitis， cervical erosion; trichomoniasis & moniliasis. To stop bleeding after biopsy & removal of cervical polyps. Decubital ulcers caused by pessaries. After electrocoagulation to activate regeneration.,Concomitant use of other topical agents in treating the affected areas.,Occasionally， mild local discomfort at beginning of treatment which disappears on discontinuation.,25℃以下,1 vaginal suppository at bedtime every 2 days.,無需調整劑量,仿單:研究至目前尚無法說明懷孕婦女給藥的危險性，尚且不知是否主成分會排除於授乳婦的乳汁內。,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,仿單:研究至目前尚無法說明懷孕婦女給藥的危險性，尚且不知是否主成分會排除於授乳婦的乳汁內。,VAG;,,,,,
EFRO,Metronidazole,栓劑Frotin 250mg,SGU,Vaginitis due to trichomonas vaginalis.,Blood dyscrasias. Active CNS disease.,GI upset， urticaria， angioedema. Rarely， drowsiness， skin reactions， darkening of urine， anaphylaxis， neuropathy， encephalopathy. Gastrointestinal: Abdominal discomfort (7%)， Loss of appetite， Metallic taste， Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )， Headache (tablets， 15% to 18%; vaginal gel， 5% )， Peripheral neuropathy Reproductive: Candida infection of genital region， Symptomatic cervicitis/vaginitis (10%)， Vaginal discharge (12%) Other: Drug interaction with alcohol， Disulfiram-like reaction,陰涼避光之處,1 suppository at bedtime for 10-21 days， after treatment 1-2 weeks or at menstrual cycle ending < 3 months must have trichomonas test.,無需調整劑量,METRONIDAZOLE BREASTFEEDING RECOMMENDATION: Hold Breastfeeding (Single Dose) Limited Human Data—Potential Toxicity (Divided Dose),無需調整劑量,可能安全,Human data suggest low risk,METRONIDAZOLE PREGNANCY RECOMMENDATION: Human Data Suggest Low Risk,Hold Breast Feeding 暫停哺乳,METRONIDAZOLE BREASTFEEDING RECOMMENDATION: Hold Breastfeeding (Single Dose) Limited Human Data—Potential Toxicity (Divided Dose),VAG;,,,,,
ILEV3,Insulin Detemir,Levemir FlexPen 100 Unit/mL， 3mL,META,Treatment of diabetes mellitus.,Hypersensitivity to insulin detemir or to any of the excipients of Levemir.,Hypoglycemia， inj site reactions. Rarely， lipodystrophy， allergic reactions.,2-8℃避光避免冷凍,SC， initial 0.1 - 0.2 unit/kg once daily in the evening or 10 units once or twice daily. The dose adjusted to achieve glycemic targets.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,SC;,,,,,
INOVX,Insulin Aspart,NovoRapid FlexPen 100 Unit/mL， 3mL,META,Treatment of patients with diabetes mellitus.,Hypoglycaemia.,Hypoglycaemia， edema， refraction anomalies， hypersensitivity reactions， lipodystrophy.,2-8℃,IVA， IVD， SC， according to the individual needs of the patient， the insulin requirements of adults and children are usually 0.5 to 1.0 unit/kg/day.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – probably compatible,,Compatible 哺乳時可使用,,IVA;IVD;SC;,,【N/S】可選 。,,使用靜脈注射時，使用 polypropylene 輸注袋，並且以 0.9% sodium chloride 或含有 40 mmol/l potassium chloride 之 5%或 10% dextrose 為輸注溶液配製濃度0.05 U/ml 到 1.0 U/ml 的 NovoRapidR100 U/ml 之輸注系統，在室溫下可維持安定達 24 小時。 雖然隨著時間能保持穩定，但有少量的胰島素在一開始會被輸注袋所吸收。 在輸注過程中，血糖的監控是必需的。,
EATREU,Atropine,Atropine Eye Drops 0.01%， 0.5mL/支,TOPH,Mydriasis， cycloplegia.,Hypersensitivity to any component of the product. Primary glaucoma or predisposition to narrow anterior chamber angle glaucoma.,Common Ophthalmic: Blurred vision， Finding of lacrimation， Decreased， Pain in eye， Photophobia， Superficial keratitis Serious Immunologic: Anaphylaxis， Hypersensitivity reaction， Ophthalmic: acute angle-closure glaucoma,25℃以下儲存,1-4 times a day， each time used 1-2 drops.,無需調整劑量,[仿單]無相關說明,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]尚未有動物生殖研究，目前尚未清楚局不Atropine是否會對胎兒造成傷害或影響生殖能力. 僅當清楚需要時，本品可以用於孕婦.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]無相關說明,OD;OL;OU;,,,,,
IBNT1,SARS-CoV-2 Spike glycoprotein [mRNA],Pfizer-BioNTech (5-11歲) 0.2mL/dose (1.3mL/vial),HIMM,The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 5 through 11 Years of Age,Hypersensitivity to the active substance or to any of the excipients.,erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.,運輸狀態而定詳閱仿單,IM， 0.2 mL， 5-11 years old， 2-dose series separated by at least 3 weeks,無需調整劑量,[仿單]預期對哺乳的新生兒／嬰兒沒有影響，因為餵哺母乳之婦女的BNT162b2疫苗全身暴露量微乎其微。 從接種疫苗後餵哺母乳之婦女的觀察資料顯示，哺乳的新生兒／嬰兒並無不良反應的風險。 餵哺母乳的婦女可接種BNT162b2疫苗。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]從懷孕中期和晚期接種BNT162b2疫苗之孕婦的大量觀察資料顯示，不良懷孕結果並未增加。 雖然目前在懷孕前三個月接種疫苗之後的懷孕結果之相關資料有限，但並未發現流產風險增加。 動物試驗並未顯示BNT162b2疫苗會對懷孕、胚胎／胎兒發育、分娩或產後發育造成直接或間接的有害影響。 接種疫苗對於孕婦和胎兒的潛在益處高於潛在風險時，可考慮在懷孕期間接種本品。,Unknown 沒有資料,[仿單]預期對哺乳的新生兒／嬰兒沒有影響，因為餵哺母乳之婦女的BNT162b2疫苗全身暴露量微乎其微。 從接種疫苗後餵哺母乳之婦女的觀察資料顯示，哺乳的新生兒／嬰兒並無不良反應的風險。 餵哺母乳的婦女可接種BNT162b2疫苗。,IM;,,,,,1.每瓶(1.3 mL)分散液，經以 1.3 mL 的 0.9%氯化鈉注射液進行稀釋後，含有 10 劑每劑 0.2mL的注射液 2.未開封的藥瓶可在8-30°C的溫度下保存12小時，且首次穿刺藥瓶，在2-30°C下可保存12小時。最多共保存24小時。 3.未開封的藥瓶在在2-8°C可保持安定達10週。
EXAM,Calcipotriol + Betamethasone,Xamiol gel 30gm,TDER,Plaque psoriasis:,Hypersensitivity to calcipotriene， betamethasone， or any component of the formulation; viral (herpes simplex， varicella， vaccinia)， fungal or bacterial infection of the skin; parasitic infections; tuberculosis of the skin; syphilitic skin infections; ophthalmic use; calcium metabolism disorders; perioral dermatitis; atrophic skin; striae atrophicae; fragility of skin veins; ichthyosis; acne vulgaris; acne rosacea; rosacea; ulcers; wounds; perianal and genital pruritus; psoriasis (guttate， erythrodermic， exfoliative); severe hepatic disorders; severe renal insufficiency,1% to 10%: Dermatologic: Pruritus (4% to 7%)， psoriasis (2% to 3%)， erythema (1% to 2%)， skin atrophy (<2%)， burning sensation of skin (1%)， ecchymoses (1%)， exfoliative dermatitis (1%)， hand dermatosis (1%)， skin depigmentation (1%)， skin irritation (1%)， folliculitis (<1%) <1% (Limited to important or life-threatening): Acneiform eruption， acne vulgaris， application-site pruritus， contact dermatitis， dermatitis， exacerbation of psoriasis， eye irritation， facial edema， HPA-axis suppression， hypercalcemia， hypercalciuria， hyperpigmentation， hypopigmentation， otitis externa， papular rash， psoriasis flare， psoriasis (rebound)， pustular psoriasis， pustular rash， skin pain， skin rash， telangiectasia， xeroderma,30℃以下儲存,Apply to the affected area once daily. Recommended treatment period: 4 weeks. After this period， repeated treatment can be initiated under medical supervision. Max daily dose: 15 g. Maximum weekly dose: 100 g. Maximum treated area: 30% of body surface.,無需調整劑量,懷孕分級: C (UpToDate),無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,懷孕分級: C (UpToDate),EXT;,,,,,
ICOVMVC,SARS-CoV-2 Spike glycoprotein,COVID-19 Vaccine Medigen 0.5mL/dose(10 dose/vial),HIMM,Medigen COVID-19 Vaccine is indicated for active immunization of individuals 20 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).,History of a severe allergic reaction after a previous dose or to a component of the formulation; history of immediate allergic reaction to a previous dose; known allergy to any component of the formulation.,erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.,避光，2-8°C，不可冷凍,Age > or = 20 years old: IM: 0.5 mL per dose for 2 doses administered 28 days apart.,無需調整劑量,[仿單] 目前並不清楚高端新冠肺炎疫苗所誘發的抗體是否會分泌到人類乳汁中。 根據大鼠生殖與發育毒性試驗的血清學數顯示，抗SARS-CoV 2重組棘蛋白之IgG抗體可能會經由乳汁轉移到仔鼠身上。 目前並無接種高端新冠肺炎疫苗對哺乳嬰兒影響的研究，但理論上無生物活性的疫苗不會感染母親或嬰兒，所以授乳可評估接種之利益與風險後接種高端新冠肺炎疫苗。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]高端新冠肺炎疫苗用於懷孕女性的臨床經驗有限。 在大鼠生殖與發育毒性試驗中，對試驗母鼠給予含量為5或25 μg SARS-CoV2重組棘蛋白輔以750 μg CpG 1080及375 μg氫氧化鋁佐劑之0.5毫升疫苗劑量；給予之時間點為：交配前毫升疫苗劑量；給予之時間點為：交配前3週、交配前1週、懷孕第6天、懷孕第18天及哺乳第7天各接受一劑 。 結果顯示，各劑量組皆未觀察到母鼠生育能力、胚胎發或仔受影響。 於懷孕期間，唯有施打高端新冠肺炎疫苗對母親和胎兒的潛在益處高於任何潛在風險時，才應考慮施打本疫苗。 可能懷孕或有計畫之女性，皆應評估接種利益與風險。,Unknown 沒有資料,[仿單] 目前並不清楚高端新冠肺炎疫苗所誘發的抗體是否會分泌到人類乳汁中。 根據大鼠生殖與發育毒性試驗的血清學數顯示，抗SARS-CoV 2重組棘蛋白之IgG抗體可能會經由乳汁轉移到仔鼠身上。 目前並無接種高端新冠肺炎疫苗對哺乳嬰兒影響的研究，但理論上無生物活性的疫苗不會感染母親或嬰兒，所以授乳可評估接種之利益與風險後接種高端新冠肺炎疫苗。,IM;,,,,,以肌肉注射的方式將 0.5 mL高端新冠肺炎疫苗注射至手臂，共兩劑，間隔 28天。 使用前請搖晃均勻，僅限以肌肉注射方式施用，最好注射於上臂的三角肌 (Deltoid)。 不可在血管內、皮下注射疫苗。 高端新冠肺炎疫苗的外觀為無色澄明液，經搖勻混濁白懸浮。如果預充填式針劑內的懸浮液變色或有顆粒，請丟棄。
EVYZ,Latanoprostene bunod,Vyzulta 0.024%， 5mL ophthalmic solution,TOPH,The reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.,Hypersensitivity to any component of the formulation.,Common Ophthalmic: Conjunctival hyperemia (6%) Serious Ophthalmic: Bacterial keratitis， Cystoid macular edema， Macular retinal edema.,2-8°C保存,1 drop in the conjunctival sac of the affected eye(s) once daily in the evening. Do not administer more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect.,無需調整劑量,[仿單] 目前並無對於 VYZULTA隨人類乳汁泌出、對於授乳嬰兒或對乳汁分泌狀況的影響的相關資料。 使用前應針對整體考量哺乳對嬰兒發育和健康的益處、母親對於VYZULTA的臨床需求，以及VYZULTA對於授乳嬰兒的可能不良效應。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 目前仍未針對人類於孕期間使用 VYZULTA的相關藥物風險評估資料。 Latanoprostene bunod曾引起兔隻流產、小產和胎兒損傷。對孕兔經靜脈（IV）施予大於臨床0.28倍之latanoprostene bunod後，發現此物質引起流產和畸胎。 自胎兔所見結構異常包括主動脈弓大血管異常、圓頂顱、胸骨與脊骨異常、肢體過度伸展及轉動異常、腹部鼓脹及水腫。以每天150 mcg/kg的劑量（臨床劑量的87倍）經靜脈使用於大鼠後，發現latanoprostene bunod對於大鼠不具致畸胎性。 目前於孕期間使用此藥品與多數新生兒缺陷及流產的風險仍未知。,Unknown 沒有資料,[仿單] 目前並無對於 VYZULTA隨人類乳汁泌出、對於授乳嬰兒或對乳汁分泌狀況的影響的相關資料。 使用前應針對整體考量哺乳對嬰兒發育和健康的益處、母親對於VYZULTA的臨床需求，以及VYZULTA對於授乳嬰兒的可能不良效應。,OD;OL;OU;,,,,,1. 未開啟的藥瓶應放入2-8°C環境保存。藥瓶開封後，可在低於25°C的環境下保存8週。運送藥瓶時，可將藥瓶保存在40°C以下的環境，且保存時間不得超過14天。
ICOVBNT,SARS-CoV-2 Spike glycoprotein [mRNA],COVID-19 Vaccine BioNTech 0.3mL/dose (0.45mL/vial),HIMM,BioNTech COVID-19 Vaccine， for active immunization to prevent COVID-19 in individuals 12 years of age and older.,Hypersensitivity to the active substance or to any of the excipients.,erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.,運輸狀態而定詳閱仿單,IM， 0.3 mL， > or = 18 years 2 doses administered 3 weeks apart. (Taiwan CDC suggests 2 doses administered 4 weeks apart.),無需調整劑量,[仿單]目前尚不清楚BNT162b2疫苗是否會分泌至母乳中，也缺乏資訊說明接種BNT162b2疫苗對哺乳嬰兒是否有影響。 哺乳期間之女性，應於接種BNT162b2疫苗前評估潛在益處是否高於潛在風險。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]孕婦接種BNT162b2疫苗的實際案例有限。 動物試驗並未顯示BNT162b2疫苗會對懷孕、胚胎/胎兒發育、分娩或產後發育造成直接或間接的有害影響。 應僅在對於孕婦和胎兒的潛在益處高於任何潛在風險時，才考慮在懷孕期間接種本品。,Unknown 沒有資料,[仿單]目前尚不清楚BNT162b2疫苗是否會分泌至母乳中，也缺乏資訊說明接種BNT162b2疫苗對哺乳嬰兒是否有影響。 哺乳期間之女性，應於接種BNT162b2疫苗前評估潛在益處是否高於潛在風險。,IM;,,,,,須採用21號或管徑更小的針頭和無菌技術，在原始藥瓶中注入1.8 mL的0.9%氯化鈉注射液進行稀釋。稀釋後，藥瓶含2.25 mL液劑，可抽取6劑0.3 mL之疫苗。每劑必須含有0.3 mL疫苗。如果藥瓶中剩餘量不夠抽取0.3 mL的完整劑量，應丟棄。任何未於稀釋後6小時內使用完畢的疫苗皆應丟棄。 解凍後的藥瓶:可於2-8 °C保存1個月。未開封的藥瓶使用前在最高30 °C的溫度下最多可保存2小時。解凍後的疫苗不可再次冷凍。使用0.9%氯化鈉注射液稀釋後，在2-30 oC下，其安定性(包括運輸期間)可維持6小時。
OLENV,Lenvatinib,Lenvima 4mg,RACA,1. Differentiated thyroid cancer (DTC): Used for adults with progressive， locally advanced， or metastatic DTC， unresponsive to radioactive iodine treatment. 2. Renal cell carcinoma (RCC): Used as a first-line treatment in combination with pembrolizumab for advanced RCC patients. Also used in combination with everolimus for advanced RCC patients who have received prior anti-angiogenic therapy. 3. Hepatocellular carcinoma (HCC): Suitable for advanced HCC patients who are ineligible for surgical resection or local therapies. 4. Endometrial carcinoma (EC): Used in combination with pembrolizumab for advanced EC patients who have had disease progression after systemic therapy and are not candidates for curative surgery or radiotherapy.,Hypersensitivity to Lenvima or any component of the formulation.,Common: Hypertension (42-73%)， Peripheral edema (14-42%)， Hand-foot syndrome due to cytotoxic therapy (23-32%)， Impaired wound healing， Rash (14-37%)， Hypothyroidism (21-67%)， Abdominal pain (31-37%)， Constipation (16-29%)， Decrease in appetite (34-54%)， Nausea (20-49%)， Stomatitis (35-44%)， Vomiting (16-48%)， Weight decreased (30-51%)， Hemorrhage (23-35%)， Arthralgia， Disorder of the musculoskeletal system (53%)， Myalgia， Headache (10-38%)， Proteinuria (26-34%)， Urinary tract infectious disease (11-31%)， Cough (24-37%)， Difficulty talking (18-31%)， Dysphonia (22-30%)， Dyspnea (35%)， Fatigue (44-73%) Serious: Myocardial dysfunction (7-10%)， Myocardial infarction， Prolonged QT interval (2-11%)， Right ventricular dysfunction， Diarrhea (39-81%)， Gastrointestinal obstruction， Malignant， Lower gastrointestinal hemorrhage， Perforation of the intestine， Anemia (Renal cell carcinoma， 6%)， Arterial thrombosis (2-5%)， Myelodysplastic syndrome， Thrombocytopenia (Renal cell carcinoma， 5%)， Hepatic encephalopathy (Hepatocellular carcinoma， 8%)， Hepatitis， Hepatorenal syndrome， Hepatotoxicity (25%)， Liver failure， Osteonecrosis of the jaw (0.4%)， Posterior reversible encephalopathy syndrome (0.3%)， Acute injury of the kidney， Nephritis， Renal failure (Renal cell carcinoma， 18%)， Renal impairment (7-18%)， Pneumonia， Pneumonitis， Pulmonary embolism， Cardiorespiratory arrest， Dehydration (9-10%)， Multiple organ failure， Sepsis,25℃以下,Endometrial cancer， Carcinoma， advanced disease， that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H)， in combination with pembrolizumab in patients with disease progression following prior systemic therapy in any setting who are not candidates for curative surgery or radiation: 20mg QD PO + pembrolizumab 200mg IV over 30 minutes Q3W. Liver carcinoma， Unresectable， first-line therapy: (<60kg) 8mg QD PO， (>=60kg) 12mg QD PO. Renal cell carcinoma， Advanced， in combination with everolimus， after 1 prior anti-angiogenic therapy: 18mg QD PO + everolimus 5mg QD PO. Renal cell carcinoma， Advanced， in combination with pembrolizumab， first-line treatment: 20mg QD PO + pembrolizumab 200 mg IV over 30 minutes Q3W up to 2 years; following 2 years of combination therapy， may give lenvatinib as a single agent until disease progression or unacceptable toxicity. Thyroid cancer， Differentiated， locally recurrent or metastatic， progressive， refractory to radioactive iodine: 24mg QD PO,需調整劑量,[仿單] 尚未知是否會分泌於人類乳汁中，然而，lenvatinib 及其代謝物會分泌至大鼠乳汁中且 其濃度高於母體血漿內的濃度。因此藥可能對哺餵之嬰兒造成嚴重不良反應， 須告知婦女使用可能對哺餵之嬰兒造成嚴重不良反應， 須告知婦女治療期間及服用最後一個劑量後至少1周需停止哺乳。,需調整劑量,沒有資料,Contraindicated,[仿單]依據作用機轉及動物生殖試驗數據，懷孕婦女使用會對胎兒造成傷害。 動物生殖試驗中，於大鼠及兔子器官發展時期口服給予 Lenvatinib， 其劑量低於人體建議劑量時，會導致胚胎毒性、胎兒毒性和致畸胎性。 對於藥物相關的風險，目前無人體試驗數據。應告知懷孕婦女，其對胎兒之潛在風險。,Contraindicated 哺乳期使用禁忌,[仿單] 尚未知是否會分泌於人類乳汁中，然而，lenvatinib 及其代謝物會分泌至大鼠乳汁中且 其濃度高於母體血漿內的濃度。因此藥可能對哺餵之嬰兒造成嚴重不良反應， 須告知婦女使用可能對哺餵之嬰兒造成嚴重不良反應， 須告知婦女治療期間及服用最後一個劑量後至少1周需停止哺乳。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有管灌需求請使用前自行處理，並注意相關風險。 LenvimaR膠囊可整粒吞服，或將膠囊先溶解於小杯液體後服用。將膠囊放入一大湯匙的水或蘋果汁中(膠囊不需打開或壓碎)，以溶解於液體。將膠囊靜置於水或蘋果汁中至少10 分鐘，再攪拌至少3分鐘。飲用混合液後，再加入一大湯匙的水或蘋果汁於玻璃杯中，攪勻後再飲用完水或蘋果汁。
ONIF,Nifedipine,Nifedipine S.R.F.C. 30mg,CAVS,Hypertension， chronic stable angina pectoris,CV shock; pregnancy & lactation. Unstable angina & after recent MI (immediate release).,Initially mild & transient vasodilatation， hypotension， rarely GI， skin & other reactions. Very rarely: transient visual change; chest discomfort (if relation established， discontinue therapy). Extremely rare: on prolonged use gingival hyperplasia， gynaecomastia (both regressing on discontinuation); hepatobiliary disorders. Cardiovascular: Hypotension (up to 5% )， Palpitations (up to 7% )， Peripheral edema (7% to 29% ) Dermatologic: Flushing (4% to 25%) Gastrointestinal: Nausea (up to 10% ) Neurologic: Dizziness (4% to 10% )， Headache (19% to 23%) Psychiatric: Feeling nervous Respiratory: Cough， Dyspnea,30℃以下,angina: 30mg QD. HTN: 30mg QD up to 120mg.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;AM;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性膜衣錠整粒吞服，不可咀嚼或磨碎。
HCVDA14,Glecaprevir + Pibrentasvir (1，3type/16週),HCVDAA0014(C肝全口服新藥健保計畫) 1或3型/16週,QANB,,,,,,,,,,,,,,,,,,,
IHER60,Trastuzumab,HERCEPTIN inj 600mg/5mL (sample),RACA,Breast cancer， adjuvant treatment， breast cancer， metastatic， gastric cancer， metastatic.,Hypersensitivity to trastuzumab， Chinese hamster ovary (CHO) cell proteins， or any component of the formulation.,>10%: Cardiovascular: Decreased left ventricular ejection fraction (4% to 22%) Central nervous system: Pain (47%)， chills (5% to 32%)， headache (10% to 26%)， insomnia (14%)， dizziness (4% to 13%) Dermatologic: Skin rash (4% to 18%) Gastrointestinal: Nausea (6% to 33%)， diarrhea (7% to 25%)， vomiting (4% to 23%)， abdominal pain (2% to 22%)， anorexia (14%) Infection: Infection (20%) Neuromuscular & skeletal: Weakness (4% to 42%)， back pain (5% to 22%) Respiratory: Cough (5% to 26%)， dyspnea (3% to 22%)， rhinitis (2% to 14%)， pharyngitis (12%) Miscellaneous: Infusion related reaction (21% to 40%， chills and fever most common; severe: 1%)， fever (6% to 36%),2-8℃避光避免冷凍,600 mg (600 mg trastuzumab and 10，000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every 3 weeks.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,SC;,,,,,1.本品僅能以皮下注射給予。注射時間應為2-5分鐘。 2.不論患者體重多寡，本品之建議固定劑量為600mg，每3週給藥ㄧ次。 3.注射部位應在左右大腿之間輪替，新的注射部位與舊的注射部位應相距至少2.5公分，且不得在皮膚發紅、瘀青、觸痛或硬塊處注射。 4.第一次皮下注射後6小時以及後續的皮下注射後2小時，應觀察患者是否出現注射相關反應。
OFRIS,Clobazam,Frisium 10mg,CNEU,Anxiety or Adjunct in epilepsy.,History of hypersensitivity to clobazam or any component of the product. Myasthenia gravis. Severe respiratory insufficiency. Sleep apnoea syndrome. Severe hepatic impairment. Lactation.,Common Gastrointestinal: Constipation (2% to 10% )， Drooling (Up to 14% ) Neurologic: Ataxia (2% to 10% )， Dysarthria (2% to 5% )， Insomnia (2% to 7% )， Lethargy (5% to 15% )， Sedated (2% to 9% )， Somnolence (16% to 25% ) Psychiatric: Aggressive behavior (3% to 14% ) Renal: Urinary tract infectious disease (2% to 5% ) Respiratory: Cough (3% to 7% ) Other: Fever (10% to 17% .) Serious Dermatologic: Stevens-Johnson syndrome， Toxic epidermal necrolysis Immunologic: Hypersensitivity reaction Respiratory: Respiratory depression,25℃以下,Anxiety: Adult: 20-30 mg daily in divided doses or as a single dose preferably at bedtime. Duration of treatment: Not exceeding 4 weeks and the patient must be re-assessed after. Use the lowest possible dose for the shortest possible time. Child > or = 3 years: Recommended dose is half of the adult dose. Elderly: 10-15 mg daily. Observe carefully during gradual dose increments. Adjunct in epilepsy: Adult: Initially， 5-15 mg daily. Max: 80 mg daily. usual Maintenance dose: 20mg/day. [Micromedex 20210922]Pediatric Dosing Lennox-Gastaut syndrome - Seizure; Adjunct 2 years or older and 30 kg or less: Initial， 5 mg orally daily; may titrate to 10 mg daily (2 divided doses) on day 7 and to 20 mg daily (2 divided doses) on day 14. 2 years or older and greater than 30 kg: Initial， 10 mg orally daily (2 divided doses); may titrate to 20 mg daily (2 divided doses) on day 7 and to 40 mg daily (2 divided doses) on day 14.,需調整劑量,[仿單]授乳婦女不可使用Frisium。,無需調整劑量,沒有資料,Human (and animal) data suggest risk,Limited Human Date - Potential Toxicity. [仿單]動物試驗證實具有生殖毒性。在上市後安全資料中，孕婦服用clobazam之資料有限，其中有關胎兒或新生兒疾病之案例也被報導過。 Clobazam可穿透胎盤。在懷孕或具有懷孕潛力但未避孕的女性，不建議使用clobazam。懷孕期間最好避免使用clobazam。只有在對胎兒之潛在利益大於風險時，懷孕婦女才可使用clobazam。 具有懷孕潛力的婦女必須被告知於懷孕期間使用clobazam的風險與利益。如果婦女計畫懷孕或已經懷孕，應小心評估其風險與利益，以及是否應該停止服用Frisium。 評估後，如果仍要繼續服用Frisium，應以最低有效劑量服用。某些病例顯示，在懷孕中期及/或懷孕後期服用benzodiazepines會造成胎兒運動減少和胎兒心率變異。 懷孕後期或分娩期間服用clobazam可能會導致新生兒出現呼吸抑制現象（包括呼吸窘迫及呼吸暫停），也有可能出現其他不適，例如，鎮靜徵兆、體溫過低、肌肉張力偏低、或餵食困難（可能導致體重增加不佳）（這些症狀及徵兆統稱為“嬰兒蹣跚症候群”(floppy infant syndrome)）。 此外，若母體長期服用benzodiazepines至懷孕後期，則嬰兒出生後可能出現生理性依賴，且有戒斷症狀的風險。建議新生兒在出生後給予適當監測。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]授乳婦女不可使用Frisium。,,,,,,
ECOL4,Mesalazine,4gm/100mLColasa enema,ALIM,Ulcerative colitis， mild to moderate proctitis and proctosigmoiditis.,Hypersensitivity to mesalazine or any component in the preparation. History of hypersensitivity to salicylate preparations. Severe liver impairment. Severe renal impairment (GFR less than 30 ml/minute/1.73m2).,Nausea， diarrhea， abdominal pain， headache.,25℃以下乾燥避光,Adults: 2gm-4gm once at night. Children: Dose is not determined.,需調整劑量,[仿單] 迄今為止哺乳之相關研究有限。嬰幼兒無法排除之過敏反應，如：腹瀉。 因此，哺乳期間使用 mesalazine 應判斷治療需要性大於可能發生之風險。 假如病人在治療期間出現嬰幼兒腹瀉症狀應立即停止哺乳。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單] Mesalazine用於懷孕婦女之臨床研究非常有限。有限的研究中並未發現mesalazine 對懷孕婦女或健康胎兒/新生兒造成傷害。 迄今為止還未有其他相關的流行病學數據。Mesalazine動物口服試驗， 對懷孕、胚胎/胎兒的發展並無直接或間接傷害，特別是產後發展。 懷孕期間，mesalazine應僅限於醫師判斷治療需要性大於可能發生之風險，且應謹慎使用。,Unknown 沒有資料,[仿單] 迄今為止哺乳之相關研究有限。嬰幼兒無法排除之過敏反應，如：腹瀉。 因此，哺乳期間使用 mesalazine 應判斷治療需要性大於可能發生之風險。 假如病人在治療期間出現嬰幼兒腹瀉症狀應立即停止哺乳。,RECT;,,,,,
IPRA,Alirocumab,Praluent solution for injection 75mg,CAVS,Hyperlipidemia， primary: Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease， who require additional lowering of LDL-C. Prevent cardiovascular events,Hypersensitivity.,Nasopharyngitis， inj site reactions， flu， UTI， diarrhea， bronchitis， myalgia， muscle spasms， sinusitis， cough， contusion， musculoskeletal pain.,2-8℃避光避免冷凍,75 mg SC once every 2 weeks or 300 mg SC monthly. Maximum dose: 150 mg SC every 2 weeks.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,No reports describing the use of alirocumab in human pregnancy have been located. Animal data suggest low risk， but the absence of human pregnancy data prevents a better assessment of the embryo–fetal risk. Based on studies in monkeys， exposure of the fetus late in pregnancy should be expected (see below). In addition， the drug is given to patients under treatment with statins. Statins are classified as contraindicated in pregnancy because interruption of cholesterol-lowering therapy during pregnancy should have no effect on the long-term treatment of hyperlipidemia and because of the human data reported with lovastatin (see Lovastatin). Consequently， alirocumab should also be classified contraindicated.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,1.未冷藏且25度C以下最多不可超過30天.
OPLK,Finasteride,Proleak 5mg,SGU,,適應症: Treatment & control of benign prostatic hyperplasia (BPH) to cause regression of enlarged prostate， improve urine flow & improve the symptoms of BPH. 副作用: Common Reproductive: Abnormal ejaculation (1.2% to 7.2% )， Breast tenderness (0.4% to 0.7% )， Reduced libido (1.8% to 10% ) Serious Endocrine metabolic: Neoplasm of male breast Reproductive: Prostate cancer， high-grade (1.8% ) Other: Neoplasm of male breast 禁忌:Hypersensitivity to any component of the product. Pregnancy， or women who may be pregnant or plan to become pregnant.,,室溫,PO 5mg daily.,無需調整劑量,[仿單]Finasteride不適用於婦女，目前尚未確知是否會排入人乳汁中. [Micromedex] Breast Feeding: Infant risk cannot be ruled out. 2020/06/01,無需調整劑量,不可使用,,[仿單]懷孕或可能懷孕之婦女禁用Finasteride.本類藥物懷孕婦女服用，可能引起男性胎兒外生殖器異常. 懷孕或可能懷孕之婦女不可接觸已壓碎或破損之Finasteride錠劑，可能經皮膚吸收而對男性胎而造成危險. [Micromedex] Pregnancy Category : X (FDA) 2020/06/01,Unknown 沒有資料,[仿單]Finasteride不適用於婦女，目前尚未確知是否會排入人乳汁中. [Micromedex] Breast Feeding: Infant risk cannot be ruled out. 2020/06/01,AC;PC;PO;WM;,,,,,
OVERZ0,Abemaciclib,Verzenio 150mg (sample) (28 tablets/box),RACA,Breast cancer， Advanced or metastatic， hormone receptor-positive disease， HER2-negative， in combination with an aromatase inhibitor for initial endocrine therapy in postmenopausal women and men. Breast cancer， Advanced or metastatic， hormone receptor-positive disease， HER2-negative， in combination with fulvestrant for progression following endocrine therapy. Breast cancer， Advanced or metastatic， hormone receptor-positive disease， HER2-negative， monotherapy for progression following endocrine therapy and prior chemotherapy in the metastatic setting. Breast cancer， Early， hormone receptor-positive， HER2-negative， node-positive， high-risk， in combination with adjuvant endocrine therapy.,Allergic to the active ingredients or excipients in Verzenio.,Common Gastrointestinal: Abdominal pain (29% to 39% )， Decrease in appetite (12% to 45% )， Diarrhea， All Grades (81% to 90% )， Nausea (39% to 64% )， Vomiting (26% to 35% ) Hematologic: Anemia， All Grades (25% to 29% )， Leukopenia， All Grades (17% to 28% )， Neutropenia， All Grades (37% to 46% ) Immunologic: Infectious disease (31% to 51% ) Neurologic: Headache (20% ) Other: Fatigue (40% to 65% ) Serious Gastrointestinal: Diarrhea， Grade 3 (8% to 20% ) Hematologic: Febrile neutropenia (Less than 1% )， Neutropenia， Grade 3 or higher (19% to 32% )， Neutropenic sepsis， Venous thromboembolism (2% to 5% ) Hepatic: ALT/SGPT level raised (Grade 3 or higher， 2% to 6% )， Aspartate aminotransferase serum level raised (Grade 3 or higher， 2% to 3% ) Neurologic: Cerebral infarction Respiratory: Interstitial lung disease， Pneumonitis,儲存於30°C以下,In combination with fulvestrant， tamoxifen， or an aromatase inhibitor， the recommended dose is 150 mg taken orally twice daily. As monotherapy， the recommended dose is 200 mg taken orally twice daily. Dose Modifications for Adverse Reactions: In combination with fulvestrant， tamoxifen， or an aromatase inhibitor: Recommended starting dose: 150 mg twice daily -> First dose reduction: 100 mg twice daily -> Second dose reduction: 50 mg twice daily -> Third dose reduction: not applicable. As monotherapy: Recommended starting dose: 200 mg twice daily -> First dose reduction: 150 mg twice daily -> Second dose reduction: 100 mg twice daily -> Third dose reduction: 50 mg twice daily.,需調整劑量,[仿單]目前沒有abemaciclib是否進入人體乳汁，對授乳嬰兒或對乳汁分泌影響的資料。由於VERZENIO可能使授乳嬰兒發生嚴重不良反應，應告知哺乳婦女於VERZENIO治療期間及接受最後一劑治療後3週內不可哺乳。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]根據動物試驗的發現及藥物作用機轉，若給予懷孕婦女VERZENIO，可能會造成胎兒傷害。目前並無人類的藥物風險資料。應告知懷孕婦女此藥物可能對胎兒造成之潛在危害。在動物生殖試驗中，在器官形成期間投予abemaciclib，abemaciclib的母體曝露量與最大建議人體劑量下的AUC之人類臨床曝露量相近時，具有致畸胎性也會導致胎兒體重減輕。應告知懷孕婦女此藥物可能對胎兒造成之潛在危害。 有關特定族群發生重大先天缺陷和流產的背景風險尚不清楚。然而在美國一般族群的臨床確認懷孕中，發生重大先天缺陷的背景風險為2至4%，流產的背景風險為15至20%。 在一項胚胎－胎兒發育試驗中，於器官形成期間給予懷孕大鼠最高達15 mg/kg/day的abemaciclib口服劑量。劑量?4 mg/kg/day會導致胎兒體重降低，及心血管和骨骼畸形與變異事件的發生率提高。這些發現包括缺乏無名動脈和主動脈弓、鎖骨下動脈錯位、胸骨未骨化、胸椎椎體的二分骨化，及雛肋或結節狀肋骨。使用4 mg/kg/day的大鼠其母體全身曝露量大約與建議劑量的人體曝露量(AUC)相當。 告知具有生育能力的女性，在VERZENIO治療期間及接受最後一劑治療後3週應採用有效的避孕措施。,Unknown 沒有資料,[仿單]目前沒有abemaciclib是否進入人體乳汁，對授乳嬰兒或對乳汁分泌影響的資料。由於VERZENIO可能使授乳嬰兒發生嚴重不良反應，應告知哺乳婦女於VERZENIO治療期間及接受最後一劑治療後3週內不可哺乳。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議病人應吞服整顆錠劑，不可將錠劑咀嚼、壓碎或切半後吞服。如果錠劑破裂、裂開或不完整，請病人不要服用。
ESPOT,Tiotropium + Olodaterol,適倍樂Spiolto Respimat 2.5/2.5mcg/puff,ERSP,a long term maintenance treatment of patients with Chronic Obstructive Pulmonary Disease， including chronic bronchitis and emphysema.,Hypersensitivity to the active substances or to any of the excipients. History of hypersensitivity to atropine or its derivatives， e.g. ipratropium or oxitropium.,Common Musculoskeletal: Backache (3.6% ) Respiratory: Nasopharyngitis (12.4% ) Serious Cardiovascular: Disorder of cardiovascular system (3% or less )， Electrocardiogram abnormal Immunologic: Hypersensitivity reaction (3% or less ) Ophthalmic: Angle-closure glaucoma， Worsening (3% or less ) Renal: Urinary retention， Worsening (3% or less ) Respiratory: Bronchospasm (3% or less )， Pneumonia,30°C以下勿冷凍,Adults: The recommended dose is 5 mcg tiotropium and 5 mcg olodaterol (2 puffs) QD， at the same time of the day. SPIOLTOR RESPIMAT should not be used more frequently than once daily. Age < 18 years: Usually will not use.,無需調整劑量,Tiotropium: BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible Olodaterol: BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible [仿單] 目前尚無 tiotropium 及/或 olodaterol 在授乳婦女使用的相關臨床資料。 Tiotropium 和 olodaterol 的動物實驗發現，在泌乳大鼠的乳汁中可偵測到本藥物及/或其代謝產物，但不清楚 tiotropium 及/或 olodaterol 是否可分泌至人乳。 在決定是否繼續/停止哺乳或繼續/停止 SPIOLTOR RESPIMATR治療時，應考量哺乳對嬰兒的益處與 SPIOLTO RESPIMAT 治療對婦女的益處。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,Tiotropium: PREGNANCY RECOMMENDATION: No Human Data—Animal Data Suggest Low Risk Olodaterol: PREGNANCY RECOMMENDATION: No Human Data—Animal Data Suggest Low Risk [仿單] Tiotropium: 關於 tiotropium 於孕婦的使用經驗，目前相關資料十分有限。臨床前研究並未顯示tiotropium 在臨床相關的劑量下，可能具有生殖毒性而造成直接或間接的傷害。 Olodaterol: 目前尚無 olodaterol 在孕婦中使用的相關臨床資料。Olodaterol 的臨床前資料顯示，在較治療劑量高出多倍的劑量下，會出現 s-腎上腺素受體促效劑的典型作用。 作為防範措施，建議懷孕期間應避免使用 SPIOLTOR RESPIMATR。如同其他 s2-腎上腺素受體促效劑，SPIOLTOR RESPIMATR所含成分 olodaterol 對子宮平滑肌具有鬆弛作用，因此可能對分娩過程具抑制作用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Tiotropium: BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible Olodaterol: BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible [仿單] 目前尚無 tiotropium 及/或 olodaterol 在授乳婦女使用的相關臨床資料。 Tiotropium 和 olodaterol 的動物實驗發現，在泌乳大鼠的乳汁中可偵測到本藥物及/或其代謝產物，但不清楚 tiotropium 及/或 olodaterol 是否可分泌至人乳。 在決定是否繼續/停止哺乳或繼續/停止 SPIOLTOR RESPIMATR治療時，應考量哺乳對嬰兒的益處與 SPIOLTO RESPIMAT 治療對婦女的益處。,IH;,,,,,
ENNG,Testosterone,Natesto nasal gel 4.5%， 11gm,HM,Testosterone replacement therapy in adult males,Natesto is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precaution. Natesto is contraindicated in women who are or who may become pregnant， or who are breastfeeding. Natesto may cause fetal harm when administered to a pregnant woman. Natesto may cause serious adverse reactions in nursing infants. Exposure of a fetus or nursing infant to androgens may result in varying degrees of virilization. If a pregnant woman is exposed to Natesto， she should be apprised of the potential hazard to the fetus.,Common Dermatologic: Acne (Up to 8% )， Application site reaction (2% to 16.1% )， Scab of skin， Nasal (3.8% to 5.8% ) Endocrine metabolic: Gynecomastia (1% to 3% ) Gastrointestinal: Oral irritation (9.2% ) Neurologic: Headache (1% to 6% ) Reproductive: Large prostate (11.7% )， Raised prostate specific antigen (1% to 11.1% ) Respiratory: Bleeding from nose (3.8% to 6.5% )， Bronchitis (3.8% to 4.3% )， Discomfort， Nasal (3.8% to 5.9% )， Nasal discharge (3.8% to 7.8% )， Nasopharyngitis (3.8% to 8.7% )， Sense of smell altered (5.8% )， Sinusitis (3.8% )， Upper respiratory infection (3.8% to 4.3% ) Serious Cardiovascular: Death， Cardiovascular， Edema， Myocardial infarction Hematologic: Deep venous thrombosis， Venous thromboembolism Hepatic: Cholestatic jaundice syndrome， Liver carcinoma， Neoplasm of liver， Peliosis hepatis Neurologic: Cerebrovascular accident Reproductive: Benign prostatic hyperplasia (Up to 2% )， Prostate cancer (Up to 1.2% ) Respiratory: Pulmonary embolism,保存於室溫下(25°C),Recommended Dose and Dosage Adjustment The recommended starting dose of NATESTO (testosterone) is 11.0 mg of testosterone (1 actuation per nostril) administered intranasally twice daily for a total daily dose of 22.0 mg. To ensure proper dosing， serum total testosterone concentrations should be measured after initiation of therapy to ensure that the desired concentrations (300 to 1050 nanogram/dL) are achieved. The NATESTO dose can be adjusted at least 30 days after starting treatment based on the serum total testosterone concentrations from a single blood draw， taken 20 minutes to 2 hours after morning administration of NATESTO. If the total testosterone measurement is less than 300 nanogram/dL， the daily testosterone dose may be increased from 22.0 mg (twice daily administration) to 33.0 mg (thrice daily administration)， as instructed by a physician. Serum total testosterone concentrations should be checked periodically. The following rules should be applied: 1. For patients on 22.0 mg (twice daily administration): If the measured serum total testosterone concentration from the single morning blood draw is less than 300 nanogram/dL， the NATESTO? Product Monograph Page 15 of 39 daily dose of NATESTO may be increased from 22.0 mg (twice daily administration) to 33.0 mg (thrice daily administration); 2. For patients on 33.0 mg (thrice daily administration): If the measured serum total testosterone concentration from the single morning blood draw is consistently less than 300 nanogram/dL， or if a desired clinical response is not achieved， NATESTO should be discontinued and an alternative treatment should be considered. If a post-dose morning total testosterone concentration consistently exceeds 1050 nanogram/dL， NATESTO should be discontinued.,無需調整劑量,[仿單] 雖然目前不清楚有多少睪固酮會進入人類乳汁， 但由於可能在喝母乳的嬰兒身上引起嚴重不良反應，因此 NATESTO 禁止用於哺乳中女性。,無需調整劑量,沒有資料,Contraindicated,[仿單]由於缺乏相關評估且可能有雄性化作用，NATESTO 並無使用於女性的適應症。 NATESTO 禁用於懷孕期間，或可能受孕的女性。睪固酮具有致畸胎性，可能對胎兒造成危害。 如果此藥在懷孕期間使用，或者患者在使用此藥期間受孕，患者應知悉可能對胎兒造成的危害。 女性胎兒若暴露於雄性素中，可能導致程度不一的雄性化。,Contraindicated 哺乳期使用禁忌,[仿單] 雖然目前不清楚有多少睪固酮會進入人類乳汁， 但由於可能在喝母乳的嬰兒身上引起嚴重不良反應，因此 NATESTO 禁止用於哺乳中女性。,IN;,,,,,每按一次給藥幫浦可送出5.5mg的睪固酮，因此左右鼻孔各給藥一次可送出11mg。
OSERM1,Nicergoline,Sermion 10mg,CAVS,Cerebral circulation disorders.,Hypersensitivity to nicergoline， or Ergotamine. Myocardial infarction. Acute bleeding. Postural hypotension. Severe bradycardia,Rare cases of mild side effects have been reported， which in general may be related to the vasoactive action of Sermion. These are hypotension and vertigo after parenteral administration， slight gastric disturbances， feeling of heat and flushing， drowsiness and insomnia.,25℃以下,5-10 mg three times daily. Take Sermion between meals.,無需調整劑量,[仿單] 目前還不知道nicergoline是否會分泌在人類母乳中。 因此，不建議哺乳期間使用nicergoline。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] Nicergoline不會造成懷孕老鼠和兔子的生殖毒性。在懷孕婦女的研究尚未進行。 就目前核准的適應症而言，不太可能會使用nicergoline於懷孕婦女和哺乳婦女。 在懷孕期間，nicergoline應僅能在對病人的潛在益處大於對胎兒的潛在風險時使用。,Unknown 沒有資料,[仿單] 目前還不知道nicergoline是否會分泌在人類母乳中。 因此，不建議哺乳期間使用nicergoline。,AC;AC15;PC;PO;,,,,,
IALF1,Alfentanil,Alfentanil inj 1mg/2mL,CNEU,An analgesic supplement and an anaesthetic induction agent.,Hypersensitivity to alfentanil or any component of the formulation. known intolerance to alfentanil or opioids.,Common Cardiovascular: Hypertension (18% )， Tachycardia (12% ) Gastrointestinal: Nausea (28% )， Vomiting (18% ) Musculoskeletal: Involuntary movement， Skeletal muscle (3% to 9% ) Serious Cardiovascular: Asystole， Bradyarrhythmia， Cardiac dysrhythmia， Hypotension (10% ) Immunologic: Anaphylaxis (Less than 1% ) Musculoskeletal: Muscle rigidity (17% ) Neurologic: Raised intracranial pressure， Seizure Respiratory: Apnea (3% to 9% )， Laryngeal spasm (0.3% to 1% )， Respiratory depression (1% to 3% ) Other: Serotonin syndrome,30℃以下,Anesthetic Induction: An intravenous bolus dose of > or =120 micrograms/kg (17mL/70kg). For short procedures or out patient， an initial dose 7-15 micrograms/kg at induction， with intermittent boluses up to 15 micrograms/kg (7-15 micrograms/kg) at 10-15 minute intervals are most useful. If the dose is less than 7 micrograms/kg and IV injection slowly， most patients can still maintain normal respiratory function. the recommended additional dose is 3.5 micrograms/kg. For procedures of longer duration， a higher dose may be given at induction and further increments titrated to effect. For procedures of longer duration， a higher dose may be given at induction and further increments titrated to effect. Duration of the procedure: 10-30 minutes; Alfentanil IV bolus dose: 20-40 Micrograms/kg; 3-6mL/70kg; Duration of the procedure: 30-60 minutes; Alfentanil IV bolus dose: 40-80 Micrograms/kg; 6-12mL/70kg; Duration of the procedure: >60 minutes; Alfentanil IV bolus dose: 80-150 Micrograms/kg; 12-20mL/70kg; When surgery is more prolonged or more traumatic， analgesia should be maintained by: either increments of up to 15 micrograms/kg (2mL/70kg) Alfentanil when required (to avoid post-operative respiratory depression， no Alfentanil should be administered during the last 10 minutes of surgery); Or an Alfentanil infusion at a rate of 0.5 to 1 microgram/kg/minutes (0.14mL/70kg/minutes) until 5 to 10 minutes before the completion of surgery. Continuous infusion is preferable for cases greater than 60 minutes duration. Alfentanil should not be given in the last 10 minutes prior to completion of surgery.,無需調整劑量,[仿單]Alfentanil injection會分泌到乳汁中，因此，在Alfentanil injection給藥後的24小時內不要授乳或餵哺擠出的母乳。,無需調整劑量,沒有資料,Human data suggest risk in 3 rd trimester,[仿單]雖然在動物實驗並沒有發現畸形或急性胎毒效應，但目前仍然沒有足夠的數據可用以評估對人類的任何有害作用，因此孕婦於給藥前應做審慎的利弊評估。 在分娩(包括剖腹生產)的過程不建議靜脈注射本品，因為Alfentanil injection會穿過胎盤，且胎兒的呼吸中樞對鴉片類藥物較敏感。 如於分娩時使用Alfentanil injection，應備妥輔助呼吸設備供母嬰需要時使用。 鴉片類藥物的拮抗劑應事先為胎兒備妥。鴉片類藥物拮抗劑的半衰期可能比Alfentanil的半衰期短，因此多劑投與鴉片類藥物拮抗劑可能是必要的。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]Alfentanil injection會分泌到乳汁中，因此，在Alfentanil injection給藥後的24小時內不要授乳或餵哺擠出的母乳。,IVD;IVPUSH;,,【D5W】可選 。【N/S】可選 。,Administered over 3 minutes.,中長時間的手術：藥物的初次劑量與手術預期時間的配合如下： 手術時間(分鐘) Alfentanil (micrograms/kg) 靜脈注射一次給藥劑量 (mL/70kg) 10-30 20~40 3-6 30-60 40~80 6-12 > 60 80~150 12-20,廠商提供的安定性試驗: 1支稀釋於500mL的注射用生理食鹽水或5%葡萄糖水中可保持24小時安定。 [Micromedex 20220526] Recommended concentration was diluted to 25 to 80 mcg/mL. [Micromedex 20220526] Induction dosage: 8 to 20 mcg/kg IV administered over 3 minutes.
IALF1BAD,Alfentanil,Alfentanil inj 1mg/2mL 殘餘銷毀,CNEU,,,,,,,,,,,,,,,,,,,
ITRUL,Dulaglutide,Trulicity inj 1.5mg/0.5mL,META,Type 2 diabetes mellitus.,Hypersensitivity to dulaglutide or any of its components. Multiple endocrine neoplasia syndrome type 2 or personal or family history of medullary thyroid carcinoma.,Common Gastrointestinal: Abdominal pain (6.5% to 9.4% )， Decrease in appetite (4.9% to 8.6% )， Diarrhea (7% to 12.6% )， Nausea (12.4% to 21.1% )， Vomiting (5.6% to 12.7% ) Serious Cardiovascular: Atrioventricular block， First degree (1.7% to 2.3% ) Endocrine metabolic: C-cell hyperplasia of thyroid， Hypoglycemia (0.3% to 77% )， Thyroid cancer Gastrointestinal: Cholecystitis， Cholelithiasis， Pancreatitis Immunologic: Anaphylaxis， Hypersensitivity reaction， Systemic (0.5% ) Ophthalmic: Retinopathy due to diabetes mellitus (1.9% ) Renal: Acute renal failure， Chronic renal failure， Exacerbation Other: Angioedema,儲存於2-8°C，不可冷凍,This product is a single dose of 1.5mg， and the dose cannot be adjusted. Initial， 0.75 mg once weekly; may increase to 1.5 mg once weekly for additional glycemic control; The maximum dose: 1.5 mg once weekly.,無需調整劑量,[仿單]目前並不清楚dulaglutide是否分泌到人類乳汁中，亦無易週糖R是否會對哺乳嬰兒或乳汁產量造成影響的相關資訊。還不確定dulaglutide是否分泌到接受治療的哺乳中動物的乳汁中。哺乳對發育和健康的益處，應與母親對易週糖R的臨床需要以及因易週糖R或母體本身狀況對哺乳嬰兒可能造成的任何不良影響一起做衡量。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]懷孕婦女使用易週糖R的數據有限，不足以確定重大出生缺陷和流產的風險與藥物相關。應留意關於懷孕期間糖尿病控制不佳在臨床考量上的風險。依據動物生殖試驗，在懷孕期間暴露於dulaglutide可能對胎兒有風險。只有當潛在益處高過對胎兒的潛在風險時，才可在懷孕期間使用易週糖R。 於懷孕大鼠的器官生成期給予dulaglutide，當全身暴露量為人類最大建議劑量（Maximum recommended human dose， MRHD，每週1.5mg）14倍以上時，曾發生早期胚胎死亡、胎兒生長遲緩和胎兒異常。於懷孕兔子的器官生成期給予dulaglutide，在13倍人類最大建議劑量（MRHD）下，曾發生重大胎兒異常。發生在動物的不良胚胎/胎兒作用與dulaglutide藥理作用造成母體體重減輕以及攝食減少相關。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並不清楚dulaglutide是否分泌到人類乳汁中，亦無易週糖R是否會對哺乳嬰兒或乳汁產量造成影響的相關資訊。還不確定dulaglutide是否分泌到接受治療的哺乳中動物的乳汁中。哺乳對發育和健康的益處，應與母親對易週糖R的臨床需要以及因易週糖R或母體本身狀況對哺乳嬰兒可能造成的任何不良影響一起做衡量。,SC;,,,,,1.本藥僅供皮下注射。 2.需於2-8°C冷藏保存，不可冷凍。若置於室溫不超過30°C只能保存14天。 3.若需調整給藥時間時，需注意兩次注射之間應間隔至少3天(超過72小時)。 4.錯過原定給藥時間且距離下一次預定給藥時間至少3日(72小時)，則應儘快使用。若距離下次預定給藥時間未滿3日，則應跳過錯過的劑量，於原本預定的日期給予下一次劑量。上述兩種情況下，病人均可恢復原本每週一次的給藥時程。
ICTX,Ceftriaxone,Ceftriaxone Kabi inj 1gm,QANB,Infections caused by pathogens sensitive to Rocephin， eg sepsis; meningitis; infection in patients with impaired defence mechanisms; UTI; infection of respiratory tract， abdominal， bone， joint， soft tissue， skin， GUT， ENT; genital infection including gonorrhea.,Known hypersensitivity to cephalosporins. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing soln or products.,GI upsets， hematological changes， skin reactions， coagulation disorders， phlebitis (IV administration). Rarely， agranulocytosis， renal precipitations.,25℃以下避光,Adults and adolescents (> 12 years) > or = 50 kg: 1-2 g Q24H (maximum 4 g); surgical prophylaxis: a single dose of 1-2 g administered 0.5-1.5 hours before surgery; uncomplicated gonococcal infections: a single IM dose of 250 mg. Children (15 days-12 years): 20-80 mg/kg Q24H (100 mg/kg/day for meningitis) (maximum 2 g/day). Newborn (0-14 days): 20-50 mg/kg Q24H. *****NEONATE ANTIBIOTICS DOSE***** Ceftriaxone (Rocephin): Sepsis: Use cefotaxime in place of ceftriaxone if hyperbilirubinemia or receiving calcium-containing intravenous solutions Body weight <1kg ge<=7day 50mg/kg QD  Age 8-14 ayd 50mg/kg QD  Age 15-28 day 50 mg/kg QD Body weight 1-2kg ge<=7day 50mg/kg QD  Age 8-14 day 50 mg/kg QD  Age 15-28 day 50 mg/kg QD Body weight >2kg Age<=7day 50 mg/kg QD  Age 8-14 day 50 mg/kg QD  Age 15-28 day 75mg/kg QD Ceftriaxone:meningitis: In neonates， IDSA guidelines suggest cefotaxime as the preferred nonpseudomonal third-generation cephalosporin; no ceftriaxone dosing is provided in the guidelines.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,IM: 3.5mL 1% Lidocaine / Water for injection; IV: 10mL Water for injection. IM若以3.5mL Water for injection稀釋後給藥，須IM Lidocaine局麻完成後再給予Ceftriaxone.,【D5W】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【D5NS】可選 。,推注時間至少2 ~ 4分鐘,以> 30分鐘緩慢滴注,1. 本藥品勿與含鈣或其他抗生素溶液混合。 2. 注射前詢問病患是否有β-醯胺類抗生素過敏史。 3. 監測體溫、CBC、肝腎功能，抗生素引起的腹瀉。 4.肌肉注射時，將Ceftriaxone Kabi 1 g乾粉注射劑溶於3.5 mL 1%鹽酸利多卡因(Lidocaine hydrochloride)溶液後注入深部臀肌。每一身側注射ceftriaxone不得超過1 g。肌肉注射每日最大劑量不得超過2 g。 5.肌肉注射Ceftriaxone Kabi 1.0克不適用於萊姆病（第II和III期）。
ITOU,Insulin glargine,Toujeo inj 300 Unit/mL， 1.5mL Pen,META,Treatment of diabetes mellitus in adults.,Hypersensitivity,Hypoglycaemia,2-8℃避光避免冷凍,SC， once daily preferably at the same time each day.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,SC;,,,,,
INOVM,Insulin Aspart 30 + NPH 70,NovoMix 30 FlexPen 100 Unit/mL， 3mL,META,Treatment of patients with diabetes mellitus.,Hypoglycaemia.,Hypoglycemia (Type 1 diabetes mellitus， 69% to 75%; type 2 diabetes mellitus， 47% to 58% ) Gastrointestinal: Abdominal pain (Type 2 diabetes mellitus， 5% )， Diarrhea (7% to 8% )， Indigestion (Type 1 diabetes mellitus， 9% )， Backache (Type 1 diabetes mellitus， 7% )， Musculoskeletal pain (Type 1 diabetes mellitus， 5% )， Headache (Type 1 diabetes mellitus， 17% to 35%; type 2 diabetes mellitus， 9% to 13% )， Neuropathy (Type 2 diabetes mellitus， 8% )， Pharyngitis (6% to 7% )， Rhinitis (5% )， Upper respiratory infection (5% to 17% )， Influenza-like symptoms (Type 1 diabetes mellitus， 13% )， Hypoglycemia (Severe) (Type 1 diabetes mellitus， 16%; type 2 diabetes mellitus， 4% )， Hypokalemia， Hypersensitivity reaction.,避光避免冷凍，開封前2-8℃，啟用後可放30℃以下並可以使用四星期,SC， according to the individual needs of the patient.,無需調整劑量,[仿單]授乳期使用 NovoMixR30 並無限制，授乳期間母親接受胰島素治療對嬰兒沒有危險性， 但 NovoMixR30 的劑量可能需要調整。,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]懷孕期使用 NovoMixR30 的臨床經驗有限。對於懷孕婦女，尚未有 NovoMixR30 之研究。 然而，自兩組隨機對照臨床試驗的資料顯示，相較於可溶性人類胰島素， insulin aspart 對於懷孕或胎兒/新生兒之健康並未出現不良反應 一般來說，對於已懷孕或計劃懷孕的糖尿病婦女建議於整個懷孕期全程採用密集血糖控制和監視。 胰島素需求量通常在懷孕的第 1 至 3 個月會下降，隨後在第4 至 9 個月則逐漸增加， 產後通常會即刻回到懷孕前的需求量。,Compatible 哺乳時可使用,[仿單]授乳期使用 NovoMixR30 並無限制，授乳期間母親接受胰島素治療對嬰兒沒有危險性， 但 NovoMixR30 的劑量可能需要調整。,SC;,,,,,在重新振搖混合後，藥品若不是呈現均勻的白色雲霧狀液體則不可使用。
INOVM5,Insulin Aspart 50 + NPH 50,50 NOVOMIX FlexPen 100 Unit/mL， 3mL,META,Treatment of patients with diabetes mellitus.,Hypoglycaemia.,Hypoglycemia (Type 1 diabetes mellitus， 69% to 75%; type 2 diabetes mellitus， 47% to 58% ) Gastrointestinal: Abdominal pain (Type 2 diabetes mellitus， 5% )， Diarrhea (7% to 8% )， Indigestion (Type 1 diabetes mellitus， 9% )， Backache (Type 1 diabetes mellitus， 7% )， Musculoskeletal pain (Type 1 diabetes mellitus， 5% )， Headache (Type 1 diabetes mellitus， 17% to 35%; type 2 diabetes mellitus， 9% to 13% )， Neuropathy (Type 2 diabetes mellitus， 8% )， Pharyngitis (6% to 7% )， Rhinitis (5% )， Upper respiratory infection (5% to 17% )， Influenza-like symptoms (Type 1 diabetes mellitus， 13% )， Hypoglycemia (Severe) (Type 1 diabetes mellitus， 16%; type 2 diabetes mellitus， 4% )， Hypokalemia， Hypersensitivity reaction.,避光避免冷凍，開封前2-8℃，啟用後可放30℃以下並可以使用四星期,SC， according to the individual needs of the patient.,無需調整劑量,[仿單]授乳期使用 NovoMixR50 並無限制， 授乳期間母親接受胰島素治療對嬰兒沒有危險性， 但 NovoMixR50 的劑量可能需要調整。,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]NovoMixR50 在懷孕期使用的臨床研究相當有限。 在動物生殖研究，顯示出 insulin aspart 和 human insulin 對於胚胎毒性及致畸性並無任何差異。 一般來說，對於已懷孕或計劃懷孕的糖尿病婦女建議於整個懷孕期全程採用密集血糖控制和監視。 胰島素需求量通常在懷孕的第 1 至 3 個月會下降，隨後在第4 至 9 個月則逐漸增加， 產後即刻回到懷孕前的需求量。,Compatible 哺乳時可使用,[仿單]授乳期使用 NovoMixR50 並無限制， 授乳期間母親接受胰島素治療對嬰兒沒有危險性， 但 NovoMixR50 的劑量可能需要調整。,SC;,,,,,在重新振搖混合後，藥品若不是呈現均勻的白色雲霧狀液體則不可使用。
OBET5,Mirabegron,Betmiga 50mg prolonged-release,SGU,Neurogenic detrusor overactivity. Overactive bladder， Monotherapy or in combination with solifenacin， with symptoms of urge urinary incontinence， urgency， and urinary frequency.,Hypersensitivity to mirabegron or any components of the product.,Common Cardiovascular: Hypertension (7% to 11.3% )， Tachycardia (1.2% to 2.2% ) Gastrointestinal: Constipation (1.2% to 4.7% )， Xerostomia (2.8% to 9.3% ) Neurologic: Headache (1.6% to 4.1% ) Renal: Urinary tract infectious disease (Adult， 2.9% to 8.4% ; pediatric， 24.4% ) Respiratory: Nasopharyngitis (3.5% to 5.8% ) Serious Neurologic: Cerebrovascular accident (0.4% ) Renal: Urinary retention Other: Cancer (0.1% to 1.3% ),30℃以下儲存,25-50 mg once daily. May be taken with or without food. Swallow whole， do not chew， divide or crush.,需調整劑量,[仿單] 對於Betmiga是否出現於人類乳汁中、對於以母乳餵養之幼兒的影響、或是對於乳汁生成的影響，目前尚無資訊。 哺乳中大鼠口服單劑10 mg/kg的14C標記的mirabegron後，可以在大鼠乳汁及幼鼠的胃中發現mirabegron相關物質。 應同時考量到哺乳對發育及健康的益處、母體對於Betmiga的臨床需求及Betmiga或母體病況對母乳餵養之幼兒的可能不良影響。,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,[仿單] 對於孕婦使用Betmiga，尚無適當且控制良好的研究。 懷孕期間僅在病人的潛在效益勝過對病人和胎兒的危險性時，才可使用Betmiga。 鼓勵在Betmiga治療期間懷孕的婦女聯繫醫師。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 對於Betmiga是否出現於人類乳汁中、對於以母乳餵養之幼兒的影響、或是對於乳汁生成的影響，目前尚無資訊。 哺乳中大鼠口服單劑10 mg/kg的14C標記的mirabegron後，可以在大鼠乳汁及幼鼠的胃中發現mirabegron相關物質。 應同時考量到哺乳對發育及健康的益處、母體對於Betmiga的臨床需求及Betmiga或母體病況對母乳餵養之幼兒的可能不良影響。,PO;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠，服用時應以水整粒吞服，不可嚼碎、切割或壓碎。
OBEL1,Lorcaserin,Belviq 10mg F.C. Tab 60's/box,META,,,,,,,,,,,,,,,,,,,
ELOC2,Amorolfine,Loceryl nail 5%， 2.5mL lacquer,TDER,Topical treatment of onychomycosis caused by dermatophytes， yeasts and moulds.,Patients who have shown hypersensitivity to any ingredient of Loceryl.,In exceptional cases， a slight， transient periungual burning sensation was observed after the application of the nail lacquer.,<30度C，避開熱源,Fungal nail infections Adult: Topical As 5% nail lacquer: Apply 1-2 times/week.,無需調整劑量,[仿單]將懷孕母兔暴露於體內高劑量amorolfine會造成胚胎再吸收(胚胎毒性)輕微增加。 由於使用Loceryl 趾(指)甲油劑之後，amorolfine的體內含量極低， 因此對於人類胎兒的風險應可忽略。 然而由於缺乏治療懷孕和哺乳母親之臨床經驗，因此本油劑應避免用於孕期和哺乳期期間。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]將懷孕母兔暴露於體內高劑量amorolfine會造成胚胎再吸收(胚胎毒性)輕微增加。 由於使用Loceryl 趾(指)甲油劑之後，amorolfine的體內含量極低， 因此對於人類胎兒的風險應可忽略。 然而由於缺乏治療懷孕和哺乳母親之臨床經驗，因此本油劑應避免用於孕期和哺乳期期間。,Unknown 沒有資料,[仿單]將懷孕母兔暴露於體內高劑量amorolfine會造成胚胎再吸收(胚胎毒性)輕微增加。 由於使用Loceryl 趾(指)甲油劑之後，amorolfine的體內含量極低， 因此對於人類胎兒的風險應可忽略。 然而由於缺乏治療懷孕和哺乳母親之臨床經驗，因此本油劑應避免用於孕期和哺乳期期間。,EXT;,,,,,
IAMII1,Amino Acids,Aminosteril infant 10% 100mL,NUTR,For partial parenteral nutrition in premature infants， babies and small children. Together with corresponding amounts of electrolytes， carbohydrates and fat emulsions as energy donors， the solution may serve for total parenteral nutrition.,Disturbances in amino acid metabolism， acidosis， hyperhydration， hypokalemia.,Fluid， electrolyte， amino acid imbalance.,25℃以下避光,Maximum Daily Dosage: 1st year of living: 1.5-2.5 g amino acids/kg body weight; 2nd year of living: 1.5 g amino acids/kg body weight; 3rd-5th year of living: 1.5 g amino acids/kg body weight.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,Maximum Infusion Rate: Up to 0.1 g amino acids/kg body weight/hr = 1 mL/kg body weight/hr.,當用於新生兒和2 歲以下兒童時，溶液和輸液袋應避光直至給藥完成。 輸注速度太快，可能經由腎臟流失，而造成氨基酸不平衡。
OSQL4,Nicotine,SMOKQUIT 4mg (24 tablets/box),ZADT,Smoking Cessation Aid.,Hypersensitivity to nicotine or any component of the product.,Common Dermatologic: Skin irritation， Patch Respiratory: Nasal irritation， Nasal spray， Oral irritation， Airway， inhaler Other: Nicotine withdrawal， Dizziness， headache， insomnia Serious Cardiovascular: Cardiac dysrhythmia (rare)， Hypertension (rare)， Tachyarrhythmia (rare) Immunologic: Hypersensitivity reaction (rare),室溫25℃以下,Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule: Weeks 1 to 6: 1 lozenge every 1 to 2 hours， use at least 9 lozenges/day. Weeks 7 to 9: 1 lozenge every 2 to 4 hours. Weeks 10 to 12: 1 lozenge every 4 to 8 hours. The recommended maximum dose: 15 lozenges/day.,無需調整劑量,[仿單] 建議孕婦及授乳婦不可使用含有尼古丁成分，如口含錠、貼片或口香糖來戒菸。,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,Contraindicated (with any use of tobacco) [仿單] 建議孕婦及授乳婦不可使用含有尼古丁成分，如口含錠、貼片或口香糖來戒菸。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 建議孕婦及授乳婦不可使用含有尼古丁成分，如口含錠、貼片或口香糖來戒菸。,SL;,,,,,[磨粉/管灌註記]本藥為口含錠，不可咀嚼或吞服。服藥後將口含錠含在口腔兩側移動，持續20-30分鐘直到完全溶解。
OENTR,Sacubitril + Valsartan,Entresto 100mg,CAVS,Heart failure， chronic， Class II to IV,■Angioedema to prior ACE inhibitor or angiotensin II receptor blocker therapy ■Concomitant aliskiren use in diabetic patients ■Concomitant use of ACE inhibitors; do not administer within 36 hours of each other ■Hypersensitivity to sacubitril， valsartan， or any component of the product,common ■Cardiovascular: Hypotension (18% ) ■Endocrine metabolic: Hyperkalemia (12% ) ■Neurologic: Dizziness (6% ) serious ■Renal: Renal failure (5% ) ■Other: Angioedema (0.5% ),30℃以下，注意防潮,CHF adult， initial 100mg BID， maintain dose: 200mg BID after 2-4 weeks. ( if Entresto switch from ACEI， it must be separated at least 36 hr),需調整劑量,[仿單] 尚無資料顯示 sacubitril/valsartan 是否會排入人類的乳汁、對接受哺乳嬰兒的影響，或對母乳分泌的作用。 但sacubitril/valsartan 會排入大鼠的乳汁中。 由於接受哺乳嬰兒暴露於 sacubitril/valsartan 可能發生嚴重不良反應，不建議在哺乳期間接受 ENTRESTOR 治療。 Sacubitril: No data Valsartan: No Human Data—Probably Compatible,無需調整劑量,盡量避免,Uknown 沒有資料,[仿單] ENTRESTOR 用於懷孕女性會對胎兒造成傷害。在妊娠第二、三期使用作用於腎素 - 血管收縮素系統的藥物，會降低胎兒腎功能並增加胎兒及新生兒疾病和死亡率。 如果懷孕，請改用其他藥物，並停用 ENTRESTOR。 然而，如果除了作用於腎素 - 血管收縮素系統的藥物，沒有其他適當替代藥物，或當本藥可救治母親性命時，請告知懷孕女性本藥物對胎兒的潛在風險。 Sacubitril: No data Valsartan: Human Data Suggest Risk in 2nd and 3rd Trimesters,Unknown 沒有資料,[仿單] 尚無資料顯示 sacubitril/valsartan 是否會排入人類的乳汁、對接受哺乳嬰兒的影響，或對母乳分泌的作用。 但sacubitril/valsartan 會排入大鼠的乳汁中。 由於接受哺乳嬰兒暴露於 sacubitril/valsartan 可能發生嚴重不良反應，不建議在哺乳期間接受 ENTRESTOR 治療。 Sacubitril: No data Valsartan: No Human Data—Probably Compatible,AC;AC15;PC;PO;WM;,,,,,
OACTN6,Acetylcysteine,Actein effervescent 600mg,ERSP,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
OIBI,Isosorbide 5-Mononitrate,Ibimo C.R.F.C. 60 mg,CAVS,Prevention of angina pectoris.,Allergic to isosorbide mononitrate， isosorbide dinitrate， other nitrates or nitrites. Low blood pressure (<90mmHg)， circulatorycollapse， Shock， or with failing heart， unless could keep blood pressure. Angina caused by hypertrophic cardiomyopathy may be aggravated. Increased intracranial pressure. Pericarditis.,Common Dizziness (Extended-release， 8% to 11%)， Headache (Extended-release， 38% to 57%)， Orthostatic Hypotension Serious Cardiovascular: Atrial fibrillation (5% or less)， Bradyarrhythmia (5% or less )， Bundle branch block (5% or less)， Chest pain (Immediate-release， up to 2% )， Heart failure (5% or less )， Hemorrhage， Ventricular tachycardia (5% or less)， Angina pectoris (5% or less)，,避光與防熱，25℃以下,60 mg in the morning， may be increased to 120 mg once daily. Reduce to 0.5 TAB when headache occurs.,無需調整劑量,[仿單]由於Isosorbide 5-Mononitrate缺少這方面的臨床經驗，因此該藥不應給予懷孕及授乳期患者服用， 若必要時，應諮詢醫師，權宜利弊使用。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,[仿單]由於Isosorbide 5-Mononitrate缺少這方面的臨床經驗，因此該藥不應給予懷孕及授乳期患者服用， 若必要時，應諮詢醫師，權宜利弊使用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]由於Isosorbide 5-Mononitrate缺少這方面的臨床經驗，因此該藥不應給予懷孕及授乳期患者服用， 若必要時，應諮詢醫師，權宜利弊使用。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效膜衣錠，可整粒或剝半吞服，但不可咬嚼、壓碎或磨粉。磨粉管灌需求院內備有同成份Coxine 20mg。
OFLU6,Acetylcysteine,Fluimucil granules 600mg/3gm,ERSP,A mucolytic agent that reduces the viscosity of respiratory mucous secretions and serves as an antidote for intentional or occasional ACETAMINOPHEN poisoning.,Hypersensitivity to acetylcysteine or to any other component in its formula.,Common: Pruritus (1-3%)， Rash (4-5%)， Urticaria， Diarrhea， Nausea (2-7%)， Vomiting (9-12%) Serious: Decreased cardiac function， Electrocardiogram abnormal， Hypervolemia， Hypersensitivity reaction (Adult， 8-18%; pediatric， 10%)， Non-allergic anaphylaxis (0.1-0.2%)， Status epilepticus， Bronchospasm， Respiratory distress,30℃以下,Aged six and above: Take 1 packet of Fluimucil orally， 1-2 times/day (preferably in the evening). Place the granules from one packet into a glass container， dissolve them with a small amount of water， mix well， and if needed， use a spoon. This will result in a palatable solution that can be consumed directly.,無需調整劑量,,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
EANO,Umeclidinium + Vilanterol trifenatate,Anoro Ellipta 55/22mcg inhalation powder,ERSP,Maintenance treatment for airway obstruction symptoms in patients with chronic obstructive pulmonary disease (COPD).,Severe hypersensitivity to milk proteins. Hypersensitivity to umeclidinium， vilanterol， or any component of the product. Asthma treatment， without use of an inhaled corticosteroid.,Common: Chest pain (1%)， Constipation (1%)， Diarrhea (2%)， Neck pain (1%)， Pain in limb (2%)， Spasm (1%)， Lower respiratory tract infection (1%)， Pharyngitis (2%)， Sinusitis (1% or greater) Serious: Atrial fibrillation (<1%)， Cardiovascular system problem， Death (Due to cardiovascular events)， Electrocardiogram abnormal， Increased heart rate， Myocardial infarction (<1%)， Prolonged QT interval， Hypersensitivity reaction， Paradoxical bronchospasm,避光乾燥30°C以下,Once-daily inhalation only. Administered orally through inhalation. Take at the same time every day. Do not use more than once in 24 hours.,無需調整劑量,[仿單] 目前並無任何關於 umeclidinium 或 vilanterol 是否會出現於人類的乳汁中、對餵哺母乳之 嬰兒的影響或對乳汁生成作用之影響等方面的資訊。投予 umeclidinium 的授乳大鼠，於 其子代血漿可偵測到 umeclidinium，推測 umeclidinium 會出現於母體乳汁中。應將餵哺母乳對 嬰兒發育與健康的效益與母親的臨床需求，以及 umeclidinium、vilanterol 或母親的基礎疾病 對餵哺母乳之嬰兒的任何可能不良影響放在一起考慮。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 沒有人體試驗評估ANORO ELLIPTA、 umeclidinium 或 vilanterol 對分娩與生產的影響。 因為β作用劑有可能干擾子宮收縮，唯有效益明顯大於風險的病人才可於分娩期間使用。,Unknown 沒有資料,[仿單] 目前並無任何關於 umeclidinium 或 vilanterol 是否會出現於人類的乳汁中、對餵哺母乳之 嬰兒的影響或對乳汁生成作用之影響等方面的資訊。投予 umeclidinium 的授乳大鼠，於 其子代血漿可偵測到 umeclidinium，推測 umeclidinium 會出現於母體乳汁中。應將餵哺母乳對 嬰兒發育與健康的效益與母親的臨床需求，以及 umeclidinium、vilanterol 或母親的基礎疾病 對餵哺母乳之嬰兒的任何可能不良影響放在一起考慮。,IH;,,,,,
LFUL,Sodium Phosphate,Fulisay oral solution 45mL (健診專用),ALIM,Relief of occasional constipation. For use as part of a bowel cleansing regimen in preparing the patient for surgery or for preparing the colon for X-ray or endoscopic exam.,CHF， renal failure， rectal bleeding， no bowel movement with in 5 hour， dehydration. Childn <5 yr.,Nausea， vomiting， bloating.,室溫,Per 15 mL Monobasic Na phosphate 7.2 g， dibasic Na phosphate 2.7 g. (Equivalent to 111.2mg sodium per mL) Laxative: Adult & children > 12 years 15-45 mL; 10-11 years 15 mL， 5-9 years 7.5 mL. Intestine cleansing: Adult & children > 12 years 30-45 mL use two times， taking interval 10-12 hours.,無需調整劑量,1. 5mL=鈉556mg，相當於每mL含鈉111.2mg 2. 一般服用30分鐘至6小時會排便,需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,1. 5mL=鈉556mg，相當於每mL含鈉111.2mg 2. 一般服用30分鐘至6小時會排便,AC;PC;PO;,,,,,
IGAR9A,HPV type 6/11/16/18/31/33/45/52/58 L1 protein,九價子宮頸癌疫苗(婦幼嘉年華專案),HIMM,,,,,,,,,,,,,,,,,,,
IETOM2,Etomidate,Etomidate inj 20mg/10mL (專案進口),ZANE,Induction of general anesthesia， Maintenance of general anesthesia; Adjunct,Hypersensitivity to etomidate products,Injection site pain ， Nausea， Vomiting,25℃以下避光避免冷凍,Adult Dosing ■Induction of general anesthesia: induction， usual dose 0.3 mg/kg IV (range 0.2 to 0.6 mg/kg) over 30 to 60 sec ■Maintenance of general anesthesia; Adjunct: maintenance， 0.01 to 0.02 mg/kg/min IV infusion; dosage must be individualized ■Procedural sedation: 0.1 to 0.2 mg/kg IV over 30 to 60 seconds， followed by 0.05 mg/kg every 3 to 5 minutes as needed for sedation ■Rapid sequence intubation， Induction: 0.15 to 0.3 mg/kg IV Pediatric Dosing ■not recommended in children under 10 y of age ■Induction of general anesthesia: (children 10 y and older) induction， usual dose 0.3 mg/kg IV (range 0.2 to 0.6 mg/kg) over 30 to 60 sec ■Rapid sequence intubation， Induction: 0.2 to 0.3 mg/kg IV,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVPUSH;,,,推注時間>30秒 Administer IV push over 30 to 60 seconds.,,1. Etomidate-Lipuro未作相容性測試前，不得與其他輸注液混合。此外，除非已確認相容性，否則Etomidate-Lipuro不得同時與其他注射液以同一輸注管給予；需要合併給予之藥物如止痛劑，以同一輸注管或個別靜脈插管接續給藥。 2. Etomidate-Lipuro不含抗菌防腐劑。因為脂肪乳劑會促進微生物生長，安瓿開瓶後應於無菌狀態下立即以注射器抽出並輸注。剩餘部份應丟棄。 3. 投予Etomidate-Lipuro前應適度前驅給藥以避免肌陣痙的發生。建議於投藥前1小時IM給予或10分鐘前IV給予BZD類藥物。
LAMO5,Amoxicillin,Amolin 50mg/mL， 60mL suspension,QANB,Infection of staphylococcus， streptococcus， pneumococcus， meningococcus， or other susceptibility bacteria.,Hypersensitivity to penicillins.,Common Dermatologic: Rash (greater than 1% ) Gastrointestinal: Diarrhea (overall， greater than 1%; Helicobacter pylori therapy， 7% to 8% )， Nausea (greater than 1% )， Vomiting (greater than 1% ) Neurologic: Headache (Helicobacter pylori therapy， 6% to 7%; extended-release tablets， 1% ) Reproductive: Vulvovaginitis， Mycotic (extended-release， 2% ) Serious Cardiovascular: Shock Dermatologic: Erythema multiforme， Stevens-Johnson syndrome， Toxic epidermal necrolysis Gastrointestinal: Clostridium difficile diarrhea Immunologic: Anaphylaxis， Drug reaction with eosinophilia and systemic symptoms， Hypersensitivity reaction Other: Angioedema,25℃以下，泡製後2-8℃冷藏可保存7天。,Adult: 250 mg 3-4 times daily; children: 20-40 mg/kg in divided doses 3-4 times daily.,無需調整劑量,[仿單]未有相關說明。,需調整劑量,沒有資料,Human data suggest low risk,[仿單]用於孕婦，本藥對妊娠之安全性尚未建立。,Compatible 哺乳時可使用,[仿單]未有相關說明。,AC;AC15;PC;PO;WM;,,,,,1. 泡製方法:先加入冷開水大約至刻度50mL後搖勻，再加水稀釋成60mL。 2. 本藥經泡製後需冷藏2-8℃，僅保存7天。每次使用前應先搖勻。
IENH0,Trastuzumab Deruxtecan,Enhertu inj 100mg (sample),RACA,Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.,There are no contraindications listed in the manufacturer's labeling.,Nausea， fatigue， vomiting， alopecia， constipation， decreased appetite， anemia， neutropenia， diarrhea， leukopenia， cough， and thrombocytopenia. Interstitial lung disease (ILD)， pneumonitis， and left ventricular dysfunction.,2-8℃冷藏,5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.,無需調整劑量,[仿單] 目前未知ENHERTUR是否會分泌至人體乳汁中，亦未知對哺乳嬰兒可能造成的影響。 因為哺乳嬰兒有發生嚴重不良反應的潛在可能，女性應於初次施用前停止哺乳。 女性可於結束治療7個月後開始哺乳。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 施用於懷孕女性可能導致胎兒傷害。目前並無使用於懷孕女性的資料。 不建議施用於懷孕女性，應在病人懷孕前告知病人藥物對於胎兒的潛在風險。 若女性於治療期間或最後一劑後7個月內懷孕，必須立即聯絡醫師，建議進行密切監測。,Unknown 沒有資料,[仿單] 目前未知ENHERTUR是否會分泌至人體乳汁中，亦未知對哺乳嬰兒可能造成的影響。 因為哺乳嬰兒有發生嚴重不良反應的潛在可能，女性應於初次施用前停止哺乳。 女性可於結束治療7個月後開始哺乳。,IVD;,Sterile Water for Injection 5 mL per 100 mg vial,【D5W】可選 仿單建議。,,Reconstitute each 100 mg vial with 5 mL of Sterile Water for Injection (final 20 mg/mL). Dilute in 100 mL of 5% Dextrose Injection. FIRST infusion over 90 minutes; subsequent infusions over 30 minutes if prior infusions were well tolerated. Cover the infusion bag to protect from light. Administer with an infusion set made of polyolefin or polybutadiene and a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter.,若出現輸注相關症狀，應降低輸注速率或中斷輸注。若發生嚴重輸注反應，應永久停用。
IACTMV10,Tocilizumab,Actemra Infusion 200mg/10mL/Vial 專案(限Covid-19),HIMM,Rheumatoid Arthritis (RA); Polyarticular Juvenile Idiopathic Arthritis (pJIA); Systemic Juvenile Idiopathic Arthritis (sJIA).,Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.,Common Cardiovascular: Hypertension (Adult， 4% to 6% ) Dermatologic: Injection site reaction ( Rheumatoid arthritis， 2.4% to 10.1% ; polyarticular juvenile idiopathic arthritis， 28.8% ; systemic juvenile idiopathic arthritis， 41.2% )， Rash (Rheumatoid arthritis， 2% to 4% ) Gastrointestinal: Diarrhea (Pediatric， greater than 5% )， Upper abdominal pain (Adult， 2% to 3% ) Hepatic: ALT/SGPT level raised (Rheumatoid arthritis， 0.7% to 48%; polyarticular or systemic juvenile idiopathic arthritis， 4% to 13% )， Aspartate aminotransferase serum level raised (Rheumatoid arthritis， 0.1% to 41%; polyarticular or systemic juvenile idiopathic arthritis， less than 1% to 5% ) Neurologic: Dizziness (Adult， 2% to 3% )， Headache (Adults， 5% to 7%; pediatric， greater than 5% ) Respiratory: Nasopharyngitis (Rheumatoid arthritis， 4% to 7%; systemic juvenile idiopathic arthritis， 5% or higher ) Other: Infusion reaction (Rheumatoid arthritis， 7% to 8%; polyarticular juvenile idiopathic arthritis， 16% to 20.2% ) Serious Gastrointestinal: Gastrointestinal perforation， Pancreatitis Hematologic: Decreased platelet count (1% to 4% )， Neutropenia (Rheumatoid arthritis， 1.8% to 3.7% ; polyarticular or systemic juvenile idiopathic arthritis， 7% to 15.4% ) Hepatic: Hepatotoxicity Immunologic: Anaphylaxis， Hypersensitivity reaction (Up to 0.9% )， Opportunistic infection， Tuberculosis Respiratory: Upper respiratory infection (Rheumatoid arthritis， 6% to 8%; systemic juvenile idiopathic arthritis， 5% or higher ) Other: Cancer， Severe infectious disease,2-8℃,TFDA新型冠狀病毒（SARS-CoV-2）感染臨床處置暫行指引第十一版: 與dexamethasone合併用於嚴重肺炎以上(未使用吸氧治療下SpO2=<94%、需使用吸氧治療、高流量氧氣或非侵襲性呼吸器、使用機械式呼吸器或ECMO)之病患；或與dexamethasone + remdesivir 合併用於未使用吸氧治療下SpO2=<94%、需使用吸氧治療、高流量氧氣或非侵襲性呼吸器之病患。病患住院3天內，且入住ICU 24小時內或未入住ICU但發炎指數上升(CRP>=7.5 mg/dL) 。劑量：8mg/kg，單次靜脈注射，至多800mg [Micromedex 20210623] COVID-19 (Severe) - Pneumonia 8 mg/kg (actual body weight) as single IV dose， Maximum dose 800 mg; give in combination with dexamethasone 6 mg IV or orally daily for up to 10 days or another corticosteroid at an equivalent dose (guideline dosage),無需調整劑量,[仿單]目前並無任何關於tocilizumab是否會出於人類乳汁、本藥對哺母乳之嬰兒的影響、或本藥對乳汁生成作用之影響等方面的資料。 母體的免疫球蛋G(lgG)會出現於人類的乳汁中。如果tocilizumab會轉移進入人類的乳汁，目前仍不確知tocilizumab在嬰兒胃腸道中的局部暴露及可能有限的全身暴會造成何種影響。 由於缺乏授乳期間的臨床資料，目前並無法確定在授乳間使用 Actemra對嬰兒所帶來的風險； 因此，應將餵哺母乳對發育與健康的好處和母親對 Actemra的臨床需求，以及或母親的基礎疾病對餵哺母乳之嬰兒的可能不良影響放在一起考慮。,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]目前關於用於孕婦的有限資料尚不足以確是否有會引發重大出生缺陷及流產的藥物相關風險？ 單株抗體如tocilizumab在第3孕期會透過主動運輸通過胎盤，並可能會影響出生前暴露於藥物之嬰兒的免疫反應。 在動物生殖研究中，於馬來猴在器官生成過程中靜脈注射投予tocilizumab，會導致流產/胚胎-胎兒的死亡，其劑量相當於人類最高建議劑量的1.25倍（含）以上。 動物試驗文獻指出，IL-6傳訊作用受到抑制可能會干擾子宮頸的成熟與擴張，以及子宮平滑肌的收縮活性，可能有使胎兒受到影響的風險。 目前並不確知本品之適用族群發生重大出生缺陷與流產的估計背景風險。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並無任何關於tocilizumab是否會出於人類乳汁、本藥對哺母乳之嬰兒的影響、或本藥對乳汁生成作用之影響等方面的資料。 母體的免疫球蛋G(lgG)會出現於人類的乳汁中。如果tocilizumab會轉移進入人類的乳汁，目前仍不確知tocilizumab在嬰兒胃腸道中的局部暴露及可能有限的全身暴會造成何種影響。 由於缺乏授乳期間的臨床資料，目前並無法確定在授乳間使用 Actemra對嬰兒所帶來的風險； 因此，應將餵哺母乳對發育與健康的好處和母親對 Actemra的臨床需求，以及或母親的基礎疾病對餵哺母乳之嬰兒的可能不良影響放在一起考慮。,IVD;,,【H/S】可選 仿單建議。【N/S】可選 仿單建議。,,30公斤以下病患:以50mL 0.9%或0.45%氯化鈉注射液稀釋。 30公斤以上病患:以100mL 0.9%或0.45%氯化鈉注射液稀釋。 稀釋時請輕輕倒置使藥劑混合，避免產生泡沫。輸注時間應超過60分鐘,本藥以0.9%氯化鈉注射液稀釋後置於2-8°C或室溫可保存24小時。以0.45%氯化鈉注射液稀釋後置於2-8°C可保存24小時或室溫可保存4小時。儲存時應避光。
OINH3,Isoniazid,ISONIAZID 300mg (政府提供),QANB,Treatment of susceptible active tuberculosis (eg， Mycobacterium tuberculosis) infections.,•Acute liver disease. •History of severe adverse reactions to isoniazid such as drug fever， chills， or arthritis. •History of isoniazid associated hepatic injury or drug induced liver injury. •Severe hypersensitivity to isoniazid.,Common •Hepatic: Increased liver enzymes (10% to 20% ) •Neurologic: Neuropathy， Neurotoxicity Serious •Dermatologic: Rash •Hematologic: Agranulocytosis， Anemia， Thrombocytopenia •Hepatic: Hepatitis (Severe)， Hepatotoxicity， Injury of liver •Immunologic: Systemic lupus erythematosus •Musculoskeletal: Rhabdomyolysis •Neurologic: Seizure,,(UpToDate) DOT = directly observed therapy. Adult: Once-daily therapy: 5 mg/kg/dose (usual dose: 300 mg) once daily; Three-times-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered 3 times weekly; Twice-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered twice weekly; Once-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered once weekly.Pediatrc: Once daily therapy: children < 15 years， weighing < or = 40 kg: 10-15 mg/kg/dose once daily (maximum 300 mg/dose); children < 15 years weighing > 40 kg or children > or = 15 years: 5 mg/kg/dose once daily; typical dose: 300 mg/dose.,需調整劑量,,無需調整劑量,,Compatible – maternal benefit >> embryo-fetal risk,PREGNANCY RECOMMENDATION: Compatible—Maternal Benefit >> Embryo–Fetal Risk,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;,,,,,
OMORC,Sulfamethoxazole + Trimethoprim,Morcasin (Baktar) 400/80mg,QANB,Infection.,History of sulfonamide- or trimethoprim-induced immune thrombocytopenia. Hypersensitivity to sulfonamides or trimethoprim. Infants younger than 2 months of age. Marked hepatic damage. Megaloblastic anemia due to folate deficiency.,Common Dermatologic: Rash， Urticaria Gastrointestinal: Loss of appetite， Nausea， Vomiting Serious Cardiovascular: Cardiogenic shock， Prolonged QT interval， Torsades de pointes， Ventricular tachycardia Dermatologic: Drug reaction with eosinophilia and systemic symptoms， Erythema multiforme， Generalized exanthematous pustulosis， acute， Stevens-Johnson syndrome， Sweet's syndrome， Toxic epidermal necrolysis Endocrine metabolic: Hyponatremia Gastrointestinal: Clostridioides difficile infection， Associated diarrhea Hematologic: Agranulocytosis， Aplastic anemia， Disorder of hematopoietic structure， Neutropenia， Thrombocytopenia Hepatic: Hepatic necrosis， Fulminant Immunologic: Anaphylaxis Musculoskeletal: Rhabdomyolysis,15-30℃,Trimethoprim-sulfamethoxazole (TMP-SMX) Adult: 160/800 mg (2 tablets) orally 3 times daily. Children (6-12 years): 80/400 mg (1 tablet) orally 3 times daily. Reduce dose for children < 6 years of age.,需調整劑量,[仿單]未有說明,需調整劑量,不可使用,Human data suggest low risk,[仿單]孕婦不可使用,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]未有說明,AC;AC15;PC;PO;WM;,,,,,
OHARV,Ledipasvir + Sofosbuvir,Harvoni 90/400mg,QANB,Treatment of chronic HCV genotype 1 infection in adults.,If ledipasvir/sofosbuvir is administered with ribavirin， the contraindications to ribavirin also apply. Hypersensitivity to any component of the formulation.,>10%: Central nervous system: Headache (11% to 29%)， fatigue (10% to 18%) Neuromuscular & skeletal: Weakness (18% to 31%) 1% to 10%: Central nervous system: Irritability (8%)， insomnia (3% to 6%)， dizziness (5%)， depression (<5%; including in subjects with preexisting history of psychiatric illness) Gastrointestinal: Nausea (6% to 9%)， increased serum lipase (>3 x ULN: ?9%)， diarrhea (3% to 7%) Hepatic: Hyperbilirubinemia (>1.5 x ULN: ?3%) Neuromuscular & skeletal: Myalgia (9%)， increased creatine phosphokinase (1%) Respiratory: Cough (5%)， dyspnea (3%) <1% (Limited to important or life-threatening): Skin rash (with blisters or angioedema-like swelling),30℃以下,One tablet once daily with concomitant ribavirin for 12 weeks.,無需調整劑量,Sofosbuvir: No Human Data—Probable Compatible (Potential toxicity if combined with Ribavirin) Ledipasvir: UNKNOW,需調整劑量,沒有資料,Uknown 沒有資料,Sofosbuvir: No Human Data—Animal Data Suggest Low Risk (Contraindicated if combined with Ribavirin) Ledipasvir: UNKNOW,Unknown 沒有資料,Sofosbuvir: No Human Data—Probable Compatible (Potential toxicity if combined with Ribavirin) Ledipasvir: UNKNOW,AC;AC15;PC;PO;WM;,,,,,
OSOV,Sofosbuvir,Sovaldi FC 400mg,QANB,Chronic hepatitis C: Treatment of genotype 1， 2， 3， or 4 chronic hepatitis C (CHC) as a component of a combination antiviral treatment regimen.,Hypersensivity， Pregnancy.,Fatigue， headache， nausea， insomnia & anemia. Pruritus， asthenia， rash， decreased appetite， chills， influenza-like illness， pyrexia， diarrhea， neutropenia， myalgia， irritability.,30℃以下室溫環境,(仿單) 400 mg oraly once daily in combination with ribavirin or pegylated interferon + ribavirin. (Uptodate) Chronic hepatitis C (CHC) infection: Adults: Genotype 3， peginterferon + ribavirin treatment–experienced patients with compensated cirrhosis (Child-Pugh class A): 400 mg once daily with concomitant elbasvir/grazoprevir for 12 weeks. All genotypes， patients with prior glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir treatment failure， + or - cirrhosis (Child-Pugh class A): 400 mg once daily in combination with ribavirin and glecaprevir/pibrentasvir for 16 weeks. Children > or =3 years and Adolescents: weight < 17 kg: 150 mg once daily; 17-35 kg: 200 mg once daily; > or = 35 kg: 400 mg once daily. Treatment duration: Genotype 2: 12 weeks. Genotype 3: 24 weeks.,無需調整劑量,No Human Data—Animal Data Suggest Low Risk (Contraindicated if combined with Ribavirin),無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,No Human Data—Animal Data Suggest Low Risk (Contraindicated if combined with Ribavirin),,,,,,
OCLON,Clonazepam,Clonopam 0.5mg,CNEU,Seizure， Lennox syndrome.,Hypersensitivity to Clonazepam. Severe hypopnea.,Common Neurologic: Ataxia (5% to 30% )， Coordination problem (6% )， Dizziness (8% )， Somnolence (37% to 50% ) Psychiatric: Problem behavior (25% ) Respiratory: Upper respiratory infection (8% ) Other: Fatigue (7% ) Serious Psychiatric: Depression (7% )， Suicidal thoughts Respiratory: Respiratory depression,25℃以下,The daily dose has to be slowly increased to a suitable maintenance dose for each patient to avoid the adverse effects of initial treatment. The daily dose can be given in a single dose at night if the target dose is reached. The maximum dose should be given at night if the daily dose must be divided several times. For adults: The maintenance dose is 2-4mg/day. The maximum dose is 20 mg/day. For infants and children under 10 years old (or weighing less than 30 Kg): The initial dose is 0.01- 0.03 mg/Kg/day. The maintenance dose is 0.05-0.1mg/Kg/day. For children over 10 years old (or weighing more than 30 Kg): The initial dose is 1-2 mg/day. The maintenance dose is 1.5-3mg/day.,無需調整劑量,Breastfeeding recommendation: Compatible but Potential toxicity if combined with other CNS depressants. [仿單] 雖然已發現Clonazepam的活性成分只有少部分會進入母乳中，進行此藥治療的母親不應授乳， 如一定要使用Clonazepam時，應停止授乳.,無需調整劑量,沒有資料,Human data suggest low risk,[仿單]從臨床前的研究中，並不能排除Clonazepam有先天畸形的可能性.從流行病學評估，證實抗痙攣藥為致畸胎原，然而，從發表的流病學報告中，很難去決定哪一個藥或藥物併用造成新生兒的缺陷.其他因素如遺傳因子或癲癇狀況本身可能比導致先天缺陷的藥物更重要的可能性存在. 在這種狀況下，給予孕婦此藥，只有當可能的效益勝過對胎兒的危險性時.在懷孕期，只有當一定要使用Clonazepam時，才給予. 在懷孕的最後三個月或分娩時給予高劑量Clonazepam可能造成未出生兒的心跳不規則， 和新生兒的體溫過低，肌張力過低，輕度呼吸抑制和poor feeding. 應牢記懷孕本身和突然停藥可能加重癲癇病情.,Compatible 哺乳時可使用,Breastfeeding recommendation: Compatible but Potential toxicity if combined with other CNS depressants. [仿單] 雖然已發現Clonazepam的活性成分只有少部分會進入母乳中，進行此藥治療的母親不應授乳， 如一定要使用Clonazepam時，應停止授乳.,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
IALF,Alfentanil,Alfentanil inj 1mg/2mL (HAMELN),CNEU,Analgesia & anaesthetic induction in both short & long surgical procedures.,Resp insufficiency. Special Precautions: CV disorders; impaired liver function.,Resp depression， apnoea， muscular rigidity， bradycardia， hypotension， dizziness， nausea， CNS disturbances.,25℃以下,Individualised dosage. ■Administration of analgesic; Adjunct - Surgical procedure: surgery duration 30 min or less; 8-20 mcg/kg IV， then continuous IV infusion of 0.5-1 mcg/kg/min; total dose 8-40 mcg/kg ■Administration of analgesic; Adjunct - Surgical procedure: surgery duration 30-60 min; 20-50 mcg/kg IV， then maintenance IV injections of 5-15 mcg/kg every 5-20 min; total dose up to 75 mcg/kg ■Administration of analgesic; Adjunct - Surgical procedure: surgery duration longer than 45 min; 50-75 mcg/kg IV， then continuous IV infusion of 0.5-3 mcg/kg/min ■Anesthesia: individualized according to type and duration of surgical procedure/anesthesia ■Anesthesia: when used as primary anesthetic agent; 130-245 mcg/kg induction dose followed by continuous IV infusion of 0.5-1.5 mcg/kg/min,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,【D5NS】可選 。【D5W】可選 。【L/R】可選 。【N/S】可選 。,Administer doses slowly over at least 3 minutes.,Continuous IV infusion 0.5-1.5 mcg/kg/min. (Alfentanil was diluted to a concentration of 25 to 80 mcg/mL in clinical studies.),Duration， general anesthesia: Discontinue use at least 10 to 15 minutes prior to the end of surgery
IMIT2,Mitomycin C,Mitonco inj 10mg (專案進口)健保110.01.01-112.09.30,RACA,Treatment of disseminated adenocarcinoma of the stomach (in combination with other chemotherapy agents) and disseminated adenocarcinoma of the pancreas (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.,Hypersensitivity to mitomycin or any component of the formulation; thrombocytopenia; coagulation disorders， or other increased bleeding tendency,Leukopenia， thrombocytopenia， anorexia， nausea/vomiting， malaise， weight loss， bleeding tendency & anemia. Haemolytic-uremic syndrome， microangiopathic hemolytic anemia， nephropathy， bone marrow depression， interstitial pneumonia， liver & biliary tract disorders.,攝氏30度C以下,(Micromedex) Carcinoma of bladder: 20-40 mg intravesically every week in 20-100 mL of normal saline or in 20-40 mL water. For gastric cancer and pancreatic cancer， 20 mg/m2/dose IV every 6-8 weeks in combination with other agents.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest high risk,,Hold Breast Feeding 暫停哺乳,,IRR;IVD;,IVD:以25mL無菌注射用水溶解,【N/S】可選 。,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、腎功能。
ITTA6,Tetanus toxoid,Tetanus vaccine 0.5mL/dose/amp(專案進口),HIMM,Active immunization of tetanus.,Febrile illness or acute infection; defer vaccination. History of systemic allergic or neurologic reactions to previous injection of the vaccine; only passive immunization should be given using Tetanus Immune Globulin (Human) (TIG). Hypersensitivity to any component of the vaccine， including thimerosal.,Common Dermatologic: Localized adverse reaction to administration of drug Gastrointestinal: Nausea Musculoskeletal: Arthralgia Other: Fever， Malaise Serious Immunologic: Anaphylaxis (rare)， Arthus type urticaria Neurologic: Encephalopathy， Guillain-Barre syndrome， Seizure Ophthalmic: Third cranial nerve weakness,2-8℃,IM， 0.5 mL， 2 doses primary immunization at an interval of 4 weeks， a booster dose after 6-12 months. Routine booster dose can be given every 5-10 years.,無需調整劑量,[Micromedex]不能排除胎兒及嬰兒的風險。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]可施打。 [Micromedex]不能排除胎兒及嬰兒的風險。,Unknown 沒有資料,[Micromedex]不能排除胎兒及嬰兒的風險。,IM;,,,,,
ILFT,Cefoxitin,Lofatin inj 2gm,QANB,Infections caused by staphylococcus， streptococcus， pneumococcus， meningococcus， and other susceptible bacteria.,Hypersensitivity to cefoxitin and cephalosporins.,1% to 10%: Gastrointestinal: Diarrhea <1%: Anaphylaxis， angioedema， bone marrow depression， dyspnea， eosinophilia， exacerbation of myasthenia gravis， exfoliative dermatitis， fever， hemolytic anemia， hypotension， increased blood urea nitrogen， increased serum creatinine， increased serum transaminases， interstitial nephritis， jaundice， leukopenia， nausea， nephrotoxicity (increased; with aminoglycosides)， phlebitis， prolonged prothrombin time， pruritus， pseudomembranous colitis， skin rash， thrombocytopenia， thrombophlebitis， toxic epidermal necrolysis， urticaria， vomiting,25°C以下避光,[仿單] 2-4g/day， divided into 2-4 doses [UpToDate] Usual adult dosage range: IV 1-2 g every 6-8 hours; pediatric (ages >=3 months) general dosing: IV 80-160 mg/kg/day divided every 4-8 hours; maximum: 12 g/day,無需調整劑量,,需調整劑量,沒有資料,Compatible,[仿單] 對孕婦之安全性尚未確立，須基於有益性之判斷再使用。,Compatible 哺乳時可使用,,IM;IVD;IVPUSH;,[仿單] 加蒸餾水、生理食鹽水行靜脈或點滴注射。 [Micromedex] For IV bolus， reconstitute 2-g vial with 10 or 20 mL sterile water for injection. For IV infusion， reconstitute 2-g vial with 10 or 20 mL sterile water for injection， bacteriostatic water for injection， NS， or D5W.,【N/S】可選 仿單建議。,[Micromedex] IV bolus >3-5 minutes. May give 1-g doses over 2 minutes， and 2-g doses over 5 minutes.,[Micromedex] Reconstituted vials may be further diluted in 50-100 mL of NS， D5W， or D10W Injection [UpToDate] intermittent infusion over 10-60 minutes,[仿單] 1. 靜脈內大量投與會引起血管痛、血栓靜脈炎，預防方法須注意注射液之調製，注射部位及注射方法，減慢注射速度。 2. 乾粉溶解後須儘速使用，稀釋於輸注液後若儲存於25°C以下可保存24小時，在2-8°C可保存5天以內使用。
EDEXO,Dexamethasone,Dexa orabase 0.1%， 5gm,TENT,Intractable stomatitis or glossitis associated with erosion or ulceration.,Patients with tuberculotic， viral or other purulent infections of the oral cavity.,Fungal or bacterial infection of the oral cavity; hypersensitivity; hypofunction of pituitary-adrenocortical system (prolonged use). Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin， Finding of skin healing， Impaired Endocrine metabolic: Cushing's syndrome， Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )， Raised intraocular pressure (25% ) Psychiatric: Depression， Euphoria Respiratory: Pulmonary tuberculosis,1 5℃-30℃,Apply adequate amount to the affected area once to several times daily.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,TOPI;,,,,,
IPLE1,Peginterferon beta-1a,Plegridy inj 63mcg (橘色),HIMM,Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.,Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.,Common Dermatologic: Erythema at injection site (subQ， 25% to 62% )， Injection site pain (11% to 15% )， Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% )， Headache (36% to 44% ) Other: Fever (45% )， Influenza-like illness (47% )， Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% )， Decreased platelet count (Less than 1% )， Decreased white blood cell count (7% )， Neutropenia (Less than 1% )， Pancytopenia (Rare )， Thrombocytopenia Hepatic: Autoimmune hepatitis， Hepatitis， Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema,2-8°C避光避免冷凍,The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0)， increasing to 94 micrograms at dose 2 (on day 14)， reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.,無需調整劑量,BREASTFEEDING RECOMMENDATION: No Human Data - Compatible. [仿單]目前不知 peginterferon beta-1a 是否會分泌於乳汁中。 關於interferon beta-1a分布到母乳中的資料有限，考量interferon beta的化學/生理學特性，母乳中分泌的interferon beta-1a的量應很少。 應考量對幼兒的潛在風險和對母親的治療效益，決定是否停止餵哺母乳或停止用藥。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest moderate risk,[仿單]來自登錄研究和上市後經驗的大量數據(超過1000個妊娠結果)顯示，在受孕前或妊娠第一孕期暴露於interferon beta，發生重大先天性異常的風險並未增加。 然而，由於在收集此數據時interferon beta尚屬懷孕期間之使用禁忌，在檢測出/或確認懷孕後可能會中斷治療，因此無法確定在妊娠第一孕期的暴露時間。而暴露於妊娠第二孕期和第三孕期的經驗非常有限。 根據動物試驗資料，自發性流產的風險可能會增加。 然而依據目前可獲得的資料，尚無法充分評估暴露於interferon beta的孕婦其自發性流產的風險，但目前該資料並未顯示有增加的風險。 如有臨床需要，可以在懷孕期間考慮使用Plegridy。,Compatible 哺乳時可使用,BREASTFEEDING RECOMMENDATION: No Human Data - Compatible. [仿單]目前不知 peginterferon beta-1a 是否會分泌於乳汁中。 關於interferon beta-1a分布到母乳中的資料有限，考量interferon beta的化學/生理學特性，母乳中分泌的interferon beta-1a的量應很少。 應考量對幼兒的潛在風險和對母親的治療效益，決定是否停止餵哺母乳或停止用藥。,SC;,,,,,1.使用前請詳閱Plegridy預充填筆型注射液注射指引。 2.貯存在原包裝中以避免光照。貯存在冰箱 (冷藏)，2-8°C。請勿冷凍。自冰箱取出後可於室溫(最高25°C)保存最多30天。若需要，可不只一次自冰箱取出再放回冷藏。但置於冰箱外的總和時間不超過30天。 3.每次注射時，請儘量在同一天的同一時間使用Plegridy。 4.請變換您皮下注射的部位。請勿在相同的注射部位連續注射。 5.請規律的用藥。若您忘記用藥，請在最短時間內補注射，之後則照常注射。然而，在7天期間內請勿注射多於1劑。不可同時注射2劑來彌補忘記注射的劑量。
IPLE2,Peginterferon beta-1a,Plegridy inj 94mcg (藍色),HIMM,Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.,Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.,Common Dermatologic: Erythema at injection site (subQ， 25% to 62% )， Injection site pain (11% to 15% )， Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% )， Headache (36% to 44% ) Other: Fever (45% )， Influenza-like illness (47% )， Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% )， Decreased platelet count (Less than 1% )， Decreased white blood cell count (7% )， Neutropenia (Less than 1% )， Pancytopenia (Rare )， Thrombocytopenia Hepatic: Autoimmune hepatitis， Hepatitis， Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema,2-8°C 避光避免冷凍,The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0)， increasing to 94 micrograms at dose 2 (on day 14)， reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.,無需調整劑量,BREASTFEEDING RECOMMENDATION: No Human Data - Compatible. [仿單]目前不知 peginterferon beta-1a 是否會分泌於乳汁中。 關於interferon beta-1a分布到母乳中的資料有限，考量interferon beta的化學/生理學特性，母乳中分泌的interferon beta-1a的量應很少。 應考量對幼兒的潛在風險和對母親的治療效益，決定是否停止餵哺母乳或停止用藥。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest moderate risk,[仿單]來自登錄研究和上市後經驗的大量數據(超過1000個妊娠結果)顯示，在受孕前或妊娠第一孕期暴露於interferon beta，發生重大先天性異常的風險並未增加。 然而，由於在收集此數據時interferon beta尚屬懷孕期間之使用禁忌，在檢測出/或確認懷孕後可能會中斷治療，因此無法確定在妊娠第一孕期的暴露時間。而暴露於妊娠第二孕期和第三孕期的經驗非常有限。 根據動物試驗資料，自發性流產的風險可能會增加。 然而依據目前可獲得的資料，尚無法充分評估暴露於interferon beta的孕婦其自發性流產的風險，但目前該資料並未顯示有增加的風險。 如有臨床需要，可以在懷孕期間考慮使用Plegridy。,Compatible 哺乳時可使用,BREASTFEEDING RECOMMENDATION: No Human Data - Compatible. [仿單]目前不知 peginterferon beta-1a 是否會分泌於乳汁中。 關於interferon beta-1a分布到母乳中的資料有限，考量interferon beta的化學/生理學特性，母乳中分泌的interferon beta-1a的量應很少。 應考量對幼兒的潛在風險和對母親的治療效益，決定是否停止餵哺母乳或停止用藥。,SC;,,,,,1.使用前請詳閱Plegridy預充填筆型注射液注射指引。 2.貯存在原包裝中以避免光照。貯存在冰箱 (冷藏)，2-8°C。請勿冷凍。自冰箱取出後可於室溫(最高25°C)保存最多30天。若需要，可不只一次自冰箱取出再放回冷藏。但置於冰箱外的總和時間不超過30天。 3.每次注射時，請儘量在同一天的同一時間使用Plegridy。 4.請變換您皮下注射的部位。請勿在相同的注射部位連續注射。 5.請規律的用藥。若您忘記用藥，請在最短時間內補注射，之後則照常注射。然而，在7天期間內請勿注射多於1劑。不可同時注射2劑來彌補忘記注射的劑量。
IPLE3,Peginterferon beta-1a,PLEGRIDY inj 125mcg,HIMM,Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.,Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.,Common Dermatologic: Erythema at injection site (subQ， 25% to 62% )， Injection site pain (11% to 15% )， Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% )， Headache (36% to 44% ) Other: Fever (45% )， Influenza-like illness (47% )， Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% )， Decreased platelet count (Less than 1% )， Decreased white blood cell count (7% )， Neutropenia (Less than 1% )， Pancytopenia (Rare )， Thrombocytopenia Hepatic: Autoimmune hepatitis， Hepatitis， Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema,2-8°C避光避免冷凍,The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0)， increasing to 94 micrograms at dose 2 (on day 14)， reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.,無需調整劑量,BREASTFEEDING RECOMMENDATION: No Human Data - Compatible. [仿單]目前不知 peginterferon beta-1a 是否會分泌於乳汁中。 關於interferon beta-1a分布到母乳中的資料有限，考量interferon beta的化學/生理學特性，母乳中分泌的interferon beta-1a的量應很少。 應考量對幼兒的潛在風險和對母親的治療效益，決定是否停止餵哺母乳或停止用藥。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest moderate risk,[仿單]來自登錄研究和上市後經驗的大量數據(超過1000個妊娠結果)顯示，在受孕前或妊娠第一孕期暴露於interferon beta，發生重大先天性異常的風險並未增加。 然而，由於在收集此數據時interferon beta尚屬懷孕期間之使用禁忌，在檢測出/或確認懷孕後可能會中斷治療，因此無法確定在妊娠第一孕期的暴露時間。而暴露於妊娠第二孕期和第三孕期的經驗非常有限。 根據動物試驗資料，自發性流產的風險可能會增加。 然而依據目前可獲得的資料，尚無法充分評估暴露於interferon beta的孕婦其自發性流產的風險，但目前該資料並未顯示有增加的風險。 如有臨床需要，可以在懷孕期間考慮使用Plegridy。,Compatible 哺乳時可使用,BREASTFEEDING RECOMMENDATION: No Human Data - Compatible. [仿單]目前不知 peginterferon beta-1a 是否會分泌於乳汁中。 關於interferon beta-1a分布到母乳中的資料有限，考量interferon beta的化學/生理學特性，母乳中分泌的interferon beta-1a的量應很少。 應考量對幼兒的潛在風險和對母親的治療效益，決定是否停止餵哺母乳或停止用藥。,SC;,,,,,1.使用前請詳閱Plegridy預充填筆型注射液注射指引。 2.貯存在原包裝中以避免光照。貯存在冰箱 (冷藏)，2-8°C。請勿冷凍。自冰箱取出後可於室溫(最高25°C)保存最多30天。若需要，可不只一次自冰箱取出再放回冷藏。但置於冰箱外的總和時間不超過30天。 3.每次注射時，請儘量在同一天的同一時間使用Plegridy。 4.請變換您皮下注射的部位。請勿在相同的注射部位連續注射。 5.請規律的用藥。若您忘記用藥，請在最短時間內補注射，之後則照常注射。然而，在7天期間內請勿注射多於1劑。不可同時注射2劑來彌補忘記注射的劑量。
IGLU1,Glucose,(化療調配用) Glucose inj 5%， 1000mL,MSIV,Provision of calories and/or fluid replacement.,Hypersensitivity to corn or corn products; hypertonic solutions in patients with intracranial or intraspinal hemorrhage， diabetic coma， or delirium tremens， especially if dehydrated; severe dehydration; glucose-galactose malabsorption syndrome.,Cardiovascular: Edema， localized phlebitis， phlebitis， venous thrombosis Central nervous system: Confusion， loss of consciousness Endocrine & metabolic: Acidosis， dehydration， glycosuria， hyperglycemia， hyperosmolar syndrome， hypervolemia， hypokalemia， hypomagnesemia， hypophosphatemia， hypovolemia， ketonuria， polydipsia Local: Local pain， local tissue necrosis Renal: Polyuria Respiratory: Pulmonary edema， tachypnea Miscellaneous: Fever,30℃以下避光,化療調配用,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,
ICOSE,Secukinumab,Cosentyx 150mg prefilled pen,HIMM,Ankylosing spondylitis Plaque psoriasis (Moderate to Severe)， In patients who are candidates for systemic therapy or phototherapy Psoriatic arthritis,Hypersensitivity to secukinumab or any component of the product.,[Common] Diarrhea (2.6% to 4.1% )， Nasopharyngitis (Ankylosing spondylitis， 2% or more ; plaque psoriasis， 11.4% to 12.3% ; psoriatic arthritis， 2% or more )， Upper respiratory infection (Ankylosing spondylitis， 2% or more ; plaque psoriasis， 2.5% to 3.2% ; psoriatic arthritis， 2% or more ) [Serious] Crohn's disease (Ankylosing spondylitis， 0.87% )， Crohn's disease， Exacerbation (Plaque psoriasis， 0.09% )， Inflammatory bowel disease， Ulcerative colitis (Ankylosing spondylitis， 0.5%; plaque psoriasis， 0.06% )， Ulcerative colitis， Exacerbation (Plaque psoriasis， 0.06% )， Anaphylaxis， Infectious disease (Ankylosing spondylitis， 31% ; plaque psoriasis (up to 12 weeks)， 28.7%; plaque psoriasis (up to 52 weeks)， 47.5% ; psoriatic arthritis， 29% ),2-8℃避光勿冷凍,SC， plaque psoriasis 300 mg weeks 0， 1， 2， 3， and 4， followed by every 4 weeks.( some patients may only need 150 mg) Psoriatic arthritis， ankylosing spondylitis， Non-radiographic axial spondyloarthritis， 150 mg weeks 0， 1， 2， 3， and 4， followed by 300 mg every 4 weeks.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,■The removable cap contains natural rubber latex and should not be handled by latex-sensitive individuals. ■Allow Sensoready(R) pen to reach room temperature (15 to 30 minutes) before injecting; administer within 1 hour after removing from refrigerator. ■Administer each injection at a different anatomic location (eg， upper arms， thighs， or any quadrant of abdomen) than the previous injection; avoid areas where skin is tender， bruised， erythematous， indurated， or affected by psoriasis.
IBNT6M,SARS-CoV-2 Spike glycoprotein [mRNA],Pfizer-BioNTech (6M-4歲) 0.2mL/dose (0.4mL/vial),HIMM,The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 months to 4 Years of Age,Hypersensitivity to the active substance or to any of the excipients.,Common Dermatologic: Erythema at injection site， Injection site pain， Swelling at injection site. Musculoskeletal: Arthralgia， Myalgia. Neurologic: Headache. Other: Fatigue， Fever， Shivering. Serious Gastrointestinal: Appendicitis. Immunologic: Anaphylaxis， Hypersensitivity reaction.,運輸狀態而定詳閱仿單,6 months to 4 years: Primary series， 0.2 mL IM for 2 doses， administered 3 weeks apart， followed by a third dose (0.2 mL) administered at least 8 weeks after the second dose.,無需調整劑量,[仿單]不適用於5歲以上的個人。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]不適用於5歲以上的個人。,Unknown 沒有資料,[仿單]不適用於5歲以上的個人。,IM;,,,,,1.每瓶(0.4 mL)分散液，經以2.2mL的0.9%氯化鈉注射液進行稀釋後，含有10劑每劑0.2mL的注射液。 2.未開封的藥瓶可在8-30°C的溫度下保存12小時，且首次穿刺藥瓶之後可保存12小時，最多共保存 24小時。 3.未開封的藥瓶在在2-8°C可保持安定達10週。
IVEK,Remdesivir,Veklury inj 100mg (公費/凍晶),QANB,Hospitalized patients of COVID-19,History of clinically significant hypersensitivity to remdesivir or any component of the product.,Common Gastrointestinal: Nausea (3% to 7% ) Serious Cardiovascular: Cardiac arrest Hepatic: ALT/SGPT level raised (2% to 7% )， Aspartate aminotransferase serum level raised (3% to 6% )， Hepatotoxicity Immunologic: Anaphylaxis， Hypersensitivity reaction (Less than 2% ) Other: Infusion reaction,30℃以下,Patients not requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1， then 100 mg IV infusion once daily for a total of 5 days; may treat for up to 10 days if patient does not demonstrate clinical improvement. Patients requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1， then 100 mg IV infusion once daily for a total of 10 days. (12 years or older and at least 40 kg) Patients not requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1， then 100 mg IV infusion once daily for a total of 5 days; may treat for up to 10 days if patient does not demonstrate clinical improvement (12 years or older and at least 40 kg) Patients requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1， then 100 mg IV infusion once daily for a total of 10 days Children <12 years: 3.5 kg to <40 kg: IV: Loading dose: 5 mg/kg/dose on day 1， followed by 2.5 mg/kg/dose once daily,需調整劑量,[仿單]應權衡治療的效益與餵哺母乳的效益，然後決定繼續或停止哺乳。 在動物研究（大鼠）中，曾在投予remdesivir之母鼠所哺乳的仔鼠體內檢出remdesivir及其代謝物，這可能是remdesivir出現於母乳中所致。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]只有在潛在效益超越潛在風險的情況下，才可對孕婦或可能懷孕的婦女投予remdesivir。 在以懷孕之大鼠和兔子所進行的胚胎 - 胎兒發育影響研究中，IV 投予劑量高達20毫克 / 公斤的remdesivir【其主要循環代謝物（核鞀似物）的全身暴露量（AUC）相當於核准劑量所達到之暴露量的4倍）】並未對胚胎-胎兒的發育造成任何影響。 在一項以母大鼠所進行的生育力與早期胚胎發育影響研究中，於靜脈投予remdesivir 10毫克/公斤【其主要循環代謝物（核鞀似物）的全身暴露量（AUC）相當於核准劑量所達到之暴露量的1.3倍】之後，曾觀察到黃體、胚胎著床及存活胚胎減少的現象。,Unknown 沒有資料,[仿單]應權衡治療的效益與餵哺母乳的效益，然後決定繼續或停止哺乳。 在動物研究（大鼠）中，曾在投予remdesivir之母鼠所哺乳的仔鼠體內檢出remdesivir及其代謝物，這可能是remdesivir出現於母乳中所致。,IVD;,19mL注射用水,【N/S】可選 仿單建議。,,對成人與體重大於 40公斤的兒童，第1天的投藥(Remdesivir 200mg)應使用2支小瓶，並應將每支小瓶中的20mL溶液(共40mL)加入生理食鹽水中，使總體積達到100mL或250mL。以30-120分鐘的時間靜脈輸注。 至於第2天起的投藥(Remdesivir 100mg)，則應將1支小瓶中的20mL溶液加入生理食鹽水中，使總體積達到100mL或250mL。以30-120分鐘的時間靜脈輸注。,1.將19mL注射用水加入小瓶中，立即再度振搖30秒。靜置2-3分鐘之後，應確認小瓶中的溶液是否澄清(濃度：5mg/mL)。如果小瓶中的內容物未完全溶解，應重複振搖小瓶，使內容物澄清。 2.輸注完成之後，請用至少30毫升的0.9%生理食鹽水沖洗。 3.以注射用水調製之後，稀釋的remdesivir溶液在20-25℃的溫度下應於4小時內進行製備，在2-8℃的溫度下應於24小時內進行製備。 4.製備好的稀釋溶液在室溫(20-25°C)下可維持安定4小時，在2-8°C的冰箱中可維持24小時。
IGLYP8,Terlipressin,Glypressin inj 0.1mg/mL， 8.5mL,HM,Bleeding oesophageal varices， and hepatorenal syndrome (HRS) Type 1,Pregnancy. Hypersensitivity to terlipressin or to any of the excipients. In patients with septic shock with a low cardiac output terlipressin should not be used. Contraindicated in patients with current or recent (within the last 3 months) ischaemic cardiovascular disease.,(1-10%) Paleness， hypertension， abdominal pain， nausea， and diarrhea. Hyponatremia， ischemia， bradycardia， respiratory failure， and Torsade de pointes.,2-8℃冷藏避光,[Bleeding oesophageal varices] Initial: 2 ampoules IV Q4H， maintained until bleeding has been controlled but up to a maximum of 48 hours. Body weight <50kg : 1 ampoule IV Q4H; maintenance dosage (if necessary)， 1 ampoule IV Q4H for a maximum of 3 days. Duration of treatment must not exceed 5 days. [Type 1 hepatorenal syndrome] 3-4 ampoules IV Q24H， divided as 3 or 4 administrations. In the absence of any reduction of the serum creatinine after 3 days of treatment， cessation of treatment is advised. In the other cases， treatment is to be pursued until the obtaining either of a serum creatinine < 130 μmol/litre or of a drop of at least 30 % in the serum creatinine with respect to the value measured at the time of diagnosis of hepatorenal syndrome. The standard average duration of treatment is 10 days.,無需調整劑量,[仿單] 關於 terlipressin 進入到人乳汁的情況，目前並沒有足夠的資料。哺乳的婦女不能使用terlipressin。,無需調整劑量,不可使用,Uknown 沒有資料,[仿單] 懷孕期間terlipressin 治療是禁忌。目前已經顯示，於懷孕初期，terlipressin 會造成子宮收縮和增加子宮內壓，以及降低子宮血流。Terlipressin 可能對懷孕及胎兒有害。 動物試驗結果顯示兔子接受terlipressin 治療後，出現自發性流產和畸形。,Unknown 沒有資料,[仿單] 關於 terlipressin 進入到人乳汁的情況，目前並沒有足夠的資料。哺乳的婦女不能使用terlipressin。,IVPUSH;,,【D5W】可選 。,IV bolus slowly >2 minutes. Flush the line after administration.,Total dose: 2 to 12 mg/day. A dose of teripressin in 5% dextrose 50mL， administered via IV pump. (備註：此用法非仿單核准，為歐洲醫藥管理局對發出的建議，用於第一型肝腎症候群，TFDA仍在評估中， 此藥仿單不建議加入其他溶液，因此目前未設定IVD途徑。),1. 假使治療持續數天，必須監測尿量及血液電解質。為了避免注射部位局部壞死，一定要靜脈注射。 2. [UpToDate] 由周邊或中央靜脈緩慢給藥（需超過2分鐘），給藥後請沖洗管路。 3. 不可超過建議劑量 (1.7 mg terlipressin /4 小時)，因為嚴重不良作用風險與劑量相關。治療期間發生心率過緩可使用 atropine 治療。
ILATO,Ketorolac,Laston inj 30mg/1mL,CNEU,Short-term (<=5 days) use for relieving moderate to severe acute pain in patients unable to take orally， typically post-surgery,1. Allergic history to this medication. 2. History of allergy due to Aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). 3. Prohibited within 14 days after Coronary Artery Bypass Graft (CABG) surgery.,Common: Edema (1-10%)， Hypertension (1-10%)， Injection site pain (injection， 1-10%)， Pruritus (1-10%)， Rash (1-10%)， Sweating (1-10%)， Abdominal pain (1-10%)， Constipation， Diarrhea， Flatulence (1-10%)， Heartburn (1-10%)， Indigestion (1-10%)， Nausea (greater than 10%)， Stomatitis (1-10%)， Vomiting (1-10%)， Anemia (1-10%)， Purpuric disorder (1-10%)， Dizziness (1-10%)， Headache (greater than 10%)， Somnolence (1-10%)， Burning sensation in eye (20-40%)， Corneal edema (1-10%)， Eye infection (1-10%)， Eye irritation (1-10%)， Iritis (1-10%)， Pain in eye (1-10%)， Superficial keratitis (1-10%)， Nasal irritation (15%)， Pain of nose (13%) Serious: Myocardial infarction， Thrombotic tendency observations， Erythroderma， Stevens-Johnson syndrome， Toxic epidermal necrolysis， Gastrointestinal hemorrhage (1-10%)， Gastrointestinal perforation， Gastrointestinal ulcer (1-10%)， Melena (<1%)， Blood coagulation disorder with prolonged bleeding time (1-10%)， Hematoma， Hemorrhage， Postoperative hemorrhage， Hepatitis (<1%)， Hepatotoxicity， Increased liver function test (1-10%)， Jaundice (<1%)， Non-allergic anaphylaxis， Cerebrovascular accident， Corneal thinning， Perforation of cornea， Hearing loss (<1%)， Injury of kidney， Nephrotic syndrome， Renal failure (<1%)， Tubulointerstitial nephritis (<1%)， Bronchospasm， Dyspnea (<1%)， Pulmonary edema (<1%),25℃以下、避光貯存(內附黑色避光袋),Single Dose Therapy: (1) Intramuscular Injection <65 years: 60mg/dose; >=65 years， renal insufficiency， body weight <50kg: 30mg/dose. (2) Intravenous Injection <65 years: 30mg/dose; >=65 years， renal insufficiency， body weight <50kg: 15mg/dose. Repeat Dosing Regimen (Intravenous or Intramuscular Injection): <65 years: 30mg q6h (maximum 120mg/day); >=65 years， renal insufficiency， body weight <50kg: 15mg q6h (maximum 60mg/day),無需調整劑量,,需調整劑量,不可使用,Human data suggest risk in 1st and 3 rd trimesters,[仿單] 本藥因會影響胎兒之循環、抑制子宮收縮以及會抑制新生兒之Prostaglandin， 故忌用於孕婦、臨盆及授乳婦女。,Contraindicated 哺乳期使用禁忌,,IM;IVP;IVPUSH;,,,administer over 15 seconds,,1. 靜脈注射 (bolus) 時間不得低於15秒，肌肉注射應採緩慢及深部投與。 2. 禁用於椎管內與硬膜外給藥。
IHUM5,Adalimumab,Humira inj 40mg/0.4mL,HIMM,Monotherapy or in combination with methotrexate or other DMARDs for reducing of the signs & symptoms & to inhibit the progression of structural damage in adult patients with moderately to severely active RA. Monotherapy or in combination with other DMARDs for reducing the signs & symptoms of active arthritis in patients with psoriatic arthritis. Reduction of signs & symptoms in patients with active ankylosing spondylitis. Reduction of signs & symptoms & inducing & maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy or if they have also lost response to or are intolerant to infliximab. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy & when other systemic therapies are medically less appropriate. Reduction of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients 13-17 years.,Known hypersensitivity to adalimumab or any of the excipients of Humira.,Resp tract infections， leucopenia， anemia， increased lipids， headache， abdominal pain， nausea & vomiting， elevated liver enzymes， rash， musculoskeletal pain， inj site reaction.,2-8℃避光避免冷凍,SC， Adult Rheumatoid arthritis， psoriatic arthritis， ankylosing spondylitis， polyarticular juvenile idiopathic arthritis 40 mg every other week. If not taking concomitantly with methotrexate， increasing the dosing frequency to 40 mg weekly may derive additional benefit. Crohn's disease， ulcerative colitis 160 mg initially at day 1 (as four 40-mg in 1 day or as two 40-mg/day for 2 consecutive days)， followed by 80 mg 2 weeks later (day 15). Another 2 weeks later (day 29) begin a maintenance dose of 40 mg every other week. Patients who experience decrease in their response may benefit from an increase in dose intensity to 40 mg every week. Plaque psoriasis Initially 80 mg， followed by 40 mg given every other week starting 1 week after the initial dose.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,
IMET5,Methylprednisolone,Mepron inj 40mg,HM,Adrenal insufficiency， acute shock， asthma， collagen diseases (systemic autoimmune diseases)， allergic reactions， and generalized infections.,Systemic fungal infections. Hypersensitivity to methylprednisolone sodium succinate or any constituent of the product. Administration of live virus vaccines; methylprednisolone formulations containing benzyl alcohol preservative are contraindicated in premature infants; IM administration in idiopathic thrombocytopenic purpura; intrathecal administration.,Common: Hypertension， Atrophic condition of skin， Impaired wound healing， Body fluid retention， Decreased body growth， Hypernatremia， Hypokalemia， Disorder of gastrointestinal tract， Peptic ulcer disease， Liver function tests outside reference range (Mild)， At risk for infection， Muscle weakness， Depression， Euphoria. Serious: Cardiac dysrhythmia， Congestive heart failure， Adrenal insufficiency， Cushing's syndrome， Hyperglycemia， Hepatotoxicity， Osteoporosis， Cerebrovascular accident， Infarction of spinal cord， Nerve injury， Paraplegia， Raised intracranial pressure， Seizure， Tetraplegia， Cataract， Cortical blindness， Glaucoma， Acute scleroderma renal crisis， Pulmonary tuberculosis.,25℃以下,For large dose， IV 30mg/kg for 10-20 minutes， could repeat every 4-6 hours in 48 hours. In other indications， 10-40mg for the first dose， adjusted by patient's condition from second dose. For multiple sclerosis， 160mg daily for one week， then 80mg every two days for one month.,無需調整劑量,[仿單] 因為使用類固醇和人類生殖之有關研究尚不足， 因此此類藥品使用於孕婦、哺乳之母親及生育年齡之婦女時， 需衡量藥效和對孕婦、胚胎和胎兒的危險性兩者間的利害得失。 [Micromedex] Infant risk cannot be ruled out.,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 因為使用類固醇和人類生殖之有關研究尚不足，因此此類藥品使用於孕婦、哺乳之母親及生育年齡之婦女時， 需衡量藥效和對孕婦、胚胎和胎兒的危險性兩者間的利害得失。 在懷孕期間曾使用大量腎上腺皮質類固醇母親所生的新生兒，應該小心觀察是否有腎上腺機能不全現象發生。 [Micromedex] Fetal risk cannot be ruled out.,Unknown 沒有資料,[仿單] 因為使用類固醇和人類生殖之有關研究尚不足， 因此此類藥品使用於孕婦、哺乳之母親及生育年齡之婦女時， 需衡量藥效和對孕婦、胚胎和胎兒的危險性兩者間的利害得失。 [Micromedex] Infant risk cannot be ruled out.,IM;IVD;IVPUSH;,40mg添加1-2mL注射用水調配注射液,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,administer slowly over 1 minute,Reconstitute 40mg with 1-2mL water for injection. Dilute with 5% dextrose， 0.9% sodium chloride or 5% dextrose and 0.9% sodium chloride injection. [UpToDate] Infused >15-60 minutes. For doses >250 mg， infused >30-60 minutes. [Micromedex] Adult: high-dose therapy (30 mg/kg) infused >30 minutes; Pediatric: high doses (15-30 mg/kg or 500-1000 mg/dose) can be diluted to a concentration of 2.5-20 mg/mL in D5W， NS and infused over 30-120 minutes.,已調配好的溶液應冷藏並應於48 小時內用完。
INSO5,Sodium Chloride,0.9% NaCl 500mL bag(Otsuka),MSIV,Water or electrolyte replenishment.,Hypernatremic and fluid retention syndromes. Immediately following surgery.,Common Cardiovascular: Phlebitis Dermatologic: Injection site extravasation， Injection site reaction Endocrine metabolic: Hypervolemia Serious Cardiovascular: Congestive heart failure Endocrine metabolic: Hypernatremia， Overhydration Hematologic: Disseminated intravascular coagulation Respiratory: Respiratory distress,30℃以下,Individualised dosage. Sodium chloride 0.9% injection contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.,無需調整劑量,[仿單]沒有資料,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]沒有資料,Unknown 沒有資料,[仿單]沒有資料,IA;IRR;IVD;,,,,To correct acute (<48 hours) or chronic (>48 hours or duration unknown). In general， a serum sodium concentration increase of 4 to 6 mEq/L within a 24-hour period is sufficient to improve most symptoms of hyponatremia. In chronic severe hyponatremia， overcorrection risks iatrogenic osmotic demyelination syndrome. Goal of initial therapy is to increase serum sodium concentration by 4 to 6 mEq/L within the first 24 hours (maximum rate: 8 mEq/L in any 24-hour period).,0.9% Sodium chloride solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.
INSO250,Sodium Chloride,0.9% NaCl 250mL bag(Otsuka),MSIV,Water or electrolyte replenishment.,Hypernatremic and fluid retention syndromes. Immediately following surgery.,Common Cardiovascular: Phlebitis Dermatologic: Injection site extravasation， Injection site reaction Endocrine metabolic: Hypervolemia Serious Cardiovascular: Congestive heart failure Endocrine metabolic: Hypernatremia， Overhydration Hematologic: Disseminated intravascular coagulation Respiratory: Respiratory distress,30℃以下,Individualised dosage. Sodium chloride 0.9% injection contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.,無需調整劑量,[仿單]沒有資料,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]沒有資料,Unknown 沒有資料,[仿單]沒有資料,IA;IRR;IVD;,,,,To correct acute (<48 hours) or chronic (>48 hours or duration unknown). In general， a serum sodium concentration increase of 4 to 6 mEq/L within a 24-hour period is sufficient to improve most symptoms of hyponatremia. In chronic severe hyponatremia， overcorrection risks iatrogenic osmotic demyelination syndrome. Goal of initial therapy is to increase serum sodium concentration by 4 to 6 mEq/L within the first 24 hours (maximum rate: 8 mEq/L in any 24-hour period).,0.9% Sodium chloride solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.
OWEC,Bethanechol Chloride,Wecoli 25mg,SGU,Treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention. Treatment of neurogenic atony of the urinary bladder with retention.,Hypersensitivity to bethanechol or any component of the formulation; hyperthyroidism， peptic ulcer disease， epilepsy， asthma， pronounced bradycardia or hypotension， vasomotor instability， coronary artery disease， or parkinsonism; mechanical obstruction of the GI or GU tract or when the strength or integrity of the GI or bladder wall is in question; when increased muscular activity of the GI tract or urinary bladder might prove harmful (eg， following urinary bladder surgery， GI resection and anastomosis， possible GI obstruction); bladder neck obstruction， spastic GI disturbances， acute inflammatory lesions of the GI tract， peritonitis， marked vagotonia.,Abdominal cramps， colic， nausea， vomiting， bloating， diarrhea， borborygmi， salivation， frequent urination， headache， flushing， sweating， asthma， lacrimation， miosis， hypotension， tachycardia， malaise， and seizure.,25℃以下,Adult: Usual dose: 10 to 50 mg 3 to 4 times daily before meals. Minimum effective dose: Initial: 5 to 10 mg; repeat the same dose hourly until effective response or a maximum of 50 mg is reached. Children and adolescents (Limited data): 0.3 to 0.6 mg/kg/day in 3 to 4 divided doses; maximum dose: 10 mg/dose for children.,無需調整劑量,[仿單] 目前還不知道本藥是否會排於母乳。 但是因為有多種藥會排於母乳，且Bethanechol 對於授乳之嬰兒可能會產生嚴重副作用； 因此在考慮藥對母親的重要性之後，再行決定是要停止哺乳，或是停止用藥。,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,[仿單] Bethanechol是否對於動物生殖系統之影響尚未研究。 其對懷孕婦女使用本藥之後是否對胎兒造成傷害，或是否會影響用藥病人的生育能力並未知。 因此，Bethanechol 應該只用於有迫切需要的懷孕婦女。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 目前還不知道本藥是否會排於母乳。 但是因為有多種藥會排於母乳，且Bethanechol 對於授乳之嬰兒可能會產生嚴重副作用； 因此在考慮藥對母親的重要性之後，再行決定是要停止哺乳，或是停止用藥。,AC;PO;,,,,,
ETRE,Fluticasone furoate + Umeclidinium + Vilanterol,Trelegy Ellipta 92/55/22 mcg Inhalation Powder,ERSP,Chronic obstructive pulmonary disease,Hypersensitivity to fluticasone， umeclidinium， vilanterol， or any component of the formulation; severe hypersensitivity to milk proteins,1% to 10%: Headache (4%)， voice disorder (>=1%)， Diarrhea (2%)， dysgeusia (2%)， constipation (>=1%)， oral candidiasis (>=1%)， gastroenteritis (1%)， Urinary tract infection (>=1%)， Influenza (>=1%)， Back pain (4%)， arthralgia (>=1%)， Pneumonia (8%)， bronchitis (>=1%)， pharyngitis (>=1%)， rhinitis (>=1%)， sinusitis (>=1%)， upper respiratory tract infection (>=1%)， cough (1%)， oropharyngeal pain (1%) Frequency not defined:Paradoxical bronchospasm <1%， postmarketing， and/or case reports: Anaphylaxis,避光乾燥30℃以下,Oral inhalation: Dry powder inhaler: One inhalation (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) once daily (maximum dose: 1 inhalation/day),無需調整劑量,[仿單](節錄) 目前無人類資料，動物實驗資料Umeclidinium會進入乳汁. FLUTICASONE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible 其他成分無資料,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 只有再潛在效益超越beta作用劑干擾子宮收縮作用方面之可能風險的情況下， 才可於懷孕後期與分娩期間使用. FLUTICASONE PREGNANCY RECOMMENDATION: Compatible 其他成分無資料,Unknown 沒有資料,[仿單](節錄) 目前無人類資料，動物實驗資料Umeclidinium會進入乳汁. FLUTICASONE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible 其他成分無資料,INHL;,,,,,
IWAT500,Water for injection,Water for injection 500mL,NUTR,,,,室溫藥品，仿單無特別指示儲存溫度條件,It is for use only as a sterile solvent or diluent vehicle for drugs or solutions suitable for parenteral administration.,無需調整劑量,,無需調整劑量,,,,,,INHL;IRR;IVD;,,,,,
OJIN4,Tolvaptan,Jinarc 45mg,CAVS,Indicated for adults with autosomal dominant polycystic kidney disease (ADPKD) and eGFR greater than 25mL/min/1.73m2 with signs of rapid disease progression， to slow the growth of cysts and decline in kidney function associated with autosomal dominant polycystic kidney disease.,Hypersensitivity to tolvaptan or any component of the product or benzazepine or benzazepine derivatives. Presence of liver enzyme elevation and/or liver damage signs or symptoms that meet the criteria for permanent discontinuation of tolvaptan before starting treatment. Anuria. Volume depletion. Hypernatremia. Unable to sense or respond to thirst. Pregnancy. Breastfeeding.,Common: Hypernatremia (0.7-25.6%)， Diarrhea (13.3%)， Increased thirst (12-63.7%)， Nausea (8-21%)， Xerostomia (7-23%)， ALT/SGPT level raised， Serum bilirubin above reference range， Asthenia (9%)， Dizziness (4.8-11.3%)， Increased frequency of urination (69.5%)， Polyuria (4-24%)， Fatigue (13.6%) Serious: Hypovolemia， Gastrointestinal hemorrhage， In cirrhotic patients (10%)， Hepatic failure， acute， Injury of liver， Osmotic demyelination syndrome,25℃以下,Take twice daily. Dosage options: 45mg + 15mg， 60mg + 30mg， or 90mg + 30mg (split dose regimen). First dose 30 minutes before breakfast. Second dose can be taken with or without food. Initial: total dose 60mg (45mg on waking， 15mg after 8 hours). If tolerated， increase to 90mg daily (60mg + 30mg)， then up to the target dose of 120mg daily (90mg + 30mg). At each dosage adjustment， allow at least one week interval.,需調整劑量,BREASTFEEDING RECOMMENDATION: No Human Data—Potential Toxicity [仿單] 目前尚不清楚 tolvaptan 是否會分泌進入人類的乳汁中，但是根據大鼠試驗顯示 tolvaptan 會分泌到乳汁中。不能排除新生兒/嬰兒的風險。哺乳期間禁用 Jinarc。,需調整劑量,不可使用,No (limited) human data – animal data suggest low risk,PREGNANCY RECOMMENDATION: No Human Data—Animal Data Suggest Low Risk [仿單] 目前在孕婦服用 tolvaptan 方面尚無資料或資料有限。動物試驗顯示本藥品具有生殖毒 性。Jinarc 不建議用於未採取避孕措施的育齡婦女。懷孕時不得服用 Jinarc。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,BREASTFEEDING RECOMMENDATION: No Human Data—Potential Toxicity [仿單] 目前尚不清楚 tolvaptan 是否會分泌進入人類的乳汁中，但是根據大鼠試驗顯示 tolvaptan 會分泌到乳汁中。不能排除新生兒/嬰兒的風險。哺乳期間禁用 Jinarc。,AC;PO;,,,,,
IGEN8,Gentamicin,Gentamycin inj 80mg/2mL,QANB,Susceptible infections， Surgical prophylaxis.,History of hypersensitivity to aminoglycoside; pregnancy; perforated ear drum.,Dizziness or vertigo; acute renal failure， interstitial nephritis， acute tubular necrosis; electrolyte imbalances; transient elevation of serum bilirubin and aminotransferases; purpura; nausea， vomiting; convulsions， mental depression， hallucinations. Atrophy or rat necrosis at inj sites.,無特別指示,(仿單) Adult: 1 mg/kg IM Q8H or 1 mg/kg IV Q8H; dose range 3-5 mg/kg QOD. Pediatric: Infants < 7 days: 3 mg/kg IM Q12H; infants > or = 7 days: 2 mg/kg IM Q8H; children 1-1.7 mg/kg IM Q8H. For IV administration， 1-2 mg/kg Q8H. (熱病) Adult: Multiple Daily Dose: 2 mg/kg load， then 1.7-2 mg/kg Q8H. Target peak 4–10 μg/mL， trough 1–2 μg/mL; Once Daily Dose: 5.1 mg/kg Q24H (7 mg/kg Q24H if critically ill). Target trough <1 μg/mL. Pediatric age > 28 days: 5-7 mg/kg/day Q24H or 2.5 mg/kg Q8H *****NEONATE ANTIBIOTICS DOSE***** Gentamicin: Draw peak 30 min after completion infusion; draw trough just before the next dose (於第4個dose給藥前) PMA <=29 week Postnatal 0 to 7 days dose : 5mg/kg Q48H PMA <=29 week Postnatal 8 to 28 days dose : 4mg/kg Q36H PMA <=29 week Postnatal >=29 days dose : 4mg/kg Q24H PMA 30 – 34 week Postnatal 0 to 7 days dose : 4.5mg/kg Q36H PMA 30 – 34 week Postnatal >= 8 days dose : 4mg/kg Q24H PMA 35 - 44 week Postnatal all dose : 4mg/kg Q24H,無需調整劑量,,需調整劑量,盡量避免,Human data suggest low risk,,Compatible 哺乳時可使用,,IH;IM;IMP;IRR;IVD;IVI;SCI;SUBCI;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【L/R】可選 。,,給藥濃度< 1 mg/mL (IV infuse over 30 minutes to 2 hours)。 NeoFax建議：Infuse over a period of 30 to 120 minutes using a concentration of 2 mg/mL or 10 mg/mL.,1. 監測體溫、CBC、肝腎功能、血鈣、血鉀、血鈉、血鎂、聽覺功能。 2. 建議監測藥物血中濃度。
OSYNG,Piracetam,Syntam granules 1200mg/包,CNEU,Treatment of cerebrovascular insufficiency & age-related cognitive impairment; adjunct in the treatment of myoclonus of cortical origin.,Cerebral hemorrhage; severe renal impairment.,Hyperkinesia， wt gain， nervousness， somnolence， depression， asthenia.,25℃以下乾燥處,Cerebrovascular insufficiency & age-related cognitive impairment Loading dose: 4.8 g daily during initial weeks of treatment. Maintenance: 1.2-2.4 g daily. maximum: 4.8g/day. Cortical myoclonus Initially 7.2 g daily， increasing by 4.8 g/day every 3-4 days to a maximum of 24 g/day in divided 2-3 doses.,無需調整劑量,[仿單]piracetam會滲入乳汁，因此授乳期間應避免使用本藥， 或是在使用piracetam 治療期間應停止授乳.,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]動物試驗顯示並不會對懷孕者，生長中的胚胎，及出生後的胎兒造成直接或間接的傷害. 但迄今並無孕婦使用piracetam 的臨床資料， piracetam會通過胎盤?新生兒體內的藥品濃度約為母體的70 -90%. 因此除非必要，懷孕期間不應使用piracetam,Unknown 沒有資料,[仿單]piracetam會滲入乳汁，因此授乳期間應避免使用本藥， 或是在使用piracetam 治療期間應停止授乳.,AC;AC15;PC;PO;WM;,,,,,
IGAR0,HPV type 6/11/16/18/31/33/45/52/58 L1 protein,Gardasil 9 (HPV疫苗，政府提供) inj 0.5mL/dose,HIMM,For 9 to 45 years old people to prevent diseases caused by human papillomavirus (HPV) (cervical cancer， genital warts & precancerous or dysplastic lesions) Precancerous lesions and cancers of the cervix， vulva， vagina and anus caused by HPV types 6， 11， 16， 18， 31， 33， 45， 52 and 58. Genital warts (condyloma acuminatum) caused by HPV types 6 and 11.,Hypersensitivity，hypersensitivity to yeast.,Injection site reactions， fever， nausea， dizziness.,2-8℃避光,IM， 0.5mL， in the deltoid region of the upper arm or in the higher anterolateral area of the thigh， 9-45 years 3 doses at 0， 2， and 6 months. 9-14 years can also take 2 doses at 0 and 6-12 months.,無需調整劑量,[仿單]現有的資料並不足以評估GARDASIL 9對餵哺母乳之嬰兒或對乳汁生成/分泌作用的影響。 應將餵哺母乳對發育及健康的效益和母親對GARDASIL 9的臨床需求，以及GARDASIL 9或母親 的基礎狀態對餵哺母乳之幼兒的任何可能不良影響放在一起考慮。 就預防性疫苗而言，母親的基礎狀態係指對該疫苗所要預防之疾病的易感性。,無需調整劑量,沒有資料,Uknown 沒有資料,[訪單]現有的人類試驗資料並未顯示在懷孕期間施打GARDASIL 9會使發生重大出生缺陷與 流產的風險因使用疫苗而升高。,Unknown 沒有資料,[仿單]現有的資料並不足以評估GARDASIL 9對餵哺母乳之嬰兒或對乳汁生成/分泌作用的影響。 應將餵哺母乳對發育及健康的效益和母親對GARDASIL 9的臨床需求，以及GARDASIL 9或母親 的基礎狀態對餵哺母乳之幼兒的任何可能不良影響放在一起考慮。 就預防性疫苗而言，母親的基礎狀態係指對該疫苗所要預防之疾病的易感性。,IM;,,,,,1. 使用前請充分搖勻，使疫苗保持懸浮液的狀態。 2. Gardasil 9 應以肌肉注射的方式施打於上臂的三角肌區域，或是大腿前外側區域較高的部位。
ESPD,Urea,Sinpharderm cream 40%， 10gm (去角質),TDER,Exfoliation,Hypersensitivity to any component of the formulation.,Local transient pain， burning sensation， itching.,30℃以下,Apply topically to affected area(s) 1-2 times daily. To soften extremely rough or dry cracked skin， calluses， and nail tissues (including ingrown nails) and relieve skin dryness: (1) Apply an appropriate amount of the cream to the affected area and cover it with gauze for protection. (2) Apply the medicine evenly to the treatment area until the cream is completely absorbed. If necessary， cover with a bandage or gauze and fix it with tape. For the nail area， it is recommended to use finger cots (plastic gloves can be used to cut suitable finger cots) for protection. (3) Wash off excess cream with soap and water， and avoid contact with eyes.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,[Briggs Drugs in Pregnancy and Lactation 12th] No Human Data—No Relevant Animal Data,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
ORPT,Rifapentine,Priftin 150mg (政府提供),QANB,Inactive tuberculosis， With isoniazid in patients with high risk of progression to active disease Tuberculosis，,Hypersensitivity to rifamycins. concomitant use with rilpivirine.,Common Dermatologic: Rash (2.5% to 4.2% ) Gastrointestinal: Clostridium difficile diarrhea Hematologic: Anemia (1.6% to 11.4% ) Hepatic: ALT/SGPT level raised (2.2% to 5% )， AST/SGOT level raised (2.2% to 4.2% ) Immunologic: Lymphocytopenia (3.2% to 10.5% ) Musculoskeletal: Arthralgia (0.9% to 3.6% ) Neurologic: Headache (0.9% to 3% ) Ophthalmic: Conjunctivitis (0.3% to 2.2% ) Respiratory: Hemoptysis (1.9% to 7.5% ) Other: Abnormal color， Red/orange body fluid Serious Hematologic: Neutropenia (6.1% to 8.5% ) Hepatic: Hepatotoxicity Immunologic: Hypersensitivity reaction (Adult， 4%; pediatric， 1.3% ),30℃以下,Adult: in combination with isoniazid 15 mg/kg (rounded up to the nearest 50 or 100 mg; Maximum: 900 mg) 25.1-32 kg once a week， Rifapentine 600 mg each time; 32.1-50 kg once a week， Rifapentine 750 mg each time; >50 kg once a week， Rifapentine 900 mg each time (maximum Dose: 900 mg) for 12 weeks. Children: in combination with isoniazid 15 mg/kg (rounded up to the nearest 50 or 100 mg; Maximum: 900 mg); 10-14 kg once a week， Rifapentine 300 mg each time; 14.1-25 kg once a week， Rifapentine 450 mg each time; 25.1-32 kg once a week， Rifapentine 600 mg each time; 32.1-50 kg once a week， Rifapentine 750 mg each time; >50 kg once a week， Rifapentine 900 mg each time (maximum dose: 900 mg) for 12 weeks.,無需調整劑量,Micromedex: Milk effects are possible.,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Micromedex: Milk effects are possible.,AC;AC15;PC;PO;WM;,,,,,
LRIV,Rivastigmine,Rivast 2mg/mL， 120mL solution,CNEU,Alzheimer's disease - Dementia (Mild to Moderate). Dementia (Mild to Moderate) - Parkinson's disease,Hypersensitivity to rivastigmine， carbamate derivatives， or other components of the product.,Common Endocrine metabolic: Weight loss (26%， female; 18%， male ) Gastrointestinal: Abdominal pain (13% )， Diarrhea (7% to 19% )， Indigestion (9% )， Loss of appetite (6% to 17% )， Nausea (29% to 47% )， Vomiting (13% to 31% ) Neurologic: Asthenia (4% to 6% )， Dizziness (6% to 21% )， Headache (4% to 17% )， Tremor (4% to 23% ) Serious Cardiovascular: Atrial fibrillation (1% or more )， Atrioventricular block (0.1% to 1% )， Myocardial infarction (1% or more )， Peripheral ischemia (0.1% to 1% )， Sick sinus syndrome (0.1% to 1% ) Endocrine metabolic: Hypokalemia (1% or more )， Hyponatremia (0.1% to 1% ) Gastrointestinal: Gastrointestinal hemorrhage (0.1% to 1% )， Hematemesis (0.1% to 1% )， Melena (0.1% to 1% )， Pancreatitis (0.1% to 1% )， Rectal hemorrhage (0.1% to 1% )， Rupture of esophagus Hepatic: Gamma-glutamyl transferase raised (0.1% to 1% )， Hepatitis， Liver function tests abnormal (0.1% to 1% ) Neurologic: Cerebrovascular accident， Intracranial hemorrhage (0.1% to 1% )， Seizure (1% or more )， Transient ischemic attack (1% or more ) Ophthalmic: Glaucoma (0.1% to 1% ) Psychiatric: Suicidal behavior Renal: Acute renal failure (0.1% to 1% ) Respiratory: Bronchospasm (0.1% to 1% ),25℃以下，不需冰存並避免陽光直射,Initial， 1.5 mg orally twice daily for 2 weeks. Titration， if well tolerated， increase in increments of 1.5 mg orally twice daily at minimum of every 2 weeks; Maximum 12 mg/day.,無需調整劑量,[仿單]Rivastigmine 會不會被分泌至人類的乳汁中，並不清楚，因此病患服用 Rivastigmine 時不可以哺乳。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]在動物研究上，Rivastigmine 不會導致畸胎(teratogenic)， 然而 Rivastigmine 在懷孕婦女身上的安全性尚未建立， 因此，對於懷孕婦女只有在治療利益大於對胎兒危險性下才能給藥。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Rivastigmine 會不會被分泌至人類的乳汁中，並不清楚，因此病患服用 Rivastigmine 時不可以哺乳。,PC;WM;,,,,,
OLID,Lithium Carbonate,Lidin 300mg,CNEU,Treatment of mania， and prevention of bipolar disorder,Significant renal or cardiovascular disease， concomitant use of diuretics， severe debilitation， severe dehydration， or sodium depletion.,Bloating， vomiting， lethargy， muscle weakness， slight tremors， dizziness， tinnitus， and polyuria.,避光避熱，儲存於30℃以下,Acute mania: 900-1800mg/day in 3 divided doses. Adjust blood lithium concentration to 1.0-1.5mEq/L. Check the blood lithium concentration twice a week until the effective blood concentration is reached and the clinical symptoms are stable. Long-term treatment: 900-1200mg in 3-4 divided doses to adjust the blood lithium concentration to 0.6-1.2mEq/L.,無需調整劑量,[仿單] 鋰能排入乳汁中，授乳者建議不要使用或權宜利弊使用。,無需調整劑量,盡量避免,Human (and animal) data suggest risk,[仿單] 有數據顯示鋰對胎兒有不良反應，在孕婦之安全性尚未建立，尤其是懷孕前三個月， 避免使用本劑。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 鋰能排入乳汁中，授乳者建議不要使用或權宜利弊使用。,AC;AC15;PC;PO;WM;,,,,,
OTAR1,Erlotinib,Tarceva 150mg,RACA,Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least 1 prior chemotherapy regimen.,Hypersensitivity to any component of the formulation.,Rash， diarrhea， anorexia， fatigue， dyspnea， cough， nausea， vomiting， stomatitis， pruritus， dry skin， conjunctivitis， keratoconjunctivitis sicca， abdominal pain. Rarely， elevated liver enzymes， GI bleeding (in association with concomitant administration of warfarin or NSAIDs). Cardiovascular: Edema (37% ) Dermatologic: Alopecia (14% )， Pruritus (7.4% to 13% )， Rash， Any grade (49.2% to 75% ) Endocrine metabolic: Weight decreased (3.9% to 39% ) Gastrointestinal: Abdominal pain (11% to 46% )， Diarrhea， Any grade (20.3% to 54% )， Flatulence (13% )， Indigestion (17% )， Inflammatory disease of mucous membrane (17% to 22% )， Loss of appetite (9.2% to 52% )， Nausea (33% to 60% )， Vomiting (23% to 42% ) Hepatic: Hyperbilirubinemia， Increased liver enzymes Immunologic: Infectious disease (39% ) Musculoskeletal: Bone pain (25% )， Myalgia (21% ) Neurologic: Headache (15% ) Ophthalmic: Conjunctivitis (12% )， Keratoconjunctivitis sicca (12% ) Psychiatric: Anxiety (13% )， Depression (19% ) Respiratory: Cough (16% to 33% )， Dyspnea (24% to 41% ) Other: Fatigue (9% to 73% )， Fever (36% ),請儲存於30℃的溫度下,[Non–small cell lung cancer (NSCLC) (as first-line therapy， maintenance treatment， or for progressive disease)] 150 mg taken on an empty stomach at least 1 hour before or 2 hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.,需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OSET,Granisetron,Setron 2mg,CNEU,Prevention or treatment of chemotherapy or radiation therapy associated nausea and vomiting.,Hypersensitivity to granisetron or any of its components.,Common Neurologic: Asthenia (oral， 14% to 18% )， Headache (8.6% to 21% )， Somnolence (up to 10% ) Other: Fever (3% to 56% ) Serious Cardiovascular: Prolonged QT interval Immunologic: Hypersensitivity reaction,請勿儲存於超過25℃的環境,Prophylaxis of Chemotherapy-induced nausea and vomiting: 2 mg QD， taking 1 hour before chemotherapy at the first time. Prophylaxis of Radiation therapy-induced nausea and vomiting: 2 mg QD， taking 1 hour before radiation therapy at the first time. Not up to a week.,無需調整劑量,[仿單]目前尚無懷孕婦女的試驗，故尚未知granisetron HCl是否會被分泌於人體乳汁中。只有當對母親之潛在益處大於對胎兒及受乳嬰兒之潛在危險的前提下，才可於懷孕及哺乳期間使用granisetron HCl (見臨床前安全性資料) 。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]目前尚無懷孕婦女的試驗，故尚未知granisetron HCl是否會被分泌於人體乳汁中。只有當對母親之潛在益處大於對胎兒及受乳嬰兒之潛在危險的前提下，才可於懷孕及哺乳期間使用granisetron HCl (見臨床前安全性資料) 。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前尚無懷孕婦女的試驗，故尚未知granisetron HCl是否會被分泌於人體乳汁中。只有當對母親之潛在益處大於對胎兒及受乳嬰兒之潛在危險的前提下，才可於懷孕及哺乳期間使用granisetron HCl (見臨床前安全性資料) 。,AC;AC15;PC;PO;WM;,,,,,
IOZE4,Semaglutide,Ozempic inj 4mg/3mL,META,Type 2 diabetes mellitus. Prophylaxis of disorder of cardiovascular system with type 2 diabetes mellitus.,Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2. Known hypersensitivity to semaglutide or any component of the product.,Common Endocrine metabolic: Hypoglycemia (Monotherapy， 1.6% to 3.8%; combination therapy， 6% to 30% ) Gastrointestinal: Abdominal pain (5.7% to 11% )， Constipation (3.1% to 6% )， Diarrhea (8.5% to 10% )， Nausea (11% to 20.3% )， Vomiting (5% to 9.2% ) Serious Endocrine metabolic: Medullary thyroid carcinoma Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Ophthalmic: Retinopathy due to diabetes mellitus,避光勿冷凍。初次使用前：請存放於2-8°C; 初次使用後請存放於30°C以下或 2-8°C 共六週,SC， 0.25 mg once weekly for 4 weeks， then increase to 0.5 mg once weekly; may increase to maximum 1 mg once weekly if additional glycemic control is needed after at least 4 weeks of the 0.5 mg weekly dosage.,無需調整劑量,[仿單] 大鼠的泌乳實驗顯示，semaglutide 會分泌至乳汁中。 由於無法排除哺乳嬰幼兒的風險，哺乳期間不應使用 semaglutide。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]在動物試驗中顯示具生殖毒性。懷孕女性使用 semaglutide 的資料有限，因此懷孕期間不可使用 semaglutide。 如果病人想要懷孕或已懷孕，應停用 semaglutide。 由於 semaglutide 的半衰期較長，計畫懷孕前至少兩個月應停用 semaglutide。,Unknown 沒有資料,[仿單] 大鼠的泌乳實驗顯示，semaglutide 會分泌至乳汁中。 由於無法排除哺乳嬰幼兒的風險，哺乳期間不應使用 semaglutide。,SC;,,,,,1.使用新的注射筆第一次注射前，請先檢查是否已排空。 2.存放於30°C以下可保存6週.不可冷凍. 3.必要時可改變每週注射的日期，但兩次注射之間應至少相隔 3 天 (超過 72 小時)。選定新的注射日之後，應持續每週注射一次。 4.如果錯過一劑藥物，應在 5 天內儘快施打。如果超過 5 天則應跳過，依原訂時程繼續注射下一劑。遇到這類情況，病人之後可恢復每週一次的用藥時程。
ISAX,Liraglutide,Saxenda inj 18mg/3mL,META,Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: **Adult** patients with an initial BMI of (1) 30 kg/m2 or higher (obese)， or (2) 27 kg/m2 or higher (overweight) and having at least one weight-related comorbid condition (such as hypertension， type 2 diabetes mellitus， or dyslipidemia). **Pediatric** patients aged 12 years or older with body weight over 60 kg， and an initial BMI equivalent to 30 kg/m2 for adults (obese) based on international standards.,Hypersensitivity to liraglutide or any component of the product. Personal or family history of medullary thyroid carcinoma. Personal of family history of multiple endocrine neoplasia syndrome type 2. Pregnancy.,[Common] Hypoglycemia (Adult， monotherapy， 7.1-12.6%; adult， combination therapy， 3.6-28.2%; pediatric， 15.2 to 21.2%)， Constipation (Type 2 diabetes， 5-9.9%; weight management， 4.8-19.4%)， Decrease in appetite (9-10%)， Diarrhea (10-22.4%)， Indigestion (4-9.6%)， Nausea (Type 2 diabetes， 18-28.4%; weight management， 39.3-42.4%)， Vomiting (Type 2 Diabetes， 6-15.7%; weight management， 34.4% (pediatric))， Headache (9.1-13.6%)， Upper respiratory infection (6-9.5%) [Serious] Breast cancer (0.6%)， C-cell hyperplasia of thyroid， Medullary thyroid carcinoma， Papillary thyroid carcinoma (0.2%)， Cholecystitis (0.8% )， Cholelithiasis (1.15-2.2%)， Colorectal cancer (0.2%)， Pancreatic cancer， Pancreatitis (0.3-0.8%)， Anaphylaxis， Suicidal， completed (Pediatric， 0.8%)， Suicidal thoughts (0.3%)， Acute renal failure， Angioedema,2-8°C冷藏，請勿冷凍,[Adults and Children >= 12 years old] Obesity， or overweight in the presence of at least one weight-related comorbidity: Initial， 0.6 mg subQ once daily for 1 week; increase weekly in increments of 0.6 mg/day until maintenance dosage of 3 mg once daily is reached.,無需調整劑量,[仿單]目前尚不清楚 liraglutide 是否會分泌到母乳。動物試驗顯示，liraglutide 和結構相近的代謝物轉移到乳汁中的機會很低，在非臨床試驗中，發現未斷奶的新生大鼠有治療相關的生長減緩問題。由於缺乏資料，哺乳期間不應使用善纖達。,需調整劑量,沒有資料,No (limited) human data – animal data suggest risk,[仿單]懷孕女性使用 liraglutide 的資料有限，動物試驗已證實具生殖毒性，但對人體的潛在風險未知。懷孕期間不應使用 liraglutide，如果病人想要懷孕或已懷孕，應停止 liraglutide 治療。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前尚不清楚 liraglutide 是否會分泌到母乳。動物試驗顯示，liraglutide 和結構相近的代謝物轉移到乳汁中的機會很低，在非臨床試驗中，發現未斷奶的新生大鼠有治療相關的生長減緩問題。由於缺乏資料，哺乳期間不應使用善纖達。,SC;,,,,,1. 未使用前於2–8°C冷藏保存，請勿冷凍。初次使用後存放於30°C以下或2–8°C冷藏，可保存1個月。 2. 限皮下注射使用，不得靜脈注射或肌肉注射。應注射在腹部、大腿或上臂。
OMIRA,Pramipexole,MiraPex 0.375mg prolonged-release,CNEU,Treatment of signs & symptoms of Parkinson's disease.,Hypersensitivity. Lactation.,Abnormal behaviors (eg， binge eating， compulsive shopping， hypersexuality， pathological gambling)， abnormal dreams， amnesia， cardiac failure， confusion， constipation， delusion， dizziness， dyskinesia， dyspnoea， fatigue， hallucinations， headache， hiccups， hyperkinesia， hyperphagia， hypotension， inappropriate antidiuretic hormone secretion， insomnia， libido disorders， nausea， paranoia， peripheral oedema; pneumonia; pruritus， rash; restlessness， somnolence， sudden onset of sleep， syncope， visual impairment including diplopia， blurred vision， reduced visual acuity; vomiting， decreased appetite， increased/decreased wt.,30℃以下，避免暴露於高濕氣,Parkinson's disease: start from 0.375 mg given once per day. Based on efficacy and tolerability， dosages may be increased gradually， not more frequently than every 5 to 7 days， first to 0.75 mg per day and then by 0.75 mg increments up to a maximum recommended dose of 4.5 mg per day. When discontinuing therapy， taper the dose gradually over a period of one week. In patients with moderate renal impairment (creatinine clearance 30-50 mL/min)， start from 0.375 mg given every other day. Dose adjustment should occur no more frequently than at weekly intervals. Maximum: 2.25 mg/day.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。
IOGI,Trastuzumab,Ogivri inj 440 mg (健保),RACA,Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer: 1.as part of a treatment regimen consisting of doxorubicin， cyclophosphamide， and either paclitaxel or docetaxel. 2.as part of a treatment regimen with docetaxel and carboplatin. 3.as a single agent following multi-modality anthracycline based therapy. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. In combination with cisplatin and capecitabine or 5-fluorouracil， for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.,Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.,Common Dermatologic: Rash (Adjuvant breast cancer， 4%; metastatic breast cancer， 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% )， Nausea (Adjuvant breast cancer， 6%; metastatic breast cancer， 33% to 76% )， Stomatitis (24% )， Vomiting (Adjuvant breast cancer， 3.5%; metastatic breast cancer， 23% to 53% ) Hematologic: Anemia， All Grades (4% to 36% )， Neutropenia， All Grades (Breast cancer， 6.4%; gastric cancer， 78% )， Thrombocytopenia， All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer， 6.2% to 10%; metastatic breast cancer， 26% to 44% )， Insomnia (Adjuvant breast cancer， 4.3%; metastatic breast cancer， 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer， 5%; metastatic breast cancer， 26% to 43% ) Other: Fatigue (29.5% to 35% )， Fever (Adjuvant breast cancer， 6%; metastatic breast cancer， 36% to 56%; gastric cancer， 18% )， Shivering (Adjuvant breast cancer， 5%; metastatic breast cancer， 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% )， Heart failure (Adjuvant breast cancer， 0.4% to 3.2%; metastatic breast cancer， 7% to 28% )， Left ventricular cardiac dysfunction (5% to 18.5% )， Myocardial ischemia， Grade 3 or 4 Hematologic: Febrile neutropenia (23% )， Neutropenia， Grade 3 or 4 (32% to 34% )， Thrombocytopenia， Grade 3 or 4 (5% )， Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer， 2.4% to 11.8%; metastatic breast cancer， 22% to 42% )， Interstitial pneumonia， acute (0.2% to 0.7% )， Pulmonary hypertension (0.2% )， Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% )， Tumor lysis syndrome,2-8℃,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion， then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks， or initial dose of 8 mg/kg over 90 minutes IV infusion， then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion， followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,無需調整劑量,[仿單]目前並不確知trastuzumab是否會分泌進入人類的乳汁，但人類的IgG會分泌進入人類的乳汁。已發表的資料顯示，乳汁抗體並不會大量進入新生兒及嬰兒的體內循環。對授乳食蟹猴投予相當於人類每週建議劑量(2毫克/公斤體重)之12.5倍的trastuzumab之後發現，trastuzumab會出現於乳汁中。血清中檢出trastuzumab的幼猴在出生後至3個月大期間並未發生任何生?或發育方面的不良影響；不過，動物乳汁中的trastuzumab含量並不能精確地反映人類乳汁中的含量。 由於許多藥物都會分泌進入人類的乳汁，且餵哺母乳的嬰兒可能會因接觸Ogivri而發生嚴重的不良反應，因此，應考慮Ogivri的排除半衰期及此藥物對母親的重要性，然後決定是否要停止餵哺母乳或是停用此藥。,無需調整劑量,沒有資料,Human data suggest risk in 2nd and 3 rd trimesters,[仿單]對孕婦投予trastuzumab會對胎兒造成傷害。根據上市後的病例報告，在懷孕期間使用trastuzumab會提高於第二及第三孕期出現羊水過少現象的風險。如果婦女在懷孕期間使用了trastuzumab，或於使用trastuzumab期間懷孕，應將胎兒可能受到的危害告知該名婦女。上市之後，在懷孕期間接受單一trastuzumab或與化學療法併用治療的婦女中曾有出現羊水過少現象的報告。其中有半數的婦女在停用trastuzumab之後即出現羊水指數上升的現象。有一個病例在羊水指數改善之後又重新開始使用trastuzumab，結果再度出現羊水過少的現象。上市之後，在接受trastuzumab的孕婦中曾有報導胎兒羊水過少症伴隨腎臟成?及/或功能受損的案例，其中有造成胎兒肺部器官發育不全而導致死亡的報導。對於在懷孕期間使用Ogivri的婦女，應監視是否出現羊水過少的現象。如果出現羊水過少的現象，即應進行適合其妊娠週數且符合社會照護標準的胎兒檢查。曾經在投予其他化學治療劑之後出現羊水過少的現象時以靜脈輸注(IV)的方式額外補充水份，結果頗有助益，但目前並不確知使用trastuzumab治療時以靜脈輸注之方式額外補充水份的效果。在以高達人類每週建議劑量(2毫克/公斤體重)之25倍的trastuzumab所進行的食蟹猴生殖研究中，並未發現任何顯示胎兒受到傷害的證據。不過，許多胚胎組織都有相當明顯的HER2蛋白過度表現的現象，包括心臟與神經組織；在缺乏HER2的突變小鼠中，胚胎皆於懷孕初期即死亡。針對猴子所進行的研究發現，在胎兒發育階段的初期(懷孕第20-50天)及後期(懷孕第120-150天)，trastuzumab會通過胎盤轉移至胎兒體內。由於動物生殖研究的結果並不？定能預測人類的反應，因此，只有在母親的潛在效益超越胎兒可能面臨之風險的情況下，才可於懷孕期間使用Ogivri。 育齡期婦女於Ogivri治療期間及治療結束後7個月內應被建議採取有效的避孕措施。 若孕婦接受Ogivri治療，或是病患在接受Ogivri治療期間或最後一劑Ogivri後7個月內懷孕，最好由跨科別團隊進行嚴密監測。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]目前並不確知trastuzumab是否會分泌進入人類的乳汁，但人類的IgG會分泌進入人類的乳汁。已發表的資料顯示，乳汁抗體並不會大量進入新生兒及嬰兒的體內循環。對授乳食蟹猴投予相當於人類每週建議劑量(2毫克/公斤體重)之12.5倍的trastuzumab之後發現，trastuzumab會出現於乳汁中。血清中檢出trastuzumab的幼猴在出生後至3個月大期間並未發生任何生?或發育方面的不良影響；不過，動物乳汁中的trastuzumab含量並不能精確地反映人類乳汁中的含量。 由於許多藥物都會分泌進入人類的乳汁，且餵哺母乳的嬰兒可能會因接觸Ogivri而發生嚴重的不良反應，因此，應考慮Ogivri的排除半衰期及此藥物對母親的重要性，然後決定是否要停止餵哺母乳或是停用此藥。,IVD;,包裝中的稀釋液(20 毫升含1.1%苯甲醇的制菌注射用水)。,,,抽取病患藥物量後加到裝有0.9%氯化鈉250 毫升的注射袋中稀釋，起始劑量建議靜脈輸注90 分鐘。維持劑量時若病人對先前劑量的耐受力佳，可輸注30 分鐘即可。,1.配製的說明: 使用無菌針筒，慢慢注入20 毫升制菌注射用水於含凍晶Ogivri 的小瓶，直接注射至凍晶塊。再溫和地轉動小瓶幫助調配，不要搖晃。 2.使用包裝中所提供的制菌注射用水混合後的配製後溶液，冷藏在2-8℃可以維持28 天的安定。如果使用滅菌水配製則僅維持24 小時安定，之後必須丟棄。 3.配製於裝有0.9%氯化鈉溶液的注射用袋中，在2-8℃下其物化性質可維持穩定24 小時。 4.禁止使用5%的dextrose 溶液，因為會引起蛋白質凝集。
IEYL0,Aflibercept,Eylea aflibercept 2mg/0.05mL (Sample),TOPH,Treatment of neovascular (wet) age-related macular degeneration (AMD).,Active intraocular inflammation. Hypersensitivity to aflibercept or any component of the product， including severe anaphylactic/anaphylactoid reactions， severe intraocular inflammation， or other hypersensitivity reactions. Ocular or periocular infections.,Common: Conjunctival hemorrhage (Adult， 12-31%; pediatric， 5-9%)， Corneal erosion (1-7%)， Pain in eye (4-13%)， Vitreous floaters (1-8%) Serious: Myocardial infarction， Arterial thrombosis (Up to 6.4%)， Hypersensitivity reaction (<1%)， Cerebrovascular accident， Cataract (Adult， up to 19%; pediatric， 1%)， Endophthalmitis (<1%)， Raised intraocular pressure (2-9%)， Retinal detachment (Up to 6%)， Retinal pigment epithelial detachment (3-5%)， Retinal tear (<1%)， Retinal venous tortuosity， Vitreous detachment (2-8%),2-8℃避光避免冷凍,Wet type (Neovascular) of age-related macular degeneration (wAMD): 2 mg every 4 weeks for the first 3 injections then every 8 weeks thereafter. Macular edema following central retinal vein occlusion (CRVO): 2 mg every 4 weeks via IVIA. Diabetic macular edema: 2 mg every 4 weeks for the first 5 injections， followed by 2 mg every 8 weeks. Macular edema induced visual impairment following branch retinal vein occlusion (BRVO): 2 mg every 4 weeks for the first 6 injections， followed by 2 mg every 8 weeks. Choroidal neovascularization(CNV) following pathological myopia: 2 mg single dose via IVIA. May repeat 1 to 3 times a year with the 1 month- interval according to the doctor's judgment on vision and/or anatomy.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVI;,,,,,僅供眼科玻璃體內注射用。EYLEA 必須由合格醫師注射。
IENH,Trastuzumab Deruxtecan,Enhertu inj 100mg,RACA,Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.,There are no contraindications listed in the manufacturer's labeling.,Nausea， fatigue， vomiting， alopecia， constipation， decreased appetite， anemia， neutropenia， diarrhea， leukopenia， cough， and thrombocytopenia. Interstitial lung disease (ILD)， pneumonitis， and left ventricular dysfunction.,2-8℃冷藏,5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.,無需調整劑量,[仿單] 目前未知ENHERTUR是否會分泌至人體乳汁中，亦未知對哺乳嬰兒可能造成的影響。 因為哺乳嬰兒有發生嚴重不良反應的潛在可能，女性應於初次施用前停止哺乳。 女性可於結束治療7個月後開始哺乳。,無需調整劑量,不可使用,Uknown 沒有資料,[仿單] 施用於懷孕女性可能導致胎兒傷害。目前並無使用於懷孕女性的資料。 不建議施用於懷孕女性，應在病人懷孕前告知病人藥物對於胎兒的潛在風險。 若女性於治療期間或最後一劑後7個月內懷孕，必須立即聯絡醫師，建議進行密切監測。,Unknown 沒有資料,[仿單] 目前未知ENHERTUR是否會分泌至人體乳汁中，亦未知對哺乳嬰兒可能造成的影響。 因為哺乳嬰兒有發生嚴重不良反應的潛在可能，女性應於初次施用前停止哺乳。 女性可於結束治療7個月後開始哺乳。,IVD;,Sterile Water for Injection 5 mL per 100 mg vial,【D5W】可選 仿單建議。,,Reconstitute each 100 mg vial with 5 mL of Sterile Water for Injection (final 20 mg/mL). Dilute in 100 mL of 5% Dextrose Injection. FIRST infusion over 90 minutes; subsequent infusions over 30 minutes if prior infusions were well tolerated. Cover the infusion bag to protect from light. Administer with an infusion set made of polyolefin or polybutadiene and a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter.,若出現輸注相關症狀，應降低輸注速率或中斷輸注。若發生嚴重輸注反應，應永久停用。
IAGG,Tirofiban,Aggrastat inj 12.5mg/50mL,HEMT,Unstable angina/non-ST-elevation myocardial infarction: To decrease the rate of thrombotic cardiovascular events (combined end point of death， MI， or refractory ischemia/repeat cardiac procedure) in patients with non-ST-elevation acute coronary syndrome (unstable angina/non-ST-elevation myocardial infarction.,Severe hypersensitivity reaction (ie， anaphylactic reaction) to tirofiban or any component of the formulation; history of thrombocytopenia following prior exposure to tirofiban; active internal bleeding or a history of bleeding diathesis， major surgical procedure， or severe physical trauma within the previous month.,>10%: Minor hemorrhage 1% to 10%:Coronary artery dissection， bradycardia， edema， vasodepressor syncope， dizziness， headache， diaphoresis， nausea， pelvic pain， major hemorrhage， leg pain， fever.,15-30°C,Non-ST elevation acute coronary syndromes: (combined with heparin) loading infusion rate as 0.4 mcg/kg/min for 30 minutes， followed by 0.1 mcg/kg/min as maintenance infusion rate for at least 48 hours， up to 108 hours. Percutaneous coronary intervention: (combined with heparin) initial bolus 25 mcg/kg for at least 3 minutes， followed by 0.15 mcg/kg/min as maintenance infusion rate for 12-24 hours， do not more than 48 hours.,無需調整劑量,,需調整劑量,沒有資料,Compatible,Compatible—Maternal Benefit >> Embryo–Fetal Risk,Hold Breast Feeding 暫停哺乳,,IVD;,,【D5W】可選 。【N/S】可選 。,,Maintenance infusion: 0.1-0.15 mcg/kg/minute according to indication.,1.使用前須稀釋不可使用原液，稀釋方法:取250mL注射用N/S或D5W抽掉50mL丟棄。加入50mL藥液稀釋於200mL溶液，使最終濃度為50 mcg/mL。 2.依體重調整適合劑量投與藥品。 3.本藥不可與diazepam 使用同—支靜脈輸注管。 4.避光儲存
EKING,Sulfamethoxazole,Kingmin 4%， 10mL opthalmic solution,TOPH,Trachoma or inclusion conjunctivitis.,Hypersensitivity to sulfonamides or sulfa drugs.,Conjunctival or corneal scarring may occur. Hypersensitivity reaction.,室溫避光保存,Instill a few drops at a time， 3 to 4 times daily.,無需調整劑量,Drugs in pregnancy and lactation(11th): SULFONAMIDES Anti-infective: Limited Human Data—Potential Toxicity [仿單]無相關紀載,無需調整劑量,沒有資料,Uknown 沒有資料,Drugs in pregnancy and lactation(11th): SULFONAMIDES Anti-infective: Human Data Suggest Risk in 3rd Trimester [仿單]無相關紀載,Unknown 沒有資料,Drugs in pregnancy and lactation(11th): SULFONAMIDES Anti-infective: Limited Human Data—Potential Toxicity [仿單]無相關紀載,OD;OL;OU;,,,,,
IETP,Ertapenem,Ertapenem inj 1gm,QANB,Treat moderate to severe infections caused by microorganisms susceptible to Ertapenem. Empiric therapy in the following infections before the causative pathogens have been identified: • Complicated intra-abdominal infections， • Complicated skin and skin structure infections • Community-acquired pneumonia • Complicated urinary tract infections， including pyelonephritis • Acute pelvic infections， including postpartum endometritis， septic abortion， and gynecological infections after surgery.,Anaphylactic reaction to beta-lactam antibiotics. Hypersensitivity to ertapenem sodium or to any other component of the product or other drugs in the carbapenem class. Hypersensitivity to amide-type local anesthetics due to lidocaine hydrochloride used as a diluent with IM route only.,[Common] Injection site pain (5.5%)， Abdominal pain (3.6-4.7%)， Constipation (2.3-4%)， Diarrhea (6.5-11.7%)， Nausea (Adult， 6.4-8.5%; pediatric， >0.5%)， Vomiting (2.1-10.2%)， Headache (4.4-6.8%)， Vaginitis (1.4-3.3%)， Infusion reaction (5.4-7.1%) [Serious] Cardiac arrest (>0.1%)， Heart failure (>0.1%)， Necrosis (>0.1%)， Clostridioides difficile infection (>0.1%)， Congenital pyloric stenosis (>0.1%)， Gastrointestinal hemorrhage (>0.1%)， Large intestine anastomotic leak (>0.5%)， Anaphylaxis， Hypersensitivity reaction， Cerebrovascular accident (>0.5%)， Seizure (>0.1-0.5%)， Subdural hemorrhage (>0.1%)， Renal impairment (>0.1%)， Atelectasis (3.4%)， Hemoptysis (>0.1%)， Hypoxemia (>0.1%)， Pleural effusion (>0.1%)， Respiratory distress (>0.1%)， Sepsis (>0.1%)， Septic shock (>0.1%),凍晶乾粉之儲存不可超過 25°C,Patients aged 13 years and older: 1 gm IV/IM q24h Children aged 3 months to 12 years: 15 mg/kg IV/IM， divided q12h (max 1 gm/day). [Sanford Guide 2023] Pediatric (age > 28 days): 30 mg/kg/day， divided q12h (max 1 gm/day).,無需調整劑量,[仿單]目前Ertapenem會分泌至人類的乳汁中。 當授乳婦女接受Ertapenem for Injection治療時，必須謹慎小心。,需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]目前尚無有關懷孕婦女之適當及設計良好的對照試驗。 僅有在對母體及胎兒的潛在益處大於危險性時，才可在懷孕期間使用Ertapenem for Injection。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前Ertapenem會分泌至人類的乳汁中。 當授乳婦女接受Ertapenem for Injection治療時，必須謹慎小心。,IM;IVD;,IVD: Reconstitute 1gm vial with 10mL water for injection or Normal Saline 10mL. Shake well. Deep IM: Reconstitute 1 gm vial with 3.2 mL of lidocaine HCl 1% or 2% injection (without epinephrine). Shake well. Use within 1 hour of preparation.,【N/S】可選 仿單建議。,,After reconstitution， further dilute dose with Normal Saline; for adolescents and adults (age >= 13 years)， transfer dose to 50 mL Normal Saline; for children (3 months to 12 years)， dilute dose to a final concentration<=20 mg/mL. Infuse over 30 minutes; complete infusion within 6 hours of reconstitution.,1. 不可以將Ertapenem for Injection與其他藥品混合或同時輸注。 2. 不可以使用含有葡萄糖(α-D-GLUCOSE)的稀釋液。 3. 注射乾粉經溶解並立即以0.9%氯化鈉注射液50mL稀釋後，可放在室溫(25°C)於6小時內使用，也可冷藏(5°C)至多24小時，自冷藏取出後須於4小時內使用。不可冷凍。
OLOW,Lorazepam,Lowen 0.5mg,CNEU,Anxiety state.,Hypersensitivity to benzodiazepines or any component of the product， polyethylene glycol， propylene glycol. Acute narrow-angle glaucoma. Respiratory insufficiency， severe; in the absence of resuscitative equipment. Sleep apnea syndrome.,Common: Neurologic: Asthenia (4.2%)， Dizziness (6.9%)， Sedated (15.9%)， Unsteadiness present (3.4%)， Depression Serious: Acidosis (<1%)， Delirium,30℃以下避光且避熱,Anxiety: 1-4 mg/day divided into 2-3 doses. Insomnia: 2-4 mg once a day， before bedtime. Prior to surgery: 2-4 mg on the night before or 1-2 hours before surgery. Elderly or debilitated patients: 1-2 mg/day in divided doses.,無需調整劑量,BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible^1 ^1 Potential toxicity if combined with other CNS depressants.,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible^1 ^1 Potential toxicity if combined with other CNS depressants.,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OMIRA1,Pramipexole,1mg MIRAPEX,CNEU,Treatment of signs & symptoms of Parkinson's disease.,Hypersensitivity. Lactation.,Abnormal behaviors (eg， binge eating， compulsive shopping， hypersexuality， pathological gambling)， abnormal dreams， amnesia， cardiac failure， confusion， constipation， delusion， dizziness， dyskinesia， dyspnoea， fatigue， hallucinations， headache， hiccups， hyperkinesia， hyperphagia， hypotension， inappropriate antidiuretic hormone secretion， insomnia， libido disorders， nausea， paranoia， peripheral oedema; pneumonia; pruritus， rash; restlessness， somnolence， sudden onset of sleep， syncope， visual impairment including diplopia， blurred vision， reduced visual acuity; vomiting， decreased appetite， increased/decreased wt.,30℃以下,Parkinson's disease: start from 0.125 mg TID for one week， increased to 0.25 mg TID in the second week， and increased to 0.5 mg TID in the third week. Dose may be further increased by 0.75 mg weekly. Maximum: 4.5 mg/day. When discontinuing therapy， taper off at a rate of 0.75 mg per day until the daily dose has been reduced to 0.75 mg. Thereafter， the dose may be reduced by 0.375 mg per day. In patients with creatinine clearance 20-50 mL/min， start from 0.125 mg BID. Maximum: 2.25 mg/day. In patients with creatinine clearance <20 mL/min， start from 0.125 mg QD. Maximum: 1.5 mg/day. Restless legs syndrome: 0.125 mg once daily initially， taken 2 to 3 hours prior to bedtime; may increase by doubling dose every 4 to 7 days if needed; maximum: 0.75 mg/day.,無需調整劑量,,無需調整劑量,,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OPAD,Mebeverine,Padalin 100mg,ALIM,Gastrointestinal tract spasm， enteritis， gastritis， irritable bowel syndrome.,Hypersensitivity to mebeverine. Paralytic ileus. Severe hepatic impairment.,Dizziness， drowsiness， headache， constipation， nausea， loss of appetite， allergies， hypersensitivity (e.g. urticaria， erythematous rash， angioedema).,室溫25℃以下,Adult: 200 mg bid， before meals.,無需調整劑量,[Micromedex] Do not administer mebeverine to women who are breastfeeding.,無需調整劑量,沒有資料,Uknown 沒有資料,[Micromedex] Do not administer mebeverine during pregnancy.,Unknown 沒有資料,[Micromedex] Do not administer mebeverine to women who are breastfeeding.,AC;PC;PO;,,,,,
OASZ,Azathioprine,Asazipam 50mg,HIMM,Adjuvant therapy for preventing rejection in kidney transplant surgery， systemic lupus erythematosus， severe rheumatoid arthritis， acute and chronic leukemia.,Hypersensitivity to azathioprine or 6-mercaptopurine (6-MP). Pregnant or potentially pregnant patients. Patients with rheumatoid arthritis previously treated with alkylating agents.,Common: Nausea and vomiting (12%) Serious: Pericarditis， Skin cancer， Pancreatitis， Hypersensitivity， Acute myeloid leukemia， Hematologic toxicity， Leukopenia (Renal transplant， >50%; rheumatoid arthritis， 28%)， Leukopenia (Severe)， <2500 cells/mm (renal transplant， 16%; rheumatoid arthritis， 5.3%)， Macrocytic anemia， Myelodysplastic syndrome， Myelosuppression (5%)， Pancytopenia， Thrombocytopenia， Hepatotoxicity (<1%)， Lymphoma involves liver， Veno-occlusive disease of the liver， Hypersensitivity reaction， Malignant lymphoma (0.5%)， T-cell lymphoma， Hepatosplenic， Progressive multifocal leukoencephalopathy， Adenocarcinoma of lung， Infectious disease (renal transplant， 20%; rheumatoid arthritis， <1%)， Neoplastic disease (0.5-11.9%),25℃以下,Organ transplantation: Adults and children - up to 5 mg/kg/day; maintenance: 1-4 mg/kg/ay. Other conditions:Adults and children - 1-3 mg/kg/day. If the patient continues to take the medication for 3 months without any improvement in symptoms， discontinuation may be considered.,無需調整劑量,[仿單] 6-Mercaptopurine已經被確認出現在接受Azathioprine治療母親之初乳及乳汁中。,無需調整劑量,沒有資料,Human data suggest risk in 3 rd trimester,[仿單] 懷孕期間要使用Azathioprine需仔細評估危險性與相對之益處。 孕婦使用Azathioprine後，於胎兒血液及羊水中發現低濃度的Azathioprine及其代謝物。 已有報告母親懷孕時期服用Azathioprine，部份新生兒出現白血球減少，及／或血小板減少症。 因此懷孕期間需額外小心監測血液。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 6-Mercaptopurine已經被確認出現在接受Azathioprine治療母親之初乳及乳汁中。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為免疫抑制劑，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OMEPR,Methylprednisolone,Methylprednisolone 4mg,HM,RA， acute & subacute bursitis， exfoliative dermatitis， allergic rhinitis， bronchial asthma， contact dermatitis & allergic conjunctivitis.,Systemic fungal infection; immunization. Lactation,Fluid & electrolyte disturbances; muscle weakness， aseptic osteonecrosis， osteoporosis; peptic ulcer with perforation， hemorrhage， abdominal distention， impaired wound healing; increased intraocular pressure; Cushingoid state， growth suppression， menstrual irregularities， posterior subcapsular cataracts.,25℃以下避光儲存,4-48mg/day,無需調整劑量,Corticosteroids are generally considered acceptable in breastfeeding women when used in usual doses; however， monitoring of the breastfeeding infant is recommended (WHO 2002). Methylprednisolone is classified as a nonfluorinated corticosteroid; when systemic corticosteroids are needed in a lactating woman for rheumatic disorders， low doses of nonfluorinated corticosteroids are preferred (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,無需調整劑量,除非治療上需要,Uknown 沒有資料,Methylprednisolone is classified as a nonfluorinated corticosteroid. When systemic corticosteroids are needed in pregnancy for rheumatic disorders， nonfluorinated corticosteroids are preferred. Chronic high doses should be avoided (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,Unknown 沒有資料,Corticosteroids are generally considered acceptable in breastfeeding women when used in usual doses; however， monitoring of the breastfeeding infant is recommended (WHO 2002). Methylprednisolone is classified as a nonfluorinated corticosteroid; when systemic corticosteroids are needed in a lactating woman for rheumatic disorders， low doses of nonfluorinated corticosteroids are preferred (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,AC;AC15;PC;PO;WM;,,,,,
EFLUT,Fluticasone,Fluticosone cream 0.05%， 5gm,TDER,Relief of the inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses such as: eczema including atopic， infantile & discoid eczemas; prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses including lichen simplex; lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus; an adjunct to systemic steroid therapy in generalised erythroderma; insect bite reactions; prickly heat.,Rosacea， acne vulgaris， perioral dermatitis; primary cutaneous viral infections (eg. Herpes simplex， chickenpox; perianal & genital pruritus， dermatoses in infant < 3 month including dermatitis & napkin eruptions. Primarily infected skin lesions caused by infection with fungi or bacteria.,Local burning， pruritus， local atrophic skin changes. Secondary infection， exacerbation of the signs & symptoms of the dermatoses， hypercorticism. Neurologic: Headache (8% to 9% ) Respiratory: Epistaxis (4% to 20% ),25℃以下,Inflammatory dermatoses Adult， children， infants >=3 months Apply thinly to the affected skin areas once or BID.,無需調整劑量,,無需調整劑量,沒有資料,Compatible,Respiratory (Corticosteroid) - Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
IHMCP,Fibrinogen human,Haemocomplettan P inj 1gm/vial,HEMT,Bleeding disorder. 1) Congenital hypo-， dys-， or afibrinogenemia. 2) Acquired hypofibrinogenemia caused by the following symptoms: a. Severe liver parenchymal injury leading to synthesis disorder. b. Excessive consumption due to disseminated intravascular coagulation (DIC) and hyperfibrinolysis response.,Contraindicated in individuals allergic to the active ingredient or any excipients. Avoid in cases of thrombosis or myocardial infarction， unless in extremely severe and life-threatening bleeding situations.,Common: Nausea (>5%)， Vomiting (>5%)， Thrombocytosis (>5%)， Headache (>1%)， Fever (>1%) Serious: Myocardial infarction， Arterial thrombosis， Deep venous thrombosis， Thromboembolic disorder， Anaphylaxis， Hypersensitivity reaction， Pulmonary embolism,2-8℃，勿冷凍，小瓶應放置於外盒內避光,Dosage for replacement therapy and duration should be based on disease severity， bleeding location and extent， and the patient's clinical condition. To calculate the patient's dosage， measure functional fibrinogen levels. Individual dosing and frequency should be determined based on routine measurements of plasma fibrinogen concentration， and continuous monitoring of the patient's clinical condition and use of other replacement therapies. Normal plasma fibrinogen: 1.5-4.5g/L. Critical plasma fibrinogen: 0.5-1.0g/L or below may result in bleeding. (1) For patients with congenital hypo-， dys-， or afibrinogenemia and known bleeding tendencies for prophylaxis: - Preventive treatment is recommended to raise fibrinogen levels to 1 g/L to ensure safe hemostasis and maintain fibrinogen levels >0.5g/L until complete wound healing. - For surgical or bleeding event treatment: Fibrinogen dosage (mg/kg) = [(Target concentration in g/L) - (Measured concentration in g/L)] / 0.017 (g/L per mg/kg). - Appropriate subsequent dosages should be based on the patient's clinical condition and laboratory reports. - Half-life of fibrinogen is 3-4 days. Repeated administration is usually unnecessary in the absence of consumption. (2) For bleeding treatment: Adults: 1-2g (or 30 mg/kg) as needed， followed by additional transfusions. Severe bleeding: 4-8g may be required. Children: 20-30mg/kg.,無需調整劑量,[仿單] Haemocomplettan 是否會分泌於人類乳汁仍未知。目前尚未建立人體血漿纖維蛋白原 產品於哺乳期間使用之安全性的臨床對照試驗。對授乳孩童的風險是無法排除的。 應考量哺乳對於孩童的利益以及治療對於女性的利益，以決定是否中斷哺乳或是中斷/避免 以Haemocomplettan 治療。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 尚未施行 Haemocomplettan 之動物生殖研究。由於是人類來源之活性成分，其與患者自身 蛋白質的分解代謝是相同的。這些人體血液的生理組成對於生殖或是胎兒未預期造成副作用。 目前尚未建立人體血漿纖維蛋白原產品使用於人體懷孕期間的安全性對照臨床試驗。 纖維蛋白原產品治療產科併發症之臨床經驗，顯示對於懷孕期間或胎兒或新生兒的健康無不良影響是可預期的。,Unknown 沒有資料,[仿單] Haemocomplettan 是否會分泌於人類乳汁仍未知。目前尚未建立人體血漿纖維蛋白原 產品於哺乳期間使用之安全性的臨床對照試驗。對授乳孩童的風險是無法排除的。 應考量哺乳對於孩童的利益以及治療對於女性的利益，以決定是否中斷哺乳或是中斷/避免 以Haemocomplettan 治療。,IVD;IVPUSH;,每瓶 Haemocomplettan 1g/vial以50mL注射用水配製。(20mg/mL),,給藥速率不超過5mL/minute。給藥前應回溫。,給藥速率不超過5mL/minute。給藥前應回溫。,1. Haemocomplettan 1g/vial以50mL注射用水配製，配置後得20毫克/毫升的人體纖維蛋白原 2. 配製後溶液應於給藥前回溫至室溫或體溫，然後以患者最舒適的速度緩慢注射或輸注。注射或輸速度約不超過5mL/minute。 3. 應將配液穿刺器插入產品瓶塞上，將針筒接到盒內隨附的過濾器，再以針筒由配液穿刺器抽取溶液。
ISLIP,MCT + Fish oil + Olive oil + Soybean oil,SMOFlipid inj 20% 250mL,NUTR,Use as part of parenteral nutrition for parients who cannot take sudiffient oral or enteral nutrition.,- Individuals who are high sensitivity to the main ingredients or excipients of this product， such as egg， soy， or peanut protein. - Severe hyperlipidemia. - Severe liver dysfunction. - Severe coagulation abnormalities. - Severe renal dysfunction and have not undergone blood filtration or dialysis treatment. - Acute shock. - Contraindications for infusion therapy: acute pulmonary edema， excessive body fluid volume， and decompensated heart failure. - Unstable conditions (e.g.， severe post-traumatic state， uncompensated diabetes， acute myocardial infarction， stroke， embolism， metabolic acidosis， severe sepsis， and hypovolemic dehydration).,Common: Hyperglycemia (2-5%)， Nausea (Adult， 2%; pediatric， 18%)， Vomiting (7-9%)， Anemia (Adult， 2%; pediatric， 18%) Serious: Aluminum poisoning， Hypertriglyceridemia， Hypervolemia (<1%)， Refeeding syndrome， Thrombophlebitis (<1%) Hepatic: Cholestasis of parenteral nutrition (2.4-4%)， Parenteral nutrition associated liver disease， Hypersensitivity reaction， Fat overload syndrome， Infectious disease， Sepsis (2%),不得超過25°C。不可冷凍。,Adults: 1-2 gm of fat/kg/day (5-10 mL/kg/day). Infusion rate: 0.125-0.15 gm of fat/kg/hour (0.63-0.75 mL/kg/hour) Newborns and infants: 0.5-1 gm of fat/kg/day; Maximum 3 gm of fat/kg/day (15 mL/kg/day). Increase dose at a rate of 0.5-1 gm of fat/kg/day. Infusion rate: <= 0.125 gm of fat/kg/hour. Children: <= 2 gm of fat/kg/day (10 mL/kg/day). Infusion rate: <= 0.15 gm of fat/kg/hour.,無需調整劑量,[仿單] 目前並無孕婦或哺乳婦女使用SMOFlipid的資料，亦無動物的生殖毒性研究資料。 懷孕和哺乳期間靜脈營養輸注可能有其必要，只有經過仔細考量後， 才可給予孕婦和哺乳婦女SMOFlipid。,無需調整劑量,沒有資料,Compatible,[仿單] 目前並無孕婦或哺乳婦女使用SMOFlipid的資料，亦無動物的生殖毒性研究資料。 懷孕和哺乳期間靜脈營養輸注可能有其必要，只有經過仔細考量後， 才可給予孕婦和哺乳婦女SMOFlipid。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 目前並無孕婦或哺乳婦女使用SMOFlipid的資料，亦無動物的生殖毒性研究資料。 懷孕和哺乳期間靜脈營養輸注可能有其必要，只有經過仔細考量後， 才可給予孕婦和哺乳婦女SMOFlipid。,IVD;,,,,Adults infusion rate: 0.125-0.15 gm of fat/kg/hour (0.63-0.75 mL/kg/hour) Newborns/infants infusion rate: <= 0.125 gm of fat/kg/hour (0.63 mL/kg/hour) Children infusion rate: <= 0.15 gm of fat/kg/hour (0.75 mL/kg/hour),1. 可由周邊或中心靜脈輸注給藥。 2. 當用於新生兒和 2 歲以下兒童時，溶液和輸液袋應避光直至給藥完成。 3. 使用前須確認乳劑沒有層相分離或沉澱物，呈均質狀態才可使用。
OKIS,Ribociclib,Kisqali 200mg,RACA,Treatment of hormone receptor (HR)-positive， human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy.,Known hypersensitivity to Ribociclib succinate.,>10%: Cardiovascular: Peripheral edema (12%) Central nervous system: Fatigue (37%)， headache (22%)， insomnia (12%) Dermatologic: Alopecia (33%)， skin rash (17%)， pruritus (14%) Endocrine & metabolic: Decreased serum potassium (11%) Gastrointestinal: Nausea (52%)， diarrhea (35%)， vomiting (29%)， constipation (25%)， decreased appetite (19%)， stomatitis (12%)， abdominal pain (11%) Genitourinary: Urinary tract infection (11%) Hematologic & oncologic: Neutropenia (75%; grade 3: 50%; grade 4: 10%)， leukopenia (33%; grade 3: 20%; grade 4: 1%)， decreased platelet count (29%; grade 3: 1%)， anemia (18%; grade 4: <1%)， abnormal phosphorus levels (decreased; 13%; grade 3: 5%; grade 4: 1%)， lymphocytopenia (11%; grade 3: 6%; grade 4: 1%) Hepatic: Increased serum ALT (<46%)， increased serum AST (<44%)， increased serum bilirubin (18%) Neuromuscular & skeletal: Back pain (20%) Renal: Increased serum creatinine (20%) Respiratory: Dyspnea (12%) Miscellaneous: Fever (13%),30℃以下,600 mg orally once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. KISQALI can be taken with or without food. Coadminister KISQALI with letrozole 2.5 mg taken once daily throughout the 28-day cycle. Patients should take their dose of KISQALI and letrozole at approximately the same time each day， preferably in themorning.  Recommended Dose Modification for Adverse Reactions: - Starting dose: 600 mg/day (three 200 mg tablets) - 1st dose reduction: 400 mg/day (two 200 mg tablets) - 2nd dose reduction: 200 mg/day (one 200 mg tablet) If further dose reduction below 200 mg/day is required， discontinue the treatment.,需調整劑量,,需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,PO;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。仿單建議應整顆吞服，勿咬嚼或壓碎。
ICOMDBA5,SARS-CoV-2 Spike glycoprotein [mRNA],BA4/5次世代Moderna(Covid19) 0.5mL/dose(2.5mL/vial),HIMM,Moderna COVID-19 Vaccine， for active immunization to prevent COVID-19 in individuals 18 years of age and older.,History of a severe allergic reaction (e.g.， anaphylaxis) to any component of the Moderna COVID-19 Vaccine.,erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.,-50℃至-15℃可保存9個月。2-8℃避免光照，可保存30天。離冷藏於8-25℃只可保存24小時,IM， 0.5 mL， > or = 12 years， As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine， bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule. IM， 0.25 mL， 6-11 years， As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine， bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule.,無需調整劑量,[仿單]由於哺乳婦女接種Spikevax原病毒株疫苗後之全身性暴露可被忽略，預期對於餵哺母乳之新生兒/嬰兒不具影響。 觀察性資料顯示哺乳婦女接種疫苗後，並未出現對餵哺母乳之新生兒/嬰兒有害的影響。 哺乳期間可以接種Spikevax原病毒株疫苗。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]大量的觀察性資料顯示，孕婦在第二與第三孕期接種 Spikevax 原病毒株疫苗並未增加不良懷孕結果。 雖然在第一孕期接種的懷孕結果資料有限，但是並未發現流產風險有上升的現象。 動物試驗並未顯示Spikevax 原病毒株疫苗會對懷孕、胚胎／胎兒發育、分娩或產後發育會造成直接或間接有害的影響。 懷孕期間可以接種Spikevax 原病毒株疫苗。,Unknown 沒有資料,[仿單]由於哺乳婦女接種Spikevax原病毒株疫苗後之全身性暴露可被忽略，預期對於餵哺母乳之新生兒/嬰兒不具影響。 觀察性資料顯示哺乳婦女接種疫苗後，並未出現對餵哺母乳之新生兒/嬰兒有害的影響。 哺乳期間可以接種Spikevax原病毒株疫苗。,IM;,,,,,1. 本藥為多劑量藥瓶。每瓶可抽取5劑，每劑0.5mL。 2. 未開封藥瓶，冷藏於2-8℃下可保存30天，室溫保存於8-25℃下可保存24小時。已抽液藥瓶，冷藏或室溫下可保存19小時，19小時後須丟棄。 3. 解凍後，請勿重新冷凍。使用前請先將藥瓶解凍，解凍方式：放置冷藏室(2-8℃)2小時30分鐘，並於施打前請將藥瓶放置室溫(15-25℃)15分鐘。或者放置室溫(15至25℃)1小時。 4. 本疫苗應以肌肉注射方式施打，理想注射部位為上臂三角肌。請勿以血管內注射、皮下注射或皮內注射方式施打本疫苗。
EPMT,Permethrin,Permethrin cream 5%， 30gm (專案進口),TDER,Permethrin 5% w/w Cream is indicated for the treatment of scabies.,Hypersensitivity to any pyrethroid or pyrethrin， or to any component of the formulation.,Localized burning， localized numbness， tingling of skin， pruritus， erythema， skin rash (scalp)， stinging of the skin， localized edema.,25℃以下,Scabies: Topical: Cream 5%: Thoroughly massage cream (30 g for average adult) from head to soles of feet; leave on for 8 to 14 hours before removing (shower or bath); for infants and the elderly， also apply on the hairline， neck， scalp， temple， and forehead; may repeat if living mites are observed 14 days after first treatment; one application is generally curative.,無需調整劑量,,無需調整劑量,,Compatible,,Compatible 哺乳時可使用,,EXT;SKIN;TOPI;,,,,,
OFUCO,Acetaminophen,Fucole Paran 500mg,CNEU,,適應症: Relief of painful disorders such as headache， dysmenorrhea， conditions involving musculoskeletal pain， myalgias & neuralgias. After dental work， tooth extractions & in teething. As an analgesic & antipyretic in conditions accompanied by discomfort & fever， such as common cold & viral infections. 副作用: Acetaminophen has rarely been found to produce any side effects. It is usually well tolerated by aspirin-sensitive patients. Severe recurrent pain or high continued fever may indicate a serious conditions. Under these circumstances consult a physician. 禁忌:When used for self-medication， do not use with other drug products containing acetaminophen or if allergic to acetaminophen or any of the inactive ingredients.,,室溫,Adult:500 mg q4h as needed， (max. 4 g/day). For long term therapy， not exceeding 2.6 g/day. Child: 10-15 mg/kg q4h as needed， (max. 65 mg/kg/day) not more than 5 doses in each 24 hrs period.,需調整劑量,,需調整劑量,可能安全,Human (and animal) data suggest risk,,Compatible 哺乳時可使用,,AC;AC15;P1;P2;P3;P4;PC;PO;,,,,,
OAVE,Moxifloxacin,Avelox 400mg,QANB,Acute infective exacerbation of the chronic obstructive pulmonary disease. Bacterial conjunctivitis. Bacterial sinusitis， acute. Community-acquired pneumonia. Infection of skin and/or subcutaneous tissue， Complicated. Infection of skin and/or subcutaneous tissue， Uncomplicated. Infectious disease of the abdomen， Complicated. Treatment and Prophylaxis of Plague.,Hypersensitivity to moxifloxacin， other quinolone antibiotics， or any component of the formulation. pregnancy and lactation women.,Common Endocrine metabolic: Hypokalemia (1% ) Gastrointestinal: Abdominal pain (2% )， Constipation (2% )， Diarrhea (6% )， Nausea (7% )， Vomiting (2% ) Hepatic: ALT/SGPT level abnormal (1% ) Neurologic: Dizziness (3% )， Headache (4% ) Ophthalmic: Dry eyes (Ophthalmic， 1% to 6% )， Keratitis (Ophthalmic， 1% to 6% )， Pain in eye (Ophthalmic， 1% to 6% )， Reduced visual acuity (Ophthalmic， 1% to 6% ) Serious Cardiovascular: Aortic aneurysm， Or dissection， Prolonged QT interval (Oral/IV， 0.1% to less than 1% )， Torsades de pointes Dermatologic: Rash (Oral/IV， 0.1% to less than 1% )， Stevens-Johnson syndrome， Toxic epidermal necrolysis Endocrine metabolic: Hyperglycemia (Oral/IV， 0.1% to less than 1% )， Hypoglycemia Gastrointestinal: Clostridium difficile diarrhea Hematologic: Agranulocytosis， Aplastic anemia， Hemolytic anemia， Pancytopenia， Thrombocytopenia (Oral/IV， 0.1% to less than 1% ) Hepatic: Hepatic necrosis， Hepatitis， Liver failure Immunologic: Hypersensitivity reaction， Non-allergic anaphylaxis Musculoskeletal: Myasthenia gravis， Exacerbation， Rupture of tendon， Tendinitis Neurologic: Disorientated， Disturbance of attention， Guillain-Barre syndrome， Memory impairment， Peripheral neuropathy， Pseudotumor cerebri， Raised intracranial pressure， Seizure Ophthalmic: Retinal detachment Psychiatric: Agitation， Feeling nervous (0.1% to less than 1% )， Paranoid disorder， Suicidal Renal: Renal failure (0.1% to less than 1% ) Respiratory: Extrinsic allergic alveolitis Other: Serum sickness due to drug,不可超過30℃，乾燥處,Community-acquired pneumonia， Adult: 400 mg once daily for 10 days. Acute bacterial exacerbation of chronic bronchitis， Adult: 400 mg once daily for 5-10 days. Acute bacterial sinusitis， Adult: 400 mg once daily for 7 days. Pelvic inflammatory disease， Adult: In combination with another antibacterial in mild to moderate cases: 400 mg once daily for 14 days. Complicated skin and skin structure infections， Adult: 400 mg once daily for 7-21 days.,無需調整劑量,[仿單]如同其他fluoroquinolones，本藥已知會導致幼年動物負重關節軟骨的損傷，臨床前資料顯示少量的moxifloxacin會分泌到人體乳汁中，目前尚無泌乳或哺乳婦女的資料， 因此使用moxifloxacin於哺乳婦女是禁止的。,無需調整劑量,沒有資料,Contraindicated,[仿單]懷孕婦女使用本藥的安全性資料尚未被建立，可逆性關節損傷發生於接受fluoroquinolones治療的小孩，然而此現象並未被報導發生於曾經暴露於moxifloxacin的胎兒，動物實驗已顯示具有生殖毒性，對人體潛在的風險目前未知。 因此，本藥於懷孕期的使用是禁止的。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]如同其他fluoroquinolones，本藥已知會導致幼年動物負重關節軟骨的損傷，臨床前資料顯示少量的moxifloxacin會分泌到人體乳汁中，目前尚無泌乳或哺乳婦女的資料， 因此使用moxifloxacin於哺乳婦女是禁止的。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議應與水整顆吞服。
IKCL5S,Potassium Chloride,20mEq KCl in【D5W 500mL】,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia， pain or phlebitis at injection site.,,Adult: Initial loading dose: 40~60 mEq， with ECG monitoring then based on serum potassium levels， Serum K>2.5 mEq/L: concentration < 30 mEq/L， with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia， treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,
OMOL,Molnupiravir,Molnupiravir 200mg (公費),QANB,An Emergency Use Authorization (EUA) for the emergency use of Molnupiravir for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in certain adults who are at high-risk for progression to severe COVID-19.,NOT for use in patients who are less than 18 years of age. NOT for initiation of treatment in patients requiring hospitalization due to COVID-19. NOT for use for longer than 5 consecutive days. NOT for use as pre-exposure or as post-exposure prophylaxis for prevention of COVID-19. Not recommended for use during pregnancy.,Common Gastrointestinal: Diarrhea (2% to 3% )， Nausea (2% ) Neurologic: Dizziness (1% )， Headache (1% ),在30℃以下保存,800 mg (four 200-mg capsules) orally every 12 hours for 5 days with or without food; administer as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset,無需調整劑量,[仿單]目前並無任何關於molnupiravir或其代謝物是否會出現於人類的乳汁方面的資料。曾在投予molnupiravir之授乳大鼠所哺乳之仔鼠的血漿中檢出NHC。目前並不確知molnupiravir是否會對餵哺母乳的嬰兒造成影響，或對乳汁生成作用造成影響。 由於嬰兒可能會對molnupiravir產生不良反應，因此，在使用molnupiravir治療期間和使用最後一劑藥物後4天內不建議餵哺母乳。在治療期間和使用最後一劑molnupiravir後4天內，哺乳病人可能要考慮中斷餵哺母乳，也可能要考慮將乳汁吸出並丟棄。 在出生前後發育研究中，對授乳大鼠投予?250毫克/公斤/日之劑量的molnupiravir之後，曾在哺乳仔鼠的血漿中檢出NHC。 根據動物研究的結果，對孕婦投予molnupiravir可能會對胎兒造成傷害。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]不建議於懷孕期間使用molnupiravir，但若處方醫師確認效益超越風險，決定對孕婦使用molnupiravir時，必須向該孕婦詳細告知在懷孕期間使用molnupiravir的風險。處方醫師應於懷孕患者使用molnupiravir期間透過電話：02-66316000或電子郵件: dpoc_taiwan@merck.com通報其曝藥情形，並建議患者依上述聯繫管道將懷孕結果通報給美商默沙東藥廠股份有限公司台灣分公司。 根據動物試驗的資料，對孕婦投予molnupiravir可能會對胎兒造成傷害。目前並無任何對孕婦使用molnupiravir的人類資料可據以評估發生重大出生缺陷、流產或母體或胎兒不良結果的風險；因此，並不建議在懷孕期間使用molnupiravir。一項動物生殖研究顯示，對懷孕大鼠於器官發生期間口服投予molnupiravir之後，在相當於人類在建議人類劑量(RHD)下所達到之人類NHC (N4-hydroxycytidine)暴露量的8倍暴露量下會導致胚胎胎兒死亡和畸形，在人類在RHD劑量下所達到之人類NHC暴露量的?3倍暴露量下會導致胎兒生長減慢。對懷孕兔子於於器官發生期間口服投予molnupiravir之後，在相當於人類在RHD劑量下所達到之人類NHC暴露量的18倍暴露量下會導致胎兒體重減輕。考慮要對孕婦使用molnupiravir時，處方醫師必須向該孕婦說明在懷孕期間使用molnupiravir的已知和潛在效益，以及潛在的風險。只有在醫療照護人員確定對個別孕婦的效益超越風險之後，才可處方molnupiravir給該個別病人。如果決定要在懷孕期間使用molnupiravir，處方醫師必須註記已向該個別孕婦說明在懷孕期間使用molnupiravir的已知和潛在效益，以及潛在的風險。在懷孕期間，未經治療的COVID-19也會為母體和胎兒帶來風險。 目前並不確知本品之適用族群發生重大出生缺陷與流產的估計背景風險。所有的懷孕都有發生出生缺陷、流產或其他不良結果的背景風險。就美國的一般人口而言，在經過臨床確認的懷孕人口中，發生重大出生缺陷與流產的背景風險分別為2至4%與15至20%。 Molnupiravir不建議用於懷孕婦女,Unknown 沒有資料,[仿單]目前並無任何關於molnupiravir或其代謝物是否會出現於人類的乳汁方面的資料。曾在投予molnupiravir之授乳大鼠所哺乳之仔鼠的血漿中檢出NHC。目前並不確知molnupiravir是否會對餵哺母乳的嬰兒造成影響，或對乳汁生成作用造成影響。 由於嬰兒可能會對molnupiravir產生不良反應，因此，在使用molnupiravir治療期間和使用最後一劑藥物後4天內不建議餵哺母乳。在治療期間和使用最後一劑molnupiravir後4天內，哺乳病人可能要考慮中斷餵哺母乳，也可能要考慮將乳汁吸出並丟棄。 在出生前後發育研究中，對授乳大鼠投予?250毫克/公斤/日之劑量的molnupiravir之後，曾在哺乳仔鼠的血漿中檢出NHC。 根據動物研究的結果，對孕婦投予molnupiravir可能會對胎兒造成傷害。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議應整粒吞服。不得打開膠囊。無法吞服患者(依臨床試驗)給藥方法:將四顆膠囊後至於調製杯或注射器中，加水40mL攪拌3分鐘且均勻混合，配製完請盡快服用或管灌，可在服用後再給予240mL以下水分確保所有藥物吞嚥完成。
OKUZ,Sodium polystyrene sulfonate,Kuzem powder 15g/pack,ZADT,Hyperkalemia.,Patients with hypokalemia or those who are hypersensitive.,Gastric irritation， anorexia， nausea， vomiting， constipation， occasional diarrhea; hypokalemia， hypocalcemia， Na retention.,25℃以下乾燥處,(仿單+Uptodate) Adult: Oral: 15 g 1-4 times daily. Rectal: 30-50 g Q6H. Children: Oral: Initail: 1 g/kg/day in divided doses (maximum: 15 g/dose); Maintenance: 0.5 g/kg/day in divided doses. Rectal: 1 g/kg/day. Neonate: Rectal: 0.5-1 g/kg/day. NOTE: Do not mix in orange juice or in any fruit juice known to contain potassium. Shake the suspension well prior to administration. For rectal doses， administer cleansing enema first， then sodium polystyrene sulfonate as a warm emulsion (body temperature). Retain the enema in the colon for at least 30-60 minutes and for 9 hours， if possible (neonates: 30 minutes). Once retention time is complete， irrigate the colon with a nonsodium-containing solution to remove resin.,無需調整劑量,藥品仿單:不建議使用懷孕及哺乳期。,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,藥品仿單:不建議使用懷孕及哺乳期。,AC;AC15;PC;PO;R;RECT;WM;,,,,,
EMET3,Metronidazole,Metrogel 0.75%， 30gm,TDER,,適應症: Topical treatment of inflammatory papules， pustules & erythema of rosacea. 副作用: Transient redness， mild dryness， burning & skin irritation. Watery (tearing) eyes if applied too near the eyes Gastrointestinal: Abdominal discomfort (7%)， Loss of appetite， Metallic taste， Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )， Headache (tablets， 15% to 18%; vaginal gel， 5% )， Peripheral neuropathy Reproductive: Candida infection of genital region， Symptomatic cervicitis/vaginitis (10%)， Vaginal discharge (12%) Other: Drug interaction with alcohol， Disulfiram-like reaction 禁忌: Hypersensitivity to metronidazole.,,室溫,Apply and rub a thin film of Metrogel topical gel twice daily， morning and evening， to the entire affected areas after washing. Significant therapeutic results should be noticed within 3 weeks. Clinical studies have demonstrated continuing improvement through 9 weeks of therapy. Areas to be treated should be cleansed before application of Metrogel. Patients may use cosmetics after application of Metrogel.,,,,沒有資料,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,EXT;,,,,,
ITRO,Sacituzumab govitecan,Trodelvy inj 180mg,RACA,Treatment of locally advanced or metastatic triple-negative breast cancer in adult patients who have previously received two or more systemic therapies (at least one for metastatic disease) and are ineligible for surgical removal.,Severe hypersensitivity reaction to sacituzumab govitecan.,Common: Alopecia (38-49%)， Rash (12-32%)， Abdominal pain (20-31%)， Constipation (34-37%)， Decrease in appetite (21-41%)， Diarrhea， All Grades (59-72%)， Inflammatory disease of mucous membrane (14%)， Nausea， All Grades (57-69%)， Vomiting， All Grades (23-49%)， Neutropenia， All Grades (64%)， Fatigue (51-68%) Serious: Diarrhea， Grade 3 or 4 (9-12%)， Nausea， Grade 3 or 4 (1-6%)， Perforation of intestine (0.09%)， Vomiting， Grade 3 or 4 (1-6%)， Anemia， Grade 3 or 4 (9-21%)， Febrile neutropenia (6-7%)， Neutropenia， Grade 3 or 4 (43-58%)， Anaphylaxis (0.2%)， Hypersensitivity reaction (35%)， Suicide， Pneumonia (4%)， Respiratory failure， Respiratory tract infection (26%),避光冷藏儲存(2-8°C)，請勿冷凍,Recommended dose: 10 mg/kg， not exceeding 10 mg/kg. Administer via intravenous infusion on Days 1 and 8 of a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity. Only use intravenous infusion; no bolus or push administration. Initial infusion: Over 3 hours with 30-minute post-infusion observation. Subsequent infusions: May be infused over 1 to 2 hours or longer if tolerated， with 30-minute post-infusion observation.,無需調整劑量,[仿單] 有關sacituzumab govitecan或SN-38是否會分泌至人類乳汁、對接受母乳哺餵的嬰兒之影響， 或對乳汁生成之影響，目前尚無相關資訊。 鑑於接受母乳哺餵的嬰兒可能會因本品發生嚴重不良反應， 建議哺乳期婦女在TRODELVY治療期間及最後一次給藥後1個月內不要哺乳。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 根據其作用機轉，當對孕婦投藥時可能導致致畸胎性及/或胚胎-胎兒致死性。 目前尚無可用的懷孕婦女數據，因此無法獲知藥物相關風險。 告知孕婦和具生育能力女性，本品對胎兒的潛在風險。 針對適應症族群，重大先天缺陷與流產的背景風險估計值目前不明。,Unknown 沒有資料,[仿單] 有關sacituzumab govitecan或SN-38是否會分泌至人類乳汁、對接受母乳哺餵的嬰兒之影響， 或對乳汁生成之影響，目前尚無相關資訊。 鑑於接受母乳哺餵的嬰兒可能會因本品發生嚴重不良反應， 建議哺乳期婦女在TRODELVY治療期間及最後一次給藥後1個月內不要哺乳。,IVD;,20mL 0.9% NaCl (Final concentration: 10 mg/mL),【N/S】可選 仿單建議。,,Dilute with 0.9% NaCl solution to a final concentration of 1.1 to 3.4 mg/mL. Infuse over 3 hours for the initial dose. Subsequent infusions may be infused over 1 to 2 hours or longer if tolerated.,1. 僅供靜脈滴注(IVD)給藥，可使用輸注幫浦。輸液袋應避光直到給藥完成，輸液過程中無需遮蓋輸液管線或使用避光管線。可使用輸注幫浦。 2. 稀釋後溶液濃度範圍為1.1 mg/mL至3.4 mg/mL (對於體重<=170kg 病人，總溶液量不應超過 500mL) 3. 含本品溶液的輸液袋於2-8°C冷藏並避光保存最長至24小時。冷藏保存後，稀釋溶液於最高至25°C的室溫下應在8小時內(含輸注所需的時間)投予。 4. 首次輸注：輸注進行時間超過3小時。後續輸注：如果對先前的輸注具有耐受性，則輸注時間可在1至2小時以上。在輸注期間和輸注後至少30分鐘觀察病人是否出現輸注相關反應的徵兆或症狀。
ICLAR2,Gadoterate meglumine,Clariscan inj 0.5 mmol/mL， 20mL/Bot,SCAN,MRI contrast agent,Have a history of allergies to gadoteric acid or gadoterate meglumine patient. Contraindications for MRI， such as the patient with rhythm regulators and those with vascular clamps.,1% to 10%:Central nervous system: Headache (<=1%)Gastrointestinal: Nausea (<=1) <1%， postmarketing， and/or case reports: Altered sense of smell， anaphylactoid reaction， anaphylaxis， angioedema， anxiety， bradycardia， bronchospasm， burning sensation， cardiac arrest， cardiac arrhythmia， circulatory shock， coma， conjunctivitis， convulsions， cyanosis， diarrhea， dizziness， drowsiness， dysgeusia， eyelid edema， fatigue， feeling hot， fever， hyperhidrosis， hypersensitivity reaction， hypertension， hypotension， increased lacrimation， increased serum creatinine， inflammation at injection site， injection site pruritus， injection site reaction (including cold， warmth)， laryngeal discomfort， laryngospasm， limb pain， malaise， muscle spasm， myasthenia， ocular hyperemia， pain， pain at injection site， palpitations， paresthesia， pharyngeal edema， phlebitis (superficial)， presyncope， pruritus， respiratory arrest， sensation of cold， sialorrhea， skin rash， swelling at injection site， syncope， tachycardia， tremor， urticaria， vomiting， weakness,30℃以下,MRI of brain and spine: Adults: The recommended dose is 0.1 mmol/kg(0.2 mL/kg). In patients with brain tumours， an additional dose of 0.2 mmol/kg(0.4 mL/kg)， may improve tumor characterisation and facilitate therapeutic decision making. Children (0-18 years): The recommended and maximum dose of Clariscan is 0.1 mmol/kg. Do not use more than one dose during a scan. Careful consideration in neonates up to 4 weeks and infants up to 1 year of age. Lack of information on repeated administration， Clariscan injections should not be repeated before 7 days. Whole body MRI (including lesions of the liver， kidneys， pancreas， pelvis， lungs， heart， breast， and musculoskeletal system): Adults and children over 6 months: The recommended dose is 0.1 mmol/kg(0.2 mL/kg). Angiography: Adults only: The recommended dose， IV injection is 0.1 mmol/kg(0.2 mL/kg).,需調整劑量,[仿單]目前尚未有gadoteric acid是否會從哺乳期母親乳汁排出的人類研究。 GBCAs用於哺乳母親有限的案例報告顯示0.01％至0.04％母體gadolinium劑量會在排出至人類母乳中。 由於許多藥物都經乳汁排出，所以當gadoteric acid用於哺乳女性時應謹慎。 含gadolinium顯影劑會有極少量由乳汁排出，於臨床劑量，因為乳汁中含量極少且腸胃吸收不佳。 醫師及哺乳的婦女應決定注射後是否繼續哺乳或停止24小時。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]使用gadoteric acid於孕婦的安全性並無資料。動物試驗無直接或間接證據顯示有生殖毒性。 GBCAs穿過人胎盤並導致胎兒暴露和gadolinium殘留，但關於GBCAs與不利胎兒結果之間關聯性人類數據仍有限和不確定。 除非臨床情況必須使用Gadoteric acid否則不應使用於懷孕婦女。,Unknown 沒有資料,[仿單]目前尚未有gadoteric acid是否會從哺乳期母親乳汁排出的人類研究。 GBCAs用於哺乳母親有限的案例報告顯示0.01％至0.04％母體gadolinium劑量會在排出至人類母乳中。 由於許多藥物都經乳汁排出，所以當gadoteric acid用於哺乳女性時應謹慎。 含gadolinium顯影劑會有極少量由乳汁排出，於臨床劑量，因為乳汁中含量極少且腸胃吸收不佳。 醫師及哺乳的婦女應決定注射後是否繼續哺乳或停止24小時。,IV;IVP;IVPUSH;,,,Administer as an IV bolus injection. Infuse at a rate of approximately 2 mL/second. To ensure complete injection of contrast agent， flush line after administration.,,給藥後，應至少觀察半小時，因為臨床經驗顯示大部分不良反應發生在這段時間內。
OARIE,Donepezil,Aricept 10mg orodispersible,CNEU,Treatment of mild to moderate dementia of the Alzheimer's type.,Patients with a known hypersensitivity to donepezil HCl， piperidine derivatives or to any excipients used in Aricept. Use in children: Aricept is not recommended for use in children.,Nausea， diarrhea， insomnia， vomiting， muscle cramp， fatigue & anorexia. Syncopal episodes have been reported. Cardiovascular: Hypertension (3% )， Syncope (2% ) Endocrine metabolic: Weight decreased (3% to 5% ) Gastrointestinal: Diarrhea (5% to 15% )， Loss of appetite (2% to 8% )， Nausea (3% to 19% )， Vomiting (3% to 9% ) Hematologic: Contusion (2% )， Ecchymosis (4% to 5% ) Musculoskeletal: Cramp (3% to 8% )， Increased creatine kinase level (3% ) Neurologic: Asthenia (1% to 2% )， Dizziness (2% to 8% )， Headache (3% to 4% )， Insomnia (2% to 14% )， Somnolence (1% to 2% ) Psychiatric: Depression (2% to 3% )， Dream disorder (3% ) Renal: Urinary incontinence (1% to 3% ) Other: Fatigue (1% to 8% ),30℃以下,Initial， 5 mg orally once daily at bedtime; if suboptimal clinical response， may titrate to 10 mg orally once daily at 4 to 6 weeks.,無需調整劑量,[仿單]Donepezil是否會被分泌至人體乳汁中尚未知悉，授乳婦女服用Aricept時應小心。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,[仿單]在懷孕婦女，尚無充足或控制良好之研究。 懷孕婦女僅能在治療效益高於對胎兒之危險性時才可以服用本藥。 懷孕大鼠和兔子在胎兒器官生成期間口服給予donepezil， 在劑量分別高達每日16 mg/kg及每日10 mg/kg時不會導致畸胎。 大鼠在妊娠晚期和整個泌乳期至斷奶期口服給予donepezil (每日1、3、10 mg/kg)， 在最高劑量組導致死產增加，並且降低產後 4 天之後代存活率。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Donepezil是否會被分泌至人體乳汁中尚未知悉，授乳婦女服用Aricept時應小心。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為口崩錠，可溶水崩散後管灌。
ILID1,Lidocaine,Lidocaine inj 20mg/mL， 1mL局麻,ZANE,Local injectable for anesthesia.,Hypersensitivity to lidocaine or any component of the formulation. History of hypersensitivity to local anesthetics of the amide type. Severe degrees of SA， AV， or intraventricular heart block.,Common Dermatologic: Erythema， Skin irritation Gastrointestinal: Hoarse， Loss of voice， Pain in throat Serious Hematologic: Methemoglobinemia Immunologic: Allergic reaction， Anaphylaxis,25℃以下,Adult Caudal anesthetic: Obstetrical analgesia， Usual dosage: 200 - 300 mg. Surgical anesthesia， Usual dosage: 225 - 300 mg. Should not be administered at intervals of less than 90 minutes. Local anesthetic lumbar epidural block Usual dosage (analgesia): 250 - 300 mg. Usual dosage (anesthesia): 200 - 300 mg. Should not be administered at intervals of less than 90 minutes. Local anesthetic intravenous regional block， Usual dosage: 50 - 300 mg Local anesthesia， by infiltration， Usual dosage: 5 - 300 mg Peripheral block anesthesia， Brachial， intercostal， paravertebral， or pudendal Brachial Nerve Block， Usual dosage: 225 - 300 mg. Intercostal Nerve Block， Usual dosage: 30 mg. Paravertebral Nerve Block， Usual dosage: 30 - 50 mg. Pudendal Nerve Block， Usual dosage: 100 mg. Paracervical block anesthesia， Usual dosage (Obstetrical analgesia): 100 mg on each side injected slowly， with a 5-minute period between sides. Peripheral block anesthesia， Dental， Usual dosage: 20 - 100 mg. Retrobulbar infiltration of local anesthetic， the Recommended dose is 120 - 200 mg. Cervical sympathetic block (Obstetrical )， Usual dosage: 50 mg Lumbar sympathetic block， Usual dosage: 50 - 100 mg Maximum single dose: 4.5 mg/kg or 300 mg total dose but Local anesthetic intravenous regional block， Maximum individual dose: 4 mg/kg. Maximum dose of Dental: 6.6mg/kg or 300 mg total dose each visit.,無需調整劑量,[仿單]授乳期婦女安全性尚未確定。,無需調整劑量,可能安全,Compatible,[仿單]未有相關敘述。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]授乳期婦女安全性尚未確定。,IRR;LA;LI;,,,,,本藥不可用於靜脈給藥。
EECO,Prednisolone,Econopred Plus 1%， 5mL ophthalmic suspension,TOPH,Steroid-responsive inflammatory conditions of the palpebral & bulbar conjunctiva， cornea & anterior segment of the globe.,Viral diseases of the cornea & conjunctiva including epithelial herpes simplex keratitis， vaccinia & varicella; mycobacterial eye infection， fungal diseases of ocular structures & acute untreated purulent ocular infections， Hypersensitivity to prednisolone， any component of the formulation.,IOP elevation w/ possible development of glaucoma & infrequent optic nerve damage， posterior subcapsular cataract formation & delayed wound healing. Acute anterior uveitis， visual field defects， globe perforation， secondary ocular infection.,30℃以下,Instill 2 drops in the affected eye(s) 2 to 4 times daily. Use with antibiotics if bacterial infection. Do not discontinue therapy hastily. If signs and symptoms fail to improve after 2 days， re-evaluate. Do not discontinue therapy prematurely; withdraw therapy with gradual tapering of dose in chronic conditions. Shake well before using.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,Monitor IOP in any patient receiving treatment for >=10 days.
OTELO,Terazosin,Telowsin 2mg,CAVS,Hypertension， benign prostatic hyperplasia (BPH).,Hypersensitivity to terazosin or any component of the formulation,Dizziness， nasal congestion， drowsiness， nausea， peripheral edema， asthenia， postural hypotension.,25℃以下,Benign prostatic hyperplasia: initially 1 mg at bedtime， increase dose in a stepwise fasion to 2 mg， 5 mg， or 10 mg once daily to achieve desired improvement. If no response after 4-6 weeks of 10 mg once daily， may increase to a maximum dose of 20 mg once daily. Hypertension: initially 1 mg at bedtime， then titrate gradually， as needed， based on response and tolerability up to 20 mg/day in 1 or 2 divided doses. Usual dosage: 1-5 mg QD.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;P;P1;P2;P3;P4;PC;PO;,,,,,
LBAR3,Barium sulfate,Baritop LV 300gm,SCAN,■Computerized axial tomography ■Endoscopy of esophagus ■Gastrointestinal investigation ■Radiography of intestine,■colon obstruction， known or suspected ■distal small bowel obstruction， suspected ■duodenal or jejunal obstruction， complete， in newborns ■gastrointestinal tract leakage， possibility of (eg， necrotizing enterocolitis， unexplained pneumoperitoneum， gasless abdomen， other bowel perforation， esophageal perforation， or postoperative anastomosis)， in infants and young children ■gastrointestinal tract perforation， known or suspected ■hypersensitivity to barium sulfate or any product component ■latex allergy or hypersensitivity; balloon retention enema tips contain latex ■obstructing lesions of the small intestine ■procedures requiring small volumes of contrast media in very small preterm infants or young babies ■pyloric stenosis ■rectal biopsy， recent ■rectum inflammation or neoplastic lesions ■swallowing disorders in infants ■tracheoesophageal fistula， suspected,■Cardiovascular: Cardiorespiratory arrest， Edema ■Gastrointestinal: Impaction of intestine， Small bowel obstruction ■Immunologic: Immune hypersensitivity reaction (rare),避免漏氣且存放在室溫乾燥處,Refer to individual product labeling for dosage and administration information.,無需調整劑量,micromedex (Pregnancy Category):Fetal risk is minimal. (TH) micromedex (Breastfeeding):Breastfeeding a) Micromedex Lactation Rating: Infant risk is minimal,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,micromedex (Pregnancy Category):Fetal risk is minimal. (TH) micromedex (Breastfeeding):Breastfeeding a) Micromedex Lactation Rating: Infant risk is minimal,PO;,,,,,
IDUPI2,Dupilumab,Dupixent inj 200mg/1.14mL,TDER,Atopic Dermatitis: For moderate to severe atopic dermatitis in adults and children (6 months and older) with inadequate response to topical prescription treatments or unsuitable for such therapy. Can be used with or without topical corticosteroid therapy. Asthma: As add-on maintenance therapy for asthma patients (6 years and older) with eosinophilic phenotype or corticosteroid-dependent asthma， who are inadequately controlled on medium to high-dose inhaled corticosteroids (ICS) and a second controller (e.g.， LABA， LTRA， LAMA， or methylxanthines)， or on high-dose ICS alone. Chronic Rhinosinusitis with Nasal Polyps: As add-on maintenance therapy for adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who remain uncontrolled despite nasal corticosteroid therapy.,Known hypersensitivity to dupilumab or any of its excipients.,Common: Injection site disorder (Adult， 6-18%; adult and pediatric， 38%)， Oral herpes simplex infection (3-4%)， Pain in throat and mouth (2%)， Herpes simplex (Excluding oral and ophthalmic herpes simplex， 1-2%)， Blepharitis (Up to 5%)， Conjunctivitis (Asthma， 1.5%; atopic dermatitis， 9-20%; chronic rhinosinusitis with nasal polyposis， 2%; prurigo nodularis， 4%)， Dry eyes (Up to 2%)， Itching of eye (1-2%)， Keratitis (Atopic dermatitis， up to 4%) Serious: Arterial thromboembolism (0-0.9%)， Vasculitis， Eosinophil count above the reference range (1-2%)， Hypersensitivity reaction (<1%)， Arthralgia (2-3%)， Pulmonary eosinophilia， Angioedema， Helminth infection,置放在原有紙盒並儲存於冰箱2°-8°C 避免光照,Atopic dermatitis - Adults: 600mg subQ once， then 300mg every 2 weeks. Children (6 months - 5 years): 5 - < 15 kg: 200mg every 4 weeks (Q4W) 15 - < 30 kg: 300mg every 4 weeks (Q4W) Children (6-17 years): 15 - < 30 kg: 600mg (300mg x 2) initially， then 300mg every 4 weeks (Q4W) 30 - < 60 kg: 400mg (200mg x 2) initially， then 200mg every 2 weeks (Q2W) > 60 kg: 600mg (300mg x 2) initially， then 300mg every 2 weeks (Q2W) Asthma - Adults and children (>12 years): Initial 400mg (200mg x 2)， then 200mg every 2 weeks (Q2W). Patients with steroid-dependent asthma， moderate to severe atopic dermatitis， or chronic rhinosinusitis with nasal polyps: Initial 600mg (300mg x 2)， then 300mg every 2 weeks (Q2W). Children (6-11 years) - 15 to < 30 kg: 100mg every 2 weeks (Q2W) or 300mg every 4 weeks (Q4W). > 30 kg: 200mg every 2 weeks (Q2W). Chronic rhinosinusitis with nasal polyps - Adults: 300mg every 2 weeks (Q2W).,無需調整劑量,[仿單] Dupilumab是否會分泌至人體乳汁、對吸吮母乳之嬰兒的影響，或對母乳生成的影響， 目前尚無相關資料。已知母體免疫球蛋白G (IgG)會進入人體乳汁。吸吮母乳之嬰兒， 其胃腸道局部暴露和全身性有限暴露於dupilumab所造成的影響，目前不得而知。 當考量哺乳對嬰兒發育及健康的益處時，應同時考慮母親之臨床需求以及潛在病況對吸吮母乳的幼兒可能造成的任何不良影響。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單] 氣喘控制差或中度控制的婦女，有證據顯示會增加母體子癲前症及新生兒早產、 低出生體重和胎兒小於妊娠年齡的風險。應嚴密監測懷孕婦女的氣喘控制狀況， 且必要時應調整治療以維持最適控制。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] Dupilumab是否會分泌至人體乳汁、對吸吮母乳之嬰兒的影響，或對母乳生成的影響， 目前尚無相關資料。已知母體免疫球蛋白G (IgG)會進入人體乳汁。吸吮母乳之嬰兒， 其胃腸道局部暴露和全身性有限暴露於dupilumab所造成的影響，目前不得而知。 當考量哺乳對嬰兒發育及健康的益處時，應同時考慮母親之臨床需求以及潛在病況對吸吮母乳的幼兒可能造成的任何不良影響。,SC;,,,,,
EQCSP,Lidocaine,Quicaine spray 10%， 50mL,ZANE,Local anesthesia.,Allergic history to local anesthetics of the amide class or other ingredients in the spray solution.,Local irritation， allergic reactions， acute systemic toxicity.,25℃以下,For mucosal surface anesthesia， effect lasts 10-15 minutes. Anesthesia occurs within 1-5 minutes， depending on the area of use. Each press of the plunger releases 10mg of Lidocaine. No need to dry the sprayed area before use. - ENT procedures: 3 sprays for maxillary sinus puncture or minor surgery. - Pleural fluid drainage: 3 sprays. - Labor and delivery: Up to 20 sprays (200mg Lidocaine) at most. - Respiratory or digestive procedures: Up to 20 sprays (200mg Lidocaine)， with a maximum of 400mg Lidocaine for prolonged procedures. Total dosage should not exceed 400mg when combined with other Lidocaine products. - Dental procedures: 1-5 mucosal sprays. Special Patients: Elderly， children above 12 years， acutely ill， or septic patients should receive appropriate doses based on their age， weight， and condition.,無需調整劑量,[仿單] 如同其他局部麻醉劑，Lidocaine 可能入母親之乳汁，但在這麼小的劑量下， 通常並無對新生兒造成影響的危險性。,無需調整劑量,沒有資料,Compatible,[仿單] 假定已有相當多之孕婦及育齡婦女已使用過Lidocaine 是很合理的。 迄今尚無對生殖過程會產生明確阻礙的報告，例如畸形的發生率並無增加。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 如同其他局部麻醉劑，Lidocaine 可能入母親之乳汁，但在這麼小的劑量下， 通常並無對新生兒造成影響的危險性。,EXT;LA;SKIN;TOPI;,,,,,
OLIX,Edoxaban,Lixiana F.C. 30mg,HEMT,Deep vein thrombosis and pulmonary embolism: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant. Nonvalvular atrial fibrillation: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF),Active pathological bleeding， hypersenstive.,>10%: Hematologic and oncologic: Hemorrhage (22%) 1% to 10%: Dermatologic: Dermal hemorrhage (6%)， skin rash (4%) Gastrointestinal: Gastrointestinal hemorrhage (4%)， lower GI bleeding (3%) Genitourinary: Vaginal hemorrhage (9%)， gross hematuria， urethral bleeding Hematologic and oncologic: Major hemorrhage， nonlife-threatening (7% to 9%; noncritical organ: 1%; critical organ: <1%)， major hemorrhage (1%)， oral hemorrhage (3%)， anemia (2%)， decreased hemoglobin (1%)， puncture site bleeding (1%) Hepatic: Abnormal hepatic function tests (5% to 8%) Respiratory: Epistaxis (5%)， pharyngeal bleeding,30℃以下,Prevent stroke and systemic embolism: oral 60mg once daily.  Treatment of DVT and PE: oral 60mg once daily after at least 5 days of parenteral anticoagulant therapy.,需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
EPULT,Budesonide,Pulmicort Turbuhaler 200mcg/dose,ERSP,Patients with bronchial asthma not well controlled by bronchodilators &/or antiallergic agents.,Hypersensitivity to budesonide or any other ingredients.,Mild throat irritation & hoarseness. Candida infection in oropharynx. Gastrointestinal: Diarrhea (inhalation， 4%; oral， 10% )， Nausea (inhalation， 1.8% to 6%; oral， 11% ) Musculoskeletal: Arthralgia (inhalation， 6%; oral， 5% ) Neurologic: Headache (inhalation， 3%; oral， 21% ) Respiratory: Epistaxis (intranasal， 8%; inhalation， 2% to 4% )， Nasal stinging/burning (intranasal， greater than 1% )， Respiratory tract infection (inhalation， 3% to 38%; oral， 11% )， Sinusitis (inhalation， 3% to 16%; oral， 8% ),30℃以下,Adult: 200-800mcg daily in divided doses 2-4 times. May increase the dosage to 1600mcg with the severe patient. The required dose can be administered at one time under 400mcg. Age >6 years: 200-800mcg daily in divided doses 2-4 times. The required dose can be administered at one time under 400mcg.,無需調整劑量,,無需調整劑量,可能安全,Compatible,PREGNANCY RECOMMENDATION: Compatible (Inhaled/Nasal) No Human Data—Animal Data Suggest Risk (Oral),No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
RIUCB,Bimekizumab/Adalimumab/Placebo,試PS0008(Bimekizumab 160mg/Adalimumab 40mg/Placebo,HIMM,,,,,,,,,,,,,,,,,,,
IEPIP3,Epinephrine,Epipen Auto-Injector 0.3mg (專案進口),ZADT,Used for emergency treatment of insect bites， food， drugs， and other allergens， as well as primary or exercise-induced severe allergic reactions (anaphylaxis).,There are no absolute contraindications to the use of injectable epinephrine in a life-threatening situation.,Common: Palpitations， Pale complexion， Sweating， Nausea and vomiting， Asthenia， Dizziness， Headache， Tremor， Anxiety， Apprehension， Restlessness， Difficulty breathing Serious: Cardiac dysrhythmia， Hypertension， acute， Ventricular fibrillation， Injection site extravasation， Cerebral hemorrhage， Renal impairment， Pulmonary edema， Injection site infection,15-30℃避光(25℃最佳)，請勿冷藏,Epinephrine auto-injector 0.3 mg for patients weighing > 30 kg. Usual dose: 0.3 mg; pediatric dose: 0.01 mg/kg. IM into the anterolateral aspect of the thigh， through clothing if necessary; may repeat every 5-15 minutes or sooner if patient does not adequately respond to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.,無需調整劑量,[仿單] 目前尚未有腎上腺素分泌至母乳、對以母乳哺育的嬰兒的影響或對母乳分泌影響的資料。 腎上腺素是用於治療過敏性反應(anaphylaxis)的第一線選擇藥物， 因此建議應該以相同的方式治療哺育中或非哺乳中的病人。,無需調整劑量,沒有資料,Human (and animal) data suggest risk,[仿單] 懷孕期間的全身性過敏反應(anaphylaxis)治療與一般人的治療相似。 腎上腺素是治療全身性過敏反應(anaphylaxis)的首選藥物； 它應該以相同的方式用於懷孕和非懷孕患者。 在施打腎上腺素後，患者應立即尋求醫療及醫院的醫療照護。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 目前尚未有腎上腺素分泌至母乳、對以母乳哺育的嬰兒的影響或對母乳分泌影響的資料。 腎上腺素是用於治療過敏性反應(anaphylaxis)的第一線選擇藥物， 因此建議應該以相同的方式治療哺育中或非哺乳中的病人。,IM;,,,,,1. 必要時可以隔著衣物施打 2. 如需要第二次劑量時不要注射在同一部位 3. 不可施打於臀部，手，腳，指頭
ODIL2,Diltiazem,DilTELAN 120mg,CAVS,Hypertension， chronic stable angina， vasospastic angina,Pregnancy， Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); hypotension (systolic <90 mm Hg); acute MI and pulmonary congestion,>10%: Cardiovascular: Peripheral edema (5% to 15%) 1% to 10%: Cardiovascular: Lower extremity edema (5% to 8%)， bradycardia (3% to 4%)， first-degree atrioventricular block (3% to 4%)， hypotension (3% to 4%)， edema (2% to 3%)， vasodilation (2% to 3%)， extrasystoles (2%)， palpitations (1% to 2%)， angina pectoris (<2%)， bundle branch block (<2%)， cardiac failure (<2%)， complete atrioventricular block (<2%)， ECG abnormality (<2%)， second degree atrioventricular block (<2%)， syncope (<2%)， tachycardia (<2%)， ventricular premature contractions (<2%)， cardiac arrhythmia (1%) Central nervous system: Dizziness (2% to 10%)， headache (2% to 8%)， pain (6%)， fatigue (5%)， nervousness (2%)， abnormal dreams (<2%)， abnormal gait (<2%)， amnesia (<2%)， depression (<2%)， drowsiness (<2%)， hallucination (<2%)， insomnia (<2%)， paresthesia (<2%)， personality changes (<2%) Dermatologic: Skin rash (1% to 2%)， pruritus (<2%)， skin photosensitivity (<2%) Endocrine & metabolic: Gout (1% to 2%)， albuminuria (<2%)， gynecomastia (<2%)， hyperglycemia (<2%)， hyperuricemia (<2%)， increased lactate dehydrogenase (<2%)， increased thirst (<2%)， weight gain (<2%) Gastrointestinal: Dyspepsia (1% to 6%)， abdominal enlargement (2%)， nausea (2%)， diarrhea (1% to 2%)， anorexia (<2%)， constipation (<2%)， dysgeusia (<2%)， vomiting (<2%)， xerostomia (<2%) Genitourinary: Impotence (2%)， crystalluria (<2%)， nocturia (<2%)， sexual difficulty (<2%) Hematologic & oncologic: Petechia (<2%) Hepatic: Increased serum alanine aminotransferase (<2%)， increased serum alkaline phosphatase (<2%)， increased serum aspartate transaminase (<2%) Hypersensitivity: Hypersensitivity reaction (<2%) Infection: Infection (1% to 6%) Local: Burning sensation at injection site (?4%)， itching at injection site (?4%) Neuromuscular & skeletal: Asthenia (1% to 4%)， myalgia (2%)， increased creatine phosphokinase in blood specimen (<2%)， muscle cramps (<2%)， neck stiffness (<2%)， osteoarthritis (<2%)， tremor (<2%) Ophthalmic: Conjunctivitis (2%)， amblyopia (<2%)， eye irritation (<2%) Otic: Tinnitus (<2%) Renal: Polyuria (<2%) Respiratory: Pharyngitis (6%)， dyspnea (1% to 6%)， bronchitis (1% to 4%)， flu-like symptoms (2%)， cough (1% to 2%)， paranasal sinus congestion (1% to 2%)， epistaxis (<2%)， rhinitis (<2%) <1%: Atrial flutter， chest pain， sinus node dysfunction， urticaria， ventricular fibrillation， ventricular tachycardia Frequency not defined: Hepatic: Hepatic injury， increased serum bilirubin Postmarketing: Acute generalized exanthematous pustulosis， alopecia， angioedema， asystole， cutaneous lupus erythematosus (Crowson 1995; Srivastava 2003)， erythema multiforme， exfoliative dermatitis， extrapyramidal reaction， gingival hyperplasia， hemolytic anemia， hypersensitivity angiitis， leukopenia， myopathy， prolonged bleeding time， purpuric disease， retinopathy， Stevens-Johnson syndrome， thrombocytopenia， toxic epidermal necrolysis,25℃以下避光儲存,HTN: adult initial 90mg QD， maximum dose: 360mg.,無需調整劑量,[仿單] 警語:經動物試驗顯示高劑量下對於生殖器官的發育產生不良反應， 建議懷孕及哺乳期婦女僅在絕對必要的情況下才使用,無需調整劑量,除非治療上需要,Human data suggest low risk,[仿單] 禁忌:孕婦及可能懷孕之婦女 警語:經動物試驗顯示高劑量下對於生殖器官的發育產生不良反應， 建議懷孕及哺乳期婦女僅在絕對必要的情況下才使用,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 警語:經動物試驗顯示高劑量下對於生殖器官的發育產生不良反應， 建議懷孕及哺乳期婦女僅在絕對必要的情況下才使用,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性膠囊應整粒吞服， 勿咬嚼或壓碎。若有磨粉管灌需求可改用院內同成分Herbesser 30mg。
ODIG2,Digoxin,Digosin 0.25mg (專案進口),CAVS,,適應症: Heart failure， atrial fibrillation &/or flutter & supraventricular tachycardia. 副作用: Arrhythmias; anorexia， nausea， vomiting; lower abdominal pain， abnormal fatigue or weakness; abnormal bradycardia; visual disturbances; diarrhea; depression & psychosis， drowsiness， headache， malaise. Gynecomastia in prolonged use. 禁忌:Intermittent complete heart block or 2nd-degree AV block， especially if there is a history of Stokes-Adams attacks; arrhythmias caused by cardiac glycoside intoxication; supraventricular arrhythmias associated with an accessory AV pathway， as in the Wolff-Parkinson-White syndrome， unless the electrophysiological characteristics of the accessory pathway & any possible deleterious effect of digoxin on these characteristics has been evaluated. If an accessory pathway is known or suspected to be present & there is no history of previous supraventricular arrhythmias. Hypertrophic obstructive cardiomyopathy unless with concomitant atrial fibrillation & heart failure. Hypersensitivity to other digitalis glycosides.,,室溫,Adult and child over 10 yrs: Oral: Rapid digitalization: A total of 1-1.5 mg divided into 2 or more doses given q6-8h. Slow digitalization: 0.125-0.5 mg qd for 7 days. Maintenance: 0.125-0.5 mg qd. Infant and child under 10 yrs: Oral: Digitalization: The following amounts divided into 2 or more doses given q6-8h. 2-10 yrs: 0.04-0.06 mg/kg. 1 month-2 yrs: 0.06-0.08 mg/kg. Under 1 month: 0.04-0.06 mg/kg. Maintenance: 1/5-1/3 of the total digitalizing dose， qd.,無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
ODCA,Thiamine， Riboflavin， Pyridoxine， Cyanocobalamin,DailyCare Actibest (Vitamin B1， B2， B6， B12),NUTR,Treatment and Prophylaxis of Thiamine， Riboflavin， Pyridoxine， and Cyanocobalamin deficiency.,Hypersensitivity to any component of the product.,Common Neurologic: Asthenia (4% to 16% )， Headache (4% to 20% )， Paresthesia (4% )， Decreased folic acid. Neurologic: Paresthesia， Somnolence. Dermatologic: Contact dermatitis. Serious Cardiovascular: Congestive heart failure， Pulmonary edema， Thrombosis. Immunologic: Anaphylaxis， Non-allergic anaphylaxis. Ophthalmic: Optic atrophy.,25℃以下,Adult 1-3 tablets daily. Each tablet contains: Thiamine disulfide 50mg， Riboflavin 5mg， Pyridoxine HCl 5mg， and Cyanocobalamine 10 mcg.,無需調整劑量,[仿單]沒有記載,無需調整劑量,沒有資料,Compatible,[仿單]沒有記載,Compatible 哺乳時可使用,[仿單]沒有記載,AC;AC15;PC;PO;WM;,,,,,
IOGIS0,Trastuzumab,Ogivri inj 440 mg (恩慈專案) (Sample),RACA,Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer: 1.as part of a treatment regimen consisting of doxorubicin， cyclophosphamide， and either paclitaxel or docetaxel. 2.as part of a treatment regimen with docetaxel and carboplatin. 3.as a single agent following multi-modality anthracycline based therapy. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. In combination with cisplatin and capecitabine or 5-fluorouracil， for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.,Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.,Common Dermatologic: Rash (Adjuvant breast cancer， 4%; metastatic breast cancer， 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% )， Nausea (Adjuvant breast cancer， 6%; metastatic breast cancer， 33% to 76% )， Stomatitis (24% )， Vomiting (Adjuvant breast cancer， 3.5%; metastatic breast cancer， 23% to 53% ) Hematologic: Anemia， All Grades (4% to 36% )， Neutropenia， All Grades (Breast cancer， 6.4%; gastric cancer， 78% )， Thrombocytopenia， All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer， 6.2% to 10%; metastatic breast cancer， 26% to 44% )， Insomnia (Adjuvant breast cancer， 4.3%; metastatic breast cancer， 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer， 5%; metastatic breast cancer， 26% to 43% ) Other: Fatigue (29.5% to 35% )， Fever (Adjuvant breast cancer， 6%; metastatic breast cancer， 36% to 56%; gastric cancer， 18% )， Shivering (Adjuvant breast cancer， 5%; metastatic breast cancer， 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% )， Heart failure (Adjuvant breast cancer， 0.4% to 3.2%; metastatic breast cancer， 7% to 28% )， Left ventricular cardiac dysfunction (5% to 18.5% )， Myocardial ischemia， Grade 3 or 4 Hematologic: Febrile neutropenia (23% )， Neutropenia， Grade 3 or 4 (32% to 34% )， Thrombocytopenia， Grade 3 or 4 (5% )， Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer， 2.4% to 11.8%; metastatic breast cancer， 22% to 42% )， Interstitial pneumonia， acute (0.2% to 0.7% )， Pulmonary hypertension (0.2% )， Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% )， Tumor lysis syndrome,2-8℃,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion， then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks， or initial dose of 8 mg/kg over 90 minutes IV infusion， then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion， followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,無需調整劑量,[仿單]目前並不確知trastuzumab是否會分泌進入人類的乳汁，但人類的IgG會分泌進入人類的乳汁。已發表的資料顯示，乳汁抗體並不會大量進入新生兒及嬰兒的體內循環。對授乳食蟹猴投予相當於人類每週建議劑量(2毫克/公斤體重)之12.5倍的trastuzumab之後發現，trastuzumab會出現於乳汁中。血清中檢出trastuzumab的幼猴在出生後至3個月大期間並未發生任何生?或發育方面的不良影響；不過，動物乳汁中的trastuzumab含量並不能精確地反映人類乳汁中的含量。 由於許多藥物都會分泌進入人類的乳汁，且餵哺母乳的嬰兒可能會因接觸Ogivri而發生嚴重的不良反應，因此，應考慮Ogivri的排除半衰期及此藥物對母親的重要性，然後決定是否要停止餵哺母乳或是停用此藥。,無需調整劑量,沒有資料,Human data suggest risk in 2nd and 3 rd trimesters,[仿單]對孕婦投予trastuzumab會對胎兒造成傷害。根據上市後的病例報告，在懷孕期間使用trastuzumab會提高於第二及第三孕期出現羊水過少現象的風險。如果婦女在懷孕期間使用了trastuzumab，或於使用trastuzumab期間懷孕，應將胎兒可能受到的危害告知該名婦女。上市之後，在懷孕期間接受單一trastuzumab或與化學療法併用治療的婦女中曾有出現羊水過少現象的報告。其中有半數的婦女在停用trastuzumab之後即出現羊水指數上升的現象。有一個病例在羊水指數改善之後又重新開始使用trastuzumab，結果再度出現羊水過少的現象。上市之後，在接受trastuzumab的孕婦中曾有報導胎兒羊水過少症伴隨腎臟成?及/或功能受損的案例，其中有造成胎兒肺部器官發育不全而導致死亡的報導。對於在懷孕期間使用Ogivri的婦女，應監視是否出現羊水過少的現象。如果出現羊水過少的現象，即應進行適合其妊娠週數且符合社會照護標準的胎兒檢查。曾經在投予其他化學治療劑之後出現羊水過少的現象時以靜脈輸注(IV)的方式額外補充水份，結果頗有助益，但目前並不確知使用trastuzumab治療時以靜脈輸注之方式額外補充水份的效果。在以高達人類每週建議劑量(2毫克/公斤體重)之25倍的trastuzumab所進行的食蟹猴生殖研究中，並未發現任何顯示胎兒受到傷害的證據。不過，許多胚胎組織都有相當明顯的HER2蛋白過度表現的現象，包括心臟與神經組織；在缺乏HER2的突變小鼠中，胚胎皆於懷孕初期即死亡。針對猴子所進行的研究發現，在胎兒發育階段的初期(懷孕第20-50天)及後期(懷孕第120-150天)，trastuzumab會通過胎盤轉移至胎兒體內。由於動物生殖研究的結果並不？定能預測人類的反應，因此，只有在母親的潛在效益超越胎兒可能面臨之風險的情況下，才可於懷孕期間使用Ogivri。 育齡期婦女於Ogivri治療期間及治療結束後7個月內應被建議採取有效的避孕措施。 若孕婦接受Ogivri治療，或是病患在接受Ogivri治療期間或最後一劑Ogivri後7個月內懷孕，最好由跨科別團隊進行嚴密監測。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]目前並不確知trastuzumab是否會分泌進入人類的乳汁，但人類的IgG會分泌進入人類的乳汁。已發表的資料顯示，乳汁抗體並不會大量進入新生兒及嬰兒的體內循環。對授乳食蟹猴投予相當於人類每週建議劑量(2毫克/公斤體重)之12.5倍的trastuzumab之後發現，trastuzumab會出現於乳汁中。血清中檢出trastuzumab的幼猴在出生後至3個月大期間並未發生任何生?或發育方面的不良影響；不過，動物乳汁中的trastuzumab含量並不能精確地反映人類乳汁中的含量。 由於許多藥物都會分泌進入人類的乳汁，且餵哺母乳的嬰兒可能會因接觸Ogivri而發生嚴重的不良反應，因此，應考慮Ogivri的排除半衰期及此藥物對母親的重要性，然後決定是否要停止餵哺母乳或是停用此藥。,IVD;,包裝中的稀釋液(20 毫升含1.1%苯甲醇的制菌注射用水)。,,,抽取病患藥物量後加到裝有0.9%氯化鈉250 毫升的注射袋中稀釋，起始劑量建議靜脈輸注90 分鐘。維持劑量時若病人對先前劑量的耐受力佳，可輸注30 分鐘即可。,1.配製的說明: 使用無菌針筒，慢慢注入20 毫升制菌注射用水於含凍晶Ogivri 的小瓶，直接注射至凍晶塊。再溫和地轉動小瓶幫助調配，不要搖晃。 2.使用包裝中所提供的制菌注射用水混合後的配製後溶液，冷藏在2-8℃可以維持28 天的安定。如果使用滅菌水配製則僅維持24 小時安定，之後必須丟棄。 3.配製於裝有0.9%氯化鈉溶液的注射用袋中，在2-8℃下其物化性質可維持穩定24 小時。 4.禁止使用5%的dextrose 溶液，因為會引起蛋白質凝集。
OCEX,Cefixime,CEXime 100mg,QANB,Streptococcus VSS S. pneumoniae， N. gonorrhoeae， Branhamella catarrhalis， E. coli， Klebsiella VSS Serratia VSS Proteus VSS H. Influenzae， the following infection caused by Cefixime susceptibility: bronchitis， bronchiectasis (infection)， secondary infection of chronic respiratory diseases， pneumonia， pyelonephritis， cystitis， bacterial urethritis， otitis media， sinusitis.,Hypersensitivity to cefixime， any component of the formulation， or other cephalosporins or penicillins,>10%: Gastrointestinal: Diarrhea (16%) 2% to 10%: Gastrointestinal: Abdominal pain， nausea， dyspepsia， flatulence， loose stools <2%: Acute renal failure， anaphylactoid reaction， anaphylaxis， angioedema， candidiasis， dizziness， drug fever， eosinophilia， erythema multiforme， facial edema， fever， headache， hepatitis， hyperbilirubinemia， increased blood urea nitrogen， increased serum creatinine， increased serum transaminases， jaundice， leukopenia， neutropenia， prolonged prothrombin time， pruritus， pseudomembranous colitis， seizure， serum sickness-like reaction， skin rash， Stevens-Johnson syndrome， thrombocytopenia， toxic epidermal necrolysis， urticaria， vaginitis， vomitingy.,25℃以下,Adults and children > 30 kg: 50-100 mg orally twice daily; 200 mg twice daily for serious infection. [Sanford Guide to Antimicrobial Therapy 2021] Pediatric dose: Age > 28days: 8 mg/kg/day， divided Q12-24H.,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
OPZA5,Pyrazinamide,Piramide 500mg,QANB,,適應症: Treatment of pulmonary & extrapulmonary TB. 副作用: Hepatotoxicity， jaundice， hyperuricemia leading to attacks of gout， anorexia， nausea， vomiting， arthralgia， malaise， fever， sideroblastic anemia， difficulty in micturition. Endocrine metabolic: Hyperuricemia Gastrointestinal: Nausea， Vomiting Musculoskeletal: Arthralgia (40%) 禁忌: Liver damage.,,,20-35 mg/kg daily in 3-4 divided doses. (max. 3 g/day).,無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IOZU,Dexamethasone,Ozurdex (intravitreal implant) 0.7mg,TOPH,Diabetic macular edema (pseudophakic or phakic patients scheduled for cataract surgery) or macular edema (following BRVO or CRVO),Hypersensitivity to dexamethasone or any component of the formulation or product; glaucoma with cup to disc ratios of >0.8; active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva， including active epithelial herpes simplex keratitis (dendritic keratitis)， vaccinia， varicella， mycobacterial infections， and fungal diseases; use in patients with a posterior lens capsule that is torn or ruptured,>10%: Hypertension (implant: 13%)， Cataract (implant: 5% to 68%; incidence increases in patients requiring a second injection)， increased intraocular pressure (implant: 5% to 25%; ?10 mm Hg: 28%， ?30 mm Hg: 15%; injection: 5% to 15%)， conjunctival hemorrhage (implant: 22% to 23%)， corneal edema (injection: 5% to 15%; implant: ?1%)， iritis (5% to 15%) 1% to 10%: Aneurysm (implant: 3%; retinal)， Foreign body sensation of eye (?5%)， headache (implant: 1% to 4%)， Anterior chamber inflammation (implant: 2% to 9%)， decreased visual acuity (1% to 9%)， eye pain (?8%)， conjunctival hyperemia (implant: ?7%)， conjunctivitis (implant: ?6%)， corneal erosion (?5%)， xerophthalmia (?5%)， conjunctival edema (implant: 5%)， ocular hypertension (implant: 5%)， blepharitis (injection: 1% to 5%)， blurred vision (injection: 1% to 5%)， cystoid macular edema (1% to 5%)， ophthalmic inflammation (injection: 1% to 5%)， photophobia (injection: 1% to 5%)， posterior capsule opacification (injection: 1% to 5%)， vitreous detachment (1% to 5%)， vitreous opacity (1% to 5%)， retinal hole without detachment (implant: 2%)， blepharoptosis (implant: ?2%)， keratitis (implant: ?2%)， Bronchitis (implant: 5%) Frequency not defined: Ophthalmic: Glaucoma (injection),25℃以下,Ocular implant: Intravitreal injection: 0.7 mg implant injected in affected eye.,無需調整劑量,DEXAMETHASONE IMPLANT OPHTHALMIC Corticosteroid BREASTFEEDING RECOMMENATION: No Human Data—Probably Compatible,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,DEXAMETHASONE IMPLANT OPHTHALMIC Corticosteroid PREGNANCY RECOMMENDATION: No Human Data—Probably Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,DEXAMETHASONE IMPLANT OPHTHALMIC Corticosteroid BREASTFEEDING RECOMMENATION: No Human Data—Probably Compatible,IVI;,,,,,1.不建議雙眼同時接受注射.
OLEEV,Imatinib,Leevk 100mg,RACA,Adult & pediatrics with newly diagnosed chronic myeloid leukemia (CML)， CML in blast crisis， accelerated phase or chronic phase after failure of interferon-α therapy. Adult with newly diagnosed Philadelphia chromosome +ve acute lymphoblastic leukemia (Ph+ALL) integrated with chemotherapy; with relapsed or refractory Ph+ALL as montherapy; myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements; systemic mastocytosis (SM) without D816V c-Kit mutation or with c-Kit mutation status unknown; hypereosinophilic syndrome (HES) &/or chronic eosinophilic leukemia (CEL); unresectable &/or metastatic， malignant GI stromal tumors (GIST); unresectable， recurrent &/or dermatofibrosarcoma protuberans (DFSP).,Hypersensitivity to imatinib or any component of the formulation,GI disturbances， anorexia， gastro-esophageal reflux， mouth ulceration， myalgia， muscle cramps， joint swelling， headache， dizziness， taste disturbance， paraesthesia， insomnia， conjunctivitis， increased lacrimation， blurred vision， epistaxis， dyspnea， weight gain， periorbital edema， dermatitis， rash， face & eyelid edema， pruritus， erythema， dry skin， alopecia， night sweats， fluid retention & edema， fatigue; pyrexia， weakness， rigors; neutropenia & febrile neutropenia， thrombocytopenia， anemia. Cardiovascular: Edema (1.1% to 86.1% ) Dermatologic: Night sweats (13% to 17% )， Rash (up to 49.8% ) Endocrine metabolic: Weight gain (up to 32% ) Gastrointestinal: Diarrhea (3% to 58.2% )， Nausea (3% to 73% )， Vomiting (2% to 58% ) Musculoskeletal: Arthralgia (12.3% to 40% )， Cramp (up to 62% )， Musculoskeletal pain (up to 49% )， Myalgia (9% to 32.2% ) Neurologic: Asthenia (15% to 21% )， Dizziness (12% to 16% )， Headache (up to 36% )， Insomnia (10% to 14% ) Respiratory: Cough (14% to 27% )， Nasopharyngitis (10% to 30.5% )， Pain， Pharyngolaryngeal (18.1% )， Pharyngitis (10% to 15% ) Other: Fatigue (25% to 48% )， Fever (16.7% to 41% )， Influenza (0.8% to 13.8% )， Rigor (10% to 12% ),30℃以下，防潮,[Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)]- Chronic phase: 400 mg once daily， may be increased to 600 mg daily- Accelerated phase or blast crisis: 600 mg once daily， may be increased to 800 mg daily (400 mg twice daily) [Ph+ acute lymphoblastic leukemia (ALL)] 600 mg once daily [Myelodysplastic/myeloproliferative disease (MDS/MPD)] 400 mg once daily [Aggressive systemic mastocytosis (ASM) associated with eosinophilia] Initiate at 100 mg once daily; if assessments demonstrate insufficient response， increase from 100-400 mg/day in the absence of adverse reactions. [ASM without D816V c-Kit mutation or c-Kit mutation status unknown] 400 mg once daily [Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)] 400 mg once daily [HES/CEL with FIP1L1-PDGFRα fusion kinase] Initiate at 100 mg once daily; if assessments demonstrate insufficient response， increase from 100-400 mg/day in the absence of adverse reactions. [Gastrointestinal stromal tumors (GIST)]- Adjuvant treatment following complete resection: 400 mg once daily; recommended treatment duration: 3 years- Unresectable and/or metastatic malignant: 400 mg once daily; may be increased up to 800 mg daily (400 mg twice daily)， if tolerated， for disease progression. [Dermatofibrosarcoma protuberans (DFSP)] 400-800 mg/day (400 mg once or twice daily),需調整劑量,,需調整劑量,盡量避免,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
OBEL,Lorcaserin,Belviq 10mg 60's/box,META,,適應症:Weight management: Chronic weight management， as an adjunct to a reduced-calorie diet and increased physical activity， in adults with either an initial body mass index (BMI) of ?30 kg/m2 or an initial BMI of ?27 kg/m2 and at least one weight-related comorbid condition (eg， hypertension， dyslipidemia， type 2 diabetes). 副作用: >10%: Central nervous system: Headache (15% to 17%) Endocrine & metabolic: Hypoglycemia (diabetic patients 29%; symptomatic 7%; severe: 2%) Hematologic: Abnormal lymphocytes (below lower limit of normal after >=1 year， 12%) Neuromuscular & skeletal: Back pain (6% to 12%) Respiratory: Upper respiratory tract infection (14%)， nasopharyngitis (11% to 13%) 禁忌:Hypersensitivity to lorcaserin or any component of the formulation; pregnancy.,,室溫,Dosing: Adult Weight management: Oral: Note: Evaluate response by week 12; if patient has not lost ?5% of baseline body weight， discontinue therapy. Immediate release: 10 mg twice daily (maximum: 20 mg/day).,,,,不可使用,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IEVU,Tixagevimab + Cilgavimab,Evusheld inj 150mg/150mg/3mL/dose (政府提供),QANB,COVID-19， Pre-exposure in patients not currently infected with SARS-CoV-2 and have not had a known recent exposure and who have moderate to severe immune compromise/may not mount an adequate response to vaccination or are unable to receive a COVID-19 vaccination; Prophylaxis,Severe hypersensitivity reactions， including anaphylaxis， to any component of the product.,Common: Headache (6%)， Cough (3%)， Fatigue (4%) Serious: Cardiac dysrhythmia， Cardiomegaly， Cardiomyopathy， Cardiorespiratory arrest， Coronary arteriosclerosis， Heart failure (0.2%)， Myocardial infarction (0.2-0.4%)， Myocardial ischemia， Sudden cardiac death (0.2%)， Anaphylaxis， Hypersensitivity reaction,避光冷藏(2-8°C),,無需調整劑量,[Micromedex] Infant risk cannot be ruled out.,無需調整劑量,沒有資料,Uknown 沒有資料,[Micromedex] Fetal risk cannot be ruled out.,Unknown 沒有資料,[Micromedex] Infant risk cannot be ruled out.,IM;,,,,,1. 藥物小瓶(vial)穿刺後須於4小時內完成給藥。 2. 在不同的注射部位連續進行兩次肌肉注射，建議注射於臀肌。
OAPR,Irbesartan,Aprovel 300mg,CAVS,,適應症: Diabetic nephropathy: Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Hypertension: Treatment of hypertension alone or in combination with other antihypertensives 副作用: >10%: Endocrine & metabolic: Hyperkalemia (diabetic nephropathy: 19%; rarely seen in hypertension) 1% to 10%: Cardiovascular: Orthostatic hypotension (diabetic nephropathy: 5%: hypertension: <1%) Central nervous system: Dizziness (diabetic nephropathy: 10%)， fatigue (4%) Gastrointestinal: Diarrhea (3%)， dyspepsia (2%) Respiratory: Upper respiratory tract infection (9%) <1%， postmarketing， and/or case reports: Abdominal distention， anemia (case report; Simonetti 2007)， angina pectoris， angioedema， arthritis， auditory disturbance， bronchitis， bursitis， cardiac arrhythmia， cardiac failure， cerebrovascular accident， chills， conjunctivitis， constipation， decreased libido， depression， dermatitis， drowsiness， dyspnea， ecchymoses， epistaxis， erythema， facial edema， fever， flatulence， flushing， gastroenteritis， gout， hepatitis， hypertension， hypertensive crisis， hypotension， increased liver enzymes， increased serum transaminases， jaundice， muscle cramps， myalgia， myasthenia， myocardial infarction， nasal congestion， noncardiac chest pain， numbness， otalgia， otic infection， paresthesia， prostatic disease， pruritus， pulmonary congestion， renal failure， renal insufficiency， sexual disorder， sleep disorder， thrombocytopenia， transient ischemic attacks， tremor， upper extremity edema， urination disorder， urticaria， visual disturbance， wheezing 禁忌:Hypersensitivity to irbesartan or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus.,,室溫,Initial dose 150 mg once daily; titrate as needed based on patient response up to 300 mg once daily， maximum dose: 300 mg/day. Elderly >75 yr & haemodialysis patients Consider initiating with 75 mg.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ICOVMDN,SARS-CoV-2 Spike glycoprotein [mRNA],COVID-19 Vaccine Moderna 0.5mL/dose (5mL/vial),HIMM,Moderna COVID-19 Vaccine， for active immunization to prevent COVID-19 in individuals 18 years of age and older.,Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g.， anaphylaxis) to any component of the Moderna COVID-19 Vaccine.,erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.,2~8℃可放一個月,IM， 0.5 mL， > or = 18 years 2 doses administered 28 days apart.,無需調整劑量,尚無數據可用於評估Moderna COVID-19疫苗對母乳餵養嬰兒或乳汁產生/分泌的影響。,無需調整劑量,沒有資料,Uknown 沒有資料,所有妊娠都有發生出生缺陷、流產或其他不良結局的風險。在美ヰ漱@般人群中，在經過臨床確認的妊娠中，重大先天缺陷和流產的估計背景風險分？為2%至4%和15%至20%。 有關孕婦接種Moderna COVID-19 疫苗的可用數據尚不足以揭示妊娠期間接種疫苗的相關風險。 在一項發育毒性研究中，在雌性大鼠交配前28天和14天、以及妊娠第1天和第13天這四種情G下，分？經肌肉接種0.2 mL疫苗製劑，其中所含的經核鉽袡◥榦RNA(100 mcg) 和其它成分與人用單次劑量的Moderna COVID-19 疫苗的含量相同。 在該研究中未報告影響雌性生育能力、胎兒發育或產後發育的與疫苗相關的不良反應。,Unknown 沒有資料,尚無數據可用於評估Moderna COVID-19疫苗對母乳餵養嬰兒或乳汁產生/分泌的影響。,IM;,,,,,1.冷儲條件: -25至-15°C冷凍保存，不得低於-40°C且不得使用乾冰冷運冷儲.若轉置到2~8°C冷藏設備保存必須於30天內使用完畢. 2.多劑量藥瓶含無防腐劑的冷凍混懸液，在接種前必須解凍.在2-8°C的冷藏條件下解凍2小時30分鐘.解凍後在接種前讓藥瓶在室溫下靜置15分鐘. 或者在15-25°C的室溫下解凍1小時. 解凍後，請勿重新冷凍. 解凍後和在每次抽藥之前，輕輕旋動藥瓶.切勿搖晃.切勿稀釋疫苗. 3.在第一劑被抽出後，藥瓶應保存在2-25°C之間.在疫苗藥瓶標籤上記錄首次使用的日期和時間.6 小時後丟棄藥瓶.切勿重新冷凍.
HCVDA17,Sofosbuvir + Velpatasvir + Voxilaprevir (1-6/12週),HCVDAA0017(C肝全口服新藥健保計畫)1-6型(S/V/V)12週,,,,,,,,,,,,,,,,,,,,
EROY,Clindamycin,Royalsense acne gel 1% 20gm,TDER,Acne vulgaris.,Allergic to Clindamycin or Lincomycin. Patients with a history of regional enteritis， ulcerative colitis， or antibiotic-associated colitis.,Skin rash， itching， redness， swelling dryness， scaliness， peeling of skin.,25°C以下,Apply twice daily to affected area.,無需調整劑量,,無需調整劑量,沒有資料,Compatible,[Briggs Drugs in Pregnancy and Lactation] Compatible—Avoid 1st Trimester if Possible [仿單]目前無可信賴之臨床試驗可證明孕婦使用之安全性，故除非必要，孕婦請勿使用本劑。,Compatible 哺乳時可使用,,EXT;SKIN;TOPI;,,,,,
IOGIS,Trastuzumab,Ogivri inj 440 mg (絕對自費),RACA,Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer: 1.as part of a treatment regimen consisting of doxorubicin， cyclophosphamide， and either paclitaxel or docetaxel. 2.as part of a treatment regimen with docetaxel and carboplatin. 3.as a single agent following multi-modality anthracycline based therapy. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. In combination with cisplatin and capecitabine or 5-fluorouracil， for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.,Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.,Common Dermatologic: Rash (Adjuvant breast cancer， 4%; metastatic breast cancer， 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% )， Nausea (Adjuvant breast cancer， 6%; metastatic breast cancer， 33% to 76% )， Stomatitis (24% )， Vomiting (Adjuvant breast cancer， 3.5%; metastatic breast cancer， 23% to 53% ) Hematologic: Anemia， All Grades (4% to 36% )， Neutropenia， All Grades (Breast cancer， 6.4%; gastric cancer， 78% )， Thrombocytopenia， All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer， 6.2% to 10%; metastatic breast cancer， 26% to 44% )， Insomnia (Adjuvant breast cancer， 4.3%; metastatic breast cancer， 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer， 5%; metastatic breast cancer， 26% to 43% ) Other: Fatigue (29.5% to 35% )， Fever (Adjuvant breast cancer， 6%; metastatic breast cancer， 36% to 56%; gastric cancer， 18% )， Shivering (Adjuvant breast cancer， 5%; metastatic breast cancer， 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% )， Heart failure (Adjuvant breast cancer， 0.4% to 3.2%; metastatic breast cancer， 7% to 28% )， Left ventricular cardiac dysfunction (5% to 18.5% )， Myocardial ischemia， Grade 3 or 4 Hematologic: Febrile neutropenia (23% )， Neutropenia， Grade 3 or 4 (32% to 34% )， Thrombocytopenia， Grade 3 or 4 (5% )， Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer， 2.4% to 11.8%; metastatic breast cancer， 22% to 42% )， Interstitial pneumonia， acute (0.2% to 0.7% )， Pulmonary hypertension (0.2% )， Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% )， Tumor lysis syndrome,2-8℃,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion， then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks， or initial dose of 8 mg/kg over 90 minutes IV infusion， then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion， followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,無需調整劑量,[仿單]目前並不確知trastuzumab是否會分泌進入人類的乳汁，但人類的IgG會分泌進入人類的乳汁。已發表的資料顯示，乳汁抗體並不會大量進入新生兒及嬰兒的體內循環。對授乳食蟹猴投予相當於人類每週建議劑量(2毫克/公斤體重)之12.5倍的trastuzumab之後發現，trastuzumab會出現於乳汁中。血清中檢出trastuzumab的幼猴在出生後至3個月大期間並未發生任何生?或發育方面的不良影響；不過，動物乳汁中的trastuzumab含量並不能精確地反映人類乳汁中的含量。 由於許多藥物都會分泌進入人類的乳汁，且餵哺母乳的嬰兒可能會因接觸Ogivri而發生嚴重的不良反應，因此，應考慮Ogivri的排除半衰期及此藥物對母親的重要性，然後決定是否要停止餵哺母乳或是停用此藥。,無需調整劑量,沒有資料,Human data suggest risk in 2nd and 3 rd trimesters,[仿單]對孕婦投予trastuzumab會對胎兒造成傷害。根據上市後的病例報告，在懷孕期間使用trastuzumab會提高於第二及第三孕期出現羊水過少現象的風險。如果婦女在懷孕期間使用了trastuzumab，或於使用trastuzumab期間懷孕，應將胎兒可能受到的危害告知該名婦女。上市之後，在懷孕期間接受單一trastuzumab或與化學療法併用治療的婦女中曾有出現羊水過少現象的報告。其中有半數的婦女在停用trastuzumab之後即出現羊水指數上升的現象。有一個病例在羊水指數改善之後又重新開始使用trastuzumab，結果再度出現羊水過少的現象。上市之後，在接受trastuzumab的孕婦中曾有報導胎兒羊水過少症伴隨腎臟成?及/或功能受損的案例，其中有造成胎兒肺部器官發育不全而導致死亡的報導。對於在懷孕期間使用Ogivri的婦女，應監視是否出現羊水過少的現象。如果出現羊水過少的現象，即應進行適合其妊娠週數且符合社會照護標準的胎兒檢查。曾經在投予其他化學治療劑之後出現羊水過少的現象時以靜脈輸注(IV)的方式額外補充水份，結果頗有助益，但目前並不確知使用trastuzumab治療時以靜脈輸注之方式額外補充水份的效果。在以高達人類每週建議劑量(2毫克/公斤體重)之25倍的trastuzumab所進行的食蟹猴生殖研究中，並未發現任何顯示胎兒受到傷害的證據。不過，許多胚胎組織都有相當明顯的HER2蛋白過度表現的現象，包括心臟與神經組織；在缺乏HER2的突變小鼠中，胚胎皆於懷孕初期即死亡。針對猴子所進行的研究發現，在胎兒發育階段的初期(懷孕第20-50天)及後期(懷孕第120-150天)，trastuzumab會通過胎盤轉移至胎兒體內。由於動物生殖研究的結果並不？定能預測人類的反應，因此，只有在母親的潛在效益超越胎兒可能面臨之風險的情況下，才可於懷孕期間使用Ogivri。 育齡期婦女於Ogivri治療期間及治療結束後7個月內應被建議採取有效的避孕措施。 若孕婦接受Ogivri治療，或是病患在接受Ogivri治療期間或最後一劑Ogivri後7個月內懷孕，最好由跨科別團隊進行嚴密監測。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]目前並不確知trastuzumab是否會分泌進入人類的乳汁，但人類的IgG會分泌進入人類的乳汁。已發表的資料顯示，乳汁抗體並不會大量進入新生兒及嬰兒的體內循環。對授乳食蟹猴投予相當於人類每週建議劑量(2毫克/公斤體重)之12.5倍的trastuzumab之後發現，trastuzumab會出現於乳汁中。血清中檢出trastuzumab的幼猴在出生後至3個月大期間並未發生任何生?或發育方面的不良影響；不過，動物乳汁中的trastuzumab含量並不能精確地反映人類乳汁中的含量。 由於許多藥物都會分泌進入人類的乳汁，且餵哺母乳的嬰兒可能會因接觸Ogivri而發生嚴重的不良反應，因此，應考慮Ogivri的排除半衰期及此藥物對母親的重要性，然後決定是否要停止餵哺母乳或是停用此藥。,IVD;,包裝中的稀釋液(20 毫升含1.1%苯甲醇的制菌注射用水)。,【N/S】可選 仿單建議。,,抽取病患藥物量後加到裝有0.9%氯化鈉250 毫升的注射袋中稀釋，起始劑量建議靜脈輸注90 分鐘。維持劑量時若病人對先前劑量的耐受力佳，可輸注30 分鐘即可。,1.配製的說明: 使用無菌針筒，慢慢注入20 毫升制菌注射用水於含凍晶Ogivri 的小瓶，直接注射至凍晶塊。再溫和地轉動小瓶幫助調配，不要搖晃。 2.使用包裝中所提供的制菌注射用水混合後的配製後溶液，冷藏在2-8℃可以維持28 天的安定。如果使用滅菌水配製則僅維持24 小時安定，之後必須丟棄。 3.配製於裝有0.9%氯化鈉溶液的注射用袋中，在2-8℃下其物化性質可維持穩定24 小時。 4.禁止使用5%的dextrose 溶液，因為會引起蛋白質凝集。
IENV,Inactivated EV71 whole virus,Envacgen inj 0.5mL/dose,HIMM,Primary immunization for infants and toddlers aged 2 months to less than 6 years to prevent diseases caused by enterovirus type 71 infection.,Previous severe allergic reaction to this vaccine. Known allergy to any vaccine component. Severe allergy to formaldehyde.,Reduced appetite， drowsiness， diarrhea， vomiting， nausea， injection site pain， fever， injection site swelling， injection site redness， injection site bruising， injection site lump， restlessness， limited limb mobility， rash， erythema， ecchymosis， urticaria， and allergy.,避光冷藏儲存(2-8℃),For infants aged 2 months to under 6 years: One 0.5 mL muscle injection in the upper arm or thigh， two doses with a 56-day gap. For infants under 2 at first dose， consider a booster after one year.,無需調整劑量,[仿單] 不適用。本疫苗施打族群為2個月以上至未滿6歲之嬰幼兒。 目前尚無本疫苗使用於授乳期間婦女之相關資料。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 不適用。本疫苗施打族群為2個月以上至未滿6歲之嬰幼兒。 目前尚無本疫苗使用於懷孕婦女之相關資料。,Unknown 沒有資料,[仿單] 不適用。本疫苗施打族群為2個月以上至未滿6歲之嬰幼兒。 目前尚無本疫苗使用於授乳期間婦女之相關資料。,IM;,,,,,1. 施打此疫苗前後14天禁止施打其他活性減毒疫苗。 2. 無相容性研究，本品不得與其他藥物混合使用。 3. 疫苗外觀為無色澄明液，使用前請輕輕上下倒轉混合均勻為混濁白色懸浮液。 4. 僅供肌肉注射，勿以血管內、皮下或皮內注射方式施打疫苗。
LOSTAS,Oseltamivir Phosphate,Oseltamivir Phosphate 6mg/mL， 60mL oral suspension,QANB,Treatment of influenza in adults and children (including full-term newborns). Prevention of influenza in adults and children aged 1 and above.,Known allergies to oseltamivir phosphate or any of its components.,Vomiting， nausea， pain， headache.,25°C以下。調配後：冷藏(2-8℃)17天或室溫(<25℃)10天,Treatment of influenza: must begin treatment within the first or second day of experiencing influenza symptoms. - Adults and adolescents (>=13years): 75mg PO BID for 5 days. - Children (dosages based on body weight): ? 15kg: 30mg (5mL) PO BID for 5 days. 15-23kg: 45mg (7.5mL) PO BID for 5 days. 23-40kg: 60mg (10mL) PO BID for 5 days. ? 40kg: 75mg (12.5mL) PO BID for 5 days. - Children under 1 year: 3mg/kg PO BID for 5 days (not for infants with a gestational age of <36 weeks). Prophylaxis of influenza: must begin prophylaxis within 2 days of exposure to the source. - Adults and adolescents: 75mg PO QD for 10 or more days (safety and efficacy confirmed for 6 weeks). - Children (dosages based on body weight): ? 15kg: 30mg (5mL) PO QD for 10 days. 15-23kg: 45mg (7.5mL) PO QD for 10 days. 23-40kg: 60mg (10mL) PO QD for 10 days. ? 40kg: 75mg (12.5mL) PO QD for 10 days.,無需調整劑量,[仿單] 在授乳大鼠中發現，Oseltamivir 及其活性代謝物會被分泌至乳汁中。授乳母親服用Oseltamivir 對吸吮母乳之幼兒的影響及Oseltamivir 排泄於乳汁中的資訊非常有限。有限的資料顯示， Oseltamivir及其活性代謝物可在乳汁中被偵測出來，但其濃度低所以對於嬰兒而言低於治療劑量。 基於上述資訊、正在流行中之流行性感冒病毒株之致病性及授乳婦女的潛在狀況，並確認 對授乳母親的益處大於可能對哺育中嬰兒的危險之後，可能可以給予授乳婦女。,需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,[仿單] 從上市後報告及觀察性研究中取得的資料和動物研究結果顯示對懷孕、胚胎/胎兒或 出生後的發育並無直接或間接的有害影響。在考量已知的安全性及效益資料、流行中之 流行性感冒病毒株的致病性、及懷孕婦女本身狀況後，懷孕婦女可能可使用。,Compatible 哺乳時可使用,[仿單] 在授乳大鼠中發現，Oseltamivir 及其活性代謝物會被分泌至乳汁中。授乳母親服用Oseltamivir 對吸吮母乳之幼兒的影響及Oseltamivir 排泄於乳汁中的資訊非常有限。有限的資料顯示， Oseltamivir及其活性代謝物可在乳汁中被偵測出來，但其濃度低所以對於嬰兒而言低於治療劑量。 基於上述資訊、正在流行中之流行性感冒病毒株之致病性及授乳婦女的潛在狀況，並確認 對授乳母親的益處大於可能對哺育中嬰兒的危險之後，可能可以給予授乳婦女。,AC;AC15;PC;PO;WM;,,,,,1. 配製方式：拍打罐子以鬆散粉末。將55毫升調冷水加入瓶中，蓋緊瓶蓋後搖勻至白色均勻懸液。 2. 調配後可冷藏(2-8℃)保存17天或室溫(<25℃)保存10天。 3. 可以和或不和食物一起服用。和食物一起服用可能可增加對藥物的耐受性。
OMAI,Methylcobalamin,Maiyitong 500mcg,CNEU,Peripheral neuropathies， megaloblastic anaemia caused by vit B12 deficiency.,Hypersensitivity to any component of the formulation.,Anorexia， nausea， vomiting and diarrhoea. Parenteral: Rash， headache， hot sensation.,對光不安定，需遮光保存,Adult: 500 mcg TID . May adjust dosage according to patient's age and synptoms.,無需調整劑量,,無需調整劑量,安全,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
OIBR,Palbociclib,IBRANCE 125mg,RACA,Breast cancer， advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive， human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy Breast cancer， advanced (with disease progression following endocrine therapy): Treatment of HR-positive， HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy,Hypersensitivity to palbociclib or any component of the formulation. Use preparations containing St. John's Wort (or Hypericum).,Common Dermatologic: Alopecia (18% to 33% )， Rash (17% to 18% ) Gastrointestinal: Constipation (20% )， Decrease in appetite (15% to 16% )， Diarrhea (24% to 26% )， Nausea (34% to 35% )， Stomatitis (28% to 30% )， Vomiting (16% to 19% ) Hematologic: Anemia， All Grades (24% to 30% )， Leukopenia， All Grades (39% to 53% )， Neutropenia， All Grades (80% to 83% )， Thrombocytopenia， All Grades (16% to 23% ) Immunologic: Infectious disease (47% to 60% ) Neurologic: Asthenia (8% to 13% )， Headache (26% )， Peripheral neuropathy (13% ) Respiratory: Bleeding from nose (6.7% to 9.2% )， Upper respiratory infection (31% ) Other: Asthenia (7.5% to 17% )， Fatigue (37% to 41% )， Fever (12% to 13% ) Serious Hematologic: Anemia， Grade 3 or 4 (Up to 5% )， Febrile neutropenia (0.9% to 2.5%)， Leukopenia， Grade 3 or 4 (Grade 3， 24% to 30%; Grade 4， up to 1% )， Neutropenia， Grade 3 or 4 (Grade 3， 55% to 56%; Grade 4， 10% to 11% )， Thrombocytopenia， Grade 3 or 4 (Up to 2% ),30 ℃以下。,The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.When given with IBRANCE， the recommended dose of fulvestrant is 500 mg administered on Days 1， 15， 29， and once monthly thereafter. Please refer to the full prescribing information of fulvestrant. Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.,需調整劑量,[仿單]目前尚未進行過任何評估palbociclib 對乳汁生成作用之影響、是否出現於乳汁中、或其對餵哺母乳之嬰兒的影響的人體研究或動物研究。 目前並不確知palbociclib 是否會分泌進入人類的乳汁。 接受palbociclib 治療的病人不可餵哺母乳。,無需調整劑量,不可使用,Contraindicated,[仿單]目前並無或僅有有限的孕婦使用palbociclib 的資料。 動物研究顯示本品具有生殖毒性。 Ibrance並不建議於懷孕期間使用，也不建議用於具生育能力但未採取避孕措施的婦女。,Contraindicated 哺乳期使用禁忌,[仿單]目前尚未進行過任何評估palbociclib 對乳汁生成作用之影響、是否出現於乳汁中、或其對餵哺母乳之嬰兒的影響的人體研究或動物研究。 目前並不確知palbociclib 是否會分泌進入人類的乳汁。 接受palbociclib 治療的病人不可餵哺母乳。,PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。仿單建議應整顆吞服，勿咀嚼、咬碎或打開膠囊。
OSQL2,Nicotine,Smokquit 2mg (24 tablets/box),ZADT,Smoking Cessation Aid,Hypersensitivity to nicotine or any component of the product.,Common Dermatologic: Skin irritation， Patch Respiratory: Nasal irritation， Nasal spray， Oral irritation， Airway， inhaler Other: Nicotine withdrawal， Dizziness， headache， insomnia Serious Cardiovascular: Cardiac dysrhythmia (rare)， Hypertension (rare)， Tachyarrhythmia (rare) Immunologic: Hypersensitivity reaction (rare),室溫25℃以下,Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule: Weeks 1 to 6: 1 lozenge every 1 to 2 hours， use at least 9 lozenges/day. Weeks 7 to 9: 1 lozenge every 2 to 4 hours. Weeks 10 to 12: 1 lozenge every 4 to 8 hours. The recommended maximum dose: 15 lozenges/day.,無需調整劑量,[仿單] 建議孕婦及授乳婦不可使用含有尼古丁成分，如口含錠、貼片或口香糖來戒菸。,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,Contraindicated (with any use of tobacco) [仿單] 建議孕婦及授乳婦不可使用含有尼古丁成分，如口含錠、貼片或口香糖來戒菸。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 建議孕婦及授乳婦不可使用含有尼古丁成分，如口含錠、貼片或口香糖來戒菸。,SL;,,,,,[磨粉/管灌註記]本藥為口含錠，不可咀嚼或吞服。服藥後將口含錠含在口腔兩側移動，持續20-30分鐘直到完全溶解。
ECRO,Cromolyn,Cromo oph drops 2%， 10mL,TOPH,,適應症:Treatment of vernal keratoconjunctivitis， vernal conjunctivitis， and vernal keratitis 副作用: Ocular: Conjunctival injection， dryness around the eye， edema， eye irritation， immediate hypersensitivity reactions， itchy eyes， puffy eyes， styes， rash， watery eyes 禁忌:Hypersensitivity to cromolyn or any component of the formulation,,室溫,Conjunctivitis and keratitis: Ophthalmic: 1-2 drops in each eye 4-6 times/day,,,,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OMIN6,Desmopressin,Minirin Melt 60mcg,HM,Central Diabetes Insipidus， Primary Nocturnal Enuresis， Renal Concentrating Capacity Test， Symptomatic treatment of nocturia in adults associated with nocturnal polyuria ie， nocturnal urine production exceeding bladder capacity. Hemophilia A and von Willebrand's Disease,Habitual and psychogenic polydipsia， syndrome of inappropriate ADH secretion (SIADH)， known hyponatremia， known or suspected cardiac decompensation and other conditions that require diuretics， moderate and severe renal impairment.,Nausea， abdominal pain， headache， nasal congestion/rhinitis， nose bleeds. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl. Dermatologic: Flushing Gastrointestinal: Nausea， Will respond to dosage decrease Neurologic: Fatigue (10% )， Headache (22.5% ),25℃以下避光,Central diabetes insipidus: Initial dose as 60mcg three times per day， followed by 60-120mcg three times per day as maintain dose.(Total daily dose:120mcg-720mcg.) Primary nocturia: 120mcg at bedtime， up to 240mcg if needed. Nocturia: 60mcg at bedtime， up to 120mcg after one week & subsequently 240mcg weekly dose escalations.To be administered sublingually.,無需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為凍晶口溶錠。可溶水崩解後管灌。
IBRID,Sugammadex,Bridion inj 200mg/2mL,ZADT,Reversal of rocuronium or vecuronium: Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery,Hypersensitivity to sugammadex or any component of the formulation,>10%: Cardiovascular: Hypotension (5% to 13%) Central nervous system: Headache (10%) Gastrointestinal: Nausea (26%)， vomiting (11% to 15%) Local: Pain at injection site (48% to 52%) 1% to 10%: Cardiovascular: Hypertension (9%)， prolonged QT interval on ECG (6%)， bradycardia (5%)， tachycardia (2% to 5%) Central nervous system: Anesthesia complication (1% to 9%)， chills (7%)， incisional pain (4% to 6%)， dizziness (3% to 6%)， insomnia (5%)， hypoesthesia (3%)， anxiety (1% to 3%)， restlessness (1% to 2%)， depression (2%) Dermatologic: Pruritus (3%)， erythema (2%) Endocrine & metabolic: Hypocalcemia (2%) Gastrointestinal: Abdominal pain (4% to 6%)， flatulence (3%)， xerostomia (2%) Hematologic & oncologic: Wound hemorrhage (2%)， decreased red blood cells (1% to 2%) Neuromuscular & skeletal: Limb pain (6%)， musculoskeletal pain (2%)， myalgia (2%)， increased creatine phosphokinase (1% to 2%)， neuromuscular blockade (<=2%; reoccurrence) Respiratory: Cough (3% to 8%) Miscellaneous: Fever (5% to 9%)， procedural complications (8%)， hysterectomy (2%) <1%， postmarketing， and/or case reports: Anaphylactic shock， anaphylactoid reaction， anaphylaxis， atrial fibrillation， atrioventricular block， bronchospasm， dyspnea， extrasystoles， hypersensitivity reaction， laryngospasm， pulmonary edema， ST segment changes on ECG， supraventricular extrasystole， supraventricular tachycardia， urticaria， ventricular fibrillation， ventricular tachycardia， wheezing,30℃避光避免冷凍,Routine reversal of rocuronium- or vecuronium-induced blockade: IV: Deep block (at least 1 to 2 post-tetanic counts but prior to appearance of T2): 4 mg/kg as a single dose Moderate block (after appearance of T2): 2 mg/kg as a single dose Readministration of rocuronium or vecuronium: Following sugammadex use for routine reversal， waiting times for readministration of rocuronium or vecuronium vary greatly (5 minutes to 24 hours) depending on agent， dose， and renal function; if immediate neuromuscular blockade is needed， a nonsteroidal neuromuscular-blocking agent may be required. Immediate reversal of rocuronium-induced blockade: IV: 16 mg/kg as a single dose administered soon (~3 minutes) after administration of a single dose of rocuronium 1.2 mg/kg. Note: This dose of sugammadex has not been evaluated following administration of vecuronium.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVP;IVPUSH;,,【D5NS】可選 。【D5W】可選 。【L/R】可選 。【N/S】可選 。,IV push over 10 seconds,不可與其他藥品混合注入，將本藥在10秒內注入現存靜脈注射管線中,IV: Administer as rapid IV push over 10 seconds; if administered in same IV line as other products， flush with saline before and after administration of sugammadex. The pH is between 7 and 8 and osmolality is between 300 and 500 mOsm/kg. 已證明首次開啟及稀釋後在5-25℃下的化學及物理穩定性可達48小時。從微生物觀點來看，稀釋後的產品應立即使用。如果未立即使用的話，除非在有控制通風的無菌狀況下進行稀釋，使用前之儲存時間與條件為使用者的責任，而且通常在5-8℃下不應超過24小時。 2歲及以上兒童和青少年，可使用0.9%NaCl將Bridion稀釋至10 mg/mL，以提高給藥的正確性。
OREV,Sildenafil,Revatio 20mg,CAVS,Pulmonary arterial hypertension (PAH),Hypersensitivity to sildenafil or any component of the formulation; concurrent use (regularly/intermittently) of organic nitrates in any form (eg， nitroglycerin， isosorbide dinitrate); concomitant use of riociguat (a guanylate cyclase stimulator).,>10%: Flushing (10% to 19%)， Headache (16% to 46%)， Dyspepsia (3% to 17%; dose-related)， Visual disturbance (2% to 11%; including vision color changes， blurred vision， and photophobia; dose-related)， Epistaxis (9% to 13%) 2% to 10%: Insomnia (7%)， dizziness (2% to 4%)， paresthesia (3%)， Erythema (6%)， skin rash (1% to 3%)， Diarrhea (3% to 9%)， gastritis (?3%)， nausea (2% to 3%)， Urinary tract infection (3%)， Increased liver enzymes (2% to 10%)， Myalgia (2% to 7%)， back pain (3% to 4%)， Nasal congestion (4% to 9%)， exacerbation of dyspnea (7%)， nasal congestion (4%)， rhinitis (4%)， sinusitis (3%)， Fever (6%),儲存於25°C,Pulmonary arterial hypertension 20 mg TID; give doses approximately 4 to 6 hours apart. (maximum: 60mg/day),無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OLONS,Trifluridine + Tipiracil,Lonsurf 20mg,RACA,Metastatic colorectal cancer in adults,There are no contraindications listed in the manufacturer's labeling.,>10%: Fatigue (52%)， Nausea (37% to 48%)， decreased appetite (34% to 39%)， diarrhea (23% to 32%)， vomiting (25% to 28%)， abdominal pain (21%)， Anemia (63% to 77%; grades 3/4: 18% to 19%)， neutropenia (66% to 67%; grades 3/4: 38%;)， thrombocytopenia (34% to 42%; grades 3/4: 5% to 6%)， febrile neutropenia (grades 3/4: 3%)， Infection (23% to 27%)， Asthenia (?52%)， Fever (19%) 1% to 10%: Pulmonary embolism (2% to 3%)， Alopecia (7%)， Stomatitis (8%; grades 3/4: <1%)， dysgeusia (7%) <1%: postmarketing， and/or case reports: Interstitial pulmonary disease,25℃以下,35 mg/m2 (based on the trifluridine component) twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle (maximum per dose: trifluridine 80 mg); continue until disease progression or unacceptable toxicity. The manufacturer recommends rounding each dose to the nearest 5 mg increment.,需調整劑量,Micromedex: Infant risk cannot be ruled out.,需調整劑量,不可使用,Uknown 沒有資料,Micromedex: Fetal risk cannot be ruled out.,Unknown 沒有資料,Micromedex: Infant risk cannot be ruled out.,PC;PO;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
IENT,Vedolizumab,Entyvio inj 300mg,HIMM,Crohn disease or ulcerative colitis,Hypersensitivity reaction， severe or serious， to vedolizumab or any of its excipients.,Common Gastrointestinal: Nausea (9% ) Musculoskeletal: Arthralgia (12% ) Neurologic: Headache (12% ) Respiratory: Nasopharyngitis (13% )， Upper respiratory infection (7% ) Other: Fatigue (6% )， Fever (9% ) Serious Hepatic: Aminotransferase abnormal， Increased (less than 2% )， Hepatitis， Serum bilirubin raised Immunologic: Anaphylaxis (0.07% )， Hypersensitivity reaction， Infusion reaction (4% ) Neurologic: Progressive multifocal leukoencephalopathy Respiratory: Tuberculosis Other: Cancer (0.4% )， Infectious disease， Sepsis (0.03% ),2-8℃避光,IVD， ulcerative colitis， Crohn's disease 300 mg at week 0， 2 and 6， followed by every 8 weeks.,無需調整劑量,[仿單] 現有的已發表文獻顯示vedolizumab會進入人類的乳汁。Vedolizumab局部胃腸道暴露及可預期的全身性低暴露對受哺乳嬰兒之影響，目前尚不清楚。在一項僅授乳來評估在接受vedolizumab治療潰瘍性結腸炎或克隆氏症授乳婦女乳汁vedolizumab濃度試驗中，在人類乳汁裡vedolizumab濃度約為母體血中濃度(取自過去vedolizumab試驗數據)的0.4%至2.2%。推估嬰兒平均每日vedolizumab攝取量為0.02 mg/kg/day，相當於母體每日攝取量的21%(經體重調整)。考慮哺乳對於發育和健康的效益時，應衡量母親對安潰悠的臨床需求，及來自安潰悠或母體基礎疾病對受哺乳嬰兒的潛在不良反應。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單] 風險摘要 依據現有的藥物安全監視資料、進行中的懷孕登錄資料、已發表的孕婦個案報告及世代研究資料，並未發現與安潰悠有關的重大先天性缺陷、流產，或母體或胎兒的不良結果。懷孕期間的發炎性腸道疾病，對母親和胎兒都有風險(參見臨床考量)。尚未進行安潰悠用於懷孕女性的試驗。動物生殖試驗中，兔子和猴子靜脈注射高於人體建議劑量20倍的vedolizumab，並未觀察到胚胎傷害(參見試驗資料)。特定族群發生重大先天性缺陷和流產的估計背景風險，目前尚不清楚。所有懷孕都有先天缺陷、流產或其他不良結果的背景風險。在美國一般族群，臨床上確認懷孕後，發生重大先天性缺陷和流產的預估背景風險，分別為2至4%及15至20%。 臨床考量 安潰悠之任何懷孕不良作用，在懷孕第二和第三孕期時可能較嚴重。單株抗體會隨孕期進展而以線性方式通過胎盤，在第三孕期的傳送量最大。 疾病相關的母體和胚胎/胎兒風險 已發表的資料顯示，罹患發炎性腸道疾病(IBD)的女性，懷孕結果不良的風險與疾病活動度增加有關。懷孕的不良結果包括早產(懷孕週數未滿37週)、嬰兒出生體重偏低(低於2500公克)及出生體重不足。 胎兒/新生兒不良反應 懷孕期間使用安潰悠，可能會影響在子宮內受暴露的新生兒及嬰兒之免疫反應。嬰兒在子宮內暴露於低濃度安潰悠之臨床影響，目前尚不清楚。受暴露的嬰兒施打活毒或減毒疫苗之安全性，目前也尚不清楚。 試驗資料 動物資料 對懷孕兔子的生殖試驗中，在妊娠第7天靜脈注射單劑最高100毫克/公斤劑量的vedolizumab(約為人體建議劑量的20倍)，並無證據顯示導致生育能力受損或胎兒傷害。一項猴子的產前及產後發育試驗中，靜脈注射最高100毫克/公斤劑量vedolizumab(約為人體建議劑量的20倍)，並無證據顯示對產前及產後發育產生任何不良作用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 現有的已發表文獻顯示vedolizumab會進入人類的乳汁。Vedolizumab局部胃腸道暴露及可預期的全身性低暴露對受哺乳嬰兒之影響，目前尚不清楚。在一項僅授乳來評估在接受vedolizumab治療潰瘍性結腸炎或克隆氏症授乳婦女乳汁vedolizumab濃度試驗中，在人類乳汁裡vedolizumab濃度約為母體血中濃度(取自過去vedolizumab試驗數據)的0.4%至2.2%。推估嬰兒平均每日vedolizumab攝取量為0.02 mg/kg/day，相當於母體每日攝取量的21%(經體重調整)。考慮哺乳對於發育和健康的效益時，應衡量母親對安潰悠的臨床需求，及來自安潰悠或母體基礎疾病對受哺乳嬰兒的潛在不良反應。,IVD;,4.8mL注射用無菌水,【L/R】可選 仿單建議。【N/S】可選 仿單建議。,,以靜脈輸注30分鐘方式給予， 請勿以靜脈注射或推注方式給藥。輸注完成後使用30mL的N/S或L/R沖洗。輸注溶液配製完成並稀釋後，請儘快使用。 稀釋說明: 將5mL(300 mg)配製完成的溶液，加入250毫升的無菌N/S或L/R，並輕輕晃動輸注袋. 請勿將其他藥品加入準備好的輸注溶液或靜脈輸注管線組.,應使用無菌技術在20-25℃下配製: 1.使用21至25 gauge針頭，以4.8mL注射用無菌水配製。 2.針頭插入並導引注射用無菌水沿藥瓶玻璃壁流下，以免產生泡沫。 3.輕晃動至少15秒，勿用力搖晃或倒轉。 4.室溫下靜置最多20分鐘，以便配製並等所有泡沫消失，如未完全溶解，可再放置10分鐘.未在30分鐘內溶解，勿使用此藥。 5.溶液應為清澈或半透明，無色至淺棕黃色，不含顆粒.若溶液顏色異常或含顆粒，勿使用。 6.輕倒轉藥瓶三次，再抽取配製好的溶液5mL，藥瓶內剩餘的溶液請丟棄。 儲存:配製後應立即使用，如冷藏可保存8小時。稀釋於N/S後20-25℃可保存12小時，2-8℃冷藏可24小時。稀釋於L/R後應立即使用，2-8℃冷藏可6小時。
IFOR25,Paclitaxel,FORMOXOL inj 150mg/25mL,RACA,,適應症: After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma. 副作用: Bone marrow suppression， peripheral neuropathy， GI disturbances， alopecia， hypersensitivity. Dermatologic: Alopecia (55% to 96% ) Gastrointestinal: Diarrhea (16% to 90% )， Inflammatory disease of mucous membrane (5% to 45% )， Nausea and vomiting， Any grade (9% to 88% ) Hematologic: Anemia， Any grade (47% to 96% )， Leukopenia (90% )， Neutropenia， Any grade (78% to 100% )， Thrombocytopenia， Any grade (4% to 68% ) Immunologic: Immune hypersensitivity reaction， Any grade (2% to 45% ) Musculoskeletal: Arthralgia， Myalgia Neurologic: Peripheral neuropathy， Any grade (42% to 79% ) 禁忌: Hypersensitivity to paclitaxel， polyoxyl 35/polyoxyethylated castor oil (Cremophor EL)， or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts <1，500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts <1，000/mm3.,,室溫,135-175 mg/m2 IV over 3 hr every 3 weeks. Patients must be premedicated dexamethasone， diphenhydramine & cimetidine prior to administration.,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 稀釋溶液與器具應使用玻璃、聚丙烯(polypropylene)、聚烯(polyolefin)材質，不可使用含DEHP的PVC塑膠材質。 3. 配製好的輸注溶液濃度在 0.3 - 1.2 mg/mL，室溫下安定性維持 27小時。 4. 注射前應先給予預防過敏的藥物。輸注開始的第一個小時應監測Vital Sign。 5. 曾使用 Paclitaxel發生心臟傳導異常的病人，之後使用Paclitaxel期間應進行連續心電圖監測。 6. 監測CBC。 7.含有蓖麻油成分，容易造成病患過敏反應，施打時應由低速率開始調整，並注意病人反應。
OSYN1,Piracetam,Syntam F.C. 1200mg(欣坦),CNEU,Cognitive disorders. Cortical myoclonus， adjunctive.,Patients who are allergic to Piracetam， or allergic to any of the compositions in Syntam， or allergic to pyrrolidone derivatives. Patients with intracerebral hemorrhage or End Stage Renal Disease.,Hyperkinesis， Weight gain， Neuroticism， Lethargy， Depression， Powerless， Dizziness， Abdominal pain， upper abdominal pain， diarrhea， nausea， vomiting， acute allergic reaction， peace of mind， imbalance， worsening epilepsy， headache， insomnia， drowsiness， emotional agitation， anxiety， disorders， hallucinations， Angioedema， dermatitis， itching， urticaria.,25℃以下乾燥處,Cognitive disorders: 1.2 to 4.8 g daily in 2 to 4 divided doses Cortical myoclonus， adjunctive: Initial: 7.2 g daily administered in 2 to 3 divided doses; may increase total daily dose by 4.8 g every 3 to 4 days if needed (maximum daily dose: 24 g),無需調整劑量,[仿單]Piracetam 會滲入乳汁，因此授乳期間應避免使用本藥，或是在使用Piracetam 治療期間應停止授乳。,需調整劑量,不可使用,Uknown 沒有資料,[仿單]動物試驗顯示 Piracetam 並不會對懷孕者、生長中的胚胎，及出生後的胎兒造成直接或間接的傷害。 但迄今並無孕婦使用Piracetam的臨床資料。Piracetam 會通過胎盤。 新生兒體內的藥品濃度約為母體的70-90%因此除非必要，懷孕期間不應使用Piracetam。,Unknown 沒有資料,[仿單]Piracetam 會滲入乳汁，因此授乳期間應避免使用本藥，或是在使用Piracetam 治療期間應停止授乳。,AC;AC15;PC;PO;WM;,,,,,
IXOL,Omalizumab,Xolair inj 150mg/1.2mL,ERSP,--Treatment of moderate to severe persistent asthma in adults and adolescents 12 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. --Chronic idiopathic urticaria: Treatment of chronic idiopathic urticaria in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamine treatment.,Hypersensitivity reaction to omalizumab or any component of the formulation,>10%: Central nervous system: Headache (6% to 12%) 1% to 10%: Cardiovascular: Peripheral edema (>2%) Central nervous system: Anxiety (>2%)， migraine (>2%) Dermatologic: Alopecia (>2%) Gastrointestinal: Toothache (>2%) Genitourinary: Urinary tract infection (>2%) Infection: Fungal infection (>2%) Local: Injection site reaction (3%) Neuromuscular & skeletal: Arthralgia (3%)， limb pain (>2%)， musculoskeletal pain (>2%)， myalgia (>2%) Respiratory: Nasopharyngitis (9%)， sinusitis (5%)， upper respiratory tract infection (3%)， asthma (>2%)， oropharyngeal pain (>2%)， sinus headache (>2%)， cough (2%)， viral upper respiratory tract infection (<2%) Miscellaneous: Fever (>2%) All indications: <1% (Limited to important or life-threatening): Alopecia， anaphylaxis， antibody development， arthritis， chest tightness， Churg-Strauss syndrome， lymphadenopathy， malignant neoplasm， pulmonary hypertension， syncope， thrombocytopenia， transient ischemic attacks,2-8℃避光避免冷凍,Allergic asthma: The appropriate dose and frequency of Xolair is determined by baseline IgE (IU/ml)， measured before the start of treatment， and body weight (kg). Prior to administration of the initial dose， patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements， 75 to 600 mg of Xolair in 1 to 4 injections may be needed for each administration. Chronic spontaneous urticaria(CSU): Usual dose: 150 or 300 mg every 4 weeks. Dosing for this indication is not dependent on serum IgE (free or total) level or body weight.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,SC;,使用所附稀釋溶液,,,,1.本藥僅供單次使用的小瓶，配製後藥品於2℃至8℃可放置8 小時，於30℃下為4 小時。 2.以配備有大內徑18 號針頭，自安瓿中抽1.4 毫升注射用水，並注入omalizumab 小瓶中。 3. 將小瓶保持直立，不停地旋轉直立小瓶（不可上下搖動），凍晶乾粉完全溶解可能花費超過20 分鐘。配製後藥品為澄清或些許不透明感。若有異物即不可使用。 4. 以 25 號針頭進行皮下注射。排除氣體、大氣泡及多餘的溶液，此注射小瓶含1.2 毫升（150 毫克）的喜瑞樂。因溶液較粘稠，注射需5-10 秒。 5. 於手臂或大腿的三角肌區域進行皮下注射，避開蕁麻疹病灶處。
OACT40,Acetylcysteine,Actein 100mg/2.5gm,ERSP,Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis， emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms.,Phenylketonuria.,Bronchospasm， GI upsets， stomatitis; rhinorrhea， fever， hemoptysis; rarely anaphylactic reactions. Dermatologic: Pruritus (1% to 4.3% )， Rash (4% to 5% )， Urticaria Gastrointestinal: Diarrhea， Nausea (2% to 7% )， Vomiting (9% to 12% ),25℃以下乾燥處所,Adult and 12 years older Children: 200 mg TID. 6-12 years old Children:100 mg TID. 3-6 years old Children: 50mg TID.,無需調整劑量,[仿單]未有建議,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,[仿單]未有建議,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]未有建議,AC;AC15;P1;P2;PC;PO;WM;,,,,,
ORIBA,Ribavirin,Ribarin 200mg (摩舒肝清),QANB,In combination with interferon α for the treatment of chronic hepatitis C in adult patients who are α-interferon-naive or who have relapsed following α-interferon therapy.,History of severe pre-existing cardiac disease; haemoglobinopathies; severe， debilitating medical conditions; severe hepatic dysfunction or decompensated liver cirrhosis; autoimmune hepatitis or a history of autoimmune disease; pre-existing thyroid disease. Pregnancy & lactation.,Haemolysis， anaemia， neutropenia， dry mouth， hyperhidrosis， asthenia， chest pain， fatigue， fever， headache， flu-like symptoms， malaise， rigors， weight loss， dizziness， paresthesia， GI disturbances， arthralgia， myalgia， CNS effects， viral infection， cough， dyspnoea， pharyngitis， rhinitis， alopecia， pruritus， rash， dry skin， parageusia， blurred vision. Dermatologic: Pruritus， Rash Gastrointestinal: Indigestion， Loss of appetite， Nausea Hematologic: Neutropenia (8% to 40% ) Neurologic: Headache Other: Fatigue,25℃以下,Adult >= 18 years 1000-1200 mg daily in 2 divided doses， in combination with interferon α soln for inj administered SC at a dose of 3MIU 3 times/wk. The recommended dose of ribavirin is based on body weight (consistent with food): 1000 mg per day for patients weighing < 75 kg and 1200 mg for weight >= 75 kg， and should be divided into twice daily doses.,無需調整劑量,,需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ISUP,Ondansetron,Supren inj 8mg/4mL(限麻醉組套),CNEU,Prevention or treatment of nausea and vomiting caused by surgery， chemotherapy or radiation therapy.,Hypersensitivity to ondansetron or any component of the formulation; concomitant use with apomorphine,Common Gastrointestinal: Constipation (11% )， Diarrhea (adults， 16%; pediatrics， 2%)， Xerostomia (5% ) Hepatic: Increased liver enzymes (17% ) Neurologic: Headache (17% ) Other: Fever (2% to 8% ) Serious Cardiovascular: Atrial fibrillation， Electrocardiogram abnormal， Prolonged QT interval， Torsades de pointes Neurologic: Oculogyric crisis Other: Serotonin syndrome,,,,,,,,,,,IM;IVD;IVPUSH;,,,,,
ITRAM,Tramadol,Tramtor inj 100mg/2mL,CNEU,Relief of moderate to moderately-severe pain,Hypersensitivity to tramadol， opioids， or any component of the formulation,Common: Flushing (7.7-15.8%)， Pruritus (3-11.9%)， Constipation (10-46%)， Nausea (13-40%)， Vomiting (3-17%)， Xerostomia (1-10%)， Dizziness (7-33%)， Headache (3-32%)， Insomnia (1-10.9%)， Somnolence (4-25%) Serious: Myocardial infarction (0.5-1%)， Hypoglycemia， Pancreatitis (0.5-1%)， Allergic reaction， Anaphylaxis， Seizure (<1%)， Difficulty breathing， Dyspnea (<5%)， Respiratory depression， Serotonin syndrome (<1%),室溫藥品，仿單無特別指示儲存溫度條件,Adults and teenagers over 12 years old: 50-100 mg(1-2 amp) every 4-6 hours.IM/IV/SC， maximum dose: 400 mg/day. If after 30-60 minutes of administration of a single dose of Tramadol hydrochloride 50 mg， pain relief cannot be achieved， a second single dose of 50 mg can be given. The dosage is higher than normal use， and the demand usually does not exceed 24 hours. Children， >1 year old: 1-2 mg/kg， maximum dose:8mg/kg/day， and don't exced 400mg/day. Elders， >75 years old: Extend the dosing interval,需調整劑量,,需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;IVD;IVP;IVPUSH;SC;,,【D5W】可選 。【L/R】可選 。【N/S】可選 。,推注時間至少2 ~ 3分鐘,infusion concentration 0.5-4 mg/mL.,
EDEX2,Dexamethasone,Dexaltin(口內膏) 0.1%， 2gm,TENT,,適應症: Intractable stomatitis or glossitis associated with erosion or ulceration. 副作用: Fungal or bacterial infection of the oral cavity; hypersensitivity; hypofunction of pituitary-adrenocortical system (prolonged use). Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin， Finding of skin healing， Impaired Endocrine metabolic: Cushing's syndrome， Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )， Raised intraocular pressure (25% ) Psychiatric: Depression， Euphoria Respiratory: Pulmonary tuberculosis 禁忌: Patients with tuberculotic， viral or other purulent infections of the oral cavity.,,室溫,Apply adequate amount to the affected area once to several times daily.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ODIBO,Acarbose,Dibose 100mg,META,Diabetes mellitus， type 2: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (noninsulin dependent， NIDDM).,Hypersensitivity to acarbose or any component of the formulation; diabetic ketoacidosis; cirrhosis; inflammatory bowel disease， colonic ulceration， partial intestinal obstruction， patients predisposed to intestinal obstruction; chronic intestinal diseases associated with marked disorders of digestion or absorption; conditions that may deteriorate as a result of increased gas formation in the intestine.,>10%: Gastrointestinal: Frequency and intensity of flatulence (74%) tend to abate with time; diarrhea (31%) and abdominal pain (19%) tend to return to pretreatment levels over time. 1% to 10%: Hepatic: Increased serum transaminases (?4%) <1%， postmarketing， and/or case reports: Edema， erythema， hepatic injury， hepatitis， intestinal obstruction， jaundice， pneumatosis cystoides intestinalis， skin rash， thrombocytopenia， urticaria,25℃以下避免潮濕及陽光照射,50-100 mg TID， maximum 200 mg TID.,無需調整劑量,,需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PO;WM;,,,,,
OVERZ,Abemaciclib,Verzenio 150mg (28 tablets/box),RACA,Breast cancer， Advanced or metastatic， hormone receptor-positive disease， HER2-negative， in combination with an aromatase inhibitor for initial endocrine therapy in postmenopausal women and men. Breast cancer， Advanced or metastatic， hormone receptor-positive disease， HER2-negative， in combination with fulvestrant for progression following endocrine therapy. Breast cancer， Advanced or metastatic， hormone receptor-positive disease， HER2-negative， monotherapy for progression following endocrine therapy and prior chemotherapy in the metastatic setting. Breast cancer， Early， hormone receptor-positive， HER2-negative， node-positive， high-risk， in combination with adjuvant endocrine therapy.,Allergic to the active ingredients or excipients in Verzenio.,Common Gastrointestinal: Abdominal pain (29% to 39% )， Decrease in appetite (12% to 45% )， Diarrhea， All Grades (81% to 90% )， Nausea (39% to 64% )， Vomiting (26% to 35% ) Hematologic: Anemia， All Grades (25% to 29% )， Leukopenia， All Grades (17% to 28% )， Neutropenia， All Grades (37% to 46% ) Immunologic: Infectious disease (31% to 51% ) Neurologic: Headache (20% ) Other: Fatigue (40% to 65% ) Serious Gastrointestinal: Diarrhea， Grade 3 (8% to 20% ) Hematologic: Febrile neutropenia (Less than 1% )， Neutropenia， Grade 3 or higher (19% to 32% )， Neutropenic sepsis， Venous thromboembolism (2% to 5% ) Hepatic: ALT/SGPT level raised (Grade 3 or higher， 2% to 6% )， Aspartate aminotransferase serum level raised (Grade 3 or higher， 2% to 3% ) Neurologic: Cerebral infarction Respiratory: Interstitial lung disease， Pneumonitis,儲存於30°C以下,In combination with fulvestrant， tamoxifen， or an aromatase inhibitor， the recommended dose is 150 mg taken orally twice daily. As monotherapy， the recommended dose is 200 mg taken orally twice daily. Dose Modifications for Adverse Reactions: In combination with fulvestrant， tamoxifen， or an aromatase inhibitor: Recommended starting dose: 150 mg twice daily -> First dose reduction: 100 mg twice daily -> Second dose reduction: 50 mg twice daily -> Third dose reduction: not applicable. As monotherapy: Recommended starting dose: 200 mg twice daily -> First dose reduction: 150 mg twice daily -> Second dose reduction: 100 mg twice daily -> Third dose reduction: 50 mg twice daily.,需調整劑量,[仿單]目前沒有abemaciclib是否進入人體乳汁，對授乳嬰兒或對乳汁分泌影響的資料。由於VERZENIO可能使授乳嬰兒發生嚴重不良反應，應告知哺乳婦女於VERZENIO治療期間及接受最後一劑治療後3週內不可哺乳。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]根據動物試驗的發現及藥物作用機轉，若給予懷孕婦女VERZENIO，可能會造成胎兒傷害。目前並無人類的藥物風險資料。應告知懷孕婦女此藥物可能對胎兒造成之潛在危害。在動物生殖試驗中，在器官形成期間投予abemaciclib，abemaciclib的母體曝露量與最大建議人體劑量下的AUC之人類臨床曝露量相近時，具有致畸胎性也會導致胎兒體重減輕。應告知懷孕婦女此藥物可能對胎兒造成之潛在危害。 有關特定族群發生重大先天缺陷和流產的背景風險尚不清楚。然而在美國一般族群的臨床確認懷孕中，發生重大先天缺陷的背景風險為2至4%，流產的背景風險為15至20%。 在一項胚胎－胎兒發育試驗中，於器官形成期間給予懷孕大鼠最高達15 mg/kg/day的abemaciclib口服劑量。劑量?4 mg/kg/day會導致胎兒體重降低，及心血管和骨骼畸形與變異事件的發生率提高。這些發現包括缺乏無名動脈和主動脈弓、鎖骨下動脈錯位、胸骨未骨化、胸椎椎體的二分骨化，及雛肋或結節狀肋骨。使用4 mg/kg/day的大鼠其母體全身曝露量大約與建議劑量的人體曝露量(AUC)相當。 告知具有生育能力的女性，在VERZENIO治療期間及接受最後一劑治療後3週應採用有效的避孕措施。,Unknown 沒有資料,[仿單]目前沒有abemaciclib是否進入人體乳汁，對授乳嬰兒或對乳汁分泌影響的資料。由於VERZENIO可能使授乳嬰兒發生嚴重不良反應，應告知哺乳婦女於VERZENIO治療期間及接受最後一劑治療後3週內不可哺乳。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議病人應吞服整顆錠劑，不可將錠劑咀嚼、壓碎或切半後吞服。如果錠劑破裂、裂開或不完整，請病人不要服用。
ICEFS,Ceftriaxone,Ceft-S inj 1gm,QANB,Infections caused by staphylococcus， streptococcus， pneumococcus， meningococcus， and other susceptible bacteria.,Concurrent administration of calcium-containing IV solutions， including continuous calcium-containing infusions such as parenteral nutrition， in neonates aged 28 days or less due to risk of fatal salt precipitation in lungs and kidneys. Hyperbilirubinemic neonates， due to increased risk of bilirubin encephalopathy (kernicterus)， especially in premature neonates. Hypersensitivity to cephalosporins. Pregnant women， especially during the first three months， should avoid using unless absolutely necessary.,Common: Injection site induration， Warmth， tightness， or induration (5-17%)， Diarrhea (2.7-5.6%)， Eosinophil count above reference range (6%)， Thrombocytosis (5.1%) Serious: Erythema multiforme， Stevens-Johnson syndrome， Toxic epidermal necrolysis， Clostridium difficile colitis， Hemolytic anemia (<1%)， Neutropenia， Hypersensitivity reaction (2.7-3.3%)， Kernicterus of newborn， Renal failure， Injury of lung,25℃以下。調配後室溫可保存6小時。,For adults: 1-2g once daily. Severe infections: maximum 4g/day， divided into two doses. For neonates (up to 2 weeks old): 20-50mg/kg/day， maximum 50mg/kg. For infants and children (3 weeks-12 years old): 20-80mg/kg/day， administered once daily. (Sanford Guide) Adult - Usual: 1-2g IV q24h. Purulent meningitis: 2g IV q12h. Gonococcal urethritis: single dose of 500mg IM (if <150kg)， 1g IM (if >=150kg). Meningococcal PEP (age >=15): single dose of 250 mg IM Pediatric - Age >28 Days: 50-100mg/kg q24h; Meningitis 50mg/kg q12h. Meningococcal PEP (age <15): 125mg IM x 1 dose,無需調整劑量,,無需調整劑量,盡量避免,Compatible,[仿單] 雖然實驗得知本品不會產生突變或畸型作用，但為了安全起見，懷孕婦女(尤其前3個月) 除非病情絕對需要，否則請勿投予本藥。,Compatible 哺乳時可使用,,IM;IVD;IVPUSH;,IV: 1 g/vial in 10 mL sterile water for injection， 0.9% sodium chloride， 5% or 10% dextrose， 0.45% sodium chloride 2% dextrose; IM: 1 g/vial in 3.5 mL 1% lidocaine IM若以3.5mL Water for injection稀釋後給藥，須IM Lidocaine局麻完成後再給予Ceftriaxone.,【D10W】可選 仿單建議。【D2.5HS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,緩慢推注至少2至4分鐘,Infuse over 5-15 minutes; 2 g in 40 mL,1. 本藥品勿與含鈣或其他抗生素溶液混合。調配後室溫可保存6小時。 2. 注射前詢問病患是否有β-醯胺類抗生素過敏史。 3. 監測體溫、CBC、肝腎功能，抗生素引起的腹瀉。 4. 靜脈滴注給藥，給藥時間30-60分鐘(濃度: 10-40 mg/mL or lower) [Micromedex] 5. 肌肉注射時，將Ceft-S 1g乾粉注射劑溶於3.5 mL 1%鹽酸利多卡因(Lidocaine hydrochloride)溶液後注入深部臀肌，每邊注射劑量不可超過1g，肌肉注射每日最大劑量不得超過2 g。Lidocaine溶液不應該靜脈給藥。
OEPR,Escitalopram,Epram 10mg,CNEU,Treatment of depression and prevention of recurrence， treatment of panic disorder， social anxiety disorder， general anxiety disorder and obsessive-compulsive disorder.,Concomitant treatment with non-selective， irreversible MAOIs.,Appetite decreased， libido decreased， anorgasmia (female)， insomnia， somnolence， dizziness， sinusitis， yawning， nausea， diarrhoea， constipation， sweating increased， ejaculation disorder， impotence， fatigue， pyrexia. Rarely， hyponatraemia， seizures， ecchymoses. Cardiovascular: Hypertension (1% or greater )， Palpitations (1% or greater ) Dermatologic: Diaphoresis (4% to 5% )， Rash (1% or greater ) Endocrine metabolic: Weight increased (1% or greater ) Gastrointestinal: Constipation (3% to 6% )， Diarrhea (6% to 14% )， Gastroenteritis (1% or greater )， Heartburn (1% or greater )， Indigestion (2% to 6% )， Nausea (15% to 18% )， Xerostomia (4% to 9% ) Musculoskeletal: Arthralgia (1% or greater )， Myalgia (1% or greater ) Neurologic: Dizziness (4% to 7% )， Headache (24% )， Insomnia (7% to 14% )， Lightheadedness (1% or greater )， Somnolence (4% to 9% ) Reproductive: Disorder of ejaculation (9% to 14%)， Impotence (3% )， Orgasm incapacity (females， 2% to 6% )， Reduced libido (males， 6%; females， 3%) Other: Fatigue (2% to 6% ),避光並於25℃以下儲存,Adults: 10 mg once a day; may be increased to maximum dose 20 mg once a day. Elderly， >65 years old: 5 mg once a day; maximum dose: 10mg/day Children， <18 years old: Contraindicated. There have been reports of suicidal behaviors or thoughts in children after taking medicine.,需調整劑量,,需調整劑量,沒有資料,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;PC;PO;WM;,,,,,
RIBISSM,Spesolimab/Placebo,試BI-655130-1368-0016 (150mg Spesolimab/Placebo),HIMM,,,,,,,,,,,,,,,,,,,
IPROD125,Hydroxyprogesterone caproate,Progeston Depot inj 125mg/1mL(普寶胎),HM,Amenorrhoea， Abnormal uterine bleeding， Recurrent miscarriage， Threatened abortion,Severe hepatic impairment;History of Pruritic Urticarial Papules and Plaques of Pregnancy,■Dermatologic: Injection site pain (34.8%)， Injection site pruritus (5.8%)， Injection site reaction (4.5%)， Pruritus (7.7%)， Swelling at injection site (17.1%)， Urticaria (12.3%) ■Gastrointestinal: Diarrhea (2.3%)， Nausea (5.8%) ■Electrolyte metabolism: Weight gain， Edema(<1%) ■Neurological: Headache(<1%)， Sleepy ■Liver: Liver dysfunction,25℃以下避光,IM 65-125mg per week.,無需調整劑量,用法用量依據仿單， Up to date,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,用法用量依據仿單， Up to date,IM;,,,,,
IVAX3,Purified Split Inactivated Influenza Virus,免費流感(3~12歲) 0.5mL/dose,HIMM,,,,,,無需調整劑量,,無需調整劑量,,Compatible,,Compatible 哺乳時可使用,,IM;,,,,,
IVAX5,Purified Split Inactivated Influenza Virus,免費幼兒流感(6M~3Y) 0.25mL/dose,HIMM,,適應症: Active immunisation against influenza. 副作用: Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome. 禁忌: Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,,2 ~ 8 °C,Adult & Children >= 36 mth IM Chidren <= 8 yr who have not been vaccinated previously， the 2nd dose can be given at an interval of at least 4 wk.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;,,,,,
IFLU4,Purified Split Inactivated Influenza Virus,GSK 4價自費流感(Fluarix Tetra)0.5mL/dose,HIMM,Active immunisation against influenza.,History of severe allergic reactions (e.g.， anaphylaxis) to any component of the vaccine.,Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome.,2-8°C.請勿冷凍,IM， 0.5 mL， > or = 6 months (< 9 years who have not been vaccinated previously， the second dose can be given after 4 weeks.),無需調整劑量,[仿單] 評估風險和益處後，懷孕及哺乳婦女得施打本疫苗。 目前尚未評估餵哺母乳的婦女施打Fluarix Tetra的安全性。 目前也不確知Fluarix Tetra是否會分泌進入人類的乳汁。,無需調整劑量,沒有資料,Compatible,[仿單]評估風險和益處後，懷孕及哺乳婦女得施打本疫苗。目前尚未於臨床試驗中評估對孕婦施打Fluarix Tetra的安全性。 根據系統性文獻綜述獲得之去活化季節性流感疫苗的安全性資料以及可用的上市後使用經驗，於妊娠期間接種去活化季節性流感疫苗，並未顯示將增加孕期不良反應的風險。 以Fluarix Tetra所進行的動物研究，並未發現任何直接或間接對生殖與發育毒性方面的有害影響(參見非臨床相關資訊)。 目前尚未評估餵哺母乳的婦女施打Fluarix Tetra的安全性。目前也不確知Fluarix Tetra是否會分泌進入人類的乳汁。,Compatible 哺乳時可使用,[仿單] 評估風險和益處後，懷孕及哺乳婦女得施打本疫苗。 目前尚未評估餵哺母乳的婦女施打Fluarix Tetra的安全性。 目前也不確知Fluarix Tetra是否會分泌進入人類的乳汁。,IM;,,,,,請保存於冰箱中(2°C至8°C)。切勿冷凍。施打前應先充分振搖針筒 Fluarix Tetra是一個去活化流感病毒疫苗，含有由雞蛋胚胎中所繁殖製造而來的抗原，含有下列流感病毒株抗原：A/Victoria/2570 /2019 (H1N1)pdm09 - like strain (A/Victoria/2570 /2019， IVR-215);A/Cambodia/e0826360/2020 (H3N2) - like strain (A/Tasmania/503/2020， IVR-221);B/Washington/02/2019 - like strain (B/Washington/02/2019， wild type);B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013， wild type).
ITET,DTaP-IPV,Tetraxim (四合一， 政府提供) 0.5mL/dose,HIMM,TETRAXIM is indicated to help protect your child against diphtheria， tetanus， pertussis and poliomyelitis in children from 2 months of age as a primary vaccination and as a booster dose during the second year of life and in children from 5 to 11 years or 11 to 13 years of age， according to national official recommendations.,Hypersensitivity. Acute illness eg febrile illness， encephalopathy of unknown origin w/in 7 days of previous pertussis vaccination. Pregnancy & lactation.,Adolescents and Adults- Injection site pain， erythema and swelling， tiredness， headache， bodyache， chills， nausea， fever， arthralgia or joint swelling (1/10) Diarrhoea， vomiting (<1/10 and >1/100) Children 5 to 6 years old - Injection site pain and swelling; fatigue (1/10) Injection site erythema and pruritus; fever >38°C (<1/10 and >1/100) Diarrhoea， vomiting (<1/100 and >1/1，000),2-8℃避免冷凍,IM， 0.5 mL， 5-13 years.,無需調整劑量,[訪單]無資料。,無需調整劑量,不可使用,Uknown 沒有資料,[訪單]無資料。,Unknown 沒有資料,[訪單]無資料。,IM;,,,,,
OMOR1,Morphine,Morphine 15mg,CNEU,Relief of moderate to severe pain. Pre-op anesth.,Respiratory depression， head injury， obstructive airways disease， paralytic ileus， GI obstruction， delayed gastric emptying， acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children < 3 years.,Nausea， vomiting， constipation， drowsiness， palpitations， headache， disorientation， vertigo， mood changes， decreased libido， ureteric spasm， urinary retention， rash， sweating， facial flushing， miosis. Cardiovascular: Peripheral edema (5% to 10% ) Dermatologic: Pruritus (up to 80% )， Rash (5% to 10% )， Sweating (5% to 10% ) Gastrointestinal: Abdominal pain (5% to 10% )， Constipation (> 10% )， Diarrhea (5% to 10% )， Loss of appetite (5% to 10% )， Nausea and vomiting (7% to 70% )， Xerostomia (5% to 10% ) Hepatic: Liver function tests abnormal (< 5% ) Musculoskeletal: Backache (5% to 10% ) Neurologic: Asthenia (5% to 10% )， Dizziness (6% )， Headache (>10% )， Insomnia (5% to 10% )， Lightheadedness， Paresthesia (5% to 10% )， Somnolence (> 10% ) Ophthalmic: Amblyopia (< 5% )， Miosis Psychiatric: Anxiety (6% )， Depression (5% to 10% ) Renal: Urinary retention (oral: < 5% ; epidural/intrathecal: 15% to 70% ) Other: Fever (5% to 10% )， Hiccoughs (< 5% ),25℃以下緊密避光容器,5-30 mg every 4 hours.,無需調整劑量,,需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
EKEL,Ketorolac,Kelac 0.5%， 5mL ophthalmic solution,TOPH,Temporary relief of ocular itching due to seasonal allergic conjunctivitis. Treatment of post-operational inflammation in patients who have undergone cataract extraction.,Patients who have previously demonstrated hypersensitivity to any of the ingredients of Kelac ophthalmic solution.,Common Ophthalmic: Burning sensation in eye (20% to 40% )， Corneal edema (1% to 10% )， Eye infection (1% to 10% )， Eye irritation (1% to 10% )， Iritis (1% to 10% )， Pain in eye (1% to 10% )， Superficial keratitis (1% to 10% ) Serious Ophthalmic: Corneal thinning， Perforation of cornea,儲存於攝氏25度以下,Relief of ocular itching due to seasonal allergic conjunctivitis: Instill 1 drop QID. Treatment of inflammation in patients who have undergone cataract extraction: Instill 1 drop QID (above 24 hrs post-operation)， and use constantly until 2 weeks after surgery.,無需調整劑量,[仿單]本品投與授乳婦時應審慎。,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,[仿單]致畸胎效應：對兔使用3.5mg/kg每日口服劑量及大鼠使用10mg/kg於器官發生其間進行生殖研究，研究結果並未造成胎兒畸形，Ketorolac tromethamine口服劑量1.5mg/kg，乃人類口服劑量之半，於大鼠妊娠17日後投藥引發難產及死亡率增高；並無用於孕婦之充分且經過徹底對照研究，故唯有於潛在效益超過對胚胎之潛在風險時方可用於孕婦。非致畸胎效應：由於已知前列腺素抑制性藥物對胎兒心血管的影響(動脈導管閉合)，因此於懷孕末期進劑使用本品。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]本品投與授乳婦時應審慎。,OD;OL;OU;,,,,,1.保管時若容器前端和蓋子出現結晶，請以乾淨紗布擦拭後使用。 2.開瓶注意事項:產品使用前，先以順時針方式向下旋緊一圈後再逆時針轉開藥瓶使用，以利藥液滴出。
EFOS,Beclomethasone + Formoterol,Foster 100/6mcg/dose,ERSP,Regular treatment of asthma for patients not adequately controlled w/ inhaled corticosteroid & inhaled short-acting β2-agonists; patients adequately controlled on both inhaled corticosteroids & long-acting β2-agonists.,Hypersensitivity.,Pharyngitis， headache， dysphonia. Common Cardiovascular: Chest pain (1.9% to 3.2% )， Palpitations Gastrointestinal: Diarrhea (4.9% )， Nausea (4.9% )， Xerostomia (1.3% to 3.3% ) Neurologic: Dizziness (0.9% to 2.4% )， Headache (Less than 5% ; oral inhalation， 8% to 25% )， Insomnia (1.5% to 2.4% )， Tremor (1.9% to 8.6% ) Serious Cardiovascular: Cardiac dysrhythmia Respiratory: Death， Asthma-related， Exacerbation of asthma (Severe) Endocrine metabolic: Hypocortisolism secondary to another disorder， Type 2 diabetes mellitus Immunologic: Hypersensitivity reaction， Immunosuppression Ophthalmic: Cataract， Glaucoma Respiratory: Bronchospasm,使用前2-8 ℃,Asthma: Adult >=18 year old， Maintenance therapy: 1 or 2 inhalations BID. the maximum daily dose: 4 inhalations; Maintenance and reliever therapy: Patients take their daily maintenance dose of Foster and in addition take Foster as needed in response to asthma symptoms. Patients should be advised to always have Foster available for rescue use. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes， an additional inhalation should be taken. The maximum daily dose is 8 inhalations. COPD: Adult >=18 year old: 2 inhalations BID.,無需調整劑量,BECLOMETHASONE BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible FORMOTEROL BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,BECLOMETHASONE PREGNANCY RECOMMENDATION: Compatible FORMOTEROL PREGNANCY RECOMMENDATION: Limited Human Data—Probably Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,BECLOMETHASONE BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible FORMOTEROL BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,IH;,,,,,發藥前：請儲存於冰箱（2-8°C）（最長可存放 18 個月）。 發藥後：請勿儲存於 25°C 以上環境（最長可存放 3 個月）。
OINS,Eplerenone,Inspra F.C. 50mg,CAVS,Congestive Heart Failure Post-Myocardial Infarction. NYHA Class 2 of Heart Failure.,For All Patients with hypersensitivity to eplerenone， hyperkalemia or clinically significant hyperkalemia， serum potassium >5.0 mEq/L at initiation， creatinine clearance < or =30 mL/min， severe hepatic insufficiency (Child-Pugh class C)， concomitant administration of strong CYP3A4 inhibitors， or concomitant administration of angiotensin-converting enzyme inhibitors(ACEI) or angiotensin receptor blockers(ARB). For the treatment of hypertension in patients with type 2 diabetes with microalbuminuria， serum creatinine >2.0 mg/dL in males or >1.8 mg/dL in females， creatinine clearance <50 mL/min， or concomitant administration of potassium supplements or potassium-sparing diuretics.,ommon Endocrine metabolic: Hyperkalemia (3.4% ) Renal: Serum creatinine raised (2.4% ) Serious Cardiovascular: Angina pectoris， Myocardial infarction,室溫,Heart failure - Myocardial infarction with complication: initial， 25 mg once daily; titration preferably within 4 weeks to 50 mg once daily. Hypertension: initial， 50 mg once daily; allow 4 weeks to achieve optimum antihypertensive effect; may increase to maximum 50 mg twice daily for inadequate response. New York Heart Association class II (chronic) heart failure: initial， 25 mg once daily， followed by an increase to 50 mg once daily after 4 weeks if potassium level no more than 5 mmol/L.,需調整劑量,micromedex:懷孕分級 B 哺乳Infant risk cannot be ruled out. 藥品仿單: 懷孕分級 C,需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,micromedex:懷孕分級 B 哺乳Infant risk cannot be ruled out. 藥品仿單: 懷孕分級 C,AC;AC15;PC;PO;WM;,,,,,
ICIP2,Ciprofloxacin,Ciproxin 針劑 200mg/100mL,QANB,Complicated UTI， bone & joint， complicated intra-abdominal & lower respiratory tract infection.,Hypersensitivity to ciprofloxacin or other quinolones. Children， adolescents， pregnancy & lactation.,Nausea， diarrhea， vomiting， dyspepsia， abdominal pain， flatulence， anorexia， dizziness， headache， tiredness， agitation， trembling. Very rarely， insomnia， peripheral paralgesia， sweating， unsteady gait， convulsions， increase in intracranial pressure， anxiety states， nightmares， confusion， depression， hallucinations， impaired taste & smell， visual disturbances， tinnitus， transitory impairment of hearing， especially at high frequencies， skin reactions.,25℃以下避光勿冷藏,Ciproxin should be infused intravenously over 60 minutes. Adults: usual dose: 100-400 mg IV Q12H; severe/complicated infections: 400 mg IV Q8H. Chiledren (aged 1-17 years): 6-10 mg/kg IV Q8-12H (maximum 400 mg/dose).,無需調整劑量,,需調整劑量,除非治療上需要,Contraindicated,PREGNANCY RECOMMENDATION: Contraindicated (Use only if no other alternatives),No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,【D10W】可選 。【D5W】可選 。【H/S】可選 。【L/R】可選 。【N/S】可選 。,,以 > 60分鐘緩慢滴注,1. 需避光儲存，光照下(未開瓶)藥效只能維持3天。 2. 監測體溫、CBC，長期使用應監測肝腎功能。
ITREM,Guselkumab,Tremfya inj 100mg/1mL,HIMM,Plaque psoriasis. Psoriatic arthritis,History of serious hypersensitivity reaction to guselkumab or to any of the excipients.,Common Respiratory: Bronchitis (1.6% )， Upper respiratory infection (14.3% ) Serious Immunologic: Anaphylaxis， Hypersensitivity reaction Respiratory: Tuberculosis Other: Infectious disease (23% ),2-8℃避光避免冷凍,SC， plaque psoriasis， palmoplantar pustulosis， psoriasis arthritis 100 mg at week 0 and week 4， followed by 100 mg every 8 weeks.,無需調整劑量,[仿單]目前並無任何關於guselkumab是否會出現於人類乳汁、對餵哺母乳之嬰兒的影響、或對乳汁生成影響方面的資料。 在泌乳食蟹猴的乳汁中並未檢出guselkumab。母體IgG已知會出現於人類的乳汁中。 應一併考慮餵哺母乳對發育與健康的好處和母親對TREMFYAR的臨床需求，以及餵哺母乳之嬰兒可能因TREMFYAR或潛在之母體疾病而受到的任何不良影響。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]目前並無任何孕婦使用TREMFYAR的資料可據以確認TREMFYAR是否存有不良發育影響方面的藥物相關風險。 人類IgG抗體已知會通過胎盤障壁；因此，TREMFYAR有可能會從母體散播至發育中的胎兒體內。在一項合併胚胎胎兒發育與周產期前後發育的研究中，於器官發生期至生產期間皮下注射劑量最高達人類最高建議劑量(MRHD)之30倍的guselkumab之後，並未發現生下的仔猴出現任何不良發育之影響。 在6至30倍MRHD的劑量下，曾觀察到新生仔猴死亡的案例。目前並不確知這些非臨床發現的臨床意義。所有的懷孕都具有出生缺陷、流產或其他不良結果的背景風險。目前並不確知本品的適用族群發生重大出生缺陷與流產的估計背景風險。就美國的一般人口而言，在經過臨床確認的懷孕人口中，重大出生缺陷與流產的估計背景風險分別為2%至4%與15%至20%。 動物試驗資料在一項合併胚胎胎兒發育與周產期前後發育的研究中，曾對懷孕的食蟹猴於器官發生期開始至生產期間每週皮下注射劑量最高達50毫 克/公斤(30倍MRHD，以毫克/公斤為比較基礎)的guselkumab。有1隻對照組猴子、3隻投予10毫克/公斤/週(6倍MRHD，以毫克/公斤 為比較基礎)之guselkumab的猴子及3隻投予50毫克/公斤/週(30倍 MRHD，以毫克/公斤為比較基礎)之guselkumab的猴子所生下的子代出現新生仔猴死亡的情況。 目前並不確知這些發現的臨床意義。 在仔猴出生後至6個月大期間，在官能發育或免疫功能發育方面皆未 發現任何與guselkumab相關的影響。,Unknown 沒有資料,[仿單]目前並無任何關於guselkumab是否會出現於人類乳汁、對餵哺母乳之嬰兒的影響、或對乳汁生成影響方面的資料。 在泌乳食蟹猴的乳汁中並未檢出guselkumab。母體IgG已知會出現於人類的乳汁中。 應一併考慮餵哺母乳對發育與健康的好處和母親對TREMFYAR的臨床需求，以及餵哺母乳之嬰兒可能因TREMFYAR或潛在之母體疾病而受到的任何不良影響。,SC;,,,,,注射之前，應先將TREMFYAR預充填式針筒或預充填式注射筆自冰箱取出，讓TREMFYAR 供皮下注射使用，絕對不可注入肌肉或血管。 注射之後，針頭會縮進此裝置的筒身中並鎖住。 達到室溫(等候30分鐘)，此時還不要移除針頭套。 在投藥之前，應目視檢查TREMFYAR是否有微粒異物或變色的現象。 TREMFYAR為澄清、無色至淡黃色的溶液，溶液中可能含有微小的半透明顆粒。 如果溶液中含有大型顆粒，或有變色或混濁的現象，切勿使用。
IKEY1,Pembrolizumab,KEYTRUDA inj 100mg/4mL,RACA,KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and， if BRAF V600 mutation positive， a BRAF inhibitor.,Hypersensitivity to pembrolizumab or any component of the formulation.,>10%: Cardiovascular: Facial edema (10%) Central nervous system: Fatigue (43%) Dermatologic: Pruritus (28%)， skin rash (24%; immune-mediated: 1%) Endocrine & metabolic: Hyperglycemia (49%)， hypoalbuminemia (37%)， hyponatremia (37%)， hypertriglyceridemia (33%)， decreased serum bicarbonate (22%)， hypocalcemia (21%) Gastrointestinal: Constipation (22%)， nausea (22%)， decreased appetite (20%)， diarrhea (20%)， abdominal pain (13%)， vomiting (13%) Hematologic & oncologic: Anemia (44%; grades 3/4: 10%)， lymphocytopenia (40%; grades 3/4: 9%) Hepatic: Increased serum alkaline phosphatase (26%)， increased serum AST (24%)， increased serum ALT (21%) Neuromuscular & skeletal: Arthralgia (14%) Respiratory: Dyspnea (?20%)， cough (18%) Miscellaneous: Fever (14%) 1% to 10%: Central nervous system: Confusion (>2%)， peripheral neuropathy (2%) Endocrine & metabolic: Hypothyroidism (immune-mediated; 9%)， hyperthyroidism (immune-mediated; 3%) Gastrointestinal: Colitis (immune-mediated; 2%) Immunologic: Antibody development (2%) Neuromuscular & skeletal: Weakness (10%)， arthritis (immune-mediated; 2%) Respiratory: Pneumonitis (3%)， pleural effusion (>2%)， pneumonia (>2%)， respiratory failure (>2%),2-8°C避光避免冷凍,[Melanoma] 2 mg/kg infused over 30 minutes once every 3 weeks until disease progression or unacceptable toxicity. [Non-Small Cell Lung Cancer (NSCLC)] 200 mg for untreated patients or 2 mg/kg as a single agent for previously treated patients infused over 30 minutes once every 3 weeks until disease progression， unacceptable toxicity， or up to 24 months. [Classical Hodgkin Lymphoma (cHL)， Head and Neck Squamous Cell Cancer (HNSCC)， Urothelial Carcinoma] 200 mg infused over 30 minutes once every 3 weeks until disease progression， unacceptable toxicity， or up to 24 months.,無需調整劑量,,無需調整劑量,,Contraindicated,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,IVD;,,【D5W】可選 。【N/S】可選 。,,IV infusion over 30 minutes.,製備: 1. 抽取需要的藥量，注入0.9%氯化鈉注射液或5%葡萄糖注射液的靜脈輸注袋中。(輕轉的方式混勻溶液)。 2. 溶液的最終濃度應為1毫克/毫升至10毫克/毫升之間。 6. 稀釋後可存放室溫，但不可超過6小時。(包括於室溫下，泡製後之藥瓶的存放時間、IV袋中之輸注溶液的存放時間、以及輸注所需要的時間)
IENT0,Vedolizumab,Entyvio 300mg (Sample),HIMM,Crohn disease or ulcerative colitis,Hypersensitivity reaction， severe or serious， to vedolizumab or any of its excipients.,Common Gastrointestinal: Nausea (9% ) Musculoskeletal: Arthralgia (12% ) Neurologic: Headache (12% ) Respiratory: Nasopharyngitis (13% )， Upper respiratory infection (7% ) Other: Fatigue (6% )， Fever (9% ) Serious Hepatic: Aminotransferase abnormal， Increased (less than 2% )， Hepatitis， Serum bilirubin raised Immunologic: Anaphylaxis (0.07% )， Hypersensitivity reaction， Infusion reaction (4% ) Neurologic: Progressive multifocal leukoencephalopathy Respiratory: Tuberculosis Other: Cancer (0.4% )， Infectious disease， Sepsis (0.03% ),2-8℃避光,IVD， ulcerative colitis， Crohn's disease 300 mg at week 0， 2 and 6， followed by every 8 weeks.,無需調整劑量,[仿單] 現有的已發表文獻顯示vedolizumab會進入人類的乳汁。Vedolizumab局部胃腸道暴露及可預期的全身性低暴露對受哺乳嬰兒之影響，目前尚不清楚。在一項僅授乳來評估在接受vedolizumab治療潰瘍性結腸炎或克隆氏症授乳婦女乳汁vedolizumab濃度試驗中，在人類乳汁裡vedolizumab濃度約為母體血中濃度(取自過去vedolizumab試驗數據)的0.4%至2.2%。推估嬰兒平均每日vedolizumab攝取量為0.02 mg/kg/day，相當於母體每日攝取量的21%(經體重調整)。考慮哺乳對於發育和健康的效益時，應衡量母親對安潰悠的臨床需求，及來自安潰悠或母體基礎疾病對受哺乳嬰兒的潛在不良反應。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單] 風險摘要 依據現有的藥物安全監視資料、進行中的懷孕登錄資料、已發表的孕婦個案報告及世代研究資料，並未發現與安潰悠有關的重大先天性缺陷、流產，或母體或胎兒的不良結果。懷孕期間的發炎性腸道疾病，對母親和胎兒都有風險(參見臨床考量)。尚未進行安潰悠用於懷孕女性的試驗。動物生殖試驗中，兔子和猴子靜脈注射高於人體建議劑量20倍的vedolizumab，並未觀察到胚胎傷害(參見試驗資料)。特定族群發生重大先天性缺陷和流產的估計背景風險，目前尚不清楚。所有懷孕都有先天缺陷、流產或其他不良結果的背景風險。在美國一般族群，臨床上確認懷孕後，發生重大先天性缺陷和流產的預估背景風險，分別為2至4%及15至20%。 臨床考量 安潰悠之任何懷孕不良作用，在懷孕第二和第三孕期時可能較嚴重。單株抗體會隨孕期進展而以線性方式通過胎盤，在第三孕期的傳送量最大。 疾病相關的母體和胚胎/胎兒風險 已發表的資料顯示，罹患發炎性腸道疾病(IBD)的女性，懷孕結果不良的風險與疾病活動度增加有關。懷孕的不良結果包括早產(懷孕週數未滿37週)、嬰兒出生體重偏低(低於2500公克)及出生體重不足。 胎兒/新生兒不良反應 懷孕期間使用安潰悠，可能會影響在子宮內受暴露的新生兒及嬰兒之免疫反應。嬰兒在子宮內暴露於低濃度安潰悠之臨床影響，目前尚不清楚。受暴露的嬰兒施打活毒或減毒疫苗之安全性，目前也尚不清楚。 試驗資料 動物資料 對懷孕兔子的生殖試驗中，在妊娠第7天靜脈注射單劑最高100毫克/公斤劑量的vedolizumab(約為人體建議劑量的20倍)，並無證據顯示導致生育能力受損或胎兒傷害。一項猴子的產前及產後發育試驗中，靜脈注射最高100毫克/公斤劑量vedolizumab(約為人體建議劑量的20倍)，並無證據顯示對產前及產後發育產生任何不良作用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 現有的已發表文獻顯示vedolizumab會進入人類的乳汁。Vedolizumab局部胃腸道暴露及可預期的全身性低暴露對受哺乳嬰兒之影響，目前尚不清楚。在一項僅授乳來評估在接受vedolizumab治療潰瘍性結腸炎或克隆氏症授乳婦女乳汁vedolizumab濃度試驗中，在人類乳汁裡vedolizumab濃度約為母體血中濃度(取自過去vedolizumab試驗數據)的0.4%至2.2%。推估嬰兒平均每日vedolizumab攝取量為0.02 mg/kg/day，相當於母體每日攝取量的21%(經體重調整)。考慮哺乳對於發育和健康的效益時，應衡量母親對安潰悠的臨床需求，及來自安潰悠或母體基礎疾病對受哺乳嬰兒的潛在不良反應。,IVD;,4.8mL注射用無菌水,【N/S】可選 仿單建議。,,以靜脈輸注30分鐘方式給予， 請勿以靜脈注射或推注方式給藥。輸注完成後使用30mL的N/S或L/R沖洗。輸注溶液配製完成並稀釋後，請儘快使用。 稀釋說明: 將5mL(300 mg)配製完成的溶液，加入250毫升的無菌N/S或L/R，並輕輕晃動輸注袋. 請勿將其他藥品加入準備好的輸注溶液或靜脈輸注管線組. 輸注溶液配製完成並稀釋後，請盡快使用.,應使用無菌技術在20-25℃下配製: 1.使用21至25 gauge針頭，以4.8mL注射用無菌水配製。 2.針頭插入並導引注射用無菌水沿藥瓶玻璃壁流下，以免產生泡沫。 3.輕晃動至少15秒，勿用力搖晃或倒轉。 4.室溫下靜置最多20分鐘，以便配製並等所有泡沫消失，如未完全溶解，可再放置10分鐘.未在30分鐘內溶解，勿使用此藥。 5.溶液應為清澈或半透明，無色至淺棕黃色，不含顆粒.若溶液顏色異常或含顆粒，勿使用。 6.輕倒轉藥瓶三次，再抽取配製好的溶液5mL，藥瓶內剩餘的溶液請丟棄。 儲存:配製後應立即使用，如冷藏可保存8小時。稀釋於N/S後20-25℃可保存12小時，2-8℃冷藏可24小時。稀釋於L/R後應立即使用，2-8℃冷藏可6小時。
EFLO,Ofloxacin,Ofloxin otic solution 0.3%， 5mL,TENT,Chronic suppurative otitis media， acute otitis media with or without tympanostomy tube， otitis externa.,Patients with a history of hypersensitivity to ofloxacin.,superinfection， earache， Vestibular nerve disorder， Hearing Impairments， ear itching， headache， redness of the ear canal， Redness of the external ear canal,儲存於攝氏25度C以下,Otitis media， chronic suppurative (with perforated tympanic membranes): Otic: Instill 6-10 drops into affected ear(s) twice daily for 14 days,無需調整劑量,[仿單]未有相關建議,無需調整劑量,沒有資料,Contraindicated,PREGNANCY RECOMMENDATION: Contraindicated (Use only if no other alternatives) [仿單]未有相關建議,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]未有相關建議,AD;AL;AS;AU;,,,,,1.保管時若容器前端和蓋子出現結晶，請以乾淨紗布擦拭後使用。 2.開瓶注意事項:產品使用前，先以順時針方式向下旋緊一圈後再逆時針轉開藥瓶使用，以利藥液滴出。
OREX,Brexpiprazole,Rexulti 1mg,CNEU,Schizophrenia.,Hypersensitivity to brexpiprazole or any component of the product.,Common Endocrine metabolic: Hyperglycemia (9% to 10% )， Serum triglycerides raised (Short-term use， 5% to 13%; long-term use， 13% to 17% )， Weight increased (Short-term use， 2% to 11%; long-term use， 20% to 30% ) Neurologic: Akathisia ( 4% to 14% )， Extrapyramidal movements， Excluding akathisia (5% to 6% )， Headache (4% to 9% ) Serious Cardiovascular: Cerebrovascular accident， Orthostatic hypotension ( 0.1% to 0.4% )， Syncope (0.1% )， Transient ischemic attack Endocrine metabolic: Diabetic ketoacidosis Hematologic: Agranulocytosis Neurologic: Seizure Psychiatric: At risk for suicide Other: Neuroleptic malignant syndrome,30°C以下,Initial， 1 mg orally once daily on days 1 through 4; titrate to 2 mg orally once daily on days 5 through 7， then to target dosage of 4 mg orally once daily beginning on day 8， based on response and tolerability; Maximum 4 mg orally once daily; periodically reassess dosage and need for treatment.,需調整劑量,[仿單]目前尚無評估 brexpiprazole 是否會分泌至人類乳汁中、brexpiprazole 對餵奶嬰兒有何影響， 或 brexpiprazole對乳汁之產生有何影響的泌乳研究。根據研究，brexpiprazole 會分泌至大鼠乳汁中。 除考量哺乳對發育及健康的益處外，亦應同時考量母親對 REXULTI 的臨床需求， 以及 REXULTI 或來自母體狀況可能對餵奶嬰兒的任何不良作用。,需調整劑量,不可使用,Uknown 沒有資料,[仿單]REXULTI 目前尚無針對懷孕女性進行之適當且控制良好的試驗，故無法提供藥物相關風險的資訊。 不過，在懷孕第三期曝露於抗精神病藥物 ( 包括 REXULTI) 的新生兒有錐體外徑症狀和 / 或禁斷症狀的風險。 在動物生殖實驗中，於胎兒器官形成期間，口服投與懷孕大鼠及兔子 brexpiprazole，給予劑量分別為人類最大建議劑量 (MRHD，根據 mg/m2 計算為 4 毫克 / 天 ) 的 73 倍與 146 倍時，並未觀察到致畸胎性。 然而，若在胎兒器官形成期至泌乳期間給予懷孕大鼠服用 brexpiprazole，在劑量為 MRHD 的 73 倍時，出生前後死亡的幼鼠數目則會增加。 目前尚不清楚適用此藥物之病人族群的重大先天缺陷與流產的背景風險。在美國的一般族群中，臨床確認懷孕者之重大先天缺陷與流產的背景風險估計值分別為 2-4% 與 15-20%。,Unknown 沒有資料,[仿單]目前尚無評估 brexpiprazole 是否會分泌至人類乳汁中、brexpiprazole 對餵奶嬰兒有何影響， 或 brexpiprazole對乳汁之產生有何影響的泌乳研究。根據研究，brexpiprazole 會分泌至大鼠乳汁中。 除考量哺乳對發育及健康的益處外，亦應同時考量母親對 REXULTI 的臨床需求， 以及 REXULTI 或來自母體狀況可能對餵奶嬰兒的任何不良作用。,AC;AC15;PC;PO;WM;,,,,,
IMUT,Nalbuphine,Mutonpain inj 10mg/1mL,CNEU,The management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine can also be used as a supplement to balanced anesthesia， for preoperative and postoperative analgesia， and for obstetrical analgesia during labor and delivery.,Hypersensitivity to nalbuphine to any of the other ingredients in Mutonpain.,Common Dermatologic: Diaphoresis (up to 9% ) Gastrointestinal: Nausea and vomiting (6% )， Xerostomia (4% ) Neurologic: Dizziness (up to 5% )， Headache (3% )， Sedated (36% )， Vertigo (up to 5% ) Serious Cardiovascular: Hypotension Endocrine metabolic: Adrenal insufficiency Immunologic: Hypersensitivity reaction (1% or less ) Neurologic: Loss of consciousness， Seizure Respiratory: Pulmonary edema， Respiratory depression (1% or less ) Other: Drug dependence， Opioid withdrawal,25℃以下避光,The usual recommended adult dose is 10 mg for a 70 kg individual administered subcutaneously， intramuscularly， or intravenously; this dose may be repeated every 3 to 6 hours as necessary. Dosage should be adjusted according to the severity of the pain， the physical status of the patient， and other medications which the patient may be receiving. In nontolerant individuals， the recommended the single maximum dose is 20 mg， and the maximum total daily dose is 160 mg. The use of Mutonpain as a supplement to balanced anesthesia requires larger doses than those recommended for analgesia. Induction doses of nalbuphine hydrochloride range from 0.3 mg/kg to 3 mg/kg intravenously to be administered over a 10 to 15 minute period with maintenance doses of 0.25 to 0.5 mg/kg in single intravenous administrations as required. The use of Mutonpain may be followed by respiratory depression which can be reversed with the opioid antagonist naloxone hydrochloride.,需調整劑量,[仿單] 有限的資料顯示本藥只有少量經由乳汁排出(少於投予劑量的百分之一)，在臨床上無顯著意義. 本藥投予哺乳婦女需小心.,需調整劑量,可能安全,Human data suggest risk in 3 rd trimester,[仿單]懷孕使用分類:B， 對大老鼠及兔子的生殖研究顯示，以高於每日最大建議劑量的十四到三十一倍的劑量投予，沒有損害生育之情形或對胎兒造成損傷. 然而因尚未有針對懷孕婦女進行之完整研究，基於動物生殖研究未能絕對適用於人體反應，所以懷孕婦女只有在確實必要時才可以給藥. 用於生產及分娩的過程: Nalbuphine 透過胎盤的轉移比率相當高且迅速，母體與胎兒的比率改變可從1：0.37 至1：1.6。曾有報告顯示， 在母體懷孕期間投予nalbuphine而影響胎兒及新生兒之副作用共包括了：胎兒心跳減緩、呼吸抑制、新生兒窒息、發紺及肌肉張力低弱。某些個案顯示，妊娠期間在母體投naloxone可矯正這些副作用。 另外，嚴重與延長胎兒心跳減緩也曾經有報告。曾發生因胎兒心跳減緩而導致胎兒永久性的神經傷害。另有報告顯示，使用nalbuphine時，胎兒出現竇狀節率（sinusoidal）之心跳，在懷孕期間或生產分娩婦女使用nalbuphine hydrochloride/須特別小心， 對新生兒更須嚴加觀察是否出現呼吸抑制、窒息、心跳減緩與心率不整。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 有限的資料顯示本藥只有少量經由乳汁排出(少於投予劑量的百分之一)，在臨床上無顯著意義. 本藥投予哺乳婦女需小心.,IM;IVD;IVPUSH;SC;,,【D10W】可選 。【D5W】可選 。【L/R】可選 。【N/S】可選 。,靜脈注射時間需超過10-15分鐘(降低劑量或延長注射時間可減少副作用),仿單並無稀釋濃度或注射速率建議，2021/04/13廠商回覆：因本藥可不經稀釋直接使用，故無配製濃度與輸注速率建議，請留意病患臨床反應，且降低流速或濃度可減少副作用。,仿單無建議的稀釋液，2021/04/13廠商回覆可依參考書 Handbook on Injectable Drugs，在D5W， D10W， Normal Saline， Ringer's solution四種稀釋溶液中可相容且安定48小時.
LWIL,Simethicone,Wilcon 20mg/mL， 60mL suspension,ALIM,Relief of pressure， bloating， fullness， and discomfort of gastrointestinal gas.,Hypersensitivity to simethicone or any component of the formulation,Loose stools,25℃以下避光保存,Adult and Children > 3 years old: 2 mL TID-QID. Children < 3 years old: depended on doctor.,無需調整劑量,[仿單]未有相關說明,無需調整劑量,沒有資料,Compatible,[仿單]未有相關說明,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]未有相關說明,AC;AC15;PC;PO;WM;,,,,,
IEVE,Romosozumab,Evenity inj 105mg/1.17mL,META,The treatment of osteoporosis in postmenopausal women at high risk for fracture， defined as a history of osteoporotic fracture， or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.,Hypocalcemia. Known hypersensitivity to Evenity.,Common Musculoskeletal: Arthralgia (8.1% to 13.1% ) Neurologic: Headache (5.2% to 6.6% ) Serious Cardiovascular: Myocardial infarction (0.3% to 0.8% ) Endocrine metabolic: Hypocalcemia (0.04% ) Immunologic: Hypersensitivity reaction (6.5% ) Musculoskeletal: Femur shaft fracture (0.02% )， Osteonecrosis of jaw (0.02% ) Neurologic: Cerebrovascular accident (0.2% to 0.6% ),2-8℃避光，勿冷凍,Two separate syringes (and two separate subcutaneous injections) are needed to administer the total dose of 210 mg of Evenity. Inject two 105 mg/1.17 mL prefilled syringes， one after the other. Should be administered by a healthcare provider. Administer 210 mg subcutaneously once every month for 12 doses in the abdomen， thigh， or upper arm. Adequately supplement calcium and vitamin D during treatment.,無需調整劑量,[仿單] EVENITY 並未核准用於具生育能力的女性。 在動物試驗中，懷孕大鼠自同居前 6 週到交配和哺乳期間，每週接受 romosozumab 10、60 或 300 毫克/公斤的劑量 (根據 AUC 比較結果，相當於每月皮下注射 210 毫克之臨床暴露量的 1.5、19 或 56 倍)，產後第 21 天，子代的 romosozumab 血清濃度呈現劑量依賴關係，介於母體暴露量 0.01 倍至 2.4 倍之間，依妊娠期和/或哺乳期的暴露量而異。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] EVENITY並未核准用於有生育能力的女性。 在動物生殖試驗中，在器官形成期每週給予懷孕大鼠romosozumab 超過32倍的臨床暴露劑量，會導致子代骨骼異常。 在交配前到哺乳結束期間給予大鼠romosozumab 1.5至56倍的人體預期暴露劑量，會導致子代的股骨骨質密度及/或骨內皮質周圍小幅或微幅減少。,Unknown 沒有資料,[仿單] EVENITY 並未核准用於具生育能力的女性。 在動物試驗中，懷孕大鼠自同居前 6 週到交配和哺乳期間，每週接受 romosozumab 10、60 或 300 毫克/公斤的劑量 (根據 AUC 比較結果，相當於每月皮下注射 210 毫克之臨床暴露量的 1.5、19 或 56 倍)，產後第 21 天，子代的 romosozumab 血清濃度呈現劑量依賴關係，介於母體暴露量 0.01 倍至 2.4 倍之間，依妊娠期和/或哺乳期的暴露量而異。,SC;,,,,,建議劑量為皮下注射 210 毫克於腹部、大腿或上臂。每個月施打一次。治療期間為每個月施打一次共計12個月。如果漏打一次Evenity，應重新安排門診時間儘快施打。之後再從最後一次注射的日期算起，排定每個月Evenity的施打時間。
OCHOP,Cholestyramine,Choles powder 4gm/Pack,CAVS,Hypercholesterolemia. Pruritus of skin with partial biliary obstruction. Diarrhea due to bile acid malabsorption.,Complete biliary obstruction. Hypersensitivity to cholestyramine or any of its components.,Common Gastrointestinal: Abdominal discomfort， Constipation， Flatulence， Nausea and vomiting.,陰涼處保存(勿超過30℃),Choles powder: 444mg/gm， 9gm/Pack， Each pack contains 4gm Cholestyramine Resin. Hypercholesterolemia: Adult: Initial， 4gm(1 pack) BID; increase gradually over 1-2 weeks intervals; maintenance: 8gm(2 packs) BID; maximum: 24gm(6 packs)/day; Recommend dose interval is BID， but daily dose could be in 1-6 divided doses a day. Pruritus of skin with partial biliary obstruction: Adult: 4-8g(1-2 packs)/day. Child: (body weight * Adult dose )/70， Recommend once daily， increase gradually 5-7days intervals based on response and tolerability. Diarrhea due to bile acid malabsorption: Adult: Initial 4g(1 pack) TID， increase gradually based on response and tolerability. Child: 2-8g(0.5-2 packs)/day in 3 divided doses. If diarrhea is progressing for 3 days， should consider changing Colestyramine therapy.,無需調整劑量,[仿單]必須警告Colestyramine Resin的授乳婦，如"孕婦"欄所述，母體可能缺乏完全的為生素吸收而影響哺乳的嬰兒,無需調整劑量,除非治療上需要,Uknown 沒有資料,[仿單]由於Colestyramine Resin為非全身性的吸收，懷孕期間依建議劑量使用，不會傷害胎兒.對孕婦並沒有足夠及控制良好的研究，已知其干擾脂溶性維生素的吸收可能有害，即使正在補充這些維生素.,Unknown 沒有資料,[仿單]必須警告Colestyramine Resin的授乳婦，如"孕婦"欄所述，母體可能缺乏完全的為生素吸收而影響哺乳的嬰兒,AC;PC;PO;,,,,,每包藥粉以120-180mL液體溶解後服用。
OERY1,Erythromycin,Erymycin 250mg,QANB,Staphylococcus， Streptococcus， Pneumococcus， Meningococcus， and other infections caused by susceptible bacteria.,Concomitant therapy with astemizole， cisapride， pimozide， or terfenadine. Hypersensitivity to erythromycin products. Pregnancy; risk of maternal hepatotoxicity.,Common: Diarrhea， Loss of appetite， Nausea， Stomach cramps， Vomiting Serious: Prolonged QT interval， Torsades de pointes， Ventricular arrhythmia， Stevens-Johnson syndrome， Toxic epidermal necrolysis due to drug， Clostridium difficile colitis， Pancreatitis， Cholestatic hepatitis， Hepatitis， Anaphylaxis， Seizure， Ototoxicity， Tubulointerstitial nephritis,陰涼(15~30℃)乾燥處,Adults: Antibacterial/Antiprotozoal: 250mg Q6H or 500mg Q12H. Maximum dose: 8g. Streptococcal Prevention for those with rheumatic heart disease or rheumatic fever: 250mg Q12H. Gonorrhea: 500mg Q6H for 7 days. Legionnaires' Disease: 250-1000mg Q6H. Syphilis: Early stage - 500mg Q6H for 15 days; Late stage - 500mg Q6H for 30 days. Children: Antibacterial: 7.5mg-25mg/kg Q6H， or 15mg-50mg/kg Q12H. Antiprotozoal: 7.5mg-12.5mg/kg Q6H for 10-14 days.,無需調整劑量,[仿單] 由於本藥會通過胎盤障壁(但在胎兒血漿濃度不高)，而且亦會排泄於乳汁中，因此， 孕婦及哺乳母親應就其使用上之危險與效益加以考慮。,無需調整劑量,沒有資料,Uknown 沒有資料,PREGNANCY RECOMMENDATION: Compatible (Excludes estolate salt) 此藥成分: Erythromycin estolate [仿單] 由於本藥會通過胎盤障壁(但在胎兒血漿濃度不高)，而且亦會排泄於乳汁中，因此， 孕婦及哺乳母親應就其使用上之危險與效益加以考慮。,Compatible 哺乳時可使用,[仿單] 由於本藥會通過胎盤障壁(但在胎兒血漿濃度不高)，而且亦會排泄於乳汁中，因此， 孕婦及哺乳母親應就其使用上之危險與效益加以考慮。,AC;AC15;PC;PO;WM;,,,,,
OBRVA,Brivaracetam,Briviact 100mg,CNEU,Adjunct in partial seizures for 4 years older.,Hypersensitivity to brivaracetam or any excipient in the product,Common Gastrointestinal: Nausea and vomiting (5% ) Neurologic: Dizziness (12% )， Sedated， Somnolence Other: Fatigue (9% ) Serious Immunologic: Hypersensitivity reaction Neurologic: Cerebellar ataxia， Impairment of balance Psychiatric: Psychiatric sign or symptom (13% )， Suicidal behavior， Suicidal thoughts Respiratory: Bronchospasm Other: Angioedema,儲存於25°C下,Adult (Age > 16): Initially， 50 mg BID (100mg/day). Maintenance and maximum dose: 25-100mg BID (50-200mg/day). Child > or = 4 years， > 50 kg: Initially， 25-50 mg BID (50-100mg/day). Maintenance and maximum dose: 25-100mg BID (50-200mg/day). Child > or = 4 years， 20-50 kg: Initially， 0.5-1 mg/kg BID (1-2mg/kg/day). Maintenance and maximum dose: 0.5-2 mg/kg BID (1-4mg/kg/day). Child > or = 4 years， 11-20 kg: Initially， 0.5-1.25 mg/kg BID (1-2.5mg/kg/day). Maintenance and maximum dose: 0.5-2.5 mg/kg BID (1-5mg/kg/day).,需調整劑量,[仿單] 並無brivaracetam 出現於人類乳汁中、對哺乳嬰兒之影響或藥物對乳汁產生之影響的相關資料。 在哺乳大鼠中的試驗已證實brivaracetam 或代謝產物會分泌到乳汁中。 應同時考慮哺乳的發育和健康效益以及母親對BRIVIACT 的臨床需求與BRIVIACT 或既有母體病症對哺乳嬰兒的任何潛在不良影響。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 關於懷孕女性使用BRIVIACT 之相關發育風險，目前並無充足的資料。 在動物試驗中，母體血漿曝藥量高於臨床曝藥量下brivaracetam 產生發育毒性的佐證(兔子中胚胎胎兒死亡率增加及胎兒體重下降；大鼠子代生長緩慢、性成熟延遲及長期神經行為變化) 。 在美國一般族群中，臨床確認之懷孕中重大生殖缺陷和流產的概估背景風險分別為2 至4%及15 至20%。在此適應症族群中重大生殖缺陷和流產的背景風險不明。,Unknown 沒有資料,[仿單] 並無brivaracetam 出現於人類乳汁中、對哺乳嬰兒之影響或藥物對乳汁產生之影響的相關資料。 在哺乳大鼠中的試驗已證實brivaracetam 或代謝產物會分泌到乳汁中。 應同時考慮哺乳的發育和健康效益以及母親對BRIVIACT 的臨床需求與BRIVIACT 或既有母體病症對哺乳嬰兒的任何潛在不良影響。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單不建議磨粉:因藥物磨粉後有苦味(廠商回覆2022.02.15)
IBCO2,Thiamine+Riboflavin+Nicotinamide+Pyridoxine,B-complex 針劑1mL,NUTR,Vit B-complex deficiency.,Hypersensitivity to any component of the formulation,Nausea， vomiting， abdominal cramps， pruritus， flushing， sensation of heat， faintness， pounding in the head,25℃以下,Adult: IV/IM 1 mL once or few times a week. Each mL contains: Thiamine HCl 60mg， Riboflavin-5 Phosphate Sodium 3mg， Nicotinamide 30mg， Pyridoxine HCl 3mg.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IM;IVD;IVP;IVPUSH;,,【D5NS】可選 。【D5W】可選 。【N/S】可選 。,文獻不建議IVP給藥,Thiamine IV route: Dilute with 100 mL of N/S or D5W， and infuse over 30 minutes. (Micromedex),Thiamine: the risk of hypersensitivity reactions is increased with repeated IV or IM administration.(Micromedex)
OZUL,Pitavastatin,Zulitor 4mg,CAVS,Primary hypercholesterolemia and mixed dyslipidemia,Active liver disease， Breastfeeding， Concomitant use of cyclosporine， Hypersensitivity to pitavastatin or any other component of the product， Pregnancy， Unexplained persistent elevations of serum transaminase levels.,Common Gastrointestinal: Constipation (1.5% to 3.6% )， Diarrhea (1.5% to 2.6% ) Musculoskeletal: Backache (1.4% to 3.9% )， Myalgia (1.9% to 3.1% )， Pain in limb (0.6% to 2.3% ) Serious Endocrine metabolic: Disorder of glucose regulation Hepatic: ALT/SGPT level raised (0.5% )， AST/SGOT level raised， Increased liver enzymes， Liver failure Musculoskeletal: Disorder of muscle， Statin-associated， Increased creatine kinase level (1.9% )， Rhabdomyolysis,25℃以下,Adult: 1-4 mg orally once daily. Dose adjustments should be made at intervals of 4 weeks.,需調整劑量,[仿單]目前未知Pitavastatin是否會排至人體母乳中， 但已證實其他同類型藥物之其中一種會有微量排至母乳。大鼠實驗證實Pitavastatin會排至乳汁中。 由於同類型藥物之其中一種會排至母乳，且HMG-CoA還原抑制劑有可能造成哺乳嬰兒的嚴重不良反應， 因此應告知需要以Pitavastatin治療的婦女不可進行哺乳或應停用Pitavastatin,需調整劑量,不可使用,Contraindicated – 1st trimester,[仿單節錄] 針對懷孕大鼠進行產前/產後(perinatal/postnatal)試驗，......結果所有劑量均具母體毒性，...... 降低了各劑量組的新生兒存活率。,Contraindicated 哺乳期使用禁忌,[仿單]目前未知Pitavastatin是否會排至人體母乳中， 但已證實其他同類型藥物之其中一種會有微量排至母乳。大鼠實驗證實Pitavastatin會排至乳汁中。 由於同類型藥物之其中一種會排至母乳，且HMG-CoA還原抑制劑有可能造成哺乳嬰兒的嚴重不良反應， 因此應告知需要以Pitavastatin治療的婦女不可進行哺乳或應停用Pitavastatin,AC;AC15;PC;PO;WM;,,,,,
ORYB,Semaglutide,Rybelsus 7mg,META,Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; can be used as monotherapy if patient is intolerant or contraindicated to metformin or be used in combination with other diabetes medications.,Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any component of the product.,[Common] Hypoglycemia (Monotherapy， 1.6-3.8%; combination therapy， 6-30% )， Abdominal pain (Diabetes， 5.7-11% ; weight management， 15-20% )， Constipation (Diabetes， 3.1-6% ; weight management， 6-24% )， Diarrhea (Diabetes， 8.5-10% ; weight management， 22-30% )， Nausea (Diabetes， 11-20.3% ; weight management， 42-44% )， Vomiting (Diabetes， 5-9.2% ; weight management， 24-36% )， Headache (14-17% ) [Serious] Increased heart rate， Medullary thyroid carcinoma， Cholecystitis (0.6-0.8% )， Cholelithiasis (0.4-3.8% )， Pancreatitis， Anaphylaxis， Hypersensitivity reaction， Retinopathy due to diabetes mellitus， Angioedema,30°C以下乾燥避光處,3 mg orally QD for 30 days， then increase dose to 7 mg QD. Dose may be increased to 14 mg QD if additional glycemic control is needed after at least 30 days receiving 7-mg dose.,無需調整劑量,[仿單] 哺乳大鼠會將 semaglutide、salcaprozate sodium 及/或其代謝物透過乳汁排出。 由於無法排除哺乳嬰幼兒的風險，哺乳期間不應使用。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 動物試驗已證實具生殖毒性，懷孕女性使用 semaglutide 的資料有限， 因此懷孕期間不可使用 semaglutide。如果病人想要懷孕或已懷孕，應停用 semaglutide。 由於 semaglutide 的半衰期較長，計畫懷孕前至少兩個月應停用。,Unknown 沒有資料,[仿單] 哺乳大鼠會將 semaglutide、salcaprozate sodium 及/或其代謝物透過乳汁排出。 由於無法排除哺乳嬰幼兒的風險，哺乳期間不應使用。,AC;PO;,,,,,[磨粉/管灌註記] 仿單建議整顆吞服。錠劑不應剝開、壓碎或咀嚼，因為尚不清楚是否會影響 semaglutide 的吸收。
ITRI1,Triamcinolone,Triamcinolone 10mg/1mL,HM,Intra-articular Inflammatory joint disease,Untreated systemic fungal， bacterial， viral or parasitic infection， hypersensitivity. Neonates (Parenteral),HPA axis supression， intracranial hypertension， Cushing's syndrome， growth retardation in children; osteoporosis， fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas， broken skin or under occlusive dressing.,25℃以下避光,Adult: INS 2.5-40mg or IM 40-60mg per time， could inject 2-3 times if symptoms reappear. Children > 6 years: IM 30-200mcg daily to weekly.,無需調整劑量,,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,ID;IM;INS;IVI;SKIN;,,,,,
IREM,Remdesivir,Remdesivir Inj. 150mg,QANB,,,,,[UpToDate]Coronavirus disease 2019: IV: Limited data available; dosing used in clinical trials: 200 mg as a single dose on day 1， followed by 100 mg once daily for a total duration of 5 to 10 days. [Micromedex]COVID-19: 1) Dosage: 200 mg IV once on day 1， then 100 mg IV daily. 2) Duration of therapy: Until respiratory symptoms improve,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,【N/S】可選 仿單建議。,,,
OHYXQ,Hydroxychloroquine,Hydroquine 200mg,QANP,,適應症:Lupus erythematosus， Malaria， Malaria(Prophylaxis)， Rheumatoid arthritis. 副作用: 1% to 10%: Retinopathy (4%; serum concentration dependent; early changes reversible [may progress despite discontinuation if advanced]) Frequency not defined: Acute generalized exanthematous pustulosis， alopecia， bullous rash， dyschromia (skin and mucosal)， erythema multiforme， exacerbation of psoriasis， exfoliative dermatitis， hair discoloration， pruritus， skin photosensitivity， skin rash， Stevens-Johnson syndrome， toxic epidermal necrolysis， urticaria， Exacerbation of porphyria， severe hypoglycemia， weight loss， Abdominal pain， decreased appetite， diarrhea， nausea， vomiting， Agranulocytosis， anemia， aplastic anemia， bone marrow failure， hemolysis (in patients with glucose-6-phosphate deficiency)， leukopenia， thrombocytopenia，Abnormal hepatic function tests， acute hepatic failure， Angioedema， Drug reaction with eosinophilia and systemic symptoms， Ataxia， dizziness， emotional lability， fatigue， headache， irritability， nervousness， nightmares， psychosis， seizure， sensorineural hearing loss， suicidal tendencies， vertigo， Myopathy (including palsy or neuromyopathy， leading to progressive weakness and atrophy of proximal muscle groups; may be associated with mild sensory changes and loss of deep tendon reflexes)， Corneal changes (corneal edema， corneal opacity， corneal sensitivity， corneal deposits， visual disturbance， blurred vision， photophobia)， decreased visual acuity， macular degeneration， maculopathy， nystagmus disorder， retinal pigment changes， retinitis pigmentosa， scotoma， vision color changes， visual field defect， Deafness， tinnitus， Bronchospasm Postmarketing: Cardiomyopathy， prolonged QT interval on ECG， torsades de pointes， ventricular arrhythmia， Hypoglycemia， Epithelial keratopathy. 禁忌: Known hypersensitivity to hydroxychloroquine， 4-aminoquinoline derivatives， or any component of the formulation. Retinopathy,,室溫25度C以下,Systemic lupus erythematosus: Oral: 200 to 400 mg daily. Due to the risk of retinal toxicity， most patients should not receive a daily dose >6.5 mg/kg/day using ideal body weight or 400 mg. Discoid lupus erythematosus and subacute cutaneous lupus erythematosus: For use if response to local therapy is inadequate or impractical due to widespread skin lesions.Oral: 200 to 400 mg daily. Due to the risk of retinal toxicity， most patients should not receive a daily dose >6.5 mg/kg/day using actual body weight or 400 mg， whichever is lower. Malaria: Initial， 800 mg orally for 1 dose followed by 400 mg at 6~8， 24， and 48 hours after the initial dose (total dose: 2g). Another way of weight-based dosage: 12.9 mg/kg (MAX， 800 mg) orally for 1 dose， followed by 6.5 mg/kg (MAX， 400 mg) orally at 6， 24， and 48 hours after the first dose. [Micromedex] Malaria; Prophylaxis: 400 mg orally once weekly on the same day each week beginning 2 weeks prior to travel to malarious area， continue on same day each week while in area and for 4 weeks after leaving area. Another way of weight-based dosage: 6.5 mg/kg (MAX 400 mg) orally once weekly on the same day each week beginning 2 weeks prior to travel to malarious area， continue on same day each week while in area and for 4 weeks after leaving area.,無需調整劑量,[仿單] 授乳期間如欲使用本藥應仔細考慮，因為有少量本藥會分泌於人類乳汁中， 而嬰兒對4-aminoquinolones的毒性相當敏感.,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單] 本藥會通過胎盤，懷孕時使用的資料有限， 但在治療劑量下使用4-aminoquinolones會造成中樞神經的損傷，包括耳毒性，視網膜出血， 不正常的視網膜色素沉積. 因此懷孕時不應使用,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 授乳期間如欲使用本藥應仔細考慮，因為有少量本藥會分泌於人類乳汁中， 而嬰兒對4-aminoquinolones的毒性相當敏感.,PC;PO;WM;,,,,,
ICISA2,Cisatracurium,Cisatracurium inj 10mg/5mL (專案),CNEU,,適應症:Muscle relaxation during surgical procedures eg cardiac surgery， other procedures & in intensive care. Adjunct to general anesth or sedation in the ICU， to relax skeletal muscles & to facilitate tracheal intubation & mechanical ventilation. 副作用:Bradycardia， hypotension. Rarely cutaneous flushing， bronchospasm， rash. 禁忌:Hypersensitivity to cisatracurium besylate or any component of the formulation; use of the 10 mL multiple-dose vials in premature infants (formulation contains benzyl alcohol),,2-8°C,IV bolus Tracheal intubation Adult Initially 0.15 mg/kg over 5-10 sec. Maintenance: 0.03 mg/kg. Childn 1 mth-12 yr Same as adult dose. Maintenance: 0.02 mg/kg. IV infusion Adult & childn 1 mth-12 yr Maintenance of neuromuscular block 3 mcg/kg/min to restore 89-99% T1 suppression then 1-2 mcg/kg/min to maintain block in this range.,無需調整劑量,以上懷孕分級為: UpToDate資料。,無需調整劑量,可能安全,,,Contraindicated 哺乳期使用禁忌,以上懷孕分級為: UpToDate資料。,IVD;IVP;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,IVP輸注時間需5-10sec (氣管內插管),IVD給藥速率為0.03-0.6 mg/kg/hr (給藥濃度 0.1-2 mg/mL) Maintenance infusion in ICU， 3 mcg/kg/min IV infusion (range of 0.5 to 10.2 mcg/kg/min due to interpatient variability).,1.僅供靜脈給藥。 2.給藥濃度 0.1-2 mg/mL。 3.本品需冷藏避光貯存 4.不可與鹼性溶液混合 5.限使用人工呼吸器治療病患使用
INPH,Insulin NPH,Insulin Insulatard HM 100U/mL， 10mL,META,,適應症: Treatment of type 1 diabetes mellitus (insulin dependent， IDDM) and type 2 diabetes mellitus (noninsulin dependent， NIDDM) to improve glycemic control. 副作用: Primarily symptoms of hypoglycemia. Pallor， palpitation， tachycardia， Fatigue， headache， hypothermia， loss of consciousness， mental confusion， Redness， urticaria， Hypoglycemia， hypokalemia， Hunger， nausea， numbness of mouth， Atrophy or hypertrophy of SubQ fat tissue; edema， itching， pain or warmth at injection site; stinging， Muscle weakness， paresthesia， tremor， Transient presbyopia or blurred vision， Anaphylaxis， diaphoresis， local and/or systemic hypersensitivity reactions. 禁忌: Hypersensitivity to insulin NPH or any component of the formulation,,2 ~ 8 °C,According to individual requirements.,無需調整劑量,,無需調整劑量,可能安全,,,Compatible 哺乳時可使用,,SC;,,,,,
IELO,Corifollitropin alfa,Elonva inj 150mcg/0.5mL,HM,Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.,Hypersensitivity to the active substance or to any of the excipients. Tumors of the ovary， breast， uterus， pituitary or hypothalamus. Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. Primary ovarian failure. Ovarian cysts or enlarged ovaries. Fibroid Tumors of the uterus incompatible with pregnancy. Malformations of the reproductive organs incompatible with pregnancy. Pregnancy (see Use in Pregnancy & Lactation). Risk factors of OHSS: A history of Ovarian Hyperstimulation Syndrome (OHSS); A previous COS cycle that resulted in more than 30 follicles > or = 11 mm measured by ultrasound examination; A basal antral follicle count > 20; Polycystic ovarian syndrome (PCOS).,Common Gastrointestinal: Nausea (2.3% ) Musculoskeletal: Discomfort， In pelvis (6% )， Pain in pelvis (2.9% ) Neurologic: Headache (4% ) Reproductive: Breast tenderness (1.3% ) Other: Fatigue (1.5% ) Serious Reproductive: Ovarian hyperstimulation syndrome (4.3% )， Torsion of ovary (0.1% to less than 1% ),2-8℃，勿冷凍,In the treatment of women of reproductive age， the dose of Elonva is based on weight and age. A single 100-microgram dose is recommended in women who weigh less than or equal to 60 kilograms and who are 36 years of age or younger. A single 150-microgram dose is recommended in women: who weigh more than 60 kilograms， regardless of age; who weigh 50 kilograms or more and who are older than 36 years of age. Women older than 36 years of age who weighed less than 50 kilograms were not studied. The recommended doses of Elonva have only been established in a treatment cycle with a GnRH antagonist that was administered from stimulation day 5 or day 6 onwards. Stimulation day 1: Elonva should be administered as a single subcutaneous injection， preferably in the abdominal wall， during the early follicular phase of the menstrual cycle. Stimulation day 5 or 6: Treatment with a Gonadotropin Releasing Hormone (GnRH) antagonist should be started on stimulation day 5 or day 6 depending on the ovarian response， i.e. the number and size of growing follicles. The concurrent determination of serum estradiol levels may also be useful. The GnRH antagonist is used to prevent premature Luteinizing Hormone (LH) surges. Stimulation day 8: Seven days after the injection with Elonva on stimulation day 1， COS treatment may be continued with daily injections of (recombinant) Follicle Stimulating Hormone ((rec)FSH) until the criterion for triggering final oocyte maturation (3 follicles > or = 17 mm) has been reached. The daily dose of (rec)FSH may depend on the ovarian response， which should be monitored by regular ultrasonographic assessments from stimulation day 5 or 6 onwards. In normal responders a daily dose of 150 IU (rec)FSH is advised. Administration of (rec)FSH on the day of human Chorionic Gonadotropin (hCG) administration can be omitted， depending on the ovarian response. In general， adequate follicular development is achieved on average by the ninth day of treatment (range 6 to 18 days). As soon as three follicles > or = 17 mm are observed， a single injection of 5，000 up to 10，000 IU urinary hCG is administered the same day or the day thereafter to induce final oocyte maturation. In case of an excessive ovarian response， see the recommendations given in Precautions in order to reduce the risk for developing ovarian hyperstimulation syndrome (OHSS).,無需調整劑量,[仿單]在餵哺母乳期間不適合使用Elonva。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]Elonva不可使用於懷孕婦女。 若在懷孕期間不小心接觸到Elonva時，現有的臨床資料並不足以排除發生懷孕不良結果的可能性。 在動物研究中曾觀察到出現生殖系統毒性的現象,Unknown 沒有資料,[仿單]在餵哺母乳期間不適合使用Elonva。,SC;,,,,,請貯存於冰箱中(2°C-8°C)。為方便使用起見，病人可將本品存放25°C或(含)以下的溫度，但不可超過1個月。 切勿冷凍。
OACZ,Der pte extract + Der far extract,Acarizax 12 SQ-HDM (30 tablets/box),HIMM,House dust mite-induced allergic rhinitis for 12-65 years old patients.,Hypersensitivity to any of the excipients. Patients with FEV1 <70% of predicted value (after adequate pharmacological treatment) at initiation of treatment. Patients who have experienced a severe asthma exacerbation within the last 3 months. In patients with asthma and experiencing an acute respiratory tract infection， initiation of ACARIZAX treatment should be postponed until the infection has resolved. Patients with active or poorly controlled autoimmune diseases， immune defects， immunodeficiencies， immunosuppression or malignant neoplastic diseases with current disease relevance. Patients with acute severe oral inflammation or oral wounds.,Common Gastrointestinal: Itching， in the mouth (63.1% )， Lip swelling (18% )， Tongue swelling (15.8% )， Uvulitis (19.8% ) Otic: Itching of ear (51.7% ) Respiratory: Throat irritation (67% ) Serious Gastrointestinal: Eosinophilic esophagitis (0.07% ) Immunologic: Allergic reaction Respiratory: Airway constriction， Asthma,不超過30 °C,Usual dosage: 1 tablet (12 SQ-HDM) daily. Without swallowing for at least 1 minute， and with no food or beverage for 5 minutes. If the treatment is interrupted for more than 7 days it is recommended to contact a physician before resuming the treatment. Active ingredient: Der pte extract (Dermatophagoides pteronyssinus)， Der far extract (Dermatophagoides farinae),無需調整劑量,[仿單] 目前尚未有在阿克立舌下錠治療期間授乳的臨床資料。 預期授乳嬰兒可不受阿克立舌下錠的影響。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]目前尚未有懷孕婦女使用阿克立舌下錠的臨床資料。 動物實驗中，使用阿克立舌下錠尚未發現有增加胎兒危害的風險。 懷孕期間不應使用阿克立舌下錠。若在阿克立舌下錠治療期間懷孕，可經由評估病人身體狀況(包含肺功能) 以及病人先前使用阿克立舌下錠的反應情況，而決定繼續用藥。 建議有氣喘病史的病人，應於懷孕期間密切監測。,Unknown 沒有資料,[仿單] 目前尚未有在阿克立舌下錠治療期間授乳的臨床資料。 預期授乳嬰兒可不受阿克立舌下錠的影響。,SL;,,,,,[磨粉/管灌註記]本藥為舌下錠，目前相關臨床研究皆以舌下給藥，未經由舌下給藥的療效與安全性無法證實。仿單建議用法:打開阿克立舌下錠的包裝泡殼，應立即用乾燥的手指將口服錠放入舌下令其溶解。應避免在大約1分鐘內吞服。接下來5分鐘內不可以吃東西或喝飲料。
OATM25,Atomoxetine,apo-ATOMOXETINE 25mg,CNEU,Attention deficit hyperactivity disorder.,Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma， current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg， 15 to 20 mm Hg) or heart rate (eg， 20 beats per minute),Common Cardiovascular: Increased heart rate (Adult， 10.2% to 22.4%; pediatric， 12.2% to 23.4% ) Endocrine metabolic: Weight decreased (Adult， 2%; pediatric， 3% ) Gastrointestinal: Abdominal pain (Adult， 7%; pediatric， 18% )， Constipation (Adult， 8%; pediatric， 1% to 2% )， Decrease in appetite (Adult， 16%; pediatric， 16% )， Nausea (Adult， 26%; pediatric， 10% )， Vomiting (Adult， 4%; pediatric， 11% )， Xerostomia (Adult， 20% ) Neurologic: Dizziness (Adult， 8%; pediatric， 5% )， Headache (Pediatric， 19% )， Insomnia (Adult， 15%; pediatric， at least 2% )， Somnolence (Adult， 8%; pediatric， 11% ) Renal: Delay when starting to pass urine (Adult， 6% ) Reproductive: Dysmenorrhea (Adult， 3% )， Erectile dysfunction (Adult， 8% ) Other: Fatigue (Adult， 10%; pediatric， 8% ) Serious Cardiovascular: Increased diastolic arterial pressure (Adult， 4.8% to 12.6%; pediatric， 9.3% to 21.5% )， Increased systolic arterial pressure (Adult， 4.2% to 12.4%; pediatric， 4.9% to 12.5% )， Myocardial infarction， Sudden cardiac death， Tachycardia (Adult， 1.5%; pediatric， 0.3% ) Hepatic: Injury of liver (Severe)， Liver failure Neurologic: Cerebrovascular accident Psychiatric: Aggressive behavior， Hostile behavior， Mania， Psychotic disorder， Suicidal thoughts (Pediatric， 0.4% ) Reproductive: Priapism,儲存於25℃以下,6 years or older， up to 70 kg: Acute treatment: Initial， approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily， as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; Maximum 1.4 mg/kg daily or 100 mg/day， whichever is less 6 years or older， greater than 70 kg: Acute treatment: Initial， 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks;Maximum 100 mg daily,需調整劑量,[仿單]Atomoxetine 及/ 或其代謝物會分泌至老鼠的乳汁中。 Atomoxetine 是否會分泌至人類母乳中則未知。 哺乳中的婦女若服用 Atomoxetine 時，應加以注意。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,[仿單] 在懷孕兔子的器官形成期間，餵食劑量最高至 100 mg/ kg/ day 的Atomoxetine。在三篇研究中的一篇，觀察到活胎數減少，早期再吸收增加。不正常頸動脈起源及缺少鎖骨下動脈的發生率稍微增加。這些結果發現於會引起輕微母體毒性的劑量。 這些結果的無作用劑量（no-effect dose）為 30 mg/ kg/ day。以mg/ m2計，100 mg/ kg 的劑量約為最高人體劑量的 23 倍，兔子血中的 Atomoxetine濃度（AUC）估計為接受最高人體劑量的人體內的 3.3 倍（快速代謝者）或 0.4 倍（緩慢代謝者）。 從交配前 2 週（母鼠）或 10 週（公鼠），到器官形成及哺乳期為止，在老鼠飲食中加入不超過大約 50 mg/ kg/ day 的 atomoxetine（以 mg/ m2計算，約為最高人體劑量的 6 倍）。 在二篇研究的其中一篇，發現小鼠體重及存活數減少。在 25 mg/ kg（非 13 mg/ kg），也發現到小鼠的存活減少的現象。 一篇從交配前 2 週（母鼠）或10 週（公鼠），到器官形成期為止，在老鼠飲食中加入 Atomoxetine 的研究中，40mg/ kg/ day（以 mg/ m2計，約為最高人體劑量的 5 倍），發現到胎鼠體重減少（僅母鼠）及椎骨弓（vertebral arch）不完全成骨的發生率增加的現象，此現象並沒有在 20 mg/ kg/ day 劑量組中發現。 在器官形成期間，以 150 mg/ kg/ day 的劑量（以 mg/ m2計，約為最高人體劑量的17 倍）餵食懷孕母鼠，胎兒並未出現任何的副作用。 目前尚無關於懷孕婦女之充分及完整的對照性研究。 懷孕期間不可服用 Atomoxetine，除非效益超過胎兒可能產生的風險性。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Atomoxetine 及/ 或其代謝物會分泌至老鼠的乳汁中。 Atomoxetine 是否會分泌至人類母乳中則未知。 哺乳中的婦女若服用 Atomoxetine 時，應加以注意。,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥請整顆膠囊吞服。若有磨粉需求請使用前自行磨粉並注意本藥粉末具有眼部刺激性。
IINVZ,Ertapenem,InVanZ inj 1gm,QANB,Treatment of moderate to severe infections caused by susceptible strains of microorganisms as well as initial empiric therapy prior to identification of causative organisms in complicated intra-abdominal infections; complicated skin & skin structure infections， including diabetic foot infections w/o osteomyelitis; community acquired pneumonia; complicated UTI including pyelonephritis; acute pelvic infections， including postpartum endomyometritis， septic abortion & post surgical gynecologic infections. Prophylaxis of surgical site infection following elective colorectal surgery in adults.,Anaphylactic reaction to beta-lactam antibiotics. Hypersensitivity to amide-type local anesthetics due to lidocaine hydrochloride used as a diluent with IM route only. Hypersensitivity to ertapenem sodium or to any other component of the product or other drugs in the carbapenem class.,Common Gastrointestinal: Abdominal pain (Adult， 3.6% to 4.3%; Pediatric， 4.7% )， Constipation (Adult， 3.3% to 4%; pediatric， 2.3% )， Diarrhea (Adult， 9.2% to 10.3%; Pediatric， 11.7% )， Nausea ( Adult， 6.4% to 8.5%; pediatric， 1.6% )， Vomiting (Adult， 3.7% to 4%; Pediatric， 10.2%) Hematologic: Neutrophil count abnormal (5.8% ) Neurologic: Headache (5.6% to 6.8% ) Reproductive: Vaginitis (1.4% ) Serious Neurologic: Seizure (0.5% ) Dermatologic: Stevens-Johnson Syndrome， Toxic Epidermal Necrolysis,不可超過25°C,Adult & children > or = 13 years: 1 g QD IM or IVD. 3 months-12 years: 15 mg/kg QD， maximum 1 g/day. IM or IVD. [The Sanford Guide to Antimicrobial Therapy 2021] Pediatric dose: Age>28 days: 30mg/kg/day， divided Q12H， the maximum dose: 1g/day.,無需調整劑量,[仿單] 目前Ertapenem會分泌至人類的乳汁中。 當授乳婦女接受INVANZ治療時，必須謹慎小心。,需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單] 目前尚無有關懷孕婦女之適當及設計良好的對照試驗。 僅有在對母體及胎兒的潛在益處大於危險性時，才可在懷孕期間使用INVANZ。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 目前Ertapenem會分泌至人類的乳汁中。 當授乳婦女接受INVANZ治療時，必須謹慎小心。,IM;IVD;,10mL的注射用水或0.9%氯化鈉注射液,【N/S】可選 仿單建議。,,靜脈輸注時間>30分鐘。 年齡>13歲: 加入10mL的注射用水或0.9%氯化鈉注射，充分搖動使藥品溶解並立刻將溶液移到50mL的0.9%氯化鈉注射液中，經稀釋的藥品必須在6小時內完成輸注。 3個月至12歲: 加入10mL的注射用水或0.9%氯化鈉注射，充分搖動使藥品溶解並立刻抽取體積相當於15mg/公斤體重的溶液(不超過1gm/天)，以0.9%氯化鈉注射液稀釋成濃度為20mg/mL或更稀，經稀釋的藥品必須在6小時內完成輸注。 [Micromedex 20211005] IV infusion should be administered over 30 minutes and completed within 6 hours of reconstitution.,乾粉經溶解並以0.9%氯化鈉注射液稀釋後可室溫(25°C)6小時內使用，也可冷藏(5°C)至多24小時，自冷藏取出後須於4小時內使用。 不可以使用含有葡萄糖的稀釋液。 肌肉注射的準備步驟: 年齡>13歲:加入3.2mL的1%或2%之lidocaine HCl注射液(不含epinephrine)。充分搖動溶解成溶液，以深部肌肉注射的方式將藥品注入到大肌肉部位(例如臀部肌肉或大腿側邊肌肉)。溶液須在1小時內使用且不可靜脈投. 若用於3個月至12歲:施打體積應為15mg/公斤體重(不超過1gm/天)的溶液.
ONER,Neratinib,Nerlynx 40 mg (180 tablets/bot),RACA,Breast cancer， Extended adjuvant， early stage， HER2-positive， following adjuvant trastuzumab based therapy.,None.,Common Dermatologic: Rash (18% ) Endocrine metabolic: Weight decreased (5% to 20% ) Gastrointestinal: Abdominal pain (36% )， Constipation (31% )， Decrease in appetite (12% to 35% )， Diarrhea (78% to 98% )， Indigestion (10% )， Nausea (43% to 53% )， Stomatitis (14% )， Vomiting (26% to 46% ) Hepatic: ALT/SGPT level raised (9% )， Aspartate aminotransferase serum level raised (7% ) Musculoskeletal: Spasm (11% ) Neurologic: Dizziness (14% ) Other: Fatigue (27% to 45% ) Serious Renal: Renal impairment (7% ),儲存於室溫30°C以下,Adjuvant treatment of HER2-positive early carcinoma of breast: As extended adjuvant treatment in patients who completed adjuvant trastuzumab-based therapy: 240 mg once daily， given continuously until disease recurrence or for up to 1 year. Antidiarrheal prophylaxis is recommended during the first 56 days of therapy; initiate with the 1st neratinib dose. Dose reduction， dosing interruption， or discontinuation may be required according to individual safety or tolerability. HER2-positive advanced carcinoma of breast， HER2-positive metastatic carcinoma of breast: In patients who have received > or = 2 prior anti-HER2 based regimens in the metastatic setting: 240 mg once daily on days 1-21 of a 21-day cycle; given with capecitabine on days 1-14 of a 21-day cycle， until disease progression or unacceptable toxicity. Antidiarrheal prophylaxis is recommended during the first 56 days of therapy; initiate with the 1st neratinib dose. Dose reduction， dosing interruption， or discontinuation may be required according to individual safety or tolerability. Nerlynx Dose Modifications for Adverse Reactions (Dose Level and Nerlynx Dose): Recommended starting dose: 240 mg daily; First dose reduction: 200 mg daily; Second dose reduction: 160 mg daily; Third dose reduction: 120 mg daily.,需調整劑量,[仿單] 關於neratinib或其代謝物出現在人類乳汁中，或其對哺乳中嬰兒或乳汁產生的影響，目前並無相關資料。 由於哺乳中嬰兒可能因NERLYNX而發生嚴重不良反應，應指示哺乳女性在服用NERLYNX期間以及最後一劑藥物後至少1個月內不得哺乳。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]根據動物試驗的發現及其作用機轉，NERLYNX投予懷孕女性時可能對胎兒造成傷害。 目前並無NERLYNX用於懷孕女性的資料可得知藥物相關風險。 在動物生殖試驗中，在器官發生期間(organogenesis)對懷孕兔子投予neratinib，在動物母體曝藥量(曲線下面積)約為接受建議劑量之病人的0.2倍之下，neratinib導致兔子發生流產、胚胎-胎兒死亡與胎兒異常。 應告知懷孕女性有關NERLYNX對於胎兒的潛在風險。 針對適應症族群，其重大先天缺陷與流產的背景風險目前不明。然而，在美國的一般族群中，臨床認知懷孕的重大先天缺陷背景風險為2%至4%，而流產則為15%至20%。,Unknown 沒有資料,[仿單] 關於neratinib或其代謝物出現在人類乳汁中，或其對哺乳中嬰兒或乳汁產生的影響，目前並無相關資料。 由於哺乳中嬰兒可能因NERLYNX而發生嚴重不良反應，應指示哺乳女性在服用NERLYNX期間以及最後一劑藥物後至少1個月內不得哺乳。,PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。仿單建議應整錠吞服，不可咬碎或撥半。
EACG,Test Strips,Accu-Chek Guide 50 strips(羅氏智航),ZOTH,For use with the Accu-Chek Guide Meter， Accu-Chek Guide Link Meter， and Accu-Chek Guide Me Meter to measure the blood glucose.,,,4-30℃，濕度10-90%；請勿冷凍、避免暴露於高溫潮濕處,For use with the Accu-Chek Guide Meter， Accu-Chek Guide Link Meter， and Accu-Chek Guide Me Meter to measure the blood glucose.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,廠商建議勿將本產品置於冰箱或防潮箱，因易產生濕度頻繁變化。
EEFU,Metronidazole,Efucon gel 0.75%， 15gm,TDER,Topical treatment of inflammatory papules， pustules & erythema of rosacea.,Hypersensitivity to metronidazole.,xeroderma， Erythema， burning sensation of skin,25℃以下,Rosacea: 0.75%: Apply and rub a thin film twice daily， morning and evening， to entire affected areas after washing.,無需調整劑量,Hold Breastfeeding (Single Dose) Limited Human Data—Potential Toxicity (Divided Dose) [仿單]無相關紀載.,無需調整劑量,沒有資料,Human data suggest low risk,[仿單]孕婦除非必要，且應小心使用.,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Hold Breastfeeding (Single Dose) Limited Human Data—Potential Toxicity (Divided Dose) [仿單]無相關紀載.,EXT;,,,,,
IKET2,Ketamine,Ketamine-hameln inj 500mg/10mL(專案進口),ZANE,Anaesthetic agent in adults and children: - for induction and maintenance of general anaesthesia， if applicable in com- bination with sleep medication (hypnotic agents)， - supplementary to other anaesthetics in local anaesthesia， - for anaesthesia and pain treatment (analgesia) in emergency medicine， - for treatment of frequent and persistent attacks of dyspnoea (treatment- resistant status asthmaticus)， - for treatment of pain during mechanical ventilation (intubation).,- Patients with hypersensitivity to ketamine or any of the excipients - Elevation of blood pressure or intracranial pressure forms a serious risk - Poorly controlled or untreated high blood pressure (arterial hypertension， systolic/diastolic resting blood pressure above 180/100 mmHg) - High blood pressure caused by pregnancy， with protein excretion in the urine (preeclampsia) and seizures (eclampsia) - Untreated or poorly treated overactive thyroid (hyperthyroidism) - Situations which require relaxed uterus myometrium e.g. threatening uterus rupture， prolapsed umbilical cord - When used as sole anaesthetic agent in patients with manifest ischaemic cardiac disorders,Common: Hypertension， Increased cardiac index， Tachycardia， Emergence from anesthesia， Psychiatric sign or symptom (12-50%) Serious: Bradyarrhythmia， Cardiac dysrhythmia， Hypotension， Anaphylaxis， Apnea， Laryngeal spasm， Pulmonary edema， Respiratory depression,避光儲存於25°C 以下。不可冷凍。,For induction of general anaesthesia: 1-2 mg/kg IV or 4-8 mg/kg IM. To maintain general anaesthesia， half of the initial dose is injected as needed， generally every 10-15 minutes. Continuous infusion: 1-6 mg/kg/hr. The dose should be reduced in cases of multiple injuries (polytrauma) or with patients in poor general condition. To supplement local anaesthetic agents， 0.25-0.5 mg/kg PRN. For analgesia during mechanical ventilation (intubated intensive-care patients)， usually 0.5 mg/kg as bolus， with subsequent continuous infusion of 0.4-1 (up to 3) mg/kg/hr with simultaneous administration of a benzodiazepine. Treatment should not extend beyond 4 to 6 weeks. For anaesthesia in emergency medicine， 0.5-1 mg/kg IM or 0.25-0.5 mg/kg IV. For the treatment of frequent and persistent dyspnoea (treatment-resistant status asthmaticus)， 1-2 (up to 5) mg/kg IV.,需調整劑量,[仿單] Ketamine is excreted into breast milk， but an effect on the child seems unlikely when using therapeutic doses.,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單] Animal reproduction studies are insufficient， but available data do not indicate any adverse effects on pregnancy， embryo-foetal development， parturition or postnatal development. The potential risk for humans is unknown. Use of ketamine should be restricted during pregnancy and only administered after consideration if the potential benefits for the mother outweighs the possible hazard for the child. Ketamine crosses the placental barrier. If doses higher than 2 mg IV per kg body weight are applied， respiratory depression in the new-born must be expected.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] Ketamine is excreted into breast milk， but an effect on the child seems unlikely when using therapeutic doses.,IM;IVD;IVPUSH;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,Administer slowly IV over 60 seconds [Micromedex],dilute in N/S or D5W to a final concentration of 1 or 2 mg/mL [Micromedex] Continuous infusion: 1-6 mg/kg/hr; 0.4-3 mg/kg/hr with simultaneous administration of a benzodiazepine. [仿單],1. Storage: [Opened vials] 28 days at 20-25°C after the first opening; [Prepared infusion solutions] Use immediately. If not， normally not be longer than 24 hours at 2-8°C. 2. 不可與barbiturates， benzodiazepines (e.g. diazepam)， 4-hydroxybutyric acid (sodium salt)， theophylline， furosemide sodium or sodium hydrogen carbonate 混和，會產生沉澱。
ELAD,Estradiol,Ladiol Gel 0.6mg/gm， 30gm,HM,Natural or surgical menopause， estrogen deficiencies; vasomotor disorders associated with menopause; tropic disorders caused by disturbances in ovarian secretions as in vag atrophy， kraurosis vulvae， female hypogonadism， castration in women， primary ovarian deficiency.,Malignant tumors of the breast or uterus. Pituitary tumors.,Cardiovascular: Edema (transdermal system， 0.5% to 13% ) Dermatologic: Application site irritation (transdermal spray， 1.3% ; transdermal system， 5.7% to 56.7% )， Chloasma， Hirsutism， Persistent erythema of skin (transdermal patch， 17% )， Pruritus (topical emulsion， 4% ; topical gel， 4.8% ) Endocrine metabolic: Weight change finding Gastrointestinal: Bloating symptom， Nausea， Vomiting Neurologic: Migraine Psychiatric: Depression (transdermal system， 1% to 8% )， Disturbance in mood Reproductive: Breast tenderness (topical gel， 2.5% to 8.8% ; transdermal spray， 5% to 7% ; transdermal system， 6.5% to 17.0% )， Disorder of menstruation， Leukorrhea， Swelling of breast， Vaginal discomfort (vaginal cream， 5% ; vaginal ring， 5% )， Withdrawal bleeding,30℃以下,Apply 2.5gm daily (preferably on the abdomen) from day 1 to day 24 every month.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Compatible 哺乳時可使用,,EXT;,,,,,避免塗抹於乳房、陰道或毛髮處。 警 語:建議塗於肩部、手臂或腹部，並勿用於兒童
IPHES,Pertuzumab + Trastuzumab,Phesgo inj 600/600mg/10mL,RACA,Breast cancer， Adjuvant， HER2-positive， early stage， at high risk of recurrence， in combination with chemotherapyView additional information. Breast cancer， Neoadjuvant， HER2-positive， locally advanced， inflammatory， or early stage (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen in combination with chemotherapyView additional information. Metastatic breast cancer， HER2-positive， in combination with docetaxel， in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease,Hypersensitivity to pertuzumab， trastuzumab， or hyaluronidase， or any component of the formulation.,Common Dermatologic: Alopecia (77% )， Injection site disorder (15% )， Radiation injury (19% )， Rash (16% ) Gastrointestinal: Constipation (22% )， Decrease in appetite (17% )， Diarrhea (60% )， Inflammatory disease of mucous membrane (15% )， Nausea (60% )， Stomatitis (25% )， Taste sense altered (17% )， Vomiting (20% ) Hematologic: Anemia， All Grades (36% )， Neutropenia， All Grades (22% ) Musculoskeletal: Arthralgia (24% ) Neurologic: Asthenia (31% )， Headache (17% )， Insomnia (17% )， Sensory neuropathy (16% ) Other: Fatigue (29% ) Serious Cardiovascular: Cardiomyopathy， Heart failure (0.8% )， Left ventricular cardiac dysfunction Hematologic: Febrile neutropenia， Grade 3 or 4 (7% )， Neutropenia， Grade 3 or 4 (14% ) Immunologic: Anaphylaxis， Hypersensitivity reaction (1.2% ) Respiratory: Pulmonary toxicity Other: Infusion reaction (21% ),裝於原盒中，避光儲存於2-8°C冰箱中。不可冷凍。不可搖晃。,Initial dosage， Pertuzumab 1200mg/Trastuzumab 600mg/Hyaluronidase-zzxf 30000units， 15mL， SC over approximately 8 minutes. Maintenance dosage: Pertuzumab 600mg/Trastuzumab 600mg/Hyaluronidase-zzxf 20000units， 10mL， SC over approximately 5 minutes every 3 weeks for 3 to 6 cycles as part of a treatment regimen.,無需調整劑量,BREASTFEEDING RECOMMENDATION: Trastuzumab: No Human Data—Potential Toxicity Pertuzumab: Contraindicated [仿單]目前未有pertuzumab、trastuzumab或玻尿酸進入人體乳汁、對於哺乳嬰兒或乳汁生成影響之資料。 已發表資料顯示，人體IgG存在於人體乳汁內，但未大量進入新生兒和嬰兒循環。 Trastuzumab存在於哺乳食蟹獼猴的乳汁內，但未出現相關新生兒毒性。 應考量哺乳對於發育和健康的利益，以及母親對於Phesgo治療的臨床需求，和Phesgo或潛在母體情況對於哺乳嬰兒的任何潛在不良作用。 此項考量也應將pertuzumab的排除半衰期及trastuzumab清除期為7個月納入考量。,無需調整劑量,沒有資料,Contraindicated,PREGNANCY RECOMMENDATION: Trastuzumab: No Human Data—Animal Data Suggest Moderate Risk Pertuzumab: Contraindicated [仿單]為懷孕女性施打Phesgo可能導致胎兒損傷。 在上市後報告中，於懷孕期間以靜脈輸注Herceptin (trastuzumab)曾引起羊水過少以及表現為肺臟發育不全、骨骼異常和新生兒死亡的羊水過少症候群。 在一項動物生殖試驗中，懷孕食蟹獼猴在器官生成階段接受臨床相關曝藥量高於2.5至20倍人體接受建議劑量之曝藥量的pertuzumab時，會導致羊水過少、胎兒腎臟發育遲緩、和胚胎-胎兒死亡。 應告知病人對於胎兒的可能風險。若在懷孕期間或受孕前7個月內使用Phesgo，應進行臨床上的考量與評估。,Contraindicated 哺乳期使用禁忌,BREASTFEEDING RECOMMENDATION: Trastuzumab: No Human Data—Potential Toxicity Pertuzumab: Contraindicated [仿單]目前未有pertuzumab、trastuzumab或玻尿酸進入人體乳汁、對於哺乳嬰兒或乳汁生成影響之資料。 已發表資料顯示，人體IgG存在於人體乳汁內，但未大量進入新生兒和嬰兒循環。 Trastuzumab存在於哺乳食蟹獼猴的乳汁內，但未出現相關新生兒毒性。 應考量哺乳對於發育和健康的利益，以及母親對於Phesgo治療的臨床需求，和Phesgo或潛在母體情況對於哺乳嬰兒的任何潛在不良作用。 此項考量也應將pertuzumab的排除半衰期及trastuzumab清除期為7個月納入考量。,SC;,,,,,1. 僅可以皮下施打於大腿。請勿施打到靜脈。以約5分鐘皮下施打，注射部位僅應在左右側大腿之間輪換。 2. 溶液已從小瓶抽取到針筒中，請將轉移針頭換成針頭蓋。儲存於冰箱(2-8°C)最多24小時及室溫(20-25°C)最多4小時。 3. 請勿與Perjeta(pertuzumab)、Herceptin(trastuzumab)、Kadcyla(trastuzumab emtansine)互相替換。
ILIG2,Lidocaine,Lignocaine inj 2% 100mg/5mL,ZANE,,適應症: Emergency treatment of ventricular arrhythmia. 副作用: Conduction block， shock. Rarely malignant hyperthermia. Confusion， dizziness， drowsiness， nervousness， euphoria， vomiting， numbness. 禁忌: Complete AV block. Sensitivity to local anesthetics of the amide type or to any other component of the product.,,25℃以下,Intravenous administration. Usually dose: 50~100 mg (1~2 mg/kg， 2.5~5 mL of 2% injection) for adults is given by intravenous injection slowly in 1~2 minutes. If no effect is observed after the first injection， the same dose may be repeated after 5 minutes. May repeat at 10-20 minutes intervals. The maximum dose within one hour is 300 mg (2% injection: 15 mL). Intravenous injection of this medicine generally is recovery within 10-20 minutes.,需調整劑量,[仿單]孕婦、產婦、授乳婦的給藥對孕婦或可能已懷孕的婦女， 限於判斷其治療上的有益性超越危險性時才可給藥（有關懷孕中給藥的安全性尚未確立）。,需調整劑量,沒有資料,Compatible,[仿單]孕婦、產婦、授乳婦的給藥對孕婦或可能已懷孕的婦女， 限於判斷其治療上的有益性超越危險性時才可給藥（有關懷孕中給藥的安全性尚未確立）。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]孕婦、產婦、授乳婦的給藥對孕婦或可能已懷孕的婦女， 限於判斷其治療上的有益性超越危險性時才可給藥（有關懷孕中給藥的安全性尚未確立）。,IVPUSH;,,,通常成人一次 50~100 mg（1~2 mg/kg，2%注射液 2.5~5 mL）以 1~2 分鐘的時間，緩慢地靜脈注射。效果不彰時，在 5 分鐘後給予相同的劑量，另外，期待效果得以持續時，以間隔 10~20 分鐘的時間追加給與相同的劑量也無妨，但一小時內最高的基準給藥量是 300 mg（2%注射液：15 mL）。,,調配時：因本劑中的 Lidocaine 是鹽酸鹽，將本藥與碳酸氫鈉等鹼性注射液混合時會使 Lidocaine 析出，因此請勿將其混合使用。
OABI,Aripiprazole,Abilify 5mg,CNEU,Schizophrenia in adults & adolescents 13-17 years. Monotherapy or adjunctive therapy to either lithium or valproate for the acute manic & mixed episodes associated with Bipolar I disorder in adults & pediatrics 10-17 years. Adjunctive treatment of major depressive disorders. Irritability associated with autistic disorder in pediatric patients 6-17 years.,Known hypersensitivity to aripiprazole.,Headache， asthenia， accidental injury， peripheral edema， hypertension， GI disturbances， myalgia， agitation， anxiety， insomnia， lightheadedness， somnolence， akathisia， extrapyramidal syndrome， tremor， increased salivation， rhinitis， pharyngitis， coughing， blurred vision. Endocrine metabolic: Weight increased (2% to 30% ) Gastrointestinal: Constipation (5% to 11% )， Nausea (8% to 15% )， Vomiting (3% to 11% ) Neurologic: Akathisia (2% to 25% )， Dizziness (4% to 10% )， Extrapyramidal disease (2% to 27.3% )， Headache (12% to 27% )， Insomnia (8% to 18% )， Sedated (1% to 8% )， Somnolence (5% to 26.3% )， Tremor (2% to 11.8% ) Ophthalmic: Blurred vision (3% to 8% ) Psychiatric: Anxiety (4% to 17% )， Restlessness (2% to 12% ) Other: Fatigue (2% to 11% ),15-30℃,Schizophrenia: Adults: 10mg or 15mg QD. Effective range: 10-30 mg/day. Do not increase the dose until the course of treatment is up to 2 weeks. Teenagers， 13-17 years old: The initial daily dose is 2 mg， and it will be adjusted to 5 mg after 2 days， and then adjusted to the target dose of 10 mg after another 2 days. Bipolar disorder manic episodes and mixed episodes: Adults: 15mg QD. The initial dose for adjuvant therapy of lithium or valproate is 10-15 mg/day. Can be increased to 30 mg/day based on clinical response. Children， 10-17 years old: The initial daily dose is 2 mg， and adjusted to 5 mg after 2 days， and then adjusted to the target dose of 10 mg after another 2 days. If necessary after the adjustment， the dose should be increased by 5 mg each time. Adjuvant treatment of major depression: Adults: Inintial dose:2-5mg/day， titrate the dose to 10 mg/day or 15 mg/day in a manner not exceeding 5 mg/day each time. The adjustment interval should be more than 1 week. Tourette syndrome， 6~18 years old: <50kg: The initial dose is 2 mg per day， and the target dose of 5 mg/day will be reached after two days. In patients whose tics are not well controlled， the dose can be increased to 10 mg/day. The dosage should be adjusted step by step not to exceed 5 mg/day each time， and the interval should not be less than 1 week. >50kg: The initial dose is 2 mg/day for 2 days， then the dose is increased to 5 mg/day for 5 days， and the target dose is 10 mg/day on the 8th day. In patients whose tics are not well controlled， the dose can be increased to 20 mg/day. The dose should be adjusted step by step not to exceed 5 mg/day each time， and the interval should not be less than 1 week.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OMIRA15,Pramipexole,1.5mg MIRAPEX prolonged-release,CNEU,,適應症:Treatment of signs & symptoms of Parkinson's disease. 副作用:Abnormal behaviors (eg， binge eating， compulsive shopping， hypersexuality， pathological gambling)， abnormal dreams， amnesia， cardiac failure， confusion， constipation， delusion， dizziness， dyskinesia， dyspnoea， fatigue， hallucinations， headache， hiccups， hyperkinesia， hyperphagia， hypotension， inappropriate antidiuretic hormone secretion， insomnia， libido disorders， nausea， paranoia， peripheral oedema; pneumonia; pruritus， rash; restlessness， somnolence， sudden onset of sleep， syncope， visual impairment including diplopia， blurred vision， reduced visual acuity; vomiting， decreased appetite， increased/decreased wt. 禁忌:Hypersensitivity. Lactation.,,,,,,,,,,,,AC;PO;WM;,,,,,
ILID,Lidocaine,Lidocaine inj 20mg/mL， 20mL局麻,ZANE,Local injectable for anesthesia.,Hypersensitivity to lidocaine or any component of the formulation. History of hypersensitivity to local anesthetics of the amide type. Severe degrees of SA， AV， or intraventricular heart block.,Common Dermatologic: Erythema， Skin irritation Gastrointestinal: Hoarse， Loss of voice， Pain in throat Serious Hematologic: Methemoglobinemia Immunologic: Allergic reaction， Anaphylaxis,25℃以下,Adult Caudal anesthetic: Obstetrical analgesia， Usual dosage: 200 - 300 mg. Surgical anesthesia， Usual dosage: 225 - 300 mg. Should not be administered at intervals of less than 90 minutes. Local anesthetic lumbar epidural block Usual dosage (analgesia): 250 - 300 mg. Usual dosage (anesthesia): 200 - 300 mg. Should not be administered at intervals of less than 90 minutes. Local anesthetic intravenous regional block， Usual dosage: 50 - 300 mg Local anesthesia， by infiltration， Usual dosage: 5 - 300 mg Peripheral block anesthesia， Brachial， intercostal， paravertebral， or pudendal Brachial Nerve Block， Usual dosage: 225 - 300 mg. Intercostal Nerve Block， Usual dosage: 30 mg. Paravertebral Nerve Block， Usual dosage: 30 - 50 mg. Pudendal Nerve Block， Usual dosage: 100 mg. Paracervical block anesthesia， Usual dosage (Obstetrical analgesia): 100 mg on each side injected slowly， with a 5-minute period between sides. Peripheral block anesthesia， Dental， Usual dosage: 20 - 100 mg. Retrobulbar infiltration of local anesthetic， the Recommended dose is 120 - 200 mg. Cervical sympathetic block (Obstetrical )， Usual dosage: 50 mg Lumbar sympathetic block， Usual dosage: 50 - 100 mg Maximum single dose: 4.5 mg/kg or 300 mg total dose but Local anesthetic intravenous regional block， Maximum individual dose: 4 mg/kg. Maximum dose of Dental: 6.6mg/kg or 300 mg total dose each visit.,無需調整劑量,[仿單]授乳期婦女安全性尚未確定。,無需調整劑量,可能安全,Compatible,[仿單]未有相關敘述。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]授乳期婦女安全性尚未確定。,IRR;LA;LI;,,,,,本藥不可用於靜脈給藥。
ITRU,Rituximab,Truxima inj 500mg/50mL,RACA,The treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL): Relapsed or refractory， low-grade or follicular， CD20-positive B-cell NHL as a single agent; OR Previously untreated follicular， CD20-positive， B-cell NHL in combination with first-line chemotherapy and， in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy， as single-agent maintenance therapy; OR Non-progressing (including stable disease)， low-grade， CD20-positive， B-cell NHL as a single agent after first-line cyclophosphamide， vincristine， and prednisone (CVP) chemotherapy. Chronic lymphoid leukemia: In combination for first-line treatment; OR in combination with fludarabine and cyclophosphamide; OR maintenance， following rituximab-containing chemotherapy. Granulomatosis with polyangiitis or Microscopic polyangiitis: In combination with glucocorticoids,Hypersensitivity to rituximab and any excipients or proteins in this product.,Common Dermatologic: Pruritus (10% to 14% ) Gastrointestinal: Nausea (23% ) Hematologic: Anemia， All Grades (8% to 35% )， Lymphocytopenia， All Grades (48% ) Neurologic: Asthenia (26% )， Headache (19% ) Other: Fever (53% )， Shivering (33% ) Serious Cardiovascular: Cardiogenic shock， Hypotension (10% )， Myocardial infarction， Ventricular fibrillation Dermatologic: Lichen simplex chronicus， Pemphigus paraneoplastica， Stevens-Johnson syndrome， Toxic epidermal necrolysis Gastrointestinal: Gastrointestinal perforation Hematologic: Anemia， Grade 3 or 4 (3% )， Leukopenia， Grade 3 or 4 (4% )， Lymphocytopenia， Grade 3 or 4 (40% )， Neutropenia， Grade 3 or 4 (4% to 6% )， Pancytopenia， Grade 3 or 4， Thrombocytopenia， Grade 3 or 4 (2%) Hepatic: Reactivation of hepatitis B viral hepatitis Neurologic: Progressive multifocal leukoencephalopathy Renal: Nephrotoxicity Respiratory: Bronchospasm (8% )， Pulmonary toxicity (18% ) Other: Angioedema (11% )， Infectious disease (19% to 37% )， Infusion reaction (Equal to or greater than 25% )， Tumor lysis syndrome,冷藏2-8°C保存。切勿冷凍。,Recommended Dose for Non-Hodgkin’s Lymphoma (NHL): The recommended dose is 375 mg/m2. Relapsed or Refractory， Low-Grade or Follicular， CD20-Positive， B-Cell NHL: Administer once weekly for 4 or 8 doses. Retreatment for Relapsed or Refractory， Low-Grade or Follicular， CD20Positive， B-Cell NHL: Administer once weekly for 4 doses. Previously Untreated， Follicular， CD20-Positive， B-Cell NHL: Administer on Day 1 of each cycle of chemotherapy， for up to 8 doses. In patients with complete or partial response， initiate TRUXIMA maintenance eight weeks following completion of a rituximab product in combination with chemotherapy. Administer TRUXIMA as a single-agent every 8 weeks for 12 doses. Non-progressing， Low-Grade， CD20-Positive， B-Cell NHL， after first-line CVP chemotherapy: Following completion of 6-8 cycles of CVP chemotherapy， administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses. First Infusion: Initiate infusion at a rate of 50 mg/hour. In the absence of infusion toxicity， increase infusion rate by 50 mg/hr increments every 30 minutes， to a maximum of 400 mg/hour. Subsequent Infusions: Standard Infusion: Initiate infusion at a rate of 100 mg/hour. In the absence of infusion toxicity， increase rate by 100 mg/hour increments at 30-minute intervals， to a maximum of 400 mg/hour. Chronic lymphocytic leukemia: 375 mg/m2 on the day prior to fludarabine/cyclophosphamide in cycle 1， then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 (in combination with fludarabine and cyclophosphamide). Granulomatosis with polyangiitis or microscopic polyangiitis:Induction therapy: 375 mg/m2 once weekly for 4 doses or 1 g once every 2 weeks for 2 doses; for either dosing regimen， administer in combination with a systemic glucocorticoid.,無需調整劑量,[仿單]Rituximab是否分泌於母乳中尚未得知。然而，既然母體的免疫球蛋白IgG會進入母乳中，不應給予授乳婦女TRUXIMAR。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]已知免疫球蛋白IgG會穿過胎盤屏障。 目前並未曾在原開發廠藥品之臨床試驗中研究過母體接觸過rituximab之人類新生兒體內的B細胞濃度。目前尚無足夠 且控制良好的孕婦研究資料，不過，在懷孕期間接觸過rituximab之母親所生下的嬰兒中，曾有一些發生暫時性B細胞 耗竭及淋巴球減少症的報告。因此不可對孕婦投予TRUXIMA，除非可能的效益超過潛在的風險。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Rituximab是否分泌於母乳中尚未得知。然而，既然母體的免疫球蛋白IgG會進入母乳中，不應給予授乳婦女TRUXIMAR。,IVD;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,不可以靜脈推注,以無菌操作方式取出所需藥量，注入0.9% NaCl或Dextrose 5%之輸注液中，稀釋後濃度需為Rituximab 1-4mg/mL。輕輕倒轉輸注袋混合溶液，避免產生泡沫。給予注射藥品之前，應目視檢查是否有顆粒物質及變色。,1.已調配之Truxima輸注液的物理及化學穩定性可在2 °C - 8 °C下維持24小時，隨後在室溫下（不超過30 °C）維持12小時。 2.未調配之Truxima應冷藏2-8°C保存.切勿冷凍. 3.治療期間及之後 12 個月內，育齡婦女應使用有效的避孕方法。
ITAK,Lansoprazole,Takepron 針劑 30mg,ALIM,As an alternative to oral therapy when oral intake is not appropriate for GERD in patients with esophagitis &/or severe symptoms of reflux & for healing of gastric ulcers associated with NSAID therapy.,Hypersensitivity to Lansoprazole.,Headache， abdominal pain， diarrhea， flatulence， nausea/vomiting， constipation. Abnormal hepatic function tests， hyperbilirubinemia， increased serum alkaline phosphatase， increased serum ALT， increased serum AST.,25℃以下,30 mg IV once or twice daily infusion over 30 minutes.,需調整劑量,,無需調整劑量,,Human data suggest low risk,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,IVD;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,Intravenous infusion over 30 minutes.,給藥途徑：僅可靜脈輸注方式投予。 配製藥品: 1. 加入5 mL 0.9%氯化鈉注射液或5%葡萄糖注射液至藥瓶內，並輕輕混合至粉末溶解。 2. 以50 mL的0.9%氯化鈉注射液或5%葡萄糖注射液稀釋配製液。 3. 混合液配製完成後不可存放，應立即使用。
OMOR1BAD,Morphine,Morphine 15mg 殘餘銷燬,CNEU,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
IELI,Leuprorelin Acetate,Eligard inj 22.5mg extended-release,RACA,For the palliative treatment of advanced prostate cancer.,Patients with hypersensitivity to GnRH， GnRH agonist analogs， or any of the components of ELIGARD. Women and pediatric patients.,Common Cardiovascular: Edema (Adults， 8.2% to 20.8% ) Dermatologic: Acne (Endometriosis 10% )， Flushing (Central precocious puberty， 5% ; prostate cancer， 52% to 73.3% )， Injection site disorder (Central precocious puberty， 9% ; prostate cancer， 8.2% to 37.5% )， Injection site pain (Central precocious puberty， 19% to 31% ; prostate cancer， 19.2% )， Rash (Central precocious puberty， 3% ; prostate cancer， 6% ) Endocrine metabolic: Increased testosterone level， Transient， Serum triglycerides raised (Endometriosis， 12% to 32% )， Weight increased (Central precocious puberty， 7% ) Gastrointestinal: Abdominal pain (Central precocious puberty， 9% )， Constipation (Central precocious puberty， 6% ; prostate cancer， 9.9% )， Nausea (Central precocious puberty， 8% )， Nausea and vomiting (Endometriosis， 13% to 29%; uterine fibroids， 4.8% to 5% )， Vomiting (Central precocious puberty， 6% ) Hematologic: Anemia (Prostate cancer， 2.3% to 6.6% ) Musculoskeletal: Arthralgia (Prostate cancer， 9.3% )， Arthropathy (Prostate cancer， 4.2% to 16.3% )， Decreased bone mineral density， Myalgia (Prostate cancer， 7.9% ) Neurologic: Asthenia (Prostate cancer， 12.2% ; uterine fibroids， 8% to 18% )， Dizziness (Endometriosis， 11% ; uterine fibroids， 1.8% )， Headache (Central precocious puberty， 2% to 16% ; endometriosis， 32% ; prostate cancer， 4.2% )， Insomnia， Lethargy Psychiatric: Mood swings (Central precocious puberty， 2% to 5% ) Renal: Dysuria (6% ) Reproductive: Atrophy of testis (Prostate cancer， 4.4% to 20.2% )， Vaginitis (Endometriosis， 8% to 28%; uterine fibroids， 11% to 11.4% ) Respiratory: Bronchospasm (Central precocious puberty， 6% )， Cough (Central precocious puberty， 13% prostate cancer， 6.6% )， Nasopharyngitis (Central precocious puberty， 22% )， Productive cough (Central precocious puberty， 6% ) Other: Fever (Central precocious puberty， 17% )， Malaise and fatigue (Prostate cancer， 6% to 17.5% )， Pain (Central precocious puberty， 3% ; endometriosis， 19% to 29% ; prostate cancer， 4.2% to 32.7% ; uterine fibroids， 8% to 6.1% ) Serious Cardiovascular: Heart failure (Adults， less than 5% )， Myocardial infarction， Prolonged QT interval Hepatic: Injury of liver Musculoskeletal: Fracture of vertebral column Neurologic: Fracture of vertebral column， Pseudotumor cerebri， Seizure (Prostate cancer， less than 0.5% ) Psychiatric: Depression (Up to 5% )， Suicidal thoughts Respiratory: Pulmonary embolism,2-8°C，室溫(<25°C)可4週,Eligard 22.5mg is administered subcutaneously every 3 months. The injection provides continuous release of leuprolide acetate over the treatment period.,無需調整劑量,[仿單]本藥禁用於婦女,無需調整劑量,不可使用,Contraindicated,[仿單]本藥禁用於婦女,Contraindicated 哺乳期使用禁忌,[仿單]本藥禁用於婦女,SC;,,,,,1. 請依照仿單圖示依步驟配製藥品，一旦配製好應立即使用，因為溶液的黏度會隨時間增加。 2. 未拆封藥品離開冰箱存放於25℃以下，可保存4週。
IKEY,Pembrolizumab,Keytruda inj 50mg/vial,RACA,,適應症:KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and， if BRAF V600 mutation positive， a BRAF inhibitor. 副作用:>10%: Cardiovascular: Facial edema (10%) Central nervous system: Fatigue (43%) Dermatologic: Pruritus (28%)， skin rash (24%; immune-mediated: 1%) Endocrine & metabolic: Hyperglycemia (49%)， hypoalbuminemia (37%)， hyponatremia (37%)， hypertriglyceridemia (33%)， decreased serum bicarbonate (22%)， hypocalcemia (21%) Gastrointestinal: Constipation (22%)， nausea (22%)， decreased appetite (20%)， diarrhea (20%)， abdominal pain (13%)， vomiting (13%) Hematologic & oncologic: Anemia (44%; grades 3/4: 10%)， lymphocytopenia (40%; grades 3/4: 9%) Hepatic: Increased serum alkaline phosphatase (26%)， increased serum AST (24%)， increased serum ALT (21%) Neuromuscular & skeletal: Arthralgia (14%) Respiratory: Dyspnea (?20%)， cough (18%) Miscellaneous: Fever (14%) 1% to 10%: Central nervous system: Confusion (>2%)， peripheral neuropathy (2%) Endocrine & metabolic: Hypothyroidism (immune-mediated; 9%)， hyperthyroidism (immune-mediated; 3%) Gastrointestinal: Colitis (immune-mediated; 2%) Immunologic: Antibody development (2%) Neuromuscular & skeletal: Weakness (10%)， arthritis (immune-mediated; 2%) Respiratory: Pneumonitis (3%)， pleural effusion (>2%)， pneumonia (>2%)， respiratory failure (>2%) 禁忌:Hypersensitivity to pembrolizumab or any component of the formulation.,,2-8°C,The recommended dose of KEYTRUDA is 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity. [OFF-LABLE USE IN TAIWAN] Colorectal cancer， Unresectable or metastatic， progressed following treatment with a fluoropyrimidine， oxaliplatin， and irinotecan - Microsatellite instability-high， Or mismatch repair deficient : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Head and neck cancer， Recurrent or metastatic， squamous cell， with disease progression on or after platinum-based chemotherapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Hodgkin's disease， Classical， refractory or relapsed after 3 or more prior lines of therapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Metastatic urothelial carcinoma， Or locally advanced， in patients not eligible for cisplatin-containing chemotherapy， or with progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Microsatellite instability-high， Or mismatch repair deficient - Solid tumor， Unresectable or metastatic， progressed following prior treatment and who have no satisfactory alternative treatment options : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Non-small cell lung cancer， Metastatic， high PD-L1 expression， first-line treatment， with no EGFR or ALK tumor aberrations : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Non-small cell lung cancer， Metastatic， PD-L1 expression， with disease progression on or after platinum-based chemotherapy; patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Nonsquamous non-small cell lung cancer， Metastatic， first-line treatment in combination with pemetrexed and carboplatin : 200 mg IV infusion over 30 minutes every 3 weeks， for up to 24 months or until disease progression or unacceptable toxicity. Give prior to pemetrexed 500 mg/m(2) IV and carboplatin AUC 5 mg/mL/min IV on day 1 of each 21-day cycle for 4 cycles， followed by pembrolizumab monotherapy with or without pemetrexed maintenance.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,IVD;,,,,,製備: 1. 沿著藥瓶內壁加入2.3毫升無菌注射用水(USP)，不要直接加在冷凍乾燥藥粉上(所形成的濃度為25毫克/毫升)。 2. 輕轉藥瓶勿震搖。靜置5分鐘，待氣泡消失。 3. 泡製後為無色至淡黃色溶液，若觀察到其他異物，則應丟棄不用。 4. 抽取需要的藥量，注入0.9%氯化鈉注射液或5%葡萄糖注射液的靜脈輸注袋中。(輕轉的方式混勻溶液)。 5. 溶液的最終濃度應為1毫克/毫升至10毫克/毫升之間。 6. 稀釋後可存放室溫，但不可超過6小時。(包括於室溫下，泡製後之藥瓶的存放時間、IV袋中之輸注溶液的存放時間、以及輸注所需要的時間)
EMYC20,Triamcinolone + Neomycin + Gramicidin + Nystatin,Mycomb 乳膏 20gm,TDER,Treatment of inflammatory skin lesions where bacterial or candidal infections are suspected.,Tuberculous & most viral lesions of skin， especially herpes simplex， vaccinia， varicella.,Skin atrophy; ototoxicity; nephrotoxicity.,25℃以下,apply BID or TID.,無需調整劑量,Triamcinolone - No Human Data—Probably Compatible Neomycin - No Human Data—Probably Compatible Gramicidin - Unknown Nystatin - Compatible,無需調整劑量,沒有資料,Uknown 沒有資料,Triamcinolone - Compatible (Inhaled) Neomycin - Human Data Suggest Low Risk Gramicidin - Unknown Nystatin - Compatible,Unknown 沒有資料,Triamcinolone - No Human Data—Probably Compatible Neomycin - No Human Data—Probably Compatible Gramicidin - Unknown Nystatin - Compatible,EXT;,,,,,
OPAX,Nirmatrelvir + Ritonavir,Paxlovid 300/100mg， 10 doses (公費),QANB,An Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing， and who are at high risk for progression to severe COVID-19， including hospitalization or death.,History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components. Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance.,Common Gastrointestinal: Diarrhea (3%)， Taste sense altered (6%) Serious Hepatic: Hepatitis， Including increased transaminase levels.,儲存於25℃以下。,Paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets. The dosage for Paxlovid is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together orally twice daily for 5 days.,需調整劑量,[仿單]關於PF-07321332是否可分泌至人或動物乳汁、對母乳餵養嬰兒的影響或對乳汁分泌的影響，目前尚無可取得的資料。在給予PF-07321332的大鼠的哺乳後代中觀察到體重暫時性下降。有限的已發表資料顯示，ritonavir出現於乳汁中。尚無關於ritonavir對母乳餵養嬰兒產生的影響或藥物對泌乳量產生的影響的資料。應考慮母乳餵養的發育和健康益處，以及母親對PAXLOVID的臨床需求以及PAXLOVID或母體基礎狀況對母乳餵養嬰兒的任何潛在不良影響。感染COVID?19的哺乳期女性應遵循臨床指引的規定，以避免使嬰兒暴露於COVID?19。 在產前和產後發育研究中，給予妊娠大鼠PF-07321332的全身暴露量(AUC24)約為PAXLOVID的核准人體劑量臨床暴露量的8倍時，在子代觀察到體重下降（最高達8%）。在母體全身暴露量(AUC24)約為PAXLOVID的核准人體劑量臨床暴露量的5倍時，未觀察到子代的體重變化。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]目前尚無妊娠期間使PF-07321332的人體資料可用於評估主要出生缺陷、流產或母體或胎兒不良的藥物相關風險。已發表的關於孕婦使用ritonavir的觀察性研究未發現重大出生缺陷的風險增加。已發表的ritonavir研究不足以確定藥物相關的流產風險。妊娠期間如不予治療，COVID-19會對母嬰構成風險。 在PF-07321332的動物胚胎-胎兒發育研究中，妊娠母兔口服給予PF-07321332，在全身暴露量(AUC)約PAXLOVID的核准人體劑量臨床暴露量的10倍時，觀察到胎兒體重減輕。在PF-07321332的動物生殖研究中，在全身暴露量(AUC)為PAXLOVID的核准人體劑量臨床暴露量的3倍或3倍以上時，未觀察到其他不良發育結果。 在ritonavir的動物生殖研究中，妊娠大鼠和母兔口服給予ritonavir，劑量（依據體表面積轉換）或全身暴露量(AUC)為臨床劑量或PAXLOVID的核准人體劑量暴露量的3倍或3倍以上時，未觀察到不良發育結果的證據。 在適用人群中，主要出生缺陷和流產的估計背景風險不明。所有妊娠均面臨出生缺陷、流產或其他不良結果的風險。在美國一般人群中，臨床確認的妊娠中主要出生缺陷和流產的估計背景風險分別為2-4%和15-20%。,Unknown 沒有資料,[仿單]關於PF-07321332是否可分泌至人或動物乳汁、對母乳餵養嬰兒的影響或對乳汁分泌的影響，目前尚無可取得的資料。在給予PF-07321332的大鼠的哺乳後代中觀察到體重暫時性下降。有限的已發表資料顯示，ritonavir出現於乳汁中。尚無關於ritonavir對母乳餵養嬰兒產生的影響或藥物對泌乳量產生的影響的資料。應考慮母乳餵養的發育和健康益處，以及母親對PAXLOVID的臨床需求以及PAXLOVID或母體基礎狀況對母乳餵養嬰兒的任何潛在不良影響。感染COVID?19的哺乳期女性應遵循臨床指引的規定，以避免使嬰兒暴露於COVID?19。 在產前和產後發育研究中，給予妊娠大鼠PF-07321332的全身暴露量(AUC24)約為PAXLOVID的核准人體劑量臨床暴露量的8倍時，在子代觀察到體重下降（最高達8%）。在母體全身暴露量(AUC24)約為PAXLOVID的核准人體劑量臨床暴露量的5倍時，未觀察到子代的體重變化。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議應整粒吞服。不得咀嚼、破壞或壓碎錠劑。
INS3YF,Sodium Chloride,3% NaCl inj 500mL(YF),NUTR,Supplementation of sodium and chloride ions (to increase the concentration of sodium and chloride ions in the serum)， Addisonian crisis， diabetic coma.,Hypersensitivity to sodium chloride or any component of the formulation; hypertonic uterus， hypernatremia， fluid retention,Common: Disorder of fluid AND/OR electrolyte， Hypercalciuria， Hypernatremia， Hypokalemia， Phlebitis， Injection site disorder， Injection site extravasation， Hypervolemia Serious: Congestive heart failure， Hypernatremia， Overhydration， Disseminated intravascular coagulation， Respiratory distress,25℃以下,[Lexicomp 20230720] Initially， 100 mL infused slowly over a 1-hour period. Before additional amounts are administered， serum electrolyte concentrations， including chloride and bicarbonate， should be determined to assess the need for additional sodium chloride. IV infusion of 3 or 5% sodium chloride injection should not exceed 100 mL/hour. Maximum 400 mL in 24 hours.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IH;IVD;LI;,,,,[Lexicomp] Infusion rate: Administer the solution slowly; maximum 100 mL/hour. Maximum 400 mL in 24 hours.,1. 本藥品為高張輸注液，須特別注意給藥速率。
IFADI,Famotidine,Fadin Lyo inj 20mg,ALIM,,適應症: Gastroesophageal reflux disease， Heartburn， Peptic ulcer disease 副作用: >10%: Central nervous system: Agitation (infants: <=14%; adults: <1%) 1% to 10%: Central nervous system: Headache (5%)， dizziness (1%) Gastrointestinal: Diarrhea (2%)， constipation (1%)， necrotizing enterocolitis Frequency not defined: Local: Irritation at injection site (IV) <1%， postmarketing， and/or case reports: Abdominal distress， acne vulgaris， agranulocytosis， alopecia， anaphylaxis， angioedema， anorexia， anxiety， arthralgia， asthenia， atrioventricular block， bronchospasm， cardiac arrhythmia， cholestatic jaundice， confusion， conjunctival injection， decreased libido， depression， drowsiness， facial edema， fatigue， fever， flushing， hallucination， hepatitis， hypersensitivity reaction， impotence， increased liver enzymes， insomnia， interstitial pneumonitis， leukopenia， muscle cramps， musculoskeletal pain， nausea， palpitations， pancytopenia， paresthesia， periorbital edema， prolonged Q-T interval on ECG， pruritus， psychiatric disturbance， rhabdomyolysis， seizure， skin rash， Stevens-Johnson syndrome， taste disorder， thrombocytopenia， tinnitus， toxic epidermal necrolysis， urticaria， vomiting， xeroderma， xerostomia Gastrointestinal: Constipation (1.2% )， Diarrhea (1.7% ) 禁忌症: Serious hypersensitivity (eg， anaphylaxis) to famotidine， other H2 antagonists， or any component of the formulation,,25度C以下室溫,20 mg twice daily,無需調整劑量,[仿單] 本藥會移行至母乳中，因此若投與授乳中之婦女，應注意不要授乳.,需調整劑量,沒有資料,Compatible,[仿單] 對於懷孕中投與之安全性尚未建立，因此孕婦或可能懷孕的婦女，最好不要投與.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 本藥會移行至母乳中，因此若投與授乳中之婦女，應注意不要授乳.,IVD;IVP;IVPUSH;,IV: 20mL N/S， D5W,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,推注時間至少 2 mins,[Micromedex]Solution for infusion: Administer over 15-30 minutes. Dilute 2 mL of famotidine 10 mg/mL solution with 100 mL of D5W or other compatible solution.,每支20mg以20mL生理食鹽水或葡萄糖水溶解後立即使用。 可靜脈緩慢注射或加入靜脈輸液點滴給予。
IKAD6,Trastuzumab Emtansine,KADCYLA inj 160mg,RACA,Metastatic breast cancer， HER2 overexpression， monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.,Specific contraindications have not been determined.,Common ■Gastrointestinal: Constipation (26.5% )， Nausea (39.8% ) ■Hematologic: Thrombocytopenia， All grades (31.2% ) ■Hepatic: Increased liver enzymes， All grades (28.8% ) ■Musculoskeletal: Musculoskeletal pain (36.1% ) ■Neurologic: Headache (28.2% ) ■Other: Fatigue (36.3% ) Serious ■Cardiovascular: Left ventricular cardiac dysfunction (1.8% ) ■Dermatologic: Injection site extravasation ■Hematologic: Anemia， Grade 3 and 4 (4.1% )， Neutropenia， Grade 3 and 4 (2% )， Thrombocytopenia， Grade 3 and 4 (14.5% ) ■Hepatic: Hepatotoxicity， Increased liver enzymes， Grades 3 and 4 (8% )， Injury of liver ■Immunologic: Anaphylactoid reaction ■Neurologic: Peripheral nerve disease， Grade 3 or 4 (2.2% ) ■Respiratory: Dyspnea (12% )， Interstitial lung disease， Pneumonitis (0.8% to 1.2% ),2-8℃,3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever， chills， or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.,無需調整劑量,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded， a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,無需調整劑量,盡量避免,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded， a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,IVD;,,,,,1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。請使用0.2-0.22微米、不吸附蛋白質的管線內 polyethersulfone (PES)過濾器。 3. 溶液配置後應立即使用，冷藏於2-8℃最多儲存24小時。 4. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 5. 監測CBC、肝腎功能。
ISYNA1,Palivizumab,Synagis inj 50mg/0.5mL,HIMM,Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease， including infants with bronchopulmonary dysplasia， a history of premature birth (<=35 weeks gestational age)， & children with hemodynamically significant congenital heart disease.,Hypersensitivity to palivizumab or humanized monoclonal antibodies.,Upper respiratory infections， otitis media， rhinitis， rash， pain， hernia， increased SGOT， pharyngitis.,2-8℃,IM， 15 mg/kg/month.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – no relevant animal data,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,
IMTX2,Methotrexate,Methotrexate inj 50mg/2mL,RACA,Trophoblastic tumors， leukemia， lymphoma， osteogenic & bronchogenic carcinoma， breast， head & neck cancer， mycosis fungoides.,Pregnancy & lactation. Psoriatic patient in a poor state of nutrition， serious renal or liver disorders， bone marrow hyperplasia， leukopenia， thrombocytopenia or anemia.,Hepatotoxicity， GI， dermatological， liver & GUT toxicity.,25℃以下避光,[Choriocarcinoma and similar trophoblastic diseases] 15-30 mg orally or intramuscularly daily for a 5-day course repeated for 3-5 times as required with rest periods of 1 or more weeks interposed between courses until any manifesting toxic symptoms subside. [Breast cancer] 40 mg/m2 IV on days 1 and 8 in combination with cyclophosphamide and fluorouracil. [Leukemia] Induction: 3.3 mg/m2 in combination with prednisolone 60 mg/m2 daily for 4-6 weeks. Maintenance therapy: administer 2 times weekly orally or IM in total weekly doses of 30 mg/m2 or 2.5 mg/kg IV every 14 days. If and when relapse occurs， repeat initial induction regimen. [Meningeal Leukemia] 0.2-0.5 mg/kg intrathecally at intervals of 2-5 days until the cell count of the cerebrospinal fluid returns to normal. At this point one additional dose is advisable. Alternative: 12 mg/m2 intrathecally once weekly for 2 weeks， then once monthly. [Lymphomas] 0.625-2.5 mg/kg daily. Treatment in all stages usually consists of several courses interposed with 7-10 day rest periods. 0.625-2.5 mg/kg daily.[Mycosis fungoides] 50 mg IM once weekly or 25 mg IM twice weekly.,無需調整劑量,,需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,IM;IVD;,,【D5NS】可選 。【D5W】可選 。【N/S】可選 。,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能。
IACET,Propacetamol,Acetamol inj 1gm,CNEU,Relief of pain， fever.,Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or severe active liver disease.,Hypertension， hypotension， peripheral edema， tachycardia， agitation (children)， anxiety， fatigue， headache (more common in adults)， insomnia (more common in adults)， trismus， pruritus (children)， skin rash， hypervolemia， hypoalbuminemia， hypokalemia， hypomagnesemia， hypophosphatemia， abdominal pain， diarrhea， headache (more common in adults)， insomnia (more common in adults)， nausea (more common in adults)， vomiting (more common in adults)， oliguria， anemia， increased serum transaminases， infusion site reaction(pain)， limb pain， muscle spasm， periorbital edema， abnormal breath sounds， atelectasis (children)， dyspnea， hypoxia， pleural effusion， pulmonary edema， stridor， wheezing， fever.,25℃以下,Pain and fever Adult: 1-2 g every 4 hr， up to 4 times daily. May be given via IV inj. Maximum dose: 8 g daily. Child: 20-30 mg/kg， given over 15 min， up to 4 times daily. Maximum dose: 120 mg/kg/day.,需調整劑量,WHO: Compatible with breastfeeding (Micromedex),需調整劑量,除非治療上需要,Human data suggest low risk,藥品仿單:懷孕初期三個月不建議使用本產品。,Compatible 哺乳時可使用,WHO: Compatible with breastfeeding (Micromedex),IVD;IVPUSH;,請使用廠商所附之專用稀釋液(5mL)。,【D5W】可選 。【N/S】可選 。,IVPUSH: 成人靜脈注射以20mL N/S稀釋，使滲透壓約為400 mOsm/L。可兩分鐘內直接注射。(緩慢推注避免注射時疼痛),IVD: 成人建議將藥物加入125mL N/S後15分鐘內輸注完畢。四歲以上(或體重17kg以上)孩童建議先加入D5W或N/S，再以每公斤體重每次注射1-2mL，於平均為時15分鐘的時間靜脈輸注。(輸注完應以10mL N/S沖管路),1.廠商建議避免IVPUSH方式給藥避免注射部位疼痛。(20211123諮詢藥廠) 2.本藥須使用廠商提供之稀釋液溶解。 3.本品開瓶後應一次使用完畢，不得分次注射。 4.本品調配後須於30分鐘內使用，不可與其他藥物混合使用。 5.病人可以口服時應盡快改用口服Acetaminophen。 6.對Acetaminophen過敏者禁用。 7.特殊族群：肝、腎功能受損者需調整劑量。
OGLUB1,Acarbose,Glucobay 100mg,META,,適應症: Additional therapy in association w/ diet in patients w/ DM. 副作用: Flatulence. Diarrhoea， GI & abdominal pain. 禁忌: Hypersensitivity; chronic intestinal disorders associated w/ distinct disturbances of digestion & absorption， conditions which may deteriorate as a result of increased intestinal gas formation. Severe renal impairment.,,室溫,Adult: Initially 50 mg tids， up to 100 mg tids.,無需調整劑量,,需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IPRM,Metoclopramide hydrochloride,Promeran inj 9.08mg/2mL,ALIM,,適應症:Prevention of nausea & vomiting， GERD & diabetic gastroparesis. 副作用:Syndrome malin. Occasionally GI disturbances， headache， lightheadedness， drowsiness. Rarely， endocrinal disorders eg. amenorrhea， hyperprolactinemia， gynecomastia in males， breast enlargement in women; extrapyrimidal symptoms， hypotension， tachycardia， arrhythmia Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )， Vomiting (1.4% to 2.1% ) Neurologic: Asthenia (10% )， Headache (4.2% to 5.2% .)， Somnolence (oral， 2.1% to 10%; IV， 70%) Other: Fatigue (2.1% to 2.8% ) 禁忌:GI hemorrhage， mechanical obstruction or digestive perforation; Pheochromocytoma; previous history of tardive dyskinesia with neuroleptics. Epilepsy,,室溫,Adult Usual dose: IM or IV 7.68mg/2mL. 1~2 times/day. Children 1/2 adult dose,,,,可能安全,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,1. 化療前靜脈注射：10 mg / 50 mL 緩慢輸注超過 15 分鐘。 2. Primperan 10 mg IV 請 slowly push (約 1~2 分鐘)，超過 1 amp 請 IV drip。(2008/03/11 藥物不良反應小組)
IPAT,Patent blue V,Patent blue V inj 50mg/2mL,ZOTH,Identification of lymph vessels and arterial territories.,Hypersensitivity.,Hypotension， nausea， laryngeal edema， pruritus.,仿單無特別指示,Location of lymphatic vessels: approximately 1mL of Patent Blue V is injected into the subcutaneous tissue. Marking lymph vessels and the sentinel node: 1 to 2 mL subcutaneously around the tumour or areola. Location of arterial territories: Intra-arterial injection of Patent Blue V results in a colouring of the tissues vascularised by the vesseis. Marking arterial regions: not more than 10 mL intra-arterially. To control the correct position of the catheter destined ti intra-arterial chimiotherapy， 50mL of a solution comprised of: 80mL of an isotonic sodium in water solution， 40mL of a 2.5% Patent Blue V solution and 20mL of a 1% xylocaine solution are perfused.,無需調整劑量,,無需調整劑量,盡量避免,,,Unknown 沒有資料,,IA;LI;SC;,,,,,1. 動脈注射Patent Blue V能將有血管的組織染色，一次灌注以下混合溶液的50mL溶液，溶液包含: *80mL等張鈉水溶液。 *40mL 2.5%Patent Blue V溶液。 *20mL 1%Xylocaine溶液。 2. Patent blue V 可能產生過敏副作用，注射前需了解病患過去有無過敏或不良反應記錄，必要時可事先投予Corticosteroid 與 Antihistamine。
IVANS,Vancomycin,Vancomycin inj 1gm,QANB,Treatment of severe infections caused by susceptible strains of methicillin-resistant staphylococci. For penicillin-allergic patients. Staphylococcal endocarditis. Infections due to staphylococci eg septicemia， bone infections， lower resp tract infections， skin & skin structure infections. Diphtheroid endocarditis. Oral treatment for antibiotic-associated pseudomembranous colitis.,Hypersensitivity.,Anaphylactoid reactions following rapid infusion. Nephrotoxicity， ototoxicity， reversible neutropenia， pseudomembranous colitis; chemical peritonitis following intraperitoneal administration.,25℃以下,Adult 500 mg Q6H or 1 g Q12H by intermittent infusion. Duration: At least 3 weeks in staphylococcal endocarditis. Prophylaxis of endocarditis in high-risk penicillin-allergic patients undergoing dental or other procedures 1 g by IV infusion as a single dose before the procedure together with gentamicin IV. Repeat doses Q8H for patients undergoing GI or GU procedures. Children 10 mg/kg body weight Q6H. Neonates initial 15 mg/kg followed by 10 mg/kg Q12H in 1st weeks of life & Q8H up to 1 month of age. *****NEONATE ANTIBIOTICS DOSE***** Vancomycin: Dilute to a final concentration <=5 mg/mL; IV infusion over 90 minutes Draw trough level within 30 mins before the fourth dose. peak level 60 mins after end of infusion Sepsis PMA <=29 week Postnatal 0-14 days， dose: 10mg/kg Q18H PMA <=29 week Postnatal >=15 days， dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days， dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days， dose: 10mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days， dose 10mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days， dose 10mg/kg Q8H PMA >=45 week: 10mg/kg Q6H Meningitis PMA<=29 week Postnatal 0-14 days dose: 15mg/kg Q18H PMA <=29 week Postnatal >=15 days， dose: : 15mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days， dose: 15mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days， dose: 15mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days， dose: 15mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days， dose: 15mg/kg Q8H PMA >=45 week: 15mg/kg Q6H,無需調整劑量,[仿單] Vancomycin會排泄到母乳中.故授乳婦使用時應注意. 由於有副作用發生的可能，須斟酌藥物對母親的重要性，決定是否停止授乳或停藥.,需調整劑量,除非治療上需要,Compatible,[仿單] 尚未有動物生殖研究，未知是否會影響生育力.有案例在臍帶血中發現本藥， 有一嬰兒，其母親於懷孕第三期使用本藥，有傳導性失聰，但非由本藥所致，在此研究中，因病人數目有限， 且只在懷孕期第二期與第三期投與本藥，做此藥是否會導致胎兒傷害，目前仍未得知. 除非確實有必要時，才給孕婦投與此藥,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] Vancomycin會排泄到母乳中.故授乳婦使用時應注意. 由於有副作用發生的可能，須斟酌藥物對母親的重要性，決定是否停止授乳或停藥.,IMP;INS;IRR;IS;IVD;IVI;SCI;SUBCI;,IVD: 20 mL D/W,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【D5NS】可選 。,,給藥濃度 2.5~5mg/mL，輸注速率< 10 mg/min，兒童至少以超過60分鐘以上時間緩慢滴注。,1. 監測體溫、CBC、腎功能、聽覺功能。 2. 注意輸注過快時的不良反應：低血壓、呼吸困難、蕁麻疹。 3. 建議監測藥物血中濃度。 4. 給藥濃度: 2.5~5mg/mL，利用輸注液給藥，濃度不可超過 5mg/mL。 5. 調配及抽藥時建議使用G21號針頭(外徑0.8mm)，並且於橡膠塞中央位置針頭90度向下穿刺，避免產生橡膠塞碎屑。 6. 加入10 mL滅菌注射用水於500 mg無菌vancomycin乾粉之小瓶內。以此法調得50 mg/ mL的溶液，須進一步稀釋。溶液調配之後需冷藏，可於冰箱中保存14天而不會明顯降低力價。
OVOS,Sofosbuvir + Velpatasvir + Voxilaprevir,Vosevi 400/100/100mg,QANB,Treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: (1) genotype 1， 2， 3， 4， 5， or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. (2) genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.,Concomitant use with rifampin. Hypersetitivity to Sofosbuvir/Velpatasvir/Voxilaprevir or any ingredients of this product.,Common Gastrointestinal: Diarrhea (13% to 14% )， Nausea Neurologic: Headache (21% to 23% ) Other: Fatigue (17% to 19% ) Serious Cardiovascular: Bradyarrhythmia， Cardiac arrest Hepatic: Decreased liver function， Liver failure， Reactivation of hepatitis B viral hepatitis,30℃以下,One tablet contains sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100mg. 1 tablet once daily with meal for 12 weeks.,需調整劑量,[仿單]目前尚不知道VOSEVI個別成分及其代謝物是否會進入人類乳汁中、是否會影響人類乳汁分泌或對被哺乳的嬰兒造成影響。對哺乳中的大鼠投予VOSEVI 個別成分後，可在乳汁中測得GS331007（sofosbuvir 的主要循環代謝物）及velpatasvir，被哺乳仔鼠的血液中可測得voxilaprevir，這可能是因為乳汁中有voxilaprevir。在被哺乳的仔鼠中並未觀察到任何藥品的顯著作用。 哺乳對嬰兒發育及健康的益處、母親對VOSEVI的需求以及VOSEVI或母親狀況對哺乳中嬰兒潛在的不良影響，都應一併考慮。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]關於VOSEVI是否對懷孕造成風險，目前尚無充足的人類資料可供判斷。在動物生殖研究中，VOSEVI個別成分（sofosbuvir、velpatasvir 或voxilaprevir）的暴露量高於人類建議劑量（RHD）之暴露量，並未觀察到不良發育的證據。在器官發生期間，velpatasvir的全身性暴露量（AUC）約達人類建議劑量（RHD）之暴露量的23（小鼠）、4（大鼠）及0.5（兔子）倍，voxilaprevir的全身性暴露量（AUC）約達人類建議劑量（RHD）之暴露量的141（大鼠）及4（兔子）倍，sofosbuvir主要循環代謝物（GS331007）的暴露量約達人類建議劑量（RHD）之暴露量的6（大鼠）及16（兔子）倍。在大鼠的出生前/後發育研究中，VOSEVI個別成分在母體內的全身性暴露量（AUC）約達人類建議劑量（RHD）之暴露量的7（sofosbuvir代謝物GS-331007）、3（velpatasvir）及238（voxilaprevir）倍。 對於特定族群之重大先天缺陷及流產的背景風險尚不清楚。在美國一般族群、臨床確認的懷孕中，重大先天缺陷及流產的背景風險估計分別為2-4%及15-20%。,Unknown 沒有資料,[仿單]目前尚不知道VOSEVI個別成分及其代謝物是否會進入人類乳汁中、是否會影響人類乳汁分泌或對被哺乳的嬰兒造成影響。對哺乳中的大鼠投予VOSEVI 個別成分後，可在乳汁中測得GS331007（sofosbuvir 的主要循環代謝物）及velpatasvir，被哺乳仔鼠的血液中可測得voxilaprevir，這可能是因為乳汁中有voxilaprevir。在被哺乳的仔鼠中並未觀察到任何藥品的顯著作用。 哺乳對嬰兒發育及健康的益處、母親對VOSEVI的需求以及VOSEVI或母親狀況對哺乳中嬰兒潛在的不良影響，都應一併考慮。,PO;WM;,,,,,
EAZL,Azelaic Acid,Azel cream 30gm,TDER,Acne vulgaris.,Hypersensitivity to propylene glycol. Hypersensitivity to azelaic acid or any component of the formulation.,Common: Burning sensation， Pruritus (Rosacea， 11% ; acne vulgaris， 1-5% )， Stinging of skin， Tingling of skin Serious: Skin irritation， Hypersensitivity reaction,30℃以下,Apply to affected skin areas twice daily， in the morning and evening， unless otherwise instructed by a physician. If skin irritation occurs， reduce the frequency to once daily until the irritation subsides， otherwise， treatment should be temporarily discontinued. Continuous use is recommended for approximately 4 weeks to several months.,無需調整劑量,[Micromedex] Infant risk cannot be ruled out - Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,無需調整劑量,沒有資料,Uknown 沒有資料,[Micromedex] Fetal risk cannot be ruled out - available evidence is inconclusive or inadequate for determining fetal risk when used in pregnant women.,Unknown 沒有資料,[Micromedex] Infant risk cannot be ruled out - Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,EXT;SKIN;TOPI;,,,,,
ICOXBB15,SARS-CoV-2 Spike glycoprotein [mRNA],COVID-19 XBB.1.5 0.5mL/dose (2.5mL/vial),HIMM,For active immunization in children aged 6 months and above， adolescents， and adults to prevent COVID-19 (severe acute respiratory syndrome coronavirus 2 disease).,Known history of severe allergic reactions (eg， anaphylaxis) to any component of the Moderna COVID-19 vaccine (inactive ingredients include tromethamine， acetic acid， sodium acetate， sucrose， sphingomyelin， cholesterol， distearoylphosphatidylcholine， and polyethylene glycol [ie， PEG2000-DMG]) or severe allergic reaction following a previous dose of a Moderna COVID-19 vaccine.,Common: Erythema at injection site (Adult， 2.4-9%; adolescent， 13.5-19.5%; pediatric， 3.5-18.7%)， Injection site pain (Adult， 73.9-89.9%; adolescent， 92.4-93.1%; pediatric， 37.4-94.8%)， Swelling at injection site (Adult， 4.5-12.7%; adolescent， 16.2-20.5%; pediatric， 2.8-17%)， Nausea and vomiting (Adult， 5.2-21.4%; adolescent， 11.3-23.9%; pediatric， 6.8-24%)， Axillary lymphadenopathy， Tenderness (Adult， 6.1-16.2%; adolescent， 21-23.3%; pediatric， 15.5-18%)， Arthralgia (Adult， 16.4-45.6%; adolescent， 15-28.9%; pediatric， 6.2-16.1%)， Myalgia (Adults， 19.7-61.7%; adolescents， 26.9-46.6%; pediatrics， 9.9-28.2%)， Headache (Adult， 24.5-63%; adolescent， 43.4-70.2%; pediatric， 11.5-54.3%)， Fatigue (Adult， 33.3-67.8%; adolescent， 47.9-67.8%; pediatric， 40.1-64.5%)， Fever (Adult， 0.3-17.4%; adolescent， 2.5-12.2%; pediatric， 3.3-23.9%)， Shivering (Adult， 5.3-48.7%; adolescent， 18.4-43%; pediatric， 6.4-30.3%) Serious: Myocarditis， Pericarditis， Facial swelling， Anaphylaxis， Hypersensitivity reaction (1.5-4.3%),未開封: -50至-15°C冷凍保存9個月。解凍後(勿再冷凍): 2-8°C下冷藏30天。離開冷藏後: 24小時。,For children aged 6 months to 4 years: (1) No prior COVID-19 vaccination and no known SARS-CoV-2 infection history: Two doses， 0.25 mL (25 micrograms) each， at least 28 days apart. (2) Previously received one dose of any Spikevax vaccine: Single 0.25 mL (25 micrograms) dose， at least 28 days after the previous dose. (3) Previously received two doses of Spikevax or had a SARS-CoV-2 infection: Single 0.25 mL (25 micrograms) dose， at least 3 months after the previous dose. For children aged 5 to 11 years: Single 0.25 mL (25 micrograms) dose， with a minimum 3-month interval if previously vaccinated. For adolescents aged 12 and adults: Single 0.5 mL (50 micrograms) dose， with a minimum 3-month interval if previously vaccinated.,無需調整劑量,[仿單] 目前尚無哺乳期使用相關資料。Spikevax XBB.1.5使用於哺乳期婦女的依據主要來自接種 Spikevax 原病毒株疫苗的經驗。由於哺乳婦女接種Spikevax原病毒株疫苗後之全身性暴露可被忽略， 預期對於餵哺母乳之新生兒/嬰兒不具影響。觀察性資料顯示哺乳婦女接種疫苗後， 並未出現對餵哺母乳之新生兒/嬰兒有害的影響。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 目前尚無在懷孕期間使用相關資料。Spikevax XBB.1.5使用於懷孕婦女的依據主要來自 接種Spikevax 原病毒株疫苗的經驗。動物試驗並未顯示 Spikevax 原病毒株疫苗對懷孕、胚胎/胎兒發育、分娩或產後發育會造成直接或間接的有害影響。 大量的臨床觀察性資料顯示，孕婦在第二孕期和第三孕期接種Spikevax 原病毒株疫苗並未增加不良懷孕結果。 雖然在第一孕期接種的懷孕結果資料有限，但未發現流產風險增加有上升的現象。,Unknown 沒有資料,[仿單] 目前尚無哺乳期使用相關資料。Spikevax XBB.1.5使用於哺乳期婦女的依據主要來自接種 Spikevax 原病毒株疫苗的經驗。由於哺乳婦女接種Spikevax原病毒株疫苗後之全身性暴露可被忽略， 預期對於餵哺母乳之新生兒/嬰兒不具影響。觀察性資料顯示哺乳婦女接種疫苗後， 並未出現對餵哺母乳之新生兒/嬰兒有害的影響。,IM;,,,,,1. 本疫苗使用應依據衛生主管機關 COVID-19 疫苗接種建議施打。 2. 冷凍保存(-50至-15°C)，使用前須解凍(置於室溫15-25°C: 1小時；冷藏2-8°C: 2.5小時)。解凍後請勿重新冷凍。 3. 僅供肌肉注射給藥。解凍後及每次抽藥前請輕晃藥瓶。不可振搖、稀釋或混合其他疫苗。 4. 第一劑抽出後在2-25°C可存放19小時；2-8°C下可30天。
OAMOX,Amoxicillin,AMOXICILLIN 500mg,QANB,G(+) & G(-) infections,Hypersensitivity to penicillins.,Nausea， vomiting， diarrhea， glossitis， stomatitis， black hairy tongue; skin rashes， urticaria， exfoliative dermatitis， erythema multiforme; anemia， thrombocytopenia， eosinophilia， leukopenia， agranulocytosis.,室溫避光,Infection of upper respiratory tract， genitourinary tract and skin/soft tissue: Adult: 250-500 mg orally once every 8 hours; children: 20-40 mg/kg/day in divided doses every 8 hours. Lower respiratory tract infection: Adult: 500 mg every 8 hours; children: 40 mg/kg/day in divided doses every 8 hours. Children > 20 kg should be dosed according to the adult recommendations. Gonorrhea， acute uncomplicated genitourinary tract infections caused by N. gonorrhoeae in males and females: Adult: 3 g as single oral dose. All patients with gonorrhea should be evaluated for syphilis. The following Pediatric dose recommendation is from Sanford Guide to Antimicrobial Therapy.(2022/11/08): Age>28 days: 25-100mg/kg/day divided Q8-12H.,無需調整劑量,,需調整劑量,可能安全,Human data suggest risk in 1st and 3 rd trimesters,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
ODEPY,Acetaminophen,Depyretin 500mg,CNEU,Relief of painful disorders such as headache， dysmenorrhea， conditions involving musculoskeletal pain， myalgias & neuralgias. After dental work， tooth extractions & in teething. As an analgesic & antipyretic in conditions accompanied by discomfort & fever， such as common cold & viral infections.,When used for self-medication， do not use with other drug products containing acetaminophen or if allergic to acetaminophen or any of the inactive ingredients.,Acetaminophen has rarely been found to produce any side effects. It is usually well tolerated by aspirin-sensitive patients. Severe recurrent pain or high continued fever may indicate a serious conditions. Under these circumstances consult a physician.,25℃以下乾燥避光,>12 years old: 500-1000mg(1-2 Tablet) Q4-6H. Use the minimum recommended dose for the first time， and then increase or decrease the dose based on symptoms. No more than 4 times in 24 hours. 6-12 years old: 1/2 of adult dose. 3-6 years old: 1/4 of adult dose.,需調整劑量,,需調整劑量,可能安全,Human data suggest low risk,,Compatible 哺乳時可使用,,AC;AC15;PC;PO;WM;,,,,,
ERINA,Betamethasone + Fradiomycin,Rinderon-A eye soln， 5mL,TOPH,,適應症: Inflammatory conditions of the eye when secondary bacteria infection is present. 副作用: Allergic reactions， superinfection， delayed wound healing， raised intraocular pressure， thinning of cornea (possible perforation). 禁忌: Viral， fungal or TB conditions; glaucoma， herpetic keratitis.,,2-8 C,1-2 drops， 3-5 times daily.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IMMR,Measles + Mumps + Rubella,Priorix inj (MMR) 0.5mL/dose (自費麻疹等三種疫苗),HIMM,Immunization against measles， mumps & rubella in individuals ≧ 12 months， non-pregnant adolescents， adult female & postpartum women. Children ≦12 months， should be revaccinated after reaching 15 months.,Pregnancy. Any febrile infection or febrile respiratory illness. Active untreated TB， blood dyscrasias， leukemia， lymphomas of any type， malignant neoplasms affecting the bone marrow or lymphatic system. Patients receiving immunosuppressive therapy. Primary & acquired immunodeficiency states， or family history of immunodeficiency. Hypersensitivity to neomycin or eggs.,Burning， stinging at inj site. Headache， fever， sore throat， GI upset， rash， arthralgia &/or arthritis， parotitis， nerve deafness， optic neuritis. Lymphadenopathy， afebrile convulsions， ataxia， Guillain-Barre syndrome， thrombocytopenia purpura， dizziness， paraesthesias.,2-8℃避光,SC， 0.5mL， children 6-12 months primary immunization， the second dose at 15 months of age， the third dose at 4-6 years or 11-12 years. Age > or = 12 months primary immunization， the second dose at 4-6 years or 11-12 years.,無需調整劑量,[仿單]有關授乳婦女使用情況的資料很少，當權衡後，其利益高於風險則可接種疫苗.,無需調整劑量,不可使用,Contraindicated,[仿單]懷孕婦女不得使用Priorix.然而，懷孕婦女在施打麻疹，腮腺炎，德國麻疹疫苗後，併無發生嚴重傷害的紀錄. 儘管原理上的風險無法被排除，但有超過3500不知已懷孕婦女，在接種包含德國麻疹疫苗後，並沒有出現有先天 性德國麻疹症候群的案例. 因此，對於不知已懷孕的婦女在非刻意接種包含麻疹，腮腺炎，或德國麻疹疫苗後，不需因此終止懷孕. 育齡婦女應避免於接種後四週內懷孕。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]有關授乳婦女使用情況的資料很少，當權衡後，其利益高於風險則可接種疫苗.,SC;,使用廠商所附稀釋溶液，使用預填充針筒配製本疫苗的步驟請詳閱仿單圖解。,,,,1. 注射MMR時，不可同時給予免疫球蛋白。肌肉注射免疫球蛋白後應間隔3個月再注射Priorix，輸血或靜脈注射血液製劑後應間隔6個月再注射Priorix，接受高劑量靜脈免疫球蛋白應間隔11個月再注射Priorix。 2. 皮下注射最好的注射位置是上臂的外側。 3. 配製後應立即使用，若配製後置於2-8度C可保存8小時。
ISONA,Perfluorobutane microbubbles,Sonazoid inj 8 microliter/mL， 2mL,SCAN,Contrast-enhanced ultrasonography of focal liver lesions and focal breast lesions.,Hypersensitivity to Perfluorobutane microbubbles.,Headache， diarrhea， nausea， vomiting， abdominal pain， fever.,25℃以下，勿冷藏,Sonazoid contain perfluorobutane (PFB) microbubbles: 8 microliter per mL， powder and solvent for dispersion for injection. Adult: subsequent dosage adjustments should be made based on body weight. IV push only. 40kg:0.6mL; 50kg:0.75mL; 60kg:0.9mL; 70kg:1.05mL; 80kg: 1.2mL; 90kg:1.35mL; 100kg:1.5mL,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVP;IVPUSH;,藥品專用稀釋液,,IV bolus for contrast-enhanced ultrasonography.,,1.使用注射針孔徑至少為22G。 2.靜置時懸浮液會分離，所以在投與之前，請立即搖晃本品，以確保內容物的均一性。 3.在投藥後應立即以少量的等張氯化鈉溶液(ISCS) 沖洗注射途徑。 4.僅供單次使用。 5.懸液應在配製後之2小時內使用
OBIN,Alendronate,Binosto effervescent 70mg,META,Treatment of osteoporosis in postmenopausal women. Treatment to increase bone mass in men with osteoporosis.,■ Abnormalities of the esophagus which delay emptying such as stricture or achalasia ■ Inability to stand/sit upright for at least 30 minutes ■ Increased risk of aspiration ■ Hypocalcemia ■ Hypersensitivity to any component of this product,Common ■ Gastrointestinal: Abdominal pain (2.1% to 6.6% )， Constipation (0.3% to 3.1% )， Diarrhea (0.6% to 3.1% )， Flatulence (2.6% to 4.1% )， Indigestion (1.7% to 3.6% )， Vomiting (pediatric patients， 29.4% ) ■ Neurologic: Headache (2.6% ) ■ Other: Fever (24% )， Influenza-like symptoms Serious ■ Gastrointestinal: Duodenal ulcer disease， Esophageal erosions， Esophageal perforation， Esophageal stricture， Esophagitis (1.5% )， Gastric ulcer (up to 13.2% )， Ulcerative pharyngitis， acute， Ulcer of esophagus (1.5% ) ■ Immunologic: Hypersensitivity reaction ■ Musculoskeletal: Arthralgia， Aseptic necrosis of bone of jaw (0.017% to 0.03% )， Bone pain， Myalgia,20-25℃避免受潮,1 tablet once weekly.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;,,,,,[磨粉/管灌註記]本藥為發泡錠，以120mL常溫白開水配製成溶液， 發泡停止後，再攪拌10秒鐘後飲盡。但本藥飲用後需保持上半身直立至少30分鐘。
OJAR2,Empagliflozin,Jardiance 25mg,META,Diabetes mellitus， type 2,History of serious hypersensitivity to empagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2)， end-stage renal disease (ESRD)， or dialysis,>10%: Endocrine & metabolic: Hypoglycemia (combination therapy with insulin: 28%， severe hypoglycemia: <=1%; combination therapy with metformin and a sulfonylurea: 12% to 16%; combination therapy with metformin: 1% to 2%) Genitourinary: Urinary tract infection (9%; females: 18%; males: 4%)， increased urine output (includes polyuria， pollakiuria， nocturia: 3%) 1% to 10%: Endocrine & metabolic: Increased LDL cholesterol (5% to 7%)， dyslipidemia (4%)， increased thirst (including polydipsia: 2%) Gastrointestinal: Nausea (2%) Hematologic & oncologic: Increased hematocrit (3% to 4%) Infection: Genitourinary fungal infection (4%; females: 5% to 6% [includes bacterial vaginosis， cervicitis， vulvitis， vulvovaginal candidiasis， vulvovaginal infection， vulvovaginitis]; males: 2% to 3% [includes balanitis， balanoposthitis， genitourinary fungal infection， penile infection， scrotal abscess]),30℃以下,Initial 10 mg once daily， may increase to 25 mg once daily as tolerated.,無需調整劑量,,需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,AC;AC15;P1;P2;P3;P4;PC;PO;,,,,,
OMIRT,Mirtazapine,MirTapine 30mg orally disintegrating,CNEU,Major depressive disorder: Treatment of major depressive disorder (MDD),Hypersensitivity to mirtazapine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either mirtazapine or the MAO inhibitor); initiation of mirtazapine in a patient receiving linezolid or intravenous methylene blue.,Increase in appetite and wt， oedema; drowsiness or sedation; dizziness， headache， increased liver enzyme levels; jaundice. Orthostatic hypotension， rash， nightmares， agitation， mania， hallucinations， paraesthesia， convulsions， tremor， myoclonus， akathisia， restless legs syndrome， arthralgia， myalgia， reversible agranulocytosis， leucopenia， granulocytopenia， hyponatraemia. Endocrine metabolic: Increased appetite (17% )， Serum triglycerides raised (increases to 500 mg/dL or greater: 6% )， Weight gain (body weight increase of 7% or greater: adults 7.5%; pediatrics 49% ) Gastrointestinal: Constipation (13% )， Xerostomia (25% ) Hepatic: ALT/SGPT level raised (2% ) Neurologic: Asthenia (8% )， Dizziness (7% )， Somnolence (54% ) Psychiatric: Disturbance in thinking (3% ),25℃以下陰暗乾燥處,Major depressive disorder (MDD): Oral: Initial: 15 mg nightly， may titrate dose up no more frequently than every 1 to 2 weeks to a maximum of 45 mg/day; dosage range: 15 to 45 mg daily.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,PO;,,,,,[磨粉/管灌註記]本藥為口溶錠，可溶水崩散後服用。
OIBR1,Palbociclib,Ibrance 100mg,RACA,Breast cancer， advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive， human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy Breast cancer， advanced (with disease progression following endocrine therapy): Treatment of HR-positive， HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy,Hypersensitivity to palbociclib or any component of the formulation. Use preparations containing St. John's Wort (or Hypericum).,Common Dermatologic: Alopecia (18% to 33% )， Rash (17% to 18% ) Gastrointestinal: Constipation (20% )， Decrease in appetite (15% to 16% )， Diarrhea (24% to 26% )， Nausea (34% to 35% )， Stomatitis (28% to 30% )， Vomiting (16% to 19% ) Hematologic: Anemia， All Grades (24% to 30% )， Leukopenia， All Grades (39% to 53% )， Neutropenia， All Grades (80% to 83% )， Thrombocytopenia， All Grades (16% to 23% ) Immunologic: Infectious disease (47% to 60% ) Neurologic: Asthenia (8% to 13% )， Headache (26% )， Peripheral neuropathy (13% ) Respiratory: Bleeding from nose (6.7% to 9.2% )， Upper respiratory infection (31% ) Other: Asthenia (7.5% to 17% )， Fatigue (37% to 41% )， Fever (12% to 13% ) Serious Hematologic: Anemia， Grade 3 or 4 (Up to 5% )， Febrile neutropenia (0.9% to 2.5%)， Leukopenia， Grade 3 or 4 (Grade 3， 24% to 30%; Grade 4， up to 1% )， Neutropenia， Grade 3 or 4 (Grade 3， 55% to 56%; Grade 4， 10% to 11% )， Thrombocytopenia， Grade 3 or 4 (Up to 2% ),30 ℃以下,The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.When given with IBRANCE， the recommended dose of fulvestrant is 500 mg administered on Days 1， 15， 29， and once monthly thereafter. Please refer to the full prescribing information of fulvestrant. Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards. Recommended Dose Modification for Adverse Reactions: (Dose Level; Dose) Recommended starting dose: 125 mg/day; First dose reduction: 100 mg/day; Second dose reduction: 75 mg/day. Dose Modification and Management – Hematologic Toxicities: Monitor complete blood counts prior to the start of IBRANCE therapy and at the beginning of each cycle， as well as on Day 15 of the first 2 cycles， and as clinically indicated. For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles， monitor complete blood counts for subsequent cycles every 3 months， prior to the beginning of a cycle and as clinically indicated. (CTCAE Grade) Grade 1 or 2: No dose adjustment is required. Grade 3: Day 1 of cycle: Withhold IBRANCE， repeat complete blood count monitoring within 1 week. When recovered to Grade 2， start the next cycle at the same dose. Day 15 of first 2 cycles: If Grade 3 on Day 15， continue IBRANCE at current dose to complete cycle and repeat complete blood count on Day 22. If Grade 4 on Day 22， see Grade 4 dose modification guidelines below. Consider dose reduction in cases of prolonged (>1 week) recovery from Grade 3 neutropenia or recurrent Grade 3 neutropenia on Day 1 of subsequent cycles. Grade 3 neutropeniab with fever more than 38.5 oC and/or infection: At any time: Withhold IBRANCE until recovery to Grade 2. Resume at the next lower dose. Grade 4: At any time: Withhold IBRANCE until recovery to Grade 2. Resume at the next lower dose.,需調整劑量,[仿單]目前尚未進行過任何評估palbociclib 對乳汁生成作用之影響、是否出現於乳汁中、或其對餵哺母乳之嬰兒的影響的人體研究或動物研究。 目前並不確知palbociclib 是否會分泌進入人類的乳汁。 接受palbociclib 治療的病人不可餵哺母乳。,無需調整劑量,不可使用,Contraindicated,[仿單]目前並無或僅有有限的孕婦使用palbociclib 的資料。 動物研究顯示本品具有生殖毒性。 Ibrance並不建議於懷孕期間使用，也不建議用於具生育能力但未採取避孕措施的婦女。,Contraindicated 哺乳期使用禁忌,[仿單]目前尚未進行過任何評估palbociclib 對乳汁生成作用之影響、是否出現於乳汁中、或其對餵哺母乳之嬰兒的影響的人體研究或動物研究。 目前並不確知palbociclib 是否會分泌進入人類的乳汁。 接受palbociclib 治療的病人不可餵哺母乳。,WM;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。仿單建議應整顆吞服，勿咀嚼、咬碎或打開膠囊。
OALP,Alprazolam,Alprazolam 0.5mg,CNEU,,適應症: Anxiety states， Anxiety with symptoms of depression. 副作用: Drowsiness. Less commonly lightheadedness， blurred vision， coordination disorders; GI effects; autonomic effects; dependence， withdrawal syndrome. Rarely， paradoxical agitation， confusion. 禁忌: Hypersensitivity to alprazolam or any component of the formulation， Acute narrow angle glaucoma.,,室溫,Anxiety states Adult 0.25-0.5 mg tid. Elderly or debilitated patient 0.25 mg bid-tid. Anxiety with symptoms of depression Adult 0.5-4 mg daily in divided doses. Elderly or presence of debilitating diseases 0.5-0.75 mg daily in divided doses.,需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OVEP5,Etoposide,Vepesid 50mg (專案進口),RACA,Small cell carcinoma of lung， In combination with other approved chemotherapeutic agents as first line， Testicular cancer， In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical， chemotherapeutic， and radiotherapeutic therapy,Hypersensitivity to etoposide or any component of the formulation. Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment,Alopecia， Shivering， Diarrhea， Inflammatory disease of mucous membrane， Loss of appetite， Nausea， Vomiting， Asthenia， Fever， Malaise,10-25℃,(無TFDA仿單) (US FDA仿單) [Testicular cancer] dose ranges from 50-100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1， 3， and 5 in combination with other approved chemotherapeutic agents. [Small cell lung cancer] dose ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity.,需調整劑量,,需調整劑量,盡量避免,Human (and animal) data suggest risk,,Contraindicated 哺乳期使用禁忌,,,,,,,
OUROD,Phenazopyridine,Urodine 100mg,SGU,Symptomatic relief of pain， burning， urgency， frequency， and other discomforts that arise from irritation of the lower urinary tract mucosa.,Hypersensitivity to phenazopyridine products. Renal insufficiency. Pyelonephritis in Pregnancy. Severe hepatitis.,Common Neurologic: Headache Serious Hematologic: Hemolytic anemia Hepatic: Hepatotoxicity Immunologic: Anaphylactoid reaction Renal: Nephrotoxicity,室溫,Adult: 100-200mg TID. [Micromedex 20210913] Dysuria， Symptomatic relief: 200 mg ORALLY 3 times a day after meals; use should not exceed 2 days when used concomitantly with an antibiotic.,無需調整劑量,BREASTFEEDING SUMMARY - No reports describing the use of phenazopyridine during human lactation have been located. The molecular weight suggests that the drug will be excreted into breast milk. Because phenazopyridine can cause methemoglobinemia， sulfhemoglobinemia， and hemolytic anemia， it should not be used during breastfeeding， especially with an infant under 1 month of age or with G-6-PD deficiency. 仿單無相關說明,需調整劑量,沒有資料,Compatible,仿單無相關說明,Contraindicated 哺乳期使用禁忌,BREASTFEEDING SUMMARY - No reports describing the use of phenazopyridine during human lactation have been located. The molecular weight suggests that the drug will be excreted into breast milk. Because phenazopyridine can cause methemoglobinemia， sulfhemoglobinemia， and hemolytic anemia， it should not be used during breastfeeding， especially with an infant under 1 month of age or with G-6-PD deficiency. 仿單無相關說明,PC;PO;WM;,,,,,
OCONI,Benidipine,Coniel 4mg,CAVS,Hypertension,Cardiogenic shock (possibly worsening symptoms). Pregnant women and women who may become pregnant.,tachycardia， flushing， headaches， Liver dysfunction， jaundice， AST (GOT)， ALT (GPT)， γ-GTP increase， Kidney BUN rises， Creatinine rises， Leukopenia， Eosinophilia， Thrombocytopenia， feeling fever， hypotensive， Chest pressure， Bradycardia， palpitations， dizziness， the dark feeling when standing， Drowsiness， numbness， Constipation， Abdominal discomfort， Vomiting， Chest tightness， Thirsty， diarrhea， Vomit， gingival hyperplasia， Rash， Itching， Photosensitivity， tinnitus， Redness of the skin of the fingers， Feeling of heat， Shoulder pain， cough， Frequent urination， Burnout， Increased plasma potassium， Gynecomastia， Conjunctival hyperemia， Blurred vision， sweat,25℃以下,HTN: adult 2-4mg QD after breakfast. Severe HTN: 4-8mg QD.,需調整劑量,[仿單] 應避免給藥於授乳婦，如果不得已必須給藥時，應該停止餵奶。 動物實驗報告有藥品轉移到母乳中的情況。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 孕婦和可能懷孕的婦女應該避免服用本品。 動物實驗(大鼠、兔子)有胎兒毒性，於妊娠末期給藥的話，有妊娠期間及分娩時間延長的報告。,Unknown 沒有資料,[仿單] 應避免給藥於授乳婦，如果不得已必須給藥時，應該停止餵奶。 動物實驗報告有藥品轉移到母乳中的情況。,PC;PO;,,,,,
OMON,Fosfomycin,Monurol 3gm/pack,QANB,,適應症: Uncomplicated urinary tract infections: Treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis. 副作用: Central nervous system: Headache (4% to 10%)， pain (2%)， dizziness (1% to 2%) Dermatologic: Rash (1%) Endocrine and metabolic: Dysmenorrhea (3%) Gastrointestinal: Diarrhea (9% to 10%)， nausea (4% to 5%)， abdominal pain (2%)， dyspepsia (1% to 2%) Genitourinary: Vaginitis (6% to 8%) Neuromuscular & skeletal: Back pain (3%)， weakness (1% to 2%) Respiratory: Rhinitis (5%)， pharyngitis (3%) 禁忌: Hypersensitivity to fosfomycin or any component of the formulation,,,Acute lower uncomplicated UTI 1 sachet. Prophylaxis prior to transurethral surgery & diagnostic procedures 2 sachets， the 1st taken 3 hrs before surgery， the 2nd 24 hr after surgery.,無需調整劑量,,需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OFUN,Terbinafine,Fungitech 250mg,QANB,Onychomycosis， Tinea capitis， derma fungal infection which is severe， extensive， and partly treated in vain.,Allergy toTerbinafine.,Common Dermatologic: Rash (oral granules， 2% ; oral tablets， 5.6% ) Gastrointestinal: Diarrhea (oral granules， 3% ; oral tablets， 5.6% )， Disorder of taste (oral tablets， 2.8% )， Indigestion (oral tablets， 4.3% )， Nausea (oral granules， 2% ; oral tablets， 2.6% )， Vomiting (oral granules， 5% ) Hepatic: Increased liver enzymes (oral tablets， 3.3% ) Neurologic: Headache (oral granules， 7% ; oral tablet， 12.9% ) Respiratory: Cough (oral granules， 6% )， Nasopharyngitis (oral granules， 10% )， Upper respiratory infection (oral granules， 5% ) Other: Fever (oral granules， 7% ) Serious Dermatologic: Cutaneous lupus erythematosus， Erythema multiforme， Generalized exanthematous pustulosis， acute， Stevens-Johnson syndrome， Toxic epidermal necrolysis Hematologic: Neutropenic disorder (Severe)， Thrombotic microangiopathy Hepatic: Liver failure Immunologic: Drug reaction with eosinophilia and systemic symptoms， Systemic lupus erythematosus Otic: Hearing loss,25℃以下,Adult: 250mg once a day. Children above 3 years old: weight<20kg: 62.5mg once a day， weight 20-40kg: 125mg once a day， weight>40kg: 250mg once a day. Treatment duration Cutaneous infection: Feet tinea(between the toes， pachyderm) 2-6weeks. Ringworm of the body tinea cruris 2-4weeks. Cutaneous candida infection 2-4weeks. Infections of scalp hair: Tinea capitis 4weeks. Tinea capitis occurs mostly in children. Onychomycosis most patients need a 6-12weeks period of treatment. In Fingernail onychomycosis， most patients need 6 weeks. In toenail onychomycosis， most patients need 12 weeks.,需調整劑量,[仿單]Terbinafine可能出現在乳汁中，口服使用黴特克舒者不可授乳。,需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]胎兒毒性與授精率的動物實驗，顯示無此不良作用。 懷孕者使用黴特克舒的經驗很少，建議懷孕婦女不要使用，除非使用黴特克舒可能的好處大於可能的危險性。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Terbinafine可能出現在乳汁中，口服使用黴特克舒者不可授乳。,AC;AC15;PC;PO;WM;,,,,,
ENICI,Nicotine,Nicorette 10mg inhaler (18 cartridges/box),ZADT,Smoking cessation aid.,Hypersensitivity to nicotine or any component of the formulation. Recent cerebrovascular accident， acute Myocardial infarction， unstable or worsening angina pectoris， severe cardiac arrhythmias.,Common Dermatologic: Skin irritation， Patch Respiratory: Nasal irritation， Nasal spray， Oral irritation， Airway， inhaler Other: Nicotine withdrawal， Dizziness， headache， insomnia Serious Cardiovascular: Cardiac dysrhythmia (rare)， Hypertension (rare)， Tachyarrhythmia (rare) Immunologic: Hypersensitivity reaction (rare),25℃以下,Initial treatment: 6 to 16 cartridges/day (at least 6 cartridges/day for the first 3 to 6 weeks) for up to 12 weeks; maximum: 16 cartridges/day. Note: Best effect achieved with frequent continuous puffing (20 minutes). Use beyond 6 months is not recommended (has not been studied). If patient is unable to stop smoking by the fourth week of therapy， consider discontinuation. Discontinuation of therapy: After initial treatment， gradually reduce daily dose over 6 to 12 weeks. Some patients may not require gradual reduction of dosage and may stop treatment abruptly.,無需調整劑量,[仿單]尼古丁會少量滲入母乳而對嬰兒造成影響，即使是治療劑量也會造成影響。 因此應避免在哺乳期間使用尼古丁吸入劑，並應在完成哺乳後使用。,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,[仿單]孕婦和哺乳的抽菸者應在諮詢過醫師的建議後才可使用吸入劑。 抽菸會嚴重傷害到幼兒，尼古丁會傳遞給胎兒，影響其呼吸運動和循環。 對呼吸和循環的影響取決於劑量大小。 因此，孕婦應該總是被告知藥在不使用尼古丁替代治療下完全戒菸。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]尼古丁會少量滲入母乳而對嬰兒造成影響，即使是治療劑量也會造成影響。 因此應避免在哺乳期間使用尼古丁吸入劑，並應在完成哺乳後使用。,INHL;,,,,,
OZYT,Abiraterone,Zytiga 250mg,RACA,Prostate cancer: Treatment of metastatic， castration-resistant prostate cancer (in combination with prednisone).,Hypersensitivity. Pregnancy.,UTI， hypokalaemia， hypertriglyceridaemia， cardiac failure， angina pectoris， arrhythmia， atrial fibrillation， tachycardia， HTN， increased ALT， peripheral oedema， fractures.,30℃以下,[Metastatic castration-resistant prostate cancer] 1000 mg orally once daily with prednisone 5 mg orally twice daily.[Metastatic castration-sensitive prostate cancer] 1000 mg orally once daily with prednisone 5 mg orally once daily.Patients receiving ZYTIGA should also receive a gonadotropin-releasinghormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ZYTIGA must be taken on an empty stomach with water at least 1 hour before or 2 hours after a meal. Do not crush or chew tablets.,需調整劑量,[仿單] 對於女性使用的安全性與療效尚未建立。目前並無關於abiraterone acetate是否會出現於人類的乳汁中、對餵哺母乳之嬰兒的影響、或對乳汁生成作用之影響等方面的資料。,無需調整劑量,不可使用,Contraindicated,[仿單] 對於女性使用的安全性與療效尚未建立。根據其作用機制與動物試驗的發現，對於孕婦使用Zytiga會造成胎兒傷害，並可能導致流產。目前並無孕婦使用的人體試驗資料。,Contraindicated 哺乳期使用禁忌,[仿單] 對於女性使用的安全性與療效尚未建立。目前並無關於abiraterone acetate是否會出現於人類的乳汁中、對餵哺母乳之嬰兒的影響、或對乳汁生成作用之影響等方面的資料。,,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。仿單建議應整錠吞服，不可咬碎或撥半。 本藥需空腹服用，服用前2小時和後1小時不要進食。
EPEDO,Minocycline,Periocure 10mg/0.5gm/syringe dental ointment,TENT,Periodontitis.,Should not be used in any patient who has a known sensitivity to minocycline or tetracyclines.,Headache， gum discomfort， pain， soreness， or toothache,25°C以下,once a week， Injection into the periodontal pockets. Periocure is indicated as an adjunct to scaling and root planing procedures for the reduction of pocket depth in patients with adult periodontitis. Periocure may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing.,無需調整劑量,[仿單]一般使用上具療效，唯於孕婦、產婦、授乳婦等使用其危險性可能相對提升 (孕婦、可能懷孕的婦女其用藥安全性仍未確定),無需調整劑量,不可使用,No (limited) human data – animal data suggest moderate risk,[仿單]一般使用上具療效，唯於孕婦、產婦、授乳婦等使用其危險性可能相對提升 (孕婦、可能懷孕的婦女其用藥安全性仍未確定),No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]一般使用上具療效，唯於孕婦、產婦、授乳婦等使用其危險性可能相對提升 (孕婦、可能懷孕的婦女其用藥安全性仍未確定),LI;,,,,,
OSUN,Asunaprevir,Sunvepra 100mg,QANB,Chronic hepatitis C: Treatment of chronic hepatitis C (CHC) in adult patients with hepatitis C virus (HCV) genotypes 1 or 4 and compensated liver disease， including cirrhosis. Must be administered as part of combination therapy with other anti-HCV agents.,Hypersensitivity to asunaprevir or any component of the formulation; moderate or severe hepatic impairment (Child-Pugh class B or C， score 7 or greater) and with decompensated hepatic disease; concurrent use with daclatasvir， peginterferon alfa， and ribavirin in women who are pregnant or may become pregnant and men whose female partners are pregnant， may be pregnant， or plan to become pregnant; concurrent use with drugs dependent on the cytochrome P450 2D6 (CYP2D6) for clearance and for which elevated plasma concentrations are associated with serious ventricular arrhythmias and sudden death; concurrent use with moderate or strong inducers and inhibitors of CYP3A or with strong inhibitors of organic anion transporting polypeptide (OATP) 1B1 or 2B1. The following drugs are included in the manufacturer labeling as being contraindicated: atazanavir， bosentan， carbamazepine， clarithromycin， cobicistat or cobicistat-containing regimens， cyclosporine， darunavir/ritonavir， dexamethasone， diltiazem， efavirenz， erythromycin， etravirine， flecainide， fluconazole， fosamprenavir， gemfibrozil， indinavir， itraconazole， ketoconazole， lopinavir/ritonavir， modafinil， nafcillin， nelfinavir， nevirapine， oxcarbazepine， phenobarbital， phenytoin， posaconazole， propafenone， rifabutin， rifampin， rifapentine， ritonavir， saquinavir， St. John’s wort， telithromycin， thioridazine， verapamil， voriconazole,>10%: Central nervous system: Fatigue (12% to 39%)， headache (6% to 28%)， insomnia (4% to 21%)， irritability (16%) Dermatologic: Pruritus (6% to 25%)， skin rash (5% to 18%)， alopecia (3% to 16%) Gastrointestinal: Nausea (4% to 15%) Hematologic & oncologic: Anemia (19%)， neutropenia Hepatic: Increased serum AST (2% to 13%)， increased serum ALT (4% to 12%) Neuromuscular & skeletal: Weakness (23%) Respiratory: Flu-like symptoms (22%) 1% to 10%: Cardiovascular: Atrial fibrillation， hypertension， syncope Central nervous system: Amnesia， anxiety， depression， disturbance in attention， dizziness， emotional lability， malaise， pain， sleep disorder， vertigo Dermatologic: Dermatitis， eczema， erythema， exfoliative dermatitis， maculopapular rash， psoriasis， seborrheic dermatitis， xeroderma Endocrine & metabolic: Weight loss Gastrointestinal: Abdominal pain， constipation， decreased appetite， diarrhea， dyspepsia， dysphagia， hemorrhoids， stomatitis， vomiting Hematologic & oncologic: Eosinophilia， leukopenia， lymphocytopenia， thrombocytopenia Hepatic: Increased serum bilirubin (1% to 10%)， hyperbilirubinemia Infection: Influenza Neuromuscular & skeletal: Arthralgia， back pain， musculoskeletal chest pain， myalgia Ophthalmic: Xerophthalmia Respiratory: Cough， dyspnea， dyspnea on exertion， nasopharyngitis， oropharyngeal pain Miscellaneous: Fever <1% (Limited to important or life-threatening): Erythema multiforme,30℃以下,For hepatitis C in adults， Genotype 1b (treatment-naive or treatment-experienced， ± compensated cirrhosis): 100 mg orally twice daily for 24 weeks in combination with daclatasvir; Genotype 1 or 4 (treatment-naive or treatment-experienced， ± compensated cirrhosis): 100 mg orally twice daily for 24 weeks in combination with daclatasvir， peginterferon alfa， and ribavirin.,需調整劑量,懷孕及哺乳建議資料來源為藥品仿單。,需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,懷孕及哺乳建議資料來源為藥品仿單。,,,,,,[磨粉/管灌註記]本藥為軟膠囊應整粒吞服， 切勿咬嚼或壓碎，無法吞服患者可以溫水溶解後服用。
OANT6,Pyridostigmine,Antilon 60mg,CNEU,Myasthenia gravis.,Hypersensitivity to anticholinesterase agents. Mechanical intestinal obstruction. Urinary obstruction.,Common Dermatologic: Diaphoresis Gastrointestinal: Diarrhea， Excessive salivation， Increased peristalsis， Stomach cramps Musculoskeletal: Cramp， Muscle fasciculation Neurologic: Asthenia Ophthalmic: Miosis Respiratory: Excessive bronchial secretion,25℃以下,Myasthenia gravis: each time 60-180 mg， BID-QID. [Micromedex 20211004] Myasthenia gravis: 600 mg (ten 60-mg tablets) orally daily， spaced throughout the day to provide maximum relief when maximum strength is needed; dosage and frequency must be individualized; mild cases may respond to 60 to 360 mg (one to six 60-mg tablets) daily， while severe cases may require up to 1500 mg (twenty five 60-mg tablets) daily.,無需調整劑量,[仿單]無相關說明,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]無相關說明,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]無相關說明,AC;AC15;PC;PO;WM;,,,,,
IXYA,Lidocaine + Epinephrine,Xylestesin-A (for Dental) 1.7mL,ZANE,Local anaesthesia (infiltration and nerve-block anaesthesia) in dentistry. Xylestesin-A is indicated in adults， children and adolescents.,- hypersensitivity to the lidocaine， adrenaline， sodium sulphite， Sodium chloride， Hydrochloric acid. - severe， uncontrolled or untreated excitation and conduction disorders of the heart (e.g. grade II and III AV block， pronounced bradycardia) - acutely decompensated heart failure， - severe hypotension - Heart diseases such as: h unstable angina pectoris， h recent myocardial infarction， h refractory arrhythmia and paroxysmal tachycardia or high-frequency， continuous arrhythmia， h untreated or uncontrolled severe hypertension， h untreated or uncontrolled congestive heart failure， { Concomitant treatment with monoamine oxidase (MAO) inhibitors or tricyclic antidepressants. { Xylestesin-A is not allowed to be used in acra of extremities. - severe bronchial asthma.,Infections and infestations: Oral herpes Immune system disorders: anaphylactic reaction， anaphylactic shock， type I hypersensitivity Psychiatric disorders: confusional state Nervous system disorders: dizziness， headache， somnolence， facial palsy， paresis， syncope， dysarthria Eye disorders: accommodation disorder， blindness， diplopia， eye swelling， vision blurred， eyelid ptosis， mydriasis， ophthalmoplegia Cardiac disorders: palpitations Vascular disorders: haematoma， pallor Respiratory， thoracic and mediastinal disorder: bronchospasm， laryngeal oedema， respiratory failure， throat tightness， wheezing， dyspnoea， cough Gastrointestinal disorders: hypoaesthesia oral， toothache， nausea， tongue oedema， vomiting Skin and subcutaneous tissue disorders: haemorrhage subcutaneous， dermatitis bullous， dermatitis contact， hypoaesthesia facial， pruritus， rash， swelling face General disorders and administration site conditions: medicine ineffective， pain， injection site swelling， injection site haematoma Investigations:allergy test positive， heart rate increased， heart rate irregular Injury， poisoning and procedural complications:Uncommon,室溫,Dosage requirements should be determined on an individual basis. For submucosal infiltration and/or nerve block injection. Avoid intravascular injection. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection. Children > 15 years and adult: dosages of 1-4 mL are usually effective. Lidocaine maximum dosage: 500mg (7 mg/kg). Epinephrine maximum dosage: 0.25mg (equivalent to 20 mL). Children 20-30 kg: 0.25-1 mL. Children 30-45 kg: 0.5-2 mL. Lidocaine maximum dosage of children: 5 mg/kg.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,LA;LI;,,,,,
EBSS1,Balanced Salt Soln,BSS sterile irrigation solusion 500mL/Bag,TOPH,For use as an extraocular and intraocular irrigating solution during ocular or other surgical procedures.,Hypersensitivity to any component of the formulation.,When the corneal endothelium is abnormal， irrigation or any other trauma may result in bullous keratopathy.,室溫,For irrigation during operations of the eyes， ears， nose and throat.,無需調整劑量,,無需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,AD;AL;AS;AU;EXT;G;GAR;IN;IRR;IRRI;OD;OL;ORO;OU;SKIN;TOPI;,,,,,
IIXE,Ixabepilone,Ixempra inj 15mg (2mg/mL),RACA,Breast cancer (metastatic or locally advanced),History of severe (grade 3 or 4) hypersensitivity to polyoxyethylated castor oil (Cremophor EL) or its derivatives; neutrophil count <1，500/mm3 or platelet count <100，000/mm3; combination therapy with ixabepilone and capecitabine in patients with AST or ALT >2.5 times ULN or bilirubin >1 times ULN,>10%: Peripheral neuropathy (63%; grades 3/4: 14%; grade 3/4 median onset: Cycle 4)， peripheral sensory neuropathy (62%; grades 3/4: 14%)， headache (11%)， Alopecia (48%)， Nausea (42%)， vomiting (29%)， mucositis (?29%)， stomatitis (?29%)， diarrhea (22%)， anorexia (19%)， constipation (16%)， abdominal pain (13%)， Leukopenia (grade 3: 36%; grade 4: 13%)， neutropenia (grade 3: 31%; grade 4: 23%)， Weakness (56%)， arthralgia (?49%)， myalgia (?49%)， musculoskeletal pain (20%) 1% to 10%: Edema (9%)， chest pain (5%)， Peripheral motor neuropathy (10%; grade 3: 1%)， pain (8%)， dizziness (7%)， insomnia (5%)， Nail disease (9%)， skin rash (9%)， palmar-plantar erythrodysesthesia (8%)， pruritus (6%)， desquamation (2%)， hyperpigmentation (2%)， Hot flash (6%)， weight loss (6%)， dehydration (2%)， Dysgeusia (6%)， gastroesophageal reflux (6%)， Anemia (grade 3: 6%; grade 4: 2%)， febrile neutropenia (3%; grade 3: 3%)， thrombocytopenia (grade 3: 5%; grade 4: 2%)， Hypersensitivity (5%; grade 3: 1%)， Infection (5%)， Increased lacrimation (4%)， Dyspnea (9%)， upper respiratory tract infection (6%)， cough (2%)， Fever (8%) <1%， postmarketing， and/or case reports: Acute hepatic failure， acute pulmonary edema， angina pectoris， atrial flutter， autonomic neuropathy， blood coagulation disorder， cardiomyopathy， cerebral hemorrhage， colitis， delayed gastric emptying， dysphagia， embolism， enterocolitis， erythema multiforme， gastrointestinal hemorrhage， hemorrhage， hypokalemia， hyponatremia， hypotension， hypovolemia， hypovolemic shock， hypoxia， increased gamma-glutamyl transferase， increased serum alkaline phosphatase， increased serum transaminases， interstitial pneumonitis， intestinal obstruction， jaundice， left ventricular dysfunction， metabolic acidosis， myocardial infarction， nephrolithiasis， neutropenic infection， orthostatic hypotension， pneumonia， pneumonitis， radiation recall phenomenon， renal failure， respiratory failure， sepsis， septic shock， supraventricular cardiac arrhythmia， syncope， thrombosis， trismus， urinary tract infection， vasculitis， voice disorder,2-8°C避光,40 mg/m2 infused intravenously over 3 hours once every 3 weeks. Doses for patients with body surface area (BSA) greater > 2.2 m2 should be calculated based on 2.2 m2.,需調整劑量,,無需調整劑量,盡量避免,No (limited) human data – animal data suggest moderate risk,,Contraindicated 哺乳期使用禁忌,,IVD;,使用包裝內附8mL稀釋液溶解乾粉，稀釋液從冰箱取出須靜置30分鐘，回到室溫後使用。,【L/R】可選 仿單建議。【N/S】可選 仿單建議。,,,1.使用0.9% Normal saline作為點滴液時，必須借由加入2mEq的碳酸氫鈉注射液將pH值調整成6.0-9.0之間. 2.本藥品需裝於不含DEHP的包裝中. 3.為容許抽取損失，本品包裝內含16mg Ixabepilone，加入8mL稀釋液後，配製成濃度2mg/mL. 4.配製本藥時，將8mL稀釋液抽取並注入藥瓶中，已輕輕旋轉及翻轉藥瓶的方式直到完全溶解.
OTRAZB,Trazodone,,CNEU,Depression.,Serious hepatic impairment. Hypersensitivity to trazodone hydrochloride.,Common Gastrointestinal: Constipation (7% to 8% )， Diarrhea (up to 9% )， Nausea (21% )， Vomiting (at least 1% )， Xerostomia (14% to 33.8% ) Musculoskeletal: Backache (5% ) Neurologic: Confusion (up to 5.7% )， Dizziness (25% )， Headache (9.9% to 33% )， Insomnia (6.4% to 9.9% )， Somnolence (23.9% to 46% ) Ophthalmic: Blurred vision (5% to 14.7% ) Psychiatric: Dream disorder (up to 5.1% )， Feeling nervous (6.4% to 14.8% ) Other: Fatigue (5.7% to 15% ) Serious Cardiovascular: Cardiac dysrhythmia， Hypotension (3.8% to 7% )， Prolonged QT interval， Torsades de pointes Immunologic: Hypersensitivity reaction (less than 1% ) Neurologic: Seizure， Serotonin syndrome Psychiatric: Suicidal thoughts (rare)， Suicide Reproductive: Priapism,25℃以下儲存。,Initial dose: 150 mg/day. Dose may be gradually increased by 50mg/day at adjustment interval of 3-4 days. maximum dose(in divided doses): Out-patient 400 mg/day， in-patient 600 mg/day.,需調整劑量,[仿單]由於缺乏經驗，本品不推薦使用在哺乳中婦女。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]由於缺乏經驗，本品不推薦使用在懷孕婦女。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]由於缺乏經驗，本品不推薦使用在哺乳中婦女。,PC;PO;WM;,,,,,
IHU50,Insulin Lispro 50% + Insulin Protamine 50%,Humalog Mix 50 kwikpen 100U/mL， 3mL,META,,適應症:type 1， type 2 DM 副作用:Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj 禁忌:Hypoglycaemia.,,2-8 ℃,Should be taken with food. (Administer w/in 15 mins before or immediately after meals.) Subcutaneous Diabetes mellitus Adult: Dosing regimen should be individualised and adjusted based on patient's glycaemic response. Administer 15 min before or immediately after a meal. Renal impairment: Decreased dose may be necessary. Hepatic impairment: Decreased dose may be necessary.,無需調整劑量,,無需調整劑量,可能安全,Uknown 沒有資料,,Compatible 哺乳時可使用,,SC;,,,,,
ORHY,Propafenone,Rhynorm 150mg (律諾),CAVS,Ventricular & supraventricular tachyarrhythmias， Wolff-Parkinson-White syndrome.,Manifest heart failure; cardiogenic shock (except for shock induced by arrhythmia); severe bradycardia within 3 months after MI; pre-existing high degree SA， AV & intraventricular disorders of impulse conduction; sick sinus syndrome; manifest disorders of electrolyte balance; severe obstructive pulmonary disease; marked hypotension， myasthenia gravis.,May induce arrhythmia eg. bradycardia， induction disorder， tachycardia. Rarely ventricular fibrillation. May increase severity of heart failure. Hypotension. GI disturbances. Paresthesia， visual disturbances， dizziness. Rarely fatigue， headache， psychotic disorders. Blood disorders. Rarely， skin allergy， bronchospasm. Cardiovascular: Chest pain (1.8% )， Edema (5% to 13% )， Palpitations (3.4% ) Gastrointestinal: Constipation (8% to 14% )， Nausea (9% to 17% )， Taste sense altered (6% to 22% )， Vomiting (0% to 6% ) Neurologic: Dizziness (21% to 23% ) Psychiatric: Anxiety (10% to 13% ) Respiratory: Dyspnea (13% to 17% )， Upper respiratory infection (8% to 12% ) Other: Fatigue (11% to 13% ),25℃以下,Adult (70 kg): Initial and maintenance dose: 450-600 mg/day in 2-3 divided doses. May increase to 900 mg/day. Dosage may be adjusted in patients with lower body weight. Children: 10-20mg/kg/day in 3-4 divided doses.,需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
INIMB,Cisatracurium,Nimbex inj 10mg/5mL,CNEU,Muscle relaxation during surgical procedures eg cardiac surgery， other procedures & in intensive care. Adjunct to general anesth or sedation in the ICU， to relax skeletal muscles & to facilitate tracheal intubation & mechanical ventilation.,Hypersensitivity to cisatracurium besylate or any component of the formulation; use of the 10 mL multiple-dose vials in premature infants (formulation contains benzyl alcohol),Bradycardia， hypotension. Rarely cutaneous flushing， bronchospasm， rash.,2-8℃避光避免冷凍,IV bolus Tracheal intubation: Adult: Initially 0.15 mg/kg over 5-10 seconds. Maintenance: 0.03 mg/kg. Children 1 month-12 years same as adult dose. Maintenance: 0.02 mg/kg. IV infusion for maintenance of neuromuscular blockade: Adult & children 1 month-12 years: 3 mcg/kg/min initially and 1-2 mcg/kg/min thereafter to maintain 89-99% neuromuscular blockade.,需調整劑量,[7] contrainication 以上懷孕分級為: UpToDate資料。,需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,[7] contrainication 以上懷孕分級為: UpToDate資料。,IVD;IVP;IVPUSH;,,【D2.5HS】可選 仿單建議。【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,,1.僅供靜脈給藥。 2.給藥濃度 0.1-2.0 mg/mL。 3.本品需冷藏避光貯存 4.不可與鹼性溶液混合 5.以小靜脈做為注射處時，應使用適當的靜脈輸注液(如0.9%氯化鈉靜脈注射液)將Nimbex注射劑洗入靜脈內.
INALD,Dinalbuphine,Naldebain ER inj 150mg/2mL,CNEU,ain management: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Surgical anesthesia supplement: Supplement to balanced anesthesia， for preoperative and postoperative analgesia， and for obstetrical analgesia during labor and delivery.,Hypersensitivity to nalbuphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; GI obstruction， including paralytic ileus (known or suspected). Documentation of allergenic cross-reactivity for opioids is limited. However， because of similarities in chemical structure and/or pharmacologic actions， the possibility of cross-sensitivity cannot be ruled out with certainty.,>10%: Central nervous system: Sedation (36%) 1% to 10%: Central nervous system: Dizziness (5%)， headache (3%) Dermatologic: Cold and clammy skin (9%) Gastrointestinal: Nausea and vomiting (6%)， xerostomia (4%),25℃以下避光,IM: Single dose 150mg,無需調整劑量,Monitor relief of pain， resp and mental status， BP.,無需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,Monitor relief of pain， resp and mental status， BP.,IM;,,,,,本品僅供肌肉注射使用。 1. 使用前回復至室溫。 2. 使用前先以酒精棉清潔玻璃小瓶之瓶蓋。 3. 抽出2 mL藥品溶液。 4. 在清潔皮膚之後，將藥品施打在臀大肌的外側上部1/4處。藥品溶液是油狀且黏稠的，故建議緩慢 地注射。 5. 輕壓注射部位防止藥品溶液漏出。 6. 請勿按摩注射部位。
IEMG,Galcanezumab,Emgality inj 120 mg/1mL,CNEU,Episodic cluster headacheView additional information. Migraine; Prophylaxis,Serious hypersensitivity to galcanezumab-gnlm or to any of the components of the product.,Common Immunologic: Injection site reaction (18% ) Serious Immunologic: Anaphylaxis， Hypersensitivity reaction Other: Angioedema,2-8℃避光避免冷凍,Migraine; Prophylaxis Usual dosage: 240 mg (2 consecutive 120-mg doses) once as a loading dose， followed by 120 mg once monthly. Missed dose: If a dose is missed， administer as soon as possible. Thereafter， schedule monthly from the date of the last dose.,無需調整劑量,[仿單]目前沒有關於 galcanezumab 進入人類乳汁、對於哺乳嬰兒或對於乳汁分泌之影響的資料。 在考量哺乳對於發育與健康之益處時，也應顧及母親對於 EMGALITY 的臨床需求， 以及 EMGALITY 或潛在的母體狀況對於哺乳嬰兒可能造成之不良影響。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 關於懷孕女性使用 EMGALITY 的發育風險無足夠的數據。於器官形成期間給予大鼠和兔子 galcanezumab， 或在大鼠的整個妊娠期和哺乳期給予高於臨床預期的血漿暴露量，並不會對發育產生不良影響。 美國一般族群中，估計在臨床上認定之懷孕過程中發生重大先天缺陷及流產的背景風險分別為 2-4%及 15-20%。 偏頭痛婦女分娩中的重大出生缺陷(2.2％-2.9％)和流產(17％)的估計發生率與無偏頭痛婦女的通報率相似。,Unknown 沒有資料,[仿單]目前沒有關於 galcanezumab 進入人類乳汁、對於哺乳嬰兒或對於乳汁分泌之影響的資料。 在考量哺乳對於發育與健康之益處時，也應顧及母親對於 EMGALITY 的臨床需求， 以及 EMGALITY 或潛在的母體狀況對於哺乳嬰兒可能造成之不良影響。,SC;,,,,,1.置於原外盒中冷藏存放於 2°C 到 8°C 之間，以免受光線照射至使用為止。 2.不可冷凍，不可搖晃。儲存於冰箱外、溫度最高 30°C以下最多 7 天。 3.若已儲存在冰箱外，請勿將EMGALITY 放回冰箱中。若超過這些儲存條件，必須丟棄 。 4.使用後應將 EMGALITY 單劑預充填注射筆丟棄於防穿刺保存盒中。
LKEP,Levetiracetam,Keppra solution 100mg/mL， 300mL,CNEU,Monotherapy for focal seizures (with or without secondary generalized seizures) in patients above 16 years of age. Adjunctive therapy for (1) focal seizures (with or without secondary generalized seizures) in children aged 4 years and above， (2) in adolescents and adults aged 12 years and above for myoclonic seizures and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy.,Hypersensitivity to levetiracetam.,Common: Loss of appetite (3-8%)， Vomiting (15%)， Infectious disease (13%)， Decreased bone mineral density (70%)， Neck pain (2-8%)， Asthenia (15%)， Dizziness (5-9%)， Headache (14-19%)， Abnormal behavior (7-37.6%)， Irritability (6-12%)， Cough (2-9%)， Nasopharyngitis (7-15%)， Fatigue (10-11%) Serious: Stevens-Johnson syndrome (SJS)， Toxic epidermal necrolysis (TEN)， Decreased erythrocyte production， Decreased white blood cell count (2.4-3.2%)， Eosinophil count above reference range (8.6%)， Neutropenia ( 2.4%)， Pancytopenia， Thrombocytopenia， Liver failure， Anaphylaxis， Somnolence (8-45%)， Suicidal intent (0.5%)， Suicide， Angioedema,30℃以下,Monotherapy: Adults， 16 Years and Older: Initial， 250 mg twice daily IV/orally; titration， may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum 3000 mg/day. Adjunctive therapy: Adults， 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily， increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.,無需調整劑量,[仿單] Levetiracetam 會排泄至人類乳汁中，故不建議授乳。 但如果在授乳期間需要服用levetiracetam，須評估治療效益及風險與授乳的重要性。,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,[仿單]在一大量上市後資料中，接受 levetiracetam 單一治療的孕婦（超過 1800 例，其中超過 1500 例發生在懷孕的前三個月期間）主要先天性畸形的風險並未增加。 關於在子宮內接受 levetiracetam 單一治療的兒童神經發育，目前僅有有限的證據。但目前流行病學研究（約 100 名兒童）並未有神經發育障礙或延遲的風險增加。 Levetiracetam 如果在經仔細評估後認為它是臨床上所需要時，才可以在懷孕期間使用。 在這種情況下，建議使用最低有效劑量。懷孕期間的生理變化也可能會影響 levetiracetam 的濃度。 曾有在懷孕期間出現血漿中 levetiracetam 濃度降低現象的報告。這種濃度降低的現象在第三孕期會更為顯著(降低程度最高可達懷孕前之基礎濃度的 60%)。 請務必為接受治療的懷孕婦女進行適當的臨床處置。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] Levetiracetam 會排泄至人類乳汁中，故不建議授乳。 但如果在授乳期間需要服用levetiracetam，須評估治療效益及風險與授乳的重要性。,AC;AC15;PC;PO;WM;,,,,,
EULTA,Sevoflurane,Ultane Inhalation Liquid 250mL,ZANE,,適應症: Induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery. 副作用: >10%: Cardiovascular: Hypotension (4% to 11%; dose-dependent) Central nervous system: Agitation (7% to 15%) Gastrointestinal: Nausea (25%)， vomiting (18%) Respiratory: Cough (5% to 11%) 1% to 10%: Cardiovascular: Tachycardia (2% to 6%)， bradycardia (5%)， hypertension (2%) Central nervous system: Drowsiness (9%)， shivering (6%)， dizziness (4%)， headache (1%)， hypothermia (1%)， myoclonus (1%)， delirium (emergence) Gastrointestinal: Sialorrhea (2% to 4%) Respiratory: Airway obstruction (8%)， laryngospasm (2% to 8%)， breath-holding (2% to 5%)， apnea (2%) Miscellaneous: Fever (1%) 禁忌:Hypersensitivity to sevoflurane， other halogenated anesthetics， or any component of the formulation; known or suspected susceptibility to malignant hyperthermia.,,15-30°C,Individualized dosage. Adult Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6%. MAC values for surgical levels of anesthesia: (25 years) Sevoflurane in oxygen: 2.6%， Sevoflurane in 65% N20/35% oxygen: 1.4% (40 years) Sevoflurane in oxygen: 2.1%， Sevoflurane in 65% N20/35% oxygen: 1.1% (60 years) Sevoflurane in oxygen: 1.7%， Sevoflurane in 65% N20/35% oxygen: 0.9% (80 years) Sevoflurane in oxygen: 1.4%， Sevoflurane in 65% N20/35% oxygen: 0.7% Pediatric Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6%. MAC values for surgical levels of anesthesia: (0 to 1 month old full-term neonates) Sevoflurane in oxygen: 3.3% (1 to <6 months) Sevoflurane in oxygen: 3% (6 months to <1 year) Sevoflurane in oxygen: 2.8%， Sevoflurane in 65% N20/35% oxygen: 2% (1 to <3 years) Sevoflurane in oxygen: 2.8%， Sevoflurane in 60% N20/40% oxygen: 2% (3-12 years) Sevoflurane in oxygen: 2.5%,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
IRAP,Alfentanil,Rapifen inj 1mg/2mL,CNEU,an analgesic supplement and an anaesthetic induction agent.,Hypersensitivity to alfentanil or any component of the formulation. known intolerance to alfentanil or opioids.,Common Cardiovascular: Hypertension (18% )， Tachycardia (12% ) Gastrointestinal: Nausea (28% )， Vomiting (18% ) Musculoskeletal: Involuntary movement， Skeletal muscle (3% to 9% ) Serious Cardiovascular: Asystole， Bradyarrhythmia， Cardiac dysrhythmia， Hypotension (10% ) Immunologic: Anaphylaxis (Less than 1% ) Musculoskeletal: Muscle rigidity (17% ) Neurologic: Raised intracranial pressure， Seizure Respiratory: Apnea (3% to 9% )， Laryngeal spasm (0.3% to 1% )， Respiratory depression (1% to 3% ) Other: Serotonin syndrome,15-30℃,Use as an Induction Agent: An intravenous bolus dose of > or =120 micrograms/kg (17mL/70kg) RAPIFEN will induce hypnosis and analgesia while maintaining good cardiovascular stability in patients with adequate muscle relaxation. For short procedures， an initial dose 7-15 micrograms/kg at induction， with intermittent boluses up to 15 micrograms/kg (7-15 micrograms/kg) at 10-15 minute intervals are most useful. If the dose is less than 7micrograms/kg and IV injection slowly， most patients can still maintain normal respiratory function. the recommended additional dose is 3.5micrograms/kg. For procedures of longer duration， a higher dose may be given at induction and further increments titrated to effect. Duration of the procedure(min):10-30; Rapifen IV bolus dose: 20-40 Micrograms/kg ; 3-6mL/70kg; Duration of the procedure(min):30-60; Rapifen IV bolus dose: 40-80 Micrograms/kg ; 6-12mL/70kg; Duration of the procedure(min):>60; Rapifen IV bolus dose: 80-150 Micrograms/kg ; 12-20mL/70kg; When surgery is more prolonged or more traumatic， analgesia should be maintained by: • either increments of up to 15 micrograms/kg (2mL/70kg) RAPIFEN when required (to avoid post-operative respiratory depression， no RAPIFEN should be administered during the last 10 minutes of surgery); • or a RAPIFEN infusion at a rate of 0.5 to 1 microgram/kg/min (0.14mL/70kg/min) until 5 to 10 minutes before the completion of surgery. Continuous infusion is preferable for cases greater than 60 minutes duration. Rapifen should not be given in the last 10 minutes prior to completion of surgery.,無需調整劑量,[仿單]Rapifen會分泌到乳汁中。因此，在Rapifen給藥後的24小時內不要授乳或餵哺擠出的母乳。,無需調整劑量,沒有資料,Human data suggest risk in 3 rd trimester,[仿單]雖然在動物實驗並沒有發現畸形或急性胎毒效應，但目前仍然沒有足夠的數據可用以評估對人類的任何有害作用。因此孕婦於給藥前應做審慎的利弊評估。 在分娩(包括剖腹生產)的過程不建議靜脈注射本品，因為Rapifen會穿過胎盤，可能會抑制新生兒的自然呼吸。 如於分娩時使用Rapifen，應備妥輔助呼吸設備供母嬰需要時使用，鴉片類藥物的拮抗劑應事先為胎兒備妥。 鴉片類藥物拮抗劑的半衰期可能比Alfentanil的半衰期短，因此多劑量投與鴉片類藥物拮抗劑可能是必要的。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]Rapifen會分泌到乳汁中。因此，在Rapifen給藥後的24小時內不要授乳或餵哺擠出的母乳。,IVD;IVPUSH;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,Administer doses slowly over at least 3 minutes.,Alfentanil was diluted to a concentration of 25 to 80 mcg/mL in clinical studies. _____________________________________________________________________________ 手術時間(分鐘) Rapifen靜脈注射一次給藥劑量(mcg/Kg) mL/70Kg 10-30 20~40 3-6 30-60 40~80 6-12 > 60 80~150 12-20,Duration， general anesthesia: Discontinue use at least 10 to 15 minutes prior to the end of surgery Rapifen不可和其他藥品混合.可以混合氯化鈉或葡萄糖靜脈輸注溶液，需在24小時內使用完畢.
ISHG,Varicella Zoster Virus glycoprotein E,Shingrix inj 0.5mL/dose,HIMM,Prevention of herpes zoster (HZ) in adults aged 50 years and older or in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.,History of severe allergic reaction (e.g.， anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX.,Pain (78%)， redness (38%)， swelling (26%)， myalgia (45%)， fatigue (45%)， headache (38%)， shivering (27%)， fever (21%)， and gastrointestinal symptoms (17%),2-8℃ 避光,IM only. Two doses (0.5 mL/dose) in total. A first dose at Month 0 followed by a second dose administered 2-6 months later. For individuals who are or will be immunodeficient or immunosuppressed and who would benefit from a shorter vaccination schedule: A first dose at Month 0 followed by a second dose administered 1-2 months later.,無需調整劑量,[仿單] 目前尚未研究母親在施打Shingrix後，對接受母乳哺育之嬰兒的影響。It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion.,無需調整劑量,不可使用,Uknown 沒有資料,[仿單] 目前並無任何懷孕婦女使用Shingrix方面的資料。動物研究結果並未顯示Shingrix對懷孕、胚胎/胎兒發育、分娩、或產後發育方面具有直接或間接的有害作用。已知懷孕的婦女應避免接種Shingrix疫苗。The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women.,Unknown 沒有資料,[仿單] 目前尚未研究母親在施打Shingrix後，對接受母乳哺育之嬰兒的影響。It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion.,IM;,使用廠商所附稀釋溶液,,不可,不可,泡製之後，疫苗應立即使用；如果無法立即使用，應將疫苗存放於冰箱中(2°C至8°C)。如果未在6小時內使用，應予以丟棄。
IFUL0,Pegfilgrastim,Fulphila inj 6mg/0.6mL (sample),HEMT,To decrease the incidence of infection， as manifested by febrile neutropenia， in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.,Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.,Common: Bone pain (31%)， Pain in limb (9%) Serious: Aortitis， Capillary leak syndrome， Acute myeloid leukemia， Leukocytosis (<1% )， Myelodysplastic syndrome， Rupture of spleen， Sickle cell anemia with crisis， Thrombocytopenia， Anaphylaxis， Glomerulonephritis， Acute respiratory distress syndrome,於盒內避光冷藏2-8℃,Patients with cancer receiving myelosuppressive chemotherapy: 6 mg subQ once per chemotherapy cycle. Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy.,無需調整劑量,[仿單] 沒有關於pegfilgrastim存在於人乳中、對哺乳兒童的影響或對產乳量的影響之數據。 其他filgrastim藥品很少被分泌於乳汁中及新生兒不會口服吸收filgrastim藥品。 於考量哺乳的發育和健康益處時，母親對pegfilgrastim的臨床需求、pegfilgrastim或潛在的母體狀況對哺乳兒童的潛在不利影響應一併列入考量。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單] 雖然在懷孕婦女中使用pegfilgrastim的現有數據不足以確定是否存在與主要先天性異常， 流產或不利於母體或胎兒相關的藥物風險，但有已公布的研究顯示懷孕婦女接觸filgrastim藥品的數據， 這些研究尚未確定懷孕期間使用filgrastim藥品與主要先天性異常，流產或不利於母體或胎兒之關聯。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 沒有關於pegfilgrastim存在於人乳中、對哺乳兒童的影響或對產乳量的影響之數據。 其他filgrastim藥品很少被分泌於乳汁中及新生兒不會口服吸收filgrastim藥品。 於考量哺乳的發育和健康益處時，母親對pegfilgrastim的臨床需求、pegfilgrastim或潛在的母體狀況對哺乳兒童的潛在不利影響應一併列入考量。,SC;,,,,,1. 避免振搖。置於室溫(不超過30℃)超過48小時後需丟棄。避免冷凍。 2. 給藥前應目視檢查顆粒物質及變色。當發現顆粒物質或變色時，請勿使用。 3. 單次使用的預充填針筒的針頭蓋含有乾燥的天然橡皮(衍生自乳膠)；對乳膠過敏的人不可使用本產品。
HCVDA16,Sofosbuvir + Velpatasvir +/- Ribavirin (1-6/12週),HCVDAA0016(C肝全口服新藥健保計畫)1-6型(E+R)12週,,,,,,,,,,,,,,,,,,,,
HCVDA15,Sofosbuvir + Velpatasvir (1-6/12週),HCVDAA0015(C肝全口服新藥健保計畫)1-6型Epclusa12週,,,,,,,,,,,,,,,,,,,,
OVIAS,Glucosamine Sulphate,Viartril-S powder 1.5gm (自費),CNEU,All forms of degenerative osteoarticular disease. Primary & secondary osteoarthrosis such as: cervical arthrosis， coxofemoral arthrosis， gonarthrosis， dorsal arthrosis， lumbosacral arthrosis， scapulohumeral arthrosis， periarthritis， lumbago， fractures， osteoarticular dystrophies， chronic & subacute arthritis.,Hypersensitivity to glucosamine and shellfish.,Headache， fatigue， drowsiness， flushing.,25℃以下乾燥地方且避免陽光直射或高溫,Sachet: 0.5 sachet once daily for 3 months. Repeat at an interval of 2 months.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OMEZ,Clozapine,MezaPin 100mg,CNEU,Schizophrenia， treatment resistant: Treatment of severely ill patients with schizophrenia who fail to respond adequately to antipsychotic treatment. Suicidal behavior in schizophrenia or schizoaffective disorder: To reduce the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for reexperiencing suicidal behavior， based on history and recent clinical state.,Serious hypersensitivity to clozapine or any component of the formulation (eg， photosensitivity， vasculitis， erythema multiforme， or Stevens-Johnson syndrome [SJS]),Initially drowsiness， hypersalivation， granulocytopenia & agranulocytosis， palpitation， fatigue. Dry mouth， blurred vision， orthostatic hypotension， disturbance in temp regulation. Tachycardia， ECG changes. Rarely: delirium， extrapyramidal reactions. Cardiovascular: Hypotension， Tachyarrhythmia (25%) Dermatologic: Rash (2%)， Sweating symptom (6%) Endocrine metabolic: Excessive salivation (31% )， Weight gain (4%) Gastrointestinal: Constipation (14% )， Excessive salivation (31% )， Nausea (5% )， Xerostomia (6% ) Musculoskeletal: Motor function behavior finding (4%)， Muscle rigidity (3%) Neurologic: Akathisia (3%)， Confusion (3%)， Dizziness (19%)， Headache (7%)， Insomnia (2%)， Somnolence (39%)， Tremor (6%)， Vertigo (19%) Ophthalmic: Visual disturbance (5%) Psychiatric: Agitation (4%)， Dyssomnia， Nightmares (4%)， Restlessness (4%) Other: Fatigue (2%)， Fever (5%) Tachycardia， ECG changes. Rarely: delirium， extrapyramidal reactions.,25℃以下避光,Schizophrenia: Oral: Initial: 12.5 mg once or twice daily; increase， as tolerated， in increments of 25 to 50 mg daily to a target dose of 300 to 450 mg daily (administered in divided doses) by the end of 2 weeks; may further titrate in increments not exceeding 100 mg and no more frequently than once or twice weekly. Maximum total daily dose: 900 mg. Suicidal behavior in schizophrenia or schizoaffective disorder: Oral: Initial: 12.5 mg once or twice daily; increased， as tolerated， in increments of 25 to 50 mg daily to a target dose of 300 to 450 mg daily (administered in divided doses) by the end of 2 weeks; may further titrate in increments not exceeding 100 mg and no more frequently than once or twice weekly. Mean dose is ~300 mg daily; maximum total daily dose: 900 mg.,無需調整劑量,,無需調整劑量,可能安全,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OBRO,Bromelain + L-Cysteine,Broen-C 20000IU/20mg,CNEU,Inflammation after operation & traumatic injury， inadequate expectoration of sputum in respiratory disease.,Digestive tract ulcers， severe liver or kidney impairment， blood coagulation disorders， allergy to pineapple.,Stomach ache， diarrhea， erythema， pruritus， palpitations(rare)， bronchial asthma (rare).,25℃以下陰涼處,3-6 tablets/day in divided doses Q6-8H.,需調整劑量,Bromelain [8] L-Cysteine [8],需調整劑量,沒有資料,Uknown 沒有資料,Bromelain [18] L-Cysteine [18],Unknown 沒有資料,Bromelain [8] L-Cysteine [8],AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為腸溶錠，請整粒吞服，切勿咬嚼或壓碎。 對鳳梨過敏者禁用
OZOP7,Zopiclone,Zolon 7.5mg,CNEU,Insomnia.,Hypersensitivity to Zopiclone， myasthenia gravis， respiratory failure， severe sleep apnea， severe hepatic insufficiency， patients who have experienced complex sleep behaviors (such as sleepwalking， dream driving， or engaging in other activities while not fully awake) after using similar drugs.,Bitter taste， drowsiness， dry mouth， dizziness， headache， nausea， vomiting， fatigue， agitation， and nightmares. Aggressive behavior， agitation， depression， confusion， falling， memory impairment， muscle spasm， dyspepsia， anaphylaxis， angioedema， delirium， delusion， disturbance in attention， drug dependence， myasthenia， outbursts of anger， rebound insomnia， restlessness， withdrawal syndrome， complex sleep related disorder (including sleep driving， sleep talking， somnambulism)， respiratory depression.,25℃以下,Adult: 7.5 mg orally， administered 30-60 minutes before bedtime. Elderly， mild-to-moderate hepatic impairment， renal impairment， respiratory impairment: Initial: 3.75 mg orally once daily at bedtime. Duration should be as short as possible， including the period of dose reduction， and should not exceed 4 weeks. Transient insomnia: 2-5 days; short-term insomnia: 2-3 weeks.,無需調整劑量,[Micromedex] Infant risk cannot be ruled out. Advise women to avoid breastfeeding during zopiclone therapy. [仿單] 目前尚無足夠的資料可評估人類在懷孕及授乳期間使用Zopiclone之安全性。 雖然母乳中Zopiclone 的濃度非常低， 授乳母親仍不應服用Zopiclone。,無需調整劑量,沒有資料,Uknown 沒有資料,[Micromedex] Fetal harm has been demonstrated. Prescribe an alternative， if possible. [仿單] 目前尚無足夠的資料可評估人類在懷孕及授乳期間使用Zopiclone之安全性。 懷孕期不推薦使用本藥。若懷孕後期三個月或分娩時服用Zopiclone，對胎兒可能會有如體溫過低，肌張力過低(Hypotonia)及呼吸抑制。 療程愈短愈好且不應超過四週(包括逐漸降低劑量的期間在內)。 若母體在懷孕後期長期使用，則嬰兒有可能出現生理上的依賴性，產後也有出現戒斷症狀的風險。 育齡期婦女若給與Zopiclone，必須告知患者當其發現或懷疑已經懷孕時，應與醫師聯繫並停用該藥物。,Unknown 沒有資料,[Micromedex] Infant risk cannot be ruled out. Advise women to avoid breastfeeding during zopiclone therapy. [仿單] 目前尚無足夠的資料可評估人類在懷孕及授乳期間使用Zopiclone之安全性。 雖然母乳中Zopiclone 的濃度非常低， 授乳母親仍不應服用Zopiclone。,PO;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OVIE,Ombitasvir + Paritaprevir + Ritonavir,Viekirax FC 12.5/75/50mg,QANB,,適應症:Treatment of chronic hepatitis C in patients with genotypes 1 and 4 in combination with other drugs. 副作用: Central nervous system: Fatigue (7%)， insomnia (5%) Dermatologic: Allergic skin reaction (5%)， pruritus (5%) Gastrointestinal: Nausea (9%) Hematologic & oncologic: Anemia， decreased hemoglobin Hepatic: Increased serum ALT Neuromuscular & skeletal: Weakness (25%) Miscellaneous: Tachyphylaxis <1%， postmarketing， and/or case reports: Hepatic failure (in patients with underlying cirrhosis; FDA Safety Alert， October 22， 2015)， hypersensitivity reaction (including angioedema)， liver decompensation (in patients with underlying cirrhosis; FDA Safety Alert， October 22， 2015)， reactivation of HBV 禁忌: Hypersensitivity to ritonavir (eg， toxic epidermal necrolysis， Stevens-Johnson syndrome) or any component of the formulation; moderate to severe hepatic impairment (Child-Pugh class B or C); concurrent use of drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events; concurrent use of moderate or strong inducers of CYP3A. Concurrent use of drugs that are contraindicated include， but are not necessarily limited to: Alfuzosin， colchicine (not in Canadian labeling)， carbamazepine， cisapride， dronedarone， ergot derivatives (ergonovine， ergotamine， dihydroergotamine， methylergonovine)， ethinyl estradiol-containing products， efavirenz， lovastatin， lurasidone， midazolam (oral)， phenobarbital， phenytoin， pimozide， ranolazine， rifampin， sildenafil (when used for the treatment of pulmonary arterial hypertension [eg， Revatio])， simvastatin， St John's wort， triazolam. Note: Contraindications to ribavirin also apply; see ribavirin prescribing information.,,,Chronic hepatitis C: Oral: Note: Ombitasvir， paritaprevir， and ritonavir are a fixed-dose combination tablet. The recommended oral dose of Viekirax is two 12.5 mg / 75 mg / 50 mg tablets once daily with food. Viekirax should be used in combination with other medicinal products for the treatment of HCV. =genotype 1: Viekirax (ombitasvir 25mg/paritaprevir 150mg/ritonavir 100mg) should be taken once daily and Exviera 250mg should be taken twice daily， with or without ribavirin taken twice daily. =genotype 4: Viekirax (ombitasvir 25mg/paritaprevir 150mg/ritonavir 100mg) once daily， taken with ribavirin dosed twice daily. =Patient population Treatment* Duration =============================================================================== Genotype 1b， without cirrhosis or with compensated cirrhosis Viekirax + dasabuvir 12 weeks Genotype 1a， without cirrhosis Viekirax + dasabuvir + ribavirin* 12 weeks Genotype 1a， with compensated cirrhosis Viekirax + dasabuvir + ribavirin* 24 weeks Genotype 4， without cirrhosis or with compensated cirrhosis Viekirax + ribavirin 12 weeks --------------------------------------------------------------------------------------------------------------------------------------- *Note: Follow the genotype 1a dosing recommendations in patients with an unknown genotype 1 subtype or with mixed genotype 1 infection.,無需調整劑量,Pregnancy Risk Factor: 禁用 (藥品仿單),無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,Pregnancy Risk Factor: 禁用 (藥品仿單),,,,,,
EFUS,Betamethasone,FUSone eye drops 0.1%， 0.5mL,TOPH,Inflammatory conditions of the eyes.,Hypersensitivity.,Increased intraocular pressure.,25℃以下,instill 1-2 drops 3 to 4 times daily into the eye.,無需調整劑量,,無需調整劑量,,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
IOPT,Ioversol,Optiray 350 inj 74% 100mL,ZOTH,Arteriography， venography， head & body CT， excretory urography.,Patients with known or suspected hypersensitivity or in clinically significant cases of hepatic & renal impairment.,Hypotension， nausea， vomiting， headache， laryngeal edema， urticaria， pruritus， extravasation.,30℃以下避光避免冷凍,Intra-arterial Procedures in Adults: Cerebral Arteriography. Peripheral Arteriography: Diagnostic area; Dose; Maximum Cumulative Dose aorta-iliac runoff; 60 mL (range 20 to 90 mL); 250 mL. common iliac， femoral; 40 mL (range 10 to 50 mL); 250 mL. subclavian， brachial; 20 mL (range 15 to 30 mL); 250 mL. Coronary Arteriography and Left Ventriculography: Diagnostic area; Dose; Maximum Cumulative Dose left coronary; 8 mL (range 2 to 10 mL); 250 mL. right coronary; 6 mL (range 1 to 10 mL); 250 mL. left ventricle; 40 mL (range 30 to 50 mL); 250 mL. Intravenous Procedures in Adults: Computed Tomography. Head Imaging: Infusion 50 to 150 mL. Body Imaging: Bolus Injection 25 to 75 mL， Infusion 50 to 150 mL. Venography: The recommended dose is 50 to 100 mL per extremity; with a maximum cumulative dose of 250 mL. Intravenous Urography: Usual Dose:50 to 75 mL， High Dose Urography: 1.4 mL/kg， Maximum Dose: 140 mL. Intravenous Digital Subtraction Angiography (IV-DSA): The recommended dose range per injection is 30 to 50 mL; may repeat as necessary with a maximum cumulative dose of 250mL. Injection rates will vary depending on the site of catheter placement and vessel size. Central catheter injections are usually made at a rate of between 10 and 30 mL/second. Peripheral injections are usually made at a rate of between 12 and 20 mL/second.,需調整劑量,仿單建議:使用藥品後停止哺乳48小時。,需調整劑量,可能安全,Uknown 沒有資料,,Unknown 沒有資料,仿單建議:使用藥品後停止哺乳48小時。,IA;IV;IVD;IVP;IVPUSH;,,,Usual rates of administration are 10 to 30 mL/second for central catheter injections and 12 to 20 mL/second for peripheral injections.,May be utilized as IV bolus， IV infusion， or combination of both; scanning intervals will vary based upon indication and target organ. Use lowest dose necessary for optimal visualization and individualize dosage.,1. For intravascular use only; not for intrathecal use. 2. Do not mix with other medications， solutions， or total parenteral nutrition. 3. Avoid extravasation during injection， especially in patients with severe arterial or venous disease. 4. Adequately hydrate patients before and after administration.
OACAM,Acamprosate,Acamprosate 333mg Delayed-Release(專案進口),ZADT,Alcoholism， maintenance of abstinence,Hypersensitivity to acamprosate calcium or any of its components， Severe renal impairment (CrCl of 30 mL/min or less).,>10% Gastrointestinal: Diarrhea (10% to 17%) 1% to 10%: Cardiovascular: Chest pain， hypertension， palpitations， peripheral edema， syncope， vasodilation Central nervous system: Insomnia (6% to 9%)， anxiety (5% to 8%)， depression (4% to 8%)， dizziness (3% to 4%)， pain (2% to 4%)， paresthesia (2% to 3%)， abnormality in thinking， amnesia， attempted suicide， chills， drowsiness， headache Dermatologic: Pruritus (3% to 4%)， diaphoresis (2% to 3%)， skin rash Endocrine & metabolic: Decreased libido， weight gain Gastrointestinal: Anorexia (2% to 5%)， nausea (3% to 4%)， flatulence (1% to 4%)， xerostomia (1% to 3%)， abdominal pain， constipation， dysgeusia， dyspepsia， increased appetite， vomiting Genitourinary: Impotence Infection: Infection Neuromuscular & skeletal: Weakness (5% to 7%)， arthralgia， back pain， myalgia， tremor Ophthalmic: Visual disturbance Respiratory: Bronchitis， dyspnea， flu-like symptoms， increased cough， pharyngitis， rhinitis <1%， postmarketing， and/or case reports: Abnormal hepatic function tests， agitation， alopecia， anemia， angina pectoris， asthma， brain disease， colitis， confusion， deafness， diabetes mellitus， duodenal ulcer， eosinophilia， epistaxis， exfoliative dermatitis， fever， gastrointestinal hemorrhage， gout， hallucination， hemorrhage， hepatic cirrhosis， hepatitis， hostility， hyperbilirubinemia， hyperesthesia， hyperglycemia， hypersensitivity reaction， hyperuricemia， hyponatremia， hypotension， hypothyroidism， increased serum creatinine， increased serum transaminases， leukopenia， lymphadenopathy， lymphocytosis， myocardial infarction， nephrolithiasis， neuralgia， ophthalmic inflammation， orthostatic hypotension， pancreatitis， pneumonia， psychoneurosis， psychosis， pulmonary embolism， rectal hemorrhage， renal failure， seizure， skin photosensitivity， suicidal ideation， tachycardia， thrombocytopenia， urticaria， withdrawal syndrome,15-30℃，25℃為佳,Alcoholism， maintenance of abstinence: 666 mg orally 3 times daily.,無需調整劑量,Micromedex: Infant risk cannot be ruled out.,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest high risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Micromedex: Infant risk cannot be ruled out.,AC;AC15;PC;PO;,,,,,[磨粉/管灌註記]本藥為緩釋錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。
ONAL,Naltrexone,Naltrexone 50mg (專案進口),ZADT,Alcohol use disorder,Hypersensitivity to naltrexone or any component of the formulation; current physiological opioid dependence or current use of opioid analgesics (including partial opioid agonists); acute opioid withdrawal; failure to pass naloxone challenge or positive urine screen for opioids,>10%: Syncope (=<13%)， Headache (25%)， insomnia (=<14%)， sleep disorder (=<14%)， dizziness (=<13%)， anxiety (12%)， Nausea (33%)， vomiting (14%)， anorexia (=<14%)， change in appetite (=<14%)， decreased appetite (=<14%)， diarrhea (13%)， abdominal pain (11%)， Increased serum transaminases (20%)， increased serum aspartate aminotransferase (2% to 14%)， Increased creatine phosphokinase in blood specimen (11% to 39%)， asthenia (23%)， arthralgia (=<12%)， arthritis (=<12%)， joint stiffness (=<12%)， Pharyngitis (11%) 1% to 10%: Depression (8% to 10%)， drowsiness (=<4%)， sedated state (=<4%)， suicidal ideation (=<1%)， suicidal tendencies (=<1%)， Skin rash (6%)， Xerostomia (5%)， Muscle cramps (8%)， back pain (=<6%)， back stiffness (=<6%),室溫藥品，仿單無特別指示儲存溫度條件,(Micromedex) Alcohol dependence， Maintenance of abstinence: 50 mg orally once daily for <= 12 weeks. Opioid dependence: 25 mg orally on day 1; if no withdrawal signs occur， may increase to 50 mg orally once daily.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;AM;PC;PO;WM;,,,,,
OKCB,Dibismuth trioxide,KCB 120mg,ALIM,gastric and duodenal ulceration.,Hypersensitivity， moderate-severe renal insufficiency.,Gray stools. Nausea， vomiting.,25℃以下,usual dose: Adult: 2 TAB BID before meal， or 1 TAB QID before meal for 4 weeks， may be extended to 8 weeks if needed.,無需調整劑量,,需調整劑量,沒有資料,Human data suggest low risk,,Human Data Suggest Potential Toxicity,,AC;PO;,,,,,
IVAB0,Faricimab,Vabysmo intravitreal inj 6mg/0.05mL(Sample),TOPH,For intravitreal injection. Neovascular (wet) age-related macular degeneration (nAMD)， diabetic macular edema (DME),Ocular or periocular infection. Active intraocular inflammation. Known hypersensitivity to faricimab or any of its excipients (allergic reactions may manifest as rash， itching， urticaria， erythema， or severe intraocular inflammation).,Common: Conjunctival hemorrhage (7-8%) Serious: Arterial thromboembolism (1-5%)， Raised intraocular pressure (3-4%)， Retinal pigment epithelial detachment with tear of retinal pigment epithelium (3%),避光冷藏(2-8°C)儲存、不可冷凍。,Neovascular age-related macular degeneration (nAMD): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Maximum interval: Every 16 weeks (4 months)， but can be adjusted to every 12 weeks (3 months) or every 8 weeks (2 months). Limited safety data for intervals shorter than 8 weeks. Diabetic macular edema (DME): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Dosing intervals: Gradual extension of injection intervals， up to every 16 weeks (4 months). No clinical trial data available for intervals shorter than 4 weeks.,無需調整劑量,[仿單] 目前未知 Vabysmo 是否會分泌至人體乳汁內。目前尚未進行試驗評估 Vabysmo 對於乳汁製造的影響或其是否會進入乳汁裡。 由於許多藥物會分泌至人體乳汁中，存在吸收而傷害嬰兒生長與發育的潛在可能， 因此 Vabysmo 給予哺乳中女性時應特別小心。應同時考慮哺乳對於發育和健康的益處， 以及母親對於 Vabysmo 的臨床需要與 Vabysmo 對於接受哺乳孩童的任何潛在不良影響。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 目前並無 Vabysmo 用於懷孕女性的資料。 目前並不知道給予懷孕女性時， Vabysmo 是否會通過胎盤或傷害胎兒。根據 VEGF 與 Ang-2抑制劑的作用機轉， 存在對女性生殖能力以及胚胎胎兒發育的潛在風險。雖然眼部給藥後全身暴露非常低， 但除非對病人的潛在效益超過對胎兒的潛在風險，否則不應於懷孕期間使用Vabysmo。,Unknown 沒有資料,[仿單] 目前未知 Vabysmo 是否會分泌至人體乳汁內。目前尚未進行試驗評估 Vabysmo 對於乳汁製造的影響或其是否會進入乳汁裡。 由於許多藥物會分泌至人體乳汁中，存在吸收而傷害嬰兒生長與發育的潛在可能， 因此 Vabysmo 給予哺乳中女性時應特別小心。應同時考慮哺乳對於發育和健康的益處， 以及母親對於 Vabysmo 的臨床需要與 Vabysmo 對於接受哺乳孩童的任何潛在不良影響。,IVI;,,,,,1. 僅供玻璃體內注射使用。Vabysmo 必須由具備玻璃體內注射經驗的合格醫師給予。每小瓶僅應使用於治療單眼。
OJIN1,Tolvaptan,Jinarc 15mg,CAVS,Indicated for adults with autosomal dominant polycystic kidney disease (ADPKD) and eGFR greater than 25mL/min/1.73m2 with signs of rapid disease progression， to slow the growth of cysts and decline in kidney function associated with autosomal dominant polycystic kidney disease.,Hypersensitivity to tolvaptan or any component of the product or benzazepine or benzazepine derivatives. Presence of liver enzyme elevation and/or liver damage signs or symptoms that meet the criteria for permanent discontinuation of tolvaptan before starting treatment. Anuria. Volume depletion. Hypernatremia. Unable to sense or respond to thirst. Pregnancy. Breastfeeding.,Common: Hypernatremia (0.7-25.6%)， Diarrhea (13.3%)， Increased thirst (12-63.7%)， Nausea (8-21%)， Xerostomia (7-23%)， ALT/SGPT level raised， Serum bilirubin above reference range， Asthenia (9%)， Dizziness (4.8-11.3%)， Increased frequency of urination (69.5%)， Polyuria (4-24%)， Fatigue (13.6%) Serious: Hypovolemia， Gastrointestinal hemorrhage， In cirrhotic patients (10%)， Hepatic failure， acute， Injury of liver， Osmotic demyelination syndrome,25℃以下,Take twice daily. Dosage options: 45mg + 15mg， 60mg + 30mg， or 90mg + 30mg (split dose regimen). First dose 30 minutes before breakfast. Second dose can be taken with or without food. Initial: total dose 60mg (45mg on waking， 15mg after 8 hours). If tolerated， increase to 90mg daily (60mg + 30mg)， then up to the target dose of 120mg daily (90mg + 30mg). At each dosage adjustment， allow at least one week interval.,需調整劑量,BREASTFEEDING RECOMMENDATION: No Human Data—Potential Toxicity [仿單] 目前尚不清楚 tolvaptan 是否會分泌進入人類的乳汁中，但是根據大鼠試驗顯示 tolvaptan 會分泌到乳汁中。不能排除新生兒/嬰兒的風險。哺乳期間禁用 Jinarc。,需調整劑量,不可使用,No (limited) human data – animal data suggest low risk,PREGNANCY RECOMMENDATION: No Human Data—Animal Data Suggest Low Risk [仿單] 目前在孕婦服用 tolvaptan 方面尚無資料或資料有限。動物試驗顯示本藥品具有生殖毒 性。Jinarc 不建議用於未採取避孕措施的育齡婦女。懷孕時不得服用 Jinarc。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,BREASTFEEDING RECOMMENDATION: No Human Data—Potential Toxicity [仿單] 目前尚不清楚 tolvaptan 是否會分泌進入人類的乳汁中，但是根據大鼠試驗顯示 tolvaptan 會分泌到乳汁中。不能排除新生兒/嬰兒的風險。哺乳期間禁用 Jinarc。,AC;PO;,,,,,
ICLI3,Clindamycin,Clincin inj 300mg/2mL,QANB,Serious infections caused by clindamycin-susceptible strains of streptococci， pneumococci and staphylococci eg， resp tract infections eg， peritonitis and intra-abdominal abscess; female pelvis and genital tract infections eg， non-gonococcal tubo-ovarian abcess， pelvic cellulitis and post-op vag cuff infection; skin and soft tissue infections.,Hypersensitivity to clindamycin or lincomycin. History of GI diseases， severe renal or liver impairment.,Common Dermatologic: Dry skin， Morbilliform eruption Gastrointestinal: Diarrhea (vaginal cream， less than 1%)， Nausea Reproductive: Candida vaginitis (vaginal cream， 14% ; vaginal suppository， 1.5%)， Vaginal pain (vaginal suppository， 1.9%) Serious Dermatologic: Erythema multiforme， Stevens-Johnson syndrome， Toxic epidermal necrolysis Gastrointestinal: Clostridium difficile colitis， Clostridium difficile colitis， Hemorrhagic diarrhea Hematologic: Agranulocytosis Hepatic: Increased liver function test， Jaundice Immunologic: Drug reaction with eosinophilia and systemic symptoms,室溫,Adults: 600-1200 mg/day IV Q6-12H; severe infection: 1.2-2.7 g/day IV Q6-12H; life-threatening: 4.8 g/day. Children > 1 month of age: 15-25 mg/kg/day (350 mg/m2/day) IV Q6-8H; severe condition: 25-40 mg/kg/day (450 mg/m2/day) IV Q6-8H. Do not exceed 600 mg in a single deep IM injection. Dilute to a concentration < 12 mg/mL for IV administration and do not exceed 1200 mg/hour. (熱病) Adult: IV/IM: 1.2-2.7 g/day divided Q8H (maximum 4.8 g/day). To avoid neuromuscular blockade， do not exceed infusion rate of 30 mg/minute. Final concentration < 18 mg/mL. Administering > 1200 mg in a 1-hr infusion not recommended. Pediatric dose for age > 28 days: IV: 20-40 mg/kg/day， divided Q6-8H. *****NEONATE ANTIBIOTICS DOSE***** Clindamycin: general infection dose 5 mg/kg/dose; infusion > 30-60min Body weight <1kg Age <=7day 5mg/kg Q12H Age 8-14 day 5 mg/kg Q12H Age 15-28 day 5 mg/kg Q8H Body weight 1-2kg Age<=7day 5 mg/kg Q12H Age 8-14 day 5 mg/kg Q8H Age 15-28 day 5 mg/kg Q8H Body weight >2kg Age<=7day 5 mg/kg Q8H Age 8-14 day 5 mg/kg Q6H Age 15-28 day 5 mg/kg Q6H,需調整劑量,Enters breast milk/not recommended (AAP rates “compatible”; AAP 2001 update pending) Breast-Feeding Considerations:Small amounts of clindamycin transfer to human milk. The manufacturer does not recommend the use of clindamycin during breast-feeding. Nondose-related effects could include modification of bowel flora. One case of bloody stools in an infant occurred after a mother received clindamycin while breast-feeding; however， a casual relationship was not confirmed.,無需調整劑量,,Compatible,,Compatible 哺乳時可使用,Enters breast milk/not recommended (AAP rates “compatible”; AAP 2001 update pending) Breast-Feeding Considerations:Small amounts of clindamycin transfer to human milk. The manufacturer does not recommend the use of clindamycin during breast-feeding. Nondose-related effects could include modification of bowel flora. One case of bloody stools in an infant occurred after a mother received clindamycin while breast-feeding; however， a casual relationship was not confirmed.,IM;IVD;,,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。【D10W】可選 。【D5NS】可選 。,,,
IRAPBAD,Alfentanil,Rapifen inj 1mg/2mL 殘餘銷毀,CNEU,,,,,,,,,,,,,,IV;IVPUSH;,,,,,
IINV2,Paliperidone,INVEGA inj 150mg (=234mg),CNEU,Acute & maintenance treatment of schizophrenia in adults.,Hypersensitivity to paliperidone or risperidone.,Cerebrovascular events including stroke. Neuroleptic malignant syndrome， QT prolongation， tardive dyskinesia， hyperglycemia & DM， wt gain， hyperprolactinemia. Orthostatic hypotension & syncope. Leukopenia， neutropenia & agranulocytosis. Cognitive & motor impairment. Seizures， dysphagia， suicide， priapism， TTP. Disruption of body temp regulation. Antiemetic effect. Inj site reactions， somnolence/sedation， dizziness， akathisia & extrapyramidal disorder.,30°C以下,Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point. Maintenance: Following the 1-week initiation regimen， adjust the dose based on response and tolerability and begin a maintenance dose of 78 to 234 mg every month administered in either the deltoid or gluteal muscle (the 39 mg dose was not studied in schizoaffective disorder trials). The monthly maintenance dose may be administered 7 days before or after the monthly time point.,無需調整劑量,Micromedex Lactation Rating: Infant risk cannot be ruled out.,需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,Micromedex Pregnancy Rating: Fetal risk cannot be ruled out. Although no structural malformations attributable to risperidone have been reported， the number of exposures is too low to fully assess the embryo–fetal risk. In addition， there is a risk of extrapyramidal and/or withdrawal symptoms in the newborn if the drug is used in the 3rd trimester. Nevertheless， risperidone is indicated for severe debilitating mental disease and the benefits to the mother appear to outweigh the potential embryo–fetal risks. Folic acid 4 mg/day has been recommended for women taking atypical antipsychotics because they may have a higher risk of neural tube defects due to inadequate folate intake and obesity,Contraindicated 哺乳期使用禁忌,Micromedex Lactation Rating: Infant risk cannot be ruled out.,IM;,,,,,1.仿單對於不同注射部位及病患體重建議使用不同的針頭，請參照. 2.請貯存於30°C以下。切勿與任何其它產品或稀釋劑混合使用。
HCVDA01,Daklinza + Sunvepra (1b/24週),HCVDAA0001(C肝全口服新藥健保計畫) 1b/24週,QANB,,,,,,,,,,,,,,,,,,,
HCVDA03,Viekirax + Exviera + Ribavirin (1a/12週),HCVDAA0003(C肝全口服新藥健保計畫) 1a/12週,QANB,,,,,,,,,,,,,,,,,,,
HCVDA02,Viekirax + Exviera (1b/12週),HCVDAA0002(C肝全口服新藥健保計畫) 1b/12週,QANB,,,,,,,,,,,,,,,,,,,
ELYC,Permethrin,Lyclear Cream 5%， 30gm (專案進口),TDER,,適應症: Head lice (lotion/cream rinse): Treatment of head lice (Pediculus humanus capitis) and its nits (eggs). Scabies (cream): Treatment of scabies (Sarcoptes scabiei) infestation 副作用: Central nervous system: Local discomfort (scalp)， localized burning， localized numbness， tingling of skin Dermatologic: Pruritus， erythema， skin rash (scalp)， stinging of the skin Local: Localized edema 禁忌: Hypersensitivity to any pyrethroid or pyrethrin， or to any component of the formulation. OTC labeling (cream rinse/lotion): When used for self-medication， do not use on infants <2 months of age; near the eyes; inside the nose， ear， mouth， or vagina. Consult health care provider for use on eyebrows or eyelashes.,,室溫,-To treat scabies Adults and adolescents over 12 years of age. Apply up to 30 g of cream (corresponding to one tube of 30 g) Children aged from 6 - 12 years. Apply up to 15 g of cream (corresponding to 1/2 tube of 30 g) Children aged from 2 months - 5 years. Apply up to 7.5 g of cream (corresponding to 1/4 tube of 30 g) -To treat crab lice Adults over 18 years of age: Apply up to 30 g of cream (corresponding to one tube of 30 g).,,Micromedex Pregnancy Category: B (FDA) Breast Feeding WHO: Compatible with breastfeeding.,,可能安全,,,Compatible 哺乳時可使用,Micromedex Pregnancy Category: B (FDA) Breast Feeding WHO: Compatible with breastfeeding.,EXT;SKIN;TOPI;,,,,,
EOES8,Estradiol,Oestrogel gel 0.75mg/pump， 64pump/bottle,HM,Hormone replacement therapy: Treatment of symptoms related to menopause (hot flushes， excessive sweating， urinary symptoms， dryness of the vagina， etc).,Ongoing thromboembolic diseases (inflammation of a vein with formation of a blood clot， obliteration of a pulmonary vessel， myocardial infarction， cerebrovascular accident related to a blood clot). Certain diseases of the liver and malignant tumours of the breast or uterus. Endometriosis Undiagnosed vaginal bleeding. Hypersensitivity to any of the components of Oestrogel. Oestrogel has no indication during pregnancy.,Common Cardiovascular: Edema (Transdermal system， 0.5% to 13% ) Dermatologic: Application site irritation (transdermal system， 5.7% to 56.7% )， Chloasma， Hirsutism， Loss of scalp hair， Persistent erythema of skin (Transdermal system， less than or equal to 3.2% ) Endocrine metabolic: Weight increased (Transdermal system， up to 8.5% ) Gastrointestinal: Abdominal pain (Topical gel， 7.7%)， Bloating symptom Neurologic: Headache (Topical gel， 9.5%) Reproductive: Breast tenderness (Topical gel， 2.5% to 8.8%)， Disorder of menstruation， Pain of breast (Topical gel， 10.7%)， Swelling of breast， Withdrawal bleeding Respiratory: Upper respiratory infection (Topical gel， 1.6% to 5.9% ) Other: Pain (Transdermal system， 0% to 11% ) Serious Cardiovascular: Heart disease， Myocardial infarction Endocrine metabolic: Body fluid retention， Hypercalcemia Gastrointestinal: Disorder of gallbladder Hematologic: Deep venous thrombosis， Venous thromboembolism Neurologic: Cerebrovascular accident， Dementia Ophthalmic: Thrombosis of retinal vein Reproductive: Breast cancer， Endometrial cancer， Ovarian cancer Respiratory: Pulmonary embolism Other: Angioedema,30℃以下,Each pump contain 1.25gm Gel = 0.75mg Estradiol. Apply 1.25mg Estradiol (2 pumps)/day 3 weeks on， 1 week off， and with oral progesterone on days 8 to 21. Topically use to clean， dry， unbroken skin on the arm; apply in a thin layer from wrist to shoulder; allow gel to dry for up to 3 minutes before dressing. If necessary， Apply 1.25mg Estradiol (2 pumps)/day on days 1 to 24， And with oral progesterone on days 8 to 21.,無需調整劑量,[仿單]已知懷孕或懷疑已懷孕者必須立即停止使用此藥，動情素治療之適應症不包含流產及抑制泌乳。,無需調整劑量,不可使用,Contraindicated,[仿單]已知懷孕或懷疑已懷孕者必須立即停止使用此藥，動情素治療之適應症不包含流產及抑制泌乳。,Compatible 哺乳時可使用,[仿單]已知懷孕或懷疑已懷孕者必須立即停止使用此藥，動情素治療之適應症不包含流產及抑制泌乳。,EXT;SKIN;TOPI;,,,,,1. 勿塗抹於乳房、陰部或陰道黏膜。 2. 儘可能地塗開於前臂、手臂、兩肩或者完整大面積的皮膚上。若敷用三分鐘後仍黏著，表示塗敷面積太小，下次使用時應塗較大面積。 3. 婦女自己塗抹。早或晚沐浴後，每天同一時間敷用。
OISO4,Verapamil,Isoptin 40mg,CAVS,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
ETRP,Brillant Green,Tripledye 500mL,TDER,,,,,,無需調整劑量,,無需調整劑量,沒有資料,,,Unknown 沒有資料,,EXT;,,,,,
IORE,Oxaliplatin,Orectalip inj 50mg/10mL,RACA,Adjuvant treatment of stage III colon cancer after complete resection of primary tumor and advanced colorectal cancer (in combination with infusional fluorouracil and leucovorin).,Hypersensitivity to oxaliplatin， other platinum-containing compounds， or any component of the formulation. Pregnancy， breast-feeding; severe renal impairment (CrCl <30 mL/minute),Nausea， vomiting， diarrhea; anemia， leucopenia， granulocytopenia， thrombocytopenia; peripheral neuropathies; fever， rash， anorexia. Gastrointestinal: Abdominal pain (monotherapy， 31%; combination therapy， up to 39% )， Constipation (combination therapy， up to 32% )， Diarrhea (monotherapy， 46%; combination therapy， up to 76% )， Loss of appetite (monotherapy， 20%; combination therapy， up to 35% )， Nausea (monotherapy， 64%; combination therapy， up to 83% )， Stomatitis (monotherapy， 14%; combination therapy， up to 42% )， Vomiting (monotherapy， 4%; combination therapy， up to 64% ) Hematologic: Anemia (monotherapy， 64%; combination therapy， up to 81% )， Neutropenia， All grades (monotherapy， 7%; combination therapy， up to 81% ) Musculoskeletal: Backache Respiratory: Cough (monotherapy， 11%; combination therapy， up to 35% ) Other: Fatigue (monotherapy， 61%; combination therapy， up to 70% )， Fever (monotherapy， 25%; combination therapy， up to 29% ),30℃以下,[Adjuvant therapy] 85 mg/m2 administered intravenously every 2 weeks for up to 12 cycles. [Colorectal cancer (advanced)] 85 mg/m2 on day 1 every 2 weeks until disease progression or unacceptable toxicity. [Gastric cancer] 130 mg/m2 every 3 weeks (either 130 mg/m2 on day 1 or 65 mg/m2 on day 1 and day 8). Administer oxaliplatin before fluoropyrimidine (ie.， 5-fluorouracil) when coadministration.,無需調整劑量,Micromedex: Infant risk cannot be ruled out. No reports describing the use of oxaliplatin during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if oxaliplatin affects the quantity and composition of breast milk. Breastfeeding is not recommended while taking oxaliplatin due to the potential risk to the nursing infant. The manufacturer recommends making a decision to discontinue nursing or delay use of oxaliplatin in breastfeeding women.,需調整劑量,盡量避免,Contraindicated – 1st trimester,藥品仿單:懷孕及授乳者禁用。,Contraindicated 哺乳期使用禁忌,Micromedex: Infant risk cannot be ruled out. No reports describing the use of oxaliplatin during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if oxaliplatin affects the quantity and composition of breast milk. Breastfeeding is not recommended while taking oxaliplatin due to the potential risk to the nursing infant. The manufacturer recommends making a decision to discontinue nursing or delay use of oxaliplatin in breastfeeding women.,IVD;,,【D5W】可選 仿單建議。,,1. IV: Dilute in 250 to 500 mL D5W (do not use NS) to a final concentration > 0.2 mg/mL. Administer as IV infusion over 2-6 hours. 2. Flush infusion line with D5W prior to administration of any concomitant medication.,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 調配與注射的器具不可含有鋁。本藥品不可使用含有氯的稀釋溶液 (例如：N/S)，給藥時避免和鹼性藥物(例如：5-FU)使用相同管路。 3. 稀釋後的輸注溶液在室溫下安定性維持24小時。 4. 監測CBC、腎功能，注意病人是否有呼吸方面的異常症狀。 5. 定期神經學檢測。
OKLAR,Clarithromycin,Klarith 500mg,QANB,,適應症: Upper & lower respiratory tract. Eradication of H. pylori when used with omeprazole. 副作用: Central nervous system: Headache， insomnia， skin rash， dysgeusia， vomiting， diarrhea， nausea， abdominal pain， dyspepsia， prolonged prothrombin time， abnormal hepatic function tests， anaphylactoid reaction， candidiasis， increased blood urea nitrogen. 禁忌: Hypersensitivity to clarithromycin， erythromycin， any of the macrolide antibiotics， or any component of the formulation; history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin; concomitant use with cisapride， pimozide， ergot alkaloids (eg， ergotamine， dihydroergotamine)， or HMG-CoA reductase inhibitors extensively metabolized by CYP3A4 (eg， lovastatin， simvastatin); concomitant use with colchicine in patients with renal or hepatic impairment.,,室溫,Oral Susceptible infections， Respiratory tract infections， Skin and soft tissue infections. Adult: 250 mg bid， increased to 500 mg bid for severe infections， if necessary， for 7-14 days. Child: 7.5 mg/kg bid for 5-10 days. Eradication of H. pylori associated with peptic ulcer disease Adult: 500 mg bid， in combination w/ another antibacterial and either a PPI or H2-receptor antagonist for 7-14 days.,需調整劑量,,需調整劑量,,Compatible,,Compatible 哺乳時可使用,,,,,,,
IOKM,Palonosetron,OKmilon inj 0.25mg/5mL,CNEU,Prevention of chemotherapy-induced nausea and vomiting. Prevention of postoperative nausea and vomiting.,Hypersensitivity to palonosetron or any component of the formulation,Common Cardiovascular: Bradyarrhythmia (1% to 4% ); Gastrointestinal: Constipation (up to 5% ); Neurologic: Headache (up to 9% ) Serious Cardiovascular: Prolonged QT interval; Immunologic: Anaphylaxis， Hypersensitivity reaction; Neurologic: Seizure; Other: Serotonin syndrome,30℃以下。避免冷凍及光照。,Chemotherapy-induced nausea and vomiting， associated with emetogenic chemotherapy; Prophylaxis: Adult: 0.25 mg IV over 30 seconds approximately 30 minutes prior to starting chemotherapy. Children and Adolescents (1 month to 17 years old): 20 mcg/kg IV over 15 minutes approximately 30 minutes prior to starting chemotherapy; maximum dose: 1.5 mg.,無需調整劑量,[仿單]目前仍未知Palonosetron是否會存在乳汁中。由於許多藥物會分泌於乳汁中，可能對受乳的嬰兒產生嚴重不良的反應，以及palonosetron在大白鼠致癌性試驗顯示可能導致產生腫瘤。 因此，當考慮到藥物對母親的重要性時，須決定停止哺乳或停止服藥。,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,[仿單]在懷孕婦女身上Palonosetron並沒有進行適當及良好控制的研究。在大白鼠及兔子的器官形成期以口服投與palonosetron的動物生殖試驗，劑量高達人類建議靜脈授予的1894倍及3789倍，觀察到對胚胎-胎兒發育無影響。 因為動物生殖試驗無法完全用以預測人類的反應，所以，在懷孕期間，Palonosetron只有確認須要時才可使用。 在動物實驗，在懷孕大白鼠的器官形成期以口服投與palonosetron高達60 mg/kg/day (約為根據體表面積所計算之人類建議靜脈投與劑量的1894倍)或在懷孕兔子的器官形成期以口服投與palonosetron高達60 mg/kg/day (約為根據體表面積所計算之人類建議靜脈投與劑量的3789倍)，觀察到對胚胎-胎兒發育無影響。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前仍未知Palonosetron是否會存在乳汁中。由於許多藥物會分泌於乳汁中，可能對受乳的嬰兒產生嚴重不良的反應，以及palonosetron在大白鼠致癌性試驗顯示可能導致產生腫瘤。 因此，當考慮到藥物對母親的重要性時，須決定停止哺乳或停止服藥。,IVD;IVPUSH;,,【N/S】可選 。,成人：靜脈注射超過30秒,兒童與青少年(1 個月大至 17 歲)：單一劑量20mcg/kg(最大劑量不可超過1500 mcg)，靜脈輸注時間須超過15分鐘。,1.本品僅供靜脈注射用，不應與其他藥物混合。投與本品前後均須用生理食鹽水沖洗輸注管線。 2.廠商提供支安定性資料: 本品3AMP(15mL)稀釋於250mL 0.9% Sodium Chloride及 2AMP(10mL)稀釋於90mL 0.9% Sodium Chloride皆有4小時的安定性。
OTET3,Tetracycline,Tetracycline 250mg,QANB,Gram-positive bacterial infections， bacterial infections， infections caused by Leptospira species， and infections caused by giant filtrating viruses.,Hypersensitivity to tetracycline products Last half of pregnancy/infancy/childhood up to 8 years of age.,Common: Tooth discolored Serious: Phototoxicity， Acidosis， Azotemia， Serum blood urea nitrogen raised， Bulging fontanelle， Pseudotumor cerebri， Raised intracranial pressure,陰涼(15-30℃)乾燥避光且兒童不易取得處,[Adult] Usual dose: 250-500mg q6h po， or 500-1000mg q12h po. Maximum 4g/day. Acne: Initial 500-2000mg/day in divided doses. Once the condition improves (typically after 3 weeks)， maintenance dose 125-500mg/day. Intermittent or alternate-day therapy can also alleviate symptoms. Gonorrhea: 500mg q6h po for 5 days Syphilis: 500mg q6h po for 15 days (early syphilis)， or 30 days (late syphilis) [Pediatric] Age >8 years: 6.5-12.5mg/kg q6h po， or 12.5-25mg q12h po,無需調整劑量,[仿單] 本藥能分泌於乳汁中，雖然可能會與乳液中的鈣離子形成不能吸收的錯合物，但因會 導致嬰兒牙齒永久性變色，齒釉質發育不全及抑制骨骼生長等，故應就其危險與效益加以考慮。,需調整劑量,不可使用,Contraindicated – 2nd and 3 rd trimesters,[仿單] 本藥能通過胎盤，導致胎兒牙齒永久性的變色，齒釉質發育不全及抑制骨骼的生長， 故在懷孕後半期間不能使用。,Compatible 哺乳時可使用,[仿單] 本藥能分泌於乳汁中，雖然可能會與乳液中的鈣離子形成不能吸收的錯合物，但因會 導致嬰兒牙齒永久性變色，齒釉質發育不全及抑制骨骼生長等，故應就其危險與效益加以考慮。,AC;AC15;PC;PO;WM;,,,,,
EHIR,Heparinoid,Hirudoid cream 0.3%， 40gm,TDER,,適應症: Treatment of superficial thrombophlebitis & relief of superficial bruising & haematoma. 副作用:Rash， pruritus 禁忌:Hypersensitivity to Heparinoid.,,室溫,Apply gently or massage 2-3 times daily.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;SKIN;TOPI;,,,,,
EALC752,Alcohol,75% Alcohol 200mL/bottle,TDER,,,,25℃以下儲存,,無需調整劑量,,無需調整劑量,,,,,,EXT;,,,,,
ETAF,Tafluprost,Taflotan oph soln 0.0015%， 2.5mL,TOPH,,適應症:Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension 副作用: >10%: Ocular: Conjunctival hyperemia (4% to 20%) 1% to 10%: Central nervous system: Headache (6%) Genitourinary: Urinary tract infection (2%) Ocular: Stinging/irritation (7%)， conjunctivitis (5%)， cataract (3%)， dry eye (3%)， ocular pain (3%)， eyelash darkening (2%)， eyelash growth (2%)， vision blurred (2%) Respiratory: Common cold (4%)， cough (3%) Postmarketing and/or case reports (Limited to important or life-threatening): Dyspnea， exacerbation of asthma; macular edema (reported with prostaglandin analog use) 禁忌:Hypersensitivity to Tafluprost.,,室溫,Glaucoma: Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage because it has been shown that more frequent administration may decrease the IOP-lowering effect.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IDUR,Carbetocin,Duratocin inj 100mcg/1mL,SGU,Prevention of uterine atony and postpartum hemorrhage following elective cesarean section under anesthesia (epidural or spinal),Hypersensitivity to carbetocin， oxytocin， or any component of the formulation; administration prior to delivery of infant for any reason (including elective or medical induction of labor); vascular disease; use in children,>10%: Cardiovascular: Flushing， hypotension Central nervous system: Headache Dermatologic: Pruritus Gastrointestinal: Abdominal pain， nausea， vomiting Neuromuscular & skeletal: Tremor Miscellaneous: Feeling of warmth,30℃以下避光避免冷凍,Caesarean section under epidural or spinal anaesthesia: Withdraw 1 ml of DuratocinR containing 100 micrograms carbetocin and administer only by intravenous injection， under adequate medical supervision in a hospital. Vaginal delivery: Withdraw 1 ml of DuratocinR containing 100 micrograms carbetocin and administer by intravenous injection or intramuscular injection， under adequate medical supervision in a hospital.,無需調整劑量,UpToDate Lactation:Enters breast milk/use caution,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,UpToDate Lactation:Enters breast milk/use caution,IVP;IVPUSH;,,,Slow IV < 100mcg/1min,,1.不可與其他藥物混合 2.對Carbetocin或oxytocin過敏者禁用
ILEV2,Norepinephrine,Norepinephrine inj 4mg/4mL,CAVS,Restoration of BP in acute hypotensive states. Adjunct in the treatment of cardiac arrest & profound hypotension.,Patients who are hypotensive from blood vol deficits except as emergency measure until blood vol therapy can be completed. Cyclopropane & halothane anesth， mesenteric or peripheral vascular thrombosis.,Occasionally， bradycardia; anxiety， transient headache. Plasma vol depletion (prolonged administration). Respiratory difficulty， ischemic injury.,30℃以下避光,Must be diluted in dextrose containing solutions prior to infusion. Add 4 mL/AMP to 1000 mL of 5% dextrose solution to final concentration of 4 mcg/mL Norepinephrine. IV infusion， Adult: 8-12 mcg/minute initially， adjust the rate of flow to establish and maintain a low normal blood pressure (usually 80 mm Hg to 100 mm Hg systolic) sufficient to maintain the circulation to vital organs. The average maintenance dose ranges from 2-4 mcg/minute. High dosage: Individual variation occurs in the dose required to attain and maintain an adequate blood pressure. Occasionally much larger or even enormous daily doses (as high as 68 mg) may be necessary if the patient remains hypotensive， but occult blood volume depletion should always be suspected and corrected when present. Central venous pressure monitoring is usually helpful in detecting and treating this situation.,無需調整劑量,,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【D10W】可選 。【L/R】可選 。,,滴注速率為 2-4 mcg/min。 IV infusion: 4 mg in 250 mL (concentration: 16 mcg/mL) or 8 mg in 250 mL (concentration: 32 mcg/mL).,1.Norepinephrine使用前應稀釋於含葡萄糖的注射液。 2.本品儘可能注射於大靜脈，特別是肘前靜脈，因為長時間的血管收縮而造成上層皮膚壞死的危險，使用本方式極少有之。也有專家建議由股靜脈注射。應避免使用導管 tie-in 技術(catheter tie-in technique)，因為管子周圍血流阻礙會造成血行停滯，並增加藥物的局部濃度。通常下肢產生閉塞性血管疾病的可能性較上肢大。因此年老患者或曾患類似疾病之患者，要避免腿部靜脈給藥，踝靜脈給藥曾有下肢末端產生壞疽的報告。
OELI,Apixaban,ELIQUIS 5mg,HEMT,Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF)， w/ >=1 risk factors [eg， prior stroke or transient ischaemic attack， age >=75 yr， HTN， DM， symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.,Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk. Lesion or condition at significant risk of major bleeding (eg， current or recent GI ulceration， presence of malignant neoplasms at high risk of bleeding; recent brain/spinal injury， brain/spinal/ophth surgery， intracranial haemorrhage; known or suspected oesophageal varices， arteriovenous malformations， vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment w/ any other anticoagulant eg， unfractionated heparin (UFH)， low molecular wt heparins， heparin derivatives， oral anticoagulants except under the circumstances of switching therapy to or from apixaban or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter.,Epistaxis， anaemia， nausea， contusion， haematuria， haematoma， vag & urethral haemorrhage; eye， GI & rectal haemorrhage; gingival bleeding.,30℃以下,Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 5 mg twice daily unless patient has any 2 of the following: Age >=80 years， body weight =<60 kg， or serum creatinine >=1.5 mg/dL， then reduce dose to 2.5 mg twice daily. Deep venous thrombosis: Oral:Treatment: 10 mg twice daily for 7 days followed by 5 mg twice daily. Reduction in the risk of recurrence: 2.5 mg twice daily after at least 6 months of treatment for DVT,需調整劑量,[仿單]目前沒有關於人類乳汁中apixaban或其代謝產物的存在，對母乳哺孩子或對泌乳量影餐的資料Apixaban和/或其代謝產物存在於大鼠乳汁中。由於尚不清楚人類是否會透過乳汁接觸藥物，因此接受ELIQUIS治療期間不建議母乳餵哺。,需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單節錄]關於孕婦使用ELIQUIS的可用資料有限，不足以顯示與藥物相的重大先天缺陷、流產或不良發育結果風險。使用本品治療可能會增加懷孕與生產期間的出血風險。在動物繁殖試驗中，於器官形成期間分？給予大鼠（口服）、兔子（靜脈注射）及小鼠（口服）相當於人類未結合apixaban曝藥量分？為4、1及19倍劑量[以血中濃度曲線下面積(AUC)為基礎，和5毫克每日兩次的人類最高建議劑量(MRHD)進行比較]，未觀察到apixaban具有對發育的不良影響。 懷孕會增加血栓栓塞的風險，對於具有潛在血栓栓塞性疾病和特定高風險妊娠狀G的婦女來說，血栓栓塞的風險更高。已發表的資料顯示，先前具有靜脈血栓形成病史的女性在懷孕期間有很高的復發風險。 使用包括ELIQUIS的抗凝血劑，可能會增加胎兒和新生兒出血的風險。 所有接受抗凝血劑治療的病人（包括孕婦），都有出血的風險。 接受椎管？麻醉的女性中，在分娩或生產期間使用ELIQUIS可能會導致硬脊膜外或脊髓血腫。可考慮於生產期間使用更短效的抗凝血劑。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]目前沒有關於人類乳汁中apixaban或其代謝產物的存在，對母乳哺孩子或對泌乳量影餐的資料Apixaban和/或其代謝產物存在於大鼠乳汁中。由於尚不清楚人類是否會透過乳汁接觸藥物，因此接受ELIQUIS治療期間不建議母乳餵哺。,AC;AC15;PC;PO;,,,,,
ITES1,Testosterone cypionate,Testosterone cypionate inj 200mg/1mL,HM,,適應症: Testosterone replacement therapy in male hypogonadal disorders. Osteoporosis due to androgen deficiency. 副作用: Priapism， signs of excessive sexual stimulation， oligospermia， decreased ejaculatory vol; fluid & salt retention. In prepubertal boys， precocious sexual development， increased frequency of erections， phallic enlargement， premature epiphyseal closure. Dermatologic: Acne (up to 8% ) Endocrine metabolic: Gynecomastia (up to 3% ) Gastrointestinal: Oral irritation， Buccal system (9.2% ) Neurologic: Headache (up to 4% ) Reproductive: Large prostate (11.7% ) 禁忌: Known or suspected prostatic or mammary carcinoma.,,室溫,IM 200 to 400 mg every 3 to 4 weeks,無需調整劑量,,無需調整劑量,不可使用,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,IM;,,,,,本藥品限用於肌肉注射。
OXIG,Dapagliflozin + Metformin,Xigduo XR 10mg/1000mg Extended-Release,META,Type 2 Diabetes Mellitus,Acute or chronic metabolic acidosis (e.g. diabetic ketoacidosis， lactic acidosis)， diabetic pre-coma， acute alcohol intoxication or alcoholism， acute or chronic disease that may cause hypoxia (e.g. cardiac or respiratory failure， recent MI， shock)， conditions which may alter renal function (e.g. severe infection， dehydration). Hepatic and moderate to severe renal impairment (CrCl <60 mL/min).,Hypoglycaemia， bone fracture， genital mycotic infections， hypotension， ketoacidosis， increased LDL-C， acute renal impairment， urinary infections (e.g. urosepsis， pyelonephritis)， vitamin B12 deficiency. Rarely， hypersensitivity reactions (e.g. angioedema， urticaria). Gastrointestinal disorders: Nausea， vomiting， diarrhoea， abdominal pain. Musculoskeletal and connective tissue disorders: Back pain. Nervous system disorders: Headache， taste disturbance， dizziness. Renal and urinary disorders: UTI， increased urination. Reproductive system and breast disorders: Vaginal moniliasis， vulvovaginitis， balanitis. Respiratory， thoracic and mediastinal disorders: Nasopharyngitis， cough. Skin and subcutaneous tissue disorders: Rash.,30℃以下,1 TAB once daily， maximum: dapagliflozin 10 mg and metformin 2000 mg daily.,需調整劑量,,需調整劑量,除非治療上需要,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,PC;PO;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠，需整顆吞服勿咀嚼、剝半或磨粉。無法吞服病患可改用院內同成份一般劑型藥物。
ICOVAZ,SARS-CoV-2 Spike glycoprotein [ChAdOx1-S],COVID-19 Vaccine AstraZeneca 0.5mL/dose (5mL/vial),HIMM,AstraZeneca COVID-19 Vaccine is indicated for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).,History of a severe allergic reaction after a previous dose or to a component of the formulation; history of immediate allergic reaction to a previous dose; known allergy to any component of the formulation.,erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.,2-8℃避光避免冷凍,IM， 0.5 mL， > or = 18 years 2 doses administered 4 to 12 weeks apart. (Taiwan CDC suggests 2 doses administered 8 to 12 weeks apart.),無需調整劑量,[仿單] 目前並不清楚本疫苗是否會分泌到人類乳汁中.,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 本疫苗用於懷孕女性的經驗有限.動物生殖毒性試驗尚未完成.根據初步試驗結果，未觀察到對胎兒發育的影響. 除非可能效益高於對母親和胎兒的潛在風險，否則懷孕期間不應施打本疫苗. 正在哺乳，可能懷孕或有計畫懷孕之女性，皆應評估接種之利益與風險.,Unknown 沒有資料,[仿單] 目前並不清楚本疫苗是否會分泌到人類乳汁中.,IM;,,,,,1.僅用於肌肉注射，最好在上臂的三角肌(Deltoid)。 2.不可與其他疫苗或藥品在同一注射器中混合使用。 3.未開封藥物需置於冰箱2-8℃冷藏，不可冷凍；開封後可以不超過30℃的情況下保存6小時，請勿再放回冰箱冷藏。 4.本疫苗不得與其他疫苗同時接種，並應與其他不活化疫苗間隔至少14天，與其他活性減毒疫苗間隔至少28天
IZOF,Ondansetron,Zofran inj 8mg/4mL(限麻醉組套),CNEU,Prevention or treatment of nausea and vomiting caused by surgery， chemotherapy or radiation therapy.,Hypersensitivity to ondansetron or any component of the formulation; concomitant use with apomorphine,Common Gastrointestinal: Constipation (11% )， Diarrhea (adults， 16%; pediatrics， 2%)， Xerostomia (5% ) Hepatic: Increased liver enzymes (17% ) Neurologic: Headache (17% ) Other: Fever (2% to 8% ) Serious Cardiovascular: Atrial fibrillation， Electrocardiogram abnormal， Prolonged QT interval， Torsades de pointes Neurologic: Oculogyric crisis Other: Serotonin syndrome,儲存於30℃以下，避光,Prevention of nausea and vomiting caused by surgery: single dose of 4 mg IM or slowly IV (more than 30 seconds). Treatment of nausea and vomiting caused by surgery: A single dose of 4 mg is recommended for most patients， administered IM or slowly IV. increased to 8 mg if necessary. Children from 1 month to 17 years: A clinical trial in children under 2-years-old has not been conducted. slow IV injection (more than 30 seconds) before， during or after induction of anesthesia， 0.1 mg/kg， and up to 4 mg. Nausea and vomiting due to chemotherapy or radiation therapy: Adult: The recommended dose is 8 mg IV or IM before treatment. After 24 hours， oral medication is recommended to prevent delayed or prolonged vomiting. For highly emetogenic chemotherapy (high dose cisplatin): a single 8 mg dose by slow IV or IM immediately before chemotherapy. 8-16 mg can only be administered by IV infusion after dilution with 50 to 100 ml of normal saline or other compatible infusion solutions， and the infusion time should be more than 15 minutes. A single dose should not exceed 16 mg， cause QT interval prolongation is dose-dependent. Slow IV injection (more than 30 seconds) or IM 8 mg before chemotherapy， and next two doses of 8 mg every 2 to 4 hours or continuous infusion (1 mg/hour) for a maximum of 24 hours. Children over 6 months and adolescents: dosage according to body surface area (BSA) or body weight. Dosage according to body surface area (BSA): administered as a single intravenous injection of 5 mg/m2 immediately before chemotherapy. It should be administered by intravenous infusion for a period of not less than 15 minutes. Oral ondansetron can begin after 12 hours and can last up to 5 days. The intravenous dose should not exceed 8 mg. Dosage according to body weight: administered as a single dose of 0.15 mg/kg given before chemotherapy by intravenous infusion for a period of not less than 15 minutes， and the intravenous dose should not exceed 8 mg. Two additional doses can be repeat 4 and 8 hours after the first dose. Oral ondansetron can begin after 12 hours and can last up to 5 days. <= 10 kg: on day 1， up to 3 doses of 0.15 mg/kg every 4 hours. > 10 kg: on day 1， up to 3 doses of 0.15 mg/kg every 4 hours.,需調整劑量,[仿單]目前不清楚Zofran是否會進入人體乳汁。 目前並無關於Zofran影響哺乳嬰兒或Zofran影響乳汁生成的資料。 然而，已知ondansetron會進入哺乳動物(大鼠)的乳汁。 因此，建議接受ondansetron的母親不應哺育嬰兒。,無需調整劑量,可能安全,Human (and animal) data suggest risk,[仿單]卓弗蘭用於孕婦的安全性目前尚未獲得證實。在大鼠和兔子的生殖試驗中，於器官生成期間分別給予依據體表面積約相當6和24倍於人體最大建議口服劑量每天24毫克的ondansetron時，未觀察到傷害胎兒的證據。 然而，由於不一定能自動物試驗預測人體反應，不建議於懷孕期間使用ondansetron 。有關懷孕期間使用ondansetron的安全性資料有限，且取自藥物流行病學試驗的發現並不一致。 上市後報告中描述了懷孕期間使用Zofran的先天畸形病例； 然而，這些報告並不足以建立因果關係。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前不清楚Zofran是否會進入人體乳汁。 目前並無關於Zofran影響哺乳嬰兒或Zofran影響乳汁生成的資料。 然而，已知ondansetron會進入哺乳動物(大鼠)的乳汁。 因此，建議接受ondansetron的母親不應哺育嬰兒。,IM;IVD;IVPUSH;,,【D10W】可選 仿單建議。【D5W】可選 仿單建議。【IKCL2】可選 仿單建議。【IKCL5S】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,IV bolus over no less than 30 seconds， preferably over 2 to 5 minutes.,Dilute 8mg (or 16 mg) dose in 50 mL (or 100mL) of compatible solutions and infuse dose over 15 minutes.,為保持良好的製劑狀態， 靜脈輸注液應於輸注前才調配， 並保持在適當的無菌條件下。無防腐劑的ondansetron和下列靜脈輸注液混合後，放置於室溫(25℃以下)的螢光燈下或冷藏，可維持安定達7天：Sodium Chloride IV Infusion BP 0.9%w/v; Glucose IV Infusion BP 5%w/v; Mannitol IV Infusion BP 10%w/v; Ringer IV Infusion; Potassium Chloride 0.3%w/v and Sodium Chloride 0.9%w/v IV Infusion BP; Potassium Chloride 0.3%w/v and Glucose5%w/v IV Infusion BP。
EDIFF,Adapalene,Differin gel 0.1%， 15gm,TDER,Treatment of acne vulgaris.,Hypersensitivity to adapalene or any component of the formulation.,>10%: Dermatologic: Xeroderma (<=45%)， exfoliation of skin (<=44%)， erythema (<=38%)， burning sensation of skin (<=29%)， stinging of the skin (<=29%) 1% to 10%: Dermatologic: Skin abnormalities (1% to 6%; discomfort)， desquamation (2%)， pruritus (<=2%)， skin irritation (1% to 2%)， sunburn (1% to 2%) ?1%， postmarketing， and/or case reports: Acne flare， angioedema (gel)， application site pain (gel)， conjunctivitis， contact dermatitis， dermatitis， eczema， eyelid edema， facial edema (gel)， skin discoloration， skin rash (cream/gel)， swelling of lips (gel),25℃以下,Acne vulgaris Apply once daily in the evening before bedtime.,無需調整劑量,[仿單]目前對本品是否被分泌於動物或人類乳汁中也尚未知。 由於多種藥物皆可能分泌於乳汁中，因此授乳期婦女使用時應謹慎。 此產品不應使用於胸部。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,[仿單]目前尚無有關Adapalene對於孕婦的影響資訊，因此不適於婦女懷孕時使用.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前對本品是否被分泌於動物或人類乳汁中也尚未知。 由於多種藥物皆可能分泌於乳汁中，因此授乳期婦女使用時應謹慎。 此產品不應使用於胸部。,EXT;,,,,,
IHYA1,Hyaluronidase,Hyalase inj 1500IU (專案進口),ZADT,Hyaluronidase can be used to enhance permeation of subcutaneous or intramuscular injections， local anaesthetics and subcutaneous infusions and to promote resorption of excess fluids and blood in the tissues.,Hypersensitivity， malignancy. Direct application to the cornea， reduction of swelling of bites or stings. Inj into or around infected area. IV admin; unexplained premature labour.,Cardiovascular: Edema Local: Injection site reaction <1% (Limited to important or life-threatening): anaphylactic-like reactions (retrobulbar block or IV injections)， anaphylaxis， hypersensitivity reaction,小於25°C,[國外仿單](https://gp2u.com.au/static/pdf/H/HYALASE-PI.pdf) Hypodermoclysis: 1500 units dissolved in sterile distilled water 1 mL. Approximately 200mL of fluid can be administered in 20 minutes. In general， 1500 units of Hyalase are sufficient for 500-1000 mL of most fluids; 3000 units may be required for whole blood.Obstetric anesthesia: the anesthetic mixture is prepared as follows: Hyalase 1500 units; Adrenaline hydrochloride 0.5 mL of 1000 dilution; Procaine hydrochloride 1% 30 mL. The needle is passed horizontally to the ischial spine， and 5mL of the solution is deposited here to anesthetize the pudendal nerve as it enters Alcock's canal. Next， 5mL of the mixture is infiltrated in the superior portion of the labia minora to anesthetize the perineal branches of the ilioinguinal nerve. The same procedure is carried out on both sides of the perineum.Prevention of postpartum hemorrhage: 1500 units in ergometrine solution 1 mL (0.5 mg) IM into the thigh at the moment of the crowning or delivery of the fetal head. Correct timing is most important.Local anesthesia in ophthalmology: 25 units of Hyalase to each mL of anesthetic solution.Local anesthesia in fracture reduction: 1500 units mixed with 1% procaine 20 mL for Colles fracture or 40 mL for Pott's fracture. Separate into 2 injections: most of the solution injected into the fracture hematoma and 2-3 mL infiltrated around the ulnar styloid process. Manipulate the fracture after needle removal.Radiography: Pyelography: 750 units added to 5 mL of 35% diodone solution and made up to 15 mL with sterile distilled water. 15 mL subcutaneously in the scapular region and followed by another 15 mL at another site. Massage the injection area to aid dispersion.,無需調整劑量,UpToDate: Pregnancy Risk Factor C,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,UpToDate: Pregnancy Risk Factor C,IM;SC;,,,,,
ONOT,Naltrexone,Notholic 50mg,ZADT,For the blockade of the effects of exogenously administered opioids. Hotholic has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.,Concomitant use of opioid analgesics. Hypersensitivity to naltrexone hydrochloride or any component of the product. Cross-sensitivity with naloxone or phenanthrene-containing opioids is unknown. Opioid dependency， including maintenance with opiate agonists (eg， methadone) or partial agonists (eg， buprenorphine). Acute opioid withdrawal. Failure to pass a naloxone challenge test or positive opioid urine screen. Acute hepatitis or liver failure.,Common Gastrointestinal: Abdominal cramps， Abdominal pain， Nausea (10% or greater ) Musculoskeletal: Arthralgia， Myalgia Neurologic: Difficulty sleeping (opioid addiction， greater than 10% )， Headache (alcoholism， 7%; opioid addiction， greater than 10% )， Lack of energy (opioid addiction， greater than 10% ) Psychiatric: Anxiety (opioid addiction， greater than 10%; alcoholism， 2% )， Feeling nervous (opioid addiction， greater than 10%; alcoholism， 4% ) Serious Hepatic: Hepatitis， Hepatotoxicity Psychiatric: Suicidal (alcoholism， up to 1% ) Other: Opioid withdrawal,25℃以下保存,Opioid use disorder， adult: Initial: 25 mg once daily. If no withdrawal signs occur， administer 50 mg once daily thereafter. Alternative maintenance dosing schedules (have to used carfully): 50 mg orally on weekdays and 100 mg on Saturday; OR 100 mg orally every other day; OR 150 mg orally every third day. [Micromedex 2022.02.13] Alcohol dependence， Maintenance of abstinence: 50 mg orally once daily for <= 12 weeks.,無需調整劑量,[仿單]Naltrexone Hydrochloride是否分泌於人乳未知，但因多種藥物均會分泌於人乳，故本品投予哺乳婦女必須小心。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest moderate risk,[仿單]口服Naltrexone (100 mg/kg/day [600 mg/m2/day];以體表面積換算後為建議劑量的16倍）引起大鼠假孕顯著增多，雌鼠受孕率下降，但這樣的劑量並未影響雄性的生育力。這些觀察與人類生育力的相關性尚不清楚。 致畸胎性: 研究顯示在大鼠給予大於30 mg/kg/day (180 mg/m2/day；以體表面積換算後為建議劑量的5倍)，兔子大於60mg/kg/day (720 mg/m2/day；以體表面積換算後為建議劑量的18倍)的口服劑量時會增加胎兒早期流失。當給予大鼠和兔子Naltrexone口服劑量高達200 mg/kg/day (以體表面積換算後分別為建議劑量的32和65倍) 時，並沒有足夠的證據證實在主要器官生成的期間會有致畸胎性。大鼠並不會生成足夠數量的人體主要代謝物6-β-naltrexol，因此尚不清楚此代謝物對大鼠的潛在生殖毒性。 尚無針對孕婦的適當且控制良好的研究，僅在潛在效益超過對於胎兒的風險時方可用於孕婦。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]Naltrexone Hydrochloride是否分泌於人乳未知，但因多種藥物均會分泌於人乳，故本品投予哺乳婦女必須小心。,AC;AC15;PC;PO;WM;,,,,,1.使用本品前7-10天，必須先停止服用類鴉片藥品。 2.藥錠可剝半分為相等的劑量，剝半後錠劑如未使用完畢，應於25℃以下環境妥善儲存，存放超過7天之拆封後剝半錠劑請勿繼續使用。
IPNE1,Pneumococcal Vaccine Polyvalent,Pneumovax 23 (23價肺炎，台北市) 0.5mL/dose,HIMM,Immunization against pneumococcal disease caused by those pneumococcal types included in the vaccine,Hypersensitivity. Revaccination of adults with Pneumovax 23 is contraindicated except for those at highest risk of pneumococcal infections. Patients with Hodgkin's disease immunised < 7 to 10 days prior to or during immunosuppressive therapy & patients with Hodgkin's disease who have received extensive chemotherapy &/or nodal irradiation.,Local inj-site soreness， warmth， erythema & swelling. Fever， headache， malaise， rash， urticaria， arthritis， arthralgia.,2-8℃,IM or SC， 0.5mL， > or = 2 years a single dose.,無需調整劑量,[仿單]目前尚不知是否會分泌至人類乳汁，因此接種之授乳婦女需注意。,無需調整劑量,沒有資料,Compatible,[仿單]目前不知懷孕婦女接種後是否會造成胎兒的傷害或影響其生育力， 只有在明確知道必施打的情況下，孕婦才能施打。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前尚不知是否會分泌至人類乳汁，因此接種之授乳婦女需注意。,IM;,,,,,
RIAB066,Risankizumab,試ABBV-066-M15-997 (Risankizumab 75mg),HIMM,,,,,,,,,,,,,,SC;,,,,,
RENP888,NP-000888/Placebo,試NP-000888-100535 (270mcg/g or Placebo),TDER,,,,,,無需調整劑量,,無需調整劑量,,Contraindicated,,Contraindicated 哺乳期使用禁忌,,EXT;,,,,,
ILIPF,Soyean oil + MCT+ Egg Yolk Phospholipids+ Glycerol,LIPOFUNDIN 10% 500mL,NUTR,,適應症: In parenteral nutrition for energy & essential fatty acids. 副作用: Adverse reactions directly related to fat emulsions in general are of 2 types: Immediate (Acute) Reactions: Dyspnea， cyanosis， allergic reactions， hyperlipaemia， hypercoagulability， nausea， vomiting， headache， flushing， hyperthermia， sweating， chills， sleepiness， chest and back pain. Delayed Reactions: Hepatomegaly， jaundice due to central lobular cholestasis， splenomegaly， thrombocytopenia， leucopenia， transient increases in liver function tests and overloading syndrome. The deposition of a brown pigmentation in the reticuloendothelial system， the so-called "IV Fat Pigment"， has also been reported. The cause and the significance of this phenomenon are unknown. 禁忌: Disturbances in fat metabolism; ketoacidosis， hypoxia， thromboembolism & acute shock states.,,低於25°C ，不得冷凍,The normal dose is 0.7-1.5 g/kg/day. The maximum dose is 2.0 g/kg/day. It should not be exceeded even patients' energy requirements are high or fat utilization is increased (eg， tumor patients). For long-term in-home intravenous nutrition therapy (> 6 months) and patients with short bowel syndrome， the intravenous fat supply should not exceed 1.0 g/kg/day. – Pediatric patients A gradual increase in fat intake of 0.5-1.0 g/kg/day may be beneficial for plasma triglyceride levels and preventing hyperlipidemia. Premature newborns， term newborns， infants and toddlers It is recommended that the amount of fat does not exceed 3.0 (maximum 4.0) g/kg/day. For preterm neonates， full-term neonates， infants and young children， the maximum daily fat mass should be infused continuously for more than 24 hours. Children and youth It is recommended that the amount of fat does not exceed 2.0-3.0 g/kg/day.,無需調整劑量,,無需調整劑量,沒有資料,,[仿單] 以人給藥劑量進行的動物實驗沒有提供任何證據證明會影響生育和繁殖功能。 沒有專門測試致畸性，因為本藥品的成分是天然物質以及/或生理代謝的中間產物， 一般認為不具致畸性。,Unknown 沒有資料,,IVD;,,,,1.輸注速率: 輸注應當在盡可能低的輸注速率下進行。輸注最開始15分鐘的輸注速率應當僅為所用最大輸注速率的一半。 2.最大輸注速率: 成人病人: 每小時每公斤體重不大於0.15 g脂肪(1.5mL/kg/hr)。 早產新生兒、足月新生兒、嬰兒及幼兒: 每小時每公斤體重不大於0.17 g脂肪(1.7mL/kg/hr)。 兒童及青少年: 每小時每公斤體重不大於0.13 g脂肪(1.3mL/kg/hr)。,1. 若脂肪乳劑與胺基酸及碳水化合物同時輸注時，Y型或側流接合器應儘可能靠近病人端。 2. 開封後，藥品應立即使用。 3. 本品不得用作電解質濃縮液或其他藥品的溶液載體，或者在未經驗證的情況下與其它注射劑混合，因為如此就不能確保乳劑的安定性。 4. 若在脂肪乳劑給藥期間，血漿三酸甘油脂濃度超過4.6 mmol/l，建議降低輸注速率。若血漿三酸甘油脂濃度超過11.4 mmol/l，必須中止輸注。若嬰兒血漿三酸甘油脂的濃度超過2.8 mmol/l，應考慮降低劑量。若年齡較大的兒童血漿三酸甘油脂濃度超過4.5 mmol/l，應考慮降低劑量。
ECLOB1,Clobetasol propionate,Clobex Shampoo 125mL， 0.05%,TDER,Topical treatment of moderate scalp psoriasis in adults.,Hypersensitivity to clobetasol propionate， other corticosteroids， or any of the ingredients in this preparation. Avoid using in areas of the skin with bacterial， mycobacterial， viral， fungal， parasitic infections， or ulcerative lesions. Avoid using on the eyes or eyelids (as there is a risk of glaucoma and cataracts).,Burning/stinging， pruritus， edema， folliculitis， acne， dry skin， irritant dermatitis， alopecia， urticaria， skin atrophy & telangiectasia.,30℃以下。使用前及使用後請保持瓶蓋緊閉。,Scalp psoriasis (Moderate to Severe) (Shampoo) Apply topically onto dry scalp once daily in a thin film to affected areas only; leave in place 15 minutes before lathering and rinsing; maximum 50 mL/week for 2 consecutive weeks,無需調整劑量,[仿單] 全身性投予皮質類固醇會出現於人類乳汁，可能抑制嬰兒的成長，干擾嬰兒內生性皮質類固醇的製造，或造成其它不良的影響。 目前未知局部投予皮質類固醇，是否可能導致有足量的全身性吸收，因而在人類乳汁內產生可檢測數量； 由於多項藥物都可能分泌於人類乳汁，因此哺乳婦使用時應審慎。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,[仿單] 實驗動物當接受以相對較低劑量濃度全身性投予皮質類固醇時， 顯示皮質類固醇具有致畸胎作用，若干皮質類固醇於經皮施用於實驗動物也顯示具有致畸胎作用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 全身性投予皮質類固醇會出現於人類乳汁，可能抑制嬰兒的成長，干擾嬰兒內生性皮質類固醇的製造，或造成其它不良的影響。 目前未知局部投予皮質類固醇，是否可能導致有足量的全身性吸收，因而在人類乳汁內產生可檢測數量； 由於多項藥物都可能分泌於人類乳汁，因此哺乳婦使用時應審慎。,EXT;SKIN;TOPI;,,,,,
LSLI,Sodium Phosphate,SlipFeel 45mL Oral Laxative (健診專用),ALIM,Relieve occasional constipation， and bowel irrigation before surgery， X-ray， or endoscopic examination.,Congestive heart failure， kidney disease， or children aged below 5 years.,Electrolyte imbalance， acute phosphate nephropathy， rash， and itching.,25°C以下,[Laxative] Do not exceed the recommended dose within 24 hours. - Adults and children >= 12: Add 15 mL to cold drinks/water 240 mL and drink it. Drink cold drinks/water at least 240 mL. Maximum daily dose: 45 mL. - Children aged 10 to 11: Add 15 mL to cold drinks/water 240 mL and drink it. Drink cold drinks/water at least 240 mL. Maximum daily dose: 15 mL - Children aged 5 to 9: Add 7.5 mL to cold drinks/water 240 mL and drink it. Drink cold drinks/water at least 240 mL. Maximum daily dose: 7.5 mL - Children under 5 years old: Not to be used. [Bowel preparation before medical procedures] Use 30 mL or 45 mL of the medicine twice for bowel preparation， with a 10-12 hour interval between doses. - Adults and children >= 12: Add 30-45 mL to cold drinks/water 240 mL and drink it. Drink cold drinks/water at least 720 mL. - Children aged 5 to 11: Ask doctor. - Children under 5 years old: Not to be used.,無需調整劑量,[仿單]懷孕、授乳、限鈉飲食或有任何醫療狀況者，請詢問過醫師後再使用。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]懷孕、授乳、限鈉飲食或有任何醫療狀況者，請詢問過醫師後再使用。,Unknown 沒有資料,[仿單]懷孕、授乳、限鈉飲食或有任何醫療狀況者，請詢問過醫師後再使用。,AC;AC15;PC;PO;,,,,,1. 本產品不含任何糖份，每mL中含鈉111.3mg。 2. 服用後約30分鐘至6小時會排便。
IFIR,Degarelix,FIRMAGON inj 120mg/3mL,RACA,Advanced hormone-dependent prostate cancer in adult male patients.,Known hypersensitivity to degarelix or any component of the formulation; pregnant.,Hot flush， inj site reactions. Anemia; increased wt; insomnia; dizziness， headache， diarrhea， nausea; increased liver transaminases; hyperhidrosis (including night sweats)， rash， musculoskeletal pain & discomfort; gynecomastia， testicular atrophy， erectile dysfunction; chills， pyrexia， fatigue， flu-like illness.,30℃以下避免冷凍,Loading dose: 240 mg administered as two 120 mg (3 mL) injections; Maintenance dose: 80 mg administered as one 4 mL injection every 28 days (beginning 28 days after initial loading dose),無需調整劑量,,無需調整劑量,,Uknown 沒有資料,,Unknown 沒有資料,,SC;,,,X,X,• THE VIALS SHOULD NOT BE SHAKEN 1. Remove the cover from the vial adapter pack 2. Prepare the pre-filled syringe by attaching the plunger rod.
OMONT4,Montelukast,Monteka 4mg,ERSP,Prevention and long-term treatment of asthma in adults and children， including prevention of daytime and nighttime asthma symptoms， and prevention of exercise-induced bronchoconstriction. Prevention and long-term treatment of daytime and nighttime allergic rhinitis in adults and children who have previously received other anti-allergic medications but have had poor efficacy or cannot tolerate them.,Hypersensitivity to any component of the product.,Common: Abdominal pain (>=2%)， Diarrhea (Pediatric， >=2%)， Headache (Adult and adolescent， 18.4%; pediatric， >=2%)， Otitis (Pediatric， >=2%)， Otitis media (Pediatric， >=2%)， Cough (>=1%)， Nasal discharge (Pediatric， >=2%)， Pharyngitis (Pediatric， >=2%)， Sinusitis (>=1%)， Upper respiratory infection (>=1%)， Fever (Adult and adolescent， 1.5%; pediatric， >=2%)， Influenza (Adult and adolescent， 4.2%; pediatric， >=2%) Serious: Eosinophilic granulomatosis with polyangiitis， Disorientated， Disturbance of attention， Insomnia (0.7-6% )， Memory impairment， Stuttering， Tic， Tremor， Aggressive behavior， Agitation， Anxiety (0.14% )， Depression (0.15% )， Dream disorder， Hallucinations， Irritability (0.27% )， Nightmares (0.12% )， Obsessive-compulsive disorder， Restlessness (0.11% )， Sleep walking disorder， Suicidal behavior， Suicidal thoughts,30℃以下，避免潮濕及光線照射,For children aged 2-5 with asthma and/or allergic rhinitis: - Asthma: 4mg once daily at bedtime; - Seasonal or perennial allergic rhinitis: 4mg once daily in any time of the day; - Patients with both asthma and allergic rhinitis: 4mg once daily at bedtime.,無需調整劑量,[仿單]目前尚未知 Montelukast 是否會分泌入人乳中。由於許多藥物會分泌入人乳中，因此當哺 乳母親服用 Montelukast 時須特別注意。,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]Montelukast 尚未於孕婦試驗。懷孕期中，只有在確定需要之下才可使用 Montelukast。 在全球上市後使用經驗中，懷孕期間曾使用 Montelukast 的婦女其小孩有先天性肢體缺陷 的案例非常罕見。而這些婦女大多數在懷孕期間，同時也服用其他氣喘治療藥物。這些事 件與 Montelukast 之間的因果關係尚未建立。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前尚未知 Montelukast 是否會分泌入人乳中。由於許多藥物會分泌入人乳中，因此當哺 乳母親服用 Montelukast 時須特別注意。,AC;AC15;PC;PO;WM;,,,,,1.本品因含有乳糖（lactose）賦形劑，因此患有罕見遺傳性疾病如半乳糖不耐症（galactose intolerance）、Lapp 乳糖酵素缺乏症（Lapp lactase deficiency）或葡萄糖-半乳糖吸收不良（glucose-galactose malabsorption）之病患不應使用本品。
ETAFS,Tafluprost,Taflotan-S 0.0015%， 0.3mL 眼藥水(30支/盒),TOPH,Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension,Hypersensitivity to Tafluprost. Used with omidenepag isopropyl.,>10%: Ocular: Conjunctival hyperemia (4% to 20%) 1% to 10%: Central nervous system: Headache (6%) Genitourinary: Urinary tract infection (2%) Ocular: Stinging/irritation (7%)， conjunctivitis (5%)， cataract (3%)， dry eye (3%)， ocular pain (3%)， eyelash darkening (2%)， eyelash growth (2%)， vision blurred (2%) Respiratory: Common cold (4%)， cough (3%) Postmarketing and/or case reports (Limited to important or life-threatening): Dyspnea， exacerbation of asthma; macular edema (reported with prostaglandin analog use),避光2-8℃,Instill 1 drop in the affected eye(s) once daily in the evening.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
IBETA,Betamethasone,Betamethasone inj 4mg/1mL,HM,,適應症:hypersensitivity disorders， bronchial asthma， severe infection. 副作用:Fluid & salt retention， edema， hypertension; amenorrhea， hyperhidrosis; mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; visual disturbances; local atrophy; increased appetite; growth retardation. 禁忌:Hypersensitivity to any component of the formulation， peptic ulcer， osteoporosis， psychoses or severe psychoneuroses， active or quiescent TB; acute infection; live vaccines,,室溫,IV or IM: 4-12mg， qd-bid. Rheumatoid and osteoarthritis: Intra-articular: 0.4 mg to 4 mg for one dose. Dose is based upon the joint size:,無需調整劑量,,無需調整劑量,,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;IS;IVD;IVP;LI;,,【D5W】仿單建議。【N/S】仿單建議。,Slow intravenous injection over half to one minute.,1-5mL (4-20mg) daily diluted in Normal Saline or Dextrose Water.,1.點滴靜脈注射，以生理食鹽水或稀葡萄糖液稀釋注射。 2.關節腔內注射0.4∼4mg 為度，但以關節之大小度量之。 3.本產品含有防腐劑成分，不應以椎管內(intracanal)或硬脊膜外(epidural)注射給藥。
LFUM,Furosemide,Fumide solution 10mg/mL， 120mL,CAVS,Edema: Management of edema associated with heart failure and hepatic or renal disease; acute pulmonary edema. Hypertension: Management of hypertension. Note: Not recommended for the initial treatment of hypertension.,Hypersensitivity to furosemide or any component of the formulation. hepatic cirrhosis; renal failure accompanied by hepatic coma and precoma; renal failure due to poisoning with nephrotoxic or hepatotoxic substances.,Cardiovascular: Necrotizing angiitis， orthostatic hypotension， thrombophlebitis， vasculitis Central nervous system: Dizziness， headache， paresthesia， restlessness， vertigo Dermatologic: Acute generalized exanthematous pustulosis， bullous pemphigoid， erythema multiforme， exfoliative dermatitis， pruritus， skin photosensitivity， skin rash， Stevens-Johnson syndrome， toxic epidermal necrolysis， urticaria Endocrine & metabolic: Glycosuria， hyperglycemia， hyperuricemia， increased serum cholesterol， increased serum triglycerides Gastrointestinal: Abdominal cramps， anorexia， constipation， diarrhea， gastric irritation， mouth irritation， nausea， pancreatitis， vomiting Genitourinary: Bladder spasm Hematologic & oncologic: Agranulocytosis， anemia， aplastic anemia， eosinophilia， hemolytic anemia， leukopenia， purpura， thrombocytopenia Hepatic: Hepatic encephalopathy， intrahepatic cholestatic jaundice， liver enzymes increased Hypersensitivity: Anaphylaxis， anaphylactoid reaction， anaphylactic shock Immunologic: DRESS syndrome Local: Pain at injection site (following IM injection) Neuromuscular & skeletal: Muscle spasm， weakness Ophthalmic: Blurred vision， xanthopsia Otic: Deafness， tinnitus Renal: Interstitial nephritis (allergic)， renal disease Miscellaneous: Fever,25℃以下,Adult oral dosage: Edema: Initial， 20 to 80 mg/dose; if response is not adequate， may repeat the same dose or increase dose in increments of 20 to 40 mg/dose; may titrate up to 600 mg/day with severe edematous states; usual maintenance dose interval is once or twice daily. Hypertension: 40 mg twice daily; usual maintenance dose: 40-80 mg/day， divided in 1-2 doses. [Micromidex 2021/07/20] Pediatric oral dosage: Edema: Initial， 2 mg/kg orally as a single dose; may increase by 1 to 2 mg/kg no sooner than 6 to 8 hours following previous dose; titrate to minimum effective level; maximum: 6 mg/kg/dose. Hypertension: (1 year or older) Initial， 0.5 to 2 mg/kg once to twice daily; maximum: 6 mg/kg/dose.,需調整劑量,,需調整劑量,除非治療上需要,Human data suggest low risk,UpToDate: Pregnancy Risk Factor: C (above table),No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;PC;PO;,,,,,
OVIS2,Dienogest,Visanne 2mg,HM,Management of pelvic pain associated with endometriosis.,Hypersensitivity to dienogest or any component of the formulation; undiagnosed abnormal vaginal bleeding; active venous thromboembolic disorder; history of or current arterial and cardiovascular disease (eg， MI， ischemic heart disease， cerebrovascular accident); diabetes mellitus with vascular involvement; history of or current severe hepatic disease where liver function tests remain abnormal; history of or current hepatic neoplasia (benign or malignant); known or suspected sex-hormone-dependent malignancy; ocular lesions due to ophthalmic vascular disease， such as partial or complete vision loss or defect in visual fields; current or history of migraine with focal aura; breast-feeding; known or suspected pregnancy.,1% to 10%: Central nervous system: Headache (7%)， depression (3%)， disturbed sleep (2%)， irritability (1%)， migraine (1%)， nervousness (1%) Dermatologic: Acne vulgaris (2%)， alopecia (1%) Endocrine & metabolic: Breast changes (discomfort: 5%)， weight gain (4%)， ovarian cyst (3%)， decreased libido (2%) Gastrointestinal: Nausea (4%)， abdominal pain (2%) Genitourinary: Vaginal hemorrhage (1%) Neuromuscular & skeletal: Weakness (2%) <1%， postmarketing， and/or case reports: Abdominal distress， anemia， anxiety， back pain， breast induration， constipation， decreased glucose tolerance， dermatitis， diarrhea， disturbance in attention， dysautonomia， edema， feeling of heaviness (extremities)， fibrocystic breast disease， flatulence， genital discharge， GI inflammation， hot flash， increased appetite， limb pain， lump in breast， mood changes， muscle spasm， onychoclasis， ostealgia， palpitations， pelvic pain， pruritus， skin pigmentation， skin photosensitivity， tinnitus， urinary tract infection， vulvovaginal candidiasis， vomiting， vulvar dryness， xeroderma， xerophthalmia.,25℃以下,1 tablet once daily.,無需調整劑量,It is not known if dienogest is present in breast milk. Use is contraindicated in breastfeeding women. The risk of thromboembolism may be increased immediately postpartum.(UpToDate)2021/01/25,無需調整劑量,不可使用,Uknown 沒有資料,Use is contraindicated during pregnancy. Based on limited data， inadvertent exposure in pregnancy has not shown adverse effects to the fetus.(UpToDate)2021/01/25,Unknown 沒有資料,It is not known if dienogest is present in breast milk. Use is contraindicated in breastfeeding women. The risk of thromboembolism may be increased immediately postpartum.(UpToDate)2021/01/25,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為賀爾蒙用藥，勿放入磨粉機分包。若有磨粉需求請使用前自行磨粉。 Oral: Administer preferably at the same time each day with liquid and without regard to meals. Tablets should be taken continuously regardless of any vaginal bleeding. If vomiting and/or diarrhea occur within 3 to 4 hours of administration， repeat dose.
OBMZ,Bromazepam,Bromazin 3mg,CNEU,Anxiety neurosis,Narrow angle glaucoma， myasthenia gravis， hypersensitivity to bromazepam， sleep apnea syndrome， severe respiratory insufficiency， severe hepatic insufficiency.,Somnolence， dizziness， headache， ataxia， nausea， constipation， fatigue， respiratory depression.,25℃以下,Adult: Usual dose 1.5 to 3mg TID; for severe cases， 6 to 12mg BID to TID.,需調整劑量,[仿單] 因使用其他Benzodiazepine 系化合物(Diazepam) 可能導致母乳中之移行而引起新生兒之嗜眠、體重減輕、黃疸之增強，故授乳婦希勿使用，若不得不使用時，請避免授乳。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 妊娠中使用其他Benzodiazepine 系化合物之患者曾有引起畸形兒及障礙兒之病例報告，故孕婦及可能懷孕婦女務請斟酌其治療上之有益性或危險性而慎重投藥。 其他Benzodiazepine系化合物(Diazepam， Nitrazepam) 曾有導致新生兒哺乳困難，肌肉緊張減低，嗜眠及黃疸之增強等症狀之報告例，故妊娠後期之婦人務須斟酌其治療上之利害關係而慎重投藥。,Unknown 沒有資料,[仿單] 因使用其他Benzodiazepine 系化合物(Diazepam) 可能導致母乳中之移行而引起新生兒之嗜眠、體重減輕、黃疸之增強，故授乳婦希勿使用，若不得不使用時，請避免授乳。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
OGLY,Glycopyrrolate,Glycopyrodyn 1mg,ALIM,,適應症: --For use as adjunctive therapy in the treatment of peptic ulcer. --Used preoperatively to inhibit salivation and excessive secretions of the respiratory tract， reduce volume and acidity of gastric secretions， and blockade of cardiac vagal inhibitory reflexes during induction of anesthesia and intubation; used intraoperatively to counteract surgically， drug-induced， or vagal mediated bradyarrhythmias; reversal of the muscarinic effects of cholinergic agents， such as neostigmine and pyridostigmine， during reversal of neuromuscular blockade. 副作用: --Cardiovascular: Arrhythmias， cardiac arrest， flushing， heart block， hyper-/hypotension， malignant hyperthermia， pallor， palpitation， QTc-interval prolongation， tachycardia --Central nervous system: Aggressiveness， agitation， confusion， crying (abnormal)， dizziness， drowsiness， excitement， headache， insomnia， irritability， mood changes， pain ， restlessness ， nervousness， seizure --Dermatologic: Dry skin， pruritus， rash， urticaria --Endocrine & metabolic: Dehydration， lactation suppression --Gastrointestinal: Abdominal distention， abdominal pain， constipation， flatulence， retching， bloated feeling， intestinal obstruction， loss of taste， nausea， pseudo-obstructio， vomiting， xerostomia --Genitourinary: Impotence， urinary hesitancy， urinary retention， urinary tract infection --Local: Injection site reactions (edema， erythema， pain) --Neuromuscular & skeletal: Weakness --Ocular: Blurred vision， cycloplegia， mydriasis， nystagmus， ocular tension increased， photophobia， sensitivity to light increased --Respiratory: Bronchial secretion (thickening)， nasal congestion， nasal dryness， pneumonia， respiratory depression， sinusitis， upper respiratory tract infection --Miscellaneous: Anaphylactoid reactions， diaphoresis decreased， hypersensitivity reactions 禁忌:Hypersensitivity to glycopyrrolate or any component of the formulation; medical conditions that preclude use of anticholinergic medication; severe ulcerative colitis， toxic megacolon complicating ulcerative colitis， paralytic ileus， obstructive disease of GI tract (eg， pyloric stenosis)， intestinal atony in the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; narrow-angle glaucoma; acute hemorrhage; tachycardia; obstructive uropathy; myasthenia gravis,,室溫,One or two tablets three times a day.Maintenance dose: 1 mg orally twice daily to a maximum of 8 mg per day.,無需調整劑量,,無需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
IFLUV1,Purified Split Inactivated Influenza Virus,免費成人4價流感 0.5mL/dose,HIMM,Active immunisation against influenza.,Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome.,2 ~ 8 °C,IM， 0.5 mL， > or = 6 months (< 9 years who have not been vaccinated previously， the second dose can be given after 4 weeks.),無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;,,,,,
IFLUV3,Purified Split Inactivated Influenza Virus,免費小兒4價流感(>3歲) 0.5mL/dose,HIMM,Active immunisation against influenza.,Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome.,2 ~ 8 °C,Adult & Children >= 36 months 0.5mL IM Chidren(>= 3years， < 9 years who have not been vaccinated previously， the second dose can be given at an interval of at least 4 weeks.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;,,,,,
IROCU,Rocuronium Bromide,Rocuronium Kabi 50mg/5mL,CNEU,Adjunct to general anaesth to facilitate tracheal intubation， during routine & rapid sequence induction， & to provide skeletal muscle relaxation during surgery. Adjunct in ICU to facilitate intubation & mechanical ventilation.,Hypersensitivity.,Anaphylactic & anaphylactoid reactions， anaphylactic & anaphylactoid shock; flaccid paralysis; tachycardia; hypotension， circulatory collapse & shock， flushing; bronchospasm; angioneurotic edema， urticaria， rash， erythematous rash; muscular weakness， steroid myopathy; face oedema， injection site pain & reaction; airway complication of anaesth， delayed recovery from anaesth.,2-8℃,Tracheal intubation: IV bolus 0.6 mg/kg. Rapid sequence induction: 1 mg/kg. Maintenance: 0.15 mg/kg. Continuous infusion: 0.3-0.4 mg/kg/hour. Elderly patients with liver/biliary disorders or renal failure: maintenance dose 0.075-0.1 mg/kg and the infusion rate 0.3-0.4 mg/kg/hour. Intensive care unit paralysis: Initial bolus of 0.6 mg/kg. When the neuromuscular blockage begins to recover to maintain the contracture response to 10% of the control contracture height or the TOF1-2 message response appears， the infusion mode is started. The recommended infusion rate for adults within the first hour of administration is 0.3-0.6 mg/kg/hr. During the next 6-12 hours， the dose should be reduced according to the patient's condition.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,IV bolus as an adjunct to facilitate tracheal intubation.,0.3~0.4mg/kg/h (濃度：0.5 mg/mL 或 2 mg/mL ),1.Rocuronium bromide 以靜脈投藥採一次注入或連續輸注方式
LKGLU,Potassium Gluconate,K-Glu oral solution 20mEq/15mL,NUTR,Hypokalemia.,Those who are allergic to Potassium Gluconate or other ingredients of this medicine. Patients with severe kidney disease. Patients with adrenal disease (Addison's disease). Patients taking potassium-sparing diuretics.,Nausea， stomach cramps， vomiting,儲存於 25℃以下。,3 - 4 times a day， each time 15mL ， can be mixed with water or juice， and taken after meals. 1 g potassium gluconate = elemental potassium 167 mg = potassium 4.3 mEq = potassium 4.3 mmol,無需調整劑量,Because potassium freely passes into and out of milk， the use of potassium by a lactating woman with normal plasma potassium levels would have no adverse effect on a nursing infant.,無需調整劑量,,Compatible,Because high or low levels are detrimental to maternal and fetal cardiac function， serum levels should be closely monitored.,Compatible 哺乳時可使用,Because potassium freely passes into and out of milk， the use of potassium by a lactating woman with normal plasma potassium levels would have no adverse effect on a nursing infant.,AC;AC15;PC;PO;WM;,,,,,
OEPC,Sofosbuvir + Velpatasvir,Epclusa 400/100mg,QANB,Treatment of adult chronic hepatitis C virus (HCV) genotype 1， 2， 3， 4， 5 or 6 infections.,Hypersensitivity to sofosbuvir， velpatasvir， or any component of the formulation. If sofosbuvir/velpatasvir is administered with ribavirin， the contraindications to ribavirin also apply. See ribavirin manufacturer's labeling information.,>10%: Central nervous system: Headache (22%)， fatigue (15%) 1% to 10%: Central nervous system: Irritability (?5%)， insomnia (5%)， depression (1%) Dermatologic: Skin rash (2%) Gastrointestinal: Nausea (9%)， increased serum lipase (>3X ULN: 3% to 6%) Neuromuscular & skeletal: Weakness (5%)， increased creatine phosphokinase (?10X ULN: 1% to 2%) Frequency not defined: Infection: Reactivation of HBV <1%: postmarketing， and/or case reports: Angioedema,室溫藥品，仿單無特別指示儲存溫度條件,One tablet contains sofosbuvir 400 mg/velpatasvir 100 mg. One tablet once daily for 12 weeks.,無需調整劑量,Sofosbuvir: No Human Data—Probable Compatible (Potential toxicity if combined with Ribavirin) Velpatasvir: UNKNOW,需調整劑量,沒有資料,Uknown 沒有資料,Sofosbuvir: No Human Data—Animal Data Suggest Low Risk (Contraindicated if combined with Ribavirin) Velpatasvir: UNKNOW,Unknown 沒有資料,Sofosbuvir: No Human Data—Probable Compatible (Potential toxicity if combined with Ribavirin) Velpatasvir: UNKNOW,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]由於本品帶有苦味，因此建議不要將膜衣錠嚼碎或研碎使用。
INSO100,Sodium Chloride,0.9% NaCl 100mL bag(Otsuka),MSIV,Water or electrolyte replenishment.,Hypernatremic and fluid retention syndromes. Immediately following surgery.,Common Cardiovascular: Phlebitis Dermatologic: Injection site extravasation， Injection site reaction Endocrine metabolic: Hypervolemia Serious Cardiovascular: Congestive heart failure Endocrine metabolic: Hypernatremia， Overhydration Hematologic: Disseminated intravascular coagulation Respiratory: Respiratory distress,30℃以下,Individualised dosage. Sodium chloride 0.9% injection contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.,無需調整劑量,[仿單]沒有資料,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]沒有資料,Unknown 沒有資料,[仿單]沒有資料,IA;IRR;IVD;,,,,To correct acute (<48 hours) or chronic (>48 hours or duration unknown). In general， a serum sodium concentration increase of 4 to 6 mEq/L within a 24-hour period is sufficient to improve most symptoms of hyponatremia. In chronic severe hyponatremia， overcorrection risks iatrogenic osmotic demyelination syndrome. Goal of initial therapy is to increase serum sodium concentration by 4 to 6 mEq/L within the first 24 hours (maximum rate: 8 mEq/L in any 24-hour period).,0.9% Sodium chloride solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.
IACTMV,Tocilizumab,Actemra Infusion 80mg/4mL/Vial 專案(限Covid-19),HIMM,Rheumatoid Arthritis (RA); Polyarticular Juvenile Idiopathic Arthritis (pJIA); Systemic Juvenile Idiopathic Arthritis (sJIA).,Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.,Common Cardiovascular: Hypertension (Adult， 4% to 6% ) Dermatologic: Injection site reaction ( Rheumatoid arthritis， 2.4% to 10.1% ; polyarticular juvenile idiopathic arthritis， 28.8% ; systemic juvenile idiopathic arthritis， 41.2% )， Rash (Rheumatoid arthritis， 2% to 4% ) Gastrointestinal: Diarrhea (Pediatric， greater than 5% )， Upper abdominal pain (Adult， 2% to 3% ) Hepatic: ALT/SGPT level raised (Rheumatoid arthritis， 0.7% to 48%; polyarticular or systemic juvenile idiopathic arthritis， 4% to 13% )， Aspartate aminotransferase serum level raised (Rheumatoid arthritis， 0.1% to 41%; polyarticular or systemic juvenile idiopathic arthritis， less than 1% to 5% ) Neurologic: Dizziness (Adult， 2% to 3% )， Headache (Adults， 5% to 7%; pediatric， greater than 5% ) Respiratory: Nasopharyngitis (Rheumatoid arthritis， 4% to 7%; systemic juvenile idiopathic arthritis， 5% or higher ) Other: Infusion reaction (Rheumatoid arthritis， 7% to 8%; polyarticular juvenile idiopathic arthritis， 16% to 20.2% ) Serious Gastrointestinal: Gastrointestinal perforation， Pancreatitis Hematologic: Decreased platelet count (1% to 4% )， Neutropenia (Rheumatoid arthritis， 1.8% to 3.7% ; polyarticular or systemic juvenile idiopathic arthritis， 7% to 15.4% ) Hepatic: Hepatotoxicity Immunologic: Anaphylaxis， Hypersensitivity reaction (Up to 0.9% )， Opportunistic infection， Tuberculosis Respiratory: Upper respiratory infection (Rheumatoid arthritis， 6% to 8%; systemic juvenile idiopathic arthritis， 5% or higher ) Other: Cancer， Severe infectious disease,2-8℃，請勿冷凍,TFDA新型冠狀病毒（SARS-CoV-2）感染臨床處置暫行指引第十一版: 與dexamethasone合併用於嚴重肺炎以上(未使用吸氧治療下SpO2=<94%、需使用吸氧治療、高流量氧氣或非侵襲性呼吸器、使用機械式呼吸器或ECMO)之病患；或與dexamethasone + remdesivir 合併用於未使用吸氧治療下SpO2=<94%、需使用吸氧治療、高流量氧氣或非侵襲性呼吸器之病患。病患住院3天內，且入住ICU 24小時內或未入住ICU但發炎指數上升(CRP>=7.5 mg/dL) 。劑量：8mg/kg，單次靜脈注射，至多800mg [Micromedex 20210623] COVID-19 (Severe) - Pneumonia 8 mg/kg (actual body weight) as single IV dose， Maximum dose 800 mg; give in combination with dexamethasone 6 mg IV or orally daily for up to 10 days or another corticosteroid at an equivalent dose (guideline dosage),無需調整劑量,[仿單]目前並無任何關於tocilizumab是否會出於人類乳汁、本藥對哺母乳之嬰兒的影響、或本藥對乳汁生成作用之影響等方面的資料。 母體的免疫球蛋G(lgG)會出現於人類的乳汁中。如果tocilizumab會轉移進入人類的乳汁，目前仍不確知tocilizumab在嬰兒胃腸道中的局部暴露及可能有限的全身暴會造成何種影響。 由於缺乏授乳期間的臨床資料，目前並無法確定在授乳間使用 Actemra對嬰兒所帶來的風險； 因此，應將餵哺母乳對發育與健康的好處和母親對 Actemra的臨床需求，以及或母親的基礎疾病對餵哺母乳之嬰兒的可能不良影響放在一起考慮。,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]目前關於用於孕婦的有限資料尚不足以確是否有會引發重大出生缺陷及流產的藥物相關風險？ 單株抗體如tocilizumab在第3孕期會透過主動運輸通過胎盤，並可能會影響出生前暴露於藥物之嬰兒的免疫反應。 在動物生殖研究中，於馬來猴在器官生成過程中靜脈注射投予tocilizumab，會導致流產/胚胎-胎兒的死亡，其劑量相當於人類最高建議劑量的1.25倍（含）以上。 動物試驗文獻指出，IL-6傳訊作用受到抑制可能會干擾子宮頸的成熟與擴張，以及子宮平滑肌的收縮活性，可能有使胎兒受到影響的風險。目前並不確知本品之適用族群發生重大出生缺陷與流產的估計背景風險。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並無任何關於tocilizumab是否會出於人類乳汁、本藥對哺母乳之嬰兒的影響、或本藥對乳汁生成作用之影響等方面的資料。 母體的免疫球蛋G(lgG)會出現於人類的乳汁中。如果tocilizumab會轉移進入人類的乳汁，目前仍不確知tocilizumab在嬰兒胃腸道中的局部暴露及可能有限的全身暴會造成何種影響。 由於缺乏授乳期間的臨床資料，目前並無法確定在授乳間使用 Actemra對嬰兒所帶來的風險； 因此，應將餵哺母乳對發育與健康的好處和母親對 Actemra的臨床需求，以及或母親的基礎疾病對餵哺母乳之嬰兒的可能不良影響放在一起考慮。,IVD;,,【H/S】可選 仿單建議。【N/S】可選 仿單建議。,,30公斤以下病患:以50mL 0.9%或0.45%氯化鈉注射液稀釋。 30公斤以上病患:以100mL 0.9%或0.45%氯化鈉注射液稀釋。 稀釋時請輕輕倒置使藥劑混合，避免產生泡沫。輸注時間應超過60分鐘,本藥以0.9%氯化鈉注射液稀釋後置於2-8°C或室溫可保存24小時。以0.45%氯化鈉注射液稀釋後置於2-8°C可保存24小時或室溫可保存4小時。儲存時應避光。
OBENT,Dicyclomine,Bentyl 10mg,ALIM,Diseases associated with smooth muscle spasm (diseases of gastrointestinal spasm， gallbladder， bile duct spasm， and ureteral spasm).,Age less than 6 months. Benign prostatic hyperplasia， urinary retention， pyloric stenosis. Use with caution in glaucoma patients.,Common Gastrointestinal: Nausea (14% )， Xerostomia (33% ) Neurologic: Asthenia (7% )， Dizziness (40% )， Feeling nervous (6% )， Somnolence (9% ) Ophthalmic: Blurred vision (27% ) Serious Cardiovascular: Syncope Dermatologic: Diminished sweating Gastrointestinal: Paralytic ileus， Perforation of intestine， Primary chronic pseudo-obstruction of colon， Toxic dilatation of intestine， Toxic megacolon Immunologic: Anaphylaxis Musculoskeletal: Poor muscle tone Neurologic: Coma， Seizure Psychiatric: Psychotic disorder Respiratory: Apnea， Dyspnea， Respiratory arrest， Respiratory depression Other: Angioedema,30℃以下,Adult: 10-20mg TID-QID.,無需調整劑量,[仿單]未有相關記載。 [Micromedex 20220803]Breastfeeding is contraindications.,無需調整劑量,可能安全,Compatible,[仿單]FDA Pregnancy category(懷孕用藥級數):B。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]未有相關記載。 [Micromedex 20220803]Breastfeeding is contraindications.,AC;AC15;PC;PO;WM;,,,,,
EMENL,Calamine + Zinc oxide,Menphencala lotion 100mL,TDER,Symptomatic relief of skin irritation & nappy rash.,Hypersensitivity to any component of the formulation,Local irritation,25℃以下,Skin protectant: Topical: Apply to affected area as often as needed.,無需調整劑量,[仿單]無建議,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]無建議,Unknown 沒有資料,[仿單]無建議,EXT;,,,,,
ISTE9,Ustekinumab,STELARA inj 90mg/1mL,TDER,Treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Treatment of adult patients with active psoriatic arthritis. Can be used alone or in combination with methotrexate (MTX). Treatment of adult patients with moderately to severely active Crohn’s disease. Treatment of adult patients with moderately to severely active ulcerative colitis.,patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients. Clinically important， active infection .,Common Dermatologic: Erythema at injection site (1% to 5% )， Pruritus (1% to 4% ) Gastrointestinal: Abdominal pain (7% )， Diarrhea (2% to 4% )， Nausea (3% )， Vomiting (4% ) Neurologic: Headache (5% to 10% ) Renal: Urinary tract infectious disease (4% ) Reproductive: Mycosis (Crohn disease， 5% ) Respiratory: Bronchitis (5% )， Nasopharyngitis (7% to 24% )， Sinusitis (3% to 4% )， Upper respiratory infection (4% to 5% ) Other: Fatigue (3% to 4% )， Fever (5% )， Infectious disease (Psoriasis， 27% to 72.3% ) Serious Dermatologic: Skin cancer， Non-melanoma (Up to 1.5% ) Gastrointestinal: Diverticulitis (Less than 1% ) Immunologic: Anaphylaxis (Crohn disease， 0.1% )， Hypersensitivity reaction (Crohn disease， 0.08% ) Neurologic: Posterior reversible encephalopathy syndrome Ophthalmic: Herpes zoster with ophthalmic complication (Less than 1% ) Respiratory: Cryptogenic organizing pneumonia， Interstitial pneumonia， Pulmonary eosinophilia Other: Angioedema， Cancer (Up to 1.7% )， Infectious disease， Serious (Up to 2.8% ),2-8°C儲存且需避光，切勿冷凍與振搖,Plaque psoriasis (Moderate to Severe) (100 kg or less) 45 mg SC initially and 4 weeks later， followed by 45 mg every 12 weeks (Greater than 100 kg) 90 mg SC initially and 4 weeks later， followed by 90 mg every 12 weeks Psoriatic arthritis 45 mg SC initially and 4 weeks later， followed by 45 mg SC every 12 weeks Coexistent moderate to severe plaque psoriasis and weight greater than 100 kg， 90 mg SC initially and 4 weeks later， followed by 90 mg SC every 12 weeks Crohn's disease & Ulcerative colitis (Moderate to Severe) (55 kg or less) Induction， 260 mg (two 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance， 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 55 kg to 85 kg) Induction， 390 mg (three 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance， 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 85 kg) Induction， 520 mg (four 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance， 90 mg SC every 8 weeks beginning 8 weeks after induction dose,無需調整劑量,[仿單]應將餵哺母乳對發育與健康的好處和母親對STELARAR的臨床需求，以及STELARAR或母親的基礎疾病對餵哺母乳之嬰兒的任何可能不良影響放在一起考慮。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]目前並無任何關於ustekinumab是否會出現於人 乳汁、對餵哺母乳之嬰兒的影響、或對乳汁生成作用之影響方面的資料。 Ustekinumab會出現於投予ustekinumab之泌乳母猴的乳汁中。由於在泌乳生理學方面有具物種特異性的差異，因此，動物試驗的資料可能無法可靠地預測人類乳汁中的藥物含量。母體的IgG已知會出現於人類的乳汁。已發表的資料顯示，餵哺母乳之嬰兒的全身暴露量預期應該很低，因為ustekinumab是大分子，並且在胃腸道中會降解。然而，如果ustekinumab會轉移進入人類的乳汁，目前並不確知胃腸道中的局部暴露會造成何種影響。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]應將餵哺母乳對發育與健康的好處和母親對STELARAR的臨床需求，以及STELARAR或母親的基礎疾病對餵哺母乳之嬰兒的任何可能不良影響放在一起考慮。,SC;,,,,,1.建議每次注射都應施打於和上次不同部位，不可注入皮膚有觸痛、瘀傷、紅斑或硬化現象的區域。 2.需冷藏貯存於2-8°C。勿冷凍。勿振搖。若貯存於高達30°C，最長達單次30天。一旦已被貯存於室溫下，勿將其放回冰箱貯存，如果沒有在30天內使用請丟棄。
IMIT3,Mitomycin C,Mitonco inj 10mg,RACA,Relief of gastric cancer， bladder cancer (Intravesical therapy)， lung cancer， sarcoma， leukemia， and other symptoms.,History of hypersensitivity or idiosyncratic reaction to mitomycin.,Common Gastrointestinal: Abdominal pain (Pyelocalyceal instillation， 28% )， Inflammatory disease of mucous membrane (20% to 40% )， Loss of appetite， Nausea (Pyelocalyceal instillation， 25% )， Nausea and vomiting (100% )， Vomiting (Pyelocalyceal instillation， 20% ) Ophthalmic: Blebitis， Cataract， Disorder of cornea， Endophthalmitis， Hyphema， Hypotony of eye， Leaking filtering bleb， Retinal hemorrhage， Thrombosis of retinal vein Renal: Dysuria (Pyelocalyceal instillation， 23% )， Flank pain (Pyelocalyceal instillation， 41% )， Hematuria (Pyelocalyceal instillation， 34% )， Renal impairment (Pyelocalyceal instillation， 25% )， Urinary tract infectious disease (Pyelocalyceal instillation， 34% ) Other: Fatigue (Pyelocalyceal instillation， 27% )， Fever (Pyelocalyceal instillation， 13% ) Serious Dermatologic: Cellulitis Hematologic: Disseminated intravascular coagulation， Myelosuppression (64.4% )， Neutropenia， Grade 3 (1.4% )， Thrombocytopenia， Grade 3 (4.2% ) Renal: Hemolytic uremic syndrome， Occlusion of ureter (Pyelocalyceal instillation， 58% ),於25℃以下陰涼處。,Bladder cancer (Intravesical therapy) for prevention of relapse: once a day or every other day， inject Mitomycin C 4-10mg into the bladder. For treatment: once a day， inject Mitomycin-C 10-40 mg into the bladder. The dosage could be increased or decreased according to age and symptoms.,無需調整劑量,[仿單]產後授乳婦女時應停止授乳，因有關的安全性尚待確立。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest high risk,[仿單]Mitomycin-C 不推薦使用於懷孕或可能懷孕的婦女。動物(小鼠)實驗顯示此藥會造成畸形胎，如胎兒生長抑制、顎裂、尾部發育不全、頜骨發育不全、缺趾等。,Hold Breast Feeding 暫停哺乳,[仿單]產後授乳婦女時應停止授乳，因有關的安全性尚待確立。,IA;IP;IPLE;IRR;IVD;,每2mg (力價)Mitomycin C用5mL Normal Saline加以溶解。,【N/S】可選 仿單建議。,,(1) 靜脈注射可能會引起血管痛、靜脈炎、血栓等，因此對注射部位，注射方法等須十分注意，注射速度應緩慢。 (2) 靜脈注射而藥液漏出血管外時，可能會引起注射部位之硬結、壞死等，因此應小心注射，使藥液不漏出血管外。 (3) 因動脈注射可能導致動脈周圍皮膚異常，如疼痛、發紅、紅斑、水泡、糜爛、潰瘍等皮膚疾病，甚至引起皮膚、肌肉壞死。如出現這種症狀時，應立即中止投與，做適當處置。,1. 本品開封、調劑後儲存於原包裝25℃以下環境，可存放24 小時。 2. Mitomycin C的藥效可能因溶解液的pH 值太低而減弱，藥液製成後儘快使用，避免與低pH值的注射液混合。 3. 注射液之調製法: 每2mg (力價)Mitomycin C用5mL Normal Saline加以溶解。
ORIF5,Rifampicin,Rifampicin 300mg (立汎黴素),QANB,TB & meningococcal carriers.,Jaundice. Hypersensitivity to rifampicin.,Skin reactions; GI discomfort; hepatitis; thrombopenia; flu-syndrome; reddish discoloration of urine， sputum & tears; stains soft contact lenses.,25℃以下乾燥避光,Neisseria meningitidis carrier: Adult: 600 mg QD for 4 days. >=5 years old: 10-20 mg/kg QD for 4 days. Tuberculosis: Adult: 600 mg QD. >=5 years old: 10-20 mg/kg QD for 4 days. Elders & weak patient: 10 mg/kg QD. Maximum: 600 mg/day. May use 1.8g/day in some types of infections.,無需調整劑量,[仿單]對於授乳婦女之投與，應權衡其治療上之有益性及危險性後慎重投與.,需調整劑量,不可使用,Compatible,[仿單]動物實驗中有催畸作用之報告，對於孕婦及可能懷孕之婦女不要投與.,Compatible 哺乳時可使用,[仿單]對於授乳婦女之投與，應權衡其治療上之有益性及危險性後慎重投與.,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥膠囊內藥粉易汙染磨粉分包機，請自行磨粉。
ELOC5,Amorolfine,Loceryl nail 5%， 3mL,TDER,,適應症: Topical treatment of onychomycosis caused by dermatophytes， yeasts and moulds. 副作用:In exceptional cases， a slight， transient periungual burning sensation was observed after the application of the nail lacquer. 禁忌: Patients who have shown hypersensitivity to any ingredient of Loceryl.,,室溫,Apply Loceryl Nail Lacquer to the affected nails at a dosage of 1 to 2 applications weekly.,無需調整劑量,[仿單]將懷孕母兔暴露於體內高劑量amorolfine會造成胚胎再吸收(胚胎毒性)輕微增加。 由於使用Loceryl 趾(指)甲油劑之後，amorolfine的體內含量極低， 因此對於人類胎兒的風險應可忽略。 然而由於缺乏治療懷孕和哺乳母親之臨床經驗，因此本油劑應避免用於孕期和 哺乳期期間。,無需調整劑量,沒有資料,,[仿單]將懷孕母兔暴露於體內高劑量amorolfine會造成胚胎再吸收(胚胎毒性)輕微增加。 由於使用Loceryl 趾(指)甲油劑之後，amorolfine的體內含量極低， 因此對於人類胎兒的風險應可忽略。 然而由於缺乏治療懷孕和哺乳母親之臨床經驗，因此本油劑應避免用於孕期和 哺乳期期間。,Unknown 沒有資料,[仿單]將懷孕母兔暴露於體內高劑量amorolfine會造成胚胎再吸收(胚胎毒性)輕微增加。 由於使用Loceryl 趾(指)甲油劑之後，amorolfine的體內含量極低， 因此對於人類胎兒的風險應可忽略。 然而由於缺乏治療懷孕和哺乳母親之臨床經驗，因此本油劑應避免用於孕期和 哺乳期期間。,EXT;,,,,,
OOFE,Nintedanib,Ofev 150mg,RACA,Idiopathic pulmonary fibrosis (IPF)， progressive pulmonary fibrosis， systemic sclerosis-associated interstitial lung disease.,Hypersensitivity to nintedanib， peanut or soya. Pregnancy & lactation.,Diarrhoea， nausea， abdominal pain; increased hepatic enzyme. Decreased wt & appetite; epistaxis; vomiting; increased alanine aminotransferase (ALT)， aspartate aminotransferase (AST) & γ-glutamyl transferase (GGT).,25℃以下，避免暴露於高度潮濕與過熱的場所,150 mg orally every 12 hours (maximum: 300 mg/day)Administer with food. Swallow capsules whole with liquid; do not chew or crush.,需調整劑量,,無需調整劑量,不可使用,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,[磨粉/管灌註記]本藥為軟膠囊應整粒吞服，切勿咬嚼或壓碎。另本藥味道極苦，且無咬嚼或壓碎軟膠囊的相關藥動學資料。
OENZI,Amantadine,Enzil 100mg,CNEU,,適應症: Parkinsonism of various origin， senile Parkinsonism， residual symptoms & discomfort after stereotactic operations. 副作用: Occasional dry mouth; dizziness. Paranoid exogenous psychoses associated with visual hallucinations， visual disturbances; motor or mental restlessness， urinary retention in the case of prostatic hypertrophy， signs of cardiac insufficiency， cardiac dysrhythmia associated with tachycardia， nausea， sleep disturbances， orthostatic dysregulation; very rarely， myoclonus & symptoms of peripheral neuropathy; livedo reticularis (marble skin) & lower-leg & ankle oedema are common occurrences; very rarely， increased photosensitivity; very rarely haematological side effects， such as leukopenia & thrombocytopenia; very rarely， anaphylactic reactions after infusion therapy. Cardiovascular: Orthostatic hypotension (1% to 5% )， Peripheral edema (1% to 5% ) Gastrointestinal: Constipation (1% to 5% )， Diarrhea (1% to 5% )， Loss of appetite (1% to 5% )， Nausea (5% to 10% )， Xerostomia (1% to 5% ) Neurologic: Ataxia (1% to 5% )， Confusion (1% to 5% )， Dizziness (5% to 10% )， Headache (1% to 5% )， Insomnia (5% to 10% )， Somnolence (1% to 5% ) Psychiatric: Agitation (1% to 5% )， Anxiety (1% to 5% )， Depression (1% to 5% )， Dream disorder (1% to 5% )， Feeling nervous (1% to 5% )， Hallucinations (1% to 5% )， Irritability (1% to 5% ) Other: Fatigue (1% to 5% ) 禁忌: Severe CHF (NYHA class IV)， cardiomyopathies & myocarditis， 2nd or 3rd degree AV block， existing bradycardia under 55 beats/min， known prolonged QT interval (Bazett QTc > 420 ms) or discernible U-waves or congenital QT syndrome in the family anamnesis ， history of serious ventricular arrhythmias including torsade de pointes， simultaneous treatment with budipine or other drugs that prolong the QT interval， reduced levels of potassium or magnesium in the blood. Pregnancy & lactation.,,室溫,Adult:100 mg/day for the first 5-7 days， followed by a once-weekly increase in daily dose of 100 mg until the maintenance dose is reached. Usual effective dose: 200-600 mg/day. child(1-9yr): 4-8mg/kg/day， maxium daily dose:150mg.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IFRA5,Dalteparin,Fragmin inj 5000 IU/0.2mL single dose syringe,HEMT,Treatment of acute deep venous thrombosis. Deep venous thrombosis， In medical patients with severely restricted mobility due to acute illness; Prophylaxis. Postoperative deep vein thrombosis; Prophylaxis - Total replacement of hip. Venous thromboembolism， Symptomatic.,Active major bleeding. History of heparin-induced thrombocytopenia with or without thrombosis. Hypersensitivity to dalteparin sodium， heparin， or pork products. In patients undergoing epidural or neuraxial anesthesia do not administer dalteparin for unstable angina， non-Q-wave myocardial infarction， or prolonged VTE prophylaxis.,Common Dermatologic: Contusion (12% )， Hematoma， Injection site (7% to 35%)， Injection site bruising (30% )， Injection site pain (4.5% to 12% ) Respiratory: Bleeding from nose (10% ) Other: Irritation symptom， Local Serious Hematologic: Extradural intracranial hematoma， Hematoma， Spinal， Hemorrhage， Major (Up to 13.6%)， Hemorrhagic cerebral infarction (8% )， Intracranial hemorrhage， Subdural hemorrhage， Intrauterine， Thrombocytopenia (Adult， non-cancer indications， less than 1%; patients with cancer， 10.9% to 13.6% ; pediatric， 21% ) Hepatic: Increased liver function test (up to 4.3%) Immunologic: Anaphylactoid reaction (rare) Neurologic: Paralysis,25℃以下,Prophylaxis of venous thromboembolism during surgical procedures: Usually: 2500 IU given 2 hours before the procedure followed by 2500 IU once daily for 5-7 days or until the patient is fully ambulant. High-risk patients: 2500 IU given 2 hours before and 8-12 hours after the procedure， and followed by 5000 IU daily for 5-10 days. Or 5000 IU single dose in the evening before the procedure， and followed by 5000 IU every evening 5-10 days. Orthopedic surgery (for example， hip replacement surgery): up to 5 weeks. 5000 IU given in the evening before surgery followed by 5000 IU each subsequent evening. Or 2500 IU given 2 hours before and 8-12 hours after the procedure， and followed by 5000 IU daily. Or 2500 IU 4-8 hours after the procedure， and followed by 5000 IU daily. Venous thromboembolism Initial， 200 IU/kg every 24 hours for the first 30 days， followed by 150 IU/kg(= or <56kg: 7500 IU; 57-68kg:10000 IU; 69-82kg: 12500 IU; 83-98kg: 15000 IU; > or =99kg: 18000 IU) every 24 hours during months 2 to 6; Maximum daily dose， 18000 IU/day. Deep venous thrombosis， In medical patients with severely restricted mobility due to acute illness; Prophylaxis 5000 IU once daily for 12 to 14 days.,無需調整劑量,[仿單]關於dalteparin是否會分泌到人類乳汁中的資料有限。 一項研究在15名接受dalteparin為預防性治療之授乳婦乳汁中偵測到少量的抗Xa因子活性，相當於乳汁/血漿比值<0.025至0.224。 低分子量肝素的口服吸收極低，因此這種少量的抗凝血活性對吃母奶嬰兒的臨床意義不明(如果的話)。,需調整劑量,沒有資料,Compatible,[仿單]若在懷孕期間使用dalteparin，對胎兒造成傷害的可能性極小： 然而因為不能完全排除傷害可能性，所以懷孕期間不該使用dalteparin，只有在顯著需要時方可使用。 在大量的孕婦使用資料中(超過1000個以上的曝藥後結果)，並未發現任何致畸性或胎兒/新生兒毒性。 如果臨床狀況需要，dalteparin sodium亦可於懷孕期間使用。目前已有超過2，000個於懷孕期間投予dalteparin的已發表病例(研究、系列病例研究與個例報告)。 報告指出，和UFH相比較，不僅出血傾向較低，發生骨質疏鬆性骨折的風險也有降低的現象。在最大型的前瞻性研究「於妊娠期間介入治療的血栓預防效果(EThIG)研究」中，一共收錄了810位孕婦，並探討每天投予介於50至150 IU/公斤體重(個別病例最高達200 IU/公斤體重)之dalteparin的孕婦特有風險分層體系(低度、高度、極高度的VTE 風險)。 不過，在對孕婦使用低分子量肝素方面，目前只有相當有限的隨機對照研究。動物試驗並未發現dalteparin具有任何致畸性或胎兒毒性。接受高劑量抗凝血劑治療之婦女在分娩時絕對不可使用硬腦膜外麻醉。 在治療出血風險較高的病人(如周產期婦女)時，建議應謹慎。懷孕婦女在妊娠第三期所測得之dalteparin抗Xa因子半衰期為4至5小時。 曾有對裝置人工心臟瓣膜之孕婦使用完整抗凝血劑量之低分子量肝素但治療失敗的報告。目前尚未充分研究過dalteparin用於裝置人工心臟瓣膜之孕婦的結果。,Compatible 哺乳時可使用,[仿單]關於dalteparin是否會分泌到人類乳汁中的資料有限。 一項研究在15名接受dalteparin為預防性治療之授乳婦乳汁中偵測到少量的抗Xa因子活性，相當於乳汁/血漿比值<0.025至0.224。 低分子量肝素的口服吸收極低，因此這種少量的抗凝血活性對吃母奶嬰兒的臨床意義不明(如果的話)。,SC;,,,,,本注射液可與裝於玻璃或塑膠容器中的生理食鹽水溶液(0.9% NaCl)或等張葡萄糖溶液(5%) 混合。
OMCL,Phenprobamate,Mocolax 400mg,CNEU,Relief of muscle tension such as muscle spasm and muscle stiffness.,Hypersensitivity to any components of the product.,Drowsiness， dizziness， headache， loss of strength， fatigue， nausea， vomiting， loss of appetite， diarrhea， constipation， stomachache.,25℃以下儲存,400mg BID-TID.,無需調整劑量,[仿單]懷孕中之服用及因還沒確定對於乳兒、小兒之安全性，所以對於孕婦或有可能懷孕之婦人，及乳兒、小兒僅在被判斷於治療上之有益性比危險性還大時才服用。又希望授乳中婦人不要服用。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]懷孕中之服用及因還沒確定對於乳兒、小兒之安全性，所以對於孕婦或有可能懷孕之婦人，及乳兒、小兒僅在被判斷於治療上之有益性比危險性還大時才服用。又希望授乳中婦人不要服用。,Unknown 沒有資料,[仿單]懷孕中之服用及因還沒確定對於乳兒、小兒之安全性，所以對於孕婦或有可能懷孕之婦人，及乳兒、小兒僅在被判斷於治療上之有益性比危險性還大時才服用。又希望授乳中婦人不要服用。,AC;AC15;PC;PO;WM;,,,,,
OBRIN,Vortioxetine,BrinteLLIX 10mg(敏特思),CNEU,Major depressive disorder.,Hypersensitivity (eg， angioedema) to vortioxetine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 21 days of discontinuing vortioxetine or within 14 days of discontinuing the MAO inhibitor); initiation of vortioxetine in a patient receiving linezolid or intravenous methylene blue.,>10%: Central nervous system: Female sexual disorder (1% to 2%; Arizona Sexual Experiences Scale: 22% to 34%)， male sexual disorder (3% to 5%; Arizona Sexual Experiences Scale: 16% to 29%). Gastrointestinal: Nausea (21% to 32%) 1% to 10%: Central nervous system: Dizziness (8% to 9%)， abnormal dreams (2% to 3%). Dermatologic: Pruritus (2% to 3%). Gastrointestinal: Diarrhea (7% to 10%)， xerostomia (7% to 8%)， constipation (5% to 6%)， vomiting (3% to 6%)， flatulence (2% to 3%). Frequency not defined: Cardiovascular: Flushing. Central nervous system: Suicidal ideation， suicidal tendencies， vertigo. Gastrointestinal: Dysgeusia， dyspepsia <1%， postmarketing， and/or case reports: Acute pancreatitis， anaphylaxis， angle-closure glaucoma， hypersensitivity reaction， hypomania， hyponatremia， mania， seizure， serotonin syndrome， skin rash， urticaria， weight gain， withdrawal syndrome,30℃以下儲存,Adults: Initial: 10 mg once daily; dosage range:5-20mg/day Elderly， > or = 65 years old: 5mg QD， dose of more than 10mg should be treated with caution. Children and teenagers (< 18 years old): No data,無需調整劑量,[仿單]動物試驗顯示，vortioxetine及其代謝產物會排泄至乳汁中。因此預期vortioxetine會被排泄至母乳中。不能排除對於餵食母乳幼兒的風險。須考量幼兒餵食母乳與對女性病人之醫療效益，決定是否中斷餵食母乳或停用/戒斷Brintellix治療。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]孕婦使用vortioxetine僅有有限臨床資料。動物研究已顯示生殖毒性。若在懷孕後期使用血清素作用藥物時，新生兒可能會出現以下症狀：呼吸窘迫、發紺、呼吸中止、痙攣、體溫不穩、餵食困難、嘔吐、血糖過低、高張力、低張力、反射亢進、顫抖、震顫、易怒、昏睡、哭鬧不停、嗜睡、和難以入睡。這些症狀可能是因戒斷反應或是過多血清素作用所引起。於大多數的案例中，上述症狀會在生產後立即或很快地(<24小時)出現。流行病學的資料顯示出在懷孕期間使用SSRI，尤其是在後期，可能會增加新生兒持續性肺動脈高血壓症(Persistent pulmonary hypertension in the new born， PPHN)的風險。雖然沒有研究報告指出vortioxetine治療與PPHN的關聯性，當考量相關的作用機轉(增加血清素濃度)時，無法排除此項的潛在風險。Brintellix應在潛在利益高於胎兒潛在風險時，方可於懷孕期間使用。觀察性數據已證明，懷孕婦女在生產前的一個月內暴露於SSRI或SNRI後，產後出血的風險增加(小於2倍)。雖然尚未研究調查vortioxetine治療和產後出血之間的關聯，但考慮到相關的作用機轉，其仍存在潛在風險。,Unknown 沒有資料,[仿單]動物試驗顯示，vortioxetine及其代謝產物會排泄至乳汁中。因此預期vortioxetine會被排泄至母乳中。不能排除對於餵食母乳幼兒的風險。須考量幼兒餵食母乳與對女性病人之醫療效益，決定是否中斷餵食母乳或停用/戒斷Brintellix治療。,AC;AC15;PC;PO;WM;,,,,,
ISKY,Risankizumab,Skyrizi 75mg/0.83mL pre-filled syringe,HIMM,Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.,Specific contraindications have not been determined,Common Dermatologic: Injection site reaction (1.5% )， Tinea (1.1% ) Immunologic: Antibody development (24%% ) Neurologic: Headache (3.5% ) Respiratory: Upper respiratory infection (13% ) Other: Fatigue (2.5% ) Serious Immunologic: Infectious disease (22.1% )， Tuberculosis,2-8°C避免冷凍,SC， 150 mg at week 0 and week 4， followed by every 12 weeks.,無需調整劑量,尚無資料顯示 risankizumab 是否會分泌至人類的乳汁，對接受哺乳的嬰兒有何影響， 或對母乳分泌的作用。雖然人類 IgG 會分泌進入乳汁，但已發表資料顯示， 乳汁中的抗體不會大量進入新生兒和嬰兒的循環系統。 應考慮哺乳對嬰幼兒的益處及使用 risankizumab 對婦女的益處決定是否停止使用 risankizumab。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]喜開悅用於懷孕女性的資料有限，不足以推導得知任何藥物相關風險。在一項綜合探討胚胎-胎兒發育與出生前後發育毒性研究中，對懷孕的食蟹猴自妊娠第20天起至生產期間每週皮下注射一次5或50mg/kg 劑量之risankizumab，並追蹤食蟹猴(母體和幼體) 至產後6個月(180天)。 未觀察到母體毒性或致畸作用。在仔猴的生長和發育，神經行為發育，以及免疫發育功能方面皆未發現與risankizumab相關的影響。然而，與對照組相比(19%)，在接受risankizumab的組別中，胎兒/仔猴死亡率呈現劑量依賴性增加(5mg/kg/week 及50mg/kg/week 分別為 32%及 43%)。 發生在 50mg/kg/week 劑量組的胎兒/仔猴死亡被認為可能與risankizumab相關，因此，不造成任何不良反應的劑量(NOAEL)訂為 5mg/kg/week(約為2倍MRHD，以mg/kg 為比較基礎)。在仔猴中，平均血清濃度以劑量相關方式增加，且約為對應母體濃度的17~86%。在生產後，risankizumab治療組的大部分成年雌性獼猴和所有仔猴，可在產後長達91天內測得血清risankizumab濃度。血清濃度在產後180天低於可檢測濃度。 有生育能力女性應在治療期間到治療後至少 21 週，使用有效避孕方法。,Unknown 沒有資料,尚無資料顯示 risankizumab 是否會分泌至人類的乳汁，對接受哺乳的嬰兒有何影響， 或對母乳分泌的作用。雖然人類 IgG 會分泌進入乳汁，但已發表資料顯示， 乳汁中的抗體不會大量進入新生兒和嬰兒的循環系統。 應考慮哺乳對嬰幼兒的益處及使用 risankizumab 對婦女的益處決定是否停止使用 risankizumab。,SC;,,,,,儲存在 2-8°C的冰箱內。不可冷凍保存。 預充填式注射器請存放於外盒包裝中，且須避光儲存。 請勿搖晃注射器。 注射前 15 至 30 分鐘將外盒從冰箱取出，並放在室溫下避開直射陽光處。 請勿以其他任何方式加熱藥物。請勿注射到相同位置。 請勿注射到疼痛、瘀青、發紅、硬化、有瘢痕或有妊娠紋的皮膚內。 請勿注射到受乾癬影響的部位。
ROVEM,Tenofovir alafenamide,試Vemlidy 25mg (臨床試驗),QANB,,,,,Adutl: 25 mg orally once daily.,需調整劑量,,需調整劑量,,,,,,PC;PO;WM;,,,,,
EDYM,Azelastine + Fluticasone,Dymista 137/50mcg/dose，120dose nasal spray,TENT,Symptomatic treatment of moderate to severe allergic rhinitis & rhinoconjunctivitis in adults and children > or = 6 years-old.,Hypersensitivity to azelastine & fluticasone.,Headache， dysgeusia， epistaxis.,室溫30°C以下，勿冷凍或冷藏,1 spray in each nostril BID (morning & evening).,無需調整劑量,AZELASTINE of BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible FLUTICASONE Respiratory of BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible [仿單節錄]目前還沒有關於azelastine hydrochloride或fluticasone propionate是否會分泌到哺乳婦女的乳汁對哺乳嬰兒、或對乳汁生成的影響之數據資料.應在哺乳婦女使用本藥的期間，應監測哺乳嬰兒對乳汁的排斥現象.Fluticasone propionat會分泌到大鼠乳汁中，其他皮質類固醇也曾在人類母乳汁中被檢測到.然而，經鼻腔吸入治療劑量後，血漿中fluticasone propionate的濃度很低，因此人類母乳汁中fluticasone propionate濃度也相應得更低.哺餵母乳所帶來的發育和健康益處，與母親在臨床上需要使用本藥以及本藥對哺乳嬰兒造成的任何可能不利影響，應同時一併考慮.應監測使用本藥治療的哺乳婦女之哺乳嬰兒對母乳排斥的現象，此現象可能與azelastine hydrochloride造成母乳的苦味有關.,無需調整劑量,沒有資料,Uknown 沒有資料,AZELASTINE of PREGNANCY RECOMMENDATION: No Human Data—Animal Data Suggest Low Risk FLUTICASONE Respiratory of PREGNANCY RECOMMENDATION: Compatible [仿單節錄]Dymista上市後有限的孕婦使用資料顯示，未發現任何與Dymista相關的流產(miscarriage)、先天性缺陷(birth defects)或其他有害母體或胎兒之風險；而Dymista內含之各別成分已上市數十年. 雖然在妊娠期使用fluticasone propionate鼻腔製劑的相關數據資料有限，但臨床研究數據資料顯示，使用吸入性fluticasone propionate並未顯示出有害母體或胎兒結果的風險增加. 目前Dymista動物生殖研究仍不可得，然而現在已經有針對Dymista的各別單方成分：azelastine hydrochloride和fluticasone propionate進行之研究.在動物生殖研究中，當投予口服azelastine hydrochloride 約10倍每日臨床劑量時，未有證據顯示azelastine hydrochloride會對動物胎兒造成傷害；在器官形成期間(organogenesis)，以口服途徑在懷孕鼷鼠、大鼠和兔子投予azelastine hydrochloride 530倍及更高於人類每日最高建議吸入劑量(maximum recommended human daily intranasal dose， MRHDID)0.548mg時，會產生發育毒性，包括結構異常(structural abnormalities)、胚胎-胎兒存活率(embryo-fetal survival)降低和胎兒體重減輕情形發生；然而，基於動物劑量轉換至人類劑量的倍數相當高，這些動物進行研究發現與人類孕婦之間的關聯性依然存疑. 在動物生殖研究中，大鼠由鼻腔吸入fluticasone propionate足以產生母體毒性之劑量(以mcg/m2為計算基準，小於人類每日最高建議吸入劑量時)，會造成胎兒體重減輕，但並不會誘發畸胎(teratogenicity).以皮下(subcutaneously)途徑投與大鼠、鼷鼠和兔子fluticasone propionate足以產生母體毒性之劑量(以mcg/m2為計算基準，小於人類每日最高建議吸入劑量200 mcg時)，可觀察到胎兒畸形，此為皮質類固醇(corticosteroids)之特性、胎兒體重減輕和／或骨骼變異(請參閱數據資料).依據皮質類固醇的使用經驗，囓齒類動物(rodents)比人類更容易受到皮質類固醇的畸胎作用(teratogenic effects)影響.特定族群的主要先天性缺陷和流產之估計背景風險值(estimated background risk)仍不清楚. 懷孕都會有先天性缺陷、流產或其他不良後果之背景風險，以美國一般群眾來說，在臨床上認可的懷孕情況下，主要先天性缺陷和流產的估計背景風險值分別為2-4％和15-20％.,Unknown 沒有資料,AZELASTINE of BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible FLUTICASONE Respiratory of BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible [仿單節錄]目前還沒有關於azelastine hydrochloride或fluticasone propionate是否會分泌到哺乳婦女的乳汁對哺乳嬰兒、或對乳汁生成的影響之數據資料.應在哺乳婦女使用本藥的期間，應監測哺乳嬰兒對乳汁的排斥現象.Fluticasone propionat會分泌到大鼠乳汁中，其他皮質類固醇也曾在人類母乳汁中被檢測到.然而，經鼻腔吸入治療劑量後，血漿中fluticasone propionate的濃度很低，因此人類母乳汁中fluticasone propionate濃度也相應得更低.哺餵母乳所帶來的發育和健康益處，與母親在臨床上需要使用本藥以及本藥對哺乳嬰兒造成的任何可能不利影響，應同時一併考慮.應監測使用本藥治療的哺乳婦女之哺乳嬰兒對母乳排斥的現象，此現象可能與azelastine hydrochloride造成母乳的苦味有關.,IN;,,,,,
OAGT,Acamprosate,Alglutol 333mg delayed-release,ZADT,Alcohol dependence， Maintenance of abstinence.,Hypersensitivity to acamprosate calcium or any of its components. Severe renal impairment (CrCl of 30 mL/min or less). Hypercalcemia (avoided long-term using this drug in patients with hypercalcemia).,Common Dermatologic: Pruritus (4% ) Gastrointestinal: Diarrhea (10% to 17% )， Flatulence (3% )， Nausea (4% ) Neurologic: Dizziness (3% )， Insomnia (7% ) Psychiatric: Anxiety (6% )， Depression (5% ) Serious Cardiovascular: Cardiomyopathy， Deep thrombophlebitis， Heart failure， Mesenteric arterial occlusion， acute， Shock Psychiatric: Suicidal intent (1% ),儲存於25℃的溫度下。,Alcoholism， maintenance of abstinence: 666 mg orally 3 times daily.,需調整劑量,[仿單]在動物研究中，口服Acamprosate calcium之哺乳大鼠的乳汁會分泌出Acamprosate，其乳汁與血液中含有的Acamprosate濃度比例為1.3:1。目前未知人體母乳是否會分泌出Acamprosate。不建議於戒酒妥腸溶錠治療期間哺乳。,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest high risk,[仿單]懷孕用藥分級為C級。目前尚未針對孕婦進行適當與控制良好的研究。僅在服用戒酒妥腸溶錠的潛在益處大於對胎兒的潛在風險時，才能在懷孕期間使用戒酒妥腸溶錠。具生育力之女性於戒酒妥腸溶錠治療期間及服用最後一劑之後一週內，應避免懷孕。 致畸胎作用：研究顯示，投予大鼠大約相當於人體劑量（以每平方公尺之毫克數計算）的Acamprosate calcium，以及將大約相當於人體劑量3倍（以每平方公尺之毫克數計算）之劑量投予兔子時，會出現致畸胎作用。大鼠口服Acamprosate calcium每日每公斤300毫克以上時 [以每平方公尺之毫克數計算，大約相當於人體每日建議最大(MRHD)口服劑量]，會增加劑量相關的畸胎數目，畸形症狀包括腎水腫、虹膜畸形、視網膜發育不良及食道後方鎖骨下動脈變異。口服劑量為每日每公斤50毫克時（以每平方公尺之毫克數計算，大約為五分之一的MRHD口服劑量），並未觀察到異常現象。當勃根地黃褐兔(Burgundy Tawny rabbits)之口服劑量為每日每公斤400毫克以上時 (以每平方公尺之毫克數計算，大約為3倍的MRHD口服劑量)，可發現腎水腫發生率增加。紐西蘭白兔(New Zealand white rabbits)之口服劑量最高達每日每公斤1000毫克時 (以每平方公尺之毫克數計算，大約為8倍的MRHD口服劑量)，未觀察到影響發育的情形。動物實驗的結果應與已知的乙醇對發育的不良影響有關，此類影響包括胎兒酒精症候群（顱顏畸形、子宮內和出生後發育遲緩、精神運動與智力發展遲緩）以及在人體發生之較輕微形式的神經與行為障礙。 非致畸胎作用：在一項針對懷孕母鼠進行之研究中，自孕期第15天起，至產後第28天哺乳期結束期間，以口服方式投予Acamprosate calcium給母鼠，當劑量為每日每公斤960毫克以上時（以每平方公尺之毫克數計算，大約為2倍的MRHD口服劑量)，會增加死胎發生率。當劑量為每日每公斤320毫克時（以每平方公尺之毫克數計算，大約為二分之一的MRHD口服劑量），未觀察到異常影響。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]在動物研究中，口服Acamprosate calcium之哺乳大鼠的乳汁會分泌出Acamprosate，其乳汁與血液中含有的Acamprosate濃度比例為1.3:1。目前未知人體母乳是否會分泌出Acamprosate。不建議於戒酒妥腸溶錠治療期間哺乳。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為腸溶錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。
ESOO,Ivermectin,Soolantra cream 1%， 15gm (專案進口),TDER,,適應症: Rosacea (Soolantra cream): Treatment of inflammatory lesions of rosacea in adult patients. 副作用: 1% to 10%: Central nervous system: Localized burning (<=1%) Dermatologic: Skin irritation (<=1%) <1% (Limited to important or life-threatening): Conjunctivitis， eye irritation， ocular hyperemia， seborrheic dermatitis of scalp， xeroderma 禁忌:Hypersensitivity (rare).,,室溫,Apply to each affected area (eg， forehead， chin， nose， each cheek) once daily.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OFLU2,Fluoxetine,Fluronin 20mg,CNEU,,適應症:Treatment of major depressive disorder (MDD); treatment of binge-eating and vomiting in patients with moderate-to-severe bulimia nervosa; obsessive-compulsive disorder (OCD); premenstrual dysphoric disorder (PMDD); panic disorder with or without agoraphobia; in combination with olanzapine for treatment-resistant or bipolar I depression. 副作用: >10%: Central nervous system: Insomnia (10% to 33%)， headache (21%)， drowsiness (5% to 17%)， anxiety (6% to 15%)， nervousness (8% to 14%)， yawning (?11%) Endocrine & metabolic: Decreased libido (1% to 11%) Gastrointestinal: Nausea (12% to 29%)， diarrhea (8% to 18%)， anorexia (4% to 17%)， xerostomia (4% to 12%) Neuromuscular & skeletal: Weakness (9% to 21%)， tremor (3% to 13%) Respiratory: Pharyngitis (10% to 11%) 其他小於10%副作用發生率，可參考UpToDate http://www.uptodate.com/contents/fluoxetine-drug-information?Source=search_result&search=Fluoxetine&selectedTitle=1%7E150#F172761 禁忌:Hypersensitivity to fluoxetine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently， within 5 weeks of discontinuing fluoxetine， or within 2 weeks of discontinuing the MAO inhibitor); initiation of fluoxetine in a patient receiving linezolid or intravenous methylene blue; use with pimozide or thioridazine (Note: Thioridazine should not be initiated until 5 weeks after the discontinuation of fluoxetine),,室溫,Depression， obsessive-compulsive disorder: Oral: 20 mg/day in the morning; may increase after several weeks by 20 mg/day increments; maximum: 80 mg/day. Bulimia nervosa: Oral: 60 mg/day; may titrate dose to 60 mg over several days.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ICHE,Labetalol,Chenday inj 25mg/5mL,CAVS,,適應症: Hypertension: Treatment of mild-to-severe hypertension; IV for severe hypertension (eg， hypertensive emergencies) 副作用: >10%: Cardiovascular: Orthostatic hypotension (intravenous: <58%) Central nervous system: Dizziness (1% to 20%)， fatigue (1% to 11%) Gastrointestinal: Nausea (<19%) 1% to 10%: Cardiovascular: Hypotension， edema， flushing， ventricular arrhythmia (intravenous: 1%) Central nervous system: Paresthesia， drowsiness， headache， vertigo Dermatologic: Tingling of the scalp， diaphoresis， pruritus， skin rash Gastrointestinal: Dyspepsia， vomiting， dysgeusia Genitourinary: Ejaculatory failure， impotence Hepatic: Increased serum transaminases Neuromuscular & skeletal: Weakness Ophthalmic: Visual disturbance Renal: Increased blood urea nitrogen Respiratory: Nasal congestion， dyspnea <1% (Limited to important or life-threatening): Anaphylactoid reaction， angioedema， bradycardia， bronchospasm， cardiac failure， cholestatic jaundice， diabetes insipidus， heart block， hepatic necrosis， hepatitis， hypersensitivity reaction， Peyronie's disease， positive ANA titer， psoriasiform eruption， Raynaud's phenomenon， syncope， systemic lupus erythematosus， toxic myopathy， transient alopecia， urinary retention， urticaria 禁忌:Hypersensitivity to labetalol or any component of the formulation; severe bradycardia; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; bronchial asthma; uncompensated cardiac failure; conditions associated with severe and prolonged hypotension.,,,Severe hypertension including hypertension in pregnancy， anesth when a hypotensive technique is indicated， hypertensive episodes following acute MI Adult Bolus inj 50 mg IV for at least 1 min. If necessary， 50 mg may be repeated at 5-mins intervals until a satisfactory response occurs. Max: 200 mg. IV infusion Dilute 8 amp to 200 mL with NaCl & dextrose inj or 5% dextrose IV infusion. Hypertension of pregnancy Start infusion at 20 mg/hr & doubled every 30 mins until a satisfactory response is obtained or 160 mg/hr is reached. Hypertensive episodes after acute MI Start infusion at 15 mg/hr & gradually increased to a max of 120 mg/hr. Hypertension due to other causes Rate of infusion: 2 mg/min. Dose range: 50-200 mg. Hypotensive anesth Initially 10-20 mg IV.,需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 。【N/S】可選 。,輸注速率 <10 mg/min,Continuous IV infusion: Initial: 0.5 to 2 mg/minute. Some patients may require doses within the range of 2 to 10 mg/minute. Usual Infusion Concentrations: Adult IV infusion: 200 mg in 200 mL (concentration: 1 mg/mL) or 500 mg in 250 mL (concentration: 2 mg/mL) of D5W. Usual Infusion Concentrations: Pediatric IV infusion: 1 mg/mL,do not mix with 5% sodium bicarbonate
IACTM,Tocilizumab,Actemra inj 162mg/0.9mL,HIMM,Moderate to severe active RA in adult patients， given alone or in combination w/ methotrexate (MTX) &/or other DMARDs.,Hypersensitivity to tocilizumab.,Upper resp tract infections， cellulitis， oral herpes simplex， herpes zoster; abdominal pain， mouth ulceration， gastritis; rash， pruritus， urticaria; headache， dizziness; increased hepatic transaminases， increased wt; HTN; leucopenia， neutropenia; hypercholesterolaemia; peripheral oedema， hypersensitivity reaction， inj site reaction; cough， dyspnoea; conjunctivitis.,2-8℃，請勿冷凍,SC， rheumatoid arthritis， giant cell arteritis: <100 kg 162 mg once every other week， increase to 162 mg once a week based on clinical response; > or =100 kg 162 mg once a week.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,
ORIFI,Rifampicin + Isoniazid,RifiNAH 300/150mg (二合一),QANB,,適應症: Treatment of all forms of TB. 副作用:Skin reactions， GI intolerance; hepatitis; thrombocytopenia; 'flu syndrome'; red discoloration of urine， sputum， tears， staining contact lenses; polyneuritis. Rarely， agranulocytosis， hemolytic anemia， convulsions; acute renal failure. 禁忌: Hypersensitivity. Jaundice.,,室溫,Rifinah 300 Patient >= 50 kg 2 cap. Other anti-TB drugs may be given concurrently until the susceptibility of the infecting organism to rifampicin & INH has been confirmed. Should be taken on an empty stomach: Take at least 0.5 hr before or 2 hr after meals.,需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,體重大於50公斤時：每日一次2顆 Rifinah 300mg
IINV,Paliperidone,Invega inj 100mg (=156mg),CNEU,Acute & maintenance treatment of schizophrenia in adults.,Hypersensitivity to paliperidone or risperidone.,Cerebrovascular events including stroke. Neuroleptic malignant syndrome， QT prolongation， tardive dyskinesia， hyperglycemia & DM， wt gain， hyperprolactinemia. Orthostatic hypotension & syncope. Leukopenia， neutropenia & agranulocytosis. Cognitive & motor impairment. Seizures， dysphagia， suicide， priapism， TTP. Disruption of body temp regulation. Antiemetic effect. Inj site reactions， somnolence/sedation， dizziness， akathisia & extrapyramidal disorder.,30℃以下,Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point. Maintenance: Following the 1-week initiation regimen， adjust the dose based on response and tolerability and begin a maintenance dose of 78 to 234 mg every month administered in either the deltoid or gluteal muscle (the 39 mg dose was not studied in schizoaffective disorder trials). The monthly maintenance dose may be administered 7 days before or after the monthly time point.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;,,,,,
IVAR2,Varicella Virus Vaccine,Varivax (水痘疫苗，政府提供) 0.5mL/dose,HIMM,Active immunisation against varicella of healthy infants from 12 months onwards， susceptible high-risk patients & their susceptible healthy close contacts.,Pregnancy. Acute febrile illness. Total lymphocyte count < 1200/mm3. Hypersensitivity to neomycin.,Fever. Occasionally， papulovesicular eruptions.,2-8℃避光,SC， 0.5 mL， 12 months-12 years 2 doses administered 3 months apart. > or = 13 years 2 doses administered 4-8 weeks apart.,無需調整劑量,[仿單]目前尚不確知是否會分泌至乳汁，由於已知有些病毒會進入人類乳汁， 因此接種之哺乳婦女須特別注意。,無需調整劑量,不可使用,Contraindicated,[仿單]目前未知懷孕婦女接種是否會對胎兒造成影響， 因此懷孕婦女不應接種，且應避免於接種後三個月內懷孕。,Compatible 哺乳時可使用,[仿單]目前尚不確知是否會分泌至乳汁，由於已知有些病毒會進入人類乳汁， 因此接種之哺乳婦女須特別注意。,SC;,使用廠商所附稀釋溶液,,,,1. Varilrix與含有麻疹成分的疫苗應間隔至少一個月以上。
IDYN,Parecoxib,Dynastat inj 40mg,CNEU,Short-term treatment of post-op pain.,Hypersensitivity to parecoxib or sulfonamides. Active peptic ulceration or GI bleeding， inflammatory bowel disease， CHF (NYHA II-IV)， severe hepatic dysfunction (serum albumin <25 g/L or Child-Pugh score >=10). Patients who have experienced asthma， urticaria or allergic-type reactions to aspirin or NSAIDs including selective COX-2 inhibitors. Treatment of post-op pain immediately following CABG surgery. Established ischemic heart disease， peripheral arterial disease &/or cerebrovascular disease. Pregnancy (3rd trimester) & lactation.,Nausea. Abdominal pain， constipation， dyspepsia， vomiting; peripheral edema; alveolar osteitis (dry socket); dizziness; insomnia; oliguria; increased sweating， pruritis; hypotension.,30℃以下,Adults: Initial dose: 40mg IV/IM， followed by 20mg Q12H or Q24H. IM: Slowly inject into the deep part of the muscle. The current clinical experience with Dynastat for more than three days is limited. Because the cardiovascular risk of the second type cyclooxygenase-2 (COX-2) specific inhibitor may increase with the increase of the dose， try to shorten the treatment period and use the lowest effective dose. Elders: >=65 years old: Generally do not need to adjust the dose. <50kg: The initial dose should be half of the general recommended dose. maximum dose:40mg/day. Children and teenagers: Not recommended.,需調整劑量,以上懷孕及哺乳分級禁忌使用為仿單建議。,需調整劑量,不可使用,Uknown 沒有資料,[20201124非類固醇消炎藥品安全資訊風險溝通表] 懷孕20週以上孕婦使用NSAIDs可能會導致胎兒腎功能障礙並導致羊水過少； 妊娠30週以上之孕婦可能導致胎兒動脈導管過早閉合的風險。,Unknown 沒有資料,以上懷孕及哺乳分級禁忌使用為仿單建議。,IM;IVP;IVPUSH;,IM: 2 mL N/S，D5W IV: 2mL N/S， D5W,,如採靜脈注射，可直接迅速地注入靜脈. (Intravenous parecoxib has been given as a bolus over at least 15 seconds[Micromedex 20220822]),本藥無IVD用法相關建議。,1.剝除parecoxib 40毫克小瓶的紫色易拉蓋。 2.用無菌注射針與針筒抽取2公撮適當的溶劑，將溶劑注入40毫克小瓶內。 3.輕輕旋轉小瓶，使粉末溶解，調配完成後的注射液應為澄清溶液。 4.注射前，應目視檢查Dynastat注射液是否變色或有不溶物質，注射液一旦變色、渾濁或有不溶物質，則不得使用 5.調配完成之Dynastat注射液應立即，否則應予以丟棄。 6.調配完成的溶液是等張溶液。
OAPA,Mifepristone,Apano 200mg (RU486),HM,,適應症:Termination of pregnancy (?49 days). 副作用:Uterine bleeding and cramps， chills， fever， malaise， dizziness， headache， diarrhoea， nausea， vomiting， urticaria， rash; hypokalaemia， GI disturbances， decreased appetite， drowsiness， fatigue， dyspnoea， anxiety， peripheral oedema， HTN， arthralgia， myalgia， back pain， endometrial thickening， cystic dilatation of endometrial glands， adrenal insufficiency， prolonged QT interval. 禁忌:Termination of pregnancy: Confirmed or suspected ectopic pregnancy， undiagnosed adnexal mass， chronic adrenal failure， porphyria， haemorrhagic disorder. Concurrent anticoagulant therapy. Cushing’s syndrome: Women w/ history of vag bleeding， endometrial hyperplasia w/ atypia or endometrial carcinoma. Pregnancy. Concomitant use w/ lovastatin， simvastatin and CYP3A4 substrates w/ narrow therapeutic range. Concurrent long-term corticosteroid use for serious medical conditions.,,室溫,Termination of pregnancy Adult: 600 mg as a single dose， followed by a prostaglandin (either misoprostol 400 mcg orally or gemeprost 1 mg vaginally) 36-48 hr later. Alternatively， 200 mg as a single dose， followed by gemeprost 1 mg vaginally 36-48 hr later.,需調整劑量,,需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;,,,,,
ONUS,Hyoscyamine,Nuspas 0.125mg,ALIM,Control gastric secretion， visceral spasm & hypermotility in spastic colitis， spastic bladder， cystitis， pylorospasm & associated abdominal cramps,Glaucoma， obstructive uropathy， GI obstruction， paralytic ileus， severe ulcerative colitis， myasthenia gravis.,Dry mouth， urinary hesitancy & retention， blur vision， tachycardia.,25℃以下,Adult & children > 12 years : 1-2 TAB 4 hourly or once when needed . Maximum: 12 TAB/day. Children 2-12 years: 0.5 -1 TAB 4 hourly or once when needed.Maximum: 6 TAB/day.,無需調整劑量,1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) No reports describing the use of hyoscyamine during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. Hyoscyamine is excreted into breast milk in trace amounts [35]. It is not known if hyoscyamine affects the quantity and composition of breastmilk. Until more data is available， use caution when considering the use of hyoscyamine in lactating women.,無需調整劑量,除非治療上需要,No (limited) human data – no relevant animal data,MicroMedex: 1) U.S. Food and Drug Administration's Pregnancy Category: Category C (All Trimesters) a) Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus. 2) Australian Drug Evaluation Committee's (ADEC) Category: B2 a) Drugs which have been taken by only a limited number of pregnant women and women of childbearing age， without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals are inadequate or may be lacking， but available data show no evidence of an increased occurrence of fetal damage. 3) Crosses Placenta: Unknown 4) Clinical Management a) There has not been sufficient clinical experience to establish the safety of hyoscyamine in general during pregnancy， and no published reports of its use in pregnancy have been located. If possible， the use of hyoscyamine in pregnancy should be avoided.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) No reports describing the use of hyoscyamine during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. Hyoscyamine is excreted into breast milk in trace amounts [35]. It is not known if hyoscyamine affects the quantity and composition of breastmilk. Until more data is available， use caution when considering the use of hyoscyamine in lactating women.,AC;P;P1;P2;P3;P4;PC;PO;,,,,,
ORIB,Amisulpride,Ribelite 200mg,CNEU,Treatment of psychoses， particularly acute or chronic schizophrenic disorders， characterized by +ve symptoms (e.g. delirium， hallucinations， thought disorders) &/or -ve symptoms (eg blunted emotions， emotional & social withdrawal)， including when the -ve symptoms predominate.,Known or suspected pheochromocytoma carriers. Children < 15 years. Lactation. Known or suspected prolactin-dependent tumour， eg prolactin-secreting pituitary adenoma & breast cancer. Severe renal insufficiency. Congenital galactosemia， glucose or galactose malabsorption syndrome or lactase deficiency (due to lactose content). In combination with sultopride; dopaminergic agonists except L-dopa (amantadine， apomorphine， bromocriptine， cabergoline， entacapone， lisuride， pergolide， piribedil， pramipexole， quinagolide， ropinirole， selegiline)， except in the case of patients with Parkinson's disease.,Insomnia， anxiety， agitation， extrapyramidal symptoms; galactorrhea， amenorrhea， gynecomastia， swollen breasts， impotence， frigidity， weight gain; GI disturbances. Occasionally， daytime drowsiness.,25℃以下,<=400 mg daily dose， single intake. >400 mg， in 2 divided doses. Predominant negative episode 50-300 mg/day as individualized dosage. Optimum dosage: 100 mg/day. Mixed episodes with positive & negative symptoms 400-800 mg/day as individualized dosage to maintain min effective dose. Acute psychotic episodes: Initiate with maximum 400 mg/day IM， replaced thereafter with 400-800 mg orally， maximum dosage: 1200 mg. Renal insufficiency CrCl 30-60 mL/min: reduce dose to 1/2. CrCl 10-30 mL/min: reduce dose to 1/3.,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
EACZ,Benzoyl Peroxide,Aczo gel 50mg/gm， 10gm,TDER,Treatment of acne vulgaris.,Hypersensitivity.,Dry skin， erythema， skin exfoliation and burning sensation， pruritus， irritation， allergic contact dermatitis， swelling face,25℃以下保存,Acne vulgaris Adult， children >= 12 years old， initialy 1 time/day. Increased to 2-3 time/day when needed.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
ICOVNVV,SARS-CoV-2 Spike glycoprotein,COVID-19 Vaccine Novavax 0.5mL/dose (5mL/vial),HIMM,COVID-19 Vaccine is indicated for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).,History of a severe allergic reaction after a previous dose or to a component of the formulation; history of immediate allergic reaction to a previous dose; known allergy to any component of the formulation.,erythema at injection site， pain at injection site， and swelling at injection site. asthenia， fatigue， fever， headache， myalgia， and nausea.,2-8℃避光避免冷凍,IM， 0.5 mL， > or = 18 years 2 doses administered > or = 3 weeks apart.,無需調整劑量,[仿單]目前尚未知 Nuvaxovid 是否會分泌至人類乳汁中。 預期對哺乳新生兒／嬰兒無影響，因為哺乳女性的 Nuvaxovid 全身性暴露量很低而可忽略。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]目前對懷孕女性接種 Nuvaxovid 的經驗有限。動物試驗並未顯示對懷孕、胚胎／胎兒發育、分娩或出生後發育有直接或間接的有害影響。 僅於對母體和胎兒的潛在益處遠高於潛在風險時，才應考慮讓懷孕女性接種 Nuvaxovid。,Unknown 沒有資料,[仿單]目前尚未知 Nuvaxovid 是否會分泌至人類乳汁中。 預期對哺乳新生兒／嬰兒無影響，因為哺乳女性的 Nuvaxovid 全身性暴露量很低而可忽略。,IM;,,,,,1.未開封藥瓶，在2-8°C避光可保存6個月，25°C下可穩定保存最多12 小時。開封後的藥瓶，已證實疫苗的化學和物理特性在2-25°C具6小時的使用安定性。請勿冷凍。 2.每一劑(0.5 毫升)內含 5 微克SARS-CoV-2棘蛋白以及佐劑Matrix-M｛含石鹼木 (Quillaja saponaria Molina)之萃取A (42.5微克)和萃取C (7.5微克)｝。
ITRU0,Rituximab,Truxima inj 500mg/50mL (sample),RACA,The treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL): Relapsed or refractory， low-grade or follicular， CD20-positive B-cell NHL as a single agent; OR Previously untreated follicular， CD20-positive， B-cell NHL in combination with first-line chemotherapy and， in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy， as single-agent maintenance therapy; OR Non-progressing (including stable disease)， low-grade， CD20-positive， B-cell NHL as a single agent after first-line cyclophosphamide， vincristine， and prednisone (CVP) chemotherapy. Chronic lymphoid leukemia: In combination for first-line treatment; OR in combination with fludarabine and cyclophosphamide; OR maintenance， following rituximab-containing chemotherapy. Granulomatosis with polyangiitis or Microscopic polyangiitis: In combination with glucocorticoids,Hypersensitivity to rituximab and any excipients or proteins in this product.,Common Dermatologic: Pruritus (10% to 14% ) Gastrointestinal: Nausea (23% ) Hematologic: Anemia， All Grades (8% to 35% )， Lymphocytopenia， All Grades (48% ) Neurologic: Asthenia (26% )， Headache (19% ) Other: Fever (53% )， Shivering (33% ) Serious Cardiovascular: Cardiogenic shock， Hypotension (10% )， Myocardial infarction， Ventricular fibrillation Dermatologic: Lichen simplex chronicus， Pemphigus paraneoplastica， Stevens-Johnson syndrome， Toxic epidermal necrolysis Gastrointestinal: Gastrointestinal perforation Hematologic: Anemia， Grade 3 or 4 (3% )， Leukopenia， Grade 3 or 4 (4% )， Lymphocytopenia， Grade 3 or 4 (40% )， Neutropenia， Grade 3 or 4 (4% to 6% )， Pancytopenia， Grade 3 or 4， Thrombocytopenia， Grade 3 or 4 (2%) Hepatic: Reactivation of hepatitis B viral hepatitis Neurologic: Progressive multifocal leukoencephalopathy Renal: Nephrotoxicity Respiratory: Bronchospasm (8% )， Pulmonary toxicity (18% ) Other: Angioedema (11% )， Infectious disease (19% to 37% )， Infusion reaction (Equal to or greater than 25% )， Tumor lysis syndrome,冷藏2-8°C保存。切勿冷凍。,Recommended Dose for Non-Hodgkin’s Lymphoma (NHL): The recommended dose is 375 mg/m2. Relapsed or Refractory， Low-Grade or Follicular， CD20-Positive， B-Cell NHL: Administer once weekly for 4 or 8 doses. Retreatment for Relapsed or Refractory， Low-Grade or Follicular， CD20Positive， B-Cell NHL: Administer once weekly for 4 doses. Previously Untreated， Follicular， CD20-Positive， B-Cell NHL: Administer on Day 1 of each cycle of chemotherapy， for up to 8 doses. In patients with complete or partial response， initiate TRUXIMA maintenance eight weeks following completion of a rituximab product in combination with chemotherapy. Administer TRUXIMA as a single-agent every 8 weeks for 12 doses. Non-progressing， Low-Grade， CD20-Positive， B-Cell NHL， after first-line CVP chemotherapy: Following completion of 6-8 cycles of CVP chemotherapy， administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses. First Infusion: Initiate infusion at a rate of 50 mg/hour. In the absence of infusion toxicity， increase infusion rate by 50 mg/hr increments every 30 minutes， to a maximum of 400 mg/hour. Subsequent Infusions: Standard Infusion: Initiate infusion at a rate of 100 mg/hour. In the absence of infusion toxicity， increase rate by 100 mg/hour increments at 30-minute intervals， to a maximum of 400 mg/hour. Chronic lymphocytic leukemia: 375 mg/m2 on the day prior to fludarabine/cyclophosphamide in cycle 1， then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 (in combination with fludarabine and cyclophosphamide). Granulomatosis with polyangiitis or microscopic polyangiitis:Induction therapy: 375 mg/m2 once weekly for 4 doses or 1 g once every 2 weeks for 2 doses; for either dosing regimen， administer in combination with a systemic glucocorticoid.,無需調整劑量,[仿單]Rituximab是否分泌於母乳中尚未得知。然而，既然母體的免疫球蛋白IgG會進入母乳中，不應給予授乳婦女TRUXIMAR。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]已知免疫球蛋白IgG會穿過胎盤屏障。 目前並未曾在原開發廠藥品之臨床試驗中研究過母體接觸過rituximab之人類新生兒體內的B細胞濃度。目前尚無足夠 且控制良好的孕婦研究資料，不過，在懷孕期間接觸過rituximab之母親所生下的嬰兒中，曾有一些發生暫時性B細胞 耗竭及淋巴球減少症的報告。因此不可對孕婦投予TRUXIMA，除非可能的效益超過潛在的風險。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Rituximab是否分泌於母乳中尚未得知。然而，既然母體的免疫球蛋白IgG會進入母乳中，不應給予授乳婦女TRUXIMAR。,IVD;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,不可以靜脈推注,以無菌操作方式取出所需藥量，注入0.9% NaCl或Dextrose 5%之輸注液中，稀釋後濃度需為Rituximab 1-4mg/mL。輕輕倒轉輸注袋混合溶液，避免產生泡沫。給予注射藥品之前，應目視檢查是否有顆粒物質及變色。,1.已調配之Truxima輸注液的物理及化學穩定性可在2 °C - 8 °C下維持24小時，隨後在室溫下（不超過30 °C）維持12小時。 2.未調配之Truxima應冷藏2-8°C保存.切勿冷凍. 3.治療期間及之後 12 個月內，育齡婦女應使用有效的避孕方法。
ERELV2,Fluticasone + Vilanterol,RELVAR Ellipta 184/22mcg(大劑量)inhalation powder,ERSP,For asthma in aged 18 years and over.,Hypersensitivity to fluticasone， vilanterol， or any component of the formulation. Severe hypersensitivity to milk proteins. Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.,Common Gastrointestinal: Difficulty talking (2% )， Oropharyngeal candidiasis， Pain， Oropharyngeal (2% or greater ) Immunologic: Influenza (3% or greater ) Neurologic: Headache (5% to 8% ) Respiratory: Bronchitis (2% or greater )， Cough (1% or greater )， Nasopharyngitis (9% to 10% )， Sinusitis (2% or greater )， Upper respiratory infection (2% to 7% ) Serious Cardiovascular: Cardiac dysrhythmia， Disorder of cardiovascular system， Electrocardiogram abnormal， Premature beats (2% or greater )， Supraventricular tachycardia Endocrine metabolic: Cushing's syndrome Immunologic: Anaphylaxis Musculoskeletal: Decreased bone mineral density， Fracture of bone (2% ) Respiratory: Death， Asthma-related， Paradoxical bronchospasm， Pneumonia (2% or greater ) Other: Angioedema,30℃以下,One inhalation of Relvar Ellipta 184/22 micrograms once daily. (maximum dose: 1 inhalation/day). A starting dose of one inhalation of Relvar Ellipta 92/22 micrograms once daily should be considered for adults who require a low to mid dose of inhaled corticosteroid in combination with a long-acting beta2-agonist. If patients are inadequately controlled on Relvar Ellipta 92/22 micrograms， the dose can be increased to 184/22 micrograms， which may provide additional improvement in asthma control.,無需調整劑量,BREASTFEEDING RECOMMENDATION - Fluticasone: No Human Data—Probably Compatible; Vilanterol: No Data. [仿單]目前並無任何關於Fluticasone及Vilanterol是否會諸現於人類的乳汁中、對餵哺母乳之嬰兒的影響或對乳汁生成作用之影響等方面的資訊。曾在人類的乳汁中檢出低濃度的其他吸入性皮質類固醇。嬰將餵哺母乳對發育與健康的效應和母親對RELVAR Ellipta臨床需求，以及Fluticasone及Vilanterol或母親的潛在疾病對餵哺母乳之嬰兒的任何可能不良影響一併考慮。,無需調整劑量,沒有資料,Uknown 沒有資料,PREGNANCY RECOMMENDATION - Fluticasone: Compatible; Vilanterol: No Data [仿單]在對孕婦使用RELVAR Ellipta， Fluticasone， Vilanterol方面，目前並無足夠的資料。在對孕婦使用RELVAR Ellipta方面有一些臨床上的考量。在一項動物生殖試驗中，對懷孕的大鼠於器官發生期間以吸入方式單獨投予或合併投予Fluticasone及Vilanterol之後，並未引發任何胎兒結構畸形。在這項試驗中所使用之Fluticasone及Vilanterol的最高劑量分別約為200與25mcg(成人)之人類每日最高建議吸入劑量(MRHDID)的5倍與40倍。(以下略),Unknown 沒有資料,BREASTFEEDING RECOMMENDATION - Fluticasone: No Human Data—Probably Compatible; Vilanterol: No Data. [仿單]目前並無任何關於Fluticasone及Vilanterol是否會諸現於人類的乳汁中、對餵哺母乳之嬰兒的影響或對乳汁生成作用之影響等方面的資訊。曾在人類的乳汁中檢出低濃度的其他吸入性皮質類固醇。嬰將餵哺母乳對發育與健康的效應和母親對RELVAR Ellipta臨床需求，以及Fluticasone及Vilanterol或母親的潛在疾病對餵哺母乳之嬰兒的任何可能不良影響一併考慮。,IH;INHL;,,,,,
OZON,Zotepine,Zonin 50mg,CNEU,Schizophrenia.,Patients with coma or circulatory collapse， patients on epinephrine， hypersensitivity to phenothiazines， suspected subcortical lesions (eg encephalitis， cerebral tumor & sequelae of brain trauma).Patients receiving central nervous system inhibitors such as Barbiturates or anesthetics (which enhance and prolong the effects of central nervous system inhibitors). Patients with Terfenadine or Astemizole (may have prolonged QT or caused ventricular arrhythmia),Sleepiness， weakness， malaise， insomnia， thirst， constipation， dizziness.,25℃以下儲存。,Adult 75-150 mg daily in divided doses， up to 450 mg/day.,無需調整劑量,(仿單)授乳婦最好避免使用本藥。若判斷必須使用本藥，於服用期間務必停止哺乳,無需調整劑量,沒有資料,Human (and animal) data suggest risk,(仿單)在動物實驗曾有新生仔死亡率增多的報告，所以對孕婦或可能懷孕的婦女，最好不要給藥,Hold Breast Feeding 暫停哺乳,(仿單)授乳婦最好避免使用本藥。若判斷必須使用本藥，於服用期間務必停止哺乳,AC;AC15;PC;PO;WM;,,,,,
IMETE2,Methylergonovine,Methylergonovine inj 0.2mg/1mL,SGU,Prevention and treatment of uterine hemorrhage， promotion of uterine contraction， postpartum hemorrhage， incomplete uterine contraction， miscarriage.,Pregnancy， before fetal delivery， hypersensitivity to methylergonovine products， hypertension， toxemia， preeclampsia,Nausea， vomiting， abdominal pain， diarrhea， hypertension， frequent or slow pulse， headache， drowsiness， thirst， tinnitus， excitement， chest tightness.,25℃以下避光,SubQ or IM injection: 0.5-1mL (0.1-0.2mg) per time; IV injection: 0.25-0.5mL (0.05-0.1mg) administer over 1 minute. (Note: IV administration should only be considered during life-threatening situations.) Postpartum hemorrhage: 0.2 mg IM after delivery of anterior shoulder， after delivery of placenta， or during puerperium; may repeat Q2-4H as needed.,無需調整劑量,,無需調整劑量,沒有資料,Contraindicated,[仿單] 禁忌,Compatible 哺乳時可使用,,IM;IVPUSH;SC;,,,administer over 1 minute,,1.發生子宮收縮作用時間：皮下或肌肉注射後3-5分鐘內；靜脈注射後0.5-1分鐘內。 2.Slowly IV over >60 seconds with careful monitoring of blood pressure. Do not routinely administer IV because of the possibility of inducing sudden hypertension and cerebrovascular accident; only consider IV administration during life-threatening situations.
HE1807,,#9 血液透析液-3.8L A液,NUTR,,,,,,,,,,,,,,,,,,,
HE1809,,#11 血液透析液-3.8L A液,NUTR,,,,,,,,,,,,,,,,,,,
HE1810,,#13 血液透析液-3.8L A液,NUTR,,,,,,,,,,,,,,,,,,,
HE1812,Sodium bicarbonate + Sodium chloride,#300 腎臟透析液-10L B桶,NUTR,,,,,,,,,,,,,,,,,,,
IFLU2,Fluorouracil,5-FU inj 1000mg/20mL,RACA,Breast cancer， Colon and rectal cancer， Gastric cancer， Pancreatic cancer. Off-Label: Anal carcinoma; Bladder cancer; Cervical cancer; Esophageal cancer， advanced; Glaucoma surgery (adjunctive therapy); Head and neck cancer; Hepatobiliary cancers (advanced).,Known hypersensitivity to fluorouracil or any component of the formulation; debilitated patients; poor nutritional state; depressed bone marrow function following radiotherapy or therapy with other antineoplastic agents; potentially serious infections.,Stomatitis， esophagopharyngitis， diarrhea， anorexia， nausea， vomiting， enteritis， cramps， abdominal pain & ulceration， glossitis， pharyngitis， leukopenia， alopecia， dermatitis， ocular irritation， central neurotoxicity (acute cerebellar syndrome)， myocardial ischemia & angina.,25℃以下避光,(仿單) Usual dose: 12 mg/kg IV daily for 4 days， if tolerated then 6 mg/kg IV daily on days 6， 8， 10， 12 (Maximum dose 800 mg/day). For patients with malnutrition or less severe condition， 6 mg/kg IV daily for 3 days; if tolerated then 3 mg/kg on days 5， 7 and 9 (Maximum dose 400 mg/day). Maintenance therapy: the first course every 30 days if tolerated. For intolerated patients， 10-15 mg/kg/week after toxic signs resulting from the initial course of therapy have subsided;Maximum dose 1 g/week. Infuse daily dose over 30-60 minutes or over 24 hours continuously.,無需調整劑量,,無需調整劑量,盡量避免,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,IVD;,,【D5W】可選 。【N/S】可選 。,,,1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、血糖變化 (DM病人)。
LLUG2,Iodine + Potassium Iodide,Lugol's soln 2%， 60mL (專案進口),META,(本院核准用法) Enhancing the detection of esophageal squamous dysplasia and early squamous cell carcinoma， thyrotoxic crisis/thyroid storm.,Hypersensitivity to iodine or any component of the formulation; active tuberculosis; dermatitis herpetiformis; hypocomplementemic vasculitis; nodular thyroid disease with heart disease,Tingling sensation， nausea， myxedema， weakness.,室溫,Enhancing the detection of esophageal squamous dysplasia and early squamous cell carcinoma acorrding to the individual needs of the patient. Thyroidectomy preparation in patients with Graves disease: Lugol's 5% solution: 5 to 7 drops (0.25 to 0.35 mL) 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery， consider concurrent beta-blockade (eg， propranolol) in the immediate preoperative period to reduce the risk of thyroid storm. Thyrotoxic crisis/thyroid storm: Lugol's 5% solution: 4 to 8 drops every 6 to 8 hours; initiate therapy at least 1 hour following the initial dose of antithyroid drug therapy.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PO;,,,,,
INUC,Mepolizumab,Nucala 100mg inj,ERSP,severe refractory eosinophilic asthma,Hypersensitivity to mepolizumab or any component of the formulation,>10%: Central nervous system: Headache (19%) Local: Injection site reaction (8% to 15%) 1% to 10%: Central nervous system: Fatigue (5%) Dermatologic: Eczema (3%)， pruritus (3%) Gastrointestinal: Upper abdominal pain (3%) Genitourinary: Urinary tract infection (3%) Hypersensitivity: Hypersensitivity reaction (eosinophilic granulomatosis: 4%)， angioedema (eosinophilic granulamatosis: 1%) Immunologic: Immunogenicity (asthma: 6%， eosinophilic granulomatosis: <2%; neutralizing: <1%) Infection: Influenza (3%) Neuromuscular & skeletal: Back pain (5%)， muscle spasm (3%) Frequency not defined: Hypersensitivity: Delayed hypersensitivity Infection: Herpes zoster,2-8℃避光避免冷凍,Asthma: Adults and Age >12 years old: 100 mg administered by subcutaneous (SC) injection once every 4 weeks. Age 6-11 years old: 40 mg administered by subcutaneous (SC) injection once every 4 weeks. Eosinophilic granulomatosis with polyangiitis: Adults and Age >12 years old: 300 mg administered by subcutaneous (SC) injection once every 4 weeks.,無需調整劑量,,無需調整劑量,沒有資料,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,1.2 毫升的無菌注射用水,,,,1.建議使用 1.2 毫升的無菌注射用水泡製，最好使用 2 或 3 毫升的針筒與 21 號針頭。勿與其他藥物混合使用。 2.請以轉圈的方式輕輕轉動小瓶直到粉末溶解為止。勿用力振搖泡製的溶液，可能會引發泡沫或沉澱。 3.泡製後存放於 30°C 以下，勿冷凍， 8 小時內使用，否則應丟棄。
IEPIP,Epinephrine,Epipen Auto-Injector 0.3mg,ZADT,anaphylaxis.,There are no absolute contraindications to the use of injectable epinephrine in a life-threatening situation.,Frequency not defined: Cardiovascular: Angina pectoris， cardiac arrhythmia， cardiomyopathy (stress)， cerebrovascular accident， chest pain， hypertension， increased cardiac work， ischemic heart disease， limb ischemia， localized blanching， myocardial infarction， palpitations， peripheral vasoconstriction， supraventricular tachycardia， tachyarrhythmia， tachycardia， vasoconstriction， ventricular arrhythmia， ventricular ectopy， ventricular fibrillation Central nervous system: Anxiety， apprehension， cerebral hemorrhage， disorientation， dizziness， drowsiness， exacerbation of Parkinson disease， headache， memory impairment， panic， paresthesia， psychomotor agitation， restlessness， tingling sensation Dermatologic: Diaphoresis， gangrene of skin or other tissue (at injection site)， pallor， piloerection Endocrine & metabolic: Hyperglycemia， hypoglycemia， hypokalemia， insulin resistance， lactic acidosis Gastrointestinal: Nausea， vomiting Local: Tissue necrosis at injection site Neuromuscular & skeletal: Asthenia， tremor Renal: Renal insufficiency Respiratory: Dyspnea， pulmonary edema， rales,15-30℃避光，25℃最佳,Epinephrine auto-injector 0.3 mg for patients weighing > 30 kg. Usual dose: 0.3 mg; pediatric dose: 0.01 mg/kg. IM into the anterolateral aspect of the thigh， through clothing if necessary; may repeat every 5-15 minutes or sooner if patient does not adequately respond to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.,無需調整劑量,,無需調整劑量,,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;,,,,,1. 必要時可以隔著衣物施打 2. 如需要第二次劑量時不要注射在同一部位 3. 不可施打於臀部，手，腳，指頭
OINH1,Isoniazid,Isoniazide 100mg,QANB,Treatment of susceptible active tuberculosis (eg， Mycobacterium tuberculosis) infections.,•Acute liver disease. •History of severe adverse reactions to isoniazid such as drug fever， chills， or arthritis. •History of isoniazid associated hepatic injury or drug induced liver injury. •Severe hypersensitivity to isoniazid.,Common •Hepatic: Increased liver enzymes (10% to 20% ) •Neurologic: Neuropathy， Neurotoxicity Serious •Dermatologic: Rash •Hematologic: Agranulocytosis， Anemia， Thrombocytopenia •Hepatic: Hepatitis (Severe)， Hepatotoxicity， Injury of liver •Immunologic: Systemic lupus erythematosus •Musculoskeletal: Rhabdomyolysis •Neurologic: Seizure,25℃以下,(仿單) Adult: 50-200 mg/day in 3-5 divided doses after meals. (UpToDate) DOT = directly observed therapy. Adult: Once-daily therapy: 5 mg/kg/dose (usual dose: 300 mg) once daily; Three-times-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered 3 times weekly; Twice-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered twice weekly; Once-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered once weekly.Pediatrc: Once daily therapy: children < 15 years， weighing < or = 40 kg: 10-15 mg/kg/dose once daily (maximum 300 mg/dose); children < 15 years weighing > 40 kg or children > or = 15 years: 5 mg/kg/dose once daily; typical dose: 300 mg/dose.,需調整劑量,,無需調整劑量,,Compatible – maternal benefit >> embryo-fetal risk,PREGNANCY RECOMMENDATION: Compatible—Maternal Benefit >> Embryo–Fetal Risk,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;,,,,,
OTET2,Tetracycline,Tetracycline 250mg,QANB,Chronic bronchitis. Brucellosis， chlamydia， mycoplasma and rikettsia.,Hypersensitivity to any of the tetracyclines or any component of the formulation.,GI upset. Rarely， hypersensitivity reactions， hepatotoxicity， blood disorders.,請保存於乾燥陰涼處(15-30℃),(仿單) Adults: 250-500 mg orally Q6H. (熱病) Pediatric: age > 8 years: 25-50 mg/kg/day orally， divided Q6H,需調整劑量,UpToDate: Tetracycline is excreted into breast milk .,需調整劑量,盡量避免,Contraindicated – 2nd and 3 rd trimesters,,Compatible 哺乳時可使用,UpToDate: Tetracycline is excreted into breast milk .,AC;AC15;PC;PO;WM;,,,,,
ESYMR,Budesonide + Formoterol,(噴霧)Symbicort Rapihaler 160/4.5mcg/dose,ERSP,Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β2-agonist) is appropriate. Symptomatic treatment of severe COPD & history of repeated exacerbation symptoms despite regular therapy with long-acting bronchodilators.,Hypersensitivity to budesonide， formoterol， or any component of the formulation.,Palpitation， oral candidiasis， headache， tremor， mild throat irritation， cough， hoarseness.,30℃以下且吸嘴朝下,Adolescents 12 to 17 years: Symbicort Rapihaler 160/4.5: 2 inhalations once to twice daily. During worsening of asthma the dose may temporarily (1 week maximum.) be increased to a maximum of 4 inhalations twice daily. Adults (18 years and older): Symbicort Rapihaler 160/4.5: 2 inhalations once or twice daily. In some cases up to a maximum of 4 inhalations twice daily may be required as maintenance dose or temporarily during worsening of asthma. Chronic Obstructive Pulmonary Disease (COPD): Adults (18 years and older): Symbicort Rapihaler 160/4.5: 2 inhalations twice daily.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,Therefore， pregnant women who require an inhaled corticosteroid， such as budesonide， for control of their asthma should be counseled as to the risks and benefits of therapy， but treatment should not be withheld because of their pregnancy. Because of the availability of extensive human pregnancy experience， either albuterol or salmeterol would be a better choice if a pregnant woman required an inhaled β-adrenergic bronchodilator.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
ITEC,Atezolizumab,Tecentriq inj 1200mg/20mL,RACA,Locally advanced or metastatic urothelial carcinoma (UC) after prior chemotherapy， or for those considered cisplatin ineligible & whose tumours have a PD-L1 expression ?5%， or those not eligible for any platinum-containing chemotherapy regardless of tumor PD-L1 expression level. 1st-line treatment in combination w/ bevacizumab， paclitaxel & carboplatin for metastatic non-squamous non-small cell lung cancer (NSCLC) w/ no EGFR or ALK genomic tumor aberrations. Locally advanced or metastatic NSCLC after prior chemotherapy. Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in combination w/ nab-paclitaxel， for those whose tumors have PD-L1 expression ?1% & who have not received prior chemotherapy for metastatic disease.,Hypersensitivity.,Diarrhea， nausea， vomiting， constipation; fatigue， asthenia， pyrexia， headache; UTI， lung infection; decreased appetite， hypomagnesemia; arthralgia， back pain， musculoskeletal pain; cough， dyspnea; rash， pruritus; anemia， neutropenia， thrombocytopenia; hypothyroidism; dizziness， peripheral neuropathy. Thrombocytopenia， decreased lymphocyte count; hypothyroidism， hyperthyroidism; dysphagia， colitis， abdominal pain， oropharyngeal pain， stomatitis; chills， flu-like illness， infusion-related reaction; increased ALT & AST， hepatitis; hypersensitivity; hypokalemia， hyponatremia， hyperglycemia; hypoxia， nasal congestion， pneumonitis， nasopharyngitis， dysphonia; hypotension; dysgeusia， syncope; proteinuria.,2-8℃避光避免冷凍,840 mg IV every 2 weeks or 1200 mg IV every 3 weeks， or 1680 mg IV every 4 weeks infused over 60 minutes; if the first infusion is tolerated， all subsequent infusions may be delivered over 30 minutes.  [Non-squamous NSCLC] In combination with bevacizumab， paclitaxel， & carboplatin: 1200 mg by IV infusion， followed by bevacizumab， paclitaxel， & then carboplatin every 3 weeks for 4 or 6 cycles during induction phase， then， followed by maintenance phase without chemotherapy and bevazicumab， in which 840 mg IV every 2 weeks or 1200 mg IV every 3 weeks， or 1680 mg IV every 4 weeks.  [Triple-negative breast cancer] In combination with nab-paclitaxel: 840 mg by IV infusion， followed by 100 mg/m2 nab-paclitaxel. For each 28-day cycle Tecentriq is administered on days 1 & 15， & nab-paclitaxel is administered on days 1， 8 & 15.  [Small cell lung cancer， SCLC] 1200 mg by IV infusion， followed by carboplatin AUC 5 mg/mL/min IV on day 1 and etoposide 100 mg/m2 IV on days 1 through 3 of each 21-day cycle for maximum of 4 cycles.  [Liver carcinoma] 1200 mg by IV infusion， followed by 15mg/kg bevacizumab every 3 weeks; continue until disease progression or unacceptable toxicity.,無需調整劑量,[仿單]目前未有atezolizumab進入人體乳汁、對於哺乳嬰兒或乳汁生成影響之資料。 由於人類免疫球蛋白G (IgG)會分泌到人類乳汁中，藥物吸收與對嬰兒可能的傷害不明。 由於Tecentriq可能對哺乳嬰兒造成嚴重不良反應， 應告知女性在治療期間與最後一劑後至少5個月內不得哺乳。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]根據其作用機轉，懷孕女性若接受Tecentriq治療可能導致胎兒傷害。 沒有關於懷孕女性使用Tecentriq的資料。動物試驗已顯示，抑制PD-L1/PD-1途徑會增加發育胎兒的免疫相關排斥風險， 而造成胎兒死亡。使用本藥前，應確認具有生育能力女性的懷孕狀態。應將藥物對胎兒的潛在風險告知具有生育能力的女性病人， 並告知具有生育能力的女性於Tecentriq治療期間以及最後一劑後至少5個月內，應採取有效的避孕措施。,Unknown 沒有資料,[仿單]目前未有atezolizumab進入人體乳汁、對於哺乳嬰兒或乳汁生成影響之資料。 由於人類免疫球蛋白G (IgG)會分泌到人類乳汁中，藥物吸收與對嬰兒可能的傷害不明。 由於Tecentriq可能對哺乳嬰兒造成嚴重不良反應， 應告知女性在治療期間與最後一劑後至少5個月內不得哺乳。,IVD;,,【N/S】可選 仿單建議。,,給藥：第一次以60分鐘透過裝或不裝有無菌、非致熱原性(non-pyrogenic)、低蛋白結合性的管線內置型過濾器(孔徑尺寸為0.2至0.22微米)靜脈給予。若病人可耐受可以30分鐘進行輸注。請勿經由相同的靜脈管線同時給予其他藥物。不得以靜脈推注(push)或快速灌注(bolus)方式給予,1.製備輸注溶液：注入含有0.9%美國藥典規格之氯化鈉注射液的250 mL聚氯乙烯(PVC)、聚乙烯(PE)或聚烯烴(PO)輸注袋中稀釋。僅可使用0.9%氯化鈉注射液稀釋。輕輕反轉以混合稀釋溶液。不可搖晃。 2.儲存溶液：於室溫下，從製備時起算不超過6小時。這包括室溫下輸注液裝於輸注袋 中，以及輸注給藥的時間，或從製備時起算，冷藏於2°C至8°C下不超過24小時。
IDYS,Botulinum Toxin type A,Dysport 500 Unit/Vial,CNEU,Symptomatic relief of blepharospasm， hemifacial spasm and associated focal dystonias. Reduction of the signs and symptoms of spasmodic torticolis (cervical dystonia). Treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients >=2 yr.,Myasthenia gravis or Eaton Lambert syndrome， infection at inj site.,Localized pain， tenderness or bruising， local weakness， ptosis， vertical deviation， irritation or tearing. Rarely， skin rash (including erythema multiforme， urticaria and psoriasiform eruption)， pruritus， allergic reactions， dysphagia， pneumonia. Dermatologic: Injection site reaction (cervical dystonia， 5% to 22%; glabellar lines， 3%) Gastrointestinal: Xerostomia (cervical dystonia， 13% to 39%) Musculoskeletal: Muscle weakness (cervical dystonia， 11% to 56%) Neurologic: Difficulty speaking (cervical dystonia， 6% to 28%)， Headache (9% to 11%) Ophthalmic: Disorder of eye (cervical dystonia， 6% to 17%) Respiratory: Nasopharyngitis (glabellar lines， 10%),2-8℃避免冷凍,Blepharospasm 1.25 ~ 2.5 units into the medial & lateral orbicularis oculi of the upper lid & into lateral orbicularis oculi of he lower lid. Maximum 100 units every 12 weeks. Hemifacial spasm， spasmodic torticolis Individulised dosage. Paediatric cerebral palsy Administer into each of 2 sites in the medial and lateral heads of the affected gastrocnemius muscle. In hemiplegia : total dose of 4 units/kg in the affected limb. In diplegia : total dose of 6 units / kg body wt divided beween the affected lims.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,
OMIR3,Mirtazapine,Mirtan 30mg,CNEU,,適應症: Depression. 副作用: Increase in appetite and wt， oedema; drowsiness or sedation; dizziness， headache， increased liver enzyme levels; jaundice. Orthostatic hypotension， rash， nightmares， agitation， mania， hallucinations， paraesthesia， convulsions， tremor， myoclonus， akathisia， restless legs syndrome， arthralgia， myalgia， reversible agranulocytosis， leucopenia， granulocytopenia， hyponatraemia. Endocrine metabolic: Increased appetite (17% )， Serum triglycerides raised (increases to 500 mg/dL or greater: 6% )， Weight gain (body weight increase of 7% or greater: adults 7.5%; pediatrics 49% ) Gastrointestinal: Constipation (13% )， Xerostomia (25% ) Hepatic: ALT/SGPT level raised (2% ) Neurologic: Asthenia (8% )， Dizziness (7% )， Somnolence (54% ) Psychiatric: Disturbance in thinking (3% ),,室溫,PO Initial: 15 mg/day; may increase gradually based on response. Usual range: 15-45 mg/day as 1-2 divided doses.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IXEN,Iobitridol,Xenetix inj 350mg/mL， 100mL,SCAN,Adults and children in a wide range of indications， including intravenous (IV) urography， head and whole body CT and intra-arterial (IA) or IV digital subtraction angiography (DSA).,Thyrotoxicosis. Hypersensitivity to Iobitridol or any components of the product.,Cardiovascular Effects: Lumbar， Abdominal， Chest or Generalized Pain (1.7%)， Transient Ischemic Attack， Ventricular Extrasystoles， Tachycardia， Hypertension And Hypotension. Dermatologic Effects: Transient Heat Sensations(35%)， Injection Site Pain(2%)， Various Skin Reactions (1%) Endocrine/metabolic Effects: Hypothermia Gastrointestinal Effects: Taste Disturbances， Nausea， Vomiting(1% or Less) Hepatic Effects: Hepatotoxicity: Temporary Impairment of Kidney Function. Immunologic Effects: Anaphylaxis， Hypersensitivity Reaction Neurologic Effects: Headaches(0.7%)， tremor， Neurological Complications Including Transient Confusion， Somnolence， Coma， Paresis， Convulsions And Facial Weakness Ophthalmic Effects: Visual Disturbances And Lacrimation Renal Effects: Urinary Urgency Respiratory Effects: Rhinitis， laryngospasm， pulmonary Edema(Intravascular Injection)， respiratory Depression(large doses).,不可高於30°C， 避光，,Urography mean dose: 1 mL/kg (minimum/maximum dose:50-100 mL). CT scan: Brain mean dose:1 mL/kg (minimum/maximum dose:40-100 mL); whole body mean dose: 1.8 mL/kg (minimum/maximum dose:90-180 mL). IV digital subtraction angiography mean dose: 2.1 mL/kg (minimum/maximum dose:95-250 mL). Arteriography: Peripheral mean dose: 2.2 mL/kg (minimum/maximum dose:105-205 mL); lower limbs mean dose: 1.8 mL/kg (minimum/maximum dose:80-190 mL); abdominal mean dose: 3.6 mL/kg (minimum/maximum dose:155-330 mL). Angiocardiography: Adult mean dose: 1.9 mL/kg (minimum/maximum dose:65-270 mL); Children mean dose: 4.6 mL/kg (minimum/maximum dose:10-130 mL).,無需調整劑量,[仿單]含碘造影劑僅少量分泌於母乳中。單獨對母親給藥後對嬰兒有輕微的風險，因此建議注射含碘造影劑後停止哺乳24小時。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]胚胎毒性 動物實驗並未顯致畸胎作用。由於對不同動物的實驗並未顯示致畸胎作用，推論在人類亦同。至今會造成人類畸形的物質通常會在執行2種合適性動物實驗顯示致畸胎作用。 胎兒毒性 在超過14週無月經情形投藥於母親會導致暫時性碳過量，可能引發胎兒甲狀腺功能異常，然而在此作用為可逆且如果單獨注射含碘造影劑對懷 孕母親的檢查有益並經過小心評估後，則可在經上述考量下投於孕婦。,Unknown 沒有資料,[仿單]含碘造影劑僅少量分泌於母乳中。單獨對母親給藥後對嬰兒有輕微的風險，因此建議注射含碘造影劑後停止哺乳24小時。,IA;IVD;IVPUSH;,,,,,1.無法預測的過敏反應通常發生於60分鐘內，但可能會延遲至檢查後7天內出現。 2.併用Metformin病患建議造影前48小時停止Metformin使用，至造影後48小時或腎功能回復時再開始使用Metformin。
OEVI6,Raloxifene,Evista 60mg,META,Treatment and prevention of osteoporosis in postmenopausal women.,Active or past history of venous thromboembolism (VTE)， including deep vein thrombosis， pulmonary embolism， and retinal vein thrombosis. Pregnancy or women who may become pregnant.,Common Endocrine metabolic: Hot sweats Musculoskeletal: Leg cramp Serious Hematologic: Deep venous thrombosis， Venous thromboembolism (1% ) Neurologic: Cerebrovascular accident Ophthalmic: Thrombosis of retinal vein (rare ) Respiratory: Pulmonary embolism,20-25℃儲存，短期運輸可15-30℃,60 mg tablet orally once daily.,無需調整劑量,[仿單]EVISTA 不適用於具有生育能力的女性。 目前尚未有 raloxifene 在人類乳汁中、對哺乳嬰兒的影響、或對乳汁分泌的影響之相關資訊。 然而，基於作用機轉，EVISTA 可能會 阻斷雌激素在哺乳期間乳腺組織中的重要功能,無需調整劑量,沒有資料,Contraindicated,[仿單] EVISTA 禁用於孕婦，且不適用於具有生育能力的女性。基於作用機轉，EVISTA 可能阻斷雌激素在妊娠中各階段的重要功能。 EVISTA 用於孕婦的數據 有限，尚未得知與藥物相關的先天性缺陷或流產風險。 在兔子和大鼠的器官形成期間或在妊娠和哺乳期間給予藥物，EVISTA 產生多種生殖和發育的不良反應，包括流產、胎兒異常、延遲或中斷分娩導致母體和新生兒死亡，其所用的劑量皆小於或與人體最大建議使用劑量相似(以人體表面積為基礎進行比較)。,Contraindicated 哺乳期使用禁忌,[仿單]EVISTA 不適用於具有生育能力的女性。 目前尚未有 raloxifene 在人類乳汁中、對哺乳嬰兒的影響、或對乳汁分泌的影響之相關資訊。 然而，基於作用機轉，EVISTA 可能會 阻斷雌激素在哺乳期間乳腺組織中的重要功能,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單無相關註記，詢問廠商不建議破壞劑型因無相關試驗可供參考。 1. 無法行走會增加靜脈血栓性栓塞危險性，應在至少 72 小時前或長時間無法行走時(如手術後恢復、長期臥床)停用本藥。一直到病人行動能力完全恢復後才可繼續使用。 2. 應告知服用 EVISTA 的婦女，長期旅行之間應保持定期的活動。
OVOC,Vonoprazan,Vocinti 20mg,ALIM,Erosive esophagitis. Gastric ulcer. Duodenal ulcer. Adjunct to Helicobacter pylori eradication.,Hypersensitivity to any component of the product. Concurrent use with atazanavir or rilpivirine.,Shock， anaphylaxis ( frequency unknown ) Pancytopenia， agranulocytosis， leukopenia， and thrombocytopenia ( frequency unknown ) Liver dysfunction: hepatotoxicity， jaundice ( frequency unknown ) Toxic epidermolysis: toxic epidermolysis (TEN) ， Stevens-Johnson syndrome， and erythema multiforme ( frequency unknown ) Severe colitis with bloody stool， such as pseudomembranous colitis， etc. ( frequency unknown ) The follwing data are based on the trials of vonoprazan ， amoxicillin and clarithromycin for gastric or duodenal ulcers. The frequencies are based on the indication for stomach ulcer， duodenal ulcer， erosive esophagitis. Gastrointestinal: Constipation， diarrhea， feeling bloated or nauseated (0.1% - < 5%) allergic reaction: rash(0.1% - < 5%) Liver: AST， ALT， ALP， LDH or γ-GTP increased(0.1% - < 5%) Other: Edema or eosinophilia(0.1% - < 5%) The frequencies are based on the indication for eradication of Helicobacter pylori. Gastrointestinal: diarrhea(10.6%)， abnormal taste， stomatitis， abdominal discomfort， or abdominal swelling(0.1% - < 5%) allergic reaction: rash(0.1% - < 5%) Liver: AST (GOT)， ALL (GPT) increased(0.1% - < 5%),30°C以下。,Erosive esophagitis: Vonoprazan 20 mg once daily， usually for no more than 4 weeks. Could be up to 8 weeks if needed. For maintenance therapy: 10 mg once daily， could be increased to 20 mg once daily if needed. The efficacy and safety data of vonoprazan in the current clinical trials are available for up to one year. Gastric ulcer， duodenal ulcer: In general， 20 mg once daily. For gastric ulcer treatment of the duration is usually no more than 8 weeks， and for duodenal ulcer， usually no more than 6 weeks. Helicobacter pylori eradication: In general， adults take the following 3 drugs orally twice a day: vonoprazan 20mg/time， amoxicillin 750mg/time and clarithromycin 200-400mg/time for 7 days. When the treatment of combination of proton pump inhibitor， amoxicillin and clarithromycin is fails， the following 3 drugs can be used as an alternative treatment: take 3 drugs orally twice a day: vonoprazan 20mg/time ， amoxicillin 750mg/time and metronidazole 250mg/time for 7 days.,需調整劑量,[仿單] 繼續或停止哺乳應考量本藥預期的治療效益和哺乳的好處。 根據大鼠動物試驗的報告，vonoprazan會進入母乳。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 只有在預期的治療效益大於可能的風險情形下，本藥才可使用於懷孕婦女或可能已懷孕的婦女。 動物試驗中，當大鼠的vonoprazan曝露量(AUC)大約達到最高臨床劑量(40 mg/day)的28倍以上時，曾觀察到有胎鼠體重和胎盤重量減輕、外觀異常(肛門狹窄和尾巴異常)及內臟異常(膜型心室中膈缺損和鎖骨下動脈異位)的情形。,Unknown 沒有資料,[仿單] 繼續或停止哺乳應考量本藥預期的治療效益和哺乳的好處。 根據大鼠動物試驗的報告，vonoprazan會進入母乳。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單未有管灌磨粉相關註記，經詢問廠商不建議管灌磨粉，因未有相關試驗。(2022/10/11)
OBET2,Mirabegron,Betmiga 25mg prolonged-release,SGU,Treatment of overactive bladder with symptoms of urinary frequency， urgency， or urge urinary incontinence,Hypersensitivity to mirabegron or any component of the formulation， severe uncontrolled hypertension (systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg),>10%: Cardiovascular: Hypertension (9% to 11%) 1% to 10%: Cardiovascular: Tachycardia (2%) Central nervous system: Headache (4%)， dizziness (3%) Gastrointestinal: Constipation (2% to 3%)， xerostomia (3%)， diarrhea (2%) Genitourinary: Urinary tract infection (3% to 6%)， cystitis (2%) Neuromuscular & skeletal: Back pain (3%)， arthralgia (2%) Respiratory: Nasopharyngitis (4%)， sinusitis (3%) Miscellaneous: Flu-like syndrome (3%) <1% (Limited to important or life-threatening): ALT/AST increased， atrial fibrillation， breast cancer， cerebrovascular accident， GGT increased， glaucoma， LDH increased， leukocytoclastic vasculitis， lung cancer， nephrolithiasis， osteoarthritis， palpitations， prostate cancer， Stevens-Johnson syndrome， urinary retention， vaginal infection， vulvovaginal pruritus,30℃以下,25-50 mg once daily. May be taken with or without food. Swallow whole， do not chew/divide/crush.,需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IVIS,Verteporfin,Visudyne inj 15mg/vial,TOPH,Subfoveal choroidal neovascularization: Treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration， pathologic myopia， or presumed ocular histoplasmosis.,Known hypersensitivity to verteporfin or any component of the formulation; porphyria,>10%: Local: Injection site reactions (including injection site discoloration， edema， extravasation， hemorrhage， inflammation， pain， and rash) Ocular: Blurred vision， flashes of light， visual acuity decreased， visual field defects (including scotoma) 1% to 10%: Cardiovascular: Atrial fibrillation， hypertension， peripheral vascular disorder， varicose veins Central nervous system: Fever， hypoesthesia， sleep disturbance， vertigo Dermatologic: Eczema， photosensitivity Gastrointestinal: Constipation， gastrointestinal cancers， nausea Genitourinary: Prostatic disorder Hematologic: Anemia， leukocytosis， leukopenia Hepatic: Liver function tests increased Neuromuscular & skeletal: Arthralgia， arthrosis， back pain (primarily during infusion)， myasthenia， weakness Ocular: Diplopia， lacrimation disorder Treatment site: Blepharitis， cataracts， conjunctivitis/conjunctival injection， dry eyes， ocular itching， severe vision loss with or without subretinal/retinal or vitreous hemorrhage (decrease in 4 lines or more within 7 days of treatment [1% to 5%]) Otic: Hearing loss Renal: Albuminuria， creatinine increased Respiratory: Cough， pharyngitis， pneumonia Miscellaneous: Flu-like syndrome,25℃以下,Adult: 6 mg/m2 by infusion over 10 min， followed by activation using a laser tuned to a wavelength of 689 nm 15 min after the start of the infusion. Recommended light dose is 50J/cm2， given over 83 sec. Repeat every 3 months for recurrent choroidal neovascular leakage.,無需調整劑量,(UptoDate)Verteporfin and its metabolite are excreted in breast milk. Milk concentrations were up to 66% of plasma levels in 1 woman following infusion; the metabolite was still detected 48 hours later. Due to the potential for serious adverse reactions in the nursing infant， the manufacturer recommends that nursing be discontinued or treatment be postponed， taking into account the importance of treatment to the mother.,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,(UptoDate)Verteporfin and its metabolite are excreted in breast milk. Milk concentrations were up to 66% of plasma levels in 1 woman following infusion; the metabolite was still detected 48 hours later. Due to the potential for serious adverse reactions in the nursing infant， the manufacturer recommends that nursing be discontinued or treatment be postponed， taking into account the importance of treatment to the mother.,IVD;,,【D5W】可選 。,,建議以10分鐘緩慢滴注. 建議使用孔徑不小於1.2μm過濾器的輸注管線.,1.不可用生理食鹽水，會沉澱。 2.以7mL"無菌注射用水"加入小瓶中，此時濃度為2mg/mL的7.5mL溶液，溶液呈不透明暗綠色溶液。 3.本品溶解稀釋後須立即使用，限單次使用。(25℃下，4個小時內化學物理安定) 4.抽出所需劑量，再以D5W稀釋成30mL輸注液，輸注10分鐘。 5.建議使用臨床試驗使用的含孔徑不小於1.2μm過濾器的輸注管線。 6.注射時應預防滲漏。若發生滲漏，應立即停止輸注，保護該部位避免強光直射直到腫脹及皮膚變色的情形消失，冷敷可減輕症狀。 7.若藥品配製時潑灑出，須以濕布擦拭。避免與眼睛及皮膚接觸。
IXYL1E,Lidocaine + Epinephrine,Xylocaine 1% + E inj 20mL,ZANE,,Local anesthesia.,,RT,Infiltration， caudal， epidural or peripheral nerve block: As needed， up to 50 ml.,,,,除非治療上需要,,,,,,,,,,
HE1813,Sodium bicarbonate + Sodium chloride,#300 腎臟透析液粉劑B粉,NUTR,,,,避光、室溫貯存，請勿冷凍。,〔使用須知] 1.腎臟透析粉三○○號(乙)加純水或R.O.水混合後之濃縮液，用於透析時必需為同一天混合的。濃縮液需以密閉容器裝好，以儘量減少CO，逸出損失及沈澱發生。 2.存放腎臟透析粉三まま號(乙)濃縮液之容器應為最小容積為10升之寬口容器，且在9.2升處要有刻度標示，混合時以符合血液透析水質標準之純水或R.O.水加至標示量9.2升處(水溫在25℃~30℃間)，接著將1袋腎臟透析粉三まま號(乙)粉末加入後徐徐攪拌至完全溶解，澄清為止。此時濃縮液全量為9.5升。 3.攪拌時請勿使用電子攪拌器或其他會造成藥液溢出或CO，逸出的劇烈攪拌方式。 4.腎臟透析粉三まま號(乙)濃縮液使用時配合“信東”血液透析液GA系列之A液，R.O.水使用。透析時請遵照人工腎臟機操作說明、操作方法進行透析，透析液為:acid concentrate: bicarbonate concentrate : purified water=1:1.83:34 〔用法及用量〕 1.本粉劑(B末)使用時，須先依使用說明配成溶液-B液，配合“信東”血液透析液GA系列之A液使用。 2.A液:B液:R.O.水=1:1.83:34,無需調整劑量,,無需調整劑量,,,,,,,,,,,
OUROS,Sodium Pentosan Polysulfate,Urosan 100mg,SGU,Relieve bladder pain or discomfort caused by interstitial cystitis.,Hypersensitivity to pentosan polysulfate sodium， any structurally related compound， or excipients.,Common: Alopecia (4%)， Rash (3%)， Abdominal pain (2%)， Diarrhea (4%)， Indigestion (Up to 2%)， Nausea (4%)， Liver enzymes level above reference range (Up to 1.2%)， Dizziness (1%)， Headache (3%) Serious: Proctitis， Rectal hemorrhage (6.3%)， Hemorrhage， Thrombocytopenia (Up to 1%)， Retinal disorder， Pigmentary changes,30° C 以下,Usual dosage (16 years or older): 300 mg， administered as 100 mg orally three times a day taken either 1 hour before or 2 hours after meals. At least 3 months of therapy should be given before patient reassessment; if no benefit is noted at 3 months， an additional 3 months of therapy is warranted， provided the patient has exhibited no limiting adverse reactions. The efficacy and safety of continued treatment beyond 6 months in patients with lack of improvement in pain is not known.,無需調整劑量,[仿單] 此藥是否會分泌至人乳中並未知。因為許多藥物會分泌至人乳中， 當哺乳婦女服用Urosan時，要小心謹慎。,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,[仿單] 在懷孕婦女方面尚未進行適合且良好控制的試驗。 因為動物試驗結果並無法預測到在人體的反應，此藥只有在確實需要時才可用於懷孕婦女。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 此藥是否會分泌至人乳中並未知。因為許多藥物會分泌至人乳中， 當哺乳婦女服用Urosan時，要小心謹慎。,AC;PO;,,,,,
IVIM,Lacosamide,Vimpat 針劑 200mg/20mL,CNEU,1. Monotherapy for localized seizures with or without secondary generalized seizures in patients aged four and above who have experienced either their first or multiple seizures. 2. Adjunctive therapy for the following conditions: (1) Patients aged four and above with complex partial seizures and simple or complex partial seizures with secondary generalization， with or without other seizure types. (2) Patients aged four and above with primary generalized tonic-clonic seizures (PGTCS) and idiopathic generalized epilepsy.,Allergic to the main ingredients or any excipients. second-or third-degree AV block.,Common: Nausea (Up to 24%)， Dizziness (Oral， 16-30% ; IV， 20-60%)， Headache (11-16%)， Diplopia (9-11%) Serious: Atrial fibrillation and flutter， First degree atrioventricular block， Asymptomatic (0.4%)， Prolonged PR interval， Drug reaction with eosinophilia and systemic symptoms， Suicidal behavior， Suicidal thoughts,20-25℃,Adults (17 years and older): Monotherapy: Initial Dosage: 100 mg twice daily (200 mg per day) Titration Regimen: Increase by 50 mg twice daily (100 mg per day) every week. Maintenance Dosage: 150 mg to 200 mg twice daily (300 mg to 400 mg per day). Adults (17 years and older): Adjunctive Therapy: Initial Dosage: 50 mg twice daily (100 mg per day) Titration Regimen: Increase by 50 mg twice daily (100 mg per day) every week. Maintenance Dosage: 100 mg to 200 mg twice daily (200 mg to 400 mg per day). Adults (17 years and older): Alternate Initial Dosage: 200 mg single loading dose， followed 12 hours later by 100 mg twice daily. Pediatric patients weighing 50 kg or more: Initial Dosage: 50 mg twice daily (100 mg per day). Titration Regimen: Increase by 50 mg twice daily (100 mg per day) every week. Maintenance Dosage: Monotherapy: 150 mg to 200 mg twice daily (300 mg to 400 mg per day). Adjunctive Therapy: 100 mg to 200 mg twice daily (200 mg to 400 mg per day). Maximum recommended dose: 400 mg per day.,需調整劑量,[仿單]Lacosamide 會分泌至人類母乳中， 因此應考慮藥物對母親的重要性，來決定是否停止哺乳或停止使用Lacosamide 。,需調整劑量,沒有資料,No (limited) human data – animal data suggest moderate risk,[仿單]對於所有的抗癲癇藥物，用於治療懷孕婦女後， 顯示其新生兒發生畸型的盛行率是一般族群盛行率(約為3%)的 2 到 3 倍。 使用抗癲癇藥物治療的懷孕婦女中，發現其中接受多重癲癇藥物治療後，將增加其新生兒畸型的比例。 但是目前尚未釐清藥物治療和/或疾病對於致畸程度之影響何者為甚。 此外，有效的抗癲癇治療不可中斷，因為疾病的惡化將不利於母親及胎兒。 使用 Lacosamide 之相關風險: 沒有孕婦使用 Lacosamide 的足夠數據。 在動物研究中，大鼠或兔子未顯示任何致畸胎作用 ，但在觀察到母體毒性劑量下，對於大鼠和兔子具胚胎毒性。 對人類潛在的風險未知。Lacosamide 不應該在懷孕期間使用，除非明確需要（如對母親的益處明顯大於對胎兒潛在的風險）。 如果婦女決定懷孕，使用本產品應仔細重新評估。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Lacosamide 會分泌至人類母乳中， 因此應考慮藥物對母親的重要性，來決定是否停止哺乳或停止使用Lacosamide 。,IVD;IVP;IVPUSH;,,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,may infuse over 15 minutes,Lacosamide injection may be administered without further dilution or mixed with NS， D5W， or LR. Preferably infuse over a period of 30 to 60 minutes; may infuse over 15 minutes if needed.,Preparation: If diluted prior to infusion， store at room temperature and administer within 4 hours of dilution.
OCAND8,Candesartan,Candis 8mg,CAVS,,適應症: Heart failure， (NYHA class II to IV， ejection fraction 40% or less) to reduce cardiovascular mortality and hospitalizations. Hypertension. 副作用: Common Cardiovascular: Hypotension (18.8% ) Musculoskeletal: Backache (3% .) Neurologic: Dizziness (less than 5% ) Respiratory: Pharyngitis (2% )， Rhinitis (2% )， Upper respiratory infection (6% ) 禁忌: Concomitant use with aliskiren in diabetic or renal impairment patients. Hypersensitivity to candesartan. Severe hepatic impairment &/or cholestasis. Lactating women and pregnant women.,,攝氏25度C以下,The recommended initial dose and maintenance dose is 8 mg， which could be increased to 16 mg. If poor control after four weeks with 16 mg once a day， the maximum dose can be increased to 32 mg once a day.,需調整劑量,[仿單]目前並未確知 Candesartan 是否會由人類乳汁中排出， 但已知 Candesartan 會由大白鼠乳汁中排出。 因為對哺乳的新生兒具有潛在的不良反應， 必須服用 Candesartan時應停止哺乳。,需調整劑量,沒有資料,Human data suggest risk in 2nd and 3 rd trimesters,[仿單]不建議使用於初期妊娠。禁用於懷孕第二期及第三期。流行病學資料尚未能證實懷孕初期暴露於ACEI可能增加畸胎的風險； 但無法排除有輕微提升的可能。雖未有angiotensin Ⅱ接受體拮抗劑在流行病學的資料， 但因屬同類產品，仍有相同的風險。除非繼續使用angiotensin Ⅱ接受體拮抗劑是必要的。 否則當病人有計畫要懷孕，就應改成其他對於使用在懷孕病人身上有安全療效的降血壓藥品。 一旦診斷懷孕，則應立即停止使用angiotensin Ⅱ接受體拮抗劑並開始使用其他合適的治療方式。 已知若懷孕第二及第三期間暴露在angiotensin Ⅱ接受體拮抗劑治療將導致畸胎。 ( 腎功能降低、羊水過少、顱骨發育遲滯 ) 及胎兒毒血症 ( 腎衰竭、低血壓、高血鉀 ) 當發生angiotensin Ⅱ接受體拮抗劑使用於懷孕第二期，建議使用超音波確認腎功能及顱部。 嚴密觀察母親使用了angiotensin Ⅱ接受體拮抗劑的嬰兒期低血壓情形。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並未確知 Candesartan 是否會由人類乳汁中排出， 但已知 Candesartan 會由大白鼠乳汁中排出。 因為對哺乳的新生兒具有潛在的不良反應， 必須服用 Candesartan時應停止哺乳。,AC;AC15;PC;PO;WM;,,,,,
IVAN1,Vancomycin,Vanlyo inj 1gm,QANB,,適應症: Caused by Staphylococcal infection: endocarditis， osteomyelitis， pneumonia， sepsis， soft tissue infection， and enteritis. Pseudomembranous colitis caused by clostridium infection. 副作用: Common Endocrine metabolic: Hypokalemia (13% ) Gastrointestinal: Abdominal pain (15% )， Diarrhea (9% )， Nausea (17% )， Vomiting ( 9% ) Serious Cardiovascular: Cardiac arrest， Hypotension Gastrointestinal: Clostridium difficile diarrhea Hematologic: Agranulocytosis， Neutropenia， Thrombocytopenia Immunologic: Anaphylaxis， Drug reaction with eosinophilia and systemic symptoms Otic: Ototoxicity Renal: Nephrotoxicity (5% ) 禁忌: Allergy to corn or corn products; premixed solution for IV use contains dextrose. Hypersensitivity to vancomycin.,,30℃以下儲存,Adult: 2 g/day IV divided every 6 to 12 hours administered over at least 60 minutes. Children: 40 mg/kg/day IV administered over at least 60 minutes. Neonates 2 to 4 weeks: Initial， 15 mg/kg IV， followed by 10 mg/kg IV every 8 hours; Neonates up to 1 week: Initial， 15 mg/kg IV， followed by 10 mg/kg IV every 12 hours. *****NEONATE ANTIBIOTICS DOSE***** Vancomycin: Dilute to a final concentration <=5 mg/mL; IV infusion over 90 minutes Draw trough level within 30 mins before the fourth dose. peak level 60 mins after end of infusion Sepsis PMA <=29 week Postnatal 0-14 days， dose: 10mg/kg Q18H PMA <=29 week Postnatal >=15 days， dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days， dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days， dose: 10mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days， dose 10mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days， dose 10mg/kg Q8H PMA >=45 week: 10mg/kg Q6H Meningitis PMA<=29 week Postnatal 0-14 days dose: 15mg/kg Q18H PMA <=29 week Postnatal >=15 days， dose: : 15mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days， dose: 15mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days， dose: 15mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days， dose: 15mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days， dose: 15mg/kg Q8H PMA >=45 week: 15mg/kg Q6H,無需調整劑量,[仿單]未有相關說明.,需調整劑量,沒有資料,Compatible,[仿單]未有相關說明.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]未有相關說明.,IMP;INS;IRR;IVD;IVI;SUBCI;,IVD: 20 mL 無菌注射用水,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,,給藥濃度 2.5~5mg/mL，輸注速率< 10 mg/min，至少以超過60分鐘以上時間緩慢滴注。對某些液體需要限制的病患，可以將濃度提高至10mg/mL。,[仿單]Vancomycin 粉末1g 瓶裝內加入 20ml 無菌注射用水。需要稀釋才能使用。配好之液可貯存於冰箱中 96 小時，且效力沒有明顯的減退。配好製劑 1g 加入 200ml 以上的稀釋液稀釋，依此劑量稀釋，且超過 60 分鐘的間歇性靜脈注射給藥。 1. 監測體溫、CBC、腎功能、聽覺功能。 2. 注意輸注過快時的不良反應：低血壓、呼吸困難、蕁麻疹。 3. 建議監測藥物血中濃度。 4. 給藥濃度: 2.5~5mg/mL，利用輸注液給藥，濃度不可超過 5mg/mL。
OBISC,Bisacodyl,Bisacodyl E.C. 5mg 秘克的腸溶錠,ALIM,,適應症:Treatment of constipation; colonic evacuation prior to procedures or examination. 副作用:Abdominal cramps (mild)， electrolyte disturbance (metabolic acidosis or alkalosis， hypocalcemia)， nausea， rectal irritation (burning)， vertigo， vomiting 禁忌:Hypersensitivity to bisacodyl or any component of the formulation; abdominal pain or obstruction， nausea， or vomiting,,攝氏25度C以下,Relief of constipation: Adult or 10 years older Children， Oral: 5-10 mg at bedtime. 4-10 years old Children， Oral: 5 mg at bedtime.,無需調整劑量,[仿單]尚未確定Bisacodyl是否進入乳汁中. 然而，如同所有的藥物，懷孕期間，除非有醫囑，否則孕婦及授乳者都不可使用.,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]尚無本藥用於懷孕婦女的適當及控制良好之研究. 長期用藥經驗顯示懷孕期間，使用本藥無不良反應或傷害性. 然而，如同所有的藥物，懷孕期間，除非有醫囑，否則孕婦及授乳者都不可使用.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]尚未確定Bisacodyl是否進入乳汁中. 然而，如同所有的藥物，懷孕期間，除非有醫囑，否則孕婦及授乳者都不可使用.,AC;PC;PO;,,,,,
ICAGL,Calcium gluconate,Calcium gluconate inj 10%， 10mL,NUTR,,適應症:Ca deficiency. 副作用: Cardiovascular (with rapid I.V. injection): Arrhythmia， bradycardia， cardiac arrest， hypotension， syncope， vasodilation Central nervous system: Sense of oppression (with rapid I.V. injection) Endocrine & metabolic: Hypercalcemia Gastrointestinal: Chalky taste Neuromuscular & skeletal: Tingling sensation (with rapid I.V. injection) Miscellaneous: Heat waves (with rapid I.V. injection) 禁忌：Ventricular fibrillation; hypercalcemia; concomitant use of I.V. calcium gluconate and ceftriaxone in neonates (risk of precipitation of calcium-ceftriaxone),,室溫,Intravenous use. (4.62mEq/10mL) Adult: The usual dose in adults is 5~10 mL per time of Calcium Gluconate 10 %. Childen patients: 2~5 mL per time of Calcium Gluconate 10 %.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,1.本品為10 mL包裝，僅供TPN調配使用。 2.adults the intravenous administration rate should not exceed 2 ml (0，45 mmol of calcium) per minute.
IGAR1,HPV type 6/11/16/18 L1 protein,Gardasil 0.5mL/dose(限專案員工用),HIMM,,適應症: Prevention of cervical cancer， genital warts & precancerous or dysplastic lesions eg， cervical adenocarcinoma in situ， cervical intraepithelial neoplasia (CIN) grades 2 & 3， vulvar intraepithelial neoplasia (VIN) grades 2 & 3， vag intraepithelial neoplasia grades 2 & 3 (VaIN)， cervical intraepithelial neoplasia grade 1 in girls & women 9-26 yr. 副作用: Injection site reactions， fever， nausea， dizziness. 禁忌: Hypersensitivity.,,2-8℃,0.5 mL IM in the deltoid region of the upper arm or in the higher anterolateral area of the thigh， according to the following schedule: 1st dose: At elected date; 2nd dose: 2 month after the 1st dose; 3rd dose: 6 month after the 1st dose.,,,,可能安全,,,,,,,,,,
OURI2,Silodosin,Urief 4mg,SGU,,適應症:Treatment of signs and symptoms of benign prostatic hyperplasia (BPH). 副作用:Drowsiness， postural hypotension， syncope， asthenia， depression， headache， dry mouth， GI disturbances， edema， blurred vision， rhinitis， erectile disorders， tachycardia， palpitation， hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy. 禁忌:Severe hepatic impairment; severe renal insufficiency.,,室溫,Oral: 4 mg bid after meal.,無需調整劑量,,需調整劑量,沒有資料,,,Unknown 沒有資料,,PC;PO;,,,,,
EFOX5,Fluorometholone,0.1% FOXONE oph susp 5mL,TOPH,,適應症: Acute & chronic iritis， iridocyclitis， scleritis， episcleritis， conjunctivitis， keratitis， resistant ocular allergy & inflammation following surgery 副作用: Glaucoma with optic nerve damage， visual acuity or field defects， raised intraocular pressure， secondary infection (persistent corneal ulceration， possibly fungal invasion)， perforation of globe， posterior subcapsular cataract formation 禁忌: Acute superficial herpes simplex keratitis， fungal diseases of ocular structure; vaccinia， varicella & other viral diseases of the cornea & conjunctiva， eye TB,,室溫,Instill 1-2 drops bid-qid,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
OTRCT,Tramadol + Acetaminophen,Traceton 37.5/325mg,CNEU,Pain， acute (Moderate to Severe)， Not responsive to non-narcotic analgesics.,Previous hypersensitivity to tramadol， acetaminophen， any other component of the product， or opioids. Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days. Significant respiratory depression. In the event of acute intoxication with alcohol， sleep aids， narcotics， centrally acting analgesics， opiates or psychotropic drugs.,Common Dermatologic: Diaphoresis (1% to 4% )， Pruritus (1% to 2% ) Gastrointestinal: Constipation (1% to 6% )， Diarrhea (1% to 3% )， Loss of appetite (1% to 3% )， Nausea (1% to 3% )， Xerostomia (1% to 2% ) Neurologic: Dizziness (1% to 3% )， Insomnia (2% )， Somnolence (1% to 6% ) Serious Dermatologic: Generalized exanthematous pustulosis， acute， Stevens-Johnson syndrome， Toxic epidermal necrolysis Hepatic: Hepatotoxicity Immunologic: Anaphylaxis Neurologic: Seizure (less than 1% ) Other: Serotonin syndrome,25℃以下儲存,Adult and children > 16 years: 1-2 tablets Q4H-Q6H， the maximum dose: 8 tablets/day.,需調整劑量,ACETAMINOPHEN: Compatible TRAMADOL: Limited Human Data—Potential Toxicity [仿單]因未曾研究本品用於嬰兒及新生兒的安全性，故不建議哺乳的母親使用本品。,需調整劑量,沒有資料,Human (and animal) data suggest risk,ACETAMINOPHEN: Human Data Suggest Low Risk TRAMADOL: Human Data Suggest Risk [仿單]已證明Tramadol會穿過胎盤。未對懷孕婦女作過充份且完善對照的研究。懷孕期間的使用安全性尚未確定。在懷孕期間延長使用本品或其他鴉片類藥物，可能導致新生兒鴉片類藥物戒斷症狀。特別在懷孕的最後三個月時會增加此風險。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,ACETAMINOPHEN: Compatible TRAMADOL: Limited Human Data—Potential Toxicity [仿單]因未曾研究本品用於嬰兒及新生兒的安全性，故不建議哺乳的母親使用本品。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
EKARY,Pirfenoxone,Kary Uni 0.005%， 5mL ophthalmic suspension,TOPH,Incipient senile cataract.,Hypersensitivity to any component of this product.,Blepharitis， contact dermatitis， itching， keratitis superficialis diffusa， conjunctival irritation.,1-30℃,Shake the bottle well， and apply 1-2 drops at a time， 3-5 times a day.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,OD;OL;OU;,,,,,
LSOR,Dextromethorphan+Guaiacol Glycolate+Ipecac extract,息咳液Sortuss Cough liquid 60mL,ERSP,Cough， expectorant,Hypersensitivity to any any excipients.,Common Neurologic: Dizziness (mild)， Somnolence (mild)， Lethargy Other: Fatigue (mild) Gastrointestinal: Diarrhea， Stomach cramps， Nausea， Vomiting Musculoskeletal: Myalgia， Chronic use Serious Renal: Nephrolithiasis， Large quantity consumption Cardiovascular: Cardiomyopathy， Chronic use,25℃以下，不需冰存並避免陽光直射,Adults:10-20 mL Q4H. Pediatric: 6-12 yrs: 6-10 mL Q4H， 2-6 yrs: 2-6 mL Q4H.,無需調整劑量,Dextromethorphan: Compatible. Guaiacol Glycolate: 沒有資料 Ipecac Fluid Extract: 沒有資料 [仿單]沒有相關敘述,無需調整劑量,沒有資料,Uknown 沒有資料,Dextromethorphan: Compatible. Guaiacol Glycolate: 沒有資料 Ipecac Fluid Extract: 沒有資料 [仿單]沒有相關敘述,Unknown 沒有資料,Dextromethorphan: Compatible. Guaiacol Glycolate: 沒有資料 Ipecac Fluid Extract: 沒有資料 [仿單]沒有相關敘述,AC;AC15;PC;PO;WM;,,,,,
IMER75,FSH 75 IU + LH 75 IU,Meriofert inj 75/75 IU,HM,Promote ovulation in women who are not ovulating and who have not responded to other treatments.,Hypersensitivity to Meriofert or any component of the formulation; primary ovarian failure as indicated by a high follicle-stimulating hormone level; uncontrolled nongonadal endocrinopathies (eg， thyroid， adrenal， pituitary); pituitary or hypothalamic tumors; sex hormone-dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement not due to polycystic ovary syndrome; pregnancy and lactation. Meriofert is contraindicated when an effective response cannot be achieved， for example， Primary ovarian failure， Malformations of sexual organs incompatible with pregnancy， and Fibroid tumors of the uterus incompatible with pregnancy.,Common(1-10%): Ovarian Hyperstimulation Syndrome (symptoms include ovarian cyst formation or enlargement of existing cysts， lower stomach pain， feeling thirsty and sick， and sometimes being sick， passing reduced quantities of concentrated urine and weight gain). The following side effects have also been reported: Very Common (likely to affect up to 10%): Headache， Swollen or bloated stomach. Common (likely to affect between 1-10%): Abdominal pain or discomfort， Pelvic pain， Back pain， Sensation of heaviness， Breast discomfort， Dizziness， Hot flushes， Thirst， Feeling sick， Tiredness， Feeling generally unwell， Injection site reactions such as pain and inflammation (frequency higher with IM than SC). Rare (likely to affect up to 0.01-0.1%): Ovarian torsion. Very rare (likely to affect up to 0.001-0.01%): Thromboembolism.,溫度不可超過25℃避光儲存,Each vial of powder contains highly purified menotrophin (human menopausal gonadotrophin， HMG) corresponding to 75 IU human follicle stimulating hormone (FSH) and 75 IU human luteinising hormone (LH) activity. A commonly used regimen starts at 75 to 150 IU of FSH per day and is increased if necessary by 37.5 IU (up to 75 IU)， with intervals of 7 or 14 days preferably， in order to achieve an adequate but not excessive response. Maximum daily dosages of HMG Meriofert should generally not exceed 225 IU. The treatment should be adjusted to the individual patient's response， assessed by measuring the follicle size by ultrasonography and/or oestrogen levels. The daily dose is then maintained until pre-ovulatory conditions are reached. Usually， 7 to 14 days of treatment is sufficient to reach this state.,無需調整劑量,[仿單] 至於HMG是否會滲透於母乳中以及對吸食母乳嬰兒的影響，是未知的。 因此，授乳婦女禁用此藥。,無需調整劑量,不可使用,Uknown 沒有資料,[仿單] 根據人體或動物實驗證實，會對胎兒有危險性。 因此在利弊相較之下，與懷孕婦女注射本藥品(HMG)是太危險的。 因此懷孕婦女禁用此藥。,Unknown 沒有資料,[仿單] 至於HMG是否會滲透於母乳中以及對吸食母乳嬰兒的影響，是未知的。 因此，授乳婦女禁用此藥。,IM;SC;,,,,,1. 混合後的Meriofert溶液必須立刻使用。
EGLIC,Povidone Iodine + Iodine,Glycerinum Iodi Compositum 450gm/bottle,TENT,As an antiseptic agent for laryngitis， tonsillitis.,Hypersensitivity to iodine or any component of the formulation exists.,Dermatologic: Localized erythema， severe dermatological reaction (localized; rare). Hypersensitivity: Local hypersensitivity reaction. Local: Application site pain (persistent or increases)， local irritation， local swelling.,30℃以下貯存,Antiseptic， Topical: Apply to the affected area 1 to 3 times daily.,無需調整劑量,[仿單] 有下列情形者，使用前請先諮詢醫師藥師藥劑生：兒童、孕婦、可能懷孕婦女及哺乳婦女。 本藥可能全身性吸收，反覆使用可能會造成新生兒甲狀腺功能低下、孕婦及其胎兒及哺乳婦女甲狀腺腫及甲狀腺功能低下。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 有下列情形者，使用前請先諮詢醫師藥師藥劑生：兒童、孕婦、可能懷孕婦女及哺乳婦女。 本藥可能全身性吸收，反覆使用可能會造成新生兒甲狀腺功能低下、孕婦及其胎兒及哺乳婦女甲狀腺腫及甲狀腺功能低下。,Unknown 沒有資料,[仿單] 有下列情形者，使用前請先諮詢醫師藥師藥劑生：兒童、孕婦、可能懷孕婦女及哺乳婦女。 本藥可能全身性吸收，反覆使用可能會造成新生兒甲狀腺功能低下、孕婦及其胎兒及哺乳婦女甲狀腺腫及甲狀腺功能低下。,EXT;,,,,,本品有效成分及含量：每1000gm含有 Iodine 10gm + Potassium Iodine 20gm
IAMII,Amino Acids,Aminosteril infant 6% 100mL,NUTR,Partial parenteral nutrition in premature infants， babies and small children.,Disturbances in amino acid metabolism， acidosis， hyperhydration， hypokalemia. Insufficient renal or hepatic function. Hyponatremia.,Fluid， electrolyte imbalance,25℃以下,As TPN material. Age of 1 year: 1.5 – 2.5 g amino acids/kg body weight/day. Age of 2-5 years: 1.5 g amino acids/kg body weight/day. Age of 6-14 years: 1.0 g amino acids/kg body weight/day. Maximum infusion rate: 0.1 g amino acids /kg body weight/hr = 1.67 mL/kg body weight/hr.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,IVD: Maximum infusion rate = 1.67 mL/kg/hour (仿單),
IDTAP,Diphtheria + Tetanus + Pertussis,SK-DPT3(三合一疫苗，政府提供) 0.5mL/dose,HIMM,,適應症:Diphtheria， tetanus， and pertussis disease prevention 副作用: Central nervous system: Drowsiness， irritability， lethargy Gastrointestinal: Decreased appetite， vomiting Local: Erythema at injection site， local pain， localized edema， tenderness at injection site Miscellaneous: Crying (prolonged or persistent)， fever， fussiness 禁忌:Hypersensitivity to diphtheria， tetanus toxoids， pertussis， or any component of the formulation; progressive neurologic disorder， including infantile spasms， uncontrolled epilepsy or progressive epilepsy (postpone until condition stabilized); encephalopathy occurring within 7 days of administration and not attributable to another cause,,冷藏 (2-8 C),0.5 mL per dose. Given at 5 to 6 years of age， prior to starting school or kindergarten; 0.5 mL IM as a single dose.,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IPV,Inactivated poliovirus vaccine,Imovax Polio(小兒麻痺疫苗，政府提供) 0.5mL/dose,HIMM,,適應症:Poliovirus prevention 副作用: Percentages noted with concomitant administration of DTP or DTaP vaccine and observed within 48 hours of injection. >10%: Central nervous system: Irritability (7% to 65%; most common in infants 2 months of age)， tiredness (4% to 61%) Gastrointestinal: Anorexia (1% to 17%) Local: Injection Site: Tenderness (?29%)， swelling (?11%) 1% to 10%: Central nervous system: Fever >39°C (?4%) Gastrointestinal: Vomiting (1% to 3%) Local: Injection site: Erythema (?3%) Miscellaneous: Persistent crying (?1% reported within 72 hours) 禁忌:Hypersensitivity to any component of the vaccine,,冷藏 (2-8 C),Immunization: IM， SubQ: Primary immunization: Infants and Children 6 weeks to 47 months: Administer three 0.5 mL doses， at 2， 4， and 6 to 18 months,,懷孕及哺乳分級參考UpToDate.,,沒有資料,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,懷孕及哺乳分級參考UpToDate.,,,,,,
ICIM,Certolizumab pegol,Cimzia inj 200mg/1mL,HIMM,Ankylosing spondylitis， Active. Crohn's disease， Active， moderate to severe. Non-radiographic axial spondyloarthritis. Plaque psoriasis， Moderate to severe. Psoriatic arthritis， Active. Rheumatoid arthritis， Active， moderate to severe.,Hypersensitivity to certolizumab pegol or any component of the product. Severe infections or Moderate to severe heart failure.,Common •Musculoskeletal: Arthralgia (6%) •Renal: Urinary tract infectious disease (7%) •Respiratory: Upper respiratory infection (19.4% to 21.9%) Serious •Cardiovascular: Cardiac dysrhythmia， Congestive heart failure， Hypertensive heart disease， Myocardial infarction， Pericardial effusion， Pericarditis •Dermatologic: Erythema multiforme， Erythema nodosum， Stevens-Johnson syndrome， Toxic epidermal necrolysis， Urticaria •Gastrointestinal: Bowel obstruction •Hematologic: Cytopenia •Immunologic: Hypersensitivity reaction (Rare )， Lupus erythematosus (Rare )， Malignant lymphoma， Opportunistic infection •Neurologic: Demyelinating disease of central nervous system (rare )， Seizure •Psychiatric: At risk for suicide •Renal: Nephrotic syndrome， Renal failure •Other: Cancer， Infectious disease， Listeriosis,2-8°C冷藏，不可冷凍,SC， Ankylosing spondylitis， non-radiographic axial spondyloarthritis， plaque psoriasis， psoriatic arthritis， rheumatoid arthritis 400 mg once and then repeat at weeks 2 and 4; maintenance， 200 mg every 2 weeks or 400 mg once every 4 weeks. Crohn's disease 400 mg (as 2 injections of 200 mg) once and then repeat at weeks 2 and 4; maintenance ， 400 mg once every 4 weeks.,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,SC;,,,,,1.以皮下注射方式給藥。注射部位必須輪替，且不可注射於皮膚脆弱、瘀血、發紅或僵硬的部位。需要注射 400毫克時 (皮下注射 200 毫克兩劑)，應分別注射於大腿或腹部的不同部位。 2. 30 分鐘後可恢復室溫。不可使用其他回溫方式。若有氣泡為正常現象，在注射前不需移除氣泡。 3.不要搓揉注射部位。
OEXV,Dasabuvir,Exviera FC 250mg,QANB,,適應症:With other antivirals for the treatment of chronic hepatitis C genotype 1. 副作用:Insomnia， nausea， pruritus， asthenia， fatigue， anaemia. Reports of hepatic decompensation and hepatic failure. 禁忌:Severe hepatic impairment. Pregnancy， lactation.,,,Treatment of chronic hepatitis C in patients with genotype 1 in combination with other drugs. 250 mg orally twice daily in the morning and evening with food in combination with other HCV drugs.,需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
EIZB,Travoprost,Izba 0.003%， 2.5mL eye drops,TOPH,Reduction of intraocular pressure in patients with open-angle glaucoma or ocular HTN.,Hypersensitivity to travoprost， benzalkonium chloride.,Ocular hyperemia， decreased visual acuity， eye discomfort， itch & pain， blepharitis， blurred vision， conjunctivitis， dry eye， foreign body sensation， iris discoloration， keratitis， photophobia & tearing. Neurologic: Foreign body sensation (5%-10%) Ophthalmic: Blepharitis， Blurred vision， Itching of eye (5%-10%)， Ocular hyperemia (35%-50%)， Pain in eye， Reduced visual acuity,30℃以下,Instill 1 drop in the affected eye(s) once every evening.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
LLACT,Lactulose,Lactul syrup 666mg/mL， 300mL,ALIM,,適應症: Chronic portal systemic encephalopathy， hepatic pre coma， hepatic coma 副作用: Flatulence， nausea， vomiting， abdominal pain & diarrhea occasionally with electrolyte imbalance (high doses only). 禁忌: Galactosemia， bowel obstruction.,,室溫,1. Chronic constipation:  Starting dose(for 3 days) aintenance -------------------- ---------------------------------- --------------------- Severe cases 0-45 ml 15-25 ml Moderate cases 5-30 ml 10-15 ml Mild cases 5ml 10 ml 7-14yr 15 ml 10-15 ml 1-6yr 5-10 ml 5-10 ml Infant 1-12mth 5 ml 5 ml All doses to be taken daily preferably as single doses. 2. Precoma & hepatic coma: Starting doses: approx 30-50 ml tid. In acute cases a retention enema is given in a proportion of 300ml Duphalac to 700 ml water. Rectal administration (retention enema): 200 g (300 mL) diluted with 700 mL of water or NS via rectal balloon catheter; retain for 30-60 minutes; may repeat every 4-6 hours; transition to oral treatment prior to discontinuing rectal administration.,無需調整劑量,Excretion in breast milk unknown/use caution,無需調整劑量,,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Excretion in breast milk unknown/use caution,,,,,,
IMEN6,FSH 600 IU + LH 600 IU,MENOPUR multidose 600 IU,HM,Treatment of infertility in anovulation， including polycystic ovarian disease (PCOD)， in women unresponsive to treatment with clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (ART)， gamete intra-fallopian transfer (GIFT)， & intracytoplasmic sperm inj (ICSI).,Hypersensitivity. Women with tumors of pituitary gland or hypothalamus; ovarian， uterine or mammary carcinoma; gynaecological haemorrhage of unknown aetiology; ovarian cysts or enlarged ovaries not due to polycystic ovarian disease; primary ovarian failure， malformation of sexual organs & fibroid tumors of the uterus incompatible with pregnancy. Pregnancy & lactation.,Abdominal pain & distention， nausea， enlarged abdomen， pain at inj site， headache， ovarian hyperstimulation syndrome (OHSS) & pelvic pain.,2-8℃避免冷凍,Anovulatory infertility (including PCOD):In menstruating patients， treatment should be started within the first 7 days of the menstrual cycle. The recommended initial dose is 75-150 IU daily， which should be maintained for at least 7 days. Adjustments in dose should not be made more frequently than every 7 days. The recommended dose increment is 37.5 IU per adjustment， and should not exceed 75 IU. Maximum daily dose < 225 IU. When an optimal response is obtained， a single injection of 5000 - 10000 IU hCG should be given 1 day after the last MENOPUR injection .Women undergoing controlled ovarian hyperstimulation for multiple follicular development for assisted reproductive technologies (ART): MENOPUR therapy should start approximately 2 weeks after the start of agonist treatment. The recommended initial dose of MENOPUR is 150-225 IU daily for at least the first 5 days of treatment. Based on clinical monitoring (including ovarian ultrasound alone or in combination with measurement of oestradiol levels) subsequent dosing should be adjusted according to individual patient response， and should not exceed more than 150 IU per adjustment. The maximum daily dose given should not be higher than 450 IU daily and in most cases dosing beyond 20 days is not recommended.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,IM;SC;,使用廠商提供之溶劑溶解,,X,X,Attach the reconstitution needle to the pre-filled syringe. Inject the total contents of the solvent into the vial containing the powder. The powder should dissolve quickly to a clear solution. If not， roll the vial gently between the hands until the solution is clear. Vigorous shaking should be avoided.
OPYRZ,Pyrazinamide,Pyrazinamide 500mg,QANB,Treatment of pulmonary & extrapulmonary TB.,Hypersensitivity to pyrazinamide or any component of the formulation; acute gout; severe hepatic damage,Hepatotoxicity， jaundice， hyperuricemia leading to attacks of gout， anorexia， nausea， vomiting， arthralgia， malaise， fever， sideroblastic anemia， difficulty in micturition. Endocrine metabolic: Hyperuricemia Gastrointestinal: Nausea， Vomiting Musculoskeletal: Arthralgia (40%),25℃以下,(仿單) 1500-2000 mg/day (3-4 tablets) divided into 1-3 doses. (熱病) Adult: 25 mg/kg po Q24H (maximum: 2.5 g/day). Pediatric: 15-30 mg/kg/day (once daily， maximum: 2 g/day) or 50 mg/kg twice weekly (maximum: 2 g/day).,無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,PREGNANCY RECOMMENDATION: Compatible—Maternal Benefit >> Embryo–Fetal Risk,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PO;WM;,,,,,
OAMIT,Amitriptyline,Pinsaun 25mg,CNEU,,適應症: Major depressive disorder 副作用: Frequency not defined. Cardiovascular: Atrioventricular conduction disturbance， cardiac arrhythmia， cardiomyopathy (rare)， cerebrovascular accident， ECG changes (nonspecific)， edema， facial edema， heart block， hypertension， myocardial infarction， orthostatic hypotension， palpitations， syncope， tachycardia Central nervous system: Anxiety， ataxia， cognitive dysfunction， coma， confusion， delusions， disorientation， dizziness， drowsiness， drug withdrawal (nausea， headache， malaise， irritability， restlessness， dream and sleep disturbance， mania [rare]， and hypomania [rare])， dysarthria， EEG pattern changes， excitement， extrapyramidal reaction (including abnormal involuntary movements and tardive dyskinesia)， fatigue， hallucination， headache， hyperpyrexia， insomnia， lack of concentration， nightmares， numbness， paresthesia， peripheral neuropathy， restlessness， sedation， seizure， tingling of extremities Dermatologic: Allergic skin rash， alopecia， diaphoresis， skin photosensitivity， urticaria Endocrine & metabolic: Altered serum glucose， decreased libido， galactorrhea， gynecomastia， increased libido， SIADH， weight gain， weight loss Gastrointestinal: Ageusia， anorexia， constipation， diarrhea， melanoglossia， nausea， paralytic ileus， parotid gland enlargement， stomatitis， unpleasant taste， vomiting， xerostomia Genitourinary: Breast hypertrophy， impotence， testicular swelling， urinary frequency， urinary retention， urinary tract dilation Hematologic & oncologic: Bone marrow depression (including agranulocytosis， leukopenia， and thrombocytopenia)， eosinophilia， purpura Hepatic: Hepatic failure， hepatitis (rare; including altered liver function and jaundice) Hypersensitivity: Tongue edema Neuromuscular & skeletal: Lupus-like syndrome， tremor， weakness Ophthalmic: Accommodation disturbance， blurred vision， increased intraocular pressure， mydriasis Otic: Tinnitus Postmarketing and/or case reports: Angle-closure glaucoma， neuroleptic malignant syndrome (rare; Stevens， 2008)， serotonin syndrome (rare) 禁忌: Hypersensitivity to amitriptyline or any component of the formulation; coadministration with or within 14 days of MAOIs; coadministration with cisapride; acute recovery phase following myocardial infarction,,25度C以下密封保存,Adult 25-50 mg bid-tid.,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest low risk,[仿單] 孕婦投與:三環系抗鬱藥物，經動物實驗有催畸形作用,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;AM;PC;PO;WM;,,,,,
OSILY,Silymarin,Silygen 70mg(複方),ALIM,Chronic liver diseases， liver cirrhosis， fatty liver.,Hypersensitivity to any ingredients of the capsule.,GI disturbance， nausea， vomiting， flatulence， diarrhea， diuresis,乾燥，25℃以下,1-2 capsules TID. after meals. Each cap contains: Exsiccated Fructus Cardui Mariae extract.................................140mg (eq. to 70mg of Silymarin Calculated as Silybin) Thiamine Hydrochloride................................................................4mg Riboflavin......................................................................................4mg Pyridoxine Hydrochloride..............................................................4mg Nicotinamide................................................................................12mg Calcium Pantothenate....................................................................8mg Cyanocobalamin..........................................................................1.2μg,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;AM;PC;PO;WM;,,,,,
OCIZO,Trazodone,Cirzodone 50mg 杏緩妥錠,CNEU,,適應症: Treatment of unipolar major depressive disorder 副作用: >10%: Central nervous system: Drowsiness (24% to 41%)， dizziness (20% to 28%)， headache (10% to 20%)， nervousness (15%)， fatigue (6% to 11%) Gastrointestinal: Xerostomia (15% to 34%)， nausea and vomiting (10% to 13%) Ophthalmic: Blurred vision (6% to 15%) 1% to 10%: Cardiovascular: Hypotension (4% to 7%)， syncope (3% to 5%)， palpitations (<2%)， sinus bradycardia (<2%)， tachycardia (<2%; may include syncope) Central nervous system: Confusion (5%)， ataxia (2% to 5%)， heavy headedness (3%)， malaise (3%)， lack of concentration (1% to 3%)， disorientation (2%)， akathisia (<2%)， chest pain (<2%)， delusions (<2%)， hallucination (<2%)， hypomania (<2%)， memory impairment (<2%)， numbness (<2%)， paresthesia (<2%)， speech disturbance (<2%) Endocrine & metabolic: Weight loss (6%)， weight gain (1% to 5%)， change in menstrual flow (<2%)， increased libido (<2%) Gastrointestinal: Constipation (7% to 8%)， gastrointestinal disease (6%)， diarrhea (5%)， flatulence (<2%)， increased appetite (<2%)， sialorrhea (<2%) Genitourinary: Early menses (<2%)， hematuria (<2%)， impotence (<2%)， retrograde ejaculation (<2%)， urinary frequency (<2%)， urinary hesitancy (<2%) Hematologic & oncologic: Anemia (<2%) Hypersensitivity: Angioedema (3% to 7%)， hypersensitivity reaction (<2%) Neuromuscular & skeletal: Myalgia (5% to 6%)， tremor (3% to 5%)， muscle twitching (<2%) Ophthalmic: Asthenopia (<=3%)， eye pruritus (<=3%)， eye redness (<=3%) Respiratory: Nasal congestion (<=6%)， paranasal sinus congestion (<=6%)， dyspnea (<2%) Frequency not defined: Cardiovascular: Hypertension， ventricular premature contractions Central nervous system: Suicidal ideation， suicidal tendencies <1%， postmarketing， and/or case reports: Abnormal dreams， agitation， alopecia， anxiety， aphasia， apnea， asthenia， atrial fibrillation， bradycardia， breast engorgement， breast hypertrophy， cardiac arrhythmia， cardiac conduction disturbance， cardiac failure， cerebrovascular accident， chills， cholestasis， diplopia， edema， esophageal achalasia， extrapyramidal reaction， female sexual disorder (clitorism)， hemolytic anemia， hirsutism， hyperbilirubinemia， increased amylase， insomnia， jaundice， lactation， leukocytosis， leukonychia， liver enzyme disorder， methemoglobinemia， myocardial infarction， orthostatic hypotension， paranoia， priapism， prolonged QT interval on ECG， pruritus， psoriasis， psychosis， SIADH， skin rash， stupor， tardive dyskinesia， tonic clonic epilepsy， torsades de pointes， urinary incontinence， urinary retention， urticaria， vasodilation， ventricular ectopy， ventricular tachycardia， vertigo 禁忌: Hypersensitivity to trazodone or any component of the formulation; use of MAOIs intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either trazodone or the MAOI); initiation of trazodone in a patient receiving linezolid or intravenous methylene blue,,室溫儲存,150 mg daily. Dose may be gradually increased. Out-patient Max: 400 mg/day. In-patient 600 mg/day.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,[仿單] 動物試驗發現30-50倍人類最大劑量會增加胎兒吸收副作用， 用於懷孕期間需評估潛在利益與胎兒潛在危險.,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
IBCGSII,BCG Immunotherapeutic,SII-ONCO-BCG inj 40mg/mL(專案進口),RACA,For treatment of flat Urothelial Cell Carcinoma in Situ of urinary bladder and as adjunctive therapy following. Transurethral resection of primary or relapsing superficial noninvasive papillary tumors that are limited to the bladder mucosa (stage Ta or T1). Intravesical BCG Immunotherapy has been shown to reduce tumor recurrence and prevent progression.,Impaired immune response irrespective of whether this impairment is congenital or caused by disease， drugs or other therapy. Positive HIV serology. Pregnancy and lactation; safety of the mode of therapy in pregnant women， nursing mothers and children has not been evaluated. Positive tuberculin reaction in conjunction with clinical evidence of existing active tuberculosis. Urinary tract infections : Treatment should be withheld till urine culture is negative and antibiotic therapy is stopped. Trauma to urinary bladder. A patient with fever needs careful evaluation before therapy is instituted. On going treatment with antitubercular agents.,Fever more than 39oC. The fever resolves within 24 – 48 hours with antipyretics and fluids. Systemic BCG infections due to traumatic catheterization， perforation of bladder or early BCG instillation after extensive TURBT which may be manifested by pneumonitis， hepatitis or cytopenia. Patients with such symptoms should be treated with tuberculostatic drugs as per treatment schedules used. Triple drug therapy with or without cycloserine for some weeks should be used. Granulomatous Prostatitis. Arthritis， Arthralgia， Haematuria， Orchitis， Transient urethral obstruction， Epididymitis or bladder contraction may occur.,2-8℃,Treatment should be started 2-3 weeks after performing TURBT(transurethral resection of bladder tumor). The treatment schedule is weekly repeated instillation 120 mg during first 6 weeks， followed by 3 consecutive weekly instillations at 3 months， at 6 months and thereafter every 6 months upto 36 months. This means that a patient who stays tumor free after the initial resection will receive a total of 27 instillations in a period of three years. The duration and frequency of maintenance treatment should be evaluated on the basis of tumor classification and clinical diagnosis.,無需調整劑量,[仿單]哺乳列於禁忌症，此治療方式對懷孕女性、哺乳婦女及孩童的安全性尚未被評估。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]懷孕列於禁忌症，此治療方式對懷孕女性、哺乳婦女及孩童的安全性尚未被評估。,Unknown 沒有資料,[仿單]哺乳列於禁忌症，此治療方式對懷孕女性、哺乳婦女及孩童的安全性尚未被評估。,IRR;,1mL無菌、不含防腐劑的生理食鹽水,,,,1.應避光儲存於2℃-8℃；重新調配前與重新調配後的內容物不可暴露於光線下；重新調配後之藥物應立即使用並丟棄沒使用的部分。 2.患者須在灌注4小時前及灌注2小時後不得攝取任何液體；若有任何出血或創傷的跡象，須延後至少一個禮拜再進行治療；建議灌注後一個禮拜不要性行為，或者使用保險套。 3.灌注後6小時內排出的尿液需經適當地消毒。(加入等量的漂白水靜置15分鐘後沖掉) 4.配製: 注入1mL無菌、不含防腐劑的生理食鹽水至瓶中，靜置數分鐘。然後輕輕旋轉藥瓶直到混合成均勻的懸浮液，，注意不可劇烈的攪動。將配製好的懸浮液轉移至50mL針筒裡，再用1mL生理食鹽水沖洗空瓶，將瓶壁上之殘留藥劑沖洗下來，將沖洗下之液體加到50mL針筒裡。最後再注入無菌生理食鹽水於針筒中，其總體積至多50mL，小心混勻後便可使用。 5.給藥: 將導尿管以無菌技術通過尿道插入膀胱，排空膀胱的尿液。將含有藥品的50mL針筒接上導尿管，利用重力慢慢注入到膀胱，應盡量停留懸浮液在膀胱2小時；開始灌注後的15分鐘內患者應先維持俯臥之姿勢，之後每15分鐘更換姿勢在每一側，以使藥物能適當的分布至整個膀胱，最後患者須以坐姿將藥物排空。
IBEX,Meningococcal group B Vaccine,Bexsero 0.5mL/dose (B型腦膜炎雙球菌疫苗),HIMM,Vaccine for 2 months older infants， children， and Adults to prevent meningococcal group B disease (also known as meningitis B) caused by Neisseria meningitidis bacteria.,Hypersensitivity， including severe allergic reaction， to any component of the vaccine， or after a previous dose of Bexsero. (List of excipients: Sodium chloride， Histidine， Sucrose， Water for injections. Kanamycin is used in early manufacturing process and is removed during the later stages of manufacture. If present， kanamycin levels in the final vaccine are less than 0.01 micrograms per dose. The safe use of Bexsero in kanamycin-sensitive individuals has not been established.),pain at the injection site (> or =83%)， myalgia (> or =48%)， erythema (> or =45%)， fatigue (> or =35%)， headache (> or =33%)， induration (> or =28%)， nausea (> or =18%)， and arthralgia (> or =13%).,2-8°C.不可冷凍,Adult and children > or = 2 years older: 2 doses (0.5 mL) at least 1 month apart. And necessity of booster dose is according to risk of exposure. Children 12-23 months old: 2 doses (0.5 mL) at least 2 month apart. And recommend booster 1 dose after 12-23 months. Infant 6-11 months old: 2 doses (0.5 mL) at least 2 month apart. And recommend booster 1 dose at 24 months old， between primary series at least 2 month apart. Infant 2-5 months old: 2 doses (0.5 mL) at least 2 month apart or 3 doses (0.5 mL) at least 1 month apart. And recommend booster 1 dose at 12-15 months old， between primary series at least 6 month apart. Children > or = 2 years older and Adult: 2 doses (0.5 mL) at least 1 month apart. Each 0.5-mL dose of Bexsero is formulated to contain 50 micrograms each of recombinant proteins Neisserial adhesin A (NadA)， Neisserial Heparin Binding Antigen (NHBA)， and factor H binding protein (fHbp)， 25 micrograms of Outer Membrane Vesicles (OMV).,無需調整劑量,[仿單]目前並沒有疫苗對哺乳期間之婦女及其幼兒之安全性方面的資料。 在決定於哺乳期間施打疫苗之前，應先評估效益風險比率。 在接種疫苗的母兔或其仔兔哺乳到第29天後，並未發現任何不良反應。 在開始哺乳前接種Bexsero疫苗的母體動物中具有免疫原性，在子代中亦可檢出抗體，但乳汁中的抗體濃度尚未被確定。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]目前並無足夠孕婦接種本疫苗的臨床資料。目前並不確知孕婦的潛在風險。 不過，當有明確的暴露於腦膜炎雙球菌感染的風險時，即不應停止接種疫苗。 在一項對母兔投予約相當於10倍人類劑量(依據體重)之Bexsero的試驗中，並無證據顯示具有母體或胎兒毒性，Bexsero也未對懷孕、母體行為、雌性生育力或出生後發育造成影響。,Unknown 沒有資料,[仿單]目前並沒有疫苗對哺乳期間之婦女及其幼兒之安全性方面的資料。 在決定於哺乳期間施打疫苗之前，應先評估效益風險比率。 在接種疫苗的母兔或其仔兔哺乳到第29天後，並未發現任何不良反應。 在開始哺乳前接種Bexsero疫苗的母體動物中具有免疫原性，在子代中亦可檢出抗體，但乳汁中的抗體濃度尚未被確定。,IM;,,,,,1.懸浮液在存放期間可能會形成細微的灰白色沉澱物。使用前請充分振搖使形成均勻的懸浮液。 2.施打此疫苗前應先目視檢查是否有微粒異物和變色的現象。如果發現任何外來微粒異物或物理性質方面的變化，切勿施打此疫苗。
OGLUC,Metformin,GlucoPHAGE 500mg (庫魯化),META,Type 2 diabetes mellitus,Acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma. Hypersensitivity to metformin. Severe renal impairment (eGFR below 30 mL/min/1.73 m(2)).,Common Endocrine metabolic: Cobalamin deficiency (7% to 17.4% ) Gastrointestinal: Diarrhea (53% (immediate-release) ; 10% to 13% (extended-release) )， Flatulence (12% )， Indigestion (7% )， Malabsorption syndrome (Up to 9.9% )， Nausea (7% (extended-release) )， Vomiting (Up to 25.5% ) Neurologic: Asthenia (9% )， Headache (6% ) Serious Endocrine metabolic: Lactic acidosis Hepatic: Hepatitis,25℃以下,According to the individual needs of the patient， maximum 3000 mg/day.Contrast media， history of liver disease， alcoholism， or heart failure， patient receiving intraarterial administration of iodinated contrast: Discontinue at time of or before procedure; evaluate eGFR 48 hours after imaging procedure; restart if renal function stable.,無需調整劑量,[仿單]Metformin會分佈至母體乳汁，從餵母乳的新生兒/嬰兒身上未觀察到有任何不良反應.然而， 相關的臨床資料有限.所以病患在接受Metformin治療期間，不建議以母乳哺育. 在決定是否停止哺乳或是停用Metformin，都應顧慮到母乳哺育的利益性，藥物對母體影響的重要性， 以及嬰兒出現副作用的潛在危險性.,需調整劑量,沒有資料,Human data suggest low risk,[仿單]懷孕期間血糖未獲控制，和出現高機率的先天性肌形和死胎是有關聯的. 有關孕婦使用Metformin臨床資料非常有限，但該資料並未顯示有胎兒先天性異常方面的高危險性. 動物研究未顯示對懷孕，胚胎或胎兒發育，分娩或是產後胎兒的發育有任何的傷害性.然而， 當患者打算懷孕以及在懷孕期間，不宜使用Metformin治療，應改用胰島素治療.,Compatible 哺乳時可使用,[仿單]Metformin會分佈至母體乳汁，從餵母乳的新生兒/嬰兒身上未觀察到有任何不良反應.然而， 相關的臨床資料有限.所以病患在接受Metformin治療期間，不建議以母乳哺育. 在決定是否停止哺乳或是停用Metformin，都應顧慮到母乳哺育的利益性，藥物對母體影響的重要性， 以及嬰兒出現副作用的潛在危險性.,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議須整粒吞服，不要咀嚼。(經詢問廠商因本藥味道極苦，故有此建議，但剝半磨粉不影響藥效。)
EHXYL,Betamethasone + Phenylephrine + Lidocaine,High-Xylmol ointment 10gm,ALIM,,適應症: External hemorrhoids， hemorrhoid bleeding， hemorrhoid pain， anal fissure， perianal inflammation， anal itching， anal eczema， anal ulcer,,室溫,Apply bid-tid.,無需調整劑量,Phenylephrine (Sympathomimetic): No Human Data - Probably Compatible. Betamethasone: No Human Data - Probably Compatible. Lidocaine (Local Anesthetic/Cardiac): Limited Human Data—Probably Compatible [仿單]沒有相關紀載,無需調整劑量,沒有資料,Human (and animal) data suggest risk,Phenylephrine (Sympathomimetic): Human Data Suggest Risk. Betamethasone: Compatible - Maternal Benefit >> Embryo - Fetal Risk Lidocaine (Local Anesthetic/Cardiac): Compatible. [仿單]沒有相關紀載,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Phenylephrine (Sympathomimetic): No Human Data - Probably Compatible. Betamethasone: No Human Data - Probably Compatible. Lidocaine (Local Anesthetic/Cardiac): Limited Human Data—Probably Compatible [仿單]沒有相關紀載,RECT;,,,,,
OPAXS,Nirmatrelvir + Ritonavir,Paxlovid (自費) 300/100mg， 10 doses,QANB,An Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing， and who are at high risk for progression to severe COVID-19， including hospitalization or death.,History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components. Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance.,Common Gastrointestinal: Diarrhea (3%)， Taste sense altered (6%) Serious Hepatic: Hepatitis， Including increased transaminase levels.,儲存於25℃以下。,Paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets. The dosage for Paxlovid is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together orally twice daily for 5 days.,需調整劑量,[仿單]關於PF-07321332是否可分泌至人或動物乳汁、對母乳餵養嬰兒的影響或對乳汁分泌的影響，目前尚無可取得的資料。在給予PF-07321332的大鼠的哺乳後代中觀察到體重暫時性下降。有限的已發表資料顯示，ritonavir出現於乳汁中。尚無關於ritonavir對母乳餵養嬰兒產生的影響或藥物對泌乳量產生的影響的資料。應考慮母乳餵養的發育和健康益處，以及母親對PAXLOVID的臨床需求以及PAXLOVID或母體基礎狀況對母乳餵養嬰兒的任何潛在不良影響。感染COVID?19的哺乳期女性應遵循臨床指引的規定，以避免使嬰兒暴露於COVID?19。 在產前和產後發育研究中，給予妊娠大鼠PF-07321332的全身暴露量(AUC24)約為PAXLOVID的核准人體劑量臨床暴露量的8倍時，在子代觀察到體重下降（最高達8%）。在母體全身暴露量(AUC24)約為PAXLOVID的核准人體劑量臨床暴露量的5倍時，未觀察到子代的體重變化。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]目前尚無妊娠期間使PF-07321332的人體資料可用於評估主要出生缺陷、流產或母體或胎兒不良的藥物相關風險。已發表的關於孕婦使用ritonavir的觀察性研究未發現重大出生缺陷的風險增加。已發表的ritonavir研究不足以確定藥物相關的流產風險。妊娠期間如不予治療，COVID-19會對母嬰構成風險。 在PF-07321332的動物胚胎-胎兒發育研究中，妊娠母兔口服給予PF-07321332，在全身暴露量(AUC)約PAXLOVID的核准人體劑量臨床暴露量的10倍時，觀察到胎兒體重減輕。在PF-07321332的動物生殖研究中，在全身暴露量(AUC)為PAXLOVID的核准人體劑量臨床暴露量的3倍或3倍以上時，未觀察到其他不良發育結果。 在ritonavir的動物生殖研究中，妊娠大鼠和母兔口服給予ritonavir，劑量（依據體表面積轉換）或全身暴露量(AUC)為臨床劑量或PAXLOVID的核准人體劑量暴露量的3倍或3倍以上時，未觀察到不良發育結果的證據。 在適用人群中，主要出生缺陷和流產的估計背景風險不明。所有妊娠均面臨出生缺陷、流產或其他不良結果的風險。在美國一般人群中，臨床確認的妊娠中主要出生缺陷和流產的估計背景風險分別為2-4%和15-20%。,Unknown 沒有資料,[仿單]關於PF-07321332是否可分泌至人或動物乳汁、對母乳餵養嬰兒的影響或對乳汁分泌的影響，目前尚無可取得的資料。在給予PF-07321332的大鼠的哺乳後代中觀察到體重暫時性下降。有限的已發表資料顯示，ritonavir出現於乳汁中。尚無關於ritonavir對母乳餵養嬰兒產生的影響或藥物對泌乳量產生的影響的資料。應考慮母乳餵養的發育和健康益處，以及母親對PAXLOVID的臨床需求以及PAXLOVID或母體基礎狀況對母乳餵養嬰兒的任何潛在不良影響。感染COVID?19的哺乳期女性應遵循臨床指引的規定，以避免使嬰兒暴露於COVID?19。 在產前和產後發育研究中，給予妊娠大鼠PF-07321332的全身暴露量(AUC24)約為PAXLOVID的核准人體劑量臨床暴露量的8倍時，在子代觀察到體重下降（最高達8%）。在母體全身暴露量(AUC24)約為PAXLOVID的核准人體劑量臨床暴露量的5倍時，未觀察到子代的體重變化。,PO;,,,,,[磨粉/管灌註記]仿單建議應整粒吞服。不得咀嚼、破壞或壓碎錠劑。
OSPL,Sulpiride,Splotin 50mg,CNEU,Treat psychotic symptoms and peptic ulcer.,Hypersensitivity to sulpiride， pheochromocytoma， parkinson's disease,Palpitations， prolonged QT interval， hypertension， diaphoresis， galactorrhea， breast engorgement， weight gain， xerostomia， nausea， vomiting， constipation， anorexia， dry mouth， leukocytosis， venous thromboembolism， cholestatic jaundice， and hepatotoxicity. Sedation or drowsiness， dizziness， depression， sleep disturbances， headache， restlessness， and impaired concentration. Parkinsonian symptoms， acute dystonias， akathisia， tardive dyskinesia， and tardive dystonia. Neuroleptic malignant syndrome， seizures， blurred vision， amenorrhea， and pulmonary embolism.,25℃以下避光密封,Schizophrenia: Adults 300-600mg per day orally in divided doses; maximum daily dose 1200mg. Depression and depressive states: Adults 150-300mg per day orally in divided doses; maximum daily dose 600mg. Gastric and duodenal ulcers: Adults 150mg per day orally in 3 divided doses， adjusted according to disease severity.,無需調整劑量,[仿單]本劑對於新生兒的安全性尚未確立，所以在授乳期間的婦女， 限於判斷其治療上的有益性超越危險時才可給藥。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]有關懷孕中給藥的安全尚未確立，所以在孕婦或可能已懷孕的婦女， 限於判斷其治療上的有益性超越危險性時才可給藥。,Unknown 沒有資料,[仿單]本劑對於新生兒的安全性尚未確立，所以在授乳期間的婦女， 限於判斷其治療上的有益性超越危險時才可給藥。,AC;AC15;PC;PO;WM;,,,,,
OVGRO,Sildenafil,Viagra ODT 50mg (4 tablets/box),SGU,Treatment of erectile dysfunction.,Patients who use nitric oxide donors or nitrates. Viagra should not be used in men for whom sexual activity is inadvisable (patients with severe CV disorders eg unstable angina or severe cardiac failure). Severe hepatic impairment， hypotension (< 90/50 mm Hg) or hypertension (> 170/100 mm Hg)， recent history of stroke or MI， known hereditary degenerative retinal disorders such as retinitis pigmentosa. Not indicated for women.,Headache， flushing， dizziness， dyspepsia， nasal congestion， altered vision. Dermatologic: Erythema (6% )， Flushing (10% ) Gastrointestinal: Indigestion (4% to 17% ) Neurologic: Headache (16% to 46% )， Insomnia (up to 7% ) Ophthalmic: Visual disturbance (3% to 11% ) Respiratory: Epistaxis (3% to 9% )， Nasal congestion (4% )， Rhinitis (4% ),30℃以下,Erectile dysfunction: Sildenafil 25 to 100 mg (50 mg usual dose) orally 1 hour (range 0.5 to 4 hours) prior to sexual activity; the maximum frequency of administration once daily.,需調整劑量,,需調整劑量,,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,AC;PO;,,,,,[磨粉/管灌註記]本藥為口溶錠，可置於舌上溶解後以水吞服或不以水直接吞服。本藥也不應用於管灌病患。
OLEE,Escitalopram,Leeyo F.C. 10mg,CNEU,,適應症: Treatment of major depressive episodes. 副作用: Appetite decreased， libido decreased， anorgasmia (female)， insomnia， somnolence， dizziness， sinusitis， yawning， nausea， diarrhoea， constipation， sweating increased， ejaculation disorder， impotence， fatigue， pyrexia. Rarely， hyponatraemia， seizures， ecchymoses. Cardiovascular: Hypertension (1% or greater )， Palpitations (1% or greater ) Dermatologic: Diaphoresis (4% to 5% )， Rash (1% or greater ) Endocrine metabolic: Weight increased (1% or greater ) Gastrointestinal: Constipation (3% to 6% )， Diarrhea (6% to 14% )， Gastroenteritis (1% or greater )， Heartburn (1% or greater )， Indigestion (2% to 6% )， Nausea (15% to 18% )， Xerostomia (4% to 9% ) Musculoskeletal: Arthralgia (1% or greater )， Myalgia (1% or greater ) Neurologic: Dizziness (4% to 7% )， Headache (24% )， Insomnia (7% to 14% )， Lightheadedness (1% or greater )， Somnolence (4% to 9% ) Reproductive: Disorder of ejaculation (9% to 14%)， Impotence (3% )， Orgasm incapacity (females， 2% to 6% )， Reduced libido (males， 6%; females， 3%) Other: Fatigue (2% to 6% ) 禁忌: Concomitant treatment with non-selective， irreversible MAOIs.,,室溫,Adult:10 mg once daily; may be increased to max 20 mg daily.,需調整劑量,,需調整劑量,,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;P1;P2;P3;P4;PC;PO;WM;,,,,,
IABI,Aripiprazole,Abilify Maintena inj 400mg,CNEU,Bipolar I disorder， Schizophrenia，,Hypersensitivity to aripiprazole or any component of the formulation.,Headache， asthenia， accidental injury， peripheral edema， hypertension， GI disturbances， myalgia， agitation， anxiety， insomnia， lightheadedness， somnolence， akathisia， extrapyramidal syndrome， tremor， increased salivation， rhinitis， pharyngitis， coughing， blurred vision. Endocrine metabolic: Weight increased (2% to 30% ) Gastrointestinal: Constipation (5% to 11% )， Nausea (8% to 15% )， Vomiting (3% to 11% ) Neurologic: Akathisia (2% to 25% )， Dizziness (4% to 10% )， Extrapyramidal disease (2% to 27.3% )， Headache (12% to 27% )， Insomnia (8% to 18% )， Sedated (1% to 8% )， Somnolence (5% to 26.3% )， Tremor (2% to 11.8% ) Ophthalmic: Blurred vision (3% to 8% ) Psychiatric: Anxiety (4% to 17% )， Restlessness (2% to 12% ) Other: Fatigue (2% to 11% ),30℃以下，不要冷凍。,400 mg once monthly (doses should be separated by more than 26 days); Tolerability should be established using oral aripiprazole prior to initiation of parenteral therapy; due to the half-life of oral aripiprazole it may take up to 2 weeks to fully assess tolerability. Continue oral aripiprazole (or other oral antipsychotic) for 14 days during initiation of parenteral therapy.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;,使用預充填雙腔注射筒內含之注射用水，依仿單指示進行混合。,,,,1.溶液應於配置後30分鐘使用完畢. 2.請依仿單建議針對不同的病患選用不同的針頭. 3.不要搓揉注射部位.
ILUMI,Brodalumab,Lumicef 210mg/1.5mL inj,HIMM,Moderate to severe plaque psoriasis， pustular psoriasis.,Crohn disease， Clinically significant hypersensitivity to brodalumab or any component of the formulation.,Common Gastrointestinal: Diarrhea (2.2% ) Immunologic: Infectious disease (25.4% )， Mycosis (1.8% to 2.4% ) Musculoskeletal: Arthralgia (4.7% ) Neurologic: Headache (4.3% ) Respiratory: Pain in throat (2.1% ) Other: Fatigue (2.6% ) Serious Hematologic: Neutropenia， Grade 3 or greater (0.5% ) Neurologic: Cryptococcal meningitis Psychiatric: Suicidal thoughts， Suicide,2-8℃避光勿冷凍勿搖,SC， 210 mg at weeks 0， 1， and 2， followed by 210 mg once every 2 weeks.,無需調整劑量,[仿單](節錄) 沒有授乳應而或乳汁分泌的影響相關資訊. 動物實驗中發現乳汁中檢測到本藥，請評估受乳嬰兒與母體狀況的風險與利益.,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單](節錄) 沒有孕婦使用的相關風險報告. 已知人類IgG抗體會穿過胎盤屏障，動物實驗中未發現有不良效益,Unknown 沒有資料,[仿單](節錄) 沒有授乳應而或乳汁分泌的影響相關資訊. 動物實驗中發現乳汁中檢測到本藥，請評估受乳嬰兒與母體狀況的風險與利益.,SC;,,,,,1.預填充針筒需儲存於2-8度C，勿冷凍. 2.請勿注射於肚臍周圍2吋內. 3.勿揉注射部位
OROMA,Dextromethorphan+Lysozyme+K Cresolsulfonate,Romicon-A 20/20/90mg,ERSP,Cough suppressant， Expectorant.,Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor. Hypersensitivity to Romicon-A or any component of the formulation.,Common Neurologic: Dizziness (mild)， Somnolence (mild) Other: Fatigue (mild),25℃以下避光,Adult (>15 years- old): one capsule each time， three times a day. [Micromedex 2021/07/30] Cough: 12 years or older: 30 mg orally every 6 to 8 hours; the maximum dose: 120 mg/day.,無需調整劑量,[仿單] 懷孕婦女，疑似懷孕婦女及哺乳婦女應避免服用本品 Lysozyme+K Cresolsulfonate無資料,無需調整劑量,沒有資料,Compatible,[仿單] 懷孕婦女，疑似懷孕婦女及哺乳婦女應避免服用本品 附註1: 除仿單資訊外，其他資料皆為Dextromethorphan單一成份的資料庫資訊. 附註2: Pregnancy Category:A - from Micromedex (AUS date). Lysozyme+K Cresolsulfonate無資料,Compatible 哺乳時可使用,[仿單] 懷孕婦女，疑似懷孕婦女及哺乳婦女應避免服用本品 Lysozyme+K Cresolsulfonate無資料,AC;P1;P2;P3;P4;PC;PO;,,,,,
ESOO3,Ivermectin,Soolantra cream 1%， 30gm,TDER,Rosacea (Soolantra cream): Treatment of inflammatory lesions of rosacea in adult patients.,Hypersensitivity (rare).,1% to 10%: Central nervous system: Localized burning (<=1%) Dermatologic: Skin irritation (<=1%) <1% (Limited to important or life-threatening): Conjunctivitis， eye irritation， ocular hyperemia， seborrheic dermatitis of scalp， xeroderma,25℃以下勿冷凍,Rosacea Topical Apply to each affected area (eg， forehead， chin， nose， each cheek) once daily， maximum for 4 month,無需調整劑量,,無需調整劑量,,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
ODOP,Amantadine,多巴定Dopadine100mg,CNEU,Parkinsonism of various origin， senile Parkinsonism， residual symptoms & discomfort after stereotactic operations.,Severe CHF (NYHA class IV)， cardiomyopathies & myocarditis， 2nd or 3rd degree AV block， existing bradycardia under 55 beats/min， known prolonged QT interval (Bazett QTc > 420 ms) or discernible U-waves or congenital QT syndrome in the family anamnesis ， history of serious ventricular arrhythmias including torsade de pointes， simultaneous treatment with budipine or other drugs that prolong the QT interval， reduced levels of potassium or magnesium in the blood. Pregnancy & lactation.,Occasional dry mouth; dizziness. Paranoid exogenous psychoses associated with visual hallucinations， visual disturbances; motor or mental restlessness， urinary retention in the case of prostatic hypertrophy， signs of cardiac insufficiency， cardiac dysrhythmia associated with tachycardia， nausea， sleep disturbances， orthostatic dysregulation; very rarely， myoclonus & symptoms of peripheral neuropathy; livedo reticularis (marble skin) & lower-leg & ankle oedema are common occurrences; very rarely， increased photosensitivity; very rarely haematological side effects， such as leukopenia & thrombocytopenia; very rarely， anaphylactic reactions after infusion therapy. Cardiovascular: Orthostatic hypotension (1% to 5% )， Peripheral edema (1% to 5% ) Gastrointestinal: Constipation (1% to 5% )， Diarrhea (1% to 5% )， Loss of appetite (1% to 5% )， Nausea (5% to 10% )， Xerostomia (1% to 5% ) Neurologic: Ataxia (1% to 5% )， Confusion (1% to 5% )， Dizziness (5% to 10% )， Headache (1% to 5% )， Insomnia (5% to 10% )， Somnolence (1% to 5% ) Psychiatric: Agitation (1% to 5% )， Anxiety (1% to 5% )， Depression (1% to 5% )， Dream disorder (1% to 5% )， Feeling nervous (1% to 5% )， Hallucinations (1% to 5% )， Irritability (1% to 5% ) Other: Fatigue (1% to 5% ),25℃以下,Parkinson's disease: Adult: Monotherapy， 100 mg orally twice daily; may titrate up to 400 mg/day in divided doses. During a serious related disease or receiving high-dose anti-Parkinson's disease treatment， the initial dose of this agent is 100 mg once a day， After 1-7 weeks， if necessary， may titrate up to 100 mg twice a day; and additionally up to 400 mg/day in divided doses. Initiating levodopa and amantadine concurrently， hold amantadine at 100 mg once or twice daily while gradually increasing levodopa. Prophylaxis or treatment of Influenza A symptoms: (Due to high resistance rates， amantadine is no longer recommended by the CDC for the treatment or prophylaxis of influenza A.) Adult: 100-200mg/day. Children > 10 years old or > 45 kg: 100mg BID. Children > 5 years old: 100mg QD.,無需調整劑量,[仿單] 本劑會分泌於乳液，授乳婦使用時應注意.,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,[仿單] 懷孕禁止使用,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 本劑會分泌於乳液，授乳婦使用時應注意.,AC;AC15;PO;WM;,,,,,
IOZE,Semaglutide,Ozempic inj 2mg/1.5mL,META,Type 2 diabetes mellitus. Prophylaxis of disorder of cardiovascular system with type 2 diabetes mellitus.,Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2. Known hypersensitivity to semaglutide or any component of the product.,Common Endocrine metabolic: Hypoglycemia (Monotherapy， 1.6% to 3.8%; combination therapy， 6% to 30% ) Gastrointestinal: Abdominal pain (5.7% to 11% )， Constipation (3.1% to 6% )， Diarrhea (8.5% to 10% )， Nausea (11% to 20.3% )， Vomiting (5% to 9.2% ) Serious Endocrine metabolic: Medullary thyroid carcinoma Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Ophthalmic: Retinopathy due to diabetes mellitus,避光勿冷凍。初次使用前：請存放於2-8°C; 初次使用後請存放於30°C以下或 2-8°C 共六週,SC， 0.25 mg once weekly for 4 weeks， then increase to 0.5 mg once weekly; may increase to maximum 1 mg once weekly if additional glycemic control is needed after at least 4 weeks of the 0.5 mg weekly dosage.,無需調整劑量,[仿單] 大鼠的泌乳實驗顯示，semaglutide 會分泌至乳汁中。 由於無法排除哺乳嬰幼兒的風險，哺乳期間不應使用 semaglutide。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]在動物試驗中顯示具生殖毒性。懷孕女性使用 semaglutide 的資料有限，因此懷孕期間不可使用 semaglutide。 如果病人想要懷孕或已懷孕，應停用 semaglutide。 由於 semaglutide 的半衰期較長，計畫懷孕前至少兩個月應停用 semaglutide。,Unknown 沒有資料,[仿單] 大鼠的泌乳實驗顯示，semaglutide 會分泌至乳汁中。 由於無法排除哺乳嬰幼兒的風險，哺乳期間不應使用 semaglutide。,SC;,,,,,1.使用新的注射筆第一次注射前，請先檢查是否已排空。 2.存放於30°C以下可保存6週.不可冷凍. 3.必要時可改變每週注射的日期，但兩次注射之間應至少相隔 3 天 (超過 72 小時)。選定新的注射日之後，應持續每週注射一次。 4.如果錯過一劑藥物，應在 5 天內儘快施打。如果超過 5 天則應跳過，依原訂時程繼續注射下一劑。遇到這類情況，病人之後可恢復每週一次的用藥時程。
ISEF,Ciprofloxacin,Seforce inj 400mg/200mL,QANB,Acute exacerbation of chronic bronchitis. Bacterial prostatitis， chronic. Bacterial sinusitis， acute. Febrile neutropenia， Empiric therapy. Gonorrhea， Uncomplicated. Infection of bone - Infectious disorder of joint. Infection of skin and/or subcutaneous tissue. Infectious diarrheal disease. Infectious disease of the abdomen， Complicated. Lower respiratory tract infection. Otitis externa， acute. Pyelonephritis. Urinary tract infectious disease.,Concomitant tizanidine administration. Hypersensitivity to ciprofloxacin or any product component， or other quinolones.,Common Dermatologic: Rash (Up to 1.8% ) Gastrointestinal: Diarrhea (Multiple indications， 1.6% to 4.8% ; Complicated UTI， 25% )， Nausea (Multiple indications， 2.5% to 4%; Complicated UTI 25% )， Vomiting (Adult， 1% to 2%; pediatric， 4.8% ) Neurologic: Headache (Up to 3% ) Psychiatric: Irritability (5% ) Respiratory: Nasal discharge (3% )， Nasopharyngitis (5% ) Serious Cardiovascular: Aortic aneurysm， Or dissection， Cardiorespiratory arrest (Up to 1% )， Myocardial infarction (Up to 1% )， Prolonged QT interval， Syncope (Up to 1% )， Torsades de pointes Dermatologic: Photosensitivity， Stevens-Johnson syndrome， Toxic epidermal necrolysis (Up to 1% ) Endocrine metabolic: Hypoglycemia (Up to 1% ) Gastrointestinal: Clostridium difficile colitis， Clostridium difficile diarrhea (Up to 1% )， Gastrointestinal hemorrhage (Up to 1% )， Pancreatitis (Up to 1% ) Hematologic: Agranulocytosis (Rare )， Aplastic anemia (Rare )， Bone marrow depression， Hemolytic anemia (Rare )， Leukopenia (0.4% )， Pancytopenia (0.1% )， Thrombocytopenia (Rare ) Hepatic: Hepatic necrosis (Up to 1% )， Hepatitis (up to 1% )， Hepatotoxicity， Liver failure Immunologic: Hypersensitivity reaction (Up to 1% ) Musculoskeletal: Myasthenia gravis， Exacerbation， Rupture of tendon， Tendinitis Neurologic: Disorientated， Disturbance of attention， Guillain-Barre syndrome， Memory impairment， Peripheral neuropathy， Pseudotumor cerebri， Raised intracranial pressure， Seizure (Less than 1% ) Ophthalmic: Retinal detachment Psychiatric: Delirium， Depression (Up to 1% )， Hallucinations， Paranoid disorder (Up to 1% )， Psychotic disorder (Up to 1% )， Suicidal behavior (Rare ) Renal: Acute renal failure (Up to 1% )， Hemorrhagic cystitis (Up to 1% )， Tubulointerstitial nephritis (Up to 1% ),25℃以下、避免冷凍、避光,Should be infused intravenously over 60 minutes. Adults: usual dose: 100-400 mg IV Q12H; severe/complicated infections: 400 mg IV Q8H. Chiledren (aged 1-17 years): 6-10 mg/kg IV Q8-12H (maximum 400 mg/dose).,無需調整劑量,[仿單]Ciprofloxacin會分泌到乳汁中，由於有關節軟骨傷害的潛在風險，哺乳婦女不可使用ciprofloxacin。,需調整劑量,沒有資料,Contraindicated,[仿單]Ciprofloxacin在懷孕婦女的安全性尚未建立。動物試驗未顯示有生殖毒性。根據動物試驗的結果，可能無法排除藥物可能會對尚未成熟生物的關節軟骨造成傷害。因此ciprofloxacin不建議在懷孕期間使用。動物實驗至今尚未有致畸胎(畸形)的證據。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Ciprofloxacin會分泌到乳汁中，由於有關節軟骨傷害的潛在風險，哺乳婦女不可使用ciprofloxacin。,IVD;,,【D10W】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,,Ciprofloxacin輸注液必須經由靜脈輸注，並且輸注時間要超過60分鐘。緩慢的將藥打入大的靜脈，可以減少病人的不適及降低靜脈刺激的危險性。可以直接給藥或與其它相容的輸注溶液混合後給藥。,1.本藥具光敏感度，藥品須在使用前再從避光袋拿出。在白晝光線下，完整的效力只能保證維持3天。 2.低溫儲存環境可能會產生沉澱，但在室溫下會再度溶解。所以不須將此輸注液置於冰箱儲存。 3.使用IV set 時請確實辨認加藥孔及輸出孔，將IV set 垂直插入至輸出孔，並確認完全插入至底部。 4.依2016年第2次ADR會議決議: 因Quinolones類藥物常見引起靜脈炎，建議輸注時間應超過60分鐘。
EBUIS,Terbutaline,Butanyl solution 5mg/2mL,ERSP,Treatment and Prophylaxis of Asthma， Bronchospasm， Reversible， associated with bronchitis and emphysema.,Hypersensitivity to sympathomimetic amines or any component of terbutaline sulfate products.,Common Cardiovascular: Palpitations， Tachyarrhythmia Neurologic: Headache， Seizure， Tremor Psychiatric: Feeling nervous Serious Cardiovascular: Cardiac dysrhythmia Respiratory: Paradoxical bronchospasm， Pulmonary edema,25℃以下避光儲存,Single dose 5mg QID. For use in a nebulizer or respirator. If a single dose is not used up， it can be stored in the storage tank of the nebulizer within 24 hours.,無需調整劑量,[仿單]Terbutaline雖流注母乳，但醫療劑量對嬰兒無不良影響。 在早產的新生兒中(其母親有使用beta-2刺激劑來治療)，有報告指出會有短暫性低血糖的情形。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]畸胎尚未見於動物及病患，但妊娠三個月以內的婦女仍須小心投與。Terbutaline經使用多年，適用於孕婦及產婦，無不良影響之報告，易不干擾生殖過程。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]Terbutaline雖流注母乳，但醫療劑量對嬰兒無不良影響。 在早產的新生兒中(其母親有使用beta-2刺激劑來治療)，有報告指出會有短暫性低血糖的情形。,IH;,,,,,1.本品非注射用，只適用於呼吸器或噴霧器。 2.將本品存於噴霧器的儲存槽可保存24小時。
INTG,Nitroglycerin,NTG inj 0.2mg/mL， 250mL (D5W) Premixed,CAVS,,適應症:Treatment or prevention of angina pectoris Intravenous (IV) administration: Treatment or prevention of angina pectoris; acute decompensated heart failure (especially when associated with acute myocardial infarction); perioperative hypertension (especially during cardiovascular surgery); induction of intraoperative hypotension. 副作用: >10%: Central nervous system: Headache (patch， ointment: 50% to 64%; sublingual powder， lingual spray: >2%) 1% to 10%: Cardiovascular: Hypotension (<4%)， syncope (<4%)， peripheral edema (lingual spray: <2%) Central nervous system: Dizziness (>2% to 6%)， paresthesia (>2%) Gastrointestinal: Abdominal pain (lingual spray: <2%) Neuromuscular & skeletal: Weakness (all sublingual forms: <2%) Respiratory: Dyspnea (<2%)， pharyngitis (lingual spray: <2%)， rhinitis (lingual spray: <2%) Frequency not defined: Cardiovascular: Bradycardia， exacerbation of angina pectoris， flushing， orthostatic hypotension Dermatologic: Diaphoresis Gastrointestinal: Vomiting Miscellaneous: Drug tolerance 禁忌: Hypersensitivity to nitroglycerin， other nitrates or nitrites， or any component of the formulation (includes adhesives for transdermal product); concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (avanafil， sildenafil， tadalafil， or vardenafil); concurrent use with soluble guanylate cyclase (sGC) stimulators (eg， riociguat). Additional contraindications for IV product: Hypersensitivity to corn or corn products (solutions containing dextrose); constrictive pericarditis; increased intracranial pressure; pericardial tamponade; restrictive cardiomyopathy; uncorrected hypovolemia.,,室溫,FOR INTRAVENOUS USE ONLY. NOT FOR DIRECT INTRAVENOUS INJECTION. SHOULD NOT BE MIXED WITH OTHER DRUGS. Initial titration should be in 5 mcg/min increments， with increases every 3-5 minutes until some response is noted. If no response is seen at 20 mcg/min， increments of 10 and later 20 mcg/min can be used. Once a partial blood pressure response is observed， the dose increase should be reduced and the interval between increases should be lengthened.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,,,IV infusion rate: 0.05 - 5 mcg/kg/min依適應症不同，應使用玻璃或non-PVC材質。,容器及輸液套需選擇non-PVC材質，使用可控制流速之輸液泵靜脈輸注。
IRAPI,Peramivir,Rapiacta 300mg/60mL Drip Infusion,QANB,Treatment of acute， influenza A or B in adults,Serious hypersensitivity or anaphylaxis to peramivir or any component of the formulation.,Cardiovascular: Hypertension Central nervous system: Insomnia Endocrine: Increased serum glucose Gastrointestinal: Constipation， diarrhea， vomiting (children & adolescents) Genitourinary: Proteinuria (children & adolescents) Hematologic and oncologic: Neutropenia Hepatic: Increased serum ALT， increased serum AST Neuromuscular & skeletal: Increased creatine phosphokinase Miscellaneous: Fever (children & adolescents) Rare but important or life-threatening: Abnormal behavior， anaphylactoid reaction， anaphylaxis， delirium， erythema multiforme， exfoliative dermatitis， hallucination， skin rash， Stevens-Johnson syndrome,25℃以下,Administer Rapiacta within 2 days of onset of symptoms of influenza. Adult: a single 300-600 mg dose IV infused over 15 minutes. Children > 1 month: a single dose of 10 mg/kg IV infused over 15 minutes (do not exceed 600 mg/dose).,無需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,,X,Administer via IV infusion over 15 to 30 minutes,1. 急性流感宜於症狀發生後48小時內使用本藥。 2. 對18歲以上成人急性流感病患之建議劑量為單次投與300 mg，15分鐘以上單次點滴靜脈注射。 3.每袋藥品賦形劑為氯化鈉540.0 mg及注射用水。(有心臟、循環器官功能不良者、腎功能不全者需注意)
OATOZ,Ezetimibe + Atorvastatin,Atozet 10/20mg,CAVS,Familial hypercholesterolemia. Hyperlipidemia， Primary. Mixed hyperlipidemia.,Active liver disease or unexplained persistent elevations in hepatic transaminases. Breastfeeding. Women who are pregnant or may become pregnant. Hypersensitivity to ezetimibe， atorvastatin， or any component of the product.,Common Gastrointestinal: Diarrhea (2.8% ) Musculoskeletal: Muscle weakness， Myalgia (3.6% ) Neurologic: Headache (5.8% ) Respiratory: Upper respiratory infection (3.6% ) Serious Dermatologic: Dermatomyositis， Subacute cutaneous lupus erythematosus Hepatic: Hepatitis， Increased liver enzymes (0.7% to 3.6% )， Jaundice， Liver failure Immunologic: Autoimmune disease Musculoskeletal: Autoimmune necrotizing myopathy， Statin-associated (Rare )， Disorder of muscle (0.2% )， Rhabdomyolysis (0.09% ) Respiratory: Bleeding from nose,30℃以下,The recommended starting dose of Atozet is ezetimibe/atorvastatin 10/10-10/20 mg once daily. Could be administered at any time of the day with or without food.,需調整劑量,BREASTFEEDING RECOMMENDATION: EZETIMIBE: Contraindicated ATORVASTATIN: Contraindicated [仿單]大鼠的研究顯示，餵哺母乳之仔鼠中的整體ezetimibe暴露量最高可達母體血漿中所觀察到之暴露量的一半。 目前並不確知ezetimibe是否會分泌進入人類的乳汁。 目前並不確知atorvastatin是否會分泌進入人類乳汁，但同類別的另一種藥物有少量會移行進入乳汁。 在餵哺母乳的仔鼠中，血漿及肝臟的atorvastatin濃度分別相當於母鼠乳汁中之濃度的50%與40%。 由於可能會使餵哺母乳的嬰兒發生不良反應，因此，使用Atozet治療的婦女不可餵哺母乳。,無需調整劑量,沒有資料,Contraindicated – 1st trimester,PREGNANCY RECOMMENDATION: EZETIMIBE: Limited Human Data - Animal Data Suggest Moderate Risk ATORVASTATIN: Contraindicated 1st Trimester [仿單]Atozet禁用於以經懷孕或可能懷孕的婦女。在正常懷孕期間，血清膽固醇與三酸甘油脂都會升高。 在懷孕期間，降血脂藥物並無法提供任何效益，因為膽固醇與膽固醇衍生物乃是正常胎兒發育所必需的物質。 動脈粥樣硬化是一個長期發展的過程，因此，在懷孕期間停用降血脂藥物對原發性高膽固醇血症之長期治療結果的影響應該極小。 (以下略),Contraindicated 哺乳期使用禁忌,BREASTFEEDING RECOMMENDATION: EZETIMIBE: Contraindicated ATORVASTATIN: Contraindicated [仿單]大鼠的研究顯示，餵哺母乳之仔鼠中的整體ezetimibe暴露量最高可達母體血漿中所觀察到之暴露量的一半。 目前並不確知ezetimibe是否會分泌進入人類的乳汁。 目前並不確知atorvastatin是否會分泌進入人類乳汁，但同類別的另一種藥物有少量會移行進入乳汁。 在餵哺母乳的仔鼠中，血漿及肝臟的atorvastatin濃度分別相當於母鼠乳汁中之濃度的50%與40%。 由於可能會使餵哺母乳的嬰兒發生不良反應，因此，使用Atozet治療的婦女不可餵哺母乳。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單載應將Atozet錠劑整粒吞服。不可將錠劑研碎、溶解或咀嚼使用。詢問廠商後回覆無破壞劑型後的安定性及有效性資料，且有效成分會被破壞失效並影響吸收。(The active ingredients can break down in the mouth and lose efficacy. This could also impair absorption.) 1. 應提醒病患若有不明原因的肌肉痛， 觸痛或無力， 且併有發燒時， 請立刻回診。 2. 若併用HIV抗病毒藥物病患可能會加重副作用，請謹慎使用。
OMOLS,Molnupiravir,(自費) Molnupiravir 200mg (40顆/瓶),QANB,An Emergency Use Authorization (EUA) for the emergency use of Molnupiravir for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in certain adults who are at high-risk for progression to severe COVID-19.,NOT for use in patients who are less than 18 years of age. NOT for initiation of treatment in patients requiring hospitalization due to COVID-19. NOT for use for longer than 5 consecutive days. NOT for use as pre-exposure or as post-exposure prophylaxis for prevention of COVID-19. Not recommended for use during pregnancy.,Common Gastrointestinal: Diarrhea (2% to 3% )， Nausea (2% ) Neurologic: Dizziness (1% )， Headache (1% ),在30℃以下保存,800 mg (four 200-mg capsules) orally every 12 hours for 5 days with or without food; administer as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset,無需調整劑量,[仿單]目前並無任何關於molnupiravir或其代謝物是否會出現於人類的乳汁方面的資料。曾在投予molnupiravir之授乳大鼠所哺乳之仔鼠的血漿中檢出NHC。目前並不確知molnupiravir是否會對餵哺母乳的嬰兒造成影響，或對乳汁生成作用造成影響。 由於嬰兒可能會對molnupiravir產生不良反應，因此，在使用molnupiravir治療期間和使用最後一劑藥物後4天內不建議餵哺母乳。在治療期間和使用最後一劑molnupiravir後4天內，哺乳病人可能要考慮中斷餵哺母乳，也可能要考慮將乳汁吸出並丟棄。 在出生前後發育研究中，對授乳大鼠投予?250毫克/公斤/日之劑量的molnupiravir之後，曾在哺乳仔鼠的血漿中檢出NHC。 根據動物研究的結果，對孕婦投予molnupiravir可能會對胎兒造成傷害。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]不建議於懷孕期間使用molnupiravir，但若處方醫師確認效益超越風險，決定對孕婦使用molnupiravir時，必須向該孕婦詳細告知在懷孕期間使用molnupiravir的風險。處方醫師應於懷孕患者使用molnupiravir期間透過電話：02-66316000或電子郵件: dpoc_taiwan@merck.com通報其曝藥情形，並建議患者依上述聯繫管道將懷孕結果通報給美商默沙東藥廠股份有限公司台灣分公司。 根據動物試驗的資料，對孕婦投予molnupiravir可能會對胎兒造成傷害。目前並無任何對孕婦使用molnupiravir的人類資料可據以評估發生重大出生缺陷、流產或母體或胎兒不良結果的風險；因此，並不建議在懷孕期間使用molnupiravir。一項動物生殖研究顯示，對懷孕大鼠於器官發生期間口服投予molnupiravir之後，在相當於人類在建議人類劑量(RHD)下所達到之人類NHC (N4-hydroxycytidine)暴露量的8倍暴露量下會導致胚胎胎兒死亡和畸形，在人類在RHD劑量下所達到之人類NHC暴露量的?3倍暴露量下會導致胎兒生長減慢。對懷孕兔子於於器官發生期間口服投予molnupiravir之後，在相當於人類在RHD劑量下所達到之人類NHC暴露量的18倍暴露量下會導致胎兒體重減輕。考慮要對孕婦使用molnupiravir時，處方醫師必須向該孕婦說明在懷孕期間使用molnupiravir的已知和潛在效益，以及潛在的風險。只有在醫療照護人員確定對個別孕婦的效益超越風險之後，才可處方molnupiravir給該個別病人。如果決定要在懷孕期間使用molnupiravir，處方醫師必須註記已向該個別孕婦說明在懷孕期間使用molnupiravir的已知和潛在效益，以及潛在的風險。在懷孕期間，未經治療的COVID-19也會為母體和胎兒帶來風險。 目前並不確知本品之適用族群發生重大出生缺陷與流產的估計背景風險。所有的懷孕都有發生出生缺陷、流產或其他不良結果的背景風險。就美國的一般人口而言，在經過臨床確認的懷孕人口中，發生重大出生缺陷與流產的背景風險分別為2至4%與15至20%。 Molnupiravir不建議用於懷孕婦女,Unknown 沒有資料,[仿單]目前並無任何關於molnupiravir或其代謝物是否會出現於人類的乳汁方面的資料。曾在投予molnupiravir之授乳大鼠所哺乳之仔鼠的血漿中檢出NHC。目前並不確知molnupiravir是否會對餵哺母乳的嬰兒造成影響，或對乳汁生成作用造成影響。 由於嬰兒可能會對molnupiravir產生不良反應，因此，在使用molnupiravir治療期間和使用最後一劑藥物後4天內不建議餵哺母乳。在治療期間和使用最後一劑molnupiravir後4天內，哺乳病人可能要考慮中斷餵哺母乳，也可能要考慮將乳汁吸出並丟棄。 在出生前後發育研究中，對授乳大鼠投予?250毫克/公斤/日之劑量的molnupiravir之後，曾在哺乳仔鼠的血漿中檢出NHC。 根據動物研究的結果，對孕婦投予molnupiravir可能會對胎兒造成傷害。,PO;,,,,,[磨粉/管灌註記]仿單建議應整粒吞服。不得打開膠囊。無法吞服患者(依臨床試驗)給藥方法:將四顆膠囊後至於調製杯或注射器中，加水40mL攪拌3分鐘且均勻混合，配製完請盡快服用或管灌，可在服用後再給予240mL以下水分確保所有藥物吞嚥完成。
OOKP,Olanzapine,Okpine F.C. 5mg,CNEU,Treatment of the manifestations of schizophrenia; treatment of acute or mixed mania episodes associated with bipolar I disorder (as monotherapy or in combination with lithium or valproate); maintenance treatment of bipolar I disorder; in combination with fluoxetine for treatment-resistant or bipolar I depression.,Hypersensitivity to olanzapine or any component of the formulation,>10%: Cardiovascular: Orthostatic hypotension (3-20%) Central nervous system: Drowsiness(20-39%)， extrapyramidal reaction (10-32%)， akathisia (3-27%)， parkinsonian-like syndrome (14% to 20%)， dizziness (8-11%)， headache (adolescents 17%)， fatigue (2% to 14%)， insomnia (12%) Endocrine & metabolic: Increased serum prolactin (30-47%)， weight gain (5-40%) Gastrointestinal: Increased appetite (3-29%)， xerostomia (3-22%)， dyspepsia (3-11%)， constipation (4-11%) Hepatic: Increased serum AST (adolescents 28%)， decreased serum bilirubin (adolescents 22%)， increased serum ALT (?3 x ULN; adolescents and adults 5% to 12%) Neuromuscular & skeletal: Weakness (8-20%) Miscellaneous: Accidental injury (12%),25℃以下，避光及防潮濕,Adults: Initial dose: Schizophrenia: 10mg QD; manic episodes of bipolar disorder: monotherapy 15mg QD， combined therapy 10mg QD; prevent the recurrence of bipolar disorder:10mg QD. The daily dose can be adjusted to 5-20 mg/day according to the patient's clinical condition. The dosing interval should not be less than 24 hours. The elderly， >65 years old: consider using a lower initial dose (5 mg/day) Children: Lack of safety and efficacy data. Not recommended for people under 18 years of age.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
OACC6,Acetylcysteine,ACC 600mg 發泡錠,ERSP,Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis， emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms.,Effervescent tab Phenylketonuria.,Bronchospasm， GI upsets， stomatitis; rhinorrhea， fever， hemoptysis; rarely anaphylactic reactions. Dermatologic: Pruritus (1% to 4.3% )， Rash (4% to 5% )， Urticaria Gastrointestinal: Diarrhea， Nausea (2% to 7% )， Vomiting (9% to 12% ),25℃以下,Effervescent tab Adult & children > 6 years 1 effervescent TAB QD- BID.,無需調整劑量,ACETYLCYSTEINE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible [仿單]無相關記載,無需調整劑量,可能安全,Compatible – maternal benefit >> embryo-fetal risk,ACETYLCYSTEINE PREGNANCY RECOMMENDATION: Compatible—Maternal Benefits >> Embryo–Fetal Risk [仿單]無相關記載,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,ACETYLCYSTEINE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible [仿單]無相關記載,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為發泡錠，服用前將此發泡錠置玻璃容器中，加少量水(60-100mL)溶解、混勻後服用。
RIBI655,Risankizumab/Placebo,試BI-655066-1311.30 (75mg Risankizumab/Placebo),HIMM,,,,,,,,,,,,,,SC;,,,,,
LCEF,Cefaclor,Cefaclor 25mg/mL， 60mL suspension,QANB,2nd generation cephalosporin with in vitro activity against Strep. pyogenes， Strep. pneumoniae， H. influenzae， E. coli， Klebsiella sp. and Proteus mirabilis.,Hypersensitivity to cefaclor.,Common Gastrointestinal: Diarrhea (1.4% ) Serious Dermatologic: Stevens-Johnson syndrome， Toxic epidermal necrolysis Gastrointestinal: Clostridium difficile colitis Hematologic: Hemolytic anemia Other: Serum sickness due to drug (0.024% to 0.5% ),15-30℃，泡製後冷藏2-8℃可保存14天,Children: 20-40 mg/kg/day in 2-3 divided doses (maximum dose 1 g/day).,無需調整劑量,[仿單]未有記載,需調整劑量,沒有資料,Compatible,[仿單]未有記載,Compatible 哺乳時可使用,[仿單]未有記載,AC;AC15;PC;PO;WM;,,,,,
OMAV,Glecaprevir + Pibrentasvir,Maviret 100/40mg,QANB,Treatment of adult chronic hepatitis C virus (HCV) genotype 1， 2， 3， 4， 5 or 6 infections.,Hypersensitivity to any component of the formulation.,Headache， fatigue， Nausea， diarrhea,30℃以下,Adults and children > or = 12 years: 3 tablets PO once daily with meals (total daily dose: glecaprevir 300 mg， pibrentasvir 120 mg) for 8-16 weeks.,需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PO;WM;,,,,,
EMTS,Mometasone,Metsone cream 0.1%， 5gm,TDER,,適應症:Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid) 副作用: Bacterial skin infection， burning， furunculosis， pruritus， skin atrophy， tingling/stinging 禁忌:Hypersensitivity to mometasone furoate， other corticosteroids， or any component of the formulation; untreated fungal， bacterial， and viral (ie， herpes simplex， chicken pox， and vaccinia) infections involving the skin.,,室溫,Apply a thin film to affected area once daily,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;,,,,,
OELI2,Apixaban,2.5mg Eliquis 艾必克凝膜衣錠,HEMT,Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF)， w/ >=1 risk factors [eg， prior stroke or transient ischaemic attack， age >=75 yr， HTN， DM， symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.,Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk. Lesion or condition at significant risk of major bleeding (eg， current or recent GI ulceration， presence of malignant neoplasms at high risk of bleeding; recent brain/spinal injury， brain/spinal/ophth surgery， intracranial haemorrhage; known or suspected oesophageal varices， arteriovenous malformations， vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment w/ any other anticoagulant eg， unfractionated heparin (UFH)， low molecular wt heparins， heparin derivatives， oral anticoagulants except under the circumstances of switching therapy to or from apixaban or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter.,Epistaxis， anaemia， nausea， contusion， haematuria， haematoma， vag & urethral haemorrhage; eye， GI & rectal haemorrhage; gingival bleeding.,30℃以下,Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 5 mg twice daily unless patient has any 2 of the following: Age >=80 years， body weight =<60 kg， or serum creatinine >=1.5 mg/dL， then reduce dose to 2.5 mg twice daily. Deep venous thrombosis: Oral:Treatment: 10 mg twice daily for 7 days followed by 5 mg twice daily. Reduction in the risk of recurrence: 2.5 mg twice daily after at least 6 months of treatment for DVT,需調整劑量,[仿單]目前沒有關於人類乳汁中apixaban或其代謝產物的存在，對母乳哺孩子或對泌乳量影餐的資料Apixaban和/或其代謝產物存在於大鼠乳汁中。由於尚不清楚人類是否會透過乳汁接觸藥物，因此接受ELIQUIS治療期間不建議母乳餵哺。,需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,No Human Data - Potential Risk. [仿單]關於孕婦使用ELIQUIS的可用資料有限，不足以顯示與藥物相關的重大先天缺陷、流產或不良發育結果風險。 使用本品治療可能會增加懷孕與生產期間的出血風險。在動物繁殖試驗中，於器官形成期間分別給予大鼠（口服）、兔子（靜脈注射）及小鼠（口服）相當於人類未結合apixaban曝藥量分？為4、1及19倍劑量，未觀察到apixaban具有對發育的不良影響。 目前尚不清楚指定族群重大先天缺陷和流產的估計背景風險。所有懷孕皆有先天缺陷、流產或其他不良結果的背景風險。在美國一般族群中，臨床公認的懷孕重大先天缺陷和流產估計背景風險分？為2%至4%和15%至20%。 臨床考量 與疾病相關的母體和/或胚胎/胎兒風險 懷孕會增加血栓栓塞的風險，對於具有潛在血栓栓塞性疾病和特定高妊娠的婦女來說，血栓栓塞的風險更高。已發表的資料顯示，先前具有血栓形成病史的女性在懷孕期間有很高的復發風險。 [仿單節錄]關於孕婦使用ELIQUIS的可用資料有限，不足以顯示與藥物相的重大先天缺陷、流產或不良發育結果風險。使用本品治療可能會增加懷孕與生產期間的出血風險。在動物繁殖試驗中，於器官形成期間分？給予大鼠（口服）、兔子（靜脈注射）及小鼠（口服）相當於人類未結合apixaban曝藥量分？為4、1及19倍劑量[以血中濃度曲線下面積(AUC)為基礎，和5毫克每日兩次的人類最高建議劑量(MRHD)進行比較]，未觀察到apixaban具有對發育的不良影響。 懷孕會增加血栓栓塞的風險，對於具有潛在血栓栓塞性疾病和特定高風險妊娠狀G的婦女來說，血栓栓塞的風險更高。已發表的資料顯示，先前具有靜脈血栓形成病史的女性在懷孕期間有很高的復發風險。 使用包括ELIQUIS的抗凝血劑，可能會增加胎兒和新生兒出血的風險。 所有接受抗凝血劑治療的病人（包括孕婦），都有出血的風險。 接受椎管？麻醉的女性中，在分娩或生產期間使用ELIQUIS可能會導致硬脊膜外或脊髓血腫。可考慮於生產期間使用更短效的抗凝血劑。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]目前沒有關於人類乳汁中apixaban或其代謝產物的存在，對母乳哺孩子或對泌乳量影餐的資料Apixaban和/或其代謝產物存在於大鼠乳汁中。由於尚不清楚人類是否會透過乳汁接觸藥物，因此接受ELIQUIS治療期間不建議母乳餵哺。,AC;AC15;PC;PO;,,,,,
IHEP20,Heparin,Hepac Plus for Dialysis 5000 Unit/20mL(250Unit/mL),HEMT,Anticoagulant for extracorporeal circulation device during hemodialysis.,Hypersensitivity to the drug， Bleeding disorders， Severe thrombocytopenia， Patients who can't undergo regular blood coagulation tests， Patients with heparin-Induced Thrombocytopenia.,Common Hematologic: Thrombocytopenia (Up to 30% ) Hepatic: Increased liver aminotransferase level Serious Hematologic: Hemorrhage (5% to 10% )， Heparin-induced thrombocytopenia (0.6% to 10% )， Heparin-induced thrombocytopenia with thrombosis (Less than 1% ) Immunologic: Hypersensitivity reaction Neurologic: Non-traumatic spinal subdural hematoma,30℃以下,1000-3000 units before general systemic heparinization， followed by 500-1500 units hourly after starting of dialysis， or adding on 500-1500 units intermittenly could be considerated.,無需調整劑量,[仿單] 投藥予孕婦、產婦、哺乳婦女: 孕婦或有懷孕可能的婦人，當治療上的效益遠大於危險性的狀況下才可投藥。 ﹝懷孕中的投藥相關安全性尚未確立。﹞,無需調整劑量,沒有資料,Compatible,[仿單] 投藥予孕婦、產婦、哺乳婦女: 孕婦或有懷孕可能的婦人，當治療上的效益遠大於危險性的狀況下才可投藥。 ﹝懷孕中的投藥相關安全性尚未確立。﹞,Compatible 哺乳時可使用,[仿單] 投藥予孕婦、產婦、哺乳婦女: 孕婦或有懷孕可能的婦人，當治療上的效益遠大於危險性的狀況下才可投藥。 ﹝懷孕中的投藥相關安全性尚未確立。﹞,IRR;,,,,注射針筒產品相關注意事項: 1)外包裝至使用前都不要開封 2)針筒有可能會破損，故需避免強烈衝擊 3)從外包裝取出時，不要由推桿取出.膠塞變形，推桿脫落的話，可能會造成藥液漏出 4)藥液漏出或是藥液裡有混濁或浮游物等異常狀況皆不要使用 5)針筒破損等異常狀況發生時不要使用 6)取下針筒前端的塞蓋後，不要接觸針筒前端部分 7)注入前後都不要拉推桿 8)開封後限一次使用，使用後的殘留液體與容器需儘速盡速丟棄 9)針筒不要再滅菌及再使用 10)接上注射針等時需注意不要刺到，並牢牢固定,使用注射幫浦投藥，應注意下述幾點: 1)務必確認可架設於注射幫浦，並且依照注射幫浦等的使用說明書投藥 2)確實架設於注射幫浦內筒滑動部(slider)的鉤子.若沒有正確架設，可能會發生虹吸(因自然落下產生快速注入)或逆流 3)本品架設於血液幫浦下游，抗凝血劑注入管線的血液迴路處.因血液迴路阻塞等會發生極端負壓，膠塞可能會從推桿脫落，或推桿可能會從注射幫浦的內筒滑動部(slider)的鉤子脫落，造成本品快速注入.
IKAD00,Trastuzumab Emtansine,KADCYLA inj 160mg (sample),RACA,Metastatic breast cancer， HER2 overexpression， monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.,適應症: Metastatic breast cancer， HER2 overexpression， monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy. 副作用: Common ■Gastrointestinal: Constipation (26.5% )， Nausea (39.8% ) ■Hematologic: Thrombocytopenia， All grades (31.2% ) ■Hepatic: Increased liver enzymes， All grades (28.8% ) ■Musculoskeletal: Musculoskeletal pain (36.1% ) ■Neurologic: Headache (28.2% ) ■Other: Fatigue (36.3% ) Serious ■Cardiovascular: Left ventricular cardiac dysfunction (1.8% ) ■Dermatologic: Injection site extravasation ■Hematologic: Anemia， Grade 3 and 4 (4.1% )， Neutropenia， Grade 3 and 4 (2% )， Thrombocytopenia， Grade 3 and 4 (14.5% ) Specific contraindications have not been determined.,Common ■Gastrointestinal: Constipation (26.5% )， Nausea (39.8% ) ■Hematologic: Thrombocytopenia， All grades (31.2% ) ■Hepatic: Increased liver enzymes， All grades (28.8% ) ■Musculoskeletal: Musculoskeletal pain (36.1% ) ■Neurologic: Headache (28.2% ) ■Other: Fatigue (36.3% ) Serious ■Cardiovascular: Left ventricular cardiac dysfunction (1.8% ) ■Dermatologic: Injection site extravasation ■Hematologic: Anemia， Grade 3 and 4 (4.1% )， Neutropenia， Grade 3 and 4 (2% )， Thrombocytopenia， Grade 3 and 4 (14.5% ) ■Hepatic: Hepatotoxicity， Increased liver enzymes， Grades 3 and 4 (8% )， Injury of liver ■Immunologic: Anaphylactoid reaction ■Neurologic: Peripheral nerve disease， Grade 3 or 4 (2.2% ) ■Respiratory: Dyspnea (12% )， Interstitial lung disease， Pneumonitis (0.8% to 1.2% ),2-8℃,3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever， chills， or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.,無需調整劑量,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded， a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,無需調整劑量,盡量避免,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded， a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,IVD;,,,,,1. 輸注溶液不可含葡萄糖。 2. 第一次使用建議施打90分鐘，之後視病人耐受程度可縮短輸注時間至最短30 分鐘。請使用0.2-0.22微米、不吸附蛋白質的管線內 polyethersulfone (PES)過濾器。 3. 溶液配置後應立即使用，冷藏於2-8℃最多儲存24小時。 4. 輸注時注意病人是否出現呼吸困難、周邊水腫、低血壓或其他急性過敏反應症狀。 5. 監測CBC、肝腎功能。
OCARD4,Propranolol,Cardolol 40mg,CAVS,Adult HTN， Angina， migraine & essential tremor， Arrhythmias， anxiety tachycardia， thyrotoxicosis， Pheochromocytoma.,History of bronchial asthma or bronchospasm， bradycardia， cardiogenic shock， hypotension， metabolic acidosis， after prolonged fasting， severe peripheral arterial circulatory disturbances， 2nd or 3rd degree heart block， sick sinus syndrome， untreated (with an alpha adrenoceptor antagonist) phaeochromocytoma， uncontrolled heart failure， Prinzmetal's angina.,Cold extremities， GI & sleep disturbances， fatigue， lassitude. Deterioration in heart failure， mood changes. Isolated cases of paresthesia. Rarely bradycardia， dizziness， postural hypotension which may be associated with syncope， heart block， alopecia， thrombocytopenia， purpura， psoriasiform skin reactions， exacerbation of psoriasis， visual disturbances， CNS symptoms including hallucinations & psychoses; hypoglycaemia in children. Rashes & dry eyes (discontinue drug). Intermittent claudication， Raynaud's phenomenon， bronchospasm， increased antinuclear antibodies. Dermatologic: Dermatitis， Pruritus， Urticaria Neurologic: Dizziness (4% to 7% ) Other: Fatigue (5% to 7% ),室溫,Angina: PO， initially， 10-20mg TID-QID; maintenance， 160-240mg/day. Arrhythmia: Adult: PO， 10-30mg TID-QID AC. Child: PO， initially， 1.5-2mg/kg/day， titrate up to a maximum. 16mg/kg/day in 4 doses. Essential tremor: PO， initially， 40mg BID; maintenance， 120-320mg/day in 3 doses. Hypertension: PO. Adult: Initially， 40mg BID; maintenance， 160-480mg/day. Child: Initially， 1mg/kg/day in 2 doses; maintenance， 1-5mg/kg/day in 2-4 doses. Migraine: PO， initially， 80mg/day in divided doses; maintenance，160-240 mg/day. Pheochromocytoma: PO， 60mg/day in divided doses for 3 days before surgery; 30 mg/day in divideddoses with an adrenergic blocker as an adjunct to prolonged treatment of intolerable pheochromocytoma. Post-MI: PO， 180-240mg/day in divided doses.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
IMMR1,Measles + Mumps + Rubella,MMR II (麻疹等三種疫苗， 政府提供) 0.5mL/dose,HIMM,Immunization against measles， mumps & rubella in individuals ≧ 12 months， non-pregnant adolescents， adult female & postpartum women. Children ≦12 months， should be revaccinated after reaching 15 months.,Pregnancy. Any febrile infection or febrile respiratory illness. Active untreated TB， blood dyscrasias， leukemia， lymphomas of any type， malignant neoplasms affecting the bone marrow or lymphatic system. Patients receiving immunosuppressive therapy. Primary & acquired immunodeficiency states， or family history of immunodeficiency. Hypersensitivity to neomycin or eggs.,Burning， stinging at inj site. Headache， fever， sore throat， GI upset， rash， arthralgia &/or arthritis， parotitis， nerve deafness， optic neuritis. Lymphadenopathy， afebrile convulsions， ataxia， Guillain-Barre syndrome， thrombocytopenia purpura， dizziness， paraesthesias.,2-8℃避光,SC， 0.5mL， children 6-12 months primary immunization， the second dose at 15 months of age， the third dose at 4-6 years or 11-12 years. Age > or = 12 months primary immunization， the second dose at 4-6 years or 11-12 years.,無需調整劑量,Measles- No Human Data-Probably Compatible Mumps- No Human Data-Probably Compatible Rubella- Compatible [仿單]有關授乳婦女使用情況的資料很少，當權衡後，其利益高於風險則可接種疫苗.,無需調整劑量,不可使用,Contraindicated,[仿單]懷孕婦女不得使用Priorix. 然而，懷孕婦女在施打麻疹，腮腺炎或德國麻疹疫苗後，並無發生嚴重傷害的記錄. 儘管原理上的風險無法被排除，但有超過3500不知已懷孕的婦女，在接種包含德國麻疹疫苗後，並沒出現有先天性德國麻疹症候群的案例. 因此，對於不知已懷孕的婦女在非刻意接種包含麻疹，腮腺炎或德國麻疹疫苗後，不需因此而終止懷孕. 育齡婦女應避免於接種後四週內懷孕。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Measles- No Human Data-Probably Compatible Mumps- No Human Data-Probably Compatible Rubella- Compatible [仿單]有關授乳婦女使用情況的資料很少，當權衡後，其利益高於風險則可接種疫苗.,SC;,使用廠商所附稀釋溶液,,,,1. 注射MMR II時，不可同時給予免疫球蛋白。 2. 皮下注射最好的注射位置是上臂的外側。 3.接受一般肌肉注射免疫球蛋白治療或B型肝炎免疫球蛋白，宜間隔3個月後再接種Priorix. 4.輸過血或接受靜脈注射血液製品者，宜間隔6個月再接種Priorix. 5.曾靜脈注射高劑量(大於等於1g/kg)免疫球蛋白治療時，宜間隔11個月後再接受Priorix.
IMMR2,Measles + Mumps + Rubella,M-M-R II 0.5mL/dose (自費麻疹等三種疫苗),HIMM,Immunization against measles， mumps & rubella in individuals ≧ 12 months， non-pregnant adolescents， adult female & postpartum women. Children ≦12 months， should be revaccinated after reaching 15 months.,Pregnancy. Any febrile infection or febrile respiratory illness. Active untreated TB， blood dyscrasias， leukemia， lymphomas of any type， malignant neoplasms affecting the bone marrow or lymphatic system. Patients receiving immunosuppressive therapy. Primary & acquired immunodeficiency states， or family history of immunodeficiency. Hypersensitivity to neomycin or eggs.,Burning， stinging at inj site. Headache， fever， sore throat， GI upset， rash， arthralgia &/or arthritis， parotitis， nerve deafness， optic neuritis. Lymphadenopathy， afebrile convulsions， ataxia， Guillain-Barre syndrome， thrombocytopenia purpura， dizziness， paraesthesias.,2-8℃,SC， 0.5mL， Children 6-12 months primary immunization， the second dose at 15 months of age， the third dose at 4-6 years or 11-12 years. Age > or = 12 months primary immunization， the second dose at 4-6 years or 11-12 years.,無需調整劑量,Measles- No Human Data-Probably Compatible Mumps- No Human Data-Probably Compatible Rubella- Compatible [仿單]有關授乳婦女使用情況的資料很少，其利益高於風險則可接種。,無需調整劑量,不可使用,Contraindicated,[仿單]當孕婦接種 M-M-RII時，是否對胎兒造成傷害或影響孕婦之生殖能力，目前尚未知曉。 因此，懷孕女性不應使用 M-M-RII。另外，婦女於接種此疫苗後 1 個月內應避免懷孕。 一項調查 18 年間，超過 1200 位於懷孕前後 3 個月內接種德國麻疹疫苗婦女的研究，未發現新生兒有先天性德國麻疹症候群之異常。 根據目前上市後報告及已發表之觀察性研究中亦尚未發現接種M-M-R II 婦女產下的新生兒出現先天性德國麻疹症候群之異常。 在懷孕的前三個月感染腮腺炎會增加自然流產的機率。雖然腮腺炎疫苗之病毒被發現會感染胎盤及胎兒，但沒有證據證明其會導致人類先天性畸形。 報告指出懷孕期間感染野生種麻疹會增加胎兒危險。自然流產、死胎、先天性缺陷及早產的機率都會增加。 減毒的麻疹疫苗病毒對懷孕之影響，尚未有足夠的研究。然而，最好小心假設這些疫苗病毒菌株也會對胎兒造成不良影響。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Measles- No Human Data-Probably Compatible Mumps- No Human Data-Probably Compatible Rubella- Compatible [仿單]有關授乳婦女使用情況的資料很少，其利益高於風險則可接種。,SC;,使用廠商所附稀釋溶液,,,,1. 注射MMR II時，不可同時給予免疫球蛋白。 2. 皮下注射最好的注射位置是上臂的外側。
IDUPI,Dupilumab,DUPIXENT inj 300mg/2mL,TDER,Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.,Known hypersensitivity to dupilumab or any component of the formulation,>10%: Local: Injection site reaction (10% to 18%) 1% to 10%: Gastrointestinal: Oral herpes simplex infection (4%) Hematologic & oncologic: Eosinophilia (<2%) Immunologic: Antibody development (6% to 9%; neutralizing: 2% to 4%) Infection: Herpes simplex infection (2%) Ophthalmic: Conjunctivitis (10%)， eye pruritus (1%) Respiratory: Oropharyngeal pain (2%),2-8℃避光避免冷凍,Atopic dermatitis， Moderate to severe Adult， initial， 600 mg (two 300 mg injections) SC， then 300 mg SC every other week Adolescents 12 to 17 Years Old， if <60kg 400 mg (two 200 mg injections) SC， then 200 mg SC every other week. If>60kg 600 mg (two 300 mg injections) SC， then 300 mg SC every other week. Concomitant therapy: Use with or without topical steroids; reserve concomitant use with topical calcineurin inhibitors for problem areas only (eg， face， neck， intertriginous and genital areas Asthma (Moderate to Severe)， Adjunct; oral corticosteroid-dependent (12 years or older) Loading， 400 mg (two 200 mg injections) SC followed by 200 mg every other week or an initial loading dose of 600 mg (two 300 mg injections) SC followed by 300 mg every other week. For patients with oral corticosteroid-dependent asthma or with comorbid moderate-to-severe atopic dermatitis， start with the 600-mg dose followed by 300 mg every other week,無需調整劑量,[仿單]Dupixent是否會分泌至人體乳汁、對吸吮母乳之嬰兒的影響，或對母乳生成的影響，目前尚無相關資料。已知母體免疫球蛋白G(IgG)會進入人體乳汁。吸吮母乳之嬰兒，其胃腸道局部暴露和全身性有限暴露於dupilumab所造成的影響，目前不得而知。當考量哺乳對嬰兒發育及健康的益處時，應同時考慮母親對Dupixent之臨床需求，以及Dupixent或母親的潛在病況對吸吮母乳的幼兒可能造成的任何不良影響。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]根據Dupixent使用於懷孕婦女的個案報告及ㄧ連串個案之現有資料，並未發現有重大出生缺陷、流產，或對母體或胎兒造成不良影響的藥物相關風險。已知人類免疫球蛋白G(IgG)會通過胎盤障壁；因此Dupixent有可能會從母體傳遞至發育中的胎兒。懷孕期氣喘會對母體和胎兒造成不良影響。在一項進階型週產期前後之幼胎發育研究中，懷孕母猴在胚胎器官形成期至分娩期間接受抗介白素-4α受體(IL-4Rα)之同源抗體(homologous antibody)至多達10倍人類最大建議劑量(MRHD)之皮下注射，未見對幼猴的發育造成不良影響。特定族群之重大出生缺陷及流產的預估背景風險並不清楚。所有的懷孕都有出生缺陷、流產或其他不良結果之背景風險。以美國一般族群來說，臨床上確認之懷孕發生重大出生缺陷及流產的預估背景風險分別為2-4%及15-20%。 氣喘控制差或中度控制的婦女，有證據顯示會增加母體子癲前症及新生兒早產、低出生體重和胎兒小於妊娠年齡的風險。應嚴密監測懷孕婦女的氣喘控制狀況，且必要時應調整治療以維持最適控制。 在一項進階型週產期前後之幼胎發育毒性研究中，懷孕食蟹猴(cynomolgus monkeys)於胚胎器官形成初期至分娩期間，每週以皮下注射方式投予至多達10倍人類最大建議劑量(MRHD)(以mg/kg為計算基礎，其劑量為100mg/kg/week)的抗介白素-4α受體(IL-4Rα)之同源抗體(homologous antibody)，仔猴從出生起至6個月大皆未觀察到此治療所造成的不良影響，包括胚胎-胎兒毒性或畸形，亦未見此治療對仔猴於型態、功能或免疫學上之發育造成不良影響。,Unknown 沒有資料,[仿單]Dupixent是否會分泌至人體乳汁、對吸吮母乳之嬰兒的影響，或對母乳生成的影響，目前尚無相關資料。已知母體免疫球蛋白G(IgG)會進入人體乳汁。吸吮母乳之嬰兒，其胃腸道局部暴露和全身性有限暴露於dupilumab所造成的影響，目前不得而知。當考量哺乳對嬰兒發育及健康的益處時，應同時考慮母親對Dupixent之臨床需求，以及Dupixent或母親的潛在病況對吸吮母乳的幼兒可能造成的任何不良影響。,SC;,,,X,X,1. 應儲存於冰箱2- 8℃，在室溫 (最高至25?℃)下可保存14天。不可震搖、加熱、冷凍注射器。 2. 使用前於平面上靜置45分鐘使其自然回溫至室溫。避免日光照射。 3. 接受Dupixent治療的病人應避免接種活性疫苗。 4. 若漏打一次劑量，應在漏打劑量後的天內補行注射，之後則按照原有時程給藥。若漏打的劑量沒有在7天內注射，則應依照原有時程等到下次劑量再給藥。
OCAL5,Calcium Carbonate,Calcium Carbonate 500mg,NUTR,Relief of the symptoms of gastric hyperacidity.,Hypercalcaemia due to myeloma， bone metastases or other malignant bone disease， sarcoidosis; primary hyperparathyroidism， vitamin D overdosage; severe renal failure.,Mild GI disturbances.,25℃以下,1 TAB equivalent to 200mg of elemental calcium. >12 years old: 2 TAB TID. 6-12 years old: 1 TAB TID. 3-6 years old: 0.5 TAB TID. [UpToDate 20210731] Adult: Antacid: Generally， 1 to 4 tablets as symptoms occur; maximum: 8 g/day as calcium carbonate for up to 2 weeks. Calcium supplementation: 500 mg to 4 g/day as calcium carbonate (equivalent to 200 mg to 1.6 g of elemental calcium) in 1 to 3 divided doses. Pediatric: Antacid: Children 2 to 5 years， weighing >10.9 kg: 375 to 400 mg of calcium carbonate as symptoms occur for up to 2 weeks; maximum daily dose: 1500 mg/day of calcium carbonate. Children 6 to 11 years: 750 to 800 mg of calcium carbonate as symptoms occur for up to 2 weeks; maximum daily dose: 3，000 mg/day of calcium carbonate. Children > or = 12 years and Adolescents: 500 to 3，000 mg of calcium carbonate as symptoms occur for up to 2 weeks; maximum daily dose: 7500 mg/day of calcium carbonate. Calcium dietary supplementation: Children 2 to 4 years: 750 mg of calcium carbonate twice daily. Children > or = 4 years and Adolescents: 750 mg of calcium carbonate 3 times daily.,無需調整劑量,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,需調整劑量,沒有資料,Compatible,,Compatible 哺乳時可使用,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,AC;AC15;PC;PO;WM;,,,,,
ETIS4,Thrombin+calcium chloride+aprotinin+protein clotta,Tisseel solution for sealant 4mL/set,HEMT,Adjunct to hemostasis in cardiopulmonary bypass surgery (including fully heparinized patients) and splenic injury (due to blunt or penetrating trauma to the abdomen) when the control of bleeding by conventional surgical techniques is ineffective or impractical; adjunctive sealant for closure of colostomies.,Hypersensitivity to aprotinin; direct intravascular injection; severe or brisk arterial bleeding,May be related to aprotinin contained in some products. Frequency may vary by product. 1% to 10%: Cardiovascular: Bradycardia (?10%) Central nervous system: Fever (6%) Dermatologic: Pruritus Gastrointestinal: Abdominal distension (4%) Hematologic & oncologic: Hematoma (Facial rhytidectomy: 1% to 4%)， hemorrhage (internal， postprocedural; 2%)， increased serum fibrinogen (2%) Immunologic: Antibody development (1% to 2%) Local: Skin graft failure (3%) Respiratory: Pulmonary embolism (<1% to 3%),-20℃以下冷凍,2mL of TISSEEL， which means 1mL TISSEEL and 1mL of thrombin solution， could cover at least 10cm2， depending on surgery type， wound size and frequency.,無需調整劑量,Pregnancy Risk Factor: C (up to date) aprotinin- No Human Data—Probably Compatible,無需調整劑量,除非治療上需要,Uknown 沒有資料,aprotinin-No Human Data—Probably Compatible,Unknown 沒有資料,Pregnancy Risk Factor: C (up to date) aprotinin- No Human Data—Probably Compatible,EXT;,,,,,
ETHEW,Thermometer,婦人基礎溫度計,ZOTH,,,,室溫,非藥品,無需調整劑量,,無需調整劑量,安全,Compatible,,Compatible 哺乳時可使用,,EXT;,,,,,
ENEED,Sterile Pen Needle,32G Pen needle 胰島素筆型針頭#320472,ZOTH,,,,無特別指示,非藥品,無需調整劑量,,無需調整劑量,,,,,,SC;,,,,,
ITIEN,Imipenem + Cilastatin Sodium,Imipenem/Cilastatin Kabi 500/500mg inj,QANB,Intra-abdominal， lower respiratory tract， gynecological， GUT， bone & joint， skin & soft tissue & mixed infections， endocarditis， septicemia. Prophylaxis of post-op infections.,Hypersensitivity to amide-type local anaesth， severe shock or heart block.,Thrombophlebitis， pain， induration， erythema & tenderness following inj. Rash， urticaria， pruritus， GI disturbances， pseudomembranous colitis， haematological disturbances， increase in liver enzymes， taste perversion. Myoclonic activity， seizures， psychic disturbances， confusional states. Dermatologic: Injection site pain Gastrointestinal: Diarrhea (1.8% )， Nausea (2% )， Vomiting (1.5% ) Hematologic: Thrombophlebitis (3.1% ),25℃以下避光,Doses based on imipenem component. Administer 500 mg by IV infusion over 20-30 minutes; 1000 mg over 40-60 minutes. Adults > 70 kg and children > or = 40 kg: 1-2 g/day (250 mg Q6H， 500 mg Q8H， 1 g Q12H); severe infections: 2-4 g/day (ranges from 500 mg Q6H to 1 g Q6-8H) (maximum: 4 g/day or 50 mg/kg/day). Post-surgical infections prophylaxis in adults: 1 g IV on induction of anesthesia and 1 g 3 hours later. For high-risk surgery， 500 mg can be given at 8 and 16 hours after induction. Children (3 months and older) < 40 kg: 15 mg/kg IV Q6H (maximum: 2 g/day).,無需調整劑量,Small amounts of imipenem–cilastatin are excreted into breast milk. These amounts are comparable to other β-lactam antibiotics. The effects， if any， on a nursing infant are unknown.,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,No reports describing the use of this antibiotic-enzyme inhibitor combination in the 1st trimester of nonterminated human pregnancies have been located. Four sources consider imipenem–cilastatin to be a safe and effective agent during the perinatal period,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Small amounts of imipenem–cilastatin are excreted into breast milk. These amounts are comparable to other β-lactam antibiotics. The effects， if any， on a nursing infant are unknown.,IVD;,N/S， D5W,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,劑量≦500 mg時，滴注時間約20 ~ 30分鐘，當劑量大於 500 mg 時，滴注時間約40 ~ 60分鐘。 輸注溶液建議濃度：5 mg/mL of imipenam。,1. 若病患有噁心感時應減慢滴注速率。 2. 監測體溫、CBC、肝腎功能，注意是否有肌肉震顫或癲癇發作徵狀。 3. 溶解或稀釋後之溶液須立即使用，由溶解開始至完成輸注時間間隔不得超逾 2 小時。 4. “卡比”疫必寧與乳酸鹽(lactate)屬化學配伍禁忌，所以不應以含乳酸鹽之溶液來稀釋。
OPLET1,Cilostazol,Pletaal 100mg,HEMT,Reduction of symptoms of intermittent claudication， as indicated by an increased walking distance.,Patients with CHF of any severity.,Abdominal pain， back pain， headache， infection， palpitation， tachycardia， GI effects， peripheral edema， myalgia， dizziness， vertigo， cough， pharyngitis， rhinitis. Cardiovascular: Palpitations (5% to 10% )， Peripheral edema (7% to 9% )， Tachyarrhythmia (4% ) Gastrointestinal: Abdominal pain (4% to 5% )， Diarrhea (12% to 19% )， Feces contents abnormal (12% to 15% )， Indigestion (6% ) Hematologic: Decreased platelet aggregation Musculoskeletal: Backache (6% to 7% )， Myalgia (2% to 3% ) Neurologic: Dizziness (9% to 10% )， Headache (27% to 34% ) Respiratory: Increasing frequency of cough (3% to 4% )， Pharyngitis (7% to 12% )， Rhinitis (7% to 12% ) Other: Infectious disease (10% to 14% ),30℃以下,Oral 100mg twice daily.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;PO;,,,,,
OXAR1,Rivaroxaban,Xarelto 10mg,HEMT,,適應症: Xarelto 10 mg Prevention of Venous Thrombosis(VTE) in adult patients undergoing elective hip or knee replacement surgery. Xarelto 15 mg & 20 mg Prevention of stroke & systemic embolism in adult patients w/ non-valvular atrial fibrillation w/ ≧1 risk factors eg CHF， HTN， age ≧75 yr， DM， prior stroke or transient ischaemic attack. Treatment of Deep Venous Thrombosis (DVT) & PE， & prevention of recurrent DVT & PE following an acute DVT in adults. 副作用: Anemia， dizziness， headache， syncope， eye haemorrhage， tachycardia， hypotension， haematoma， epistaxis， GI disorders， pruritus， pain in extremity， urogenital tract haemorrhage， fever， peripheral oedema， decreased general strength & energy， increased transaminases， postprocedural haemorrhage. 禁忌:Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk including cirrhotic Child-Pugh B & C patients. Pregnancy & lactation.,,室溫,Dosing: Adult Deep vein thrombosis (DVT)， pulmonary embolism (PE) treatment: Oral: Initial: 15 mg twice daily with food for 3 weeks followed by 20 mg once daily with food. Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 20 mg once daily with the evening meal. Postoperative DVT thromboprophylaxis: Oral: Note: Initiate therapy after hemostasis has been established， 6-10 hours postoperatively. Knee replacement: 10 mg once daily; recommended total duration of therapy: 12-14 days. Hip replacement: 10 mg once daily; total duration of therapy: 35 days.,需調整劑量,,需調整劑量,除非治療上需要,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IVAX,Purified Split Inactivated Influenza Virus,自費3價流感 (Vaxigrip)0.5mL/dose,HIMM,,適應症: Active immunisation against influenza. 副作用: Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome. 禁忌: Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,,2 ~ 8 °C,Adult & Children >= 36 mth 0.5ml IM Chidren <= 8 yr who have not been vaccinated previously， the 2nd dose can be given at an interval of at least 4 wk.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;,,,,,
IVAX1,Purified Split Inactivated Influenza Virus,免費成人流感 0.5mL/dose,HIMM,,適應症: Active immunisation against influenza. 副作用: Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome. 禁忌: Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,,2 ~ 8 °C,Adult & Children >= 36 mth 0.5ml IM Chidren <= 8 yr who have not been vaccinated previously， the 2nd dose can be given at an interval of at least 4 wk.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,Compatible 哺乳時可使用,,IM;SC;,,,,,
EMEL1,Hydroquinone,Melquine ointment 4% 10gm,TDER,,適應症:Skin bleaching: Gradual bleaching of hyperpigmented skin conditions， such as chloasma， melasma， freckles， senile lentigines， and other unwanted areas of melanin hyperpigmentation. 副作用: Dermatologic: Allergic skin reaction， dermatitis， erythema， inflammation， stinging of the skin， xeroderma Local: Local irritation 禁忌:Hypersensitivity to hydroquinone or any component of the formulation,,室溫,Hyperpigmentated skin conditions Adult: Topical apply and rub in a thin layer to affected area bid， in the morning and evening.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,EXT;SKIN;TOPI;,,,,,
OFYC,Perampanel,Fycompa 2mg,CNEU,Adjunctive treatment of partial-onset seizures w/ or w/o secondarily generalized seizures in patients >12 yr w/ epilepsy.,Hypersensitivity.,Dizziness， somnolence. Decreased/increased appetite; aggression， anger， anxiety， confusional state; ataxia， dysarthria， balance disorder， irritability; diplopia， blurred vision; vertigo; nausea; back pain; gait disturbance， fatigue; increased wt; fall.,30℃以下,For mono/adjuvant treatment of Local epilepsy : Adult & adolescent(A40>12 years) Initially 2 mg daily， may be increased by 2-mg increments to a maintenance dose of 4-8 mg daily. Then， further increase by 2-mg increments to 12 mg daily. Child (4-11years) (>=30kg):Initially 2 mg daily， may be increased by 2-mg increments to a maintenance dose of 4-I418 mg daily. Then， further increase by 2-mg increments to 12 mg daily. Child (4-11years) (20-30kg):Initially 1mg daily， may be increased by 1-mg increments to a maintenance dose of 4-6mg daily. Then， further increase by 1-mg increments to 8mg daily. Child (J404-11years) (<20kg):Initially 1mg daily， may be increased by 1-mg increments to a maintenance dose of 2-4mg daily. Then， further increase by 0.5-mg increments to 6mg daily. For adjuvant treatment of Primary generalized tonic-clonic seizures : Adult & adolescent(>12 years) Initially 2 mg daily， may be increased by 2-mg increments to a maintenance dose of 8mg daily. Then， further increase by 2-mg increments to 12 mg daily. Child (7-11years) (>=30kg):Initially 2 mg daily， may be increased by 2-mg increments to a maintenance dose of 4-8 mg daily. Then， further increase by 2-mg increments to 12 mg daily. Child (7-11years) (20-30kg):Initially 1mg daily， may be increased by 1-mg increments to a maintenance dose of 4-6mg daily. Then， further increase by 1-mg increments to 8mg daily. Child (7-11years) (<20kg):Initially 1mg daily， may be increased by 1-mg increments to a maintenance dose of 2-4mg daily. Then， further increase by 0.5-mg increments to 6mg daily.,需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議應整粒吞服， 切勿咬嚼或壓碎
IHER6,Trastuzumab,HERCEPTIN inj 600mg/5mL,RACA,Breast cancer， adjuvant treatment， breast cancer， metastatic， gastric cancer， metastatic.,Hypersensitivity to trastuzumab， Chinese hamster ovary (CHO) cell proteins， or any component of the formulation.,>10%: Cardiovascular: Decreased left ventricular ejection fraction (4% to 22%) Central nervous system: Pain (47%)， chills (5% to 32%)， headache (10% to 26%)， insomnia (14%)， dizziness (4% to 13%) Dermatologic: Skin rash (4% to 18%) Gastrointestinal: Nausea (6% to 33%)， diarrhea (7% to 25%)， vomiting (4% to 23%)， abdominal pain (2% to 22%)， anorexia (14%) Infection: Infection (20%) Neuromuscular & skeletal: Weakness (4% to 42%)， back pain (5% to 22%) Respiratory: Cough (5% to 26%)， dyspnea (3% to 22%)， rhinitis (2% to 14%)， pharyngitis (12%) Miscellaneous: Infusion related reaction (21% to 40%， chills and fever most common; severe: 1%)， fever (6% to 36%),2-8℃避光避免冷凍,600 mg (600 mg trastuzumab and 10，000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every 3 weeks.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,SC;,,,,,1.本品僅能以皮下注射給予。注射時間應為2-5分鐘。 2.不論患者體重多寡，本品之建議固定劑量為600mg，每3週給藥ㄧ次。 3.注射部位應在左右大腿之間輪替，新的注射部位與舊的注射部位應相距至少2.5公分，且不得在皮膚發紅、瘀青、觸痛或硬塊處注射。 4.第一次皮下注射後6小時以及後續的皮下注射後2小時，應觀察患者是否出現注射相關反應。
OXOFL,Baloxavir marboxil,Xofluza 20mg,QANB,Treatment of acute infections of type A and B influenza viruses for adults and children over 12 years old.,History of hypersensitivity to baloxavir marboxil or any of its ingredients.,Nausea， diarrhea， elevated ALT (GPT).,25°C以下,Treatment should ideally begin within 48 hours of symptom onset. Influenza， Uncomplicated: Adults (1) 20kg to <80kg: 40mg as a single oral dose; (2) >=80kg: 80mg as a single oral dose. 5 Years or Older (1)<20kg: 2mg/kg as a single oral dose; (2) 20kg to <80kg: 40mg as a single oral dose; (3) >=80kg: 80mg as a single oral dose Influenza; Prophylaxis: Adults (1) 20kg to <80kg: 40mg as a single oral dose; (2) >=80kg: 80mg as a single oral dose. 5 Years or Older (1) <20kg: 2mg/kg as a single dose; (2) 20kg to <80kg: 40mg as a single oral dose; (3) >=80kg: 80mg as a single oral dose.,無需調整劑量,[仿單]哺乳婦請於投藥療程中避免母乳哺餵。 尚未確立本藥是否會分泌至人類乳汁，但大鼠的研究中有本藥分泌至乳汁的報告,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 對於孕婦或可能懷孕之婦女，在判斷其於治療上的有益性高於危險性時才可投與。 孕期投藥之相關安全性尚未確立。動物實驗 (大鼠、兔子)中，雖認為無致畸胎性， 但以高劑量投於兔子時， 有流產及頸部贅生肋骨(extra cervical rib)的報告、 於大鼠則認為 本藥會通過胎盤。,Unknown 沒有資料,[仿單]哺乳婦請於投藥療程中避免母乳哺餵。 尚未確立本藥是否會分泌至人類乳汁，但大鼠的研究中有本藥分泌至乳汁的報告,AC;AC15;PC;PO;,,,,,
EOPI,Fentanyl,Opiodur Patch 12mcg/h,CNEU,Narcotic analgesics for chronic and intractable pain.,the management of acute pain or patients who require opioid analgesia for a short period of time. the management of post-operative pain. patients with known hypersensitivity to fentanyl or any components of this product.,Common Dermatologic: Diaphoresis (1% to 6% )， Pruritus (Adult， 1% to 6% ; pediatric， 13% )， Rash (2% to 6% ) Gastrointestinal: Abdominal pain (1% to 9% )， Constipation (9% to 13% )， Diarrhea (1% to 13% )， Indigestion (1% or greater )， Loss of appetite (1% to 5% )， Nausea (Adult， 39% to 41% ; pediatric， 24% )， Vomiting (Adult， 10.3% to 26% ; pediatric， 34% )， Xerostomia (1% to 4% ) Hematologic: Anemia (3% ) Neurologic: Asthenia (Adult， 2% to 9.7%; pediatric， 1% )， Confusion (1% or greater )， Dizziness (Adult， 3% to 10% ; pediatric， 2% )， Headache (9% to 16%)， Insomnia (1% to 10% )， Somnolence (Adult， 1% to 19% ; pediatric， 5% ) Psychiatric: Anxiety (3% to 5.9% )， Depression (1% or greater )， Hallucinations (1% to 2% ) Renal: Urinary retention (Up to 3% ) Respiratory: Dyspnea (10.4% ) Other: Fatigue (1% to 6% ) Serious Cardiovascular: Bradyarrhythmia， Chest pain (1% or greater )， Hypotension (2% ) Endocrine metabolic: Adrenal insufficiency Gastrointestinal: Paralytic ileus Neurologic: Coma， Seizure Respiratory: Respiratory depression (1% ) Other: Drug dependence， Neonatal Abstinence Syndrome， Serotonin syndrome,25°C以下,Transdermal system provides continuous systemic delivery of fentanyl for 72 hours. Individualized dosage based on patient's opioid history， degree of opioid tolerance， current general condition & medical status. Equianalgesic potency conversion Drug Name: IM (mg) => PO (mg) Equianalgesic Dose Morphine: 10 => 60 (acute); 30(chronic) Hydromorphone: 1.5 => 7.5 Methadone: 10 => 20 Oxycodone: 15 => 30 Levorphanol: 2 => 4 Oxymorphone: 1 => 10 (rectal) Meperidine: 75 => --- Codeine: 130 => 200 Buprenorphine: 0.4 => 0.8(Sublingual) Tramadol: 100 => 120 Recommended dose based upon daily oral morphine dose. Oral 24-hour Morphine(mg/day) => Fentanyl Dose(mcg/hr) 30-44(children) => 12 45-134(children) => 25 <135(adult) => 25 135-224 => 50 225-314 => 75 315-404 => 100 405-494 => 125 495-584 => 150 585-674 => 175 675-764 => 200 765-854 => 225 855-944 => 250 945-1034 => 275 1035-1124 => 300,需調整劑量,[仿單] Fentanyl會排泄到人體乳汁內且可能會對被餵乳的新生兒造成鎮靜/呼吸抑制。 因此，對授乳婦女不建議使用本品。,需調整劑量,沒有資料,Human (and animal) data suggest risk,[仿單]未有充分關於懷孕婦女使用fentanyl穿皮貼片的資料。在動物試驗中曾顯示具有某些生殖毒性。 縱使作為靜脈麻醉劑的fentanyl曾被發現在人類早期懷孕時會穿過胎盤，但對於人類的潛在危險性仍屬未知。 母親在懷孕期間長期使用fentanyl穿皮貼片的新生嬰兒曾被報導有新生兒戒斷症狀。 懷孕期間不能使用本品，除非確實有必要。 不建議在分娩期間使用本品，因為本品不應用於控制急性或術後疼痛。 此外，由於fentanyl會穿過胎盤，在分娩時使用本品可能會導致新生兒的呼吸抑制。,Compatible 哺乳時可使用,[仿單] Fentanyl會排泄到人體乳汁內且可能會對被餵乳的新生兒造成鎮靜/呼吸抑制。 因此，對授乳婦女不建議使用本品。,EXT;SKIN;,,,,,
IADDV,Cr+Cu+Fe+Zn+Mn+Se+I+F+Mo,Addaven inj 10mL/amp (成人用),NUTR,Supplement of trace elements， diluted in TPN soln.,- Conditions with total biliary obstruction. - Hypersensitivity to the active substances or to any of the excipients. - Wilson’s disease， hemochromatosis. - Children less than 15 kg body weight.,Hypersensitivity reactions of iodide.,30°C 以下,As TPN material ， for TPN Adult: 5mL/day Each mL contains: Chromic chloride hexahydrate eq. to Chromium 1.0 mcg Copper chloride dihydrate eq. to Copper 38 mcg Ferric chloride hexahydrate eq. to Ferrum 110 mcg Manganese chloride tetrahydrate eq. to Manganese 5.5 mcg Potassium iodide eq. to Iodine 13 mcg Sodium fluoride eq. to Fluoride 95 mcg Sodium molybdate dehydrate eq. to Molybdenum 1.9 mcg Sodium selenite anhydrous eq. to Selenium 7.9 mcg Zinc chloride eq. to Zinc 500 mcg,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,
ICER0,HPV type16/18 L1 protein,Cervarix (人類乳突病毒疫苗，政府提供) 0.5mL/dose,HIMM,Prevention of cervical cancer in females 10-25 years， by protecting against incident & persistent infections， cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) & cervical intraepithelial neoplasia (CIN)， CIN1 & pre-cancerous lesions (CIN2 & CIN3) caused by HPV Types 16 & 18.,Subjects with known hypersensitivity to any component of Cervarix.,Headache， GI disturbances， itch， rash， myalgia， arthralgia， inj site reactions， fatigue， fever.,2-8℃避光避免冷凍,IM， 0.5mL， > or = 15 years 3 doses at 0， 1， and 6 months. 9-14 years can take 3 doses at 0， 1， and 6 months or 2 doses at 0 and 6-12 months.,無需調整劑量,[仿單]目前尚未有臨床研究評估對餵哺母乳之嬰兒的影響，只有在潛在效益超越 可能面臨之風險時才可使用。,無需調整劑量,可能安全,No (limited) human data – probably compatible,[仿單]臨床試驗、懷孕資料庫和流行病學試驗中，並無發現接種會增加新生兒包括 生育缺陷在內的不正常情況。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前尚未有臨床研究評估對餵哺母乳之嬰兒的影響，只有在潛在效益超越 可能面臨之風險時才可使用。,IM;,,,,,1. 使用前應先充分搖勻。 2. 應以肌肉注射的方式施打於上臂三角肌部位。
OCHEY,Soybean and probiotics fermentation product,Chemo young 4mL/bottle (14bottles/box),RACA,Ameliorating fatique and appetite loss associated with cancer chemotheraphy.,There are no contraindications listed on the label.,constipation， diarrhea.,室溫下避光保存,4mL twice daily on an empty stomach， after diluting in 100mL of warm water.,無需調整劑量,仿單未有相關資訊,無需調整劑量,沒有資料,Uknown 沒有資料,仿單未有相關資訊,Unknown 沒有資料,仿單未有相關資訊,AC;PO;,,,,,
OAPR2,Hydralazine,Stable 25mg,CAVS,Hypertension.,Hypersensitivity to Hydralazine.,Common Cardiovascular: Angina pectoris， Edema， Palpitations， Tachycardia Gastrointestinal: Diarrhea， Loss of appetite， Nausea， Vomiting Neurologic: Headache Serious Hematologic: Agranulocytosis， Leukopenia Hepatic: Hepatotoxicity Immunologic: Lupus pneumonia (Acute)， Systemic lupus erythematosus,陰涼乾燥處(15-30℃),Adult: Initial， 10 mg orally 4 times daily for 2 to 4 days; increase to 25 mg orally 4 times daily for remainder of week 1; week 2 and subsequent weeks， increase to 50mg QID or 100mg BID. Maintenance， adjust to lowest effective dose according to individual response. Maximum dose: 300 mg/day. Children: 0.75mg/kg/day in 2 to 4 divided doses; may increase gradually over 3 to 4 weeks， maximum dose: 300 mg/day or 7.5 mg/kg/day.,無需調整劑量,[仿單]無相關記載,無需調整劑量,除非治療上需要,Human data suggest risk in 3 rd trimester,[仿單]尚無文獻顯示Hydralazine會對孕婦產生任何問題，但使用時仍應就其危險與效益加以考慮，因其在動物試驗上曾引起畸形胎。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]無相關記載,AC;AC15;PC;PO;WM;,,,,,
IRYZ,Insulin Aspart 30+ Insulin Degludec 70,Ryzodeg FlexTouch 100 Unit/mL， 3mL,META,Ryzodeg 70/30 is a mixture of insulin degludec， a long-acting human insulin analog， and insulin aspart， a rapid-acting human insulin analog， indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.,During episodes of hypoglycemia. Hypersensitivity to Ryzodeg 70/30 or one of its excipients.,Nasopharyngitis(11.1-24.6%)， Headache(9.7%)， Upper respiratory tract infection(5.7-9.1%)， Influenza(6.9%)， Headache(5.6%). Peripheral Edema: sodium retention and edema(1.8-2.2%). Weight Gain. Injection Site Reactions(2.0%)， including injection site hematoma， pain， hemorrhage， erythema， nodules， swelling， discoloration， pruritus， warmth， and injection site mass. lipodystrophy(0.1%). Allergic Reactions， including anaphylaxis， generalized skin reactions， angioedema， bronchospasm， hypotension， and shock. Hypersensitivity， manifested with swelling of tongue and lips， diarrhea， nausea， tiredness and itching， and urticaria(0.5%).,未使用應儲存於2-8℃，勿冷凍.開封(使用中)若保存於冰箱或室溫以下(2-30℃)，開封後可保28天.,Starting Dose in Insulin-Naive Patients Type 1 Diabetes Mellitus: The recommended starting dose of Ryzodeg 70/30 in insulin-naive patients with type 1 diabetes is approximately one-third to one-half of the total daily insulin dose. The remainder of the total daily insulin dose should be administered as short-or rapid-acting insulin divided between each daily meal. As a general rule， 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes. Type 2 Diabetes Mellitus: The recommended starting dose of Ryzodeg 70/30 in insulin-naive patients with type 2 diabetes mellitus is 10 units once daily. Starting Dose in Patients with Type 1 or Type 2 Diabetes on a Once or Twice Daily Premix or Self-mix Insulin Alone or as Part of a Regimen of Multiple Daily Injections Adults with Type 1 or Type 2 Diabetes Start Ryzodeg 70/30 at the same unit dose and injection schedule as the premix or self-mix insulin. In patients also using short-or rapid-acting insulin at mealtimes continue the short-or rapid-acting insulin at the same dose for meals NOT covered by Ryzodeg 70/30. Pediatric Patients 1 Year of Age and Older with Type 1 or Type 2 Diabetes Start Ryzodeg 70/30 at 80% of the total daily mixed insulin dose in order to minimize the risk of hypoglycemia and administer once daily with the main meal of the day. In patients also using short-or rapid-acting insulin at mealtimes continue the short-or rapid-acting insulin at the same dose for meals NOT covered by Ryzodeg 70/30. Starting Dose in Patients with Type 1 or Type 2 Diabetes on a Once or Twice Daily Basal Insulin Alone or as Part of a Regimen of Multiple Daily Injections Adults with Type 1 or Type 2 Diabetes In patients with type 2 diabetes switching from a regimen that includes only a once-or twice-daily basal insulin， start Ryzodeg 70/30 at the same unit dose and injection schedule. For patients switching from once-daily basal insulin to once-daily Ryzodeg 70/30， monitor blood glucose after starting therapy due to the rapid-acting insulin component. In patients switching from a multiple daily injections regimen that includes a basal and short-or rapid-acting insulin at mealtimes， start Ryzodeg 70/30 once daily with the main meal at the same unit dose as the basal insulin. Continue the short-or rapid-acting insulin at the same dose for meals NOT covered by Ryzodeg 70/30. Pediatric Patients 1 Year of Age and Older with Type 1 or Type 2 Diabetes Start Ryzodeg 70/30 at 80% of the long-or intermediate-acting insulin component of the daily regimen in order to minimize the risk of hypoglycemia and administer once daily with the main meal of the day. In patients also using short-or rapid-acting insulin at mealtimes continue the short-or rapid-acting insulin at the same dose for meals NOT covered by Ryzodeg 70/30.,無需調整劑量,BREASTFEEDING RECOMMENDATION: Insulin Aspart: No Human Data—Probably Compatible， Insulin Degludec: Compatible [仿單]目前沒有關於RyzodegR 或insulin degludec會分泌到人類乳汁中、對被哺乳的嬰兒、或對於泌乳影響的資料。 Insulin degludec會分泌到大鼠的乳汁中。在一個小型的試驗中顯示，外源性的胰島素，包括insulin aspart，會分泌到人類乳汁中。 然而並無足夠的資料以了解insulin aspart對哺育母乳嬰兒的影響，亦無資料以了解insulin aspart對泌乳的影響。 哺育母乳的優點應與哺育母乳母親對於insulin需求以及RyzodegR、insulin degludec、insulin aspart或母親既有疾病對哺育母乳嬰兒可能產生之副作用一起考量。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,PREGNANCY RECOMMENDATION: Insulin Aspart: No Human Data—Animal Data Suggest Low Risk， Insulin Degludec: Limited Human Data—Probably Compatible. [仿單]目前並無RyzodegR或insulin degludec用於懷孕女性中的資料說明藥物相關的重大先天缺陷或流產風險。Insulin aspart則有隨機分配、對照實驗顯示於懷孕二期使用insulin aspart與重大先天缺陷或孕婦/胎兒不良結果無關。懷孕期間控制不良的糖尿病對於孕婦及胎兒是有風險的。 在動物生殖毒性試驗中，將懷孕的大鼠於臟器生成期皮下注射insulin degludec/insulin aspart。試驗結果顯示暴露劑量為人體暴露劑量8倍劑量下(人類暴露劑量以人類皮下劑量1.08 unit/kg/day時計算) ，觀察到內臟/骨骼異常。這些影響與在大鼠給予人類胰島素(NPH)觀察到的影響是一致的。 在大鼠與兔子生殖毒性試驗中，於臟器生成期暴露insulin degludec。試驗結果顯示insulin degludec的暴露劑量在在大鼠與兔子各約為人體暴露劑量的5倍與10倍劑量下(人類暴露劑量皆以人類皮下劑量0.75 unit/kg/day時計算) ，觀察到著床前與著床後流產以及內臟/ 骨骼異常。Insulin degludec的影響與在大鼠給予人類胰島素(NPH)觀察到的影響是一致的。 在動物生殖毒性試驗中，懷孕的大鼠及兔子在臟器生成期皮下注射insulin aspart。試驗結果顯示insulin aspart的暴露劑量在大鼠與兔子各約為人體暴露劑量8倍與相等劑量下(人體暴露劑量皆以人類皮下劑量1.0 unit/kg/day時計算) ，並未造成不良的影響。在更高的暴露劑量下觀察到著床前與著床後流產以及內臟/骨骼異常，這些影響可能是來自母體低血糖。這些影響與在大鼠給予常規人類胰島素(regular human insulin)觀察到的影響是一致的。 在患有妊娠前糖尿病且HbA1c>7的婦女，懷孕發生重大先天缺陷的預估背景風險為6~10%，HbA1c>10的婦女則曾被報告有高達20~25%的風險。流產的預估背景風險在這個族群的數據未知。在美國一般族群中，臨床確認的懷孕發生重大先天缺陷及流產的預估背景風險分別為2-4%及15-20%。 (以下略),No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,BREASTFEEDING RECOMMENDATION: Insulin Aspart: No Human Data—Probably Compatible， Insulin Degludec: Compatible [仿單]目前沒有關於RyzodegR 或insulin degludec會分泌到人類乳汁中、對被哺乳的嬰兒、或對於泌乳影響的資料。 Insulin degludec會分泌到大鼠的乳汁中。在一個小型的試驗中顯示，外源性的胰島素，包括insulin aspart，會分泌到人類乳汁中。 然而並無足夠的資料以了解insulin aspart對哺育母乳嬰兒的影響，亦無資料以了解insulin aspart對泌乳的影響。 哺育母乳的優點應與哺育母乳母親對於insulin需求以及RyzodegR、insulin degludec、insulin aspart或母親既有疾病對哺育母乳嬰兒可能產生之副作用一起考量。,SC;,,,,,1. 請勿以靜脈注射、肌肉注射，或裝於胰島素輸注幫浦中投予Ryzodeg。請勿稀釋Ryzodeg，或將其與任何其他胰島素藥品或溶液混合。 2. 若忘記注射本藥，應於當天下一次正餐時注射，並於之後恢復的給藥時程。病人不應注射額外的劑量以補足忘記注射的劑量。 3. 同一區域內每次都輪流注射於不同部位，以降低脂肪代謝障礙(lipodystrophy)和局部皮膚類澱粉沉積症(cutaneous amyloidosis)的風險。請勿注射至脂肪代謝障礙或局部皮膚類澱粉沉積症的部位。 4. 在變更病人胰島素療法期間，請增加血糖監測頻率。
OKAS4,Dimethicone,Kascoal 40mg,ALIM,Relief of pressure， bloating， fullness， and discomfort of gastrointestinal gas.,Hypersensitivity to simethicone or any component of the formulation,Loose stools,25℃以下,Adult & children > 3 years: 2 tablets TID to QID or taken when needed; Children < 3 years: should consult with doctor.,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
IFAS0,Fulvestrant,Faslodex inj 250mg/5mL (sample),RACA,Breast cancer， metastatic， breast cancer， advanced or metastatic (second-line endocrine-based combination therapy),a) hypersensitivity to fulvestrant or to any of its components b) suspected or known pregnancy Precautions A) hepatic impairment Serious Adverse Effects: a) Anemia b) Angioedema,>10%: Central nervous system: Fatigue (8% to 29%)， headache (8% to 20%) Gastrointestinal: Nausea (10% to 28%)， diarrhea (19%)， constipation (5% to 16%)， stomatitis (13%) Hematologic & oncologic: Anemia (13% to 40%; grade 3: 2%) Hepatic: Increased liver enzymes (>15%; grades 3/4: 1% to 2%) Infection: Infection (31%; including nasopharyngitis， upper respiratory infection， urinary tract infection， influenza， bronchitis， rhinitis， conjunctivitis， pneumonia， sinusitis， cystitis， oral herpes， respiratory tract infection) Local: Pain at injection site (12%; including neuralgia， peripheral neuropathy， sciatica) 1% to 10%: Dermatologic: Alopecia (6%)， skin rash (6%)， xeroderma (1%) Endocrine & metabolic: Hot flash (7%) Gastrointestinal: Decreased appetite (8%)， anorexia (6%)， vomiting (6%)， dysgeusia (3%) Hematologic & oncologic: Decreased platelet count (10%)， leukopenia (5%; grade 3: 1%; grade 4: 1%)， neutropenia (4%; grade 3: 1%)， febrile neutropenia (1%; grade 4: 1%) Neuromuscular & skeletal: Ostealgia (9%)， arthralgia (8%)， back pain (8%)， limb pain (7%)， musculoskeletal pain (6%)， weakness (5% to 6%) Ophthalmic: Blurred vision (2%)， dry eye syndrome (2%)， increased lacrimation (1%) Respiratory: Cough (5%)， dyspnea (4%)， epistaxis (2%),2-8℃避光,500 mg administered intramuscularly into the buttocks (gluteal area) slowly (1 -2 minutes per injection) as two 5 mL injections， one in each buttock， on Days 1， 15， 29， and once monthly thereafter.,需調整劑量,,需調整劑量,盡量避免,Contraindicated,,Contraindicated 哺乳期使用禁忌,,IM;,,,,,投與Faslodex應以兩次連續的5毫升在臀部肌肉處緩慢注射(1-2分鐘注射)，一邊一次。
EDUR2,Fentanyl,DUROGESIC D-trans Patch 25mcg/h,CNEU,,適應症: Intractable cancer pain 副作用: Nausea， vomiting; bradycardia， oedema， CNS depression， confusion， dizziness，drowsiness， headache， sedation， transient hypotension， peripheral vasodilation; increased intracranial pressure. High IV dose may cause chest wall rigidity. Transdermal: Rash， erythema and itching. 禁忌: Hypersensitivity.,,室溫,Initial: Apply patch that delivers <=25 mcg/hr of fentanyl in opioid-naive patients. Adjust dose according to response. For patients who have been receiving a strong opioid， initial dose should be based on the previous 24-hr opioid requirement. Replace patch 72 hrly and apply new patch to a different site.,需調整劑量,,需調整劑量,除非治療上需要,,,Compatible 哺乳時可使用,,EXT;,,,,,
IFEN10,Fentanyl,FENTANYL inj 0.5mg/10mL,CNEU,Premed prior to surgery， Adjunct to general anesth induction， Adjunct to regional anesth， Post-operatively .,Children <2 years， bronchial asthma， respiratory depression & head injury. Patients who received MAOIs within previous 14 days.,Respiratory depression， apnoea， muscle rigidity & bradycardia.,15-30℃避光,"As a general anesthesia analgesic aid:Low dose: 2 mcg/kg IV (Minor surgery)Medium dose: 2-20 mcg/kg IV (Complex surgery)High dose: 20-50 mcg/kg IV (Prolonged major surgery. Use with Oxygen， Nitrous Oxide to avoid body's stress response)IV injection 25-250 mcg/kg (0.5-5mL) can be given to extend the action time until the completion of the operation.As an anesthetic:When it is important to reduce the stress response during surgery， fentanyl can be administered intravenously 50-100 mcg/kg， combined with Oxygen and Muscle Relaxants without adding additional anesthetics. This method is often used for heart surgery and other needs to protect the myocardium from hypoxia.Elderly patients: similar to other opioids， the dose of the elderly and frail patients should be lowered.Children: The induction and maintenance of anesthesia for children between 2-12 years old， the dose should be reduced to 2-3 mcg/kg IV.",無需調整劑量,,無需調整劑量,盡量避免,Human (and animal) data suggest risk,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,,【D5W】可選 。【N/S】可選 。,推注時間成人 > 1-2分鐘，兒童 > 2-5分鐘,Usual Infusion Concentrations IV infusion: 10 mcg/mL,
OXTA,Enzalutamide,Xtandi 40mg,RACA,Prostate cancer， metastatic: Treatment of metastatic， castration-resistant prostate cancer.,Hypersensitivity. Pregnancy.,Asthenia/fatigue; headache; hot flush， HTN. Anxiety; memory impairment， amnesia， attention disturbance， restless legs syndrome; gynaecomastia; dry skin， pruritus; fractures; falls.,30℃以下,160 mg (four 40 mg capsules) administered orally with or without food once daily. Swallow capsules whole. Patients receiving enzalutamide should also receive a gonadotropin-releasing hormone analog concurrently (or have had a bilateral orchiectomy). If a patient experiences a ≧ Grade 3 toxicity or an intolerable side effect， withhold dosing for one week or until symptoms to ≦ Grade 2， and then resume the original dose treatment. If necessary， the dose can be reduced (120 mg or 80 mg).,無需調整劑量,,需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;,,,,,[磨粉/管灌註記]本藥為軟膠囊，需應整粒吞服，勿咀嚼、溶解或打開。
IKCL7S,Potassium Chloride,20mEq KCl in【D5NS 500mL】,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia， pain or phlebitis at injection site.,室溫,Adult: Initial loading dose: 40~60 mEq， with ECG monitoring then based on serum potassium levels， Serum K>2.5 mEq/L: concentration < 30 mEq/L， with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia， treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,無需調整劑量,,無需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,,,,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
IKCL8S,Potassium Chloride,1.49% KCl (20mEq) in 0.9%NaCl 100mL,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia， pain or phlebitis at injection site.,室溫,Only for central vein. Serum K> 2.5 mEq/L: should not usually exceed 10 mEq/hour or 200 mEq for a 24 hour period. Serum K< 2 mEq/L: injection speed can increase to 40 mEq/hour or 400 mEq over a 24 hour period with ECG monitoring.,無需調整劑量,,需調整劑量,除非治療上需要,Uknown 沒有資料,,Unknown 沒有資料,,CVC;,,,,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr， with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day. Central line infusion: maximum rate 40 mEq/hr. peripheral IV infusion: maximum rate 10 mEq/hr.,1.使用期間應嚴密監測病患血鉀濃度與心電圖。 2.與ACE抑制劑併用可能引起高血鉀症。 3.與保鉀型利尿劑併用可能引起嚴重高血鉀症、心律不整與心跳停止。 4.鉀離子排除功能受損或輸注太快時，可能發生致命性高血鉀症。
OOMA,Omega-3- Acid Ethyl Esters 90,Omacor Soft 1000mg,CAVS,Treatment of hypertriglyceridemia.,Hypersensitivity to the active substance， to soya or to any of the excipients.,Nausea， dyspepsia， pruritus， skin rash， Increased serum ALT or AST,30℃以下室溫，不可冷凍,Adult: 1-2 capsule orally twice daily after meals.,無需調整劑量,仿單懷孕分級:C,無需調整劑量,沒有資料,Compatible,OMEGA-3 FATTY ACID SUPPLEMENTS PREGNANCY RECOMMENDATION: Compatible BREASTFEEDING RECOMMENDATION: Compatible,Compatible 哺乳時可使用,仿單懷孕分級:C,PC;PO;,,,,,[磨粉/管灌註記]本藥為軟膠囊，請整粒吞服，不可切開。
OFAL,Flunitrazepam,Fallep 2mg,CNEU,Insomnia.,Preexisting CNS depression or coma， resp depression， acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; chronic psychosis， phobic or obsessional states; may precipitate suicide or aggressive behavior; not to be used alone to treat depression or anxiety associated with depression; glaucoma. Pregnancy， lactation. Neonates.,Drowsiness & lightheadedness the next day; confusion & ataxia; dependence.,25℃以下避光,Adult 0.5-1 mg at bedtime. Maximum : 2 mg/day. Elderly or debilitated patients Initially 0.5 mg at bedtime. Maximum : 1 mg/day.,無需調整劑量,,無需調整劑量,盡量避免,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]為避免管制藥品汙染分包機，管制藥品不磨粉，請使用前自行研磨。
IBOO,Diphtheria + Tetanus + Pertussis,Boostrix 0.5mL/dose (三合一補追疫苗),HIMM,Active booster immunization for the prevention of tetanus diphtheria & pertussis in children， adolescents & >= 4 years.,Hypersensitivity. Progressive neurological disorders， uncontrolled epilepsy or progressive encephalopathy. Encephalopathy not attributable to identifiable cause. Pregnancy.,Pain， swelling， erythema at inj site. Tiredness， headache， fever (> 38°C). Axillary lymph node swelling， rash， body ache or muscle weakness， sore or swollen joints. Nausea， diarrhea， vomiting. Demyelinating CNS diseases， peripheral mononeuropathies， cranial mononeuropathies & EEG disturbances with encephalopathy (with or without permanent intellectual &/or motor function impairment).,2-8℃,IM， 0.5mL， > or = 4 years as a single dose,無需調整劑量,[仿單] 目前尚未評估在授乳期間使用的安全性，只有當潛在效益大於潛在危險時， 才可在授乳期間使用。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]第二、三孕期可使用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 目前尚未評估在授乳期間使用的安全性，只有當潛在效益大於潛在危險時， 才可在授乳期間使用。,IM;,,,,,
INOB,Levetiracetam,Nobelin inj 500mg/100mL,CNEU,,適應症:Monotherapy in partial seizures with or without secondary generalisation in patients with newly diagnosed epilepsy. Adjunct in partial seizures with or without secondary generalisation. Adjunct in juvenile myoclonic epilepsy. Adjunct in idiopathic generalised epilepsy. 副作用: >10%: Cardiovascular: Increased blood pressure (diastolic; infants and children: 17%) Central nervous system: Behavioral problems (includes aggression， agitation， anger， anxiety， apathy， depersonalization， emotional lability， irritability， neurosis: children and adolescents: 7% to 38%; adults: 7% to 13%)， headache (14% to 19%)， drowsiness (8% to 15%); immediate release 4，000 mg/day， no titration: 45%; serious [patients hospitalized]: <1%)， psychotic symptoms (infants and children: 17%; adults: 1%)， irritability (infants， children， and adolescents: 6% to 12%)， fatigue (10% to 11%) Gastrointestinal: Vomiting (children and adolescents: 15%) Infection: Infection (13%) Neuromuscular & skeletal: Weakness (15%) Respiratory: Nasopharyngitis (7% to 15%) 禁忌: Hypersensitivity to levetiracetam or any component of the formulation.,,室溫,Monotherapy: Initially 250mg twice daily， increasing to 500mg twice daily after 2 weeks， then by 250mg twice daily every 2 weeks according to response; max 1.5g twice daily. Add-on therapy: Initially 500mg twice daily. If necessary， increase in increments of 500mg twice daily every 2—4 weeks; max 1.5g twice daily. IV: For IV use only; infuse over 15 minutes for max 4 days.,無需調整劑量,,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,,,以15分鐘的靜脈輸注時間給藥,1. 僅靜脈輸注使用，不可稀釋，以15分鐘的靜脈輸注時間給藥。
ITTA5,Tetanus toxoid,Tetana vaccine 0.5mL/dose， 0.5mL/amp (專案進口),HIMM,,適應症: Active immunization of tetanus. 副作用: Drowsiness， malaise， hypersensitivity. 禁忌：Hypersensitivity to tetanus toxoid or any component of the formulation,,2-8℃,IM， 0.5 mL/dose. Primary immunization: I.M.: 0.5 mL; repeat 0.5 mL at 4-8 weeks after first dose and at 6-12 months after second dose Routine booster dose: Recommended every 10 years Tetanus prophylaxis in wound management: Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated， the immunization status of the patient， proper use of tetanus toxoid and/or tetanus immune globulin (TIG)， wound cleaning， and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until >10 years after the most recent dose even if they have a wound that is neither clean nor minor.,無需調整劑量,Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules.,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,,Compatible 哺乳時可使用,Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules.,IM;,,,,,仿單使用方法：深層皮下注射，一般於高位上臂肌肉(三角肌)接受注射。本品嚴禁血管內注射。 已詢問藥商國光生物科技，深層皮下一詞翻譯自波蘭原廠仿單的當地用語，上臂三角肌只適合肌肉注射，仿單的用法意指「肌肉注射」。
OEFI3,Prasugrel,Efient 3.75mg,HEMT,Percutaneous coronary intervention (PCI) for Acute coronary syndrome (ACS),Hypersensitivity (eg， anaphylaxis) to prasugrel or any component of the formulation; active pathological bleeding (eg， peptic ulcer， intracranial hemorrhage); prior transient ischemic attack or stroke.,1% to 10%: Cardiovascular: Hypertension (8%)， hypotension (4%)， atrial fibrillation (3%)， bradycardia (3%)， peripheral edema (3%) Central nervous system: Headache (6%)， dizziness (4%)， fatigue (4%)， noncardiac chest pain (3%) Dermatologic: Skin rash (3%) Endocrine & metabolic: Hypercholesterolemia (?7%)， hyperlipidemia (?7%) Gastrointestinal: Nausea (5%)， diarrhea (2%)， gastrointestinal hemorrhage (2%) Hematologic & oncologic: Leukopenia (3%)， anemia (2%)， major hemorrhage (2%)， minor hemorrhage (2%)， major hemmorhage (life-threatening: 1%) Neuromuscular & skeletal: Back pain (5%)， limb pain (3%) Respiratory: Epistaxis (6%)， dyspnea (5%)， cough (4%) Miscellaneous: Fever (3%) <1%， postmarketing， and/or case reports: Abnormal hepatic function tests， anaphylaxis， angioedema， hematoma， hemoptysis， hemorrhage (requiring inotropes or transfusion)， hypersensitivity reaction， intracranial hemorrhage (symptomatic)， re-operation due to bleeding， thrombocytopenia， thrombotic thrombocytopenic purpura,室溫下儲存(25℃以下),Loading dose: 20 mg; Maintenance dose: 3.75 mg QD. Not recommended taking Efient on empty stomach except loading dose.,無需調整劑量,[仿單] 哺乳母親在服用時應避免授乳。 已知本藥代謝物會分泌至大鼠的乳汁中。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單] 只有在預期的治療效益高於可能的風險時，才建議懷孕和可能懷孕的女性使用。 尚未建立懷孕女性的安全性，且已知本藥代謝物會分泌至大鼠的胎兒中。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 哺乳母親在服用時應避免授乳。 已知本藥代謝物會分泌至大鼠的乳汁中。,PC;PO;WM;,,,,,
OIBR0,Palbociclib,Ibrance 125mg (Sample),RACA,Breast cancer， advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive， human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy Breast cancer， advanced (with disease progression following endocrine therapy): Treatment of HR-positive， HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy,Hypersensitivity to palbociclib or any component of the formulation,>10%: Central nervous system: Fatigue (41%)， headache (26%)， peripheral neuropathy (13%) Dermatologic: Alopecia (18% to 22%)， skin rash (17%) Gastrointestinal: Nausea (25% to 34%)， stomatitis (25% to 28%)， diarrhea (21% to 24%)， constipation (20%)， vomiting (15% to 19%)， decreased appetite (16%) Hematologic & oncologic: Neutropenia (75% to 83%; grade 3: 48% to 55%; grade 4: 6% to 11%)， decreased absolute lymphocyte count (81%; grade 3: 17%; grade 4: 1%)， anemia (30% to 78%; grade 3: 3% to 5%; grade 4: ?1%)， leukopenia (43% to 53%; grade 3: 19% to 30%; grade 4: ?1%)， thrombocytopenia (17% to 23%; grade 3: 2%; grade 4: ?1%) Infection: Infection (47% to 55%) Neuromuscular & skeletal: Weakness (8% to 13%) Respiratory: Upper respiratory tract infection (31%)， epistaxis (7% to 11%) Miscellaneous: Fever (13%) 1% to 10%: Cardiovascular: Pulmonary embolism (1% to 5%) Dermatologic: Xeroderma (6%) Gastrointestinal: Dysgeusia (7%) Hematologic & oncologic: Febrile neutropenia (1%; grade 3: 1%) Ophthalmic: Blurred vision (6%)， increased lacrimation (6%)， dry eye syndrome (4%),30 ℃以下,125 mg capsule taken orally once daily for 21 days followed by 7 days off treatment to comprise a complete cycle of 28 days.IBRANCE should be taken with food. Administer the recommended dose of an aromatase inhibitor when given with IBRANCE. When given with IBRANCE， the recommended dose of fulvestrant is 500 mg administered on Days 1， 15， 29， and once monthly thereafter.Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards. For men treated with combination IBRANCE plus aromatase inhibitor therapy， consider treatment with an LHRH agonist according to current clinical practice standards. Luteinizing hormone-releasing hormone (LHRH) also called Gonadotropin-Releasing Hormone (GnRH).,需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,PO;WM;,,,,,
OSYNT,Carvedilol,Syntrend 25mg,CAVS,,適應症: Hypertension， Heart failure: 副作用: > 10% Cardiovascular: Hypotension (9% to 20%) Central nervous system: Dizziness (2% to 32%)， fatigue (4% to 24%) Endocrine & metabolic: Hyperglycemia (5% to 12%) Gastrointestinal: Weight gain (10% to 12%)， diarrhea (1% to 12%) Neuromuscular & skeletal: Weakness (7% to 11%) 禁忌:Serious hypersensitivity to carvedilol or any component of the formulation; decompensated cardiac failure requiring intravenous inotropic therapy; bronchial asthma or related bronchospastic conditions; second- or third-degree AV block， sick sinus syndrome， and severe bradycardia (except in patients with a functioning artificial pacemaker); cardiogenic shock; severe hepatic impairment.,,室溫,Essential hypertension Initially 12.5mg once daily for 2 days，then 25 mg qd. Max:50 mg daily.,需調整劑量,Thomson: Infant risk cannot be ruled out,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Thomson: Infant risk cannot be ruled out,,,,,,
OFAMO,Famotidine,Famotidine 20mg,ALIM,Gastric ulcer， duodenal ulcer， anastomotic ulcer， upper gastrointestinal bleeding (peptic ulcer， acute stress ulcer， hemorrhagic gastritis)， reflux esophagitis， Zollinger-Ellison syndrome,Serious hypersensitivity (eg， anaphylaxis) to famotidine， other H2 antagonists， or any component of the formulation,>10%: Central nervous system: Agitation (infants: ?14%; adults: <1%) 1% to 10%: Central nervous system: Headache (5%)， dizziness (1%) Gastrointestinal: Diarrhea (2%)， constipation (1%)， necrotizing enterocolitis (very low birth weight neonates; Guillet 2006) Frequency not defined: Local: <1%， postmarketing， and/or case reports: Abdominal distress， acne vulgaris， agranulocytosis， alopecia， anaphylaxis， angioedema， anorexia， anxiety， arthralgia， asthenia， atrioventricular block， bronchospasm， cardiac arrhythmia， cholestatic jaundice， confusion， conjunctival injection， decreased libido， depression， drowsiness， facial edema， fatigue， fever， flushing， hallucination， hepatitis， hypersensitivity reaction， impotence， increased liver enzymes， insomnia， interstitial pneumonitis， leukopenia， muscle cramps， musculoskeletal pain， nausea， palpitations， pancytopenia， paresthesia， periorbital edema， prolonged Q-T interval on ECG， pruritus， psychiatric disturbance， rhabdomyolysis， seizure， skin rash， Stevens-Johnson syndrome， taste disorder， thrombocytopenia， tinnitus， toxic epidermal necrolysis， urticaria， vomiting， xeroderma， xerostomia,避光室溫30℃以下儲存,usual dose: 20mg BID or 40mg HS,無需調整劑量,,需調整劑量,,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
OBIOP,Antibiotics-resistant Lactic Acid Bacteriae,Biofermin-R 6mg/1gm Powder,AI-04-00,Treatment of symptoms caused by abnormal enteric microflora during administration of antibiotics or chemotherapeutic agents.,Hypersensitivity to any component of the product.,No side effects listed in package insert.,室溫保存，開封後避免濕氣。,Adult: 1gm (1 pack) TID， after meals. Increase or decrease dosage according to age and symptoms.,無需調整劑量,仿單未見相關敘述,無需調整劑量,沒有資料,Uknown 沒有資料,仿單未見相關敘述,Unknown 沒有資料,仿單未見相關敘述,AC;AC15;PC;PO;WM;,,,,,1. 與Aminophylline或Isoniazid混合時，會使本藥品變色，應避免與上述兩種成份之藥品混合。 2. 藥品為白色至微淡黃褐色粉末狀，稍具甜味。 3. 主成分耐性乳酸菌 (Antibiotics-resistant Lactic Acid Bacteriae)，菌種：Streptococcus faecalis。
OATM40,Atomoxetine,40mg APO-ATOMOXETINE,CNEU,Attention deficit hyperactivity disorder.,Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma， current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg， 15 to 20 mm Hg) or heart rate (eg， 20 beats per minute),Common Cardiovascular: Increased heart rate (Adult， 10.2% to 22.4%; pediatric， 12.2% to 23.4% ) Endocrine metabolic: Weight decreased (Adult， 2%; pediatric， 3% ) Gastrointestinal: Abdominal pain (Adult， 7%; pediatric， 18% )， Constipation (Adult， 8%; pediatric， 1% to 2% )， Decrease in appetite (Adult， 16%; pediatric， 16% )， Nausea (Adult， 26%; pediatric， 10% )， Vomiting (Adult， 4%; pediatric， 11% )， Xerostomia (Adult， 20% ) Neurologic: Dizziness (Adult， 8%; pediatric， 5% )， Headache (Pediatric， 19% )， Insomnia (Adult， 15%; pediatric， at least 2% )， Somnolence (Adult， 8%; pediatric， 11% ) Renal: Delay when starting to pass urine (Adult， 6% ) Reproductive: Dysmenorrhea (Adult， 3% )， Erectile dysfunction (Adult， 8% ) Other: Fatigue (Adult， 10%; pediatric， 8% ) Serious Cardiovascular: Increased diastolic arterial pressure (Adult， 4.8% to 12.6%; pediatric， 9.3% to 21.5% )， Increased systolic arterial pressure (Adult， 4.2% to 12.4%; pediatric， 4.9% to 12.5% )， Myocardial infarction， Sudden cardiac death， Tachycardia (Adult， 1.5%; pediatric， 0.3% ) Hepatic: Injury of liver (Severe)， Liver failure Neurologic: Cerebrovascular accident Psychiatric: Aggressive behavior， Hostile behavior， Mania， Psychotic disorder， Suicidal thoughts (Pediatric， 0.4% ) Reproductive: Priapism,儲存於25℃以下,6 years or older， up to 70 kg: Acute treatment: Initial， approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily， as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; Maximum 1.4 mg/kg daily or 100 mg/day， whichever is less 6 years or older， greater than 70 kg: Acute treatment: Initial， 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks;Maximum 100 mg daily,需調整劑量,[仿單]Atomoxetine 及/ 或其代謝物會分泌至老鼠的乳汁中。 Atomoxetine 是否會分泌至人類母乳中則未知。 哺乳中的婦女若服用 Atomoxetine 時，應加以注意。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,[仿單] 在懷孕兔子的器官形成期間，餵食劑量最高至 100 mg/ kg/ day 的Atomoxetine。在三篇研究中的一篇，觀察到活胎數減少，早期再吸收增加。不正常頸動脈起源及缺少鎖骨下動脈的發生率稍微增加。這些結果發現於會引起輕微母體毒性的劑量。 這些結果的無作用劑量（no-effect dose）為 30 mg/ kg/ day。以mg/ m2計，100 mg/ kg 的劑量約為最高人體劑量的 23 倍，兔子血中的 Atomoxetine濃度（AUC）估計為接受最高人體劑量的人體內的 3.3 倍（快速代謝者）或 0.4 倍（緩慢代謝者）。 從交配前 2 週（母鼠）或 10 週（公鼠），到器官形成及哺乳期為止，在老鼠飲食中加入不超過大約 50 mg/ kg/ day 的 atomoxetine（以 mg/ m2計算，約為最高人體劑量的 6 倍）。 在二篇研究的其中一篇，發現小鼠體重及存活數減少。在 25 mg/ kg（非 13 mg/ kg），也發現到小鼠的存活減少的現象。 一篇從交配前 2 週（母鼠）或10 週（公鼠），到器官形成期為止，在老鼠飲食中加入 Atomoxetine 的研究中，40mg/ kg/ day（以 mg/ m2計，約為最高人體劑量的 5 倍），發現到胎鼠體重減少（僅母鼠）及椎骨弓（vertebral arch）不完全成骨的發生率增加的現象，此現象並沒有在 20 mg/ kg/ day 劑量組中發現。 在器官形成期間，以 150 mg/ kg/ day 的劑量（以 mg/ m2計，約為最高人體劑量的17 倍）餵食懷孕母鼠，胎兒並未出現任何的副作用。 目前尚無關於懷孕婦女之充分及完整的對照性研究。 懷孕期間不可服用 Atomoxetine，除非效益超過胎兒可能產生的風險性。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Atomoxetine 及/ 或其代謝物會分泌至老鼠的乳汁中。 Atomoxetine 是否會分泌至人類母乳中則未知。 哺乳中的婦女若服用 Atomoxetine 時，應加以注意。,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥請整顆膠囊吞服。若有磨粉需求請使用前自行磨粉並注意本藥粉末具有眼部刺激性。
IMEPI,Mepivacaine,Mepivastesin 3%(for Dental) 1.7mL,ZANE,Dental infiltration and dental nerve block.,Complete heart block. Porphyria. Do not inject through infected skin when using for epidural anaesthesia.,Restlessness， excitement， nervousness， paraesthesias; dizziness， tinnitus， blurred vision; nausea， vomiting; muscle twitching， tremors， convulsions; numbness of the tongue and perioral region; lightheadedness， drowsiness， respiratory failure， coma， hypotension.,室溫,Mepivacaine 30mg/mL. Dosage requirements should be determined on an individual basis. For submucosal infiltration and/or nerve block injection. Avoid intravascular injection. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection. Adult: dosages of 1-4 mL are usually effective. Children 20-30 kg: 0.25-1 mL. Children 30-45 kg: 0.5-2 mL. Mepivacaine maximum dose: 4 mg/kg (equivalent to 0.133 mL).,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,LI;,,,,,
EFOX1,Fluorometholone,0.1% FOXONE 10mL ophthalmic suspension,TOPH,Acute & chronic iritis， iridocyclitis， scleritis， episcleritis， conjunctivitis， keratitis， resistant ocular allergy & inflammation following surgery,Acute superficial herpes simplex keratitis， fungal diseases of ocular structure; vaccinia， varicella & other viral diseases of the cornea & conjunctiva， eye TB,Glaucoma with optic nerve damage， visual acuity or field defects， raised intraocular pressure， secondary infection (persistent corneal ulceration， possibly fungal invasion)， perforation of globe， posterior subcapsular cataract formation,25℃以下,Instill 1 to 2 drops into conjunctival sac 2 to 4 times daily; may instill 2 drops every 2 hours or 1 drop every 4 hours during initial 24 to 48 hours. Shake well before use.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AD;AL;AS;AU;OD;OL;OU;,,,,,
EGEN3,Gentamicin,Gentamicin 眼藥膏 0.3%， 5gm,TOPH,Treatment of ocular infections due to susceptible organisms.,Hypersensitivity.,Rarely， transient stinging.,30℃以下,Apply a small amount of ointment to the affected eye(s) two or three times a day.,無需調整劑量,,無需調整劑量,,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AD;AL;AS;AU;EXT;IN;OD;OL;OU;SKIN;TOPI;,,,,,
IVER,Verapamil,U-sodin inj 5mg/2mL (Verapamil),CAVS,Angina pectoris， hypertension， arrhythmias.,2nd or 3rd degree AV block; hypotension; bradycardia; sick sinus syndrome; cardiogenic shock， sino-atrial block; history of heart failure or significantly impaired left ventricular function; atrial flutter or fibrillation complicating Wolff-Parkinson-White syndrome.,Flushing， constipation， bradycardia， hypotension， dizziness， headache， fatigue， peripheral oedema， allergic reactions (rare)， 1st or 2nd degree AV block (after IV administration or high doses). Cardiovascular: Edema (up to 3.7% )， Hypotension (1.5% to 3% ) Gastrointestinal: Constipation (7.3% to 13% ) Neurologic: Dizziness (3% to 5.9% )， Headache (2.2% to 12.1% ) Respiratory: Pharyngitis (3% )， Sinusitis (3% ) Other: Influenza-like symptoms (3.7% ),需避光儲存以穩定藥效,Acute ventricular rate control (in hemodynamically stable patients， due to Atrial fibrillation and flutter): Initial: bolus 5 to 10 mg over > or = 2 min; dose may be repeated after 15 to 30 min， may repeat 2-3 times per day. [Micromedex 20211013] Atrial fibrillation and flutter 0.075 to 0.15 mg/kg IV bolus over 2 minutes; may give an additional 10 mg after 30 minutes if no response， then 0.005 mg/kg/min infusion.,需調整劑量,,無需調整劑量,除非治療上需要,Compatible,The use of verapamil in any stage of pregnancy appears to be low risk. The drug was not teratogenic in two animal species， but did cause death and growth restriction in one species.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;IVP;IVPUSH;,,【D5W】可選 。【D5NS】可選 。【N/S】可選 。,推注時間至少5分鐘,,1.不可與含sodium lactate藥物混合. 2.不可與pH值大於6的藥物混合，會有沉澱發生。 (Micromedex)
EANE,Adapalene,Anefree gel 0.1% 15gm,TDER,,適應症: Treatment of acne vulgaris. 副作用: >10%: Dermatologic: Xeroderma (<=45%)， exfoliation of skin (<=44%)， erythema (<=38%)， burning sensation of skin (<=29%)， stinging of the skin (<=29%) 1% to 10%: Dermatologic: Skin abnormalities (1% to 6%; discomfort)， desquamation (2%)， pruritus (<=2%)， skin irritation (1% to 2%)， sunburn (1% to 2%) ?1%， postmarketing， and/or case reports: Acne flare， angioedema (gel)， application site pain (gel)， conjunctivitis， contact dermatitis， dermatitis， eczema， eyelid edema， facial edema (gel)， skin discoloration， skin rash (cream/gel)， swelling of lips (gel) 禁忌: Hypersensitivity to adapalene or any component of the formulation.,,25度C以下,Apply once daily in the evening before bedtime.,無需調整劑量,[仿單]目前對本品是否被分泌於動物或人類乳汁中也尚未知。 由於多種藥物皆可能分泌於乳汁中，因此授乳期婦女使用Adapalene凝膠時應謹慎。 避免產品直接接觸嬰兒此產品不應使用於胸部。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,[仿單]目前對於孕婦的影響資訊有限，但是Adapalene有很低的可能性會經由皮膚吸收， 因此，懷孕及即將懷孕的病患應停止使用。如果有非預期懷孕的情形，治療亦應停止。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前對本品是否被分泌於動物或人類乳汁中也尚未知。 由於多種藥物皆可能分泌於乳汁中，因此授乳期婦女使用Adapalene凝膠時應謹慎。 避免產品直接接觸嬰兒此產品不應使用於胸部。,EXT;,,,,,
OCINO,Ciprofloxacin,Cinolone F.C. 250mg,QANB,UTI .Respiratory tract， bone and joint and biliary tract infection.GI (infectious diarrhea). Gonorrhea.,Hypersensitivity to ciprofloxacin or other quinolones. Children， adolescents， pregnancy and lactation.,Nausea， diarrhoea， vomiting， dyspepsia， abdominal pain， flatulence， anorexia， dizziness， headache， tiredness， agitation， trembling. Very rarely， insomnia， peripheral paralgesia， sweating， unsteady gait， convulsions， increase in intracranial pressure， anxiety states， nightmares， confusion， depression， hallucinations， impaired taste & smell， visual disturbances， tinnitus， transitory impairment of hearing， especially at high frequencies， skin reactions.,30℃以下，緊密阻光容器中儲存,Take with or without food; do not take with milk， yogurt， or calcium-fortified juice; but may be taken with meals that contain these products. Adults: 250-750 mg orally Q12H. Children (1-17 years of age): 10-20 mg/kg Q12H (maximum. 750 mg/dose); inhalational anthrax (post-exposure): 15 mg/kg orally Q12H for 60 days (maximum. 500 mg/dose).,無需調整劑量,,需調整劑量,不可使用,Contraindicated,,Human Data Suggest Potential Toxicity,,AC;AC15;PC;PO;,,,,,
IALC,Alcohol,99.5% Alcohol inj 5mL,RACA,Percutaneous ehtanol injection therapy for hepatocellular carcinoma.,Hypersensitivity to ethyl alcohol or any component of the formulation; seizure disorder and diabetic coma; subarachnoid injection of dehydrated alcohol in patients receiving anticoagulants,Increased serum transaminases， fever， gastric ulcer， throboembolism,25℃以下,Anhydrous alcohol injection was performed under the guidance of ultrasound imaging.Tumor number less than or equal to 3 numbers， and tumor smaller than 3 cm in diameter: 1-10mL 99.5% Alcohol is injected directly to the liver tumors via percutaneous injection， once or twice a week. Maximum: 4-6 times a week.,無需調整劑量,,無需調整劑量,不可使用,Contraindicated,,Hold Breast Feeding 暫停哺乳,,PI;,,,,,
IFAMO,Famotidine,Famoster inj. 20mg/2mL,ALIM,,,,,,,,,,,,,,IM;IVD;IVP;,,,,,
OMUL,Dronedarone,Multaq 400mg,CAVS,Paroxysmal or persistent atrial fibrillation: To reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF,Hypersensitivity to dronedarone or any component of the formulation; permanent atrial fibrillation (patients in whom normal sinus rhythm will not or cannot be restored); symptomatic heart failure (heart failure with recent [within the last 4 weeks] decompensation requiring hospitalization or NYHA Class III or IV symptoms); liver or lung toxicity related to previous amiodarone use; second-degree or third-degree atrioventricular block or sick sinus syndrome (except when used in conjunction with a functioning artificial pacemaker); bradycardia <50 bpm; concomitant use of strong CYP3A4 inhibitors (eg， ketoconazole， itraconazole， voriconazole， cyclosporine， telithromycin， clarithromycin， nefazodone， ritonavir); concomitant use of drugs or herbal products known to prolong the QT interval increasing the risk for torsade de pointes (eg， phenothiazine antipsychotics， tricyclic antidepressants， certain oral macrolide antibiotics， class I and III antiarrhythmics); QTc (Bazett) interval ?500 msec or PR interval >280 msec; severe hepatic impairment; pregnancy; breastfeeding,>10%: Cardiovascular: Prolonged Q-T interval on ECG (Bazett; 28% [placebo: 19%]; defined as >450 msec in males or >470 msec in female); Renal: Increased serum creatinine (51%; increased >10%; occurred 5 days after initiation) 1% to 10%: Cardiovascular: Bradycardia (3%); Dermatologic: Allergic dermatitis (<=5%)， dermatitis (<=5%)， eczema (<=5%)， pruritus (<=5%)， skin rash (<=5%; described as generalized， macular， maculopapular， erythematous); Gastrointestinal: Diarrhea (9%)， nausea (5%)， abdominal pain (4%)， dyspepsia (2%)， vomiting (2%); Neuromuscular & skeletal: Weakness (7%) <1%， postmarketing， and/or case reports: Acute hepatic failure (requiring transplant)， anaphylaxis， angioedema， atrial flutter (with 1:1 atrioventricular conduction)， cardiac failure (new or worsened)， dysgeusia， hepatic injury， hyperbilirubinemia， hypersensitivity angiitis， increased blood urea nitrogen， increased liver enzymes， interstitial pulmonary disease， pneumonitis， pulmonary fibrosis， skin photosensitivity， vasculitis,30°C 以下儲存,400 mg twice daily with meals,需調整劑量,[仿單] 禁忌,無需調整劑量,不可使用,Human (and animal) data suggest risk,[仿單] 禁忌,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單] 禁忌,WM;,,,,,
IALB20,Albumin,Albumin inj 20% 50mL (TBSF),HEMT,Hypovolemic shock， conditions when there is severe hypoalbuminemia， as an adjunct in hemodialysis & in cardiopulmonary bypass procedures. In conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia.,History of hypersensitivity reaction to albumin preparations or to any component of the product. Patients with severe anemia or cardiac failure with normal or increased intravascular volume. Patients at risk for circulatory overload (eg， history of congestive cardiac failure， renal insufficiency， or stabilized chronic anemia). Patients with chronic kidney disease injected with 20% albumin solution will be rapidly excreted by the kidneys and cannot relieve chronic edema. Not suitable for hypoalbuminemia caused by chronic liver cirrhosis， malabsorption， intestinal protein loss， pancreatic insufficiency and malnutrition.,Allergic reactions， nausea， vomiting， increased salivation， fever and chills; vascular overload， haemodilution， and pulmonary edema. Serious Endocrine metabolic: Hypovolemia Immunologic: Hypersensitivity reaction,30°C 以下不可冷凍,Hypoproteinaemia in the acutely ill patient The usual daily dose is 50–75 g human albumin (250-375 mL of “TBSF” (20%) Human Albumin Solution). The rate of administration should not exceed 2 mL per minute， as more rapid infusion may precipitate circulatory overload and pulmonary edema. The infusion of “TBSF” (20%) Human Albumin Solution is not justified in hypoproteinaemic states associated with chronic cirrhosis， malabsorption， protein-losing enteropathies， pancreatic insufficiency， or undernutrition. Shock The dose should be determined by the patient’s condition and response to treatment. The usual initial dose of 20 g human albumin (100 mL of “TBSF” (20%) Human Albumin Solution) may be administered as a blood volume expander at a rate of 2 to 4 mL per minute. The rate of infusion may be increased in emergencies and repeated in 15 to 30 minutes if necessary. The total dose should not exceed the level of albumin found in the normal individual i.e. about 2 g per kg body weight in the absence of active bleeding. If concentrated albumin (>4–5%) is given， it should be accompanied by the intravenous infusion of a crystalloid solution. Failure to supply this additional fluid may lead to dehydration of the tissues. The precise nature and strength of the crystalloid solution will depend on the requirements of the patient for electrolytes and fluid. Burns The usual dose is 20-80 g human albumin (100-400 mL of “TBSF” (20%) Human Albumin Solution) given daily at the rate of about 1 mL per minute. Beyond 24 hours， “TBSF” (20%) Human Albumin Solution can be used to maintain plasma colloid osmotic pressure. A reasonable goal is the maintenance of a plasma albumin concentration of 25 g/L or a colloid osmotic pressure of 20 mmHg. The continuing need for albumin is occasioned by losses from denuded areas and decreased albumin synthesis.,無需調整劑量,[仿單]與內生性血清白蛋白相似， “國血製劑益康”(20%)人血清白蛋白注射劑可能分泌至乳汁。 尚無此方面的安全資訊。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]尚未有“國血製劑益康”(20%)人血清白蛋白注射劑在動物生殖毒性的研究。 因為在動物模式中會對人類白蛋白產生抗體而無法進行此研究。 在懷孕期間使用“國血製劑益康”(20%)人血清白蛋白注射劑，尚未建立於對照臨床試驗中確立， 因此，如有明確的需要才可給予孕婦。,Unknown 沒有資料,[仿單]與內生性血清白蛋白相似， “國血製劑益康”(20%)人血清白蛋白注射劑可能分泌至乳汁。 尚無此方面的安全資訊。,IVD;,,【D5W】可選 。【N/S】可選 。,,國血製劑益康(20%)人血清白蛋白注射劑可稀釋成等膠體滲透壓之蛋白質溶液(4~5%白蛋白)，其比例為1mL國血製劑益康(20%)人血清白蛋白注射劑比4mL晶體溶液，再以平常的靜脈注射法給予。 輸注速率： 急性病人的低蛋白血症：<2mL/分鐘 休克(當做血液體積的擴張劑)：2-4mL/分鐘 燒傷：1mL/分鐘,1.若須稀釋須使用晶體溶液，但仿單中無建議之溶液，廠商亦無法提供相容性文件。 2.不可用水來稀釋，因為其低滲透壓會導致血管內溶血。 3.本產品不含任何抗微生物防腐劑，因此，在開瓶後應馬上使用。 4.切勿使用曾經被冷凍過的溶液。
ERELV,Fluticasone + Vilanterol,Relvar Ellipta 92/22mcg inhalation powder,ERSP,Asthma， and chronic obstructive pulmonary disease of maintenance.,Hypersensitivity to fluticasone， vilanterol， or any component of the formulation. Severe hypersensitivity to milk proteins. Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.,Common Gastrointestinal: Difficulty talking (2% )， Oropharyngeal candidiasis， Pain， Oropharyngeal (2% or greater ) Immunologic: Influenza (3% or greater ) Neurologic: Headache (5% to 8% ) Respiratory: Bronchitis (2% or greater )， Cough (1% or greater )， Nasopharyngitis (9% to 10% )， Sinusitis (2% or greater )， Upper respiratory infection (2% to 7% ) Serious Cardiovascular: Cardiac dysrhythmia， Disorder of cardiovascular system， Electrocardiogram abnormal， Premature beats (2% or greater )， Supraventricular tachycardia Endocrine metabolic: Cushing's syndrome Immunologic: Anaphylaxis Musculoskeletal: Decreased bone mineral density， Fracture of bone (2% ) Respiratory: Death， Asthma-related， Paradoxical bronchospasm， Pneumonia (2% or greater ) Other: Angioedema,30℃以下,One inhalation of Relvar Ellipta 92/22 micrograms once daily. (maximum dose: 1 inhalation/day). A starting dose of one inhalation of Relvar Ellipta 92/22 micrograms once daily should be considered for adults who require a low to mid dose of inhaled corticosteroid in combination with a long-acting beta2-agonist. If patients are inadequately controlled on Relvar Ellipta 92/22 micrograms， the dose can be increased to 184/22 micrograms， which may provide additional improvement in asthma control.,無需調整劑量,BREASTFEEDING RECOMMENDATION - Fluticasone: No Human Data—Probably Compatible; Vilanterol: No Data. [仿單]目前並無任何關於Fluticasone及Vilanterol是否會諸現於人類的乳汁中、對餵哺母乳之嬰兒的影響或對乳汁生成作用之影響等方面的資訊。曾在人類的乳汁中檢出低濃度的其他吸入性皮質類固醇。嬰將餵哺母乳對發育與健康的效應和母親對RELVAR Ellipta臨床需求，以及Fluticasone及Vilanterol或母親的潛在疾病對餵哺母乳之嬰兒的任何可能不良影響一併考慮。,無需調整劑量,沒有資料,Uknown 沒有資料,PREGNANCY RECOMMENDATION - Fluticasone: Compatible; Vilanterol: No Data [仿單]在對孕婦使用RELVAR Ellipta， Fluticasone， Vilanterol方面，目前並無足夠的資料。在對孕婦使用RELVAR Ellipta方面有一些臨床上的考量。在一項動物生殖試驗中，對懷孕的大鼠於器官發生期間以吸入方式單獨投予或合併投予Fluticasone及Vilanterol之後，並未引發任何胎兒結構畸形。在這項試驗中所使用之Fluticasone及Vilanterol的最高劑量分別約為200與25mcg(成人)之人類每日最高建議吸入劑量(MRHDID)的5倍與40倍。(以下略),Unknown 沒有資料,BREASTFEEDING RECOMMENDATION - Fluticasone: No Human Data—Probably Compatible; Vilanterol: No Data. [仿單]目前並無任何關於Fluticasone及Vilanterol是否會諸現於人類的乳汁中、對餵哺母乳之嬰兒的影響或對乳汁生成作用之影響等方面的資訊。曾在人類的乳汁中檢出低濃度的其他吸入性皮質類固醇。嬰將餵哺母乳對發育與健康的效應和母親對RELVAR Ellipta臨床需求，以及Fluticasone及Vilanterol或母親的潛在疾病對餵哺母乳之嬰兒的任何可能不良影響一併考慮。,IH;,,,,,
IPEY,Caffeine Citrate,Peyona inj 20mg/1mL (for infusion and oral),CNEU,Treatment of primary apnoea of premature newborns.,Hypersensitivity to the active substance or to any of the excipients.,Cardiovascular: Angina pectoris， chest pain， flushing， palpitations， sinus tachycardia， supraventricular tachycardia， vasodilatation， ventricular arrhythmia Central nervous system: Agitation， delirium， dizziness， hallucination， headache， insomnia， irritability， psychosis， restlessness Dermatologic: Urticaria Gastrointestinal: Esophageal motility disorder (sphincter tone decreased)， gastritis Genitourinary: Diuresis Neuromuscular & skeletal: Fasciculations Ophthalmic: Increased intraocular pressure (>180 mg caffeine)， miosis,室溫藥品，仿單無特別指示儲存溫度條件,Each 1 mL ampoule contains 20 mg caffeine citrate (equivalent to 10 mg caffeine) Apnea of prematurity: Neonates:Loading dose: Minimum dose: 20 mg/kg as caffeine citrate， Intravenous infusion over 30 minutes， a second loading dose of 10 -20 mg/kg maximum may be given after 24 hours; Maintenance dose: 5 mg/kg/day as caffeine citrate once daily starting 24 hours after the loading dose， Intravenous infusion (over 10 minutes) or by oral administration.Oral: May be administered without regard to feedings or meals.,無需調整劑量,,無需調整劑量,沒有資料,Compatible,,Compatible 哺乳時可使用,,AC;AC15;IVD;PC;PO;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,X,Infuse loading dose 20 mg/kg as caffeine citrate may be infused over at least 30 minutes; maintenance dose 5 mg/kg/day as caffeine citrate once daily may be infused over at least 10 minutes.,1.Caffeine citrate can be either used without dilution or diluted in sterile solutions for infusion such as glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) or calcium gluconate 100 mg/mL (10%) immediately after withdrawal from the ampoule. 2.Blood samples for monitoring should be taken just before the next dose in the case of therapeutic failure and 2 to 4 hours after the previous dose when suspecting toxicity.
EPROT1,Tacrolimus,Protopic ointment 0.1%，10gm,TDER,Atopic dermatitis (Moderate to Severe)， Second-line Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis for 16 years old and above.,Allergic to Tacrolimus， any macrolides， or any other component of Protopic.,Infections and parasites: Local skin infections， whether or not they have a clear cause， include but are not limited to herpetic eczema， folliculitis， herpes simplex， herpes virus infection， Kaposi's varicella-like rash， Eye herpes infection. Metabolic and nutritional diseases: Alcohol intolerance (face flushing or skin irritation after ingesting alcoholic beverages) Nervous system disease: Sensation abnormalities and dullness (hyperesthesia， burning sensation) Skin and subcutaneous tissue diseases: Itching， acne， vinasse， sunburn Systemic diseases and symptoms of the administration site: Administration site burning， administration site itching， administration site warmth， administration site erythema， administration site pain， administration site irritation， administration site paresthesia， administration site rash， administration site edema,25℃以下,Atopic dermatitis (Moderate to Severe)， Second-line Adolescents (>16 years) active phase， Apply thin layer ointment to affected areas twice daily until signs and symptoms resolve; use minimum amount and rub in gently and completely chronic phase: apply ointment as two times a week to three times a week ， re-exame symptoms after 12 months.,無需調整劑量,[仿單]人類數據證實全身性投藥後，tacrolimus 會分泌至乳汁內。 儘管臨床數據顯示使用 tacrolimus 軟膏的全身性暴露量低， 但仍不建議於接受 Protopic 軟膏治療期間進行哺乳。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]目前缺乏懷孕女性使用 tacrolimus 軟膏的適當數據。 動物試驗證實全身性投藥會造成生殖毒性。 對人類的潛在風險仍未知。 懷孕期間不得使用 Protopic 軟膏，除非具有明確必要性。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]人類數據證實全身性投藥後，tacrolimus 會分泌至乳汁內。 儘管臨床數據顯示使用 tacrolimus 軟膏的全身性暴露量低， 但仍不建議於接受 Protopic 軟膏治療期間進行哺乳。,EXT;,,,,,
OQTE,Saxagliptin + Dapagliflozin,Qtern 5/10mg,META,Adults aged 18 years and older with type 2 diabetes mellitus: 1. to improve glycaemic control when metformin and one of the monocomponents of Qtern do not provide adequate glycaemic control. 2. already being treated with the free combination of dapagliflozin and saxagliptin.,history of any serious hypersensitivity reaction to the active substances or to any of the excipients， including anaphylaxis or angioedema following exposure to any dipeptidyl peptidase-4 (DPP4) inhibitor.,Common Endocrine metabolic: Hypoglycemia (1% ) Respiratory: Upper respiratory infection (13.6% ) Serious Cardiovascular: Heart failure， Hypotension Endocrine metabolic: Diabetic ketoacidosis Gastrointestinal: Pancreatitis (0.2% ) Immunologic: Hypersensitivity reaction Renal: Acute kidney injury， nontraumatic， Urinary tract infectious disease (5.7% ) Reproductive: Necrotizing fasciitis， Perineum,儲存於 30°C以下,1 tablet QD. Each tablet contains saxagliptin 5mg and dapagliflozin 10mg.,無需調整劑量,BREASTFEEDING RECOMMENDATION: Dapagliflozin: No Human Data—Potential Toxicity Saxagliptin: No Human Data—Probably Compatible. [仿單]尚無資料顯示Qtern或其成分(saxagliptin 和dapagliflozin)是否會排入人類的乳汁、對接受哺乳嬰兒的影響，或對母乳分泌的作用。Saxagliptin和dapagliflozin會分泌至哺乳大鼠的乳汁中 。 由於人類腎臟會在子宮以及出生後 2 年期間成熟，而這段期間可能會透過哺乳暴露，因此可能會對發育中人類腎臟造成風險。因為對於哺乳新生兒可能導致嚴重不良反應，應告知女性在哺乳期間不建議使用Qtern。 Dapagliflozin在乳汁/血漿中出現的比率為 0.49，顯示dapagliflozin和其代謝物會轉移進入乳汁，其濃度約為母體血漿中的50%。直接暴露到dapagliflozin的幼鼠顯示在成熟期間具有腎臟發育風險(腎盂和腎小管擴張)。 Saxagliptin會以相對於血漿藥品濃度之1:1 比率，分泌到哺乳大鼠的乳汁中。,需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,PREGNANCY RECOMMENDATION: Dapagliflozin: No Human Data—Animal Data Suggest Low Risk. Saxagliptin: No Human Data—Animal Data Suggest Low Risk. [仿單]依據動物數據顯示，dapagliflozin具有對腎臟的不良作用，不建議在懷孕的第二和第三孕期中使用Qtern。 Qtern或其成分(saxagliptin和dapagliflozin)用於懷孕女性的數據有限，不足以判定是否具有重大生育缺陷或流產之藥品相關風險。懷孕期間控制不良的糖尿病，對母親和胎兒都有相關風險。 在動物試驗中，在對應至人類懷孕第二孕期後期和第三孕期的腎臟發育期間，大鼠暴露於dapagliflozin(Qtern的成分之一) 時，所有測試劑量皆曾觀察到非完全可逆的腎盂及腎小管不良擴張；最低劑量的暴露量是10mg臨床劑量的15倍。 給予懷孕大鼠和兔子Saxagliptin時，並未觀察到不良發育反應。 患有妊娠前糖尿病且HbA1c >7%的女性，重大先天缺陷之估計背景風險約為6%至10%；而 HbA1c >10%的女性，則曾通報高達20至25%的背景風險。有關特定族群發生流產的預估背景風險尚不清楚。在美國一般族群，臨床確認的懷孕中，發生重大先天缺陷和流產的預估背景風險比例分別為2至4%和15至20%。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,BREASTFEEDING RECOMMENDATION: Dapagliflozin: No Human Data—Potential Toxicity Saxagliptin: No Human Data—Probably Compatible. [仿單]尚無資料顯示Qtern或其成分(saxagliptin 和dapagliflozin)是否會排入人類的乳汁、對接受哺乳嬰兒的影響，或對母乳分泌的作用。Saxagliptin和dapagliflozin會分泌至哺乳大鼠的乳汁中 。 由於人類腎臟會在子宮以及出生後 2 年期間成熟，而這段期間可能會透過哺乳暴露，因此可能會對發育中人類腎臟造成風險。因為對於哺乳新生兒可能導致嚴重不良反應，應告知女性在哺乳期間不建議使用Qtern。 Dapagliflozin在乳汁/血漿中出現的比率為 0.49，顯示dapagliflozin和其代謝物會轉移進入乳汁，其濃度約為母體血漿中的50%。直接暴露到dapagliflozin的幼鼠顯示在成熟期間具有腎臟發育風險(腎盂和腎小管擴張)。 Saxagliptin會以相對於血漿藥品濃度之1:1 比率，分泌到哺乳大鼠的乳汁中。,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議不可剝半磨粉。(經詢問廠商本藥無特殊控釋或緩釋劑型，但無相關試驗佐證磨粉的藥動或安全性。2022/01/02)
IGCSF3,Nivestim 300 mcg/0.5mL,Nivestim 300 mcg/0.5mL,HEMT,,,,,,,,,,,,,,,,,,,
HCVDA12,Glecaprevir + Pibrentasvir (1~6type/8週),HCVDAA0012(C肝全口服新藥健保計畫) 1-6型/8週,QANB,,,,,,,,,,,,,,,,,,,
EAZET,Azelastine,Azetin Nasal Spray 140 mcg/dose,TENT,Allergic rhinitis,Hypersensitivity to any ingredients of Azelastine,Disorder of taste (Adults and adolescents， 4% to 19.7%; pediatrics， 2% to 4% or more )， Vomiting (Pediatrics， 2% or more )， Headache， Somnolence， Epistaxis (Adults and adolescents， 1% to 3.2% ; pediatrics， 2% to 5% or more )， Nasal irritation (less than 1% to 4% )， Pain of nose (Adults and adolescents， 1% to 4%; pediatrics， less than 1% to 4% or more )， Sneezing (Adults and adolescents， 1% to 3.1% ; pediatrics， 2% to 3% or more )， Fatigue (Nasal， less than 1% to 2.3% ; ophthalmic， 1% to 10% ),25℃以下儲存,Seasonal allergic rhinitis: Intranasal One or two sprays in each nostril twice daily,無需調整劑量,,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IN;,,,,,
EALC755,Alcohol,75% Alcohol 500mL/bottle,TDER,,,,25℃以下,,無需調整劑量,,無需調整劑量,,,,,,EXT;,,,,,
OLAB,Labetalol,Labtal 200mg,CAVS,Hypertension.,Bronchial asthma. Cardiogenic shock. Overt cardiac failure. Second and third degree heart block. Severe bradycardia. Conditions associated with severe and prolonged hypotension. Hypersensitivity to labetalol or any component of the product.,Common Gastrointestinal: Nausea (Oral， 6%) Neurologic: Dizziness (Oral， 11%) Other: Fatigue (Oral， 5% ) Serious Cardiovascular: Decreased cardiac output， Heart failure， Hypertension， Paradoxical， Myocardial ischemia， Orthostatic hypotension (Oral， 1% ; IV， 58% ) Hepatic: Hepatocellular liver damage， Jaundice Immunologic: Anaphylaxis Ophthalmic: Intraoperative floppy iris syndrome,25℃以下,Hypertension: Initially 100 mg BID. May increase in increments of 100 mg twice daily intermittently every 2-14 days. Usual maintenance: 200mg BID. Maximum: 800 mg/day in 2 divided doses. Patients with severe hypertension may require 2400 mg/day， in 3-4 divided doses. Older Adult， Initial: 50 mg twice daily and consider lower maintenance doses. Gestational hypertension: Initially 100 mg BID. May increase in increments of 100 mg twice daily intermittently in the 1-week intervals. The total daily dose may be divided into 3 divided doses for patients with severe hypertension. Maximum: 2400mg/day.,需調整劑量,[仿單]Labetalol可從乳汁中排出，但未有任何報告指出到哺乳的嬰兒有不良反應。,無需調整劑量,除非治療上需要,Human data suggest low risk,[仿單]FDA Pregnancy Category(懷孕用藥級數):C. Labetalol在懷孕安全性尚未建立，必要時應權衡利弊使用。應記得 Labetalo可通過胎盤障壁而可能造成胎兒及新生兒的(α及β型腎上腺接受體阻斷。有極少數的報告談及妊娠前後及新生兒障礙(心動徐緩、 低血壓、呼吸抑制、低血糖、低體溫等)。有時此類症狀在出生後一天或二天才發生。此時應給予緊急的治療措施(例如，靜脈注射液體及葡萄糖)，但伴有嚴重的子癇先兆，尤以持久性的靜脈注射Labetalol之後，則復原時間會較慢，這可能和早產兒的肝代謝功能不完全有關。雖然也曾有子宮內及新生兒死亡的報告，但可能與其他藥物(如:血管舒張劑、呼吸抑制劑)以及子癇先兆、子宮內成長遲滯和早產等作用有關。以上這些臨床經驗警示不可有不適當的長期高劑量使用Labetalol 延遲分娩以及併用Hydralazine,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]Labetalol可從乳汁中排出，但未有任何報告指出到哺乳的嬰兒有不良反應。,PC;PO;WM;,,,,,氣喘或呼吸道障礙患者應謹慎使用。
OATM10,Atomoxetine,apo-Atomoxetine 10mg,CNEU,Attention deficit hyperactivity disorder.,Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma， current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg， 15 to 20 mm Hg) or heart rate (eg， 20 beats per minute),Common Cardiovascular: Increased heart rate (Adult， 10.2% to 22.4%; pediatric， 12.2% to 23.4% ) Endocrine metabolic: Weight decreased (Adult， 2%; pediatric， 3% ) Gastrointestinal: Abdominal pain (Adult， 7%; pediatric， 18% )， Constipation (Adult， 8%; pediatric， 1% to 2% )， Decrease in appetite (Adult， 16%; pediatric， 16% )， Nausea (Adult， 26%; pediatric， 10% )， Vomiting (Adult， 4%; pediatric， 11% )， Xerostomia (Adult， 20% ) Neurologic: Dizziness (Adult， 8%; pediatric， 5% )， Headache (Pediatric， 19% )， Insomnia (Adult， 15%; pediatric， at least 2% )， Somnolence (Adult， 8%; pediatric， 11% ) Renal: Delay when starting to pass urine (Adult， 6% ) Reproductive: Dysmenorrhea (Adult， 3% )， Erectile dysfunction (Adult， 8% ) Other: Fatigue (Adult， 10%; pediatric， 8% ) Serious Cardiovascular: Increased diastolic arterial pressure (Adult， 4.8% to 12.6%; pediatric， 9.3% to 21.5% )， Increased systolic arterial pressure (Adult， 4.2% to 12.4%; pediatric， 4.9% to 12.5% )， Myocardial infarction， Sudden cardiac death， Tachycardia (Adult， 1.5%; pediatric， 0.3% ) Hepatic: Injury of liver (Severe)， Liver failure Neurologic: Cerebrovascular accident Psychiatric: Aggressive behavior， Hostile behavior， Mania， Psychotic disorder， Suicidal thoughts (Pediatric， 0.4% ) Reproductive: Priapism,儲存於25℃以下,6 years or older， up to 70 kg: Acute treatment: Initial， approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily， as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; Maximum 1.4 mg/kg daily or 100 mg/day， whichever is less 6 years or older， greater than 70 kg: Acute treatment: Initial， 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks;Maximum 100 mg daily,需調整劑量,[仿單]Atomoxetine 及/ 或其代謝物會分泌至老鼠的乳汁中。 Atomoxetine 是否會分泌至人類母乳中則未知。 哺乳中的婦女若服用 Atomoxetine 時，應加以注意。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,[仿單] 在懷孕兔子的器官形成期間，餵食劑量最高至 100 mg/ kg/ day 的Atomoxetine。在三篇研究中的一篇，觀察到活胎數減少，早期再吸收增加。不正常頸動脈起源及缺少鎖骨下動脈的發生率稍微增加。這些結果發現於會引起輕微母體毒性的劑量。 這些結果的無作用劑量（no-effect dose）為 30 mg/ kg/ day。以mg/ m2計，100 mg/ kg 的劑量約為最高人體劑量的 23 倍，兔子血中的 Atomoxetine濃度（AUC）估計為接受最高人體劑量的人體內的 3.3 倍（快速代謝者）或 0.4 倍（緩慢代謝者）。 從交配前 2 週（母鼠）或 10 週（公鼠），到器官形成及哺乳期為止，在老鼠飲食中加入不超過大約 50 mg/ kg/ day 的 atomoxetine（以 mg/ m2計算，約為最高人體劑量的 6 倍）。 在二篇研究的其中一篇，發現小鼠體重及存活數減少。在 25 mg/ kg（非 13 mg/ kg），也發現到小鼠的存活減少的現象。 一篇從交配前 2 週（母鼠）或10 週（公鼠），到器官形成期為止，在老鼠飲食中加入 Atomoxetine 的研究中，40mg/ kg/ day（以 mg/ m2計，約為最高人體劑量的 5 倍），發現到胎鼠體重減少（僅母鼠）及椎骨弓（vertebral arch）不完全成骨的發生率增加的現象，此現象並沒有在 20 mg/ kg/ day 劑量組中發現。 在器官形成期間，以 150 mg/ kg/ day 的劑量（以 mg/ m2計，約為最高人體劑量的17 倍）餵食懷孕母鼠，胎兒並未出現任何的副作用。 目前尚無關於懷孕婦女之充分及完整的對照性研究。 懷孕期間不可服用 Atomoxetine，除非效益超過胎兒可能產生的風險性。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Atomoxetine 及/ 或其代謝物會分泌至老鼠的乳汁中。 Atomoxetine 是否會分泌至人類母乳中則未知。 哺乳中的婦女若服用 Atomoxetine 時，應加以注意。,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥請整顆膠囊吞服。若有磨粉需求請使用前自行磨粉並注意本藥粉末具有眼部刺激性。
IALFBAD,Alfentanil,Alfentanil inj 殘餘銷毀 (HAMELN),CNEU,,,,,,,,,,,,,,IV;,,【D5NS】可選 。【D5W】可選 。【L/R】可選 。【N/S】可選 。,,,
ICYR,Ramucirumab,Cyramza inj 100mg/10mL,RACA,Gastric cancer: (1) Ramucirumab combined with paclitaxel is used for the treatment of advanced or metastatic gastric adenocarcinoma (or gastroesophageal junction adenocarcinoma) that is receiving or receiving chemotherapy with fluoropyrimidine and platinum but the disease has deteriorated. (2) Ramucirumab is used as a single drug for the treatment of advanced or metastatic gastric adenocarcinoma (or gastroesophageal junction adenocarcinoma) that is receiving or has received fluoropyrimidine or platinum chemotherapy but the disease has deteriorated and is not suitable for receiving paclitaxel-containing drugs. Non-small cell lung cancer (NSCLC): (1) Ramucirumab and erlotinib are used in the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. (2) Ramucirumab combined with docetaxel is used to treat locally advanced or metastatic non-small cell lung cancer that is receiving or receiving platinum-containing chemotherapy but the disease has deteriorated. Colorectal cancer: Ramucirumab and FOLFIRI (irinotecan， folic acid， and 5-fluorouracil) are used for the treatment of metastatic colorectal cancer (mCRC) that is receiving or receiving bevacizumab， oxaliplatin， and fluoropyrimidine treatment but the disease has deteriorated. Hepatocellular carcinoma (HCC): Ramucirumab monotherapy is used for hepatocellular carcinoma patients who have received sorafenib treatment and have alpha-fetoprotein (AFP) ?400 ng/mL.,Hypersensitivity. For NSCLC， tumour cavitation or tumour involvement of major vessels.,Neutropenia， febrile neutropenia; leukopenia， thrombocytopenia; hypoalbuminaemia; HTN; epistaxis; GI haemorrhage events， stomatitis; proteinuria; fatigue/asthenia; peripheral oedema; abdominal pain， diarrhea; palmar-plantar erythrodysaesthesia syndrome; mucosal inflammation; hypokalaemia; hyponatraemia; headache.,2-8℃避光避免冷凍,Premedicate prior to infusion with an IV H1 antagonist (eg， diphenhydramine); for patients who experienced a grade 1 or 2 infusion reaction with a prior infusion， also premedicate with dexamethasone (or equivalent) and acetaminophen. [Gastric Cancer] 8 mg/kg (either as a single agent or in combination with weekly paclitaxel) every 2 weeks administered by intravenous infusion over 60 minutes. If the first infusion is tolerated， all subsequent infusions may be administered over 30 minutes. Continue CYRAMZA until disease progression orunacceptable toxicity. When given in combination with paclitaxel， administer CYRAMZA prior to administration of paclitaxel. [Non-Small Cell Lung Cancer (NSCLC)] - EGFR Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations – CYRAMZA in Combination with Erlotinib: 10 mg/kg infused over 60 minutes every 2 weeks.- Disease Progression On Or After Platinum-based Chemotherapy – CYRAMZA in Combination with Docetaxel: 10 mg/kg infused over 60 minutes on Day 1of a 21-day cycle prior to docetaxel infusion. [Colorectal Cancer] 8 mg/kg infused over 60 minutes every 2 weeks prior to FOLFIRI administration. [Hepatocellular Carcinoma] 8 mg/kg infused over 60 minutes every 2 weeks.,無需調整劑量,As a risk to newborns/infants cannot be excluded， breast-feeding should be discontinued during treatment with Cyramza and for at least 3 months after the last dose.,無需調整劑量,不可使用,Contraindicated,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,As a risk to newborns/infants cannot be excluded， breast-feeding should be discontinued during treatment with Cyramza and for at least 3 months after the last dose.,IVD;,,【N/S】可選 仿單建議。,Do not administer as an IV push or bolus.,Dilute with only 0.9% saline to a final volume of 250 mL. Infuse over 60 minutes through a separate infusion line using an infusion pump; the use of a 0.22 micron protein sparing filter is recommended. Do not administer as an IV push or bolus. Flush the line with NS after infusion is complete.,Do not administer as an IV push or bolus. Do not use dextrose containing solutions. Dilute with only 0.9% saline to a final volume of 250 mL. Infuse over 60 minutes through a separate infusion line using an infusion pump; the use of a 0.22 micron protein sparing filter is recommended.
ESIM,Brinzolamide + Brimonidine tartrate,Simbrinza eye drops 1%/0.2%， 5mL,TOPH,Use Reduction of intraocular pressure: Treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.,Hypersensitivity to brinzolamide， brimonidine or other sulphonamides. Hyperchloraemic acidosis. Concomitant MAOI therapy， antidepressants affecting noradrenergic transmission. Severe renal impairment. children.,Somnolence， dizziness， dysgeusia， eye allergy & pain， keratitis， ocular discomfort & hyperaemia， blurred & abnormal vision， conjunctival blanching， dry mouth.,25℃以下,Adult including elderly: Instill 1 drop in the affected eye BID. Age 2-18 years: Limited data available with child between 2-18 years old. Not recommend use. Age <2 years: Do not use in child under 2 years old.,無需調整劑量,,需調整劑量,,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,OD;OL;OU;,,,,,
IFLUV5,Purified Split Inactivated Influenza Virus,免費幼兒4價流感(6M~3Y) 0.5mL/dose,HIMM,Active immunisation against influenza.,Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome.,,IM， 0.5 mL， > or = 6 months (< 9 years who have not been vaccinated previously， the second dose can be given after 4 weeks.),無需調整劑量,,無需調整劑量,,Compatible,,Compatible 哺乳時可使用,,,,,,,
OGIK,Polyethylene Glycol 3350,GI Klean Powder,ALIM,Bowel prep before colonoscopy， colonic surgery， radiological exam & other related procedures.,GI obstruction or perforation， ileus， gastric retention， acute intestinal or gastric ulceration， toxic colitis or megacolon.,Nausea， bloatedness， abdominal pain， vomiting. Rarely rectal irritation.,25℃以下，乾燥儲存,Adult including elderly & renal insufficiency patient 1 sachet In 1 L water. 250mL to be drunk rapidly every 10-15 mins until all soln has been consumed. Until the rectal effuent is clear or repeat procedure with 4 sachets . Need to be taken within 4-6 hours. Avoid non-fluid food 2 hours before medication.,無需調整劑量,,無需調整劑量,除非治療上需要,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PO;,,,,,
EMIR3,Brimonidine,Mirvaso 3mg/gm gel， 30gm,TDER,Symptomatic treatment of facial erythema of rosacea in adult patients.,Hypersensitivity. Patients receiving MAOIs (eg， selegeline or moclobemide) & tricyclic (eg， imipramine) or tetracyclic (eg， maprotiline， mianserin or mirtazapin) antidepressants. Do not use in childn or adolescents 2-18 yr or childn <2 yr.,Flushing， erythema， pruritus， skin burning sensation.,25℃以下,Rosacea， Persistent (nontransient) facial erythema Apply once daily as long as facial erythema is present. Maximum daily recommended dose: 1 g gel， divided into 5 pea size amounts on forehead， cheeks， nose & 2- chin smooth evenly over entire face avoiding lips and eyes.,無需調整劑量,藥品仿單:懷孕建議: 因資料有限，最好不要在懷孕期間使用Mirvaso。,無需調整劑量,沒有資料,No (limited) human data – probably compatible,藥品仿單:哺乳建議:不應於哺乳期間使用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,藥品仿單:懷孕建議: 因資料有限，最好不要在懷孕期間使用Mirvaso。,EXT;,,,,,
ICAG1,Calcium gluconate,Calcium gluconate inj 10%， 10mL (專案進口),NUTR,,適應症:Ca deficiency. 副作用: Cardiovascular (with rapid I.V. injection): Arrhythmia， bradycardia， cardiac arrest， hypotension， syncope， vasodilation Central nervous system: Sense of oppression (with rapid I.V. injection) Endocrine & metabolic: Hypercalcemia Gastrointestinal: Chalky taste Neuromuscular & skeletal: Tingling sensation (with rapid I.V. injection) Miscellaneous: Heat waves (with rapid I.V. injection) 禁忌：Ventricular fibrillation; hypercalcemia; concomitant use of I.V. calcium gluconate and ceftriaxone in neonates (risk of precipitation of calcium-ceftriaxone),,室溫,Intravenous use or intramuscular use. (4.66mEq/10mL) 10 ml contain 940 mg calcium gluconate as active ingredient， equivalent to 2.10 mmol calcium. Adult: The usual initial dose in adults is 10 ml of Calcium Gluconate 10 % w/v Injection BP， corresponding to 2.25 mmol of calcium.If necessary， the dose may be repeated， depending on the patient’s clinical condition. Subsequent doses should be adjusted according to the actual serum calcium level. Paediatric patients (< 18 years): Age: 3 months 0.4-0.9mL/kg; 6 months 0.3-0.7mL/kg; 1year 0.2-0.5mL/kg; 3 years 0.4-0.7mL/kg; 7.5 years 0.2-0.4mL/kg; 12 years 0.1-0.3mL/kg; >12 years as for adults,,,,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,1.本品為10 mL包裝，僅供TPN調配使用。 2.Paediatric patients (< 18 years):The intravenous administration rate should not exceed 5 ml of a 1:10 dilution per minute of Calcium Gluconate 10% B. Braun in children and adolescents. 3.Intramuscular injections should not be performed in paediatric patients. 4.adults the intravenous administration rate should not exceed 2 ml (0，45 mmol of calcium) per minute.
OAZI,Azithromycin,Aziciin 250mg,QANB,,適應症: Upper & lower respiratory tract infections; skin & soft tissue infections; otitis media; uncomplicated genital infections due to Chlamydia trachomatis & Neisseria gonorrheae. 副作用: Nausea， abdominal discomfort， vomiting， flatulence， diarrhoea & loose stools. Hearing impairment， interstitial nephritis， acute renal failure， abnormal liver function， dizziness/vertigo， convulsions， headache， somnolence. 禁忌: Hypersensitivity to macrolides.,,,Adults: Sexually transmitted diseases caused by Chlamydia trachomatis or susceptible Neisseria gonorrhoeae the dose is 1g as a single oral dose. Acute infective exacerbation of chronic obstructive pulmonary disease (Mild to Moderate): 500 mg ORALLY once daily for 3 days or 500 mg ORALLY on day 1 followed by 250 mg/day ORALLY on days 2 to day 5. Other infections: 500 mg daily for 3 days. Childn: A single daily dose of 10 mg/kg for 3 days.,無需調整劑量,,需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
ISTO,Cimetidine,Stogamet inj 200mg/2mL,ALIM,Gastric ulcer. Ulcer of duodenum. Erosive esophagitis.,Hypersensitivity to cimetidine or any component of this product.,Common Endocrine metabolic: Gynecomastia (up to 4% ) Serious Gastrointestinal: Gastric cancer， Necrotizing enterocolitis in fetus OR newborn， Pancreatitis Psychiatric: Psychotic disorder,25℃以下,usual dose: IM: 300mg Q6-8H IV: 300mg in 100mL D5W for 15-20 min， Q6- 8H. maximum 2.4 g/day children: limitied data， usual dose 20-40mg/kg/day IV,無需調整劑量,[仿單]Cimetidine 可分泌於乳汁中．病人服藥的階段不宜授乳。 孕婦臨產受剖腹產術時，進行全身麻醉，同時授與時，由於本藥半衰期(2 小時)較短，在病人復元至可哺乳時，本品分泌於乳汁中含量已所存無幾。,需調整劑量,可能安全,Compatible,[仿單]本劑使用於懷孕婦女之經驗仍有限。雖然研究顯示懷孕中投與本劑後，不會有致畸胎的危險，但在其他動物和人類的研究中發現本劑可以通過胎盤屏障，因此若非醫師研判預期的利益大於可能的危險，懷孕期間最好避免使用本品。,Compatible 哺乳時可使用,[仿單]Cimetidine 可分泌於乳汁中．病人服藥的階段不宜授乳。 孕婦臨產受剖腹產術時，進行全身麻醉，同時授與時，由於本藥半衰期(2 小時)較短，在病人復元至可哺乳時，本品分泌於乳汁中含量已所存無幾。,IM;IVD;IVPUSH;,,【D10W】可選 仿單建議。【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,以適合的溶液把300mg本品稀釋成20mL溶液，以長於2分鐘的速率緩慢的靜脈注射，這種給藥方式應避免使用在患有心臟血管疾病的患者。,本品300mg稀釋在100mL適合的靜脈注射溶液中，靜脈點滴15-20分鐘以上，點滴的平均速率在24小時期間不超過75mg/小時。,Cimetidine 注射液以0.9%氯化鈉注射液，5%或10%右旋醣注射液，乳酸化林格氏液稀釋後於室溫下可保存1個星期。
LSCR,Sucralfate,Scrat 1gm/10mL/pack suspension,ALIM,Short-term (?8 weeks) management of duodenal ulcers; maintenance therapy for duodenal ulcers,Hypersensitivity to sucralfate or any component of the formulation,1% to 10%: Gastrointestinal: Constipation (2%) <1%， postmarketing， and/or case reports: Anaphylaxis， back pain， bezoar formation， bronchospasm， diarrhea， dizziness， drowsiness， dyspepsia， flatulence， headache; hypersensitivity (urticaria， angioedema， facial swelling， laryngospasm， respiratory difficulty， rhinitis); insomnia， nausea， pruritus， skin rash， stomach pain， vertigo， vomiting， xerostomia,室溫藥品，仿單無特別指示儲存溫度條件,usual dose: 1 pack QID on empty stomach,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
IIMO,Japanese Encephalitis Vaccine,Imojev inj 0.5mL/dose (自費日本腦炎疫苗),HIMM,Active immunisation against encephalitis due to Japanese encephalitis virus,Avoid use in the following unless absolutely necessary: patients with fever or severe malnutrition; CV， renal or hepatic diseases in acute， exacerbating or active phases; history of abnormal adverse reactions caused by this vaccine; history of spasmodic symptoms within 1 yr; pregnancy.,Local reactions eg redness， swelling， tenderness or systemic reactions eg fever， chill， headache， lassitude. Rarely， severe adverse reactions manifesting as generalized urticaria or angioedema may occur.,2-8℃避光避免冷凍,IM， 0.5mL， Age > or = 9 months - < 18 years: primary immunization.A booster dose after 12-24 months. Age > or = 18 years: a single dose.,無需調整劑量,[仿單]動物試驗並無直接或間接證據顯示對懷孕、胚胎發展、分娩、產後胎兒、泌乳具傷害性， 禁用於壞孕及授乳婦女。,無需調整劑量,不可使用,Uknown 沒有資料,[仿單]動物試驗並無直接或間接證據顯示對懷孕、胚胎發展、分娩、產後胎兒、泌乳具傷害性， 禁用於壞孕及授乳婦女。,Unknown 沒有資料,[仿單]動物試驗並無直接或間接證據顯示對懷孕、胚胎發展、分娩、產後胎兒、泌乳具傷害性， 禁用於壞孕及授乳婦女。,SC;,使用廠商所附之稀釋液,,,,IMOJEV should not be injected directly into veins.
IJEV0,Japanese Encephalitis Vaccine,Imojev (減毒日腦，政府提供) 0.5mL/dose,HIMM,Active immunisation against encephalitis due to Japanese encephalitis virus,Avoid use in the following unless absolutely necessary: patients with fever or severe malnutrition; CV， renal or hepatic diseases in acute， exacerbating or active phases; history of abnormal adverse reactions caused by this vaccine; history of spasmodic symptoms within 1 yr; pregnancy.,Local reactions eg redness， swelling， tenderness or systemic reactions eg fever， chill， headache， lassitude. Rarely， severe adverse reactions manifesting as generalized urticaria or angioedema may occur.,2-8℃避光避免冷凍,IM， 0.5mL， Age > or = 9 months - < 18 years: primary immunization.A booster dose after 12-24 months. Age > or = 18 years: a single dose.,無需調整劑量,[仿單]動物試驗並無直接或間接證據顯示對懷孕、胚胎發展、分娩、產後胎兒、泌乳具傷害性， 禁用於壞孕及授乳婦女。,無需調整劑量,不可使用,Uknown 沒有資料,[仿單]動物試驗並無直接或間接證據顯示對懷孕、胚胎發展、分娩、產後胎兒、泌乳具傷害性， 禁用於壞孕及授乳婦女。,Unknown 沒有資料,[仿單]動物試驗並無直接或間接證據顯示對懷孕、胚胎發展、分娩、產後胎兒、泌乳具傷害性， 禁用於壞孕及授乳婦女。,SC;,使用廠商所附之稀釋液,,,,IMOJEV should not be injected directly into veins.
IHBV,Hepatitis B Vaccine,Engerix-B 1mL/dose (自費B肝疫苗),HIMM,Active immunisation against hepatitis B virus infection,Hypersensitivity.,Redness， pain， swelling at inj site. Rarely， fatigue， fever， malaise， influenza-like symptoms， dizziness， headache， paresthesia， nausea， vomiting， diarrhea， abdominal pain， abnormal liver function tests， arthralgia， myalgia， rash， pruritus， urticaria.,2-8℃避光避免冷凍,IM， > or = 20 years 20 mcg/1mL/dose， < or = 19 years 10 mcg/0.5 mL/dose， 3 doses at 0， 1， and 6 months or 4 doses at 0， 1， 2， and 12 months. > or = 20 years rapid immunization 3 doses at 0， 7， and 21 days with a booster at 12 months. Renal insufficiency > or = 16 years 4 double doses (20 mcg x 2) at 0， 1， 2， and 6 months. 11-15 years 2 doses (20 mcg) at 0 and 6 months.,無需調整劑量,[仿單]並無足夠授乳期間使用之資料及動物生殖研究，尚未確認有任何禁忌。,無需調整劑量,可能安全,Compatible,[訪單]並無足夠人類懷孕期間使用之資料及動物生殖研究， 只有在明確必要且潛在效益超越對胎兒的潛在危險性時，才可在懷孕期間使用。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]並無足夠授乳期間使用之資料及動物生殖研究，尚未確認有任何禁忌。,IM;,,,,,1. 以肌肉注射於成人或兒童的手臂三角肌部位，或新生兒、嬰兒、幼童的大腿前外側。 2. 血小板減少症或出血性疾病患者可以皮下注射方式投與。
IHAV1,Inactivated Hepatitis A Virus Vaccine,HAVRIX 1440， 1mL/dose (成人A肝疫苗),HIMM,Active immunisation against infections caused by hepatitis A virus.,Hypersensitivity.,Inj site soreness， mild redness & swelling， headache， malaise， vomiting， fever， nausea & loss of appetite.,2-8℃避光避免冷凍,IM， 0.5mL， > or = 19 years primary immunization. A booster dose after 6-12 months.,無需調整劑量,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料，絕對需要時才給予。,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料，絕對需要時才給予。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並無人類懷孕期間及授乳期間使用之適合資料，絕對需要時才給予。,IM;,,,,,1. 肌肉注射於成人或孩童的三角肌部位，嬰兒則應注射於大腿前側部位。
OJAR,Empagliflozin,Jardiance FC 10mg,META,,適應症:Diabetes mellitus， type 2 副作用:>10%: Endocrine & metabolic: Hypoglycemia (combination therapy with insulin: 28%， severe hypoglycemia: <=1%; combination therapy with metformin and a sulfonylurea: 12% to 16%; combination therapy with metformin: 1% to 2%) Genitourinary: Urinary tract infection (9%; females: 18%; males: 4%)， increased urine output (includes polyuria， pollakiuria， nocturia: 3%) 1% to 10%: Endocrine & metabolic: Increased LDL cholesterol (5% to 7%)， dyslipidemia (4%)， increased thirst (including polydipsia: 2%) Gastrointestinal: Nausea (2%) Hematologic & oncologic: Increased hematocrit (3% to 4%) Infection: Genitourinary fungal infection (4%; females: 5% to 6% [includes bacterial vaginosis， cervicitis， vulvitis， vulvovaginal candidiasis， vulvovaginal infection， vulvovaginitis]; males: 2% to 3% [includes balanitis， balanoposthitis， genitourinary fungal infection， penile infection， scrotal abscess]) 禁忌:History of serious hypersensitivity to empagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2)， end-stage renal disease (ESRD)， or dialysis,,室溫,Diabetes mellitus， type 2: Oral: Initial: 10 mg once daily; may increase to 25 mg once daily,無需調整劑量,,需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,AC;PC;PO;,,,,,
OCAP5,Capecitabine,Calveda 500mg,RACA,Colon cancer， Adjuvant therapy， Duke's Stage C， when treatment with a fluoropyrimidine alone is preferred. Metastatic breast cancer， metastatic colorectal cancer， 1-line therapy when treatment with a fluoropyrimidine alone is preferred.,Known hypersensitivity to capecitabine， fluorouracil， or any component of the formulation; severe renal impairment (CrCl <30 mL/minute). Canadian labeling: Additional contraindications (not in the US labeling): Known complete absence of dihydropyrimidine dehydrogenase (DPD) activity; concomitant administration with sorivudine or chemically related analogues (eg， brivudine).,GI disturbances; hand-foot syndrome， alopecia， pruritus， rash; fatigue， pyrexia， lethargy， asthenia; dizziness， taste disturbance; anorexia; conjunctivitis; neutropenia. Dermatologic: Dermatitis (27% to 37% ) Gastrointestinal: Abdominal pain， Constipation， Loss of appetite， Nausea， Stomatitis， Vomiting Other: Fatigue,25℃以下,Adjuvant treatment is recommended for a total of 6 months (8 cycles) [Metastatic Colorectal Cancer， Adjuvant Colorectal Cancer， Dukes’ C colon cancer (adjuvant treatment)] 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles for a total of 8 cycles (24 weeks) [Metastatic Breast Cancer] Monotherapy: 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles; Combination: 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period， combined with docetaxel at 75 mg/m2 as a 1-hour intravenous infusion every 3 weeks.,需調整劑量,,需調整劑量,盡量避免,No (limited) human data – animal data suggest risk,,Contraindicated 哺乳期使用禁忌,,PC;PO;,,,,,[磨粉/管灌註記]本藥為癌症用藥，不宜破壞原劑型。若有磨粉需求請使用前自行磨粉，並注意相關風險。
IBIC,Penicillin G Benzathine,Bicillin L-A inj 2.4 MIU/4mL,QANB,Susceptible infections， including mild to moderate upper respiratory strep infections， syphilis. Follow-up prophylaxis of rheumatic heart disease， acute glomerulonephritis.,Hypersensitivity to penicillins. Avoid intraarterial， intravascular， or intraneural injection.,Rash， serum sickness， anaphylaxis， blood dyscrasias， neuropathy， nephropathy， inj site reactions.,2-8℃避免冷凍,(仿單+Uptodate) Streptococcus， group A (pharyngitis): adults and children > 27 kg: 1.2 million units IM as a single dose; children < 27 kg 0.6 million units IM as a single dose. Syphilis: Primary， Secondary， Early Latent (<1-year duration): 2.4 million units as a single dose. Late Latent， Latent with unknown duration， Tertiary Syphilis (with normal CSF examination)， or Neurosyphilis: 2.4 million units IM once weekly for 3 doses. Yaws， bejel， and pinta: 1.2 million units IM as a single dose. Rheumatic fever， secondary prevention: 1.2 million units every 4 weeks， for patients with high risks， every 3 weeks. Prevention of glomerulonephritis: 1.2 million units once monthly if needed.,無需調整劑量,,需調整劑量,可能安全,Compatible,,Compatible 哺乳時可使用,,IM;,,,不可使用IV.,不可使用IV.,1.Bicillin L-A僅限深層肌肉注射使用。 2.請勿注射至動脈或神經內或其周圍，或經由靜脈途徑注射，或與其他靜脈注射液摻混。 3.請以深層肌肉注射方式，注射至臀部的外上側(背側臀肌區)或腹側臀肌區。在新生兒、嬰兒及年幼兒童中，可能以大腿的中外側為首選。
OSINM2,Carbidopa + Levodopa,25/250mg SINEMET,CNEU,,適應症: Symptomatic treatment of Parkinsonism. 副作用: Dyskinesia including choreiform， dystonic & other involuntary movements. Mental changes including paranoid ideation & psychotic episodes; depression with or without development of suicidal tendencies; dementia; & GI disturbances. Gastrointestinal: Nausea (5.5% to 5.7% ) 禁忌: Narrow-angle glaucoma. Undiagnosed skin lesions or history of melanoma. Hypersensitivity to any component of this product.,,室溫,1 tab tid. Max: 8 tab.,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
OAMIO2,Amiodarone,Amiorone 200mg,CAVS,,適應症: Ventricular arrhythmia， Life-threatening; Treatment and Prophylaxis 副作用: Common Cardiovascular: Hypotension (Oral， less than 1%; IV， 15.6% ) Dermatologic: Photodermatitis (2% to 24% )， Photosensitivity (3% to 10% ) Endocrine metabolic: Thyroid dysfunction Gastrointestinal: Constipation (4% to 9% )， Loss of appetite (4% to 9% )， Nausea (10% to 33% )， Vomiting (10% to 33% ) Hepatic: Increased liver enzymes Neurologic: Abnormal gait (4% to 9% )， Coordination problem (4% to 9% )， Dizziness (4% to 9% )， Involuntary movement (4% to 9% )， Movement disorder (4% to 9% )， Paresthesia (4% to 9% )， Peripheral neuropathy Ophthalmic: Corneal deposit， Microdeposits， Visual disturbance (4% to 9% ) Other: Malaise and fatigue (4% to 9% ) Serious Cardiovascular: Bradyarrhythmia， Cardiac dysrhythmia， Congestive heart failure， High threshold for implanted defibrillator， Prolonged QT interval， Sinus arrest， Torsades de pointes， Vasculitis， Ventricular arrhythmia Dermatologic: Injection site extravasation， Stevens-Johnson syndrome， Toxic epidermal necrolysis Endocrine metabolic: Hyperthyroidism (2% )， Hypothyroidism (Up to 10% .)， Thyroid cancer， Thyrotoxicosis Hematologic: Thrombocytopenia Hepatic: Hepatotoxicity Immunologic: Anaphylaxis， Hypersensitivity reaction， Lupus erythematosus Musculoskeletal: Low back pain， acute， Rhabdomyolysis Neurologic: Pseudotumor cerebri， Raised intracranial pressure Ophthalmic: Blindness AND/OR vision impairment level， Optic neuritis， Toxic optic neuropathy Renal: Renal impairment Respiratory: Acute respiratory distress syndrome (2% )， Pulmonary fibrosis， Pulmonary toxicity (Up to 17% ) 禁忌: Cardiogenic shock. Hypersensitivity to amiodarone or to any of its components， including iodine. Sick sinus syndrome， second- or third-degree atrioventricular block， bradycardia leading to syncope without a functioning pacemaker. Severe sinus bradycardia or second or third degree atrioventricular block， if no pacemaker is present. Pregnancy， lactation.,,攝氏25度C以下,initial 200mg tid for 8-10 days maintenance dose: 100-400 mg 5 days a week.,無需調整劑量,[仿單]Amiodarone及其代謝產物與碘分子，皆會以高於在母體的血漿濃度存在於乳汁中. 由於其對新生兒有產生甲狀腺低下的危險，所以使用本品的母親禁止以母乳哺育嬰兒.,無需調整劑量,,Human (and animal) data suggest risk,[仿單節錄]動物實驗未顯示有任何致畸性...... 由於胎兒的甲狀腺在懷孕後第14週才開始和碘結合，因此在此之前服用本藥並不預期對胎兒的甲狀腺有任何作用. 然而，在懷孕超過這期間服用Amiodarone，會使體內碘過多，造成胎兒在生物或臨床上(甲狀腺腫)上的甲狀腺功能低下. 所以，自懷孕第2期(第4-6個月)開始，禁止使用Amiodarone.,Contraindicated 哺乳期使用禁忌,[仿單]Amiodarone及其代謝產物與碘分子，皆會以高於在母體的血漿濃度存在於乳汁中. 由於其對新生兒有產生甲狀腺低下的危險，所以使用本品的母親禁止以母乳哺育嬰兒.,,,,,,
EENO,Enoxolone,Enoxolone Gingival Paste 1%， 80gm,TENT,To relieve pain due to disease of the gums and wounds prosthesis.,Hypersensitivity to any component of the formulation.,Hypersensivity.,25℃以下,Brushing followed by a massage gums after meal for a few minutes， then rinse.,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,TOPI;,,,,,
IHIB0,Haemophilus b Conjugate Vaccine,Act-HIB 0.5mL(嗜血桿菌疫苗， 政府提供),HIMM,,適應症:Active immunization for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib) 副作用: >10%: Central nervous system: Irritability (infants: 67% to 76%; children: 13% to 27%)， drowsiness (infants: 49% to 66%; adults: 60%; children: 13% to 36%) Gastrointestinal: Anorexia (infants: 28% to 33%; children: 6% to 13%)， diarrhea (booster dose in children: 15%) Local: Pain at injection site (infants: 43% to 57%; children: 21%)， erythema at injection site (infants: 19% to 32%; children: <1%)， swelling at injection site (infants: 13% to 22%; children: <=4%)， tenderness at injection site (<=20%) Miscellaneous: Fever (1% to 35%) 1% to 10%: Gastrointestinal: Vomiting (children: <=5%) Local: Induration (children: <=6%) Frequency not defined: Central nervous system: Guillain-Barre syndrome， seizure Dermatologic: Skin rash， urticaria Hematologic & oncologic: Thrombocytopenia Local: Injection site: soreness Otic: Otitis media Respiratory: Tracheitis， upper respiratory tract infection 禁忌:Hypersensitivity to Haemophilus b polysaccharide， tetanus toxoid-containing vaccine (Hiberix and ActHIB only)， or any component of the formulation,,2-8℃,Infants 6 weeks to 6 months: Minimum age for first dose is 6 weeks. -Before 6 months of age: IM: 3 successive 0.5 mL doses at one or two month intervals followed by a booster injection (0.5mL) at 18 months of age. -Between 6 and 12 months， two 0.5mL doses at a one month interval followed by a booster injection (0.5mL) at 18 months of age. -From 1 to 5 years:IM: 0.5 mL as a single dose,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,疫苗凍晶粉與專用稀釋液混合後使用。
OFRIN,Iron(III) + Cyanocobalamin + Folic acid,Ferrin 150/0.025/1mg,NUTR,,適應症:Treatment of iron deficiency anemia， vit B12 & folic acid deficiency. 副作用:GI irritation， constipation， nausea. 禁忌:Known hypersensitivity to polysaccharide-iron complex or any component of the formulations; hemochromatosis; hemosiderosis.,,室溫,1 tab once daily.,無需調整劑量,,無需調整劑量,沒有資料,,,Contraindicated 哺乳期使用禁忌,,,,,,,
IFIR8,Degarelix,Firmagon inj 80mg/4mL,RACA,Advanced hormone-dependent prostate cancer in adult male patients.,Known hypersensitivity to degarelix or any component of the formulation; pregnant.,Hot flush， inj site reactions. Anemia; increased wt; insomnia; dizziness， headache， diarrhea， nausea; increased liver transaminases; hyperhidrosis (including night sweats)， rash， musculoskeletal pain & discomfort; gynecomastia， testicular atrophy， erectile dysfunction; chills， pyrexia， fatigue， flu-like illness.,30℃以下避免冷凍,Loading dose: 240 mg administered as two 120 mg (3 mL) injections; Maintenance dose: 80 mg administered as one 4 mL injection every 28 days (beginning 28 days after initial loading dose),無需調整劑量,It is not known if degarelix is excreted in breast milk. This product is not indicated for use in women.,無需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,It is not known if degarelix is excreted in breast milk. This product is not indicated for use in women.,SC;,,,X,X,• THE VIALS SHOULD NOT BE SHAKEN 1. Remove the cover from the vial adapter pack 2. Prepare the pre-filled syringe by attaching the plunger rod.
IHEX,DTaP-IPV-HIB-HBV,Hexaxim (六合一，政府提供) 0.5mL/dose,HIMM,,適應症:Primary and booster vaccination of infants and toddlers (6 weeks to 24 months) against diphtheria， tetanus， pertussis， hepatitis B， poliomyelitis and invasive diseases caused by Haemophilus influenzae type B (Hib). 副作用:Anorexia (decreased appetite)， crying， somnolence， abnormal crying (prolonged crying)， vomiting， diarrhea， injection-site pain， erythema and swelling， irritability， pyrexia (body temperature >38°C). 禁忌:Hypersensitivity to diphtheria， tetanus， acellular pertussis， hepatitis B (rDNA)， inactivated poliomyelitis and adsorbed Hib conjugate vaccine or to any of the excipients of Hexaxim， to trace residuals (glutaraldehyde， formaldehyde， neomycin， streptomycin and polymyxin B)， to any pertussis vaccine or after previous administration of Hexaxim or a vaccine containing the same components or constituents.,,2-8℃,Primary Vaccination: 3 doses of 0.5 mL to be administered at intervals of at least 4 weeks and as per schedules 6， 10， 14 weeks; 2， 3， 4 months; 3， 4， 5 months; 2， 4， 6 months. Booster vaccination 2nd yr of life at least 6 mth after last priming dose.,無需調整劑量,,無需調整劑量,沒有資料,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,
OVIM,Lacosamide,Vimpat 100mg,CNEU,1. Monotherapy for localized seizures with or without secondary generalized seizures in patients aged four and above who have experienced either their first or multiple seizures. 2. Adjunctive therapy for the following conditions: (1) Patients aged four and above with complex partial seizures and simple or complex partial seizures with secondary generalization， with or without other seizure types. (2) Patients aged four and above with primary generalized tonic-clonic seizures (PGTCS) and idiopathic generalized epilepsy.,Allergic to the main ingredients or any excipients. second-or third-degree AV block.,Common: Nausea (Up to 24%)， Dizziness (Oral， 16-30% ; IV， 20-60%)， Headache (11-16%)， Diplopia (9-11%) Serious: Atrial fibrillation and flutter， First degree atrioventricular block， Asymptomatic (0.4%)， Prolonged PR interval， Drug reaction with eosinophilia and systemic symptoms， Suicidal behavior， Suicidal thoughts,25℃以下,Children and adolescents bodyweight >=50 kg and adults: Monotherapy and Adjunctive Therapy: Initial Dosage: 50 mg twice daily. One week later， the initial therapeutic dose was increased to 100 mg twice a day. According to response and tolerability， the maintenance dose can be increased by 50 mg twice a day (100 mg/day) per week， to the maximum recommended daily dose: 200 mg twice a day. Start treatment with a fast-acting dose of Lacosamide:200 mg as a single dose. After 12 hours，100 mg twice a day (200 mg/day) as a maintenance dose. Discontinue the drug: recommended to gradually reduce the dose (for example， reduce the daily dose by 200 mg/week). For patients with severe cardiac arrhythmia， clinical benefit/risk assessment should be performed， and Lacosamide should be discontinued if necessary. Switch from a single antiepileptic drug (AED) to Lacosamide monotherapy: The anti-epileptic drugs should not be discontinued until the therapeutic dose of Lacosamide is reached for at least 3 days. It is recommended to gradually stop using anti-epileptic drugs for at least 6 weeks.,需調整劑量,[仿單]Lacosamide 會分泌至人類母乳中， 因此應考慮藥物對母親的重要性，來決定是否停止哺乳或停止使用Lacosamide 。,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,[仿單]對於所有的抗癲癇藥物，用於治療懷孕婦女後， 顯示其新生兒發生畸型的盛行率是一般族群盛行率(約為3%)的 2 到 3 倍。 使用抗癲癇藥物治療的懷孕婦女中，發現其中接受多重癲癇藥物治療後，將增加其新生兒畸型的比例。 但是目前尚未釐清藥物治療和/或疾病對於致畸程度之影響何者為甚。 此外，有效的抗癲癇治療不可中斷，因為疾病的惡化將不利於母親及胎兒。 使用 Lacosamide 之相關風險: 沒有孕婦使用 Lacosamide 的足夠數據。 在動物研究中，大鼠或兔子未顯示任何致畸胎作用 ，但在觀察到母體毒性劑量下，對於大鼠和兔子具胚胎毒性。 對人類潛在的風險未知。Lacosamide 不應該在懷孕期間使用，除非明確需要（如對母親的益處明顯大於對胎兒潛在的風險）。 如果婦女決定懷孕，使用本產品應仔細重新評估。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Lacosamide 會分泌至人類母乳中， 因此應考慮藥物對母親的重要性，來決定是否停止哺乳或停止使用Lacosamide 。,AC;AC15;PC;PO;WM;,,,,,
OCLOPD,Clopidogrel,Clopidogrel 75mg,HEMT,Prevention of atherothrombotic events in patients suffering from MI， ischemic stroke or established peripheral arterial disease; in patients suffering from non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) in combination with aspirin. ST segment elevation acute MI in combination with aspirin in patients eligible for thrombolytic therapy.,Severe liver impairment. Peptic ulcer & intracranial haemorrhage. Lactation.,GI bleeding， purpura， bruising， haematoma， epistaxis， haematuria， ocular haemorrhage， intracranial bleeding， abdominal pain， dyspepsia， gastritis & diarrhoea， rash， pruritus. Cardiovascular: Chest pain， Hypertension (4.3% ) Dermatologic: Pruritus (3.3% )， Purpuric disorder (5.3% )， Rash (4.2% ) Endocrine metabolic: Hypercholesterolemia Gastrointestinal: Abdominal pain， Constipation， Diarrhea， Gastritis， Indigestion Hematologic: Epistaxis (2.9% )， Purpura (5.3% ) Musculoskeletal: Arthralgia (6.3% )， Backache (5.8% ) Neurologic: Headache (7.6% ),25℃以下,Adult & elderly recommend 75 mg once daily. Patients with non-ST segment elevation acute coronary syndrome: Initially giving 300 mg as loading dose， continued with 75 mg once daily (combined with 75-325 mg aspirin daily). Dose of aspirin should be less than 100 mg. ST segment elevation acute MI: 75 mg daily， combined with aspirin.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – probably compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
ICARN,L-carnitine,L-Carnit inj 1gm/5mL,NUTR,Carnitine deficiency in patients with end-stage renal disease requiring hemodialysis (injection only)， primary systemic carnitine deficiency and secondary carnitine deficiency.,Hypersensitivity to levocarnitine or any component of the formulation.,>10%: Cardiovascular: Hypertension (intravenous: 18% to 21%)， chest pain (intravenous: 15%) Central nervous system: Headache (intravenous: 37%)， dizziness (intravenous: 15% to 18%)， paresthesia (intravenous: 12%) Endocrine & metabolic: Hypercalcemia (intravenous: 6% to 15%) Gastrointestinal: Diarrhea (intravenous: 35%)， abdominal pain (intravenous: 21%)， vomiting (intravenous: 21%)， nausea (intravenous: 12%) Hematologic & oncologic: Anemia (intravenous: 5% to 12%) Infection: Infection (intravenous: 24%) Neuromuscular & skeletal: Weakness (intravenous: 9% to 12%) Respiratory: Cough (intravenous: 18%)， rhinitis (intravenous: 11%) Miscellaneous: Accidental injury (intravenous: 12%)， fever (intravenous: 6% to 12%),30℃以下避光,Carnitine deficiency causes Hemodialysis: 2g IV over 2 to 3 min after dialysis. [Micromedex 20210731] Carnitine deficiency， Secondary - Inborn error of metabolism • initial， 50 mg/kg IV bolus (over 2 to 3 min) or infusion; repeat 50 mg/kg IV daily if clinically indicated; Maximum dose 300 mg/kg. • severe metabolic crisis， initial， 50 mg/kg IV over 2 to 3 min bolus injection or infusion， repeat 50 mg/kg IV in divided dose over 24 hr (every 3 to 4 hr and not less than every 6 hr); repeat 50 mg/kg IV daily if clinically indicated; Maximum dose 300 mg/kg. Carnitine deficiency; Treatment and Prophylaxis - End-stage renal disease - Hemodialysis • initial， 10 to 20 mg/kg (dry weight) over 2 to 3 min bolus injection after dialysis; subsequent dose titration determined by trough (predialysis) levocarnitine concentrations.,無需調整劑量,,無需調整劑量,沒有資料,Compatible,,Unknown 沒有資料,,IVD;IVP;IVPUSH;,,【L/R】可選 仿單建議。【N/S】可選 仿單建議。,Administer as a bolus dose over 2 to 3 minutes or by infusion.,Intermittent infusion over 15 to 30 minutes. Drug concentrations ranging 0.5-8 mg/mL.,Compatible when mixed with Normal Saline or Lactated Ringer's in concentrations ranging from 0.5 mg/mL to 8 mg/mL
OURI8,Silodosin,Urief F.C. 8mg,SGU,Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).,Severe hepatic impairment; severe renal insufficiency.,Drowsiness， postural hypotension， syncope， asthenia， depression， headache， dry mouth， GI disturbances， edema， blurred vision， rhinitis， erectile disorders， tachycardia， palpitation， hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy.,請保存於密閉容器、避光、25°C以下,4 mg BID， after breakfast and evening meal. Or 8mg QD after meal.,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PC;PO;,,,,,
ILEV,Norepinephrine,Levophed inj 4mg/4mL,CAVS,,適應症: Restoration of BP in acute hypotensive states. Adjunct in the treatment of cardiac arrest & profound hypotension. 副作用: Occasionally， bradycardia; anxiety， transient headache. Plasma vol depletion (prolonged administration). Respiratory difficulty， ischemic injury. 禁忌: Patients who are hypotensive from blood vol deficits except as emergency measure until blood vol therapy can be completed. Cyclopropane & halothane anesth， mesenteric or peripheral vascular thrombosis.,,室溫,IV infusion， Adult: 8-12 mcg/min initially， adjusting rate to maintenance a systolic blood pressure = 80-100 mmHg， average maintenance dose: 2-4 mcg/min. Child: 2 mcg/m2/min (max. 6 mcg/m2/min).,無需調整劑量,,無需調整劑量,除非治療上需要,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IVD;,,【D5NS】可選 仿單建議。【D5W】可選 仿單建議。,不可IVP使用。,仿單建議：1 vial (4mg/4 mL) diluted to 1000 mL of 5% dextrose solution (concentration: 4 mcg/mL)，滴注速率為 2-4 mcg/min。,1.不可用生理食鹽水稀釋。 2.本藥品應注射於大靜脈，並隨時檢查注射部位血管是否通暢，避免藥品外滲到附近組織。因藥物的強力血管收縮作用可能造成局部組織壞死。
OFOR,Dapagliflozin,Forxiga 10mg,META,Chronic kidney disease， (At risk of progression) to reduce the risk of sustained estimated GFR decline， end-stage kidney disease， cardiovascular death， and hospitalization for heart failureView additional information. Disorder of cardiovascular system; Prophylaxis - Type 2 diabetes mellitusView additional information. Heart failure， (NYHA class II to IV， reduced ejection fraction) to reduce risk of cardiovascular death and hospitalizationView additional information. Type 2 diabetes mellitus.,Dialysis. Serious hypersensitivity reaction (eg， anaphylactic reaction or angioedema) to dapagliflozin.,Common Renal: Urinary tract infectious disease (4.3% to 5.7% ) Reproductive: Female genital infection (6.9% to 8.4% ) Respiratory: Nasopharyngitis (6.3% to 6.6% ) Serious Cardiovascular: Hypotension Endocrine metabolic: Diabetic ketoacidosis (0.3% )， Hypoglycemia Immunologic: Hypersensitivity reaction (Severe) (0.3% ) Renal: Acute injury of kidney， Pyelonephritis， Sepsis due to urinary tract infection Reproductive: Fournier's gangrene， Genital infection (4.8% to 5.7% ),30℃以下,Type 2 diabetes initial 5 mg once daily， max 10 mg/day.Heart failure 10 mg once daily.,無需調整劑量,Micromedex: 懷孕: C 哺乳:Micromedex: Infant risk cannot be ruled out.,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Micromedex: 懷孕: C 哺乳:Micromedex: Infant risk cannot be ruled out.,AC;AC15;PC;PO;WM;,,,,,
OMEV4,Pravastatin,Mevalotin 40mg,CAVS,Hyperlipidemia Dysbetalipoproteinemia: Treatment of primary dysbetalipoproteinemia (Fredrickson type III) in patients who do not respond adequately to diet. Heterozygous familial hypercholesterolemia: Adjunct to diet in children >= 8 years and adolescents with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: LDL-C >= 190 mg/dL or LDL >=160 mg/dL with positive family history of premature cardiovascular disease (CVD)， or with 2 or more other CVD risk factors. Hypercholesterolemia and mixed dyslipidemia: Adjunct to diet to reduce elevated total cholesterol， LDL-C， apo B， and triglyceride (TG) levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).,Hypersensitivity to pravastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding,1% to 10%: Cardiovascular: Chest pain (4%) Central nervous system: Headache (2% to 6%)， fatigue (4%)， dizziness (1% to 3%) Dermatologic: Skin rash (4%) Gastrointestinal: Nausea (<7%)， vomiting (<7%)， diarrhea (6%)， heartburn (3%) Genitourinary: Cystitis (interstitial; Huang 2015) Hepatic: Increased serum transaminases (>3x normal on 2 occasions: 1%) Infection: Influenza (2%) Neuromuscular & skeletal: Myalgia (2%) Respiratory: Cough (3%) <1%， postmarketing， and/or case reports: Alopecia， amnesia (reversible)， anaphylaxis， angioedema， cataract， change in libido， cholestatic jaundice， cognitive dysfunction (reversible)， confusion (reversible)， cranial nerve dysfunction， decreased appetite， dermatitis， dermatomyositis， dysgeusia， edema， erythema multiforme， fever， flushing， fulminant hepatic necrosis， gynecomastia， hemolytic anemia， hepatic cirrhosis， hepatic neoplasm， hepatitis， hypersensitivity reaction， increased erythrocyte sedimentation rate， insomnia， lupus-like syndrome， memory impairment (reversible)， myasthenia， myopathy， neuropathy， pancreatitis， paresthesia， peripheral nerve palsy， polymyalgia rheumatica， positive ANA titer， pruritus， purpura， rhabdomyolysis， sexual disorder， Stevens-Johnson syndrome， tremor， urticaria， vasculitis， vertigo， xeroderma,25℃以下,Adut: 10-40 mg orally once daily in the evening with or without food.,無需調整劑量,,需調整劑量,不可使用,Contraindicated – 1st trimester,,Contraindicated 哺乳期使用禁忌,,AC;AC15;PC;PO;WM;,,,,,
IZOX,zoster virus vaccine live,Zostavax 0.65mL/dose,HIMM,Prevention of herpes zoster & herpes zoster-related post-herpetic neuralgia. Reduction of acute & chronic zoster-associated pain. Immunization of adults ≧50 yr.,Hypersensitivity. History of anaphylactoid reaction to neomycin. Acute & chronic leukemias; lymphoma; other conditions affecting bone marrow or lymphatic system; immunosuppression due to HIV/AIDS; cellular immune deficiencies. Active untreated TB. Pregnancy.,Erythema， pain， swelling， pruritus; headache， hematoma， warmth， induration， pain in extremity.,2-8℃避光,SC， 0.65 mL， 50-79 years a single dose.,無需調整劑量,[仿單]目前尚不確知是否會分泌至乳汁，由於已知有些病毒會進入人類乳汁， 因此哺乳婦女接種時應謹慎。,無需調整劑量,不可使用,Uknown 沒有資料,[UpToDate2021/0125]ZVL should not be administered to pregnant women; however， this scenario is unlikely since it is not indicated for women of childbearing age. [仿單]目前未知懷孕婦女接種是否會對胎兒造成傷害或影響生殖能力，已知自然發生的水痘帶狀皰疹病 毒感染有時會造成胎兒影響，因此不可用於孕婦，且應避免於接種後三個月內懷孕。,Unknown 沒有資料,[仿單]目前尚不確知是否會分泌至乳汁，由於已知有些病毒會進入人類乳汁， 因此哺乳婦女接種時應謹慎。,SC;,使用廠商所附稀釋溶液,,不可,不可,
IHBV2,Hepatitis B Vaccine,H-B-VAX II 1mL/dose(自費B肝疫苗 MSD),HIMM,,適應症:Active immunisation against hepatitis B virus infection 副作用:Redness， pain， swelling at inj site. Rarely， fatigue， fever， malaise， influenza-like symptoms， dizziness， headache， paresthesia， nausea， vomiting， diarrhea， abdominal pain， abnormal liver function tests， arthralgia， myalgia， rash， pruritus， urticaria. 禁忌:Hypersensitivity.,,2-8℃,By IM inj . Pediatric/Adolescent <16 years: 5 mcg/0.5mL/Dose， primary immunisation 3 doses at 0， 1 & 6 months Adult and >16 years: 10 mcg/1mL/dose， primary immunisation 3 doses at 0， 1 & 6 months,無需調整劑量,,無需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IM;,,,,,
OKAS5,Dimethicone,KASCOAL 50mg,ALIM,,適應症: Relief of pressure， bloating， fullness， and discomfort of gastrointestinal gas. 副作用:Loose stools 禁忌:Hypersensitivity to simethicone or any component of the formulation,,,Adult Gas retention: Oral: Usual dose: 40 to 125 mg 4 times daily as needed after meals and at bedtime; may administer single doses of up to 160 to 500 mg after meals or at bedtime， not to exceed a maximum daily dose of 500 mg/day. Infants and Children <2 years or <11 kg: 20 mg 4 times daily after meals and at bedtime， as needed (maximum: 240 mg/day) Children >2 years or >11 kg: 40 mg 4 times daily after meals and at bedtime， as needed (maximum: 480 mg/day),無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;P;P1;P2;P3;P4;PC;PO;,,,,,
ISIMD,Levosimendan,Simdax inj 12.5mg/5mL,CAVS,Short-term treatment of acutely decompensated severe chronic heart failure (ADHF) wherein conventional therapy is not sufficient & in cases where inotropic support is appropriate.,Hypersensitivity. Severe hypotension & tachycardia. Significant mechanical obstructions affecting ventricular filling or outflow or both. Severe renal impairment (CrCl <30 mL/min) & severe hepatic impairment. History of Torsades de Pointes， hypotension(SBP<100 mmHg或DBP<60 mmHg).,Headache; ventricular tachycardia; hypotension. Hypokalaemia; insomnia; dizziness; atrial fibrillation， tachycardia， ventricular extrasystoles， cardiac failure， myocardial ischaemia， extrasystoles; nausea， constipation， diarrhoea， vomiting; decreased Hb.,2-8°C避免冷凍,For the short-term treatment of patients with acute decompensated heart failure when conventional therapies are insufficient and inotropic support is appropriate Adults: IV: Initial: 6 to 12 mcg/kg infused over 10 minutes. Maintenance: 0.05 to 0.1 mcg/kg/minute by continuous infusion for 24hr only.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,IVD;,,【D5W】可選 仿單建議。,X,Dilute to 0.025 - 0.05 mg/mL before administration. Initial bolus dose: 6-12 mcg/kg over 10 minutes. Continuous infusion dose: 0.05-0.2 mcg/kg/min.,Lower loading dose of 6 mcg/kg is recommended in patients on concomitant IV vasodilators or inotropes or both at start of infusion. Rate of infusion may be decreased to 0.05 mcg/kg/min or discontinued if response is deemed excessive; may be increased to 0.2 mcg/kg/min if initial dose is tolerated. Duration of infusion: 24 hr. 稀釋後的藥品，其化學及物理安定性於25°C下可維持24小時。 對於急性失代償性嚴重慢性心衰竭病人的建議輸注時間為24小時。
IHEXA,DTaP-IPV-HIB-HBV,Hexaxim inj (六合一) 0.5mL/dose,HIMM,Diphtheria， tetanus toxoids， acellular pertussis， inactivated poliovirus， Haemophilus influenzae type B， hepatitis B conjugate vaccine over 6 weeks old.,History of an anaphylactic reaction after a previous administration of Hexaxim. Hypersensitivity to the active substances， to any of the excipients to trace residual (glutaraldehyde， formaldehyde， neomycin， streptomycin and polymyxin B)， to any pertussis vaccine， or after previous administration of Hexaxim or a vaccine containing the same components or constituents. Vaccination with Hexaxim is contraindicated if the individual has experienced an encephalopathy of unknown aetiology， occurring within 7 days following prior vaccination with a pertussis containing vaccine (whole cell or acellular pertussis vaccines). In these circumstances pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria， tetanus， hepatitis B， poliomyelitis and Hib vaccines. Pertussis vaccine should not be administered to individuals with uncontrolled neurologic disorder or uncontrolled epilepsy until treatment for the condition has been established， the condition has stabilized and the benefit clearly outweighs the risk.,Hypersensitivity reaction， Anaphylactic reaction， Anorexia (decreased appetite)， Crying， somnolence， Abnormal crying (prolonged crying)， Convulsions with or without fever， Hypotonic reactions or hypotonichyporesponsive episodes (HHE)， Vomiting， Diarrhoea， Rash， Injection-site pain， injection-site erythema， injection-site swelling Irritability Pyrexia (body temperature ? 38.0°C)， Injection-site induration， Injection-site nodule Pyrexia (body temperature ? 39.6°C)， Extensive limb swelling.,2-8℃避光避免冷凍,Primary Vaccination: 3 doses of 0.5 mL to be administered at intervals of at least 4 weeks and as per schedules 6， 10， 14 weeks; 2， 3， 4 months; 3， 4， 5 months; 2， 4， 6 months. Booster vaccination second year of life at least 6 months after last priming dose.,無需調整劑量,[訪單]無資料。,無需調整劑量,,Uknown 沒有資料,[訪單]無資料。,Unknown 沒有資料,[訪單]無資料。,IM;,,,,,
LDUP5,Lactulose,500mL DUPHALAC(667mg/mL) oral solution,ALIM,Chronic portal systemic encephalopathy， hepatic pre coma， hepatic coma， Chronic constipation.,Galactosemia， Gastrointestinal perforation， Risk of gastrointestinal perforation.,Common Gastrointestinal: Bloating symptom， Diarrhea， Epigastric pain， Flatulence， Nausea， Vomiting Musculoskeletal: Cramp Serious Endocrine metabolic: Hypernatremia， Hypokalemia,25℃以下,Chronic constipation: adult: Initial: 10-45 mL; Maintain dose: 10-25 mL. 7-14 years: Initial: 15 mL; Maintain dose: 10-15 mL. 1-6 years: Initial: 5-10 mL; Maintain dose: 5-10 mL. infant: Initial: 5 mL; Maintain dose: 5 mL. Orally once daily in the morning. It takes about 48 hours for a normal bowel movement if there is no response after taking the medicine for two days， should consider increasing the dose. Hepatic encephalopathy: adult: Initial dosage: 30-50 mL orally 3 times daily. Maintenance dosage: Adjust every day to achieve 2 to 3 soft formed stools daily. <6years old Children & infant: Initial: 5ml orally 4 times daily for10-12 days. The second and third course of treatment will adjust the dose according to individual conditions. [Micromedex 20210101] Rectal route: Treatment and Prophylaxis of Hepatic encephalopathy: Usual dosage: Mix lactulose 300 mL with 700 mL water or NS and administer rectally via rectal balloon catheter; retain for 30 to 60 minutes. Repeat dosages: Enema may be repeated every 4 to 6 hours for reversal of coma stage; if inadvertently evacuated too promptly， repeat immediately. Conversion to oral: When the oral route is viable， initiate oral administration before rectal administration is terminated.,無需調整劑量,[仿單]本品對母乳餵養的新生兒或嬰兒預期無任何影響， 因lactulose在授乳婦女之全身性暴露量極微. 因此，授乳期間可使用本品.,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]懷孕期間使用本品預期不會對胎兒造成影響，因lactulose再懷孕婦女之全身性暴露量極微. 因此，懷孕期間可使用本品.在現有的數據中無畸形或胎兒/新生兒毒性. 動物試驗中無顯示直接或間接對懷孕，胚胎/新生兒發展，分娩或產後發展有害.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]本品對母乳餵養的新生兒或嬰兒預期無任何影響， 因lactulose在授乳婦女之全身性暴露量極微. 因此，授乳期間可使用本品.,AC;PC;PO;RECT;WM;,,,,,
OPRM,Metoclopramide,Promeran 3.84mg,ALIM,Prophylaxis of nausea and vomiting， Gastroesophageal reflux disease， Gastroparesis due to diabetes mellitus.,History of tardive dyskinesia. Preexisting pheochromocytoma or other catecholamine-releasing paragangliomas; increased risk of hypertensive crisis. Sensitivity or intolerance to metoclopramide products.,Common Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )， Taste sense altered (Nasal route， 15% )， Vomiting (1.4% to 2.1% ) Neurologic: Asthenia， Headache (4.2% to 5.2% )， Somnolence (Oral， 2.1% to 2.8%) Serious Neurologic: Neuroleptic malignant syndrome， Tardive dyskinesia,25℃以下,Adult: 1-2 tablets TID before meals. The following does recommend is according to Micromedex (2022/12/06): Adult: Gastroesophageal reflux disease， After failure of conventional therapy: Continuous dosing， 10 to 15 mg orally 4 times daily given 30 minutes before meals and at bedtime for 4 to 12 weeks depending on endoscopic response; MAX dose， 60 mg/day; avoid use for longer than 12 weeks. Gastroparesis due to diabetes mellitus: Earliest symptoms of diabetic gastric stasis， 10 mg orally 4 times daily given 30 minutes before each meal and at bedtime for 2 to 8 weeks depending on symptomatic response; MAX dosage 40 mg/day; avoid use for longer than 12 weeks. Pediatric: Chemotherapy-Induced Nausea and Vomiting， Adjunct for Breakthrough: 0.1 to 0.2 mg/kg/dose orally every 6 hours; maximum 10 mg/dose. Gastroesophageal Reflux Disease: 0.1 to 0.15 mg/kg orally 4 times a day; maximum 10 mg/dose.,需調整劑量,[仿單]有關懷孕中及授乳期中給藥的安全性尚未確立，所以在孕婦或可能已懷孕的婦女及授乳期中婦女，限於判斷其治療上的有益性超越危險性時，才可給藥。,需調整劑量,可能安全,Compatible,[仿單]有關懷孕中及授乳期中給藥的安全性尚未確立，所以在孕婦或可能已懷孕的婦女及授乳期中婦女，限於判斷其治療上的有益性超越危險性時，才可給藥。,Compatible 哺乳時可使用,[仿單]有關懷孕中及授乳期中給藥的安全性尚未確立，所以在孕婦或可能已懷孕的婦女及授乳期中婦女，限於判斷其治療上的有益性超越危險性時，才可給藥。,AC;PO;,,,,,1. 遲發性運動障礙(Tarddive dyskinesia)發生的風險與總累積劑量有正相關性，分析後有20%病患使用超過12週，故不建議長期(>12週)使用，除非經過評估其治療效益高於Tarddive dyskinesia之風險。 2. 出現錐體外副作用症狀時請停止給藥。 3. 罕有內分泌異常(Gonadotropin及Prolactin分泌異常)的副作用，導致無月經、持續性乳汁分泌、男子女乳症，若有這些症狀請停止給藥。
IEPH4,Ephedrine,Ephedrine inj 40mg/1mL,CAVS,,適應症:Treatment of anesthesia-induced hypotension Note: The use of ephedrine for the treatment of acute bronchospasm， Stokes-Adams syndrome (ie， presyncope/syncope) with complete heart block， narcolepsy， or depression has fallen out of favor given the availability of more effective agents for these conditions. 副作用: Cardiovascular: Angina pectoris， cardiac arrhythmia， hypertension， palpitations， tachycardia Central nervous system: Anxiety， confusion， delirium， dizziness， hallucination， headache， insomnia， intracranial hemorrhage， nervousness， precordial pain， restlessness， tension， vertigo Dermatologic: Diaphoresis， pallor Gastrointestinal: Anorexia， nausea， vomiting Genitourinary: Dysuria， urinary retention (males with prostatism) Neuromuscular & skeletal: Tremor， vesicle sphincter spasm， weakness Respiratory: Dyspnea 禁忌:Hypersensitivity to ephedrine or any component of the formulation; angle-closure glaucoma; concurrent use of other sympathomimetic agents,,室溫,Bronchospasm， acute: 12.5 to 25 mg SUBQ/IM administered according to patient response Hypotension induced by anesthesia: IV: 5 to 25 mg/dose slow IV push repeated after 5 to 10 minutes as needed to maintain blood pressure,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,
ILEVET,Levetiracetam,Levetir inj 500mg/5mL,CNEU,,適應症:Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years with epilepsy. As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults & children > 4 years with epilepsy. Adjunctive therapy in the treatment of myoclonic seizures in adults & adolescents from 12 years with Juvenile Myoclonic Epilepsy. Adjunctive therapy for patients > 16 years with Primary Generalized Tonic， Clonic Seizure (PGTCS). 副作用: Most common: Somnolence， asthenia. Others: dizziness， convulsion， headache， hyperkinesia. ataxia， tremor， amnesia， agitation， aggression， anger， anxiety， confusion， depression， emotional instability， hallucination， hostility， insomnia， irritability， or nervousness， mental disorder， personality disorders， thinking abnormal， suicide， suicide attempt & suicidal ideation， GI disturbances， anorexia， vertigo， accidental injury， infection， cough increased， rash， alopecia， diplopia， decreased number of RBC， WBC &/or blood platelets. Gastrointestinal: Loss of appetite (partial onset seizures， adults， 3% ; pediatrics， 13% )， Vomiting (partial onset seizures， pediatrics， 15% ) Immunologic: Infectious disease (partial onset seizures， adults， 13% ) Neurologic: Asthenia (partial onset seizures， adults， 14.7% ; pediatrics， 8.9% )， Dizziness (5% to 9% )， Headache (partial onset seizures， adults， 14% )， Somnolence (8% to 45% ) Psychiatric: Abnormal behavior， Depression (3% to 5% )， Feeling nervous (partial onset seizures， adults， 4% ; pediatrics， 10% )， Hostile behavior (partial onset seizures， adults， 2% ; pediatrics， 12% )， Mood disorder， Mood swings (2% to 6% ) Respiratory: Cough (partial onset seizures， adults， 2% ; pediatrics， 11% )， Nasopharyngitis (7% to 14% )， Pharyngitis (6% to 10% )， Rhinitis (partial onset seizures， adults， 4% ; pediatrics， 13% ) Other: Fatigue (primary generalized tonic-clonic seizures， 10% )， Pain (partial onset seizures， adults， 7% ; pediatrics， 6% ) 禁忌: Patients with hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients of levetir.,,,Focal (partial) onset seizures and generalized onset seizures Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose based on response and tolerability to a maximum of 1，500 mg twice daily (3000 mg/day),無需調整劑量,1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) Levetiracetam is detected in breastmilk， with a mean milk/maternal plasma ratio of approximately 1; adverse effects in the nursing infants were not reported. Based on limited data， maternal use of levetiracetam appears to be safe for the nursing infant. However， the manufacturer cautions that due to the potential for adverse reactions in nursing infants， either nursing or the drug should be discontinued.,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) Levetiracetam is detected in breastmilk， with a mean milk/maternal plasma ratio of approximately 1; adverse effects in the nursing infants were not reported. Based on limited data， maternal use of levetiracetam appears to be safe for the nursing infant. However， the manufacturer cautions that due to the potential for adverse reactions in nursing infants， either nursing or the drug should be discontinued.,IVD;,,【D5W】可選 仿單建議。【N/S】可選 仿單建議。,,必需稀釋到至少100 mL的相容稀釋液後，建議以15分鐘緩慢滴注。,1. 僅供靜脈輸注使用，建議劑量必需稀釋到至少100 mL的相容稀釋液中，以15分鐘的靜脈輸注時間給藥。 2.本品稀釋後應立即使用，若在無菌環境下操作，與相容稀釋液在室溫保存在PVC袋中，化學穩定性可維持24小時。
IBEN,Belimumab,Benlysta inj 400mg,HIMM,Reducing disease activity in adult patients with active autoantibody positive SLE receiving standard therapy.,Hypersensitivity.,Infections. Hypersensitivity reaction; pyrexia， infusion-related reaction.,2-8℃避光避免冷凍,IVD， 10 mg/kg over 1 hour every 2 weeks for the first 3 doses and every 4 weeks thereafter.,無需調整劑量,,無需調整劑量,,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,IVD: 4.8mL D/W,【H/S】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,X,Benlysta should be infused in 250mL infusion solution over a 1 hour period.,1. The total time from reconstitution of Benlysta to completion of infusion should not exceed 8 hours. 2. Benlysta should not be infused concomitantly in the same IV line with other agents. 3.The 400-mg single-use vial of Benlysta should be reconstituted with 4.8 mL of sterile water for injections to yield a final concentration of belimumab 80 mg/mL. 4.Do not shake. 5.Protect the reconstituted solution from sunlight.
OTRO,Topiramate,Trokendi XR 50mg,CNEU,Migraine prophylaxis. Epilepsy monotherapy or adjuvant therapy.,Recent alcohol use within 6 hours prior to or 6 hours after topiramate use. Metabolic acidosis with concomitant metformin use.,Common Dermatologic: Flushing (Pediatric， 5% ) Endocrine metabolic: Serum bicarbonate level abnormal (25% to 67% ) Gastrointestinal: Loss of appetite (10% to 24% )， Weight decreased (4% to 21% ) Immunologic: Infectious disease (2% to 8% ) Neurologic: Confusion (3% to 11% )， Dizziness (4% to 25% )， Impaired cognition (2% to 7% )， Impaired psychomotor performance (2% to 13%)， Memory impairment (3% to 12% )， Paresthesia (1% to 51% )， Reduced concentration span (2% to 10% )， Somnolence (6% to 29% ) Psychiatric: Feeling nervous (4% to 16% )， Mood disorder (4% to 11% ) Other: Fatigue (6% to 16% )， Fever (1% to 12% ) Serious Dermatologic: Erythema multiforme， Stevens-Johnson syndrome， Toxic epidermal necrolysis Endocrine metabolic: Hyperammonemia (Adolescent， 26% )， Hypohidrosis， Increased body temperature， Metabolic acidosis (Adult， 14% to 44%; pediatric， 9% to 77% ) Hepatic: Liver failure Neurologic: Drug-induced encephalopathy Ophthalmic: Angle-closure glaucoma， Glaucoma， Myopia， Visual field defect (Epilepsy， 0.1% to 1% ) Psychiatric: Suicidal thoughts Renal: Nephrolithiasis (Adult， 1% to 3% ) Other: Withdrawal symptom,25℃以下，避免受潮及日光照射,Partial seizure or primary generalized tonic-clonic seizure， Initial monotherapy: 10 years older: First week， 50 mg orally once daily; second week， 100 mg once daily; third week， 150 mg once daily; fourth week， 200 mg once daily; fifth week， 300 mg once daily; sixth week and thereafter， 400 mg once daily. 6-10 years old: Initial， 25 to 50 mg orally once daily; may increase by 25 to 50 mg/day at 1-week intervals to usual maintenance dose of 200 to 400 mg/day. Minimum and maximum maintenance dose: 11kg or less: 150-250 mg/day; 12-22kg: 200-300 mg/day; 23-31kg: 200-350 mg/day; 32-38kg: 250-350 mg/day; up to 38kg: 250-400 mg/day. Partial seizure， primary generalized tonic-clonic seizure or Lennox-Gastaut syndrome， Adjunct: 6 to 16 years: Initial， 25 mg orally (1 to 3 mg/kg/day) once daily at nighttime for 1 week; increase by 1 to 3 mg/kg/day at 1- to 2-week intervals to achieve optimal response; maintenance， 5 to 9 mg/kg/day. 17 years or older: Initial， 25 to 50 mg orally once daily; may increase by 25 to 50 mg/day at 1-week intervals to usual maintenance dose of 200 to 400 mg/day. Migraine prophylaxis: 12 years or older: Initial， 25 mg orally once daily at nighttime for 1 week; titration， increase by 25 mg/day in weekly intervals to 100 mg/day， longer titration intervals may be used; dosage and titration rate should be based on clinical outcome.,無需調整劑量,[仿單]Topiramate 可分泌於人乳中【請參閱資料】。哺乳中嬰兒暴露於topiramate 中的影響仍不明。 哺乳對發育和健康的益處，應連同母親在臨床上對TROKENDI XR 的需求， 以及TROKENDI XR 或潛在母體狀況對哺乳中嬰兒可能產生的任何不良反應一併考量。 關於在泌乳期間接受 topiramate 治療的5 名癲癇女性患者的有限資料顯示， 藥物在乳汁中的濃度係與在母體血漿中的濃度相近。,需調整劑量,沒有資料,Human (and animal) data suggest risk,[仿單] 對具有生育能力的女性開立 topiramate 時，尤其是考慮以 topiramate 治療通常不會造成永久性傷害或死亡的狀況時，請考慮此藥的效益及風險。 由於可能使胎兒發生口裂（發生於許多女性仍不知自身懷孕的第一孕期），因此應告知所有具有生育能力的女性接受 topiramate 暴露可能使胎兒承受的危險。 正計畫懷孕的女性應獲得相關諮詢，以了解懷孕期間使用 topiramate 的相對風險及效益，且應考慮讓這類患者使用替代性治療選項。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Topiramate 可分泌於人乳中【請參閱資料】。哺乳中嬰兒暴露於topiramate 中的影響仍不明。 哺乳對發育和健康的益處，應連同母親在臨床上對TROKENDI XR 的需求， 以及TROKENDI XR 或潛在母體狀況對哺乳中嬰兒可能產生的任何不良反應一併考量。 關於在泌乳期間接受 topiramate 治療的5 名癲癇女性患者的有限資料顯示， 藥物在乳汁中的濃度係與在母體血漿中的濃度相近。,AC;PC;PO;,,,,,[磨粉/管灌註記]本藥為膠囊請整顆吞服，請勿灑於食物上、咀嚼或咬碎。本藥由三種不同釋放時間的控釋微粒組成，因此管灌者可以拆膠囊使用，但不建議拆膠囊後分次服藥。
IFLUCEL,Purified Split Inactivated Influenza Virus,Flucelvax quad (輔流威適流感疫苗) 0.5mL/dose,HIMM,Active immunisation against influenza.,History of severe allergic reactions (e.g.， anaphylaxis) to any component of the vaccine.,Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome.,2-8°C.請勿冷凍,IM， 0.5 mL， > or = 6 months (< 9 years who have not been vaccinated previously， the second dose can be given after 4 weeks.),無需調整劑量,[仿單]目前不清楚FLUCELVAX QUAD是否會分泌於母乳中。 尚無數據可評估FLUCELVAX QUAD對於哺乳嬰兒或對母乳產量／分泌影響。 應整體考量哺乳對於幼童發育和健康的益處、母親接種疫苗之臨床效益、FLUCELVAX QUAD或母親身體狀況對母乳哺餵孩童的任何潛在不良影響。 預防性疫苗可避免母親身體狀況或是母乳分泌受到流感的影響。,無需調整劑量,沒有資料,Compatible,[仿單]風險摘要 所有懷孕均具有出生缺陷、流產或其他不良結果之背景風險。目前關於孕婦接種FLUCELVAX QUAD的數據不足，尚無法確立於懷孕期間與接種疫苗的風險。 尚未針對FLUCELVAX QUAD進行動物發育毒性研究。有項FLUCELVAX（三價配方）的發育毒性研究，研究對象為雌性兔子，於交配前與懷孕期間施打，每次施打劑量為0.5毫升（人體單劑量為0.5毫升）。該研究顯示FLUCELVAX（三價配方）並未對胎兒有害（請參見8.1數據）。 臨床考量: 與疾病有關的母體及／或胚胎-胎兒風險 與非孕婦相比，孕婦因流感而罹患重症的風險較高。罹患流感的孕婦出現不良妊娠結果的風險較高，包括早產和分娩。 動物數據: 一項發育毒性研究顯示，雌性兔子在交配前1、3和5週及懷孕第7和20天透過肌肉注射施打FLUCELVAX（三價配方）。每次施打劑量為0.5毫升（人體單劑量為0.5毫升）。該項研究未觀察到與疫苗有關的胎兒畸形或變異，以及離乳前發育的不良反應。,Compatible 哺乳時可使用,[仿單]目前不清楚FLUCELVAX QUAD是否會分泌於母乳中。 尚無數據可評估FLUCELVAX QUAD對於哺乳嬰兒或對母乳產量／分泌影響。 應整體考量哺乳對於幼童發育和健康的益處、母親接種疫苗之臨床效益、FLUCELVAX QUAD或母親身體狀況對母乳哺餵孩童的任何潛在不良影響。 預防性疫苗可避免母親身體狀況或是母乳分泌受到流感的影響。,IM;,,,,,2°C至8°C.請勿冷凍. 應搖晃均勻後再施打. 四種流感病毒株各含有15微克血球凝集素：A/Washington/19/2020 (an A/Wisconsin/588/2019 (H1N1)pdm09-like virus)、 A/Tasmania/503/2020 (an A/Cambodia/e0826360/2020 (H3N2)-like virus)、 B/Darwin/7/2019 (a B/Washington/02/2019-like virus)、 B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)。
IPER4,FSH 450IU + LH 225IU,Pergoveris 450 IU + 225 IU,HM,Infertility in male & female.,Pregnancy & lactation; enlargement of the ovaries or cysts not due to polycystic ovarian syndrome; gynaecological bleeding of unknown origin; tumors in the uterus， ovaries & breasts.,Ovarian hyperstimulation， ascites， hydrothorax， oliguria， hypotension， thromboembolism， hypersensitivity reactions， fever， nausea & vomiting， inj site reactions， unintentional multiple pregnancies.,2-8℃避光避免冷凍,FSH 150 IU + LH 75 IU daily， adjusted dosage after start treatment 7-14 days， each treatment cycle can be extended up to 5 weeks depending on the clinical condition. 5000-10000 IU of hCG or 250 mcg of r-hCG should be given after 24-48 hours of the last dose of Pergoveris.,無需調整劑量,,無需調整劑量,不可使用,,,Contraindicated 哺乳期使用禁忌,,SC;,,,,,
OMEZA,Mesalazine,MezaVant XL 1200mg prolonged release,ALIM,Treatment of moderately active ulcerative colitis,U.S. labeling: Hypersensitivity to mesalamine， aminosalicylates， salicylates， or any component of the formulation (including suppository vehicle of vegetable fatty acid esters) Canadian labeling: Hypersensitivity to mesalamine， salicylates， or any component of the formulation; severe renal impairment (GFR <30 mL/minute/1.73 m2); severe hepatic impairment Additional contraindications per specific Canadian product labeling: Existing gastric or duodenal ulcer， urinary tract obstruction， use in children <2 years of age (Asacol， Asacol 800， Mesasal， Pentasa， Salofalk); hemorrhagic diathesis (Mesasal); patients unable to swallow intact tablet (Asacol， Asacol 800); renal parenchymal disease (Pentasa),>10%: Central nervous system: Headache (2% to 35%)， pain (?14%) Gastrointestinal: Abdominal pain (1% to 18%)， eructation (16%)， nausea (3% to 13%) Respiratory: Pharyngitis (11%),25℃以下,2.4 to 4.8g (2 to 4 tablets) QD,需調整劑量,,需調整劑量,可能安全,Compatible,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,WM;,,,,,[磨粉/管灌註記]本藥為長效腸溶膜衣錠，應整粒吞服，不可咬碎或咀嚼。無法吞服患者可考慮使用同成份Colasa enema 2gm/100mL。
LCLO,Chloral hydrate,Clodrin 100mg/mL， 30mL oral solution,CNEU,Sedation， mechanically-ventilated patients OR sedation， procedural (eg， echocardiogram or EEG).,Marked liver or kidney impairment， severe heart disease， Severe gastritis， esophagitis， gastric ulcer or duodenal ulcer， Purpura， Allergic to Chloral hydrate or any component of the formulation， Patients with life safety due to risk of respiratory obstruction or disabled Patients with severe obstructive sleep apnea,Central nervous system: Abnormal gait， ataxia， confusion， delirium， dizziness， drowsiness， hallucinations， hangover effect， malaise， nightmares， paradoxical excitation， somnambulism， vertigo Dermatologic: Skin rash (including erythema， eczematoid dermatitis， urticaria， scarlatiniform exanthems) Endocrine & metabolic: Acute porphyria， ketonuria Gastrointestinal: Diarrhea， flatulence， gastric irritation， nausea， vomiting Hematologic & oncologic: Acute porphyria， eosinophilia， leukopenia,密封儲存於25℃以下，不需冰存並避免陽光直射,The sedative drug used before the non-painful procedure for children must be carried out in a medical institution and properly monitored. The dosage of medication must be strictly controlled according to different ages and weights of children. Electroencephalogram (EEG): Infants (1 month to <1 year) and children: 25-50 mg/kg orally. The total maximum dose does not exceed 100mg/kg and infants do not exceed 1g， children do not exceed 2g. Sedation before painless examination or treatment (administered 30-60 minutes before process): Infants (1 month to <1 year): 30-50 mg/kg orally. The total maximum dose does not exceed 100 mg/kg and the infant does not exceed 1 g. Children: 50-60mg/kg orally， if necessary， an additional 10-20mg/kg can be given after 30 minutes. The total maximum dose does not exceed 100 mg/kg and the child dose does not exceed 2 g.,需調整劑量,仿單未有相關記載,需調整劑量,沒有資料,No (limited) human data – no relevant animal data,仿單未有相關記載,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,仿單未有相關記載,PO;,,,,,請密封儲存於 25℃以下，毋須冰存並避免陽光直射。 開封後之保存期限為 30 天，儲存溫度為 25℃，未使用完應丟棄。
OQUEP,Quetiapine,Quelip XR 200mg,CNEU,Schizophrenia. Schizophrenia， Maintenance. Bipolar disorder， depressed phase， Acute management， monotherapy. Bipolar I disorder， Acute management， in combination with lithium or divalproex. Bipolar I disorder， Acute management， monotherapy. Bipolar I disorder， Maintenance， in combination with lithium or divalproex. Major depressive disorder.,Hypersensitivity to quetiapine or any component of the product. Anaphylactic reactions have been reported.,Common Cardiovascular: Increased diastolic arterial pressure (Pediatric， 40.6% )， Increased systolic arterial pressure (Pediatric， 15.2% )， Orthostatic hypotension (Up to 7% )， Tachycardia (Up to 6% ) Endocrine metabolic: Serum cholesterol raised (7% to 18% )， Serum triglycerides raised (8% to 28% )， Weight gain (3% to 28% ) Gastrointestinal: Abdominal pain (3% to 7% )， Constipation (2% to 11% )， Increased appetite (2% to 12% )， Indigestion (2% to 7% )， Nausea (Pediatric， 6% to 10% )， Vomiting (Pediatric， 7% to 8% )， Xerostomia (Adult， 9% to 44%; pediatric， 4% to 10% ) Hepatic: Increased liver enzymes (1% to 6% ) Musculoskeletal: Backache (3% to 5% ) Neurologic: Asthenia (Up to 10% )， Dizziness (8% to 19% )， Extrapyramidal disease (1.1% to 12.9% )， Headache (17% to 21% )， Insomnia (8% to 12% )， Lethargy (1% to 5% )， Somnolence (18% to 57% )， Tremor (2% to 8% ) Psychiatric: Agitation (6% to 20% ) Respiratory: Nasal congestion (3% to 5% )， Pharyngitis (4% to 6% ) Other: Fatigue (3% to 14% )， Pain (7% ) Serious Cardiovascular: Prolonged QT interval (0.1% to less than 1% )， Sudden cardiac death， Syncope (0.3% to 2% ) Endocrine metabolic: Diabetic ketoacidosis Gastrointestinal: Bowel obstruction， Pancreatitis Hematologic: Agranulocytosis， Leukopenia， Neutropenia (0.3% to 1.5% ) Immunologic: Anaphylaxis Neurologic: Seizure (0.05% to 0.5% )， Tardive dyskinesia Psychiatric: Suicidal thoughts Reproductive: Priapism Other: Neuroleptic malignant syndrome,30℃以下,Schizophrenia (Acute): 300 mg orally in the evening on day 1 and titrate to usual maintenance dose between 400 to 800 mg once daily; dose increases may occur at intervals of at least 1 day in increments of up to 300 mg/day; Maximum dose 800 mg/day The safety of doses above 800 mg/day has not been evaluated in clinical trials. Bipolar disorder， depressed phase， Acute management， monotherapy: 50 mg orally once daily on day 1; 100 mg once daily on day 2; 200 mg once daily on day 3; and then 300 mg once daily on day 4， with doses given in the evening; usual and Maximum dose is 300 mg/day Bipolar I disorder， Acute management， in combination with lithium or divalproex: 300 mg orally in the evening on day 1; 600 mg in the evening on day 2; with further dosage adjustment to usual maintenance dose between 400 and 800 mg once daily beginning on day 3， depending on patient response and tolerance; Maximum dose 800 mg/day Major depressive disorder， Monotherapy: Initial， 50 mg orally once daily on days 1 and 2， 150 mg once daily on days 3 and 4， and 300 mg once daily thereafter， with discontinuation of previous antidepressant complete by day 7; may extend titration period to include 3 additional days， and reach 300 mg/day by day 8 and reduce to 150 to 200 mg/day for intolerance.,需調整劑量,[仿單]Quetiapine XR 會分泌到人類乳汁中。將 Quetiapine XR 投予授乳婦時應小心。 在出版的病例報告中，quetiapine 在乳汁中的濃度從可檢測程度到 170 μg/L。 估計的嬰兒劑量是經體重校正的母親劑量的0.09%至 0.43%。 根據有限的母親/嬰兒配對數(N=8)，算出嬰兒每日劑量從小於 0.01 mg/kg (母親劑量高達每天 400 mg)至 0.1 mg/kg (母親劑量高達每天 400 mg)。,無需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,[仿單]目前對於 Quetiapine XR 使用於孕婦，還沒有適當且控制良好的研究。 在有限的出版文獻中，沒有重大畸形與懷孕期間暴露於 quetiapine 有關。 在追蹤一些於孕期使用 qutiapine 的病人後，有出現新生兒戒斷症候群的案例。 在動物試驗發生過胚胎-胎兒毒性。 只有在治療效益大於潛在危險時方可在懷孕期間使用Quetiapine XR。 關於在懷孕期間使用 quetiapine 治療思覺失調症及其他精神疾病的出版資料有限。 在一項前瞻性觀察研究中，21 名在懷孕期間暴露於 quetiapine 及其他精神活性藥物的婦女生出的嬰兒沒有重大畸形。 在42 名由懷孕期間使用 quetiapine 的婦女所生出的嬰兒中，沒有重大畸形報告(一項研究有 36 名婦女，6 個病例報告)。 由於懷孕期間暴露於本藥的人數有限，這些上市後的資料並不能可靠的估計頻率或沒有不良結果。 當懷孕的大鼠與兔子在器官發生期暴露於quetiapine，在高達治療思覺失調症的人類最高建議劑量 2.4倍的劑量下(MRHD，依 mg/m2 計算，每天 800 mg)，胎兒重大畸形的發生率並未增加；然而確實有胚胎/胎兒毒性的證據。 胎兒骨骼骨化延遲發生在接受人類最高劑量的 0.6 至 2.4 倍劑量的大鼠，以及接受人類最高劑量的 1.2 至 2.4 倍劑量的兔子。 在人類最高劑量的 2.4 倍劑量下，兔子胎兒的腕/跗彎曲(輕微軟組織異常)發生率增加，這兩種動物均有胎兒體重減輕的現象。 母體毒性(即體重增加減少及/或死亡)發生在接受人類最高劑量的 2.4 倍劑量的大鼠，以及接受人類最高劑量的 0.6 至 2.4 倍劑量(所有的劑量)的兔子。 在一項大鼠周產期/產後生殖研究中，在接受人類最高劑量的 0.01、0.12 及 0.24 倍劑量治療的懷孕婦女並未觀察到與藥物有關的影響。然而，在一項初步周產期/產後生殖研究中，在人類最高劑量的 3.0倍的劑量下，有胎兒和仔鼠死亡增加，平均窩重減輕的現象。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Quetiapine XR 會分泌到人類乳汁中。將 Quetiapine XR 投予授乳婦時應小心。 在出版的病例報告中，quetiapine 在乳汁中的濃度從可檢測程度到 170 μg/L。 估計的嬰兒劑量是經體重校正的母親劑量的0.09%至 0.43%。 根據有限的母親/嬰兒配對數(N=8)，算出嬰兒每日劑量從小於 0.01 mg/kg (母親劑量高達每天 400 mg)至 0.1 mg/kg (母親劑量高達每天 400 mg)。,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]持續性藥效錠應整粒吞服， 勿咬嚼或壓碎。院內另有同成份一般劑型Seroquel 25mg。
ECLOO2,Clobetasol,Clobetasol ointment 0.05% 25gm,TDER,Psoriasis; recalcitrant eczema; lichen planus; discoid lupus erythematosus & other skin conditions which do not respond satisfactorily to less active steroids.,Hypersensitivity to clobetasol or any ingredient in the preparation. Primary scalp infection. Apply the smallest amount that will cover affected area. For topical use only; avoid contact with eyes and mucous membranes. Do not apply to face， scalp， axilla， groin， or intertriginous areas. Do not use if there is atrophy at the treatment site. Minimize contact to nonaffected areas of the body. Wash hands after use.,Common Dermatologic: Asteatotic eczema (2% )， Atrophic condition of skin (Up to 4.2% )， Burning sensation， Discomfort， Skin (1.3% )， Dry skin (1% to 2% )， Pruritus (0.5% to 3% ) Respiratory: Nasopharyngitis (5% )， Upper respiratory infection (8% ) Serious Endocrine metabolic: Hypothalamic-pituitary-adrenal axis dysfunction (Adult， 15% to 30.8% ; pediatric， 42% to 47% ) Neurologic: Intracranial hypertension， acute,25℃以下儲存,Apply sparingly to the affected area once daily or BID.,無需調整劑量,[仿單]無相關記載.,無需調整劑量,沒有資料,No (limited) human data – animal data suggest risk,[仿單]妊娠期不可廣泛使用本藥.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]無相關記載.,EXT;,,,,,
EFOSN,Beclomethasone + Formoterol,(乾粉) Foster Nexthaler 100/6mcg/dose,ERSP,Regular treatment of asthma for patients not adequately controlled w/ inhaled corticosteroids & as needed inhaled short-acting β2-agonist or on both inhaled corticosteroids & long-acting β2-agonists.,Hypersensitivity.,Tremor， pneumonia (in COPD patients) Common Cardiovascular: Chest pain (1.9% to 3.2% )， Palpitations Gastrointestinal: Diarrhea (4.9% )， Nausea (4.9% )， Xerostomia (1.3% to 3.3% ) Neurologic: Dizziness (0.9% to 2.4% )， Headache (Less than 5% ; oral inhalation， 8% to 25% )， Insomnia (1.5% to 2.4% )， Tremor (1.9% to 8.6% ) Serious Cardiovascular: Cardiac dysrhythmia Respiratory: Death， Asthma-related， Exacerbation of asthma (Severe) Endocrine metabolic: Hypocortisolism secondary to another disorder， Type 2 diabetes mellitus Immunologic: Hypersensitivity reaction， Immunosuppression Ophthalmic: Cataract， Glaucoma Respiratory: Bronchospasm,打開保護袋前30℃以下,Asthma: Adult >=18 year old， Maintenance therapy: 1 or 2 inhalations BID. the maximum daily dose: 4 inhalations; Maintenance and reliever therapy: Patients take their daily maintenance dose and in addition take Foster Nexthaler as needed in response to asthma symptoms. Patients should be advised to always have Foster Nexthaler available for rescue use. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes， an additional inhalation should be taken. The maximum daily dose is 8 inhalations. COPD: Adult >=18 year old: 2 inhalations BID.,無需調整劑量,BECLOMETHASONE BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible FORMOTEROL BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,,No (limited) human data – probably compatible,BECLOMETHASONE PREGNANCY RECOMMENDATION: Compatible FORMOTEROL PREGNANCY RECOMMENDATION: Limited Human Data—Probably Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,BECLOMETHASONE BREASTFEEDING RECOMMENDATION: Limited Human Data—Probably Compatible FORMOTEROL BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,IH;INHL;,,,,,
OCOX,Isosorbide 5-Mononitrate,Coxine 20mg,CAVS,Prophylaxis of angina pectoris.,Marked hypotension， hypertrophic obstructive cardiomyopathy， constrictive pericarditis， aortic & mitral stenosis， increased intracranial pressure， MI with low filling pressure. Avoid sildenafil， tadalafil， vardenafil.,Transient headache， nausea， dizziness， weakness， vomiting， tachycardia， decreased BP， possible formation of methemoglobin， rarely allergic skin reactions. Neurologic: Dizziness (8% to 11% )， Headache (38% to 57% ),避光防熱儲存,Initial dose: 5-10 mg (1/4-1/2 tablets) BID separate 7 hours apart for day 1 and day 2， then increase to 20 mg BID for 2 days. Maintain dose: 20 mg BID.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,PC;PO;,,,,,
OACH,Carisoprodol + Acetaminophen,Achelex 175/350mg,CNEU,Symptomatic relief of mild to moderate pain of acute musculoskeletal disorders e.g. stiff shoulder， sprains， strains， lumbago， arthralgia & myalgia.,Hypersensitivity to any components of the product.,Common Neurologic: Dermatologic: Pruritus (5% or greater ) Gastrointestinal: Constipation (5% or greater )， Nausea (adult， 34%; pediatric， 5% or greater )， Vomiting (adult， 15%; pediatric， 5% or greater ) Neurologic: Headache (1% to 10% )， Insomnia (1% to 7% )， Dizziness (7% to 8% )， Somnolence (13% to 17% ) Psychiatric: Agitation (5% or greater ) Respiratory: Atelectasis (5% or greater ) Serious Neurologic: Seizure Other: Drug abuse， Drug dependence， Withdrawal symptom Dermatologic: Generalized exanthematous pustulosis， acute， Stevens-Johnson syndrome， Toxic epidermal necrolysis Hepatic: Liver failure Respiratory: Pneumonitis,30℃以下避光,Adult : 1-2 tablets QID， after meals or before sleeping.,需調整劑量,Acetaminophen: Compatible Carisoprodol: Limited Human Data - Probably Compatible [仿單]未有相關說明,需調整劑量,沒有資料,No (limited) human data – no relevant animal data,Acetaminophen: Human Data Suggest Low Risk Carisoprodol: Limited Human Data - No Relevant Animal Data [仿單]未有相關說明,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Acetaminophen: Compatible Carisoprodol: Limited Human Data - Probably Compatible [仿單]未有相關說明,AC;AC15;PC;PO;WM;,,,,,
OMOC,Flupentixol + Melitracen,Mocalm 0.5/10mg (永康緒),CNEU,Treat mental depressive and anxious symptoms,Hypersensitivity to any components of the product,Restlessness， insomnia， Suicidal tendency.,25℃以下,Adults: 0.5/10mg(1 Tablet) in the morning and afternoon. The dose may be increased to 2 TABlets in the morning dose if need. Elderly: 0.5/10mg(1 Tablet) in the morning. Maintenance dosage: 0.5/10mg(1 Tablet) in the morning. If patients who have severe anxiety and insomnia could consider adding on sedatives.,無需調整劑量,[仿單]不可使用於孕婦與授乳婦,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]不可使用於孕婦與授乳婦,Unknown 沒有資料,[仿單]不可使用於孕婦與授乳婦,AC;AC15;PO;WM;,,,,,
OAKY,Netupitant + Palonosetron,Akynzeo 300/0.5mg,CNEU,Chemotherapy-induced nausea and vomiting， Acute and delayed; Prophylaxis.,Specific contraindications have not been determined.,Common Dermatologic: Erythema (3% ) Gastrointestinal: Constipation (3% )， Indigestion (4% ) Musculoskeletal: Asthenia (8% ) Neurologic: Headache (9% ) Other: Fatigue (4% to 7% ) Serious Other: Serotonin syndrome,容許範圍15-30℃，25℃為佳,Highly emetogenic chemotherapy (including cisplatin-based regimens): Administer netupitant 300 mg/palonosetron 0.5 mg (1 capsule) orally 1 hour prior to chemotherapy on day 1; coadminister dexamethasone 12 mg orally 30 minutes prior to chemotherapy on day 1， and 8 mg QD through day 2 to day 4. Anthracycline and cyclophosphamide-based regimens and other regimens not highly emetogenic: Administer netupitant 300 mg/palonosetron 0.5 mg (1 capsule) orally 1 hour prior to chemotherapy on day 1; coadminister dexamethasone 12 mg orally 30 minutes before chemotherapy on day 1.,需調整劑量,Netupitant: 沒有資料 Palonosetron: No Human Data - Probably Compatible [仿單]目前尚未知Akynzeo是否會進入人體乳汁中.由於許多藥物會進入人體乳汁中，且palonosteron 在大鼠致癌性研究中顯示有潛在致腫瘤性，故應考量藥物對於母親的的重要性來決定是否停止 哺乳或停藥.,需調整劑量,沒有資料,Uknown 沒有資料,Netupitant: 沒有資料 Palonosetron: No Human Data - Animal Data Suggest Low Risk [仿單]上未針對懷孕女性進行充分且對照良好的Akynzeo研究...略...給與母鼠最高至相當於3.7倍 人體建議劑量AUC的netupitant劑量時，幼鼠並未觀察到不良反應的發生.在palonosteron的動物生殖 研究中，於胎兒的器官生成階段分別給予大鼠及大白兔口服相當於達人體口服建議劑量921與 1841倍藥物時，未觀察到影響胚胎-胎兒的發育.Akynzeo應在潛在利益高於胎兒潛在風險時，方可 於懷孕期間使用.,Unknown 沒有資料,Netupitant: 沒有資料 Palonosetron: No Human Data - Probably Compatible [仿單]目前尚未知Akynzeo是否會進入人體乳汁中.由於許多藥物會進入人體乳汁中，且palonosteron 在大鼠致癌性研究中顯示有潛在致腫瘤性，故應考量藥物對於母親的的重要性來決定是否停止 哺乳或停藥.,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥膠囊中含有三片小藥錠及一粒小膠囊，若病患有需求可以拆開後依序吞服。但不建議再將小藥錠及小膠囊拆開或磨粉。
OKLA5X,Clarithromycin,Klaricid XL 500mg,QANB,As an antibacterial agents for Clarithromycin-sensitive bacterial infections. Treatment of Lower respiratory tract infections， for example acute and chronic bronchitis and pneumonia; Upper respiratory tract infections， for example sinusitis and pharyngitis.,Patients with known hypersensitivity to macrolide antibiotic drugs or any of the excipients. Prolonged Release Tablets are contraindicated in patients with creatinine clearance less than 30 mL/min. Concomitant administration of clarithromycin and any of the following drugs: cisapride， pimozide， astemizole， terfenadine， or domperidone， due to the risk of QT prolongation or ventricular cardiac arrhythmia， including torsades de pointe Concomitant administration of clarithromycin and any of the following drugs: ergot alkaloids， like ergotamine or dihydroergotamine， due to the risk of ergot toxicity. Concomitant administration of clarithromycin and midazolam. Patients with a history of QT prolongation or ventricular cardiac arrhythmia， including torsades de pointe. Patients with severe hepatic failure with renal impairment. Concomitant administration of clarithromycin with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CP3A4， (lovastatin or simvastatin)， due to the risk of myopathy， including rhabdomyolysis. Concomitant administration of clarithromycin (or other strong CYP3A4 inhibitors) and Colchicine. Concomitant administration of clarithromycin with ticagrelor or ranolazine.,Common Gastrointestinal: Abdominal pain (1% to 8% )， Diarrhea (2% to 9% )， Disorder of taste (8% to 19% )， Indigestion (4% )， Nausea (3% to 28% )， Vomiting (1% to 25% ) Neurologic: Headache (up to 9% ) Serious Cardiovascular: Death， Cardiovascular， out of hospital， Prolonged QT interval (less than 1% ) Dermatologic: Immunoglobulin A vasculitis， Stevens-Johnson syndrome， Toxic epidermal necrolysis Gastrointestinal: Clostridium difficile diarrhea Hepatic: Hepatitis (greater than or equal to 1% )， Liver failure Immunologic: Anaphylaxis， Drug reaction with eosinophilia and systemic symptoms Neurologic: Cerebrovascular disease,30℃以下，避光儲存。,Adults: The usual recommended dose: 500mg (1 prolonged release tablet) to be taken with food. In more severe infections: can be increased to 1000mg (2 prolonged release tablets) taken as one dose daily. The usual duration of treatment is 7 to 14 days. Children > or = 12 years old: as for adults. Children < 12 years old: Not suitable for children younger than 12 years. An alternative formulation of clarithromycin suitable for children should be used in this patient population， like suspension.,需調整劑量,[仿單] Clarithromycin用於授乳期間的安全性尚未建立。 Clarithromycin會分泌到人類母乳中。,需調整劑量,沒有資料,Compatible,[仿單] Clarithromycin用於懷孕期間的安全性尚未建立。 因此，若未仔細衡量利益與風險，本品不建議使用於懷孕婦女。,Compatible 哺乳時可使用,[仿單] Clarithromycin用於授乳期間的安全性尚未建立。 Clarithromycin會分泌到人類母乳中。,PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠，請整粒吞服，不可撥半或磨粉。 本藥建議隨餐使用。
OTAI,Nemonoxacin,Taigexyn 250mg,QANB,Treatment of infections， sensitive to nemonoxacin in adults.,Allergic to any component of this drug， or to other quinolones. Pregnant， breastfeeding women， or children.,Gastrointestinal Diseases: Nausea (2.5%)， Diarrhea (1.3%)， Vomiting (1.2%) Blood and Lymphatic System Diseases: Neutropenia (1.9%) Nervous system diseases: Dizziness (1.9%)， Headache (1.0%) Other: ALT (SGPT) increased (4.4%)， Reduction in white blood cell count (2.1%)， AST (SGOT) increased (1.9%)， AST (SGOT) increased ( 1.9%),儲存乾燥處，溫度不可超過25℃,Adults: 500mg (2 capsules) once a day on an empty stomach (take at least two hours before or at least two hours after eating) for 7-10 days.,無需調整劑量,[仿單]本藥品用於哺乳中婦女的安全性尚未確立，不能確保哺乳中婦女的用藥安全，所以哺乳中婦女禁用。 只有當對哺乳中婦女潛在益處大於潛在危險時才能將本藥品用於哺乳中婦女，但應暫停哺乳。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]本藥品用於懷孕女性的安全性尚未確立，不能確保懷孕女性的用藥安全，所以懷孕或有可能懷孕的女性禁用。,Unknown 沒有資料,[仿單]本藥品用於哺乳中婦女的安全性尚未確立，不能確保哺乳中婦女的用藥安全，所以哺乳中婦女禁用。 只有當對哺乳中婦女潛在益處大於潛在危險時才能將本藥品用於哺乳中婦女，但應暫停哺乳。,AC;PO;,,,,,[磨粉/管灌註記]仿單建議本藥以水整粒吞服。 1. 勿與鐵鹽、鈣片、制酸劑、含咖啡因及乳製品的食物併服 2. 重症肌無力患者不建議使用
ISONV,Sulphur hexafluoride microbubbles,SonoVue inj 60.7mg,SCAN,Echocardiography. Ultrasonography of liver， To characterize focal liver lesions.,Hypersensitivity to sulfur hexafluoride or any component of the formulation.,Common Gastrointestinal: Nausea (0.5% ) Neurologic: Headache (1% ) Serious Cardiovascular: Cardiac arrest， Chest pain (0.2% )， Shock， Syncope， Ventricular fibrillation， Ventricular tachycardia Immunologic: Anaphylaxis (0.01% )， Hypersensitivity reaction (0.01% ) Neurologic: Seizure Respiratory: Respiratory arrest,儲存於25℃,Cardiovascular imaging: 2 mL IV followed by a 5 mL 0.9%NaCl flush; may administer a second 2 mL IV dose followed by a 5 mL 0.9%NaCl flush during the same imaging session to prolong image enhancement. Hepatic ultrasonography: 2.4 mL IV during the procedure; may administer a second 2.4 mL dose during a single examination， if needed. Follow injection with an IV flush using 5 mL 0.9%NaCl for injection.,無需調整劑量,[仿單]未評估SonoVue於人體乳汁中的暴露程度、對哺乳應而的影響、或對乳汁分泌影響的數據。 應同時考慮哺乳對嬰兒發育及健康的益處、任何被哺乳的嬰兒可能因SonoVue或母親原發疾病而產生的副作用。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]目前沒有SonoVue使用於孕婦的資料來評估與藥品相關的風險。 動物生殖試驗顯示於懷孕大鼠和兔子的器官生成期間，依其體表面積，分別給予六氟化硫微泡至少10和20倍的人類最大建議使用劑量4.8mL，並沒有發現對牠們的發育產生不良影響。 在美國的一般族群，重大出生缺陷(major birth defect)及流產的背景風險(backgroung risk)估計分別為2~4%及15~20%。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]未評估SonoVue於人體乳汁中的暴露程度、對哺乳應而的影響、或對乳汁分泌影響的數據。 應同時考慮哺乳對嬰兒發育及健康的益處、任何被哺乳的嬰兒可能因SonoVue或母親原發疾病而產生的副作用。,IVD;IVPUSH;,隨貨附給的生理食鹽水注射液5mL,【N/S】可選 仿單建議。,,,1. 使用廠商隨貨附給的生理食鹽水注射液與柏朗注射器，依照仿單進行配製。配製完成後室溫保存，須於3小時內使用。若配製完沒有立即使用，應搖晃藥物數秒使微泡重新懸浮。 2. 本藥不可動脈內給藥 3. 給藥後請密切觀察病患反應至少30分鐘，大多數嚴重的不良反應在用藥後30分鐘內發生。
IVEKS,Remdesivir,Veklury (自費) inj 100mg (凍晶),QANB,Hospitalized patients of COVID-19,History of clinically significant hypersensitivity to remdesivir or any component of the product.,Common Gastrointestinal: Nausea (3% to 7% ) Serious Cardiovascular: Cardiac arrest Hepatic: ALT/SGPT level raised (2% to 7% )， Aspartate aminotransferase serum level raised (3% to 6% )， Hepatotoxicity Immunologic: Anaphylaxis， Hypersensitivity reaction (Less than 2% ) Other: Infusion reaction,30℃以下,Patients not requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1， then 100 mg IV infusion once daily for a total of 5 days; may treat for up to 10 days if patient does not demonstrate clinical improvement. Patients requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1， then 100 mg IV infusion once daily for a total of 10 days. (12 years or older and at least 40 kg) Patients not requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1， then 100 mg IV infusion once daily for a total of 5 days; may treat for up to 10 days if patient does not demonstrate clinical improvement (12 years or older and at least 40 kg) Patients requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1， then 100 mg IV infusion once daily for a total of 10 days Children <12 years: 3.5 kg to <40 kg: IV: Loading dose: 5 mg/kg/dose on day 1， followed by 2.5 mg/kg/dose once daily,需調整劑量,[仿單]應權衡治療的效益與餵哺母乳的效益，然後決定繼續或停止哺乳。 在動物研究（大鼠）中，曾在投予remdesivir之母鼠所哺乳的仔鼠體內檢出remdesivir及其代謝物，這可能是remdesivir出現於母乳中所致。,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]只有在潛在效益超越潛在風險的情況下，才可對孕婦或可能懷孕的婦女投予remdesivir。 在以懷孕之大鼠和兔子所進行的胚胎 - 胎兒發育影響研究中，IV 投予劑量高達20毫克 / 公斤的remdesivir【其主要循環代謝物（核鞀似物）的全身暴露量（AUC）相當於核准劑量所達到之暴露量的4倍）】並未對胚胎-胎兒的發育造成任何影響。 在一項以母大鼠所進行的生育力與早期胚胎發育影響研究中，於靜脈投予remdesivir 10毫克/公斤【其主要循環代謝物（核鞀似物）的全身暴露量（AUC）相當於核准劑量所達到之暴露量的1.3倍】之後，曾觀察到黃體、胚胎著床及存活胚胎減少的現象。,Unknown 沒有資料,[仿單]應權衡治療的效益與餵哺母乳的效益，然後決定繼續或停止哺乳。 在動物研究（大鼠）中，曾在投予remdesivir之母鼠所哺乳的仔鼠體內檢出remdesivir及其代謝物，這可能是remdesivir出現於母乳中所致。,IVD;,19mL注射用水,【N/S】可選 仿單建議。,,對成人與體重大於 40公斤的兒童，第1天的投藥(Remdesivir 200mg)應使用2支小瓶，並應將每支小瓶中的20mL溶液(共40mL)加入生理食鹽水中，使總體積達到100mL或250mL。以30-120分鐘的時間靜脈輸注。 至於第2天起的投藥(Remdesivir 100mg)，則應將1支小瓶中的20mL溶液加入生理食鹽水中，使總體積達到100mL或250mL。以30-120分鐘的時間靜脈輸注。,1.將19mL注射用水加入小瓶中，立即再度振搖30秒。靜置2-3分鐘之後，應確認小瓶中的溶液是否澄清(濃度：5mg/mL)。如果小瓶中的內容物未完全溶解，應重複振搖小瓶，使內容物澄清。 2.輸注完成之後，請用至少30毫升的0.9%生理食鹽水沖洗。 3.以注射用水調製之後，稀釋的remdesivir溶液在20-25℃的溫度下應於4小時內進行製備，在2-8℃的溫度下應於24小時內進行製備。 4.製備好的稀釋溶液在室溫(20-25°C)下可維持安定4小時，在2-8°C的冰箱中可維持24小時。
EPOP5,Polymyxin B + Neomycin + Prednisolone,Poly-Pred oph susp 5mL,TOPH,,適應症:Inflammatory ocular conditions: Management of corticosteroid-responsive inflammatory ocular conditions where bacterial infection or a risk of bacterial infection exists 副作用: Hypersensitivity: Hypersensitivity reaction Ophthalmic: Glaucoma， increased intraocular pressure， optic nerve damage (infrequent)， subcapsular posterior cataract 禁忌:Hypersensitivity to neomycin， polymyxin B， prednisolone， or any component of the formulation; viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis， vaccinia， varicella); mycobacterial ophthalmic infection; fungal diseases of ocular structures.,,15-25 C,Suspension: Eye drops 1 drop 3-4 hrly. The frequency may be increased in severe disease; frequency should decrease as signs and symptoms improve.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
HCVDA04,Viekirax + Exviera + Ribavirin (1a/24週),HCVDAA0004(C肝全口服新藥健保計畫) 1a/24週,QANB,,,,,,,,,,,,,,,,,,,
LATH,Ketotifen,Athmin syrup 0.2mg/mL， 60mL,HIMM,Bronchial asthma， allergic bronchitis， prevention of asthma and hay fever symptoms， prevention and treatment of allergic rhinitis or allergic skin reactions.,Hypersensitivity to ketotifen products or benzoate compounds,Common Neurologic: Headache (10%-25%) Respiratory: Pharyngitis， Rhinitis (10%-25%) Other: Influenza,25℃以下，不需冰存並避免陽光直射,Children 6 months to 3 years: 0.25 mL/kg BID. Children >3 years: 5 mL BID. Patients sensitive to sedation: Initial: half of the recommended dose once daily or in 2 divided doses for 5 days; and up to dose to target dose in 5 days.,無需調整劑量,[仿單]未載相關資料,無需調整劑量,沒有資料,No (limited) human data – probably compatible,[仿單]未載相關資料,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]未載相關資料,AC;AC15;PC;PO;WM;,,,,,
ECOLO5,Hydroquinone + Tretinoin + Dexamethasone,Color cream 5gm,TDER,Hyperpigmentation of skin,Hypersensitivity to hydroquinone or any component of the formulation.,Common Dermatologic: Burning sensation， Contact dermatitis， localized， Erythema,25℃以下儲存,Hyperpigmentation of skin apply 1-2 times at night,無需調整劑量,Hydroquinone: No Human Data - Probably Compatible. Tretinoin: No Human Data - Probably Compatible. Dexamethasone: No Human Data - Probably Compatible.,無需調整劑量,沒有資料,Human data suggest risk in 1st trimester,Hydroquinone: Limited Human Data - Probably Compatible. Tretinoin: Contraindicated - 1st Trimester. Dexamethasone: Compatible - Maternal Benefit >> Embryo–Fetal Risk.,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Hydroquinone: No Human Data - Probably Compatible. Tretinoin: No Human Data - Probably Compatible. Dexamethasone: No Human Data - Probably Compatible.,EXT;,,,,,
OOKW,Omeprazole,OKWE 20mg,ALIM,Ulcer of duodenum. Gastroesophageal reflux disease. Gastric ulcer. Erosive esophagitis. Zollinger-Ellison Syndrome,Concomitant use of rilpivirine-containing products. Hypersensitivity to any component of the product or to substituted benzimidazoles; anaphylaxis and acute interstitial nephritis have been reported.,Common Dermatologic: Rash (2% ) Gastrointestinal: Abdominal pain (5% )， Constipation (2% )， Diarrhea (4% )， Flatulence (3% )， Nausea (4% )， Regurgitation， Acid (2% )， Vomiting (3% ) Neurologic: Asthenia (2% )， Dizziness (2% )， Headache (7% ) Respiratory: Upper respiratory infection (Adult， 2% ) Other: Fever (1 to less than 2 years， 33% ) Serious Dermatologic: Cutaneous lupus erythematosus， Erythema multiforme， Stevens-Johnson syndrome， Toxic epidermal necrolysis Endocrine metabolic: Hypomagnesemia Gastrointestinal: Atrophic gastritis， Clostridium difficile diarrhea， Fundic gland polyposis of stomach， Pancreatitis Hematologic: Hemolytic anemia Hepatic: Hepatic encephalopathy， Hepatic necrosis， Liver failure Immunologic: Anaphylaxis Musculoskeletal: Fracture of bone， Hip fracture， Rhabdomyolysis Renal: Tubulointerstitial nephritis， acute Other: Angioedema,30℃以下避光，本品怕潮，請務必將瓶蓋緊封,Peptic or duodenal ulcer: adult， initial 20 mg QD for 2 weeks; if necessary， 20- 40mg QD for another 2 weeks Gastric ulcer & GERD: 20 mg QD for 4 weeks; if necessary， 20- 40mg QD for another 4 weeks Zollinger-Ellison syndrome: Initial， 60 mg QD; may increase up to 120 mg once daily; doses greater than 80 mg/day should be administered in divided doses， and the dose should be individualized for each patient.,需調整劑量,[仿單]Omeprazole可由乳汁排除，其對小孩的影響不明.,無需調整劑量,除非治療上需要,Human data suggest low risk,[仿單]由執行良好的流病學研究指出，Omeprazole對懷孕或對胎兒/新生兒的健康沒有不良影響. 因此在懷孕期間可以使用Omeprazole.,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Omeprazole可由乳汁排除，其對小孩的影響不明.,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]本錠劑應整粒以液體吞服，不可嚼破或壓破。若需拆膠囊請勿將膠囊中的小藥球咬碎或壓碎。
LCHH10,Chloral hydrate,Chloral hydrate 10%， 30mL (專案製造),CNEU,,適應症: Short-term sedative and hypnotic (<2 weeks)， sedative/hypnotic prior to nonpainful therapeutic or diagnostic procedures (eg， EEG， CT scan， MRI， ophthalmic exam， dental procedure) 副作用: Gastric irritation， abdominal distention and flatulence， vertigo， ataxia， staggering gait， rashes， malaise， lightheadedness， headache， ketonuria， excitement， nightmares， delirium (especially in elderly)， eosinophilia， reduction in white blood cell count; dependence on prolonged use. 禁忌: Hepatic or renal impairment， cardiac disease， hypersensitivity， porphyria， oesophagitis， gastritis. Pregnancy and lactation.,,,Chloral hydrate 10%= 100 mg/mL --Dosing: Adult Sedation， anxiety: Oral: 250 mg 3 times daily Hypnotic: Oral: 500-1000 mg 15-30 minutes before bedtime or 30 minutes prior to procedure， not to exceed 2000 mg per 24 hours --Dosing: Pediatric Hypnotic: Oral: 50 mg/kg/day in 1 or more divided doses; maximum single dose: 1000 mg Sedation or anxiety: Oral: 25 mg/kg/day in 1 or more divided doses; maximum single dose: 500 mg Procedural sedation: Oral: 25-50 mg/kg/dose， 30 minutes prior to procedure; may repeat in 30 minutes using half the dose,無需調整劑量,,無需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
RIBMK,Bimekizumab,試PS0014-Bimekizumab 160mg/Pre-filled Syringe,HIMM,,,,,,,,,,,,,,SC;,,,,,
ESOJ,Sevoflurane,Sojourn Inhalation Liquid 250mL(限麻醉科),ZANE,Induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery.,Hypersensitivity to sevoflurane， other halogenated anesthetics， or any component of the formulation; known or suspected susceptibility to malignant hyperthermia.,>10%: Cardiovascular: Hypotension (4% to 11%; dose-dependent) Central nervous system: Agitation (7% to 15%) Gastrointestinal: Nausea (25%)， vomiting (18%) Respiratory: Cough (5% to 11%) 1% to 10%: Cardiovascular: Tachycardia (2% to 6%)， bradycardia (5%)， hypertension (2%) Central nervous system: Drowsiness (9%)， shivering (6%)， dizziness (4%)， headache (1%)， hypothermia (1%)， myoclonus (1%)， delirium (emergence) Gastrointestinal: Sialorrhea (2% to 4%) Respiratory: Airway obstruction (8%)， laryngospasm (2% to 8%)， breath-holding (2% to 5%)， apnea (2%) Miscellaneous: Fever (1%),20-25°C,Individualized dosage. Adult Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide. Minimum Alveolar Concentration (MAC) values for surgical levels of anesthesia: (25 years) Sevoflurane in oxygen: 2.6%， Sevoflurane in 65% N2O/35% oxygen: 1.4% (40 years) Sevoflurane in oxygen: 2.1%， Sevoflurane in 65% N2O/35% oxygen: 1.1% (60 years) Sevoflurane in oxygen: 1.7%， Sevoflurane in 65% N2O/35% oxygen: 0.9% (80 years) Sevoflurane in oxygen: 1.4%， Sevoflurane in 65% N2O/35% oxygen: 0.7% Pediatric Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide. MAC values for surgical levels of anesthesia: (0 to 1 month old full-term neonates) Sevoflurane in oxygen: 3.3% (1 to <6 months) Sevoflurane in oxygen: 3% (6 months to <1 year) Sevoflurane in oxygen: 2.8%， Sevoflurane in 65% N2O/35% oxygen: 2% (1 to <3 years) Sevoflurane in oxygen: 2.8%， Sevoflurane in 60% N2O/40% oxygen: 2% (3-12 years) Sevoflurane in oxygen: 2.5%,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IH;,,,,,
OGXB,Empagliflozin + Linagliptin,Glyxambi 25/5mg,META,Type 2 diabetes mellitus,Severe renal impairment， dialysis， or end-stage renal disease. Hypersensitivity reaction to empagliflozin， linagliptin， or any of the excipients; anaphylaxis， angioedema， exfoliative skin conditions， urticaria， or bronchial hyperreactivity have occurred.,Common Renal: Urinary tract infectious disease (11.4% to 12.5% ) Respiratory: Nasopharyngitis (5.9% to 6.6% )， Upper respiratory infection (7% ) Serious Cardiovascular: Heart failure， Hypotension Endocrine metabolic: Diabetic ketoacidosis， Hypoglycemia (2.2% to 3.6% ) Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Musculoskeletal: Arthralgia Renal: Creatinine clearance-glomerular filtration abnormal， Decreased， Pyelonephritis， Sepsis due to urinary tract infection， Serum creatinine raised Reproductive: Necrotizing fasciitis， Perineum Other: Angioedema,30°C 以下,Initial empagliflozin 10 mg/linagliptin 5 mg orally once daily in the morning， may increase to empagliflozin 25 mg/linagliptin 5 mg once daily if tolerated.,無需調整劑量,Empagliflozin: No Human Data—Potential Toxicity. Linagliptin: No Human Data—Probably Compatible. [仿單]關於GLYXAMBI或其個別成分是否會進入人類的乳汁以及其對哺乳嬰兒或乳汁生成有何影響， 目前尚無相關資料。Empagliflozin和linagliptin會分泌到授乳中大鼠的乳汁內。 由於人類的腎臟是在子宮內到出生後2年內逐漸成熟 (此時可能因哺乳而暴露)， 因此人類腎臟的發育可能處於風險之中。因為GLYXAMBI可能對接受哺乳的嬰兒造成嚴重的不良反應(包括empagliflozin可能影響出生後的腎臟發育)， 應告知病人，不建議在哺乳期間使用GLYXAMBI。,需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,Empagliflozin: No Human Data-Animal Data Suggest Low Risk. Linagliptin: No Human Data-Animal Data Suggest Low Risk [仿單]由於empagliflozin的動物研究資料顯示有不良腎臟影響， 因此不建議在懷孕第二孕期和第三孕期時使用GLYXAMBI。 在懷孕婦女使用GLYXAMBI、linagliptin或empagliflozin的現有資料極少， 因此無法據以判定藥物與重大先天缺陷和流產風險之間是否具有相關性。 懷孕期間糖尿病控制不佳可能對母體和胎兒造成風險,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,Empagliflozin: No Human Data—Potential Toxicity. Linagliptin: No Human Data—Probably Compatible. [仿單]關於GLYXAMBI或其個別成分是否會進入人類的乳汁以及其對哺乳嬰兒或乳汁生成有何影響， 目前尚無相關資料。Empagliflozin和linagliptin會分泌到授乳中大鼠的乳汁內。 由於人類的腎臟是在子宮內到出生後2年內逐漸成熟 (此時可能因哺乳而暴露)， 因此人類腎臟的發育可能處於風險之中。因為GLYXAMBI可能對接受哺乳的嬰兒造成嚴重的不良反應(包括empagliflozin可能影響出生後的腎臟發育)， 應告知病人，不建議在哺乳期間使用GLYXAMBI。,AC;PC;PO;WM;,,,,,
OATMX,Atomoxetine,APO-Atomoxetine 18mg,CNEU,Attention deficit hyperactivity disorder,Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma， current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg， 15 to 20 mm Hg) or heart rate (eg， 20 beats per minute),Common Cardiovascular: Increased heart rate (Adult， 10.2% to 22.4%; pediatric， 12.2% to 23.4% ) Endocrine metabolic: Weight decreased (Adult， 2%; pediatric， 3% ) Gastrointestinal: Abdominal pain (Adult， 7%; pediatric， 18% )， Constipation (Adult， 8%; pediatric， 1% to 2% )， Decrease in appetite (Adult， 16%; pediatric， 16% )， Nausea (Adult， 26%; pediatric， 10% )， Vomiting (Adult， 4%; pediatric， 11% )， Xerostomia (Adult， 20% ) Neurologic: Dizziness (Adult， 8%; pediatric， 5% )， Headache (Pediatric， 19% )， Insomnia (Adult， 15%; pediatric， at least 2% )， Somnolence (Adult， 8%; pediatric， 11% ) Renal: Delay when starting to pass urine (Adult， 6% ) Reproductive: Dysmenorrhea (Adult， 3% )， Erectile dysfunction (Adult， 8% ) Other: Fatigue (Adult， 10%; pediatric， 8% ) Serious Cardiovascular: Increased diastolic arterial pressure (Adult， 4.8% to 12.6%; pediatric， 9.3% to 21.5% )， Increased systolic arterial pressure (Adult， 4.2% to 12.4%; pediatric， 4.9% to 12.5% )， Myocardial infarction， Sudden cardiac death， Tachycardia (Adult， 1.5%; pediatric， 0.3% ) Hepatic: Injury of liver (Severe)， Liver failure Neurologic: Cerebrovascular accident Psychiatric: Aggressive behavior， Hostile behavior， Mania， Psychotic disorder， Suicidal thoughts (Pediatric， 0.4% ) Reproductive: Priapism,25℃以下乾燥環境,Acute treatment:6 years or older， up to 70 kg: Acute treatment: Initial， approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily， as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; maximum 1.4 mg/kg daily or 100 mg/day， whichever is less Acute treatment: 6 years or older， greater than 70 kg: Acute treatment: Initial， 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks; maximum 100 mg daily. Maintenance / continuous treatment: 1.2∼1.8 mg/ kg/ day.,需調整劑量,[仿單]Atomoxetine 及/ 或其代謝物會分泌至老鼠的乳汁中。 Atomoxetine 是否會分泌至人類母乳中則未知。 哺乳中的婦女若服用 Atomoxetine 時，應加以注意。,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,[仿單] 在懷孕兔子的器官形成期間，餵食劑量最高至 100 mg/ kg/ day 的Atomoxetine。在三篇研究中的一篇，觀察到活胎數減少，早期再吸收增加。不正常頸動脈起源及缺少鎖骨下動脈的發生率稍微增加。這些結果發現於會引起輕微母體毒性的劑量。 這些結果的無作用劑量（no-effect dose）為 30 mg/ kg/ day。以mg/ m2計，100 mg/ kg 的劑量約為最高人體劑量的 23 倍，兔子血中的 Atomoxetine濃度（AUC）估計為接受最高人體劑量的人體內的 3.3 倍（快速代謝者）或 0.4 倍（緩慢代謝者）。 從交配前 2 週（母鼠）或 10 週（公鼠），到器官形成及哺乳期為止，在老鼠飲食中加入不超過大約 50 mg/ kg/ day 的 atomoxetine（以 mg/ m2計算，約為最高人體劑量的 6 倍）。 在二篇研究的其中一篇，發現小鼠體重及存活數減少。在 25 mg/ kg（非 13 mg/ kg），也發現到小鼠的存活減少的現象。 一篇從交配前 2 週（母鼠）或10 週（公鼠），到器官形成期為止，在老鼠飲食中加入 Atomoxetine 的研究中，40mg/ kg/ day（以 mg/ m2計，約為最高人體劑量的 5 倍），發現到胎鼠體重減少（僅母鼠）及椎骨弓（vertebral arch）不完全成骨的發生率增加的現象，此現象並沒有在 20 mg/ kg/ day 劑量組中發現。 在器官形成期間，以 150 mg/ kg/ day 的劑量（以 mg/ m2計，約為最高人體劑量的17 倍）餵食懷孕母鼠，胎兒並未出現任何的副作用。 目前尚無關於懷孕婦女之充分及完整的對照性研究。 懷孕期間不可服用 Atomoxetine，除非效益超過胎兒可能產生的風險性。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]Atomoxetine 及/ 或其代謝物會分泌至老鼠的乳汁中。 Atomoxetine 是否會分泌至人類母乳中則未知。 哺乳中的婦女若服用 Atomoxetine 時，應加以注意。,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥請整顆膠囊吞服。若有磨粉需求請使用前自行磨粉並注意本藥粉末具有眼部刺激性。
IDUP,Diazepam,Diazepam(Dupin) inj 10mg/2mL,CNEU,Insomnia， anxiety， muscle spasm， status epilepticus.,Respiratory depression; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment.,Drowsiness & lightheadedness; confusion & ataxia; amnesia; dependence; paradoxical increase in aggression; muscle weakness; headache， vertigo， hypotension， salivation changes， GI disturbances， visual disturbances， dysarthria， tremor， changes in libido， incontinence， urinary retention; thrombophlebitis. Cardiovascular: Hypotension Dermatologic: Rash (3%， rectal gel ) Gastrointestinal: Diarrhea (4%， rectal gel ) Musculoskeletal: Muscle weakness Neurologic: Ataxia， Incoordination (3%， rectal gel )， Somnolence Psychiatric: Euphoria (3%， rectal gel ) Respiratory: Respiratory depression Other: Fatigue,30℃以下避光避免冷凍,Adults: Anxiety:1.Before surgery:5-10mg IM/IV. 2.Anxiety symptoms:2mg-10 mg IM/IV. If necessary， repeat 3-4 hours later. Alcohol withdrawal:10mg IM/IV. If necessary， 5-10mg every 3-4 hours. Amnestic:1.Cardioversion:5-15mg IV， 5-10 minutes before the procedure. 2. Endoscopy: IV: up to 20 mg before the procedure. IM:5-10mg 30 minutes before the procedure. Spasm:Initial dose:5-10mg IM/IV， If necessary， repeat every 10-15 minutes.maximum dose:30 mg. Skeletal muscle relaxation: Initial dose:5-10mg IM/IV， If necessary， repeat every 3-4 hours. Elderly or frail patients: Initial dose:2-5mg IM/IV， increase as needed and tolerable.IV: slowly Inject， at least 1 minute per 5mg(1mL) injection time. Children: Not recommended for newborns. Epilepsy and severe recurrent seizures: Infants over 30 days old to children under 5 years old: IV/IM:200-500mcg (0.2-0.5mg) every 2-5 minutes， maximum dose :5mg， if necessary， repeat every 2-4 hours. Children 5 years and over 5 years of age: IV/IM:1mg every 2-5 minutes， maximum dose:10mg. If necessary， repeat every 2-4 hours. Tonic spasms: Infants over 30 days to children under 5 years of age: IV/IM:1-2 mg， repeat every 3-4 hours as needed. Children 5 years and older: IV/IM:5-10 mg， repeat every 3-4 hours as needed.,無需調整劑量,,無需調整劑量,盡量避免,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,IM;IVPUSH;,,,推注速率< 5 mg/min,1.本藥不可與其它溶液、靜脈輸注液或其他藥物混合或稀釋，因為有使Diazepam 沈澱之可能，而且Diazepam 會被輸液袋及輸液管所吸附，因此本藥不宜作靜脈輸注。 2.如果不能直接靜脈注射，也可緩慢注入輸液管內，但要盡量接近注射點（Insertion Point）。 3.靜脈注射時，應勿使用手背或手腕之小靜脈，而且還要避免注射到血管外，也勿作動脈注射，以防靜脈栓塞、靜脈炎、局部刺激、腫脹以及血管損傷。,1. IM: inject deeply into muscle mass. 2. IV: inject slowly; do not administer faster than 5 mg/min. Do not use small veins for injection; if direct injection is not feasible， may inject through infusion tubing as close as possible to the vein insertion. 3. Do not mix or dilute with other solutions or drugs in syringe or infusion flask.
IPHE,Phenobarbital,Phenobital inj 100mg/1mL,CNEU,Seizures.,Hypersensitivity to phenobarbital， barbiturates or any component of the formulation; marked hepatic impairment; dyspnea or airway obstruction; porphyria (manifest and latent); intra-arterial administration， subcutaneous administration (not recommended); use in patients with a history of sedative/hypnotic addiction; nephritic patients (large doses).,Cardiovascular: Bradycardia， hypotension， syncope， thrombophlebitis (IV) Central nervous system: Agitation， anxiety， ataxia， central nervous system stimulation， central nervous system depression， confusion， dizziness， drowsiness， hallucination， hangover effect， headache， impaired judgement， insomnia， lethargy， nervousness， nightmares Dermatologic: Exfoliative dermatitis， skin rash， Stevens-Johnson syndrome Gastrointestinal: Constipation， nausea， vomiting Genitourinary: Oliguria Hematologic & oncologic: Agranulocytosis， thrombocytopenia， megaloblastic anemia Local: Pain at injection site Neuromuscular & skeletal: Hyperkinesia， laryngospasm Respiratory: Apnea (especially with rapid IV use)， hypoventilation， respiratory depression,25℃以下,Adult dosing: 1-2 mL QD， 15-7 years :0-1.5mL ， 2-7 years :0.5-0.7mL， <2 years: 0.2-0.5mL， depending on the symptoms， it can be changed to 2~3 times a day.Can only be injected IM or SC， not IV.,需調整劑量,,需調整劑量,盡量避免,Human (and animal) data suggest risk,藥品仿單:不可使用在懷孕及哺乳婦女。,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,IM;IVD;,,【D10W】可選 。【D5NS】可選 。【D5W】可選 。【H/S】可選 。【L/R】可選 。【N/S】可選 。,Avoid IV push.,(Children) Inject IV at a rate not to exceed 30 mg/min. (Adult) Inject IV at a rate not to exceed 60 mg/min.,IM: Inject deeply into a large muscle. Avoid injection into or near peripheral nerves due to the risk of permanent neurological deficit. IV: Inject slowly to avoid severe respiratory depression， apnea， laryngospasm， hypertension or vasodilation with fall in blood pressure.
OSTRM,Ivermectin,Stromectol 3mg,TDER,Scabies， Onchocerciasis， Intestinal strongyloidiasis.,Hypersensitivity to oral ivermectin or any other component of the product. Specific contraindications have not been determined for topical ivermectin.,Common Dermatologic: Pruritus (2.8% )， Urticaria (Oral， 0.9% ) Neurologic: Dizziness (2.8% ) Serious Immunologic: Mazzotti reaction Neurologic: Seizure,30℃以下,Scabies: Oral: 200 mcg/kg as a single dose， dose could follow (3mg/TAB): 15-24kg:1TAB; 25-35kg: 2 TAB; 36-50kg:3 TAB; 51-65kg: 4TAB; 66-79kg: 5 TAB; >=80kg:200 mcg/kg. If the symptoms of infection are still present and the test is positive， Could be administered again after 8-15 days. Onchocerciasis: Oral: 200 mcg/kg as a single dose， dose could follow (3mg/TAB): 15-24kg:1 TAB; 25-35kg:2 TAB; 36-50kg:3 TAB; 51-65kg: 4 TAB; 66-79kg: 5 TAB; >=80kg:200 mcg/kg. Intestinal strongyloidiasis: Oral: 200 mcg/kg as a single dose， dose could follow (3mg/TAB): 15-24kg:1TAB ; 25-35kg:2 TAB; 36-50kg:3 TAB ; 51-65kg:4 TAB ; 66-79kg:5 TAB ; >=80kg:200 mcg/kg.,無需調整劑量,[仿單]Ivermectin 會排泄於乳汁中，對新生兒之安全性尚未建立。在大鼠，控制組的幼鼠及在子宮內曾接受暴露的幼鼠， 與治療過的母鼠進行交叉飼養，皆觀察到降低幼鼠之存活率。然而在控制組幼鼠及在子宮內曾接受暴露的 幼鼠，與控制組母鼠進行交叉飼養下，則皆未發現幼鼠之存活率降低現象。 只有在治療母親的效益超越餵哺母乳之嬰兒所可能面臨之風險的情況下，才可對授乳母親投予本藥， 且準備為嬰兒餵哺母乳的母親應延後到嬰兒出生至少 1 週後再進行治療。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單]因目前尚未有ivermectin使用在孕婦的安全性報告，孕婦應勿使用ivermectin。 分別投予口服劑量 0.4 和 10 毫克/公斤/天的 ivermectin，會導致小鼠和大鼠顎裂， 投予口服劑量 3 毫克/公斤/天的 ivermectin，會導致兔子顎裂和前爪內翻。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]Ivermectin 會排泄於乳汁中，對新生兒之安全性尚未建立。在大鼠，控制組的幼鼠及在子宮內曾接受暴露的幼鼠， 與治療過的母鼠進行交叉飼養，皆觀察到降低幼鼠之存活率。然而在控制組幼鼠及在子宮內曾接受暴露的 幼鼠，與控制組母鼠進行交叉飼養下，則皆未發現幼鼠之存活率降低現象。 只有在治療母親的效益超越餵哺母乳之嬰兒所可能面臨之風險的情況下，才可對授乳母親投予本藥， 且準備為嬰兒餵哺母乳的母親應延後到嬰兒出生至少 1 週後再進行治療。,AC;,,,,,
LSUT,Butamirate,Sutussi liquid 0.8mg/mL， 60mL,ERSP,Antitussive. Cough caused by cold， bronchitis， or asthmatic bronchitis.,Patients with Hypersensitivity or allergy to Butamirate,Allergic reactions， Skin rash， Nausea， Vertigo， Diarrhea， Dizziness.,25℃以下，不需冰存並避免陽光直射,Children: 5ml TID. Adult: 7.5ml TID-QID.,無需調整劑量,[仿單]由於缺乏關於本藥的主成份是否會從母體進入母乳內的資料，為了安全起見， 母親在哺乳期間欲使用本藥應特別小心.,無需調整劑量,可能安全,Uknown 沒有資料,[仿單]懷孕危險等級B.這表示在動物身上進行的生殖試驗中，並未顯示特別嚴重的危險.但目前為止尚無孕婦試驗報告的發表. 因此為了安全起見，懷孕初期3個月內一避免服用此劑;3個月後方可服用.,Unknown 沒有資料,[仿單]由於缺乏關於本藥的主成份是否會從母體進入母乳內的資料，為了安全起見， 母親在哺乳期間欲使用本藥應特別小心.,AC;AC15;PC;PO;WM;,,,,,
ONLD,Aluminum Hydroxide + Butinolin + Calcium carbonate,Nolidin 200/2/300mg,ALIM,Cramps and pain caused by hyperacidity， gastritis， duodenitis， gastric and duodenal ulcers,Hypersensitivity to any component of the formulation.,Frequency not defined. Gastrointestinal: Constipation， fecal discoloration (white speckles)， fecal impaction， nausea， stomach cramps， vomiting Endocrine & metabolic: Hypomagnesemia， hypophosphatemia,25℃以下儲存，避免陽光直射,Nolidin 200/2/300mg: Aluminum Hydroxide 200mg + Butinolin 2mg + Calcium carbonate 300mg. usual dose: adult， 1 tab TID.,無需調整劑量,Aluminum Hydroxide， Butinolin: 沒有資料 Calcium carbonate: Compatible. [仿單]沒有相關紀載,無需調整劑量,沒有資料,Uknown 沒有資料,Aluminum Hydroxide， Butinolin: 沒有資料 Calcium carbonate: Compatible. [仿單]沒有相關紀載,Unknown 沒有資料,Aluminum Hydroxide， Butinolin: 沒有資料 Calcium carbonate: Compatible. [仿單]沒有相關紀載,AC;AC15;PC;PO;WM;,,,,,
ONES,Alogliptin,NESINA 25mg,META,Diabetes mellitus， type 2,History of serious hypersensitivity (eg， anaphylaxis， angioedema， severe cutaneous reactions) to alogliptin or any component of the formulation.,1% to 10%: Cardiovascular: Cardiac failure (4%) Central nervous system: Headache (4%) Genitourinary: Decreased estimated GFR (5%) Hepatic: Increased serum ALT (>3 times ULN: 1%) Renal: Renal function abnormality (3%; patients with high cardiovascular risk: 23%)， renal disease (patients with high cardiovascular risk: 17%)， renal insufficiency (patients with high cardiovascular risk: 8%) Respiratory: Nasopharyngitis (5%)， upper respiratory tract infection (5%) <1%， postmarketing， and/or case reports: Anaphylaxis， angioedema， constipation， decreased creatinine clearance， diarrhea， hepatic failure， hypersensitivity reaction， increased liver enzymes， intestinal obstruction， nausea， pancreatitis， serum sickness， severe arthralgia (FDA Safety Alert， Aug 28， 2015)， skin rash， Stevens-Johnson syndrome， urticaria.,25℃以下,25 mg once daily.,無需調整劑量,,需調整劑量,,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
ERES,Cyclosporin,Restasis 0.05%， 0.4mL eye emulsion,TOPH,Keratoconjunctivitis sicca.,Active ocular infections. Hypersensitivity to cyclosporine or any of ingredient in the formulation of the product.,Common Ophthalmic: Blepharitis (Ophthalmic route 1% to 5% )， Burning sensation in eye (Ophthalmic route， 17% )， Conjunctival hyperemia (Ophthalmic route， 1% to 6% )， Eye irritation (Ophthalmic route， 1% to 5% )， Pain in eye (Ophthalmic route， emulsion 1% to 5% ; solution， 22% ) Serious Endocrine metabolic: Hyperkalemia， Hypomagnesemia Hepatic: Hepatotoxicity (7% or less ) Immunologic: Disease due to Polyomavirus Neurologic: Encephalopathy， Progressive multifocal leukoencephalopathy， Seizure (1% to 5% ) Renal: Hemolytic uremic syndrome， Nephrotoxicity (25% to 38% ) Other: Infectious disease,15℃- 25℃,Ophthalmic: Instill 1 drop in each eye twice daily (approximately 12 hours apart) Before use， turn the ampoule upside down several times to form a uniform white opaque emulsion， and then drop one drop in each eye， which can be combined with artificial liquid， but the use of two drugs should be separated by 15 minutes.,無需調整劑量,[仿單]Cyclosporine已知於全身性投藥後會分泌於人類乳汁， 但未曾進行局部治療是否會分泌於人類乳汁的研究； 雖然局部投予RESTASISR眼用乳劑後血中濃度偵測不到， 但RESTASISR投予哺乳婦時應審慎。 CYCLOSPORINE OPHTHALMIC Immunologic (Immunosuppressant) BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,除非治療上需要,No (limited) human data – probably compatible,[仿單]......截錄...... RESTASISR尚未於孕婦進行充分且有良好對照組之臨床研究。 局部眼用 Cyclosporine 0.05%眼用乳劑不會造成全身性吸收，且使用於孕婦也不會對胎兒造成影響。 動物試驗中，唯有在高劑量母體毒性時顯示有生殖毒性。 CYCLOSPORINE OPHTHALMIC Immunologic (Immunosuppressant) PREGNANCY RECOMMENDATION: No Human Data—Probably Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]Cyclosporine已知於全身性投藥後會分泌於人類乳汁， 但未曾進行局部治療是否會分泌於人類乳汁的研究； 雖然局部投予RESTASISR眼用乳劑後血中濃度偵測不到， 但RESTASISR投予哺乳婦時應審慎。 CYCLOSPORINE OPHTHALMIC Immunologic (Immunosuppressant) BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,OD;OL;OU;,,,,,每瓶限單次使用，小瓶中的乳劑須在開封後即刻點於單眼或雙眼，剩餘藥液須於投藥後即刻拋棄。不要讓藥瓶尖端接觸到眼球或任何其它表面，以免污染本品或視力損害。RESTASISR禁忌於佩戴隱形眼鏡狀態下投藥，若有佩戴隱形眼鏡，須在本品投藥前取下隱形眼鏡，等RESTASISR眼用乳 劑投藥後15分鐘，再重新戴上隱形眼鏡。
OCONT,Naltrexone + Bupropion,Contrave 8/90mg extended-release,META,An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g.， hypertension， type 2 diabetes mellitus， or dyslipidemia).,Uncontrolled hypertension. Seizure disorder or a history of seizures. Use of other bupropion-containing products (including， but not limited to， WELLBUTRIN， WELLBUTRIN SR， WELLBUTRIN XL， and APLENZIN). Bulimia or anorexia nervosa， which increase the risk for seizure. Chronic opioid or opiate agonist (e.g.， methadone) or partial agonists (e.g.， buprenorphine) use， or acute opiate withdrawal. Patients undergoing an abrupt discontinuation of alcohol， benzodiazepines， barbiturates， and antiepileptic drugs. Concomitant administration of monoamine oxidase inhibitors (MAOI). At least 14 days should elapse between discontinuation of MAOI and initiation of treatment with CONTRAVE. There is an increased risk of hypertensive reactions when CONTRAVE is used concomitantly with MAOIs. Starting CONTRAVE in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated. Known allergy to bupropion， naltrexone or any other component of CONTRAVE. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported with bupropion. Pregnancy.,Common Gastrointestinal: Constipation (19.2% )， Diarrhea (7.1% )， Nausea (32.5% )， Vomiting (10.7% )， Xerostomia (8.1% ) Neurologic: Dizziness (9.9% )， Headache (17.6% )， Insomnia (9.2% ) Psychiatric: Anxiety (4.2% ) Serious Cardiovascular: Hypertension (3.2% )， Increased heart rate， Myocardial infarction (Less than 2% ) Dermatologic: Erythema multiforme (Rare )， Stevens-Johnson syndrome (Rare ) Endocrine metabolic: Hypoglycemia Gastrointestinal: Cholecystitis (Less than 2% )， Hematochezia (Less than 2% ) Hepatic: Hepatotoxicity Immunologic: Anaphylaxis， Delayed hypersensitivity disorder Musculoskeletal: Intervertebral disc prolapse (Less than 2% ) Neurologic: Amnesia (Less than 2% )， Seizure (0.1% ) Ophthalmic: Angle-closure glaucoma Psychiatric: Depression (6.3% to 7.1% )， Mania， Psychiatric symptom， Suicidal thoughts (0.03% ) Renal: Infectious disorder of kidney (Less than 2% )， Serum creatinine raised (Less than 2% ) Respiratory: Pneumonia (Less than 2% ),30℃以下,Extended-Release Tablets: Naltrexone 8mg + Bupropion 90mg. CONTRAVE dosing should be escalated according to the following schedule: Week 1: 1 tablet in the morning. Week 2: 1 tablet BID. Week 3: 2 tablets in the morning and 1 tablet in the evening. Week 4 - Onward: 2 tablets BID. A total daily dosage of two CONTRAVE 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.,無需調整劑量,BREASTFEEDING RECOMMENDATION: BUPROPION: Limited Human Data—Potential Toxicity NALTREXONE: Limited Human Data—Probably Compatible [仿單]已發表的文獻資料曾指出bupropion及其代謝產物會出現在人類乳汁中。 在泌乳期間使用bupropion的上市後報告的有限資料中，並未發現哺乳嬰兒身上不良反應的明確相關性。 Naltrexone及其主要代謝產物6β-naltrexol，也曾出現在人類乳汁中。 目前沒有bupropion、naltrexone或其代謝產物對乳汁生成造成影響的相關資料。 哺餵母乳在發育和健康方面帶來的效益，應與母親在臨床上對CONTRAVE的需求，以及CONTRAVE或母親的既有病症對哺乳嬰兒可能造成的任何不良反應一併考量。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest moderate risk,PREGNANCY RECOMMENDATION: BUPROPION: Human Data Suggest Risk NALTREXONE: Limited Human Data—Animal Data Suggest Moderate Risk [仿單]體重減輕對懷孕病人沒有益處，且可能對胎兒有害。確認懷孕時，請向懷孕病人告知胎兒承受的風險並停用CONTRAVE。現有藥物監測資料以及在懷孕病人中使用CONTRAVE個別成分的臨床試驗所得到的資料，未顯示重大出生缺陷、流產或不良母親或胎兒結果的藥物相關風險。 Bupropion 針對在第一孕期受到bupropion暴露的懷孕病人進行的流行病學研究，其資料並未發現整體而言先天性畸形的風險上升（參閱數據資料）。在器官發生期間對懷孕大鼠施用 bupropion時，在最高至360 mg/日之最大建議人體劑量 (MRHD) 的大約20倍劑量下，並無胎鼠發生畸形的證據。在器官發生期間對懷孕兔隻給藥時，在約兩倍MRHD及更高的劑量下，曾觀察到胎兔畸形發生率出現非劑量相關上升現象以及骨骼變異。在5倍MRHD及更高的劑量下，曾觀察到胎兔體重減少。 Naltrexone 在第一孕期中受到naltrexone暴露的懷孕病人的有限個案報告資料，並非發現整體而言先天性畸形的風險上升。研究已顯示在器官發生期間每日經口給與naltrexone，分別在 ? 15倍和 ? 60 MRHD（32 mg/日）的劑量下增加了大鼠和兔隻中早期胎鼠/兔流失的發生率。在最高分別為約100和200倍MHRD的劑量下，在大鼠和兔隻中並無胎鼠/兔畸形的證據。 對於適應症族群而言，重大出生缺陷和流產的背景風險估計值仍屬未知。在美國總人口當中，在臨床上證實之懷孕案例中重大出生缺陷和流產的背景風險估計值分別為2-4% 和15-20%。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,BREASTFEEDING RECOMMENDATION: BUPROPION: Limited Human Data—Potential Toxicity NALTREXONE: Limited Human Data—Probably Compatible [仿單]已發表的文獻資料曾指出bupropion及其代謝產物會出現在人類乳汁中。 在泌乳期間使用bupropion的上市後報告的有限資料中，並未發現哺乳嬰兒身上不良反應的明確相關性。 Naltrexone及其主要代謝產物6β-naltrexol，也曾出現在人類乳汁中。 目前沒有bupropion、naltrexone或其代謝產物對乳汁生成造成影響的相關資料。 哺餵母乳在發育和健康方面帶來的效益，應與母親在臨床上對CONTRAVE的需求，以及CONTRAVE或母親的既有病症對哺乳嬰兒可能造成的任何不良反應一併考量。,AC;PC;PO;WM;,,,,,[磨粉/管灌註記]仿單建議本藥應整顆吞服，勿剝半、咀嚼或壓碎。 1. 請提醒病患近兩週有使用類鴉片止痛藥或抗鬱藥物請主動告知醫師。 2. 不可搭配高脂餐點併用。
OBNG,當歸，黃芩，紅耆，天竺黃，人參，柴胡，黃連，甘草,BNG-1 3gm/pack， 84pack/盒,HEMT,In combination with Aspirin to assist in improving activities of daily living for adult patients from 20 to under 65 years of age who have an ischemic stroke.,Pregnancy. Lactation. Patients under 20 years of age or above 65 years of age.,Constipation， diarrhea， upper abdominal pain， pyrexia， liver function test abnormal， allergic rhinitis， nasopharyngitis， upper respiratory tract infection， back pain， dizziness， headache， anxiety， haematuria， nocturia， cough.,25℃以下,1 sachet TID for 4 weeks. Take with warm water， and take on an empty stomach (1 hour before meals or 2 hours after meals). BNG-1 and aspirin should be taken at least one hour apart.,無需調整劑量,[仿單] 本品對於懷孕婦女、哺乳婦女，安全性及有效證據尚未確立，應避免使用。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單] 本品對於懷孕婦女、哺乳婦女，安全性及有效證據尚未確立，應避免使用。,Unknown 沒有資料,[仿單] 本品對於懷孕婦女、哺乳婦女，安全性及有效證據尚未確立，應避免使用。,AC;PO;,,,,,
ILUC3,Ranibizumab,Lucentis inj 10mg/mL， 0.165mL,TOPH,Diabetic macular edema: Treatment of diabetic macular edema (DME). Diabetic retinopathy: Treatment of diabetic retinopathy Macular degeneration: Treatment of neovascular (wet) age-related macular degeneration (AMD) Macular edema: Treatment of macular edema following retinal vein occlusion (RVO) Myopic choroidal neovascularization: Treatment of myopic choroidal neovascularization (mCNV).,Active or suspected ocular or periocular infections， active intraocular inflammation.,Nasopharyngitis， influenza; anemia; anxiety; headache， stroke; intraocular inflammation， vitritis， vitreous detachment， retinal hemorrhage， visual disturbance， eye pain， vitreous floaters， conjunctival hemorrhage， eye irritation， foreign body sensation in eyes， lacrimation increased， blepharitis， dry eye， ocular hyperemia， eye pruritus; retinal degeneration， retinal disorder， retinal detachment， retinal tear， detachment of retinal pigment epithelium， retinal pigment epithelium tear， visual acuity reduced， vitreous hemorrhage， vitreous disorder， uveitis， iritis， iridacyclitis， cataract， calaract subcapsular， posterior capsule opacification， punctuate keratitis， corneal abrasion， anterior chamber flare， vision blurred， inj site hemorrhage， eye hemorrhage， conjunctivitis， conjunctivitis allergic， eye discharge， photopsia， photophobia， ocular discomfort， eyelid edema， eyelid pain， conjunctival hyperemia; cough; nausea; allergic reactions; arthralgia; intraocular pressure increased. Common Ophthalmic: Cataract ( eovascular(wet) age-related macular degeneration 11% to 17%;macular edema following retinal vein occlusion，2%) ， conjunctival hemorrhage (neovascular (wet) age- related macular degeneration 64% to 74%; macular edema following retinal vein occlusion， 48%) ， Eye irritation (neovascular (wet) age- related macular degeneration 13% to 15% ; macular edema following retinal vein occlusion，7%) ， Foreign body sensation， in the eyes (neovascular (wet) age- related macular degeneration 13% to 16%; macular edema following retinal vein occlusion， 7% to 16%) ，Inflammatory disorder of the eye (neovascular (wet) age- related macular degeneration 13% to 18% )， Pain in eye (neovascular (wet) age- related macular degeneration 26 % to 35% ; macular edema following retinal vein occlusion， 17% )， Raised intraocular pressure (neovascular (wet) age- related macular degeneration 17% to 24% ; macular edema following retinal vein occlusion，7% ) ，Visual disturbance (neovascular (wet) age- related macular degeneration 13% to 18% ; macular edema following retinal vein occlusion，5% )， Vitreous detachment (neovascular (wet) age- related macular degeneration 15% to 21% ; macular edema following retinal vein occlusion，4% ) ， Vitreous floaters (neovascular (wet) age- related macular degeneration19 % to 27% ; macular edema following retinal vein occlusion， 7 %),2-8℃避光避免冷凍,0.5mg via IVIA. The second injections into the same eyeball must be at least 4 weeks apart. The initial treatment may require 3 months or longer until no vision and/or anatomy in patient with wet type (Neovascular) of age-related macular degeneration (wAMD)， diabetic macular edema(DME)， retinal vein occlusion (RVO).,無需調整劑量,仿單：目前未知Lucentis 是否會分泌於人體乳汁中。為了小心起見，婦女在使用Lucentis 的治療期間不建議餵哺母乳。 RANIBIZUMAB OPHTHALMIC Selective Vascular Endothelial Growth Factor Antagonist BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,沒有資料,No (limited) human data – probably compatible,仿單：1.預計懷孕的婦女：具生育能力的婦女於治療期間內須使用有效的避孕措施。 對於想懷孕的婦女，建議於施打最後一劑ranibizumab至少三個月後方進行懷孕。 2.目前尚無孕婦使用ranibizumab 的臨床資料。眼內注射ranibizumab 的全身暴露量較低，但是由於ranibizumab 的作用機轉，必須考慮其潛在造成致畸胎性 及對胎兒/ 胚胎發育不良影響的可能性。懷孕時不建議使用ranibizumab。 RANIBIZUMAB OPHTHALMIC Selective Vascular Endothelial Growth Factor Antagonist PREGNANCY RECOMMENDATION: Limited Human Data—Probably Compatible,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,仿單：目前未知Lucentis 是否會分泌於人體乳汁中。為了小心起見，婦女在使用Lucentis 的治療期間不建議餵哺母乳。 RANIBIZUMAB OPHTHALMIC Selective Vascular Endothelial Growth Factor Antagonist BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,IVI;,,,,,1.Lucentis 必須由對玻璃體注射有經驗之合格的眼科醫生來使用。 2.建議劑量為一次在玻璃體內注射0.5 mg的Lucentis。注射至同一個眼球內的兩次劑量，至少需間 隔4 週。 3.曾經有Lucentis 與雷射光凝療法同時使用的經驗。在同一天施行治療時，應於雷射光凝療法完成後至少30 分鐘再施打Lucentis。
EALC754,Alcohol,75% Alcohol 4000mL/bottle,TDER,,,,25℃以下儲存,,無需調整劑量,,無需調整劑量,,,,,,EXT;,,,,,
OXAR25,Rivaroxaban,Xarelto 2.5mg,HEMT,Cardiovascular event risk; Prophylaxis of Peripheral arterial occlusive disease and Coronary arteriosclerosis， In combination with aspirin.,Active pathological bleeding. Severe hypersensitivity reaction (eg， anaphylaxis) to rivaroxaban. Patients with severe hepatic impairment or with any degree of hepatic disease associated with coagulopathy. Patients with severe progressive bleeding (such as intracranial hemorrhage， gastrointestinal hemorrhage). PREGNANCY and BREASTFEEDING. Patients with CrCl <15 mL/min.,Common Hematologic: Hemorrhage (DVT prophylaxis following hip or knee replacement， 5.8%; treatment of DVT or pulmonary embolism， 28.3%; reduction in risk of recurrence of DVT or pulmonary embolism， 13.4% ; prophylaxis of VTE in acutely ill medical patients， 2.9% ) Serious Cardiovascular: Syncope (1.2% ) Gastrointestinal: Gastrointestinal hemorrhage (0.5% to 2% )， Upper gastrointestinal bleeding Hematologic: Hematoma， Epidural or spinal， Hemorrhage， Major (Stroke prevention in nonvalvular atrial fibrillation， 3.6%; DVT prophylaxis following hip or knee replacement， 0.3%; treatment of DVT or pulmonary embolism， 1%; reduction in risk of recurrence of DVT or pulmonary embolism， 0.4%; prophylaxis of VTE in acutely ill medical patients， 0.7% ) Immunologic: Angioedema Other: Drug withdrawal， Stroke and non-CNS embolism.,儲存溫度不可超過 30℃,Prophylaxis of CAD and PAD: 2.5mg BID combined with aspirin 100mg QD. This regimen should not be used when acute thrombosis happened.,需調整劑量,[仿單]無授乳婦女使用本品的安全性與有效性資料可供參考。 在老鼠試驗中顯示rivaroxaban可分泌至母乳中，因此僅能在斷奶後使用本品,需調整劑量,沒有資料,No (limited) human data – animal data suggest moderate risk,[仿單]無孕婦使用本品的安全性與有效性資料可供參考。在動物試驗中顯示本品有生殖性毒性。 由於潛在的母體毒性與致畸胎性以及內在的出血風險。 加上rivaroxaban可穿過胎盤，懷孕婦女禁止使用本品。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]無授乳婦女使用本品的安全性與有效性資料可供參考。 在老鼠試驗中顯示rivaroxaban可分泌至母乳中，因此僅能在斷奶後使用本品,AC;AC15;PC;PO;WM;,,,,,
ORANC,Ranolazine,Rancad 500mg extended release,CAVS,Stable angina.,Concurrent use of CYP3A inducers， such as rifampin， rifabutin， rifapentine， phenobarbital， phenytoin， carbamazepine， and St John's wort. Concurrent use of strong CYP3A inhibitors such as ketoconazole， itraconazole， clarithromycin， nefazodone， nelfinavir， ritonavir， indinavir， and saquinavir. Hepatic cirrhosis,Common Gastrointestinal: Constipation (4.5% )， Nausea (4.4% ) Neurologic: Dizziness (6.2% )， Headache (5.5% ) Serious Cardiovascular: Prolonged QT interval， Vasovagal syncope (0.5% to 4% ),25°C以下,Oral: Initial: 500 mg twice daily; may increase to 1000 mg twice daily as needed (based on symptoms); maximum recommended dose: 1000 mg twice daily.,需調整劑量,[仿單]目前沒有Ranolazine分泌於人類乳汁、影響母乳餵養的嬰兒、或影響乳汁分泌的數據。 然而，Ranolazine會出現在授乳大鼠的乳汁內。除考量以母乳哺育的發育和健康益處外，母親對Ranolazine的臨床需求，或任何可能出現在接受Ranolazine母乳餵養之嬰兒或母體潛在的不良反應亦應一併考量。 成年雌性大鼠從妊娠第6天到幼崽出生後第20天口服給予Ranolazine。在母體投與60mg/kg/day 的劑量水平下(根據AUC推定，相當於MRHD)未觀察到對幼崽發育、行為或生殖參數的不良反應。 在導致母體毒性的劑量下，會出現雄性和雌性幼崽死亡率增加和體重減輕，以及雌性幼崽活動力增加的情況。幼崽可能透過母乳接受了少量的Ranolazine。,需調整劑量,沒有資料,No (limited) human data – animal data suggest risk,[仿單]沒有任何孕婦使用 Ranolazine 治療後發生與藥物相關的風險數據。 根據大鼠和兔子的動物試驗結果顯示，當動物曝藥量為最大建議人體劑量(MRHD)的 4 倍時，無證據顯示對胎兒造成損害。 在美國的總人口中，重大先天性缺陷和臨床確診流產的預期背景風險機率分別為 2-4% 和 15-20%。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]目前沒有Ranolazine分泌於人類乳汁、影響母乳餵養的嬰兒、或影響乳汁分泌的數據。 然而，Ranolazine會出現在授乳大鼠的乳汁內。除考量以母乳哺育的發育和健康益處外，母親對Ranolazine的臨床需求，或任何可能出現在接受Ranolazine母乳餵養之嬰兒或母體潛在的不良反應亦應一併考量。 成年雌性大鼠從妊娠第6天到幼崽出生後第20天口服給予Ranolazine。在母體投與60mg/kg/day 的劑量水平下(根據AUC推定，相當於MRHD)未觀察到對幼崽發育、行為或生殖參數的不良反應。 在導致母體毒性的劑量下，會出現雄性和雌性幼崽死亡率增加和體重減輕，以及雌性幼崽活動力增加的情況。幼崽可能透過母乳接受了少量的Ranolazine。,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥為持續性藥效錠，勿將此藥錠咬碎，壓碎，剝半或磨粉。
ORISD,Risperidone,Apa-Risdol 2mg,CNEU,Treatment of schizophrenia， including 1st episode psychoses， acute schizophrenic exacerbations， chronic schizophrenia， & other psychotic conditions. Alleviates affective symptoms (eg. depression， guilt feelings， anxiety) associated with schizophrenia. Long-term therapy for the prevention of relapse in chronic schizophrenia. Treatment of behavioral disturbances in patients with dementia. As adjunctive therapy to mood stabilizers or monotherapy in the treatment of manic episodes associated with bipolar disorder. Treatment of conduct & other disruptive behavioral disorders in children， adolescents & adults with subaverage intellectual functioning or mental retardation.,Hypersensitivity to any component of the formulation.,Common: insomnia， agitation， anxiety， headache. Less common: somnolence， fatigue， dizziness， impaired concentration， constipation， dyspepsia， nausea/vomiting， abdominal pain， blurred vision， priapism， erectile dysfunction， ejaculatory dysfunction， urinary incontinence， rhinitis， rash & other allergic reactions. Occasionally， orthostatic hypotension， reflex tachycardia or hypertension. Cardiovascular: Peripheral edema (adults， up to 3%; children， less than 5% .)， Tachycardia (oral， adults， up to 5%; children， up to 7% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% ) Dermatologic: Rash (oral， adults， 2% to 4%; children， up to 11% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% ) Endocrine metabolic: Hyperprolactinemia (oral， adults， less than 1%; children， 49% to 87% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Weight gain (oral， adults， up to 18%; children， up to 14%; intramuscular， schizophrenia， 4% to 5%; bipolar I disorder， 5% to 7% ) Gastrointestinal: Abdominal pain (oral， adults， 2% to 4%; children， 15% to 18% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Constipation (oral， adults， 5% to 9%; children， 21% ; intramuscular， schizophrenia， 5% to 7% )， Diarrhea (oral， adults， up to 6%; children， 7% to 8% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Excessive salivation (oral， adults， 1% to 4%; children， up to 22% ; intramuscular， schizophrenia， 1% to 4% )， Increased appetite (oral， children， 4 to 49% ; intramuscular， bipolar I disorder， 4% )， Indigestion (oral， adults， 4% to 10%; children， 5% to 16% ; intramuscular， schizophrenia， 6% )， Nausea (oral， adults， 4% to 9%; children， 8% to 16% ; intramuscular， schizophrenia， 3% to 4% )， Vomiting (oral， children， 10% to 12% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Xerostomia (oral， adults， up to 4%; children， up to 13% ; intramuscular， schizophrenia， 0% to 7%) Musculoskeletal: Pain， in Extremity (intramuscular， schizophrenia， 2% to 6% ) Neurologic: Akathisia (oral， adults， 5% to 9%; children， up to 10% ; intramuscular， schizophrenic adults， 4% to 11% )， Dizziness (oral， adults， 4% to 11%; children， 7% to 16% ; intramuscular， schizophrenia， 7% to 11%; bipolar I disorder， 3% )， Extrapyramidal disease (adults， 7% to 31% )， Headache (intramuscular， 15% to 21% )， Insomnia (oral， adults， less than 1%; children， less than 5% ; intramuscular， schizophrenia， less than 2%; bipolar I disorder， less than 4% )， Parkinsonism (oral， adults， 0.6% to 20%; children， 2% to 16% ; intramuscular， schizophrenia， 8% to 15%; bipolar I disorder， 15% )， Somnolence (oral， adults， 5% to 14%; children， 12% to 67% ; intramuscular， schizophrenia， 5% to 6%; bipolar I disorder， 7% )， Tremor (oral， adults， up to 5% to 6%; children， 10% to 12% ; intramuscular， schizophrenia， 0% to 3%; bipolar I disorder， 24% ),25℃以下乾燥避光,Schizophrenia: Adults: Initial dose:2mg/day， in single-dose， or 2 divided doses. The dose can be increased to 4mg the next day. General dose:4-6mg /day. Dose exceeding 10 mg/day may cause extrapyramidal symptoms. maximum: 16mg/day. Children， 13-17 years old: Initial dose: 0.5mg QD， in the morning or afternoon. Increased by 0.5mg or 1mg daily adjust to 3mg/day. The adjustment interval cannot be less than 24 hours. Effective range:1-6mg/day. Children under 13 years old: lack of data. Elderly (65 years old and above):0.5mg BID， then increased by 0.5mg each dose twice a day to target dose 1-2 mg BID. Manic episodes of bipolar disorder: Adults: Initial dose:2mg or 3mg QD. Increase by 1mg/day if necessary. The adjustment interval cannot be less than 24 hours. Effective range:1-6mg/day. Children， 10-17 years old: Initial dose:0.5mg QD. If necessary， increase by 0.5mg/day or 1mg/day adjust to target dose 2.5mg/day. The adjustment interval cannot be less than 24 hours. Effective range:0.5-6mg. Children under 10 years old: lack of data. Agitation， aggressive behavior， or psychotic symptoms in patients with Alzheimer's disease: Initial dose:0.25mg BID， increased by 0.25mg each dose twice a day adjust to target dose 0.5-1 mg BID. Behavioral Disorders and Other Disruptive Behavior Disorders (5-18 years old): >=50kg:Initial dose:Initial dose:0.5mg/day， increased by 0.5mg/day every two days when necessary. Effective range:0.5-1.5mg. <50kg:Initial dose:Initial dose:0.25mg/day， increased by 0.25mg/day every two days when necessary. Effective range:0.25-0.75mg. Children under 5 years old: lack of data. Agitated symptoms in children and adolescents with autism， children(5-17 years old): <20kg:Initial dose:0.25mg/day(day1-day3)， 0.5mg/day(day4-day14). If necessary， increase by 0.25/day at more than two weeks adjustment interval. Effective range:0.5mg-1.5mg/day >=20kg:Initial dose:0.5mg/day(day1-day3)， 1mg/day(day4-day14). If necessary， increase by 0.5/day at more than two weeks adjustment interval. Effective range:1mg-2.5mg/day.The maximum dose for patients > 45 kg is 3.5 mg/day. Children under 5 years old: lack of data.,需調整劑量,,需調整劑量,除非治療上需要,Compatible – maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,
IADD,Cr+Cu+Fe+Zn+Mn+Se+I+F+Mo,Addamel N inj 10mL/vial (成人用),NUTR,,,,,,,,,,,,,,,,,,,
IPEDI,Cu+Zn+Mn+Se+I+F,Peditrace inj 10mL/vial (小兒用),NUTR,,,,,As TPN material， for TPN Pediatric: 1mL/kg/day， Maximum dose: 15 mL. Each mL contains: Copper chloride dihydrate eq. to Copper 20 mcg Manganese chloride tetrahydrate eq. to Manganese 1 mcg Potassium iodide eq. to Iodine 1 mcg Sodium fluoride eq. to Fluoride 57 mcg Sodium selenite anhydrous eq. to Selenium 2 mcg Zinc chloride eq. to Zinc 250 mcg,無需調整劑量,,無需調整劑量,,,,,,IVA;,,,,,
ODIF5,Fluconazole,Diflucan 50mg,QANB,,適應症: Dermatomycosis including tinea pedis， tinea corporis， tinea cruris， tinea versicolor and candidal infections. 副作用: Nausea， abdominal pain， diarrhoea; rash. 禁忌: Patients with known hypersensitivity to fluconazole or to related azole compounds.,,室溫,Candidemia，disseminated candidiasis & invasive candidias is 400mg daily followed by 200mg daily. Oropharyngeal candidiasis 50mg daily for 7-14 days. Vag candidiasis :150mg as a single dose. Cryptococcosis : Initially 400mg then 200mg daily for 6-8 weeks. Dermal infection (tinea corporis， cruris & dermal candidal infection)150mg once wkly or 50 mg daily 2-4wk， tinea pedis 150 mg once wkly or 50 mg daily for 2-6 wk; tinea versicolor 50mg once daily for 2-4 wk. Prevention of fungal infection in patients with AIDS 50 mg daily.,,,,盡量避免,,,Compatible 哺乳時可使用,,,,,,,
IAPCN,Penicillin G,Penicilina Atral inj 1 MIU/vial,QANB,,Bacterial endocarditis Adult: 1.2 g every 4 hr by slow inj or infusion， usually used with an aminoglycoside. Renal impairment: Dose adjustments may be necessary. Intrapartum prophylaxis against group B Streptoccocal infection in neonates Adult: Initially， 3 g via IV inj， followed by 1.5 g every 4 hr until delivery. Child: 150 mg/kg daily in 4 divided doses. Renal impairment: Dose adjustments may be necessary. Meningococcal meningitis Adult: 2.4 g every 4 hr by slow inj or infusion. Up to 18 g/day in meningococcal meningitis. Administer high doses (>1.2 g) at a rate not >300 mg/minute to prevent CNS irritation and electrolyte imbalance. Child: 1 mth-12 yr: 180-300 mg/kg daily in 4-6 divided doses. Infant 1-4 wk: 150 mg/kg daily in 3 divided doses. Premature infant and neonate: 100 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary. Pneumococcal meningitis Adult: 2.4 g every 4 hr by slow inj or infusion. Up to 18 g/day in meningococcal meningitis. Administer high doses (>1.2 g) at a rate not >300 mg/minute to prevent CNS irritation and electrolyte imbalance. Child: 1 mth-12 yr: 180-300 mg/kg daily in 4-6 divided doses. Infant 1-4 wk: 150 mg/kg daily in 3 divided doses. Premature infant and neonate: 100 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary. Susceptible infections Adult: 0.6-4.8 g/day in 2-4 divided doses via IM， slow IV inj or infusion， higher doses may be needed in more serious infections. IV doses >1.2 g should be given at a rate of not >300 mg/minute. Child: 1 mth-12 yr: 100 mg/kg daily in 4 divided doses. Infant 1-4 wk: 75 mg/kg daily in 3 divided doses. Premature infant and neonate up to 7 days old: 50 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary.,,室溫,Bacterial endocarditis Adult: 1.2 g every 4 hr by slow inj or infusion， usually used with an aminoglycoside. Renal impairment: Dose adjustments may be necessary. Intrapartum prophylaxis against group B Streptoccocal infection in neonates Adult: Initially， 3 g via IV inj， followed by 1.5 g every 4 hr until delivery. Child: 150 mg/kg daily in 4 divided doses. Renal impairment: Dose adjustments may be necessary. Meningococcal meningitis Adult: 2.4 g every 4 hr by slow inj or infusion. Up to 18 g/day in meningococcal meningitis. Administer high doses (>1.2 g) at a rate not >300 mg/minute to prevent CNS irritation and electrolyte imbalance. Child: 1 mth-12 yr: 180-300 mg/kg daily in 4-6 divided doses. Infant 1-4 wk: 150 mg/kg daily in 3 divided doses. Premature infant and neonate: 100 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary. Pneumococcal meningitis Adult: 2.4 g every 4 hr by slow inj or infusion. Up to 18 g/day in meningococcal meningitis. Administer high doses (>1.2 g) at a rate not >300 mg/minute to prevent CNS irritation and electrolyte imbalance. Child: 1 mth-12 yr: 180-300 mg/kg daily in 4-6 divided doses. Infant 1-4 wk: 150 mg/kg daily in 3 divided doses. Premature infant and neonate: 100 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary. Susceptible infections Adult: 0.6-4.8 g/day in 2-4 divided doses via IM， slow IV inj or infusion， higher doses may be needed in more serious infections. IV doses >1.2 g should be given at a rate of not >300 mg/minute. Child: 1 mth-12 yr: 100 mg/kg daily in 4 divided doses. Infant 1-4 wk: 75 mg/kg daily in 3 divided doses. Premature infant and neonate up to 7 days old: 50 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary.,,,,可能安全,,,Compatible 哺乳時可使用,,IM;IV;,,,,,1. 注射前檢查病患是否有PCN過敏史。 2. 注射高劑量 (每日大於1千萬單位) 時，應減慢注射速率並監測電解質狀態。 3. Penicillin G sodium 含鈉量：1.68 mEq/100萬單位 (每瓶含有5.04 mEq 鈉)。 4. (IV infusion) 以適當輸注液稀釋成 50，000-100，000 unit/mL，緩慢滴注15 ~ 30分鐘。 5. 滲透壓與周邊靜脈給藥最大稀釋濃度：154000 units/mL in D/W，76000 units/mL in N/S，85000 units/mL in D5W。
OBOW,Picosulfate + MgO + Citric acid,Bowklean powder 16.2gm， 2pk/box,ALIM,Bowel cleansing prior to colonoscopy,Hypersensitivity to sodium picosulfate， magnesium oxide， anhydrous citric acid， or any component of the formulation; GI obstruction or ileus; bowel perforation; gastric retention; toxic colitis; toxic megacolon; severe renal impairment (CrCl <30 mL/minute).,>10%: Endocrine & metabolic: Hypermagnesemia (9% to 12%) Genitourinary: Decreased estimated GFR (eGFR; ?48 hours after colonoscopy: 10% to 29%) 1% to 10%: Central nervous system: Headache (2% to 3%) Endocrine & metabolic: Hypokalemia (5% to 7%)， hypochloremia (1% to 4%)， hyponatremia (1% to 4%) Gastrointestinal: Nausea (3%)， vomiting (1%) Renal: Increased serum creatinine (5%) <1% (Limited to important or life-threatening): Hypersensitivity reaction， ischemic colitis， seizure， ulcer (aphthoid ileal),25℃以下,First sachet in 150 mL water， in the evening before the colonoscopy (5 PM-9 PM)， (After taking the medicine， replenish 250mL clear liquid drink at least 5 times before going to bed， and drink it within 5 hours). Followed by the second sachet in 150 mL water (5 oz) ~5 hours before the colonoscopy. (After taking the second dose ， replenish 250mL clear liquid drink at least 3 times ， and drink it before the colonoscopy 2 hours.),無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,PO;,,,,,
OREOS,Risedronic acid,Reosteo 150mg,META,Treatment of osteoporosis in postmenopausal women to increase bone mass & reduce incidence of fractures， including those of the hip & spine (vertebral compression fractures). Treatment of osteoporosis in men to increase bone mass.,Esophageal abnormalities (eg， stricture or achalasia) that delay esophageal emptying. Hypersensitivity to risedronate or any component of the product. Inability to sit or stand upright for at least 30 minutes. Hypocalcemia.,Common Dermatologic: Rash (osteoporosis， 7.9%; Paget disease， 11.5% ) Gastrointestinal: Abdominal pain (osteoporosis， 2.9% to 12.2% ; Paget disease， 11.5% )， Constipation (osteoporosis， 2.9% to 12.9% ; osteoporosis prevention， 6.5%; Paget disease， 6.6% )， Diarrhea (osteoporosis， 4.9% to 10.8% ; Paget disease， 19.7% )， Indigestion (3.9% to 10.8% )， Nausea (osteoporosis， 3.6% to 3.9% ; osteoporosis prevention， 7.3% to 13.2% ; Paget disease， 9.8% ) Musculoskeletal: Backache (adult， 5.9% to 28% ; pediatric， 17% ) Renal: Urinary tract infectious disease (11.1% ) Other: Influenza-like illness (up to 9.8% ) Serious Cardiovascular: Cardiac dysrhythmia (men， 2% )， Peripheral edema (8.2% ) Dermatologic: Hypersensitivity reaction Musculoskeletal: Arthralgia (osteoporosis， 6.8% to 24.7% ; osteoporosis prevention， 13.9%; Paget disease， 32.8% )， Bone pain (adult， 5.3%; acute phase reaction， 1.1% to 7.6%; pediatric， 10% )， Myalgia (1% to 6.7% ; osteoporosis prevention， 5.1% )， Osteonecrosis of jaw Ophthalmic: Iritis， Uveitis Renal: Nephrolithiasis (3% ) Reproductive: Benign prostatic hyperplasia (5% ),25℃以下,150 mg TAB ORALLY taken once monthly or 35 mg TAB orally taken once weekly; take with 6 to 8 ounces of water at least 30 minutes prior to the first food or drink of the day.,無需調整劑量,[仿單]未有相關紀載,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]未有相關紀載,Unknown 沒有資料,[仿單]未有相關紀載,AC;,,,,,[磨粉/管灌註記]本藥不可吸吮、咬碎、壓碎、剝半或磨粉，避免刺激口咽部。
EFPX,Plectranthus amboinicus + Centella asiatica,Fespixon cream 1.25%， 15 gm,TDER,Diabetic foot ulcer.,Hypersensitive to the ingredients of the cream， including Plectranthus amboinicus， Centella asiatica， or excipients.,Cellulitis(6.6%)， Upper respiratory tract infection(4.9%)， Skin ulcer(11.5%)， Hypertension(2.5%)， Peripheral swelling(0.8%)， Staphylococcal infection(0.8%)， Would complication(0.8%)， weight increased(0.8%)， Hyperuricaemia(1.6%)， Dermatitis contact(0.8%)， Eczema(1.6%)， Erythema(0.8%)， Rash(0.8%).,25℃室溫,Apply to the lesion twice a day by fully covering the ulcer. Cream 1.25% contains extracts of Plectranthus amboinicus(PA-F4)， 0.25% + Centella asiatica(S1)， 1%.,無需調整劑量,[仿單]尚不確定PA-F4和S1是否會被分泌至人類乳汁。 由於許多藥物會被分泌至乳汁中，在給授乳的母親使用本品時應格外小心。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]大鼠口服致畸胎性試驗顯示本品不具有致畸胎性。 然而，目前尚未針對懷孕或授乳婦女等特殊族群進行研究，仍不清楚在孕婦使用時是否會造成胎兒傷害，或者會影響生育能力。 只有在明確需要時才可供給孕婦使用。,Unknown 沒有資料,[仿單]尚不確定PA-F4和S1是否會被分泌至人類乳汁。 由於許多藥物會被分泌至乳汁中，在給授乳的母親使用本品時應格外小心。,EXT;,,,,,
OFLAT,Otilonium,Flatin 40mg,ALIM,Relief of abdominal pain due to irritable bowel syndrome.,Glaucoma. Hypersensitivity to Otilonium or any component of product.,Upper abdominal pain， dizziness， headache， dry mouth， nausea， tiredness， itching， erythema， urticaria， angioedema,25℃以下,Oral， 40 mg BID-TID. Adult: Up to 120 mg daily.,無需調整劑量,[仿單]尚無完整的人體懷孕及授乳婦女的研究試驗資料，於此其間不建議使用本藥物。但動物實驗並無致畸胎性報告。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]尚無完整的人體懷孕及授乳婦女的研究試驗資料，於此其間不建議使用本藥物。但動物實驗並無致畸胎性報告。,Unknown 沒有資料,[仿單]尚無完整的人體懷孕及授乳婦女的研究試驗資料，於此其間不建議使用本藥物。但動物實驗並無致畸胎性報告。,AC;AC15;PC;PO;WM;,,,,,
OMEYD,Methylphenidate,Methydur 22mg sustained release,CNEU,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
OCAR1,Propranolol,Cardiolol 10mg,CAVS,Angina， arrhythmias (ventricular and supraventricular)， primary and renal hypertension， migraine， essential tremor， anxiety-induced tachycardia， adjunct in hyperthyroidism， pheochromocytoma.,History of bronchial asthma or bronchospasm， Cardiogenic shock， Decompensated heart failure， Second or third degree heart block (if no pacemaker is present)， Sick sinus syndrome (if no pacemaker is present)， Sinus bradycardia (if no pacemaker is present) [Micromdex] Blood pressure <50/30 mmHg， Hypersensitivity to propranolol hydrochloride or any component of the product， Pheochromocytoma， Premature infants with corrected age <5 weeks， Infants weighing <2 kg,Common: Diarrhea， Vomiting， Dizziness (Hypertension， 4-7% )， Sleep disorder， Fatigue (5-7% ) Serious: Bradyarrhythmia， Cardiogenic shock， Congestive heart failure， Heart block， Heart failure， Hypotension， Prolonged PR interval， Shortened QT interval， Erythroderma， Stevens-Johnson syndrome， Toxic epidermal necrolysis， Hypoglycemia， Anaphylaxis， Cerebrovascular accident， Bronchospasm， Withdrawal symptom,儲存於緊密容器，25℃以下乾燥避光,[Adult dosage] Angina pectoris: Initially 10-20 mg TID-QID， may titrate every 3-7 days gradually to 320 mg/day. Arrhythmia: 10-30mg TID-QID. Migraine prophylaxis: Initially 20mg QID; then up to 160-240 mg/day in divided doses. Hypertension: 120-240 mg/day， may increase to 640mg based on response and tolerability. Thyrotoxicosis: 10-40mg TID-QID. Pheochromocytoma: 20 mg before surgery， TID for 3 days， should be used in conjunction with an alpha-blocker. (Do not start using propranolol before the alpha-blocker has taken effect.) [Pediatric dosage] not yet established. Supraventricular tachycardia: 0.5 to 1 mg/kg/day in 3-4 divided doses.,無需調整劑量,[仿單]有少量排泄於乳汁中，哺乳婦使用時，應就其使用上之危險與效益加以考慮。,無需調整劑量,除非治療上需要,Human data suggest risk in 2nd and 3 rd trimesters,[仿單]本藥在齧齒動物及家兔以高於人用最大劑量數倍的各種劑量下， 研究顯現出胚胎毒與胎兒再吸收。雖然在人體之研究尚未做過， 但是孕婦使用時應就其使用上的危險與效益加以考慮。 新生兒之心動徐緩、低血糖症及呼吸抑制，就認為與懷孕期中使用本藥治療有關。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,[仿單]有少量排泄於乳汁中，哺乳婦使用時，應就其使用上之危險與效益加以考慮。,AC;AC15;PC;PO;WM;,,,,,
ISLQ,Insulin glargine + Lixisenatide,Soliqua inj 100 Unit/50mcg/mL， 3mL Pen,META,Use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who have inadequate control with (1) metformin in combination with another oral antidiabetic agent or metformin in combination with basal insulin (daily dose <60 units)， (2) metformin in combination with a glucagon-like peptide-1 (GLP-1) receptor agonist or metformin in combination with another oral antidiabetic agent and a GLP-1 receptor agonist， or (3) basal insulin (daily dose less than 60 units) or lixisenatide.,History of serious hypersensitivity to insulin glargine， lixisenatide， or any component of the formulation; during episodes of hypoglycemia.,Common: Diarrhea (7%)， Nausea (10%)， Headache (5.4%)， Nasopharyngitis (7%)， Upper respiratory infection (5.5%) Serious: Hypoglycemia (17.8%)， Hypokalemia， Pancreatitis， Cholecystitis， Cholelithiasis， Disorder of gallbladder， Anaphylaxis， Hypersensitivity reaction， Acute injury of kidney， Angioedema,未開封：冷藏(2-8°C)。開封後：不可冷藏，室溫<25°C可保存28天；室溫<30°C可保存14天。,Administer once daily， injected within 1 hour before the same meal each day. Discontinue basal insulin or glucagon-like peptide-1 (GLP-1) receptor agonist therapy prior to initiation. Initial dose: (1) If no previous use of insulin: 10 units (10 units/5 mcg). (2) If using <20 units of **insulin glargine (100 units/ml)**: 10 units (10 units/5 mcg). (3) If using 20-30 units of **insulin glargine (100 units/ml)**: 20 units (20 units/10 mcg). Max: 40 units/day (insulin glargine 40 units + lixisenatide 20 mcg). **Note**: If a different basal insulin is used: - If the basal insulin is given twice daily or if daily insulin glargine (300 units/mL) is used， the previous total daily dose should be reduced by 20% as the starting dose for Soliqua. - For any other basal insulin， the calculation method is the same as for insulin glargine (100 units/mL).,需調整劑量,Insulin glargine: Compatible; lixisenatide: No Human Data—Probably Compatible [仿單] Insulin glargine或lixisenatide是否會從人類乳汁中分泌仍不得而知。 Soliqua不可在哺乳期間使用。,需調整劑量,沒有資料,No (limited) human data – animal data suggest risk,Insulin glargine: Compatible; lixisenatide: No Human Data—Animal Data Suggest Risk [仿單] 尚無Soliqua、insulin glargine或lixisenatide 在對照性臨床試驗中使用於懷孕婦女之臨床資料。對人類的潛在風險尚不清楚。 目前尚無懷孕婦女使用lixisenatide的足夠資料。動物試驗的結果顯示，lixisenatide具有生殖毒性。 Soliqua不應在懷孕期間使用。若病人想要懷孕或已經懷孕，應停用Soliqua。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Insulin glargine: Compatible; lixisenatide: No Human Data—Probably Compatible [仿單] Insulin glargine或lixisenatide是否會從人類乳汁中分泌仍不得而知。 Soliqua不可在哺乳期間使用。,SC;,,,,,1. 未開封時應冷藏(2-8°C)，不可冷凍。開封後：不可冷藏/冷凍，室溫<25°C可保存28天；室溫<30°C可保存14天。 2. Soliqua應注射於腹部、上臂或大腿的皮下。 3. 請勿稀釋本藥或將其與任何其他胰島素藥混合。 4. 不可使用注射器抽取Soliqua預填注射筆卡匣內之藥物。
IFUL,Pegfilgrastim,Fulphila inj 6mg/0.6mL,HEMT,To decrease the incidence of infection， as manifested by febrile neutropenia， in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.,Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.,Common: Bone pain (31%)， Pain in limb (9%) Serious: Aortitis， Capillary leak syndrome， Acute myeloid leukemia， Leukocytosis (<1% )， Myelodysplastic syndrome， Rupture of spleen， Sickle cell anemia with crisis， Thrombocytopenia， Anaphylaxis， Glomerulonephritis， Acute respiratory distress syndrome,於盒內避光冷藏2-8℃,Patients with cancer receiving myelosuppressive chemotherapy: 6 mg subQ once per chemotherapy cycle. Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy.,無需調整劑量,[仿單] 沒有關於pegfilgrastim存在於人乳中、對哺乳兒童的影響或對產乳量的影響之數據。 其他filgrastim藥品很少被分泌於乳汁中及新生兒不會口服吸收filgrastim藥品。 於考量哺乳的發育和健康益處時，母親對pegfilgrastim的臨床需求、pegfilgrastim或潛在的母體狀況對哺乳兒童的潛在不利影響應一併列入考量。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,[仿單] 雖然在懷孕婦女中使用pegfilgrastim的現有數據不足以確定是否存在與主要先天性異常， 流產或不利於母體或胎兒相關的藥物風險，但有已公布的研究顯示懷孕婦女接觸filgrastim藥品的數據， 這些研究尚未確定懷孕期間使用filgrastim藥品與主要先天性異常，流產或不利於母體或胎兒之關聯。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 沒有關於pegfilgrastim存在於人乳中、對哺乳兒童的影響或對產乳量的影響之數據。 其他filgrastim藥品很少被分泌於乳汁中及新生兒不會口服吸收filgrastim藥品。 於考量哺乳的發育和健康益處時，母親對pegfilgrastim的臨床需求、pegfilgrastim或潛在的母體狀況對哺乳兒童的潛在不利影響應一併列入考量。,SC;,,,,,1. 避免振搖。置於室溫(不超過30℃)超過48小時後需丟棄。避免冷凍。 2. 給藥前應目視檢查顆粒物質及變色。當發現顆粒物質或變色時，請勿使用。 3. 單次使用的預充填針筒的針頭蓋含有乾燥的天然橡皮(衍生自乳膠)；對乳膠過敏的人不可使用本產品。
IKET2BAD,Ketamine,Ketamine-hameln 殘餘銷燬(專案) inj 500mg/10mL,ZANE,,,,,,,,,,,,,,IM;IV;IVPUSH;,,,,,
OMTD22,Methylphenidate,Methydur 22mg sustained release,CNEU,Treatment for Attention Deficit Hyperactivity Disorder (ADHD),Hypersensitivity to methylphenidate or other components of the product， Marked agitation， anxiety， and tension; may aggravate symptoms， Glaucoma， Motor tics， Concomitant use of MAOIs， or use within 14 days of MAOI discontinuation， Family history or diagnosis of Tourette syndrome， Fructose intolerance， glucose-galactose malabsorption， or sucrase-isomaltase insufficiency; contains sucrose.,Common: Tachycardia (4.8-7%)， Diaphoresis (Adult， 5.1%)， Weight decreased (2.4-12%)， Abdominal pain (Pediatric 4-15%)， Decrease in appetite (2-35%)， Loss of appetite (Adult 1.7% ; pediatric 3.1-9% or greater )， Nausea (2.4-12.8%)， Vomiting (1.7-9%)， Xerostomia (3-14%)， Dizziness (Adult 6.7%; pediatric 1.9-3%)， Headache (Adult 22.2% ; pediatric 2.4-19%)， Insomnia (2.8-41%)， Anxiety (Adult 8.2%)， Depression (Adult 1.7-3.9%)， Irritability (5.8-10%) Serious: Myocardial infarction， Raynaud's phenomenon， Sudden cardiac death， Decreased body growth， Gastrointestinal obstruction， With preexisting severe gastrointestinal narrowing and use of controlled-release formulations， Abnormal liver function， Cerebral artery occlusion， Cerebral hemorrhage， Cerebrovascular accident， Lowered convulsive threshold， Seizure， Blurred vision (>1.7-2%)， Aggressive behavior (1.7-2.4%)， Mania， Psychotic disorder， Priapism， Drug abuse， Substance dependence,25℃以下乾燥處,Take once daily， within 20 minutes after breakfast， with water. Do not chew， split， or crush the capsules. For patients not previously taking Methylphenidate or other stimulants: 22mg/day. If the desired effect is not achieved: increase dose by 11mg every 7 days (max 44mg/day).,無需調整劑量,,無需調整劑量,除非治療上需要,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記] 本藥為長效錠，請整粒吞服，不可剝半或磨粉。
RIHUM,Adalimumab/Placebo,試Humira-1311.30 (40 mg Adalimumab/Placebo),HIMM,,,,,,,,,,,,,,SC;,,,,,
OCELL,Mycophenolate mofetil,Cellcept 250mg,HIMM,Prophylaxis of acute organ rejection in patients receiving allogeneic renal， cardiac & hepatic transplants， concomitantly w/ cyclosporin & corticosteroids. Induction & maintenance treatment of lupus nephritis， concomitantly w/ corticosteroids.,Hypersensitivity to mycophenolate mofetil or mycophenolic acid (MPA).,Diarrhoea， dyspepsia， vomiting， elevated liver function test， acne， leucopenia， sepsis， certain infections; CV， metabolic， CNS & musculoskeletal events.,25℃以下,Renal transplant 1 g BID. Cardiac & hepatic transplant 1.5 g BID. Lupus nephritis induction dose 0.75-1.5 g BID， maintenance dose 0.25-1 g BID.,需調整劑量,仿單建議:孕婦禁用,需調整劑量,盡量避免,Human (and animal) data suggest risk,,Contraindicated 哺乳期使用禁忌,仿單建議:孕婦禁用,AC;AC15;PC;PO;WM;,,,,,[磨粉/管灌註記]本藥應整粒吞服， 切勿咬嚼、壓碎或打開膠囊。本藥具致畸胎性，請注意相關暴露風險，尤其是婦女及小孩。
IFIB2,Sodium Tetradecyl Sulphate,Fibro-Vein inj 3%， 2mL (專案進口),ZOTH,For the treatment of uncomplicated primary varicose veins， recurrent or residual varicose veins following surgery， reticular veins， venules， and spider veins of the lower extremities that show simple dilation.,Hypersensitivity to sodium tetradecyl sulfate or to any component of the preparation and allergic conditions. Patients were unable to walk due to any cause， bedridden patients. Patients with a high risk of thrombosis e.g. patients with a congenital predisposition to blood clots or with multiple risk factors such as hormonal contraception or hormone replacement therapy， significant obesity， smoking， or extended periods of immobility. Recent acute superficial thrombophlebitis， deep vein thrombosis， or pulmonary embolism. Recent surgery. Varicosities caused by pelvic or abdominal tumors unless the tumor has been removed. Uncontrolled systemic disease such as diabetes mellitus， toxic hyperthyroidism， tuberculosis， asthma， neoplasm， sepsis， blood dyscrasias， and acute respiratory or skin diseases. Evolutive cancer. Significant valvular incompetence of the deep veins. Occlusive arterial disease. Huge superficial veins with wide open communications to deeper veins. Phlebitis migrans. Acute cellulitis. Acute infections. In addition when the sclerosant has been converted to foam: Known symptomatic patent foramen ovale (PFO).,Common Dermatologic: Injection site pain， Injection site ulcer， Injection site urticaria Gastrointestinal: Nausea， Vomiting Neurologic: Headache Serious Cardiovascular: Myocardial infarction Dermatologic: Skin necrosis， Tissue necrosis Hematologic: Arterial embolism， Deep venous thrombosis Immunologic: Allergic reaction， Anaphylaxis Neurologic: Cerebrovascular accident Respiratory: Pulmonary embolism,25℃以下避光避免冷凍,[Micromedex2021/07/29] Venous varices: Because hypersensitivities have occurred， a test dose of 0.5 mL followed by several hours of observation is recommended before larger doses are administered. 0.5 to 2 mL (preferably 1 mL Maximum) IV into the vein intended for sclerosis; the 1% solution is used most often， with the 3% solution being reserved for larger varicosities; Maximum single treatment 10 mL,無需調整劑量,[仿單] It is not known whether sodium tetradecyl sulfate is excreted in human milk. Caution should be exercised when used in nursing mothers. Fertility It is not known whether sodium tetradecyl sulfate affects fertility.,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]Safety for use in pregnancy has not been established. There are no or limited amount of data from the use of sodium tetradecyl sulfate in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. Treatment should be postponed until after childbirth. Fibrovein should be used only when clearly needed for symptomatic relief and when the potential benefits outweigh the potential hazards to the fetus.,Unknown 沒有資料,[仿單] It is not known whether sodium tetradecyl sulfate is excreted in human milk. Caution should be exercised when used in nursing mothers. Fertility It is not known whether sodium tetradecyl sulfate affects fertility.,,,,,,Fibrovein is a single-use parenteral product. Once the container is opened， use immediately and discard any unused portion.
OCAPA,Nefopam,Capain 30mg,CNEU,Relief of pain,Patients with history of syncope. patients with myocardial infarction,Nausea， dizziness， drowsiness， dry mouth， insomnia， paraesthesia， Night sweats.,25℃以下避光,30-60 mg 3 times daily.,無需調整劑量,[仿單]人類哺乳期使用本季之資料缺乏， 故使用時宜小心衡量其優點以及對母子所可能造成之損害.,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]雖在動物試驗未發現畸形胎，但本劑如其他藥一樣，於垣W前三個月內使用時宜謹慎.,Unknown 沒有資料,[仿單]人類哺乳期使用本季之資料缺乏， 故使用時宜小心衡量其優點以及對母子所可能造成之損害.,AC;AC15;PC;PO;WM;,,,,,
LMOR,Morphine,Morphine Sulfate 2mg/mL， 60mL,CNEU,,適應症: Relief of moderate to severe pain. 副作用: Nausea， vomiting， constipation， drowsiness， palpitations， headache， disorientation， vertigo， mood changes， decreased libido， ureteric spasm， urinary retention， rash， sweating， facial flushing， miosis. Cardiovascular: Peripheral edema (5% to 10% ) Dermatologic: Pruritus (up to 80% )， Rash (5% to 10% )， Sweating (5% to 10% ) Gastrointestinal: Abdominal pain (5% to 10% )， Constipation (> 10% )， Diarrhea (5% to 10% )， Loss of appetite (5% to 10% )， Nausea and vomiting (7% to 70% )， Xerostomia (5% to 10% ) Hepatic: Liver function tests abnormal (< 5% ) Musculoskeletal: Backache (5% to 10% ) Neurologic: Asthenia (5% to 10% )， Dizziness (6% )， Headache (>10% )， Insomnia (5% to 10% )， Lightheadedness， Paresthesia (5% to 10% )， Somnolence (> 10% ) Ophthalmic: Amblyopia (< 5% )， Miosis Psychiatric: Anxiety (6% )， Depression (5% to 10% ) Renal: Urinary retention (oral: < 5% ; epidural/intrathecal: 15% to 70% ) Other: Fever (5% to 10% )， Hiccoughs (< 5% ) 禁忌: Respiratory depression， head injury， obstructive airways disease， paralytic ileus， GI obstruction， delayed gastric emptying， acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children < 3 years.,,室溫,10 to 20 mg every 4 hours as needed.,,,,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ITDP4,Tdap-IPV,Boostrix-Polio (四合一，政府提供),HIMM,,適應症: For active immunisation against diphtheria， tetanus， pertussis and poliomyelitis in adults， adolescents and children aged 4 years and older as a booster following primary immunisation. Children 4-6 years of age should have already received four doses of DTPa and IPV or OPV. 副作用: Adolescents and Adults- Injection site pain， erythema and swelling， tiredness， headache， bodyache， chills， nausea， fever， arthralgia or joint swelling (?1/10) Diarrhoea， vomiting (<1/10 and ?1/100) Children 5 to 6 years old - Injection site pain and swelling; fatigue (?1/10) Injection site erythema and pruritus; fever ?38°C (<1/10 and ?1/100) Diarrhoea， vomiting (<1/100 and ?1/1，000) 禁忌: Hypersensitivity. Acute illness eg febrile illness， encephalopathy of unknown origin w/in 7 days of previous pertussis vaccination. Pregnancy & lactation.,,2-8℃,A single 0.5 mL dose， may be administered from the age of four years onwards.,,,,不可使用,,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),,,,,,,
IVAXS,Purified Split Inactivated Influenza Virus,4價自費流感 (VaxigripTetra)0.5mL/dose,HIMM,Active immunisation against influenza， Influenza Vaccine for children aged > or = 6 months and adult.,Hypersensitivity to the active substances， to any of the excipients listed in Description or to any component that may be present as traces such as eggs (ovalbumin， chicken proteins)， neomycin， formaldehyde and octoxinol-9.,Inj site soreness， fever， malaise， myalgia， headache， GI disturbances， lymphadenitis， oculorespiratory syndrome.,2-8°C.請勿冷凍,IM， 0.5 mL， > or = 6 months (< 9 years who have not been vaccinated previously， the 2nd dose can be given after 4 weeks.),無需調整劑量,[仿單]VaxigripTetra可在授乳期間使用。,無需調整劑量,沒有資料,Compatible,[仿單]懷孕婦女是流感併發症的高危險者，包括早產、住院和死亡，所以懷孕婦女應該接種流感疫苗。 VaxigripTetra可在懷孕的任何時期接種。 相較於第一孕期，不活化流感疫苗的安全性資料更多來自於第二孕期及第三孕期接種，第一孕期接種的資料較少。從全球使用不活化流感疫苗（包括VaxigripTetra及三價不活化流感疫苗Vaxigrip）的數據來看，不活化流感疫苗對胎兒及母體並無任何不良影響。 此與第二孕期或第三孕期懷孕婦女接種VaxigripTetra及Vaxigrip (VaxigripTetra接種組有230名孕婦及231名活產嬰兒，Vaxigrip接種組有116名孕婦及119名活產嬰兒)的一項臨床試驗所觀察到的結果一致。 四個臨床研究第二孕期及第三孕期的懷孕婦女接種三價不活化流感疫苗Vaxigrip（超過5000個懷孕接種及超過5000個嬰兒追蹤至產後約6個月）的資料中，胎兒、嬰兒及母親皆沒有顯示任何與疫苗相關的嚴重結果。 在南非及尼泊爾進行的臨床研究，三價不活化流感疫苗Vaxigrip組與安慰劑組在胎兒、新生兒、嬰兒及母親安全性結果方面（包括流產、死胎、早產及低出生體重），兩組間並沒有顯著差異。 一個在馬利(Mali)進行的臨床研究，Vaxigrip組與對照組（四價流行性腦脊髓膜炎疫苗）在早產、死胎及低出生體重/胎兒小於妊娠年齡的發生率，兩組間並沒有顯著差異。 根據一項動物研究的結果顯示，VaxigripTetra不會對懷孕、胚胎/胎兒的發育及出生後的早期發育有直接或間接的傷害。,Compatible 哺乳時可使用,[仿單]VaxigripTetra可在授乳期間使用。,IM;SC;,,,,,1. 可能含有微量雞蛋內容物，例如卵白蛋白(ovalbumin)以及在製程中使用的新黴素(neomycin)、甲醛(formaldehyde)和辛苯聚醇9 (octoxynol-9). 2. 菲流達四價流感疫苗每0.5毫升之劑量含有以下的流感病毒株*（不活化、裂解）： · A/Victoria/2570/2019 (H1N1)pdm09 - like strain (A/Victoria/2570/2019， IVR-215)…15 micrograms HA** · A/Darwin/9/2021 (H3N2) - like strain (A/Darwin/9/2021， IVR-228)…15 micrograms HA** · B/Austria/1359417/2021 - like strain (B/Michigan/01/2021， wild type，)…15 micrograms HA** · B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013， wild type)…15 micrograms HA**
OKIS0,Ribociclib,Kisqali 200mg 63#/盒 (sample),RACA,Treatment of hormone receptor (HR)-positive， human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy.,Known hypersensitivity to Ribociclib succinate.,>10%: Cardiovascular: Peripheral edema (12%) Central nervous system: Fatigue (37%)， headache (22%)， insomnia (12%) Dermatologic: Alopecia (33%)， skin rash (17%)， pruritus (14%) Endocrine & metabolic: Decreased serum potassium (11%) Gastrointestinal: Nausea (52%)， diarrhea (35%)， vomiting (29%)， constipation (25%)， decreased appetite (19%)， stomatitis (12%)， abdominal pain (11%) Genitourinary: Urinary tract infection (11%) Hematologic & oncologic: Neutropenia (75%; grade 3: 50%; grade 4: 10%)， leukopenia (33%; grade 3: 20%; grade 4: 1%)， decreased platelet count (29%; grade 3: 1%)， anemia (18%; grade 4: <1%)， abnormal phosphorus levels (decreased; 13%; grade 3: 5%; grade 4: 1%)， lymphocytopenia (11%; grade 3: 6%; grade 4: 1%) Hepatic: Increased serum ALT (<46%)， increased serum AST (<44%)， increased serum bilirubin (18%) Neuromuscular & skeletal: Back pain (20%) Renal: Increased serum creatinine (20%) Respiratory: Dyspnea (12%) Miscellaneous: Fever (13%),30℃以下,600 mg orally once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. KISQALI can be taken with or without food. Coadminister KISQALI with letrozole 2.5 mg taken once daily throughout the 28-day cycle. Patients should take their dose of KISQALI and letrozole at approximately the same time each day， preferably in themorning.  Recommended Dose Modification for Adverse Reactions: - Starting dose: 600 mg/day (three 200 mg tablets) - 1st dose reduction: 400 mg/day (two 200 mg tablets) - 2nd dose reduction: 200 mg/day (one 200 mg tablet) If further dose reduction below 200 mg/day is required， discontinue the treatment.,需調整劑量,,需調整劑量,不可使用,Uknown 沒有資料,,Unknown 沒有資料,,PO;,,,,,
LTRIL,Oxcarbazepine,Trileptal 60mg/mL， 100mL oral suspension,CNEU,Epilepsy: Partial & generalized tonic-clonic seizures.,Hypersensitivity.,Somnolence， headache， dizziness; diplopia; vomiting， nausea; fatigue. Hyponatremia; agitation， affect lability， confusional state， depression， apathy; ataxia， tremor， nystagmus， disturbance in attention， amnesia; blurred vision， visual disturbance; vertigo; diarrhea， abdominal pain， constipation; rash， alopecia， acne; asthenia. Children 1 mth to <4 yr: Ataxia， irritability， vomiting， lethargy， fatigue， nystagmus， tremor， decreased appetite & increased blood uric acid.,30℃以下,Adult & elderly Mono or combine therapy: 600 mg/day (8-10 mg/kg/day) in 2 divided doses. Maintenance: 600 mg/day & 2400 mg/day. May be increased by a maximum of 600 mg/day increments at approximate weekly intervals. Maximum: 2400 mg/day over 48 hr in a controlled hospital setting. -Childn Mono-& adjunctive therapy: 8-10 mg/kg/day in 2 divided doses. Maintenance: 31-60 mg/kg/day for adjunctive therapy. May be increased by a maximum of 10 mg/kg/day increments at approximate weekly intervals from starting dose to maximum daily dose of 60 mg/kg/day. -Renal impairment CrCl <30 mL/min Start at 300 mg/day & increase slowly to achieve the desired clinical response.,無需調整劑量,,需調整劑量,除非治療上需要,No (limited) human data – animal data suggest risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
HCVDA10,Harvoni +/- Ribavirin (1、4、5、6/12週),HCVDAA0010(C肝全口服新藥健保計畫) 1、4、5、6/12週,QANB,,,,,,,,,,,,,,,,,,,
HCVDA11,Sovaldi + Ribavirin (2/12週),HCVDAA0011(C肝全口服新藥健保計畫) 2/12週,QANB,,,,,,,,,,,,,,,,,,,
EALM,Antazoline + Tetrahydrozoline + Chlorhexidine,Alminto eye drops 10mL,TOPH,Irritant conjunctivitis， allergic inflammatory conditions of the conjunctiva， particularly hay fever conjunctivitis & vernal conjunctivitis.,Narrow-angle glaucoma.,Mild burning sensation; Blurred vision,25℃以下避光儲存,instill 1-2 drops 3 to 4 times daily into the eye.,無需調整劑量,TETRAHYDROZOLINE OPHTHALMIC Sympathomimetic (α-adrenergic) BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible CHLORHEXIDINE Anti-infective BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,無需調整劑量,沒有資料,Uknown 沒有資料,TETRAHYDROZOLINE OPHTHALMIC Sympathomimetic (α-adrenergic) PREGNANCY RECOMMENDATION: No Human Data—Probably Compatible CHLORHEXIDINE Anti-infective PREGNANCY RECOMMENDATION: Compatible,Unknown 沒有資料,TETRAHYDROZOLINE OPHTHALMIC Sympathomimetic (α-adrenergic) BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible CHLORHEXIDINE Anti-infective BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible,OD;OL;OU;,,,,,
ODOM,Domperidone,Domper 10mg,ALIM,Nausea and vomiting or GI motility disorder,Hypersensitivity to domperidone or any component of the formulation; prolactin-releasing pituitary tumor (prolactinoma); known existing prolongation of cardiac conduction intervals， particularly QT; significant electrolyte disturbances; underlying cardiac disease (eg， heart failure); moderate or severe hepatic impairment; patients with GI hemorrhage， mechanical obstruction， or perforation; concomitant use with potent CYP3A4 inhibitors such as azole antifungals (eg， ketoconazole)， macrolides (eg， erythromycin)， protease inhibitors， or nefazodone; concomitant use with QT-prolonging drugs,1% to 10%: Central nervous system: Headache， migraine Gastrointestinal: Xerostomia <1%， postmarketing， and/or case reports: Abdominal cramps， acid regurgitation， change in appetite， conjunctivitis， constipation， diarrhea， dizziness， dysuria， edema， extrapyramidal reaction (rare)， galactorrhea， gynecomastia， heartburn， hot flash， increased serum ALT， increased serum AST， increased serum cholesterol， increased serum prolactin， increased thirst， insomnia， irritability， leg cramps， lethargy， mastalgia， menstrual disease， nausea， nervousness， palpitations， pruritus， skin rash， stomatitis， torsades de pointes， urinary frequency， urticaria， weakness,25℃以下避光,Adult & children > 12 years with > 35kg: 10mg each time， up to 3 times a day; Children < 12 years or > 12 years with < 35kg: 0.25mg/kg each time， up to 3 times a day.,需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
ICER,HPV type16/18 L1 protein,保蓓Cervarix (gsk) 0.5mL/dose,HIMM,Prevention of cervical cancer in females 10-25 years， by protecting against incident & persistent infections， cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) & cervical intraepithelial neoplasia (CIN)， CIN1 & pre-cancerous lesions (CIN2 & CIN3) caused by HPV Types 16 & 18.,Subjects with known hypersensitivity to any component of Cervarix.,Headache， GI disturbances， itch， rash， myalgia， arthralgia， inj site reactions， fatigue， fever.,2-8℃避光避免冷凍,IM， 0.5mL， > or = 15 years 3 doses at 0， 1， and 6 months. 9-14 years can take 3 doses at 0， 1， and 6 months or 2 doses at 0 and 6-12 months.,無需調整劑量,[仿單]目前尚未有臨床研究評估對餵哺母乳之嬰兒的影響， 只有在潛在效益超越可能面臨之風險時才可使用。,無需調整劑量,可能安全,No (limited) human data – probably compatible,[仿單]臨床試驗、懷孕資料庫和流行病學試驗中， 並無發現接種會增加新生兒包括生育缺陷在內的不正常情況。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前尚未有臨床研究評估對餵哺母乳之嬰兒的影響， 只有在潛在效益超越可能面臨之風險時才可使用。,IM;,,,,,1. 使用前應先充分搖勻。 2. 應以肌肉注射的方式施打於上臂三角肌部位。
IGAR,HPV type 6/11/16/18 L1 protein,Gardasil inj 0.5mL/dose (自費),HIMM,,適應症: Prevention of cervical cancer， genital warts & precancerous or dysplastic lesions eg， cervical adenocarcinoma in situ， cervical intraepithelial neoplasia (CIN) grades 2 & 3， vulvar intraepithelial neoplasia (VIN) grades 2 & 3， vag intraepithelial neoplasia grades 2 & 3 (VaIN)， cervical intraepithelial neoplasia grade 1 in girls & women 9-26 yr. 副作用: Injection site reactions， fever， nausea， dizziness. 禁忌: Hypersensitivity.,,2-8℃,0.5 mL IM in the deltoid region of the upper arm or in the higher anterolateral area of the thigh， according to the following schedule: 1st dose: At elected date; 2nd dose: 2 month after the 1st dose; 3rd dose: 6 month after the 1st dose. Girls between the ages of 9 and 13 can also take two doses of vaccination， the second dose should be given 6 to 12 months after the first dose.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – probably compatible,,Compatible 哺乳時可使用,,IM;,,,,,1. 使用前請充分搖勻，使疫苗保持懸浮液的狀態。 2. Gardasil 應以肌肉注射的方式施打於上臂的三角肌區域，或是大腿前外側區域較高的部位。
IGAR9,HPV type 6/11/16/18/31/33/45/52/58 L1 protein,(九價) Gardasil 9 inj 0.5mL/dose,HIMM,For 9 to 45 years old people to prevent diseases caused by human papillomavirus (HPV) (cervical cancer， genital warts & precancerous or dysplastic lesions) Precancerous lesions and cancers of the cervix， vulva， vagina and anus caused by HPV types 6， 11， 16， 18， 31， 33， 45， 52 and 58. Genital warts (condyloma acuminatum) caused by HPV types 6 and 11.,Hypersensitivity，hypersensitivity to yeast.,Injection site reactions， fever， nausea， dizziness.,2-8℃避光,IM， 0.5mL， in the deltoid region of the upper arm or in the higher anterolateral area of the thigh， 9-45 years 3 doses at 0， 2， and 6 months. 9-14 years can also take 2 doses at 0 and 6-12 months.,無需調整劑量,[仿單]現有的資料並不足以評估GARDASIL 9對餵哺母乳之嬰兒或對乳汁生成/分泌作用的影響。 應將餵哺母乳對發育及健康的效益和母親對GARDASIL 9的臨床需求，以及GARDASIL 9或母親 的基礎狀態對餵哺母乳之幼兒的任何可能不良影響放在一起考慮。 就預防性疫苗而言，母親的基礎狀態係指對該疫苗所要預防之疾病的易感性。,無需調整劑量,可能安全,Uknown 沒有資料,[訪單]現有的人類試驗資料並未顯示在懷孕期間施打GARDASIL 9會使發生重大出生缺陷與 流產的風險因使用疫苗而升高。,Unknown 沒有資料,[仿單]現有的資料並不足以評估GARDASIL 9對餵哺母乳之嬰兒或對乳汁生成/分泌作用的影響。 應將餵哺母乳對發育及健康的效益和母親對GARDASIL 9的臨床需求，以及GARDASIL 9或母親 的基礎狀態對餵哺母乳之幼兒的任何可能不良影響放在一起考慮。 就預防性疫苗而言，母親的基礎狀態係指對該疫苗所要預防之疾病的易感性。,IM;,,,,,1. 使用前請充分搖勻，使疫苗保持懸浮液的狀態。 2. Gardasil 9 應以肌肉注射的方式施打於上臂的三角肌區域，或是大腿前外側區域較高的部位。
IGAR9S,HPV type 6/11/16/18/31/33/45/52/58 L1 protein,(九價) Gardasil (限專案員工用) 9 inj 0.5mL/dose,HIMM,,,,,,,,,,,,,,IM;,,,,,
IPED0,DTaP-IPV-HIB,Infanrix (五合一，政府提供) 0.5mL/dose,HIMM,Active immunization of children from 2 months of age to 7 years against diphtheria， tetanus， pertussis， poliomyelitis & invasive Haemophilus influenzae type b disease.,Hypersensitivity to neomycin， streptomycin or polymyxin B. Postpone vaccination in acute febrile illness. Children > 7 yr， adults.,Redness， tenderness & swelling at inj site; fever， crying， drowsiness; decreased feeding， vomiting， irritability.,2-8℃避免冷凍,IM， 0.5 mL， 4 doses at 2， 4， 6 and 18 months. Where more rapid protection is preferred， the first 3 doses may be administered at intervals of 4 weeks.,無需調整劑量,DPT-3 No human Data- Probably Compatible IPV- No Human Data—Probably Compatible HIB-Compatible [仿單]無資料。不應使用於小於六週或滿七歲的孩童或成人。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest low risk,DPT-5 No human data - animal data suggest low risk. IPV-Compatible HIB-Compatible [仿單]無資料。不應使用於小於六週或滿七歲的孩童或成人。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,DPT-3 No human Data- Probably Compatible IPV- No Human Data—Probably Compatible HIB-Compatible [仿單]無資料。不應使用於小於六週或滿七歲的孩童或成人。,IM;,,,,,1. 注射前應充分搖勻。 2. 應以肌肉注射方式投予，最好注射於大腿中段的前外側 (股外側肌) 或手臂的三角肌。超過一歲的孩童，最好是注射在三角肌。
IMAXI,Cefepime,Maxipime inj 500mg,QANB,Treatment of resp tract & skin infections; UTI.,Hypersensitivity to cefepime， other cephalosporins， penicillins， other beta-lactam antibiotics， or any component of the formulation.,Anaphylaxis， rash， pruritus， urticaria; diarrhea， nausea， vomiting， oral moniliasis， colitis， (including pseudomembranous colitis)， taste perversion， constipation， abdominal pain， dyspepsia; vasodilation; dyspnea; headache， dizziness， paresthesia; fever， vaginitis， erythema， genital pruritus， chills & unspecified moniliasis. Local reactions eg phlebitis & inflammation at IV inj site & inflammation or pain at IM inj site; elevations in ALT， AST， alkaline phosphate， total bilirubin， eosinophilia， anemia， thrombocytopenia， prolonged prothrombin time， partial thromboplastin time & +ve Coombs' test w/o hemolysis; transient elevations of BUN &/or serum creatinine， & thrombocytopenia.,30℃以下避光,Adults and children > 40 kg: 0.5-1 g IV/IM every 12 hours; 2 g IV q8-12h for serious infection. Children (2 months to 12 years) 50 mg/kg IV q8-12h; (1 month to 2 months) 30 mg/kg IV q8-12h. *****NEONATE ANTIBIOTICS DOSE***** Cefepime: mild to moderate infection: 30mg/kg Q12H Cefepime: pneumonia or meningitis (due to Pseudomonas aeruginosa or Enterobacter spp) Body weight <1kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50mg/kg Q12H  Age 15-28 day 50 mg/kg Q8H Body weight 1-2kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age<=7ayd 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50mg/kg Q8H,無需調整劑量,,需調整劑量,可能安全,,,Compatible 哺乳時可使用,,IM;IVD;IVP;IVPUSH;,IM: 1.3 mL D/W， N/S，D5W，0.5% Lidocaine IV: 5mL D/W， N/S， D5W,【N/S】可選 。【D5W】可選 。,推注時間至少3 ~ 5分鐘,建議以30分鐘緩慢滴注,1.勿與aminoglycoside類抗生素混合或同時注射 2.勿與vancomycin混合 3.稀釋後，安定性(室溫24小時; 冷藏7日) 4.本產品建議使用20.21或22號針頭進行調配，避免產生膠塞剝落情形.
OCOP,Clopidogrel + Acetylsalicylic acid,CoPlavix 75/100mg,HEMT,Prevention of atherothrombotic events in adult patients already taking both clopidogrel + aspirin. Fixed-dose combination for continuation of therapy in: Non-ST-segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) including patients undergoing stent placement following percutaneous coronary intervention; ST-segment elevation acute MI in medically-treated patients eligible for thrombolytic therapy.,Hypersensitivity to clopidogrel， aspirin or NSAIDs. Patients w/ syndrome of asthma， rhinitis & nasal polyps. Severe hepatic & renal impairment. Active pathological bleeding eg peptic ulcer or intracranial hemorrhage. Pregnancy (3rd trimester).,Dyspepsia， abdominal pain， diarrhea; bleeding， hematoma， epistaxis; esophagitis， esophageal ulceration， perforation; fixed eruption.,25℃以下,75mg/100mg QD.,需調整劑量,,需調整劑量,盡量避免,No (limited) human data – probably compatible,藥品仿單:懷孕前6個月不應使用，最後3個月禁用。,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,PC;PO;,,,,,
IZOL1,Goserelin,10.8mg ZOLADEX LA DEPOT (三個月),RACA,Treatment of prostate cancer. Treatment of breast cancer for premenopausal women.,Hypersensitivity to goserelin， gonadotropin releasing hormone (GnRH)， GnRH agonist analogues， or any component of the product. Pregnancy in females with endometriosis or endometrial thinning， as drug may cause fetal harm and has increased risk of pregnancy loss; must exclude pregnancy prior to therapy and use nonhormonal contraception during therapy and 12 weeks after discontinuation.,Common Cardiovascular: Peripheral edema (21% ) Dermatologic: Acne (42% )， Seborrhea (26% )， Sweating (1% to 45% ) Endocrine metabolic: Atrophy of breast (33% ) Neurologic: Headache (men， greater than 1% to less than 5%; women， 32% to 75% ) Psychiatric: Depression (men， greater than 1% to less than 5%; women， 54% )， Mood swings (60% ) Reproductive: Erectile dysfunction (18% )， Flushing (46% to 96% )， Reduced libido (47.7% to 61% )， Sexual dysfunction (21% )， Vaginitis (5% to 75% ) Other: Pain (8% to 17% ) Serious Cardiovascular: Cardiovascular event risk， Congestive heart failure (5% )， Hemorrhagic shock， Myocardial infarction (greater than 1% to less than 5% )， Prolonged QT interval Dermatologic: Injection site hemorrhage Endocrine metabolic: Diabetes mellitus (10.9% to 22.2% )， Pituitary apoplexy (rare )， Pituitary tumor (rare )， Tumor flare (23% ) Hematologic: Hemorrhage Immunologic: Anaphylaxis， Hypersensitivity reaction (1% or greater ) Neurologic: Cerebrovascular accident (greater than 1% to less than 5% ) Renal: Renal impairment (greater than 1% to less than 5% ) Respiratory: Chronic obstructive pulmonary disease (5% ) Other: Tumor flare (23% ),25℃以下,10.8 mg SC every 12 weeks,無需調整劑量,[仿單]不建議在哺乳期間使用 ZOLADEX LA 10.8mg。,無需調整劑量,沒有資料,Uknown 沒有資料,[仿單]由於在懷孕期間使用 LHRH 促效劑，理論上有造成流產或胎兒異常的風險，因此懷孕期間不應使用 ZOLADEX LA 10.8 mg。 可能懷孕的婦女在使用本品前應仔細檢驗，排除已懷孕的可能。 治療期間應採取荷爾蒙以外之避孕方法，直到月經恢復。,Unknown 沒有資料,[仿單]不建議在哺乳期間使用 ZOLADEX LA 10.8mg。,SC;,,,,,
IPREC,Dexmedetomidine,Precedex inj 200mcg/2mL,ZANE,Sedation during surgery or procedure and during ICU care,Hypersensitivity to dexmedetomidine or any component of the formulation.,>10%:Hypotension (24% to 56%)， bradycardia (5% to 42%)， systolic hypertension (28%)， tachycardia (25%)， hypertension (diastolic; 12%)， hypertension (11%)， Agitation (5% to 14%)， Constipation (6% to 14%)， nausea (3% to 11%)， Respiratory depression (37%; placebo 32%) 1% to 10%: Atrial fibrillation (2% to 9%)， peripheral edema (3% to 7%)， hypovolemia (3%)， edema (2%)， Anxiety (5% to 9%)， Hypokalemia (9%)， hyperglycemia (7%)， hypoglycemia (5%)， increased thirst (2%)， hypocalcemia (1%)， hypomagnesemia (1%)， Xerostomia (3% to 4%)， Oliguria (2%)， Anemia (3%)， Acute renal failure (2% to 3%)， decreased urine output (1%)， Respiratory failure (2% to 10%)， adult respiratory distress syndrome (1% to 9%)， pleural effusion (2%)， wheezing (?1%)， Fever (5% to 7%)， withdrawal syndrome (ICU sedation; 3% to 5%) Postmarketing and/or case reports: Abdominal pain， acidosis， apnea， atrioventricular block， bronchospasm， cardiac arrhythmia， cardiac disease， chills， confusion， convulsions， decreased visual acuity， delirium， diaphoresis， diarrhea， dizziness， drug tolerance (use >24 hours)， dyspnea， extrasystoles， hallucination， headache， heart block， hemorrhage， hepatic insufficiency， hyperbilirubinemia， hypercapnia， hyperkalemia， hypernatremia， hyperpyrexia， hypoventilation， hypoxia， illusion， increased blood urea nitrogen， increased gamma-glutamyl transferase， increased serum alkaline phosphatase， increased serum ALT， increased serum AST， inversion T-wave on ECG， myocardial infarction， neuralgia， neuritis， pain， photopsia， polyuria， prolonged Q-T interval on ECG， pulmonary congestion， respiratory acidosis， rigors， seizure， sinoatrial arrest， speech disturbance， supraventricular tachycardia， tachyphylaxis (use >24 hours)， variable blood pressure， ventricular arrhythmia， ventricular tachycardia， visual disturbance， vomiting,室溫 20-25℃,Precedex injection do not continue infusion for more than 24 hours. ICU sedation: IV: Initial: Loading infusion of 0.5-1 mcg/kg over 10 minutes， followed by a maintenance infusion of 0.2-0.7 mcg/kg/hour; adjust rate to desired level of sedation; titration no more frequently than every 30 minutes may reduce the incidence of hypotension. Procedural sedation: IV: Initial: Loading infusion of 0.5-1 mcg/kg (0.5 mcg/kg for less invasive procedures) over 10 minutes， followed by a maintenance infusion of 0.2-1 mcg/kg/hour， titrate to desired effect. Fiberoptic intubation (awake): IV: Initial: Loading infusion of 1 mcg/kg over 10 minutes， followed by a maintenance infusion of 0.7 mcg/kg/hour until endotracheal tube is secured.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,IVD;,,【D5W】可選 仿單建議。【L/R】可選 仿單建議。【N/S】可選 仿單建議。,,使用Precedex之前，必須以0.9%氯化鈉溶液稀釋至所需要的濃度（4 mcg/mL）。無論是準備初始劑量或維持劑量，製備輸注溶液的方式都一樣，且均須嚴守無菌操作。 準備輸注溶液時，抽出2 mL Precedex，加入48 mL 0.9%氯化鈉溶液中使成為50 mL。輕搖混勻。,使用注射製劑前，在溶液與容器許可的狀況下，都應目視檢查是否有微粒物質及變色情形。
IXOL0,Omalizumab,Xolair inj 150mg/1.2mL (sample),ERSP,--Treatment of moderate to severe persistent asthma in adults and adolescents 12 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. --Chronic idiopathic urticaria: Treatment of chronic idiopathic urticaria in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamine treatment.,Hypersensitivity reaction to omalizumab or any component of the formulation,副作用: >10%: Central nervous system: Headache (6% to 12%) 1% to 10%: Cardiovascular: Peripheral edema (>2%) Central nervous system: Anxiety (>2%)， migraine (>2%) Dermatologic: Alopecia (>2%) Gastrointestinal: Toothache (>2%) Genitourinary: Urinary tract infection (>2%) Infection: Fungal infection (>2%) Local: Injection site reaction (3%) Neuromuscular & skeletal: Arthralgia (3%)， limb pain (>2%)， musculoskeletal pain (>2%)， myalgia (>2%) Respiratory: Nasopharyngitis (9%)， sinusitis (5%)， upper respiratory tract infection (3%)， asthma (>2%)， oropharyngeal pain (>2%)， sinus headache (>2%)， cough (2%)， viral upper respiratory tract infection (<2%) Miscellaneous: Fever (>2%) All indications: <1% (Limited to important or life-threatening): Alopecia， anaphylaxis， antibody development， arthritis， chest tightness， Churg-Strauss syndrome， lymphadenopathy， malignant neoplasm， pulmonary hypertension， syncope， thrombocytopenia， transient ischemic attacks,2-8℃避光避免冷凍,Allergic asthma: The appropriate dose and frequency of Xolair is determined by baseline IgE (IU/ml)， measured before the start of treatment， and body weight (kg). Prior to administration of the initial dose， patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements， 75 to 600 mg of Xolair in 1 to 4 injections may be needed for each administration. Chronic spontaneous urticaria(CSU): Usual dose: 150 or 300 mg every 4 weeks. Dosing for this indication is not dependent on serum IgE (free or total) level or body weight.,無需調整劑量,,無需調整劑量,可能安全,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,SC;,使用所附稀釋溶液,,,,1.本藥僅供單次使用的小瓶，配製後藥品於2℃至8℃可放置8 小時，於30℃下為4 小時。 2.以配備有大內徑18 號針頭，自安瓿中抽1.4 毫升注射用水，並注入omalizumab 小瓶中。 3. 將小瓶保持直立，不停地旋轉直立小瓶（不可上下搖動），凍晶乾粉完全溶解可能花費超過20 分鐘。配製後藥品為澄清或些許不透明感。若有異物即不可使用。 4. 以 25 號針頭進行皮下注射。排除氣體、大氣泡及多餘的溶液，此注射小瓶含1.2 毫升（150 毫克）的喜瑞樂。因溶液較粘稠，注射需5-10 秒。 5. 於手臂或大腿的三角肌區域進行皮下注射，避開蕁麻疹病灶處。
ODAK,Daclatasvir,Daklinza 60mg,QANB,Chronic hepatitis C: Treatment of chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection in combination with sofosbuvir， with or without ribavirin,Concurrent use of strong CYP3A inducers (eg， carbamazepine， phenytoin， rifampin， St John's wort). When used in combination with other agents (eg， ribavirin)， the contraindications to those agents also apply (refer to respective labeling information).,>10%: Central nervous system: Fatigue (14% to 15%)， headache (12% to 14%) Gastrointestinal: Nausea (8% to 15%) Hematologic & Oncologic: Anemia (20%) 1~10% Central nervous system: Drowsiness (5%)， insomnia (3%) Dermatologic: Skin rash (8%) Gastrointestinal: Diarrhea (3% to 5%)， increased serum lipase (>3x ULN， transient),30℃以下,Not indicated as monotherapy. The American Association for the Study of Liver Diseases/Infectious Diseases Society of America guidelines for testing， managing， and treating hepatitis C no longer include daclatasvir as a component of recommended treatment regimens for hepatitis C virus infection (AASLD/IDSA 2020). (仿單) 60 mg orally once daily with or without food in combination with other agents for chronic hepatitis C.,無需調整劑量,以上懷孕及哺乳分級參考資料來源為藥品仿單,無需調整劑量,不可使用,No (limited) human data – animal data suggest low risk,,No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體),以上懷孕及哺乳分級參考資料來源為藥品仿單,AC;AC15;PC;PO;WM;,,,,,
OSEF,Ceftibuten,Seftem 100mg,QANB,,適應症:Treatment of acute bacterial exacerbations of chronic bronchitis and acute bacterial otitis media. 副作用: Central nervous system: Headache (<3%)， dizziness (<1%) Gastrointestinal: Nausea (<4%)， diarrhea (3% to 4%)， dyspepsia (<2%)， loose stools (<2%)， abdominal pain (1% to 2%)， vomiting (1% to 2%) Hematologic & oncologic: Eosinophilia (3%)， decreased hemoglobin (1% to 2%)， change in platelet count (increase: <1%) Hepatic: Increased serum ALT (<1%)， increased serum bilirubin (<1%) Renal: Increased blood urea nitrogen (2% to 4%) <1%， postmarketing， and/or case reports: Agitation， anorexia， aphasia， candidiasis， constipation， dehydration， diaper rash， drowsiness， dysgeusia， dyspnea， dysuria， eructation， fatigue， fever， flatulence， hematuria， hyperkinesia， increased serum alkaline phosphatase， increased serum AST， increased serum creatinine， insomnia， irritability， jaundice， leukopenia， melena， nasal congestion， paresthesia， pruritus， pseudomembranous colitis， psychosis， rigors， serum sickness， skin rash， Stevens-Johnson syndrome， stridor， thrombocytopenia， toxic epidermal necrolysis， urticaria， vaginitis， xerostomia 禁忌:Hypersensitivity to ceftibuten， other cephalosporins， or any component of the formulation.,,,Adult:200 mg twice daily Gonorrhea urethritis:100 mg 3 times daily Acute bacterial otitis media:Infants and Children 6 months to <12 years: Oral: 9 mg/kg/dose once daily (maximum dose: 400 mg/day) for 10 days; Children >=12 years and Adolescents: Oral: Refer to adult dosing.,無需調整劑量,,需調整劑量,可能安全,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,,,,,,
ORIZ,Rizatriptan,Rizatan 5mg,CNEU,Acute treatment of migraine with or without aura,Hypersensitivity to rizatriptan or any component of the formulation; documented ischemic heart disease or other significant cardiovascular disease; coronary artery vasospasm (including Prinzmetal's angina); history of stroke or transient ischemic attack; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; basilar or hemiplegic migraine; during or within 2 weeks of MAO inhibitors; during or within 24 hours of treatment with another 5-HT1 agonist， or an ergot-containing or ergot-type medication (eg， methysergide， dihydroergotamine),Cardiovascular: Chest pain (<3%)， flushing (>1%)， palpitations (>1%)， flushing Central nervous system: Dizziness (4% to 9%)， drowsiness (4% to 8%)， fatigue (adults: 4% to 7%; children: >1%)， paresthesia (3% to 4%)， pain (3%)， feeling of heaviness (<2%)， headache (<2%)， euphoria (>1%)， hypoesthesia (>1%) Gastrointestinal: Nausea (4% to 6%)， xerostomia (3%)， sore throat (<2%)， abdominal distress (children: >1%)， diarrhea (>1%)， vomiting (>1%) Neuromuscular & skeletal: Weakness (4% to 7%)， jaw pain (<2%)， jaw pressure (<2%)， jaw tightness (<2%)， neck pain (<2%)， neck pressure (<2%)， neck tightness (<2%)， tremor (>1%) Respiratory: Pharyngeal edema (<2%)， pressure on pharynx (<2%)， dyspnea (>1%),30℃以下,Migraine， acute: Adult: 5-10 mg， repeat after 2 hours if significant relief is not attained; maximum: 30 mg/24 hours. Children 6-17 years old: < 40 kg， 5 mg; > 40 kg， 10 mg. Maximum: 1 dose/24 hour. Children with concomitant propranolol use: > 40 kg， 5 mg in a 24-hour period; < 40 kg， rizatriptan is not recommended.,無需調整劑量,,無需調整劑量,除非治療上需要,No (limited) human data – animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,,AC;AC15;PC;PO;WM;,,,,,
LPIR,Piracetam,Piracetam soln 200mg/mL， 200mL,CNEU,Treatment of cerebrovascular insufficiency & age-related cognitive impairment; adjunct in the treatment of myoclonus of cortical origin.,Severe renal impairment. Cerebral haemorrhage. Pregnancy and lactation.,Hyperkinesia， nervousness， depression， diarrhoea， rashes. CNS stimulation， sleep disturbances， dizziness， excitement， insomnia， somnolence， wt gain.,室溫,Oral Cognitive enhancer in cerebrocortical insufficiency Adult: 1.2~2.4 g daily. Up to 4.8 g daily may be used in severe cases. Adjunct in cortical myoclonus [Handbook of Pediatric Drug Therapy and Immunization. 3rd Edition(2020)] Children:40mg/kg/day divided Q8H Adult: 7.2 g daily in 2-3 divided doses， increased by 4.8 g/day every 3-4 days. Maximum dose: 24 g daily.,無需調整劑量,,需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,AC;AC15;PC;PO;WM;,,,,,
OESM,Ulipristal,Esmya 5mg,HM,,適應症:Pre-op or intermittent treatment of moderate to severe uterine fibroids in women of reproductive age. 副作用: >10%: Central nervous system: Headache (1% to 16%) Endocrine & metabolic: Hot flash (1% to 25%) 1% to 10%: Cardiovascular: Edema (<=1%)， hypotension (<=1%)， sinus bradycardia (<=1%) Central nervous system: Fatigue (<=4%)， vertigo (<=4%)， insomnia (<=2%)， dizziness (1%)， aggressive behavior (<=1%)， drowsiness (<=1%)， emotional lability (<=1%)， migraine (<=1%)， sleep disorder (<=1%) Dermatologic: Night sweats (<=2%)， acne vulgaris (<=1%)， alopecia (<=1%)， seborrhea (<=1%)， xeroderma (<=1%) Endocrine & metabolic: Hypercholesterolemia (3%)， hypertriglyceridemia (<=3%)， hypothyroidism (<=2%)， obesity (1%)， amenorrhea (<=1%)， increased gamma-glutamyl transferase (<=1%)， ovarian cyst (<=1%)， ovarian hyperstimulation (<=1%)， thyroid disease (<=1%) Gastrointestinal: Nausea (3%)， constipation (1%)， dyspepsia (<=1%)， upper abdominal pain (<=1%) Genitourinary: Mastalgia (2%)， pelvic pain (1% to 2%)， endometrial hyperplasia (<=2%)， genital bleeding (<=2%)， breast swelling (<=1%)， breast tenderness (<=1%)， genital discharge (<=1%)， uterine disease (<=1%)， uterine hemorrhage (<=1%)， vaginal dryness (<=1%)， vulvovaginal candidiasis (<=1%) Infection: Herpes virus infection (<=1%) Neuromuscular & skeletal: Arthralgia (2%)， muscle spasm (<=2%)， back pain (<=1%)， limb pain (<=1%) Respiratory: Dyspnea (<=1%)， epistaxis (<=1%)， pharyngitis (<=1%) Miscellaneous: Fever (<=1%) 禁忌:Hypersensitivity to ulipristal or any component of the formulation; pregnancy; breast-feeding; genital bleeding of unknown etiology or for reasons other than uterine fibroids; cancer of the breast， cervix， uterus， or ovaries; continuous use longer than 3 months,,室溫,Adult 1 tab once daily for up to 3 mth. Start during the 1st wk of menstruation. If required， 3-mth treatment course can be repeated once. Start treatment at the earliest during 2nd menstruation after completing the initial course,,,無需調整劑量,不可使用,Contraindicated,,Contraindicated 哺乳期使用禁忌,,,,,,,
OUFR,Levetiracetam,UFree ER 500mg,CNEU,,適應症:Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 12 years with epilepsy. 副作用: Most common: Somnolence， asthenia. Others: dizziness， convulsion， headache， hyperkinesia. ataxia， tremor， amnesia， agitation， aggression， anger， anxiety， confusion， depression， emotional instability， hallucination， hostility， insomnia， irritability， or nervousness， mental disorder， personality disorders， thinking abnormal， suicide， suicide attempt & suicidal ideation， GI disturbances， anorexia， vertigo， accidental injury， infection， cough increased， rash， alopecia， diplopia， decreased number of RBC， WBC &/or blood platelets. Gastrointestinal: Loss of appetite (partial onset seizures， adults， 3% ; pediatrics， 13% )， Vomiting (partial onset seizures， pediatrics， 15% ) Immunologic: Infectious disease (partial onset seizures， adults， 13% ) Neurologic: Asthenia (partial onset seizures， adults， 14.7% ; pediatrics， 8.9% )， Dizziness (5% to 9% )， Headache (partial onset seizures， adults， 14% )， Somnolence (8% to 45% ) Psychiatric: Abnormal behavior， Depression (3% to 5% )， Feeling nervous (partial onset seizures， adults， 4% ; pediatrics， 10% )， Hostile behavior (partial onset seizures， adults， 2% ; pediatrics， 12% )， Mood disorder， Mood swings (2% to 6% ) Respiratory: Cough (partial onset seizures， adults， 2% ; pediatrics， 11% )， Nasopharyngitis (7% to 14% )， Pharyngitis (6% to 10% )， Rhinitis (partial onset seizures， adults， 4% ; pediatrics， 13% ) Other: Fatigue (primary generalized tonic-clonic seizures， 10% )， Pain (partial onset seizures， adults， 7% ; pediatrics， 6% ) 禁忌: Patients with hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients of Keppra.,,室溫,Monotherapy for partial seizures with or without secondary generalisation Adult: Recommended starting dose is 250 mg bid， increased to an initial therapeutic dose of 500 mg bid after 2 wk. May further increase by 250 mg bid every 2 wk depending upon response. Max: 1，500 mg bid.,無需調整劑量,1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) Levetiracetam is detected in breastmilk， with a mean milk/maternal plasma ratio of approximately 1; adverse effects in the nursing infants were not reported. Based on limited data， maternal use of levetiracetam appears to be safe for the nursing infant. However， the manufacturer cautions that due to the potential for adverse reactions in nursing infants， either nursing or the drug should be discontinued.,需調整劑量,除非治療上需要,,,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) Levetiracetam is detected in breastmilk， with a mean milk/maternal plasma ratio of approximately 1; adverse effects in the nursing infants were not reported. Based on limited data， maternal use of levetiracetam appears to be safe for the nursing infant. However， the manufacturer cautions that due to the potential for adverse reactions in nursing infants， either nursing or the drug should be discontinued.,,,,,,
ILEV1,Norepinephrine,Levophed Bitartrate inj 4mg/4mL,CAVS,,適應症: Restoration of BP in acute hypotensive states. Adjunct in the treatment of cardiac arrest & profound hypotension. 副作用: Occasionally， bradycardia; anxiety， transient headache. Plasma vol depletion (prolonged administration). Respiratory difficulty， ischemic injury. 禁忌: Patients who are hypotensive from blood vol deficits except as emergency measure until blood vol therapy can be completed. Cyclopropane & halothane anesth， mesenteric or peripheral vascular thrombosis.,,室溫,4 mL amp to 1000 mL of 5% dextrose soln. IV infusion， Adult: 8-12 mcg/min initially， adjusting rate to maintenance a systolic blood pressure = 80-100 mmHg， average maintenance dose: 2-4 mcg/min. Child: 2 mcg/m2/min (max. 6 mcg/m2/min).,,,,除非治療上需要,,,No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用,,,,,,,1.不建議用NS
OFZP,Flunitrazepam,Fluzepam 2mg,CNEU,,適應症: Insomnia. 副作用: Drowsiness & lightheadedness the next day; confusion & ataxia; dependence. 禁忌: Preexisting CNS depression or coma， resp depression， acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; chronic psychosis， phobic or obsessional states; may precipitate suicide or aggressive behavior; not to be used alone to treat depression or anxiety associated with depression; glaucoma. Pregnancy， lactation. Neonates.,,室溫,Adult 0.5-1 mg at bedtime. Max: 2 mg/day. Elderly or debilitated patients Initially 0.5 mg at bedtime. Max: 1 mg/day.,,,,盡量避免,,,Human Data Suggest Potential Toxicity,,,,,,,
EFUC2,Fusidic Acid,Fucidin cream 2%， 15gm,TDER,Skin infections caused by Staph， Strep & other organisms sensitive to fusidic acid.,Hypersensitivity to fusidic acid or any component of the formulation.,Angioedema， application site irritation， application site pain， conjunctivitis， dermatitis， erythema， hypersensitivity reaction， pruritus， skin blister， skin irritation， skin rash， urticaria.,30℃以下,Apply BID-TID,無需調整劑量,,無需調整劑量,沒有資料,Uknown 沒有資料,,Unknown 沒有資料,,EXT;,,,,,
IPNE,Pneumococcal Vaccine Polyvalent,Pneumovax 23 (自費) 0.5mL/dose 23價肺炎疫苗,HIMM,Immunization against pneumococcal disease caused by those pneumococcal types included in the vaccine,Hypersensitivity. Revaccination of adults with Pneumovax 23 is contraindicated except for those at highest risk of pneumococcal infections. Patients with Hodgkin's disease immunised < 7 to 10 days prior to or during immunosuppressive therapy & patients with Hodgkin's disease who have received extensive chemotherapy &/or nodal irradiation.,Local inj-site soreness， warmth， erythema & swelling. Fever， headache， malaise， rash， urticaria， arthritis， arthralgia.,2-8℃,IM or SC， 0.5mL， > or = 2 years a single dose.,無需調整劑量,[仿單]目前尚不知是否會分泌至人類乳汁，因此接種之授乳婦女需注意。,無需調整劑量,除非治療上需要,Compatible,[訪單]目前不知懷孕婦女接種後是否會造成胎兒的傷害或影響其生育力， 只有在明確知道必施打的情況下，孕婦才能施打。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前尚不知是否會分泌至人類乳汁，因此接種之授乳婦女需注意。,IM;,,,,,
IPNE0,Pneumococcal Vaccine Polyvalent,Pneumovax 23 (23價肺炎，政府提供) 0.5mL/dose,HIMM,Immunization against pneumococcal disease caused by those pneumococcal types included in the vaccine,Hypersensitivity. Revaccination of adults with Pneumovax 23 is contraindicated except for those at highest risk of pneumococcal infections. Patients with Hodgkin's disease immunised < 7 to 10 days prior to or during immunosuppressive therapy & patients with Hodgkin's disease who have received extensive chemotherapy &/or nodal irradiation.,Local inj-site soreness， warmth， erythema & swelling. Fever， headache， malaise， rash， urticaria， arthritis， arthralgia.,2-8℃,IM or SC， 0.5mL， > or = 2 years a single dose.,無需調整劑量,[訪單]目前尚不知是否會分泌至人類乳汁，因此接種之授乳婦女需注意。,無需調整劑量,沒有資料,Compatible,[訪單]目前不知懷孕婦女接種後是否會造成胎兒的傷害或影響其生育力， 只有在明確知道必施打的情況下，孕婦才能施打。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[訪單]目前尚不知是否會分泌至人類乳汁，因此接種之授乳婦女需注意。,IM;,,,,,
IPR13,Pneumococcal Vaccine Polyvalent,Prevenar 0.5mL/dose (13價肺炎疫苗),HIMM,Active immunisation of infants & toddlers against invasive disease caused by Strep pneumoniae serotypes (4， 6B， 9V， 14， 18C， 19F & 23F) at 2， 4， 6 & 12-15 months of age. Active immunisation of infants & toddlers < 2 years against otitis media caused by Strep pneumoniae serotypes (1， 2， 3， 4， 5， 6A， 7F， 9V， 14， 18C， 19A， 19F & 23F).,Hypersensitivity to any component of the formulation.,Decreased appetite， vomiting， diarrhoea， injection site reactions (e.g. erythema， induration/swelling， pain/tenderness)， tenderness interfering with movement， fever， irritability， drowsiness， restless sleep.,2-8℃避免冷凍,IM， 0.5mL， children 2-6 months 3 doses primary immunization at intervals of 1 month (the 1st dose can be given at 6 weeks of age)， a booster dose at 12-15 months. 7-11 months 2 doses primary immunization at an interval of 1 month ， a booster dose at 12 months. 12-23 months 2 doses at intervals of 2 months. > or = 2 years a single dose.,無需調整劑量,[仿單]目前並不確知是否會分泌進入人類乳汁。,無需調整劑量,除非治療上需要,Compatible,[仿單]目前並無任何對孕婦接種的資料可參考，因此懷孕期間應避免接種。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單]目前並不確知是否會分泌進入人類乳汁。,IM;,,,,,1. 應以肌肉注射方式投予，最好注射在嬰兒大腿前外側的股外側肌，或是幼童上臂的三角肌。
IVAR,Varicella Virus Vaccine,Varivax 0.5mL/dose(自費水痘疫苗),HIMM,Active immunisation against varicella of healthy infants from 12 months onwards， susceptible high-risk patients & their susceptible healthy close contacts.,Pregnancy. Acute febrile illness. Total lymphocyte count < 1200/mm3. Hypersensitivity to neomycin.,Fever. Occasionally， papulovesicular eruptions.,2-8℃避光,SC， 0.5 mL， 12 months-12 years 2 doses administered 3 months apart. > or = 13 years 2 doses administered 4-8 weeks apart.,無需調整劑量,[仿單]目前尚不確知是否會分泌至乳汁，由於已知有些病毒會進入人類乳汁， 因此接種之哺乳婦女須特別注意。,無需調整劑量,不可使用,Contraindicated,[仿單]目前未知懷孕婦女接種是否會對胎兒造成影響，因此懷孕婦女不應接種， 且應避免於接種後三個月內懷孕。,Compatible 哺乳時可使用,[仿單]目前尚不確知是否會分泌至乳汁，由於已知有些病毒會進入人類乳汁， 因此接種之哺乳婦女須特別注意。,SC;,使用廠商所附稀釋溶液,,,,1. Varilrix與含有麻疹成分的疫苗應間隔至少一個月以上。
ICISA,Cisatracurium,Cisatracurium inj 10mg/5mL,CNEU,,適應症:Muscle relaxation during surgical procedures eg cardiac surgery， other procedures & in intensive care. Adjunct to general anesth or sedation in the ICU， to relax skeletal muscles & to facilitate tracheal intubation & mechanical ventilation. 副作用:Bradycardia， hypotension. Rarely cutaneous flushing， bronchospasm， rash. 禁忌:Hypersensitivity to cisatracurium besylate or any component of the formulation; use of the 10 mL multiple-dose vials in premature infants (formulation contains benzyl alcohol),,2-8°C,IV bolus Tracheal intubation Adult Initially 0.15 mg/kg over 5-10 sec. Maintenance: 0.03 mg/kg.(about 20 mins effic Childn 1 mth-12 yr Same as adult dose. Maintenance: 0.02 mg/kg. IV infusion Adult & childn 1 mth-12 yr Maintenance of neuromuscular block 3 mcg/kg/min to restore 89-99% T1 suppression then 1-2 mcg/kg/min to maintain block in this range.,無需調整劑量,[仿單] 授乳: 目前尚未得知 cisatracurium 或其代謝物是否會分泌於人類乳汁中。,無需調整劑量,沒有資料,,[仿單] 生育力: 尚未進行生育力研究。 懷孕: 只有在藥物對母親產生的預期利益大於對胎兒造成的潛在危險時，本產品才可使用於懷孕期間。 畸形: 動物研究指出，cisatracurium 對於胎兒的發育沒有不良影響。,Unknown 沒有資料,[仿單] 授乳: 目前尚未得知 cisatracurium 或其代謝物是否會分泌於人類乳汁中。,IVD;IVP;IVPUSH;,,【D5W】可選 。【N/S】可選 。,IVP輸注時間需5-10sec (氣管內插管),IVD給藥速率為0.03-0.6 mg/kg/hr (給藥濃度 0.1-2 mg/mL) Maintenance infusion in ICU， 3 mcg/kg/min IV infusion (range of 0.5 to 10.2 mcg/kg/min due to interpatient variability).,1.僅供靜脈給藥。 2.給藥濃度 0.1-2 mg/mL。 3.本品需冷藏避光貯存 4.不可與鹼性溶液混合 5.限使用人工呼吸器治療病患使用
INF333,速克伏 3HP短程治療處方,潛伏結核感染之治療 (Treatment of LTBI),QANB,,,,,,,,,,,,,,,,,,,
IREB,Interferon beta-1a,Rebif inj 44mcg,HIMM,Multiple sclerosis.,Pregnancy， People currently with severe depression and / or suicidal tendency， Hypersensitivity to natural or recombinant interferon beta or any other component of the formulation.,>10%: Headache (58% to 70%)， fatigue (33% to 41%)， depression (18% to 25%)， pain (23%)， chills (19%)， dizziness (14%)， Nausea (23%)， abdominal pain (8% to 22%)， Urinary tract infection (17%)， Leukopenia (28% to 36%)， lymphadenopathy (11% to 12%)， Increased serum ALT (20% to 27%)， increased serum AST (10% to 17%)， Antibody development (neutralizing; significance not known; Rebif: 24% to 31%; Avonex: 5%)， Injection site reaction (3% to 92%)， Myalgia (25% to 29%)， back pain (23% to 25%)， weakness (24%)， skeletal pain (10% to 15%)， rigors (6% to 13%)， Visual disturbance (7% to 13%)， Flu-like symptoms (49% to 59%)， sinusitis (14%)， upper respiratory tract infection (14%)， Fever (20% to 28%) 1% to 10%: Chest pain (5% to 8%)， vasodilation (2%)， Hypertonia (6% to 7%)， migraine (5%)， ataxia (4% to 5%)， drowsiness (4% to 5%)， malaise (4% to 5%)， seizure (1% to 5%)， suicidal tendencies (4%) Dermatologic: Erythematous rash (5% to 7%)， maculopapular rash (4% to 5%)， alopecia (4%)， hyperhidrosis (4%)， urticaria， Thyroid disease (4% to 6%)， Xerostomia (1% to 5%)， toothache (3%)， Urinary frequency (2% to 7%)， urinary incontinence (2% to 4%)， urine abnormality (3%)， Thrombocytopenia (2% to 8%)， anemia (3% to 5%)， Hyperbilirubinemia (2% to 3%)， Infection (7%)， Pain at injection site (8%)， bruising at injection site (6%)， inflammation at injection site (6%)， tissue necrosis at injection site (1% to 3%)， Arthralgia (9%)， Eye disease (4%)， xerophthalmia (1% to 3%)， Bronchitis (8%),2-8℃避光避免冷凍,SC， initial: 8.8 mcg 3 times weekly on week 1-2.Titration: 22 mcg 3 times weekly on week 3-4.Target dose: 44 mcg 3 times weekly after week 5. target dose may be decreased to 22 mcg if necessary.,無需調整劑量,[仿單] 關於 interferon beta-1a 是否會分佈到母乳中，目前可獲得的資訊有限。 若一併考量interferon beta 的化學/生理學特性，則乳汁中分泌的 interferon beta-1a 濃度應很低。 哺乳的效益及可能風險應與病人對於 interferon beta-1a 治療的臨床需求一併考量。,無需調整劑量,沒有資料,No (limited) human data – animal data suggest moderate risk,[仿單]數據指出，於受孕前或妊娠第一期時暴露於 interferon beta， 其發生重大先天性異常的風險並未增加。收集數據時 interferon beta 尚屬懷孕期間之使用禁忌，在檢測出/或確認懷孕後可能會中斷治療，因此無法確定在妊娠第一期的暴露時間，而暴露於妊娠第二期及第三期的經驗非常有限。 依據動物試驗數據，自發性流產的風險可能會增加。 然而依據目前可獲得的數據，尚無法充分評估暴露於interferon beta 的孕婦其自發性流產的風險，但目前該數據並未顯示有增加的風險。 如有臨床需要，可以在懷孕期間考慮使用 Rebif。,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,[仿單] 關於 interferon beta-1a 是否會分佈到母乳中，目前可獲得的資訊有限。 若一併考量interferon beta 的化學/生理學特性，則乳汁中分泌的 interferon beta-1a 濃度應很低。 哺乳的效益及可能風險應與病人對於 interferon beta-1a 治療的臨床需求一併考量。,SC;,,,,,單次使用。只有澄清至乳白色溶液、無顆粒、無可見變質跡象的注射液才可使用。
IFMR,Flomoxef,Flumarin inj 1gm,QANB,Flomoxef sodium susceptible strains of Staphylococcus sp.， Streptococcus sp.， Pneumococcus sp.， Neisseria gonorrhoeae， Moraxella (Branhamella) catarrhalis， Escherichia coli， Klebsiella sp.， Proteus sp.， Morganella morganii， Providencia sp.， Haemophilus influenzae， Peptostreptococcus sp.， Bacteroides sp.， Prevotella sp. (excluding Prevotella bivia),Patients with a history of shock following exposure to any of the ingredients in this product. RELATIVE CONTRAINDICATIONS: Patients with a history of hypersensitivity to any of the ingredients in this product or to other cephalosporin antibiotics Careful Administration: Patients with a history of hypersensitivity to penicillins. Patients with a personal or familial predisposition to allergic reactions such as bronchial asthma， rash and urticaria. Patients with severe renal dysfunction. Patients of poor oral ingestion， patients receiving parenteral feeding， or patients in poor general condition. Elderly patients.,Rash， Anemia (decreased RBC， decreased hemoglobin， decreased hematocrit)， eosinophilia， granulocytopenia， Increased SGOT(AST)， increased SGPT (ALT)， increased Al-P， increased gamma-GTP， Diarrhea，,25℃以下,Adult: 1-4 g/day IV Q6H-Q12H in divided doses. Children: 60-150 mg/kg/day IV Q6H-Q8H in divided doses. Neonates and preterm infants: 20 mg/kg IV Q8H-Q12H within 3 days of birth， then Q6H-Q8H from the 4th day after birth (maximum dose: 150 mg/kg/day Q6H-Q8H),無需調整劑量,[仿單]關於懷孕期投予的安全性尚未確立， 孕婦或有可能懷孕的婦人，在治療上判斷其有益性高於危險性時才能投與,需調整劑量,沒有資料,Uknown 沒有資料,[仿單]關於懷孕期投予的安全性尚未確立， 孕婦或有可能懷孕的婦人，在治療上判斷其有益性高於危險性時才能投與,Unknown 沒有資料,[仿單]關於懷孕期投予的安全性尚未確立， 孕婦或有可能懷孕的婦人，在治療上判斷其有益性高於危險性時才能投與,IVD;IVPUSH;,1g的vial包裝，以4mL以上的注射用水，5%葡萄糖注射液，或生理食鹽水加入後溶解.,【D5W】可選 。【N/S】可選 。,緩慢注射3分鐘,仿單無建議滴注時間，但動力學資料是將藥物以1小時點滴輸注.,1. 調配後室溫可保存6小時，冷藏可保存24小時。 2. 仿單無稀釋後安定性資料。2021/1/24廠商提供安定性資料，1g稀釋於5%葡萄糖注射液或生理食鹽水100mL或500mL在攝氏25度以下可有6小時安定，冷藏可有24小時安定。 3. 臨床試驗中靜脈注射flomoxef 1g給藥時間為3分鐘內，緩慢注射可能避免給藥不適。
ECASI,Betamethasone + Lidocaine + Phenylephrine,Calmsit cream 15gm,ALIM,External hemorrhoids， hemorrhoid bleeding， hemorrhoid pain， anal fissure， perianal inflammation， anal itching， anal eczema， anal ulcer,Avoid contact with eyes or oral consumption.,Common Dermatologic: Burning sensation， Itching， Stinging of skin Serious Endocrine metabolic: Cushing's syndrome， Hyperglycemia， Hypothalamic-pituitary-adrenal axis dysfunction， Suppression. Immunologic: Anaphylaxis Dermatologic: Necrosis,25℃以下儲存,2-3 times daily. Calmsit 1 gm: Betamethasone 0.42mg + Lidocaine 25mg + Phenylephrine 1mg.,無需調整劑量,Phenylephrine (Sympathomimetic): No Human Data - Probably Compatible. Betamethasone: No Human Data - Probably Compatible. Lidocaine (Local Anesthetic/Cardiac): Limited Human Data—Probably Compatible [仿單]沒有相關紀載,無需調整劑量,沒有資料,Human (and animal) data suggest risk,Phenylephrine (Sympathomimetic): Human Data Suggest Risk. Betamethasone: Compatible - Maternal Benefit >> Embryo - Fetal Risk Lidocaine (Local Anesthetic/Cardiac): Compatible. [仿單]沒有相關紀載,No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用,Phenylephrine (Sympathomimetic): No Human Data - Probably Compatible. Betamethasone: No Human Data - Probably Compatible. Lidocaine (Local Anesthetic/Cardiac): Limited Human Data—Probably Compatible [仿單]沒有相關紀載,EXT;RECT;,,,,,
